
<html lang="en"     class="pb-page"  data-request-id="42b422b5-db9f-44b3-b49a-67662a914d92"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2020.63.issue-23;requestedJournal:journal:jmcmar;article:article:10.1021/acs.jmedchem.0c01013;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Why All the Fuss about Oxidative Phosphorylation (OXPHOS)?" /></meta><meta name="dc.Creator" content="Yibin  Xu" /></meta><meta name="dc.Creator" content="Ding  Xue" /></meta><meta name="dc.Creator" content="Armand  Bankhead, III" /></meta><meta name="dc.Creator" content="Nouri  Neamati" /></meta><meta name="dc.Description" content="Certain subtypes of cancer cells require oxidative phosphorylation (OXPHOS) to survive. Increased OXPHOS dependency is frequently a hallmark of cancer stem cells and cells resistant to chemotherapy..." /></meta><meta name="Description" content="Certain subtypes of cancer cells require oxidative phosphorylation (OXPHOS) to survive. Increased OXPHOS dependency is frequently a hallmark of cancer stem cells and cells resistant to chemotherapy..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="October 26, 2020" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01013" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01013" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01013" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01013" /></link>
        
    
    

<title>Why All the Fuss about Oxidative Phosphorylation (OXPHOS)? | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01013" /></meta><meta property="og:title" content="Why All the Fuss about Oxidative Phosphorylation (OXPHOS)?" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0015.jpeg" /></meta><meta property="og:description" content="Certain subtypes of cancer cells require oxidative phosphorylation (OXPHOS) to survive. Increased OXPHOS dependency is frequently a hallmark of cancer stem cells and cells resistant to chemotherapy and targeted therapies. Suppressing the OXPHOS function might also influence the tumor microenvironment by alleviating hypoxia and improving the antitumor immune response. Thus, targeting OXPHOS is a promising strategy to treat various cancers. A growing arsenal of therapeutic agents is under development to inhibit this biological process. This Perspective provides an overview of the structure and function of OXPHOS complexes, their biological functions in cancer, relevant research tools and models, as well as the limitations of OXPHOS as drug targets. We also focus on the current development status of OXPHOS inhibitors and potential therapeutic strategies to strengthen their clinical applications." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01013"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01013">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01013&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01013&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01013&amp;href=/doi/10.1021/acs.jmedchem.0c01013" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 23</span><span class="cit-fg-pageRange">, 14276-14307</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/23" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00960" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c01055" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Why All the Fuss about Oxidative Phosphorylation (OXPHOS)?</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Yibin Xu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yibin Xu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, College of Pharmacy, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan 48109, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yibin++Xu">Yibin Xu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8261-3286" title="Orcid link">http://orcid.org/0000-0002-8261-3286</a></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Ding Xue</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ding Xue</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, College of Pharmacy, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan 48109, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ding++Xue">Ding Xue</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Armand Bankhead III</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Armand Bankhead, III</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Computational Medicine and Bioinformatics, University of Michigan Medical School, Ann Arbor, Michigan 48109, United States</div><div class="loa-info-affiliations-info">Department of Biostatistics, University of Michigan, School of Public Health, Ann Arbor, Michigan 48109, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Armand++Bankhead%2C++III">Armand Bankhead, III</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor">Nouri Neamati</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nouri Neamati</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, College of Pharmacy, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan 48109, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Tel: (734) 647-2732. Email: <a href="/cdn-cgi/l/email-protection#741a11151915001d3401191d171c5a111001"><span class="__cf_email__" data-cfemail="8ae4efebe7ebfee3caffe7e3e9e2a4efeeff">[emailÂ protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nouri++Neamati">Nouri Neamati</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3291-7131" title="Orcid link">http://orcid.org/0000-0003-3291-7131</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01013&amp;href=/doi/10.1021%2Facs.jmedchem.0c01013" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 23</span><span class="cit-pageRange">, 14276â14307</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">October 26, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>14 June 2020</li><li><span class="item_label"><b>Published</b> online</span>26 October 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 December 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01013" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01013</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D14276%26pageCount%3D32%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYibin%2BXu%252C%2BDing%2BXue%252C%2BArmand%2BBankhead%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D23%26contentID%3Dacs.jmedchem.0c01013%26title%3DWhy%2BAll%2Bthe%2BFuss%2Babout%2BOxidative%2BPhosphorylation%2B%2528OXPHOS%2529%253F%26numPages%3D32%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D14307%26publicationDate%3DDecember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01013"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1514</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">2</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01013" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Why All the Fuss about Oxidative Phosphorylation (OXPHOS)?&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Yibin&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Ding&quot;,&quot;last_name&quot;:&quot;Xue&quot;},{&quot;first_name&quot;:&quot;Armand&quot;,&quot;last_name&quot;:&quot;Bankhead&quot;},{&quot;first_name&quot;:&quot;Nouri&quot;,&quot;last_name&quot;:&quot;Neamati&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;10&quot;,&quot;day&quot;:&quot;26&quot;,&quot;issue&quot;:&quot;23&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;14276-14307&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01013&quot;},&quot;abstract&quot;:&quot;Certain subtypes of cancer cells require oxidative phosphorylation (OXPHOS) to survive. Increased OXPHOS dependency is frequently a hallmark of cancer stem cells and cells resistant to chemotherapy and targeted therapies. Suppressing the OXPHOS function might also influence the tumor microenvironment by alleviating hypoxia and improving the antitumor immune response. Thus, targeting OXPHOS is a promising strategy to treat various cancers. A growing arsenal of therapeutic agents is under development to inhibit this biological process. This Perspective provides an overview of the structure and function of OXPHOS complexes, their biological functions in cancer, relevant research tools and models, as well as the limitations of OXPHOS as drug targets. We also focus on the current development status of OXPHOS inhibitors and potential therapeutic strategies to strengthen their clinical applications.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01013&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01013" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01013&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01013" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01013&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01013" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01013&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01013&amp;href=/doi/10.1021/acs.jmedchem.0c01013" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01013" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01013" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (14 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01013%26sid%3Dliteratum%253Aachs%26pmid%3D33103432%26genre%3Darticle%26aulast%3DXu%26date%3D2020%26atitle%3DWhy%2BAll%2Bthe%2BFuss%2Babout%2BOxidative%2BPhosphorylation%2B%2528OXPHOS%2529%253F%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D23%26spage%3D14276%26epage%3D14307%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/23" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/jmcmar.2020.63.issue-23/20201210/jmcmar.2020.63.issue-23.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/medium/jm0c01013_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01013&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Certain subtypes of cancer cells require oxidative phosphorylation (OXPHOS) to survive. Increased OXPHOS dependency is frequently a hallmark of cancer stem cells and cells resistant to chemotherapy and targeted therapies. Suppressing the OXPHOS function might also influence the tumor microenvironment by alleviating hypoxia and improving the antitumor immune response. Thus, targeting OXPHOS is a promising strategy to treat various cancers. A growing arsenal of therapeutic agents is under development to inhibit this biological process. This Perspective provides an overview of the structure and function of OXPHOS complexes, their biological functions in cancer, relevant research tools and models, as well as the limitations of OXPHOS as drug targets. We also focus on the current development status of OXPHOS inhibitors and potential therapeutic strategies to strengthen their clinical applications.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27403" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27403" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Targeting metabolic reprogramming is an emerging strategy in the discovery of anticancer drugs.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Ever since the discovery of the Warburg effect, numerous efforts have focused on the pharmacological inhibition of glycolysis. However, many glycolysis inhibitors (such as 2-deoxyglucose) do not seem to have a significant effect on tumor growth as expected. Recent studies provide strong evidence that tumors are metabolically heterogeneous. Certain tumors rely on oxidative phosphorylation (OXPHOS) for their bioenergetics<a onclick="showRef(event, 'ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4">(2â4)</a> and, more importantly, biomass production, which are essential for enhanced tumor growth,<a onclick="showRef(event, 'ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7">(5â7)</a> suggesting that targeting OXPHOS will generate opportunities for effective cancer therapeutics.</div><div class="NLM_p">OXPHOS is a fundamental mitochondrial process, linking the tricarboxylic acid (TCA) cycle to the production of adenosine triphosphate (ATP). Subpopulations of tumor cells are strongly dependent on OXPHOS, for example, glycolysis-deficient cells,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> PTEN-null cells,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> and SWI/SNF complex-mutated cells in lung cancer.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> In addition, increased OXPHOS dependency is frequently exhibited by cancer stem cells (CSCs),<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11,12)</a> as well as KRAS ablation-resistant cells in pancreatic cancers.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Importantly, OXPHOS inhibition can overcome resistance to chemotherapy<a onclick="showRef(event, 'ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16">(14â16)</a> and tyrosine kinase inhibitors.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Thus, inhibition of OXPHOS can be a promising therapeutic strategy to treat select cancers.</div><div class="NLM_p last">In recent years, extensive studies have reported novel uses for OXPHOS inhibitors in the treatment of cancer.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a> Metformin, a biguanide drug widely prescribed for the treatment of type 2 diabetes, lowers the incidence of cancer<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> and is an OXPHOS inhibitor,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> suggesting that inhibition of OXPHOS can be safe and efficacious. Another potent and selective OXPHOS inhibitor, IACS-010759, robustly inhibits proliferation and induces apoptosis at well-tolerated doses in select types of cancer reliant on OXPHOS.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> The results from Phase I clinical trials of IACS-010759 in relapsed/refractory AML and solid tumors showed IACS-010759 is well-tolerated with preliminary evidence of antitumor activity.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Until now, there have been limited numbers of OXPHOS inhibitors in preclinical or clinical studies. Thus, the discovery and development of OXPHOS inhibitors is a largely unexplored but promising field in cancer treatment.</div></div><div id="sec-162-51C22D3C" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Structure and Function of Multisubunit Complexes of OXPHOS</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02230" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02230" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">The mitochondrial OXPHOS system is the final biochemical pathway in the production of ATP and requires the orchestrated action of electron transport chain (ETC) complexes and ATP synthase located in the inner mitochondrial membrane. The OXPHOS machinery consists of five complexes, the individual subunits of which are encoded either by the mitochondrial or by the nuclear genome. Tremendous efforts were undertaken to understand the structure, coupling mechanism, and pathology of OXPHOS complexes. Structures of OXPHOS complexes and super complexes<a onclick="showRef(event, 'ref24 ref25 ref26 ref27 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26 ref27 ref28 ref29">(24â29)</a> from different species were solved by cryo-EM (cryo-electron microscopy) or X-ray diffraction, providing further insight into understanding the structure and function of OXPHOS complexes.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Structure and Ligand Binding Sites of OXPHOS Complexes</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40577" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40577" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Five complexes are involved in OXPHOS: NADH-ubiquinone oxidoreductase (complex I), succinate-ubiquinone oxidoreductase (complex II), ubiquinolâcytochrome c oxidoreductase (complex III, or cytochrome bc1 complex), cytochrome c oxidase (complex IV), and ATP synthase (complex V) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Complexes IâIV, also called ETC, transfer electrons from donors generated by the TCA cycle or fatty acid oxidation to oxygen. The proton gradient generated in this process is then utilized by complex V to synthesize ATP.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/medium/jm0c01013_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Function of OXPHOS complexes. The OXPHOS machinery consists of five multiprotein complexes (complex IâV), transferring electrons and creating an electrochemical proton gradient to drive the synthesis of adenosine triphosphate (ATP). Electrons are transferred from NADH or succinate to ubiquinone (Q) through complex I or II; then, the electrons are removed from QH<sub>2</sub> in complex III to form a proton gradient. In complex IV, electrons are transferred to the terminal electron acceptor oxygen (O<sub>2</sub>). All of the protons pumped into the intermembrane space by complex I, III, and IV create a proton gradient that facilitates ATP production by ATP synthase (complex V). Structural genes for each complex are listed in the table below. Genes encoded by mitochondrial DNA are highlighted in red.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01013&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Complex I (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A) is one of the largest membrane proteins known and consists of 45 subunits with a molecular weight of nearly 1 MDa. It is an L-shaped protein complex with two distinguishable arms.<a onclick="showRef(event, 'ref24 ref30 ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref24 ref30 ref31 ref32">(24,30â32)</a> The hydrophobic membrane arm, which contains all the mtDNA-encoded subunits, is embedded in the inner mitochondrial membrane, and the hydrophilic peripheral arm protrudes into the matrix. NADH is oxidized to NAD<sup>+</sup> at the hydrophilic arm by flavin mononucleotide (FMN), releasing a pair of electrons. The electrons are then transferred by eight FeâS clusters to ubiquinone at its binding pocket located at the interface of the 49 kDa (NDUFS2 in <i>Homo sapiens</i>) and PSST subunits (NDUFS7 in <i>Homo sapiens</i>). Ubiquinone is believed to âslideâ through a putative â¼30 Ã long access channel from an entrance at the ND1 subunit to its binding pocket.<a onclick="showRef(event, 'ref32 ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref32 ref33 ref34">(32â34)</a> Other possible entrances have also been proposed.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Most complex I inhibitors bind in the ubiquinone pocket. Mutagenesis and photoaffinity labeling experiments suggest that these inhibitors bind to different but partially overlapping sites in this large pocket.<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36,37)</a> Several other inhibitors that bind to the ND1 subunit, like IACS-010759, bullatacin, are also reported.<a onclick="showRef(event, 'ref22 ref38'); return false;" href="javascript:void(0);" class="ref ref22 ref38">(22,38)</a> They induce a structural change in the ubiquinone pocket and affect the redox reaction indirectly. However, no definitive structural difference with ubiquinone pocket inhibitors has been proposed. Complex II (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B) comprises four subunits (SDHA, SDHB, SDHC, and SDHD) encoded by nuclear DNA (nDNA) in a head-to-tail arrangement. The hydrophilic head consisting of the flavoprotein SDHA and the ironâsulfur SDHB subunit protrudes into the matrix, while the hydrophobic subunits SDHC and SDHD are embedded in the inner mitochondrial membrane. Complex II oxidizes succinate generated from the TCA cycle to fumarate and transfers its electrons to ubiquinone via FAD and three FeâS clusters embedded in the SDHA and SDHB subunits. Similar to complex I, ubiquinone binds at its binding site (Qp site) proximal to the terminal FeâS cluster on the SDHC subunit, while a second binding site called the Qd site on the intermembrane side is also proposed.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> The electron transfer to ubiquinone at the distal Qd site may involve an additional heme molecule, and the physiological relevance of the Qd site in complex II remains debatable.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Inhibitors of complex II bind at one of the two Q sites or at the succinate binding site.<a onclick="showRef(event, 'ref39 ref41 ref42 ref43 ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref39 ref41 ref42 ref43 ref44 ref45">(39,41â45)</a> Complex III (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C) is a symmetrical dimer, with three core subunits: cytochrome <i>b</i> (cyt <i>b</i>), with two b-type hemes (<i>b</i><sub>L</sub> and <i>b</i><sub>H</sub>), cytochrome <i>c</i><sub>1</sub> (cyt <i>c</i><sub>1</sub>) and the ironâsulfur protein (ISP) with a FeâS cluster.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Cyt <i>b</i> contains two distinct quinone-binding sites (Qi and Qo site) located on opposite sides of the membrane that form the center of the complex, to which both cyt <i>c</i><sub>1</sub> and ISP anchor through a single transmembrane helix (TMH).<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> It functions through a Q-cycle mechanism transferring two electrons from ubiquinol to cytochrome <i>c</i>. Inhibitors of complex III are classified based on their binding to either the Qi site or the Qo site, or both.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Complex IV (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>D) transfers four electrons from cytochrome c to the terminal electron acceptor O<sub>2</sub>. It is composed of 14 different subunits in mammals and has diverse interactions with complex I. Two heme molecules (heme a and heme a<sub>3</sub>) along with two binuclear copper centers (Cu<sub>A</sub> and Cu<sub>B</sub>) embedded in the structure are critical for the electron transfer from cytochrome <i>c</i> to molecular oxygen. Inhibitors of complex IV, e.g., cyanides, carbon monoxide, or azides, are believed to bind metal ions in the binuclear center, hampering the oxidoreduction process. Complex V (ATP synthase) (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>E) is composed of F<sub>o</sub>, a motor that is powered by protons flowing across the membrane and embedded within the membrane of the mitochondria, F<sub>1</sub>, another motor that is used to generate ATP and is located within the mitochondrial matrix, and stator that is a peripheral stalk anchored at the top of F<sub>1</sub>.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> A large number of ATP synthase inhibitors are known and have been demonstrated to bind to different subunits across both the F<sub>o</sub> and F<sub>1</sub> sectors.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/medium/jm0c01013_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of OXPHOS complexes. (A) Complex I consists of a peripheral arm and membrane arm. The 49 kDa (light yellow) and PSST (cyan) subunits forming the ubiquinone-binding pocket and ND1 subunit (gray) forming the entrance of the ubiquinone access channel are shown. The FMN and FeâS clusters that form the electron transfer chain are shown (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5LC5">5LC5</a>). (B) Complex II comprises four subunits: SDHA (Fp, green), SDHB (Ip, cyan), SDHC (CybL, yellow), SDHD (CybS, blue), with two ubiquinone-binding sites (Qp and Qd site) and a succinate binding site. The FeâS clusters and heme that are essential for electron transfer are shown. (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ZOY">1ZOY</a>). (C) Complex III is a symmetrical dimer with three core subunits: cytochrome <i>b</i> (cyt <i>b</i>, gray) with two b-type hemes (<i>b</i><sub>L</sub> and b<sub>H</sub>), cytochrome <i>c</i><sub>1</sub> (cyt <i>c</i><sub>1</sub>, yellow) and the ironâsulfur protein (ISP) with a FeâS cluster (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1BGY">1BGY</a>). (D) The structure of complex IV. Two heme molecules (heme <i>a</i> and heme <i>a</i><sub>3</sub>) along with two binuclear copper centers (Cu<sub>A</sub> and Cu<sub>B</sub>) embedded in the structure are critical for the electron transfer (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WAU">5WAU</a>). (E) Complex V (ATP synthase) is composed of the F<sub>o</sub> sector and F<sub>1</sub> sector (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CP6">6CP6</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01013&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec-163-514C0A1A" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">Role of OXPHOS in Cellular Respiration</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02746" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02746" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">The mitochondrial OXPHOS system plays a key role in energy production. The energy released from the oxidation of NADH and succinate is used to pump protons across the inner membrane of the mitochondria. This causes protons to build up in the intermembrane space and generate an electrochemical gradient across the membrane. The energy stored in this electrochemical gradient is then used by ATP synthase (complex V) to produce ATP (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Recent studies revealed that a major function of OXPHOS is to consume NADH and recycle NAD+ to reduce âreductive stressâ and provide electron acceptors for aspartate synthesis.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Thus, OXPHOS defects not only cause a reduction in ATP production but also decrease the production of aspartate,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> a limiting metabolite for cell proliferation. Metabolic pathways, including glycolysis, the TCA cycle, and Î²-oxidation, produce the electron donors that fuel the ETC. In turn, ETC activity impacts a variety of processes beyond energy balance,<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> such as reactive oxygen species (ROS) production,<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> the redox state,<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> mitochondrial membrane potential,<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> apoptosis, and signaling.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">OXPHOS Gene Expression and Mutation Survey in Cancer</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13736" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13736" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The regulation of OXPHOS activity and mitochondrial function is complicated. Gene expression has been used to reveal the upregulated OXPHOS activity in breast cancer patient populations<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> and in patients with poor prognosis among several cohorts across 10 cancer types,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> suggesting OXPHOS gene expression is dysregulated in cancer and may be useful in predicting patient prognosis. Additionally, mutations in mitochondrial genes will significantly alter OXPHOS function and dependency. Thus, we conducted a pan-cancer gene expression survey and a hotspot mutation survey of OXPHOS genes to summarize the OXPHOS function and reveal the mutations related to OXPHOS dependency in cancer patients.</div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> OXPHOS Pan-Cancer Gene Expression Survey</h3><div class="NLM_p">To examine the transcription of OXPHOS genes in multiple cancer types, we surveyed OXPHOS gene expression in the Cancer Genome Atlas (TCGA) across multiple patient cohorts.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> In addition to genes encoding components of the ETC complexes, many other genes can regulate the OXPHOS function, including assembly factors, TCA cycle genes, and genes involved in glycolysis. Thus, we collected OXPHOS genes sourced from MSigDB Hallmark,<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> KEGG,<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> GO (GO:0006119),<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> and a literature review to construct a comprehensive canonical OXPHOS gene set (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01013/suppl_file/jm0c01013_si_001.pdf" class="ext-link">Supplemental Tables 1 and 2</a>). We performed two analyses using TCGA RNA-Seq patient data. The first analysis focused on surveying OXPHOS gene expression across all TCGA cohorts and using patient tumor RNA-Seq profiles only. The second analysis focused on comparing OXPHOS gene expression in TCGA tumor versus normal RNA-Seq profiles.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/medium/jm0c01013_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. OXPHOS gene expression is higher than average in multiple cancer types. (A) ChowâRuskey Venn diagram shows 67 genes in common between Hallmark, KEGG, and GO (GO:0006119) OXPHOS gene sets with a custom literature-based gene set. (B) An OXPHOS gene set combining all four gene sets described above was mapped to 320 genes and associated expression values for TCGA patients. The pan-cancer heatmap shows z-score normalized gene expression values per patient with diseases ranked by average patient expression. KICH, ACC, LIHC, UVM, and DLBC have the highest average expression. (C) GSEA was performed to show enrichment significance of high expressing OXPHOS genes for each TCGA disease by ranking genes using average z-score value per gene per disease. A total of 10â¯000 random permutations were performed to illustrate the FDR-adjusted <i>p</i>-value significance. The top five diseases are shown (as ranked by NES). NES = normalized enrichment score; FDR= false discovery rate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01013&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">For the first analysis, 9726 total non-normal samples were evaluated across 33 total disease groups. RSEM values from the TCGA GDAC Firehose were upper-quartile normalized per disease, and log2 + 1 transformed prior to z-score normalizing per patient. A pan-cancer heatmap was constructed after diseases were ranked by average expression across genes and patients to highlight diseases with the highest relative OXPHOS expression (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B). Kidney chromophobe (KICH), adrenocortical carcinoma (ACC), liver hepatocellular carcinoma (LIHC), uveal melanoma (UVM), and lymphoid neoplasm diffuse large B-cell lymphoma (DLBC) are the top 5 diseases with the highest OXPHOS gene expression. To evaluate significance, we used GSEA to calculate normalized enrichment score (NES) and FDR-adjusted <i>p</i>-value statistics of OXPHOS expression.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> A gene expression ranking was constructed per disease by taking the average z-scores per gene per disease and rank ordering genes by the resulting average z-score. Weighted mode scoring was used with 10,000 gene set permutations. GSEA enrichment plots of the top 5 diseases (KICH, ACC, LHC, UVM, and DLBC) are shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C to support the hypothesis that OXPHOS genes are significantly upregulated.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Additionally, we surveyed the expression of genes belonging to canonical glycolysis (GO:0061621) and found that glycolysis genes (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01013/suppl_file/jm0c01013_si_001.pdf" class="ext-link">Supplemental Table 3</a>) were also most significantly upregulated in UVM, ACC, and KICH (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01013/suppl_file/jm0c01013_si_001.pdf" class="ext-link">Supplemental Figure 1</a>), suggesting these cancer types utilize both OXPHOS and glycolysis to meet their nutrient needs. In summary, contradictory to the impression that OXPHOS genes are downregulated in cancer, our analysis indicates that many cancer types express and use OXPHOS metabolic pathways. These findings indicate that some cancer types may be particularly vulnerable to OXPHOS inhibitors.</div><div class="NLM_p">Since the majority of TCGA diseases have fewer than 30 patients with tumor and matched normal samples profiled with RNA-Seq, we concentrated on the two most well-studied diseases with the largest number of patients with matched normal samples: breast carcinoma (BRCA, <i>N</i> = 112) and lung adenocarcinoma (LUAD, <i>N</i> = 58). RSEM values from the TCGA GDAC Firehose<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> were upper-quartile normalized per disease and log2 + 1 transformed prior to z-score normalizing per patient. Patient z-scores were averaged across all OXPHOS genes for tumor and normal samples. Consistent with other studies, we found the expression of OXPHOS genes are significantly increased in tumor samples compared to normal samples in breast cancer (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A) and lung cancer (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B). Heatmaps in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a> show the top 30 genes for BRCA and LUAD ranked by the average difference between tumor and normal samples as calculated by subtracting log2 RSEM values. The top significantly upregulated genes in OXPHOS gene sets include CDK1, CCNB1, IDH2, NDUFAF6, and SHMT2. As essential genes involved in the cell cycle, cyclin-dependent kinase 1 (CDK1) and cyclin B1 (CCNB1) also influence the function of OXPHOS. CyclinB1/cyclin-dependent kinase 1 proteins phosphorylates complex I subunit and enhanced complex I activity to provide more efficient bioenergy for cell cycle.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Isocitrate dehydrogenase 2 (IDH2) is a mitochondria protein carboxylating Î±-KG from glutamine to citrate and functions for redox homeostasis in cancer cells.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> IDH2 links the metabolic switch between glycolysis and OXPHOS,<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> and OXPHOS inhibitor IACS-010759 sensitizes IDH mutant inhibitors in acute myeloid leukemia.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> NDUFAF6 is a typical OXPHOS gene belonging to the complex I assembly factor, and its mutation leads to Leigh syndrome.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> Serine hydroxymethyltransferase (SHMT2), an essential protein in one-carbon metabolism, also participates in OXPHOS complex I assembly and is important for mitochondrial translation initiation.<a onclick="showRef(event, 'ref68 ref69'); return false;" href="javascript:void(0);" class="ref ref68 ref69">(68,69)</a></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/medium/jm0c01013_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. OXPHOS gene expression shown for TCGA BRCA (A) and LUAD (B) patients with matched tumor and normal samples. Violin plots show patient average z-scores for the OXPHOS union gene set are significantly increased in tumor samples compared to normal samples using a paired Wilcoxon test. Heatmaps show the top 30 OXPHOS genes as ranked by average fold change of tumor to normal expression per gene. Thirteen genes were in common between BRCA and LUAD top 30 gene lists: ADCK5, CCNB1, CDK1, COA6, IDH2, MRPS12, MRPS30, NDUFAF6, PGK1, SHMT2, TIMM17A, UQCC2, and UQCC3 (<i>p</i> = 1.19 Ã 10<sup>â07</sup>, Odds Ratio = 12.1). (C) There were 222 genes in BRCA and 185 genes in LUAD with average fold changes greater than zero. Of the 321 total OXPHOS genes, 155 had increased expression on average in both BRCA and LUAD. (D) Three of these common genes mapped to kinases (ADCK2, ADCK5, CDK1) are highlighted in magenta on a kinome map, while a total of 6 OXHPOS genes were mapped to kinases. ADCK2: BRCA W <i>p</i> = 2.59 Ã 10<sup>â10</sup>, LUAD W <i>p</i> = 0.365. ADCK5: BRCA W <i>p</i> = 4.17 Ã 10<sup>â09</sup>, LUAD W <i>p</i> = 4.59 Ã 10<sup>â10</sup>. CDK1: BRCA W <i>p</i> = 4.27 Ã 10<sup>â20</sup>, LUAD W <i>p</i> = 1.24e-10. The remaining 3 kinases (ADCK1, PDK4, PINK1) are colored green.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01013&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We found that 155 OXPHOS genes commonly had higher tumor expression in both BRCA and LUAD cohorts and that this overlap was statistically significant (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C). We also identified six of the OXPHOS genes as kinases, and of these, half are commonly up-regulated in both BRCA and LUAD (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>D) including CDK1, ADCK2, and ADCK5. CDK1 is involved in complex I assembly factor while AarF domain-containing kinases (ADCK2/5) are implicated in the coenzyme-Q biosynthesis.<a onclick="showRef(event, 'ref70 ref71'); return false;" href="javascript:void(0);" class="ref ref70 ref71">(70,71)</a></div><div class="NLM_p last">Although our OXPHOS gene expression survey shows increased OXPHOS gene expression in select disease types, there are other elements that should be considered when correlated to the increased dependency of OXPHOS. It is important to note that environmental conditions including hypoxia, acidosis, and availability of substrates significantly alter mitochondrial function without necessarily altering gene expression. An excess or lack of specific nutrients will affect the metabolic vulnerability of cancer cells. Thus, our OXPHOS gene expression survey provides informative insights but does not directly lead to the conclusion of OXPHOS dependency in these cancer types.</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> OXPHOS Pan-Cancer Hotspot Mutation Survey</h3><div class="NLM_p">While not all DNA mutations are functional or clinically relevant, it has been shown that hotspot variants in oncology cohorts, or variants occurring at the same amino acid position across multiple cancer patients, often highlight long-established oncogenes as cancer drivers.<a onclick="showRef(event, 'ref72 ref73 ref74'); return false;" href="javascript:void(0);" class="ref ref72 ref73 ref74">(72â74)</a> Such hotspot variants are powerful tools used in precision medicine when matching patients with targeted therapies.</div><div class="NLM_p">Mutations from the TCGA cohort called using the Mutect2 somatic variant workflow were downloaded for all genes from the GDC data portal and then annotated using hotspot mutations from <a href="http://www.cancerhotspots.org" class="extLink">www.cancerhotspots.org</a><a onclick="showRef(event, 'ref72 ref75'); return false;" href="javascript:void(0);" class="ref ref72 ref75">(72,75)</a> where hotspots from all diseases were considered. Results were visualized using the maftools R package.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> We examined hotspot mutation status frequency for all OXPHOS genes across all 33 diseases by considering patients mutated with a hotspot in any OXPHOS gene (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A). The highest frequency of mutations was observed in lower-grade glioma (LGG), in which 410 of 510 (80.7%) patients had an isocitrate dehydrogenase 1 (IDH1) (R132) or isocitrate dehydrogenase 2 (IDH2) (R172) hotspot variant. Cholangiocarcinoma (CHOL), acute myeloid leukemia (LAML), glioblastoma multiforme (GBM), Lymphoid neoplasm diffuse large B-cell lymphoma (DLBC), stomach adenocarcinoma (STAD), and skin cutaneous melanoma (SKCM) also had the highest frequency of hotspot OXPHOS variants with at least 3% of mutated patients. Oncoprints for the top 7 diseases are shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01013/suppl_file/jm0c01013_si_001.pdf" class="ext-link">Supplemental Figure 2</a>. The majority of patients in STAD and SKCM have at least one OXPHOS gene mutation (hotspot or nonhotspot). However, an additional experimental investigation is required to determine if and how the nonhotspot variants impact protein function. Lollipop plots show the gene body position of hotspot variants from IDH1 and small GTPase RAS homologue gene family, member A (RHOA) (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C). IDH1(R132) mutation is one of the most frequent mutation forms in a variety of human cancers,<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> and it has prognostic significance in patients with diffusely infiltrating gliomas.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> RHOA mutations also occur in several cancer types with a relatively high mutation rate.<a onclick="showRef(event, 'ref79 ref80 ref81'); return false;" href="javascript:void(0);" class="ref ref79 ref80 ref81">(79â81)</a> Its gain-of-function Y42C mutation activates RHOA and serves as an ontogenetic mutant in diffuse gastric cancer.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/medium/jm0c01013_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. TCGA OXPHOS Hotspot Variant Survey. (A) Hotspot gain-of-function variants were identified in 22 of 33 diseases with the highest percentage of patients with OXPHOS hotspot variants in LGG (81%) in which the majority of patients had an IDH1 R132 hotspot or IDH2 R172. (B) Oncoprint visualizations for several diseases with the highest number of OXPHOS hotspot variants from the top 20 mutated OXPHOS genes. The remaining top disease Oncoprints are in <a href="/doi/suppl/10.1021/acs.jmedchem.0c01013/suppl_file/jm0c01013_si_001.pdf" class="ext-link">Supplemental Figure 2</a>. (C) Lollipop visualizations of the hotspot variants for GBM, SKCM, and STAD. Oncoprint and lollipop visualizations generated using the Maftools package. IDH1 and RHOA amino acid coordinates use NM_005896 and NM_001664 transcripts, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01013&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">IDH1 and IDH2 are important metabolic enzymes in the TCA cycle that generate Î±-ketoglutarate (Î±KG). Cancer-associated IDH1 and IDH2 hotspot mutations, which occur at distinct arginine residues in the enzyme active site (R132 in IDH1 and R172 in IDH2), result in the production of 2-hydroxyglutarate (2-HG) and inhibition of Î±-ketoglutarate-dependent dioxygenases and eventually promote tumorigenesis. Importantly, IDH1 mutations enhance the dependence of cancer cells on OXPHOS<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> and increase the sensitivity of OXPHOS inhibition.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> RhoA is an intracellular signal transducer of the Rho family small GTPases and plays a role in diverse cellular functions.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> Although how mutated RHOA contributes to the metabolic adaption in cancer cells is still illusive, research has shown that the Y42C/Y42S mutation upregulates transcription of OXPHOS genes,<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> which might lead to increased OXPHOS dependency. Thus, our mutation survey of OXPHOS genes reveals highly recurrent IDH1, IDH2, and ROHA mutations in select disease types related to enhanced dependence on OXPHOS, providing insight into sensitive patient populations and clear biomarkers for OXPHOS inhibition sensitivity.</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">OXPHOS as an Emerging Target in Cancer Therapy</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50758" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50758" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The Warburg effect suggests that cancer cells display high glucose consumption and high lactate production regardless of the oxygen level. This observation of upregulated glycolysis led to the assumption that OXPHOS is downregulated in cancer. However, accumulating evidence is emerging that select cancers are heavily dependent on OXPHOS, suggesting that inhibition of OXPHOS warrant clinical development.</div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> OXPHOS is Dysregulated in Cancer</h3><div class="NLM_p last">OXPHOS is globally upregulated in classical Hodgkinâs lymphoma, with an increase in expression of OXPHOS genes, mitochondrial mass, ETC protein expression, and oxygen consumption rate (OCR).<a onclick="showRef(event, 'ref87 ref88'); return false;" href="javascript:void(0);" class="ref ref87 ref88">(87,88)</a> In addition, ER+ breast cancer cells are more dependent on OXPHOS.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> OXPHOS upregulation is also highlighted in specific cancer subtypes. For example, diffuse large B-cell lymphomas (DLBCL) can be divided into OXPHOS-high and OXPHOS-low subsets.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> Moreover, OXPHOS is upregulated in breast cancer micrometastases, and pharmacological inhibition of OXPHOS attenuates metastasis,<a onclick="showRef(event, 'ref91 ref92'); return false;" href="javascript:void(0);" class="ref ref91 ref92">(91,92)</a> suggesting OXPHOS inhibitors might be applied in preventing metastatic spread in breast cancer patients. Acute myeloid leukemia (AML) cells with low basal phosphorylation of Akt or low basal glycolysis have increased OXPHOS and greater sensitivity to the complex I inhibitor metformin.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> Complex I inhibition exerts <i>in vitro</i> and <i>in vivo</i> selective activity against a distinct and large subset of poor-outcome AML specimens, which exhibit OXPHOS hyperactivity.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> In pancreatic ductal adenocarcinoma (PDAC), a subpopulation of dormant tumor cells surviving KRAS ablation relies on OXPHOS for survival and can be specifically targeted by OXPHOS inhibitors.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Cancer Stem Cells Rely on OXPHOS</h3><div class="NLM_p last">As key drivers of tumor progression, CSCs present a distinct metabolic phenotype.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> In lung cancer,<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> glioblastoma,<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> and PDAC,<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> CSCs are more dependent on OXPHOS than a bulk tumor. Chemotherapy-resistant CSCs in triple-negative breast cancer increase OXPHOS upon MYC and MCL1 coamplification.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> Enhanced OXPHOS dependency in AML stem cells requires BCL-2 expression. Inhibition of BCL-2 reduces OXPHOS and selectively eradicates quiescent chemotherapy-resistant AML stem cells.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> Characterized with nutrient-deprived environments, CSCs show metabolic plasticity<a onclick="showRef(event, 'ref97 ref100'); return false;" href="javascript:void(0);" class="ref ref97 ref100">(97,100)</a> and are more sensitive toward OXPHOS inhibitors. Pharmacological inhibition of OXPHOS induces apoptosis in PDAC<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> and breast<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> mammospheres, decreases lung spheroids,<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> and colon cancer 3D microtissues.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> Thus, OXPHOS inhibitors show great promise in targeting CSCs, further supporting the application of OXPHOS inhibitors in cancer treatment.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Mutation-Driven OXPHOS Upregulation</h3><div class="NLM_p last">OXPHOS is highly upregulated in breast cancers with RB1 deficiency, which comprises 20%â30% of basal-like breast cancers.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> The mitochondrial translation inhibitor, tigecycline, strongly attenuates the growth of RB1-deficient MDA-MB-436 breast xenografts.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> SMARCA4 is one of the most frequently inactivated subunits of the SWI/SNF complex at a frequency of 8% in lung adenocarcinoma.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> SMARCA4 mutation leads to enhanced OXPHOS and increased sensitivity toward OXPHOS inhibition.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> In advanced prostate cancer, the codeletion of PTEN and TP53 is associated with highly advanced and metastatic disease.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Inhibiting complex I can achieve selective killing of PTEN-null cells and target lethal prostate cancer.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> In addition, lack of enolase 1 (ENO1) or phosphoglycerate dehydrogenase (PGD), which leads to glycolysis deficiency, can also enhance the cell dependency on OXPHOS and sensitize the cell toward OXPHOS inhibition.<a onclick="showRef(event, 'ref14 ref45'); return false;" href="javascript:void(0);" class="ref ref14 ref45">(14,45)</a> Gene mutations leading to increased OXPHOS dependency may also provide therapeutic opportunities for OXPHOS inhibitors.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Targeted Therapies Cause Upregulation of OXPHOS</h3><div class="NLM_p">More than 50 FDA approved drugs target various kinases.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> Treatment with tyrosine kinase inhibitors (TKIs) upregulates OXPHOS and may contribute to drug resistance. For example, in a gastrointestinal stromal tumor (GIST), imatinib therapy causes a metabolic shift signifying decreased glucose uptake and upregulation of mitochondrial function.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> Combining imatinib with OXPHOS inhibitors exerts significant antitumor activity, suggesting that targeting OXPHOS is a promising approach to overcome imatinib resistance.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> In mantle cell lymphoma (MCL), a B-cell lymphoma subtype with poor clinical outcome, Brutonâs tyrosine kinase (BTK) inhibitor ibrutinib treatment leads to resistance, characterized by metabolic reprogramming toward OXPHOS and glutaminolysis.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> OXPHOS inhibitors significantly blocked ibrutinib-resistant patient-derived cancer models.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Therefore, OXPHOS inhibitors might be useful to overcome drug resistance in patients treated with TKIs.</div><div class="NLM_p last">Some other targeted therapies also increase dependency on OXPHOS. Treatment of BRAF-mutated melanomas with BRAF inhibitors renders them addicted to OXPHOS, and BRAF inhibition can be combined with phenformin to reduce melanoma progression.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> The BCL-2 antagonist venetoclax is highly effective in specific types of multiple myeloma (MM) patients.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> Myeloma sensitive to venetoclax showed reduced mitochondrial respiration, and pharmacological inhibition of OXPHOS through complex I or II sensitizes resistant MM to venetoclax.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> Thus, OXPHOS is a potential target to resensitize tumors to a BRAF inhibitor or venetoclax and a potential predictor of patient responses.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Function of OXPHOS Inhibitors in Solid Tumors</h3><div class="NLM_p last">Tumor cells in the deep parenchyma or poorly vascularized tumor regions signify limited access to nutrients and oxygen levels, which might expose the vulnerability to OXPHOS inhibition due to the lack of metabolic plasticity. Accordingly, OXPHOS inhibitors are more effective in tumor cells at the core region of multicellular tumor spheroids with low oxygen and nutrient gradients.<a onclick="showRef(event, 'ref110 ref111'); return false;" href="javascript:void(0);" class="ref ref110 ref111">(110,111)</a> In addition, hypoxia is a nonphysiological level of oxygen (oxygen tension) observed in the majority of solid tumors. Closely related to tumor progression and metastasis, tumor hypoxia is associated with poor clinical outcomes in many cancers.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> The hypoxia-inducible factor-1 (HIF-1) drives hypoxic gene expression changes that cause the induction of glycolytic enzymes and inhibition of OXPHOS. Mitochondrial deficiency, on the other hand, impairs HIF-1 transcriptional activity induced by hypoxia and retards tumor growth.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> Accordingly, OXPHOS inhibitors significantly decrease HIF-1Î± level and reduce hypoxia despite their different mechanisms.<a onclick="showRef(event, 'ref114 ref115'); return false;" href="javascript:void(0);" class="ref ref114 ref115">(114,115)</a> Thus, by inhibiting cell growth in tumor regions with limited nutrient and alleviating hypoxia, OXPHOS inhibitors can be effective in improving the prognosis and increase the therapeutic window in patients with solid tumors.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Impact of OXPHOS Inhibitors on Tumor Microenvironments</h3><div class="NLM_p last">Tumor progression is profoundly influenced by the interaction of cancer cells with their surrounding environment, especially the infiltrating immune cells. Metabolic pathways provide intermediary metabolites that affect the functions of epigenetic enzymes, which play important roles in modulating T-cell differentiation.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> Although the direct impact of OXPHOS inhibitors on the tumor microenvironment is not well-studied or established, OXPHOS inhibition is implicated in autoimmune diseases.<a onclick="showRef(event, 'ref117 ref118'); return false;" href="javascript:void(0);" class="ref ref117 ref118">(117,118)</a> Immune cells in cancer are metabolically heterogeneous with differential metabolic requirements, which offers an opportunity to modulate immune cell functions by selectively targeting their metabolic dependency.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> The differentiation and functions of effector CD8+ T cells, Th1, Th2, and Th17 CD4+ T cells rely on aerobic glycolysis,<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> and antitumor M1 macrophages<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> also rely on glycolysis. Inhibition of OXPHOS can lead to the upregulation of glycolysis and lactate secretion, which facilitates the activation of cytotoxic T cells and M1 macrophages and result in improved antitumor engagement of immune cells. On the other hand, immunosuppressive M2 macrophages and other pro-tumor cells, including regulatory T cells and myeloid-derived suppressor cells,<a onclick="showRef(event, 'ref120 ref121 ref122'); return false;" href="javascript:void(0);" class="ref ref120 ref121 ref122">(120â122)</a> depend on various mitochondrial functions including OXPHOS. Thus, in addition to the direct killing of tumor cells, inhibition of OXPHOS might also indirectly boost antitumor effects through the modulation of tumor microenvironments. Considering the complexity of immune cell infiltration and activation, the impact of OXPHOS inhibitors on tumor microenvironments is still not conclusive, and more research will be needed to define its specific function.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Other Clinical Applications of OXPHOS Inhibition</h3><div class="NLM_p">OXPHOS inhibitors also exhibit clinical utility in diseases besides cancer. Immune and inflammatory diseases are caused by inappropriate and prolonged activation of immune cells. Alloreactive T cells, which are essential in graft-versus-host disease (GVHD), increase OXPHOS upon activation, and OXPHOS inhibitors have demonstrated promise as a metabolic therapy for GVHD by reducing anaplerosis in alloreactive T cells.<a onclick="showRef(event, 'ref117 ref123'); return false;" href="javascript:void(0);" class="ref ref117 ref123">(117,123)</a> In addition, OXPHOS inhibitors are also implicated in chronic plaque-type psoriasis and chronic and inflammatory bowel disease (Phase II clinical trail, NCT027625). Thus, targeting metabolic pathways through inhibition of OXPHOS could lead to selective regulation of the immune system to fight various diseases.</div><div class="NLM_p">Agents that blunt mitochondrial respiration can offer prophylaxis against cell death after ischemia and reperfusion in the heart or brain.<a onclick="showRef(event, 'ref124 ref125'); return false;" href="javascript:void(0);" class="ref ref124 ref125">(124,125)</a> This effect is thought to occur through suppressing oxidative injury and may be related to the protection conferred by ischemic preconditioning. Notably, redirecting energy metabolism toward glycolysis can reduce oxidative damage and suppresses apoptosis.<a onclick="showRef(event, 'ref126 ref127'); return false;" href="javascript:void(0);" class="ref ref126 ref127">(126,127)</a> Several OXPHOS inhibitors including amobarbital,<a onclick="showRef(event, 'ref128 ref129'); return false;" href="javascript:void(0);" class="ref ref128 ref129">(128,129)</a> ranolazine,<a onclick="showRef(event, 'ref130 ref131'); return false;" href="javascript:void(0);" class="ref ref130 ref131">(130,131)</a> atpenin A5<a onclick="showRef(event, 'ref132 ref133'); return false;" href="javascript:void(0);" class="ref ref132 ref133">(132,133)</a> have shown a cardioprotective effect. However, none of these OXPHOS inhibitors have advanced to clinical trials.</div><div class="NLM_p">OXPHOS inhibitors metformin and phenformin are used in the treatment of diabetes. The inhibition of OXPHOS induces the activation of AMPK, an intracellular metabolic sensor to maintain ATP levels.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> AMPK activation and inhibition of complex I contributes to the mechanism of action for metformin in diabetes.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> In light of this, complex I inhibitors RTC1 and RTB70 show antidiabetic effects by efficiently restoring glucose-handling abilities in models of high-fat-fed mice.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> Although more mechanistic studies and animal models are needed to further elucidate the function of complex I inhibitors in diabetes, this study provides the rationale for a new therapeutic area for OXPHOS inhibitors.</div><div class="NLM_p last">Inhibition of OXPHOS is always accompanied by compensatory elevated glycolysis, resulting in enhanced glucose consumption and lactate production. Hair follicle stem cells (HFSCs), which are essential in maintaining hair growth cycles, are heavily dependent on glycolysis, and its activation is driven by LDHA activity.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> Accordingly, a complex I inhibitor, IM176OUT05 derived from metformin, significantly activates stem cell metabolism and promotes hair regrowth.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> However, relatively short-term treatment was applied in a mouse model, and the side effects caused by long-term treatment of OXPHOS inhibitors should be carefully considered.</div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Assays to Monitor OXPHOS Modulation</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16257" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16257" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Screening Compounds in Medium Enriched with Galactose versus Glucose</h3><div class="NLM_p">Differential activity of compounds in glucose versus galactose medium is based on the evidence that mammalian cells shift their energy dependency in response to the available sugar source.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> Culturing cells in galactose, forcing mammalian cells to rely on OXPHOS, were previously used to diagnose human mitochondrial disorders<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> and drug toxicity.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> Cells grown in high glucose-containing medium use glycolysis for ATP generation while cells grown in galactose-containing medium rely almost exclusively on mitochondria for their ATP production and, hence, are very sensitive to mitochondrial inhibition (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A). This method is further verified by the fact that OXPHOS inhibitors show selective cell killing in galactose medium.<a onclick="showRef(event, 'ref8 ref22 ref138'); return false;" href="javascript:void(0);" class="ref ref8 ref22 ref138">(8,22,138)</a> Screening for compounds that selectively inhibit cell growth and proliferation in galactose, relative to glucose-containing media, will lead to the discovery of compounds specifically inhibiting mitochondrial function. This high-throughput method can be utilized in the initial screening and OXPHOS inhibition validation. It should be noted that the selective activity in galactose/glucose medium screening indicates that the compound impairs mitochondrial function. The specific mechanism should be further elucidated together with respiratory complex activity and other readouts.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/medium/jm0c01013_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Assays to monitor OXPHOS modulation. (A) Screening compounds in medium enriched with galactose versus glucose. Cells grown in a high glucose-containing medium use glycolysis for ATP generation while cells grown in a galactose-containing medium rely almost exclusively on mitochondria for their ATP production. (B) Determination of the oxygen consumption rate, mitochondrial potential, and NADH/NAD+ ratio is also indicative of the OXPHOS function. (C) Each OXPHOS complex has a unique enzymatic activity, which facilitates the determination of the compound function.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01013&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Determination of Oxygen Consumption Rate (OCR)</h3><div class="NLM_p last">Oxygen consumption is a relatively informative read-out for mitochondrial respiratory activity (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B). Measurement of OCR is routinely used to determine underlying mitochondrial dysfunction.<a onclick="showRef(event, 'ref141 ref142'); return false;" href="javascript:void(0);" class="ref ref141 ref142">(141,142)</a> With appropriate pharmacological manipulation, different respiratory states can be isolated and diverse functions can be evaluated.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> Seahorse is a widely used instrument to evaluate oxygen consumption, and OCR measurements have been used to study the effect of OXPHOS inhibitors. OCR can be measured in isolated mitochondria or permeabilized cells to interpret specific complex activity and identify inhibition of individual complexes.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Mitochondrial Membrane Potential</h3><div class="NLM_p">The mitochondrial membrane potential (ÎÎ¨m) is an important component in the process of energy storage and conversion (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B). Increased H<sup>+</sup> flow through complex V to produce ATP and complete electron transfer. The levels of ÎÎ¨m and ATP in the cell are relatively stable, and ÎÎ¨m plays a key role in mitochondrial homeostasis. Fluctuations of ÎÎ¨m and ATP level may be deleterious and cause cell death and various pathologies.</div><div class="NLM_p last">Fluorescent probes, such as tetramethylrhodamine methyl (TMRM) and ethyl (TMRE) ester, rhodamine 123 (Rhod123), 3,3â²-dihexyloxacarbocyanine iodide (DiOC6), and 5,5â²,6,6â²-tetrachloro-1,1â²,3,3â²-tetraethylbenzimidazolylcarbocyanine iodide (JC-1) are frequently used to assess ÎÎ¨m.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> A combination of both the ÎÎ¨m and the mitochondrial pH gradient drive protons to transfer into mitochondria and ÎÎ¨m is also influenced by the function of OXPHOS. In addition, ÎÎ¨m is influenced by cytoplasmic ATP that is generated by glycolysis. Thus, ÎÎ¨m is considered a semiquantitative parameter for the full proton motive force,<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> and ÎÎ¨m results should therefore be interpreted together with other measurements.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Determination of the Cellular NADH/NAD+ Ratio</h3><div class="NLM_p last">As the principal electron donor in the respiratory chain, NADH is oxidized to NAD<sup>+</sup> at complex I to initiate mitochondrial OXPHOS (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B). Mitochondrial NADH is maintained by the reduction of NAD<sup>+</sup> to NADH in the TCA cycle and via the import of NAD<sup>+</sup> driven by the malate/aspartate shuttle. Since both the TCA cycle and the ETC require NAD<sup>+</sup> and NADH, an optimal NADH/NAD<sup>+</sup> ratio should be maintained for efficient mitochondrial metabolism.<a onclick="showRef(event, 'ref52 ref146'); return false;" href="javascript:void(0);" class="ref ref52 ref146">(52,146)</a> Measurement of the mitochondrial NADH/NAD<sup>+</sup> ratio can be most informative when linked to the complex I activity assay. An increase in the mitochondrial NADH/NAD<sup>+</sup> ratio indicates several physiological changes including suppressed respiratory chain activity, decreased NAD<sup>+</sup> production, or enhanced NAD<sup>+</sup> consumption. Detection of the NADH/NAD<sup>+</sup> ratio has the disadvantage of requiring fresh samples and, as a result, is not a practical method for high-throughput screening.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Enzymatic Activities of Individual ETC Complexes</h3><div class="NLM_p">Although the determination of OCR is informative and can isolate different respiratory states with the help of pharmacological stimulants, it is still of interest to assess ETC enzymatic activities in isolated mitochondria. Each complex has its specific enzymatic functions (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>C), which facilitate the determination of activity upon drug treatment. For example, complex I catalyzes the electron transfer from NADH to ubiquinone, and its activity can be monitored by the oxidation of NADH as a decrease in absorbance or optical density (OD) at 340 nm. The activity of complex II can be assessed by the detection of ubiquinol production since it catalyzes the electron transfer from succinate to the electron carrier, ubiquinone.</div><div class="NLM_p last">A potential limitation of these assays is that it might not be suitable to run the experiments under physiological pH, osmolarity, and desired substrate concentrations. However, it can provide quantitative information and is easy to reproduce and can be performed using frozen tissue samples.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a></div></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">Animal Models and Biomarkers</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71504" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71504" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In this section, we provide a summary of xenograft models with information about the types of tumors tested and OXPHOS inhibitors used for validation (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). One limitation of current animal models is that most OXPHOS inhibitors were tested in immunodeficient mice. Since the tumor microenvironment plays an important role in the long-term success of cancer treatment, it will be important to investigate the function of OXPHOS inhibition on the immune system. The antitumor activity of OXPHOS inhibitors should be tested in immunocompetent mice bearing murine tumors or in mice bearing a âhumanizedâ immune system together with patient-derived xenograft models.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Animal Models Used for OXPHOS Inhibitor Development</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">mechanism</th><th class="colsep0 rowsep0" align="center">animal model</th><th class="colsep0 rowsep0" align="center">disease type</th><th class="colsep0 rowsep0" align="center">OXPHOS inhibitors used for validation</th><th class="colsep0 rowsep0" align="center">refs</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">glycolysis deficiency</td><td class="colsep0 rowsep0" align="left">NB-1 xenograft</td><td class="colsep0 rowsep0" align="left">neuroblastoma</td><td class="colsep0 rowsep0" align="left">IACS-010759</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">glycolysis deficiency</td><td class="colsep0 rowsep0" align="left">Gli56 orthotopic xenograft</td><td class="colsep0 rowsep0" align="left">glioblastoma</td><td class="colsep0 rowsep0" align="left">IACS-010759</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">glycolysis deficiency</td><td class="colsep0 rowsep0" align="left">D423 orthotopic xenograft</td><td class="colsep0 rowsep0" align="left">glioblastoma</td><td class="colsep0 rowsep0" align="left">IACS-010759</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AML</td><td class="colsep0 rowsep0" align="left">OCI-AML3 cell line xenograft</td><td class="colsep0 rowsep0" align="left">AML</td><td class="colsep0 rowsep0" align="left">IACS-010759</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AML refractory to standard-of- care treatment</td><td class="colsep0 rowsep0" align="left">PDX-4030094</td><td class="colsep0 rowsep0" align="left">AML</td><td class="colsep0 rowsep0" align="left">IACS-010759</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">complex cytogenetics and unfavorable prognosis AML</td><td class="colsep0 rowsep0" align="left">PDX-S6-AP</td><td class="colsep0 rowsep0" align="left">AML</td><td class="colsep0 rowsep0" align="left">IACS-010759</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SMARCA4-deficient cells</td><td class="colsep0 rowsep0" align="left">KPS xenograft</td><td class="colsep0 rowsep0" align="left">lung cancer</td><td class="colsep0 rowsep0" align="left">IACS-010759</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">deficient in ARID1A</td><td class="colsep0 rowsep0" align="left">lung cancer patient-derived xenograft</td><td class="colsep0 rowsep0" align="left">lung cancer</td><td class="colsep0 rowsep0" align="left">IACS-010759</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">KRAS-ablation</td><td class="colsep0 rowsep0" align="left">KRAS-inducible KPC model</td><td class="colsep0 rowsep0" align="left">pancreatic cancer</td><td class="colsep0 rowsep0" align="left">oligomycin</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PTEN-null</td><td class="colsep0 rowsep0" align="left">endogenous lethal metastatic PC</td><td class="colsep0 rowsep0" align="left">prostate cancer</td><td class="colsep0 rowsep0" align="left">deguelin</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">high dependency on OXPHOS</td><td class="colsep0 rowsep0" align="left">adverse cytogenetic risk HOX-high AML xenograft</td><td class="colsep0 rowsep0" align="left">AML</td><td class="colsep0 rowsep0" align="left">mubritinib</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">high dependency on OXPHOS</td><td class="colsep0 rowsep0" align="left">NPM1-, FLT3-ITD-, and DNMT3A-mutated AML xenograft</td><td class="colsep0 rowsep0" align="left">AML</td><td class="colsep0 rowsep0" align="left">mubritinib</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">impaired glucose utilization</td><td class="colsep0 rowsep0" align="left">NCI-H929</td><td class="colsep0 rowsep0" align="left">lymphoma</td><td class="colsep0 rowsep0" align="left">phenformin</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">impaired glucose utilization</td><td class="colsep0 rowsep0" align="left">KMS-26</td><td class="colsep0 rowsep0" align="left">myeloma</td><td class="colsep0 rowsep0" align="left">phenformin</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mitochondrial complex I mutation</td><td class="colsep0 rowsep0" align="left">U-937</td><td class="colsep0 rowsep0" align="left">lymphoma</td><td class="colsep0 rowsep0" align="left">phenformin</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mitochondrial complex I mutation</td><td class="colsep0 rowsep0" align="left">Cal-62</td><td class="colsep0 rowsep0" align="left">thyroid cancer</td><td class="colsep0 rowsep0" align="left">phenformin</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ibrutinib-resistant MCL</td><td class="colsep0 rowsep0" align="left">ibrutinib-resistant MCL PDX mouse model</td><td class="colsep0 rowsep0" align="left">mantle cell lymphoma</td><td class="colsep0 rowsep0" align="left">IACS-010759</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">primary GBM</td><td class="colsep0 rowsep0" align="left">primary high-throughput GBM sphere (HTS) cells</td><td class="colsep0 rowsep0" align="left">GBM</td><td class="colsep0 rowsep0" align="left">gboxin</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AML</td><td class="colsep0 rowsep0" align="left">MOLM14</td><td class="colsep0 rowsep0" align="left">AML</td><td class="colsep0 rowsep0" align="left">metformin</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a></td></tr></tbody></table></div></div><div class="NLM_p">SMARC4-mutation, ENO1-deficiency, and PGD-null lead to dependency on OXPHOS, deficiency in glycolysis, and have been used as biomarkers in clinical trials for OXPHOS inhibitors. SMARC4 codes for the protein SWI/SNF-related, matrix-associated, and actin-dependent regulator of chromatin, subfamily A, member 4, one of the most frequently mutated complexes in components of the SWI/SNF chromatin. SMARC4 acts as a tumor suppressor in lung cancer, and its deficiency is associated with enhanced OXPHOS dependency.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Enolase 1 (ENO1) catalyzes the dehydration of 2-phospho-<span class="smallcaps smallerCapital">d</span>-glycerate to phosphoenolpyruvate in the glycolysis pathway. The loss of ENO1 leads to glycolysis deficiency and the induction of a targetable dependency on OXPHOS. Phosphogluconate dehydrogenase (PGD) is a metalloenzyme in the pentose phosphate pathway (PPP), catalyzing 6-phosphogluconate (6PG) to ribulose-5-phosphate (Ru5P).<a onclick="showRef(event, 'ref22 ref149'); return false;" href="javascript:void(0);" class="ref ref22 ref149">(22,149)</a> Deletion of PGD in cancer cells aborted glycolysis, inhibited reductive carboxylation of glutamine, disrupted redox homeostasis, and exposed vulnerability for OXPHOS inhibition.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> Overall, although the SMARC4-mutation, ENO1-deficiency, and PGD-null might profoundly increase the efficacy of OXPHOS inhibitors, the incidence of these mutations is relatively low, which limits their clinical use.</div><div class="NLM_p">PTEN-null in prostate cancer increases the dependency on OXPHOS and can also be used as a biomarker.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> Phosphatase and tensin homologues deleted on chromosome 10 (PTEN) act as both a tumor suppressor and a metabolic regulator. The loss of PTEN promotes tumorigenesis and mechanistically induces PI3K/AKT signal modulating glucose metabolism and OXPHOS.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> In localized prostate cancer, the incidence of homozygous deletion of PTEN has been found to occur at around 40% in localized prostate cancers,<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> while, in advanced and metastatic prostate cancer, the incidence rises to 60%.<a onclick="showRef(event, 'ref152 ref153'); return false;" href="javascript:void(0);" class="ref ref152 ref153">(152,153)</a> In addition, the frequency of RB-1 deficiency is around 20â30% in basal-like breast cancer.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> Despite the higher incidence of PTEN mutation, more proof of concept studies will be needed to validate their clinical utility. Potential biomarkers for OXPHOS inhibitors and their incidence in select disease types are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Potential Biomarkers for OXPHOS Inhibitor Development</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">biomarkers</th><th class="colsep0 rowsep0" align="center">mechanism</th><th class="colsep0 rowsep0" align="center">disease type</th><th class="colsep0 rowsep0" align="center">incidence</th><th class="colsep0 rowsep0" align="center">refs</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ENO1-deficient</td><td class="colsep0 rowsep0" align="left">glycolysis deficiency</td><td class="colsep0 rowsep0" align="left">glioblastoma</td><td class="colsep0 rowsep0" align="left">1.4% (TCGA database) or 3.3% (MD Anderson database)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SMARCA4-deficient</td><td class="colsep0 rowsep0" align="left">increased OXPHOS dependency</td><td class="colsep0 rowsep0" align="left">lung adenocarcinoma</td><td class="colsep0 rowsep0" align="left">8%</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PGD-null</td><td class="colsep0 rowsep0" align="left">glycolysis deficiency</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a>, <a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PTEN-null</td><td class="colsep0 rowsep0" align="left">increased OXPHOS dependency</td><td class="colsep0 rowsep0" align="left">prostate cancer</td><td class="colsep0 rowsep0" align="left">â¼40% of localized prostate cancers and 60% in advanced/metastatic prostate cancer</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a>, <a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a>, <a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a>, <a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a></td></tr></tbody></table></div></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">OXPHOS Inhibitors in Clinical Trials and under Development</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58712" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58712" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Given the implication of OXPHOS in cancer and other diseases, an interest in the development of OXPHOS inhibitors is emerging. OXPHOS inhibitors that reached clinical trials or that are under development for cancer treatment are listed in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>. We will discuss the discovery, mechanism of action, and development of representative inhibitors. Other OXPHOS inhibitors that are used for diseases other than cancer are also briefly discussed.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Representative OXPHOS Inhibitors Developed for Cancer Treatment</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">name</th><th class="colsep0 rowsep0" align="center">development stage</th><th class="colsep0 rowsep0" align="center">target OXPHOS complex</th><th class="colsep0 rowsep0" align="center">other potential targets/MOA</th><th class="colsep0 rowsep0" align="center">refs</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">metformin</td><td class="colsep0 rowsep0" align="left">Phase I/II and experimental</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a>, <a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a>, <a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a>, <a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a>, <a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a>, <a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a>, <a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a>, <a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phenformin</td><td class="colsep0 rowsep0" align="left">Phase I and experimental</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a>, <a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IM156 (HL156A)</td><td class="colsep0 rowsep0" align="left">Phase I</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a>, <a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BAY 87-2243</td><td class="colsep0 rowsep0" align="left">Phase I (terminated)</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">HIF-1Î±</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a>, <a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a>, <a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IACS-010759</td><td class="colsep0 rowsep0" align="left">Phase I</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a>, <a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a>, <a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a>, <a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a>, <a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a>, <a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">VLX600</td><td class="colsep0 rowsep0" align="left">Phase I (terminated)</td><td class="colsep0 rowsep0" align="left">I, II, and IV</td><td class="colsep0 rowsep0" align="left">iron chelation</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a>, <a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a>, <a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a>, <a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">lonidamine</td><td class="colsep0 rowsep0" align="left">Phase II</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">MCT, hexokinase</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a>, <a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a>, <a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">atovaquone</td><td class="colsep0 rowsep0" align="left">Phase I</td><td class="colsep0 rowsep0" align="left">III</td><td class="colsep0 rowsep0" align="left">STAT3</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a>, <a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a>, <a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a>, <a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a>, <a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AG311</td><td class="colsep0 rowsep0" align="left">experimental</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">RTK, thymidylate synthase</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a>, <a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a>, <a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Mito-Met<sub>10</sub> (norMitoMet)</td><td class="colsep0 rowsep0" align="left">experimental</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a>, <a onclick="showRef(event, 'ref182'); return false;" href="javascript:void(0);" class="ref ref182">(182)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mubritinib</td><td class="colsep0 rowsep0" align="left">experimental</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">HER-2</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">carboxyamidotriazole</td><td class="colsep0 rowsep0" align="left">experimental</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">nonvoltage-gated calcium channels</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a>, <a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a>, <a onclick="showRef(event, 'ref185'); return false;" href="javascript:void(0);" class="ref ref185">(185)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ME344</td><td class="colsep0 rowsep0" align="left">experimental</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">HO-1</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a>, <a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a>, <a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">fenofibrate</td><td class="colsep0 rowsep0" align="left">experimental</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">PPARÎ±</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref188'); return false;" href="javascript:void(0);" class="ref ref188">(188)</a>, <a onclick="showRef(event, 'ref189'); return false;" href="javascript:void(0);" class="ref ref189">(189)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">deguelin</td><td class="colsep0 rowsep0" align="left">experimental</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">Akt, Hsp90</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a>, <a onclick="showRef(event, 'ref190'); return false;" href="javascript:void(0);" class="ref ref190">(190)</a>, <a onclick="showRef(event, 'ref191'); return false;" href="javascript:void(0);" class="ref ref191">(191)</a>, <a onclick="showRef(event, 'ref192'); return false;" href="javascript:void(0);" class="ref ref192">(192)</a>, <a onclick="showRef(event, 'ref193'); return false;" href="javascript:void(0);" class="ref ref193">(193)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">papaverine</td><td class="colsep0 rowsep0" align="left">experimental</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">PDE10A</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a>, <a onclick="showRef(event, 'ref194'); return false;" href="javascript:void(0);" class="ref ref194">(194)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Î±-TOS</td><td class="colsep0 rowsep0" align="left">experimental</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref195'); return false;" href="javascript:void(0);" class="ref ref195">(195)</a>, <a onclick="showRef(event, 'ref196'); return false;" href="javascript:void(0);" class="ref ref196">(196)</a>, <a onclick="showRef(event, 'ref197'); return false;" href="javascript:void(0);" class="ref ref197">(197)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">neoantimycin F</td><td class="colsep0 rowsep0" align="left">experimental</td><td class="colsep0 rowsep0" align="left">III</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref198'); return false;" href="javascript:void(0);" class="ref ref198">(198)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ADDA 5</td><td class="colsep0 rowsep0" align="left">experimental</td><td class="colsep0 rowsep0" align="left">IV</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(199)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Gboxin</td><td class="colsep0 rowsep0" align="left">experimental</td><td class="colsep0 rowsep0" align="left">V</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">oligomycin A</td><td class="colsep0 rowsep0" align="left">experimental</td><td class="colsep0 rowsep0" align="left">V</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">apoptolidin</td><td class="colsep0 rowsep0" align="left">experimental</td><td class="colsep0 rowsep0" align="left">V</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref200'); return false;" href="javascript:void(0);" class="ref ref200">(200)</a>, <a onclick="showRef(event, 'ref201'); return false;" href="javascript:void(0);" class="ref ref201">(201)</a>, <a onclick="showRef(event, 'ref202'); return false;" href="javascript:void(0);" class="ref ref202">(202)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bedaquiline</td><td class="colsep0 rowsep0" align="left">experimental</td><td class="colsep0 rowsep0" align="left">V</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a></td></tr></tbody></table></div></div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i28">OXPHOS Inhibitors in Clinical Trials</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53152" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53152" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec8_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Biguanides</h3><div class="NLM_p">As one of the most well-known antidiabetic biguanides, metformin has been used as the first-line medication for the treatment of type 2 diabetes for decades, indicating its favorable safety profile. Although its exact mechanism of action has not been fully elucidated, numerous studies have indicated that the inhibition of complex I and subsequently activation of AMPK play a central role in its suppression of hepatic gluconeogenesis.<a onclick="showRef(event, 'ref154 ref203 ref204'); return false;" href="javascript:void(0);" class="ref ref154 ref203 ref204">(154,203,204)</a> In recent years, epidemiological studies have shown a decreased risk of cancer in metformin-treated patients,<a onclick="showRef(event, 'ref205 ref206'); return false;" href="javascript:void(0);" class="ref ref205 ref206">(205,206)</a> justifying its use as an anticancer drug. Its inhibition of OXPHOS by targeting complex I leads to modification of the AMPK/mTOR axis and reduces cancer cell growth.<a onclick="showRef(event, 'ref207'); return false;" href="javascript:void(0);" class="ref ref207">(207)</a> The inhibition of complex I also results in reduced ATP production and energy crisis, which leads to cell death.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> Metformin inhibits cell proliferation <i>in vitro</i> in several types of cancer cells including breast cancer, pancreatic cancer, and leukemia,<a onclick="showRef(event, 'ref155 ref208 ref209 ref93'); return false;" href="javascript:void(0);" class="ref ref155 ref208 ref209 ref93">(155,208,209,93)</a> although at high micromolar concentrations. The <i>in vivo</i> efficacy was also observed in several animal models.<a onclick="showRef(event, 'ref21 ref210'); return false;" href="javascript:void(0);" class="ref ref21 ref210">(21,210)</a> There are a large number of clinical trials evaluating metformin as a single agent and in combination with various drugs for cancer prevention and treatment.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> A more lipophilic analogue of metformin, phenformin, was also a marketed drug for diabetes (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). Despite its withdrawal in 1977 in the US due to the high risk of lactic acidosis,<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> plenty of ongoing research has indicated its effectiveness in cancer. A clinical trial evaluating its effect in combination with BRAF inhibitors dabrafenib and trametinib in melanoma is now in Phase I clinical trials (ClinicalTrials.gov identifier: NCT03026517).</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/medium/jm0c01013_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Structures of select biguanides as OXPHOS inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01013&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Metformin is almost completely in a protonated cationic form under physiological conditions due to its strong basicity (p<i>K</i><sub>a</sub> = 12.4).<a onclick="showRef(event, 'ref211'); return false;" href="javascript:void(0);" class="ref ref211">(211)</a> Along with the substantial hydrophilicity caused by its biguanide structure, it is not likely that metformin can be taken up by passive diffusion. In fact, the cellular uptake of metformin largely relies on membrane transporters like organic cation transporters (OCTs);<a onclick="showRef(event, 'ref212'); return false;" href="javascript:void(0);" class="ref ref212">(212)</a> thus, the expression level of OCTs in different tissues and different tumor types will greatly influence its absorption, distribution, and efficacy. The millimolar range concentration needed in <i>in vitro</i> experiments also raises the question of whether it can achieve such a high concentration in target tumor tissues, although lower concentrations <i>in vivo</i> might still be sufficient to achieve a similar effect.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> The benefit of metformin to cancer patients still needs rigorous evaluation.</div><div class="NLM_p">Ongoing studies aim to improve the mitochondria-targeting potential of metformin to enhance its efficacy. Several metformin analogues conjugating a mitochondrial directing triphenylphosphonium (TPP<sup>+</sup>) group via an aliphatic linker (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>) have been described.<a onclick="showRef(event, 'ref182'); return false;" href="javascript:void(0);" class="ref ref182">(182)</a> A longer linker was favored for cellular uptake, and the most potent analogue Mito-Met<sub>10</sub> was more than 1000-fold more effective than metformin in inhibiting complex I and PDAC proliferation <i>in vitro</i> (0.4 Î¼M vs 1.1 mM). Mito-Met<sub>10</sub> was also considerably more effective than metformin in mitigating PDAC growth <i>in vivo</i>, and it enhanced the radiation sensitivity of PDAC at 1000-fold lower concentrations (1 Î¼M vs 1 mM). NorMitoMet, which is identical to Mito-Met<sub>10</sub>, is 20 times more effective than its corresponding <i>N</i>-methyl counterpart (MitoMet) in inhibiting PANC-1 cells.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> However, caution should be taken since lipophilic cations could lead to toxicity as a result of causing mitochondrial membrane depolarization and ATP synthesis disruption.</div><div class="NLM_p last">To improve the permeability and bioavailability of metformin, a more lipophilic analogue HL156A was developed by HanAll BioPharma Co. Ltd. (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). Following oral administration (30 mg/kg) in mice, the bioavailability was â¼72.9% (vs 50â60% for metformin). Its brain-to-plasma (BP) ratio (0.37) was also significantly higher than that of metformin (0.10).<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> HL156A prevents oral cancer progression,<a onclick="showRef(event, 'ref213'); return false;" href="javascript:void(0);" class="ref ref213">(213)</a> and the combination of HL156A and temozolomide inhibited the glioblastoma tumor spheres and showed survival benefits in an orthotopic xenograft mouse model.<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> IM156 (formerly HL156A) entered Phase I clinical trial in 2017 for the treatment of advanced solid tumors (ClinicalTrials.gov identifier: NCT03272256).<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> Preliminary results indicated an overall good safety profile with mild adverse events, and the best response was stable disease in 5 out of 12 patients.<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> IM188 (structure not disclosed) is another biguanide that is used to target immune suppressor cells that adapt an OXPHOS-dependent metabolism in the tumor microenvironment to promote the effect of tumor immunotherapies.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> These therapeutically promising compounds illustrate the potential of OXPHOS inhibitors in altering the immunosuppressive tumor microenvironment and the potential for combination therapy with the current antitumor immunotherapies like anti-PD-1/PD-L1 antibodies.</div></div><div id="sec8_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> BAY 87-2243 and IACS-010759</h3><div class="NLM_p">A high-throughput screen of compounds inhibiting HIF-1Î± target gene expression was carried out by Bayer Pharma AG and led to the identification of a class of aminoalkyl-substituted compounds represented by BAY 87-2243 (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). It inhibited HIF-1Î± and HIF-2Î± protein accumulation under hypoxic conditions. The <i>in vivo</i> antitumor activity was verified in an H460 xenograft model and found to be associated with the suppression of HIF1Î± protein level and expression of its target genes.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> BAY 87-2243 was also demonstrated to effectively suppress tumor growth in several other subcutaneous tumor models including prostate carcinoma, lung carcinoma, neuroblastoma, colorectal, and mammary carcinomas.<a onclick="showRef(event, 'ref214'); return false;" href="javascript:void(0);" class="ref ref214">(214)</a> When dosed in combination with tyrosine kinase inhibitors regorafenib, sorafenib, and bevacizumab, BAY 87-2243 produced long-term tumor growth control or tumor stasis of colorectal, lung, and prostate carcinoma xenograft models. Combination treatment of BAY 87-2243 and a single subcurative irradiation dose (8 Gy) in a radioresistant, severely hypoxic head and neck squamous cell carcinoma xenograft (UT-SCC-5) led to tumor regression.<a onclick="showRef(event, 'ref215'); return false;" href="javascript:void(0);" class="ref ref215">(215)</a> BAY 87-2243 did not affect the proliferation of a panel of tumor cells in the glucose-containing medium, while it inhibited the growth of H460 cells at an EC<sub>50</sub> of â¼3 nM in galactose-containing medium, strongly indicating its inhibition of mitochondria function. Further experiments showed that the reduced HIF activity is evoked by its inhibition of complex I (IC<sub>50</sub> = 10 nM).<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> In line with other OXPHOS inhibitors, BAY 87-2243 reduced OCR and cellular ATP levels and activated AMPK, causing energy crisis and promoting cell death mediated by stimulation of ROS production in melanoma cells.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a></div><div class="NLM_p">Due to its outstanding profile in preclinical development, BAY 87-2243 was advanced into a Phase I clinical trial in 2011 in subjects with advanced malignancies (ClinicalTrials.gov identifier: NCT01297530). The study was later prematurely terminated due to recurrent vomiting, despite dose reduction and a change of formulation. Other drug-related adverse events included fatigue, nausea, and anorexia. Those adverse events were not expected since preclinical studies did not predict the related risks, indicating that caution should be taken when translating the preclinical safety data into clinical trials. It should be noted that only five patients were studied; thus, the results from this single trial might not be conclusive.</div><div class="NLM_p">IACS-010759, developed by The University of Texas MD Anderson Cancer Center, is a new generation OXPHOS inhibitor now in a Phase I clinical trial for cancer treatment (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). It shares a similar structural motif with BAY 87-2243 and is one of the most potent inhibitors for complex I (OCR IC<sub>50</sub> = 1.4 nM). Exome sequencing of resistant clones established its binding in or at the entrance to the ubiquinone channel in the ND1 subunit. Its binding to ND1 was further confirmed by a photoaffinity labeling experiment.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> IACS-010759 exhibited <i>in vitro</i> inhibition of the majority of 76 tested cancer cell lines with minimal or no inhibition of normal diploid cells, indicative of a favorable therapeutic window. It was especially effective in ENO1-null or PGD-null glycolysis-deficient tumor cells as well as OXPHOS-dependent AML cells. A PK study indicated that IACS-010759 displayed slow clearance with a high volume of distribution, resulting in a prolonged terminal half-life. It was well tolerated in an NB-1 xenograft model and exhibited tumor suppression after oral administration. Moreover, it extended survival in a mouse refractory AML model and led to the depletion of energy and nucleotide biosynthesis.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> In subsequent studies, IACS-010759 showed growth inhibition <i>in vitro</i> and <i>in vivo</i> in ibrutinib-resistant patient-derived cancer models<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> and enhanced sensitivity to PGD inhibition <i>in vitro</i> and <i>in vivo</i>,<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> demonstrating its further utility. It was advanced into the Phase I clinical trial in 2016 for AML (ClinicalTrials.gov identifier: NCT02882321) and 2017 for lymphoma or solid tumors (ClinicalTrials.gov identifier: NCT03291938), respectively.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Preliminary results indicated that the compound was generally well-tolerated, with grade 1â2 drug-related toxicities like nausea, vomiting, and fatigue in 67% of patients. Seven out of 18 patients had the best RECIST response of stable disease, and a patient with heavily pretreated castration-resistant prostate cancer (CRPC) achieved a RECIST partial response with a resolution of CRPC-related pain,<a onclick="showRef(event, 'ref216'); return false;" href="javascript:void(0);" class="ref ref216">(216)</a> favoring further development of this compound.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/medium/jm0c01013_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Structures of representative OXPHOS inhibitors. The model for binding of VLX600 to iron was reproduced from the original report.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01013&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec8_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Lonidamine and Mito-LND</h3><div class="NLM_p">Lonidamine (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>), discovered in the late 1970s, was originally used as an antispermatogenic agent. After the establishment of its anticancer activity, lonidamine received extensive clinical testing from Phase I to Phase III in the 1980s and 1990s, as a single agent or in combination with chemotherapies for the treatment of various cancers.<a onclick="showRef(event, 'ref217'); return false;" href="javascript:void(0);" class="ref ref217">(217)</a><a onclick="showRef(event, 'ref218 ref219'); return false;" href="javascript:void(0);" class="ref ref218 ref219">(218,219)</a> Lonidamine generally showed a good safety profile and was found to be effective in certain studies. Lonidamine has multiple mechanisms of action. It causes intracellular acidification by inhibiting a mitochondrial pyruvate carrier (MPC) at a <i>K</i><sub>i</sub> of 2.5 Î¼M with moderate inhibition of monocarboxylate transporter (MCT)-mediated lactic acid efflux.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> Interestingly, lonidamine was found to inhibit both aerobic glycolysis and OXPHOS through inhibition of mitochondrially bound hexokinase and complex II,<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> respectively.</div><div class="NLM_p last">Although the antitumor effect of lonidamine was partially mediated by OXPHOS inhibition, it was recently proposed that MPC inhibition is the most likely antitumor target for lonidamine.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> To improve its mitochondrial targeting, Mito-LND was developed by conjugating lonidamine to TPP<sup>+</sup> via an aliphatic linker (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>).<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> It was 188- and 300-fold more potent than lonidamine in inhibiting H2030BrM3 and A549 cells (0.74 Î¼M vs 139 Î¼M, 0.69 Î¼M vs 208 Î¼M, respectively) and mitigates lung cancer cell viability, growth, progression, and metastasis <i>in vivo</i>. It was more potent than lonidamine in inhibiting complex I and II and subsequently stimulates ROS release. It should be noted that the similar extents of inhibition of complex I and II in the experiment might indicate that the inhibition lies in the latter portions of the respiratory chain.<a onclick="showRef(event, 'ref220'); return false;" href="javascript:void(0);" class="ref ref220">(220)</a> Mito-LND could also represent one of the least toxic mitochondria-targeted cationic agents developed to date, with no observable toxicity in an 8 week toxicology study in mice at an effective dose. That being said, Mito-LND might not address the selectivity issue of lonidamine, since MPC and hexokinase are also abundantly found in mitochondria. As mentioned above, the potential toxicity caused by TPP<sup>+</sup> also requires further evaluation and precaution for its development.</div></div><div id="sec8_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> VLX600</h3><div class="NLM_p">A screening of 10â¯000 compounds for the inhibition of HCT116 colon carcinoma multicellular spheroids was carried out to identify compounds that eliminate dormant malignant cells responsible for tumor relapse.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> This effort led to the discovery of VLX600 that inhibits the proliferation of several types of colon carcinoma cell lines (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). The mechanistic study revealed its induction of cell death was related to autophagy and dysfunction of mitochondria. Further investigation revealed its partial inhibition of complex I, II, and IV. Although the exact molecular target was not further confirmed, a later study proposed that its cytotoxicity was mediated through iron chelation.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> This is reasonable because ironâsulfur clusters are present in multiple OXPHOS complexes, and switching the position of the nitrogen in the pyridine moiety abolished its chelating ability and inhibition of HCT116 cell proliferation. The <i>in vivo</i> study indicated that VLX600 was rapidly distributed and eliminated with a half-life of â¼4â5 h after 16 mg/kg intravenous administration. With minimal systemic toxicity, the compound achieved tumor suppression in both HCT116 and HT29 colon cancer xenografts. Synergy was observed when VLX600 was combined with drugs routinely used for clinical management of colon carcinoma patients, both <i>in vitro</i> and <i>in vivo</i>. When combined with imatinib, VLX600 increased apoptosis compared to imatinib alone and showed antitumor efficacy in a <i>Kit</i><sup><i>V558del</i>/+</sup> mouse model, despite the fact that VLX600 alone did not induce tumor cell death.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a></div><div class="NLM_p last">A Phase I trial of VLX600 was initiated by Vivolux AB in 2015 for the treatment of advanced solid tumors (ClinicalTrials.gov identifier: NCT02222363). Results demonstrated that it was reasonably well-tolerated, with the most frequent drug-related adverse events being fatigue, nausea, constipation, increased alkaline phosphatase, anemia, and decreased appetite. No objective responses were observed, although 32% of the patients had stable disease as the best response.<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a> The study was terminated due to slow recruitment and lack of efficacy.</div></div><div id="sec8_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Atovaquone</h3><div class="NLM_p last">Atovaquone is a marketed drug mainly used for the treatment of pneumocystis pneumonia (PCP) and malaria (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). Although not fully elucidated, its mechanism of action against <i>Pneumocystis carinii</i> is largely attributed to the targeting of complex III. As a naphthoquinone compound, atovaquone is a close analogue of ubiquinone and presumably acts as a ubiquinone antagonist. It was reported that atovaquone inhibits complex III from <i>R. capsulatus</i> strains at IC<sub>50</sub> of â¼10 nM by locking the ironâsulfur subunit in its Cytochrome <i>b</i>-binding conformation.<a onclick="showRef(event, 'ref174 ref175'); return false;" href="javascript:void(0);" class="ref ref174 ref175">(174,175)</a> Atovaquone inhibits OCR in MCF7 breast cancer cells and induces aerobic glycolysis and oxidative stress. It potently inhibits MCF7-derived cancer stem cells with an IC<sub>50</sub> of 1 Î¼M. Atovaquone also induces apoptosis in both CD44+/CD24low/â CSC and ALDH+ CSC populations and yet has no effect on oxygen consumption in normal human fibroblasts.<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a> Atovaquone decreases hypoxia in FaDu, HCT116, and H1299 spheroids and in FaDu and HCT116 mice xenografts, causing significant tumor growth delay when combined with radiation.<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a> Several studies reported the application of atovaquone in combination with other drugs for the treatment of cancers.<a onclick="showRef(event, 'ref221 ref222'); return false;" href="javascript:void(0);" class="ref ref221 ref222">(221,222)</a> These results shed light on the repurposing of atovaquone as an anticancer drug. It was advanced into early Phase I clinical trials in 2015 to assess its effect on reducing tumor hypoxia in adult patients referred for surgery with suspected nonsmall cell lung cancer (ClinicalTrials.gov identifier: NCT02628080). It should be noted that atovaquone was also identified as a STAT3 inhibitor, and this may also contribute to its antitumor activity.<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a> As oxidative and electrophilic species, naphthoquinones are also frequently involved in the modulation of multiple cellular targets and pathways including ROS, oxidative stress, and topoisomerases. Further mechanistic studies are needed to elucidate atovaquoneâs impact and role in modulating these important cancer-related pathways.</div></div></div><div id="sec9" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i34">OXPHOS Inhibitors under Development</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54681" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54681" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec9_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Gboxin</h3><div class="NLM_p">Gboxin was originally discovered as inhibitors of primary mouse GBM cell lines (IC<sub>50</sub> = â¼150 nM) and patient-derived glioblastoma cultures (IC<sub>50</sub> = â¼1 Î¼M), while not affecting the viability of primary mouse embryonic fibroblasts or astrocytes (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>).<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> A microarray analysis suggested that Gboxin disrupted GBM cell metabolism. Gboxin causes acute OCR depletion and increases phospho-AMPK, indicative of its inhibition of OXPHOS. This was validated by biotinylation pull-down experiments showing its interaction with complex V.</div><div class="NLM_p">Gboxin is metabolically stable with a murine S9 half-life of 217 min, while its plasma stability is low (<i>t</i><sub>1/2</sub> = 4 min), along with a low <i>in vivo</i><i>C</i><sub>max</sub> (2.7 ng/mL). SAR studies were carried out to identify analogues suitable for <i>in vivo</i> studies. By replacing the 2-ethyl with a 3-trifluorophenyl group on the benzimidazole core, a functional analogue S-Gboxin was developed with improved plasma stability (<i>t</i><sub>1/2</sub> = 306 min) and <i>in vivo</i> pharmacokinetic properties (<i>t</i><sub>1/2</sub> = 909 min, <i>C</i><sub>max</sub> = 375 ng/g). S-Gboxin suppressed tumor growth in a mouse GBM model and increased the rate of survival when administrated daily at 10 mg/kg intraperitoneally. Its <i>in vivo</i> efficacy was further validated in PDX models.</div><div class="NLM_p last">As a lipophilic cation, the positive charge of Gboxin is essential for its accumulation into mitochondria. The cationic feature might prevent its bloodâbrain barrier (BBB) penetration. Thus, additional modification and evaluation are required for further development.</div></div><div id="sec9_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> AG311</h3><div class="NLM_p">AG311 is an agent developed to effectively treat resistant breast cancer through the inhibition of complex I (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>).<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a> AG311 induced cell membrane permeabilization and rapid mitochondrial membrane changes in tumor cells, causing mitochondrial dysfunction and increased superoxide production. Moreover, it reduced primary tumor growth more significantly as compared with doxorubicin in an MDA-MB-435 orthotopic xenograft model. In a TNBC orthotopic allograft model, AG311 significantly reduced primary tumor growth, comparable with docetaxel with a lower systemic toxicity. A mechanistic study showed that AG311 inhibited complex I by competing with ubiquinone for its binding site.<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a> The IC<sub>50</sub> of AG311 on complex I (9.9 Î¼M) was comparable with that for cancer cell growth (13.9 Î¼M). Like other OXPHOS inhibitors, AG311 rapidly and significantly reduces OCR, increases p-AMPK levels <i>in vitro</i> and <i>in vivo</i>, and prevents HIF-1Î± stabilization under hypoxia. AG311 was also synergistic with dichloroacetate, a pyruvate dehydrogenase kinase inhibitor that induces mitochondrial activity, in an orthotopic MDA-MB-435 tumor model.</div><div class="NLM_p last">It is likely that complex I inhibition only partly contributes to the therapeutic efficacy of AG311. It was previously reported that AG311 also works as an inhibitor for receptor tyrosine kinases and thymidylate synthases.<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a> This is not surprising since the 7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine-2,4-diamine core is frequently found in inhibitors of kinases and associated enzymes. The inhibition of AG311 on complex I is also relatively weak compared to other inhibitors, and as a result, the associated downstream pathway effects and <i>in vivo</i> efficacy need careful interpretation. Further structural optimizations are needed to improve its potency and selectivity.</div></div><div id="sec9_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> Mubritinib</h3><div class="NLM_p last">Mubritinib was originally discovered as a selective HER2 inhibitor that exhibited <i>in vivo</i> efficacy against several cancers (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>).<a onclick="showRef(event, 'ref223'); return false;" href="javascript:void(0);" class="ref ref223">(223)</a> It was evaluated in a Phase I trial for HER2-expressing tumors and was not further developed. A recent study showed that the compound did not colocalize with HER2 in BT474 breast cancer cells, questioning its HER2 inhibitory activity.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> A further mechanistic study demonstrated that its antitumor effect is not mediated by HER2 inhibition, at least in the context of AML, but rather through impairing mitochondrial respiration and inducing oxidative stress. A screening of the enzymatic inhibition of each OXPHOS complex revealed that mubritinib inhibits complex I leading to an IC<sub>50</sub> of 51 nM while not affecting other complexes. Mubritinib did not affect ubiquinone-independent diaphorase activity of NADH dehydrogenase, suggesting it may bind at or near the ubiquinone-binding site. Its <i>in vivo</i> efficacy in AML patients warrants further investigation.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a></div></div><div id="sec9_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> Oligomycin A</h3><div class="NLM_p last">Oligomycin A is a naturally occurring OXPHOS inhibitor that specifically targets complex V by blocking its proton channel (Fo domain) (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) and is commonly used as a complex V inhibitor. It was previously demonstrated that a subpopulation of PDAC cells surviving KRAS ablation and responsible for tumor relapse has features of cancer stem cells and relies on OXPHOS for survival. Exposure to oligomycin A completely abrogated the ability of surviving cells to form tumor spheres upon KRAS re-expression, whereas KRAS-expressing cells were unaffected. Short exposure of surviving cells in patient-derived xenografts to oligomycin decreased their ability to form 3D spheroids. These data highlight mitochondrial respiration as an attractive, druggable target that may inhibit surviving cells in PDAC.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div></div><div id="sec9_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> Papaverine</h3><div class="NLM_p">Papaverine is an FDA-approved phosphodiesterase 10A (PDE10A) inhibitor used as a smooth muscle relaxant for the treatment of vasospasm and erectile dysfunction (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). While previous screens have demonstrated its inhibition of mitochondria functions,<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> a recent study confirmed its inhibition of complex I through binding to the rotenone-binding site, and this directly led to a reduction in tumor hypoxia and enhanced response to radiation therapy.<a onclick="showRef(event, 'ref194'); return false;" href="javascript:void(0);" class="ref ref194">(194)</a></div><div class="NLM_p last">A structural modification, aiming to reduce the <i>in vivo</i> toxicity by increasing its selectivity toward complex I, led to the discovery of SMV-32 (mitochondrial IC<sub>50</sub>, 7.2 versus 15.4 Î¼M; PDE10A IC<sub>20</sub>, 13.42 vs 0.65 Î¼M), which exhibited similar radiosensitization activity compared with papaverine with reduced <i>in vivo</i> toxicity. It is possible that the relatively weak inhibition of complex I by papaverine and its derivatives played an important role in keeping a good balance over toxicity to normal tissues, considering that they were developed as a radiosensitizer instead of directly killing cancer cells. Their application in sensitizing radiotherapy represents another feasible pathway for expanding the therapeutic window and applications of OXPHOS inhibitors.</div></div><div id="sec9_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> Other Notable Compounds</h3><div class="NLM_p">Rotenone, a natural product from the seeds and stems of several plants, has been used as a pesticide for decades. It inhibits complex I by hampering the transfer of electrons from the ironâsulfur cluster to ubiquinone (IC<sub>50</sub> = â¼0.1 Î¼M). It is one of the most commonly used tool compounds for complex I inhibition, and a number of studies have shown its effect on inducing cancer cell apoptosis through ROS production and autophagic flux regulation.<a onclick="showRef(event, 'ref224 ref225 ref226'); return false;" href="javascript:void(0);" class="ref ref224 ref225 ref226">(224â226)</a> Its cytotoxicity is also reported to be mediated by microtubule destabilization via GSK3Î² activation.<a onclick="showRef(event, 'ref227'); return false;" href="javascript:void(0);" class="ref ref227">(227)</a> Deguelin is a naturally occurring rotenone analogue that inhibits tumor cell proliferation with modest toxicity.<a onclick="showRef(event, 'ref190 ref191'); return false;" href="javascript:void(0);" class="ref ref190 ref191">(190,191)</a> A recent study showed that deguelin selectively kills PTEN-null prostate cancer cells through inhibition of mitochondrial complex I both <i>in vitro</i> and <i>in vivo</i>.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Antimycin A is a piscicide used in fisheries management since the 1960s and is a secondary metabolite of <i>Streptomyces</i> bacteria. It exerts its effect by binding to the Qi site of complex III<a onclick="showRef(event, 'ref228'); return false;" href="javascript:void(0);" class="ref ref228">(228)</a> and thus has been widely used as one of the tool compounds targeting this complex. Several reports also demonstrated its therapeutic potential in the blocking growth of HL-60, HeLa, A549 cancer cells, A549 cancer stem cells as well as gefitinib-resistant PC-9/GR cells.<a onclick="showRef(event, 'ref229 ref230 ref231 ref232'); return false;" href="javascript:void(0);" class="ref ref229 ref230 ref231 ref232">(229â232)</a> A couple of other macrocyclic antimycin analogues are also studied in terms of their anticancer activities, including neoantimycin F, one of antimycinâs 15-membered ring depsipeptide analogues, which was reported to induce apoptotic cell death in human NSCLCs.<a onclick="showRef(event, 'ref198'); return false;" href="javascript:void(0);" class="ref ref198">(198)</a> Apoptolidin is another macrolide with structural similarity to oligomycin that inhibits complex V (<i>K</i><sub>i</sub> = â¼4â5 Î¼M). It regulates apoptotic pathways and induced cancer cell death in select cancer types.<a onclick="showRef(event, 'ref200 ref201 ref202'); return false;" href="javascript:void(0);" class="ref ref200 ref201 ref202">(200â202)</a> Bedaquiline is a complex V inhibitor approved by the FDA for the treatment of tuberculosis. A recent study indicated that bedaquiline inhibits proliferative expansion of stem-like cancer cells, warranting its preclinical and clinical studies in cancer, considering that it is well-tolerated in patients treated for tuberculosis infections.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> Î±-Tocopheryl succinate (Î±-TOS) is a vitamin E analogue that targets Qp or Qd sites in complex II.<a onclick="showRef(event, 'ref195'); return false;" href="javascript:void(0);" class="ref ref195">(195)</a> It induced ROS production and subsequent cancer cell apoptosis and showed <i>in vivo</i> efficacy against prostate cancer.<a onclick="showRef(event, 'ref196 ref197'); return false;" href="javascript:void(0);" class="ref ref196 ref197">(196,197)</a> ADDA 5 is a complex IV inhibitor that was discovered through high-throughput screening. It inhibited the proliferation of chemo-sensitive and chemo-resistant glioma cells and showed <i>in vivo</i> efficacy<a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(199)</a> (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>).</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/medium/jm0c01013_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Structures of representative OXPHOS inhibitors used for cancer treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01013&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As mentioned above, OXPHOS inhibitors are also used in other therapeutics areas or as tool compounds to study the biological function and binding sites of corresponding OXPHOS complexes. A nonexhaustive list of those inhibitors can be found in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. OXPHOS Inhibitors Used in Other Therapeutic Areas or as Tool Compounds<a onclick="showRef(event, 'ref233 ref234 ref235 ref236 ref237 ref238 ref239 ref240 ref241 ref242 ref243 ref244'); return false;" href="javascript:void(0);" class="ref ref233 ref234 ref235 ref236 ref237 ref238 ref239 ref240 ref241 ref242 ref243 ref244">()</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/medium/jm0c01013_0014.gif" alt="" id="fx1" /></img><div></div></div></div></div><div id="sec10" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i42">Potential Therapeutic Strategies to Enhance the Efficacy of OXPHOS Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04866" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04866" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">At least three potential strategies can be employed for the clinical development of OXPHOS inhibitors (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>): First, an increase in the sensitivity of OXPHOS inhibitors by selecting patients with specific biomarkers could lead to an improved therapeutic window to control and/or reduce side effects. Second, OXPHOS inhibitors can be combined with targeted therapies or used in resistant patient subpopulations to aid the front-line clinical therapies. Third, the combination of OXPHOS inhibitors with other cancer metabolic modulators may lead to a synthetically lethal combination of drugs effective at killing cancer cells. Since we have described potential biomarkers in a previous section, here, we will focus on the other two strategies. Examples of combination studies of OXPHOS inhibitors with other drugs are listed in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/medium/jm0c01013_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Potential strategies to enhance the efficacy of OXPHOS inhibitors in clinical applications: utilize biomarkers to select patients sensitive to OXPHOS inhibitors, apply OXPHOS inhibitors in targeted therapy for resistant patients, and combine OXPHOS inhibitors with other metabolic modulators to achieve synthetic lethality.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01013&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Combination of OXPHOS Inhibitors with Other Drugs</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">OXPHOS inhibitor</th><th class="colsep0 rowsep0" align="center">drug combination (MOA)</th><th class="colsep0 rowsep0" align="center">cancer type</th><th class="colsep0 rowsep0" align="center">status</th><th class="colsep0 rowsep0" align="center">refs</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">metformin</td><td class="colsep0 rowsep0" align="center">sapanisertib (mTOR inhibitor)</td><td class="colsep0 rowsep0" align="center">malignant solid neoplasm</td><td class="colsep0 rowsep0" align="center">Phase I</td><td class="colsep0 rowsep0" align="center">NCT03017833</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">metformin</td><td class="colsep0 rowsep0" align="center">taxotere (tubulin inhibitor), carboplatin (alkylating agent), herceptin + pertuzumab (HER2 antibody)</td><td class="colsep0 rowsep0" align="center">HER2-positive breast cancer</td><td class="colsep0 rowsep0" align="center">Phase II</td><td class="colsep0 rowsep0" align="center">NCT03238495</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">metformin</td><td class="colsep0 rowsep0" align="center">salvage radiotherapy</td><td class="colsep0 rowsep0" align="center">prostate cancer</td><td class="colsep0 rowsep0" align="center">Phase II</td><td class="colsep0 rowsep0" align="center">NCT02945813</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">metformin</td><td class="colsep0 rowsep0" align="center">atorvastatin (HMG-CoA reductase inhibitor)</td><td class="colsep0 rowsep0" align="center">breast cancer</td><td class="colsep0 rowsep0" align="center">Phase I</td><td class="colsep0 rowsep0" align="center">NCT01980823</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">metformin</td><td class="colsep0 rowsep0" align="center">enzalutamide (androgen receptor inhibitor)</td><td class="colsep0 rowsep0" align="center">prostate cancer</td><td class="colsep0 rowsep0" align="center">Phase II</td><td class="colsep0 rowsep0" align="center">NCT02640534</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">phenformin</td><td class="colsep0 rowsep0" align="center">dabrafenib/trametinib (BRAF inhibitor)</td><td class="colsep0 rowsep0" align="center">melanoma</td><td class="colsep0 rowsep0" align="center">Phase I</td><td class="colsep0 rowsep0" align="center">NCT03026517</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">metformin</td><td class="colsep0 rowsep0" align="center">MLN4924 (NAE inhibitor)</td><td class="colsep0 rowsep0" align="center">breast cancer</td><td class="colsep0 rowsep0" align="center">experimental</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref245'); return false;" href="javascript:void(0);" class="ref ref245">(245)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">phenformin</td><td class="colsep0 rowsep0" align="center">PLX4720 (BRAF inhibitor)</td><td class="colsep0 rowsep0" align="center">melanoma</td><td class="colsep0 rowsep0" align="center">experimental</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref246'); return false;" href="javascript:void(0);" class="ref ref246">(246)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">phenformin</td><td class="colsep0 rowsep0" align="center">GNE-140 (LDHA inhibitor)</td><td class="colsep0 rowsep0" align="center">pancreatic cancer</td><td class="colsep0 rowsep0" align="center">experimental</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref247'); return false;" href="javascript:void(0);" class="ref ref247">(247)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">VLX600</td><td class="colsep0 rowsep0" align="center">imatinib (cKIT inhibitor)</td><td class="colsep0 rowsep0" align="center">gastrointestinal stromal tumor</td><td class="colsep0 rowsep0" align="center">experimental</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">IACS-010759</td><td class="colsep0 rowsep0" align="center">ibrutinib (BTK inhibitor)</td><td class="colsep0 rowsep0" align="center">mantle cell lymphoma</td><td class="colsep0 rowsep0" align="center">experimental</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">IACS-010759</td><td class="colsep0 rowsep0" align="center">doxorubicin (topoisomerase II inhibitor)</td><td class="colsep0 rowsep0" align="center">acute myeloid leukemia</td><td class="colsep0 rowsep0" align="center">experimental</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref248'); return false;" href="javascript:void(0);" class="ref ref248">(248)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">BAY87-2243</td><td class="colsep0 rowsep0" align="center">DMKG (glycolysis inhibitor)</td><td class="colsep0 rowsep0" align="center">lung cancer</td><td class="colsep0 rowsep0" align="center">experimental</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref249'); return false;" href="javascript:void(0);" class="ref ref249">(249)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">BAY87-2243</td><td class="colsep0 rowsep0" align="center">2-DG (glycolysis inhibitor)</td><td class="colsep0 rowsep0" align="center">lung cancer</td><td class="colsep0 rowsep0" align="center">experimental</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref249'); return false;" href="javascript:void(0);" class="ref ref249">(249)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">rotenone, tetrathiomolybdate</td><td class="colsep0 rowsep0" align="center">Akti-1/2 (Akt inhibitor)</td><td class="colsep0 rowsep0" align="center">neuroblastoma</td><td class="colsep0 rowsep0" align="center">experimental</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref250'); return false;" href="javascript:void(0);" class="ref ref250">(250)</a></td></tr></tbody></table></div></div><div id="sec10_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> Synergism of OXPHOS Inhibitors with Targeted Therapies</h3><div class="NLM_p last">Targeted therapies exemplified by tyrosine kinase inhibitors have been one of the major advances in cancer treatment in the past two decades. All kinase inhibitors suffer from drug resistance caused by target gene modification and activation of compensatory signaling pathways.<a onclick="showRef(event, 'ref251 ref252'); return false;" href="javascript:void(0);" class="ref ref251 ref252">(251,252)</a> Interestingly, several recent studies have revealed that the treatment of cells with targeted therapy renders cancer cells addicted to OXPHOS while suppressing glycolysis. This kind of adaptive metabolic reprogramming opens up an opportunity for OXPHOS inhibitors to compensate for current front-line cancer therapies. Osimertinib is a new generation EGFR inhibitor targeting both T790 M and activating mutant forms of EGFR to overcome the resistance to first-generation tyrosine kinase inhibitors.<a onclick="showRef(event, 'ref253'); return false;" href="javascript:void(0);" class="ref ref253">(253)</a> However, resistance still arises after the initial response. Osimertinib suppresses glycolysis, leading cancer cells to become dependent on OXPHOS. The combination of osimertinib and phenformin/metformin delays or prevents its resistance in a lung cancer model.<a onclick="showRef(event, 'ref253'); return false;" href="javascript:void(0);" class="ref ref253">(253)</a> OXPHOS is also found to be a compensatory mechanism after Akt kinase inhibition in neuroblastoma cells, and the combination of rotenone or tetrathiomolybdate with Akt inhibitor Akti-1/2 reduced the viability of neuroblastoma cells and their ability to form spheroids in a synergistic manner.<a onclick="showRef(event, 'ref250'); return false;" href="javascript:void(0);" class="ref ref250">(250)</a> Similarly, imatinib was found to decrease glycolysis and upregulate OXPHOS in gastrointestinal stromal tumors.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> Oligomycin-A was also reported to sensitize AML cells to imatinib, dasatinib, and quizartinib <i>in vitro</i> and <i>in vivo</i>, and this sensitization was attributed to the altered metabolic state triggered by kinase inhibition.<a onclick="showRef(event, 'ref254'); return false;" href="javascript:void(0);" class="ref ref254">(254)</a> Interestingly, AMPK activation was found to play a critical role in the synergistic effect of phenformin and BRAF inhibitor PLX4720.<a onclick="showRef(event, 'ref246'); return false;" href="javascript:void(0);" class="ref ref246">(246)</a> The oncogenic BRAF V600E mutant was found to suppress AMPK activity leading to melanoma cell proliferation and anchorage-independent growth.<a onclick="showRef(event, 'ref246 ref255'); return false;" href="javascript:void(0);" class="ref ref246 ref255">(246,255)</a> Treatment of BRAF-mutated melanoma cells with BRAF inhibitors leads to OXPHOS addiction.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> Thus, the combination of phenformin and PLX4720 induced tumor regression in both nude mice bearing melanoma xenografts and in a genetically engineered BRAF<sup>V600E</sup>/PTEN<sup>null</sup>-driven mouse model of melanoma. A recent study revealed that therapeutic resistance to the BTK inhibitor ibrutinib in mantle cell lymphoma is strongly associated with metabolic reprogramming toward OXPHOS.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> IACS-010759 shows growth inhibition <i>in vitro</i> and <i>in vivo</i> in ibrutinib-resistant patient-derived cancer models.</div></div><div id="sec10_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> Combination of Metabolic Modulators with OXPHOS Inhibition</h3><div class="NLM_p">Glycolysis and OXPHOS are the two major sources of ATP production in cancer cells. The plasticity of cancer cells facilitates metabolic reprograming between glycolysis and OXPHOS according to the microenvironment. Therefore, the combination of OXPHOS inhibitors and glycolysis inhibitors could substantially shut down the bioenergetic process and lead to cell death (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>). 2-Deoxyglucose (2-DG), a glucose mimic that competitively inhibits the production of glucose-6-phosphate from glucose in the second step of glycolysis,<a onclick="showRef(event, 'ref256'); return false;" href="javascript:void(0);" class="ref ref256">(256)</a> has not been successful in clinical trials due to cardiac side effects and lack of efficacy.<a onclick="showRef(event, 'ref257 ref258'); return false;" href="javascript:void(0);" class="ref ref257 ref258">(257,258)</a> OXPHOS inhibitors, like BAY87-2243, metformin, carboxyamidotriazole (CAI), Mito-Q, and berberine, have been successfully combined with 2-DG <i>in vitro</i> and <i>in vivo</i>, exhibiting enhanced antitumor efficacy in different mouse models.<a onclick="showRef(event, 'ref184 ref249 ref259 ref260 ref261'); return false;" href="javascript:void(0);" class="ref ref184 ref249 ref259 ref260 ref261">(184,249,259â261)</a> OXPHOS inhibitors are also found to be useful in sensitizing pancreatic cell lines to an inhibitor of lactate dehydrogenase A (LDHA).<a onclick="showRef(event, 'ref247'); return false;" href="javascript:void(0);" class="ref ref247">(247)</a> LDHA catalyzes the conversion of pyruvate to lactate and is closely related to glycolysis. The inhibition of LDHA by a novel inhibitor GNE-140 kills glycolytically dependent pancreatic cancer cells while OXPHOS-dependent cells are inherently resistant. Acquired resistance to LDHA inhibitor GNE-140 was also mediated by increased OXPHOS, and phenformin was effectively used in combination to extend the clinical utility of LDHA inhibitors and reduce the emergence of resistance to LDHA inhibition. Similarly, IACS-010759 combined with LDH inhibitor NCI-006 suppresses metabolic plasticity, causing metabolic quiescence <i>in vitro</i> and tumor growth inhibition <i>in vivo</i>.<a onclick="showRef(event, 'ref262'); return false;" href="javascript:void(0);" class="ref ref262">(262)</a> In a screen of agents that induce synthetic lethality with BAY87-2243, it was shown that dimethyl Î±-ketoglutarate (DMKG) exhibited strong synergy with BAY87-2243 both <i>in vitro</i> and <i>in vivo</i>. Mechanistic studies revealed the effect was due to MDM2-dependent transcriptional reprogramming that blocked glycolysis and synergized with the concomitant inhibition of OXPHOS.<a onclick="showRef(event, 'ref249'); return false;" href="javascript:void(0);" class="ref ref249">(249)</a> MLN4924, an inhibitor of the post-translational modification neddylation, induces TCA cycle inhibition and promotes mitochondrial OXPHOS. The combination of MLN4924 with metformin significantly reduced tumor growth <i>in vitro</i> and <i>in vivo</i>.<a onclick="showRef(event, 'ref245'); return false;" href="javascript:void(0);" class="ref ref245">(245)</a> However, the combination might also increase the toxicity in normal tissues, especially in tissues with a high ATP metabolic rate including the heart and brain. Thus, although the combination might significantly increase the efficacy of OXPHOS inhibitors, side effects should be carefully evaluated before advancing to human studies.</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/medium/jm0c01013_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Combination of metabolic modulators with OXPHOS inhibitors. (A) Metabolic pathways including glycolysis and lactate production were compensatorily upregulated in response to OXPHOS inhibition. (B) A combination of the glycolysis inhibitor and LDHA inhibitor with the OXPHOS inhibitor significantly shuts down the compensatory effect and leads to synthetic lethality.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01013&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec11" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i46">Evaluation of Toxicity of OXPHOS Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30031" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30031" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Despite mitochondrial OXPHOS becoming an increasingly attractive area for therapeutic exploitation in cancer and other diseases, OXPHOS is obviously required for intracellular oxygenation and normal physiological processes. Clinically, OXPHOS defects are related to various heterogeneous metabolic diseases of different degrees of severity including lethal infantile mitochondrial disease, mitochondrial encephalomyopathy, and Leigh syndrome.<a onclick="showRef(event, 'ref263 ref264'); return false;" href="javascript:void(0);" class="ref ref263 ref264">(263,264)</a> Thus, the potential toxicity of OXPHOS inhibitors will always need to be carefully managed.</div><div class="NLM_p">Due to the limited number of OXPHOS inhibitors tested in clinical trials to date, there is some concern over whether OXPHOS inhibition is tolerable in patients. As the most widely prescribed drug to treat patients with type 2 diabetes, metformin has been safely used for decades. Metformin and other biguanides are reported to exert their function as complex I inhibitors, leading to reduced tumorigenesis.<a onclick="showRef(event, 'ref21 ref158 ref265 ref266'); return false;" href="javascript:void(0);" class="ref ref21 ref158 ref265 ref266">(21,158,265,266)</a> VLX600,<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a> a complex I, II, and IV inhibitor, and LYC-30937,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> a complex V inhibitor, were both well-tolerated in Phase I clinical trials. In a Phase I trial of IACS-010759, a potent and selective complex I inhibitor, no metabolic acidosis was observed, and low-grade nausea, fatigue, myalgia, and neuropathy were the main side effects.<a onclick="showRef(event, 'ref216'); return false;" href="javascript:void(0);" class="ref ref216">(216)</a> However, the Phase I trial of the OXPHOS inhibitor BAY 87-2243 was prematurely terminated due to the reoccurrence of adverse events, and phenformin was withdrawn due to the high risk of lactic acidosis.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> As a widely used OXPHOS inhibitor, metformin is always used as evidence to demonstrate that OXPHOS inhibitors can be safe and efficacious. However, metformin is a weak and nonspecific OXPHOS inhibitor, and its effects on other pathological processes, besides OXPHOS, might also contribute to its effects on tumor progression. Importantly, the dose of metformin used for diabetes treatment is likely not sufficient for cancer treatment. Thus, more clinical trial results are needed to shed light on the toxicity of OXPHOS inhibitors.</div><div id="sec11_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> Lactic Acidosis</h3><div class="NLM_p last">Suppressing OXPHOS causes metabolic adaptation with compensatory increased glycolysis, which potentially leads to metabolic acidosis. Lactic acidosis is also responsible for the withdrawal of phenformin from the market. Several case reports of rotenone or metformin overdose produced severe metabolic acidosis.<a onclick="showRef(event, 'ref267 ref268'); return false;" href="javascript:void(0);" class="ref ref267 ref268">(267,268)</a> Increased lactate was also observed in patients treated with IACS-010759 but was not correlated with acidosis. The acidosis can be properly controlled by cautiously tailoring the drug dose.</div></div><div id="sec11_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> Potential Organ Toxicity of OXPHOS Inhibitors</h3><div class="NLM_p">OXPHOS defects show clinical symptoms as classical encephalomyopathy, hepatopathy, nephropathy, and hematologic findings.<a onclick="showRef(event, 'ref263 ref269'); return false;" href="javascript:void(0);" class="ref ref263 ref269">(263,269)</a> Due to the fundamental functions of OXPHOS, OXPHOS inhibitors might cause universal safety concerns across multiple organs. To elucidate the potential toxicity of OXPHOS inhibitors, we analyzed the average expression of OXPHOS genes in different organs as quantified by GTEx tissue samples (<a href="https://www.gtexportal.org/" class="extLink">https://www.gtexportal.org/</a>).<a onclick="showRef(event, 'ref270'); return false;" href="javascript:void(0);" class="ref ref270">(270)</a> Results show that the heart, muscle, kidney, adrenal gland, liver, and brain tissues have the highest average expression of OXPHOS genes (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>). Indeed, symptoms related to impaired muscle function including fatigue and myalgia are typical symptoms of OXPHOS inhibitors.<a onclick="showRef(event, 'ref271'); return false;" href="javascript:void(0);" class="ref ref271">(271)</a> Moreover, cardiotoxicity, hepatotoxicity, and brain toxicity are the three most concerning side effects caused by OXPHOS inhibitors. Thus, we will focus our discussions on these organs.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/medium/jm0c01013_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Violin plot shows average z-scores for oxidative phosphorylation genes for GTEx tissue samples. Heart, muscle, and kidney tissues have the highest average expression of OXPHOS genes. GTEx patient RNA-Seq and sample attribute data were sourced from <a href="https://www.gtexportal.org/" class="extLink">https://www.gtexportal.org/</a>.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> RNA-Seq gene expression values were downloaded, upper-quartile normalized, and log2 + 1 transformed. RNA-Seq values were converted to z-scores per patient sample. EBV-transformed lymphocytes and cultured fibroblast samples were excluded.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01013&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Direct or indirect inhibition of OXPHOS is leading the cause of mitochondria-related cardiotoxicity.<a onclick="showRef(event, 'ref272'); return false;" href="javascript:void(0);" class="ref ref272">(272)</a> Drugs inhibiting OXPHOS (cyclosporine-A, carbon monoxide, and arsenic trioxide) or interfering with mitochondrial membrane potential (doxorubicin) show cardiotoxicity including heart failure, arrhythmias, and angina. Since other components including electrophysiology, calcium/sodium transients, and contractility also contribute to cardiotoxicity,<a onclick="showRef(event, 'ref273'); return false;" href="javascript:void(0);" class="ref ref273">(273)</a> OXPHOS inhibitors affecting these physiological processes will increase the cardiotoxicity risk. Thus, it is important to screen OXPHOS inhibitors in appropriate assays to better assess cardiotoxicity.</div><div class="NLM_p">OXPHOS inhibition leading to mitochondrial dysfunctions brings up the concern for drug-induced liver injury. A screen of 228 drugs in a mitochondrial toxicity assay suggests that mitochondrial dysfunction highly correlates to hepatoxicity with the sensitivity of 63%.<a onclick="showRef(event, 'ref274 ref275'); return false;" href="javascript:void(0);" class="ref ref274 ref275">(274,275)</a> Interestingly, drugs that tested positive in the mitochondrial function assays possess distinct physicochemical properties, highlighting increased lipophilicity with higher cLogP values. The mitochondrial assay is also useful in several models for predicting hepatoxicity.<a onclick="showRef(event, 'ref276'); return false;" href="javascript:void(0);" class="ref ref276">(276)</a> However, many of the drugs that impair mitochondrial functions and show hepatotoxicity target other non-OXPHOS proteins, which might largely impact the pathological outcomes. Interestingly, metformin-induced liver injury is rare,<a onclick="showRef(event, 'ref277'); return false;" href="javascript:void(0);" class="ref ref277">(277)</a> and hepatotoxicity was not reported in the Phase I clinical trial of IACS-010759 or VLX600. However, the long-term incidence of liver injury should be carefully evaluated in future clinical trials.</div><div class="NLM_p">The clinical phenotypes associated with OXPHOS defects are relatively heterogeneous, but encephalomyopathy is present in most cases. It is well accepted that neurons are highly dependent on mitochondrial OXPHOS function. Inhibiting OXPHOS may promote the progression of neurodegenerative diseases.<a onclick="showRef(event, 'ref278'); return false;" href="javascript:void(0);" class="ref ref278">(278)</a> In fact, rotenone is used in experimental animal models to establish Parkinsonâs Disease.<a onclick="showRef(event, 'ref279'); return false;" href="javascript:void(0);" class="ref ref279">(279)</a> Peripheral neuropathy has also been observed in a clinical trial of IACS-010759. Thus, much attention should be paid to OXPHOS inhibitors that can pass through the bloodâbrain barrier, and long-term studies evaluating OXPHOS inhibitors in neuronal damage would be necessary.</div><div class="NLM_p last">Managing toxicity is one of the most challenging issues in the development of OXPHOS inhibitors. Predictable and well-behaved pharmacokinetics may be essential in order to maintain an adequate therapeutic window and mitigate the risk of side effects. It is important to understand drug distribution to avoid drug accumulation in the brain, heart, and liver. The dose of OXPHOS inhibitors should be well balanced to ameliorate the expected and unexpected adverse events. Overall, the pharmacokinetic properties and potency of OXPHOS inhibitors must be carefully tailored.</div></div><div id="sec11_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> Toxicity Prediction Using Physicochemical Descriptors of OXPHOS Inhibitors</h3><div class="NLM_p">The physicochemical properties are strongly associated with the ADME and toxicity of drugs and are used in many models to predict the risk of molecules for systematic or certain organ toxicities.<a onclick="showRef(event, 'ref276 ref280'); return false;" href="javascript:void(0);" class="ref ref276 ref280">(276,280)</a> We calculated the physicochemical properties of 45 reported OXPHOS inhibitors (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01013/suppl_file/jm0c01013_si_001.pdf" class="ext-link">Supplemental Table 4</a>) including the number of H-bond donor/acceptor, molecular weight, cLogP, tPSA, and Fsp3, and the distributions are shown in <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>. Based on the reported classification standards,<a onclick="showRef(event, 'ref276 ref281 ref282'); return false;" href="javascript:void(0);" class="ref ref276 ref281 ref282">(276,281,282)</a> high and low systematic toxicity ratios have been previously calculated and compared with the ratio of 215 marketed drugs using reported data.<a onclick="showRef(event, 'ref276'); return false;" href="javascript:void(0);" class="ref ref276">(276)</a> The results indicate that the physiochemical properties of OXPHOS inhibitors, when compared with marketed drugs, show a higher ratio of cLogP â¥ 3 (69% vs 46%) and tPSA < 75 Ã<sup>2</sup> (56% vs 49%). This suggests that increased hydrophobicity and permeability are associated with OXPHOS inhibition. This might be attributed to the requirement of passing multiple phospholipid bilayers to bind OXPHOS complexes in mitochondria and that OXPHOS complexes and binding sites favor hydrophobic interactions. Of note, facile permeability increases the chance of crossing the bloodâbrain barrier, potentially leading to neuronal toxicity. High molecular weight (>400) and low Fsp3 (<0.28) are correlated with a higher risk of overall toxicities. OXPHOS inhibitors have higher MW and lower Fsp3 than marketed drugs (MW > 400:40% vs 34%; Fsp3 < 0.28:42% vs 33%). On the other hand, other criteria for drug toxicity such as an excessive number of H-bond donors (>5) or acceptors (<7) are not seen in the majority of OXPHOS inhibitors. Although the on-target toxicity of OXPHOS inhibition might be the major cause for side effects, the incorporation of physicochemical properties to evaluate and tailor the structural modification is still desired to diminish off-target toxicities and achieve a better therapeutic window.</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/medium/jm0c01013_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Physicochemical property distributions of OXPHOS inhibitors. (A) cLogP distribution. (B) Topological polar surface area (tPSA) distribution. (C) Fraction of sp3 hybridized carbons (Fsp3) distribution. (D) Molecular weight (MW) distribution. (E) Hydrogen bond donor (HBD) counts distribution. (F) Hydrogen bond acceptor (HBA) counts distribution. High toxicity risk groups are labeled in red.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01013&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec12" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i50">Summary and Future Perspectives</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10054" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10054" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Proposed nearly 100 years ago, the Warburg effect has been recognized as a fundamental hallmark of cancer metabolism, portraying cancer to be highly dependent on glycolysis. Despite this, the substantial effort of targeting the cancer cell glycolysis pathway as a cancer treatment has not been successful. Emerging research in recent years has pointed out the importance of OXPHOS for cancer cell metabolism, and this is not surprising considering the heterogeneity among different cancer types. Certain cancer types rely largely on OXPHOS for bioenergetic processes and biomass generation. The transcriptional upregulation of OXPHOS has been well documented in multiple types of cancer, and some subtypes of cancer, especially glycolysis-deficient cancers, are particularly sensitive to OXPHOS inhibitors. These facts unambiguously support the case for the therapeutic use of OXPHOS inhibitors.</div><div class="NLM_p">That being said, no OXPHOS inhibitors have advanced to late-stage clinical development. Careful patient selection should be carried out to capture the full potential of OXPHOS inhibitors and to avoid excessive toxicity. Robust yet sensitive biomarkers are needed to optimize patient selection for OXPHOS inhibitors. Potential examples include ENO1 loss and SMARCA4 mutation, but we suspect a multigene gene signature will be needed, given the heterogeneous nature of cancer. Bioenergetic effects of the inhibitors of respiratory enzymes intricately vary in terms of mitochondrial potential and ROS production, suggesting that these biomarkers should be validated in inhibitors targeting other complexes. This variability highlights the need for the development of other biomarkers in addition to the current ones validated for the complex I inhibitors. Combination with the current standard of care chemotherapy and immunotherapy represents an intriguing strategy for the therapeutic application of OXPHOS inhibitors. Targeted therapies, especially TKIs, suffer from the rapid emergence of drug resistance clones. The important role of OXPHOS as a resistance mechanism of various drugs supports the use of OXPHOS inhibitors in combination with different drugs. For example, several ongoing clinical trials are evaluating biguanides in combination with chemotherapy and targeted therapy. Besides this, the rational combination of OXPHOS inhibitors with other metabolic modifiers such as glycolysis inhibitors is also a promising approach to effectively treat select cancers. As demonstrated using mouse models with metformin, combining hypoglycemia caused by intermittent fasting, a clinically feasible approach to reduce glucose availability, with OXPHOS inhibitors, may increase the effectiveness of OXPHOS-targeting therapies in the clinic.<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> The dependency of cancer stem cells on OXPHOS offers another opportunity for OXPHOS inhibitors to treat refractory cancer types along with standard therapy to achieve better overall outcomes.</div><div class="NLM_p">One of the major challenges for the development of OXPHOS inhibitors is to address the toxicity issue. Mitochondrial inhibition is generally considered to cause hepatoxicity and neurotoxicity and is shown to be one of the mechanisms of toxicity of certain marketed drugs.<a onclick="showRef(event, 'ref283'); return false;" href="javascript:void(0);" class="ref ref283">(283)</a> Mitochondrial dysfunction is also implicated in several neurological diseases, and certain OXPHOS inhibitors produce lactic acidosis. Interestingly, many of the reported OXPHOS inhibitors show significant selective cytotoxicity against cancer cells versus normal cells, and several OXPHOS inhibitors like metformin have been safely administrated for decades. Thorough PK and tissue distribution studies should be considered for any drug to select the optimal dose and route of administration. Prediction of the toxicity of OXPHOS inhibitors based on physicochemical properties in early development is also desirable.</div><div class="NLM_p last">Another issue with the current OXPHOS inhibitors is the lack of selectivity. Many such inhibitors bind other targets resulting in off-target toxicity. Also, many of the OXPHOS inhibitors were identified based on phenotypic assays, and their actual targets were identified at much later dates. The rational design of OXPHOS inhibitors remains challenging, given that the binding modes of many of the OXPHOS inhibitors to ETC complexes are largely unknown. The large size and flexibility of those complexes, especially complex I, cause difficulties in obtaining high-quality cocrystal structures of OXPHOS complexes with their inhibitors. The diverse structures of OXPHOS inhibitors also indicate that their binding to OXPHOS complexes is likely diverse. Mutagenesis and photoaffinity labeling experiments could aid the elucidation of the binding mode of given OXPHOS inhibitors to shed light on structure-based drug design. Moreover, a rational screening of OXPHOS inhibitors could be initiated by using a galactose versus glucose medium as described above. A subsequent conformational assay determining the OCR or enzymatic function inhibition of each complex will further confirm their molecular target. More effort is still needed to further validate the clinical use and to boost the potential of OXPHOS inhibitors as anticancer drugs.</div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i51"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01013" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35812" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35812" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01013?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01013</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Heatmap; oncoprints for brain lower grade gliomOXPHOS structure genes; OXPHOS assembly factors and biogenesis genes; canonical glycolysis genes; list of physicochemical properties of 45 OXPHOS inhibitors (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01013/suppl_file/jm0c01013_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01013/suppl_file/jm0c01013_si_001.pdf">jm0c01013_si_001.pdf (1.12 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01013" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34783" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34783" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nouri Neamati</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, College of Pharmacy, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan 48109, United States</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3291-7131" title="Orcid link">http://orcid.org/0000-0003-3291-7131</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#204e45414d41544960554d4943480e454455"><span class="__cf_email__" data-cfemail="432d26222e22372a03362e2a202b6d262736">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yibin Xu</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, College of Pharmacy, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan 48109, United States</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8261-3286" title="Orcid link">http://orcid.org/0000-0002-8261-3286</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ding Xue</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, College of Pharmacy, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan 48109, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Armand Bankhead</span> - <span class="hlFld-Affiliation affiliation">Department
of Computational Medicine and Bioinformatics, University of Michigan Medical School, Ann Arbor, Michigan 48109, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Department
of Biostatistics, University of Michigan,
School of Public Health, Ann Arbor, Michigan 48109, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Y.X. and D.X. contributed equally.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77430" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77430" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Yibin Xu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01013&amp;id=BIO-d7e2905-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Yibin Xu</b> obtained her B.S. degree in Biopharmaceutics from Huazhong University of Science and Technology. After finishing her Ph.D. in Pharmacology at Shanghai Institute of Materia Medica, Chinese Academy of Sciences, she worked as an analytical scientist at Shanghai Institute of Drug and Food Control, CFDA. She is now enjoying her research as a senior research fellow in Prof. Nouri Neamatiâs lab at the College of Pharmacy, University of Michigan. Her research interests mainly focus on the discovery, evaluation, and mechanistic study of novel small molecule cancer therapeutics.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Ding Xue</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01013&amp;id=BIO-d7e2910-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Ding Xue</b> received his B.S. degree in Pharmaceutical Sciences from Sun Yat-sen University. He then completed his Ph.D. in medicinal chemistry under the supervision of Prof. Ya-qiu Long at Shanghai Institute of Materia Medica, Chinese Academy of Sciences. After working at Wuxi Apptec as a senior scientist, he is currently working as a senior research fellow in the laboratory of Prof. Nouri Neamati at the College of Pharmacy, University of Michigan. His research interests mainly focus on the discovery and development of anticancer drugs based on cutting-edge technologies.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Armand Bankhead, III</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01013&amp;id=BIO-d7e2915-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Armand Bankhead III</b> is a bioinformatics data analyst with 13 years of postgraduate experience in processing and summarizing high-throughput genomic data sets (e.g., RNA-Seq, DNA-Seq, RPPA, drug response) and partnering with translational scientists to make biomedical discoveries. He obtained his Ph.D. in Computational Biology and Bioinformatics from the University of Idaho and was a postdoctoral researcher at Merck and Oregon Health and Science University. Dr. Bankhead currently has appointments in the Department of Biostatistics and the Department of Computational Medicine and Bioinformatics at the University of Michigan, where he participates in Rogel Cancer Center research and teaching graduate-level courses in bioinformatics. His research interests include using systems biology and artificial intelligence methods for insight into large genomic cancer datasets.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Nouri Neamati</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01013&amp;id=BIO-d7e2920-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Nouri Neamati</b> is the John G. Searle Professor of Medicinal Chemistry at the College of Pharmacy, University of Michigan. He obtained his Ph.D. in Biomedical Sciences from the University of Texas Graduate School of Biomedical Sciences and MD Anderson Cancer Center, Houston, Texas, in 1995. From 1995 to 2000, he was a postdoctoral and a research fellow at the National Institutes of Health. In September 2000, he joined the University of Southern California, School of Pharmacy, and rose through the ranks to Full Professor in 2011. In 2013, he moved to the Department of Medicinal Chemistry, University of Michigan. He has published >270 peer-reviewed manuscripts, 20 book chapters, and over 40 patents in different areas of drug design and discovery.</p></figure></div><div class="ack" id="ACK-d7e2943-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i57">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88256" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88256" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Dr. Peter L. Toogood for critical reading of the manuscript. This work was supported by NIH grant R01 CA188252. The OXPHOS pan-cancer gene expression results shown here are in whole or part based upon data generated by the TCGA Research Network: <a href="https://www.cancer.gov/tcga" class="extLink">https://www.cancer.gov/tcga</a>.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ACC</td><td class="NLM_def"><p class="first last">adrenocortical carcinoma</p></td></tr><tr><td class="NLM_term">ALDH</td><td class="NLM_def"><p class="first last">aldehyde dehydrogenase</p></td></tr><tr><td class="NLM_term">AML</td><td class="NLM_def"><p class="first last">acute myeloid leukemia</p></td></tr><tr><td class="NLM_term">AMPK</td><td class="NLM_def"><p class="first last">5â² AMP-activated protein kinase</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">BBB</td><td class="NLM_def"><p class="first last">bloodâbrain barrier</p></td></tr><tr><td class="NLM_term">BLBC</td><td class="NLM_def"><p class="first last">basal-like breast cancer</p></td></tr><tr><td class="NLM_term">BRAF</td><td class="NLM_def"><p class="first last">serine/threonine-protein kinase B-Raf</p></td></tr><tr><td class="NLM_term">BRCA</td><td class="NLM_def"><p class="first last">breast carcinoma</p></td></tr><tr><td class="NLM_term">BTK</td><td class="NLM_def"><p class="first last">Brutonâs tyrosine kinase</p></td></tr><tr><td class="NLM_term">CAI</td><td class="NLM_def"><p class="first last">carboxyamidotriazole</p></td></tr><tr><td class="NLM_term">CCNB1</td><td class="NLM_def"><p class="first last">cyclin B1</p></td></tr><tr><td class="NLM_term">CDK1</td><td class="NLM_def"><p class="first last">cyclin-dependent kinase 1</p></td></tr><tr><td class="NLM_term">CHOL</td><td class="NLM_def"><p class="first last">cholangiocarcinoma</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>max</sub></td><td class="NLM_def"><p class="first last">maximum serum concentration</p></td></tr><tr><td class="NLM_term">CRPC</td><td class="NLM_def"><p class="first last">castration-resistant prostate cancer</p></td></tr><tr><td class="NLM_term">CSC</td><td class="NLM_def"><p class="first last">cancer stem cells</p></td></tr><tr><td class="NLM_term">cyt b</td><td class="NLM_def"><p class="first last">cytochrome <i>b</i></p></td></tr><tr><td class="NLM_term">cyt c1</td><td class="NLM_def"><p class="first last">cytochrome c1</p></td></tr><tr><td class="NLM_term">2-DG</td><td class="NLM_def"><p class="first last">2-deocyglucose</p></td></tr><tr><td class="NLM_term">DiOC6</td><td class="NLM_def"><p class="first last">3,3â²-dihexyloxacarbocyanine iodide</p></td></tr><tr><td class="NLM_term">DLBCL</td><td class="NLM_def"><p class="first last">diffuse large B-cell lymphomas</p></td></tr><tr><td class="NLM_term">DMKG</td><td class="NLM_def"><p class="first last">dimethyl Î±-ketoglutarate</p></td></tr><tr><td class="NLM_term">ETC</td><td class="NLM_def"><p class="first last">electron transport chain</p></td></tr><tr><td class="NLM_term">ENO1</td><td class="NLM_def"><p class="first last">enolase 1</p></td></tr><tr><td class="NLM_term">FMN</td><td class="NLM_def"><p class="first last">flavin mononucleotide</p></td></tr><tr><td class="NLM_term">GBM</td><td class="NLM_def"><p class="first last">glioblastoma</p></td></tr><tr><td class="NLM_term">GIST</td><td class="NLM_def"><p class="first last">gastrointestinal stromal tumor</p></td></tr><tr><td class="NLM_term">GVHD</td><td class="NLM_def"><p class="first last">graft-versus-host disease</p></td></tr><tr><td class="NLM_term">HIF</td><td class="NLM_def"><p class="first last">hypoxia-inducible factor</p></td></tr><tr><td class="NLM_term">IDH1</td><td class="NLM_def"><p class="first last">isocitrate dehydrogenase 1</p></td></tr><tr><td class="NLM_term">IDH2</td><td class="NLM_def"><p class="first last">isocitrate dehydrogenase 2</p></td></tr><tr><td class="NLM_term">IMM</td><td class="NLM_def"><p class="first last">inner mitochondrial membrane</p></td></tr><tr><td class="NLM_term">ISP</td><td class="NLM_def"><p class="first last">ironâsulfur protein</p></td></tr><tr><td class="NLM_term">JC-1,5,5â²,6,6â²-tetrachloro-1,1â²,3,3â²</td><td class="NLM_def"><p class="first last">tetraethylbenzimidazolylcarbocyanine iodide</p></td></tr><tr><td class="NLM_term">KICH</td><td class="NLM_def"><p class="first last">kidney chromophobe</p></td></tr><tr><td class="NLM_term">LDHA</td><td class="NLM_def"><p class="first last">lactate dehydrogenase</p></td></tr><tr><td class="NLM_term">LGG</td><td class="NLM_def"><p class="first last">lower grade glioma</p></td></tr><tr><td class="NLM_term">LIHC</td><td class="NLM_def"><p class="first last">liver hepatocellular carcinoma</p></td></tr><tr><td class="NLM_term">LND</td><td class="NLM_def"><p class="first last">Lonidamine</p></td></tr><tr><td class="NLM_term">LUAD</td><td class="NLM_def"><p class="first last">lung adenocarcinoma</p></td></tr><tr><td class="NLM_term">MTD</td><td class="NLM_def"><p class="first last">maximum tolerated dose</p></td></tr><tr><td class="NLM_term">MCL</td><td class="NLM_def"><p class="first last">mantle cell lymphoma</p></td></tr><tr><td class="NLM_term">MCT</td><td class="NLM_def"><p class="first last">monocarboxylate transporter</p></td></tr><tr><td class="NLM_term">MPC</td><td class="NLM_def"><p class="first last">mitochondrial pyruvate carrier</p></td></tr><tr><td class="NLM_term">mTOR</td><td class="NLM_def"><p class="first last">mammalian target of rapamycin</p></td></tr><tr><td class="NLM_term">nDNA</td><td class="NLM_def"><p class="first last">nuclear DNA</p></td></tr><tr><td class="NLM_term">NES</td><td class="NLM_def"><p class="first last">normalized enrichment score</p></td></tr><tr><td class="NLM_term">NOAELs</td><td class="NLM_def"><p class="first last">no-observed-adverse-effect dose levels</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">nonsmall cell lung cancer</p></td></tr><tr><td class="NLM_term">OCR</td><td class="NLM_def"><p class="first last">oxygen consumption rate</p></td></tr><tr><td class="NLM_term">OCT</td><td class="NLM_def"><p class="first last">organic cation transporter</p></td></tr><tr><td class="NLM_term">OXPHOS</td><td class="NLM_def"><p class="first last">oxidative phosphorylation</p></td></tr><tr><td class="NLM_term">PCP</td><td class="NLM_def"><p class="first last">pneumocystis pneumonia</p></td></tr><tr><td class="NLM_term">PDAC</td><td class="NLM_def"><p class="first last">pancreatic ductal adenoma cell</p></td></tr><tr><td class="NLM_term">PDE 10A</td><td class="NLM_def"><p class="first last">phosphodiesterase 10A</p></td></tr><tr><td class="NLM_term">PDX</td><td class="NLM_def"><p class="first last">patient-derived xenograft</p></td></tr><tr><td class="NLM_term">ÎÎ¨m</td><td class="NLM_def"><p class="first last">mitochondrial membrane potential</p></td></tr><tr><td class="NLM_term">PGD</td><td class="NLM_def"><p class="first last">phosphoglycerate dehydrogenase</p></td></tr><tr><td class="NLM_term">p<i>K</i><sub>a</sub></td><td class="NLM_def"><p class="first last">acid dissociation constant</p></td></tr><tr><td class="NLM_term">RECIST</td><td class="NLM_def"><p class="first last">response evaluation criteria in solid tumors</p></td></tr><tr><td class="NLM_term">Rhod123</td><td class="NLM_def"><p class="first last">rhodamine 123</p></td></tr><tr><td class="NLM_term">RHOA</td><td class="NLM_def"><p class="first last">small GTPase RAS homologue gene family, member A</p></td></tr><tr><td class="NLM_term">ROS</td><td class="NLM_def"><p class="first last">reactive oxygen species</p></td></tr><tr><td class="NLM_term">RTK</td><td class="NLM_def"><p class="first last">receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">SHMT2</td><td class="NLM_def"><p class="first last">serine hydroxymethyltransferase</p></td></tr><tr><td class="NLM_term">SKCM</td><td class="NLM_def"><p class="first last">skin cutaneous melanoma</p></td></tr><tr><td class="NLM_term">SLE</td><td class="NLM_def"><p class="first last">systemic lupus erythematosus</p></td></tr><tr><td class="NLM_term">STAD</td><td class="NLM_def"><p class="first last">stomach adenocarcinoma</p></td></tr><tr><td class="NLM_term">TCA</td><td class="NLM_def"><p class="first last">tricarboxylic acid</p></td></tr><tr><td class="NLM_term">TCGA</td><td class="NLM_def"><p class="first last">the Cancer Genome Atlas</p></td></tr><tr><td class="NLM_term">TKI</td><td class="NLM_def"><p class="first last">tyrosine kinase inhibitor</p></td></tr><tr><td class="NLM_term">TMH</td><td class="NLM_def"><p class="first last">transmembrane helix</p></td></tr><tr><td class="NLM_term">TMRE</td><td class="NLM_def"><p class="first last">tetramethylrhodamine ethyl ester</p></td></tr><tr><td class="NLM_term">TMRM</td><td class="NLM_def"><p class="first last">tetramethylrhodamine methyl</p></td></tr><tr><td class="NLM_term">TNBC</td><td class="NLM_def"><p class="first last">triple-negative breast cancer</p></td></tr><tr><td class="NLM_term">TPP</td><td class="NLM_def"><p class="first last">triphenylphosphonium</p></td></tr><tr><td class="NLM_term">UVM</td><td class="NLM_def"><p class="first last">uveal melanoma</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i59">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86632" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86632" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 283 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luengo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gui, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vander
Heiden, M. G.</span></span> <span> </span><span class="NLM_article-title">Targeting metabolism for cancer therapy</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1161</span>â <span class="NLM_lpage">1180</span>, <span class="refDoi">Â DOI: 10.1016/j.chembiol.2017.08.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.chembiol.2017.08.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=28938091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFGgurfO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=1161-1180&author=A.+Luengoauthor=D.+Y.+Guiauthor=M.+G.+Vander%0AHeiden&title=Targeting+metabolism+for+cancer+therapy&doi=10.1016%2Fj.chembiol.2017.08.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Metabolism for Cancer Therapy</span></div><div class="casAuthors">Luengo, Alba; Gui, Dan Y.; Vander Heiden, Matthew G.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1161-1180</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Metabolic reprogramming contributes to tumor development and introduces metabolic liabilities that can be exploited to treat cancer.  Chemotherapies targeting metab. have been effective cancer treatments for decades, and the success of these therapies demonstrates that a therapeutic window exists to target malignant metab.  New insights into the differential metabolic dependencies of tumors have provided novel therapeutic strategies to exploit altered metab., some of which are being evaluated in preclin. models or clin. trials.  Here, we review our current understanding of cancer metab. and discuss how this might guide treatments targeting the metabolic requirements of tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUOppBTjvuc7Vg90H21EOLACvtfcHk0lj9wrnYXmTObQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFGgurfO&md5=c702238d8642e06df9accd5414b64936</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2017.08.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2017.08.028%26sid%3Dliteratum%253Aachs%26aulast%3DLuengo%26aufirst%3DA.%26aulast%3DGui%26aufirst%3DD.%2BY.%26aulast%3DVander%2BHeiden%26aufirst%3DM.%2BG.%26atitle%3DTargeting%2520metabolism%2520for%2520cancer%2520therapy%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2017%26volume%3D24%26spage%3D1161%26epage%3D1180%26doi%3D10.1016%2Fj.chembiol.2017.08.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locasale, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielas, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâSullivan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheahan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vander
Heiden, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitkup, D.</span></span> <span> </span><span class="NLM_article-title">Heterogeneity of tumor-induced gene expression changes in the human metabolic network</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">522</span>â <span class="NLM_lpage">529</span>, <span class="refDoi">Â DOI: 10.1038/nbt.2530</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fnbt.2530" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=23604282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmt1Sqs7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=522-529&author=J.+Huauthor=J.+W.+Locasaleauthor=J.+H.+Bielasauthor=J.+O%E2%80%99Sullivanauthor=K.+Sheahanauthor=L.+C.+Cantleyauthor=M.+G.+Vander%0AHeidenauthor=D.+Vitkup&title=Heterogeneity+of+tumor-induced+gene+expression+changes+in+the+human+metabolic+network&doi=10.1038%2Fnbt.2530"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Heterogeneity of tumor-induced gene expression changes in the human metabolic network</span></div><div class="casAuthors">Hu, Jie; Locasale, Jason W.; Bielas, Jason H.; O'Sullivan, Jacintha; Sheahan, Kieran; Cantley, Lewis C.; Vander Heiden, Matthew G.; Vitkup, Dennis</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">522-529</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Reprogramming of cellular metab. is an emerging hallmark of neoplastic transformation.  However, it is not known how the expression of metabolic genes in tumors differs from that in normal tissues, or whether different tumor types exhibit similar metabolic changes.  Here we compare expression patterns of metabolic genes across 22 diverse types of human tumors.  Overall, the metabolic gene expression program in tumors is similar to that in the corresponding normal tissues.  Although expression changes of some metabolic pathways (e.g., upregulation of nucleotide biosynthesis and glycolysis) are frequently obsd. across tumors, expression changes of other pathways (e.g., oxidative phosphorylation) are very heterogeneous.  Our anal. also suggests that the expression changes of some metabolic genes (e.g., isocitrate dehydrogenase and fumarate hydratase) may enhance or mimic the effects of recurrent mutations in tumors.  On the level of individual biochem. reactions, many hundreds of metabolic isoenzymes show significant and tumor-specific expression changes.  These isoenzymes are potential targets for anticancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocriTCxH6Jl7Vg90H21EOLACvtfcHk0lj9wrnYXmTObQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmt1Sqs7s%253D&md5=730c42d523bac78aa4b076c78239a6d6</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2530&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2530%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DLocasale%26aufirst%3DJ.%2BW.%26aulast%3DBielas%26aufirst%3DJ.%2BH.%26aulast%3DO%25E2%2580%2599Sullivan%26aufirst%3DJ.%26aulast%3DSheahan%26aufirst%3DK.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DVander%2BHeiden%26aufirst%3DM.%2BG.%26aulast%3DVitkup%26aufirst%3DD.%26atitle%3DHeterogeneity%2520of%2520tumor-induced%2520gene%2520expression%2520changes%2520in%2520the%2520human%2520metabolic%2520network%26jtitle%3DNat.%2520Biotechnol.%26date%3D2013%26volume%3D31%26spage%3D522%26epage%3D529%26doi%3D10.1038%2Fnbt.2530" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roesch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vultur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogeski, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speicher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korbel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laschke, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gimotty, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philipp, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krause, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patzold, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villanueva, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krepler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukunaga-Kalabis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastian, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herlyn, M.</span></span> <span> </span><span class="NLM_article-title">Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">811</span>â <span class="NLM_lpage">825</span>, <span class="refDoi">Â DOI: 10.1016/j.ccr.2013.05.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.ccr.2013.05.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=23764003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptFKku7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=811-825&author=A.+Roeschauthor=A.+Vulturauthor=I.+Bogeskiauthor=H.+Wangauthor=K.+M.+Zimmermannauthor=D.+Speicherauthor=C.+Korbelauthor=M.+W.+Laschkeauthor=P.+A.+Gimottyauthor=S.+E.+Philippauthor=E.+Krauseauthor=S.+Patzoldauthor=J.+Villanuevaauthor=C.+Kreplerauthor=M.+Fukunaga-Kalabisauthor=M.+Hothauthor=B.+C.+Bastianauthor=T.+Vogtauthor=M.+Herlyn&title=Overcoming+intrinsic+multidrug+resistance+in+melanoma+by+blocking+the+mitochondrial+respiratory+chain+of+slow-cycling+JARID1B%28high%29+cells&doi=10.1016%2Fj.ccr.2013.05.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells</span></div><div class="casAuthors">Roesch, Alexander; Vultur, Adina; Bogeski, Ivan; Wang, Huan; Zimmermann, Katharina M.; Speicher, David; Koerbel, Christina; Laschke, Matthias W.; Gimotty, Phyllis A.; Philipp, Stephan E.; Krause, Elmar; Paetzold, Sylvie; Villanueva, Jessie; Krepler, Clemens; Fukunaga-Kalabis, Mizuho; Hoth, Markus; Bastian, Boris C.; Vogt, Thomas; Herlyn, Meenhard</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">811-825</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Despite success with BRAFV600E inhibitors, therapeutic responses in patients with metastatic melanoma are short-lived because of the acquisition of drug resistance.  We identified a mechanism of intrinsic multidrug resistance based on the survival of a tumor cell subpopulation.  Treatment with various drugs, including cisplatin and vemurafenib, uniformly leads to enrichment of slow-cycling, long-term tumor-maintaining melanoma cells expressing the H3K4-demethylase JARID1B/KDM5B/PLU-1.  Proteome-profiling revealed an upregulation in enzymes of mitochondrial oxidative-ATP-synthesis (oxidative phosphorylation) in this subpopulation.  Inhibition of mitochondrial respiration blocked the emergence of the JARID1Bhigh subpopulation and sensitized melanoma cells to therapy, independent of their genotype.  Our findings support a two-tiered approach combining anticancer agents that eliminate rapidly proliferating melanoma cells with inhibitors of the drug-resistant slow-cycling subpopulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLdv3RllMhCbVg90H21EOLACvtfcHk0lgtrqQBUWRrzg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptFKku7s%253D&md5=ba9ce8134c1fc0f17c44aebae7e760f0</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2013.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2013.05.003%26sid%3Dliteratum%253Aachs%26aulast%3DRoesch%26aufirst%3DA.%26aulast%3DVultur%26aufirst%3DA.%26aulast%3DBogeski%26aufirst%3DI.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DZimmermann%26aufirst%3DK.%2BM.%26aulast%3DSpeicher%26aufirst%3DD.%26aulast%3DKorbel%26aufirst%3DC.%26aulast%3DLaschke%26aufirst%3DM.%2BW.%26aulast%3DGimotty%26aufirst%3DP.%2BA.%26aulast%3DPhilipp%26aufirst%3DS.%2BE.%26aulast%3DKrause%26aufirst%3DE.%26aulast%3DPatzold%26aufirst%3DS.%26aulast%3DVillanueva%26aufirst%3DJ.%26aulast%3DKrepler%26aufirst%3DC.%26aulast%3DFukunaga-Kalabis%26aufirst%3DM.%26aulast%3DHoth%26aufirst%3DM.%26aulast%3DBastian%26aufirst%3DB.%2BC.%26aulast%3DVogt%26aufirst%3DT.%26aulast%3DHerlyn%26aufirst%3DM.%26atitle%3DOvercoming%2520intrinsic%2520multidrug%2520resistance%2520in%2520melanoma%2520by%2520blocking%2520the%2520mitochondrial%2520respiratory%2520chain%2520of%2520slow-cycling%2520JARID1B%2528high%2529%2520cells%26jtitle%3DCancer%2520Cell%26date%3D2013%26volume%3D23%26spage%3D811%26epage%3D825%26doi%3D10.1016%2Fj.ccr.2013.05.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sriskanthadevan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeyaraju, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skrtic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurren, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gronda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jitkova, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukhai, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maclean, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laister, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goard, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullen, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penn, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minden, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schimmer, A. D.</span></span> <span> </span><span class="NLM_article-title">AML cells have low spare reserve capacity in their respiratory chain that renders them susceptible to oxidative metabolic stress</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">2120</span>â <span class="NLM_lpage">2130</span>, <span class="refDoi">Â DOI: 10.1182/blood-2014-08-594408</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1182%2Fblood-2014-08-594408" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=25631767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtV2mtbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2015&pages=2120-2130&author=S.+Sriskanthadevanauthor=D.+V.+Jeyarajuauthor=T.+E.+Chungauthor=S.+Prabhaauthor=W.+Xuauthor=M.+Skrticauthor=B.+Jhasauthor=R.+Hurrenauthor=M.+Grondaauthor=X.+M.+Wangauthor=Y.+Jitkovaauthor=M.+A.+Sukhaiauthor=F.+H.+Linauthor=N.+Macleanauthor=R.+Laisterauthor=C.+A.+Goardauthor=P.+J.+Mullenauthor=S.+Xieauthor=L.+Z.+Pennauthor=I.+M.+Rogersauthor=J.+E.+Dickauthor=M.+D.+Mindenauthor=A.+D.+Schimmer&title=AML+cells+have+low+spare+reserve+capacity+in+their+respiratory+chain+that+renders+them+susceptible+to+oxidative+metabolic+stress&doi=10.1182%2Fblood-2014-08-594408"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">AML cells have low spare reserve capacity in their respiratory chain that renders them susceptible to oxidative metabolic stress</span></div><div class="casAuthors">Sriskanthadevan, Shrivani; Jeyaraju, Danny V.; Chung, Timothy E.; Prabha, Swayam; Xu, Wei; Skrtic, Marko; Jhas, Bozhena; Hurren, Rose; Gronda, Marcela; Wang, Xiaoming; Jitkova, Yulia; Sukhai, Mahadeo A.; Lin, Feng-Hsu; MacLean, Neil; Laister, Rob; Goard, Carolyn A.; Mullen, Peter J.; Xie, Stephanie; Penn, Linda Z.; Rogers, Ian M.; Dick, John E.; Minden, Mark D.; Schimmer, Aaron D.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2120-2130</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Mitochondrial respiration is a crucial component of cellular metab. that can become dysregulated in cancer.  Compared with normal hematopoietic cells, acute myeloid leukemia (AML) cells and patient samples have higher mitochondrial mass, without a concomitant increase in respiratory chain complex activity.  Hence these cells have a lower spare reserve capacity in the respiratory chain and are more susceptible to oxidative stress.  We therefore tested the effects of increasing the electron flux through the respiratory chain as a strategy to induce oxidative stress and cell death preferentially in AML cells.  Treatment with the fatty acid palmitate induced oxidative stress and cell death in AML cells, and it suppressed tumor burden in leukemic cell lines and primary patient sample xenografts in the absence of overt toxicity to normal cells and organs.  These data highlight a unique metabolic vulnerability in AML, and identify a new therapeutic strategy that targets abnormal oxidative metab. in this malignancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlrSxX37aGirVg90H21EOLACvtfcHk0lgtrqQBUWRrzg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtV2mtbc%253D&md5=d3b672e10dadfdaca69257d5336fae81</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1182%2Fblood-2014-08-594408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2014-08-594408%26sid%3Dliteratum%253Aachs%26aulast%3DSriskanthadevan%26aufirst%3DS.%26aulast%3DJeyaraju%26aufirst%3DD.%2BV.%26aulast%3DChung%26aufirst%3DT.%2BE.%26aulast%3DPrabha%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DSkrtic%26aufirst%3DM.%26aulast%3DJhas%26aufirst%3DB.%26aulast%3DHurren%26aufirst%3DR.%26aulast%3DGronda%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DX.%2BM.%26aulast%3DJitkova%26aufirst%3DY.%26aulast%3DSukhai%26aufirst%3DM.%2BA.%26aulast%3DLin%26aufirst%3DF.%2BH.%26aulast%3DMaclean%26aufirst%3DN.%26aulast%3DLaister%26aufirst%3DR.%26aulast%3DGoard%26aufirst%3DC.%2BA.%26aulast%3DMullen%26aufirst%3DP.%2BJ.%26aulast%3DXie%26aufirst%3DS.%26aulast%3DPenn%26aufirst%3DL.%2BZ.%26aulast%3DRogers%26aufirst%3DI.%2BM.%26aulast%3DDick%26aufirst%3DJ.%2BE.%26aulast%3DMinden%26aufirst%3DM.%2BD.%26aulast%3DSchimmer%26aufirst%3DA.%2BD.%26atitle%3DAML%2520cells%2520have%2520low%2520spare%2520reserve%2520capacity%2520in%2520their%2520respiratory%2520chain%2520that%2520renders%2520them%2520susceptible%2520to%2520oxidative%2520metabolic%2520stress%26jtitle%3DBlood%26date%3D2015%26volume%3D125%26spage%3D2120%26epage%3D2130%26doi%3D10.1182%2Fblood-2014-08-594408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gui, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosios, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bush, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freinkman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vander Heiden, M. G.</span></span> <span> </span><span class="NLM_article-title">Supporting aspartate biosynthesis is an essential function of respiration in proliferating cells</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">552</span>â <span class="NLM_lpage">563</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2015.07.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.cell.2015.07.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=26232225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht12jsrrO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2015&pages=552-563&author=L.+B.+Sullivanauthor=D.+Y.+Guiauthor=A.+M.+Hosiosauthor=L.+N.+Bushauthor=E.+Freinkmanauthor=M.+G.+Vander+Heiden&title=Supporting+aspartate+biosynthesis+is+an+essential+function+of+respiration+in+proliferating+cells&doi=10.1016%2Fj.cell.2015.07.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Supporting aspartate biosynthesis is an essential function of respiration in proliferating cells</span></div><div class="casAuthors">Sullivan, Lucas B.; Gui, Dan Y.; Hosios, Aaron M.; Bush, Lauren N.; Freinkman, Elizaveta; Vander Heiden, Matthew G.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">552-563</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Mitochondrial respiration is important for cell proliferation; however, the specific metabolic requirements fulfilled by respiration to support proliferation have not been defined.  Here, the authors show that a major role of respiration in proliferating cells is to provide electron acceptors for aspartate biosynthesis.  This finding was consistent with the observation that cells lacking a functional respiratory chain are auxotrophic for pyruvate, which serves as an exogenous electron acceptor.  Further, the pyruvate requirement could be fulfilled with an alternative electron acceptor, Î±-ketobutyrate, which provides cells neither carbon nor ATP.  Î±-Ketobutyrate restores proliferation when respiration is inhibited, suggesting that an alternative electron acceptor can substitute for respiration to support proliferation.  The authors found that electron acceptors were limiting for producing aspartate, and that supplying aspartate enabled proliferation of respiration-deficient cells in the absence of exogenous electron acceptors.  Together, these data argue a major function of respiration in proliferating cells is to support aspartate biosynthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodRkr248gPCLVg90H21EOLACvtfcHk0lgtrqQBUWRrzg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht12jsrrO&md5=73ee8247da401b5dbdac31ca1954383e</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2015.07.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2015.07.017%26sid%3Dliteratum%253Aachs%26aulast%3DSullivan%26aufirst%3DL.%2BB.%26aulast%3DGui%26aufirst%3DD.%2BY.%26aulast%3DHosios%26aufirst%3DA.%2BM.%26aulast%3DBush%26aufirst%3DL.%2BN.%26aulast%3DFreinkman%26aufirst%3DE.%26aulast%3DVander%2BHeiden%26aufirst%3DM.%2BG.%26atitle%3DSupporting%2520aspartate%2520biosynthesis%2520is%2520an%2520essential%2520function%2520of%2520respiration%2520in%2520proliferating%2520cells%26jtitle%3DCell%26date%3D2015%26volume%3D162%26spage%3D552%26epage%3D563%26doi%3D10.1016%2Fj.cell.2015.07.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Birsoy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freinkman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abu-Remaileh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span> <span> </span><span class="NLM_article-title">An essential role of the mitochondrial electron transport chain in cell proliferation is to enable aspartate synthesis</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">540</span>â <span class="NLM_lpage">551</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2015.07.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.cell.2015.07.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=26232224" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht12jsrrL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2015&pages=540-551&author=K.+Birsoyauthor=T.+Wangauthor=W.+W.+Chenauthor=E.+Freinkmanauthor=M.+Abu-Remailehauthor=D.+M.+Sabatini&title=An+essential+role+of+the+mitochondrial+electron+transport+chain+in+cell+proliferation+is+to+enable+aspartate+synthesis&doi=10.1016%2Fj.cell.2015.07.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">An essential role of the mitochondrial electron transport chain in cell proliferation is to enable aspartate synthesis</span></div><div class="casAuthors">Birsoy, Kivanc; Wang, Tim; Chen, Walter W.; Freinkman, Elizaveta; Abu-Remaileh, Monther; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">540-551</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The mitochondrial electron transport chain (ETC) enables many metabolic processes, but why its inhibition suppresses cell proliferation is unclear.  It is also not well understood why pyruvate supplementation allows cells lacking ETC function to proliferate.  Here, the authors used a CRISPR-based genetic screen to identify genes whose loss sensitizes human cells to phenformin, a complex I inhibitor.  The screen yielded GOT1, the cytosolic aspartate aminotransferase, loss of which kills cells upon ETC inhibition.  GOT1 normally consumes aspartate to transfer electrons into mitochondria, but, upon ETC inhibition, it reverses to generate aspartate in the cytosol, which partially compensates for the loss of mitochondrial aspartate biosynthesis.  Pyruvate stimulates aspartate biosynthesis in a GOT1-dependent fashion, which is required for pyruvate to rescue proliferation of cells with ETC dysfunction.  Aspartate supplementation or overexpression of an aspartate transporter allows cells without ETC activity to proliferate.  Thus, enabling aspartate biosynthesis is an essential role of the ETC in cell proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSh9Ap9MlPcbVg90H21EOLACvtfcHk0lh3QOsyhPRgDQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht12jsrrL&md5=d2e142821b9e2e5ff8932c6ba60f0892</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2015.07.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2015.07.016%26sid%3Dliteratum%253Aachs%26aulast%3DBirsoy%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DW.%2BW.%26aulast%3DFreinkman%26aufirst%3DE.%26aulast%3DAbu-Remaileh%26aufirst%3DM.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DAn%2520essential%2520role%2520of%2520the%2520mitochondrial%2520electron%2520transport%2520chain%2520in%2520cell%2520proliferation%2520is%2520to%2520enable%2520aspartate%2520synthesis%26jtitle%3DCell%26date%3D2015%26volume%3D162%26spage%3D540%26epage%3D551%26doi%3D10.1016%2Fj.cell.2015.07.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Reyes, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardona, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McElroy, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kihshen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reczek, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinert, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piseaux, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budinger, G. R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandel, N. S.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial ubiquinol oxidation is necessary for tumour growth</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>585</i></span>,  <span class="NLM_fpage">288</span>â <span class="NLM_lpage">292</span>, <span class="refDoi">Â DOI: 10.1038/s41586-020-2475-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fs41586-020-2475-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=32641834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlCqtb3L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=585&publication_year=2020&pages=288-292&author=I.+Martinez-Reyesauthor=L.+R.+Cardonaauthor=H.+Kongauthor=K.+Vasanauthor=G.+S.+McElroyauthor=M.+Wernerauthor=H.+Kihshenauthor=C.+R.+Reczekauthor=S.+E.+Weinbergauthor=P.+Gaoauthor=E.+M.+Steinertauthor=R.+Piseauxauthor=G.+R.+S.+Budingerauthor=N.+S.+Chandel&title=Mitochondrial+ubiquinol+oxidation+is+necessary+for+tumour+growth&doi=10.1038%2Fs41586-020-2475-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial ubiquinol oxidation is necessary for tumour growth</span></div><div class="casAuthors">Martinez-Reyes, Inmaculada; Cardona, Luzivette Robles; Kong, Hyewon; Vasan, Karthik; McElroy, Gregory S.; Werner, Marie; Kihshen, Hermon; Reczek, Colleen R.; Weinberg, Samuel E.; Gao, Peng; Steinert, Elizabeth M.; Piseaux, Raul; Budinger, G. R. Scott; Chandel, Navdeep S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">585</span>
        (<span class="NLM_cas:issue">7824</span>),
    <span class="NLM_cas:pages">288-292</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: The mitochondrial electron transport chain (ETC) is necessary for tumor growth1-6 and its inhibition has demonstrated anti-tumor efficacy in combination with targeted therapies7-9.  Furthermore, human brain and lung tumors display robust glucose oxidn. by mitochondria10,11.  However, it is unclear why a functional ETC is necessary for tumor growth in vivo.  ETC function is coupled to the generation of ATP-i.e., oxidative phosphorylation and the prodn. of metabolites by the tricarboxylic acid (TCA) cycle.  Mitochondrial complexes I and II donate electrons to ubiquinone, resulting in the generation of ubiquinol and the regeneration of the NAD+ and FAD cofactors, and complex III oxidizes ubiquinol back to ubiquinone, which also serves as an electron acceptor for dihydroorotate dehydrogenase (DHODH)-an enzyme necessary for de novo pyrimidine synthesis.  Here we show impaired tumor growth in cancer cells that lack mitochondrial complex III.  This phenotype was rescued by ectopic expression of Ciona intestinalis alternative oxidase (AOX)12, which also oxidizes ubiquinol to ubiquinone.  Loss of mitochondrial complex I, II or DHODH diminished the tumor growth of AOX-expressing cancer cells deficient in mitochondrial complex III, which highlights the necessity of ubiquinone as an electron acceptor for tumor growth.  Cancer cells that lack mitochondrial complex III but can regenerate NAD+ by expression of the NADH oxidase from Lactobacillus brevis (LbNOX)13 targeted to the mitochondria or cytosol were still unable to grow tumors.  This suggests that regeneration of NAD+ is not sufficient to drive tumor growth in vivo.  Collectively, our findings indicate that tumor growth requires the ETC to oxidize ubiquinol, which is essential to drive the oxidative TCA cycle and DHODH activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH8z7CmqLcCbVg90H21EOLACvtfcHk0lh3QOsyhPRgDQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlCqtb3L&md5=2df7dc3ff7e24711c075a3e9f671c79c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fs41586-020-2475-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-020-2475-6%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez-Reyes%26aufirst%3DI.%26aulast%3DCardona%26aufirst%3DL.%2BR.%26aulast%3DKong%26aufirst%3DH.%26aulast%3DVasan%26aufirst%3DK.%26aulast%3DMcElroy%26aufirst%3DG.%2BS.%26aulast%3DWerner%26aufirst%3DM.%26aulast%3DKihshen%26aufirst%3DH.%26aulast%3DReczek%26aufirst%3DC.%2BR.%26aulast%3DWeinberg%26aufirst%3DS.%2BE.%26aulast%3DGao%26aufirst%3DP.%26aulast%3DSteinert%26aufirst%3DE.%2BM.%26aulast%3DPiseaux%26aufirst%3DR.%26aulast%3DBudinger%26aufirst%3DG.%2BR.%2BS.%26aulast%3DChandel%26aufirst%3DN.%2BS.%26atitle%3DMitochondrial%2520ubiquinol%2520oxidation%2520is%2520necessary%2520for%2520tumour%2520growth%26jtitle%3DNature%26date%3D2020%26volume%3D585%26spage%3D288%26epage%3D292%26doi%3D10.1038%2Fs41586-020-2475-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Birsoy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Possemato, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorbeer, F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayraktar, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiru, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yucel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clish, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span> <span> </span><span class="NLM_article-title">Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>508</i></span>,  <span class="NLM_fpage">108</span>â <span class="NLM_lpage">112</span>, <span class="refDoi">Â DOI: 10.1038/nature13110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fnature13110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=24670634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlsFyjs7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=508&publication_year=2014&pages=108-112&author=K.+Birsoyauthor=R.+Possematoauthor=F.+K.+Lorbeerauthor=E.+C.+Bayraktarauthor=P.+Thiruauthor=B.+Yucelauthor=T.+Wangauthor=W.+W.+Chenauthor=C.+B.+Clishauthor=D.+M.+Sabatini&title=Metabolic+determinants+of+cancer+cell+sensitivity+to+glucose+limitation+and+biguanides&doi=10.1038%2Fnature13110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides</span></div><div class="casAuthors">Birsoy, Kivanc; Possemato, Richard; Lorbeer, Franziska K.; Bayraktar, Erol C.; Thiru, Prathapan; Yucel, Burcu; Wang, Tim; Chen, Walter W.; Clish, Clary B.; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">508</span>
        (<span class="NLM_cas:issue">7494</span>),
    <span class="NLM_cas:pages">108-112</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">As the concns. of highly consumed nutrients, particularly glucose, are generally lower in tumors than in normal tissues, cancer cells must adapt their metab. to the tumor microenvironment.  A better understanding of these adaptations might reveal cancer cell liabilities that can be exploited for therapeutic benefit.  Here we developed a continuous-flow culture app. (Nutrostat) for maintaining proliferating cells in low-nutrient media for long periods of time, and used it to undertake competitive proliferation assays on a pooled collection of barcoded cancer cell lines cultured in low-glucose conditions.  Sensitivity to low glucose varies amongst cell lines, and an RNA interference (RNAi) screen pinpointed mitochondrial oxidative phosphorylation (OXPHOS) as the major pathway required for optimal proliferation in low glucose.  We found that cell lines most sensitive to low glucose are defective in the OXPHOS upregulation that is normally caused by glucose limitation as a result of either mitochondrial DNA (mtDNA) mutations in complex I genes or impaired glucose utilization.  These defects predict sensitivity to biguanides, antidiabetic drugs that inhibit OXPHOS, when cancer cells are grown in low glucose or as tumor xenografts.  Notably, the biguanide sensitivity of cancer cells with mtDNA mutations was reversed by ectopic expression of yeast NDI1, a ubiquinone oxidoreductase that allows bypass of complex I function.  Thus, we conclude that mtDNA mutations and impaired glucose utilization are potential biomarkers for identifying tumors with increased sensitivity to OXPHOS inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQuk6Z79FsXLVg90H21EOLACvtfcHk0ljXB7k27bHdeg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlsFyjs7k%253D&md5=1678d30d921453149c0da2c87adf3ccd</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnature13110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13110%26sid%3Dliteratum%253Aachs%26aulast%3DBirsoy%26aufirst%3DK.%26aulast%3DPossemato%26aufirst%3DR.%26aulast%3DLorbeer%26aufirst%3DF.%2BK.%26aulast%3DBayraktar%26aufirst%3DE.%2BC.%26aulast%3DThiru%26aufirst%3DP.%26aulast%3DYucel%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DW.%2BW.%26aulast%3DClish%26aufirst%3DC.%2BB.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DMetabolic%2520determinants%2520of%2520cancer%2520cell%2520sensitivity%2520to%2520glucose%2520limitation%2520and%2520biguanides%26jtitle%3DNature%26date%3D2014%26volume%3D508%26spage%3D108%26epage%3D112%26doi%3D10.1038%2Fnature13110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naguib, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reczek, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watrud, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herzka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salas, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Amine, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Francesco, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marszalek, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappin, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandel, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trotman, L. C.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial complex I inhibitors expose a vulnerability for selective killing of Pten-null cells</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">58</span>â <span class="NLM_lpage">67</span>, <span class="refDoi">Â DOI: 10.1016/j.celrep.2018.03.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.celrep.2018.03.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=29617673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVKqtro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=58-67&author=A.+Naguibauthor=G.+Mathewauthor=C.+R.+Reczekauthor=K.+Watrudauthor=A.+Ambricoauthor=T.+Herzkaauthor=I.+C.+Salasauthor=M.+F.+Leeauthor=N.+El-Amineauthor=W.+Zhengauthor=M.+E.+Di+Francescoauthor=J.+R.+Marszalekauthor=D.+J.+Pappinauthor=N.+S.+Chandelauthor=L.+C.+Trotman&title=Mitochondrial+complex+I+inhibitors+expose+a+vulnerability+for+selective+killing+of+Pten-null+cells&doi=10.1016%2Fj.celrep.2018.03.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial Complex I Inhibitors Expose a Vulnerability for Selective Killing of Pten-Null Cells</span></div><div class="casAuthors">Naguib, Adam; Mathew, Grinu; Reczek, Colleen R.; Watrud, Kaitlin; Ambrico, Alexandra; Herzka, Tali; Salas, Irene Casanova; Lee, Matthew F.; El-Amine, Nour; Zheng, Wu; Di Francesco, M. Emilia; Marszalek, Joseph R.; Pappin, Darryl J.; Chandel, Navdeep S.; Trotman, Lloyd C.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-67</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A hallmark of advanced prostate cancer (PC) is the concomitant loss of PTEN and p53 function.  To selectively eliminate such cells, we screened cytotoxic compds. on Pten-/-;Trp53-/- fibroblasts and their Pten-WT ref.  Highly selective killing of Pten-null cells can be achieved by deguelin, a natural insecticide.  Deguelin eliminates Pten-deficient cells through inhibition of mitochondrial complex I (CI).  Five hundred-fold higher drug doses are needed to obtain the same killing of Pten-WT cells, even though deguelin blocks their electron transport chain equally well.  Selectivity arises because mitochondria of Pten-null cells consume ATP through complex V, instead of producing it.  The resulting glucose dependency can be exploited to selectively kill Pten-null cells with clin. relevant CI inhibitors, esp. if they are lipophilic.  In vivo, deguelin suppressed disease in our genetically engineered mouse model for metastatic PC.  Our data thus introduce a vulnerability for highly selective targeting of incurable PC with inhibitors of CI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSXqfatJ1anLVg90H21EOLACvtfcHk0ljXB7k27bHdeg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVKqtro%253D&md5=175649704577b3877aaa723a0ab1ec4c</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2018.03.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2018.03.032%26sid%3Dliteratum%253Aachs%26aulast%3DNaguib%26aufirst%3DA.%26aulast%3DMathew%26aufirst%3DG.%26aulast%3DReczek%26aufirst%3DC.%2BR.%26aulast%3DWatrud%26aufirst%3DK.%26aulast%3DAmbrico%26aufirst%3DA.%26aulast%3DHerzka%26aufirst%3DT.%26aulast%3DSalas%26aufirst%3DI.%2BC.%26aulast%3DLee%26aufirst%3DM.%2BF.%26aulast%3DEl-Amine%26aufirst%3DN.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DDi%2BFrancesco%26aufirst%3DM.%2BE.%26aulast%3DMarszalek%26aufirst%3DJ.%2BR.%26aulast%3DPappin%26aufirst%3DD.%2BJ.%26aulast%3DChandel%26aufirst%3DN.%2BS.%26aulast%3DTrotman%26aufirst%3DL.%2BC.%26atitle%3DMitochondrial%2520complex%2520I%2520inhibitors%2520expose%2520a%2520vulnerability%2520for%2520selective%2520killing%2520of%2520Pten-null%2520cells%26jtitle%3DCell%2520Rep.%26date%3D2018%26volume%3D23%26spage%3D58%26epage%3D67%26doi%3D10.1016%2Fj.celrep.2018.03.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lissanu
Deribe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terranova, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Ledesma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullinax, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khor, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kochat, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asara, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadimitrakopoulou, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wistuba, I. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marszalek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Futreal, P. A.</span></span> <span> </span><span class="NLM_article-title">Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1047</span>â <span class="NLM_lpage">1057</span>, <span class="refDoi">Â DOI: 10.1038/s41591-018-0019-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fs41591-018-0019-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=29892061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFWru7jF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=1047-1057&author=Y.+Lissanu%0ADeribeauthor=Y.+Sunauthor=C.+Terranovaauthor=F.+Khanauthor=J.+Martinez-Ledesmaauthor=J.+Gayauthor=G.+Gaoauthor=R.+A.+Mullinaxauthor=T.+Khorauthor=N.+Fengauthor=Y.+H.+Linauthor=C.+C.+Wuauthor=C.+Reyesauthor=Q.+Pengauthor=F.+Robinsonauthor=A.+Inoueauthor=V.+Kochatauthor=C.+G.+Liuauthor=J.+M.+Asaraauthor=C.+Moranauthor=F.+Mullerauthor=J.+Wangauthor=B.+Fangauthor=V.+Papadimitrakopoulouauthor=I.+I.+Wistubaauthor=K.+Raiauthor=J.+Marszalekauthor=P.+A.+Futreal&title=Mutations+in+the+SWI%2FSNF+complex+induce+a+targetable+dependence+on+oxidative+phosphorylation+in+lung+cancer&doi=10.1038%2Fs41591-018-0019-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer</span></div><div class="casAuthors">Lissanu Deribe, Yonathan; Sun, Yuting; Terranova, Christopher; Khan, Fatima; Martinez-Ledesma, Juan; Gay, Jason; Gao, Guang; Mullinax, Robert A.; Khor, Tin; Feng, Ningping; Lin, Yu-Hsi; Wu, Chia-Chin; Reyes, Claudia; Peng, Qian; Robinson, Frederick; Inoue, Akira; Kochat, Veena; Liu, Chang-Gong; Asara, John M.; Moran, Cesar; Muller, Florian; Wang, Jing; Fang, Bingliang; Papadimitrakopoulou, Vali; Wistuba, Ignacio I.; Rai, Kunal; Marszalek, Joseph; Futreal, P. Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1047-1057</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Lung cancer is a devastating disease that remains a top cause of cancer mortality.  Despite improvements with targeted and immunotherapies, the majority of patients with lung cancer lack effective therapies, underscoring the need for addnl. treatment approaches.  Genomic studies have identified frequent alterations in components of the SWI/SNF chromatin remodeling complex including SMARCA4 and ARID1A.  To understand the mechanisms of tumorigenesis driven by mutations in this complex, we developed a genetically engineered mouse model of lung adenocarcinoma by ablating Smarca4 in the lung epithelium.  We demonstrate that Smarca4 acts as a bona fide tumor suppressor and cooperates with p53 loss and Kras activation.  Gene expression analyses revealed the signature of enhanced oxidative phosphorylation (OXPHOS) in SMARCA4 mutant tumors.  We further show that SMARCA4 mutant cells have enhanced oxygen consumption and increased respiratory capacity.  Importantly, SMARCA4 mutant lung cancer cell lines and xenograft tumors have marked sensitivity to inhibition of OXPHOS by a novel small mol., IACS-010759, that is under clin. development.  Mechanistically, we show that SMARCA4-deficient cells have a blunted transcriptional response to energy stress creating a therapeutically exploitable synthetic lethal interaction.  These findings provide the mechanistic basis for further development of OXPHOS inhibitors as therapeutics against SWI/SNF mutant tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEF3LTCtYtm7Vg90H21EOLACvtfcHk0ljXB7k27bHdeg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFWru7jF&md5=4a8b608f4317ba3e44b9d4753a643242</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fs41591-018-0019-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41591-018-0019-5%26sid%3Dliteratum%253Aachs%26aulast%3DLissanu%2BDeribe%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DTerranova%26aufirst%3DC.%26aulast%3DKhan%26aufirst%3DF.%26aulast%3DMartinez-Ledesma%26aufirst%3DJ.%26aulast%3DGay%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DG.%26aulast%3DMullinax%26aufirst%3DR.%2BA.%26aulast%3DKhor%26aufirst%3DT.%26aulast%3DFeng%26aufirst%3DN.%26aulast%3DLin%26aufirst%3DY.%2BH.%26aulast%3DWu%26aufirst%3DC.%2BC.%26aulast%3DReyes%26aufirst%3DC.%26aulast%3DPeng%26aufirst%3DQ.%26aulast%3DRobinson%26aufirst%3DF.%26aulast%3DInoue%26aufirst%3DA.%26aulast%3DKochat%26aufirst%3DV.%26aulast%3DLiu%26aufirst%3DC.%2BG.%26aulast%3DAsara%26aufirst%3DJ.%2BM.%26aulast%3DMoran%26aufirst%3DC.%26aulast%3DMuller%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DFang%26aufirst%3DB.%26aulast%3DPapadimitrakopoulou%26aufirst%3DV.%26aulast%3DWistuba%26aufirst%3DI.%2BI.%26aulast%3DRai%26aufirst%3DK.%26aulast%3DMarszalek%26aufirst%3DJ.%26aulast%3DFutreal%26aufirst%3DP.%2BA.%26atitle%3DMutations%2520in%2520the%2520SWI%252FSNF%2520complex%2520induce%2520a%2520targetable%2520dependence%2520on%2520oxidative%2520phosphorylation%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26spage%3D1047%26epage%3D1057%26doi%3D10.1038%2Fs41591-018-0019-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sancho, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barneda, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heeschen, C.</span></span> <span> </span><span class="NLM_article-title">Hallmarks of cancer stem cell metabolism</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">1305</span>â <span class="NLM_lpage">1312</span>, <span class="refDoi">Â DOI: 10.1038/bjc.2016.152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fbjc.2016.152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27219018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC28Xos1Wnsrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2016&pages=1305-1312&author=P.+Sanchoauthor=D.+Barnedaauthor=C.+Heeschen&title=Hallmarks+of+cancer+stem+cell+metabolism&doi=10.1038%2Fbjc.2016.152"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Hallmarks of cancer stem cell metabolism</span></div><div class="casAuthors">Sancho, Patricia; Barneda, David; Heeschen, Christopher</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1305-1312</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cancer cells adapt cellular metab. to cope with their high proliferation rate.  Instead of primarily using oxidative phosphorylation (OXPHOS), cancer cells use less efficient glycolysis for the prodn. of ATP and building blocks (Warburg effect).  However, tumors are not uniform, but rather functionally heterogeneous and harbor a subset of cancer cells with stemness features.  Such cancer cells have the ability to repopulate the entire tumor and thus have been termed cancer stem cells (CSCs) or tumor-initiating cells (TICs).  As opposed to differentiated bulk tumor cells relying on glycolysis, CSCs show a distinct metabolic phenotype that, depending on the cancer type, can be highly glycolytic or OXPHOS dependent.  In either case, mitochondrial function is crit. and takes center stage in CSC functionality.  Remaining controversies in this young and emerging research field may be related to CSC isolation techniques and/or the use of less suitable model systems.  Still, the apparent dependence of CSCs on mitochondrial function, regardless of their primary metabolic phenotype, represents a previously unrecognised Achilles heel amendable for therapeutic intervention.  Elimination of highly chemoresistant CSCs as the root of many cancers via inhibition of mitochondrial function bears the potential to prevent relapse from disease and thus improve patients' long-term outcome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWf3G0xGM-TLVg90H21EOLACvtfcHk0lgshC8sPhgPNQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xos1Wnsrw%253D&md5=5371db328bc3616ad92d716a47c4a26c</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2016.152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2016.152%26sid%3Dliteratum%253Aachs%26aulast%3DSancho%26aufirst%3DP.%26aulast%3DBarneda%26aufirst%3DD.%26aulast%3DHeeschen%26aufirst%3DC.%26atitle%3DHallmarks%2520of%2520cancer%2520stem%2520cell%2520metabolism%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2016%26volume%3D114%26spage%3D1305%26epage%3D1312%26doi%3D10.1038%2Fbjc.2016.152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuntz, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baquero, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michie, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tardito, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holyoake, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helgason, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottlieb, E.</span></span> <span> </span><span class="NLM_article-title">Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1234</span>â <span class="NLM_lpage">1240</span>, <span class="refDoi">Â DOI: 10.1038/nm.4399</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fnm.4399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=28920959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFSku7%252FE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=1234-1240&author=E.+M.+Kuntzauthor=P.+Baqueroauthor=A.+M.+Michieauthor=K.+Dunnauthor=S.+Tarditoauthor=T.+L.+Holyoakeauthor=G.+V.+Helgasonauthor=E.+Gottlieb&title=Targeting+mitochondrial+oxidative+phosphorylation+eradicates+therapy-resistant+chronic+myeloid+leukemia+stem+cells&doi=10.1038%2Fnm.4399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells</span></div><div class="casAuthors">Kuntz, Elodie M.; Baquero, Pablo; Michie, Alison M.; Dunn, Karen; Tardito, Saverio; Holyoake, Tessa L.; Helgason, G. Vignir; Gottlieb, Eyal</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1234-1240</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Treatment of chronic myeloid leukemia (CML) with imatinib mesylate and other second- and/or third-generation c-Abl-specific tyrosine kinase inhibitors (TKIs) has substantially extended patient survival.  However, TKIs primarily target differentiated cells and do not eliminate leukemic stem cells (LSCs).  Therefore, targeting minimal residual disease to prevent acquired resistance and/or disease relapse requires identification of new LSC-selective target(s) that can be exploited therapeutically.  Considering that malignant transformation involves cellular metabolic changes, which may in turn render the transformed cells susceptible to specific assaults in a selective manner, we searched for such vulnerabilities in CML LSCs.  We performed metabolic analyses on both stem cell-enriched (CD34+ and CD34+CD38-) and differentiated (CD34-) cells derived from individuals with CML, and we compared the signature of these cells with that of their normal counterparts.  Through combination of stable isotope-assisted metabolomics with functional assays, we demonstrate that primitive CML cells rely on upregulated oxidative metab. for their survival.  We also show that combination treatment with imatinib and tigecycline, an antibiotic that inhibits mitochondrial protein translation, selectively eradicates CML LSCs both in vitro and in a xenotransplantation model of human CML.  Our findings provide a strong rationale for investigation of the use of TKIs in combination with tigecycline to treat patients with CML with minimal residual disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_DS1g9Q8oLLVg90H21EOLACvtfcHk0lgshC8sPhgPNQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFSku7%252FE&md5=e3758c3177849483ae61fdb51351ba49</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnm.4399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.4399%26sid%3Dliteratum%253Aachs%26aulast%3DKuntz%26aufirst%3DE.%2BM.%26aulast%3DBaquero%26aufirst%3DP.%26aulast%3DMichie%26aufirst%3DA.%2BM.%26aulast%3DDunn%26aufirst%3DK.%26aulast%3DTardito%26aufirst%3DS.%26aulast%3DHolyoake%26aufirst%3DT.%2BL.%26aulast%3DHelgason%26aufirst%3DG.%2BV.%26aulast%3DGottlieb%26aufirst%3DE.%26atitle%3DTargeting%2520mitochondrial%2520oxidative%2520phosphorylation%2520eradicates%2520therapy-resistant%2520chronic%2520myeloid%2520leukemia%2520stem%2520cells%26jtitle%3DNat.%2520Med.%26date%3D2017%26volume%3D23%26spage%3D1234%26epage%3D1240%26doi%3D10.1038%2Fnm.4399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Viale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettazzoni, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyssiotis, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ying, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchesini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carugo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuliani, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kost-Alimova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nezi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deem, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapoor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunetto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asara, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffernan, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimmelman, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DePinho, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Draetta, G. F.</span></span> <span> </span><span class="NLM_article-title">Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>514</i></span>,  <span class="NLM_fpage">628</span>â <span class="NLM_lpage">632</span>, <span class="refDoi">Â DOI: 10.1038/nature13611</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fnature13611" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=25119024" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlGnt7vO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=514&publication_year=2014&pages=628-632&author=A.+Vialeauthor=P.+Pettazzoniauthor=C.+A.+Lyssiotisauthor=H.+Yingauthor=N.+Sanchezauthor=M.+Marchesiniauthor=A.+Carugoauthor=T.+Greenauthor=S.+Sethauthor=V.+Giulianiauthor=M.+Kost-Alimovaauthor=F.+Mullerauthor=S.+Collaauthor=L.+Neziauthor=G.+Genoveseauthor=A.+K.+Deemauthor=A.+Kapoorauthor=W.+Yaoauthor=E.+Brunettoauthor=Y.+Kangauthor=M.+Yuanauthor=J.+M.+Asaraauthor=Y.+A.+Wangauthor=T.+P.+Heffernanauthor=A.+C.+Kimmelmanauthor=H.+Wangauthor=J.+B.+Flemingauthor=L.+C.+Cantleyauthor=R.+A.+DePinhoauthor=G.+F.+Draetta&title=Oncogene+ablation-resistant+pancreatic+cancer+cells+depend+on+mitochondrial+function&doi=10.1038%2Fnature13611"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function</span></div><div class="casAuthors">Viale, Andrea; Pettazzoni, Piergiorgio; Lyssiotis, Costas A.; Ying, Haoqiang; Sanchez, Nora; Marchesini, Matteo; Carugo, Alessandro; Green, Tessa; Seth, Sahil; Giuliani, Virginia; Kost-Alimova, Maria; Muller, Florian; Colla, Simona; Nezi, Luigi; Genovese, Giannicola; Deem, Angela K.; Kapoor, Avnish; Yao, Wantong; Brunetto, Emanuela; Kang, Ya'an; Yuan, Min; Asara, John M.; Wang, Y. Alan; Heffernan, Timothy P.; Kimmelman, Alec C.; Wang, Huamin; Fleming, Jason B.; Cantley, Lewis C.; De Pinho, Ronald A.; Draetta, Giulio F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">514</span>
        (<span class="NLM_cas:issue">7524</span>),
    <span class="NLM_cas:pages">628-632</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers in western countries, with a median survival of 6 mo and an extremely low percentage of long-term surviving patients.  KRAS mutations are known to be a driver event of PDAC, but targeting mutant KRAS has proved challenging.  Targeting oncogene-driven signaling pathways is a clin. validated approach for several devastating diseases.  Still, despite marked tumor shrinkage, the frequency of relapse indicates that a fraction of tumor cells survives shut down of oncogenic signaling.  Here we explore the role of mutant KRAS in PDAC maintenance using a recently developed inducible mouse model of mutated Kras (KrasG12D, herein KRas) in a p53LoxP/WT background.  We demonstrate that a subpopulation of dormant tumor cells surviving oncogene ablation (surviving cells) and responsible for tumor relapse has features of cancer stem cells and relies on oxidative phosphorylation for survival.  Transcriptomic and metabolic analyses of surviving cells reveal prominent expression of genes governing mitochondrial function, autophagy and lysosome activity, as well as a strong reliance on mitochondrial respiration and a decreased dependence on glycolysis for cellular energetics.  Accordingly, surviving cells show high sensitivity to oxidative phosphorylation inhibitors, which can inhibit tumor recurrence.  Our integrated analyses illuminate a therapeutic strategy of combined targeting of the KRAS pathway and mitochondrial respiration to manage pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlrfVMNnxZUbVg90H21EOLACvtfcHk0lgshC8sPhgPNQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlGnt7vO&md5=4241d53d0bb097a2e8d5775948154a8d</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnature13611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13611%26sid%3Dliteratum%253Aachs%26aulast%3DViale%26aufirst%3DA.%26aulast%3DPettazzoni%26aufirst%3DP.%26aulast%3DLyssiotis%26aufirst%3DC.%2BA.%26aulast%3DYing%26aufirst%3DH.%26aulast%3DSanchez%26aufirst%3DN.%26aulast%3DMarchesini%26aufirst%3DM.%26aulast%3DCarugo%26aufirst%3DA.%26aulast%3DGreen%26aufirst%3DT.%26aulast%3DSeth%26aufirst%3DS.%26aulast%3DGiuliani%26aufirst%3DV.%26aulast%3DKost-Alimova%26aufirst%3DM.%26aulast%3DMuller%26aufirst%3DF.%26aulast%3DColla%26aufirst%3DS.%26aulast%3DNezi%26aufirst%3DL.%26aulast%3DGenovese%26aufirst%3DG.%26aulast%3DDeem%26aufirst%3DA.%2BK.%26aulast%3DKapoor%26aufirst%3DA.%26aulast%3DYao%26aufirst%3DW.%26aulast%3DBrunetto%26aufirst%3DE.%26aulast%3DKang%26aufirst%3DY.%26aulast%3DYuan%26aufirst%3DM.%26aulast%3DAsara%26aufirst%3DJ.%2BM.%26aulast%3DWang%26aufirst%3DY.%2BA.%26aulast%3DHeffernan%26aufirst%3DT.%2BP.%26aulast%3DKimmelman%26aufirst%3DA.%2BC.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DFleming%26aufirst%3DJ.%2BB.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DDePinho%26aufirst%3DR.%2BA.%26aulast%3DDraetta%26aufirst%3DG.%2BF.%26atitle%3DOncogene%2520ablation-resistant%2520pancreatic%2520cancer%2520cells%2520depend%2520on%2520mitochondrial%2520function%26jtitle%3DNature%26date%3D2014%26volume%3D514%26spage%3D628%26epage%3D632%26doi%3D10.1038%2Fnature13611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giltnane, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balko, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero-Zotano, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nixon, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrada, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lluch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Fidalgo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrejeva, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathmell, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fesik, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arteaga, C. L.</span></span> <span> </span><span class="NLM_article-title">MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">633</span>â <span class="NLM_lpage">647</span>, <span class="refDoi">Â DOI: 10.1016/j.cmet.2017.09.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.cmet.2017.09.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=28978427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Siur7I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2017&pages=633-647&author=K.+M.+Leeauthor=J.+M.+Giltnaneauthor=J.+M.+Balkoauthor=L.+J.+Schwarzauthor=A.+L.+Guerrero-Zotanoauthor=K.+E.+Hutchinsonauthor=M.+J.+Nixonauthor=M.+V.+Estradaauthor=V.+Sanchezauthor=M.+E.+Sandersauthor=T.+Leeauthor=H.+Gomezauthor=A.+Lluchauthor=A.+Perez-Fidalgoauthor=M.+M.+Wolfauthor=G.+Andrejevaauthor=J.+C.+Rathmellauthor=S.+W.+Fesikauthor=C.+L.+Arteaga&title=MYC+and+MCL1+cooperatively+promote+chemotherapy-resistant+breast+cancer+stem+cells+via+regulation+of+mitochondrial+oxidative+phosphorylation&doi=10.1016%2Fj.cmet.2017.09.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation</span></div><div class="casAuthors">Lee, Kyung-min; Giltnane, Jennifer M.; Balko, Justin M.; Schwarz, Luis J.; Guerrero-Zotano, Angel L.; Hutchinson, Katherine E.; Nixon, Mellissa J.; Estrada, Monica V.; Sanchez, Violeta; Sanders, Melinda E.; Lee, Taekyu; Gomez, Henry; Lluch, Ana; Perez-Fidalgo, J. Alejandro; Wolf, Melissa Magdalene; Andrejeva, Gabriela; Rathmell, Jeffrey C.; Fesik, Stephen W.; Arteaga, Carlos L.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">633-647.e7</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Most patients with advanced triple-neg. breast cancer (TNBC) develop drug resistance.  MYC and MCL1 are frequently co-amplified in drug-resistant TNBC after neoadjuvant chemotherapy.  Herein, we demonstrate that MYC and MCL1 cooperate in the maintenance of chemotherapy-resistant cancer stem cells (CSCs) in TNBC.  MYC and MCL1 increased mitochondrial oxidative phosphorylation (mtOXPHOS) and the generation of reactive oxygen species (ROS), processes involved in maintenance of CSCs.  A mutant of MCL1 that cannot localize in mitochondria reduced mtOXPHOS, ROS levels, and drug-resistant CSCs without affecting the anti-apoptotic function of MCL1.  Increased levels of ROS, a byproduct of activated mtOXPHOS, led to the accumulation of HIF-1Î±.  Pharmacol. inhibition of HIF-1Î± attenuated CSC enrichment and tumor initiation in vivo.  These data suggest that (1) MYC and MCL1 confer resistance to chemotherapy by expanding CSCs via mtOXPHOS and (2) targeting mitochondrial respiration and HIF-1Î± may reverse chemotherapy resistance in TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrePHBTkM8-9LVg90H21EOLACvtfcHk0liNeFr5mQ18qA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Siur7I&md5=f4843d94793a47b7e8b8eb45b002b730</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2017.09.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2017.09.009%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%2BM.%26aulast%3DGiltnane%26aufirst%3DJ.%2BM.%26aulast%3DBalko%26aufirst%3DJ.%2BM.%26aulast%3DSchwarz%26aufirst%3DL.%2BJ.%26aulast%3DGuerrero-Zotano%26aufirst%3DA.%2BL.%26aulast%3DHutchinson%26aufirst%3DK.%2BE.%26aulast%3DNixon%26aufirst%3DM.%2BJ.%26aulast%3DEstrada%26aufirst%3DM.%2BV.%26aulast%3DSanchez%26aufirst%3DV.%26aulast%3DSanders%26aufirst%3DM.%2BE.%26aulast%3DLee%26aufirst%3DT.%26aulast%3DGomez%26aufirst%3DH.%26aulast%3DLluch%26aufirst%3DA.%26aulast%3DPerez-Fidalgo%26aufirst%3DA.%26aulast%3DWolf%26aufirst%3DM.%2BM.%26aulast%3DAndrejeva%26aufirst%3DG.%26aulast%3DRathmell%26aufirst%3DJ.%2BC.%26aulast%3DFesik%26aufirst%3DS.%2BW.%26aulast%3DArteaga%26aufirst%3DC.%2BL.%26atitle%3DMYC%2520and%2520MCL1%2520cooperatively%2520promote%2520chemotherapy-resistant%2520breast%2520cancer%2520stem%2520cells%2520via%2520regulation%2520of%2520mitochondrial%2520oxidative%2520phosphorylation%26jtitle%3DCell%2520Metab.%26date%3D2017%26volume%3D26%26spage%3D633%26epage%3D647%26doi%3D10.1016%2Fj.cmet.2017.09.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhalla, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girnun, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clish, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granter, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widlund, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiegelman, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puigserver, P.</span></span> <span> </span><span class="NLM_article-title">PGC1 alpha expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">287</span>â <span class="NLM_lpage">301</span>, <span class="refDoi">Â DOI: 10.1016/j.ccr.2012.11.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.ccr.2012.11.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=23416000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3sXis1Oqs7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=287-301&author=F.+Vazquezauthor=J.+H.+Limauthor=H.+Chimauthor=K.+Bhallaauthor=G.+Girnunauthor=K.+Pierceauthor=C.+B.+Clishauthor=S.+R.+Granterauthor=H.+R.+Widlundauthor=B.+M.+Spiegelmanauthor=P.+Puigserver&title=PGC1+alpha+expression+defines+a+subset+of+human+melanoma+tumors+with+increased+mitochondrial+capacity+and+resistance+to+oxidative+stress&doi=10.1016%2Fj.ccr.2012.11.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">PGC1Î± Expression Defines a Subset of Human Melanoma Tumors with Increased Mitochondrial Capacity and Resistance to Oxidative Stress</span></div><div class="casAuthors">Vazquez, Francisca; Lim, Ji-Hong; Chim, Helen; Bhalla, Kavita; Girnun, Geoff; Pierce, Kerry; Clish, Clary B.; Granter, Scott R.; Widlund, Hans R.; Spiegelman, Bruce M.; Puigserver, Pere</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">287-301</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Cancer cells reprogram their metab. using different strategies to meet energy and anabolic demands to maintain growth and survival.  Understanding the mol. and genetic determinants of these metabolic programs is crit. to successfully exploit them for therapy.  Here, we report that the oncogenic melanocyte lineage-specification transcription factor MITF drives PGC1Î± (PPARGC1A) overexpression in a subset of human melanomas and derived cell lines.  Functionally, PGC1Î± pos. melanoma cells exhibit increased mitochondrial energy metab. and reactive oxygen species (ROS) detoxification capacities that enable survival under oxidative stress conditions.  Conversely, PGC1Î± neg. melanoma cells are more glycolytic and sensitive to ROS-inducing drugs.  These results demonstrate that differences in PGC1Î± levels in melanoma tumors have a profound impact in their metab., biol., and drug sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW8PE2o4ONBLVg90H21EOLACvtfcHk0liNeFr5mQ18qA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXis1Oqs7c%253D&md5=42d9791393a3b0fddb55e5db66ced740</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2012.11.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2012.11.020%26sid%3Dliteratum%253Aachs%26aulast%3DVazquez%26aufirst%3DF.%26aulast%3DLim%26aufirst%3DJ.%2BH.%26aulast%3DChim%26aufirst%3DH.%26aulast%3DBhalla%26aufirst%3DK.%26aulast%3DGirnun%26aufirst%3DG.%26aulast%3DPierce%26aufirst%3DK.%26aulast%3DClish%26aufirst%3DC.%2BB.%26aulast%3DGranter%26aufirst%3DS.%2BR.%26aulast%3DWidlund%26aufirst%3DH.%2BR.%26aulast%3DSpiegelman%26aufirst%3DB.%2BM.%26aulast%3DPuigserver%26aufirst%3DP.%26atitle%3DPGC1%2520alpha%2520expression%2520defines%2520a%2520subset%2520of%2520human%2520melanoma%2520tumors%2520with%2520increased%2520mitochondrial%2520capacity%2520and%2520resistance%2520to%2520oxidative%2520stress%26jtitle%3DCancer%2520Cell%26date%3D2013%26volume%3D23%26spage%3D287%26epage%3D301%26doi%3D10.1016%2Fj.ccr.2012.11.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Farge, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saland, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Toni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aroua, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosseini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosc, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraisse, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scotland, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larrue, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boutzen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feliu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolau-Travers, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassant-Sourdy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serhan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarry, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavitian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaoma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallar, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacovoni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linares, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montersino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellano, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griessinger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collette, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duchamp, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barreira, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gales, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delhommeau, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garmy-Susini, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portais, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danet-Desnoyers, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Recher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarry, J. E.</span></span> <span> </span><span class="NLM_article-title">Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">716</span>â <span class="NLM_lpage">735</span>, <span class="refDoi">Â DOI: 10.1158/2159-8290.CD-16-0441</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F2159-8290.CD-16-0441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=28416471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFCisrbF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=716-735&author=T.+Fargeauthor=E.+Salandauthor=F.+de+Toniauthor=N.+Arouaauthor=M.+Hosseiniauthor=R.+Perryauthor=C.+Boscauthor=M.+Sugitaauthor=L.+Stuaniauthor=M.+Fraisseauthor=S.+Scotlandauthor=C.+Larrueauthor=H.+Boutzenauthor=V.+Feliuauthor=M.+L.+Nicolau-Traversauthor=S.+Cassant-Sourdyauthor=N.+Broinauthor=M.+Davidauthor=N.+Serhanauthor=A.+Sarryauthor=S.+Tavitianauthor=T.+Kaomaauthor=L.+Vallarauthor=J.+Iacovoniauthor=L.+K.+Linaresauthor=C.+Montersinoauthor=R.+Castellanoauthor=E.+Griessingerauthor=Y.+Colletteauthor=O.+Duchampauthor=Y.+Barreiraauthor=P.+Hirschauthor=T.+Palamaauthor=L.+Galesauthor=F.+Delhommeauauthor=B.+H.+Garmy-Susiniauthor=J.+C.+Portaisauthor=F.+Vergezauthor=M.+Selakauthor=G.+Danet-Desnoyersauthor=M.+Carrollauthor=C.+Recherauthor=J.+E.+Sarry&title=Chemotherapy-resistant+human+acute+myeloid+leukemia+cells+are+not+enriched+for+leukemic+stem+cells+but+require+oxidative+metabolism&doi=10.1158%2F2159-8290.CD-16-0441"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism</span></div><div class="casAuthors">Farge, Thomas; Saland, Estelle; de Toni, Fabienne; Aroua, Nesrine; Hosseini, Mohsen; Perry, Robin; Bosc, Claudie; Sugita, Mayumi; Stuani, Lucille; Fraisse, Marine; Scotland, Sarah; Larrue, Clement; Boutzen, Heeleeena; Feeeeliu, Virginie; Nicolau-Travers, Marie-Laure; Cassant-Sourdy, Steeeeephanie; Broin, Nicolas; David, Marion; Serhan, Nizar; Sarry, Audrey; Tavitian, Suzanne; Kaoma, Tony; Vallar, Laurent; Iacovoni, Jason; Linares, Laetitia K.; Montersino, Camille; Castellano, Reeeeeemy; Griessinger, Emmanuel; Collette, Yves; Duchamp, Olivier; Barreira, Yara; Hirsch, Pierre; Palama, Tony; Gales, Lara; Delhommeau, Francois; Garmy-Susini, Barbara H.; Portais, Jean-Charles; Vergez, Francois; Selak, Mary; Danet-Desnoyers, Gwenn; Carroll, Martin; Reeeeeeecher, Christian; Sarry, Jean-Emmanuel</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">716-735</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Chemotherapy-resistant human acute myeloid leukemia (AML) cells are thought to be enriched in quiescent immature leukemic stem cells (LSC).  To validate this hypothesis in vivo, we developed a clin. relevant chemotherapeutic approach treating patient-derived xenografts (PDX) with cytarabine (AraC).  AraC residual AML cells are enriched in neither immature, quiescent cells nor LSCs.  Strikingly, AraC-resistant preexisting and persisting cells displayed high levels of reactive oxygen species, showed increased mitochondrial mass, and retained active polarized mitochondria, consistent with a high oxidative phosphorylation (OXPHOS) status.  AraC residual cells exhibited increased fatty-acid oxidn., upregulated CD36 expression, and a high OXPHOS gene signature predictive for treatment response in PDX and patients with AML.  High OXPHOS but not low OXPHOS human AML cell lines were chemoresistant in vivo.  Targeting mitochondrial protein synthesis, electron transfer, or fatty-acid oxidn. induced an energetic shift toward low OXPHOS and markedly enhanced antileukemic effects of AraC.  Together, this study demonstrates that essential mitochondrial functions contribute to AraC resistance in AML and are a robust hallmark of AraC sensitivity and a promising therapeutic avenue to treat AML residual disease.  Significance: AraC-resistant AML cells exhibit metabolic features and gene signatures consistent with a high OXPHOS status.  In these cells, targeting mitochondrial metab. through the CD36-FAO-OXPHOS axis induces an energetic shift toward low OXPHOS and strongly enhanced antileukemic effects of AraC, offering a promising avenue to design new therapeutic strategies and fight AraC resistance in AML.  Cancer Discov; 7(7); 716-35. Â©2017 AACR.  See related commentary by Schimmer, p. 670.  This article is highlighted in the In This Issue feature, p.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-lpeAaUawsbVg90H21EOLACvtfcHk0ljEeB0BnZhGEQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFCisrbF&md5=1490353bd019a1fbc41ee61ed77ba34d</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-16-0441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-16-0441%26sid%3Dliteratum%253Aachs%26aulast%3DFarge%26aufirst%3DT.%26aulast%3DSaland%26aufirst%3DE.%26aulast%3Dde%2BToni%26aufirst%3DF.%26aulast%3DAroua%26aufirst%3DN.%26aulast%3DHosseini%26aufirst%3DM.%26aulast%3DPerry%26aufirst%3DR.%26aulast%3DBosc%26aufirst%3DC.%26aulast%3DSugita%26aufirst%3DM.%26aulast%3DStuani%26aufirst%3DL.%26aulast%3DFraisse%26aufirst%3DM.%26aulast%3DScotland%26aufirst%3DS.%26aulast%3DLarrue%26aufirst%3DC.%26aulast%3DBoutzen%26aufirst%3DH.%26aulast%3DFeliu%26aufirst%3DV.%26aulast%3DNicolau-Travers%26aufirst%3DM.%2BL.%26aulast%3DCassant-Sourdy%26aufirst%3DS.%26aulast%3DBroin%26aufirst%3DN.%26aulast%3DDavid%26aufirst%3DM.%26aulast%3DSerhan%26aufirst%3DN.%26aulast%3DSarry%26aufirst%3DA.%26aulast%3DTavitian%26aufirst%3DS.%26aulast%3DKaoma%26aufirst%3DT.%26aulast%3DVallar%26aufirst%3DL.%26aulast%3DIacovoni%26aufirst%3DJ.%26aulast%3DLinares%26aufirst%3DL.%2BK.%26aulast%3DMontersino%26aufirst%3DC.%26aulast%3DCastellano%26aufirst%3DR.%26aulast%3DGriessinger%26aufirst%3DE.%26aulast%3DCollette%26aufirst%3DY.%26aulast%3DDuchamp%26aufirst%3DO.%26aulast%3DBarreira%26aufirst%3DY.%26aulast%3DHirsch%26aufirst%3DP.%26aulast%3DPalama%26aufirst%3DT.%26aulast%3DGales%26aufirst%3DL.%26aulast%3DDelhommeau%26aufirst%3DF.%26aulast%3DGarmy-Susini%26aufirst%3DB.%2BH.%26aulast%3DPortais%26aufirst%3DJ.%2BC.%26aulast%3DVergez%26aufirst%3DF.%26aulast%3DSelak%26aufirst%3DM.%26aulast%3DDanet-Desnoyers%26aufirst%3DG.%26aulast%3DCarroll%26aufirst%3DM.%26aulast%3DRecher%26aufirst%3DC.%26aulast%3DSarry%26aufirst%3DJ.%2BE.%26atitle%3DChemotherapy-resistant%2520human%2520acute%2520myeloid%2520leukemia%2520cells%2520are%2520not%2520enriched%2520for%2520leukemic%2520stem%2520cells%2520but%2520require%2520oxidative%2520metabolism%26jtitle%3DCancer%2520Discovery%26date%3D2017%26volume%3D7%26spage%3D716%26epage%3D735%26doi%3D10.1158%2F2159-8290.CD-16-0441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorence, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badillo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Francesco, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackintosh, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, X. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenzi, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marszalek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffernan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Draetta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Futreal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span> <span> </span><span class="NLM_article-title">Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">eaau1167</span>, <span class="refDoi">Â DOI: 10.1126/scitranslmed.aau1167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1126%2Fscitranslmed.aau1167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=31068440" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=eaau1167&author=L.+Zhangauthor=Y.+X.+Yaoauthor=S.+J.+Zhangauthor=Y.+Liuauthor=H.+Guoauthor=M.+Ahmedauthor=T.+Bellauthor=H.+Zhangauthor=G.+C.+Hanauthor=E.+Lorenceauthor=M.+Badilloauthor=S.+H.+Zhouauthor=Y.+T.+Sunauthor=M.+E.+Di+Francescoauthor=N.+P.+Fengauthor=R.+Haunauthor=R.+Lanauthor=S.+G.+Mackintoshauthor=X.+Z.+Maoauthor=X.+Z.+Songauthor=J.+H.+Zhangauthor=L.+V.+Phamauthor=P.+L.+Lorenziauthor=J.+Marszalekauthor=T.+Heffernanauthor=G.+Draettaauthor=P.+Jonesauthor=A.+Futrealauthor=K.+Nomieauthor=L.+H.+Wangauthor=M.+Wang&title=Metabolic+reprogramming+toward+oxidative+phosphorylation+identifies+a+therapeutic+target+for+mantle+cell+lymphoma&doi=10.1126%2Fscitranslmed.aau1167"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aau1167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aau1167%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DYao%26aufirst%3DY.%2BX.%26aulast%3DZhang%26aufirst%3DS.%2BJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DAhmed%26aufirst%3DM.%26aulast%3DBell%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DHan%26aufirst%3DG.%2BC.%26aulast%3DLorence%26aufirst%3DE.%26aulast%3DBadillo%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DS.%2BH.%26aulast%3DSun%26aufirst%3DY.%2BT.%26aulast%3DDi%2BFrancesco%26aufirst%3DM.%2BE.%26aulast%3DFeng%26aufirst%3DN.%2BP.%26aulast%3DHaun%26aufirst%3DR.%26aulast%3DLan%26aufirst%3DR.%26aulast%3DMackintosh%26aufirst%3DS.%2BG.%26aulast%3DMao%26aufirst%3DX.%2BZ.%26aulast%3DSong%26aufirst%3DX.%2BZ.%26aulast%3DZhang%26aufirst%3DJ.%2BH.%26aulast%3DPham%26aufirst%3DL.%2BV.%26aulast%3DLorenzi%26aufirst%3DP.%2BL.%26aulast%3DMarszalek%26aufirst%3DJ.%26aulast%3DHeffernan%26aufirst%3DT.%26aulast%3DDraetta%26aufirst%3DG.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DFutreal%26aufirst%3DA.%26aulast%3DNomie%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DL.%2BH.%26aulast%3DWang%26aufirst%3DM.%26atitle%3DMetabolic%2520reprogramming%2520toward%2520oxidative%2520phosphorylation%2520identifies%2520a%2520therapeutic%2520target%2520for%2520mantle%2520cell%2520lymphoma%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2019%26volume%3D11%26spage%3Deaau1167%26doi%3D10.1126%2Fscitranslmed.aau1167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenna, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunz-Schughart, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, G. S.</span></span> <span> </span><span class="NLM_article-title">Oxidative phosphorylation as an emerging target in cancer therapy</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">2482</span>â <span class="NLM_lpage">2490</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-17-3070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F1078-0432.CCR-17-3070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=29420223" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVKjsbnI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=2482-2490&author=T.+M.+Ashtonauthor=W.+G.+McKennaauthor=L.+A.+Kunz-Schughartauthor=G.+S.+Higgins&title=Oxidative+phosphorylation+as+an+emerging+target+in+cancer+therapy&doi=10.1158%2F1078-0432.CCR-17-3070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidative Phosphorylation as an Emerging Target in Cancer Therapy</span></div><div class="casAuthors">Ashton, Thomas M.; McKenna, W. Gillies; Kunz-Schughart, Leoni A.; Higgins, Geoff S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2482-2490</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Cancer cells have upregulated glycolysis compared with normal cells, which has led many to the assumption that oxidative phosphorylation (OXPHOS) is downregulated in all cancers.  However, recent studies have shown that OXPHOS can be also upregulated in certain cancers, including leukemias, lymphomas, pancreatic ductal adenocarcinoma, high OXPHOS subtype melanoma, and endometrial carcinoma, and that this can occur even in the face of active glycolysis.  OXPHOS inhibitors could therefore be used to target cancer subtypes in which OXPHOS is upregulated and to alleviate therapeutically adverse tumor hypoxia.  Several drugs including metformin, atovaquone, and arsenic trioxide are used clin. for non-oncol. indications, but emerging data demonstrate their potential use as OXPHOS inhibitors.  We highlight novel applications of OXPHOS inhibitors with a suitable therapeutic index to target cancer cell metab.  Clin Cancer Res; 24(11); 2482-90. Â©2018 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCsSJ9tK4SdrVg90H21EOLACvtfcHk0ljEeB0BnZhGEQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVKjsbnI&md5=1cb7d3f2151ec4079de982206bb5e6af</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-3070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-3070%26sid%3Dliteratum%253Aachs%26aulast%3DAshton%26aufirst%3DT.%2BM.%26aulast%3DMcKenna%26aufirst%3DW.%2BG.%26aulast%3DKunz-Schughart%26aufirst%3DL.%2BA.%26aulast%3DHiggins%26aufirst%3DG.%2BS.%26atitle%3DOxidative%2520phosphorylation%2520as%2520an%2520emerging%2520target%2520in%2520cancer%2520therapy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26spage%3D2482%26epage%3D2490%26doi%3D10.1158%2F1078-0432.CCR-17-3070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sica, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo-San Pedro, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoll, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroemer, G.</span></span> <span> </span><span class="NLM_article-title">Oxidative phosphorylation as a potential therapeutic target for cancer therapy</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">10</span>â <span class="NLM_lpage">17</span>, <span class="refDoi">Â DOI: 10.1002/ijc.32616</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1002%2Fijc.32616" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=31396957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslCnsrvI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2020&pages=10-17&author=V.+Sicaauthor=J.+M.+Bravo-San+Pedroauthor=G.+Stollauthor=G.+Kroemer&title=Oxidative+phosphorylation+as+a+potential+therapeutic+target+for+cancer+therapy&doi=10.1002%2Fijc.32616"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidative phosphorylation as a potential therapeutic target for cancer therapy</span></div><div class="casAuthors">Sica, Valentina; Bravo-San Pedro, Jose Manuel; Stoll, Gautier; Kroemer, Guido</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">10-17</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  In contrast to prior belief, cancer cells require oxidative phosphorylation (OXPHOS) to strive, and exacerbated OXPHOS dependency frequently characterizes cancer stem cells, as well as primary or acquired resistance against chemotherapy or tyrosine kinase inhibitors.  A growing arsenal of therapeutic agents is being designed to suppress the transfer of mitochondria from stromal to malignant cells, to interfere with mitochondrial biogenesis, to directly inhibit respiratory chain complexes, or to disrupt mitochondrial function in other ways.  For the exptl. treatment of cancers, OXPHOS inhibitors can be advantageously combined with tyrosine kinase inhibitors, as well as with other strategies to inhibit glycolysis, thereby causing a lethal energy crisis.  Unfortunately, most of the preclin. data arguing in favor of OXPHOS inhibition have been obtained in xenograft models, in which human cancer cells are implanted in immunodeficient mice.  Future studies on OXPHOS inhibitors should elaborate optimal treatment schedules and combination regimens that stimulate-or at least are compatible with-anticancer immune responses for long-term tumor control.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6Ie7GAQZq1rVg90H21EOLACvtfcHk0ljDrrHFTEyknw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslCnsrvI&md5=0b966390751635974e6b91bd00626699</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fijc.32616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.32616%26sid%3Dliteratum%253Aachs%26aulast%3DSica%26aufirst%3DV.%26aulast%3DBravo-San%2BPedro%26aufirst%3DJ.%2BM.%26aulast%3DStoll%26aufirst%3DG.%26aulast%3DKroemer%26aufirst%3DG.%26atitle%3DOxidative%2520phosphorylation%2520as%2520a%2520potential%2520therapeutic%2520target%2520for%2520cancer%2520therapy%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2020%26volume%3D146%26spage%3D10%26epage%3D17%26doi%3D10.1002%2Fijc.32616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pernicova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korbonits, M.</span></span> <span> </span><span class="NLM_article-title">Metformin-mode of action and clinical implications for diabetes and cancer</span>. <i>Nat. Rev. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">143</span>â <span class="NLM_lpage">156</span>, <span class="refDoi">Â DOI: 10.1038/nrendo.2013.256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fnrendo.2013.256" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=24393785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtVSitA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=143-156&author=I.+Pernicovaauthor=M.+Korbonits&title=Metformin-mode+of+action+and+clinical+implications+for+diabetes+and+cancer&doi=10.1038%2Fnrendo.2013.256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Metformin-mode of action and clinical implications for diabetes and cancer</span></div><div class="casAuthors">Pernicova, Ida; Korbonits, Marta</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Endocrinology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">143-156</span>CODEN:
                <span class="NLM_cas:coden">NREABD</span>;
        ISSN:<span class="NLM_cas:issn">1759-5029</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Metformin has been the mainstay of therapy for diabetes mellitus for many years; however, the mechanistic aspects of metformin action remained ill-defined.  Recent advances revealed that this drug, in addn. to its glucose-lowering action, might be promising for specifically targeting metabolic differences between normal and abnormal metabolic signalling.  The knowledge gained from dissecting the principal mechanisms by which metformin works can help us to develop novel treatments.  The center of metformin's mechanism of action is the alteration of the energy metab. of the cell.  Metformin exerts its prevailing, glucose-lowering effect by inhibiting hepatic gluconeogenesis and opposing the action of glucagon.  The inhibition of mitochondrial complex I results in defective cAMP and protein kinase A signalling in response to glucagon.  Stimulation of 5'-AMP-activated protein kinase, although dispensable for the glucose-lowering effect of metformin, confers insulin sensitivity, mainly by modulating lipid metab.  Metformin might influence tumorigenesis, both indirectly, through the systemic redn. of insulin levels, and directly, via the induction of energetic stress; however, these effects require further investigation.  Here, we discuss the updated understanding of the antigluconeogenic action of metformin in the liver and the implications of the discoveries of metformin targets for the treatment of diabetes mellitus and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWcJQOW14oCLVg90H21EOLACvtfcHk0ljDrrHFTEyknw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtVSitA%253D%253D&md5=bca85cb11f26bf607ccee93506e0986e</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnrendo.2013.256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrendo.2013.256%26sid%3Dliteratum%253Aachs%26aulast%3DPernicova%26aufirst%3DI.%26aulast%3DKorbonits%26aufirst%3DM.%26atitle%3DMetformin-mode%2520of%2520action%2520and%2520clinical%2520implications%2520for%2520diabetes%2520and%2520cancer%26jtitle%3DNat.%2520Rev.%2520Endocrinol.%26date%3D2014%26volume%3D10%26spage%3D143%26epage%3D156%26doi%3D10.1038%2Fnrendo.2013.256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wheaton, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamanaka, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soberanes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anso, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glasauer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufour, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mutlu, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budigner, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandel, N. S.</span></span> <span> </span><span class="NLM_article-title">Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">e02242</span>, <span class="refDoi">Â DOI: 10.7554/eLife.02242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.7554%2FeLife.02242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=24843020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1SjsbfM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=e02242&author=W.+W.+Wheatonauthor=S.+E.+Weinbergauthor=R.+B.+Hamanakaauthor=S.+Soberanesauthor=L.+B.+Sullivanauthor=E.+Ansoauthor=A.+Glasauerauthor=E.+Dufourauthor=G.+M.+Mutluauthor=G.+S.+Budignerauthor=N.+S.+Chandel&title=Metformin+inhibits+mitochondrial+complex+I+of+cancer+cells+to+reduce+tumorigenesis&doi=10.7554%2FeLife.02242"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis</span></div><div class="casAuthors">Wheaton, William W.; Weinberg, Samuel E.; Hamanaka, Robert B.; Soberanes, Saul; Sullivan, Lucas B.; Anso, Elena; Glasauer, Andrea; Dufour, Eric; Mutlu, Gokhan M.; Budigner, G. R. Scott; Chandel, Navdeep S.</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e02242/1-e02242/18, 18</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">Recent epidemiol. and lab.-based studies suggest that the anti-diabetic drug metformin prevents cancer progression.  How metformin diminishes tumor growth is not fully understood.  In this study, we report that in human cancer cells, metformin inhibits mitochondrial complex I (NADH dehydrogenase) activity and cellular respiration.  Metformin inhibited cellular proliferation in the presence of glucose, but induced cell death upon glucose deprivation, indicating that cancer cells rely exclusively on glycolysis for survival in the presence of metformin.  Metformin also reduced hypoxic activation of hypoxia-inducible factor 1 (HIF-1).  All of these effects of metformin were reversed when the metformin-resistant Saccharomyces cerevisiae NADH dehydrogenase NDI1 was overexpressed.  In vivo, the administration of metformin to mice inhibited the growth of control human cancer cells but not those expressing NDI1.  Thus, we have demonstrated that metformin's inhibitory effects on cancer progression are cancer cell autonomous and depend on its ability to inhibit mitochondrial complex I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8q1O2aH9ltLVg90H21EOLACvtfcHk0ljDrrHFTEyknw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1SjsbfM&md5=3719e29f8fdbc7721b382b2f45b37ae9</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.7554%2FeLife.02242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.02242%26sid%3Dliteratum%253Aachs%26aulast%3DWheaton%26aufirst%3DW.%2BW.%26aulast%3DWeinberg%26aufirst%3DS.%2BE.%26aulast%3DHamanaka%26aufirst%3DR.%2BB.%26aulast%3DSoberanes%26aufirst%3DS.%26aulast%3DSullivan%26aufirst%3DL.%2BB.%26aulast%3DAnso%26aufirst%3DE.%26aulast%3DGlasauer%26aufirst%3DA.%26aulast%3DDufour%26aufirst%3DE.%26aulast%3DMutlu%26aufirst%3DG.%2BM.%26aulast%3DBudigner%26aufirst%3DG.%2BS.%26aulast%3DChandel%26aufirst%3DN.%2BS.%26atitle%3DMetformin%2520inhibits%2520mitochondrial%2520complex%2520I%2520of%2520cancer%2520cells%2520to%2520reduce%2520tumorigenesis%26jtitle%3DeLife%26date%3D2014%26volume%3D3%26spage%3De02242%26doi%3D10.7554%2FeLife.02242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Molina, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Protopopova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gera, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bristow, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAfoos, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morlacchi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ackroyd, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agip, A. N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Atrash, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asara, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardenhagen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrillo, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciurea, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czako, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deem, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daver, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Groot, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuliani, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirst, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khor, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konoplev, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lofton, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahendra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matre, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullinax, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peoples, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrocchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Canale, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serreli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theroff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiziani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DePinho, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toniatti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Draetta, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffernan, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konopleva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Francesco, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marszalek, J. R.</span></span> <span> </span><span class="NLM_article-title">An inhibitor of oxidative phosphorylation exploits cancer vulnerability</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1036</span>â <span class="NLM_lpage">1046</span>, <span class="refDoi">Â DOI: 10.1038/s41591-018-0052-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fs41591-018-0052-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=29892070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFWru7bN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=1036-1046&author=J.+R.+Molinaauthor=Y.+T.+Sunauthor=M.+Protopopovaauthor=S.+Geraauthor=M.+Bandiauthor=C.+Bristowauthor=T.+McAfoosauthor=P.+Morlacchiauthor=J.+Ackroydauthor=A.+N.+A.+Agipauthor=G.+Al-Atrashauthor=J.+Asaraauthor=J.+Bardenhagenauthor=C.+C.+Carrilloauthor=C.+Carrollauthor=E.+Changauthor=S.+Ciureaauthor=J.+B.+Crossauthor=B.+Czakoauthor=A.+Deemauthor=N.+Daverauthor=J.+F.+de+Grootauthor=J.+W.+Dongauthor=N.+P.+Fengauthor=G.+Gaoauthor=J.+Gayauthor=M.+G.+Doauthor=J.+Greerauthor=V.+Giulianiauthor=J.+Hanauthor=L.+N.+Hanauthor=V.+K.+Henryauthor=J.+Hirstauthor=S.+Huangauthor=Y.+Y.+Jiangauthor=Z.+J.+Kangauthor=T.+Khorauthor=S.+Konoplevauthor=Y.+H.+Linauthor=G.+Liuauthor=A.+Lodiauthor=T.+Loftonauthor=H.+Maauthor=M.+Mahendraauthor=P.+Matreauthor=R.+Mullinaxauthor=M.+Peoplesauthor=A.+Petrocchiauthor=J.+Rodriguez-Canaleauthor=R.+Serreliauthor=T.+Shiauthor=M.+Smithauthor=Y.+Tabeauthor=J.+Theroffauthor=S.+Tizianiauthor=Q.+Y.+Xuauthor=Q.+Zhangauthor=F.+Mullerauthor=R.+A.+DePinhoauthor=C.+Toniattiauthor=G.+F.+Draettaauthor=T.+P.+Heffernanauthor=M.+Konoplevaauthor=P.+Jonesauthor=M.+E.+Di+Francescoauthor=J.+R.+Marszalek&title=An+inhibitor+of+oxidative+phosphorylation+exploits+cancer+vulnerability&doi=10.1038%2Fs41591-018-0052-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">An inhibitor of oxidative phosphorylation exploits cancer vulnerability</span></div><div class="casAuthors">Molina, Jennifer R.; Sun, Yuting; Protopopova, Marina; Gera, Sonal; Bandi, Madhavi; Bristow, Christopher; McAfoos, Timothy; Morlacchi, Pietro; Ackroyd, Jeffrey; Agip, Ahmed-Noor A.; Al-Atrash, Gheath; Asara, John; Bardenhagen, Jennifer; Carrillo, Caroline C.; Carroll, Christopher; Chang, Edward; Ciurea, Stefan; Cross, Jason B.; Czako, Barbara; Deem, Angela; Daver, Naval; de Groot, John Frederick; Dong, Jian-Wen; Feng, Ningping; Gao, Guang; Gay, Jason; Do, Mary Geck; Greer, Jennifer; Giuliani, Virginia; Han, Jing; Han, Lina; Henry, Verlene K.; Hirst, Judy; Huang, Sha; Jiang, Yongying; Kang, Zhijun; Khor, Tin; Konoplev, Sergej; Lin, Yu-Hsi; Liu, Gang; Lodi, Alessia; Lofton, Timothy; Ma, Helen; Mahendra, Mikhila; Matre, Polina; Mullinax, Robert; Peoples, Michael; Petrocchi, Alessia; Rodriguez-Canale, Jaime; Serreli, Riccardo; Shi, Thomas; Smith, Melinda; Tabe, Yoko; Theroff, Jay; Tiziani, Stefano; Xu, Quanyun; Zhang, Qi; Muller, Florian; De Pinho, Ronald A.; Toniatti, Carlo; Draetta, Giulio F.; Heffernan, Timothy P.; Konopleva, Marina; Jones, Philip; Di Francesco, M. Emilia; Marszalek, Joseph R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1036-1046</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Metabolic reprograming is an emerging hallmark of tumor biol. and an actively pursued opportunity in discovery of oncol. drugs.  Extensive efforts have focused on therapeutic targeting of glycolysis, whereas drugging mitochondrial oxidative phosphorylation (OXPHOS) has remained largely unexplored, partly owing to an incomplete understanding of tumor contexts in which OXPHOS is essential.  Here, we report the discovery of IACS-010759, a clin.-grade small-mol. inhibitor of complex I of the mitochondrial electron transport chain.  Treatment with IACS-010759 robustly inhibited proliferation and induced apoptosis in models of brain cancer and acute myeloid leukemia (AML) reliant on OXPHOS, likely owing to a combination of energy depletion and reduced aspartate prodn. that leads to impaired nucleotide biosynthesis.  In models of brain cancer and AML, tumor growth was potently inhibited in vivo following IACS-010759 treatment at well-tolerated doses.  IACS-010759 is currently being evaluated in phase 1 clin. trials in relapsed/refractory AML and solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYy9jYNGBbO7Vg90H21EOLACvtfcHk0ljhBRS9i6SVoQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFWru7bN&md5=51b8bf30a5897f8827d300377eb419f5</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fs41591-018-0052-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41591-018-0052-4%26sid%3Dliteratum%253Aachs%26aulast%3DMolina%26aufirst%3DJ.%2BR.%26aulast%3DSun%26aufirst%3DY.%2BT.%26aulast%3DProtopopova%26aufirst%3DM.%26aulast%3DGera%26aufirst%3DS.%26aulast%3DBandi%26aufirst%3DM.%26aulast%3DBristow%26aufirst%3DC.%26aulast%3DMcAfoos%26aufirst%3DT.%26aulast%3DMorlacchi%26aufirst%3DP.%26aulast%3DAckroyd%26aufirst%3DJ.%26aulast%3DAgip%26aufirst%3DA.%2BN.%2BA.%26aulast%3DAl-Atrash%26aufirst%3DG.%26aulast%3DAsara%26aufirst%3DJ.%26aulast%3DBardenhagen%26aufirst%3DJ.%26aulast%3DCarrillo%26aufirst%3DC.%2BC.%26aulast%3DCarroll%26aufirst%3DC.%26aulast%3DChang%26aufirst%3DE.%26aulast%3DCiurea%26aufirst%3DS.%26aulast%3DCross%26aufirst%3DJ.%2BB.%26aulast%3DCzako%26aufirst%3DB.%26aulast%3DDeem%26aufirst%3DA.%26aulast%3DDaver%26aufirst%3DN.%26aulast%3Dde%2BGroot%26aufirst%3DJ.%2BF.%26aulast%3DDong%26aufirst%3DJ.%2BW.%26aulast%3DFeng%26aufirst%3DN.%2BP.%26aulast%3DGao%26aufirst%3DG.%26aulast%3DGay%26aufirst%3DJ.%26aulast%3DDo%26aufirst%3DM.%2BG.%26aulast%3DGreer%26aufirst%3DJ.%26aulast%3DGiuliani%26aufirst%3DV.%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DHan%26aufirst%3DL.%2BN.%26aulast%3DHenry%26aufirst%3DV.%2BK.%26aulast%3DHirst%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DJiang%26aufirst%3DY.%2BY.%26aulast%3DKang%26aufirst%3DZ.%2BJ.%26aulast%3DKhor%26aufirst%3DT.%26aulast%3DKonoplev%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DY.%2BH.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DLodi%26aufirst%3DA.%26aulast%3DLofton%26aufirst%3DT.%26aulast%3DMa%26aufirst%3DH.%26aulast%3DMahendra%26aufirst%3DM.%26aulast%3DMatre%26aufirst%3DP.%26aulast%3DMullinax%26aufirst%3DR.%26aulast%3DPeoples%26aufirst%3DM.%26aulast%3DPetrocchi%26aufirst%3DA.%26aulast%3DRodriguez-Canale%26aufirst%3DJ.%26aulast%3DSerreli%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DM.%26aulast%3DTabe%26aufirst%3DY.%26aulast%3DTheroff%26aufirst%3DJ.%26aulast%3DTiziani%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DQ.%2BY.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DMuller%26aufirst%3DF.%26aulast%3DDePinho%26aufirst%3DR.%2BA.%26aulast%3DToniatti%26aufirst%3DC.%26aulast%3DDraetta%26aufirst%3DG.%2BF.%26aulast%3DHeffernan%26aufirst%3DT.%2BP.%26aulast%3DKonopleva%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DDi%2BFrancesco%26aufirst%3DM.%2BE.%26aulast%3DMarszalek%26aufirst%3DJ.%2BR.%26atitle%3DAn%2520inhibitor%2520of%2520oxidative%2520phosphorylation%2520exploits%2520cancer%2520vulnerability%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26spage%3D1036%26epage%3D1046%26doi%3D10.1038%2Fs41591-018-0052-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><a href="https://clinicaltrials.gov/" class="extLink">https://clinicaltrials.gov/</a> (accessed Sep 19, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fclinicaltrials.gov%2F+%28accessed+Sep+19%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M. J.</span></span> <span> </span><span class="NLM_article-title">Structure of mammalian respiratory supercomplex I1III2IV1</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>167</i></span>,  <span class="NLM_fpage">1598</span>â <span class="NLM_lpage">1609</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2016.11.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.cell.2016.11.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27912063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVSms7fO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2016&pages=1598-1609&author=M.+Wuauthor=J.+K.+Guauthor=R.+Y.+Guoauthor=Y.+S.+Huangauthor=M.+J.+Yang&title=Structure+of+mammalian+respiratory+supercomplex+I1III2IV1&doi=10.1016%2Fj.cell.2016.11.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of mammalian respiratory supercomplex I1III2IV1</span></div><div class="casAuthors">Wu, Meng; Gu, Jinke; Guo, Runyu; Huang, Yushen; Yang, Maojun</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1598-1609.e10</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The mammalian respiratory chain complexes assemble into supercomplexes (SCs) and reside in the inner mitochondrial membrane to transfer electrons and establish the proton gradient for complex V to synthesize ATP.  The precise arrangement of SCs is largely unknown.  Here, the authors report a 4.0-Ã cryo-electron microscopy (cryo-EM) structure of the major SC of porcine heart, the 1.7-MDa SCI1III2IV1 enzyme supercomplex .  Respiratory complex III (CIII; quinol-cytochrome c reductase) dimer and complex IV [CIV; cytochrome c oxidase (also COX)] bound at the same side of the L-shaped complex I (CI; ubiquinone reductase).  Several accessory or supernumerary subunits of CI, such as NDUFA11, NDUFB4, NDUFB8, and NDUFB9, directly contributed to the oligomerization of CI, CIII, and CIV.  Subunits COX7C and COX7A of CIV attached CIV to the concave surface formed by CIII and the distal end of the membrane arm of CI.  The structure suggested a possible mechanism by which electrons are transferred from NADH to cytochrome c and provided a platform for future functional dissection of respiration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqU5D7qe8MBELVg90H21EOLACvtfcHk0lh3z0KPW-Effw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVSms7fO&md5=039931d1e204eb876b52d465c11235fd</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2016.11.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2016.11.012%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DM.%26aulast%3DGu%26aufirst%3DJ.%2BK.%26aulast%3DGuo%26aufirst%3DR.%2BY.%26aulast%3DHuang%26aufirst%3DY.%2BS.%26aulast%3DYang%26aufirst%3DM.%2BJ.%26atitle%3DStructure%2520of%2520mammalian%2520respiratory%2520supercomplex%2520I1III2IV1%26jtitle%3DCell%26date%3D2016%26volume%3D167%26spage%3D1598%26epage%3D1609%26doi%3D10.1016%2Fj.cell.2016.11.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sousa, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vonck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhlbrandt, W.</span></span> <span> </span><span class="NLM_article-title">Functional asymmetry and electron flow in the bovine respirasome</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">e21290</span>, <span class="refDoi">Â DOI: 10.7554/eLife.21290</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.7554%2FeLife.21290" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27830641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVSru7nK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=e21290&author=J.+S.+Sousaauthor=D.+J.+Millsauthor=J.+Vonckauthor=W.+Kuhlbrandt&title=Functional+asymmetry+and+electron+flow+in+the+bovine+respirasome&doi=10.7554%2FeLife.21290"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Functional asymmetry and electron flow in the bovine respirasome</span></div><div class="casAuthors">Sousa, Joana S.; Mills, Deryck J.; Vonck, Janet; Kuehlbrandt, Werner</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e21290/1-e21290/17</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">Respirasomes are macromol. assemblies of the respiratory chain complexes I, III and IV in the inner mitochondrial membrane.  We detd. the structure of supercomplex I1III2IV1 from bovine heart mitochondria by cryo-EM at 9 Ã resoln.  Most protein-protein contacts between complex I, III and IV in the membrane are mediated by supernumerary subunits.  Of the two Rieske iron-sulfur cluster domains in the complex III dimer, one is resolved, indicating that this domain is immobile and unable to transfer electrons.  The central position of the active complex III monomer between complex I and IV in the respirasome is optimal for accepting reduced quinone from complex I over a short diffusion distance of 11 nm, and delivering reduced cytochrome c to complex IV.  The functional asymmetry of complex III provides strong evidence for directed electron flow from complex I to complex IV through the active complex III monomer in the mammalian supercomplex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqenZJeGzhaw7Vg90H21EOLACvtfcHk0lh3z0KPW-Effw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVSru7nK&md5=b608e92d89c1e39b5a670da0ebdaeba1</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.7554%2FeLife.21290&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.21290%26sid%3Dliteratum%253Aachs%26aulast%3DSousa%26aufirst%3DJ.%2BS.%26aulast%3DMills%26aufirst%3DD.%2BJ.%26aulast%3DVonck%26aufirst%3DJ.%26aulast%3DKuhlbrandt%26aufirst%3DW.%26atitle%3DFunctional%2520asymmetry%2520and%2520electron%2520flow%2520in%2520the%2520bovine%2520respirasome%26jtitle%3DeLife%26date%3D2016%26volume%3D5%26spage%3De21290%26doi%3D10.7554%2FeLife.21290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Letts, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiedorczuk, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sazanov, L. A.</span></span> <span> </span><span class="NLM_article-title">The architecture of respiratory supercomplexes</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>537</i></span>,  <span class="NLM_fpage">644</span>â <span class="NLM_lpage">648</span>, <span class="refDoi">Â DOI: 10.1038/nature19774</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fnature19774" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27654913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFClsrrM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=537&publication_year=2016&pages=644-648&author=J.+A.+Lettsauthor=K.+Fiedorczukauthor=L.+A.+Sazanov&title=The+architecture+of+respiratory+supercomplexes&doi=10.1038%2Fnature19774"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The architecture of respiratory supercomplexes</span></div><div class="casAuthors">Letts, James A.; Fiedorczuk, Karol; Sazanov, Leonid A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">537</span>
        (<span class="NLM_cas:issue">7622</span>),
    <span class="NLM_cas:pages">644-648</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Mitochondrial electron transport chain complexes are organized into supercomplexes responsible for carrying out cellular respiration.  Here we present three architectures of mammalian (ovine) supercomplexes detd. by cryo-electron microscopy.  We identify two distinct arrangements of supercomplex CICIII2CIV (the respirasome)-a major 'tight' form and a minor 'loose' form (resolved at the resoln. of 5.8 Ã and 6.7 Ã, resp.), which may represent different stages in supercomplex assembly or disassembly.  We have also detd. an architecture of supercomplex CICIII2 at 7.8 Ã resoln.  All obsd. d. can be attributed to the known 80 subunits of the individual complexes, including 132 transmembrane helixes.  The individual complexes form tight interactions that vary between the architectures, with complex IV subunit COX7a switching contact from complex III to complex I.  The arrangement of active sites within the supercomplex may help control reactive oxygen species prodn.  To our knowledge, these are the first complete architectures of the dominant, physiol. relevant state of the electron transport chain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr91FqsT_FIfrVg90H21EOLACvtfcHk0lh3z0KPW-Effw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFClsrrM&md5=e080b01abdee073c6e0459131bdeaf07</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnature19774&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature19774%26sid%3Dliteratum%253Aachs%26aulast%3DLetts%26aufirst%3DJ.%2BA.%26aulast%3DFiedorczuk%26aufirst%3DK.%26aulast%3DSazanov%26aufirst%3DL.%2BA.%26atitle%3DThe%2520architecture%2520of%2520respiratory%2520supercomplexes%26jtitle%3DNature%26date%3D2016%26volume%3D537%26spage%3D644%26epage%3D648%26doi%3D10.1038%2Fnature19774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M. J.</span></span> <span> </span><span class="NLM_article-title">The architecture of the mammalian respirasome</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>537</i></span>,  <span class="NLM_fpage">639</span>â <span class="NLM_lpage">643</span>, <span class="refDoi">Â DOI: 10.1038/nature19359</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fnature19359" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27654917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFClsr3I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=537&publication_year=2016&pages=639-643&author=J.+K.+Guauthor=M.+Wuauthor=R.+Y.+Guoauthor=K.+G.+Yanauthor=J.+L.+Leiauthor=N.+Gaoauthor=M.+J.+Yang&title=The+architecture+of+the+mammalian+respirasome&doi=10.1038%2Fnature19359"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The architecture of the mammalian respirasome</span></div><div class="casAuthors">Gu, Jinke; Wu, Meng; Guo, Runyu; Yan, Kaige; Lei, Jianlin; Gao, Ning; Yang, Maojun</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">537</span>
        (<span class="NLM_cas:issue">7622</span>),
    <span class="NLM_cas:pages">639-643</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The respiratory chain complexes I, III and IV (CI, CIII and CIV) are present in the bacterial membrane or the inner mitochondrial membrane and have a role of transferring electrons and establishing the proton gradient for ATP synthesis by complex V.  The respiratory chain complexes can assemble into supercomplexes (SCs), but their precise arrangement is unknown.  Here we report a 5.4 Ã cryo-electron microscopy structure of the major 1.7 megadalton SCI1III2IV1 respirasome purified from porcine heart.  The CIII dimer and CIV bind at the same side of the L-shaped CI, with their transmembrane domains essentially aligned to form a transmembrane disk.  Compared to free CI, the CI in the respirasome is more compact because of interactions with CIII and CIV.  The NDUFA11 and NDUFB9 supernumerary subunits of CI contribute to the oligomerization of CI and CIII.  The structure of the respirasome provides information on the precise arrangements of the respiratory chain complexes in mitochondria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB51UYyLnnwrVg90H21EOLACvtfcHk0lh3z0KPW-Effw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFClsr3I&md5=e6c15c9d3ced5e0250809ac3e2368773</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnature19359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature19359%26sid%3Dliteratum%253Aachs%26aulast%3DGu%26aufirst%3DJ.%2BK.%26aulast%3DWu%26aufirst%3DM.%26aulast%3DGuo%26aufirst%3DR.%2BY.%26aulast%3DYan%26aufirst%3DK.%2BG.%26aulast%3DLei%26aufirst%3DJ.%2BL.%26aulast%3DGao%26aufirst%3DN.%26aulast%3DYang%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520architecture%2520of%2520the%2520mammalian%2520respirasome%26jtitle%3DNature%26date%3D2016%26volume%3D537%26spage%3D639%26epage%3D643%26doi%3D10.1038%2Fnature19359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M. J.</span></span> <span> </span><span class="NLM_article-title">Architecture of human mitochondrial respiratory megacomplex I2III2IV2</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>170</i></span>,  <span class="NLM_fpage">1247</span>â <span class="NLM_lpage">1257</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2017.07.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.cell.2017.07.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=28844695" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlylsb%252FO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2017&pages=1247-1257&author=R.+Y.+Guoauthor=S.+Zongauthor=M.+Wuauthor=J.+K.+Guauthor=M.+J.+Yang&title=Architecture+of+human+mitochondrial+respiratory+megacomplex+I2III2IV2&doi=10.1016%2Fj.cell.2017.07.050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Architecture of human mitochondrial respiratory megacomplex I2III2IV2</span></div><div class="casAuthors">Guo, Runyu; Zong, Shuai; Wu, Meng; Gu, Jinke; Yang, Maojun</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1247-1257.e12</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The respiratory megacomplex represents the highest-order assembly of respiratory chain complexes, and it allows mitochondria to respond to energy-requiring conditions.  To understand its architecture, we examd. human respiratory chain megacomplex I2III2IV2 (MCI2III2IV2) with 140 subunits and a subset of assocd. cofactors using cryo-electron microscopy.  The MCI2III2IV2 megacomplex forms a circular structure with the dimeric CIII located in the center, where it is surrounded by 2 copies each of CI and CIV.  Two cytochrome mols. are positioned to accept electrons on the surface of the c1 state CIII dimer.  Analyses indicated that CII could insert into the gaps between CI and CIV to form a closed ring, which we termed the electron transport chain supercomplex.  The structure not only revealed the precise assignment of individual subunits of human CI and CIII, but also enabled future in-depth anal. of the electron transport chain as a whole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouObX0EVYN7LVg90H21EOLACvtfcHk0ljdM7OY2eLeDQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlylsb%252FO&md5=51151bba713ee27ceb635527e8bbfbc8</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.07.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.07.050%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DR.%2BY.%26aulast%3DZong%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DM.%26aulast%3DGu%26aufirst%3DJ.%2BK.%26aulast%3DYang%26aufirst%3DM.%2BJ.%26atitle%3DArchitecture%2520of%2520human%2520mitochondrial%2520respiratory%2520megacomplex%2520I2III2IV2%26jtitle%3DCell%26date%3D2017%26volume%3D170%26spage%3D1247%26epage%3D1257%26doi%3D10.1016%2Fj.cell.2017.07.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Letts, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiedorczuk, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degliesposti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skehel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sazanov, L. A.</span></span> <span> </span><span class="NLM_article-title">Structures of respiratory supercomplex I+III2 reveal functional and conformational crosstalk</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">1131</span>â <span class="NLM_lpage">1146</span>, <span class="refDoi">Â DOI: 10.1016/j.molcel.2019.07.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.molcel.2019.07.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=31492636" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs12qs7%252FM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2019&pages=1131-1146&author=J.+A.+Lettsauthor=K.+Fiedorczukauthor=G.+Degliespostiauthor=M.+Skehelauthor=L.+A.+Sazanov&title=Structures+of+respiratory+supercomplex+I%2BIII2+reveal+functional+and+conformational+crosstalk&doi=10.1016%2Fj.molcel.2019.07.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of Respiratory Supercomplex I+III2 Reveal Functional and Conformational Crosstalk</span></div><div class="casAuthors">Letts, James A.; Fiedorczuk, Karol; Degliesposti, Gianluca; Skehel, Mark; Sazanov, Leonid A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1131-1146.e6</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The mitochondrial electron transport chain complexes are organized into supercomplexes (SCs) of defined stoichiometry, which have been proposed to regulate electron flux via substrate channeling.  We demonstrate that CoQ trapping in the isolated SC I+III2 limits complex (C)I turnover, arguing against channeling.  The SC structure, resolved at up to 3.8 Ã in four distinct states, suggests that CoQ oxidn. may be rate limiting because of unequal access of CoQ to the active sites of CIII2.  CI shows a transition between "closed" and "open" conformations, accompanied by the striking rotation of a key transmembrane helix.  Furthermore, the state of CI affects the conformational flexibility within CIII2, demonstrating crosstalk between the enzymes.  CoQ was identified at only three of the four binding sites in CIII2, suggesting that interaction with CI disrupts CIII2 symmetry in a functionally relevant manner.  Together, these observations indicate a more nuanced functional role for the SCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1uIOktwYRQrVg90H21EOLACvtfcHk0ljdM7OY2eLeDQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs12qs7%252FM&md5=fd10b0046a3268376468d7d5db135991</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2019.07.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2019.07.022%26sid%3Dliteratum%253Aachs%26aulast%3DLetts%26aufirst%3DJ.%2BA.%26aulast%3DFiedorczuk%26aufirst%3DK.%26aulast%3DDegliesposti%26aufirst%3DG.%26aulast%3DSkehel%26aufirst%3DM.%26aulast%3DSazanov%26aufirst%3DL.%2BA.%26atitle%3DStructures%2520of%2520respiratory%2520supercomplex%2520I%252BIII2%2520reveal%2520functional%2520and%2520conformational%2520crosstalk%26jtitle%3DMol.%2520Cell%26date%3D2019%26volume%3D75%26spage%3D1131%26epage%3D1146%26doi%3D10.1016%2Fj.molcel.2019.07.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Y. D.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial respiratory complex I: structure, function and implication in human diseases</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1266</span>â <span class="NLM_lpage">1277</span>, <span class="refDoi">Â DOI: 10.2174/092986709787846578</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.2174%2F092986709787846578" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=19355884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltVeqsb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=1266-1277&author=L.+K.+Sharmaauthor=J.+X.+Luauthor=Y.+D.+Bai&title=Mitochondrial+respiratory+complex+I%3A+structure%2C+function+and+implication+in+human+diseases&doi=10.2174%2F092986709787846578"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial respiratory complex I: structure, function and implication in human diseases</span></div><div class="casAuthors">Sharma, Lokendra K.; Lu, Jianxin; Bai, Yidong</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1266-1277</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Mitochondria are ubiquitous organelles in eukaryotic cells whose primary function is to generate energy supplies in the form of ATP through oxidative phosphorylation.  As the entry point for most electrons into the respiratory chain, NADH:ubiquinone oxidoreductase, or complex I, is the largest and least understood component of the mitochondrial oxidative phosphorylation system.  Substantial progress has been made in recent years in understanding its subunit compn., its assembly, the interaction among complex I and other respiratory components, and its role in oxidative stress and apoptosis.  This review provides an updated overview of the structure of complex I, as well as its cellular functions, and discusses the implication of complex I dysfunction in various human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOAZkT2bfgDbVg90H21EOLACvtfcHk0ljdM7OY2eLeDQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltVeqsb4%253D&md5=d6e05fca2d0c9eb5d0c1c073412d0247</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.2174%2F092986709787846578&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986709787846578%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DL.%2BK.%26aulast%3DLu%26aufirst%3DJ.%2BX.%26aulast%3DBai%26aufirst%3DY.%2BD.%26atitle%3DMitochondrial%2520respiratory%2520complex%2520I%253A%2520structure%252C%2520function%2520and%2520implication%2520in%2520human%2520diseases%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2009%26volume%3D16%26spage%3D1266%26epage%3D1277%26doi%3D10.2174%2F092986709787846578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parey, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegmund, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vonck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhlbrandt, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zickermann, V.</span></span> <span> </span><span class="NLM_article-title">Cryo-EM structure of respiratory complex I at work</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e39213</span>, <span class="refDoi">Â DOI: 10.7554/eLife.39213</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.7554%2FeLife.39213" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=30277212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlyrtbbP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&pages=e39213&author=K.+Pareyauthor=U.+Brandtauthor=H.+Xieauthor=D.+J.+Millsauthor=K.+Siegmundauthor=J.+Vonckauthor=W.+Kuhlbrandtauthor=V.+Zickermann&title=Cryo-EM+structure+of+respiratory+complex+I+at+work&doi=10.7554%2FeLife.39213"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Cryo-EM structure of respiratory complex I at work</span></div><div class="casAuthors">Parey, Kristian; Brandt, Ulrich; Xie, Hao; Mills, Deryck J.; Siegmund, Karin; Vonck, Janet; Kuehlbrandt, Werner; Zickermann, Volker</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e39213/1-e39213/28</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">Mitochondrial complex I has a key role in cellular energy metab., generating a major portion of the proton motive force that drives aerobic ATP synthesis.  The hydrophilic arm of the L-shaped â¼1 MDa membrane protein complex transfers electrons from NADH to ubiquinone, providing the energy to drive proton pumping at distant sites in the membrane arm.  The crit. steps of energy conversion are assocd. with the redox chem. of ubiquinone.  We report the cryo-EM structure of complete mitochondrial complex I from the aerobic yeast Yarrowia lipolytica both in the deactive form and after capturing the enzyme during steady-state activity.  The site of ubiquinone binding obsd. during turnover supports a two-state stabilization change mechanism for complex I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9CdwogB-8H7Vg90H21EOLACvtfcHk0lh13ElOgCKiew"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlyrtbbP&md5=bd985b3dba1b6c962e176a42da8b8ea0</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.7554%2FeLife.39213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.39213%26sid%3Dliteratum%253Aachs%26aulast%3DParey%26aufirst%3DK.%26aulast%3DBrandt%26aufirst%3DU.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DMills%26aufirst%3DD.%2BJ.%26aulast%3DSiegmund%26aufirst%3DK.%26aulast%3DVonck%26aufirst%3DJ.%26aulast%3DKuhlbrandt%26aufirst%3DW.%26aulast%3DZickermann%26aufirst%3DV.%26atitle%3DCryo-EM%2520structure%2520of%2520respiratory%2520complex%2520I%2520at%2520work%26jtitle%3DeLife%26date%3D2018%26volume%3D7%26spage%3De39213%26doi%3D10.7554%2FeLife.39213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baradaran, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berrisford, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minhas, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sazanov, L. A.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the entire respiratory complex I</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>494</i></span>,  <span class="NLM_fpage">443</span>â <span class="NLM_lpage">448</span>, <span class="refDoi">Â DOI: 10.1038/nature11871</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fnature11871" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=23417064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtFWiu70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=494&publication_year=2013&pages=443-448&author=R.+Baradaranauthor=J.+M.+Berrisfordauthor=G.+S.+Minhasauthor=L.+A.+Sazanov&title=Crystal+structure+of+the+entire+respiratory+complex+I&doi=10.1038%2Fnature11871"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the entire respiratory complex I</span></div><div class="casAuthors">Baradaran, Rozbeh; Berrisford, John M.; Minhas, Gurdeep S.; Sazanov, Leonid A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">494</span>
        (<span class="NLM_cas:issue">7438</span>),
    <span class="NLM_cas:pages">443-448</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Complex I/NADH;ubiquinone reductase is the 1st and largest enzyme of the respiratory chain and plays a central role in cellular energy prodn. through the coupling of NADH:ubiquinone electron transfer to proton translocation.  It is also implicated in many common human neurodegenerative diseases.  Here, the authors report the 1st crystal structure of the entire, intact complex I (from Thermus thermophilus) at 3.3 Ã resoln.  The structure of the 536-kDa complex comprises 16 different subunits, with a total of 64 transmembrane helixes and 9 Fe-S clusters.  The core fold of subunit Nqo8 (ND1 in humans) was, unexpectedly, similar to a half-channel of the antiporter-like subunits.  Small subunits nearby formed a linked 2nd half-channel, which completed the 4th proton-translocation pathway (present in addn. to the channels in 3 antiporter-like subunits).  The quinone-binding site was unusually long, narrow, and enclosed.  The quinone headgroup bound at the deep end of this chamber, near Fe-S cluster N2.  Notably, the chamber was linked to the 4th channel by a 'funnel' of charged residues.  The link continued over the entire membrane domain as a flexible central axis of charged and polar residues, and probably plays a leading role in the propagation of conformational changes, aided by coupling elements.  The structure suggests that a unique, out-of-the-membrane quinone-reaction chamber enables the redox energy to drive concerted long-range conformational changes in the 4 antiporter-like domains, resulting in translocation of 4 protons per cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4GfRTgPHKVrVg90H21EOLACvtfcHk0lh13ElOgCKiew"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtFWiu70%253D&md5=9e0beca1b6c80367e223d74556b1d58e</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fnature11871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11871%26sid%3Dliteratum%253Aachs%26aulast%3DBaradaran%26aufirst%3DR.%26aulast%3DBerrisford%26aufirst%3DJ.%2BM.%26aulast%3DMinhas%26aufirst%3DG.%2BS.%26aulast%3DSazanov%26aufirst%3DL.%2BA.%26atitle%3DCrystal%2520structure%2520of%2520the%2520entire%2520respiratory%2520complex%2520I%26jtitle%3DNature%26date%3D2013%26volume%3D494%26spage%3D443%26epage%3D448%26doi%3D10.1038%2Fnature11871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hunte, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zickermann, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, U.</span></span> <span> </span><span class="NLM_article-title">Functional modules and structural basis of conformational coupling in mitochondrial complex I</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>329</i></span>,  <span class="NLM_fpage">448</span>â <span class="NLM_lpage">451</span>, <span class="refDoi">Â DOI: 10.1126/science.1191046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1126%2Fscience.1191046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=20595580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptVWgtrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=329&publication_year=2010&pages=448-451&author=C.+Hunteauthor=V.+Zickermannauthor=U.+Brandt&title=Functional+modules+and+structural+basis+of+conformational+coupling+in+mitochondrial+complex+I&doi=10.1126%2Fscience.1191046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Functional Modules and Structural Basis of Conformational Coupling in Mitochondrial Complex I</span></div><div class="casAuthors">Hunte, Carola; Zickermann, Volker; Brandt, Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">329</span>
        (<span class="NLM_cas:issue">5990</span>),
    <span class="NLM_cas:pages">448-451</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Proton-pumping respiratory complex I is one of the largest and most complicated membrane protein complexes.  Its function is crit. for efficient energy supply in aerobic cells, and malfunctions are implicated in many neurodegenerative disorders.  Here, we report an x-ray crystallog. anal. of mitochondrial complex I.  The positions of all iron-sulfur clusters relative to the membrane arm were detd. in the complete enzyme complex.  The ubiquinone redn. site resides close to 30 angstroms above the membrane domain.  The arrangement of functional modules suggests conformational coupling of redox chem. with proton pumping and essentially excludes direct mechanisms.  We suggest that a ~60-angstrom-long helical transmission element is crit. for transducing conformational energy to proton-pumping elements in the distal module of the membrane arm.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBztImW48wyLVg90H21EOLACvtfcHk0lh13ElOgCKiew"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptVWgtrY%253D&md5=fd3597e3d5270c741e925047561f073b</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1126%2Fscience.1191046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1191046%26sid%3Dliteratum%253Aachs%26aulast%3DHunte%26aufirst%3DC.%26aulast%3DZickermann%26aufirst%3DV.%26aulast%3DBrandt%26aufirst%3DU.%26atitle%3DFunctional%2520modules%2520and%2520structural%2520basis%2520of%2520conformational%2520coupling%2520in%2520mitochondrial%2520complex%2520I%26jtitle%3DScience%26date%3D2010%26volume%3D329%26spage%3D448%26epage%3D451%26doi%3D10.1126%2Fscience.1191046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zickermann, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nasiri, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegmund, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwalbe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunte, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, U.</span></span> <span> </span><span class="NLM_article-title">Mechanistic insight from the crystal structure of mitochondrial complex I</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>347</i></span>,  <span class="NLM_fpage">44</span>â <span class="NLM_lpage">49</span>, <span class="refDoi">Â DOI: 10.1126/science.1259859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1126%2Fscience.1259859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=25554780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsF2jsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2015&pages=44-49&author=V.+Zickermannauthor=C.+Wirthauthor=H.+Nasiriauthor=K.+Siegmundauthor=H.+Schwalbeauthor=C.+Hunteauthor=U.+Brandt&title=Mechanistic+insight+from+the+crystal+structure+of+mitochondrial+complex+I&doi=10.1126%2Fscience.1259859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic insight from the crystal structure of mitochondrial complex I</span></div><div class="casAuthors">Zickermann, Volker; Wirth, Christophe; Nasiri, Hamid; Siegmund, Karin; Schwalbe, Harald; Hunte, Carola; Brandt, Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">6217</span>),
    <span class="NLM_cas:pages">44-49</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Proton-pumping complex I/ubiquinone reductase (I) of the mitochondrial respiratory chain is among the largest and most complicated membrane protein complexes.  I contributes substantially to oxidative energy conversion in eukaryotic cells.  Its malfunctions are implicated in many hereditary and degenerative disorders.  Here, the authors report the x-ray crystal structure of I at a resoln. of 3.6-3.9 Ã, describing in detail the central subunits that execute the bioenergetic function.  A continuous axis of basic and acidic residues running centrally through the membrane arm was found to connect the ubiquinone redn. site in the hydrophilic arm to 4 putative proton-pumping units.  The binding position for a substrate analogous inhibitor and blockage of the predicted ubiquinone binding site provide a model for the "deactive" form of the enzyme.  The proposed transition into the active form is based on a concerted structural rearrangement at the ubiquinone redn. site, providing support for a 2-state stabilization-change mechanism of proton pumping.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcVpKidjRGvrVg90H21EOLACvtfcHk0lhbsRtTjSHMFA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsF2jsg%253D%253D&md5=a0274bab4e65652e3dd656af7d966d3a</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1126%2Fscience.1259859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1259859%26sid%3Dliteratum%253Aachs%26aulast%3DZickermann%26aufirst%3DV.%26aulast%3DWirth%26aufirst%3DC.%26aulast%3DNasiri%26aufirst%3DH.%26aulast%3DSiegmund%26aufirst%3DK.%26aulast%3DSchwalbe%26aufirst%3DH.%26aulast%3DHunte%26aufirst%3DC.%26aulast%3DBrandt%26aufirst%3DU.%26atitle%3DMechanistic%2520insight%2520from%2520the%2520crystal%2520structure%2520of%2520mitochondrial%2520complex%2520I%26jtitle%3DScience%26date%3D2015%26volume%3D347%26spage%3D44%26epage%3D49%26doi%3D10.1126%2Fscience.1259859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uno, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyoshi, H.</span></span> <span> </span><span class="NLM_article-title">Exploring the quinone/inhibitor-binding pocket in mitochondrial respiratory complex I by chemical biology approaches</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>294</i></span>,  <span class="NLM_fpage">679</span>â <span class="NLM_lpage">696</span>, <span class="refDoi">Â DOI: 10.1074/jbc.RA118.006056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1074%2Fjbc.RA118.006056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=30425100" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1Cjtbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=294&publication_year=2019&pages=679-696&author=S.+P.+Unoauthor=H.+Kimuraauthor=M.+Muraiauthor=H.+Miyoshi&title=Exploring+the+quinone%2Finhibitor-binding+pocket+in+mitochondrial+respiratory+complex+I+by+chemical+biology+approaches&doi=10.1074%2Fjbc.RA118.006056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring the quinone/inhibitor-binding pocket in mitochondrial respiratory complex I by chemical biology approaches</span></div><div class="casAuthors">Uno, Shinpei; Kimura, Hironori; Murai, Masatoshi; Miyoshi, Hideto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">294</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">679-696</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">NADH-quinone oxidoreductase (respiratory complex I) couples NADH-to-quinone electron transfer to the translocation of protons across the membrane.  Even though the architecture of the quinone-access channel in the enzyme has been modeled by X-ray crystallog. and cryo-EM, conflicting findings raise the question whether the models fully reflect physiol. relevant states present throughout the catalytic cycle.  To gain further insights into the structural features of the binding pocket for quinone/inhibitor, we performed chem. biol. expts. using bovine heart sub-mitochondrial particles.  We synthesized ubiquinones (UQs) that are oversized ,(i.e., SF-UQs) or lipid-like (i.e., PC-UQs) and are highly unlikely to enter and transit the predicted narrow channel.  We found that SF-UQs and PC-UQs can be catalytically reduced by complex I, albeit only at moderate or low rates.  Moreover, quinone-site inhibitors completely blocked the catalytic redn. and the membrane potential formation coupled to this redn.  Photoaffinity-labeling expts. revealed that amiloride-type inhibitors bind to the interfacial domain of multiple core subunits (49 kDa, ND1, and PSST) and the 39-kDa supernumerary subunit, although the latter does not make up the channel cavity in the current models.  The binding of amilorides to the multiple target subunits was remarkably suppressed by other quinone-site inhibitors and SF-UQs.  Taken together, the present results are difficult to reconcile with the current channel models.  On the basis of comprehensive interpretations of the present results and of previous findings, we discuss the physiol. relevance of these models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrJm9y50UP1LVg90H21EOLACvtfcHk0lhbsRtTjSHMFA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1Cjtbw%253D&md5=2140567aa4ce686fa6571be9fc50b10a</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1074%2Fjbc.RA118.006056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.RA118.006056%26sid%3Dliteratum%253Aachs%26aulast%3DUno%26aufirst%3DS.%2BP.%26aulast%3DKimura%26aufirst%3DH.%26aulast%3DMurai%26aufirst%3DM.%26aulast%3DMiyoshi%26aufirst%3DH.%26atitle%3DExploring%2520the%2520quinone%252Finhibitor-binding%2520pocket%2520in%2520mitochondrial%2520respiratory%2520complex%2520I%2520by%2520chemical%2520biology%2520approaches%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2019%26volume%3D294%26spage%3D679%26epage%3D696%26doi%3D10.1074%2Fjbc.RA118.006056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tocilescu, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fendel, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwicker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerscher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, U.</span></span> <span> </span><span class="NLM_article-title">Exploring the ubiquinone binding cavity of respiratory complex I</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>282</i></span>,  <span class="NLM_fpage">29514</span>â <span class="NLM_lpage">29520</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M704519200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1074%2Fjbc.M704519200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=17681940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtV2ntbbE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=29514-29520&author=M.+A.+Tocilescuauthor=U.+Fendelauthor=K.+Zwickerauthor=S.+Kerscherauthor=U.+Brandt&title=Exploring+the+ubiquinone+binding+cavity+of+respiratory+complex+I&doi=10.1074%2Fjbc.M704519200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring the ubiquinone binding cavity of respiratory complex I</span></div><div class="casAuthors">Tocilescu, Maja A.; Fendel, Uta; Zwicker, Klaus; Kerscher, Stefan; Brandt, Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">282</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">29514-29520</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Proton pumping respiratory complex I/ubiquinone reductase is a major player in mitochondrial energy conversion.  However, little is known about the mol. mechanism of this large membrane protein complex.  Understanding the details of ubiquinone redn. will be prerequisite for elucidating this mechanism.  Based on a recently published partial structure of the bacterial enzyme, the authors scanned the proposed ubiquinone-binding cavity of complex I by site-directed mutagenesis in the strictly aerobic yeast Yarrowia lipolytica.  The obsd. changes in catalytic activity and inhibitor sensitivity followed a consistent pattern and allowed the authors to define 3 functionally important regions near ubiquinone-reducing Fe-S cluster N2.  The authors identified a likely entry path for the substrate, ubiquinone, and defined a region involved in inhibitor binding within the cavity.  Finally, the authors were able to highlight a functionally crit. structural motif in the active site that consisted of Tyr-144 in the 49-kDa subunit, surrounded by 3 conserved hydrophobic residues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk5zzIPT6DTbVg90H21EOLACvtfcHk0lhbsRtTjSHMFA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtV2ntbbE&md5=b87793238b13b906992950cc7fb7b2f9</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M704519200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M704519200%26sid%3Dliteratum%253Aachs%26aulast%3DTocilescu%26aufirst%3DM.%2BA.%26aulast%3DFendel%26aufirst%3DU.%26aulast%3DZwicker%26aufirst%3DK.%26aulast%3DKerscher%26aufirst%3DS.%26aulast%3DBrandt%26aufirst%3DU.%26atitle%3DExploring%2520the%2520ubiquinone%2520binding%2520cavity%2520of%2520respiratory%2520complex%2520I%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D29514%26epage%3D29520%26doi%3D10.1074%2Fjbc.M704519200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fendel, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tocilescu, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerscher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, U.</span></span> <span> </span><span class="NLM_article-title">Exploring the inhibitor binding pocket of respiratory complex I</span>. <i>Biochim. Biophys. Acta, Bioenerg.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>1777</i></span>,  <span class="NLM_fpage">660</span>â <span class="NLM_lpage">665</span>, <span class="refDoi">Â DOI: 10.1016/j.bbabio.2008.04.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.bbabio.2008.04.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=18486594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsFCms70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1777&publication_year=2008&pages=660-665&author=U.+Fendelauthor=M.+A.+Tocilescuauthor=S.+Kerscherauthor=U.+Brandt&title=Exploring+the+inhibitor+binding+pocket+of+respiratory+complex+I&doi=10.1016%2Fj.bbabio.2008.04.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring the inhibitor binding pocket of respiratory complex I</span></div><div class="casAuthors">Fendel, Uta; Tocilescu, Maja A.; Kerscher, Stefan; Brandt, Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Bioenergetics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">1777</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">660-665</span>CODEN:
                <span class="NLM_cas:coden">BBBEB4</span>;
        ISSN:<span class="NLM_cas:issn">0005-2728</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Numerous hydrophobic and amphipathic compds. including several detergents are known to inhibit the ubiquinone reductase reaction of respiratory chain complex I (proton pumping NADH:ubiquinone oxidoreductase).  Guided by the X-ray structure of the peripheral arm of complex I from Thermus thermophilus we have generated a large collection of site-directed mutants in the yeast Yarrowia lipolytica targeting the proposed ubiquinone and inhibitor binding pocket of this huge multiprotein complex at the interface of the 49-kDa and PSST subunits.  We could identify a no. of residues where mutations changed I 50 values for representatives from all three groups of hydrophobic inhibitors.  Many mutations around the domain of the 49-kDa subunit that is homologous to the [NiFe] center binding region of hydrogenase conferred resistance to DQA (class I/type A) and rotenone (class II/type B) indicating a wider overlap of the binding sites for these two types of inhibitors.  In contrast, a region near iron-sulfur cluster N2, where the binding of the n-alkyl-polyoxyethylene-ether detergent C12E8 (type C) was exclusively affected, appeared comparably well sepd.  Taken together, our data provide structure-based support for the presence of distinct but overlapping binding sites for hydrophobic inhibitors possibly extending into the ubiquinone redn. site of mitochondrial complex I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv-gMvoWhvHrVg90H21EOLACvtfcHk0liEbASdJb6S0Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsFCms70%253D&md5=5bd4dbc81d0b221865e335daa74e9fd2</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.bbabio.2008.04.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbabio.2008.04.033%26sid%3Dliteratum%253Aachs%26aulast%3DFendel%26aufirst%3DU.%26aulast%3DTocilescu%26aufirst%3DM.%2BA.%26aulast%3DKerscher%26aufirst%3DS.%26aulast%3DBrandt%26aufirst%3DU.%26atitle%3DExploring%2520the%2520inhibitor%2520binding%2520pocket%2520of%2520respiratory%2520complex%2520I%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Bioenerg.%26date%3D2008%26volume%3D1777%26spage%3D660%26epage%3D665%26doi%3D10.1016%2Fj.bbabio.2008.04.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsuji, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyoshi, H.</span></span> <span> </span><span class="NLM_article-title">IACS-010759, a potent inhibitor of glycolysis-deficient hypoxic tumor cells, inhibits mitochondrial respiratory complex I through a unique mechanism</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>295</i></span>,  <span class="NLM_fpage">7481</span>, <span class="refDoi">Â DOI: 10.1074/jbc.RA120.013366</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1074%2Fjbc.RA120.013366" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=32295842" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1Wqt7vM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=295&publication_year=2020&pages=7481&author=A.+Tsujiauthor=T.+Akaoauthor=T.+Masuyaauthor=M.+Muraiauthor=H.+Miyoshi&title=IACS-010759%2C+a+potent+inhibitor+of+glycolysis-deficient+hypoxic+tumor+cells%2C+inhibits+mitochondrial+respiratory+complex+I+through+a+unique+mechanism&doi=10.1074%2Fjbc.RA120.013366"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">IACS-010759, a potent inhibitor of glycolysis-deficient hypoxic tumor cells, inhibits mitochondrial respiratory complex I through a unique mechanism</span></div><div class="casAuthors">Tsuji, Atsuhito; Akao, Takumi; Masuya, Takahiro; Murai, Masatoshi; Miyoshi, Hideto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">295</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7481-7492</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">1083-351X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The small mol. IACS-010759 has been reported to potently inhibit the proliferation of glycolysis-deficient hypoxic tumor cells by interfering with the functions of mitochondrial NADH-ubiquinone oxidoreductase (complex I) without exhibiting cytotoxicity at tolerated doses in normal cells.  Considering the significant cytotoxicity of conventional quinone-site inhibitors of complex I, such as piericidin and acetogenin families, we hypothesized that the mechanism of action of IACS-010759 on complex I differs from that of other known quinone-site inhibitors.  To test this possibility, here we investigated IACS-010759's mechanism in bovine heart submitochondrial particles.  We found that IACS-010759, like known quinone-site inhibitors, suppresses chem. modification by the tosyl reagent AL1 of Asp160 in the 49-kDa subunit, located deep in the interior of a previously proposed quinone-access channel.  However, contrary to the other inhibitors, IACS-010759 direction-dependently inhibited forward and reverse electron transfer and did not suppress binding of the quinazoline-type inhibitor [125I]AzQ to the N terminus of the 49-kDa subunit.  Photoaffinity labeling expts. revealed that the photoreactive deriv. [125I]IACS-010759-PD1 binds to the middle of the membrane subunit ND1 and that inhibitors that bind to the 49-kDa or PSST subunit cannot suppress the binding.  We conclude that IACS-010759's binding location in complex I differs from that of any other known inhibitor of the enzyme.  Our findings, along with those from previous study, reveal that the mechanisms of action of complex I inhibitors with widely different chem. properties are more diverse than can be accounted for by the quinone-access channel model proposed by structural biol. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYNQGiooIoy7Vg90H21EOLACvtfcHk0liEbASdJb6S0Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1Wqt7vM&md5=2f2c06cef38bdf327edc2978a9175243</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1074%2Fjbc.RA120.013366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.RA120.013366%26sid%3Dliteratum%253Aachs%26aulast%3DTsuji%26aufirst%3DA.%26aulast%3DAkao%26aufirst%3DT.%26aulast%3DMasuya%26aufirst%3DT.%26aulast%3DMurai%26aufirst%3DM.%26aulast%3DMiyoshi%26aufirst%3DH.%26atitle%3DIACS-010759%252C%2520a%2520potent%2520inhibitor%2520of%2520glycolysis-deficient%2520hypoxic%2520tumor%2520cells%252C%2520inhibits%2520mitochondrial%2520respiratory%2520complex%2520I%2520through%2520a%2520unique%2520mechanism%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2020%26volume%3D295%26spage%3D7481%26doi%3D10.1074%2Fjbc.RA120.013366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartlam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Z. H.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of mitochondrial respiratory membrane protein complex II</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">1043</span>â <span class="NLM_lpage">1057</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2005.05.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.cell.2005.05.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=15989954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtF2nsbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2005&pages=1043-1057&author=F.+Sunauthor=X.+Huoauthor=Y.+J.+Zhaiauthor=A.+J.+Wangauthor=J.+X.+Xuauthor=D.+Suauthor=M.+Bartlamauthor=Z.+H.+Rao&title=Crystal+structure+of+mitochondrial+respiratory+membrane+protein+complex+II&doi=10.1016%2Fj.cell.2005.05.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of mitochondrial respiratory membrane protein complex II</span></div><div class="casAuthors">Sun, Fei; Huo, Xia; Zhai, Yujia; Wang, Aojin; Xu, Jianxing; Su, Dan; Bartlam, Mark; Rao, Zihe</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1043-1057</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The mitochondrial respiratory Complex II or succinate: ubiquinone oxidoreductase (SQR) is an integral membrane protein complex in both the tricarboxylic acid cycle and aerobic respiration.  Here we report the first crystal structure of Complex II from porcine heart at 2.4 Ã resoln. and its complex structure with inhibitors 3-nitropropionate and 2-thenoyltrifluoroacetone (TTFA) at 3.5 Ã resoln.  Complex II is comprised of two hydrophilic proteins, flavoprotein (Fp) and iron-sulfur protein (Ip), and two transmembrane proteins (CybL and CybS), as well as prosthetic groups required for electron transfer from succinate to ubiquinone.  The structure correlates the protein environments around prosthetic groups with their unique midpoint redox potentials.  Two ubiquinone binding sites are discussed and elucidated by TTFA binding.  The Complex II structure provides a bona fide model for study of the mitochondrial respiratory system and human mitochondrial diseases related to mutations in this complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobGlznAZ9XtLVg90H21EOLACvtfcHk0liEbASdJb6S0Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtF2nsbc%253D&md5=04ad855f63cbd25e31be9bf64df28b84</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2005.05.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2005.05.025%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DF.%26aulast%3DHuo%26aufirst%3DX.%26aulast%3DZhai%26aufirst%3DY.%2BJ.%26aulast%3DWang%26aufirst%3DA.%2BJ.%26aulast%3DXu%26aufirst%3DJ.%2BX.%26aulast%3DSu%26aufirst%3DD.%26aulast%3DBartlam%26aufirst%3DM.%26aulast%3DRao%26aufirst%3DZ.%2BH.%26atitle%3DCrystal%2520structure%2520of%2520mitochondrial%2520respiratory%2520membrane%2520protein%2520complex%2520II%26jtitle%3DCell%26date%3D2005%26volume%3D121%26spage%3D1043%26epage%3D1057%26doi%3D10.1016%2Fj.cell.2005.05.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maklashina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cecchini, G.</span></span> <span> </span><span class="NLM_article-title">The quinone-binding and catalytic site of complex II</span>. <i>Biochim. Biophys. Acta, Bioenerg.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1797</i></span>,  <span class="NLM_fpage">1877</span>â <span class="NLM_lpage">1882</span>, <span class="refDoi">Â DOI: 10.1016/j.bbabio.2010.02.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.bbabio.2010.02.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=20175986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVansrbE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1797&publication_year=2010&pages=1877-1882&author=E.+Maklashinaauthor=G.+Cecchini&title=The+quinone-binding+and+catalytic+site+of+complex+II&doi=10.1016%2Fj.bbabio.2010.02.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The quinone-binding and catalytic site of complex II</span></div><div class="casAuthors">Maklashina, Elena; Cecchini, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Bioenergetics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1797</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1877-1882</span>CODEN:
                <span class="NLM_cas:coden">BBBEB4</span>;
        ISSN:<span class="NLM_cas:issn">0005-2728</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  The complex II family of proteins includes succinate-quinone oxidoreductase (SQR) and quinol:fumarate oxidoreductase (QFR).  In the facultative bacterium, Escherichia coli, both are expressed as part of the aerobic (SQR) and anaerobic (QFR) respiratory chains.  SQR of E. coli is homologous to mitochondrial complex II and has proven to be an excellent model system for structure-function studies of the enzyme.  Both SQR and QFR of E. coli are tetrameric membrane-bound enzymes that couple succinate-fumarate interconversion with quinone/quinol redn./oxidn.  Both enzymes are capable of binding either ubiquinone or menaquinone; however, they have adopted different quinone-binding sites where catalytic reactions with quinones occur.  A comparison of the structures of the quinone-binding sites in SQR and QFR reveals how the enzymes have adapted in order to accommodate both benzoquinones and naphthoquinones.  A combination of structural, computational, and kinetic studies of members of the complex II family of enzymes has revealed that the catalytic quinone adopts different positions in the quinone-binding pocket.  These data suggest that movement of the quinone within the quinone-binding pocket is essential for catalysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvjswaQSgZ6LVg90H21EOLACvtfcHk0liEbASdJb6S0Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVansrbE&md5=0cafcfcc9e44d279759c786a771746c4</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.bbabio.2010.02.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbabio.2010.02.015%26sid%3Dliteratum%253Aachs%26aulast%3DMaklashina%26aufirst%3DE.%26aulast%3DCecchini%26aufirst%3DG.%26atitle%3DThe%2520quinone-binding%2520and%2520catalytic%2520site%2520of%2520complex%2520II%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Bioenerg.%26date%3D2010%26volume%3D1797%26spage%3D1877%26epage%3D1882%26doi%3D10.1016%2Fj.bbabio.2010.02.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bezawork-Geleta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohlena, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacak, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuzil, J.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial complex II: at the crossroads</span>. <i>Trends Biochem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">312</span>â <span class="NLM_lpage">325</span>, <span class="refDoi">Â DOI: 10.1016/j.tibs.2017.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.tibs.2017.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=28185716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVeitb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2017&pages=312-325&author=A.+Bezawork-Geletaauthor=J.+Rohlenaauthor=L.+F.+Dongauthor=K.+Pacakauthor=J.+Neuzil&title=Mitochondrial+complex+II%3A+at+the+crossroads&doi=10.1016%2Fj.tibs.2017.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial Complex II: At the Crossroads</span></div><div class="casAuthors">Bezawork-Geleta, Ayenachew; Rohlena, Jakub; Dong, Lanfeng; Pacak, Karel; Neuzil, Jiri</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biochemical Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">312-325</span>CODEN:
                <span class="NLM_cas:coden">TBSCDB</span>;
        ISSN:<span class="NLM_cas:issn">0968-0004</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Mitochondrial complex II (CII), also called succinate dehydrogenase (SDH), is a central purveyor of the reprogramming of metabolic and respiratory adaptation in response to various intrinsic and extrinsic stimuli and abnormalities.  In this review we discuss recent findings regarding SDH biogenesis, which requires four known assembly factors, and modulation of its enzymic activity by acetylation, succinylation, phosphorylation, and proteolysis.  We further focus on the emerging role of both genetic and epigenetic aberrations leading to SDH dysfunction assocd. with various clin. manifestations.  This review also covers the recent discovery of the role of SDH in inflammation-linked pathologies.  Conceivably, SDH is a potential target for several hard-to-treat conditions, including cancer, that remains to be fully exploited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfI9EMqCqg27Vg90H21EOLACvtfcHk0ligGltu1aR4rQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVeitb0%253D&md5=7b65555d34bfa8215e9eceb70e707716</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.tibs.2017.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tibs.2017.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DBezawork-Geleta%26aufirst%3DA.%26aulast%3DRohlena%26aufirst%3DJ.%26aulast%3DDong%26aufirst%3DL.%2BF.%26aulast%3DPacak%26aufirst%3DK.%26aulast%3DNeuzil%26aufirst%3DJ.%26atitle%3DMitochondrial%2520complex%2520II%253A%2520at%2520the%2520crossroads%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D2017%26volume%3D42%26spage%3D312%26epage%3D325%26doi%3D10.1016%2Fj.tibs.2017.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span> <span> </span><span class="NLM_article-title">Thiabendazole inhibits ubiquinone reduction activity of mitochondrial respiratory complex II via a water molecule mediated binding feature</span>. <i>Protein Cell</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">531</span>â <span class="NLM_lpage">542</span>, <span class="refDoi">Â DOI: 10.1007/s13238-011-1079-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1007%2Fs13238-011-1079-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=21822798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVShsrrM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=531-542&author=Q.+J.+Zhouauthor=Y.+J.+Zhaiauthor=J.+Z.+Louauthor=M.+Liuauthor=X.+Y.+Pangauthor=F.+Sun&title=Thiabendazole+inhibits+ubiquinone+reduction+activity+of+mitochondrial+respiratory+complex+II+via+a+water+molecule+mediated+binding+feature&doi=10.1007%2Fs13238-011-1079-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Thiabendazole inhibits ubiquinone reduction activity of mitochondrial respiratory complex II via a water molecule mediated binding feature</span></div><div class="casAuthors">Zhou, Qiangjun; Zhai, Yujia; Lou, Jizhong; Liu, Man; Pang, Xiaoyun; Sun, Fei</div><div class="citationInfo"><span class="NLM_cas:title">Protein & Cell</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">531-542</span>CODEN:
                <span class="NLM_cas:coden">PCREFB</span>;
        ISSN:<span class="NLM_cas:issn">1674-800X</span>.
    
            (<span class="NLM_cas:orgname">Higher Education Press</span>)
        </div><div class="casAbstract">The mitochondrial respiratory complex II or succinate:ubiquinone oxidoreductase (SQR) is a key membrane complex in both the tricarboxylic acid cycle and aerobic respiration.  Five disinfectant compds. were investigated with their potent inhibition effects on the ubiquinone redn. activity of the porcine mitochondrial SQR by enzymic assay and crystallog.  Crystal structure of the SQR bound with thiabendazole (TBZ) reveals a different inhibitor-binding feature at the ubiquinone binding site where a water mol. plays an important role.  The obvious inhibitory effect of TBZ based on the biochem. data (IC50 â¼100 Î¼mol/L) and the significant structure-based binding affinity calcn. (â¼94 Î¼mol/L) draw the suspicion of using TBZ as a good disinfectant compd. for nematode infections treatment and fruit storage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGop5Kr-Hw2UjLVg90H21EOLACvtfcHk0ligGltu1aR4rQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVShsrrM&md5=4600d5d1dc84c56f782878367499f727</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1007%2Fs13238-011-1079-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13238-011-1079-1%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DQ.%2BJ.%26aulast%3DZhai%26aufirst%3DY.%2BJ.%26aulast%3DLou%26aufirst%3DJ.%2BZ.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DPang%26aufirst%3DX.%2BY.%26aulast%3DSun%26aufirst%3DF.%26atitle%3DThiabendazole%2520inhibits%2520ubiquinone%2520reduction%2520activity%2520of%2520mitochondrial%2520respiratory%2520complex%2520II%2520via%2520a%2520water%2520molecule%2520mediated%2520binding%2520feature%26jtitle%3DProtein%2520Cell%26date%3D2011%26volume%3D2%26spage%3D531%26epage%3D542%26doi%3D10.1007%2Fs13238-011-1079-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobessi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tung, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, E. A.</span></span> <span> </span><span class="NLM_article-title">3-Nitropropionic acid is a suicide inhibitor of mitochondrial respiration that, upon oxidation by Complex II, forms a covalent adduct with a catalytic base arginine in the active site of the enzyme</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>281</i></span>,  <span class="NLM_fpage">5965</span>â <span class="NLM_lpage">5972</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M511270200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1074%2Fjbc.M511270200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=16371358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD28XhvVeju7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2006&pages=5965-5972&author=L.+S.+Huangauthor=G.+Sunauthor=D.+Cobessiauthor=A.+C.+Wangauthor=J.+T.+Shenauthor=E.+Y.+Tungauthor=V.+E.+Andersonauthor=E.+A.+Berry&title=3-Nitropropionic+acid+is+a+suicide+inhibitor+of+mitochondrial+respiration+that%2C+upon+oxidation+by+Complex+II%2C+forms+a+covalent+adduct+with+a+catalytic+base+arginine+in+the+active+site+of+the+enzyme&doi=10.1074%2Fjbc.M511270200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">3-Nitropropionic Acid Is a Suicide Inhibitor of Mitochondrial Respiration That, upon Oxidation by Complex II, Forms a Covalent Adduct with a Catalytic Base Arginine in the Active Site of the Enzyme</span></div><div class="casAuthors">Huang, Li-shar; Sun, Gang; Cobessi, David; Wang, Andy C.; Shen, John T.; Tung, Eric Y.; Anderson, Vernon E.; Berry, Edward A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">281</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5965-5972</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">We report three new structures of mitochondrial respiratory Complex II (succinate ubiquinone oxidoreductase, E.C. 1.3.5.1) at up to 2.1 Ã resoln., with various inhibitors.  The structures define the conformation of the bound inhibitors and suggest the residues involved in substrate binding and catalysis at the dicarboxylate site.  In particular they support the role of Arg297 as a general base catalyst accepting a proton in the dehydrogenation of succinate.  The dicarboxylate ligand in oxaloacetate-contg. crystals appears to be the same as that reported for Shewanella flavocytochrome c treated with fumarate.  The plant and fungal toxin 3-nitropropionic acid (3-NP), an irreversible inactivator of succinate dehydrogenase, forms a covalent adduct with the side chain of Arg297.  The modification eliminates a trypsin cleavage site in the flavoprotein, and tandem mass spectroscopic anal. of the new fragment shows the mass of Arg297 to be increased by 83 Da and to have the potential of losing 44 Da, consistent with decarboxylation, during fragmentation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqri-wDnBFEtLVg90H21EOLACvtfcHk0ligGltu1aR4rQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhvVeju7w%253D&md5=afbb05c11db4357ff3a7f9f2902afd5d</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M511270200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M511270200%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DL.%2BS.%26aulast%3DSun%26aufirst%3DG.%26aulast%3DCobessi%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DA.%2BC.%26aulast%3DShen%26aufirst%3DJ.%2BT.%26aulast%3DTung%26aufirst%3DE.%2BY.%26aulast%3DAnderson%26aufirst%3DV.%2BE.%26aulast%3DBerry%26aufirst%3DE.%2BA.%26atitle%3D3-Nitropropionic%2520acid%2520is%2520a%2520suicide%2520inhibitor%2520of%2520mitochondrial%2520respiration%2520that%252C%2520upon%2520oxidation%2520by%2520Complex%2520II%252C%2520forms%2520a%2520covalent%2520adduct%2520with%2520a%2520catalytic%2520base%2520arginine%2520in%2520the%2520active%2520site%2520of%2520the%2520enzyme%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2006%26volume%3D281%26spage%3D5965%26epage%3D5972%26doi%3D10.1074%2Fjbc.M511270200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, E. A.</span></span> <span> </span><span class="NLM_article-title">Crystallographic studies of the binding of ligands to the dicarboxylate site of Complex II, and the identity of the ligand in the â³oxaloacetate-inhibitedâ³ state</span>. <i>Biochim. Biophys. Acta, Bioenerg.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>1757</i></span>,  <span class="NLM_fpage">1073</span>â <span class="NLM_lpage">1083</span>, <span class="refDoi">Â DOI: 10.1016/j.bbabio.2006.06.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.bbabio.2006.06.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=16935256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVanurvN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1757&publication_year=2006&pages=1073-1083&author=L.+S.+Huangauthor=J.+T.+Shenauthor=A.+C.+Wangauthor=E.+A.+Berry&title=Crystallographic+studies+of+the+binding+of+ligands+to+the+dicarboxylate+site+of+Complex+II%2C+and+the+identity+of+the+ligand+in+the+%E2%80%B3oxaloacetate-inhibited%E2%80%B3+state&doi=10.1016%2Fj.bbabio.2006.06.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Crystallographic studies of the binding of ligands to the dicarboxylate site of Complex II, and the identity of the ligand in the "oxaloacetate-inhibited" state</span></div><div class="casAuthors">Huang, Li-Shar; Shen, John T.; Wang, Andy C.; Berry, Edward A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Bioenergetics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">1757</span>
        (<span class="NLM_cas:issue">9-10</span>),
    <span class="NLM_cas:pages">1073-1083</span>CODEN:
                <span class="NLM_cas:coden">BBBEB4</span>;
        ISSN:<span class="NLM_cas:issn">0005-2728</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Mitochondrial Complex II (succinate:ubiquinone oxidoreductase) is purified in a partially inactivated state, which can be activated by removal of tightly bound oxaloacetate (E. B. Kearney, et al., Biochem. Biophys. Res. Commun. 49 1115-1121).  We crystd. Complex II in the presence of oxaloacetate or with the endogenous inhibitor bound.  The structure showed a ligand essentially identical to the "malate-like intermediate" found in Shewanella Flavocytochrome c crystd. with fumarate (P. Taylor, et al., Nat. Struct. Biol. 6 1108-1112).  Crystn. of Complex II in the presence of excess fumarate also gave the malate-like intermediate or a mixt. of that and fumarate at the active site.  In order to more conveniently monitor the occupation state of the dicarboxylate site, we are developing a library of UV/Vis spectral effects induced by binding different ligands to the site.  Treatment with fumarate results in rapid development of the fumarate difference spectrum and then a very slow conversion into a species spectrally similar to the OAA-liganded complex.  Complex II is known to be capable of oxidizing malate to the enol form of oxaloacetate (Y. O. Belikova, et al., Biochim. Biophys. Acta 936 1-9).  The observations above suggest it may also be capable of interconverting fumarate and malate.  It may be useful for understanding the mechanism and regulation of the enzyme to identify the malate-like intermediate and its pathway of formation from oxaloacetate or fumarate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp89KlBK_X6vLVg90H21EOLACvtfcHk0lgqXQMu81Nprw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVanurvN&md5=e1d68bddf59e906f98e2c68e2354678f</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.bbabio.2006.06.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbabio.2006.06.015%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DL.%2BS.%26aulast%3DShen%26aufirst%3DJ.%2BT.%26aulast%3DWang%26aufirst%3DA.%2BC.%26aulast%3DBerry%26aufirst%3DE.%2BA.%26atitle%3DCrystallographic%2520studies%2520of%2520the%2520binding%2520of%2520ligands%2520to%2520the%2520dicarboxylate%2520site%2520of%2520Complex%2520II%252C%2520and%2520the%2520identity%2520of%2520the%2520ligand%2520in%2520the%2520%25E2%2580%25B3oxaloacetate-inhibited%25E2%2580%25B3%2520state%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Bioenerg.%26date%3D2006%26volume%3D1757%26spage%3D1073%26epage%3D1083%26doi%3D10.1016%2Fj.bbabio.2006.06.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Inaoka, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiba, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balogun, E. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagahama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuoka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohmori, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harada, S.</span></span> <span> </span><span class="NLM_article-title">Structural insights into the molecular design of flutolanil derivatives targeted for fumarate respiration of parasite mitochondria</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">15287</span>â <span class="NLM_lpage">15308</span>, <span class="refDoi">Â DOI: 10.3390/ijms160715287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.3390%2Fijms160715287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=26198225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVeitrjP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=15287-15308&author=D.+K.+Inaokaauthor=T.+Shibaauthor=D.+Satoauthor=E.+O.+Balogunauthor=T.+Sasakiauthor=M.+Nagahamaauthor=M.+Odaauthor=S.+Matsuokaauthor=J.+Ohmoriauthor=T.+Honmaauthor=M.+Inoueauthor=K.+Kitaauthor=S.+Harada&title=Structural+insights+into+the+molecular+design+of+flutolanil+derivatives+targeted+for+fumarate+respiration+of+parasite+mitochondria&doi=10.3390%2Fijms160715287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into the molecular design of flutolanil derivatives targeted for fumarate respiration of parasite mitochondria</span></div><div class="casAuthors">Inaoka, Daniel Ken; Shiba, Tomoo; Sato, Dan; Balogun, Emmanuel Oluwadare; Sasaki, Tsuyoshi; Nagahama, Madoka; Oda, Masatsugu; Matsuoka, Shigeru; Ohmori, Junko; Honma, Teruki; Inoue, Masayuki; Kita, Kiyoshi; Harada, Shigeharu</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">15287-15308</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Recent studies on the respiratory chain of Ascaris suum showed that the mitochondrial NADH-fumarate reductase system composed of complex I, rhodoquinone and complex II plays an important role in the anaerobic energy metab. of adult A. suum.  The system is the major pathway of energy metab. for adaptation to a hypoxic environment not only in parasitic organisms, but also in some types of human cancer cells.  Thus, enzymes of the pathway are potential targets for chemotherapy.  We found that flutolanil is an excellent inhibitor for A. suum complex II (IC50 = 0.058 Î¼M) but less effectively inhibits homologous porcine complex II (IC50 = 45.9 Î¼M).  In order to account for the specificity of flutolanil to A. suum complex II from the standpoint of structural biol., we detd. the crystal structures of A. suum and porcine complex IIs binding flutolanil and its deriv. compds.  The structures clearly demonstrated key interactions responsible for its high specificity to A. suum complex II and enabled us to find analog compds., which surpass flutolanil in both potency and specificity to A. suum complex II.  Structures of complex IIs binding these compds. will be helpful to accelerate structure-based drug design targeted for complex IIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_Pko-YiLNyrVg90H21EOLACvtfcHk0lgqXQMu81Nprw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVeitrjP&md5=4bae2fd0d741bfc9017fb5d3b4de66d0</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.3390%2Fijms160715287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms160715287%26sid%3Dliteratum%253Aachs%26aulast%3DInaoka%26aufirst%3DD.%2BK.%26aulast%3DShiba%26aufirst%3DT.%26aulast%3DSato%26aufirst%3DD.%26aulast%3DBalogun%26aufirst%3DE.%2BO.%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DNagahama%26aufirst%3DM.%26aulast%3DOda%26aufirst%3DM.%26aulast%3DMatsuoka%26aufirst%3DS.%26aulast%3DOhmori%26aufirst%3DJ.%26aulast%3DHonma%26aufirst%3DT.%26aulast%3DInoue%26aufirst%3DM.%26aulast%3DKita%26aufirst%3DK.%26aulast%3DHarada%26aufirst%3DS.%26atitle%3DStructural%2520insights%2520into%2520the%2520molecular%2520design%2520of%2520flutolanil%2520derivatives%2520targeted%2520for%2520fumarate%2520respiration%2520of%2520parasite%2520mitochondria%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2015%26volume%3D16%26spage%3D15287%26epage%3D15308%26doi%3D10.3390%2Fijms160715287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xia, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kachurin, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deisenhofer, J.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the cytochrome bc(1) complex from bovine heart mitochondria</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">60</span>, <span class="refDoi">Â DOI: 10.1126/science.277.5322.60</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1126%2Fscience.277.5322.60" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=9204897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADyaK2sXksVyhu70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=1997&pages=60&author=D.+Xiaauthor=C.+A.+Yuauthor=H.+Kimauthor=J.+Z.+Xiaauthor=A.+M.+Kachurinauthor=L.+Zhangauthor=L.+Yuauthor=J.+Deisenhofer&title=Crystal+structure+of+the+cytochrome+bc%281%29+complex+from+bovine+heart+mitochondria&doi=10.1126%2Fscience.277.5322.60"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the cytochrome bc1 complex from bovine heart mitochondria</span></div><div class="casAuthors">Xia, Di; Yu, Chang-An; Kim, Hoeon; Xia, Jia-Zhi; Kachurin, Anatoly M.; Zhang, Li; Yu, Linda; Deisenhofer, Johann</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">5322</span>),
    <span class="NLM_cas:pages">60-66</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">On the basis of x-ray diffraction data to a resoln. of 2.9 Ã, at. models of most protein components of the bovine ubiquinol-cytochrome c reductase (cytochrome bc1 complex) (I) were built, including core 1, core 2, cytochrome b, subunit 6, subunit 7, a C-terminal fragment of cytochrome c1, and an N-terminal fragment of the Fe-S protein.  The positions of the 4 Fe centers within I and the binding sites of the 2 specific respiratory inhibitors, antimycin A and myxothiazol, were identified.  The membrane-spanning region of each I monomer consisted of 13 transmembrane helixes, 8 of which belonged to cytochrome b.  Closely interacting monomers were arranged as sym. dimers and formed cavities through which the inhibitor binding pockets could be accessed.  The proteins, core 1 and core 2, were structurally similar to each other and consisted of 2 domains of roughly equal size and identical folding topol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGot3G2U821pybVg90H21EOLACvtfcHk0lgqXQMu81Nprw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXksVyhu70%253D&md5=28d7354b93bdd04e3f0e3f67d9f10764</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1126%2Fscience.277.5322.60&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.277.5322.60%26sid%3Dliteratum%253Aachs%26aulast%3DXia%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DC.%2BA.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DXia%26aufirst%3DJ.%2BZ.%26aulast%3DKachurin%26aufirst%3DA.%2BM.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DDeisenhofer%26aufirst%3DJ.%26atitle%3DCrystal%2520structure%2520of%2520the%2520cytochrome%2520bc%25281%2529%2520complex%2520from%2520bovine%2520heart%2520mitochondria%26jtitle%3DScience%26date%3D1997%26volume%3D277%26spage%3D60%26doi%3D10.1126%2Fscience.277.5322.60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Esser, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elberry, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, D.</span></span> <span> </span><span class="NLM_article-title">Crystallographic studies of quinol oxidation site inhibitors: a modified classification of inhibitors for the cytochrome bc(1) complex</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>341</i></span>,  <span class="NLM_fpage">281</span>â <span class="NLM_lpage">302</span>, <span class="refDoi">Â DOI: 10.1016/j.jmb.2004.05.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.jmb.2004.05.065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=15312779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVynsLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=2004&pages=281-302&author=L.+Esserauthor=B.+Quinnauthor=Y.+F.+Liauthor=M.+Zhangauthor=M.+Elberryauthor=L.+Yuauthor=C.+A.+Yuauthor=D.+Xia&title=Crystallographic+studies+of+quinol+oxidation+site+inhibitors%3A+a+modified+classification+of+inhibitors+for+the+cytochrome+bc%281%29+complex&doi=10.1016%2Fj.jmb.2004.05.065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Crystallographic studies of quinol oxidation site inhibitors: A modified classification of inhibitors for the cytochrome bc1 complex</span></div><div class="casAuthors">Esser, Lothar; Quinn, Byron; Li, Yong-Fu; Zhang, Minquan; Elberry, Maria; Yu, Linda; Yu, Chang-An; Di, Xia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">281-302</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Cytochrome bc1 is an integral membrane protein complex essential for cellular respiration and photosynthesis; it couples electron transfer from quinol to cytochrome c to proton translocation across the membrane.  Specific bc1 inhibitors have not only played crucial roles in elucidating the mechanism of bc1 function but have also provided leads for the development of novel antibiotics.  Crystal structures of bovine bc1 in complex with the specific Qo site inhibitors azoxystrobin, MOAS, myxothiazol, stigmatellin and 5-undecyl-6-hydroxy-4,7-dioxobenzothiazole were detd.  Interactions, conformational changes and possible mechanisms of resistance, specific to each inhibitor, were defined.  Residues and secondary structure elements that are capable of discriminating different classes of Qo site inhibitors were identified for the cytochrome b subunit.  Directions in the displacement of the cd1 helix of cytochrome b subunit in response to various Qo site inhibitors were correlated to the binary conformational switch of the extrinsic domain of the iron-sulfur protein subunit.  The new structural information, together with structures previously detd., provide a basis that, combined with biophys. and mutational data, suggest a modification to the existing classification of bc1 inhibitors.  Bc1 inhibitors are grouped into three classes: class P inhibitors bind to the Qo site, class N inhibitors bind to the Qi site and the class PN inhibitors target both sites.  Class P contains two subgroups, Pm and Pf, that are distinct by their ability to induce mobile or fixed conformation of iron-sulfur protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwlmXa-g_8ibVg90H21EOLACvtfcHk0lgD0b1XTTlcxg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVynsLk%253D&md5=e066653a7e3d31bf41edf7f67a8e3270</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2004.05.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2004.05.065%26sid%3Dliteratum%253Aachs%26aulast%3DEsser%26aufirst%3DL.%26aulast%3DQuinn%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DY.%2BF.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DElberry%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DC.%2BA.%26aulast%3DXia%26aufirst%3DD.%26atitle%3DCrystallographic%2520studies%2520of%2520quinol%2520oxidation%2520site%2520inhibitors%253A%2520a%2520modified%2520classification%2520of%2520inhibitors%2520for%2520the%2520cytochrome%2520bc%25281%2529%2520complex%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2004%26volume%3D341%26spage%3D281%26epage%3D302%26doi%3D10.1016%2Fj.jmb.2004.05.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symersky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faraldo-Gomez, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, D. M.</span></span> <span> </span><span class="NLM_article-title">High-resolution cryo-EM analysis of the yeast ATP synthase in a lipid membrane</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>360</i></span>,  <span class="NLM_fpage">eaas9699</span>, <span class="refDoi">Â DOI: 10.1126/science.aas9699</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1126%2Fscience.aas9699" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=29650704" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=360&publication_year=2018&pages=eaas9699&author=A.+P.+Srivastavaauthor=M.+Luoauthor=W.+C.+Zhouauthor=J.+Symerskyauthor=D.+Y.+Baiauthor=M.+G.+Chambersauthor=J.+D.+Faraldo-Gomezauthor=M.+F.+Liaoauthor=D.+M.+Mueller&title=High-resolution+cryo-EM+analysis+of+the+yeast+ATP+synthase+in+a+lipid+membrane&doi=10.1126%2Fscience.aas9699"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1126%2Fscience.aas9699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aas9699%26sid%3Dliteratum%253Aachs%26aulast%3DSrivastava%26aufirst%3DA.%2BP.%26aulast%3DLuo%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DW.%2BC.%26aulast%3DSymersky%26aufirst%3DJ.%26aulast%3DBai%26aufirst%3DD.%2BY.%26aulast%3DChambers%26aufirst%3DM.%2BG.%26aulast%3DFaraldo-Gomez%26aufirst%3DJ.%2BD.%26aulast%3DLiao%26aufirst%3DM.%2BF.%26aulast%3DMueller%26aufirst%3DD.%2BM.%26atitle%3DHigh-resolution%2520cryo-EM%2520analysis%2520of%2520the%2520yeast%2520ATP%2520synthase%2520in%2520a%2520lipid%2520membrane%26jtitle%3DScience%26date%3D2018%26volume%3D360%26spage%3Deaas9699%26doi%3D10.1126%2Fscience.aas9699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, P. L.</span></span> <span> </span><span class="NLM_article-title">ATP synthase and the actions of inhibitors utilized to study its roles in human health, disease, and other scientific areas</span>. <i>Microbiol. Mol. Biol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">590</span>â <span class="NLM_lpage">641</span>, <span class="refDoi">Â DOI: 10.1128/MMBR.00016-08</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1128%2FMMBR.00016-08" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=19052322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD1MXps1Gktg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2008&pages=590-641&author=S.+Hongauthor=P.+L.+Pedersen&title=ATP+synthase+and+the+actions+of+inhibitors+utilized+to+study+its+roles+in+human+health%2C+disease%2C+and+other+scientific+areas&doi=10.1128%2FMMBR.00016-08"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">ATP synthase and the actions of inhibitors utilized to study its roles in human health, disease, and other scientific areas</span></div><div class="casAuthors">Hong, Sangjin; Pedersen, Peter L.</div><div class="citationInfo"><span class="NLM_cas:title">Microbiology and Molecular Biology Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">590-641</span>CODEN:
                <span class="NLM_cas:coden">MMBRF7</span>;
        ISSN:<span class="NLM_cas:issn">1092-2172</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A review.  ATP synthase, a double-motor enzyme, plays various roles in the cell, participating not only in ATP synthesis but in ATP hydrolysis-dependent processes and in the regulation of a proton gradient across some membrane-dependent systems.  Recent studies of ATP synthase as a potential mol. target for the treatment of some human diseases have displayed promising results, and this enzyme is now emerging as an attractive mol. target for the development of new therapies for a variety of diseases.  Significantly, ATP synthase, because of its complex structure, is inhibited by a no. of different inhibitors and provides diverse possibilities in the development of new ATP synthase-directed agents.  In this review, we classify over 250 natural and synthetic inhibitors of ATP synthase reported to date and present their inhibitory sites and their known or proposed modes of action.  The rich source of ATP synthase inhibitors and their known or purported sites of action presented in this review should provide valuable insights into their applications as potential scaffolds for new therapeutics for human and animal diseases as well as for the discovery of new pesticides and herbicides to help protect the world's food supply.  Finally, as ATP synthase is now known to consist of two unique nanomotors involved in making ATP from ADP and Pi, the information provided in this review may greatly assist those investigators entering the emerging field of nanotechnol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry4Ml0XiLFxLVg90H21EOLACvtfcHk0lgD0b1XTTlcxg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXps1Gktg%253D%253D&md5=8a963fffa390545d34df022f5b9f4930</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1128%2FMMBR.00016-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMMBR.00016-08%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DS.%26aulast%3DPedersen%26aufirst%3DP.%2BL.%26atitle%3DATP%2520synthase%2520and%2520the%2520actions%2520of%2520inhibitors%2520utilized%2520to%2520study%2520its%2520roles%2520in%2520human%2520health%252C%2520disease%252C%2520and%2520other%2520scientific%2520areas%26jtitle%3DMicrobiol.%2520Mol.%2520Biol.%2520Rev.%26date%3D2008%26volume%3D72%26spage%3D590%26epage%3D641%26doi%3D10.1128%2FMMBR.00016-08" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pagliarini, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutter, J.</span></span> <span> </span><span class="NLM_article-title">Hallmarks of a new era in mitochondrial biochemistry</span>. <i>Genes Dev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">2615</span>â <span class="NLM_lpage">2627</span>, <span class="refDoi">Â DOI: 10.1101/gad.229724.113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1101%2Fgad.229724.113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=24352419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFChuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=2615-2627&author=D.+J.+Pagliariniauthor=J.+Rutter&title=Hallmarks+of+a+new+era+in+mitochondrial+biochemistry&doi=10.1101%2Fgad.229724.113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Hallmarks of a new era in mitochondrial biochemistry</span></div><div class="casAuthors">Pagliarini, David J.; Rutter, Jared</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2615-2627</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">A review.  Stemming from the pioneering studies of bioenergetics in the 1950s, 1960s, and 1970s, mitochondria have become ingrained in the collective psyche of scientists as the "powerhouses" of the cell.  While this remains a worthy moniker, more recent efforts have revealed that these organelles are home to a vast array of metabolic and signaling processes and possess a proteomic landscape that is both highly varied and largely uncharted.  As mitochondrial dysfunction is increasingly being implicated in a spectrum of human diseases, it is imperative that we construct a more complete framework of these organelles by systematically defining the functions of their component parts.  Powerful new approaches in biochem. and systems biol. are helping to fill in the gaps.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVbASorr3MPbVg90H21EOLACvtfcHk0lgt7lqYbZ8Saw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFChuw%253D%253D&md5=a97e67615c437422141c3cd40145b497</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1101%2Fgad.229724.113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.229724.113%26sid%3Dliteratum%253Aachs%26aulast%3DPagliarini%26aufirst%3DD.%2BJ.%26aulast%3DRutter%26aufirst%3DJ.%26atitle%3DHallmarks%2520of%2520a%2520new%2520era%2520in%2520mitochondrial%2520biochemistry%26jtitle%3DGenes%2520Dev.%26date%3D2013%26volume%3D27%26spage%3D2615%26epage%3D2627%26doi%3D10.1101%2Fgad.229724.113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bell, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klimova, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenbart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moraes, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budinger, G. R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandel, N. S.</span></span> <span> </span><span class="NLM_article-title">The Q(o) site of the mitochondrial complex III is required for the transduction of hypoxic signaling via reactive oxygen species production</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>177</i></span>,  <span class="NLM_fpage">1029</span>â <span class="NLM_lpage">1036</span>, <span class="refDoi">Â DOI: 10.1083/jcb.200609074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1083%2Fjcb.200609074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=17562787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmvF2ru7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=177&publication_year=2007&pages=1029-1036&author=E.+L.+Bellauthor=T.+A.+Klimovaauthor=J.+Eisenbartauthor=C.+T.+Moraesauthor=M.+P.+Murphyauthor=G.+R.+S.+Budingerauthor=N.+S.+Chandel&title=The+Q%28o%29+site+of+the+mitochondrial+complex+III+is+required+for+the+transduction+of+hypoxic+signaling+via+reactive+oxygen+species+production&doi=10.1083%2Fjcb.200609074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">The Qo site of the mitochondrial complex III is required for the transduction of hypoxic signaling via reactive oxygen species production</span></div><div class="casAuthors">Bell, Eric L.; Klimova, Tatyana A.; Eisenbart, James; Moraes, Carlos T.; Murphy, Michael P.; Budinger, G. R. Scott; Chandel, Navdeep S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">177</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1029-1036</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Mammalian cells increase transcription of genes for adaptation to hypoxia through the stabilization of hypoxia-inducible factor 1Î± (HIF-1Î±) protein.  How cells transduce hypoxic signals to stabilize the HIF-1Î± protein remains unresolved.  We demonstrate that cells deficient in the complex III subunit cytochrome b, which are respiratory incompetent, increase ROS levels and stabilize the HIF-1Î± protein during hypoxia.  RNA interference of the complex III subunit Rieske iron sulfur protein in the cytochrome b-null cells and treatment of wild-type cells with stigmatellin abolished reactive oxygen species (ROS) generation at the Qo site of complex III.  These interventions maintained hydroxylation of HIF-1Î± protein and prevented stabilization of HIF-1Î± protein during hypoxia.  Antioxidants maintained hydroxylation of HIF-1Î± protein and prevented stabilization of HIF-1Î± protein during hypoxia.  Exogenous hydrogen peroxide under normoxia prevented hydroxylation of HIF-1Î± protein and stabilized HIF-1Î± protein.  These results provide genetic and pharmacol. evidence that the Qo site of complex III is required for the transduction of hypoxic signal by releasing ROS to stabilize the HIF-1Î± protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqotS4i8nOa0rVg90H21EOLACvtfcHk0lgt7lqYbZ8Saw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmvF2ru7o%253D&md5=9e2d684659f0abbfdf8a192ba61dc6ae</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1083%2Fjcb.200609074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.200609074%26sid%3Dliteratum%253Aachs%26aulast%3DBell%26aufirst%3DE.%2BL.%26aulast%3DKlimova%26aufirst%3DT.%2BA.%26aulast%3DEisenbart%26aufirst%3DJ.%26aulast%3DMoraes%26aufirst%3DC.%2BT.%26aulast%3DMurphy%26aufirst%3DM.%2BP.%26aulast%3DBudinger%26aufirst%3DG.%2BR.%2BS.%26aulast%3DChandel%26aufirst%3DN.%2BS.%26atitle%3DThe%2520Q%2528o%2529%2520site%2520of%2520the%2520mitochondrial%2520complex%2520III%2520is%2520required%2520for%2520the%2520transduction%2520of%2520hypoxic%2520signaling%2520via%2520reactive%2520oxygen%2520species%2520production%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2007%26volume%3D177%26spage%3D1029%26epage%3D1036%26doi%3D10.1083%2Fjcb.200609074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stein, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imai, S.</span></span> <span> </span><span class="NLM_article-title">The dynamic regulation of NAD metabolism in mitochondria</span>. <i>Trends Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">420</span>â <span class="NLM_lpage">428</span>, <span class="refDoi">Â DOI: 10.1016/j.tem.2012.06.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.tem.2012.06.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=22819213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVOqtb%252FN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=420-428&author=L.+R.+Steinauthor=S.+Imai&title=The+dynamic+regulation+of+NAD+metabolism+in+mitochondria&doi=10.1016%2Fj.tem.2012.06.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">The dynamic regulation of NAD metabolism in mitochondria</span></div><div class="casAuthors">Stein, Liana Roberts; Imai, Shin-ichiro</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">420-428</span>CODEN:
                <span class="NLM_cas:coden">TENME4</span>;
        ISSN:<span class="NLM_cas:issn">1043-2760</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Mitochondria are intracellular powerhouses that produce ATP and carry out diverse functions for cellular energy metab.  Although the maintenance of an optimal NAD/NADH ratio is essential for mitochondrial function, it has recently become apparent that the maintenance of the mitochondrial NAD pool is also of crucial importance.  The biosynthesis, transport, and catabolism of NAD and its key intermediates play an important role in the regulation of NAD-consuming mediators, such as sirtuins, poly-ADP-ribose polymerases, and CD38/157 ectoenzymes, in intra- and extracellular compartments.  Mitochondrial NAD biosynthesis is also modulated in response to nutritional and environmental stimuli.  In this article, we discuss this dynamic regulation of NAD metab. in mitochondria to shed light on the intimate connection between NAD and mitochondrial function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_7T9cRqoaFbVg90H21EOLACvtfcHk0lgt7lqYbZ8Saw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVOqtb%252FN&md5=aabe2e6e8863913dae3567c5062f40f3</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.tem.2012.06.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tem.2012.06.005%26sid%3Dliteratum%253Aachs%26aulast%3DStein%26aufirst%3DL.%2BR.%26aulast%3DImai%26aufirst%3DS.%26atitle%3DThe%2520dynamic%2520regulation%2520of%2520NAD%2520metabolism%2520in%2520mitochondria%26jtitle%3DTrends%2520Endocrinol.%2520Metab.%26date%3D2012%26volume%3D23%26spage%3D420%26epage%3D428%26doi%3D10.1016%2Fj.tem.2012.06.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birsoy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mihaylova, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snitkin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stasinski, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yucel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayraktar, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carette, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clish, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brummelkamp, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of ATPIF1 ameliorates severe mitochondrial respiratory chain dysfunction in mammalian cells</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">27</span>â <span class="NLM_lpage">34</span>, <span class="refDoi">Â DOI: 10.1016/j.celrep.2014.02.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.celrep.2014.02.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=24685140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFCktLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=27-34&author=W.+W.+Chenauthor=K.+Birsoyauthor=M.+M.+Mihaylovaauthor=H.+Snitkinauthor=I.+Stasinskiauthor=B.+Yucelauthor=E.+C.+Bayraktarauthor=J.+E.+Caretteauthor=C.+B.+Clishauthor=T.+R.+Brummelkampauthor=D.+D.+Sabatiniauthor=D.+M.+Sabatini&title=Inhibition+of+ATPIF1+ameliorates+severe+mitochondrial+respiratory+chain+dysfunction+in+mammalian+cells&doi=10.1016%2Fj.celrep.2014.02.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of ATPIF1 Ameliorates Severe Mitochondrial Respiratory Chain Dysfunction in Mammalian Cells</span></div><div class="casAuthors">Chen, Walter W.; Birsoy, Kivanc; Mihaylova, Maria M.; Snitkin, Harriet; Stasinski, Iwona; Yucel, Burcu; Bayraktar, Erol C.; Carette, Jan E.; Clish, Clary B.; Brummelkamp, Thijn R.; Sabatini, David D.; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-34</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Mitochondrial respiratory chain disorders are characterized by loss of electron transport chain (ETC) activity.  Although the causes of many such diseases are known, there is a lack of effective therapies.  To identify genes that confer resistance to severe ETC dysfunction when inactivated, we performed a genome-wide genetic screen in haploid human cells with the mitochondrial complex III inhibitor antimycin.  This screen revealed that loss of ATPIF1 strongly protects against antimycin-induced ETC dysfunction and cell death by allowing for the maintenance of mitochondrial membrane potential.  ATPIF1 loss protects against other forms of ETC dysfunction and is even essential for the viability of human ÏÂ° cells lacking mitochondrial DNA, a system commonly used for studying ETC dysfunction.  Importantly, inhibition of ATPIF1 ameliorates complex III blockade in primary hepatocytes, a cell type afflicted in severe mitochondrial disease.  Altogether, these results suggest that inhibition of ATPIF1 can ameliorate severe ETC dysfunction in mitochondrial pathol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9ENNqggtkfbVg90H21EOLACvtfcHk0lgeVhuiv83NNw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFCktLw%253D&md5=cb5f695d125eb8ee763405ddc381cf76</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2014.02.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2014.02.046%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DW.%2BW.%26aulast%3DBirsoy%26aufirst%3DK.%26aulast%3DMihaylova%26aufirst%3DM.%2BM.%26aulast%3DSnitkin%26aufirst%3DH.%26aulast%3DStasinski%26aufirst%3DI.%26aulast%3DYucel%26aufirst%3DB.%26aulast%3DBayraktar%26aufirst%3DE.%2BC.%26aulast%3DCarette%26aufirst%3DJ.%2BE.%26aulast%3DClish%26aufirst%3DC.%2BB.%26aulast%3DBrummelkamp%26aufirst%3DT.%2BR.%26aulast%3DSabatini%26aufirst%3DD.%2BD.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DInhibition%2520of%2520ATPIF1%2520ameliorates%2520severe%2520mitochondrial%2520respiratory%2520chain%2520dysfunction%2520in%2520mammalian%2520cells%26jtitle%3DCell%2520Rep.%26date%3D2014%26volume%3D7%26spage%3D27%26epage%3D34%26doi%3D10.1016%2Fj.celrep.2014.02.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chandel, N. S.</span></span> <span> </span><span class="NLM_article-title">Mitochondria as signaling organelles</span>. <i>BMC Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">34</span>, <span class="refDoi">Â DOI: 10.1186/1741-7007-12-34</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1186%2F1741-7007-12-34" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=24884669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjt1ajsb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=34&author=N.+S.+Chandel&title=Mitochondria+as+signaling+organelles&doi=10.1186%2F1741-7007-12-34"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondria as signaling organelles</span></div><div class="casAuthors">Chandel, Navdeep S.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">34/1-34/7, 7</span>CODEN:
                <span class="NLM_cas:coden">BBMIF7</span>;
        ISSN:<span class="NLM_cas:issn">1741-7007</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review. Almost 20 yr ago, the discovery that mitochondrial release of cytochrome c initiates a cascade that leads to cell death brought about a wholesale change in how cell biologists think of mitochondria.  Formerly viewed as sites of biosynthesis and bioenergy prodn., these double membrane organelles could now be thought of as regulators of signal transduction.  Within a few years, multiple other mitochondria-centric signaling mechanisms have been proposed, including release of reactive O species and the scaffolding of signaling complexes on the outer mitochondrial membrane.  It has also been shown that mitochondrial dysfunction causes induction of stress responses, bolstering the idea that mitochondria communicate their fitness to the rest of the cell.  In the past decade, multiple new modes of mitochondrial signaling have been discovered.  These include the release of metabolites, mitochondrial motility and dynamics, and interaction with other organelles such as endoplasmic reticulum in regulating signaling.  Collectively these studies have established that mitochondria-dependent signaling has diverse physiol. and pathophysiol. outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOsteP0hdF47Vg90H21EOLACvtfcHk0lgeVhuiv83NNw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjt1ajsb8%253D&md5=8d1f5e1300f156947bb17f74706559fc</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1186%2F1741-7007-12-34&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1741-7007-12-34%26sid%3Dliteratum%253Aachs%26aulast%3DChandel%26aufirst%3DN.%2BS.%26atitle%3DMitochondria%2520as%2520signaling%2520organelles%26jtitle%3DBMC%2520Biol.%26date%3D2014%26volume%3D12%26spage%3D34%26doi%3D10.1186%2F1741-7007-12-34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whitaker-Menezes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Outschoorn, U. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flomenberg, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birbe, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witkiewicz, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavlides, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsirigos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ertel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pestell, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broda, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minetti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lisanti, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotgia, F.</span></span> <span> </span><span class="NLM_article-title">Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">4047</span>â <span class="NLM_lpage">4064</span>, <span class="refDoi">Â DOI: 10.4161/cc.10.23.18151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.4161%2Fcc.10.23.18151" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=22134189" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsV2mtrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=4047-4064&author=D.+Whitaker-Menezesauthor=U.+E.+Martinez-Outschoornauthor=N.+Flomenbergauthor=R.+C.+Birbeauthor=A.+K.+Witkiewiczauthor=A.+Howellauthor=S.+Pavlidesauthor=A.+Tsirigosauthor=A.+Ertelauthor=R.+G.+Pestellauthor=P.+Brodaauthor=C.+Minettiauthor=M.+P.+Lisantiauthor=F.+Sotgia&title=Hyperactivation+of+oxidative+mitochondrial+metabolism+in+epithelial+cancer+cells+in+situ%3A+visualizing+the+therapeutic+effects+of+metformin+in+tumor+tissue&doi=10.4161%2Fcc.10.23.18151"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue</span></div><div class="casAuthors">Whitaker-Menezes, Diana; Martinez-Outschoorn, Ubaldo E.; Flomenberg, Neal; Birbe, Ruth C.; Witkiewicz, Agnieszka K.; Howell, Anthony; Pavlides, Stephanos; Tsirigos, Aristotelis; Ertel, Adam; Pestell, Richard G.; Broda, Paolo; Minetti, Carlo; Lisanti, Michael P.; Sotgia, Federica</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4047-4064</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1538-4101</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">We have recently proposed a new mechanism for explaining energy transfer in cancer metab.  In this scenario, cancer cells behave as metabolic parasites, by extg. nutrients from normal host cells, such as fibroblasts, via the secretion of hydrogen peroxide as the initial trigger.  Oxidative stress in the tumor microenvironment then leads to autophagy-driven catabolism, mitochondrial dys-function and aerobic glycolysis.  This, in turn, produces high-energy nutrients (such as L-lactate, ketones and glutamine) that drive the anabolic growth of tumor cells, via oxidative mitochondrial metab.  A logical prediction of this new "parasitic" cancer model is that tumor-assocd. fibroblasts should show evidence of mitochondrial dys-function (mitophagy and aerobic glycolysis).  In contrast, epithelial cancer cells should increase their oxidative mitochondrial capacity.  To further test this hypothesis, here we subjected frozen sections from human breast tumors to a staining procedure that only detects functional mitochondria.  This method detects the in situ enzymic activity of cytochrome C oxidase (COX), also known as Complex IV.  Remarkably, cancer cells show an over-abundance of COX activity, while adjacent stromal cells remain essentially neg.  Adjacent normal ductal epithelial cells also show little or no COX activity, relative to epithelial cancer cells.  Thus, oxidative mitochondrial activity is selectively amplified in cancer cells.  Although COX activity staining has never been applied to cancer tissues, it could now be used routinely to distinguish cancer cells from normal cells, and to establish neg. margins during cancer surgery.  Similar results were obtained with NADH activity staining, which measures Complex I activity, and succinate dehydrogenase (SDH) activity staining, which measures Complex II activity.  COX and NADH activities were blocked by electron transport inhibitors, such as Metformin.  This has mechanistic and clin. implications for using Metformin as an anti-cancer drug, both for cancer therapy and chemo-prevention.  We also immuno-stained human breast cancers for a series of well-established protein biomarkers of metab.  More specifically, we now show that cancer-assocd. fibroblasts overexpress markers of autophagy (cathepsin B), mitophagy (BNIP3L) and aerobic glycolysis (MCT4).  Conversely, epithelial cancer cells show the overexpression of a mitochondrial membrane marker (TOMM20), as well as key components of Complex IV (MT-CO1) and Complex II (SDH-B).  We also validated our observations using a bioinformatics approach with data from >2,000 breast cancer patients, which showed the transcriptional upregulation of mitochondrial oxidative phosphorylation (OXPHOS) in human breast tumors (p < 10-20), and a specific assocn. with metastasis.  Therefore, upregulation of OXPHOS in epithelial tumor cells is a common feature of human breast cancers.  In summary, our data provide the first functional in vivo evidence that epithelial cancer cells perform enhanced mitochondrial oxidative phosphorylation, allowing them to produce high amts. of ATP.  Thus, we believe that mitochondria are both the "powerhouse" and "Achilles' heel" of cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXlAskwAucT7Vg90H21EOLACvtfcHk0lhHLSEB-wJYBQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsV2mtrk%253D&md5=847d969e30d882ddb9528cd3e3327577</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.4161%2Fcc.10.23.18151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.10.23.18151%26sid%3Dliteratum%253Aachs%26aulast%3DWhitaker-Menezes%26aufirst%3DD.%26aulast%3DMartinez-Outschoorn%26aufirst%3DU.%2BE.%26aulast%3DFlomenberg%26aufirst%3DN.%26aulast%3DBirbe%26aufirst%3DR.%2BC.%26aulast%3DWitkiewicz%26aufirst%3DA.%2BK.%26aulast%3DHowell%26aufirst%3DA.%26aulast%3DPavlides%26aufirst%3DS.%26aulast%3DTsirigos%26aufirst%3DA.%26aulast%3DErtel%26aufirst%3DA.%26aulast%3DPestell%26aufirst%3DR.%2BG.%26aulast%3DBroda%26aufirst%3DP.%26aulast%3DMinetti%26aufirst%3DC.%26aulast%3DLisanti%26aufirst%3DM.%2BP.%26aulast%3DSotgia%26aufirst%3DF.%26atitle%3DHyperactivation%2520of%2520oxidative%2520mitochondrial%2520metabolism%2520in%2520epithelial%2520cancer%2520cells%2520in%2520situ%253A%2520visualizing%2520the%2520therapeutic%2520effects%2520of%2520metformin%2520in%2520tumor%2520tissue%26jtitle%3DCell%2520Cycle%26date%3D2011%26volume%3D10%26spage%3D4047%26epage%3D4064%26doi%3D10.4161%2Fcc.10.23.18151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Broad Institute TCGA Genome Data Analysis Center</span> (<span class="NLM_year">2016</span>): Firehose stddata__2016_01_28
run. <span class="NLM_publisher-name">Broad Institute of MIT</span>: <span class="NLM_publisher-loc">Harvard</span>.<span class="refDoi">Â DOI: 10.7908/C11G0KM9</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.7908%2FC11G0KM9" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Broad+Institute+TCGA+Genome+Data+Analysis+Center+%282016%29%3A+Firehose+stddata__2016_01_28%0Arun.+Broad+Institute+of+MIT%3A+Harvard.+10.7908%2FC11G0KM9."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.7908%2FC11G0KM9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.7908%252FC11G0KM9%26sid%3Dliteratum%253Aachs%26aulast%3D%26date%3D2016%26pub%3DBroad%2520Institute%2520of%2520MIT%26doi%3D10.7908%2FC11G0KM9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liberzon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorvaldsdottir, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghandi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesirov, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamayo, P.</span></span> <span> </span><span class="NLM_article-title">The molecular signatures database hallmark gene set collection</span>. <i>Cell Syst.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">417</span>â <span class="NLM_lpage">425</span>, <span class="refDoi">Â DOI: 10.1016/j.cels.2015.12.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.cels.2015.12.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=26771021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFaltLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2015&pages=417-425&author=A.+Liberzonauthor=C.+Birgerauthor=H.+Thorvaldsdottirauthor=M.+Ghandiauthor=J.+P.+Mesirovauthor=P.+Tamayo&title=The+molecular+signatures+database+hallmark+gene+set+collection&doi=10.1016%2Fj.cels.2015.12.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">The Molecular Signatures Database Hallmark Gene Set Collection</span></div><div class="casAuthors">Liberzon, Arthur; Birger, Chet; Thorvaldsdottir, Helga; Ghandi, Mahmoud; Mesirov, Jill P.; Tamayo, Pablo</div><div class="citationInfo"><span class="NLM_cas:title">Cell Systems</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">417-425</span>CODEN:
                <span class="NLM_cas:coden">CSEYA4</span>;
        ISSN:<span class="NLM_cas:issn">2405-4712</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The Mol. Signatures Database (MSigDB) is one of the most widely used and comprehensive databases of gene sets for performing gene set enrichment anal.  Since its creation, MSigDB has grown beyond its roots in metabolic disease and cancer to include >10,000 gene sets.  These better represent a wider range of biol. processes and diseases, but the utility of the database is reduced by increased redundancy across, and heterogeneity within, gene sets.  To address this challenge, here we use a combination of automated approaches and expert curation to develop a collection of "hallmark" gene sets as part of MSigDB.  Each hallmark in this collection consists of a "refined" gene set, derived from multiple "founder" sets, that conveys a specific biol. state or process and displays coherent expression.  The hallmarks effectively summarize most of the relevant information of the original founder sets and, by reducing both variation and redundancy, provide more refined and concise inputs for gene set enrichment anal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBEddnjUes8rVg90H21EOLACvtfcHk0lhHLSEB-wJYBQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFaltLc%253D&md5=2438d023b171d006ca04b20b7fdfc665</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.cels.2015.12.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cels.2015.12.004%26sid%3Dliteratum%253Aachs%26aulast%3DLiberzon%26aufirst%3DA.%26aulast%3DBirger%26aufirst%3DC.%26aulast%3DThorvaldsdottir%26aufirst%3DH.%26aulast%3DGhandi%26aufirst%3DM.%26aulast%3DMesirov%26aufirst%3DJ.%2BP.%26aulast%3DTamayo%26aufirst%3DP.%26atitle%3DThe%2520molecular%2520signatures%2520database%2520hallmark%2520gene%2520set%2520collection%26jtitle%3DCell%2520Syst.%26date%3D2015%26volume%3D1%26spage%3D417%26epage%3D425%26doi%3D10.1016%2Fj.cels.2015.12.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kanehisa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, S.</span></span> <span> </span><span class="NLM_article-title">KEGG: Kyoto encyclopedia of genes and genomes</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">27</span>â <span class="NLM_lpage">30</span>, <span class="refDoi">Â DOI: 10.1093/nar/28.1.27</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1093%2Fnar%2F28.1.27" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10592173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhvVGqu74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2000&pages=27-30&author=M.+Kanehisaauthor=S.+Goto&title=KEGG%3A+Kyoto+encyclopedia+of+genes+and+genomes&doi=10.1093%2Fnar%2F28.1.27"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">KEGG: Kyoto Encyclopedia of Genes and Genomes</span></div><div class="casAuthors">Kanehisa, Minoru; Goto, Susumu</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-30</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">KEGG (Kyoto Encyclopedia of Genes and Genomes) is a knowledge base for systematic anal. of gene functions, linking genomic information with higher order functional information.  The genomic information is stored in the GENES database, which is a collection of gene catalogs for all the completely sequenced genomes and some partial genomes with up-to-date annotation of gene functions.  The higher order functional information is stored in the PATHWAY database, which contains graphical representations of cellular processes, such as metab., membrane transport, signal transduction and cell cycle.  The PATHWAY database is supplemented by a set of ortholog group tables for the information about conserved subpath-ways (pathway motifs), which are often encoded by positionally coupled genes on the chromosome and which are esp. useful in predicting gene functions.  A third database in KEGG is LIGAND for the information about chem. compds., enzyme mols. and enzymic reactions.  KEGG provides Java graphics tools for browsing genome maps, comparing two genome maps and manipulating expression maps, as well as computational tools for sequence comparison, graph comparison and path computation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVAZngEAfzebVg90H21EOLACvtfcHk0lhHLSEB-wJYBQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhvVGqu74%253D&md5=16eab4d6d4c3b6b987645f8ba2e84fe9</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1093%2Fnar%2F28.1.27&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252F28.1.27%26sid%3Dliteratum%253Aachs%26aulast%3DKanehisa%26aufirst%3DM.%26aulast%3DGoto%26aufirst%3DS.%26atitle%3DKEGG%253A%2520Kyoto%2520encyclopedia%2520of%2520genes%2520and%2520genomes%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2000%26volume%3D28%26spage%3D27%26epage%3D30%26doi%3D10.1093%2Fnar%2F28.1.27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harris, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ireland, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lomax, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashburner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foulger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eilbeck, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mungall, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bult, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drabkin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eppig, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ringwald, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balakrishnan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherry, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costanzo, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwight, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisk, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirschman, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nash, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sethuraman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theesfeld, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botstein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolinski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feierbach, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardini, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mundodi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhee, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apweiler, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimmer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chisholm, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaudet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kibbe, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kishore, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sternberg, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gwinn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannick, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wortman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berriman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Cruz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonellato, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaiswal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seigfried, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Consortium, G. O.</span></span> <span> </span><span class="NLM_article-title">The gene ontology (GO) database and informatics resource</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">258D</span>, <span class="refDoi">Â DOI: 10.1093/nar/gkh036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1093%2Fnar%2Fgkh036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=14681407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BD3srpvFyhtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2004&pages=258D&author=M.+A.+Harrisauthor=J.+Clarkauthor=A.+Irelandauthor=J.+Lomaxauthor=M.+Ashburnerauthor=R.+Foulgerauthor=K.+Eilbeckauthor=S.+Lewisauthor=B.+Marshallauthor=C.+Mungallauthor=J.+Richterauthor=G.+M.+Rubinauthor=J.+A.+Blakeauthor=C.+Bultauthor=M.+Dolanauthor=H.+Drabkinauthor=J.+T.+Eppigauthor=D.+P.+Hillauthor=L.+Niauthor=M.+Ringwaldauthor=R.+Balakrishnanauthor=J.+M.+Cherryauthor=K.+R.+Christieauthor=M.+C.+Costanzoauthor=S.+S.+Dwightauthor=S.+Engelauthor=D.+G.+Fiskauthor=J.+E.+Hirschmanauthor=E.+L.+Hongauthor=R.+S.+Nashauthor=A.+Sethuramanauthor=C.+L.+Theesfeldauthor=D.+Botsteinauthor=K.+Dolinskiauthor=B.+Feierbachauthor=T.+Berardiniauthor=S.+Mundodiauthor=S.+Y.+Rheeauthor=R.+Apweilerauthor=D.+Barrellauthor=E.+Camonauthor=E.+Dimmerauthor=V.+Leeauthor=R.+Chisholmauthor=P.+Gaudetauthor=W.+Kibbeauthor=R.+Kishoreauthor=E.+M.+Schwarzauthor=P.+Sternbergauthor=M.+Gwinnauthor=L.+Hannickauthor=J.+Wortmanauthor=M.+Berrimanauthor=V.+Woodauthor=N.+de+la+Cruzauthor=P.+Tonellatoauthor=P.+Jaiswalauthor=T.+Seigfriedauthor=R.+Whiteauthor=G.+O.+Consortium&title=The+gene+ontology+%28GO%29+database+and+informatics+resource&doi=10.1093%2Fnar%2Fgkh036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">The Gene Ontology (GO) database and informatics resource</span></div><div class="casAuthors">Harris M A; Clark J; Ireland A; Lomax J; Ashburner M; Foulger R; Eilbeck K; Lewis S; Marshall B; Mungall C; Richter J; Rubin G M; Blake J A; Bult C; Dolan M; Drabkin H; Eppig J T; Hill D P; Ni L; Ringwald M; Balakrishnan R; Cherry J M; Christie K R; Costanzo M C; Dwight S S; Engel S; Fisk D G; Hirschman J E; Hong E L; Nash R S; Sethuraman A; Theesfeld C L; Botstein D; Dolinski K; Feierbach B; Berardini T; Mundodi S; Rhee S Y; Apweiler R; Barrell D; Camon E; Dimmer E; Lee V; Chisholm R; Gaudet P; Kibbe W; Kishore R; Schwarz E M; Sternberg P; Gwinn M; Hannick L; Wortman J; Berriman M; Wood V; de la Cruz N; Tonellato P; Jaiswal P; Seigfried T; White R</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic acids research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">Database issue</span>),
    <span class="NLM_cas:pages">D258-61</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The Gene Ontology (GO) project (http://www. geneontology.org/) provides structured, controlled vocabularies and classifications that cover several domains of molecular and cellular biology and are freely available for community use in the annotation of genes, gene products and sequences.  Many model organism databases and genome annotation groups use the GO and contribute their annotation sets to the GO resource.  The GO database integrates the vocabularies and contributed annotations and provides full access to this information in several formats.  Members of the GO Consortium continually work collectively, involving outside experts as needed, to expand and update the GO vocabularies.  The GO Web resource also provides access to extensive documentation about the GO project and links to applications that use GO data for functional analyses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTEDpG4UCQUFROk4JA3soTqfW6udTcc2ealsPew8PaE67ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3srpvFyhtw%253D%253D&md5=21f56d1ec289881d76badbafb67663bb</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkh036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkh036%26sid%3Dliteratum%253Aachs%26aulast%3DHarris%26aufirst%3DM.%2BA.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DIreland%26aufirst%3DA.%26aulast%3DLomax%26aufirst%3DJ.%26aulast%3DAshburner%26aufirst%3DM.%26aulast%3DFoulger%26aufirst%3DR.%26aulast%3DEilbeck%26aufirst%3DK.%26aulast%3DLewis%26aufirst%3DS.%26aulast%3DMarshall%26aufirst%3DB.%26aulast%3DMungall%26aufirst%3DC.%26aulast%3DRichter%26aufirst%3DJ.%26aulast%3DRubin%26aufirst%3DG.%2BM.%26aulast%3DBlake%26aufirst%3DJ.%2BA.%26aulast%3DBult%26aufirst%3DC.%26aulast%3DDolan%26aufirst%3DM.%26aulast%3DDrabkin%26aufirst%3DH.%26aulast%3DEppig%26aufirst%3DJ.%2BT.%26aulast%3DHill%26aufirst%3DD.%2BP.%26aulast%3DNi%26aufirst%3DL.%26aulast%3DRingwald%26aufirst%3DM.%26aulast%3DBalakrishnan%26aufirst%3DR.%26aulast%3DCherry%26aufirst%3DJ.%2BM.%26aulast%3DChristie%26aufirst%3DK.%2BR.%26aulast%3DCostanzo%26aufirst%3DM.%2BC.%26aulast%3DDwight%26aufirst%3DS.%2BS.%26aulast%3DEngel%26aufirst%3DS.%26aulast%3DFisk%26aufirst%3DD.%2BG.%26aulast%3DHirschman%26aufirst%3DJ.%2BE.%26aulast%3DHong%26aufirst%3DE.%2BL.%26aulast%3DNash%26aufirst%3DR.%2BS.%26aulast%3DSethuraman%26aufirst%3DA.%26aulast%3DTheesfeld%26aufirst%3DC.%2BL.%26aulast%3DBotstein%26aufirst%3DD.%26aulast%3DDolinski%26aufirst%3DK.%26aulast%3DFeierbach%26aufirst%3DB.%26aulast%3DBerardini%26aufirst%3DT.%26aulast%3DMundodi%26aufirst%3DS.%26aulast%3DRhee%26aufirst%3DS.%2BY.%26aulast%3DApweiler%26aufirst%3DR.%26aulast%3DBarrell%26aufirst%3DD.%26aulast%3DCamon%26aufirst%3DE.%26aulast%3DDimmer%26aufirst%3DE.%26aulast%3DLee%26aufirst%3DV.%26aulast%3DChisholm%26aufirst%3DR.%26aulast%3DGaudet%26aufirst%3DP.%26aulast%3DKibbe%26aufirst%3DW.%26aulast%3DKishore%26aufirst%3DR.%26aulast%3DSchwarz%26aufirst%3DE.%2BM.%26aulast%3DSternberg%26aufirst%3DP.%26aulast%3DGwinn%26aufirst%3DM.%26aulast%3DHannick%26aufirst%3DL.%26aulast%3DWortman%26aufirst%3DJ.%26aulast%3DBerriman%26aufirst%3DM.%26aulast%3DWood%26aufirst%3DV.%26aulast%3Dde%2Bla%2BCruz%26aufirst%3DN.%26aulast%3DTonellato%26aufirst%3DP.%26aulast%3DJaiswal%26aufirst%3DP.%26aulast%3DSeigfried%26aufirst%3DT.%26aulast%3DWhite%26aufirst%3DR.%26aulast%3DConsortium%26aufirst%3DG.%2BO.%26atitle%3DThe%2520gene%2520ontology%2520%2528GO%2529%2520database%2520and%2520informatics%2520resource%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2004%26volume%3D32%26spage%3D258D%26doi%3D10.1093%2Fnar%2Fgkh036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamayo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mootha, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukherjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillette, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulovich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomeroy, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golub, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lander, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesirov, J. P.</span></span> <span> </span><span class="NLM_article-title">Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">15545</span>â <span class="NLM_lpage">15550</span>, <span class="refDoi">Â DOI: 10.1073/pnas.0506580102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1073%2Fpnas.0506580102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=16199517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1ShtrnO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=15545-15550&author=A.+Subramanianauthor=P.+Tamayoauthor=V.+K.+Moothaauthor=S.+Mukherjeeauthor=B.+L.+Ebertauthor=M.+A.+Gilletteauthor=A.+Paulovichauthor=S.+L.+Pomeroyauthor=T.+R.+Golubauthor=E.+S.+Landerauthor=J.+P.+Mesirov&title=Gene+set+enrichment+analysis%3A+A+knowledge-based+approach+for+interpreting+genome-wide+expression+profiles&doi=10.1073%2Fpnas.0506580102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles</span></div><div class="casAuthors">Subramanian, Aravind; Tamayo, Pablo; Mootha, Vamsi K.; Mukherjee, Sayan; Ebert, Benjamin L.; Gillette, Michael A.; Paulovich, Amanda; Pomeroy, Scott L.; Golub, Todd R.; Lander, Eric S.; Mesirov, Jill P.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">15545-15550</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Although genomewide RNA expression anal. has become a routine tool in biomedical research, extg. biol. insight from such information remains a major challenge.  Here, we describe a powerful anal. method called Gene Set Enrichment Anal. (GSEA) for interpreting gene expression data.  The method derives its power by focusing on gene sets, i.e., groups of genes that share common biol. function, chromosomal location, or regulation.  We demonstrate how GSEA yields insights into several cancer-related data sets, including leukemia and lung cancer.  Notably, where single-gene anal. finds little similarity between two independent studies of patients survival in lung cancer, GSEA reveals many biol. pathways in common.  The GSEA method is embodied in a freely available software package, together with an initial database of 1,325 biol. defined gene sets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH2_E6gWd0yrVg90H21EOLACvtfcHk0lhZdCFY7BNrbw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1ShtrnO&md5=ca2eb221010f20379199e6442c65fc2e</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0506580102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0506580102%26sid%3Dliteratum%253Aachs%26aulast%3DSubramanian%26aufirst%3DA.%26aulast%3DTamayo%26aufirst%3DP.%26aulast%3DMootha%26aufirst%3DV.%2BK.%26aulast%3DMukherjee%26aufirst%3DS.%26aulast%3DEbert%26aufirst%3DB.%2BL.%26aulast%3DGillette%26aufirst%3DM.%2BA.%26aulast%3DPaulovich%26aufirst%3DA.%26aulast%3DPomeroy%26aufirst%3DS.%2BL.%26aulast%3DGolub%26aufirst%3DT.%2BR.%26aulast%3DLander%26aufirst%3DE.%2BS.%26aulast%3DMesirov%26aufirst%3DJ.%2BP.%26atitle%3DGene%2520set%2520enrichment%2520analysis%253A%2520A%2520knowledge-based%2520approach%2520for%2520interpreting%2520genome-wide%2520expression%2520profiles%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2005%26volume%3D102%26spage%3D15545%26epage%3D15550%26doi%3D10.1073%2Fpnas.0506580102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">R
Core Team</span> (<span class="NLM_year">2019</span>).  <i>R:
A language and environment for statistical computing</i>; <span class="NLM_publisher-name">R Foundation for Statistical Computing</span>: <span class="NLM_publisher-loc">Vienna, Austria</span>. <a href="https://www.R-project.org/" class="extLink">https://www.R-project.org/</a> (accessed Sep 19, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=R%0ACore+Team&title=R%3A%0AA+language+and+environment+for+statistical+computing"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3D%26date%3D2019%26btitle%3DR%253A%250AA%2520language%2520and%2520environment%2520for%2520statistical%2520computing%26pub%3DR%2520Foundation%2520for%2520Statistical%2520Computing" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Broad Institute TCGA Genome Data Analysis Center</span> (<span class="NLM_year">2016</span>): Firehose stddata_2016_01_28
run. <span class="NLM_publisher-name">Broad Institute of MIT</span>: <span class="NLM_publisher-loc">Harvard</span>. <span class="refDoi">Â DOI: 10.7908/C11G0KM9</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.7908%2FC11G0KM9" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Broad+Institute+TCGA+Genome+Data+Analysis+Center+%282016%29%3A+Firehose+stddata_2016_01_28%0Arun.+Broad+Institute+of+MIT%3A+Harvard.+10.7908%2FC11G0KM9."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.7908%2FC11G0KM9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.7908%252FC11G0KM9%26sid%3Dliteratum%253Aachs%26aulast%3D%26date%3D2016%26pub%3DBroad%2520Institute%2520of%2520MIT%26doi%3D10.7908%2FC11G0KM9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Candas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eldridge, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wachsmann-Hogiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chromy, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nantajit, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duru, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finkel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. J.</span></span> <span> </span><span class="NLM_article-title">Cyclin B1/Cdk1 coordinates mitochondrial respiration for cell-cycle G2/M progression</span>. <i>Dev. Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">217</span>â <span class="NLM_lpage">232</span>, <span class="refDoi">Â DOI: 10.1016/j.devcel.2014.03.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.devcel.2014.03.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=24746669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmsVCht7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2014&pages=217-232&author=Z.+Wangauthor=M.+Fanauthor=D.+Candasauthor=T.+Q.+Zhangauthor=L.+Qinauthor=A.+Eldridgeauthor=S.+Wachsmann-Hogiuauthor=K.+M.+Ahmedauthor=B.+A.+Chromyauthor=D.+Nantajitauthor=N.+Duruauthor=F.+Heauthor=M.+Chenauthor=T.+Finkelauthor=L.+S.+Weinsteinauthor=J.+J.+Li&title=Cyclin+B1%2FCdk1+coordinates+mitochondrial+respiration+for+cell-cycle+G2%2FM+progression&doi=10.1016%2Fj.devcel.2014.03.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin B1/Cdk1 Coordinates Mitochondrial Respiration for Cell-Cycle G2/M Progression</span></div><div class="casAuthors">Wang, Zhaoqing; Fan, Ming; Candas, Demet; Zhang, Tie-Qiao; Qin, Lili; Eldridge, Angela; Wachsmann-Hogiu, Sebastian; Ahmed, Kazi M.; Chromy, Brett A.; Nantajit, Danupon; Duru, Nadire; He, Fuchu; Chen, Min; Finkel, Toren; Weinstein, Lee S.; Li, Jian Jian</div><div class="citationInfo"><span class="NLM_cas:title">Developmental Cell</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">217-232</span>CODEN:
                <span class="NLM_cas:coden">DCEEBE</span>;
        ISSN:<span class="NLM_cas:issn">1534-5807</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A substantial amt. of mitochondrial energy is required for cell-cycle progression.  The mechanisms underlying the coordination of the mitochondrial respiration with cell-cycle progression, esp. the G2/M transition, remain to be elucidated.  Here, we show that a fraction of cyclin B1/Cdk1 proteins localizes to the matrix of mitochondria and phosphorylates a cluster of mitochondrial proteins, including the complex I (CI) subunits in the respiratory chain.  Cyclin B1/Cdk1-mediated CI phosphorylation enhances CI activity, whereas deficiency of such phosphorylation in each of the relevant CI subunits results in impairment of CI function.  Mitochondria-targeted cyclin B1/Cdk1 increases mitochondrial respiration with enhanced oxygen consumption and ATP generation, which provides cells with efficient bioenergy for G2/M transition and shortens overall cell-cycle time.  Thus, cyclin B1/Cdk1-mediated phosphorylation of mitochondrial substrates allows cells to sense and respond to increased energy demand for G2/M transition and, subsequently, to upregulate mitochondrial respiration for successful cell-cycle progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8A5dc209Mm7Vg90H21EOLACvtfcHk0lhZdCFY7BNrbw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmsVCht7Y%253D&md5=2f95e9ad8d22502a7ce640f02fc0ecea</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.devcel.2014.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.devcel.2014.03.012%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DFan%26aufirst%3DM.%26aulast%3DCandas%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DT.%2BQ.%26aulast%3DQin%26aufirst%3DL.%26aulast%3DEldridge%26aufirst%3DA.%26aulast%3DWachsmann-Hogiu%26aufirst%3DS.%26aulast%3DAhmed%26aufirst%3DK.%2BM.%26aulast%3DChromy%26aufirst%3DB.%2BA.%26aulast%3DNantajit%26aufirst%3DD.%26aulast%3DDuru%26aufirst%3DN.%26aulast%3DHe%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DFinkel%26aufirst%3DT.%26aulast%3DWeinstein%26aufirst%3DL.%2BS.%26aulast%3DLi%26aufirst%3DJ.%2BJ.%26atitle%3DCyclin%2520B1%252FCdk1%2520coordinates%2520mitochondrial%2520respiration%2520for%2520cell-cycle%2520G2%252FM%2520progression%26jtitle%3DDev.%2520Cell%26date%3D2014%26volume%3D29%26spage%3D217%26epage%3D232%26doi%3D10.1016%2Fj.devcel.2014.03.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smolkova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jezek, P.</span></span> <span> </span><span class="NLM_article-title">The role of mitochondrial NADPH-dependent isocitrate dehydrogenase in cancer cells</span>. <i>Int. J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2012</i></span>,  <span class="NLM_fpage">273947</span>, <span class="refDoi">Â DOI: 10.1155/2012/273947</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1155%2F2012%2F273947" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=22675360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BC38npslaitA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2012&publication_year=2012&pages=273947&author=K.+Smolkovaauthor=P.+Jezek&title=The+role+of+mitochondrial+NADPH-dependent+isocitrate+dehydrogenase+in+cancer+cells&doi=10.1155%2F2012%2F273947"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of Mitochondrial NADPH-Dependent Isocitrate Dehydrogenase in Cancer Cells</span></div><div class="casAuthors">Smolkova Katarina; Jezek Petr</div><div class="citationInfo"><span class="NLM_cas:title">International journal of cell biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2012</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">273947</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Isocitrate dehydrogenase 2 (IDH2) is located in the mitochondrial matrix.  IDH2 acts in the forward Krebs cycle as an NADP(+)-consuming enzyme, providing NADPH for maintenance of the reduced glutathione and peroxiredoxin systems and for self-maintenance by reactivation of cystine-inactivated IDH2 by glutaredoxin 2.  In highly respiring cells, the resulting NAD(+) accumulation then induces sirtuin-3-mediated activating IDH2 deacetylation, thus increasing its protective function.  Reductive carboxylation of 2-oxoglutarate by IDH2 (in the reverse Krebs cycle direction), which consumes NADPH, may follow glutaminolysis of glutamine to 2-oxoglutarate in cancer cells.  When the reverse aconitase reaction and citrate efflux are added, this overall "anoxic" glutaminolysis mode may help highly malignant tumors survive aglycemia during hypoxia.  Intermittent glycolysis would hypothetically be required to provide ATP.  When oxidative phosphorylation is dormant, this mode causes substantial oxidative stress.  Arg172 mutants of human IDH2-frequently found with similar mutants of cytosolic IDH1 in grade 2 and 3 gliomas, secondary glioblastomas, and acute myeloid leukemia-catalyze reductive carboxylation of 2-oxoglutarate and reduction to D-2-hydroxyglutarate, which strengthens the neoplastic phenotype by competitive inhibition of histone demethylation and 5-methylcytosine hydroxylation, leading to genome-wide histone and DNA methylation alternations.  D-2-hydroxyglutarate also interferes with proline hydroxylation and thus may stabilize hypoxia-induced factor Î±.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSAE3tlxufovBpyrDyM_m9cfW6udTcc2eaUoCtosEkinrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38npslaitA%253D%253D&md5=a61ea44f8954fb09ec69aed9c2699b84</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1155%2F2012%2F273947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2012%252F273947%26sid%3Dliteratum%253Aachs%26aulast%3DSmolkova%26aufirst%3DK.%26aulast%3DJezek%26aufirst%3DP.%26atitle%3DThe%2520role%2520of%2520mitochondrial%2520NADPH-dependent%2520isocitrate%2520dehydrogenase%2520in%2520cancer%2520cells%26jtitle%3DInt.%2520J.%2520Cell%2520Biol.%26date%3D2012%26volume%3D2012%26spage%3D273947%26doi%3D10.1155%2F2012%2F273947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Z. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, X. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bode, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span> <span> </span><span class="NLM_article-title">Wild-type IDH2 promotes the Warburg effect and tumor growth through HIF1 alpha in lung cancer</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">4050</span>â <span class="NLM_lpage">4061</span>, <span class="refDoi">Â DOI: 10.7150/thno.21524</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.7150%2Fthno.21524" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=30128035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1MXivVSktbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=4050-4061&author=J.+J.+Liauthor=Y.+Heauthor=Z.+Q.+Tanauthor=J.+C.+Luauthor=L.+L.+Liauthor=X.+Songauthor=F.+Shiauthor=L.+L.+Xieauthor=S.+Youauthor=X.+J.+Luoauthor=N.+M.+Liauthor=Y.+S.+Liauthor=X.+L.+Liuauthor=M.+Tangauthor=X.+X.+Wengauthor=W.+Yiauthor=J.+Fanauthor=J.+Zhouauthor=G.+Qiangauthor=S.+J.+Qiuauthor=W.+Z.+Wuauthor=A.+M.+Bodeauthor=Y.+Cao&title=Wild-type+IDH2+promotes+the+Warburg+effect+and+tumor+growth+through+HIF1+alpha+in+lung+cancer&doi=10.7150%2Fthno.21524"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Wild-type IDH2 promotes the Warburg effect and tumor growth through HIF1Î± in lung cancer</span></div><div class="casAuthors">Li, Jiangjiang; He, Ya; Tan, Zheqiong; Lu, Jingchen; Li, Liling; Song, Xin; Shi, Feng; Xie, Longlong; You, Shuo; Luo, Xiangjian; Li, Namei; Li, Yueshuo; Liu, Xiaolan; Tang, Min; Weng, Xinxian; Yi, Wei; Fan, Jia; Zhou, Jian; Qiang, Gao; Qiu, Shuangjian; Wu, Weizhong; Bode, Ann M.; Cao, Ya</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4050-4061</span>CODEN:
                <span class="NLM_cas:coden">THERDS</span>;
        ISSN:<span class="NLM_cas:issn">1838-7640</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">Hotspot mutations of isocitrate dehydrogenase 1 and 2 (IDH1/2) have been studied in several cancers.  However, the function of wild-type IDH2 in lung cancer and the mechanism of its contribution to growth of cancer cells remain unknown.  Here, we explored the role and mechanism of wild-type IDH2 in promoting growth of lung cancer.  Methods: Information regarding genomic and clin. application focusing on IDH2 in cancer was examd. in several databases of more than 1,000 tumor samples.  IDH2 expression was assessed by immunohistochem. in tissues from lung cancer patients.  The biol. functions of IDH2 were evaluated by using cell-based assays and in vivo xenograft mouse models.  Results: Here we reported that wild-type IDH2 is up-regulated and is an indicator of poor survival in lung cancer and several other cancers.  Targeting IDH2 with shRNA resulted in decreased HIF1Î± expression, leading to the attenuation of lung cancer cell proliferation and tumor growth.  Treatment of lung cancer cells with AGI-6780 (a small mol. inhibitor of IDH2), PX-478 (an inhibitor of HIF1Î±) or incubation with octyl-Î±-KG inhibited lung cancer cell proliferation.  Conclusion: IDH2 promotes the Warburg effect and lung cancer cell growth, which is mediated through HIF1Î± activation followed by decreased Î±-KG.  Therefore, IDH2 could possibly serve as a novel therapeutic target for lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcAS3iSfZ7H7Vg90H21EOLACvtfcHk0libNttW-UEhtg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXivVSktbk%253D&md5=77a5d86857629b0e7efbc62369557e89</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.7150%2Fthno.21524&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.21524%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%2BJ.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DTan%26aufirst%3DZ.%2BQ.%26aulast%3DLu%26aufirst%3DJ.%2BC.%26aulast%3DLi%26aufirst%3DL.%2BL.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DF.%26aulast%3DXie%26aufirst%3DL.%2BL.%26aulast%3DYou%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DX.%2BJ.%26aulast%3DLi%26aufirst%3DN.%2BM.%26aulast%3DLi%26aufirst%3DY.%2BS.%26aulast%3DLiu%26aufirst%3DX.%2BL.%26aulast%3DTang%26aufirst%3DM.%26aulast%3DWeng%26aufirst%3DX.%2BX.%26aulast%3DYi%26aufirst%3DW.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DQiang%26aufirst%3DG.%26aulast%3DQiu%26aufirst%3DS.%2BJ.%26aulast%3DWu%26aufirst%3DW.%2BZ.%26aulast%3DBode%26aufirst%3DA.%2BM.%26aulast%3DCao%26aufirst%3DY.%26atitle%3DWild-type%2520IDH2%2520promotes%2520the%2520Warburg%2520effect%2520and%2520tumor%2520growth%2520through%2520HIF1%2520alpha%2520in%2520lung%2520cancer%26jtitle%3DTheranostics%26date%3D2018%26volume%3D8%26spage%3D4050%26epage%3D4061%26doi%3D10.7150%2Fthno.21524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stuani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poupin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosc, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saland, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gales, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montersino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turtoi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaoma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farge, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larrue, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baran, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loric, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouchel, P.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GotanÃ¨gre, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernando, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cognet, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zavoriti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosseini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boutzen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Futreal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu-Van, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cam, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selak, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vey, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calmettes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pigneux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bidet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellano, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenaille, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turtoi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cazals, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bories, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibon, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolay, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronseaux, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marszalek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiNardo, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konopleva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collette, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linares, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellvert, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jourdan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">RÃ©cher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portais, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarry, J.-E.</span></span> <span> </span><span class="NLM_article-title">Combinatory therapy targeting mitochondrial oxidative phosphorylation improves efficacy of IDH mutant inhibitors in acute myeloid leukemia</span>. <i>bioRxiv</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_fpage">749580</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&pages=749580&author=L.+Stuaniauthor=M.+Sabatierauthor=F.+Wangauthor=N.+Poupinauthor=C.+Boscauthor=E.+Salandauthor=F.+Castelliauthor=L.+Galesauthor=C.+Montersinoauthor=E.+Boetauthor=E.+Turtoiauthor=T.+Kaomaauthor=T.+Fargeauthor=N.+Broinauthor=C.+Larrueauthor=N.+Baranauthor=M.+Contiauthor=S.+Loricauthor=P.-L.+Mouchelauthor=M.+Gotan%C3%A8greauthor=C.+Cassanauthor=L.+Fernandoauthor=G.+Cognetauthor=A.+Zavoritiauthor=M.+Hosseiniauthor=H.+Boutzenauthor=K.+Moritaauthor=A.+Futrealauthor=E.+Chu-Vanauthor=L.+L.+Camauthor=M.+Carrollauthor=M.+A.+Selakauthor=N.+Veyauthor=C.+Calmettesauthor=A.+Pigneuxauthor=A.+Bidetauthor=R.+Castellanoauthor=F.+Fenailleauthor=A.+Turtoiauthor=G.+Cazalsauthor=P.+Boriesauthor=Y.+Gibonauthor=B.+Nicolayauthor=S.+Ronseauxauthor=J.+Marszalekauthor=C.+D.+DiNardoauthor=M.+Konoplevaauthor=Y.+Colletteauthor=L.+K.+Linaresauthor=F.+Bellvertauthor=F.+Jourdanauthor=K.+Takahashiauthor=C.+R%C3%A9cherauthor=J.-C.+Portaisauthor=J.-E.+Sarry&title=Combinatory+therapy+targeting+mitochondrial+oxidative+phosphorylation+improves+efficacy+of+IDH+mutant+inhibitors+in+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStuani%26aufirst%3DL.%26aulast%3DSabatier%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DPoupin%26aufirst%3DN.%26aulast%3DBosc%26aufirst%3DC.%26aulast%3DSaland%26aufirst%3DE.%26aulast%3DCastelli%26aufirst%3DF.%26aulast%3DGales%26aufirst%3DL.%26aulast%3DMontersino%26aufirst%3DC.%26aulast%3DBoet%26aufirst%3DE.%26aulast%3DTurtoi%26aufirst%3DE.%26aulast%3DKaoma%26aufirst%3DT.%26aulast%3DFarge%26aufirst%3DT.%26aulast%3DBroin%26aufirst%3DN.%26aulast%3DLarrue%26aufirst%3DC.%26aulast%3DBaran%26aufirst%3DN.%26aulast%3DConti%26aufirst%3DM.%26aulast%3DLoric%26aufirst%3DS.%26aulast%3DMouchel%26aufirst%3DP.-L.%26aulast%3DGotan%25C3%25A8gre%26aufirst%3DM.%26aulast%3DCassan%26aufirst%3DC.%26aulast%3DFernando%26aufirst%3DL.%26aulast%3DCognet%26aufirst%3DG.%26aulast%3DZavoriti%26aufirst%3DA.%26aulast%3DHosseini%26aufirst%3DM.%26aulast%3DBoutzen%26aufirst%3DH.%26aulast%3DMorita%26aufirst%3DK.%26aulast%3DFutreal%26aufirst%3DA.%26aulast%3DChu-Van%26aufirst%3DE.%26aulast%3DCam%26aufirst%3DL.%2BL.%26aulast%3DCarroll%26aufirst%3DM.%26aulast%3DSelak%26aufirst%3DM.%2BA.%26aulast%3DVey%26aufirst%3DN.%26aulast%3DCalmettes%26aufirst%3DC.%26aulast%3DPigneux%26aufirst%3DA.%26aulast%3DBidet%26aufirst%3DA.%26aulast%3DCastellano%26aufirst%3DR.%26aulast%3DFenaille%26aufirst%3DF.%26aulast%3DTurtoi%26aufirst%3DA.%26aulast%3DCazals%26aufirst%3DG.%26aulast%3DBories%26aufirst%3DP.%26aulast%3DGibon%26aufirst%3DY.%26aulast%3DNicolay%26aufirst%3DB.%26aulast%3DRonseaux%26aufirst%3DS.%26aulast%3DMarszalek%26aufirst%3DJ.%26aulast%3DDiNardo%26aufirst%3DC.%2BD.%26aulast%3DKonopleva%26aufirst%3DM.%26aulast%3DCollette%26aufirst%3DY.%26aulast%3DLinares%26aufirst%3DL.%2BK.%26aulast%3DBellvert%26aufirst%3DF.%26aulast%3DJourdan%26aufirst%3DF.%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DR%25C3%25A9cher%26aufirst%3DC.%26aulast%3DPortais%26aufirst%3DJ.-C.%26aulast%3DSarry%26aufirst%3DJ.-E.%26atitle%3DCombinatory%2520therapy%2520targeting%2520mitochondrial%2520oxidative%2520phosphorylation%2520improves%2520efficacy%2520of%2520IDH%2520mutant%2520inhibitors%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DbioRxiv%26date%3D2019%26spage%3D749580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemire, B. D.</span></span> <span> </span><span class="NLM_article-title">Evolution, structure and membrane association of NDUFAF6, an assembly factor for NADH:ubiquinone oxidoreductase (Complex I)</span>. <i>Mitochondrion</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">13</span>â <span class="NLM_lpage">22</span>, <span class="refDoi">Â DOI: 10.1016/j.mito.2017.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.mito.2017.04.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=28476317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnsV2lsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=13-22&author=B.+D.+Lemire&title=Evolution%2C+structure+and+membrane+association+of+NDUFAF6%2C+an+assembly+factor+for+NADH%3Aubiquinone+oxidoreductase+%28Complex+I%29&doi=10.1016%2Fj.mito.2017.04.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Evolution, structure and membrane association of NDUFAF6, an assembly factor for NADH:ubiquinone oxidoreductase (Complex I)</span></div><div class="casAuthors">Lemire, Bernard D.</div><div class="citationInfo"><span class="NLM_cas:title">Mitochondrion</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13-22</span>CODEN:
                <span class="NLM_cas:coden">MITOCN</span>;
        ISSN:<span class="NLM_cas:issn">1567-7249</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The NADH:ubiquinone oxidoreductase (complex I) is the largest member of the mitochondrial respiratory chain.  Its FMN cofactor accepts two electrons from NADH and transfers them to ubiquinone via a chain of iron-sulfur centers.  A central core of 14 highly conserved subunits can couple electron transfer to proton translocation.  The mammalian enzyme has an addnl. â¼ 30 accessory subunits.  Complex I has important bioenergetic and metabolic functions and is a known source of reactive oxygen species; these functions link it to a no. of hereditary and degenerative diseases.  For many complex I deficiencies, the primary defect is not in a subunit-encoding gene, but rather in an assembly factor or chaperone that participates in the biogenesis of newly synthesized complex I from individual subunits and cofactors.  NDUFAF6 encodes a complex I assembly factor and mutations result in complex I deficiency, Leigh syndrome or Acadian variant Fanconi syndrome.  Human NDUFAF6 is a mitochondria-targeted 333-amino acid protein belonging to the family of squalene and phytoene synthases.  Sequence and structural information suggests that NDUFAF6 likely has enzymic activity, but one that has evolved considerable differences from canonical squalene and phytoene synthases.  Most but not all metazoans have an NDUFAF6 ortholog, indicating that in some organisms, complex I biogenesis does not require this protein.  NDUFAF6 is a peripheral membrane protein and predictions identify a conserved C-terminal attachment site that have implications for substrate access.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOP81Q60izarVg90H21EOLACvtfcHk0ljyw4jwQ3SwRg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnsV2lsrg%253D&md5=e4eb126e106f9e01a81e17e7fad3c3a7</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.mito.2017.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mito.2017.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DLemire%26aufirst%3DB.%2BD.%26atitle%3DEvolution%252C%2520structure%2520and%2520membrane%2520association%2520of%2520NDUFAF6%252C%2520an%2520assembly%2520factor%2520for%2520NADH%253Aubiquinone%2520oxidoreductase%2520%2528Complex%2520I%2529%26jtitle%3DMitochondrion%26date%3D2017%26volume%3D35%26spage%3D13%26epage%3D22%26doi%3D10.1016%2Fj.mito.2017.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Minton, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayraktar, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sviderskiy, V. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papagiannakopoulos, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birsoy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Possemato, R.</span></span> <span> </span><span class="NLM_article-title">Serine catabolism by SHMT2 is required for proper mitochondrial translation initiation and maintenance of formylmethionyl-tRNAs</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">610</span>â <span class="NLM_lpage">621</span>, <span class="refDoi">Â DOI: 10.1016/j.molcel.2018.01.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.molcel.2018.01.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=29452640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFSgsLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2018&pages=610-621&author=D.+R.+Mintonauthor=M.+Namauthor=D.+J.+McLaughlinauthor=J.+Shinauthor=E.+C.+Bayraktarauthor=S.+W.+Alvarezauthor=V.+O.+Sviderskiyauthor=T.+Papagiannakopoulosauthor=D.+M.+Sabatiniauthor=K.+Birsoyauthor=R.+Possemato&title=Serine+catabolism+by+SHMT2+is+required+for+proper+mitochondrial+translation+initiation+and+maintenance+of+formylmethionyl-tRNAs&doi=10.1016%2Fj.molcel.2018.01.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Serine Catabolism by SHMT2 Is Required for Proper Mitochondrial Translation Initiation and Maintenance of Formylmethionyl-tRNAs</span></div><div class="casAuthors">Minton, Denise R.; Nam, Minwoo; McLaughlin, Daniel J.; Shin, Jong; Bayraktar, Erol C.; Alvarez, Samantha W.; Sviderskiy, Vladislav O.; Papagiannakopoulos, Thales; Sabatini, David M.; Birsoy, Kivanc; Possemato, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">610-621.e5</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Upon glucose restriction, eukaryotic cells upregulate oxidative metab. to maintain homeostasis.  Using genetic screens, we find that the mitochondrial serine hydroxymethyltransferase (SHMT2) is required for robust mitochondrial oxygen consumption and low glucose proliferation.  SHMT2 catalyzes the first step in mitochondrial one-carbon metab., which, particularly in proliferating cells, produces tetrahydrofolate (THF)-conjugated one-carbon units used in cytoplasmic reactions despite the presence of a parallel cytoplasmic pathway.  Impairing cytoplasmic one-carbon metab. or blocking efflux of one-carbon units from mitochondria does not phenocopy SHMT2 loss, indicating that a mitochondrial THF cofactor is responsible for the obsd. phenotype.  The enzyme MTFMT utilizes one such cofactor, 10-formyl THF, producing formylmethionyl-tRNAs, specialized initiator tRNAs necessary for proper translation of mitochondrially encoded proteins.  Accordingly, SHMT2 null cells specifically fail to maintain formylmethionyl-tRNA pools and mitochondrially encoded proteins, phenotypes similar to those obsd. in MTFMT-deficient patients.  These findings provide a rationale for maintaining a compartmentalized one-carbon pathway in mitochondria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_Rpzyr03vWbVg90H21EOLACvtfcHk0ljyw4jwQ3SwRg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFSgsLY%253D&md5=398878e531d48c7ee4e01fc9be9e05d6</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2018.01.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2018.01.024%26sid%3Dliteratum%253Aachs%26aulast%3DMinton%26aufirst%3DD.%2BR.%26aulast%3DNam%26aufirst%3DM.%26aulast%3DMcLaughlin%26aufirst%3DD.%2BJ.%26aulast%3DShin%26aufirst%3DJ.%26aulast%3DBayraktar%26aufirst%3DE.%2BC.%26aulast%3DAlvarez%26aufirst%3DS.%2BW.%26aulast%3DSviderskiy%26aufirst%3DV.%2BO.%26aulast%3DPapagiannakopoulos%26aufirst%3DT.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26aulast%3DBirsoy%26aufirst%3DK.%26aulast%3DPossemato%26aufirst%3DR.%26atitle%3DSerine%2520catabolism%2520by%2520SHMT2%2520is%2520required%2520for%2520proper%2520mitochondrial%2520translation%2520initiation%2520and%2520maintenance%2520of%2520formylmethionyl-tRNAs%26jtitle%3DMol.%2520Cell%26date%3D2018%26volume%3D69%26spage%3D610%26epage%3D621%26doi%3D10.1016%2Fj.molcel.2018.01.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morscher, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ducker, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S. H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gitai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabinowitz, J. D.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial translation requires folate-dependent tRNA methylation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>554</i></span>,  <span class="NLM_fpage">128</span>â <span class="NLM_lpage">132</span>, <span class="refDoi">Â DOI: 10.1038/nature25460</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fnature25460" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=29364879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs12gsL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=554&publication_year=2018&pages=128-132&author=R.+J.+Morscherauthor=G.+S.+Duckerauthor=S.+H.+J.+Liauthor=J.+A.+Mayerauthor=Z.+Gitaiauthor=W.+Sperlauthor=J.+D.+Rabinowitz&title=Mitochondrial+translation+requires+folate-dependent+tRNA+methylation&doi=10.1038%2Fnature25460"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial translation requires folate-dependent tRNA methylation</span></div><div class="casAuthors">Morscher, Raphael J.; Ducker, Gregory S.; Li, Sophia Hsin-Jung; Mayer, Johannes A.; Gitai, Zemer; Sperl, Wolfgang; Rabinowitz, Joshua D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">554</span>
        (<span class="NLM_cas:issue">7690</span>),
    <span class="NLM_cas:pages">128-132</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Folates enable the activation and transfer of one-carbon units for the biosynthesis of purines, thymidine and methionine.  Antifolates are important immunosuppressive and anticancer agents.  In proliferating lymphocytes and human cancers, mitochondrial folate enzymes are particularly strongly upregulated.  This in part reflects the need for mitochondria to generate one-carbon units and export them to the cytosol for anabolic metab.  The full range of uses of folate-bound one-carbon units in the mitochondrial compartment itself, however, has not been thoroughly explored.  Here we show that loss of the catalytic activity of the mitochondrial folate enzyme serine hydroxymethyltransferase 2 (SHMT2), but not of other folate enzymes, leads to defective oxidative phosphorylation in human cells due to impaired mitochondrial translation.  We find that SHMT2, presumably by generating mitochondrial 5,10-methylenetetrahydrofolate, provides Me donors to produce the taurinomethyluridine base at the wobble position of select mitochondrial tRNAs.  Mitochondrial ribosome profiling in SHMT2-knockout human cells reveals that the lack of this modified base causes defective translation, with preferential mitochondrial ribosome stalling at certain lysine (AAG) and leucine (UUG) codons.  This results in the impaired expression of respiratory chain enzymes.  Stalling at these specific codons also occurs in certain inborn errors of mitochondrial metab.  Disruption of whole-cell folate metab., by either folate deficiency or antifolate treatment, also impairs the respiratory chain.  In summary, mammalian mitochondria use folate-bound one-carbon units to methylate tRNA, and this modification is required for mitochondrial translation and thus oxidative phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWhflym_kZO7Vg90H21EOLACvtfcHk0ljyw4jwQ3SwRg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs12gsL0%253D&md5=6e198c91d31fb19fcec7b53a569fd109</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1038%2Fnature25460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature25460%26sid%3Dliteratum%253Aachs%26aulast%3DMorscher%26aufirst%3DR.%2BJ.%26aulast%3DDucker%26aufirst%3DG.%2BS.%26aulast%3DLi%26aufirst%3DS.%2BH.%2BJ.%26aulast%3DMayer%26aufirst%3DJ.%2BA.%26aulast%3DGitai%26aufirst%3DZ.%26aulast%3DSperl%26aufirst%3DW.%26aulast%3DRabinowitz%26aufirst%3DJ.%2BD.%26atitle%3DMitochondrial%2520translation%2520requires%2520folate-dependent%2520tRNA%2520methylation%26jtitle%3DNature%26date%3D2018%26volume%3D554%26spage%3D128%26epage%3D132%26doi%3D10.1038%2Fnature25460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez-Fonseca, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navas-Enamorado, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos-Ocana, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez-Camacho, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerra, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascajo, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Cuesta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horvath, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siendones, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casado, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez-Rios, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brea-Calvo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Lluch, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Ayala, D. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Aguilera, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matte, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prieto-Soler, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez-del-Toro, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">di Francesco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aon, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salviati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artuch, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Cabo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navas, P.</span></span> <span> </span><span class="NLM_article-title">ADCK2 haploinsufficiency reduces mitochondrial lipid oxidation and causes myopathy associated with CoQ deficiency</span>. <i>J. Clin. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1374</span>, <span class="refDoi">Â DOI: 10.3390/jcm8091374</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.3390%2Fjcm8091374" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2019&pages=1374&author=L.+Vazquez-Fonsecaauthor=J.+Schaferauthor=I.+Navas-Enamoradoauthor=C.+Santos-Ocanaauthor=J.+D.+Hernandez-Camachoauthor=I.+Guerraauthor=M.+V.+Cascajoauthor=A.+Sanchez-Cuestaauthor=Z.+Horvathauthor=E.+Siendonesauthor=C.+Jouauthor=M.+Casadoauthor=P.+Gutierrez-Riosauthor=G.+Brea-Calvoauthor=G.+Lopez-Lluchauthor=D.+J.+M.+Fernandez-Ayalaauthor=A.+B.+Cortesauthor=J.+C.+Rodriguez-Aguileraauthor=C.+Matteauthor=A.+Ribesauthor=S.+Y.+Prieto-Solerauthor=E.+Dominguez-del-Toroauthor=A.+di+Francescoauthor=M.+A.+Aonauthor=M.+Bernierauthor=L.+Salviatiauthor=R.+Artuchauthor=R.+de+Caboauthor=S.+Jacksonauthor=P.+Navas&title=ADCK2+haploinsufficiency+reduces+mitochondrial+lipid+oxidation+and+causes+myopathy+associated+with+CoQ+deficiency&doi=10.3390%2Fjcm8091374"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.3390%2Fjcm8091374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fjcm8091374%26sid%3Dliteratum%253Aachs%26aulast%3DVazquez-Fonseca%26aufirst%3DL.%26aulast%3DSchafer%26aufirst%3DJ.%26aulast%3DNavas-Enamorado%26aufirst%3DI.%26aulast%3DSantos-Ocana%26aufirst%3DC.%26aulast%3DHernandez-Camacho%26aufirst%3DJ.%2BD.%26aulast%3DGuerra%26aufirst%3DI.%26aulast%3DCascajo%26aufirst%3DM.%2BV.%26aulast%3DSanchez-Cuesta%26aufirst%3DA.%26aulast%3DHorvath%26aufirst%3DZ.%26aulast%3DSiendones%26aufirst%3DE.%26aulast%3DJou%26aufirst%3DC.%26aulast%3DCasado%26aufirst%3DM.%26aulast%3DGutierrez-Rios%26aufirst%3DP.%26aulast%3DBrea-Calvo%26aufirst%3DG.%26aulast%3DLopez-Lluch%26aufirst%3DG.%26aulast%3DFernandez-Ayala%26aufirst%3DD.%2BJ.%2BM.%26aulast%3DCortes%26aufirst%3DA.%2BB.%26aulast%3DRodriguez-Aguilera%26aufirst%3DJ.%2BC.%26aulast%3DMatte%26aufirst%3DC.%26aulast%3DRibes%26aufirst%3DA.%26aulast%3DPrieto-Soler%26aufirst%3DS.%2BY.%26aulast%3DDominguez-del-Toro%26aufirst%3DE.%26aulast%3Ddi%2BFrancesco%26aufirst%3DA.%26aulast%3DAon%26aufirst%3DM.%2BA.%26aulast%3DBernier%26aufirst%3DM.%26aulast%3DSalviati%26aufirst%3DL.%26aulast%3DArtuch%26aufirst%3DR.%26aulast%3Dde%2BCabo%26aufirst%3DR.%26aulast%3DJackson%26aufirst%3DS.%26aulast%3DNavas%26aufirst%3DP.%26atitle%3DADCK2%2520haploinsufficiency%2520reduces%2520mitochondrial%2520lipid%2520oxidation%2520and%2520causes%2520myopathy%2520associated%2520with%2520CoQ%2520deficiency%26jtitle%3DJ.%2520Clin.%2520Med.%26date%3D2019%26volume%3D8%26spage%3D1374%26doi%3D10.3390%2Fjcm8091374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thiriet, M.</span></span> <span> </span><span class="NLM_article-title">Protein Kinase Classification</span>. In  <i>Intracellular signaling mediators in the circulatory and ventilatory systems</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiriet, M.</span></span>, Ed.; <span class="NLM_publisher-name">Springer International Publishing</span>: <span class="NLM_publisher-loc">Cham</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=M.+Thirietauthor=M.+Thiriet&title=Intracellular+signaling+mediators+in+the+circulatory+and+ventilatory+systems"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DThiriet%26aufirst%3DM.%26atitle%3DProtein%2520Kinase%2520Classification%26btitle%3DIntracellular%2520signaling%2520mediators%2520in%2520the%2520circulatory%2520and%2520ventilatory%2520systems%26aulast%3DThiriet%26aufirst%3DM.%26pub%3DSpringer%2520International%2520Publishing%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattarai, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schram, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielski, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donoghue, M. T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonsson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravarty, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kandoth, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorelick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shamu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumer, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kundra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Razavi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reales, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Socci, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayakumaran, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zehir, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benayed, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandarlapaty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, B. S.</span></span> <span> </span><span class="NLM_article-title">Accelerating discovery of functional mutant alleles in cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">174</span>â <span class="NLM_lpage">183</span>, <span class="refDoi">Â DOI: 10.1158/2159-8290.CD-17-0321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F2159-8290.CD-17-0321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=29247016" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFCrt7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=174-183&author=M.+T.+Changauthor=T.+S.+Bhattaraiauthor=A.+M.+Schramauthor=C.+M.+Bielskiauthor=M.+T.+A.+Donoghueauthor=P.+Jonssonauthor=D.+Chakravartyauthor=S.+Phillipsauthor=C.+Kandothauthor=A.+Pensonauthor=A.+Gorelickauthor=T.+Shamuauthor=S.+Patelauthor=C.+Harrisauthor=J.+Gaoauthor=S.+O.+Sumerauthor=R.+Kundraauthor=P.+Razaviauthor=B.+T.+Liauthor=D.+N.+Realesauthor=N.+D.+Socciauthor=G.+Jayakumaranauthor=A.+Zehirauthor=R.+Benayedauthor=M.+E.+Arcilaauthor=S.+Chandarlapatyauthor=M.+Ladanyiauthor=N.+Schultzauthor=J.+Baselgaauthor=M.+F.+Bergerauthor=N.+Rosenauthor=D.+B.+Solitauthor=D.+M.+Hymanauthor=B.+S.+Taylor&title=Accelerating+discovery+of+functional+mutant+alleles+in+cancer&doi=10.1158%2F2159-8290.CD-17-0321"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Accelerating Discovery of Functional Mutant Alleles in Cancer</span></div><div class="casAuthors">Chang, Matthew T.; Bhattarai, Tripti Shrestha; Schram, Alison M.; Bielski, Craig M.; Donoghue, Mark T. A.; Jonsson, Philip; Chakravarty, Debyani; Phillips, Sarah; Kandoth, Cyriac; Penson, Alexander; Gorelick, Alexander; Shamu, Tambudzai; Patel, Swati; Harris, Christopher; Gao, Jian Jiong; Sumer, Selcuk Onur; Kundra, Ritika; Razavi, Pedram; Li, Bob T.; Reales, Dalicia N.; Socci, Nicholas D.; Jayakumaran, Gowtham; Zehir, Ahmet; Benayed, Ryma; Arcila, Maria E.; Chandarlapaty, Sarat; Ladanyi, Marc; Schultz, Nikolaus; Baselga, Jose; Berger, Michael F.; Rosen, Neal; Solit, David B.; Hyman, David M.; Taylor, Barry S.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">174-183</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Most mutations in cancer are rare, which complicates the identification of therapeutically significant mutations and thus limits the clin. impact of genomic profiling in patients with cancer.  Here, we analyzed 24,592 cancers including 10,336 prospectively sequenced patients with advanced disease to identify mutant residues arising more frequently than expected in the absence of selection.  We identified 1,165 statistically significant hotspot mutations of which 80% arose in 1 in 1,000 or fewer patients.  Of 55 recurrent in-frame indels, we validated that novel AKT1 duplications induced pathway hyperactivation and conferred AKT inhibitor sensitivity.  Cancer genes exhibit different rates of hotspot discovery with increasing sample size, with few approaching satn.  Consequently, 26% of all hotspots in therapeutically actionable oncogenes were novel.  Upon matching a subset of affected patients directly to molecularly targeted therapy, we obsd. radiog. and clin. responses.  Population-scale mutant allele discovery illustrates how the identification of driver mutations in cancer is far from complete.  Our systematic computational, exptl., and clin. anal. of hotspot mutations in approx. 25,000 human cancers demonstrates that the long right tail of biol. and therapeutically significant mutant alleles is still incompletely characterized.  Sharing prospective genomic data will accelerate hotspot identification, thereby expanding the reach of precision oncol. in patients with cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyHExer4GLcbVg90H21EOLACvtfcHk0libeISE8-DSlw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFCrt7o%253D&md5=691bbfdf71137fa95192b2cbbd3e5fec</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-17-0321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-17-0321%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DM.%2BT.%26aulast%3DBhattarai%26aufirst%3DT.%2BS.%26aulast%3DSchram%26aufirst%3DA.%2BM.%26aulast%3DBielski%26aufirst%3DC.%2BM.%26aulast%3DDonoghue%26aufirst%3DM.%2BT.%2BA.%26aulast%3DJonsson%26aufirst%3DP.%26aulast%3DChakravarty%26aufirst%3DD.%26aulast%3DPhillips%26aufirst%3DS.%26aulast%3DKandoth%26aufirst%3DC.%26aulast%3DPenson%26aufirst%3DA.%26aulast%3DGorelick%26aufirst%3DA.%26aulast%3DShamu%26aufirst%3DT.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DHarris%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DSumer%26aufirst%3DS.%2BO.%26aulast%3DKundra%26aufirst%3DR.%26aulast%3DRazavi%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DB.%2BT.%26aulast%3DReales%26aufirst%3DD.%2BN.%26aulast%3DSocci%26aufirst%3DN.%2BD.%26aulast%3DJayakumaran%26aufirst%3DG.%26aulast%3DZehir%26aufirst%3DA.%26aulast%3DBenayed%26aufirst%3DR.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DChandarlapaty%26aufirst%3DS.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DSchultz%26aufirst%3DN.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DBerger%26aufirst%3DM.%2BF.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26aulast%3DHyman%26aufirst%3DD.%2BM.%26aulast%3DTaylor%26aufirst%3DB.%2BS.%26atitle%3DAccelerating%2520discovery%2520of%2520functional%2520mutant%2520alleles%2520in%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2018%26volume%3D8%26spage%3D174%26epage%3D183%26doi%3D10.1158%2F2159-8290.CD-17-0321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nussinov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, F.</span></span> <span> </span><span class="NLM_article-title">Review: Precision medicine and driver mutations: computational methods, functional assays and conformational principles for interpreting cancer drivers</span>. <i>PLoS Comput. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">e1006658</span>, <span class="refDoi">Â DOI: 10.1371/journal.pcbi.1006658</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1371%2Fjournal.pcbi.1006658" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=30921324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVSis7fK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=e1006658&author=R.+Nussinovauthor=H.+Jangauthor=C.+J.+Tsaiauthor=F.+Cheng&title=Review%3A+Precision+medicine+and+driver+mutations%3A+computational+methods%2C+functional+assays+and+conformational+principles+for+interpreting+cancer+drivers&doi=10.1371%2Fjournal.pcbi.1006658"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Review: precision medicine and driver mutations: computational methods, functional assays and conformational principles for interpreting cancer drivers</span></div><div class="casAuthors">Nussinov, Ruth; Jang, Hyunbum; Tsai, Chung-Jung; Cheng, Feixiong</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Computational Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e1006658/1-e1006658/54</span>CODEN:
                <span class="NLM_cas:coden">PCBLBG</span>;
        ISSN:<span class="NLM_cas:issn">1553-7358</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">At the root of the so-called precision medicine or precision oncol., which is our focus here, is the hypothesis that cancer treatment would be considerably better if therapies were guided by a tumor's genomic alterations.  This hypothesis has sparked major initiatives focusing on whole-genome and/or exome sequencing, creation of large databases, and developing tools for their statistical analyses-all aspiring to identify actionable alterations, and thus mol. targets, in a patient.  At the center of the massive amt. of collected sequence data is their interpretations that largely rest on statistical anal. and phenotypic observations.  Statistics is vital, because it guides identification of cancer-driving alterations.  However, statistics of mutations do not identify a change in protein conformation; therefore, it may not define sufficiently accurate actionable mutations, neglecting those that are rare.  Among the many thematic overviews of precision oncol., this review innovates by further comprehensively including precision pharmacol., and within this framework, articulating its protein structural landscape and consequences to cellular signaling pathways.  It provides the underlying physicochem. basis, thereby also opening the door to a broader community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0IoAh4ESb5rVg90H21EOLACvtfcHk0li4MvoanO77jA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVSis7fK&md5=dee7b00c4bfff0f6f5cd9d7d203a5a63</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.1006658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.1006658%26sid%3Dliteratum%253Aachs%26aulast%3DNussinov%26aufirst%3DR.%26aulast%3DJang%26aufirst%3DH.%26aulast%3DTsai%26aufirst%3DC.%2BJ.%26aulast%3DCheng%26aufirst%3DF.%26atitle%3DReview%253A%2520Precision%2520medicine%2520and%2520driver%2520mutations%253A%2520computational%2520methods%252C%2520functional%2520assays%2520and%2520conformational%2520principles%2520for%2520interpreting%2520cancer%2520drivers%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2019%26volume%3D15%26spage%3De1006658%26doi%3D10.1371%2Fjournal.pcbi.1006658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mardis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanton, C.</span></span> <span> </span><span class="NLM_article-title">Prioritizing targets for precision cancer medicine</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">2295</span>â <span class="NLM_lpage">2303</span>, <span class="refDoi">Â DOI: 10.1093/annonc/mdu478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1093%2Fannonc%2Fmdu478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=25344359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BC2M3jtFCqtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=2295-2303&author=F.+Andreauthor=E.+Mardisauthor=M.+Salmauthor=J.+C.+Soriaauthor=L.+L.+Siuauthor=C.+Swanton&title=Prioritizing+targets+for+precision+cancer+medicine&doi=10.1093%2Fannonc%2Fmdu478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Prioritizing targets for precision cancer medicine</span></div><div class="casAuthors">Andre F; Mardis E; Salm M; Soria J-C; Siu L L; Swanton C</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2295-2303</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The implementation of cancer genomic testing into the clinical setting has brought major opportunities.  However, as our understanding of cancer initiation, maintenance and progression improves through detailed cancer genomic studies, the challenges associated with driver identification and target classification in the clinical setting become clearer.  Here, we review recent insights into cancer genomic testing in the clinical setting, and suggest a target classification approach that considers the levels of evidence supporting the prioritization of tumour drivers for therapeutic targeting in light of complex cancer clonal and sub-clonal structures and clinical successes and failures in the field.  We argue that such classification approaches, together with transparent reporting of both positive and negative clinical data and continued research to identify the sub-clonal dynamics of driver events during the disease course, will facilitate inter-trial comparisons, optimize patient informed consent and provide a critically balanced evaluation of genomic testing in clinical practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSgOUn0MkqMAPIW7hznt0zpfW6udTcc2eZOTHt46Z39B7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M3jtFCqtw%253D%253D&md5=8eb716308c603785f18bf9c2430ed0af</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdu478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdu478%26sid%3Dliteratum%253Aachs%26aulast%3DAndre%26aufirst%3DF.%26aulast%3DMardis%26aufirst%3DE.%26aulast%3DSalm%26aufirst%3DM.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DSiu%26aufirst%3DL.%2BL.%26aulast%3DSwanton%26aufirst%3DC.%26atitle%3DPrioritizing%2520targets%2520for%2520precision%2520cancer%2520medicine%26jtitle%3DAnn.%2520Oncol.%26date%3D2014%26volume%3D25%26spage%3D2295%26epage%3D2303%26doi%3D10.1093%2Fannonc%2Fmdu478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grossman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heath, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferretti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varmus, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowy, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kibbe, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudt, L. M.</span></span> <span> </span><span class="NLM_article-title">Toward a shared vision for cancer genomic data</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>375</i></span>,  <span class="NLM_fpage">1109</span>â <span class="NLM_lpage">1112</span>, <span class="refDoi">Â DOI: 10.1056/NEJMp1607591</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1056%2FNEJMp1607591" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27653561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BC2svivFyntg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2016&pages=1109-1112&author=R.+L.+Grossmanauthor=A.+P.+Heathauthor=V.+Ferrettiauthor=H.+E.+Varmusauthor=D.+R.+Lowyauthor=W.+A.+Kibbeauthor=L.+M.+Staudt&title=Toward+a+shared+vision+for+cancer+genomic+data&doi=10.1056%2FNEJMp1607591"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Toward a Shared Vision for Cancer Genomic Data</span></div><div class="casAuthors">Grossman Robert L; Heath Allison P; Ferretti Vincent; Varmus Harold E; Lowy Douglas R; Kibbe Warren A; Staudt Louis M</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1109-12</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRZwIDiaUsY2DQLBVDQn4bCfW6udTcc2eZOTHt46Z39B7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svivFyntg%253D%253D&md5=2a6eebabdf4e7c5b1efea3eb6ab49a5a</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1056%2FNEJMp1607591&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMp1607591%26sid%3Dliteratum%253Aachs%26aulast%3DGrossman%26aufirst%3DR.%2BL.%26aulast%3DHeath%26aufirst%3DA.%2BP.%26aulast%3DFerretti%26aufirst%3DV.%26aulast%3DVarmus%26aufirst%3DH.%2BE.%26aulast%3DLowy%26aufirst%3DD.%2BR.%26aulast%3DKibbe%26aufirst%3DW.%2BA.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26atitle%3DToward%2520a%2520shared%2520vision%2520for%2520cancer%2520genomic%2520data%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D375%26spage%3D1109%26epage%3D1112%26doi%3D10.1056%2FNEJMp1607591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mayakonda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assenov, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plass, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeffler, H. P.</span></span> <span> </span><span class="NLM_article-title">Maftools: efficient and comprehensive analysis of somatic variants in cancer</span>. <i>Genome Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1747</span>â <span class="NLM_lpage">1756</span>, <span class="refDoi">Â DOI: 10.1101/gr.239244.118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1101%2Fgr.239244.118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=30341162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXis1Shtb7M" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=1747-1756&author=A.+Mayakondaauthor=D.+C.+Linauthor=Y.+Assenovauthor=C.+Plassauthor=H.+P.+Koeffler&title=Maftools%3A+efficient+and+comprehensive+analysis+of+somatic+variants+in+cancer&doi=10.1101%2Fgr.239244.118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Maftools: efficient and comprehensive analysis of somatic variants in cancer</span></div><div class="casAuthors">Mayakonda, Anand; Lin, De-Chen; Assenov, Yassen; Plass, Christoph; Koeffler, H. Phillip</div><div class="citationInfo"><span class="NLM_cas:title">Genome Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1747-1756</span>CODEN:
                <span class="NLM_cas:coden">GEREFS</span>;
        ISSN:<span class="NLM_cas:issn">1088-9051</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">Numerous large-scale genomic studies of matched tumor-normal samples have established the somatic landscapes of most cancer types.  However, the downstream anal. of data from somatic mutations entails a no. of computational and statistical approaches, requiring usage of independent software and numerous tools.  Here, we describe an R Bioconductor package, Maftools, which offers a multitude of anal. and visualization modules that are commonly used in cancer genomic studies, including driver gene identification, pathway, signature, enrichment, and assocn. analyses.  Maftools only requires somatic variants in Mutation Annotation Format (MAF) and is independent of larger alignment files.  With the implementation of well-established statistical and computational methods, Maftools facilitates data-driven research and comparative anal. to discover novel results from publicly available data sets.  In the present study, using three of the well-annotated cohorts from The Cancer Genome Atlas (TCGA), we describe the application of Maftools to reproduce known results.  More importantly, we show that Maftools can also be used to uncover novel findings through integrative anal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW6Xk7CGN1L7Vg90H21EOLACvtfcHk0li4MvoanO77jA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXis1Shtb7M&md5=d9558d907292c3fee17f3ff49735005b</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1101%2Fgr.239244.118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgr.239244.118%26sid%3Dliteratum%253Aachs%26aulast%3DMayakonda%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DD.%2BC.%26aulast%3DAssenov%26aufirst%3DY.%26aulast%3DPlass%26aufirst%3DC.%26aulast%3DKoeffler%26aufirst%3DH.%2BP.%26atitle%3DMaftools%253A%2520efficient%2520and%2520comprehensive%2520analysis%2520of%2520somatic%2520variants%2520in%2520cancer%26jtitle%3DGenome%2520Res.%26date%3D2018%26volume%3D28%26spage%3D1747%26epage%3D1756%26doi%3D10.1101%2Fgr.239244.118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waitkus, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diplas, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, H.</span></span> <span> </span><span class="NLM_article-title">Biological role and therapeutic potential of IDH mutations in cancer</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">186</span>â <span class="NLM_lpage">195</span>, <span class="refDoi">Â DOI: 10.1016/j.ccell.2018.04.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.ccell.2018.04.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=29805076" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVajurbL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2018&pages=186-195&author=M.+S.+Waitkusauthor=B.+H.+Diplasauthor=H.+Yan&title=Biological+role+and+therapeutic+potential+of+IDH+mutations+in+cancer&doi=10.1016%2Fj.ccell.2018.04.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Biological Role and Therapeutic Potential of IDH Mutations in Cancer</span></div><div class="casAuthors">Waitkus, Matthew S.; Diplas, Bill H.; Yan, Hai</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">186-195</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Hotspot mutations in isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) occur in a variety of myeloid malignancies and solid tumors.  Mutant IDH proteins acquire a neomorphic enzyme activity to produce the putative oncometabolite D-2-hydroxyglutarate, which is thought to block cellular differentiation by competitively inhibiting Î±-ketoglutarate-dependent dioxygenases involved in histone and DNA demethylation.  Small-mol. inhibitors of mutant IDH1 and IDH2 have been developed and are progressing through pre-clin. and clin. development.  In this review, we provide an overview of mutant IDH-targeted therapy and discuss a no. of important recent pre-clin. studies using models of IDH-mutant solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2Xkgqc-UL3rVg90H21EOLACvtfcHk0ljBGSAFtqrwwQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVajurbL&md5=fb4231473619c7e1e62465e1a08ed2a9</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2018.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2018.04.011%26sid%3Dliteratum%253Aachs%26aulast%3DWaitkus%26aufirst%3DM.%2BS.%26aulast%3DDiplas%26aufirst%3DB.%2BH.%26aulast%3DYan%26aufirst%3DH.%26atitle%3DBiological%2520role%2520and%2520therapeutic%2520potential%2520of%2520IDH%2520mutations%2520in%2520cancer%26jtitle%3DCancer%2520Cell%26date%3D2018%26volume%3D34%26spage%3D186%26epage%3D195%26doi%3D10.1016%2Fj.ccell.2018.04.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span> <span> </span><span class="NLM_article-title">IDH1/2 gene hotspot mutations in central nervous system tumours: analysis of 922 Chinese patients</span>. <i>Pathology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">675</span>â <span class="NLM_lpage">683</span>, <span class="refDoi">Â DOI: 10.1016/j.pathol.2016.07.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.pathol.2016.07.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27780605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslCktbfN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2016&pages=675-683&author=N.+Chenauthor=T.+Yuauthor=J.+Gongauthor=L.+Nieauthor=X.+Chenauthor=M.+Zhangauthor=M.+Xuauthor=J.+Tanauthor=Z.+Suauthor=J.+Zhongauthor=Q.+Zhou&title=IDH1%2F2+gene+hotspot+mutations+in+central+nervous+system+tumours%3A+analysis+of+922+Chinese+patients&doi=10.1016%2Fj.pathol.2016.07.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">IDH1/2 gene hotspot mutations in central nervous system tumours: analysis of 922 Chinese patients</span></div><div class="casAuthors">Chen, Ni; Yu, Tianpin; Gong, Jing; Nie, Ling; Chen, Xueqin; Zhang, Mengni; Xu, Miao; Tan, Junya; Su, Zhengzheng; Zhong, Jinjing; Zhou, Qiao</div><div class="citationInfo"><span class="NLM_cas:title">Pathology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">675-683</span>CODEN:
                <span class="NLM_cas:coden">PTLGAX</span>;
        ISSN:<span class="NLM_cas:issn">0031-3025</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Mutations of isocitrate dehydrogenase 1 (IDH1) or 2 (IDH2) genes have been identified as early mol. events in the development of astrocytomas and oligodendrogliomas.  Data regarding the status and prevalence of IDH1/2 mutations in Chinese patients are limited.  Herein we report our data from West China Hospital, a major Chinese medical center.  IDH1(R132H) mutation was analyzed by immunohistochem. with the mutation-specific IDH1(R132H) antibody in 1011 patients, including 922 central nervous system (CNS) tumors and 89 non-neoplastic CNS lesions, and PCR-based direct sequencing of IDH1/2 gene mutation in 570 of these samples.  Correlation with clinicopathol. features and immunohistochem. expression of p53, EGFR, PTEN and Ki-67 was examd.  Our data showed that IDH1/2 mutation was present in oligodendrogliomas, anaplastic oligodendrogliomas, diffuse or anaplastic astrocytomas, and glioblastomas, with decreasing frequency, but not in other types of CNS tumors or non-neoplastic lesions examd.  IDH1(R132) mutation was most frequent in oligodendrogliomas (57/62, 91.9%), with IDH1(R132H) mutation as the most frequent mutation form.  Only one case for each of the rare mutations (R132C, R132G, R132L, and R132S) was identified in the 570 samples analyzed by sequencing.  Younger age, low expression of p53 and low Ki-67 index were significantly correlated with IDH1 mutation status (p = 0.000).  All tumors with IDH1(R132) mutations were supratentorial, with frontal lobe as the most frequent site for IDH-mutated gliomas.  Only three IDH2(R172) mutation cases were detected in this series.  Univariate survival anal. in 459 glioma patients with diffusely infiltrating gliomas showed that IDH1 mutations as well as the more classical prognosticators (age, WHO grade, p53 and Ki-67 index) were of prognostic significance.  Multivariate anal. by Cox proportional hazard regression model demonstrated that lack of IDH1 mutation was an independent prognostic factor for both progression-free survival [relative risk (RR) = 2.450, 95% confidence interval (CI) = 1.351-4.444] and disease-specific survival (RR = 2.489, 95%CI = 1.155-5.363).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVf-nMldO1ErVg90H21EOLACvtfcHk0ljBGSAFtqrwwQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslCktbfN&md5=a23346fd7e351f1444a9d3e58ce3884e</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2Fj.pathol.2016.07.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pathol.2016.07.010%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DN.%26aulast%3DYu%26aufirst%3DT.%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DNie%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DZ.%26aulast%3DZhong%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DQ.%26atitle%3DIDH1%252F2%2520gene%2520hotspot%2520mutations%2520in%2520central%2520nervous%2520system%2520tumours%253A%2520analysis%2520of%2520922%2520Chinese%2520patients%26jtitle%3DPathology%26date%3D2016%26volume%3D48%26spage%3D675%26epage%3D683%26doi%3D10.1016%2Fj.pathol.2016.07.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rocken, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behrens, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruger, S.</span></span> <span> </span><span class="NLM_article-title">Clinicopathological characteristics of RHOA mutations in a Central European gastric cancer cohort</span>. <i>J. Clin. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">70</span>â <span class="NLM_lpage">75</span>, <span class="refDoi">Â DOI: 10.1136/jclinpath-2015-202980</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1136%2Fjclinpath-2015-202980" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=26251521" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BC287gsFOisg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2016&pages=70-75&author=C.+Rockenauthor=H.+M.+Behrensauthor=C.+Bogerauthor=S.+Kruger&title=Clinicopathological+characteristics+of+RHOA+mutations+in+a+Central+European+gastric+cancer+cohort&doi=10.1136%2Fjclinpath-2015-202980"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Clinicopathological characteristics of RHOA mutations in a Central European gastric cancer cohort</span></div><div class="casAuthors">Rocken Christoph; Behrens Hans-Michael; Boger Christine; Kruger Sandra</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical pathology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">70-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Genomically stable gastric cancers (GCs) are enriched for the diffuse phenotype and hotspot mutations of RHOA.  Here we aimed to validate the occurrence, phenotype and clinicopathological characteristics of RHOA mutant GCs in an independent Central European GC cohort consisting of 415 patients.  The RHOA genotype (exon 2 and 3) was correlated with various genotypic, phenotypic and clinicopathological patient characteristics.  Sixteen (3.9%) tumours had a RHOA mutation including four hitherto unreported mutations, that is, p.G17Efs*24, p.V24F, p.T37A and p.L69R.  RHOA mutation was more prevalent in women (5.4% vs 2.8%), distal GCs (4.5% vs 2.4%), in poorly differentiated GCs (G3/G4; 4.8% vs 1.1%), T1/T2 tumours (6.2% vs 3.1%) and lacked distant metastases.  Nine RHOA mutant GCs had a diffuse, four an intestinal, two an unclassified and one a mixed Lauren phenotype.  KRAS and RHOA mutations were mutually exclusive.  A single case showed both a RHOA and a PIK3CA mutation.  No significant difference was found in the overall survival between RHOA mutant and wildtype GCs.  Our study confirms the occurrence and clinicopathological characteristics of RHOA hotspot mutations in an independent patient cohort.  However, we found no evidence for a prognostic or growth advantageous effect of RHOA mutations in GC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSi9f53xe7BppggzHGM8X5CfW6udTcc2eYeszrN-yqMsrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287gsFOisg%253D%253D&md5=12238bc396771b8eaa8ac65043ae7b5b</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1136%2Fjclinpath-2015-202980&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fjclinpath-2015-202980%26sid%3Dliteratum%253Aachs%26aulast%3DRocken%26aufirst%3DC.%26aulast%3DBehrens%26aufirst%3DH.%2BM.%26aulast%3DBoger%26aufirst%3DC.%26aulast%3DKruger%26aufirst%3DS.%26atitle%3DClinicopathological%2520characteristics%2520of%2520RHOA%2520mutations%2520in%2520a%2520Central%2520European%2520gastric%2520cancer%2520cohort%26jtitle%3DJ.%2520Clin.%2520Pathol.%26date%3D2016%26volume%3D69%26spage%3D70%26epage%3D75%26doi%3D10.1136%2Fjclinpath-2015-202980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kakiuchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishizawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotoh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatsuno, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katoh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ushiku, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funahashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tateishi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wada, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koike, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukayama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aburatani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, S.</span></span> <span> </span><span class="NLM_article-title">Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">583</span>â <span class="NLM_lpage">587</span>, <span class="refDoi">Â DOI: 10.1038/ng.2984</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fng.2984" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=24816255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnslGqtrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2014&pages=583-587&author=M.+Kakiuchiauthor=T.+Nishizawaauthor=H.+Uedaauthor=K.+Gotohauthor=A.+Tanakaauthor=A.+Hayashiauthor=S.+Yamamotoauthor=K.+Tatsunoauthor=H.+Katohauthor=Y.+Watanabeauthor=T.+Ichimuraauthor=T.+Ushikuauthor=S.+Funahashiauthor=K.+Tateishiauthor=I.+Wadaauthor=N.+Shimizuauthor=S.+Nomuraauthor=K.+Koikeauthor=Y.+Setoauthor=M.+Fukayamaauthor=H.+Aburataniauthor=S.+Ishikawa&title=Recurrent+gain-of-function+mutations+of+RHOA+in+diffuse-type+gastric+carcinoma&doi=10.1038%2Fng.2984"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma</span></div><div class="casAuthors">Kakiuchi, Miwako; Nishizawa, Takashi; Ueda, Hiroki; Gotoh, Kengo; Tanaka, Atsushi; Hayashi, Akimasa; Yamamoto, Shogo; Tatsuno, Kenji; Katoh, Hiroto; Watanabe, Yoshiaki; Ichimura, Takashi; Ushiku, Tetsuo; Funahashi, Shinichi; Tateishi, Keisuke; Wada, Ikuo; Shimizu, Nobuyuki; Nomura, Sachiyo; Koike, Kazuhiko; Seto, Yasuyuki; Fukayama, Masashi; Aburatani, Hiroyuki; Ishikawa, Shumpei</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">583-587</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Diffuse-type gastric carcinoma (DGC) is characterized by a highly malignant phenotype with prominent infiltration and stromal induction.  We performed whole-exome sequencing on 30 DGC cases and found recurrent RHOA nonsynonymous mutations.  With validation sequencing of an addnl. 57 cases, RHOA mutation was obsd. in 25.3% (22/87) of DGCs, with mutational hotspots affecting the Tyr42, Arg5 and Gly17 residues in RHOA protein.  These positions are highly conserved among RHO family members, and Tyr42 and Arg5 are located outside the guanine nucleotide-binding pocket.  Several lines of functional evidence indicated that mutant RHOA works in a gain-of-function manner.  Comparison of mutational profiles for the major gastric cancer subtypes showed that RHOA mutations occur specifically in DGCs, the majority of which were histopathol. characterized by the presence of poorly differentiated adenocarcinomas together with more differentiated components in the gastric mucosa.  Our findings identify a potential therapeutic target for this poor-prognosis subtype of gastric cancer with no available molecularly targeted drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo64ww_rUNuzbVg90H21EOLACvtfcHk0lhM7DOJlt1x1w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnslGqtrY%253D&md5=7f3aec15808cfcae7923c557c535fed5</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1038%2Fng.2984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.2984%26sid%3Dliteratum%253Aachs%26aulast%3DKakiuchi%26aufirst%3DM.%26aulast%3DNishizawa%26aufirst%3DT.%26aulast%3DUeda%26aufirst%3DH.%26aulast%3DGotoh%26aufirst%3DK.%26aulast%3DTanaka%26aufirst%3DA.%26aulast%3DHayashi%26aufirst%3DA.%26aulast%3DYamamoto%26aufirst%3DS.%26aulast%3DTatsuno%26aufirst%3DK.%26aulast%3DKatoh%26aufirst%3DH.%26aulast%3DWatanabe%26aufirst%3DY.%26aulast%3DIchimura%26aufirst%3DT.%26aulast%3DUshiku%26aufirst%3DT.%26aulast%3DFunahashi%26aufirst%3DS.%26aulast%3DTateishi%26aufirst%3DK.%26aulast%3DWada%26aufirst%3DI.%26aulast%3DShimizu%26aufirst%3DN.%26aulast%3DNomura%26aufirst%3DS.%26aulast%3DKoike%26aufirst%3DK.%26aulast%3DSeto%26aufirst%3DY.%26aulast%3DFukayama%26aufirst%3DM.%26aulast%3DAburatani%26aufirst%3DH.%26aulast%3DIshikawa%26aufirst%3DS.%26atitle%3DRecurrent%2520gain-of-function%2520mutations%2520of%2520RHOA%2520in%2520diffuse-type%2520gastric%2520carcinoma%26jtitle%3DNat.%2520Genet.%26date%3D2014%26volume%3D46%26spage%3D583%26epage%3D587%26doi%3D10.1038%2Fng.2984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oda, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekine, S.</span></span> <span> </span><span class="NLM_article-title">RHOA mutations and CLDN18-ARHGAP fusions in intestinal-type adenocarcinoma with anastomosing glands of the stomach</span>. <i>Mod. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">568</span>â <span class="NLM_lpage">575</span>, <span class="refDoi">Â DOI: 10.1038/s41379-018-0181-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fs41379-018-0181-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=30425335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlSrtb3I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2019&pages=568-575&author=T.+Hashimotoauthor=R.+Ogawaauthor=T.+Y.+Tangauthor=H.+Yoshidaauthor=H.+Taniguchiauthor=H.+Kataiauthor=I.+Odaauthor=S.+Sekine&title=RHOA+mutations+and+CLDN18-ARHGAP+fusions+in+intestinal-type+adenocarcinoma+with+anastomosing+glands+of+the+stomach&doi=10.1038%2Fs41379-018-0181-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">RHOA mutations and CLDN18-ARHGAP fusions in intestinal-type adenocarcinoma with anastomosing glands of the stomach</span></div><div class="casAuthors">Hashimoto, Taiki; Ogawa, Reiko; Tang, Tzu-Yin; Yoshida, Hiroshi; Taniguchi, Hirokazu; Katai, Hitoshi; Oda, Ichiro; Sekine, Shigeki</div><div class="citationInfo"><span class="NLM_cas:title">Modern Pathology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">568-575</span>CODEN:
                <span class="NLM_cas:coden">MODPEO</span>;
        ISSN:<span class="NLM_cas:issn">0893-3952</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A subtype of intestinal-type adenocarcinoma of the stomach, characterized by low-grade cytol. atypia and anastomosing glands, has been described in several reports under different names.  One of the remarkable features of these lesions, herein referred to as intestinal-type adenocarcinoma with anastomosing glands, is the frequent assocn. of poorly differentiated adenocarcinoma components.  Here we analyzed 44 intestinal-type adenocarcinomas with anastomosing glands focusing on the mol. abnormalities that are common in diffuse-type gastric cancers.  Next-generation sequencing identified RHOA and CDH1 mutations in 22 (50%) and one lesion (2%), resp.  Reverse transcription-PCR detected CLDN18-ARHGAP fusions in three lesions (7%).  Immunohistochem., none of the lesions showed abnormal p53 expression patterns whereas focal and diffuse loss of ARID1A was obsd. in four and one lesion, resp.  Examn. of 37 lesions of dysplasia and 26 usual-type intramucosal adenocarcinomas identified one RHOA mutation in adenocarcinoma and no CLDN18-ARHGAP fusions, indicating that these genetic alterations are highly specific to intestinal-type adenocarcinomas with anastomosing glands among differentiated-type intramucosal neoplasms.  The present study showed that intestinal-type adenocarcinoma with anastomosing glands represents a genetically distinct group of tumors with the frequent presence of RHOA mutations and CLDN18-ARHGAP fusions, which are thought to be specific to diffuse-type gastric cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLDADGiJ89H7Vg90H21EOLACvtfcHk0lhM7DOJlt1x1w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlSrtb3I&md5=f42aba8bc1f850c2307848f6eca27ee6</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1038%2Fs41379-018-0181-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41379-018-0181-9%26sid%3Dliteratum%253Aachs%26aulast%3DHashimoto%26aufirst%3DT.%26aulast%3DOgawa%26aufirst%3DR.%26aulast%3DTang%26aufirst%3DT.%2BY.%26aulast%3DYoshida%26aufirst%3DH.%26aulast%3DTaniguchi%26aufirst%3DH.%26aulast%3DKatai%26aufirst%3DH.%26aulast%3DOda%26aufirst%3DI.%26aulast%3DSekine%26aufirst%3DS.%26atitle%3DRHOA%2520mutations%2520and%2520CLDN18-ARHGAP%2520fusions%2520in%2520intestinal-type%2520adenocarcinoma%2520with%2520anastomosing%2520glands%2520of%2520the%2520stomach%26jtitle%3DMod.%2520Pathol.%26date%3D2019%26volume%3D32%26spage%3D568%26epage%3D575%26doi%3D10.1038%2Fs41379-018-0181-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodge, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papageorge, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stachler, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akarca, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Klerk, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derks, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierobon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoadley, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Church, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petricoin, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowy, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Der, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bass, A. J.</span></span> <span> </span><span class="NLM_article-title">Gain-of-function RHOA mutations promote focal adhesion kinase activation and dependency in diffuse gastric cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">288</span>â <span class="NLM_lpage">305</span>, <span class="refDoi">Â DOI: 10.1158/2159-8290.CD-19-0811</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F2159-8290.CD-19-0811" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=31771969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVGisb3N" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=288-305&author=H.+Zhangauthor=A.+Schaeferauthor=Y.+Wangauthor=R.+G.+Hodgeauthor=D.+R.+Blakeauthor=J.+N.+Diehlauthor=A.+G.+Papageorgeauthor=M.+D.+Stachlerauthor=J.+Liaoauthor=J.+Zhouauthor=Z.+Wuauthor=F.+G.+Akarcaauthor=L.+K.+de+Klerkauthor=S.+Derksauthor=M.+Pierobonauthor=K.+A.+Hoadleyauthor=T.+C.+Wangauthor=G.+Churchauthor=K.+K.+Wongauthor=E.+F.+Petricoinauthor=A.+D.+Coxauthor=D.+R.+Lowyauthor=C.+J.+Derauthor=A.+J.+Bass&title=Gain-of-function+RHOA+mutations+promote+focal+adhesion+kinase+activation+and+dependency+in+diffuse+gastric+cancer&doi=10.1158%2F2159-8290.CD-19-0811"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Gain-of-function RHOA mutations promote focal adhesion kinase activation and dependency in diffuse gastric cancer</span></div><div class="casAuthors">Zhang, Haisheng; Schaefer, Antje; Wang, Yichen; Hodge, Richard G.; Blake, Devon R.; Diehl, J. Nathaniel; Papageorge, Alex G.; Stachler, Matthew D.; Liao, Jennifer; Zhou, Jin; Wu, Zhong; Akarca, Fahire G.; de Klerk, Leonie K.; Derks, Sarah; Pierobon, Mariaelena; Hoadley, Katherine A.; Wang, Timothy C.; Church, George; Wong, Kwok-Kin; Petricoin, Emanuel F.; Cox, Adrienne D.; Lowy, Douglas R.; Der, Channing J.; Bass, Adam J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">288-305</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Diffuse gastric cancer (DGC) is a lethal malignancy lacking effective systemic therapy.  Among the most provocative recent results in DGC has been that of highly recurrent missense mutations in the GTPase RHOA.  The function of these mutations has remained unresolved.  We demonstrate that RHOAY42C, the most common RHOA mutation in DGC, is a gain-of-function oncogenic mutant, and that expression of RHOAY42C with inactivation of the canonical tumor suppressor Cdh1 induces metastatic DGC in a mouse model.  Biochem., RHOAY42C exhibits impaired GTP hydrolysis and enhances interaction with its effector ROCK.  RHOAY42C mutation and Cdh1 loss induce actin/cytoskeletal rearrangements and activity of focal adhesion kinase (FAK), which activates YAP-TAZ, PI3K-AKT, and Î²-catenin.  RHOAY42C murine models were sensitive to FAK inhibition and to combined YAP and PI3K pathway blockade.  These results, coupled with sensitivity to FAK inhibition in patient-derived DGC cell lines, nominate FAK as a novel target for these cancers.  The functional significance of recurrent RHOA mutations in DGC has remained unresolved.  Through biochem. studies and mouse modeling of the hotspot RHOAY42C mutation, we establish that these mutations are activating, detail their effects upon cell signaling, and define how RHOA-mediated FAK activation imparts sensitivity to pharmacol. FAK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomtMM-p2C5WLVg90H21EOLACvtfcHk0lgbV03uUsbgfg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVGisb3N&md5=9ddc924e7cd3402278c5916ca3075bdd</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-19-0811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-19-0811%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DSchaefer%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHodge%26aufirst%3DR.%2BG.%26aulast%3DBlake%26aufirst%3DD.%2BR.%26aulast%3DDiehl%26aufirst%3DJ.%2BN.%26aulast%3DPapageorge%26aufirst%3DA.%2BG.%26aulast%3DStachler%26aufirst%3DM.%2BD.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DAkarca%26aufirst%3DF.%2BG.%26aulast%3Dde%2BKlerk%26aufirst%3DL.%2BK.%26aulast%3DDerks%26aufirst%3DS.%26aulast%3DPierobon%26aufirst%3DM.%26aulast%3DHoadley%26aufirst%3DK.%2BA.%26aulast%3DWang%26aufirst%3DT.%2BC.%26aulast%3DChurch%26aufirst%3DG.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DPetricoin%26aufirst%3DE.%2BF.%26aulast%3DCox%26aufirst%3DA.%2BD.%26aulast%3DLowy%26aufirst%3DD.%2BR.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26aulast%3DBass%26aufirst%3DA.%2BJ.%26atitle%3DGain-of-function%2520RHOA%2520mutations%2520promote%2520focal%2520adhesion%2520kinase%2520activation%2520and%2520dependency%2520in%2520diffuse%2520gastric%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2020%26volume%3D10%26spage%3D288%26epage%3D305%26doi%3D10.1158%2F2159-8290.CD-19-0811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grassian, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Divakaruni, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slocum, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickers, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joud-Caldwell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handly, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straub, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Growney, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vander
Heiden, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagliarini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metallo, C. M.</span></span> <span> </span><span class="NLM_article-title">IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">3317</span>â <span class="NLM_lpage">3331</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-14-0772-T</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F0008-5472.CAN-14-0772-T" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=24755473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2cXps1Cmurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=3317-3331&author=A.+R.+Grassianauthor=S.+J.+Parkerauthor=S.+M.+Davidsonauthor=A.+S.+Divakaruniauthor=C.+R.+Greenauthor=X.+Zhangauthor=K.+L.+Slocumauthor=M.+Puauthor=F.+Linauthor=C.+Vickersauthor=C.+Joud-Caldwellauthor=F.+Chungauthor=H.+Yinauthor=E.+D.+Handlyauthor=C.+Straubauthor=J.+D.+Growneyauthor=M.+G.+Vander%0AHeidenauthor=A.+N.+Murphyauthor=R.+Pagliariniauthor=C.+M.+Metallo&title=IDH1+mutations+alter+citric+acid+cycle+metabolism+and+increase+dependence+on+oxidative+mitochondrial+metabolism&doi=10.1158%2F0008-5472.CAN-14-0772-T"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">IDH1 Mutations Alter Citric Acid Cycle Metabolism and Increase Dependence on Oxidative Mitochondrial Metabolism</span></div><div class="casAuthors">Grassian, Alexandra R.; Parker, Seth J.; Davidson, Shawn M.; Divakaruni, Ajit S.; Green, Courtney R.; Zhang, Xiamei; Slocum, Kelly L.; Pu, Minying; Lin, Fallon; Vickers, Chad; Joud-Caldwell, Carol; Chung, Franklin; Yin, Hong; Handly, Erika D.; Straub, Christopher; Growney, Joseph D.; Vander Heiden, Matthew G.; Murphy, Anne N.; Pagliarini, Raymond; Metallo, Christian M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3317-3331</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Oncogenic mutations in isocitrate dehydrogenase I and 2 (IDH1/2) occur in several types of cancer, but the metabolic consequences of these genetic changes are not fully understood.  In this study, we performed 13C metabolic flux anal. on a panel of isogenic cell lines contg. heterozygous IDH1/2 mutations.  We obsd. that under hypoxic conditions, IDH1-mutant cells exhibited increased oxidative tricarboxylic acid metab. along with decreased reductive glutamine metab., but not IDH2-mutant cells.  However, selective inhibition of mutant IDH1 enzyme function could not reverse the defect in reductive carboxylation activity.  Furthermore, this metabolic reprogramming increased the sensitivity of IDH1-mutant cells to hypoxia or electron transport chain inhibition in vitro.  Lastly, IDHl-mutant cells also grew poorly as s.c. xenografts within a hypoxic in vivo microenvironment.  Together, our results suggest therapeutic opportunities to exploit the metabolic vulnerabilities specific to IDH1 mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSn8rEPLZvc7Vg90H21EOLACvtfcHk0lgbV03uUsbgfg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXps1Cmurw%253D&md5=f75db701c8b99057cc2de565315467c0</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-0772-T&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-0772-T%26sid%3Dliteratum%253Aachs%26aulast%3DGrassian%26aufirst%3DA.%2BR.%26aulast%3DParker%26aufirst%3DS.%2BJ.%26aulast%3DDavidson%26aufirst%3DS.%2BM.%26aulast%3DDivakaruni%26aufirst%3DA.%2BS.%26aulast%3DGreen%26aufirst%3DC.%2BR.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DSlocum%26aufirst%3DK.%2BL.%26aulast%3DPu%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DF.%26aulast%3DVickers%26aufirst%3DC.%26aulast%3DJoud-Caldwell%26aufirst%3DC.%26aulast%3DChung%26aufirst%3DF.%26aulast%3DYin%26aufirst%3DH.%26aulast%3DHandly%26aufirst%3DE.%2BD.%26aulast%3DStraub%26aufirst%3DC.%26aulast%3DGrowney%26aufirst%3DJ.%2BD.%26aulast%3DVander%2BHeiden%26aufirst%3DM.%2BG.%26aulast%3DMurphy%26aufirst%3DA.%2BN.%26aulast%3DPagliarini%26aufirst%3DR.%26aulast%3DMetallo%26aufirst%3DC.%2BM.%26atitle%3DIDH1%2520mutations%2520alter%2520citric%2520acid%2520cycle%2520metabolism%2520and%2520increase%2520dependence%2520on%2520oxidative%2520mitochondrial%2520metabolism%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D3317%26epage%3D3331%26doi%3D10.1158%2F0008-5472.CAN-14-0772-T" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarry, J.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Recher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portais, J.-C.</span></span> <span> </span><span class="NLM_article-title">Catabolic flexibility enhances drug resistance but induces selective vulnerability to new mitochondrial-targeted therapeutic combinations in IDH mutant leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">5238</span>â <span class="NLM_lpage">5238</span>, <span class="refDoi">Â DOI: 10.1182/blood-2018-99-112523</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1182%2Fblood-2018-99-112523" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2018&pages=5238-5238&author=J.-E.+Sarryauthor=C.+Recherauthor=L.+Stuaniauthor=J.-C.+Portais&title=Catabolic+flexibility+enhances+drug+resistance+but+induces+selective+vulnerability+to+new+mitochondrial-targeted+therapeutic+combinations+in+IDH+mutant+leukemia&doi=10.1182%2Fblood-2018-99-112523"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1182%2Fblood-2018-99-112523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2018-99-112523%26sid%3Dliteratum%253Aachs%26aulast%3DSarry%26aufirst%3DJ.-E.%26aulast%3DRecher%26aufirst%3DC.%26aulast%3DStuani%26aufirst%3DL.%26aulast%3DPortais%26aufirst%3DJ.-C.%26atitle%3DCatabolic%2520flexibility%2520enhances%2520drug%2520resistance%2520but%2520induces%2520selective%2520vulnerability%2520to%2520new%2520mitochondrial-targeted%2520therapeutic%2520combinations%2520in%2520IDH%2520mutant%2520leukemia%26jtitle%3DBlood%26date%3D2018%26volume%3D132%26spage%3D5238%26epage%3D5238%26doi%3D10.1182%2Fblood-2018-99-112523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. H.</span></span> <span> </span><span class="NLM_article-title">RHOA in gastric cancer: functional roles and therapeutic potential</span>. <i>Front. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">438</span>, <span class="refDoi">Â DOI: 10.3389/fgene.2019.00438</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.3389%2Ffgene.2019.00438" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=31156701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsl2ntrzP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=438&author=S.+Namauthor=J.+H.+Kimauthor=D.+H.+Lee&title=RHOA+in+gastric+cancer%3A+functional+roles+and+therapeutic+potential&doi=10.3389%2Ffgene.2019.00438"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">RHOA in gastric cancer: functional roles and therapeutic potential</span></div><div class="casAuthors">Nam, Seungyoon; Kim, Jung Ho; Lee, Dae Ho</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Genetics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">438</span>CODEN:
                <span class="NLM_cas:coden">FGREBR</span>;
        ISSN:<span class="NLM_cas:issn">1664-8021</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  The well-known signal mediator and small GTPase family member, RHOA, has now been assocd. with the progression of specific malignancies.  In this review, we appraise the biomedical literature regarding the role of this enzyme in gastric cancer (GC) signaling, suggesting potential clin. significance.  To that end, we examd. RHOA activity, with regard to second-generation hallmarks of cancer, finding particular assocn. with the hallmark "activation of invasion and metastasis." Moreover, an abundance of studies show RHOA assocn. with Lauren classification diffuse subtype, in addn. to poorly differentiated GC.  With regard to therapeutic value, we found RHOA signaling to influence the activity of specific widely used chemotherapeutics, and its possible antagonism by various dietary constituents.  We also review currently available targeted therapies for GC.  The latter, however, showed a paucity of such agents, underscoring the urgent need for further investigation into treatments for this highly lethal malignancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCzvkdi-kb0bVg90H21EOLACvtfcHk0lgKEcrfXDlXOA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsl2ntrzP&md5=5bc6f78ec48e565e09a49fcccfff5473</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.3389%2Ffgene.2019.00438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffgene.2019.00438%26sid%3Dliteratum%253Aachs%26aulast%3DNam%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DLee%26aufirst%3DD.%2BH.%26atitle%3DRHOA%2520in%2520gastric%2520cancer%253A%2520functional%2520roles%2520and%2520therapeutic%2520potential%26jtitle%3DFront.%2520Genet.%26date%3D2019%26volume%3D10%26spage%3D438%26doi%3D10.3389%2Ffgene.2019.00438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishizawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komura, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuroiwa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishimaru, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monnai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aburatani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, M.</span></span> <span> </span><span class="NLM_article-title">In vivo effects of mutant RHOA on tumor formation in an orthotopic inoculation model</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">1745</span>â <span class="NLM_lpage">1754</span>, <span class="refDoi">Â DOI: 10.3892/or.2019.7300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.3892%2For.2019.7300" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=31485674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlsV2itLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2019&pages=1745-1754&author=T.+Nishizawaauthor=K.+Nakanoauthor=E.+Fujiiauthor=D.+Komuraauthor=Y.+Kuroiwaauthor=C.+Ishimaruauthor=M.+Monnaiauthor=H.+Aburataniauthor=S.+Ishikawaauthor=M.+Suzuki&title=In+vivo+effects+of+mutant+RHOA+on+tumor+formation+in+an+orthotopic+inoculation+model&doi=10.3892%2For.2019.7300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo effects of mutant RHOA on tumor formation in an orthotopic inoculation model</span></div><div class="casAuthors">Nishizawa, Takashi; Nakano, Kiyotaka; Fujii, Etsuko; Komura, Daisuke; Kuroiwa, Yoshie; Ishimaru, Chisako; Monnai, Makoto; Aburatani, Hiroyuki; Ishikawa, Shumpei; Suzuki, Masami</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1745-1754</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1791-2431</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">The contribution of RHOA mutations to tumor morphol. was investigated using an orthotopic xenograft model using the gastric cancer cell line MKN74, in which WT or mutated (Y42C and Y42S) RHOA had been introduced.  When we conducted RNA sequencing to distinguish between the genes expressed in human tumor tissues from those in mouse stroma, the expression profiles of the tumors were clearly divided into a Y42C/Y42S group and a mock/WT group.  Through gene set enrichment anal., it was revealed that inflammation- and hypoxia-related pathways were enriched in the mock/WT tumors; however, cell metab.- and cell cycle-related pathways such as Myc, E2F, oxidative phosphorylation and G2M checkpoint were enriched in the Y42C/Y42S tumors.  In addn., the gene set related to ROCK signaling inhibition was enriched in the RHOA-mutated group, which indicated that a series of events are related to ROCK inhibition induced by RHOA mutations.  Furthermore, unlike mock/WT, the RHOA-mutated tumor cells had little antitumor host reaction in the invasive front, which is similar to the pattern of mucosal invasion in clin. RHOA-mutated DGC.  These transcriptome, pathol. analyses revealed that mutated RHOA functionally contributes to the acquisition of DGC features, which will accelerate our understanding of the contribution of RHOA mutations in DGC biol., the development of further therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVXonUwTCijrVg90H21EOLACvtfcHk0lgKEcrfXDlXOA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlsV2itLs%253D&md5=fda4fb1f23c8896677db8b95eaee563c</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.3892%2For.2019.7300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2019.7300%26sid%3Dliteratum%253Aachs%26aulast%3DNishizawa%26aufirst%3DT.%26aulast%3DNakano%26aufirst%3DK.%26aulast%3DFujii%26aufirst%3DE.%26aulast%3DKomura%26aufirst%3DD.%26aulast%3DKuroiwa%26aufirst%3DY.%26aulast%3DIshimaru%26aufirst%3DC.%26aulast%3DMonnai%26aufirst%3DM.%26aulast%3DAburatani%26aufirst%3DH.%26aulast%3DIshikawa%26aufirst%3DS.%26aulast%3DSuzuki%26aufirst%3DM.%26atitle%3DIn%2520vivo%2520effects%2520of%2520mutant%2520RHOA%2520on%2520tumor%2520formation%2520in%2520an%2520orthotopic%2520inoculation%2520model%26jtitle%3DOncol.%2520Rep.%26date%3D2019%26volume%3D42%26spage%3D1745%26epage%3D1754%26doi%3D10.3892%2For.2019.7300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reznik, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senbabaoglu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riaz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarungbam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tickoo, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Ahmadie, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seshan, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hakimi, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sander, C.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial DNA copy number variation across human cancers</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">e10769</span>, <span class="refDoi">Â DOI: 10.7554/eLife.10769</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.7554%2FeLife.10769" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=26901439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotFGjsb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=e10769&author=E.+Reznikauthor=M.+L.+Millerauthor=Y.+Senbabaogluauthor=N.+Riazauthor=J.+Sarungbamauthor=S.+K.+Tickooauthor=H.+A.+Al-Ahmadieauthor=W.+Leeauthor=V.+E.+Seshanauthor=A.+A.+Hakimiauthor=C.+Sander&title=Mitochondrial+DNA+copy+number+variation+across+human+cancers&doi=10.7554%2FeLife.10769"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial DNA copy number variation across human cancers</span></div><div class="casAuthors">Reznik, Ed; Miller, Martin L.; Senbabaoglu, Yasin; Riaz, Nadeem; Sarungbam, Judy; Tickoo, Satish K.; Al-Ahmadie, Hikmat A.; Lee, William; Seshan, Venkatraman E.; Hakimi, A. Ari; Sander, Chris</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e10769/1-e10769/20</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">Mutations, deletions, and changes in copy no. of mitochondrial DNA (mtDNA), are obsd. throughout cancers.  Here, we survey mtDNA copy no. variation across 22 tumor types profiled by The Cancer Genome Atlas project.  We observe a tendency for some cancers, esp. of the bladder, breast, and kidney, to be depleted of mtDNA, relative to matched normal tissue.  Anal. of genetic context reveals an assocn. between incidence of several somatic alterations, including IDH1 mutations in gliomas, and mtDNA content.  In some but not all cancer types, mtDNA content is correlated with the expression of respiratory genes, and anticorrelated to the expression of immune response and cell-cycle genes.  In tandem with immunohistochem. evidence, we find that some tumors may compensate for mtDNA depletion to sustain levels of respiratory proteins.  Our results highlight the extent of mtDNA copy no. variation in tumors and point to related therapeutic opportunities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGo26OnVCagbVg90H21EOLACvtfcHk0lgKEcrfXDlXOA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotFGjsb8%253D&md5=5ed342536bb679eedcdd732ad5e8080b</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.7554%2FeLife.10769&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.10769%26sid%3Dliteratum%253Aachs%26aulast%3DReznik%26aufirst%3DE.%26aulast%3DMiller%26aufirst%3DM.%2BL.%26aulast%3DSenbabaoglu%26aufirst%3DY.%26aulast%3DRiaz%26aufirst%3DN.%26aulast%3DSarungbam%26aufirst%3DJ.%26aulast%3DTickoo%26aufirst%3DS.%2BK.%26aulast%3DAl-Ahmadie%26aufirst%3DH.%2BA.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DSeshan%26aufirst%3DV.%2BE.%26aulast%3DHakimi%26aufirst%3DA.%2BA.%26aulast%3DSander%26aufirst%3DC.%26atitle%3DMitochondrial%2520DNA%2520copy%2520number%2520variation%2520across%2520human%2520cancers%26jtitle%3DeLife%26date%3D2016%26volume%3D5%26spage%3De10769%26doi%3D10.7554%2FeLife.10769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Birkenmeier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drose, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittig, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkelmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kafer, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doring, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichert, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansmann, M. L.</span></span> <span> </span><span class="NLM_article-title">Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma are highly dependent on oxidative phosphorylation</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">2231</span>â <span class="NLM_lpage">2246</span>, <span class="refDoi">Â DOI: 10.1002/ijc.29934</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1002%2Fijc.29934" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=26595876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC28XovFamsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2016&pages=2231-2246&author=K.+Birkenmeierauthor=S.+Droseauthor=I.+Wittigauthor=R.+Winkelmannauthor=V.+Kaferauthor=C.+Doringauthor=S.+Hartmannauthor=T.+Wenzauthor=A.+S.+Reichertauthor=U.+Brandtauthor=M.+L.+Hansmann&title=Hodgkin+and+Reed-Sternberg+cells+of+classical+Hodgkin+lymphoma+are+highly+dependent+on+oxidative+phosphorylation&doi=10.1002%2Fijc.29934"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma are highly dependent on oxidative phosphorylation</span></div><div class="casAuthors">Birkenmeier, Katrin; Droese, Stefan; Wittig, Ilka; Winkelmann, Ria; Kaefer, Viktoria; Doering, Claudia; Hartmann, Sylvia; Wenz, Tina; Reichert, Andreas S.; Brandt, Ulrich; Hansmann, Martin-Leo</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2231-2246</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The metabolic properties of lymphomas derived from germinal center (GC) B cells have important implications for therapeutic strategies.  In this study, we have compared metabolic features of Hodgkin-Reed-Sternberg (HRS) cells, the tumor cells of classical Hodgkin's lymphoma (cHL), one of the most frequent (post-)GC-derived B-cell lymphomas, with their normal GC B cell counterparts.  We found that the ratio of oxidative to nonoxidative energy conversion was clearly shifted toward oxidative phosphorylation (OXPHOS)-linked ATP synthesis in HRS cells as compared to GC B cells.  Mitochondrial mass, the expression of numerous key proteins of oxidative metab. and markers of mitochondrial biogenesis were markedly upregulated in cHL cell lines and in primary cHL cases.  NFkappaB promoted this shift to OXPHOS.  Functional anal. indicated that both cell growth and viability of HRS cells depended on OXPHOS.  The high rates of OXPHOS correlated with an almost complete lack of lactate prodn. in HRS cells not obsd. in other GC B-cell lymphoma cell lines.  Overall, we conclude that OXPHOS dominates energy conversion in HRS cells, while nonoxidative ATP prodn. plays a subordinate role.  Our results suggest that OXPHOS could be a new therapeutic target and may provide an avenue toward new treatment strategies in cHL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnuxqK7mMcwbVg90H21EOLACvtfcHk0lh3nE7vSemrPA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XovFamsQ%253D%253D&md5=17e77b41883428f195c7207a5283ad4d</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1002%2Fijc.29934&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.29934%26sid%3Dliteratum%253Aachs%26aulast%3DBirkenmeier%26aufirst%3DK.%26aulast%3DDrose%26aufirst%3DS.%26aulast%3DWittig%26aufirst%3DI.%26aulast%3DWinkelmann%26aufirst%3DR.%26aulast%3DKafer%26aufirst%3DV.%26aulast%3DDoring%26aufirst%3DC.%26aulast%3DHartmann%26aufirst%3DS.%26aulast%3DWenz%26aufirst%3DT.%26aulast%3DReichert%26aufirst%3DA.%2BS.%26aulast%3DBrandt%26aufirst%3DU.%26aulast%3DHansmann%26aufirst%3DM.%2BL.%26atitle%3DHodgkin%2520and%2520Reed-Sternberg%2520cells%2520of%2520classical%2520Hodgkin%2520lymphoma%2520are%2520highly%2520dependent%2520on%2520oxidative%2520phosphorylation%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2016%26volume%3D138%26spage%3D2231%26epage%3D2246%26doi%3D10.1002%2Fijc.29934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lanning, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castle, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leon, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tovar, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanghera, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKeigan, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filipp, F. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graveel, C. R.</span></span> <span> </span><span class="NLM_article-title">Metabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities</span>. <i>Cancer Metab.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">6</span>, <span class="refDoi">Â DOI: 10.1186/s40170-017-0168-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1186%2Fs40170-017-0168-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=28852500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BC1cbislymuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&pages=6&author=N.+J.+Lanningauthor=J.+P.+Castleauthor=S.+J.+Singhauthor=A.+N.+Leonauthor=E.+A.+Tovarauthor=A.+Sangheraauthor=J.+P.+MacKeiganauthor=F.+V.+Filippauthor=C.+R.+Graveel&title=Metabolic+profiling+of+triple-negative+breast+cancer+cells+reveals+metabolic+vulnerabilities&doi=10.1186%2Fs40170-017-0168-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities</span></div><div class="casAuthors">Lanning Nathan J; Leon Andre N; Castle Joshua P; Tovar Elizabeth A; MacKeigan Jeffrey P; Graveel Carrie R; Singh Simar J; Sanghera Amandeep; Filipp Fabian V; MacKeigan Jeffrey P</div><div class="citationInfo"><span class="NLM_cas:title">Cancer & metabolism</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6</span>
        ISSN:<span class="NLM_cas:issn">2049-3002</span>.
    </div><div class="casAbstract">BACKGROUND:  Among breast cancers, the triple-negative breast cancer (TNBC) subtype has the worst prognosis with no approved targeted therapies and only standard chemotherapy as the backbone of systemic therapy.  Unique metabolic changes in cancer progression provide innovative therapeutic opportunities.  The receptor tyrosine kinases (RTKs) epidermal growth factor receptor (EGFR), and MET receptor are highly expressed in TNBC, making both promising therapeutic targets.  RTK signaling profoundly alters cellular metabolism by increasing glucose consumption and subsequently diverting glucose carbon sources into metabolic pathways necessary to support the tumorigenesis.  Therefore, detailed metabolic profiles of TNBC subtypes and their response to tyrosine kinase inhibitors may identify therapeutic sensitivities.  METHODS:  We quantified the metabolic profiles of TNBC cell lines representing multiple TNBC subtypes using gas chromatography mass spectrometry.  In addition, we subjected MDA-MB-231, MDA-MB-468, Hs578T, and HCC70 cell lines to metabolic flux analysis of basal and maximal glycolytic and mitochondrial oxidative rates.  Metabolic pool size and flux measurements were performed in the presence and absence of the MET inhibitor, INC280/capmatinib, and the EGFR inhibitor, erlotinib.  Further, the sensitivities of these cells to modulators of core metabolic pathways were determined.  In addition, we annotated a rate-limiting metabolic enzymes library and performed a siRNA screen in combination with MET or EGFR inhibitors to validate synergistic effects.  RESULTS:  TNBC cell line models displayed significant metabolic heterogeneity with respect to basal and maximal metabolic rates and responses to RTK and metabolic pathway inhibitors.  Comprehensive systems biology analysis of metabolic perturbations, combined siRNA and tyrosine kinase inhibitor screens identified a core set of TCA cycle and fatty acid pathways whose perturbation sensitizes TNBC cells to small molecule targeting of receptor tyrosine kinases.  CONCLUSIONS:  Similar to the genomic heterogeneity observed in TNBC, our results reveal metabolic heterogeneity among TNBC subtypes and demonstrate that understanding metabolic profiles and drug responses may prove valuable in targeting TNBC subtypes and identifying therapeutic susceptibilities in TNBC patients.  Perturbation of metabolic pathways sensitizes TNBC to inhibition of receptor tyrosine kinases.  Such metabolic vulnerabilities offer promise for effective therapeutic targeting for TNBC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTLo7wd5Jz078yail4HZd-ifW6udTcc2eZUq584yH_7W7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbislymuw%253D%253D&md5=8b0fc545febd991c24720755f9c838ef</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1186%2Fs40170-017-0168-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40170-017-0168-x%26sid%3Dliteratum%253Aachs%26aulast%3DLanning%26aufirst%3DN.%2BJ.%26aulast%3DCastle%26aufirst%3DJ.%2BP.%26aulast%3DSingh%26aufirst%3DS.%2BJ.%26aulast%3DLeon%26aufirst%3DA.%2BN.%26aulast%3DTovar%26aufirst%3DE.%2BA.%26aulast%3DSanghera%26aufirst%3DA.%26aulast%3DMacKeigan%26aufirst%3DJ.%2BP.%26aulast%3DFilipp%26aufirst%3DF.%2BV.%26aulast%3DGraveel%26aufirst%3DC.%2BR.%26atitle%3DMetabolic%2520profiling%2520of%2520triple-negative%2520breast%2520cancer%2520cells%2520reveals%2520metabolic%2520vulnerabilities%26jtitle%3DCancer%2520Metab.%26date%3D2017%26volume%3D5%26spage%3D6%26doi%3D10.1186%2Fs40170-017-0168-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caro, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kishan, A. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanley, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapuy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ficarro, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polak, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tondera, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gounarides, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marto, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipp, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danial, N. N.</span></span> <span> </span><span class="NLM_article-title">Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">547</span>â <span class="NLM_lpage">560</span>, <span class="refDoi">Â DOI: 10.1016/j.ccr.2012.08.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.ccr.2012.08.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=23079663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFWitbbO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=547-560&author=P.+Caroauthor=A.+U.+Kishanauthor=E.+Norbergauthor=I.+A.+Stanleyauthor=B.+Chapuyauthor=S.+B.+Ficarroauthor=K.+Polakauthor=D.+Tonderaauthor=J.+Gounaridesauthor=H.+Yinauthor=F.+Zhouauthor=M.+R.+Greenauthor=L.+Chenauthor=S.+Montiauthor=J.+A.+Martoauthor=M.+A.+Shippauthor=N.+N.+Danial&title=Metabolic+signatures+uncover+distinct+targets+in+molecular+subsets+of+diffuse+large+B+cell+lymphoma&doi=10.1016%2Fj.ccr.2012.08.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic Signatures Uncover Distinct Targets in Molecular Subsets of Diffuse Large B Cell Lymphoma</span></div><div class="casAuthors">Caro, Pilar; Kishan, Amar U.; Norberg, Erik; Stanley, Illana A.; Chapuy, Bjoern; Ficarro, Scott B.; Polak, Klaudia; Tondera, Daniel; Gounarides, John; Yin, Hong; Zhou, Feng; Green, Michael R.; Chen, Linfeng; Monti, Stefano; Marto, Jarrod A.; Shipp, Margaret A.; Danial, Nika N.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">547-560</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Mol. signatures have identified several subsets of diffuse large B cell lymphoma (DLBCL) and rational targets within the B cell receptor (BCR) signaling axis.  The OxPhos-DLBCL subset, which harbors the signature of genes involved in mitochondrial metab., is insensitive to inhibition of BCR survival signaling but is functionally undefined.  We show that, compared with BCR-DLBCLs, OxPhos-DLBCLs display enhanced mitochondrial energy transduction, greater incorporation of nutrient-derived carbons into the tricarboxylic acid cycle, and increased glutathione levels.  Moreover, perturbation of the fatty acid oxidn. program and glutathione synthesis proved selectively toxic to this tumor subset.  Our anal. provides evidence for distinct metabolic fingerprints and assocd. survival mechanisms in DLBCL and may have therapeutic implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFccRUow25JbVg90H21EOLACvtfcHk0lh3nE7vSemrPA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFWitbbO&md5=cc9e0ced5202e9e61ec7ee3baf4d7306</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2012.08.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2012.08.014%26sid%3Dliteratum%253Aachs%26aulast%3DCaro%26aufirst%3DP.%26aulast%3DKishan%26aufirst%3DA.%2BU.%26aulast%3DNorberg%26aufirst%3DE.%26aulast%3DStanley%26aufirst%3DI.%2BA.%26aulast%3DChapuy%26aufirst%3DB.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DPolak%26aufirst%3DK.%26aulast%3DTondera%26aufirst%3DD.%26aulast%3DGounarides%26aufirst%3DJ.%26aulast%3DYin%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DGreen%26aufirst%3DM.%2BR.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DMonti%26aufirst%3DS.%26aulast%3DMarto%26aufirst%3DJ.%2BA.%26aulast%3DShipp%26aufirst%3DM.%2BA.%26aulast%3DDanial%26aufirst%3DN.%2BN.%26atitle%3DMetabolic%2520signatures%2520uncover%2520distinct%2520targets%2520in%2520molecular%2520subsets%2520of%2520diffuse%2520large%2520B%2520cell%2520lymphoma%26jtitle%3DCancer%2520Cell%26date%3D2012%26volume%3D22%26spage%3D547%26epage%3D560%26doi%3D10.1016%2Fj.ccr.2012.08.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabra, M. B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phung, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefebvre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alshetaiwi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locasale, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Digman, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mjolsness, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werb, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, D. A.</span></span> <span> </span><span class="NLM_article-title">Transcriptional diversity and bioenergetic shift in human breast cancer metastasis revealed by single-cell RNA sequencing</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">310</span>â <span class="NLM_lpage">320</span>, <span class="refDoi">Â DOI: 10.1038/s41556-020-0477-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fs41556-020-0477-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=32144411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksFCjur0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2020&pages=310-320&author=R.+T.+Davisauthor=K.+Blakeauthor=D.+Maauthor=M.+B.+I.+Gabraauthor=G.+A.+Hernandezauthor=A.+T.+Phungauthor=Y.+Yangauthor=D.+Maurerauthor=A.+Lefebvreauthor=H.+Alshetaiwiauthor=Z.+Xiaoauthor=J.+Liuauthor=J.+W.+Locasaleauthor=M.+A.+Digmanauthor=E.+Mjolsnessauthor=M.+Kongauthor=Z.+Werbauthor=D.+A.+Lawson&title=Transcriptional+diversity+and+bioenergetic+shift+in+human+breast+cancer+metastasis+revealed+by+single-cell+RNA+sequencing&doi=10.1038%2Fs41556-020-0477-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Transcriptional diversity and bioenergetic shift in human breast cancer metastasis revealed by single-cell RNA sequencing</span></div><div class="casAuthors">Davis, Ryan T.; Blake, Kerrigan; Ma, Dennis; Gabra, Mari B. Ishak; Hernandez, Grace A.; Phung, Anh T.; Yang, Ying; Maurer, Dustin; Lefebvre, Austin E. Y. T.; Alshetaiwi, Hamad; Xiao, Zhengtao; Liu, Juan; Locasale, Jason W.; Digman, Michelle A.; Mjolsness, Eric; Kong, Mei; Werb, Zena; Lawson, Devon A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">310-320</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: Although metastasis remains the cause of most cancer-related mortality, mechanisms governing seeding in distal tissues are poorly understood.  Here, we establish a robust method for the identification of global transcriptomic changes in rare metastatic cells during seeding using single-cell RNA sequencing and patient-derived-xenograft models of breast cancer.  We find that both primary tumors and micrometastases display transcriptional heterogeneity but micrometastases harbor a distinct transcriptome program conserved across patient-derived-xenograft models that is highly predictive of poor survival of patients.  Pathway anal. revealed mitochondrial oxidative phosphorylation as the top pathway upregulated in micrometastases, in contrast to higher levels of glycolytic enzymes in primary tumor cells, which we corroborated by flow cytometric and metabolomic analyses.  Pharmacol. inhibition of oxidative phosphorylation dramatically attenuated metastatic seeding in the lungs, which demonstrates the functional importance of oxidative phosphorylation in metastasis and highlights its potential as a therapeutic target to prevent metastatic spread in patients with breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrm60v_V_SPmrVg90H21EOLACvtfcHk0lhzDk-v8iiyVw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksFCjur0%253D&md5=cc38756196aab2c523ee9bbbd0cb4021</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1038%2Fs41556-020-0477-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41556-020-0477-0%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DR.%2BT.%26aulast%3DBlake%26aufirst%3DK.%26aulast%3DMa%26aufirst%3DD.%26aulast%3DGabra%26aufirst%3DM.%2BB.%2BI.%26aulast%3DHernandez%26aufirst%3DG.%2BA.%26aulast%3DPhung%26aufirst%3DA.%2BT.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DMaurer%26aufirst%3DD.%26aulast%3DLefebvre%26aufirst%3DA.%26aulast%3DAlshetaiwi%26aufirst%3DH.%26aulast%3DXiao%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLocasale%26aufirst%3DJ.%2BW.%26aulast%3DDigman%26aufirst%3DM.%2BA.%26aulast%3DMjolsness%26aufirst%3DE.%26aulast%3DKong%26aufirst%3DM.%26aulast%3DWerb%26aufirst%3DZ.%26aulast%3DLawson%26aufirst%3DD.%2BA.%26atitle%3DTranscriptional%2520diversity%2520and%2520bioenergetic%2520shift%2520in%2520human%2520breast%2520cancer%2520metastasis%2520revealed%2520by%2520single-cell%2520RNA%2520sequencing%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2020%26volume%3D22%26spage%3D310%26epage%3D320%26doi%3D10.1038%2Fs41556-020-0477-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simoes, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serganova, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruchevsky, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leftin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shestov, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thaler, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukenick, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locasale, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasberg, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koutcher, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ackerstaff, E.</span></span> <span> </span><span class="NLM_article-title">Metabolic plasticity of metastatic breast cancer cells: adaptation to changes in the microenvironment</span>. <i>Neoplasia</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">671</span>â <span class="NLM_lpage">684</span>, <span class="refDoi">Â DOI: 10.1016/j.neo.2015.08.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.neo.2015.08.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=26408259" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVeqtbjL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=671-684&author=R.+V.+Simoesauthor=I.+S.+Serganovaauthor=N.+Kruchevskyauthor=A.+Leftinauthor=A.+A.+Shestovauthor=H.+T.+Thalerauthor=G.+Sukenickauthor=J.+W.+Locasaleauthor=R.+G.+Blasbergauthor=J.+A.+Koutcherauthor=E.+Ackerstaff&title=Metabolic+plasticity+of+metastatic+breast+cancer+cells%3A+adaptation+to+changes+in+the+microenvironment&doi=10.1016%2Fj.neo.2015.08.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic Plasticity of Metastatic Breast Cancer Cells: Adaptation to Changes in the Microenvironment</span></div><div class="casAuthors">Simoes, Rui V.; Serganova, Inna S.; Kruchevsky, Natalia; Leftin, Avigdor; Shestov, Alexander A.; Thaler, Howard T.; Sukenick, George; Locasale, Jason W.; Blasberg, Ronald G.; Koutcher, Jason A.; Ackerstaff, Ellen</div><div class="citationInfo"><span class="NLM_cas:title">Neoplasia (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">671-684</span>CODEN:
                <span class="NLM_cas:coden">NEOPFL</span>;
        ISSN:<span class="NLM_cas:issn">1476-5586</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Cancer cells adapt their metab. during tumorigenesis.  We studied two isogenic breast cancer cells lines (highly metastatic 4T1; nonmetastatic 67NR) to identify differences in their glucose and glutamine metab. in response to metabolic and environmental stress.  Dynamic magnetic resonance spectroscopy of 13C-isotopomers showed that 4T1 cells have higher glycolytic and tricarboxylic acid (TCA) cycle flux than 67NR cells and readily switch between glycolysis and oxidative phosphorylation (OXPHOS) in response to different extracellular environments.  OXPHOS activity increased with metastatic potential in isogenic cell lines derived from the same primary breast cancer: 4T1 > 4T07 and 168FARN (local micrometastasis only) > 67NR.  We obsd. a restricted TCA cycle flux at the succinate dehydrogenase step in 67NR cells (but not in 4T1 cells), leading to succinate accumulation and hindering OXPHOS.  In the four isogenic cell lines, environmental stresses modulated succinate dehydrogenase subunit A expression according to metastatic potential.  Moreover, glucose-derived lactate prodn. was more glutamine dependent in cell lines with higher metastatic potential.  These studies show clear differences in TCA cycle metab. between 4T1 and 67NR breast cancer cells.  They indicate that metastases-forming 4T1 cells are more adept at adjusting their metab. in response to environmental stress than isogenic, nonmetastatic 67NR cells.  We suggest that the metabolic plasticity and adaptability are more important to the metastatic breast cancer phenotype than rapid cell proliferation alone, which could 1) provide a new biomarker for early detection of this phenotype, possibly at the time of diagnosis, and 2) lead to new treatment strategies of metastatic breast cancer by targeting mitochondrial metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCrwKHrIpvVbVg90H21EOLACvtfcHk0lhzDk-v8iiyVw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVeqtbjL&md5=2a4d5e141435c89d3d99da04474d3773</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2Fj.neo.2015.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neo.2015.08.005%26sid%3Dliteratum%253Aachs%26aulast%3DSimoes%26aufirst%3DR.%2BV.%26aulast%3DSerganova%26aufirst%3DI.%2BS.%26aulast%3DKruchevsky%26aufirst%3DN.%26aulast%3DLeftin%26aufirst%3DA.%26aulast%3DShestov%26aufirst%3DA.%2BA.%26aulast%3DThaler%26aufirst%3DH.%2BT.%26aulast%3DSukenick%26aufirst%3DG.%26aulast%3DLocasale%26aufirst%3DJ.%2BW.%26aulast%3DBlasberg%26aufirst%3DR.%2BG.%26aulast%3DKoutcher%26aufirst%3DJ.%2BA.%26aulast%3DAckerstaff%26aufirst%3DE.%26atitle%3DMetabolic%2520plasticity%2520of%2520metastatic%2520breast%2520cancer%2520cells%253A%2520adaptation%2520to%2520changes%2520in%2520the%2520microenvironment%26jtitle%3DNeoplasia%26date%3D2015%26volume%3D17%26spage%3D671%26epage%3D684%26doi%3D10.1016%2Fj.neo.2015.08.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scotland, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saland, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skuli, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Toni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boutzen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Micklow, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senegas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peyraud, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peyriga, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theodoro, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martineau, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danet-Desnoyers, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bono, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levade, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manenti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Junot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portais, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alet, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Recher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selak, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarry, J. E.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial energetic and AKT status mediate metabolic effects and apoptosis of metformin in human leukemic cells</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">2129</span>â <span class="NLM_lpage">2138</span>, <span class="refDoi">Â DOI: 10.1038/leu.2013.107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fleu.2013.107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=23568147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslaru7zO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=2129-2138&author=S.+Scotlandauthor=E.+Salandauthor=N.+Skuliauthor=F.+de+Toniauthor=H.+Boutzenauthor=E.+Micklowauthor=I.+Senegasauthor=R.+Peyraudauthor=L.+Peyrigaauthor=F.+Theodoroauthor=E.+Dumonauthor=Y.+Martineauauthor=G.+Danet-Desnoyersauthor=F.+Bonoauthor=C.+Rocherauthor=T.+Levadeauthor=S.+Manentiauthor=C.+Junotauthor=J.+C.+Portaisauthor=N.+Aletauthor=C.+Recherauthor=M.+A.+Selakauthor=M.+Carrollauthor=J.+E.+Sarry&title=Mitochondrial+energetic+and+AKT+status+mediate+metabolic+effects+and+apoptosis+of+metformin+in+human+leukemic+cells&doi=10.1038%2Fleu.2013.107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial energetic and AKT status mediate metabolic effects and apoptosis of metformin in human leukemic cells</span></div><div class="casAuthors">Scotland, S.; Saland, E.; Skuli, N.; de Toni, F.; Boutzen, H.; Micklow, E.; Senegas, I.; Peyraud, R.; Peyriga, L.; Theodoro, F.; Dumon, E.; Martineau, Y.; Danet-Desnoyers, G.; Bono, F.; Rocher, C.; Levade, T.; Manenti, S.; Junot, C.; Portais, J-C.; Alet, N.; Recher, C.; Selak, M. A.; Carroll, M.; Sarry, J-E.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2129-2138</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Previous reports demonstrate that metformin, an anti-diabetic drug, can decrease the risk of cancer and inhibit cancer cell growth.  However, its mechanism in cancer cells is still unknown.  Metformin significantly blocks cell cycle and inhibits cell proliferation and colony formation of leukemic cells.  However, the apoptotic response to metformin varies.  Furthermore, daily treatment with metformin induces apoptosis and reduces tumor growth in vivo.  While metformin induces early and transient activation of AMPK, inhibition of AMPKÎ±1/2 does not abrogate anti-proliferative or pro-apoptotic effects of metformin.  Metformin decreases electron transport chain complex I activity, oxygen consumption and mitochondrial ATP synthesis, while stimulating glycolysis for ATP and lactate prodn., pentose phosphate pathway for purine biosynthesis, fatty acid metab., as well as anaplerotic and mitochondrial gene expression.  Importantly, leukemic cells with high basal AKT phosphorylation, glucose consumption or glycolysis exhibit a markedly reduced induction of the Pasteur effect in response to metformin and are resistant to metformin-induced apoptosis.  Accordingly, glucose starvation or treatment with deoxyglucose or an AKT inhibitor induces sensitivity to metformin.  Overall, metformin elicits reprogramming of intermediary metab. leading to inhibition of cell proliferation in all leukemic cells and apoptosis only in leukemic cells responding to metformin with AKT phosphorylation and a strong Pasteur effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRpmYpLAxu5bVg90H21EOLACvtfcHk0lizsYJrefqpNg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslaru7zO&md5=1d317587f742965aa66a4f311abeed7d</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1038%2Fleu.2013.107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2013.107%26sid%3Dliteratum%253Aachs%26aulast%3DScotland%26aufirst%3DS.%26aulast%3DSaland%26aufirst%3DE.%26aulast%3DSkuli%26aufirst%3DN.%26aulast%3Dde%2BToni%26aufirst%3DF.%26aulast%3DBoutzen%26aufirst%3DH.%26aulast%3DMicklow%26aufirst%3DE.%26aulast%3DSenegas%26aufirst%3DI.%26aulast%3DPeyraud%26aufirst%3DR.%26aulast%3DPeyriga%26aufirst%3DL.%26aulast%3DTheodoro%26aufirst%3DF.%26aulast%3DDumon%26aufirst%3DE.%26aulast%3DMartineau%26aufirst%3DY.%26aulast%3DDanet-Desnoyers%26aufirst%3DG.%26aulast%3DBono%26aufirst%3DF.%26aulast%3DRocher%26aufirst%3DC.%26aulast%3DLevade%26aufirst%3DT.%26aulast%3DManenti%26aufirst%3DS.%26aulast%3DJunot%26aufirst%3DC.%26aulast%3DPortais%26aufirst%3DJ.%2BC.%26aulast%3DAlet%26aufirst%3DN.%26aulast%3DRecher%26aufirst%3DC.%26aulast%3DSelak%26aufirst%3DM.%2BA.%26aulast%3DCarroll%26aufirst%3DM.%26aulast%3DSarry%26aufirst%3DJ.%2BE.%26atitle%3DMitochondrial%2520energetic%2520and%2520AKT%2520status%2520mediate%2520metabolic%2520effects%2520and%2520apoptosis%2520of%2520metformin%2520in%2520human%2520leukemic%2520cells%26jtitle%3DLeukemia%26date%3D2013%26volume%3D27%26spage%3D2129%26epage%3D2138%26doi%3D10.1038%2Fleu.2013.107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baccelli, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gareau, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehnertz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingras, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinella, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corneau, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayotte, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frechette, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blouin-Chagnon, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leveille, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boivin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacRae, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krosl, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiollier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavallee, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanshin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertomeu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulombe-Huntington, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St-Denis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordeleau, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucher, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roux, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemieux, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thibault, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hebert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauvageau, G.</span></span> <span> </span><span class="NLM_article-title">Mubritinib targets the electron transport chain complex I and reveals the landscape of OXPHOS dependency in acute myeloid leukemia</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">84</span>â <span class="NLM_lpage">99</span>, <span class="refDoi">Â DOI: 10.1016/j.ccell.2019.06.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.ccell.2019.06.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=31287994" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlersbzO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2019&pages=84-99&author=I.+Baccelliauthor=Y.+Gareauauthor=B.+Lehnertzauthor=S.+Gingrasauthor=J.+F.+Spinellaauthor=S.+Corneauauthor=N.+Mayotteauthor=S.+Girardauthor=M.+Frechetteauthor=V.+Blouin-Chagnonauthor=K.+Leveilleauthor=I.+Boivinauthor=T.+MacRaeauthor=J.+Kroslauthor=C.+Thiollierauthor=V.+P.+Lavalleeauthor=E.+Kanshinauthor=T.+Bertomeuauthor=J.+Coulombe-Huntingtonauthor=C.+St-Denisauthor=M.+E.+Bordeleauauthor=G.+Boucherauthor=P.+P.+Rouxauthor=S.+Lemieuxauthor=M.+Tyersauthor=P.+Thibaultauthor=J.+Hebertauthor=A.+Marinierauthor=G.+Sauvageau&title=Mubritinib+targets+the+electron+transport+chain+complex+I+and+reveals+the+landscape+of+OXPHOS+dependency+in+acute+myeloid+leukemia&doi=10.1016%2Fj.ccell.2019.06.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Mubritinib Targets the Electron Transport Chain Complex I and Reveals the Landscape of OXPHOS Dependency in Acute Myeloid Leukemia</span></div><div class="casAuthors">Baccelli, Irene; Gareau, Yves; Lehnertz, Bernhard; Gingras, Stephane; Spinella, Jean-Francois; Corneau, Sophie; Mayotte, Nadine; Girard, Simon; Frechette, Melanie; Blouin-Chagnon, Valerie; Leveille, Koryne; Boivin, Isabel; MacRae, Tara; Krosl, Jana; Thiollier, Clarisse; Lavallee, Vincent-Philippe; Kanshin, Evgeny; Bertomeu, Thierry; Coulombe-Huntington, Jasmin; St-Denis, Corinne; Bordeleau, Marie-Eve; Boucher, Genevieve; Roux, Philippe P.; Lemieux, Sebastien; Tyers, Mike; Thibault, Pierre; Hebert, Josee; Marinier, Anne; Sauvageau, Guy</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">84-99.e8</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">To identify therapeutic targets in acute myeloid leukemia (AML), we chem. interrogated 200 sequenced primary specimens.  Mubritinib, a known ERBB2 inhibitor, elicited strong anti-leukemic effects in vitro and in vivo.  In the context of AML, mubritinib functions through ubiquinone-dependent inhibition of electron transport chain (ETC) complex I activity.  Resistance to mubritinib characterized normal CD34+ hematopoietic cells and chemotherapy-sensitive AMLs, which displayed transcriptomic hallmarks of hypoxia.  Conversely, sensitivity correlated with mitochondrial function-related gene expression levels and characterized a large subset of chemotherapy-resistant AMLs with oxidative phosphorylation (OXPHOS) hyperactivity.  Altogether, our work thus identifies an ETC complex I inhibitor and reveals the genetic landscape of OXPHOS dependency in AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra90vl42LHXrVg90H21EOLACvtfcHk0lizsYJrefqpNg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlersbzO&md5=f2627e1db6c0cddd427a44eba0ac9dd9</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2019.06.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2019.06.003%26sid%3Dliteratum%253Aachs%26aulast%3DBaccelli%26aufirst%3DI.%26aulast%3DGareau%26aufirst%3DY.%26aulast%3DLehnertz%26aufirst%3DB.%26aulast%3DGingras%26aufirst%3DS.%26aulast%3DSpinella%26aufirst%3DJ.%2BF.%26aulast%3DCorneau%26aufirst%3DS.%26aulast%3DMayotte%26aufirst%3DN.%26aulast%3DGirard%26aufirst%3DS.%26aulast%3DFrechette%26aufirst%3DM.%26aulast%3DBlouin-Chagnon%26aufirst%3DV.%26aulast%3DLeveille%26aufirst%3DK.%26aulast%3DBoivin%26aufirst%3DI.%26aulast%3DMacRae%26aufirst%3DT.%26aulast%3DKrosl%26aufirst%3DJ.%26aulast%3DThiollier%26aufirst%3DC.%26aulast%3DLavallee%26aufirst%3DV.%2BP.%26aulast%3DKanshin%26aufirst%3DE.%26aulast%3DBertomeu%26aufirst%3DT.%26aulast%3DCoulombe-Huntington%26aufirst%3DJ.%26aulast%3DSt-Denis%26aufirst%3DC.%26aulast%3DBordeleau%26aufirst%3DM.%2BE.%26aulast%3DBoucher%26aufirst%3DG.%26aulast%3DRoux%26aufirst%3DP.%2BP.%26aulast%3DLemieux%26aufirst%3DS.%26aulast%3DTyers%26aufirst%3DM.%26aulast%3DThibault%26aufirst%3DP.%26aulast%3DHebert%26aufirst%3DJ.%26aulast%3DMarinier%26aufirst%3DA.%26aulast%3DSauvageau%26aufirst%3DG.%26atitle%3DMubritinib%2520targets%2520the%2520electron%2520transport%2520chain%2520complex%2520I%2520and%2520reveals%2520the%2520landscape%2520of%2520OXPHOS%2520dependency%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DCancer%2520Cell%26date%3D2019%26volume%3D36%26spage%3D84%26epage%3D99%26doi%3D10.1016%2Fj.ccell.2019.06.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ye, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, X. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, G. S.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial and energy metabolism-related properties as novel indicators of lung cancer stem cells</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">820</span>â <span class="NLM_lpage">831</span>, <span class="refDoi">Â DOI: 10.1002/ijc.25944</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1002%2Fijc.25944" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=21520032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnvFansrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2011&pages=820-831&author=X.+Q.+Yeauthor=Q.+Liauthor=G.+H.+Wangauthor=F.+F.+Sunauthor=G.+J.+Huangauthor=X.+W.+Bianauthor=S.+C.+Yuauthor=G.+S.+Qian&title=Mitochondrial+and+energy+metabolism-related+properties+as+novel+indicators+of+lung+cancer+stem+cells&doi=10.1002%2Fijc.25944"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial and energy metabolism-related properties as novel indicators of lung cancer stem cells</span></div><div class="casAuthors">Ye, Xiao-Qun; Li, Qi; Wang, Guang-Hui; Sun, Fen-Fen; Huang, Gui-Jun; Bian, Xiu-Wu; Yu, Shi-Cang; Qian, Gui-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">820-831</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Energy metab. is the foundation of survival for all organisms, and mitochondria are the most important energy-supplying organelles in eukaryotic cells.  However, the mitochondrial and energy/metab.-related properties of cancer stem cells (CSCs), the stem cell-like subpopulation in tumor masses, remain unknown.  In our study, we compared the masses of mitochondria and mitochondrial DNA (mtDNA), the mitochondrial membrane potential (ÎÏm), oxygen/glucose consumption, and the concn. of reactive oxygen species (ROS) and ATP between lung CSCs (LCSCs) and non-LCSCs.  In addn., the change in features during differentiation was examd.  Some mitochondrial and energy metab.-related properties, such as perinuclear mitochondrial distribution, a lower quantity of mtDNA, higher ÎÏm, lower oxygen/glucose consumption, and lower intracellular concns. of ROS and ATP, can be used as indicators of LCSCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5oGtdCBkC3LVg90H21EOLACvtfcHk0lizsYJrefqpNg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnvFansrw%253D&md5=dbd5de94171982142f01b6b6dcff2af2</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1002%2Fijc.25944&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.25944%26sid%3Dliteratum%253Aachs%26aulast%3DYe%26aufirst%3DX.%2BQ.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DG.%2BH.%26aulast%3DSun%26aufirst%3DF.%2BF.%26aulast%3DHuang%26aufirst%3DG.%2BJ.%26aulast%3DBian%26aufirst%3DX.%2BW.%26aulast%3DYu%26aufirst%3DS.%2BC.%26aulast%3DQian%26aufirst%3DG.%2BS.%26atitle%3DMitochondrial%2520and%2520energy%2520metabolism-related%2520properties%2520as%2520novel%2520indicators%2520of%2520lung%2520cancer%2520stem%2520cells%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2011%26volume%3D129%26spage%3D820%26epage%3D831%26doi%3D10.1002%2Fijc.25944" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janiszewska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suva, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riggi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamenkovic, I.</span></span> <span> </span><span class="NLM_article-title">Imp2 controls oxidative phosphorylation in glioblastoma cancer stem cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">1926</span>â <span class="NLM_lpage">1944</span>, <span class="refDoi">Â DOI: 10.1158/1538-7445.AM2012-1137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F1538-7445.AM2012-1137" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=1926-1944&author=M.+Janiszewskaauthor=M.+L.+Suvaauthor=N.+Riggiauthor=I.+Stamenkovic&title=Imp2+controls+oxidative+phosphorylation+in+glioblastoma+cancer+stem+cells&doi=10.1158%2F1538-7445.AM2012-1137"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2012-1137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2012-1137%26sid%3Dliteratum%253Aachs%26aulast%3DJaniszewska%26aufirst%3DM.%26aulast%3DSuva%26aufirst%3DM.%2BL.%26aulast%3DRiggi%26aufirst%3DN.%26aulast%3DStamenkovic%26aufirst%3DI.%26atitle%3DImp2%2520controls%2520oxidative%2520phosphorylation%2520in%2520glioblastoma%2520cancer%2520stem%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D1926%26epage%3D1944%26doi%3D10.1158%2F1538-7445.AM2012-1137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sancho, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgos-Ramos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavera, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kheir, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jagust, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoenhals, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barneda, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campos-Olivas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grana, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viera, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuneva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sainz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heeschen, C.</span></span> <span> </span><span class="NLM_article-title">MYC/PGC-1 alpha balance determines the metabolic phenotype and plasticity of pancreatic cancer stem cells</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">590</span>â <span class="NLM_lpage">605</span>, <span class="refDoi">Â DOI: 10.1016/j.cmet.2015.08.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.cmet.2015.08.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=26365176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsV2ls7bM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=590-605&author=P.+Sanchoauthor=E.+Burgos-Ramosauthor=A.+Taveraauthor=T.+B.+Kheirauthor=P.+Jagustauthor=M.+Schoenhalsauthor=D.+Barnedaauthor=K.+Sellersauthor=R.+Campos-Olivasauthor=O.+Granaauthor=C.+R.+Vieraauthor=M.+Yunevaauthor=B.+Sainzauthor=C.+Heeschen&title=MYC%2FPGC-1+alpha+balance+determines+the+metabolic+phenotype+and+plasticity+of+pancreatic+cancer+stem+cells&doi=10.1016%2Fj.cmet.2015.08.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">MYC/PGC-1Î± Balance Determines the Metabolic Phenotype and Plasticity of Pancreatic Cancer Stem Cells</span></div><div class="casAuthors">Sancho, Patricia; Burgos-Ramos, Emma; Tavera, Alejandra; Bou Kheir, Tony; Jagust, Petra; Schoenhals, Matthieu; Barneda, David; Sellers, Katherine; Campos-Olivas, Ramon; Grana, Osvaldo; Viera, Catarina R.; Yuneva, Mariia; Sainz, Bruno, Jr.; Heeschen, Christopher</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">590-605</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The anti-diabetic drug metformin targets pancreatic cancer stem cells (CSCs), but not their differentiated progenies (non-CSCs), which may be related to distinct metabolic phenotypes.  Here we conclusively demonstrate that while non-CSCs were highly glycolytic, CSCs were dependent on oxidative metab. (OXPHOS) with very limited metabolic plasticity.  Thus, mitochondrial inhibition, e.g., by metformin, translated into energy crisis and apoptosis.  However, resistant CSC clones eventually emerged during treatment with metformin due to their intermediate glycolytic/respiratory phenotype.  Mechanistically, suppression of MYC and subsequent increase of PGC-1Î± were identified as key determinants for the OXPHOS dependency of CSCs, which was abolished in resistant CSC clones.  Intriguingly, no resistance was obsd. for the mitochondrial ROS inducer menadione and resistance could also be prevented/reversed for metformin by genetic/pharmacol. inhibition of MYC.  Thus, the specific metabolic features of pancreatic CSCs are amendable to therapeutic intervention and could provide the basis for developing more effective therapies to combat this lethal cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-SwmwcfA1-LVg90H21EOLACvtfcHk0ljW3qMcmtGflQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsV2ls7bM&md5=9ca91da8a48f4d75779cfb2a549ead0a</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2015.08.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2015.08.015%26sid%3Dliteratum%253Aachs%26aulast%3DSancho%26aufirst%3DP.%26aulast%3DBurgos-Ramos%26aufirst%3DE.%26aulast%3DTavera%26aufirst%3DA.%26aulast%3DKheir%26aufirst%3DT.%2BB.%26aulast%3DJagust%26aufirst%3DP.%26aulast%3DSchoenhals%26aufirst%3DM.%26aulast%3DBarneda%26aufirst%3DD.%26aulast%3DSellers%26aufirst%3DK.%26aulast%3DCampos-Olivas%26aufirst%3DR.%26aulast%3DGrana%26aufirst%3DO.%26aulast%3DViera%26aufirst%3DC.%2BR.%26aulast%3DYuneva%26aufirst%3DM.%26aulast%3DSainz%26aufirst%3DB.%26aulast%3DHeeschen%26aufirst%3DC.%26atitle%3DMYC%252FPGC-1%2520alpha%2520balance%2520determines%2520the%2520metabolic%2520phenotype%2520and%2520plasticity%2520of%2520pancreatic%2520cancer%2520stem%2520cells%26jtitle%3DCell%2520Metab.%26date%3D2015%26volume%3D22%26spage%3D590%26epage%3D605%26doi%3D10.1016%2Fj.cmet.2015.08.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giltnane, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balko, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arteaga, C.</span></span> <span> </span><span class="NLM_article-title">MYC and MCL1 cooperatively promote chemotherapy-resistant cancer stem cells through regulation of mitochondrial biogenesis and oxidative phosphorylation</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">633</span>â <span class="NLM_lpage">647</span>, <span class="refDoi">Â DOI: 10.1158/1538-7445.AM2016-3328</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F1538-7445.AM2016-3328" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=633-647&author=K.+M.+Leeauthor=J.+Giltnaneauthor=J.+Balkoauthor=C.+Arteaga&title=MYC+and+MCL1+cooperatively+promote+chemotherapy-resistant+cancer+stem+cells+through+regulation+of+mitochondrial+biogenesis+and+oxidative+phosphorylation&doi=10.1158%2F1538-7445.AM2016-3328"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2016-3328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2016-3328%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%2BM.%26aulast%3DGiltnane%26aufirst%3DJ.%26aulast%3DBalko%26aufirst%3DJ.%26aulast%3DArteaga%26aufirst%3DC.%26atitle%3DMYC%2520and%2520MCL1%2520cooperatively%2520promote%2520chemotherapy-resistant%2520cancer%2520stem%2520cells%2520through%2520regulation%2520of%2520mitochondrial%2520biogenesis%2520and%2520oxidative%2520phosphorylation%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26spage%3D633%26epage%3D647%26doi%3D10.1158%2F1538-7445.AM2016-3328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lagadinou, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sach, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callahan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neering, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minhajuddin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grose, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâDwyer, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liesveld, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brookes, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, C. T.</span></span> <span> </span><span class="NLM_article-title">BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells</span>. <i>Cell Stem Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">329</span>â <span class="NLM_lpage">341</span>, <span class="refDoi">Â DOI: 10.1016/j.stem.2012.12.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.stem.2012.12.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=23333149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Gntbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=329-341&author=E.+D.+Lagadinouauthor=A.+Sachauthor=K.+Callahanauthor=R.+M.+Rossiauthor=S.+J.+Neeringauthor=M.+Minhajuddinauthor=J.+M.+Ashtonauthor=S.+S.+Peiauthor=V.+Groseauthor=K.+M.+O%E2%80%99Dwyerauthor=J.+L.+Liesveldauthor=P.+S.+Brookesauthor=M.+W.+Beckerauthor=C.+T.+Jordan&title=BCL-2+inhibition+targets+oxidative+phosphorylation+and+selectively+eradicates+quiescent+human+leukemia+stem+cells&doi=10.1016%2Fj.stem.2012.12.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells</span></div><div class="casAuthors">Lagadinou, Eleni D.; Sach, Alexander; Callahan, Kevin; Rossi, Randall M.; Neering, Sarah J.; Minhajuddin, Mohammad; Ashton, John M.; Pei, Shanshan; Grose, Valerie; O'Dwyer, Kristen M.; Liesveld, Jane L.; Brookes, Paul S.; Becker, Michael W.; Jordan, Craig T.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Stem Cell</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-341</span>CODEN:
                <span class="NLM_cas:coden">CSCEC4</span>;
        ISSN:<span class="NLM_cas:issn">1875-9777</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Most forms of chemotherapy employ mechanisms involving induction of oxidative stress, a strategy that can be effective due to the elevated oxidative state commonly obsd. in cancer cells.  However, recent studies have shown that relative redox levels in primary tumors can be heterogeneous, suggesting that regimens dependent on differential oxidative state may not be uniformly effective.  To investigate this issue in hematol. malignancies, we evaluated mechanisms controlling oxidative state in primary specimens derived from acute myelogenous leukemia (AML) patients.  Our studies demonstrate three striking findings.  First, the majority of functionally defined leukemia stem cells (LSCs) are characterized by relatively low levels of reactive oxygen species (termed "ROS-low").  Second, ROS-low LSCs aberrantly overexpress BCL-2.  Third, BCL-2 inhibition reduced oxidative phosphorylation and selectively eradicated quiescent LSCs.  Based on these findings, we propose a model wherein the unique physiol. of ROS-low LSCs provides an opportunity for selective targeting via disruption of BCL-2-dependent oxidative phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfldXzIARw0rVg90H21EOLACvtfcHk0ljW3qMcmtGflQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Gntbs%253D&md5=182aff14ca9f1ab26a13a9fb7e59c0a0</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2Fj.stem.2012.12.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.stem.2012.12.013%26sid%3Dliteratum%253Aachs%26aulast%3DLagadinou%26aufirst%3DE.%2BD.%26aulast%3DSach%26aufirst%3DA.%26aulast%3DCallahan%26aufirst%3DK.%26aulast%3DRossi%26aufirst%3DR.%2BM.%26aulast%3DNeering%26aufirst%3DS.%2BJ.%26aulast%3DMinhajuddin%26aufirst%3DM.%26aulast%3DAshton%26aufirst%3DJ.%2BM.%26aulast%3DPei%26aufirst%3DS.%2BS.%26aulast%3DGrose%26aufirst%3DV.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DK.%2BM.%26aulast%3DLiesveld%26aufirst%3DJ.%2BL.%26aulast%3DBrookes%26aufirst%3DP.%2BS.%26aulast%3DBecker%26aufirst%3DM.%2BW.%26aulast%3DJordan%26aufirst%3DC.%2BT.%26atitle%3DBCL-2%2520inhibition%2520targets%2520oxidative%2520phosphorylation%2520and%2520selectively%2520eradicates%2520quiescent%2520human%2520leukemia%2520stem%2520cells%26jtitle%3DCell%2520Stem%2520Cell%26date%3D2013%26volume%3D12%26spage%3D329%26epage%3D341%26doi%3D10.1016%2Fj.stem.2012.12.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janiszewska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suva, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riggi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houtkooper, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auwerx, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clement-Schatlo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radovanovic, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rheinbay, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Provero, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamenkovic, I.</span></span> <span> </span><span class="NLM_article-title">Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells</span>. <i>Genes Dev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1926</span>â <span class="NLM_lpage">1944</span>, <span class="refDoi">Â DOI: 10.1101/gad.188292.112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1101%2Fgad.188292.112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=22899010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVSlsb3K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=1926-1944&author=M.+Janiszewskaauthor=M.+L.+Suvaauthor=N.+Riggiauthor=R.+H.+Houtkooperauthor=J.+Auwerxauthor=V.+Clement-Schatloauthor=I.+Radovanovicauthor=E.+Rheinbayauthor=P.+Proveroauthor=I.+Stamenkovic&title=Imp2+controls+oxidative+phosphorylation+and+is+crucial+for+preserving+glioblastoma+cancer+stem+cells&doi=10.1101%2Fgad.188292.112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells</span></div><div class="casAuthors">Janiszewska, Michalina; Suva, Mario L.; Riggi, Nicolo; Houtkooper, Riekelt H.; Auwerz, Johan; Clement-Schatlo, Virginie; Radovanovic, Ivan; Rheinbay, Esther; Provero, Paolo; Stamenkovic, Ivan</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1926-1944</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">Growth of numerous cancer types is believed to be driven by a subpopulation of poorly differentiated cells, often referred to as cancer stem cells (CSCs), that have the capacity for self-renewal, tumor initiation, and generation of nontumorigenic progeny.  Despite their potentially key role in tumor establishment and maintenance, the energy requirements of these cells and the mechanisms that regulate their energy prodn. are unknown.  Here, we show that the oncofetal insulin-like growth factor 2 mRNA-binding protein 2 (IMP2, IGF2BP2) regulates oxidative phosphorylation (OXPHOS) in primary glioblastoma (GBM) sphere cultures (gliomaspheres), an established in vitro model for CSC expansion.  We demonstrate that IMP2 binds several mRNAs that encode mitochondrial respiratory chain complex subunits and that it interacts with complex I (NADH:ubiquinone oxidoreductase) proteins.  Depletion of IMP2 in gliomaspheres decreases their oxygen consumption rate and both complex I and complex IV activity that results in impaired clonogenicity in vitro and tumorigenicity in vivo.  Importantly, inhibition of OXPHOS but not of glycolysis abolishes GBM cell clonogenicity.  Our observations suggest that gliomaspheres depend on OXPHOS for their energy prodn. and survival and that IMP2 expression provides a key mechanism to ensure OXPHOS maintenance by delivering respiratory chain subunit-encoding mRNAs to mitochondria and contributing to complex I and complex IV assembly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQUr96F-y-SLVg90H21EOLACvtfcHk0lht5M-Uw5unFg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVSlsb3K&md5=93f963a970386a4eb584b284349f0908</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1101%2Fgad.188292.112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.188292.112%26sid%3Dliteratum%253Aachs%26aulast%3DJaniszewska%26aufirst%3DM.%26aulast%3DSuva%26aufirst%3DM.%2BL.%26aulast%3DRiggi%26aufirst%3DN.%26aulast%3DHoutkooper%26aufirst%3DR.%2BH.%26aulast%3DAuwerx%26aufirst%3DJ.%26aulast%3DClement-Schatlo%26aufirst%3DV.%26aulast%3DRadovanovic%26aufirst%3DI.%26aulast%3DRheinbay%26aufirst%3DE.%26aulast%3DProvero%26aufirst%3DP.%26aulast%3DStamenkovic%26aufirst%3DI.%26atitle%3DImp2%2520controls%2520oxidative%2520phosphorylation%2520and%2520is%2520crucial%2520for%2520preserving%2520glioblastoma%2520cancer%2520stem%2520cells%26jtitle%3DGenes%2520Dev.%26date%3D2012%26volume%3D26%26spage%3D1926%26epage%3D1944%26doi%3D10.1101%2Fgad.188292.112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fiorillo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanowitz, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappello, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Outschoorn, U. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotgia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lisanti, M. P.</span></span> <span> </span><span class="NLM_article-title">Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs)</span>. <i>Aging</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1593</span>â <span class="NLM_lpage">1607</span>, <span class="refDoi">Â DOI: 10.18632/aging.100983</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.18632%2Faging.100983" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27344270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotlyrtb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=1593-1607&author=M.+Fiorilloauthor=R.+Lambauthor=H.+B.+Tanowitzauthor=A.+R.+Cappelloauthor=U.+E.+Martinez-Outschoornauthor=F.+Sotgiaauthor=M.+P.+Lisanti&title=Bedaquiline%2C+an+FDA-approved+antibiotic%2C+inhibits+mitochondrial+function+and+potently+blocks+the+proliferative+expansion+of+stem-like+cancer+cells+%28CSCs%29&doi=10.18632%2Faging.100983"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs)</span></div><div class="casAuthors">Fiorillo, Marco; Lamb, Rebecca; Tanowitz, Herbert B.; Cappello, Anna Rita; Martinez-Outschoorn, Ubaldo E.; Sotgia, Federica; Lisanti, Michael P.</div><div class="citationInfo"><span class="NLM_cas:title">Aging</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1593-1607</span>CODEN:
                <span class="NLM_cas:coden">AGINCN</span>;
        ISSN:<span class="NLM_cas:issn">1945-4589</span>.
    
            (<span class="NLM_cas:orgname">Impact Journals LLC</span>)
        </div><div class="casAbstract">Bedaquiline (a.k.a., Sirturo) is an anti-microbial agent, which is approved by the FDA for the treatment of multi-drug resistant pulmonary tuberculosis (TB).  Bedaquiline is a first-in-class diaryl-quinoline compd., that mechanistically inhibits the bacterial ATP-synthase, and shows potent activity against both drug-sensitive and drug-resistant TB.  Interestingly, eukaryotic mitochondria originally evolved from engulfed aerobic bacteria.  Thus, we hypothesized that, in mammalian cells, bedaquiline might also target the mitochondrial ATP-synthase, leading to mitochondrial dysfunction and ATP depletion.  Here, we show that bedaquiline has anti-cancer activity, directed against Cancer Stem-like Cells (CSCs).  More specifically, we demonstrate that bedaquiline treatment of MCF7 breast cancer cells inhibits mitochondrial oxygen-consumption, as well as glycolysis, but induces oxidative stress.  Importantly, bedaquiline significantly blocks the propagation and expansion of MCF7-derived CSCs, with an IC-50 of approx. 1-Î¼M, as detd. using the mammosphere assay.  Similarly, bedaquiline also reduces both the CD44+/CD24low/- CSC and ALDH+ CSC populations, under anchorage-independent growth conditions.  In striking contrast, bedaquiline significantly increases oxygen consumption in normal human fibroblasts, consistent with the fact that it is well-tolerated in patients treated for TB infections.  As such, future pre-clin. studies and human clin. trials in cancer patients may be warranted.  Interestingly, we also highlight that bedaquiline shares certain structural similarities with trans-piceatannol and trans-resveratrol, which are known natural flavonoid inhibitors of the mitochondrial ATP-synthase (complex V) and show anti-aging properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBH-lz9QVs9bVg90H21EOLACvtfcHk0lht5M-Uw5unFg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotlyrtb0%253D&md5=f5a17262b385e1b1a6c0cb6c91dee919</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.18632%2Faging.100983&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Faging.100983%26sid%3Dliteratum%253Aachs%26aulast%3DFiorillo%26aufirst%3DM.%26aulast%3DLamb%26aufirst%3DR.%26aulast%3DTanowitz%26aufirst%3DH.%2BB.%26aulast%3DCappello%26aufirst%3DA.%2BR.%26aulast%3DMartinez-Outschoorn%26aufirst%3DU.%2BE.%26aulast%3DSotgia%26aufirst%3DF.%26aulast%3DLisanti%26aufirst%3DM.%2BP.%26atitle%3DBedaquiline%252C%2520an%2520FDA-approved%2520antibiotic%252C%2520inhibits%2520mitochondrial%2520function%2520and%2520potently%2520blocks%2520the%2520proliferative%2520expansion%2520of%2520stem-like%2520cancer%2520cells%2520%2528CSCs%2529%26jtitle%3DAging%26date%3D2016%26volume%3D8%26spage%3D1593%26epage%3D1607%26doi%3D10.18632%2Faging.100983" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, P. M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shieh, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jan, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuang, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, A. T. H.</span></span> <span> </span><span class="NLM_article-title">A preclinical evaluation of antimycin A as a potential antilung cancer stem cell agent</span>. <i>Evid. Based Complement. Alternat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>2013</i></span>,  <span class="NLM_fpage">1</span>, <span class="refDoi">Â DOI: 10.1155/2013/910451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1155%2F2013%2F910451" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2013&publication_year=2013&pages=1&author=C.+T.+Yehauthor=C.+L.+Suauthor=C.+Y.+F.+Huangauthor=J.+K.+Y.+Linauthor=W.+H.+Leeauthor=P.+M.+H.+Changauthor=Y.+L.+Kuoauthor=Y.+W.+Liuauthor=L.+S.+Wangauthor=C.+H.+Wuauthor=Y.+S.+Shiehauthor=Y.+H.+Janauthor=Y.+J.+Chuangauthor=M.+Hsiaoauthor=A.+T.+H.+Wu&title=A+preclinical+evaluation+of+antimycin+A+as+a+potential+antilung+cancer+stem+cell+agent&doi=10.1155%2F2013%2F910451"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1155%2F2013%2F910451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2013%252F910451%26sid%3Dliteratum%253Aachs%26aulast%3DYeh%26aufirst%3DC.%2BT.%26aulast%3DSu%26aufirst%3DC.%2BL.%26aulast%3DHuang%26aufirst%3DC.%2BY.%2BF.%26aulast%3DLin%26aufirst%3DJ.%2BK.%2BY.%26aulast%3DLee%26aufirst%3DW.%2BH.%26aulast%3DChang%26aufirst%3DP.%2BM.%2BH.%26aulast%3DKuo%26aufirst%3DY.%2BL.%26aulast%3DLiu%26aufirst%3DY.%2BW.%26aulast%3DWang%26aufirst%3DL.%2BS.%26aulast%3DWu%26aufirst%3DC.%2BH.%26aulast%3DShieh%26aufirst%3DY.%2BS.%26aulast%3DJan%26aufirst%3DY.%2BH.%26aulast%3DChuang%26aufirst%3DY.%2BJ.%26aulast%3DHsiao%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DA.%2BT.%2BH.%26atitle%3DA%2520preclinical%2520evaluation%2520of%2520antimycin%2520A%2520as%2520a%2520potential%2520antilung%2520cancer%2520stem%2520cell%2520agent%26jtitle%3DEvid.%2520Based%2520Complement.%2520Alternat.%2520Med.%26date%3D2013%26volume%3D2013%26spage%3D1%26doi%3D10.1155%2F2013%2F910451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fryknas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernlund, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fayad, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Milito, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olofsson, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogvadze, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pahlman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schughart, L. A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rickardson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darcy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gullbo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nygren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linder, S.</span></span> <span> </span><span class="NLM_article-title">Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">3295</span>, <span class="refDoi">Â DOI: 10.1038/ncomms4295</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fncomms4295" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=24548894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BC2cvmt1Snuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=3295&author=X.+N.+Zhangauthor=M.+Fryknasauthor=E.+Hernlundauthor=W.+Fayadauthor=A.+De+Militoauthor=M.+H.+Olofssonauthor=V.+Gogvadzeauthor=L.+Dangauthor=S.+Pahlmanauthor=L.+A.+K.+Schughartauthor=L.+Rickardsonauthor=P.+Darcyauthor=J.+Gullboauthor=P.+Nygrenauthor=R.+Larssonauthor=S.+Linder&title=Induction+of+mitochondrial+dysfunction+as+a+strategy+for+targeting+tumour+cells+in+metabolically+compromised+microenvironments&doi=10.1038%2Fncomms4295"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments</span></div><div class="casAuthors">Zhang Xiaonan; Fayad Walid; Fryknas Marten; Hernlund Emma; De Milito Angelo; Olofsson Maria Hagg; D'Arcy Padraig; Gogvadze Vladimir; Dang Long; Pahlman Sven; Schughart Leoni A Kunz; Rickardson Linda; Larsson Rolf; Gullbo Joachim; Nygren Peter; Linder Stig</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3295</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Abnormal vascularization of solid tumours results in the development of microenvironments deprived of oxygen and nutrients that harbour slowly growing and metabolically stressed cells.  Such cells display enhanced resistance to standard chemotherapeutic agents and repopulate tumours after therapy.  Here we identify the small molecule VLX600 as a drug that is preferentially active against quiescent cells in colon cancer 3-D microtissues.  The anticancer activity is associated with reduced mitochondrial respiration, leading to bioenergetic catastrophe and tumour cell death.  VLX600 shows enhanced cytotoxic activity under conditions of nutrient starvation.  Importantly, VLX600 displays tumour growth inhibition in vivo.  Our findings suggest that tumour cells in metabolically compromised microenvironments have a limited ability to respond to decreased mitochondrial function, and suggest a strategy for targeting the quiescent populations of tumour cells for improved cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR5TABksD1e0acY7HFp97qMfW6udTcc2eYPjoR1EicMg7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cvmt1Snuw%253D%253D&md5=0167667cf70a7a672960cd32bf8fe39c</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1038%2Fncomms4295&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms4295%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%2BN.%26aulast%3DFryknas%26aufirst%3DM.%26aulast%3DHernlund%26aufirst%3DE.%26aulast%3DFayad%26aufirst%3DW.%26aulast%3DDe%2BMilito%26aufirst%3DA.%26aulast%3DOlofsson%26aufirst%3DM.%2BH.%26aulast%3DGogvadze%26aufirst%3DV.%26aulast%3DDang%26aufirst%3DL.%26aulast%3DPahlman%26aufirst%3DS.%26aulast%3DSchughart%26aufirst%3DL.%2BA.%2BK.%26aulast%3DRickardson%26aufirst%3DL.%26aulast%3DDarcy%26aufirst%3DP.%26aulast%3DGullbo%26aufirst%3DJ.%26aulast%3DNygren%26aufirst%3DP.%26aulast%3DLarsson%26aufirst%3DR.%26aulast%3DLinder%26aufirst%3DS.%26atitle%3DInduction%2520of%2520mitochondrial%2520dysfunction%2520as%2520a%2520strategy%2520for%2520targeting%2520tumour%2520cells%2520in%2520metabolically%2520compromised%2520microenvironments%26jtitle%3DNat.%2520Commun.%26date%3D2014%26volume%3D5%26spage%3D3295%26doi%3D10.1038%2Fncomms4295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zacksenhaus, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrestha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vorobieva, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, P. E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ju, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nir, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial OXPHOS induced by RB1 deficiency in breast cancer: implications for anabolic metabolism, stemness, and metastasis</span>. <i>Trends in Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">768</span>â <span class="NLM_lpage">779</span>, <span class="refDoi">Â DOI: 10.1016/j.trecan.2017.09.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.trecan.2017.09.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=29120753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1MXksVygsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=768-779&author=E.+Zacksenhausauthor=M.+Shresthaauthor=J.+C.+Liuauthor=I.+Vorobievaauthor=P.+E.+D.+Chungauthor=Y.+J.+Juauthor=U.+Nirauthor=Z.+Jiang&title=Mitochondrial+OXPHOS+induced+by+RB1+deficiency+in+breast+cancer%3A+implications+for+anabolic+metabolism%2C+stemness%2C+and+metastasis&doi=10.1016%2Fj.trecan.2017.09.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial OXPHOS Induced by RB1 Deficiency in Breast Cancer: Implications for Anabolic Metabolism, Stemness, and Metastasis</span></div><div class="casAuthors">Zacksenhaus, Eldad; Shrestha, Mariusz; Liu, Jeff C.; Vorobieva, Ioulia; Chung, Philip E. D.; Ju, YoungJun; Nir, Uri; Jiang, Zhe</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">768-779</span>CODEN:
                <span class="NLM_cas:coden">TCRAB5</span>;
        ISSN:<span class="NLM_cas:issn">2405-8033</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  A switch from catabolic to anabolic metab., a major hallmark of cancer, enables rapid cell duplication, and is driven by multiple oncogenic alterations, including PIK3CA mutation, MYC amplification, and TP53 loss.  However, tumor growth requires active mitochondrial function and oxidative phosphorylation (OXPHOS).  Recently, loss of the retinoblastoma (RB1) tumor suppressor in breast cancer was shown to induce mitochondrial protein translation (MPT) and OXPHOS.  Here, we discuss how increased OXPHOS can enhance anabolic metab. and cell proliferation, as well as cancer stemness and metastasis.  Mitochondrial STAT3, FER/FER-T, and CHCHD2 are also implicated in OXPHOS.  We propose that RB1 loss represents a prototypic oncogenic alteration that promotes OXPHOS, that aggressive tumors acquire lethal combinations of oncogenes and tumor suppressors that stimulate anabolism vs. OXPHOS, and that targeting both metabolic pathways would be therapeutic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqG3gGHwo-LLbVg90H21EOLACvtfcHk0ljbYvsRmQZUNA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXksVygsA%253D%253D&md5=09d3a5508deb5c89be61d39f6551de60</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1016%2Fj.trecan.2017.09.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.trecan.2017.09.002%26sid%3Dliteratum%253Aachs%26aulast%3DZacksenhaus%26aufirst%3DE.%26aulast%3DShrestha%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DJ.%2BC.%26aulast%3DVorobieva%26aufirst%3DI.%26aulast%3DChung%26aufirst%3DP.%2BE.%2BD.%26aulast%3DJu%26aufirst%3DY.%2BJ.%26aulast%3DNir%26aufirst%3DU.%26aulast%3DJiang%26aufirst%3DZ.%26atitle%3DMitochondrial%2520OXPHOS%2520induced%2520by%2520RB1%2520deficiency%2520in%2520breast%2520cancer%253A%2520implications%2520for%2520anabolic%2520metabolism%252C%2520stemness%252C%2520and%2520metastasis%26jtitle%3DTrends%2520in%2520Cancer%26date%3D2017%26volume%3D3%26spage%3D768%26epage%3D779%26doi%3D10.1016%2Fj.trecan.2017.09.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrestha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voisin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ju, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellecchia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fell, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muthuswamy, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Datti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egan, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schimmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zacksenhaus, E.</span></span> <span> </span><span class="NLM_article-title">RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">3739</span>â <span class="NLM_lpage">3757</span>, <span class="refDoi">Â DOI: 10.1172/JCI81568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1172%2FJCI81568" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27571409" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BC2szltVOqsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2016&pages=3739-3757&author=R.+A.+Jonesauthor=T.+J.+Robinsonauthor=J.+C.+Liuauthor=M.+Shresthaauthor=V.+Voisinauthor=Y.+Juauthor=P.+E.+Chungauthor=G.+Pellecchiaauthor=V.+L.+Fellauthor=S.+Baeauthor=L.+Muthuswamyauthor=A.+Dattiauthor=S.+E.+Eganauthor=Z.+Jiangauthor=G.+Leoneauthor=G.+D.+Baderauthor=A.+Schimmerauthor=E.+Zacksenhaus&title=RB1+deficiency+in+triple-negative+breast+cancer+induces+mitochondrial+protein+translation&doi=10.1172%2FJCI81568"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation</span></div><div class="casAuthors">Jones Robert A; Robinson Tyler J; Liu Jeff C; Shrestha Mariusz; Voisin Veronique; Ju YoungJun; Chung Philip E D; Pellecchia Giovanna; Fell Victoria L; Bae SooIn; Muthuswamy Lakshmi; Datti Alessandro; Egan Sean E; Jiang Zhe; Leone Gustavo; Bader Gary D; Schimmer Aaron; Zacksenhaus Eldad</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3739-3757</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Triple-negative breast cancer (TNBC) includes basal-like and claudin-low subtypes for which no specific treatment is currently available.  Although the retinoblastoma tumor-suppressor gene (RB1) is frequently lost together with TP53 in TNBC, it is not directly targetable.  There is thus great interest in identifying vulnerabilities downstream of RB1 that can be therapeutically exploited.  Here, we determined that combined inactivation of murine Rb and p53 in diverse mammary epithelial cells induced claudin-low-like TNBC with Met, Birc2/3-Mmp13-Yap1, and Pvt1-Myc amplifications.  Gene set enrichment analysis revealed that Rb/p53-deficient tumors showed elevated expression of the mitochondrial protein translation (MPT) gene pathway relative to tumors harboring p53 deletion alone.  Accordingly, bioinformatic, functional, and biochemical analyses showed that RB1-E2F complexes bind to MPT gene promoters to regulate transcription and control MPT.  Additionally, a screen of US Food and Drug Administration-approved (FDA-approved) drugs identified the MPT antagonist tigecycline (TIG) as a potent inhibitor of Rb/p53-deficient tumor cell proliferation.  TIG preferentially suppressed RB1-deficient TNBC cell proliferation, targeted both the bulk and cancer stem cell fraction, and strongly attenuated xenograft growth.  It also cooperated with sulfasalazine, an FDA-approved inhibitor of cystine xCT antiporter, in culture and xenograft assays.  Our results suggest that RB1 deficiency promotes cancer cell proliferation in part by enhancing mitochondrial function and identify TIG as a clinically approved drug for RB1-deficient TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT4-V_8AROavGhHGZei4OW9fW6udTcc2eYPjoR1EicMg7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2szltVOqsg%253D%253D&md5=c004a203c08d1c20c81ed552184010c0</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1172%2FJCI81568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI81568%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DR.%2BA.%26aulast%3DRobinson%26aufirst%3DT.%2BJ.%26aulast%3DLiu%26aufirst%3DJ.%2BC.%26aulast%3DShrestha%26aufirst%3DM.%26aulast%3DVoisin%26aufirst%3DV.%26aulast%3DJu%26aufirst%3DY.%26aulast%3DChung%26aufirst%3DP.%2BE.%26aulast%3DPellecchia%26aufirst%3DG.%26aulast%3DFell%26aufirst%3DV.%2BL.%26aulast%3DBae%26aufirst%3DS.%26aulast%3DMuthuswamy%26aufirst%3DL.%26aulast%3DDatti%26aufirst%3DA.%26aulast%3DEgan%26aufirst%3DS.%2BE.%26aulast%3DJiang%26aufirst%3DZ.%26aulast%3DLeone%26aufirst%3DG.%26aulast%3DBader%26aufirst%3DG.%2BD.%26aulast%3DSchimmer%26aufirst%3DA.%26aulast%3DZacksenhaus%26aufirst%3DE.%26atitle%3DRB1%2520deficiency%2520in%2520triple-negative%2520breast%2520cancer%2520induces%2520mitochondrial%2520protein%2520translation%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2016%26volume%3D126%26spage%3D3739%26epage%3D3757%26doi%3D10.1172%2FJCI81568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roskoski, R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>152</i></span>,  <span class="NLM_fpage">104609</span>, <span class="refDoi">Â DOI: 10.1016/j.phrs.2019.104609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.phrs.2019.104609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=31862477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisV2ktbrE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2020&pages=104609&author=R.+Roskoski&title=Properties+of+FDA-approved+small+molecule+protein+kinase+inhibitors%3A+A+2020+update&doi=10.1016%2Fj.phrs.2019.104609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update</span></div><div class="casAuthors">Roskoski, Robert Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104609</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Because genetic alterations including mutations, overexpression, translocations, and dysregulation of protein kinases are involved in the pathogenesis of many illnesses, this enzyme family is currently the subject of many drug discovery programs in the pharmaceutical industry.  The US FDA approved four small mol. protein kinase antagonists in 2019; these include entrectinib, erdafitinib, pexidartinib, and fedratinib.  Entrectinib binds to TRKA/B/C and ROS1 and is prescribed for the treatment of solid tumors with NTRK fusion proteins and for ROS1-postive non-small cell lung cancers.  Erdafitinib inhibits fibroblast growth factor receptors 1-4 and is used in the treatment of urothelial bladder cancers.  Pexidartinib is a CSF1R antagonist that is prescribed for the treatment of tenosynovial giant cell tumors.  Fedratinib blocks JAK2 and is used in the treatment of myelofibrosis.  Overall, the US FDA has approved 52 small mol. protein kinase inhibitors, nearly all of which are orally effective with the exceptions of temsirolimus (which is given i.v.) and netarsudil (an eye drop).  Of the 52 approved drugs, eleven inhibit protein-serine/threonine protein kinases, two are directed against dual specificity protein kinases, eleven target non-receptor protein-tyrosine kinases, and 28 block receptor protein-tyrosine kinases.  The data indicate that 46 of these drugs are used in the treatment of neoplastic diseases (eight against non-solid tumors such as leukemias and 41 against solid tumors including breast and lung cancers; some drugs are used against both tumor types).  Eight drugs are employed in the treatment of non-malignancies: fedratinib, myelofibrosis; ruxolitinib, myelofibrosis and polycythemia vera; fostamatinib, chronic immune thrombocytopenia; baricitinib, rheumatoid arthritis; sirolimus, renal graft vs. host disease; nintedanib, idiopathic pulmonary fibrosis; netarsudil, glaucoma; and tofacitinib, rheumatoid arthritis, Crohn disease, and ulcerative colitis.  Moreover, sirolimus and ibrutinib are used for the treatment of both neoplastic and non-neoplastic diseases.  Entrectinib and larotrectinib are tissue-agnostic anti-cancer small mol. protein kinase inhibitors.  These drugs are prescribed for the treatment of any solid cancer harboring NTRK1/2/3 fusion proteins regardless of the organ, tissue, anatomical location, or histol. type.  Of the 52 approved drugs, seventeen are used in the treatment of more than one disease.  Imatinib, for example, is approved for the treatment of eight disparate disorders.  The most common drug targets of the approved pharmaceuticals include BCR-Abl, B-Raf, vascular endothelial growth factor receptors (VEGFR), epidermal growth factor receptors (EGFR), and ALK.  Most of the approved small mol. protein kinase antagonists (49) bind to the protein kinase domain and six of them bind covalently.  In contrast, everolimus, temsirolimus, and sirolimus are larger mols. (MW â 1000) that bind to FK506 binding protein-12 (FKBP-12) to generate a complex that inhibits the mammalian target of rapamycin (mTOR) protein kinase complex.  This review presents the physicochem. properties of all of the FDA-approved small mol. protein kinase inhibitors.  Twenty-two of the 52 drugs have mol. wts. greater than 500, exceeding a Lipinski rule of five criterion.  Excluding the macrolides (everolimus, sirolimus, temsirolimus), the av. mol. wt. of the approved drugs is 480 with a range of 306 (ruxolitinib) to 615 (trametinib).  More than half of the antagonists (29) have lipophilic efficiency values of less than five while the recommended optima range from 5 to 10.  One of the troublesome problems with both targeted and cytotoxic drugs in the treatment of malignant diseases is the near universal development of resistance to every therapeutic modality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRgMvsJqanSLVg90H21EOLACvtfcHk0ljighgT73f5_w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisV2ktbrE&md5=7753f0e8c04a145e15b09b3e55e09cde</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2019.104609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2019.104609%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DProperties%2520of%2520FDA-approved%2520small%2520molecule%2520protein%2520kinase%2520inhibitors%253A%2520A%25202020%2520update%26jtitle%3DPharmacol.%2520Res.%26date%3D2020%26volume%3D152%26spage%3D104609%26doi%3D10.1016%2Fj.phrs.2019.104609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vitiello, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowler, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loo, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Param, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moral, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonescu, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balachandran, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMatteo, R. P.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial inhibition augments the efficacy of imatinib by resetting the metabolic phenotype of gastrointestinal stromal tumor</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">972</span>â <span class="NLM_lpage">984</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-17-2697</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F1078-0432.CCR-17-2697" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=29246941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXislyrtbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=972-984&author=G.+A.+Vitielloauthor=B.+D.+Medinaauthor=S.+Zengauthor=T.+G.+Bowlerauthor=J.+Q.+Zhangauthor=J.+K.+Looauthor=N.+J.+Paramauthor=M.+Liuauthor=A.+J.+Moralauthor=J.+N.+Zhaoauthor=F.+Rossiauthor=C.+R.+Antonescuauthor=V.+P.+Balachandranauthor=J.+R.+Crossauthor=R.+P.+DeMatteo&title=Mitochondrial+inhibition+augments+the+efficacy+of+imatinib+by+resetting+the+metabolic+phenotype+of+gastrointestinal+stromal+tumor&doi=10.1158%2F1078-0432.CCR-17-2697"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial Inhibition Augments the Efficacy of Imatinib by Resetting the Metabolic Phenotype of Gastrointestinal Stromal Tumor</span></div><div class="casAuthors">Vitiello, Gerardo A.; Medina, Benjamin D.; Zeng, Shan; Bowler, Timothy G.; Zhang, Jennifer Q.; Loo, Jennifer K.; Param, Nesteene J.; Liu, Mengyuan; Moral, Alec J.; Zhao, Julia N.; Rossi, Ferdinand; Antonescu, Cristina R.; Balachandran, Vinod P.; Cross, Justin R.; De Matteo, Ronald P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">972-984</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Imatinib dramatically reduces gastrointestinal stromal tumor (GIST) 18F-FDG uptake, providing an early indicator of treatment response.  Despite decreased glucose internalization, many GIST cells persist, suggesting that alternative metabolic pathways are used for survival.  The role of mitochondria in imatinib-treated GIST is largely unknown.  Exptl. Design: We quantified the metabolic activity of several human GIST cell lines.  We treated human GIST xenografts and genetically engineered KitV558del/+ mice with the mitochondrial oxidative phosphorylation inhibitor VLX600 in combination with imatinib and analyzed tumor vol., wt., histol., mol. signaling, and cell cycle activity.  In vitro assays on human GIST cell lines were also performed.  Results: Imatinib therapy decreased glucose uptake and downstream glycolytic activity in GIST-T1 and HG129 cells by approx. half and upregulated mitochondrial enzymes and improved mitochondrial respiratory capacity.  Mitochondrial inhibition with VLX600 had a direct antitumor effect in vitro while appearing to promote glycolysis through increased AKT signaling and glucose transporter expression.  When combined with imatinib, VLX600 prevented imatinib-induced cell cycle escape and reduced p27 expression, leading to increased apoptosis when compared to imatinib alone.  In KitV558del/+ mice, VLX600 alone did not induce tumor cell death, but had a profound antitumor effect when combined with imatinib.  Conclusions: Our findings show that imatinib alters the metabolic phenotype of GIST, and this may contribute to imatinib resistance.  Our work offers preclin. proof of concept of metabolic targeting as an effective strategy for the treatment of GIST.  Clin Cancer Res; 24(4); 972-84. Â©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryVpvwzuJYMLVg90H21EOLACvtfcHk0ljighgT73f5_w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXislyrtbY%253D&md5=b525679a1fbfa2fb1dc3551dfd669e55</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-2697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-2697%26sid%3Dliteratum%253Aachs%26aulast%3DVitiello%26aufirst%3DG.%2BA.%26aulast%3DMedina%26aufirst%3DB.%2BD.%26aulast%3DZeng%26aufirst%3DS.%26aulast%3DBowler%26aufirst%3DT.%2BG.%26aulast%3DZhang%26aufirst%3DJ.%2BQ.%26aulast%3DLoo%26aufirst%3DJ.%2BK.%26aulast%3DParam%26aufirst%3DN.%2BJ.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DMoral%26aufirst%3DA.%2BJ.%26aulast%3DZhao%26aufirst%3DJ.%2BN.%26aulast%3DRossi%26aufirst%3DF.%26aulast%3DAntonescu%26aufirst%3DC.%2BR.%26aulast%3DBalachandran%26aufirst%3DV.%2BP.%26aulast%3DCross%26aufirst%3DJ.%2BR.%26aulast%3DDeMatteo%26aufirst%3DR.%2BP.%26atitle%3DMitochondrial%2520inhibition%2520augments%2520the%2520efficacy%2520of%2520imatinib%2520by%2520resetting%2520the%2520metabolic%2520phenotype%2520of%2520gastrointestinal%2520stromal%2520tumor%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26spage%3D972%26epage%3D984%26doi%3D10.1158%2F1078-0432.CCR-17-2697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haq, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoag, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreu-Perez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edelman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederick, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurley, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nellore, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wargo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arany, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widlund, H. R.</span></span> <span> </span><span class="NLM_article-title">Oncogenic BRAF regulates oxidative metabolism via PGC1 alpha and MITF</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">302</span>â <span class="NLM_lpage">315</span>, <span class="refDoi">Â DOI: 10.1016/j.ccr.2013.02.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.ccr.2013.02.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=23477830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktVOksbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=302-315&author=R.+Haqauthor=J.+Shoagauthor=P.+Andreu-Perezauthor=S.+Yokoyamaauthor=H.+Edelmanauthor=G.+C.+Roweauthor=D.+T.+Frederickauthor=A.+D.+Hurleyauthor=A.+Nelloreauthor=A.+L.+Kungauthor=J.+A.+Wargoauthor=J.+S.+Songauthor=D.+E.+Fisherauthor=Z.+Aranyauthor=H.+R.+Widlund&title=Oncogenic+BRAF+regulates+oxidative+metabolism+via+PGC1+alpha+and+MITF&doi=10.1016%2Fj.ccr.2013.02.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogenic BRAF Regulates Oxidative Metabolism via PGC1Î± and MITF</span></div><div class="casAuthors">Haq, Rizwan; Shoag, Jonathan; Andreu-Perez, Pedro; Yokoyama, Satoru; Edelman, Hannah; Rowe, Glenn C.; Frederick, Dennie T.; Hurley, Aeron D.; Nellore, Abhinav; Kung, Andrew L.; Wargo, Jennifer A.; Song, Jun S.; Fisher, David E.; Arany, Zolt; Widlund, Hans R.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">302-315</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Activating mutations in BRAF are the most common genetic alterations in melanoma.  Inhibition of BRAF by small mols. leads to cell-cycle arrest and apoptosis.  We show here that BRAF inhibition also induces an oxidative phosphorylation gene program, mitochondrial biogenesis, and the increased expression of the mitochondrial master regulator, PGC1Î±.  We further show that a target of BRAF, the melanocyte lineage factor MITF, directly regulates the expression of PGC1Î±.  Melanomas with activation of the BRAF/MAPK pathway have suppressed levels of MITF and PGC1Î± and decreased oxidative metab.  Conversely, treatment of BRAF-mutated melanomas with BRAF inhibitors renders them addicted to oxidative phosphorylation.  Our data thus identify an adaptive metabolic program that limits the efficacy of BRAF inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvDmASYzGCu7Vg90H21EOLACvtfcHk0lhwWMykSpT-Yw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktVOksbk%253D&md5=118e15e89222a6bc79a3b6f872ee96fd</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2013.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2013.02.003%26sid%3Dliteratum%253Aachs%26aulast%3DHaq%26aufirst%3DR.%26aulast%3DShoag%26aufirst%3DJ.%26aulast%3DAndreu-Perez%26aufirst%3DP.%26aulast%3DYokoyama%26aufirst%3DS.%26aulast%3DEdelman%26aufirst%3DH.%26aulast%3DRowe%26aufirst%3DG.%2BC.%26aulast%3DFrederick%26aufirst%3DD.%2BT.%26aulast%3DHurley%26aufirst%3DA.%2BD.%26aulast%3DNellore%26aufirst%3DA.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DWargo%26aufirst%3DJ.%2BA.%26aulast%3DSong%26aufirst%3DJ.%2BS.%26aulast%3DFisher%26aufirst%3DD.%2BE.%26aulast%3DArany%26aufirst%3DZ.%26aulast%3DWidlund%26aufirst%3DH.%2BR.%26atitle%3DOncogenic%2520BRAF%2520regulates%2520oxidative%2520metabolism%2520via%2520PGC1%2520alpha%2520and%2520MITF%26jtitle%3DCancer%2520Cell%26date%3D2013%26volume%3D23%26spage%3D302%26epage%3D315%26doi%3D10.1016%2Fj.ccr.2013.02.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bajpai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Achreja, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edgar, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddiqa, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matulis, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBrayer, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rupji, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barwick, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lonial, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nooka, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boise, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagrath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shanmugam, M.</span></span> <span> </span><span class="NLM_article-title">Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1228</span>, <span class="refDoi">Â DOI: 10.1038/s41467-020-15051-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fs41467-020-15051-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=32144272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlt1Sgt7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1228&author=R.+Bajpaiauthor=A.+Sharmaauthor=A.+Achrejaauthor=C.+L.+Edgarauthor=C.+Weiauthor=A.+A.+Siddiqaauthor=V.+A.+Guptaauthor=S.+M.+Matulisauthor=S.+K.+McBrayerauthor=A.+Mittalauthor=M.+Rupjiauthor=B.+G.+Barwickauthor=S.+Lonialauthor=A.+K.+Nookaauthor=L.+H.+Boiseauthor=D.+Nagrathauthor=M.+Shanmugam&title=Electron+transport+chain+activity+is+a+predictor+and+target+for+venetoclax+sensitivity+in+multiple+myeloma&doi=10.1038%2Fs41467-020-15051-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma</span></div><div class="casAuthors">Bajpai, Richa; Sharma, Aditi; Achreja, Abhinav; Edgar, Claudia L.; Wei, Changyong; Siddiqa, Arusha A.; Gupta, Vikas A.; Matulis, Shannon M.; McBrayer, Samuel K.; Mittal, Anjali; Rupji, Manali; Barwick, Benjamin G.; Lonial, Sagar; Nooka, Ajay K.; Boise, Lawrence H.; Nagrath, Deepak; Shanmugam, Mala</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1228</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The BCL-2 antagonist venetoclax is highly effective in multiple myeloma (MM) patients exhibiting the 11;14 translocation, the mechanistic basis of which is unknown.  In evaluating cellular energetics and metab. of t(11;14) and non-t(11;14) MM, we det. that venetoclax-sensitive myeloma has reduced mitochondrial respiration.  Consistent with this, low electron transport chain (ETC) Complex I and Complex II activities correlate with venetoclax sensitivity.  Inhibition of Complex I, using IACS-010759, an orally bioavailable Complex I inhibitor in clin. trials, as well as succinate ubiquinone reductase (SQR) activity of Complex II, using thenoyltrifluoroacetone (TTFA) or introduction of SDHC R72C mutant, independently sensitize resistant MM to venetoclax.  We demonstrate that ETC inhibition increases BCL-2 dependence and the 'primed' state via the ATF4-BIM/NOXA axis.  Further, SQR activity correlates with venetoclax sensitivity in patient samples irresp. of t(11;14) status.  Use of SQR activity in a functional-biomarker informed manner may better select for MM patients responsive to venetoclax therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIekJotsNUVbVg90H21EOLACvtfcHk0lhwWMykSpT-Yw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlt1Sgt7w%253D&md5=21d8e4083c7c5d7d8ea45de407efe134</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1038%2Fs41467-020-15051-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-020-15051-z%26sid%3Dliteratum%253Aachs%26aulast%3DBajpai%26aufirst%3DR.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DAchreja%26aufirst%3DA.%26aulast%3DEdgar%26aufirst%3DC.%2BL.%26aulast%3DWei%26aufirst%3DC.%26aulast%3DSiddiqa%26aufirst%3DA.%2BA.%26aulast%3DGupta%26aufirst%3DV.%2BA.%26aulast%3DMatulis%26aufirst%3DS.%2BM.%26aulast%3DMcBrayer%26aufirst%3DS.%2BK.%26aulast%3DMittal%26aufirst%3DA.%26aulast%3DRupji%26aufirst%3DM.%26aulast%3DBarwick%26aufirst%3DB.%2BG.%26aulast%3DLonial%26aufirst%3DS.%26aulast%3DNooka%26aufirst%3DA.%2BK.%26aulast%3DBoise%26aufirst%3DL.%2BH.%26aulast%3DNagrath%26aufirst%3DD.%26aulast%3DShanmugam%26aufirst%3DM.%26atitle%3DElectron%2520transport%2520chain%2520activity%2520is%2520a%2520predictor%2520and%2520target%2520for%2520venetoclax%2520sensitivity%2520in%2520multiple%2520myeloma%26jtitle%3DNat.%2520Commun.%26date%3D2020%26volume%3D11%26spage%3D1228%26doi%3D10.1038%2Fs41467-020-15051-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Senkowski, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olofsson, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isacson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoglund, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafsson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nygren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linder, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fryknas, M.</span></span> <span> </span><span class="NLM_article-title">Three-dimensional cell culture-based screening identifies the anthelmintic drug nitazoxanide as a candidate for treatment of colorectal cancer</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1504</span>â <span class="NLM_lpage">1516</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-14-0792</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F1535-7163.MCT-14-0792" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=25911689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsFOntLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=1504-1516&author=W.+Senkowskiauthor=X.+Zhangauthor=M.+H.+Olofssonauthor=R.+Isacsonauthor=U.+Hoglundauthor=M.+Gustafssonauthor=P.+Nygrenauthor=S.+Linderauthor=R.+Larssonauthor=M.+Fryknas&title=Three-dimensional+cell+culture-based+screening+identifies+the+anthelmintic+drug+nitazoxanide+as+a+candidate+for+treatment+of+colorectal+cancer&doi=10.1158%2F1535-7163.MCT-14-0792"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Three-Dimensional Cell Culture-Based Screening Identifies the Anthelmintic Drug Nitazoxanide as a Candidate for Treatment of Colorectal Cancer</span></div><div class="casAuthors">Senkowski, Wojciech; Zhang, Xiaonan; Olofsson, Maria Haegg; Isacson, Ruben; Hoeglund, Urban; Gustafsson, Mats; Nygren, Peter; Linder, Stig; Larsson, Rolf; Fryknaes, Marten</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1504-1516</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Because dormant cancer cells in hypoxic and nutrient-deprived regions of solid tumors provide a major obstacle to treatment, compds. targeting those cells might have clin. benefits.  Here, we describe a high-throughput drug screening approach, using glucose-deprived multicellular tumor spheroids (MCTS) with inner hypoxia, to identify compds. that specifically target this cell population.  We used a concept of drug repositioning-using known mols. for new indications.  This is a promising strategy to identify mols. for rapid clin. advancement.  By screening 1,600 compds. with documented clin. history, we aimed to identify candidates with unforeseen potential for repositioning as anticancer drugs.  Our screen identified five mols. with pronounced MCTS-selective activity: nitazoxanide, niclosamide, closantel, pyrvinium pamoate, and salinomycin.  Herein, we show that all five compds. inhibit mitochondrial respiration.  This suggests that cancer cells in low glucose concns. depend on oxidative phosphorylation rather than solely glycolysis.  Importantly, continuous exposure to the compds. was required to achieve effective treatment.  Nitazoxanide, an FDA-approved antiprotozoal drug with excellent pharmacokinetic and safety profile, is the only mol. among the screening hits that reaches high plasma concns. persisting for up to a few hours after single oral dose.  Nitazoxanide activated the AMPK pathway and downregulated c-Myc, mTOR, and Wnt signaling at clin. achievable concns.  Nitazoxanide combined with the cytotoxic drug irinotecan showed anticancer activity in vivo.  We here report that the FDA-approved anthelmintic drug nitazoxanide could be a potential candidate for advancement into cancer clin. trials.  Mol Cancer Ther; 14(6); 1504-16. cpr2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqml-pjMEW-7rVg90H21EOLACvtfcHk0lhwWMykSpT-Yw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsFOntLg%253D&md5=101482f0d7752634f892c766186496e5</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0792&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0792%26sid%3Dliteratum%253Aachs%26aulast%3DSenkowski%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DOlofsson%26aufirst%3DM.%2BH.%26aulast%3DIsacson%26aufirst%3DR.%26aulast%3DHoglund%26aufirst%3DU.%26aulast%3DGustafsson%26aufirst%3DM.%26aulast%3DNygren%26aufirst%3DP.%26aulast%3DLinder%26aufirst%3DS.%26aulast%3DLarsson%26aufirst%3DR.%26aulast%3DFryknas%26aufirst%3DM.%26atitle%3DThree-dimensional%2520cell%2520culture-based%2520screening%2520identifies%2520the%2520anthelmintic%2520drug%2520nitazoxanide%2520as%2520a%2520candidate%2520for%2520treatment%2520of%2520colorectal%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26spage%3D1504%26epage%3D1516%26doi%3D10.1158%2F1535-7163.MCT-14-0792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wenzel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riefke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grundemann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krebs, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osterland, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golfier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rase, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ansari, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bickle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pampaloni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattheyer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stelzer, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parczyk, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prechtl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steigemann, P.</span></span> <span> </span><span class="NLM_article-title">3D high-content screening for the identification of compounds that target cells in dormant tumor spheroid regions</span>. <i>Exp. Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>323</i></span>,  <span class="NLM_fpage">131</span>â <span class="NLM_lpage">43</span>, <span class="refDoi">Â DOI: 10.1016/j.yexcr.2014.01.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.yexcr.2014.01.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=24480576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisFCiu78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=323&publication_year=2014&pages=131-43&author=C.+Wenzelauthor=B.+Riefkeauthor=S.+Grundemannauthor=A.+Krebsauthor=S.+Christianauthor=F.+Prinzauthor=M.+Osterlandauthor=S.+Golfierauthor=S.+Raseauthor=N.+Ansariauthor=M.+Esnerauthor=M.+Bickleauthor=F.+Pampaloniauthor=C.+Mattheyerauthor=E.+H.+Stelzerauthor=K.+Parczykauthor=S.+Prechtlauthor=P.+Steigemann&title=3D+high-content+screening+for+the+identification+of+compounds+that+target+cells+in+dormant+tumor+spheroid+regions&doi=10.1016%2Fj.yexcr.2014.01.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">3D high-content screening for the identification of compounds that target cells in dormant tumor spheroid regions</span></div><div class="casAuthors">Wenzel, Carsten; Riefke, Bjoern; Gruendemann, Stephan; Krebs, Alice; Christian, Sven; Prinz, Florian; Osterland, Marc; Golfier, Sven; Raese, Sebastian; Ansari, Nariman; Esner, Milan; Bickle, Marc; Pampaloni, Francesco; Mattheyer, Christian; Stelzer, Ernst H.; Parczyk, Karsten; Prechtl, Stefan; Steigemann, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Cell Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">323</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">131-143</span>CODEN:
                <span class="NLM_cas:coden">ECREAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-4827</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Cancer cells in poorly vascularized tumor regions need to adapt to an unfavorable metabolic microenvironment.  As distance from supplying blood vessels increases, oxygen and nutrient concns. decrease and cancer cells react by stopping cell cycle progression and becoming dormant.  As cytostatic drugs mainly target proliferating cells, cancer cell dormancy is considered as a major resistance mechanism to this class of anti-cancer drugs.  Therefore, substances that target cancer cells in poorly vascularized tumor regions have the potential to enhance cytostatic-based chemotherapy of solid tumors.With three-dimensional growth conditions, multicellular tumor spheroids (MCTS) reproduce several parameters of the tumor microenvironment, including oxygen and nutrient gradients as well as the development of dormant tumor regions.We here report the setup of a 3D cell culture compatible high-content screening system and the identification of nine substances from two com. available drug libraries that specifically target cells in inner MCTS core regions, while cells in outer MCTS regions or in 2D cell culture remain unaffected.  We elucidated the mode of action of the identified compds. as inhibitors of the respiratory chain and show that induction of cell death in inner MCTS core regions critically depends on extracellular glucose concns.  Finally, combinational treatment with cytostatics showed increased induction of cell death in MCTS.  The data presented here shows for the first time a high-content based screening setup on 3D tumor spheroids for the identification of substances that specifically induce cell death in inner tumor spheroid core regions.  This validates the approach to use 3D cell culture screening systems to identify substances that would not be detectable by 2D based screening in otherwise similar culture conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLuyxz92LlK7Vg90H21EOLACvtfcHk0lgVuegI7gouIw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisFCiu78%253D&md5=8397a1bfd22d0433d53f82f79ca3b61a</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2Fj.yexcr.2014.01.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yexcr.2014.01.017%26sid%3Dliteratum%253Aachs%26aulast%3DWenzel%26aufirst%3DC.%26aulast%3DRiefke%26aufirst%3DB.%26aulast%3DGrundemann%26aufirst%3DS.%26aulast%3DKrebs%26aufirst%3DA.%26aulast%3DChristian%26aufirst%3DS.%26aulast%3DPrinz%26aufirst%3DF.%26aulast%3DOsterland%26aufirst%3DM.%26aulast%3DGolfier%26aufirst%3DS.%26aulast%3DRase%26aufirst%3DS.%26aulast%3DAnsari%26aufirst%3DN.%26aulast%3DEsner%26aufirst%3DM.%26aulast%3DBickle%26aufirst%3DM.%26aulast%3DPampaloni%26aufirst%3DF.%26aulast%3DMattheyer%26aufirst%3DC.%26aulast%3DStelzer%26aufirst%3DE.%2BH.%26aulast%3DParczyk%26aufirst%3DK.%26aulast%3DPrechtl%26aufirst%3DS.%26aulast%3DSteigemann%26aufirst%3DP.%26atitle%3D3D%2520high-content%2520screening%2520for%2520the%2520identification%2520of%2520compounds%2520that%2520target%2520cells%2520in%2520dormant%2520tumor%2520spheroid%2520regions%26jtitle%3DExp.%2520Cell%2520Res.%26date%3D2014%26volume%3D323%26spage%3D131%26epage%3D43%26doi%3D10.1016%2Fj.yexcr.2014.01.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Puente, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azab, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azab, A. K.</span></span> <span> </span><span class="NLM_article-title">The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy</span>. <i>Hypoxia</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">83</span>â <span class="NLM_lpage">92</span>, <span class="refDoi">Â DOI: 10.2147/HP.S93413</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.2147%2FHP.S93413" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27774485" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BC2srlsV2ntQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&pages=83-92&author=B.+Muzauthor=P.+de+la+Puenteauthor=F.+Azabauthor=A.+K.+Azab&title=The+role+of+hypoxia+in+cancer+progression%2C+angiogenesis%2C+metastasis%2C+and+resistance+to+therapy&doi=10.2147%2FHP.S93413"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy</span></div><div class="casAuthors">Muz Barbara; de la Puente Pilar; Azab Feda; Azab Abdel Kareem</div><div class="citationInfo"><span class="NLM_cas:title">Hypoxia (Auckland, N.Z.)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">83-92</span>
        ISSN:<span class="NLM_cas:issn">2324-1128</span>.
    </div><div class="casAbstract">Hypoxia is a non-physiological level of oxygen tension, a phenomenon common in a majority of malignant tumors.  Tumor-hypoxia leads to advanced but dysfunctional vascularization and acquisition of epithelial-to-mesenchymal transition phenotype resulting in cell mobility and metastasis.  Hypoxia alters cancer cell metabolism and contributes to therapy resistance by inducing cell quiescence.  Hypoxia stimulates a complex cell signaling network in cancer cells, including the HIF, PI3K, MAPK, and NF B pathways, which interact with each other causing positive and negative feedback loops and enhancing or diminishing hypoxic effects.  This review provides background knowledge on the role of tumor hypoxia and the role of the HIF cell signaling involved in tumor blood vessel formation, metastasis, and development of the resistance to therapy.  Better understanding of the role of hypoxia in cancer progression will open new windows for the discovery of new therapeutics targeting hypoxic tumor cells and hypoxic microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQpEDGDmxV0EPx2phytoz6_fW6udTcc2eaOJUDRW6RZ_rntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2srlsV2ntQ%253D%253D&md5=aa65f7fa9839ceffb5147fcb2aa8d2ba</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.2147%2FHP.S93413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FHP.S93413%26sid%3Dliteratum%253Aachs%26aulast%3DMuz%26aufirst%3DB.%26aulast%3Dde%2Bla%2BPuente%26aufirst%3DP.%26aulast%3DAzab%26aufirst%3DF.%26aulast%3DAzab%26aufirst%3DA.%2BK.%26atitle%3DThe%2520role%2520of%2520hypoxia%2520in%2520cancer%2520progression%252C%2520angiogenesis%252C%2520metastasis%252C%2520and%2520resistance%2520to%2520therapy%26jtitle%3DHypoxia%26date%3D2015%26volume%3D3%26spage%3D83%26epage%3D92%26doi%3D10.2147%2FHP.S93413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koido, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haga, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furuno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukahara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakurai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tani, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomida, A.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial deficiency impairs hypoxic induction of HIF-1 transcriptional activity and retards tumor growth</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">11841</span>â <span class="NLM_lpage">11854</span>, <span class="refDoi">Â DOI: 10.18632/oncotarget.14415</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.18632%2Foncotarget.14415" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=28060746" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BC1c7jtVOmtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=11841-11854&author=M.+Koidoauthor=N.+Hagaauthor=A.+Furunoauthor=S.+Tsukaharaauthor=J.+Sakuraiauthor=Y.+Taniauthor=S.+Satoauthor=A.+Tomida&title=Mitochondrial+deficiency+impairs+hypoxic+induction+of+HIF-1+transcriptional+activity+and+retards+tumor+growth&doi=10.18632%2Foncotarget.14415"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial deficiency impairs hypoxic induction of HIF-1 transcriptional activity and retards tumor growth</span></div><div class="casAuthors">Koido Masaru; Haga Naomi; Furuno Aki; Tsukahara Satomi; Sakurai Junko; Tani Yuri; Sato Shigeo; Tomida Akihiro; Koido Masaru; Tomida Akihiro</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">11841-11854</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Mitochondria can be involved in regulating cellular stress response to hypoxia and tumor growth, but little is known about that mechanistic relationship.  Here, we show that mitochondrial deficiency severely retards tumor xenograft growth with impairing hypoxic induction of HIF-1 transcriptional activity.  Using mtDNA-deficient Ï0 cells, we found that HIF-1 pathway activation was comparable in slow-growing Ï0 xenografts and rapid-growing parental xenografts.  Interestingly, we found that ex vivo Ï0 cells derived from Ï0 xenografts exhibited slightly increased HIF-1Î± expression and modest HIF-1 pathway activation regardless of oxygen concentration.  Surprisingly, Ï0 cells, as well as parental cells treated with oxidative phosphorylation inhibitors, were unable to boost HIF-1 transcriptional activity during hypoxia, although HIF-1Î± protein levels were ordinarily increased in these cells under hypoxic conditions.  These findings indicate that mitochondrial deficiency causes loss of hypoxia-induced HIF-1 transcriptional activity and thereby might lead to a constitutive HIF-1 pathway activation as a cellular adaptation mechanism in tumor microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRr6PjoGs2VCqe0F5ixvZgXfW6udTcc2eaOJUDRW6RZ_rntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7jtVOmtw%253D%253D&md5=6c2201ac5090711f97b1b2feba09e7fa</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.14415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.14415%26sid%3Dliteratum%253Aachs%26aulast%3DKoido%26aufirst%3DM.%26aulast%3DHaga%26aufirst%3DN.%26aulast%3DFuruno%26aufirst%3DA.%26aulast%3DTsukahara%26aufirst%3DS.%26aulast%3DSakurai%26aufirst%3DJ.%26aulast%3DTani%26aufirst%3DY.%26aulast%3DSato%26aufirst%3DS.%26aulast%3DTomida%26aufirst%3DA.%26atitle%3DMitochondrial%2520deficiency%2520impairs%2520hypoxic%2520induction%2520of%2520HIF-1%2520transcriptional%2520activity%2520and%2520retards%2520tumor%2520growth%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D11841%26epage%3D11854%26doi%3D10.18632%2Foncotarget.14415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chua, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufour, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dassa, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rustin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagen, T.</span></span> <span> </span><span class="NLM_article-title">Stabilization of hypoxia-inducible factor-1alpha protein in hypoxia occurs independently of mitochondrial reactive oxygen species production</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>285</i></span>,  <span class="NLM_fpage">31277</span>â <span class="NLM_lpage">31284</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M110.158485</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1074%2Fjbc.M110.158485" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=20675386" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1aqtrnK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=2010&pages=31277-31284&author=Y.+L.+Chuaauthor=E.+Dufourauthor=E.+P.+Dassaauthor=P.+Rustinauthor=H.+T.+Jacobsauthor=C.+T.+Taylorauthor=T.+Hagen&title=Stabilization+of+hypoxia-inducible+factor-1alpha+protein+in+hypoxia+occurs+independently+of+mitochondrial+reactive+oxygen+species+production&doi=10.1074%2Fjbc.M110.158485"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Stabilization of Hypoxia-inducible Factor-1Î± Protein in Hypoxia Occurs Independently of Mitochondrial Reactive Oxygen Species Production</span></div><div class="casAuthors">Chua, Yee Liu; Dufour, Eric; Dassa, Emmanuel P.; Rustin, Pierre; Jacobs, Howard T.; Taylor, Cormac T.; Hagen, Thilo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">285</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">31277-31284</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The transcription factor hypoxia-inducible factor-1Î± (HIF-1Î±) is a master regulator of the cellular response to low oxygen.  HIF-1Î± protein accumulates in hypoxia due to inhibition of prolyl hydroxylase enzymes, which under normoxic conditions use mol. oxygen to hydroxylate HIF-1Î± on two conserved proline residues (Pro402 and Pro564), thus targeting the protein for 26 S proteasome-dependent degrdn.  A functional mitochondrial electron transport chain is known to be necessary for HIF-1Î± stabilization in hypoxia.  It has been reported that reactive oxygen species (ROS), produced under hypoxia by complex III of the mitochondrial electron transport chain, play a crit. role in the stabilization of the HIF-1Î± protein, possibly by directly inhibiting prolyl hydroxylase enzymes.  In contrast, we found that ROS prodn. by complex III is not required for hypoxia-induced HIF-1Î± stabilization.  Thus, reestablishing mitochondrial oxygen consumption in the presence of a complex III inhibitor by using an artificial electron donor to complex IV or by overexpressing Ciona intestinalis alternative oxidase results in HIF-1Î± protein stabilization in hypoxia.  Furthermore, five inhibitors that target different sites of the mitochondrial electron transport chain have similar effects on the HIF-1Î± protein half-life in hypoxia but vary in their effects on mitochondrial ROS prodn.  Finally, ROS do not regulate prolyl hydroxylase activity directly.  We conclude that HIF-1Î± protein stabilization in hypoxia occurs independently of mitochondrial ROS prodn.  However, mitochondria can modulate the cellular hypoxic response through altered respiratory activity, likely by regulating the cellular oxygen availability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_s55UK1NpCbVg90H21EOLACvtfcHk0lj8SwRHHY9pJA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1aqtrnK&md5=f7f4b8592bc558fdea69e5ace627b977</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M110.158485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M110.158485%26sid%3Dliteratum%253Aachs%26aulast%3DChua%26aufirst%3DY.%2BL.%26aulast%3DDufour%26aufirst%3DE.%26aulast%3DDassa%26aufirst%3DE.%2BP.%26aulast%3DRustin%26aufirst%3DP.%26aulast%3DJacobs%26aufirst%3DH.%2BT.%26aulast%3DTaylor%26aufirst%3DC.%2BT.%26aulast%3DHagen%26aufirst%3DT.%26atitle%3DStabilization%2520of%2520hypoxia-inducible%2520factor-1alpha%2520protein%2520in%2520hypoxia%2520occurs%2520independently%2520of%2520mitochondrial%2520reactive%2520oxygen%2520species%2520production%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2010%26volume%3D285%26spage%3D31277%26epage%3D31284%26doi%3D10.1074%2Fjbc.M110.158485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ellinghaus, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heisler, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unterschemmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haerter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greschat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flamme, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oehme, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thierauch, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michels, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess-Stumpp, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegelbauer, K.</span></span> <span> </span><span class="NLM_article-title">BAY 87-2243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumor activities by inhibition of mitochondrial complex I</span>. <i>Cancer Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">611</span>â <span class="NLM_lpage">624</span>, <span class="refDoi">Â DOI: 10.1002/cam4.112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1002%2Fcam4.112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=24403227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsF2htLbL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=611-624&author=P.+Ellinghausauthor=I.+Heislerauthor=K.+Unterschemmannauthor=M.+Haerterauthor=H.+Beckauthor=S.+Greschatauthor=A.+Ehrmannauthor=H.+Summerauthor=I.+Flammeauthor=F.+Oehmeauthor=K.+Thierauchauthor=M.+Michelsauthor=H.+Hess-Stumppauthor=K.+Ziegelbauer&title=BAY+87-2243%2C+a+highly+potent+and+selective+inhibitor+of+hypoxia-induced+gene+activation+has+antitumor+activities+by+inhibition+of+mitochondrial+complex+I&doi=10.1002%2Fcam4.112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">BAY 87-2243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumor activities by inhibition of mitochondrial complex I</span></div><div class="casAuthors">Ellinghaus, Peter; Heisler, Iring; Unterschemmann, Kerstin; Haerter, Michael; Beck, Hartmut; Greschat, Susanne; Ehrmann, Alexander; Summer, Holger; Flamme, Ingo; Oehme, Felix; Thierauch, Karlheinz; Michels, Martin; Hess-Stumpp, Holger; Ziegelbauer, Karl</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">611-624</span>CODEN:
                <span class="NLM_cas:coden">CMAEDL</span>;
        ISSN:<span class="NLM_cas:issn">2045-7634</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">The activation of the transcription factor hypoxia-inducible factor-1 (HIF-1) plays an essential role in tumor development, tumor progression, and resistance to chemo- and radiotherapy.  In order to identify compds. targeting the HIF pathway, a small mol. library was screened using a luciferase-driven HIF-1 reporter cell line under hypoxia.  The high-throughput screening led to the identification of a class of aminoalkyl-substituted compds. that inhibited hypoxia-induced HIF-1 target gene expression in human lung cancer cell lines at low nanomolar concns.  Lead structure BAY 87-2243 was found to inhibit HIF-1Î± and HIF-2Î± protein accumulation under hypoxic conditions in non-small cell lung cancer (NSCLC) cell line H460 but had no effect on HIF-1Î± protein levels induced by the hypoxia mimetics desferrioxamine or cobalt chloride.  BAY 87-2243 had no effect on HIF target gene expression levels in RCC4 cells lacking Von Hippel-Lindau (VHL) activity nor did the compd. affect the activity of HIF prolyl hydroxylase-2.  Antitumor activity of BAY 87-2243, suppression of HIF-1Î± protein levels, and redn. of HIF-1 target gene expression in vivo were demonstrated in a H460 xenograft model.  BAY 87-2243 did not inhibit cell proliferation under std. conditions.  However under glucose depletion, a condition favoring mitochondrial ATP generation as energy source, BAY 87-2243 inhibited cell proliferation in the nanomolar range.  Further expts. revealed that BAY 87-2243 inhibits mitochondrial complex I activity but has no effect on complex III activity.  Interference with mitochondrial function to reduce hypoxia-induced HIF-1 activity in tumors might be an interesting therapeutic approach to overcome chemo- and radiotherapy-resistance of hypoxic tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmP6qdK8PRqrVg90H21EOLACvtfcHk0lj8SwRHHY9pJA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsF2htLbL&md5=7ff152754b6379af91c65c838b0a1c3f</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1002%2Fcam4.112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcam4.112%26sid%3Dliteratum%253Aachs%26aulast%3DEllinghaus%26aufirst%3DP.%26aulast%3DHeisler%26aufirst%3DI.%26aulast%3DUnterschemmann%26aufirst%3DK.%26aulast%3DHaerter%26aufirst%3DM.%26aulast%3DBeck%26aufirst%3DH.%26aulast%3DGreschat%26aufirst%3DS.%26aulast%3DEhrmann%26aufirst%3DA.%26aulast%3DSummer%26aufirst%3DH.%26aulast%3DFlamme%26aufirst%3DI.%26aulast%3DOehme%26aufirst%3DF.%26aulast%3DThierauch%26aufirst%3DK.%26aulast%3DMichels%26aufirst%3DM.%26aulast%3DHess-Stumpp%26aufirst%3DH.%26aulast%3DZiegelbauer%26aufirst%3DK.%26atitle%3DBAY%252087-2243%252C%2520a%2520highly%2520potent%2520and%2520selective%2520inhibitor%2520of%2520hypoxia-induced%2520gene%2520activation%2520has%2520antitumor%2520activities%2520by%2520inhibition%2520of%2520mitochondrial%2520complex%2520I%26jtitle%3DCancer%2520Med.%26date%3D2013%26volume%3D2%26spage%3D611%26epage%3D624%26doi%3D10.1002%2Fcam4.112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, X.</span></span> <span> </span><span class="NLM_article-title">Metabolic control of T-cell immunity via epigenetic mechanisms</span>. <i>Cell. Mol. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">203</span>â <span class="NLM_lpage">205</span>, <span class="refDoi">Â DOI: 10.1038/cmi.2017.115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fcmi.2017.115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=29082922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BC1M7lslOhtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=203-205&author=X.+Zhangauthor=J.+Liuauthor=X.+Cao&title=Metabolic+control+of+T-cell+immunity+via+epigenetic+mechanisms&doi=10.1038%2Fcmi.2017.115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic control of T-cell immunity via epigenetic mechanisms</span></div><div class="casAuthors">Zhang Xiaomin; Liu Juan; Cao Xuetao; Cao Xuetao</div><div class="citationInfo"><span class="NLM_cas:title">Cellular & molecular immunology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">203-205</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQnXgNumm1KP9enUz0lpNqnfW6udTcc2eZYgfCvAEgQjLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7lslOhtw%253D%253D&md5=692e59181e02a767a454def39060a3d9</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1038%2Fcmi.2017.115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcmi.2017.115%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DCao%26aufirst%3DX.%26atitle%3DMetabolic%2520control%2520of%2520T-cell%2520immunity%2520via%2520epigenetic%2520mechanisms%26jtitle%3DCell.%2520Mol.%2520Immunol.%26date%3D2018%26volume%3D15%26spage%3D203%26epage%3D205%26doi%3D10.1038%2Fcmi.2017.115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gatza, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahl, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opipari, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundberg, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glick, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrara, J. L.</span></span> <span> </span><span class="NLM_article-title">Manipulating the bioenergetics of alloreactive T cells causes their selective apoptosis and arrests graft-versus-host disease</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">67ra8</span>, <span class="refDoi">Â DOI: 10.1126/scitranslmed.3001975</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1126%2Fscitranslmed.3001975" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=21270339" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=67ra8&author=E.+Gatzaauthor=D.+R.+Wahlauthor=A.+W.+Opipariauthor=T.+B.+Sundbergauthor=P.+Reddyauthor=C.+Liuauthor=G.+D.+Glickauthor=J.+L.+Ferrara&title=Manipulating+the+bioenergetics+of+alloreactive+T+cells+causes+their+selective+apoptosis+and+arrests+graft-versus-host+disease&doi=10.1126%2Fscitranslmed.3001975"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3001975&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3001975%26sid%3Dliteratum%253Aachs%26aulast%3DGatza%26aufirst%3DE.%26aulast%3DWahl%26aufirst%3DD.%2BR.%26aulast%3DOpipari%26aufirst%3DA.%2BW.%26aulast%3DSundberg%26aufirst%3DT.%2BB.%26aulast%3DReddy%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DGlick%26aufirst%3DG.%2BD.%26aulast%3DFerrara%26aufirst%3DJ.%2BL.%26atitle%3DManipulating%2520the%2520bioenergetics%2520of%2520alloreactive%2520T%2520cells%2520causes%2520their%2520selective%2520apoptosis%2520and%2520arrests%2520graft-versus-host%2520disease%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2011%26volume%3D3%26spage%3D67ra8%26doi%3D10.1126%2Fscitranslmed.3001975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wahl, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glick, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opipari, A. W.</span></span> <span> </span><span class="NLM_article-title">Characterization of the metabolic phenotype of chronically activated lymphocytes</span>. <i>Lupus</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1492</span>â <span class="NLM_lpage">1501</span>, <span class="refDoi">Â DOI: 10.1177/0961203310373109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1177%2F0961203310373109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=20647250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1SisbvL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2010&pages=1492-1501&author=D.+R.+Wahlauthor=B.+Petersenauthor=R.+Warnerauthor=B.+C.+Richardsonauthor=G.+D.+Glickauthor=A.+W.+Opipari&title=Characterization+of+the+metabolic+phenotype+of+chronically+activated+lymphocytes&doi=10.1177%2F0961203310373109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the metabolic phenotype of chronically activated lymphocytes</span></div><div class="casAuthors">Wahl, D. R.; Petersen, B.; Warner, R.; Richardson, B. C.; Glick, G. D.; Opipari, A. W.</div><div class="citationInfo"><span class="NLM_cas:title">Lupus</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1492-1501</span>CODEN:
                <span class="NLM_cas:coden">LUPUES</span>;
        ISSN:<span class="NLM_cas:issn">0961-2033</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">Activated lymphocytes proliferate, secrete cytokines, and can make antibodies.  Normally activated B and T cells meet the bioenergetic demand for these processes by up-regulating aerobic glycolysis.  In contrast, several lines of evidence suggest that pathogenic lymphocytes in autoimmune diseases like lupus meet ATP demands through oxidative phosphorylation.  Using 13C-glucose as a stable tracer, we found that splenocytes from mice with lupus derive the same fraction of lactate from glucose as control animals, suggesting comparable levels of glycolysis and non-oxidative ATP prodn.  However, lupus splenocytes increase glucose oxidn. by 40% over healthy control animals.  The ratio between pentose phosphate cycle (PPC) activity and glycolysis is the same for each group, indicating that increased glucose oxidn. is due to increased activity of the TCA cycle in lupus splenocytes.  Repetitive stimulation of cultured human T cells was used to model chronic lymphocyte activation, a phenotype assocd. with lupus.  Chronically activated T cells rely primarily on oxidative metab. for ATP synthesis suggesting that chronic antigen stimulation may be the basis for the metabolic findings obsd. in lupus mice.  Identification of disease-related bioenergetic phenotypes should contribute to new diagnostic and therapeutic strategies for immune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpy3z-gVsUbgbVg90H21EOLACvtfcHk0lgN5XT7rdestQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1SisbvL&md5=e2e2358ec97b2eb102e0b4b38fc5a7f6</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1177%2F0961203310373109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0961203310373109%26sid%3Dliteratum%253Aachs%26aulast%3DWahl%26aufirst%3DD.%2BR.%26aulast%3DPetersen%26aufirst%3DB.%26aulast%3DWarner%26aufirst%3DR.%26aulast%3DRichardson%26aufirst%3DB.%2BC.%26aulast%3DGlick%26aufirst%3DG.%2BD.%26aulast%3DOpipari%26aufirst%3DA.%2BW.%26atitle%3DCharacterization%2520of%2520the%2520metabolic%2520phenotype%2520of%2520chronically%2520activated%2520lymphocytes%26jtitle%3DLupus%26date%3D2010%26volume%3D19%26spage%3D1492%26epage%3D1501%26doi%3D10.1177%2F0961203310373109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leone, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, J. D.</span></span> <span> </span><span class="NLM_article-title">Metabolism of immune cells in cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">516</span>, <span class="refDoi">Â DOI: 10.1038/s41568-020-0273-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fs41568-020-0273-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=32632251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlaitrvO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2020&pages=516&author=R.+D.+Leoneauthor=J.+D.+Powell&title=Metabolism+of+immune+cells+in+cancer&doi=10.1038%2Fs41568-020-0273-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism of immune cells in cancer</span></div><div class="casAuthors">Leone, Robert D.; Powell, Jonathan D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">516-531</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: Through the successes of checkpoint blockade and adoptive cellular therapy, immunotherapy has become an established treatment modality for cancer.  Cellular metab. has emerged as a crit. determinant of the viability and function of both cancer cells and immune cells.  In order to sustain prodigious anabolic needs, tumors employ a specialized metab. that differs from untransformed somatic cells.  This metab. leads to a tumor microenvironment that is commonly acidic, hypoxic and/or depleted of crit. nutrients required by immune cells.  In this context, tumor metab. itself is a checkpoint that can limit immune-mediated tumor destruction.  Because our understanding of immune cell metab. and cancer metab. has grown significantly in the past decade, we are on the cusp of being able to unravel the interaction of cancer cell metab. and immune metab. in therapeutically meaningful ways.  Although there are metabolic processes that are seemingly fundamental to both cancer and responding immune cells, metabolic heterogeneity and plasticity may serve to distinguish the two.  As such, understanding the differential metabolic requirements of the diverse cells that comprise an immune response to cancer offers an opportunity to selectively regulate immune cell function.  Such a nuanced evaluation of cancer and immune metab. can uncover metabolic vulnerabilities and therapeutic windows upon which to intervene for enhanced immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrR0xV0Vx2JbVg90H21EOLACvtfcHk0lgN5XT7rdestQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlaitrvO&md5=00bd3f1ad849e1c5ad282ffca6e6b736</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1038%2Fs41568-020-0273-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41568-020-0273-y%26sid%3Dliteratum%253Aachs%26aulast%3DLeone%26aufirst%3DR.%2BD.%26aulast%3DPowell%26aufirst%3DJ.%2BD.%26atitle%3DMetabolism%2520of%2520immune%2520cells%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2020%26volume%3D20%26spage%3D516%26doi%3D10.1038%2Fs41568-020-0273-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salmond, R. J.</span></span> <span> </span><span class="NLM_article-title">mTOR regulation of glycolytic metabolism in T cells</span>. <i>Front. Cell Dev. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">122</span>, <span class="refDoi">Â DOI: 10.3389/fcell.2018.00122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.3389%2Ffcell.2018.00122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=30320109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BB3czpt1ertA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&pages=122&author=R.+J.+Salmond&title=mTOR+regulation+of+glycolytic+metabolism+in+T+cells&doi=10.3389%2Ffcell.2018.00122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR Regulation of Glycolytic Metabolism in T Cells</span></div><div class="casAuthors">Salmond Robert J</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in cell and developmental biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">122</span>
        ISSN:<span class="NLM_cas:issn">2296-634X</span>.
    </div><div class="casAbstract">T cell activation, differentiation and effector function is intrinsically linked to the regulation of metabolic pathways.  Evidence has shown that inflammatory T cell responses are dependent upon the adoption of aerobic glycolytic metabolism.  Furthermore, activation and regulation of the mechanistic target of rapamycin signaling pathway serves a key determinant of T cell metabolism, with subsequent effects on T cell effector responses.  In this mini-review, we discuss the mechanisms underpinning the function of the Warburg effect in T cell responses and the role of mTOR in these processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQpNpVRuQHC2bYtC3U5jeOifW6udTcc2eYL_jgxBkq2sLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3czpt1ertA%253D%253D&md5=67a879880570804682299d2d9b23ec25</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.3389%2Ffcell.2018.00122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffcell.2018.00122%26sid%3Dliteratum%253Aachs%26aulast%3DSalmond%26aufirst%3DR.%2BJ.%26atitle%3DmTOR%2520regulation%2520of%2520glycolytic%2520metabolism%2520in%2520T%2520cells%26jtitle%3DFront.%2520Cell%2520Dev.%2520Biol.%26date%3D2018%26volume%3D6%26spage%3D122%26doi%3D10.3389%2Ffcell.2018.00122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diskin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palsson-McDermott, E. M.</span></span> <span> </span><span class="NLM_article-title">Metabolic modulation in macrophage effector function</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">270</span>, <span class="refDoi">Â DOI: 10.3389/fimmu.2018.00270</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.3389%2Ffimmu.2018.00270" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=29520272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1ahsLnI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=270&author=C.+Diskinauthor=E.+M.+Palsson-McDermott&title=Metabolic+modulation+in+macrophage+effector+function&doi=10.3389%2Ffimmu.2018.00270"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic modulation in macrophage effector function</span></div><div class="casAuthors">Diskin, Ciana; Palsson-McDermott, Eva M.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">270/1-270/17</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Traditionally cellular respiration or metab. has been viewed as catabolic and anabolic pathways generating energy and biosynthetic precursors required for growth and general cellular maintenance.  However, growing literature provides evidence of a much broader role for metabolic reactions and processes in controlling immunol. effector functions.  Much of this research into immunometabolism has focused on macrophages, cells that are central in pro- as well as anti-inflammatory responses-responses that in turn are a direct result of metabolic reprogramming.  As we learn more about the precise role of metabolic pathways and pathway intermediates in immune function, a novel opportunity to target immunometabolism therapeutically has emerged.  Here, we review the current understanding of the regulation of macrophage function through metabolic remodeling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKNesU-BBWX7Vg90H21EOLACvtfcHk0lhMItsXigCMRg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1ahsLnI&md5=55848a095c712d064477c26bcdf2a10d</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2018.00270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2018.00270%26sid%3Dliteratum%253Aachs%26aulast%3DDiskin%26aufirst%3DC.%26aulast%3DPalsson-McDermott%26aufirst%3DE.%2BM.%26atitle%3DMetabolic%2520modulation%2520in%2520macrophage%2520effector%2520function%26jtitle%3DFront.%2520Immunol.%26date%3D2018%26volume%3D9%26spage%3D270%26doi%3D10.3389%2Ffimmu.2018.00270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tcyganov, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabrilovich, D. I.</span></span> <span> </span><span class="NLM_article-title">The nature of myeloid-derived suppressor cells in the tumor microenvironment</span>. <i>Trends Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">208</span>â <span class="NLM_lpage">220</span>, <span class="refDoi">Â DOI: 10.1016/j.it.2016.01.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.it.2016.01.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=26858199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFKltbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=208-220&author=V.+Kumarauthor=S.+Patelauthor=E.+Tcyganovauthor=D.+I.+Gabrilovich&title=The+nature+of+myeloid-derived+suppressor+cells+in+the+tumor+microenvironment&doi=10.1016%2Fj.it.2016.01.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment</span></div><div class="casAuthors">Kumar, Vinit; Patel, Sima; Tcyganov, Evgenii; Gabrilovich, Dmitry I.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Immunology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">208-220</span>CODEN:
                <span class="NLM_cas:coden">TIRMAE</span>;
        ISSN:<span class="NLM_cas:issn">1471-4906</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Myeloid-derived suppressor cells (MDSC) are one of the major components of the tumor microenvironment.  The main feature of these cells is their potent immune suppressive activity.  MDSC are generated in the bone marrow and, in tumor-bearing hosts, migrate to peripheral lymphoid organs and the tumor to contribute to the formation of the tumor microenvironment.  Recent findings have revealed differences in the function and fate of MDSC in the tumor and peripheral lymphoid organs.  We review these findings here and, in this context, we discuss the current understanding as to the nature of these differences, the underlying mechanisms, and their potential impact on the regulation of tumor progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8ikkrNPPenrVg90H21EOLACvtfcHk0lhMItsXigCMRg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFKltbc%253D&md5=333aec052efcefad2de3f8a5b572637d</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1016%2Fj.it.2016.01.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.it.2016.01.004%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DTcyganov%26aufirst%3DE.%26aulast%3DGabrilovich%26aufirst%3DD.%2BI.%26atitle%3DThe%2520nature%2520of%2520myeloid-derived%2520suppressor%2520cells%2520in%2520the%2520tumor%2520microenvironment%26jtitle%3DTrends%2520Immunol.%26date%3D2016%26volume%3D37%26spage%3D208%26epage%3D220%26doi%3D10.1016%2Fj.it.2016.01.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glick, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossignol, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyssiotis, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurd, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrara, J. L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tkachev, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byersdorfer, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boros, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opipari, A. W.</span></span> <span> </span><span class="NLM_article-title">Anaplerotic metabolism of alloreactive T cells provides a metabolic approach to treat graft-versus-host disease</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>351</i></span>,  <span class="NLM_fpage">298</span>â <span class="NLM_lpage">307</span>, <span class="refDoi">Â DOI: 10.1124/jpet.114.218099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1124%2Fjpet.114.218099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=25125579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslKisbzI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2014&pages=298-307&author=G.+D.+Glickauthor=R.+Rossignolauthor=C.+A.+Lyssiotisauthor=D.+Wahlauthor=C.+Leschauthor=B.+Sanchezauthor=X.+K.+Liuauthor=L.+Y.+Haoauthor=C.+Taylorauthor=A.+Hurdauthor=J.+L.+M.+Ferraraauthor=V.+Tkachevauthor=C.+A.+Byersdorferauthor=L.+Borosauthor=A.+W.+Opipari&title=Anaplerotic+metabolism+of+alloreactive+T+cells+provides+a+metabolic+approach+to+treat+graft-versus-host+disease&doi=10.1124%2Fjpet.114.218099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplerotic metabolism of alloreactive T cells provides a metabolic approach to treat graft-versus-host disease</span></div><div class="casAuthors">Glick, Gary D.; Rossignol, Rodrigue; Lyssiotis, Costas A.; Wahl, Daniel; Lesch, Charles; Sanchez, Brian; Liu, Xikui; Hao, Ling-Yang; Taylor, Clarke; Hurd, Alexander; Ferrara, James L. M.; Tkachev, Victor; Byersdorfer, Craig A.; Boros, Laszlo; Opipari, Anthony W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">351</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">298-307, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">T-cell activation requires increased ATP and biosynthesis to support proliferation and effector function.  Most models of T-cell activation are based on in vitro culture systems and posit that aerobic glycolysis is employed to meet increased energetic and biosynthetic demands.  By contrast, T cells activated in vivo by alloantigens in graft-vs.-host disease (GVHD) increase mitochondrial oxygen consumption, fatty acid uptake and oxidn., with small increases of glucose uptake and aerobic glycolysis.  Here we show that these differences are not a consequence of alloactivation, because T cells activated in vitro either in a mixed lymphocyte reaction to the same alloantigens used in vivo or with agonistic anti-CD3/anti-CD28 antibodies increased aerobic glycolysis.  Using targeted metabolic 13C tracer fate assocns., we elucidated the metabolic pathway(s) employed by alloreactive T cells in vivo that support this phenotype.  We find that glutamine (Gln)-dependent tricarboxylic acid cycle anaplerosis is increased in alloreactive T cells and that Gln carbon contributes to ribose biosynthesis.  Pharmacol. modulation of oxidative phosphorylation rapidly reduces anaplerosis in alloreactive T cells and improves GVHD.  On the basis of these data, we propose a model of T-cell metab. that is relevant to activated lymphocytes in vivo, with implications for the discovery of new drugs for immune disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJFflA0P_Ii7Vg90H21EOLACvtfcHk0lhMItsXigCMRg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslKisbzI&md5=9eda7d2a42d22d75ee2859ad8b32eef3</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.218099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.218099%26sid%3Dliteratum%253Aachs%26aulast%3DGlick%26aufirst%3DG.%2BD.%26aulast%3DRossignol%26aufirst%3DR.%26aulast%3DLyssiotis%26aufirst%3DC.%2BA.%26aulast%3DWahl%26aufirst%3DD.%26aulast%3DLesch%26aufirst%3DC.%26aulast%3DSanchez%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DX.%2BK.%26aulast%3DHao%26aufirst%3DL.%2BY.%26aulast%3DTaylor%26aufirst%3DC.%26aulast%3DHurd%26aufirst%3DA.%26aulast%3DFerrara%26aufirst%3DJ.%2BL.%2BM.%26aulast%3DTkachev%26aufirst%3DV.%26aulast%3DByersdorfer%26aufirst%3DC.%2BA.%26aulast%3DBoros%26aufirst%3DL.%26aulast%3DOpipari%26aufirst%3DA.%2BW.%26atitle%3DAnaplerotic%2520metabolism%2520of%2520alloreactive%2520T%2520cells%2520provides%2520a%2520metabolic%2520approach%2520to%2520treat%2520graft-versus-host%2520disease%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D351%26spage%3D298%26epage%3D307%26doi%3D10.1124%2Fjpet.114.218099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burwell, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadtochiy, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brookes, P. S.</span></span> <span> </span><span class="NLM_article-title">Cardioprotection by metabolic shut-down and gradual wake-up</span>. <i>J. Mol. Cell. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">804</span>â <span class="NLM_lpage">810</span>, <span class="refDoi">Â DOI: 10.1016/j.yjmcc.2009.02.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.yjmcc.2009.02.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=19285082" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtVSht7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2009&pages=804-810&author=L.+S.+Burwellauthor=S.+M.+Nadtochiyauthor=P.+S.+Brookes&title=Cardioprotection+by+metabolic+shut-down+and+gradual+wake-up&doi=10.1016%2Fj.yjmcc.2009.02.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Cardioprotection by metabolic shut-down and gradual wake-up</span></div><div class="casAuthors">Burwell, Lindsay S.; Nadtochiy, Sergiy M.; Brookes, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular and Cellular Cardiology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">804-810</span>CODEN:
                <span class="NLM_cas:coden">JMCDAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-2828</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Mitochondria play a crit. role in cardiac function, and are also increasingly recognized as end effectors for various cardioprotective signaling pathways.  Mitochondria use oxygen as a substrate, so by default their respiration is inhibited during hypoxia/ischemia.  However, at reperfusion a surge of oxygen and metabolic substrates into the cell is thought to lead to rapid reestablishment of respiration, a burst of reactive oxygen species (ROS) generation and mitochondrial Ca2+ overload.  Subsequently these events ppt. opening of the mitochondrial permeability transition (PT) pore, which leads to myocardial cell death and dysfunction.  Given that mitochondrial respiration is already inhibited during hypoxia/ischemia, it is somewhat surprising that many respiratory inhibitors can improve recovery from ischemia-reperfusion (IR) injury.  In addn. ischemic preconditioning (IPC), in which short non-lethal cycles of IR can protect against subsequent prolonged IR injury, is known to lead to endogenous inhibition of several respiratory complexes and glycolysis.  This has led to a hypothesis that the wash-out of inhibitors or reversal of endogenous inhibition at reperfusion may afford protection by facilitating a more gradual wake-up of mitochondrial function, thereby avoiding a burst of ROS and Ca2+ overload.  This paper will review the evidence in support of this hypothesis, with a focus on inhibition of each of the mitochondrial respiratory complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqItjFgDsQHcrVg90H21EOLACvtfcHk0lgIgplz_9mk6g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtVSht7Y%253D&md5=31fbf76d06eeb2fe1f9dd471f6d60bf7</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.yjmcc.2009.02.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yjmcc.2009.02.026%26sid%3Dliteratum%253Aachs%26aulast%3DBurwell%26aufirst%3DL.%2BS.%26aulast%3DNadtochiy%26aufirst%3DS.%2BM.%26aulast%3DBrookes%26aufirst%3DP.%2BS.%26atitle%3DCardioprotection%2520by%2520metabolic%2520shut-down%2520and%2520gradual%2520wake-up%26jtitle%3DJ.%2520Mol.%2520Cell.%2520Cardiol.%26date%3D2009%26volume%3D46%26spage%3D804%26epage%3D810%26doi%3D10.1016%2Fj.yjmcc.2009.02.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camara, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stowe, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoppel, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesnefsky, E. J.</span></span> <span> </span><span class="NLM_article-title">Modulation of electron transport protects cardiac mitochondria and decreases myocardial injury during ischemia and reperfusion</span>. <i>Am. J. Physiol. Cell Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>292</i></span>,  <span class="NLM_fpage">C137</span>â <span class="NLM_lpage">147</span>, <span class="refDoi">Â DOI: 10.1152/ajpcell.00270.2006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1152%2Fajpcell.00270.2006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=16971498" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD2sXisFCrtbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=292&publication_year=2007&pages=C137-147&author=Q.+Chenauthor=A.+K.+Camaraauthor=D.+F.+Stoweauthor=C.+L.+Hoppelauthor=E.+J.+Lesnefsky&title=Modulation+of+electron+transport+protects+cardiac+mitochondria+and+decreases+myocardial+injury+during+ischemia+and+reperfusion&doi=10.1152%2Fajpcell.00270.2006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of electron transport protects cardiac mitochondria and decreases myocardial injury during ischemia and reperfusion</span></div><div class="casAuthors">Chen, Qun; Camara, Amadou K. S.; Stowe, David F.; Hoppel, Charles L.; Lesnefsky, Edward J.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Physiology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">292</span>
        (<span class="NLM_cas:issue">1, Pt. 1</span>),
    <span class="NLM_cas:pages">C137-C147</span>CODEN:
                <span class="NLM_cas:coden">AJPHAP</span>;
        ISSN:<span class="NLM_cas:issn">0002-9513</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">A review.  Mitochondria are increasingly recognized as lynchpins in the evolution of cardiac injury during ischemia and reperfusion.  This review addresses the emerging concept that modulation of mitochondrial respiration during and immediately following an episode of ischemia can attenuate the extent of myocardial injury.  The blockade of electron transport and the partial uncoupling of respiration are two mechanisms whereby manipulation of mitochondrial metab. during ischemia decreases cardiac injury.  Although protection by inhibition of electron transport or uncoupling of respiration initially appears to be counterintuitive, the continuation of mitochondrial oxidative phosphorylation in the pathol. milieu of ischemia generates reactive oxygen species, mitochondrial calcium overload, and the release of cytochrome c.  The initial target of these deleterious mitochondrial-driven processes is the mitochondria themselves.  Consequences to the cardiomyocyte, in turn, include oxidative damage, the onset of mitochondrial permeability transition, and activation of apoptotic cascades, all favoring cardiomyocyte death.  Ischemia-induced mitochondrial damage carried forward into reperfusion further amplifies these mechanisms of mitochondrial-driven myocyte injury.  Interruption of mitochondrial respiration during early reperfusion by pharmacol. blockade of electron transport or even recurrent hypoxia or brief ischemia paradoxically decreases cardiac injury.  It increasingly appears that the cardioprotective paradigms of ischemic preconditioning and post-conditioning utilize modulation of mitochondrial oxidative metab. as a key effector mechanism.  The initially counterintuitive approach to inhibit mitochondrial respiration provides a new cardioprotective paradigm to decrease cellular injury during both ischemia and reperfusion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFV4YFMYs3arVg90H21EOLACvtfcHk0lgIgplz_9mk6g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXisFCrtbo%253D&md5=424c7a16c836cb8d15df9ec788918dca</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1152%2Fajpcell.00270.2006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpcell.00270.2006%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DCamara%26aufirst%3DA.%2BK.%26aulast%3DStowe%26aufirst%3DD.%2BF.%26aulast%3DHoppel%26aufirst%3DC.%2BL.%26aulast%3DLesnefsky%26aufirst%3DE.%2BJ.%26atitle%3DModulation%2520of%2520electron%2520transport%2520protects%2520cardiac%2520mitochondria%2520and%2520decreases%2520myocardial%2520injury%2520during%2520ischemia%2520and%2520reperfusion%26jtitle%3DAm.%2520J.%2520Physiol.%2520Cell%2520Physiol.%26date%3D2007%26volume%3D292%26spage%3DC137%26epage%3D147%26doi%3D10.1152%2Fajpcell.00270.2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, I. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, I. Y.</span></span> <span> </span><span class="NLM_article-title">Modification of glycolysis affects cell sensitivity to apoptosis induced by oxidative stress and mediated by mitochondria</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>313</i></span>,  <span class="NLM_fpage">984</span>â <span class="NLM_lpage">991</span>, <span class="refDoi">Â DOI: 10.1016/j.bbrc.2003.12.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.bbrc.2003.12.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=14706639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD2cXosFCm" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=313&publication_year=2004&pages=984-991&author=D.+W.+Jeongauthor=T.+S.+Kimauthor=I.+T.+Choauthor=I.+Y.+Kim&title=Modification+of+glycolysis+affects+cell+sensitivity+to+apoptosis+induced+by+oxidative+stress+and+mediated+by+mitochondria&doi=10.1016%2Fj.bbrc.2003.12.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Modification of glycolysis affects cell sensitivity to apoptosis induced by oxidative stress and mediated by mitochondria</span></div><div class="casAuthors">Jeong, Dae-won; Kim, Tae-Soo; Cho, Il Taeg; Kim, Ick Young</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">313</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">984-991</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science</span>)
        </div><div class="casAbstract">The effect of alteration of the glycolytic pathway on cell damage induced by oxidative stress was investigated with dihydrofolate reductase-deficient Chinese hamster ovary (CHO) cells that either overexpress cytosolic glycerol-3-phosphate dehydrogenase (CHO/cGPDH cells) or are depleted of the A subunit of lactate dehydrogenase as a result of anti-sense RNA expression (CHO/anti-LDH cells).  The extent of oxidative phosphorylation in CHO/anti-LDH and CHO/cGPDH cells was increased and decreased, resp., relative to that in parental CHO cells, as revealed by measurement of the intracellular content of ATP, the rate of cellular O2 consumption, the mitochondrial membrane potential (ÎÎ¨m), and the generation of reactive oxygen species.  The sensitivity of these cell lines to cell death induced by the exogenous oxidant tert-Bu hydroperoxide decreased according to the rank order CHO/anti-LDH > CHO > CHO/cGPDH.  Exogenous pyruvate markedly increased the sensitivity of CHO/cGPDH cells to oxidant-induced death.  The differences among the three cell lines in susceptibility to oxidant-induced death were reflected in the proportion of oxidant-treated cells with a subdiploid DNA content, with a collapsed ÎÎ¨m, and with cytochrome c in the cytosol, indicating that death was mediated by apoptosis.  These results demonstrate that the influx of respiratory substrate into mitochondria is an important determinant of cell sensitivity to oxidant-induced apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHI8kF2mhqALVg90H21EOLACvtfcHk0lgIgplz_9mk6g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXosFCm&md5=19e19165c98698c2c0cde2450e9f1c45</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2003.12.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2003.12.033%26sid%3Dliteratum%253Aachs%26aulast%3DJeong%26aufirst%3DD.%2BW.%26aulast%3DKim%26aufirst%3DT.%2BS.%26aulast%3DCho%26aufirst%3DI.%2BT.%26aulast%3DKim%26aufirst%3DI.%2BY.%26atitle%3DModification%2520of%2520glycolysis%2520affects%2520cell%2520sensitivity%2520to%2520apoptosis%2520induced%2520by%2520oxidative%2520stress%2520and%2520mediated%2520by%2520mitochondria%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2004%26volume%3D313%26spage%3D984%26epage%3D991%26doi%3D10.1016%2Fj.bbrc.2003.12.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vaughn, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, M.</span></span> <span> </span><span class="NLM_article-title">Glucose metabolism inhibits apoptosis in neurons and cancer cells by redox inactivation of cytochrome c</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1477</span>â <span class="NLM_lpage">1483</span>, <span class="refDoi">Â DOI: 10.1038/ncb1807</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fncb1807" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=19029908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVentbbE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=1477-1483&author=A.+E.+Vaughnauthor=M.+Deshmukh&title=Glucose+metabolism+inhibits+apoptosis+in+neurons+and+cancer+cells+by+redox+inactivation+of+cytochrome+c&doi=10.1038%2Fncb1807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Glucose metabolism inhibits apoptosis in neurons and cancer cells by redox inactivation of cytochrome c</span></div><div class="casAuthors">Vaughn, Allyson E.; Deshmukh, Mohanish</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1477-1483</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Neurons and cancer cells use glucose extensively, yet the precise advantage of this adaptation remains unclear.  These two seemingly disparate cell types also show an increased regulation of the apoptotic pathway, which allows for their long-term survival.  Here, we show that both neurons and cancer cells strictly inhibit cytochrome c-mediated apoptosis by a mechanism dependent on glucose metab.  We report that the pro-apoptotic activity of cytochrome c is influenced by its redox state and that increases in reactive oxygen species (ROS) following an apoptotic insult lead to the oxidn. and activation of cytochrome c.  In healthy neurons and cancer cells, however, cytochrome c is reduced and held inactive by intracellular glutathione (GSH), generated as a result of glucose metab. by the pentose phosphate pathway.  These results uncover a striking similarity in apoptosis regulation between neurons and cancer cells and provide insight into an adaptive advantage offered by the Warburg effect for cancer cell evasion of apoptosis and for long-term neuronal survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe03U9SKMYw7Vg90H21EOLACvtfcHk0lgIgplz_9mk6g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVentbbE&md5=e08afc286f343190c84d0940a77efb19</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1038%2Fncb1807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncb1807%26sid%3Dliteratum%253Aachs%26aulast%3DVaughn%26aufirst%3DA.%2BE.%26aulast%3DDeshmukh%26aufirst%3DM.%26atitle%3DGlucose%2520metabolism%2520inhibits%2520apoptosis%2520in%2520neurons%2520and%2520cancer%2520cells%2520by%2520redox%2520inactivation%2520of%2520cytochrome%2520c%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2008%26volume%3D10%26spage%3D1477%26epage%3D1483%26doi%3D10.1038%2Fncb1807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoppel, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesnefsky, E. J.</span></span> <span> </span><span class="NLM_article-title">Blockade of electron transport before cardiac ischemia with the reversible inhibitor amobarbital protects rat heart mitochondria</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>316</i></span>,  <span class="NLM_fpage">200</span>â <span class="NLM_lpage">207</span>, <span class="refDoi">Â DOI: 10.1124/jpet.105.091702</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1124%2Fjpet.105.091702" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=16174799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhsleqtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2006&pages=200-207&author=Q.+Chenauthor=C.+L.+Hoppelauthor=E.+J.+Lesnefsky&title=Blockade+of+electron+transport+before+cardiac+ischemia+with+the+reversible+inhibitor+amobarbital+protects+rat+heart+mitochondria&doi=10.1124%2Fjpet.105.091702"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Blockade of electron transport before cardiac ischemia with the reversible inhibitor amobarbital protects rat heart mitochondria</span></div><div class="casAuthors">Chen, Qun; Hoppel, Charles L.; Lesnefsky, Edward J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">316</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">200-207</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Cardiac ischemia damages the mitochondrial electron transport chain.  Irreversible blockade of electron transport at complex I by rotenone decreases ischemic damage to cardiac mitochondria by decreasing the loss of cytochrome c and preserving respiration through cytochrome oxidase.  Therapeutic intervention to protect myocardium during ischemia and reperfusion requires the use of a reversible inhibitor that allows resumption of oxidative metab. during reperfusion.  Amobarbital is a reversible inhibitor at the rotenone site of complex I.  We asked whether amobarbital administered immediately before ischemia protected respiratory function.  Isolated rat hearts were perfused for 15 min followed by 25-min global ischemia at 37Â°.  Amobarbital-treated hearts received drug for 1 min before ischemia.  Subsarcolemmal (SSM) and interfibrillar (IFM) populations of mitochondria were isolated after ischemia, and oxidative phosphorylation was measured.  Amobarbital protected oxidative phosphorylation, including through cytochrome oxidase, in both SSM and IFM in a dose-dependent manner, with an optimal dose of 2 to 2.5 mM.  Amobarbital also preserved cytochrome c content in both SSM and IFM.  Thus, reversible blockade of the electron transport chain during ischemia protects mitochondrial respiration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj-3A9Kx8mDrVg90H21EOLACvtfcHk0lg2l49J7xRk6A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhsleqtg%253D%253D&md5=ddb82ae9cc62734e7d785620a7b7f79d</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.091702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.091702%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DHoppel%26aufirst%3DC.%2BL.%26aulast%3DLesnefsky%26aufirst%3DE.%2BJ.%26atitle%3DBlockade%2520of%2520electron%2520transport%2520before%2520cardiac%2520ischemia%2520with%2520the%2520reversible%2520inhibitor%2520amobarbital%2520protects%2520rat%2520heart%2520mitochondria%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2006%26volume%3D316%26spage%3D200%26epage%3D207%26doi%3D10.1124%2Fjpet.105.091702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aidakkak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stowe, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesnefsky, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camara, A. K. S.</span></span> <span> </span><span class="NLM_article-title">Inhibited mitochondrial respiration by amobarbital during cardiac ischaemia improves redox state and reduces matrix Ca2+ overload and ROS release</span>. <i>Cardiovasc. Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">406</span>â <span class="NLM_lpage">415</span>, <span class="refDoi">Â DOI: 10.1016/j.cardiores.2007.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.cardiores.2007.08.008" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2007&pages=406-415&author=M.+Aidakkakauthor=D.+F.+Stoweauthor=Q.+Chenauthor=E.+J.+Lesnefskyauthor=A.+K.+S.+Camara&title=Inhibited+mitochondrial+respiration+by+amobarbital+during+cardiac+ischaemia+improves+redox+state+and+reduces+matrix+Ca2%2B+overload+and+ROS+release&doi=10.1016%2Fj.cardiores.2007.08.008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1016%2Fj.cardiores.2007.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cardiores.2007.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DAidakkak%26aufirst%3DM.%26aulast%3DStowe%26aufirst%3DD.%2BF.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DLesnefsky%26aufirst%3DE.%2BJ.%26aulast%3DCamara%26aufirst%3DA.%2BK.%2BS.%26atitle%3DInhibited%2520mitochondrial%2520respiration%2520by%2520amobarbital%2520during%2520cardiac%2520ischaemia%2520improves%2520redox%2520state%2520and%2520reduces%2520matrix%2520Ca2%252B%2520overload%2520and%2520ROS%2520release%26jtitle%3DCardiovasc.%2520Res.%26date%3D2007%26volume%3D77%26spage%3D406%26epage%3D415%26doi%3D10.1016%2Fj.cardiores.2007.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCormack, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanley, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolff, A. A.</span></span> <span> </span><span class="NLM_article-title">Ranolazine: a novel metabolic modulator for the treatment of angina</span>. <i>Gen. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">639</span>â <span class="NLM_lpage">645</span>, <span class="refDoi">Â DOI: 10.1016/S0306-3623(97)00301-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2FS0306-3623%2897%2900301-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=9559312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADyaK1cXisVSmsrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1998&pages=639-645&author=J.+G.+McCormackauthor=W.+C.+Stanleyauthor=A.+A.+Wolff&title=Ranolazine%3A+a+novel+metabolic+modulator+for+the+treatment+of+angina&doi=10.1016%2FS0306-3623%2897%2900301-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Ranolazine: a novel metabolic modulator for the treatment of angina</span></div><div class="casAuthors">McCormack, James G.; Stanley, William C.; Wolff, Andrew A.</div><div class="citationInfo"><span class="NLM_cas:title">General Pharmacology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">639-645</span>CODEN:
                <span class="NLM_cas:coden">GEPHDP</span>;
        ISSN:<span class="NLM_cas:issn">0306-3623</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review with â¼40 refs.  1. Ranolazine shifts ATP prodn. away from fatty acid oxidn. toward glucose oxidn.  2. Because more oxygen is required to phosphorylate a given amt. of ATP during fatty acid oxidn. than during carbohydrate oxidn., the ranolazine-induced shift in substrate selection reduces the cell's demand for oxygen without decreasing its ability to do work.  The shift also maintains coupling of glycolysis to glucose oxidn. during ischemia, thus reducing tissue acidosis.  3. This unique, non-hemodynamic mechanism offers the potential to treat angina without reducing blood pressure, heart rate or myocardial contractility.  4. At least three double-blind, randomized, placebo-controlled clin. trials have yielded data consistent with this hypothesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobLv0eFcDoQrVg90H21EOLACvtfcHk0lg2l49J7xRk6A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXisVSmsrc%253D&md5=153f2ecebae88b181cced9eed6e1ae93</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1016%2FS0306-3623%2897%2900301-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0306-3623%252897%252900301-7%26sid%3Dliteratum%253Aachs%26aulast%3DMcCormack%26aufirst%3DJ.%2BG.%26aulast%3DStanley%26aufirst%3DW.%2BC.%26aulast%3DWolff%26aufirst%3DA.%2BA.%26atitle%3DRanolazine%253A%2520a%2520novel%2520metabolic%2520modulator%2520for%2520the%2520treatment%2520of%2520angina%26jtitle%3DGen.%2520Pharmacol.%26date%3D1998%26volume%3D30%26spage%3D639%26epage%3D645%26doi%3D10.1016%2FS0306-3623%2897%2900301-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wyatt, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skene, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veitch, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hue, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mccormack, J. G.</span></span> <span> </span><span class="NLM_article-title">The antianginal agent ranolazine Is a weak inhibitor of the respiratory Complex-I, but with greater potency in broken or uncoupled than in coupled mitochondria</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">1599</span>â <span class="NLM_lpage">1606</span>, <span class="refDoi">Â DOI: 10.1016/0006-2952(95)02042-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2F0006-2952%2895%2902042-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=7503762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADyaK2MXpvVWltr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1995&pages=1599-1606&author=K.+M.+Wyattauthor=C.+Skeneauthor=K.+Veitchauthor=L.+Hueauthor=J.+G.+Mccormack&title=The+antianginal+agent+ranolazine+Is+a+weak+inhibitor+of+the+respiratory+Complex-I%2C+but+with+greater+potency+in+broken+or+uncoupled+than+in+coupled+mitochondria&doi=10.1016%2F0006-2952%2895%2902042-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">The antianginal agent ranolazine is a weak inhibitor of the respiratory complex I, but with greater potency in broken or uncoupled than in coupled mitochondria</span></div><div class="casAuthors">Wyatt, Katrina M.; Skene, Caroline; Veitch, Keith; Hue, Louis; McCormack, James G.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1599-606</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Ranolazine (RS-43285) has shown antianginal effects in clin. trials and cardiac anti-ischemic activity in several in vivo and in vitro animal models, but without affecting hemodynamics.  Its mechanism is thought to mainly involve a switch in substrate utilization from fatty acids to glucose to, thus, improve efficiency of O2 use; however, its precise mol. target(s) are unknown.  In studies to investigate its action further, using isolated rat heart mitochondria, ranolazine was found to weakly inhibit (pIC50 values > 300 Î¼M) respiration by coupled mitochondria provided with NAD+-linked substrates but not with succinate.  With broken mitochondrial membranes or submitochondrial particles, ranolazine inhibited NADH but not succinate oxidn. and with pIC50 values in the lower range of 3-50 Î¼M.  Studies with different electron acceptors and respiratory inhibitors indicated that it inhibits respiratory Complex I at a site between ferricyanide and mendadione and ubiquinone-1 redn. (i.e. at a similar locus to rotenone).  However, unlike rotenone, ranolazine was an uncompetitive inhibitor with respect to ubiquinone-1.  Ranolazine inhibition of Complex I was reversible and occurred also with mitochondria from pig, guinea pig, and human heart, and rat liver.  Further studies using rat heart mitochondria in different energization states (i.e. broken, uncoupled, or coupled) showed a 50-100-fold shift to greater potency of ranolazine in the broken compared to the coupled; with the uncoupled it was about 2-fold less potent than the broken.  These shifts in potency were not found with rotenone or amytal.  Studies with radiolabeled ranolazine showed that it bound to mitochondrial membranes with greater affinity in the broken compared to the coupled or uncoupled conditions.  Rotenone displaced radiolabeled ranolazine from its binding site.  This property of ranolazine may play some in its anti-ischemic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkP6-MMnFKQrVg90H21EOLACvtfcHk0lg9B8SF_INjjw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXpvVWltr8%253D&md5=0f4e1afda8849f6fe15ec615e0642692</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2895%2902042-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252895%252902042-X%26sid%3Dliteratum%253Aachs%26aulast%3DWyatt%26aufirst%3DK.%2BM.%26aulast%3DSkene%26aufirst%3DC.%26aulast%3DVeitch%26aufirst%3DK.%26aulast%3DHue%26aufirst%3DL.%26aulast%3DMccormack%26aufirst%3DJ.%2BG.%26atitle%3DThe%2520antianginal%2520agent%2520ranolazine%2520Is%2520a%2520weak%2520inhibitor%2520of%2520the%2520respiratory%2520Complex-I%252C%2520but%2520with%2520greater%2520potency%2520in%2520broken%2520or%2520uncoupled%2520than%2520in%2520coupled%2520mitochondria%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1995%26volume%3D50%26spage%3D1599%26epage%3D1606%26doi%3D10.1016%2F0006-2952%2895%2902042-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wojtovich, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brookes, P. S.</span></span> <span> </span><span class="NLM_article-title">The complex II inhibitor atpenin A5 protects against cardiac ischemia-reperfusion injury via activation of mitochondrial K-ATP channels</span>. <i>Basic Res. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">121</span>â <span class="NLM_lpage">129</span>, <span class="refDoi">Â DOI: 10.1007/s00395-009-0001-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1007%2Fs00395-009-0001-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=19242645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVSisL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2009&pages=121-129&author=A.+P.+Wojtovichauthor=P.+S.+Brookes&title=The+complex+II+inhibitor+atpenin+A5+protects+against+cardiac+ischemia-reperfusion+injury+via+activation+of+mitochondrial+K-ATP+channels&doi=10.1007%2Fs00395-009-0001-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">The complex II inhibitor atpenin A5 protects against cardiac ischemia-reperfusion injury via activation of mitochondrial KATP channels</span></div><div class="casAuthors">Wojtovich, Andrew P.; Brookes, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">Basic Research in Cardiology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">121-129</span>CODEN:
                <span class="NLM_cas:coden">BRCAB7</span>;
        ISSN:<span class="NLM_cas:issn">0300-8428</span>.
    
            (<span class="NLM_cas:orgname">Steinkopff Verlag</span>)
        </div><div class="casAbstract">The cardioprotective effects of ischemic preconditioning (IPC) can be mimicked or blocked by pharmacol. agents, which modulate the mitochondrial ATP-sensitive potassium (mKATP) channel, thereby implicating this channel in the mechanism of IPC.  Cardioprotection can also be achieved via inhibition of mitochondrial respiratory complex II, and significant pharmacol. overlap exists between complex II inhibitors and mKATP channel agonists.  However, the relationship between complex II and the mKATP channel remains unclear.  Atpenin A5 (AA5) is a potent and specific complex II inhibitor, and herein we report that AA5 (1 nM) also activates the mKATP channel and protects against simulated ischemia-reperfusion (IR) injury in isolated cardiomyocytes.  Similar to known mKATP agonists, AA5-mediated protection was sensitive to the mKATP antagonists 5-hydroxydecanoate (5HD) and glyburide.  Notably, the optimal mKATP opening and protective concn. of AA5 had no effect on complex II enzymic activity, suggesting an interaction of AA5 with complex II, but not inhibition of the complex per se, is necessary for protection.  A cardioprotective effect of AA5 was also obsd. in isolated perfused hearts, wherein AA5 increased post-IR contractile function and decreased infarct size, in a 5HD-sensitive manner.  In conclusion, the specific complex II inhibitor AA5 is the most potent mKATP activator discovered to date, and provides a novel method of activating mKATP channels and protecting the heart from IR injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxHQQgJptwI7Vg90H21EOLACvtfcHk0lg9B8SF_INjjw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVSisL4%253D&md5=83cc7391a1ad168e6c1bc050deb7121a</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1007%2Fs00395-009-0001-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00395-009-0001-y%26sid%3Dliteratum%253Aachs%26aulast%3DWojtovich%26aufirst%3DA.%2BP.%26aulast%3DBrookes%26aufirst%3DP.%2BS.%26atitle%3DThe%2520complex%2520II%2520inhibitor%2520atpenin%2520A5%2520protects%2520against%2520cardiac%2520ischemia-reperfusion%2520injury%2520via%2520activation%2520of%2520mitochondrial%2520K-ATP%2520channels%26jtitle%3DBasic%2520Res.%2520Cardiol.%26date%3D2009%26volume%3D104%26spage%3D121%26epage%3D129%26doi%3D10.1007%2Fs00395-009-0001-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drose, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bleier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, U.</span></span> <span> </span><span class="NLM_article-title">A common mechanism links differently acting Complex II inhibitors to cardioprotection: modulation of mitochondrial reactive oxygen species production</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">814</span>â <span class="NLM_lpage">822</span>, <span class="refDoi">Â DOI: 10.1124/mol.110.070342</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1124%2Fmol.110.070342" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=21278232" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BC3Mvksleitw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2011&pages=814-822&author=S.+Droseauthor=L.+Bleierauthor=U.+Brandt&title=A+common+mechanism+links+differently+acting+Complex+II+inhibitors+to+cardioprotection%3A+modulation+of+mitochondrial+reactive+oxygen+species+production&doi=10.1124%2Fmol.110.070342"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">A common mechanism links differently acting complex II inhibitors to cardioprotection: modulation of mitochondrial reactive oxygen species production</span></div><div class="casAuthors">Drose Stefan; Bleier Lea; Brandt Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">Molecular pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">814-22</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In this study, we have analyzed the effect of different cardioprotective complex II inhibitors on the mitochondrial production of reactive oxygen species (ROS) because ROS seem to be essential for signaling during preconditioning to prevent ischemia/reperfusion injury.  Despite different binding sites and concentrations required for half-maximal inhibition-ranging from nanomolar for the Q site inhibitor atpenin A5 to millimolar for the succinate analog malonate-all inhibitors modulated ROS production in the same ambivalent fashion: they promoted the generation of superoxide at the Q(o) site of complex III under conditions of "oxidant-induced reduction" but attenuated ROS generated at complex I due to reverse electron transfer.  All inhibitors showed these ambivalent effects independent of the presence of K(+).  These findings suggest a direct modulation of mitochondrial ROS generation during cardioprotection via complex II inhibition and question the recently proposed role of complex II as a regulatory component of the putative mitochondrial K(ATP) channel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQF_CEOTX_Zxb7NkxioyDXTfW6udTcc2eZpXBehQ4mklLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mvksleitw%253D%253D&md5=78d9bffad4940551e0fa09b8df741daf</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1124%2Fmol.110.070342&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.110.070342%26sid%3Dliteratum%253Aachs%26aulast%3DDrose%26aufirst%3DS.%26aulast%3DBleier%26aufirst%3DL.%26aulast%3DBrandt%26aufirst%3DU.%26atitle%3DA%2520common%2520mechanism%2520links%2520differently%2520acting%2520Complex%2520II%2520inhibitors%2520to%2520cardioprotection%253A%2520modulation%2520of%2520mitochondrial%2520reactive%2520oxygen%2520species%2520production%26jtitle%3DMol.%2520Pharmacol.%26date%3D2011%26volume%3D79%26spage%3D814%26epage%3D822%26doi%3D10.1124%2Fmol.110.070342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rena, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardie, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, E. R.</span></span> <span> </span><span class="NLM_article-title">The mechanisms of action of metformin</span>. <i>Diabetologia</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1577</span>â <span class="NLM_lpage">1585</span>, <span class="refDoi">Â DOI: 10.1007/s00125-017-4342-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1007%2Fs00125-017-4342-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=28776086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1yiurvP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1577-1585&author=G.+Renaauthor=D.+G.+Hardieauthor=E.+R.+Pearson&title=The+mechanisms+of+action+of+metformin&doi=10.1007%2Fs00125-017-4342-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">The mechanisms of action of metformin</span></div><div class="casAuthors">Rena, Graham; Hardie, D. Grahame; Pearson, Ewan R.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetologia</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1577-1585</span>CODEN:
                <span class="NLM_cas:coden">DBTGAJ</span>;
        ISSN:<span class="NLM_cas:issn">0012-186X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Metformin is a widely-used drug that results in clear benefits in relation to glucose metab. and diabetes-related complications.  The mechanisms underlying these benefits are complex and still not fully understood.  Physiol., metformin has been shown to reduce hepatic glucose prodn., yet not all of its effects can be explained by this mechanism and there is increasing evidence of a key role for the gut.  At the mol. level the findings vary depending on the doses of metformin used and duration of treatment, with clear differences between acute and chronic administration.  Metformin has been shown to act via both AMP-activated protein kinase (AMPK)-dependent and AMPK-independent mechanisms; by inhibition of mitochondrial respiration but also perhaps by inhibition of mitochondrial glycerophosphate dehydrogenase, and a mechanism involving the lysosome.  In the last 10 years, we have moved from a simple picture, that metformin improves glycemia by acting on the liver via AMPK activation, to a much more complex picture reflecting its multiple modes of action.  More work is required to truly understand how this drug works in its target population: individuals with type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1XNiaJVVDOLVg90H21EOLACvtfcHk0li00w9sjRuRZg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1yiurvP&md5=52c9c90d4a3968f61a500ec87884dab4</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1007%2Fs00125-017-4342-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00125-017-4342-z%26sid%3Dliteratum%253Aachs%26aulast%3DRena%26aufirst%3DG.%26aulast%3DHardie%26aufirst%3DD.%2BG.%26aulast%3DPearson%26aufirst%3DE.%2BR.%26atitle%3DThe%2520mechanisms%2520of%2520action%2520of%2520metformin%26jtitle%3DDiabetologia%26date%3D2017%26volume%3D60%26spage%3D1577%26epage%3D1585%26doi%3D10.1007%2Fs00125-017-4342-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devine, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redondo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinsella, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breen, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEneaney, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munsey, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivaprasadarao, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Findlay, J. B.</span></span> <span> </span><span class="NLM_article-title">Novel mitochondrial complex I inhibitors restore glucose-handling abilities of high-fat fed mice</span>. <i>J. Mol. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">261</span>â <span class="NLM_lpage">271</span>, <span class="refDoi">Â DOI: 10.1530/JME-15-0225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1530%2FJME-15-0225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=26759391" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslOlt7rL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2016&pages=261-271&author=D.+S.+Martinauthor=S.+Leonardauthor=R.+Devineauthor=C.+Redondoauthor=G.+K.+Kinsellaauthor=C.+J.+Breenauthor=V.+McEneaneyauthor=M.+F.+Rooneyauthor=T.+S.+Munseyauthor=R.+K.+Porterauthor=A.+Sivaprasadaraoauthor=J.+C.+Stephensauthor=J.+B.+Findlay&title=Novel+mitochondrial+complex+I+inhibitors+restore+glucose-handling+abilities+of+high-fat+fed+mice&doi=10.1530%2FJME-15-0225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mitochondrial complex I inhibitors restore glucose-handling abilities of high-fat fed mice</span></div><div class="casAuthors">Martin, Darren S. D.; Leonard, Siobhan; Devine, Robert; Redondo, Clara; Kinsella, Gemma K.; Breen, Conor J.; McEneaney, Victoria; Rooney, Mary F.; Munsey, Tim S.; Porter, Richard K.; Sivaprasadarao, Asipu; Stephens, John C.; Findlay, John B. C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Endocrinology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">261-271</span>CODEN:
                <span class="NLM_cas:coden">JMLEEI</span>;
        ISSN:<span class="NLM_cas:issn">0952-5041</span>.
    
            (<span class="NLM_cas:orgname">BioScientifica Ltd.</span>)
        </div><div class="casAbstract">Metformin is the main drug of choice for treating type 2 diabetes, yet the therapeutic regimens and side effects of the compd. are all undesirable and can lead to reduced compliance.  The aim of this study was to elucidate the mechanism of action of two novel compds. which improved glucose handling and wt. gain in mice on a high-fat diet.  Wildtype C57Bl/6 male mice were fed on a high-fat diet and treated with novel, anti-diabetic compds.  Both compds. restored the glucose handling ability of these mice.  At a cellular level, these compds. achieve this by inhibiting complex I activity in mitochondria, leading to AMP-activated protein kinase activation and subsequent increased glucose uptake by the cells, as measured in the mouse C2C12 muscle cell line.  Based on the inhibition of NADH dehydrogenase (IC50 27Î¼molL-1), one of these compds. is close to a thousand fold more potent than metformin.  There are no indications of off target effects.  The compds. have the potential to have a greater anti-diabetic effect at a lower dose than metformin and may represent a new anti-diabetic compd. class.  The mechanism of action appears not to be as an insulin sensitizer but rather as an insulin substitute.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoL6N8DXMcaN7Vg90H21EOLACvtfcHk0li00w9sjRuRZg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslOlt7rL&md5=bec695982d143851a4b49ba5de3cb837</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1530%2FJME-15-0225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1530%252FJME-15-0225%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DD.%2BS.%26aulast%3DLeonard%26aufirst%3DS.%26aulast%3DDevine%26aufirst%3DR.%26aulast%3DRedondo%26aufirst%3DC.%26aulast%3DKinsella%26aufirst%3DG.%2BK.%26aulast%3DBreen%26aufirst%3DC.%2BJ.%26aulast%3DMcEneaney%26aufirst%3DV.%26aulast%3DRooney%26aufirst%3DM.%2BF.%26aulast%3DMunsey%26aufirst%3DT.%2BS.%26aulast%3DPorter%26aufirst%3DR.%2BK.%26aulast%3DSivaprasadarao%26aufirst%3DA.%26aulast%3DStephens%26aufirst%3DJ.%2BC.%26aulast%3DFindlay%26aufirst%3DJ.%2BB.%26atitle%3DNovel%2520mitochondrial%2520complex%2520I%2520inhibitors%2520restore%2520glucose-handling%2520abilities%2520of%2520high-fat%2520fed%2520mice%26jtitle%3DJ.%2520Mol.%2520Endocrinol.%26date%3D2016%26volume%3D56%26spage%3D261%26epage%3D271%26doi%3D10.1530%2FJME-15-0225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flores, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krall, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jelinek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miranda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grigorian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graeber, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evseenko, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coller, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christofk, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowry, W. E.</span></span> <span> </span><span class="NLM_article-title">Lactate dehydrogenase activity drives hair follicle stem cell activation</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1017</span>â <span class="NLM_lpage">1026</span>, <span class="refDoi">Â DOI: 10.1038/ncb3575</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fncb3575" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=28812580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlKjtb3F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=1017-1026&author=A.+Floresauthor=J.+Schellauthor=A.+S.+Krallauthor=D.+Jelinekauthor=M.+Mirandaauthor=M.+Grigorianauthor=D.+Braasauthor=A.+C.+Whiteauthor=J.+L.+Zhouauthor=N.+A.+Grahamauthor=T.+Graeberauthor=P.+Sethauthor=D.+Evseenkoauthor=H.+A.+Collerauthor=J.+Rutterauthor=H.+R.+Christofkauthor=W.+E.+Lowry&title=Lactate+dehydrogenase+activity+drives+hair+follicle+stem+cell+activation&doi=10.1038%2Fncb3575"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Lactate dehydrogenase activity drives hair follicle stem cell activation</span></div><div class="casAuthors">Flores, Aimee; Schell, John; Krall, Abigail S.; Jelinek, David; Miranda, Matilde; Grigorian, Melina; Braas, Daniel; White, Andrew C.; Zhou, Jessica L.; Graham, Nicholas A.; Graeber, Thomas; Seth, Pankaj; Evseenko, Denis; Coller, Hilary A.; Rutter, Jared; Christofk, Heather R.; Lowry, William E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1017-1026</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Although normally dormant, hair follicle stem cells (HFSCs) quickly become activated to divide during a new hair cycle.  The quiescence of HFSCs is known to be regulated by a no. of intrinsic and extrinsic mechanisms.  Here we provide several lines of evidence to demonstrate that HFSCs utilize glycolytic metab. and produce significantly more lactate than other cells in the epidermis.  Furthermore, lactate generation appears to be crit. for the activation of HFSCs as deletion of lactate dehydrogenase (Ldha) prevented their activation.  Conversely, genetically promoting lactate prodn. in HFSCs through mitochondrial pyruvate carrier 1 (Mpc1) deletion accelerated their activation and the hair cycle.  Finally, we identify small mols. that increase lactate prodn. by stimulating Myc levels or inhibiting Mpc1 carrier activity and can topically induce the hair cycle.  These data suggest that HFSCs maintain a metabolic state that allows them to remain dormant and yet quickly respond to appropriate proliferative stimuli.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4OuPv43seibVg90H21EOLACvtfcHk0li00w9sjRuRZg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlKjtb3F&md5=92499916ee28424785ce7fa6a1519506</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1038%2Fncb3575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncb3575%26sid%3Dliteratum%253Aachs%26aulast%3DFlores%26aufirst%3DA.%26aulast%3DSchell%26aufirst%3DJ.%26aulast%3DKrall%26aufirst%3DA.%2BS.%26aulast%3DJelinek%26aufirst%3DD.%26aulast%3DMiranda%26aufirst%3DM.%26aulast%3DGrigorian%26aufirst%3DM.%26aulast%3DBraas%26aufirst%3DD.%26aulast%3DWhite%26aufirst%3DA.%2BC.%26aulast%3DZhou%26aufirst%3DJ.%2BL.%26aulast%3DGraham%26aufirst%3DN.%2BA.%26aulast%3DGraeber%26aufirst%3DT.%26aulast%3DSeth%26aufirst%3DP.%26aulast%3DEvseenko%26aufirst%3DD.%26aulast%3DColler%26aufirst%3DH.%2BA.%26aulast%3DRutter%26aufirst%3DJ.%26aulast%3DChristofk%26aufirst%3DH.%2BR.%26aulast%3DLowry%26aufirst%3DW.%2BE.%26atitle%3DLactate%2520dehydrogenase%2520activity%2520drives%2520hair%2520follicle%2520stem%2520cell%2520activation%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2017%26volume%3D19%26spage%3D1017%26epage%3D1026%26doi%3D10.1038%2Fncb3575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Son, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mun, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kook, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, K. S.</span></span> <span> </span><span class="NLM_article-title">A novel and safe small molecule enhances hair follicle regeneration by facilitating metabolic reprogramming</span>. <i>Exp. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">15</span>, <span class="refDoi">Â DOI: 10.1038/s12276-018-0185-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fs12276-018-0185-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=30523246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFCktbrL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2018&pages=1-15&author=M.+J.+Sonauthor=J.+K.+Jeongauthor=Y.+Kwonauthor=J.+S.+Ryuauthor=S.+J.+Munauthor=H.+J.+Kimauthor=S.+W.+Kimauthor=S.+Yooauthor=J.+Kookauthor=H.+Leeauthor=J.+Kimauthor=K.+S.+Chung&title=A+novel+and+safe+small+molecule+enhances+hair+follicle+regeneration+by+facilitating+metabolic+reprogramming&doi=10.1038%2Fs12276-018-0185-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Cell-penetrating artificial mitochondria-targeting peptide-conjugated metallothionein 1A alleviates mitochondrial damage in Parkinson's disease models</span></div><div class="casAuthors">Kang, Young Cheol; Son, Minuk; Kang, Sora; Im, Suyeol; Piao, Ying; Lim, Kwang Suk; Song, Min-Young; Park, Kang-Sik; Kim, Yong-Hee; Pak, Youngmi Kim</div><div class="citationInfo"><span class="NLM_cas:title">Experimental & Molecular Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1-13</span>CODEN:
                <span class="NLM_cas:coden">EMMEF3</span>;
        ISSN:<span class="NLM_cas:issn">2092-6413</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">An excess of reactive oxygen species (ROS) relative to the antioxidant capacity causes oxidative stress, which plays a role in the development of Parkinson's disease (PD).  Because mitochondria are both sites of ROS generation and targets of ROS damage, the delivery of antioxidants to mitochondria might prevent or alleviate PD.  To transduce the antioxidant protein human metallothionein 1A (hMT1A) into mitochondria, we computationally designed a cell-penetrating artificial mitochondria-targeting peptide (CAMP).  The recombinant CAMP-conjugated hMT1A fusion protein (CAMP-hMT1A) successfully localized to the mitochondria.  Treating a cell culture model of PD with CAMP-hMT1A restored tyrosine hydroxylase expression and mitochondrial activity and reduced ROS prodn.  Furthermore, injection of CAMP-hMT1A into the brain of a mouse model of PD rescued movement impairment and dopaminergic neuronal degeneration.  CAMP-hMT1A delivery into mitochondria might be therapeutic against PD by alleviating mitochondrial damage, and we predict that CAMP could be used to deliver other cargo proteins to the mitochondria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFFVO9GLAQebVg90H21EOLACvtfcHk0lizR4cSoCig4g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFCktbrL&md5=c44cd32d370f7f68263c544946d2e31b</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1038%2Fs12276-018-0185-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs12276-018-0185-z%26sid%3Dliteratum%253Aachs%26aulast%3DSon%26aufirst%3DM.%2BJ.%26aulast%3DJeong%26aufirst%3DJ.%2BK.%26aulast%3DKwon%26aufirst%3DY.%26aulast%3DRyu%26aufirst%3DJ.%2BS.%26aulast%3DMun%26aufirst%3DS.%2BJ.%26aulast%3DKim%26aufirst%3DH.%2BJ.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DYoo%26aufirst%3DS.%26aulast%3DKook%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DChung%26aufirst%3DK.%2BS.%26atitle%3DA%2520novel%2520and%2520safe%2520small%2520molecule%2520enhances%2520hair%2520follicle%2520regeneration%2520by%2520facilitating%2520metabolic%2520reprogramming%26jtitle%3DExp.%2520Mol.%2520Med.%26date%3D2018%26volume%3D50%26spage%3D1%26epage%3D15%26doi%3D10.1038%2Fs12276-018-0185-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gohil, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheth, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wojtovich, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perocchi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clish, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayata, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brookes, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mootha, V. K.</span></span> <span> </span><span class="NLM_article-title">Nutrient-sensitized screening for drugs that shift energy metabolism from mitochondrial respiration to glycolysis</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">249</span>â <span class="NLM_lpage">255</span>, <span class="refDoi">Â DOI: 10.1038/nbt.1606</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fnbt.1606" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=20160716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitVWnsL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=249-255&author=V.+M.+Gohilauthor=S.+A.+Shethauthor=R.+Nilssonauthor=A.+P.+Wojtovichauthor=J.+H.+Leeauthor=F.+Perocchiauthor=W.+Chenauthor=C.+B.+Clishauthor=C.+Ayataauthor=P.+S.+Brookesauthor=V.+K.+Mootha&title=Nutrient-sensitized+screening+for+drugs+that+shift+energy+metabolism+from+mitochondrial+respiration+to+glycolysis&doi=10.1038%2Fnbt.1606"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Nutrient-sensitized screening for drugs that shift energy metabolism from mitochondrial respiration to glycolysis</span></div><div class="casAuthors">Gohil, Vishal M.; Sheth, Sunil A.; Nilsson, Roland; Wojtovich, Andrew P.; Lee, Jeong Hyun; Perocchi, Fabiana; Chen, William; Clish, Clary B.; Ayata, Cenk; Brookes, Paul S.; Mootha, Vamsi K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">249-255</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Most cells have the inherent capacity to shift their reliance on glycolysis relative to oxidative metab., and studies in model systems have shown that targeting such shifts may be useful in treating or preventing a variety of diseases ranging from cancer to ischemic injury.  However, we currently have a limited no. of mechanistically distinct classes of drugs that alter the relative activities of these two pathways.  We screen for such compds. by scoring the ability of >3500 small mols. to selectively impair growth and viability of human fibroblasts in media contg. either galactose or glucose as the sole sugar source.  We identify several clin. used drugs never linked to energy metab., including the antiemetic meclizine, which attenuates mitochondrial respiration through a mechanism distinct from that of canonical inhibitors.  We further show that meclizine pretreatment confers cardioprotection and neuroprotection against ischemia-reperfusion injury in murine models.  Nutrient-sensitized screening may provide a useful framework for understanding gene function and drug action within the context of energy metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGof1g9JzGGiFLVg90H21EOLACvtfcHk0lizR4cSoCig4g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitVWnsL0%253D&md5=3156e31467369716d7dff37487015015</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1606&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1606%26sid%3Dliteratum%253Aachs%26aulast%3DGohil%26aufirst%3DV.%2BM.%26aulast%3DSheth%26aufirst%3DS.%2BA.%26aulast%3DNilsson%26aufirst%3DR.%26aulast%3DWojtovich%26aufirst%3DA.%2BP.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DPerocchi%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DClish%26aufirst%3DC.%2BB.%26aulast%3DAyata%26aufirst%3DC.%26aulast%3DBrookes%26aufirst%3DP.%2BS.%26aulast%3DMootha%26aufirst%3DV.%2BK.%26atitle%3DNutrient-sensitized%2520screening%2520for%2520drugs%2520that%2520shift%2520energy%2520metabolism%2520from%2520mitochondrial%2520respiration%2520to%2520glycolysis%26jtitle%3DNat.%2520Biotechnol.%26date%3D2010%26volume%3D28%26spage%3D249%26epage%3D255%26doi%3D10.1038%2Fnbt.1606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrova-Benedict, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buncic, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, D. C.</span></span> <span> </span><span class="NLM_article-title">Nonviability of cells with oxidative defects in galactose medium: a screening test for affected patient fibroblasts</span>. <i>Biochem. Med. Metab. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">122</span>â <span class="NLM_lpage">126</span>, <span class="refDoi">Â DOI: 10.1016/0885-4505(92)90056-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2F0885-4505%2892%2990056-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1329873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADyaK38Xmt12gtbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=1992&pages=122-126&author=B.+H.+Robinsonauthor=R.+Petrova-Benedictauthor=J.+R.+Buncicauthor=D.+C.+Wallace&title=Nonviability+of+cells+with+oxidative+defects+in+galactose+medium%3A+a+screening+test+for+affected+patient+fibroblasts&doi=10.1016%2F0885-4505%2892%2990056-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Nonviability of cells with oxidative defects in galactose medium:  a screening test for affected patient fibroblasts</span></div><div class="casAuthors">Robinson, B. H.; Petrova-Benedict, R.; Buncic, J. R.; Wallace, D. C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Medicine and Metabolic Biology</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">122-6</span>CODEN:
                <span class="NLM_cas:coden">BMMBES</span>;
        ISSN:<span class="NLM_cas:issn">0885-4505</span>.
    </div><div class="casAbstract">Diagnosis of respiratory chain defects in cultured skin fibroblasts is a difficult diagnostic procedure.  The feasibility of using survival of skin fibroblasts in culture medium with galactose as the major C source was investigated as a method of quickly diagnosing cell lines compromised in oxidative metab.  Cells from patients with most forms of cytochrome oxidase deficiency, cells with complex I deficiency, cells with multiple respiratory chain defects and cells with severe pyruvate dehydrogenase (PDH) complex deficiency failed to survive when subcultured in galactose (5 mM) medium.  Cells from patients with Lebers hereditary optic neuropathy, Kearns-Sayre syndrome, myoclonus-epilepsy-lactic acidosis-stroke, the hepatic form of cytochrome oxidase deficiency, and mild PDH complex deficiency survived well in galactose-contg. medium.  This could be used as a rapid screening test for skin fibroblasts with major oxidative defects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo61ebnsG3l7Vg90H21EOLACvtfcHk0lizR4cSoCig4g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38Xmt12gtbw%253D&md5=085b11e9e3935712adbddcbaec6c6828</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1016%2F0885-4505%2892%2990056-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0885-4505%252892%252990056-5%26sid%3Dliteratum%253Aachs%26aulast%3DRobinson%26aufirst%3DB.%2BH.%26aulast%3DPetrova-Benedict%26aufirst%3DR.%26aulast%3DBuncic%26aufirst%3DJ.%2BR.%26aulast%3DWallace%26aufirst%3DD.%2BC.%26atitle%3DNonviability%2520of%2520cells%2520with%2520oxidative%2520defects%2520in%2520galactose%2520medium%253A%2520a%2520screening%2520test%2520for%2520affected%2520patient%2520fibroblasts%26jtitle%3DBiochem.%2520Med.%2520Metab.%2520Biol.%26date%3D1992%26volume%3D48%26spage%3D122%26epage%3D126%26doi%3D10.1016%2F0885-4505%2892%2990056-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marroquin, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hynes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dykens, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, Y.</span></span> <span> </span><span class="NLM_article-title">Circumventing the Crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">539</span>â <span class="NLM_lpage">547</span>, <span class="refDoi">Â DOI: 10.1093/toxsci/kfm052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1093%2Ftoxsci%2Fkfm052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=17361016" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsV2is7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2007&pages=539-547&author=L.+D.+Marroquinauthor=J.+Hynesauthor=J.+A.+Dykensauthor=J.+D.+Jamiesonauthor=Y.+Will&title=Circumventing+the+Crabtree+effect%3A+replacing+media+glucose+with+galactose+increases+susceptibility+of+HepG2+cells+to+mitochondrial+toxicants&doi=10.1093%2Ftoxsci%2Fkfm052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Circumventing the Crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants</span></div><div class="casAuthors">Marroquin, Lisa D.; Hynes, James; Dykens, James A.; Jamieson, Joseph D.; Will, Yvonne</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">539-547</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-6080</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Many highly proliferative cells generate almost all ATP via glycolysis despite abundant O2 and a normal complement of fully functional mitochondria, a circumstance known as the Crabtree effect.  Such anaerobically poised cells are resistant to xenobiotics that impair mitochondrial function, such as the inhibitors rotenone, antimycin, oligomycin, and compds. like carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP), that uncouple the respiratory electron transfer system from phosphorylation.  These cells are also resistant to the toxicity of many drugs whose deleterious side effect profiles are either caused, or exacerbated, by impairment of mitochondrial function.  Drug-induced mitochondrial toxicity is shown by members of important drug classes, including the thiazolidinediones, statins, fibrates, antivirals, antibiotics, and anticancer agents.  To increase detection of drug-induced mitochondrial effects in a preclin. cell-based assay, HepG2 cells were forced to rely on mitochondrial oxidative phosphorylation rather than glycolysis by substituting galactose for glucose in the growth media.  Oxygen consumption doubles in galactose-grown HepG2 cells and their susceptibility to canonical mitochondrial toxicants correspondingly increases.  Similarly, toxicity of several drugs with known mitochondrial liabilities is more readily apparent in aerobically poised HepG2 cells compared to glucose-grown cells.  Some drugs were equally toxic to both glucose- and galactose-grown cells, suggesting that mitochondrial impairment is likely secondary to other cytotoxic mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2Zb0elenmNbVg90H21EOLACvtfcHk0lh1lY-itRwmuA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsV2is7w%253D&md5=53d6a955ad0a942d1ced5043668bed19</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfm052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfm052%26sid%3Dliteratum%253Aachs%26aulast%3DMarroquin%26aufirst%3DL.%2BD.%26aulast%3DHynes%26aufirst%3DJ.%26aulast%3DDykens%26aufirst%3DJ.%2BA.%26aulast%3DJamieson%26aufirst%3DJ.%2BD.%26aulast%3DWill%26aufirst%3DY.%26atitle%3DCircumventing%2520the%2520Crabtree%2520effect%253A%2520replacing%2520media%2520glucose%2520with%2520galactose%2520increases%2520susceptibility%2520of%2520HepG2%2520cells%2520to%2520mitochondrial%2520toxicants%26jtitle%3DToxicol.%2520Sci.%26date%3D2007%26volume%3D97%26spage%3D539%26epage%3D547%26doi%3D10.1093%2Ftoxsci%2Fkfm052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brand, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholls, D. G.</span></span> <span> </span><span class="NLM_article-title">Assessing mitochondrial dysfunction in cells</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>435</i></span>,  <span class="NLM_fpage">297</span>â <span class="NLM_lpage">312</span>, <span class="refDoi">Â DOI: 10.1042/BJ20110162</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1042%2FBJ20110162" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=21726199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvFOjurs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=435&publication_year=2011&pages=297-312&author=M.+D.+Brandauthor=D.+G.+Nicholls&title=Assessing+mitochondrial+dysfunction+in+cells&doi=10.1042%2FBJ20110162"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Assessing mitochondrial dysfunction in cells</span></div><div class="casAuthors">Brand, Martin D.; Nicholls, David G.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">435</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">297-312</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Assessing mitochondrial dysfunction requires definition of the dysfunction to be investigated.  Usually, it is the ability of the mitochondria to make ATP appropriately in response to energy demands.  Where other functions are of interest, tailored solns. are required.  Dysfunction can be assessed in isolated mitochondria, in cells or in vivo, with different balances between precise exptl. control and physiol. relevance.  There are many methods to measure mitochondrial function and dysfunction in these systems.  Generally, measurements of fluxes give more information about the ability to make ATP than do measurements of intermediates and potentials.  For isolated mitochondria, the best assay is mitochondrial respiratory control: the increase in respiration rate in response to ADP.  For intact cells, the best assay is the equiv. measurement of cell respiratory control, which reports the rate of ATP prodn., the proton leak rate, the coupling efficiency, the max. respiratory rate, the respiratory control ratio and the spare respiratory capacity.  Measurements of membrane potential provide useful addnl. information.  Measurement of both respiration and potential during appropriate titrns. enables the identification of the primary sites of effectors and the distribution of control, allowing deeper quant. analyses.  Many other measurements in current use can be more problematic, as discussed in the present review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpogtjN5LPjXrVg90H21EOLACvtfcHk0lh1lY-itRwmuA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvFOjurs%253D&md5=fd7d4c6ffa1d0ba4427fc27dcafb7d1d</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1042%2FBJ20110162&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20110162%26sid%3Dliteratum%253Aachs%26aulast%3DBrand%26aufirst%3DM.%2BD.%26aulast%3DNicholls%26aufirst%3DD.%2BG.%26atitle%3DAssessing%2520mitochondrial%2520dysfunction%2520in%2520cells%26jtitle%3DBiochem.%2520J.%26date%3D2011%26volume%3D435%26spage%3D297%26epage%3D312%26doi%3D10.1042%2FBJ20110162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tilmant, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerets, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Ron, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bento-Pereira, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atienzar, F. A.</span></span> <span> </span><span class="NLM_article-title">In vitro screening of cell bioenergetics to assess mitochondrial dysfunction in drug development</span>. <i>Toxicol. In Vitro</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">374</span>â <span class="NLM_lpage">383</span>, <span class="refDoi">Â DOI: 10.1016/j.tiv.2018.07.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.tiv.2018.07.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=30030051" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVCntrnE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2018&pages=374-383&author=K.+Tilmantauthor=H.+Geretsauthor=P.+De+Ronauthor=E.+Hanonauthor=C.+Bento-Pereiraauthor=F.+A.+Atienzar&title=In+vitro+screening+of+cell+bioenergetics+to+assess+mitochondrial+dysfunction+in+drug+development&doi=10.1016%2Fj.tiv.2018.07.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro screening of cell bioenergetics to assess mitochondrial dysfunction in drug development</span></div><div class="casAuthors">Tilmant, K.; Gerets, H.; De Ron, P.; Hanon, E.; Bento-Pereira, C.; Atienzar, F. A.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology In Vitro</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">374-383</span>CODEN:
                <span class="NLM_cas:coden">TIVIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0887-2333</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Drug-induced mitochondrial toxicity is considered as a common cellular mechanism that can induce a variety of organ toxicities.  In the present manuscript, 17 in vitro mitochondrial toxic drugs, reported to induce Drug-Induced Liver Injury (DILI) and 6 non-mitochondrial toxic drugs (3 with DILI and 3 without DILI concern), were tested in HepG2 cells using a bioenergetics system.  The 17 mitochondrial toxic drugs represent a wide variety of mitochondrial dysfunctions as well as DILI and include 4 pairs of drugs which are structurally related but assocd. with different DILI concerns in human.  Cell bioenergetics were measured using the XF96e analyzer which simultaneous monitor oxygen consumption rate (OCR) and extracellular acidification rate (ECAR), indirect measurements of oxidative phosphorylation and glycolysis, resp.  OCR assocd. with ATP prodn., maximal respiration, proton leak and spare respiratory capacity, were also assessed.  Duplicate expts. resulted in a sensitivity of 82% (14/17) and specificity of 83% (5/6).  The addn. of stressors improved specificity considerably.  Cut-offs, statistics and rules are clearly discussed to facilitate the use of this assay for screening purposes.  Overall, the authors consider that this assay should be part of the battery of safety screening assays at early stages of drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwxA5f95FBMrVg90H21EOLACvtfcHk0lh1lY-itRwmuA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVCntrnE&md5=ba0bfeecf14ad629a4a0b3dfef5ee8c8</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1016%2Fj.tiv.2018.07.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tiv.2018.07.012%26sid%3Dliteratum%253Aachs%26aulast%3DTilmant%26aufirst%3DK.%26aulast%3DGerets%26aufirst%3DH.%26aulast%3DDe%2BRon%26aufirst%3DP.%26aulast%3DHanon%26aufirst%3DE.%26aulast%3DBento-Pereira%26aufirst%3DC.%26aulast%3DAtienzar%26aufirst%3DF.%2BA.%26atitle%3DIn%2520vitro%2520screening%2520of%2520cell%2520bioenergetics%2520to%2520assess%2520mitochondrial%2520dysfunction%2520in%2520drug%2520development%26jtitle%3DToxicol.%2520In%2520Vitro%26date%3D2018%26volume%3D52%26spage%3D374%26epage%3D383%26doi%3D10.1016%2Fj.tiv.2018.07.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, N. M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theurey, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adam-Vizi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazan, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernardi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolanos, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culmsee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duchen, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dussmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiskum, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galindo, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardingham, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardwick, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jekabsons, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonas, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipton, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manfredi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattson, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Methner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholls, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polster, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pozzan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzuto, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satrustegui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slack, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanson, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swerdlow, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ying, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joselin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gioran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinho, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watters, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvucci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llorente-Folch, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bano, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ankarcrona, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prehn, J. H. M.</span></span> <span> </span><span class="NLM_article-title">Guidelines on experimental methods to assess mitochondrial dysfunction in cellular models of neurodegenerative diseases</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">542</span>â <span class="NLM_lpage">572</span>, <span class="refDoi">Â DOI: 10.1038/s41418-017-0020-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fs41418-017-0020-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=29229998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkslagsbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=542-572&author=N.+M.+C.+Connollyauthor=P.+Theureyauthor=V.+Adam-Viziauthor=N.+G.+Bazanauthor=P.+Bernardiauthor=J.+P.+Bolanosauthor=C.+Culmseeauthor=V.+L.+Dawsonauthor=M.+Deshmukhauthor=M.+R.+Duchenauthor=H.+Dussmannauthor=G.+Fiskumauthor=M.+F.+Galindoauthor=G.+E.+Hardinghamauthor=J.+M.+Hardwickauthor=M.+B.+Jekabsonsauthor=E.+A.+Jonasauthor=J.+Jordanauthor=S.+A.+Liptonauthor=G.+Manfrediauthor=M.+P.+Mattsonauthor=B.+McLaughlinauthor=A.+Methnerauthor=A.+N.+Murphyauthor=M.+P.+Murphyauthor=D.+G.+Nichollsauthor=B.+M.+Polsterauthor=T.+Pozzanauthor=R.+Rizzutoauthor=J.+Satrusteguiauthor=R.+S.+Slackauthor=R.+A.+Swansonauthor=R.+H.+Swerdlowauthor=Y.+Willauthor=Z.+Yingauthor=A.+Joselinauthor=A.+Gioranauthor=C.+M.+Pinhoauthor=O.+Wattersauthor=M.+Salvucciauthor=I.+Llorente-Folchauthor=D.+S.+Parkauthor=D.+Banoauthor=M.+Ankarcronaauthor=P.+Pizzoauthor=J.+H.+M.+Prehn&title=Guidelines+on+experimental+methods+to+assess+mitochondrial+dysfunction+in+cellular+models+of+neurodegenerative+diseases&doi=10.1038%2Fs41418-017-0020-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Guidelines on experimental methods to assess mitochondrial dysfunction in cellular models of neurodegenerative diseases</span></div><div class="casAuthors">Connolly, Niamh M. C.; Theurey, Pierre; Adam-Vizi, Vera; Bazan, Nicolas G.; Bernardi, Paolo; Bolanos, Juan P.; Culmsee, Carsten; Dawson, Valina L.; Deshmukh, Mohanish; Duchen, Michael R.; Dussmann, Heiko; Fiskum, Gary; Galindo, Maria F.; Hardingham, Giles E.; Hardwick, J. Marie; Jekabsons, Mika B.; Jonas, Elizabeth A.; Jordan, Joaquin; Lipton, Stuart A.; Manfredi, Giovanni; Mattson, Mark P.; McLaughlin, BethAnn; Methner, Axel; Murphy, Anne N.; Murphy, Michael P.; Nicholls, David G.; Polster, Brian M.; Pozzan, Tullio; Rizzuto, Rosario; Satrustegui, Jorgina; Slack, Ruth S.; Swanson, Raymond A.; Swerdlow, Russell H.; Will, Yvonne; Ying, Zheng; Joselin, Alvin; Gioran, Anna; Moreira Pinho, Catarina; Watters, Orla; Salvucci, Manuela; Llorente-Folch, Irene; Park, David S.; Bano, Daniele; Ankarcrona, Maria; Pizzo, Paola; Prehn, Jochen H. M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Differentiation</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">542-572</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Neurodegenerative diseases are a spectrum of chronic, debilitating disorders characterised by the progressive degeneration and death of neurons.  Mitochondrial dysfunction has been implicated in most neurodegenerative diseases, but in many instances it is unclear whether such dysfunction is a cause or an effect of the underlying pathol., and whether it represents a viable therapeutic target.  It is therefore imperative to utilize and optimize cellular models and exptl. techniques appropriate to det. the contribution of mitochondrial dysfunction to neurodegenerative disease phenotypes.  In this consensus article, we collate details on and discuss pitfalls of existing exptl. approaches to assess mitochondrial function in in vitro cellular models of neurodegenerative diseases, including specific protocols for the measurement of oxygen consumption rate in primary neuron cultures, and single-neuron, time-lapse fluorescence imaging of the mitochondrial membrane potential and mitochondrial NAD(P)H.  As part of the Cellular Bioenergetics of Neurodegenerative Diseases (CeBioND) consortium (www.cebiond.org), we are performing cross-disease analyses to identify common and distinct mol. mechanisms involved in mitochondrial bioenergetic dysfunction in cellular models of Alzheimer's, Parkinson's, and Huntington's diseases.  Here we provide detailed guidelines and protocols as standardised across the five collaborating labs. of the CeBioND consortium, with addnl. contributions from other experts in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq95eOahbCNrbVg90H21EOLACvtfcHk0liMbRrFi3aLIA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkslagsbY%253D&md5=338513b244a7c1b447ee19159a76e7d9</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1038%2Fs41418-017-0020-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41418-017-0020-4%26sid%3Dliteratum%253Aachs%26aulast%3DConnolly%26aufirst%3DN.%2BM.%2BC.%26aulast%3DTheurey%26aufirst%3DP.%26aulast%3DAdam-Vizi%26aufirst%3DV.%26aulast%3DBazan%26aufirst%3DN.%2BG.%26aulast%3DBernardi%26aufirst%3DP.%26aulast%3DBolanos%26aufirst%3DJ.%2BP.%26aulast%3DCulmsee%26aufirst%3DC.%26aulast%3DDawson%26aufirst%3DV.%2BL.%26aulast%3DDeshmukh%26aufirst%3DM.%26aulast%3DDuchen%26aufirst%3DM.%2BR.%26aulast%3DDussmann%26aufirst%3DH.%26aulast%3DFiskum%26aufirst%3DG.%26aulast%3DGalindo%26aufirst%3DM.%2BF.%26aulast%3DHardingham%26aufirst%3DG.%2BE.%26aulast%3DHardwick%26aufirst%3DJ.%2BM.%26aulast%3DJekabsons%26aufirst%3DM.%2BB.%26aulast%3DJonas%26aufirst%3DE.%2BA.%26aulast%3DJordan%26aufirst%3DJ.%26aulast%3DLipton%26aufirst%3DS.%2BA.%26aulast%3DManfredi%26aufirst%3DG.%26aulast%3DMattson%26aufirst%3DM.%2BP.%26aulast%3DMcLaughlin%26aufirst%3DB.%26aulast%3DMethner%26aufirst%3DA.%26aulast%3DMurphy%26aufirst%3DA.%2BN.%26aulast%3DMurphy%26aufirst%3DM.%2BP.%26aulast%3DNicholls%26aufirst%3DD.%2BG.%26aulast%3DPolster%26aufirst%3DB.%2BM.%26aulast%3DPozzan%26aufirst%3DT.%26aulast%3DRizzuto%26aufirst%3DR.%26aulast%3DSatrustegui%26aufirst%3DJ.%26aulast%3DSlack%26aufirst%3DR.%2BS.%26aulast%3DSwanson%26aufirst%3DR.%2BA.%26aulast%3DSwerdlow%26aufirst%3DR.%2BH.%26aulast%3DWill%26aufirst%3DY.%26aulast%3DYing%26aufirst%3DZ.%26aulast%3DJoselin%26aufirst%3DA.%26aulast%3DGioran%26aufirst%3DA.%26aulast%3DPinho%26aufirst%3DC.%2BM.%26aulast%3DWatters%26aufirst%3DO.%26aulast%3DSalvucci%26aufirst%3DM.%26aulast%3DLlorente-Folch%26aufirst%3DI.%26aulast%3DPark%26aufirst%3DD.%2BS.%26aulast%3DBano%26aufirst%3DD.%26aulast%3DAnkarcrona%26aufirst%3DM.%26aulast%3DPizzo%26aufirst%3DP.%26aulast%3DPrehn%26aufirst%3DJ.%2BH.%2BM.%26atitle%3DGuidelines%2520on%2520experimental%2520methods%2520to%2520assess%2520mitochondrial%2520dysfunction%2520in%2520cellular%2520models%2520of%2520neurodegenerative%2520diseases%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2018%26volume%3D25%26spage%3D542%26epage%3D572%26doi%3D10.1038%2Fs41418-017-0020-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perry, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbieri, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelbard, H. A.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial membrane potential probes and the proton gradient: a practical usage guide</span>. <i>BioTechniques</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">98</span>â <span class="NLM_lpage">115</span>, <span class="refDoi">Â DOI: 10.2144/000113610</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.2144%2F000113610" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=21486251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvFGrtb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=98-115&author=S.+W.+Perryauthor=J.+P.+Normanauthor=J.+Barbieriauthor=E.+B.+Brownauthor=H.+A.+Gelbard&title=Mitochondrial+membrane+potential+probes+and+the+proton+gradient%3A+a+practical+usage+guide&doi=10.2144%2F000113610"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial membrane potential probes and the proton gradient: a practical usage guide</span></div><div class="casAuthors">Perry, Seth W.; Norman, John P.; Barbieri, Justin; Brown, Edward B.; Gelbard, Harris A.</div><div class="citationInfo"><span class="NLM_cas:title">BioTechniques</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">98-100,102-104,106,108,110-115</span>CODEN:
                <span class="NLM_cas:coden">BTNQDO</span>;
        ISSN:<span class="NLM_cas:issn">0736-6205</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Fluorescent probes for monitoring mitochondrial membrane potential are frequently used for assessing mitochondrial function, particularly in the context of cell fate detn. in biol. and biomedical research.  However, valid interpretation of results obtained with such probes requires careful consideration of numerous controls, as well as possible effects of non-protonic charges on dye behavior.  In this context, we provide an overview of some of the important tech. considerations, controls, and parallel complementary assays that can be employed to help ensure appropriate interpretation of results, thus providing a practical usage guide for monitoring mitochondrial membrane potentials with cationic probes.  In total, this review will help illustrate both the strengths and potential pitfalls of common mitochondrial membrane potential dyes, and highlight best-usage approaches for their efficacious application in life sciences research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbiG_ThFfCMbVg90H21EOLACvtfcHk0liMbRrFi3aLIA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvFGrtb0%253D&md5=88634b0b0ab36d3d9f4e734fa69411fa</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.2144%2F000113610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2144%252F000113610%26sid%3Dliteratum%253Aachs%26aulast%3DPerry%26aufirst%3DS.%2BW.%26aulast%3DNorman%26aufirst%3DJ.%2BP.%26aulast%3DBarbieri%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DE.%2BB.%26aulast%3DGelbard%26aufirst%3DH.%2BA.%26atitle%3DMitochondrial%2520membrane%2520potential%2520probes%2520and%2520the%2520proton%2520gradient%253A%2520a%2520practical%2520usage%2520guide%26jtitle%3DBioTechniques%26date%3D2011%26volume%3D50%26spage%3D98%26epage%3D115%26doi%3D10.2144%2F000113610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jastroch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Divakaruni, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mookerjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treberg, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brand, M. D.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial proton and electron leaks</span>. <i>Essays Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">53</span>â <span class="NLM_lpage">67</span>, <span class="refDoi">Â DOI: 10.1042/bse0470053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1042%2Fbse0470053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=20533900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvFKkt78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2010&pages=53-67&author=M.+Jastrochauthor=A.+S.+Divakaruniauthor=S.+Mookerjeeauthor=J.+R.+Trebergauthor=M.+D.+Brand&title=Mitochondrial+proton+and+electron+leaks&doi=10.1042%2Fbse0470053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial proton and electron leaks</span></div><div class="casAuthors">Jastroch, Martin; Divakaruni, Ajit S.; Mookerjee, Shona; Treberg, Jason R.; Brand, Martin D.</div><div class="citationInfo"><span class="NLM_cas:title">Essays in Biochemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">Mitochondrial Function</span>),
    <span class="NLM_cas:pages">53-67</span>CODEN:
                <span class="NLM_cas:coden">ESBIAV</span>;
        ISSN:<span class="NLM_cas:issn">0071-1365</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Mitochondrial proton and electron leak have a major impact on mitochondrial coupling efficiency and prodn. of reactive oxygen species.  In the first part of this chapter, we address the mol. nature of the basal and inducible proton leak pathways, and their physiol. importance.  The basal leak is unregulated, and a major proportion can be attributed to mitochondrial anion carriers, whereas the proton leak through the lipid bilayer appears to be minor.  The basal proton leak is cell-type specific and correlates with metabolic rate.  The inducible leak through the ANT (adenine nucleotide translocase) and UCPs (uncoupling proteins) can be activated by fatty acids, superoxide or lipid peroxidn. products.  The physiol. role of inducible leak through UCP1 in mammalian brown adipose tissue is heat prodn., whereas the roles of non-mammalian UCP1 and its paralogous proteins, in particular UCP2 and UCP3, are not yet resolved.  The second part of the chapter focuses on the electron leak that occurs in the mitochondrial electron transport chain.  Exit of electrons prior to the redn. of oxygen to water at cytochrome c oxidase causes superoxide prodn.  As the mechanisms of electron leak are crucial to understanding their physiol. relevance, we summarize the mechanisms and topol. of electron leak from complexes I and III in studies using isolated mitochondria.  We also highlight recent progress and challenges of assessing electron leak in the living cell.  Finally, we emphasize the importance of proton and electron leak as therapeutic targets in body mass regulation and insulin secretion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrM97KNAYlxp7Vg90H21EOLACvtfcHk0lgU9MM5zZ6sRA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvFKkt78%253D&md5=a842d59c70b92905d220a55b4b61551a</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1042%2Fbse0470053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbse0470053%26sid%3Dliteratum%253Aachs%26aulast%3DJastroch%26aufirst%3DM.%26aulast%3DDivakaruni%26aufirst%3DA.%2BS.%26aulast%3DMookerjee%26aufirst%3DS.%26aulast%3DTreberg%26aufirst%3DJ.%2BR.%26aulast%3DBrand%26aufirst%3DM.%2BD.%26atitle%3DMitochondrial%2520proton%2520and%2520electron%2520leaks%26jtitle%3DEssays%2520Biochem.%26date%3D2010%26volume%3D47%26spage%3D53%26epage%3D67%26doi%3D10.1042%2Fbse0470053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ying, W. H.</span></span> <span> </span><span class="NLM_article-title">NAD(+)/ NADH and NADP(+)/NADPH in cellular functions and cell death: Regulation and biological consequences</span>. <i>Antioxid. Redox Signaling</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">179</span>â <span class="NLM_lpage">206</span>, <span class="refDoi">Â DOI: 10.1089/ars.2007.1672</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1089%2Fars.2007.1672" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=18020963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1ShtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=179-206&author=W.+H.+Ying&title=NAD%28%2B%29%2F+NADH+and+NADP%28%2B%29%2FNADPH+in+cellular+functions+and+cell+death%3A+Regulation+and+biological+consequences&doi=10.1089%2Fars.2007.1672"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">NAD+/NADH and NADP+/NADPH in Cellular Functions and Cell Death: Regulation and Biological Consequences</span></div><div class="casAuthors">Ying, Weihai</div><div class="citationInfo"><span class="NLM_cas:title">Antioxidants & Redox Signaling</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-206</span>CODEN:
                <span class="NLM_cas:coden">ARSIF2</span>;
        ISSN:<span class="NLM_cas:issn">1523-0864</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">A review.  Accumulating evidence has suggested that NAD (including NAD+ and NADH) and NADP (including NADP+ and NADPH) could belong to the fundamental common mediators of various biol. processes, including energy metab., mitochondrial functions, calcium homeostasis, antioxidn./generation of oxidative stress, gene expression, immunol. functions, aging, and cell death.  First, it is established that NAD mediates energy metab. and mitochondrial functions; second, NADPH is a key component in cellular antioxidn. systems; and NADH-dependent reactive oxygen species (ROS) generation from mitochondria and NADPH oxidase-dependent ROS generation are two crit. mechanisms of ROS generation; third, cyclic ADP-ribose and several other mols. that are generated from NAD and NADP could mediate calcium homeostasis; fourth, NAD and NADP modulate multiple key factors in cell death, such as mitochondrial permeability transition, energy state, poly(ADP-ribose) polymerase-1, and apoptosis-inducing factor; and fifth, NAD and NADP profoundly affect aging-influencing factors such as oxidative stress and mitochondrial activities, and NAD-dependent sirtuins also mediate the aging process.  Moreover, many recent studies have suggested novel paradigms of NAD and NADP metab.  Future investigation into the metab. and biol. functions of NAD and NADP may expose fundamental properties of life, and suggest new strategies for treating diseases and slowing the aging process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob_u0TKtM48LVg90H21EOLACvtfcHk0lgU9MM5zZ6sRA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1ShtA%253D%253D&md5=9690d9d5e0df236658c9e5b641ffd13b</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1089%2Fars.2007.1672&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fars.2007.1672%26sid%3Dliteratum%253Aachs%26aulast%3DYing%26aufirst%3DW.%2BH.%26atitle%3DNAD%2528%252B%2529%252F%2520NADH%2520and%2520NADP%2528%252B%2529%252FNADPH%2520in%2520cellular%2520functions%2520and%2520cell%2520death%253A%2520Regulation%2520and%2520biological%2520consequences%26jtitle%3DAntioxid.%2520Redox%2520Signaling%26date%3D2008%26volume%3D10%26spage%3D179%26epage%3D206%26doi%3D10.1089%2Fars.2007.1672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spinazzi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casarin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertegato, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salviati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angelini, C.</span></span> <span> </span><span class="NLM_article-title">Assessment of mitochondrial respiratory chain enzymatic activities on tissues and cultured cells</span>. <i>Nat. Protoc.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1235</span>â <span class="NLM_lpage">1246</span>, <span class="refDoi">Â DOI: 10.1038/nprot.2012.058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fnprot.2012.058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=22653162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC38XnslWgtrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=1235-1246&author=M.+Spinazziauthor=A.+Casarinauthor=V.+Pertegatoauthor=L.+Salviatiauthor=C.+Angelini&title=Assessment+of+mitochondrial+respiratory+chain+enzymatic+activities+on+tissues+and+cultured+cells&doi=10.1038%2Fnprot.2012.058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of mitochondrial respiratory chain enzymatic activities on tissues and cultured cells</span></div><div class="casAuthors">Spinazzi, Marco; Casarin, Alberto; Pertegato, Vanessa; Salviati, Leonardo; Angelini, Corrado</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1235-1246, S1235/1</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The assessment of mitochondrial respiratory chain (RC) enzymic activities is essential for investigating mitochondrial function in several situations, including mitochondrial disorders, diabetes, cancer, aging and neurodegeneration, as well as for many toxicol. assays.  Muscle is the most commonly analyzed tissue because of its high metabolic rates and accessibility, although other tissues and cultured cell lines can be used.  We describe a step-by-step protocol for a simple and reliable assessment of the RC enzymic function (complexes I-IV) for minute quantities of muscle, cultured cells and isolated mitochondria from a variety of species and tissues, by using a single-wavelength spectrophotometer.  An efficient tissue disruption and the choice for each assay of specific buffers, substrates, adjuvants and detergents in a narrow concn. range allow maximal sensitivity, specificity and linearity of the kinetics.  This protocol can be completed in 3 h.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJxT-BOo_P9LVg90H21EOLACvtfcHk0lgU9MM5zZ6sRA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnslWgtrg%253D&md5=d8b99fedb21e9c14895868d1fac12448</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2012.058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2012.058%26sid%3Dliteratum%253Aachs%26aulast%3DSpinazzi%26aufirst%3DM.%26aulast%3DCasarin%26aufirst%3DA.%26aulast%3DPertegato%26aufirst%3DV.%26aulast%3DSalviati%26aufirst%3DL.%26aulast%3DAngelini%26aufirst%3DC.%26atitle%3DAssessment%2520of%2520mitochondrial%2520respiratory%2520chain%2520enzymatic%2520activities%2520on%2520tissues%2520and%2520cultured%2520cells%26jtitle%3DNat.%2520Protoc.%26date%3D2012%26volume%3D7%26spage%3D1235%26epage%3D1246%26doi%3D10.1038%2Fnprot.2012.058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Q. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Brabander, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parada, L. F.</span></span> <span> </span><span class="NLM_article-title">Gboxin is an oxidative phosphorylation inhibitor that targets glioblastoma</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>567</i></span>,  <span class="NLM_fpage">341</span>â <span class="NLM_lpage">346</span>, <span class="refDoi">Â DOI: 10.1038/s41586-019-0993-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fs41586-019-0993-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=30842654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmsV2iurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=567&publication_year=2019&pages=341-346&author=Y.+F.+Shiauthor=S.+K.+Limauthor=Q.+R.+Liangauthor=S.+V.+Iyerauthor=H.+Y.+Wangauthor=Z.+L.+Wangauthor=X.+H.+Xieauthor=D.+C.+Sunauthor=Y.+J.+Chenauthor=V.+Tabarauthor=P.+Gutinauthor=N.+Williamsauthor=J.+K.+De+Brabanderauthor=L.+F.+Parada&title=Gboxin+is+an+oxidative+phosphorylation+inhibitor+that+targets+glioblastoma&doi=10.1038%2Fs41586-019-0993-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Gboxin is an oxidative phosphorylation inhibitor that targets glioblastoma</span></div><div class="casAuthors">Shi, Yufeng; Lim, S. Kyun; Liang, Qiren; Iyer, Swathi V.; Wang, Hua-Yu; Wang, Zilai; Xie, Xuanhua; Sun, Daochun; Chen, Yu-Jung; Tabar, Viviane; Gutin, Philip; Williams, Noelle; De Brabander, Jef K.; Parada, Luis F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">567</span>
        (<span class="NLM_cas:issue">7748</span>),
    <span class="NLM_cas:pages">341-346</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Cancer-specific inhibitors that reflect the unique metabolic needs of cancer cells are rare.  Here we describe Gboxin, a small mol. that specifically inhibits the growth of primary mouse and human glioblastoma cells but not that of mouse embryonic fibroblasts or neonatal astrocytes.  Gboxin rapidly and irreversibly compromises oxygen consumption in glioblastoma cells.  Gboxin relies on its pos. charge to assoc. with mitochondrial oxidative phosphorylation complexes in a manner that is dependent on the proton gradient of the inner mitochondrial membrane, and it inhibits the activity of F0F1 ATP synthase.  Gboxin-resistant cells require a functional mitochondrial permeability transition pore that regulates pH and thus impedes the accumulation of Gboxin in the mitochondrial matrix.  Administration of a metabolically stable Gboxin analog inhibits glioblastoma allografts and patient-derived xenografts.  Gboxin toxicity extends to established human cancer cell lines of diverse organ origin, and shows that the increased proton gradient and pH in cancer cell mitochondria is a mode of action that can be targeted in the development of antitumor reagents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqUFaigZHY4rVg90H21EOLACvtfcHk0livDylcUsTLMQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmsV2iurg%253D&md5=a37c5d43053bc43d5e7e73d01ef61212</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1038%2Fs41586-019-0993-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-019-0993-x%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DY.%2BF.%26aulast%3DLim%26aufirst%3DS.%2BK.%26aulast%3DLiang%26aufirst%3DQ.%2BR.%26aulast%3DIyer%26aufirst%3DS.%2BV.%26aulast%3DWang%26aufirst%3DH.%2BY.%26aulast%3DWang%26aufirst%3DZ.%2BL.%26aulast%3DXie%26aufirst%3DX.%2BH.%26aulast%3DSun%26aufirst%3DD.%2BC.%26aulast%3DChen%26aufirst%3DY.%2BJ.%26aulast%3DTabar%26aufirst%3DV.%26aulast%3DGutin%26aufirst%3DP.%26aulast%3DWilliams%26aufirst%3DN.%26aulast%3DDe%2BBrabander%26aufirst%3DJ.%2BK.%26aulast%3DParada%26aufirst%3DL.%2BF.%26atitle%3DGboxin%2520is%2520an%2520oxidative%2520phosphorylation%2520inhibitor%2520that%2520targets%2520glioblastoma%26jtitle%3DNature%26date%3D2019%26volume%3D567%26spage%3D341%26epage%3D346%26doi%3D10.1038%2Fs41586-019-0993-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lofton, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bristow, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carugo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullinax, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyers, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuliani, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czako, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mseeh, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asara, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morlacchi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peoples, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tieu, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmoes, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenzi, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DePinho, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Draetta, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toniatti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffernan, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marszalek, J. R.</span></span> <span> </span><span class="NLM_article-title">Functional genomics reveals synthetic lethality between phosphogluconate dehydrogenase and oxidative phosphorylation</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">469</span>â <span class="NLM_lpage">482</span>, <span class="refDoi">Â DOI: 10.1016/j.celrep.2018.12.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.celrep.2018.12.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=30625329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1MXms1yitQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=469-482&author=Y.+Sunauthor=M.+Bandiauthor=T.+Loftonauthor=M.+Smithauthor=C.+A.+Bristowauthor=A.+Carugoauthor=N.+Rogersauthor=P.+Leonardauthor=Q.+Changauthor=R.+Mullinaxauthor=J.+Hanauthor=X.+Shiauthor=S.+Sethauthor=B.+A.+Meyersauthor=M.+Millerauthor=L.+L.+Miaoauthor=X.+Y.+Maauthor=N.+P.+Fengauthor=V.+Giulianiauthor=M.+G.+Doauthor=B.+Czakoauthor=W.+S.+Palmerauthor=F.+Mseehauthor=J.+M.+Asaraauthor=Y.+Y.+Jiangauthor=P.+Morlacchiauthor=S.+P.+Zhaoauthor=M.+Peoplesauthor=T.+N.+Tieuauthor=M.+O.+Warmoesauthor=P.+L.+Lorenziauthor=F.+L.+Mullerauthor=R.+A.+DePinhoauthor=G.+F.+Draettaauthor=C.+Toniattiauthor=P.+Jonesauthor=T.+P.+Heffernanauthor=J.+R.+Marszalek&title=Functional+genomics+reveals+synthetic+lethality+between+phosphogluconate+dehydrogenase+and+oxidative+phosphorylation&doi=10.1016%2Fj.celrep.2018.12.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Functional Genomics Reveals Synthetic Lethality between Phosphogluconate Dehydrogenase and Oxidative Phosphorylation</span></div><div class="casAuthors">Sun, Yuting; Bandi, Madhavi; Lofton, Timothy; Smith, Melinda; Bristow, Christopher A.; Carugo, Alessandro; Rogers, Norma; Leonard, Paul; Chang, Qing; Mullinax, Robert; Han, Jing; Shi, Xi; Seth, Sahil; Meyers, Brooke A.; Miller, Meredith; Miao, Lili; Ma, Xiaoyan; Feng, Ningping; Giuliani, Virginia; Geck Do, Mary; Czako, Barbara; Palmer, Wylie S.; Mseeh, Faika; Asara, John M.; Jiang, Yongying; Morlacchi, Pietro; Zhao, Shuping; Peoples, Michael; Tieu, Trang N.; Warmoes, Marc O.; Lorenzi, Philip L.; Muller, Florian L.; De Pinho, Ronald A.; Draetta, Giulio F.; Toniatti, Carlo; Jones, Philip; Heffernan, Timothy P.; Marszalek, Joseph R.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">469-482.e5</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The plasticity of a preexisting regulatory circuit compromises the effectiveness of targeted therapies, and leveraging genetic vulnerabilities in cancer cells may overcome such adaptations.  Hereditary leiomyomatosis renal cell carcinoma (HLRCC) is characterized by oxidative phosphorylation (OXPHOS) deficiency caused by fumarate hydratase (FH) nullizyogosity.  To identify metabolic genes that are synthetically lethal with OXPHOS deficiency, we conducted a genetic loss-of-function screen and found that phosphogluconate dehydrogenase (PGD) inhibition robustly blocks the proliferation of FH mutant cancer cells both in vitro and in vivo.  Mechanistically, PGD inhibition blocks glycolysis, suppresses reductive carboxylation of glutamine, and increases the NADP+/NADPH ratio to disrupt redox homeostasis.  Furthermore, in the OXPHOS-proficient context, blocking OXPHOS using the small-mol. inhibitor IACS-010759 enhances sensitivity to PGD inhibition in vitro and in vivo.  Together, our study reveals a dependency on PGD in OXPHOS-deficient tumors that might inform therapeutic intervention in specific patient populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFxV9JZbezMbVg90H21EOLACvtfcHk0livDylcUsTLMQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXms1yitQ%253D%253D&md5=9f93c828b588d802c6f3d0bf5813e9cb</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2018.12.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2018.12.043%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DY.%26aulast%3DBandi%26aufirst%3DM.%26aulast%3DLofton%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DM.%26aulast%3DBristow%26aufirst%3DC.%2BA.%26aulast%3DCarugo%26aufirst%3DA.%26aulast%3DRogers%26aufirst%3DN.%26aulast%3DLeonard%26aufirst%3DP.%26aulast%3DChang%26aufirst%3DQ.%26aulast%3DMullinax%26aufirst%3DR.%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DSeth%26aufirst%3DS.%26aulast%3DMeyers%26aufirst%3DB.%2BA.%26aulast%3DMiller%26aufirst%3DM.%26aulast%3DMiao%26aufirst%3DL.%2BL.%26aulast%3DMa%26aufirst%3DX.%2BY.%26aulast%3DFeng%26aufirst%3DN.%2BP.%26aulast%3DGiuliani%26aufirst%3DV.%26aulast%3DDo%26aufirst%3DM.%2BG.%26aulast%3DCzako%26aufirst%3DB.%26aulast%3DPalmer%26aufirst%3DW.%2BS.%26aulast%3DMseeh%26aufirst%3DF.%26aulast%3DAsara%26aufirst%3DJ.%2BM.%26aulast%3DJiang%26aufirst%3DY.%2BY.%26aulast%3DMorlacchi%26aufirst%3DP.%26aulast%3DZhao%26aufirst%3DS.%2BP.%26aulast%3DPeoples%26aufirst%3DM.%26aulast%3DTieu%26aufirst%3DT.%2BN.%26aulast%3DWarmoes%26aufirst%3DM.%2BO.%26aulast%3DLorenzi%26aufirst%3DP.%2BL.%26aulast%3DMuller%26aufirst%3DF.%2BL.%26aulast%3DDePinho%26aufirst%3DR.%2BA.%26aulast%3DDraetta%26aufirst%3DG.%2BF.%26aulast%3DToniatti%26aufirst%3DC.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DHeffernan%26aufirst%3DT.%2BP.%26aulast%3DMarszalek%26aufirst%3DJ.%2BR.%26atitle%3DFunctional%2520genomics%2520reveals%2520synthetic%2520lethality%2520between%2520phosphogluconate%2520dehydrogenase%2520and%2520oxidative%2520phosphorylation%26jtitle%3DCell%2520Rep.%26date%3D2019%26volume%3D26%26spage%3D469%26epage%3D482%26doi%3D10.1016%2Fj.celrep.2018.12.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beltran, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yelensky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frampton, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downing, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacDonald, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarosz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tagawa, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanus, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosquera, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronin, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, M. A.</span></span> <span> </span><span class="NLM_article-title">Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity</span>. <i>Eur. Urol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">920</span>â <span class="NLM_lpage">926</span>, <span class="refDoi">Â DOI: 10.1016/j.eururo.2012.08.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.eururo.2012.08.053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=22981675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlGntrjL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2013&pages=920-926&author=H.+Beltranauthor=R.+Yelenskyauthor=G.+M.+Framptonauthor=K.+Parkauthor=S.+R.+Downingauthor=T.+Y.+MacDonaldauthor=M.+Jaroszauthor=D.+Lipsonauthor=S.+T.+Tagawaauthor=D.+M.+Nanusauthor=P.+J.+Stephensauthor=J.+M.+Mosqueraauthor=M.+T.+Croninauthor=M.+A.+Rubin&title=Targeted+next-generation+sequencing+of+advanced+prostate+cancer+identifies+potential+therapeutic+targets+and+disease+heterogeneity&doi=10.1016%2Fj.eururo.2012.08.053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease Heterogeneity</span></div><div class="casAuthors">Beltran, Himisha; Yelensky, Roman; Frampton, Garrett M.; Park, Kyung; Downing, Sean R.; MacDonald, Theresa Y.; Jarosz, Mirna; Lipson, Doron; Tagawa, Scott T.; Nanus, David M.; Stephens, Philip J.; Mosquera, Juan Miguel; Cronin, Maureen T.; Rubin, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">European Urology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">920-926</span>CODEN:
                <span class="NLM_cas:coden">EUURAV</span>;
        ISSN:<span class="NLM_cas:issn">0302-2838</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Background: Most personalized cancer care strategies involving DNA sequencing are highly reliant on acquiring sufficient fresh or frozen tissue.  It has been challenging to comprehensively evaluate the genome of advanced prostate cancer (PCa) because of limited access to metastatic tissue.  Objective: To demonstrate the feasibility of a novel next-generation sequencing (NGS)-based platform that can be used with archival formalin-fixed paraffin-embedded (FFPE) biopsy tissue to evaluate the spectrum of DNA alterations seen in advanced PCa.  Design, setting, and participants: FFPE samples (including archival prostatectomies and prostate needle biopsies) were obtained from 45 patients representing the spectrum of disease: localized PCa, metastatic hormone-naive PCa, and metastatic castration-resistant PCa (CRPC).  We also assessed paired primaries and metastases to understand disease heterogeneity and disease progression.  Intervention: At least 50 ng of tumor DNA was extd. from FFPE samples and used for hybridization capture and NGS using the Illumina HiSeq 2000 platform.  Outcome measures and statistical anal.: A total of 3320 exons of 182 cancer-assocd. genes and 37 introns of 14 commonly rearranged genes were evaluated for genomic alterations.  Resulsts and limitations: We obtained an av. sequencing depth of >900X.  Overall, 44% of CRPCs harbored genomic alterations involving the androgen receptor gene (AR), including AR copy no. gain (24% of CRPCs) or AR point mutation (20% of CRPCs).  Other recurrent mutations included transmembrane protease, serine 2 gene (TMPRSS2):v-ets erythroblastosis virus E26 oncogene homolog (avian) gene (ERG) fusion (44%); phosphatase and tensin homolog gene (PTEN) loss (44%); tumor protein p53 gene (TP53) mutation (40%); retinoblastoma gene (RB) loss (28%); v-myc myelocytomatosis viral oncogene homolog (avian) gene (MYC) gain (12%); and phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit Î± gene (PIK3CA) mutation (4%).  There was a high incidence of genomic alterations involving key genes important for DNA repair, including breast cancer 2, early onset gene (BRCA2) loss (12%) and ataxia telangiectasia mutated gene (ATM) mutations (8%); these alterations are potentially targetable with poly(ADP-ribose)polymerase inhibitors.  A novel and actionable rearrangement involving the v-raf murine sarcoma viral oncogene homolog B1 gene (BRAF) was also detected.  Conclusions: This first-in-principle study demonstrates the feasibility of performing in-depth DNA analyses using FFPE tissue and brings new insight toward understanding the genomic landscape within advanced PCa.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsI-Y6MADh47Vg90H21EOLACvtfcHk0lgV6tPB-YSQoQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlGntrjL&md5=97b35e71616f8b4a7020078630d3059a</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1016%2Fj.eururo.2012.08.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.eururo.2012.08.053%26sid%3Dliteratum%253Aachs%26aulast%3DBeltran%26aufirst%3DH.%26aulast%3DYelensky%26aufirst%3DR.%26aulast%3DFrampton%26aufirst%3DG.%2BM.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DDowning%26aufirst%3DS.%2BR.%26aulast%3DMacDonald%26aufirst%3DT.%2BY.%26aulast%3DJarosz%26aufirst%3DM.%26aulast%3DLipson%26aufirst%3DD.%26aulast%3DTagawa%26aufirst%3DS.%2BT.%26aulast%3DNanus%26aufirst%3DD.%2BM.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DMosquera%26aufirst%3DJ.%2BM.%26aulast%3DCronin%26aufirst%3DM.%2BT.%26aulast%3DRubin%26aufirst%3DM.%2BA.%26atitle%3DTargeted%2520next-generation%2520sequencing%2520of%2520advanced%2520prostate%2520cancer%2520identifies%2520potential%2520therapeutic%2520targets%2520and%2520disease%2520heterogeneity%26jtitle%3DEur.%2520Urol.%26date%3D2013%26volume%3D63%26spage%3D920%26epage%3D926%26doi%3D10.1016%2Fj.eururo.2012.08.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stiles, B. L.</span></span> <span> </span><span class="NLM_article-title">PTEN: tumor suppressor and metabolic regulator</span>. <i>Front. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">338</span>, <span class="refDoi">Â DOI: 10.3389/fendo.2018.00338</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.3389%2Ffendo.2018.00338" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=30038596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BB3c7ht1WrsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=338&author=C.+Y.+Chenauthor=J.+Y.+Chenauthor=L.+N.+Heauthor=B.+L.+Stiles&title=PTEN%3A+tumor+suppressor+and+metabolic+regulator&doi=10.3389%2Ffendo.2018.00338"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">PTEN: Tumor Suppressor and Metabolic Regulator</span></div><div class="casAuthors">Chen Chien-Yu; Chen Jingyu; He Lina; Stiles Bangyan L; Stiles Bangyan L</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in endocrinology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">338</span>
        ISSN:<span class="NLM_cas:issn">1664-2392</span>.
    </div><div class="casAbstract">Phosphatase and Tensin Homolog deleted on Chromosome 10 (PTEN) is a dual phosphatase with both protein and lipid phosphatase activities.  PTEN was first discovered as a tumor suppressor with growth and survival regulatory functions.  In recent years, the function of PTEN as a metabolic regulator has attracted significant attention.  As the lipid phosphatase that dephosphorylates phosphatidylinositol-3, 4, 5-phosphate (PIP3), PTEN reduces the level of PIP3, a critical 2nd messenger mediating the signal of not only growth factors but also insulin.  In this review, we introduced the discovery of PTEN, the PTEN-regulated canonical and nuclear signals, and PTEN regulation.  We then focused on the role of PTEN and PTEN-regulated signals in metabolic regulation.  This included the role of PTEN in glycolysis, gluconeogenesis, glycogen synthesis, lipid metabolism as well as mitochondrial metabolism.  We also included how PTEN and PTEN regulated metabolic functions may act paradoxically toward insulin sensitivity and tumor metabolism and growth.  Further understanding of how PTEN regulates metabolism and how such regulations lead to different biological outcomes is necessary for interventions targeting at the PTEN-regulated signals in either cancer or diabetes treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQD8rCBbEd17SM8MEzWGjS9fW6udTcc2eZL73fhlpkMdbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7ht1WrsA%253D%253D&md5=251cfe39fd7465710509a5d9c0d7fcdc</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.3389%2Ffendo.2018.00338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffendo.2018.00338%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.%2BY.%26aulast%3DChen%26aufirst%3DJ.%2BY.%26aulast%3DHe%26aufirst%3DL.%2BN.%26aulast%3DStiles%26aufirst%3DB.%2BL.%26atitle%3DPTEN%253A%2520tumor%2520suppressor%2520and%2520metabolic%2520regulator%26jtitle%3DFront.%2520Endocrinol.%26date%3D2018%26volume%3D9%26spage%3D338%26doi%3D10.3389%2Ffendo.2018.00338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vlietstra, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Alewijk, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermans, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Steenbrugge, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapman, J.</span></span> <span> </span><span class="NLM_article-title">Frequent inactivation of PTEN in prostate cancer cell lines and xenografts</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">2720</span>â <span class="NLM_lpage">2723</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=9661880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADyaK1cXksFCqsbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1998&pages=2720-2723&author=R.+J.+Vlietstraauthor=D.+C.+van+Alewijkauthor=K.+G.+Hermansauthor=G.+J.+van+Steenbruggeauthor=J.+Trapman&title=Frequent+inactivation+of+PTEN+in+prostate+cancer+cell+lines+and+xenografts"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Frequent inactivation of PTEN in prostate cancer cell lines and xenografts</span></div><div class="casAuthors">Vlietstra, Remko J.; Van Alewijk, Dirk C. J. G.; Hermans, Karin G. L.; Van Steenbrugge, Gert J.; Trapman, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2720-2723</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Loss of chromosome 10q is a frequently obsd. genetic defect in prostate cancer.  Recently, the PTEN/MMAC1 tumor suppressor gene was identified and mapped to chromosome 10q23.3.  The authors studied PTEN structure and expression in 4 in vitro cell lines and 11 in vivo xenografts derived from six primary and nine metastatic human prostate cancers.  DNA samples were allelotyped for eight polymorphic markers within and surrounding the PTEN gene.  Addnl., the nine PTEN exons were tested for deletions.  In five samples (PC3, PC133, PCEW, PC295, and PC324), homozygous deletions of the PTEN gene or parts of the gene were detected.  PC295 contained a small homozygous deletion encompassing PTEN exon 5.  In two DNAs (PC82 and PC346), nonsense mutations were found, and in two (LNCaP and PC374), frame-shift mutations were found.  Missense mutations were not detected.  PTEN mRNA expression was clearly obsd. in all cell lines and xenografts without large homozygous deletions, showing that PTEN down-regulation is not an important mechanism of PTEN inactivation.  The high frequency (60%) of PTEN mutations and deletions indicates a significant role of this tumor suppressor gene in the pathogenesis of prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZJMu-jwfpQbVg90H21EOLACvtfcHk0lgV6tPB-YSQoQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXksFCqsbc%253D&md5=b64bc13e2ec5d299208f275501857d68</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVlietstra%26aufirst%3DR.%2BJ.%26aulast%3Dvan%2BAlewijk%26aufirst%3DD.%2BC.%26aulast%3DHermans%26aufirst%3DK.%2BG.%26aulast%3Dvan%2BSteenbrugge%26aufirst%3DG.%2BJ.%26aulast%3DTrapman%26aufirst%3DJ.%26atitle%3DFrequent%2520inactivation%2520of%2520PTEN%2520in%2520prostate%2520cancer%2520cell%2520lines%2520and%2520xenografts%26jtitle%3DCancer%2520Res.%26date%3D1998%26volume%3D58%26spage%3D2720%26epage%3D2723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cotter, P. D.</span></span> <span> </span><span class="NLM_article-title">Genomic rearrangements of PTEN in prostate cancer</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">240</span>, <span class="refDoi">Â DOI: 10.3389/fonc.2013.00240</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.3389%2Ffonc.2013.00240" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=24062990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BC2cflt12jsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=240&author=S.+Phinauthor=M.+W.+Mooreauthor=P.+D.+Cotter&title=Genomic+rearrangements+of+PTEN+in+prostate+cancer&doi=10.3389%2Ffonc.2013.00240"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Genomic Rearrangements of PTEN in Prostate Cancer</span></div><div class="casAuthors">Phin Sopheap; Moore Mathew W; Cotter Philip D</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">240</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">The phosphatase and tensin homolog gene (PTEN) on chromosome 10q23.3 is a negative regulator of the PIK3/Akt survival pathway and is the most frequently deleted tumor suppressor gene in prostate cancer.  Monoallelic loss of PTEN is present in up to 60% of localized prostate cancers and complete loss of PTEN in prostate cancer is linked to metastasis and androgen-independent progression.  Studies on the genomic status of PTEN in prostate cancer initially used a two-color fluorescence in situ hybridization (FISH) assay for PTEN copy number detection in formalin fixed paraffin embedded tissue preparations.  More recently, a four-color FISH assay containing two additional control probes flanking the PTEN locus with a lower false-positive rate was reported.  Combined with the detection of other critical genomic biomarkers for prostate cancer such as ERG, androgen receptor, and MYC, the evaluation of PTEN genomic status has proven to be invaluable for patient stratification and management.  Although less frequent than allelic deletions, point mutations in the gene and epigenetic silencing are also known to contribute to loss of PTEN function, and ultimately to prostate cancer initiation.  Overall, it is clear that PTEN is a powerful biomarker for prostate cancer.  Used as a companion diagnostic for emerging therapeutic drugs, FISH analysis of PTEN is promisingly moving human prostate cancer closer to more effective cancer management and therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTiyQIXPBx6kYxhnOQkIHOxfW6udTcc2eZRnfp_6RbUYrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cflt12jsQ%253D%253D&md5=5d197daa05f995aba985b2cd11dc3d69</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2013.00240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2013.00240%26sid%3Dliteratum%253Aachs%26aulast%3DPhin%26aufirst%3DS.%26aulast%3DMoore%26aufirst%3DM.%2BW.%26aulast%3DCotter%26aufirst%3DP.%2BD.%26atitle%3DGenomic%2520rearrangements%2520of%2520PTEN%2520in%2520prostate%2520cancer%26jtitle%3DFront.%2520Oncol.%26date%3D2013%26volume%3D3%26spage%3D240%26doi%3D10.3389%2Ffonc.2013.00240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vial, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Detaille, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guigas, B.</span></span> <span> </span><span class="NLM_article-title">Role of mitochondria in the mechanism(s) of action of metformin</span>. <i>Front. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">294</span>, <span class="refDoi">Â DOI: 10.3389/fendo.2019.00294</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.3389%2Ffendo.2019.00294" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=31133988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BB3M3gt1Onsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=294&author=G.+Vialauthor=D.+Detailleauthor=B.+Guigas&title=Role+of+mitochondria+in+the+mechanism%28s%29+of+action+of+metformin&doi=10.3389%2Ffendo.2019.00294"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Mitochondria in the Mechanism(s) of Action of Metformin</span></div><div class="casAuthors">Vial Guillaume; Vial Guillaume; Detaille Dominique; Guigas Bruno</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in endocrinology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">294</span>
        ISSN:<span class="NLM_cas:issn">1664-2392</span>.
    </div><div class="casAbstract">Metformin is a drug from the biguanide family that is used for decades as the first-line therapeutic choice for the treatment of type 2 diabetes.  Despite its worldwide democratization, owing to its clinical efficacy, high safety profile and cheap cost, the exact mechanism(s) of action of this anti-hyperglycemic molecule with pleiotropic properties still remains to be fully elucidated.  The concept that metformin would exert some of its actions though modulation of the mitochondrial bioenergetics was initially forged in the 50s but undeniably revived at the beginning of the twenty-first century when it was shown to induce a weak but specific inhibition of the mitochondrial respiratory-chain complex 1.  Furthermore, metformin has been reported to reduce generation of reactive oxygen species at the complex 1 and to prevent mitochondrial-mediated apoptosis, suggesting that it can protect against oxidative stress-induced cell death.  Nevertheless, despite some recent progress and the demonstration of its key role in the inhibition of hepatic gluconeogenesis, the exact nature of the mitochondrial interaction between the drug and the complex 1 is still poorly characterized.  Recent studies reported that metformin may also have anti-neoplastic properties by inhibiting cancer cell growth and proliferation, at least partly through its mitochondrial action.  As such, many trials are currently conducted for exploring the repositioning of metformin as a potential drug for cancer therapy.  In this mini-review, we discuss both historical and more recent findings on the central role played by the interaction between metformin and the mitochondria in its cellular mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSfCHeylKUnZRWfpMXQLRstfW6udTcc2eZRnfp_6RbUYrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3gt1Onsg%253D%253D&md5=82b173c693cb30cd0840998a359da78b</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.3389%2Ffendo.2019.00294&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffendo.2019.00294%26sid%3Dliteratum%253Aachs%26aulast%3DVial%26aufirst%3DG.%26aulast%3DDetaille%26aufirst%3DD.%26aulast%3DGuigas%26aufirst%3DB.%26atitle%3DRole%2520of%2520mitochondria%2520in%2520the%2520mechanism%2528s%2529%2520of%2520action%2520of%2520metformin%26jtitle%3DFront.%2520Endocrinol.%26date%3D2019%26volume%3D10%26spage%3D294%26doi%3D10.3389%2Ffendo.2019.00294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zakikhani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowling, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantus, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonenberg, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollak, M.</span></span> <span> </span><span class="NLM_article-title">Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">10269</span>â <span class="NLM_lpage">10273</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-06-1500</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F0008-5472.CAN-06-1500" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=17062558" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFGjsrvK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=10269-10273&author=M.+Zakikhaniauthor=R.+Dowlingauthor=I.+G.+Fantusauthor=N.+Sonenbergauthor=M.+Pollak&title=Metformin+is+an+AMP+kinase-dependent+growth+inhibitor+for+breast+cancer+cells&doi=10.1158%2F0008-5472.CAN-06-1500"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Metformin is an AMP Kinase-Dependent Growth Inhibitor for Breast Cancer Cells</span></div><div class="casAuthors">Zakikhani, Mahvash; Dowling, Ryan; Fantus, I. George; Sonenberg, Nahum; Pollak, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">10269-10273</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Recent population studies provide clues that the use of metformin may be assocd. with reduced incidence and improved prognosis of certain cancers.  This drug is widely used in the treatment of type 2 diabetes, where it is often referred to as an "insulin sensitizer" because it not only lowers blood glucose but also reduces the hyperinsulinemia assocd. with insulin resistance.  As insulin and insulin-like growth factors stimulate proliferation of many normal and transformed cell types, agents that facilitate signaling through these receptors would be expected to enhance proliferation.  We show here that metformin acts as a growth inhibitor rather than an insulin sensitizer for epithelial cells.  Breast cancer cells can be protected against metformin-induced growth inhibition by small interfering RNA against AMP kinase.  This shows that AMP kinase pathway activation by metformin, recently shown to be necessary for metformin inhibition of gluconeogenesis in hepatocytes, is also involved in metformin-induced growth inhibition of epithelial cells.  The growth inhibition was assocd. with decreased mammalian target of rapamycin and S6 kinase activation and a general decrease in mRNA translation.  These results provide evidence for a mechanism that may contribute to the antineoplastic effects of metformin suggested by recent population studies and justify further work to explore potential roles for activators of AMP kinase in cancer prevention and treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3WMUDTWsgYrVg90H21EOLACvtfcHk0lgzocMkXf7-bg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFGjsrvK&md5=7de1b4c02ce71146445523af4e21ff11</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-1500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-1500%26sid%3Dliteratum%253Aachs%26aulast%3DZakikhani%26aufirst%3DM.%26aulast%3DDowling%26aufirst%3DR.%26aulast%3DFantus%26aufirst%3DI.%2BG.%26aulast%3DSonenberg%26aufirst%3DN.%26aulast%3DPollak%26aufirst%3DM.%26atitle%3DMetformin%2520is%2520an%2520AMP%2520kinase-dependent%2520growth%2520inhibitor%2520for%2520breast%2520cancer%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D10269%26epage%3D10273%26doi%3D10.1158%2F0008-5472.CAN-06-1500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dowling, R. J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouaaz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiyota, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Awar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stambolic, V.</span></span> <span> </span><span class="NLM_article-title">Metformin pharmacokinetics in mouse tumors: implications for human therapy</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">567</span>â <span class="NLM_lpage">568</span>, <span class="refDoi">Â DOI: 10.1016/j.cmet.2016.03.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.cmet.2016.03.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27076069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsVWmt78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=567-568&author=R.+J.+O.+Dowlingauthor=S.+Lamauthor=C.+Bassiauthor=S.+Mouaazauthor=A.+Amanauthor=T.+Kiyotaauthor=R.+Al-Awarauthor=P.+J.+Goodwinauthor=V.+Stambolic&title=Metformin+pharmacokinetics+in+mouse+tumors%3A+implications+for+human+therapy&doi=10.1016%2Fj.cmet.2016.03.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Metformin Pharmacokinetics in Mouse Tumors: Implications for Human Therapy</span></div><div class="casAuthors">Dowling, Ryan J. O.; Lam, Sonya; Bassi, Christian; Mouaaz, Samar; Aman, Ahmed; Kiyota, Taira; Al-awar, Rima; Goodwin, Pamela J.; Stambolic, Vuk</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">567-568</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review discussing mouse models of antitumor action of metformin and its pharmacokinetics.  It also discusses that consistent delivery of metformin at effective antitumor concns. will allow It also discusses comprehensive characterization of metformin's mechanism of action and assessment of its efficacy as a viable anticancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXYhX75e3hlbVg90H21EOLACvtfcHk0lgzocMkXf7-bg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsVWmt78%253D&md5=3cdf6c9753104d3f16751b3b6a8343d1</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2016.03.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2016.03.006%26sid%3Dliteratum%253Aachs%26aulast%3DDowling%26aufirst%3DR.%2BJ.%2BO.%26aulast%3DLam%26aufirst%3DS.%26aulast%3DBassi%26aufirst%3DC.%26aulast%3DMouaaz%26aufirst%3DS.%26aulast%3DAman%26aufirst%3DA.%26aulast%3DKiyota%26aufirst%3DT.%26aulast%3DAl-Awar%26aufirst%3DR.%26aulast%3DGoodwin%26aufirst%3DP.%2BJ.%26aulast%3DStambolic%26aufirst%3DV.%26atitle%3DMetformin%2520pharmacokinetics%2520in%2520mouse%2520tumors%253A%2520implications%2520for%2520human%2520therapy%26jtitle%3DCell%2520Metab.%26date%3D2016%26volume%3D23%26spage%3D567%26epage%3D568%26doi%3D10.1016%2Fj.cmet.2016.03.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elgendy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosseini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiszmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzarella, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cazzoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curigliano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeCensi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonanni, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budillon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelicci, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssens, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogris, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baccarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanfrancone, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weckwerth, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foiani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minucci, S.</span></span> <span> </span><span class="NLM_article-title">Combination of hypoglycemia and metformin impairs tumor metabolic plasticity and growth by modulating the PP2A-GSK3 beta-MCL-1 axis</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">798</span>â <span class="NLM_lpage">815</span>, <span class="refDoi">Â DOI: 10.1016/j.ccell.2019.03.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.ccell.2019.03.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=31031016" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1MXosVSgtbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2019&pages=798-815&author=M.+Elgendyauthor=M.+Ciroauthor=A.+Hosseiniauthor=J.+Weiszmannauthor=L.+Mazzarellaauthor=E.+Ferrariauthor=R.+Cazzoliauthor=G.+Curiglianoauthor=A.+DeCensiauthor=B.+Bonanniauthor=A.+Budillonauthor=P.+G.+Pelicciauthor=V.+Janssensauthor=M.+Ogrisauthor=M.+Baccariniauthor=L.+Lanfranconeauthor=W.+Weckwerthauthor=M.+Foianiauthor=S.+Minucci&title=Combination+of+hypoglycemia+and+metformin+impairs+tumor+metabolic+plasticity+and+growth+by+modulating+the+PP2A-GSK3+beta-MCL-1+axis&doi=10.1016%2Fj.ccell.2019.03.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of Hypoglycemia and Metformin Impairs Tumor Metabolic Plasticity and Growth by Modulating the PP2A-GSK3Î²-MCL-1 Axis</span></div><div class="casAuthors">Elgendy, Mohamed; Ciro, Marco; Hosseini, Amir; Weiszmann, Jakob; Mazzarella, Luca; Ferrari, Elisa; Cazzoli, Riccardo; Curigliano, Giuseppe; DeCensi, Andrea; Bonanni, Bernardo; Budillon, Alfredo; Pelicci, Pier Giuseppe; Janssens, Veerle; Ogris, Manfred; Baccarini, Manuela; Lanfrancone, Luisa; Weckwerth, Wolfram; Foiani, Marco; Minucci, Saverio</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">798-815.e5</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Tumor cells may adapt to metabolic challenges by alternating between glycolysis and oxidative phosphorylation (OXPHOS).  To target this metabolic plasticity, we combined intermittent fasting, a clin. feasible approach to reduce glucose availability, with the OXPHOS inhibitor metformin.  In mice exposed to 24-h feeding/fasting cycles, metformin impaired tumor growth only when administered during fasting-induced hypoglycemia.  Synergistic anti-neoplastic effects of the metformin/hypoglycemia combination were mediated by glycogen synthase kinase 3Î² (GSK3Î²) activation downstream of PP2A, leading to a decline in the pro-survival protein MCL-1, and cell death.  Mechanistically, specific activation of the PP2A-GSK3Î² axis was the sum of metformin-induced inhibition of CIP2A, a PP2A suppressor, and of upregulation of the PP2A regulatory subunit B56d by low glucose, leading to an active PP2A-B56d complex with high affinity toward GSK3Î².</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRILTKao3tHbVg90H21EOLACvtfcHk0ljBvmsiUNBNhQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXosVSgtbg%253D&md5=ea976a0b726fa45a869a0af745f98736</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2019.03.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2019.03.007%26sid%3Dliteratum%253Aachs%26aulast%3DElgendy%26aufirst%3DM.%26aulast%3DCiro%26aufirst%3DM.%26aulast%3DHosseini%26aufirst%3DA.%26aulast%3DWeiszmann%26aufirst%3DJ.%26aulast%3DMazzarella%26aufirst%3DL.%26aulast%3DFerrari%26aufirst%3DE.%26aulast%3DCazzoli%26aufirst%3DR.%26aulast%3DCurigliano%26aufirst%3DG.%26aulast%3DDeCensi%26aufirst%3DA.%26aulast%3DBonanni%26aufirst%3DB.%26aulast%3DBudillon%26aufirst%3DA.%26aulast%3DPelicci%26aufirst%3DP.%2BG.%26aulast%3DJanssens%26aufirst%3DV.%26aulast%3DOgris%26aufirst%3DM.%26aulast%3DBaccarini%26aufirst%3DM.%26aulast%3DLanfrancone%26aufirst%3DL.%26aulast%3DWeckwerth%26aufirst%3DW.%26aulast%3DFoiani%26aufirst%3DM.%26aulast%3DMinucci%26aufirst%3DS.%26atitle%3DCombination%2520of%2520hypoglycemia%2520and%2520metformin%2520impairs%2520tumor%2520metabolic%2520plasticity%2520and%2520growth%2520by%2520modulating%2520the%2520PP2A-GSK3%2520beta-MCL-1%2520axis%26jtitle%3DCancer%2520Cell%26date%3D2019%26volume%3D35%26spage%3D798%26epage%3D815%26doi%3D10.1016%2Fj.ccell.2019.03.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollak, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirst, J.</span></span> <span> </span><span class="NLM_article-title">Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>462</i></span>,  <span class="NLM_fpage">475</span>â <span class="NLM_lpage">487</span>, <span class="refDoi">Â DOI: 10.1042/BJ20140620</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1042%2FBJ20140620" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=25017630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVeksb7M" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2014&pages=475-487&author=H.+R.+Bridgesauthor=A.+J.+Jonesauthor=M.+N.+Pollakauthor=J.+Hirst&title=Effects+of+metformin+and+other+biguanides+on+oxidative+phosphorylation+in+mitochondria&doi=10.1042%2FBJ20140620"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria</span></div><div class="casAuthors">Bridges, Hannah R.; Jones, Andrew J. Y.; Pollak, Michael N.; Hirst, Judy</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">475-487</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">The biguanide metformin is widely prescribed for Type II diabetes and has anti-neoplastic activity in lab. models.  Despite evidence that inhibition of mitochondrial respiratory complex I by metformin is the primary cause of its cell-lineage-specific actions and therapeutic effects, the mol. interaction(s) between metformin and complex I remain uncharacterized.  In the present paper, we describe the effects of five pharmacol. relevant biguanides on oxidative phosphorylation in mammalian mitochondria.  We report that biguanides inhibit complex I by inhibiting ubiquinone redn. (but not competitively) and, independently, stimulate reactive oxygen species prodn. by the complex I flavin.  Biguanides also inhibit mitochondrial ATP synthase, and two of them inhibit only ATP hydrolysis, not synthesis.  Thus we identify biguanides as a new class of complex I and ATP synthase inhibitor.  By comparing biguanide effects on isolated complex I and cultured cells, we distinguish three anti-diabetic and potentially anti-neoplastic biguanides (metformin, buformin and phenformin) from two anti-malarial biguanides (cycloguanil and proguanil): the former are accumulated into mammalian mitochondria and affect oxidative phosphorylation, whereas the latter are excluded so act only on the parasite.  Our mechanistic and pharmacokinetic insights are relevant to understanding and developing the role of biguanides in new and existing therapeutic applications, including cancer, diabetes and malaria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooOOWC7Pvp_7Vg90H21EOLACvtfcHk0ljBvmsiUNBNhQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVeksb7M&md5=553caf4d88caa939a4a8dd526ed4e13c</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1042%2FBJ20140620&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20140620%26sid%3Dliteratum%253Aachs%26aulast%3DBridges%26aufirst%3DH.%2BR.%26aulast%3DJones%26aufirst%3DA.%2BJ.%26aulast%3DPollak%26aufirst%3DM.%2BN.%26aulast%3DHirst%26aufirst%3DJ.%26atitle%3DEffects%2520of%2520metformin%2520and%2520other%2520biguanides%2520on%2520oxidative%2520phosphorylation%2520in%2520mitochondria%26jtitle%3DBiochem.%2520J.%26date%3D2014%26volume%3D462%26spage%3D475%26epage%3D487%26doi%3D10.1042%2FBJ20140620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pollak, M. N.</span></span> <span> </span><span class="NLM_article-title">Investigating metformin for cancer prevention and treatment: the end of the beginning</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">778</span>â <span class="NLM_lpage">790</span>, <span class="refDoi">Â DOI: 10.1158/2159-8290.CD-12-0263</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F2159-8290.CD-12-0263" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=22926251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlGgsb3O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=778-790&author=M.+N.+Pollak&title=Investigating+metformin+for+cancer+prevention+and+treatment%3A+the+end+of+the+beginning&doi=10.1158%2F2159-8290.CD-12-0263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Investigating Metformin for Cancer Prevention and Treatment: The End of the Beginning</span></div><div class="casAuthors">Pollak, Michael N.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">778-790</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Lab. research and pharmacoepidemiol. are providing converging evidence that the widely used antidiabetic drug metformin has antineoplastic activity, but there are caveats.  Although population studies suggest that metformin exposure is assocd. with reduced cancer risk and/or improved prognosis, these data are mostly retrospective and nonrandomized.  Lab. models show antineoplastic activity, but metformin concns. used in many expts. exceed those achieved with conventional doses used for diabetes treatment.  Ongoing translational research should be useful in guiding design of clin. trials, not only to evaluate metformin at conventional antidiabetic doses, where redn. of elevated insulin levels may contribute to antineoplastic activity for certain subsets of patients, but also to explore more aggressive dosing of biguanides, which may lead to reprogramming of energy metab. in a manner that could provide important opportunities for synthetic lethality through rational drug combinations or in the context of genetic lesions assocd. with hypersensitivity to energetic stress.  Significance: There are tantalizing clues that justify the investigation of antineoplastic activities of biguanides.  The complexity of their biol. effects requires further translational research to guide clin. trial design.  Cancer Discov; 2(9); 778-90. Â©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpd63Z56aY40rVg90H21EOLACvtfcHk0ljBvmsiUNBNhQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlGgsb3O&md5=e251de39cd610d015d44527822154d49</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-12-0263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-12-0263%26sid%3Dliteratum%253Aachs%26aulast%3DPollak%26aufirst%3DM.%2BN.%26atitle%3DInvestigating%2520metformin%2520for%2520cancer%2520prevention%2520and%2520treatment%253A%2520the%2520end%2520of%2520the%2520beginning%26jtitle%3DCancer%2520Discovery%26date%3D2012%26volume%3D2%26spage%3D778%26epage%3D790%26doi%3D10.1158%2F2159-8290.CD-12-0263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boukalova, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stursa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ezrova, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerny, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezawork-Geleta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pecinova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drahota, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuzil, J.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial targeting of metformin enhances its activity against pancreatic cancer</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">2875</span>â <span class="NLM_lpage">2886</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-15-1021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F1535-7163.MCT-15-1021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27765848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFynt7vL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=2875-2886&author=S.+Boukalovaauthor=J.+Stursaauthor=L.+Wernerauthor=Z.+Ezrovaauthor=J.+Cernyauthor=A.+Bezawork-Geletaauthor=A.+Pecinovaauthor=L.+F.+Dongauthor=Z.+Drahotaauthor=J.+Neuzil&title=Mitochondrial+targeting+of+metformin+enhances+its+activity+against+pancreatic+cancer&doi=10.1158%2F1535-7163.MCT-15-1021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial Targeting of Metformin Enhances Its Activity against Pancreatic Cancer</span></div><div class="casAuthors">Boukalova, Stepana; Stursa, Jan; Werner, Lukas; Ezrova, Zuzana; Cerny, Jiri; Bezawork-Geleta, Ayenachew; Pecinova, Alena; Dong, Lanfeng; Drahota, Zdenek; Neuzil, Jiri</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2875-2886</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Pancreatic cancer is one of the hardest-to-treat types of neoplastic diseases.  Metformin, a widely prescribed drug against type 2 diabetes mellitus, is being trialed as an agent against pancreatic cancer, although its efficacy is low.  With the idea of delivering metformin to its mol. target, the mitochondrial complex I (CI), we tagged the agent with the mitochondrial vector, triphenylphosphonium group.  Mitochondrially targeted metformin (MitoMet) was found to kill a panel of pancreatic cancer cells three to four orders of magnitude more efficiently than found for the parental compd.  Respiration assessment documented CI as the mol. target for MitoMet, which was corroborated by mol. modeling.  MitoMet also efficiently suppressed pancreatic tumors in three mouse models.  We propose that the novel mitochondrially targeted agent is clin. highly intriguing, and it has a potential to greatly improve the bleak prospects of patients with pancreatic cancer.  Mol Cancer Ther; 15(12); 2875-86. 2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg7XRRxwPY3rVg90H21EOLACvtfcHk0ljyDsa5cS_G2w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFynt7vL&md5=15a12f077f56cd6423dbc404b228cbe1</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-1021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-1021%26sid%3Dliteratum%253Aachs%26aulast%3DBoukalova%26aufirst%3DS.%26aulast%3DStursa%26aufirst%3DJ.%26aulast%3DWerner%26aufirst%3DL.%26aulast%3DEzrova%26aufirst%3DZ.%26aulast%3DCerny%26aufirst%3DJ.%26aulast%3DBezawork-Geleta%26aufirst%3DA.%26aulast%3DPecinova%26aufirst%3DA.%26aulast%3DDong%26aufirst%3DL.%2BF.%26aulast%3DDrahota%26aufirst%3DZ.%26aulast%3DNeuzil%26aufirst%3DJ.%26atitle%3DMitochondrial%2520targeting%2520of%2520metformin%2520enhances%2520its%2520activity%2520against%2520pancreatic%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26spage%3D2875%26epage%3D2886%26doi%3D10.1158%2F1535-7163.MCT-15-1021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pollak, M.</span></span> <span> </span><span class="NLM_article-title">Potential applications for biguanides in oncology</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">3693</span>â <span class="NLM_lpage">3700</span>, <span class="refDoi">Â DOI: 10.1172/JCI67232</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1172%2FJCI67232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=23999444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVenu7bF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2013&pages=3693-3700&author=M.+Pollak&title=Potential+applications+for+biguanides+in+oncology&doi=10.1172%2FJCI67232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Potential applications for biguanides in oncology</span></div><div class="casAuthors">Pollak, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3693-3700</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  Metformin is widely prescribed for the treatment of type II diabetes.  Recently, it has been proposed that this compd. or related biguanides may have antineoplastic activity.  Biguanides may exploit specific metabolic vulnerabilities of transformed cells by acting on them directly, or may act by indirect mechanisms that involve alterations of the host environment.  Preclin. data suggest that drug exposure levels are a key determinant of proposed direct actions.  With respect to indirect mechanisms, it will be important to det. whether recently demonstrated metformin-induced changes in levels of candidate systemic mediators such as insulin or inflammatory cytokines are of sufficient magnitude to achieve therapeutic benefit.  Results of the first generation of clin. trials now in progress are eagerly anticipated.  Ongoing investigations may justify a second generation of trials that explore pharmacokinetic optimization, rational drug combinations, synthetic lethality strategies, novel biguanides, and the use of predictive biomarkers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj7_vP2GmvzLVg90H21EOLACvtfcHk0ljyDsa5cS_G2w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVenu7bF&md5=19d8e4713e9effcf64af8c8a8e6fcd1d</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1172%2FJCI67232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI67232%26sid%3Dliteratum%253Aachs%26aulast%3DPollak%26aufirst%3DM.%26atitle%3DPotential%2520applications%2520for%2520biguanides%2520in%2520oncology%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2013%26volume%3D123%26spage%3D3693%26epage%3D3700%26doi%3D10.1172%2FJCI67232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mcguinness, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talbert, R. L.</span></span> <span> </span><span class="NLM_article-title">Phenformin-induced lactic-acidosis - a forgotten adverse drug reaction</span>. <i>Ann. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1183</span>â <span class="NLM_lpage">1187</span>, <span class="refDoi">Â DOI: 10.1177/106002809302701004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1177%2F106002809302701004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=8251683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADyaK2c%252Fnt1Orsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1993&pages=1183-1187&author=M.+E.+Mcguinnessauthor=R.+L.+Talbert&title=Phenformin-induced+lactic-acidosis+-+a+forgotten+adverse+drug+reaction&doi=10.1177%2F106002809302701004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Phenformin-induced lactic acidosis: a forgotten adverse drug reaction</span></div><div class="casAuthors">McGuinness M E; Talbert R L</div><div class="citationInfo"><span class="NLM_cas:title">The Annals of pharmacotherapy</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1183-7</span>
        ISSN:<span class="NLM_cas:issn">1060-0280</span>.
    </div><div class="casAbstract">OBJECTIVE:  To document a case of severe metabolic and lactic acidosis secondary to phenformin.  This adverse effect has almost been forgotten as 15 years have passed since its withdrawal from the US market.  CASE SUMMARY:  A 64-year-old man presented with a four-day history of left upper abdominal pain and a one-week history of constipation and diarrhea.  His arterial blood gases were pH 6.7, pCO2 2.80 kPa, and pO2 12.00 kPa with 90% oxygen saturation on room air.  Serum chemistries indicated an unmeasurable serum bicarbonate concentration, anion gap 52 mmol/L, lactate concentration 29.5 mmol/L, blood urea nitrogen 6.63 mmol/L, creatinine 229.84 mumol/L, and blood glucose 4.35 mmol/L.  There were low levels of urine and serum ketones.  In the emergency department, he required resuscitation for hypotension and bradycardia.  His diagnosis was lactic and ketoacidosis secondary to phenformin.  The patient was treated with NaCl 0.9%, sodium bicarbonate, insulin, and hemodialysis.  Although he survived the initial insult of lactic and ketoacidosis, his hospital course was complicated and he died on hospital day 105.  CONCLUSIONS:  Treatment of lactic acidosis is difficult and challenging.  The continued availability of phenformin in neighboring countries, and the renewed interest in biguanide therapy for treating diabetes mellitus make it an important diagnosis of exclusion in diabetic patients who present with severe acidosis.  Metformin, another biguanide under investigation for the treatment of diabetes mellitus, is associated with a much lower incidence of lactic acidosis than is phenformin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT3yEWY8NqsaBJ5E29YNGvQfW6udTcc2eZsMLvGrxC23Lntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2c%252Fnt1Orsw%253D%253D&md5=f9782924f1839b89472c40406ed8f4c4</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1177%2F106002809302701004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F106002809302701004%26sid%3Dliteratum%253Aachs%26aulast%3DMcguinness%26aufirst%3DM.%2BE.%26aulast%3DTalbert%26aufirst%3DR.%2BL.%26atitle%3DPhenformin-induced%2520lactic-acidosis%2520-%2520a%2520forgotten%2520adverse%2520drug%2520reaction%26jtitle%3DAnn.%2520Pharmacother.%26date%3D1993%26volume%3D27%26spage%3D1183%26epage%3D1187%26doi%3D10.1177%2F106002809302701004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shim, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yook, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huh, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, J. H.</span></span> <span> </span><span class="NLM_article-title">Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with Temozolomide and a newly designed biguanide (HL156A)</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">65643</span>â <span class="NLM_lpage">65659</span>, <span class="refDoi">Â DOI: 10.18632/oncotarget.11595</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.18632%2Foncotarget.11595" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27582539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BC2szmsVGluw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=65643-65659&author=J.+Choiauthor=J.+H.+Leeauthor=I.+Kohauthor=J.+K.+Shimauthor=J.+Parkauthor=J.+Y.+Jeonauthor=M.+Yunauthor=S.+H.+Kimauthor=J.+I.+Yookauthor=E.+H.+Kimauthor=J.+H.+Changauthor=S.+H.+Kimauthor=Y.+M.+Huhauthor=S.+J.+Leeauthor=M.+Pollakauthor=P.+Kimauthor=S.+G.+Kangauthor=J.+H.+Cheong&title=Inhibiting+stemness+and+invasive+properties+of+glioblastoma+tumorsphere+by+combined+treatment+with+Temozolomide+and+a+newly+designed+biguanide+%28HL156A%29&doi=10.18632%2Foncotarget.11595"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (HL156A)</span></div><div class="casAuthors">Choi Junjeong; Choi Junjeong; Lee Ji-Hyun; Shim Jin-Kyoung; Park Junseong; Kim Eui Hyun; Chang Jong Hee; Kim Sun Ho; Kang Seok-Gu; Koh Ilkyoo; Kim Pilnam; Jeon Jeong Yong; Yun Mijin; Kim Se Hoon; Yook Jong In; Huh Yong Min; Lee Su Jae; Pollak Michael; Cheong Jae-Ho</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">65643-65659</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Studies have investigated biguanide-derived agents for the treatment of cancers and have reported their effects against tumorspheres (TSs).  The purpose of this study was determining the effects of HL156A, a newly designed biguanide with improved pharmacokinetics, on glioblastoma TSs (GMB TSs) and assess the feasibility of this drug as a new line of therapy against glioblastoma, alone or combined with a conventional therapeutic agent, temozolomide(TMZ).  The effects of HL156A, alone and combined with TMZ, on the stemness and invasive properties of GBM TSs and survival of orthotopic xenograft animals were assessed.  HL156A, combined with TMZ, inhibited the stemness of GBM TSs, proven by neurosphere formation assay and marker expression.  Three-dimensional collagen matrix invasion assays provided evidence that combined treatment inhibited invasive properties, compared with control and TMZ-alone treatment groups.  TMZ alone and combined treatment repressed the expression of epithelial-mesenchymal transition-related genes.  A gene ontology comparison of TMZ and combination-treatment groups revealed altered expression of genes encoding proteins involved in cellular adhesion and migration.  Combined treatment with HL156A and TMZ showed survival benefits in an orthotopic xenograft mouse model.  The inhibitory effect of combination treatment on the stemness and invasive properties of GBM TSs suggest the potential usage of this regimen as a novel strategy for the treatment of GBM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS4YQ9NwXQVQSSm0e6ZOaemfW6udTcc2eYbDysYFOF_g7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2szmsVGluw%253D%253D&md5=9bccb22236fb3a64fb982645dc2dbb37</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.11595&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.11595%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DKoh%26aufirst%3DI.%26aulast%3DShim%26aufirst%3DJ.%2BK.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DJeon%26aufirst%3DJ.%2BY.%26aulast%3DYun%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DYook%26aufirst%3DJ.%2BI.%26aulast%3DKim%26aufirst%3DE.%2BH.%26aulast%3DChang%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DHuh%26aufirst%3DY.%2BM.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DPollak%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DP.%26aulast%3DKang%26aufirst%3DS.%2BG.%26aulast%3DCheong%26aufirst%3DJ.%2BH.%26atitle%3DInhibiting%2520stemness%2520and%2520invasive%2520properties%2520of%2520glioblastoma%2520tumorsphere%2520by%2520combined%2520treatment%2520with%2520Temozolomide%2520and%2520a%2520newly%2520designed%2520biguanide%2520%2528HL156A%2529%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D65643%26epage%3D65659%26doi%3D10.18632%2Foncotarget.11595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rha, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beom, S. H. B. S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yim, D.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâNeill, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janku, F.</span></span> <span> </span><span class="NLM_article-title">Abstract CT021: Phase I study of an oxidative phosphorylation inhibitor IM156 in patients with advanced solid tumors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">CT021</span>â <span class="NLM_lpage">CT021</span>, <span class="refDoi">Â DOI: 10.1158/1538-7445.SABCS18-CT021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F1538-7445.SABCS18-CT021" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=CT021-CT021&author=S.+Y.+Rhaauthor=S.+H.+B.+S.+H.+Beomauthor=G.+M.+Kimauthor=Y.+G.+Shinauthor=D.-S.+Yimauthor=H.+S.+Kimauthor=J.+H.+Changauthor=J.-H.+Cheongauthor=Y.+W.+Leeauthor=Y.+S.+Chongauthor=V.+O%E2%80%99Neillauthor=S.+H.+Yooauthor=F.+Janku&title=Abstract+CT021%3A+Phase+I+study+of+an+oxidative+phosphorylation+inhibitor+IM156+in+patients+with+advanced+solid+tumors&doi=10.1158%2F1538-7445.SABCS18-CT021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.SABCS18-CT021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.SABCS18-CT021%26sid%3Dliteratum%253Aachs%26aulast%3DRha%26aufirst%3DS.%2BY.%26aulast%3DBeom%26aufirst%3DS.%2BH.%2BB.%2BS.%2BH.%26aulast%3DKim%26aufirst%3DG.%2BM.%26aulast%3DShin%26aufirst%3DY.%2BG.%26aulast%3DYim%26aufirst%3DD.-S.%26aulast%3DKim%26aufirst%3DH.%2BS.%26aulast%3DChang%26aufirst%3DJ.%2BH.%26aulast%3DCheong%26aufirst%3DJ.-H.%26aulast%3DLee%26aufirst%3DY.%2BW.%26aulast%3DChong%26aufirst%3DY.%2BS.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DV.%26aulast%3DYoo%26aufirst%3DS.%2BH.%26aulast%3DJanku%26aufirst%3DF.%26atitle%3DAbstract%2520CT021%253A%2520Phase%2520I%2520study%2520of%2520an%2520oxidative%2520phosphorylation%2520inhibitor%2520IM156%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D2019%26volume%3D79%26spage%3DCT021%26epage%3DCT021%26doi%3D10.1158%2F1538-7445.SABCS18-CT021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Helbig, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruchner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurtner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess-Stumpp, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unterschemmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zips, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yaromina, A.</span></span> <span> </span><span class="NLM_article-title">BAY 87-2243, a novel inhibitor of hypoxia-induced gene activation, improves local tumor control after fractionated irradiation in a schedule-dependent manner in head and neck human xenografts</span>. <i>Radiat. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">207</span>, <span class="refDoi">Â DOI: 10.1186/1748-717X-9-207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1186%2F1748-717X-9-207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=25234922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFGnt7jN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=207&author=L.+Helbigauthor=L.+Koiauthor=K.+Bruchnerauthor=K.+Gurtnerauthor=H.+Hess-Stumppauthor=K.+Unterschemmannauthor=M.+Baumannauthor=D.+Zipsauthor=A.+Yaromina&title=BAY+87-2243%2C+a+novel+inhibitor+of+hypoxia-induced+gene+activation%2C+improves+local+tumor+control+after+fractionated+irradiation+in+a+schedule-dependent+manner+in+head+and+neck+human+xenografts&doi=10.1186%2F1748-717X-9-207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">BAY 87-2243, a novel inhibitor of hypoxia-induced gene activation, improves local tumor control after fractionated irradiation in a schedule-dependent manner in head and neck human xenografts</span></div><div class="casAuthors">Helbig, Linda; Koi, Lydia; Bruechner, Kerstin; Gurtner, Kristin; Hess-Stumpp, Holger; Unterschemmann, Kerstin; Baumann, Michael; Zips, Daniel; Yaromina, Ala</div><div class="citationInfo"><span class="NLM_cas:title">Radiation Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">207/1-207/19, 19 pp.</span>CODEN:
                <span class="NLM_cas:coden">ROANCM</span>;
        ISSN:<span class="NLM_cas:issn">1748-717X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">The transcription factor hypoxia-inducible factor-1 (HIF-1) pathway plays an important role in tumor response to cytotoxic treatments.  We investigated the effects of a novel small mol. inhibitor of mitochondrial complex I and hypoxia-induced HIF-1 activity BAY-87-2243, on tumor microenvironment and response of human squamous cell carcinoma (hSCC) to clin. relevant fractionated radiotherapy (RT) with and without concomitant chemotherapy.  When UT-SCC-5 hSCC xenografts in nude mice reached 6 mm in diam. BAY-87-2243 or carrier was administered before and/or during RT or radiochemotherapy with concomitant cisplatin (RCT).  Local tumor control was evaluated 150 days after irradn. and the doses to control 50% of tumors (TCD50) were compared between treatment arms.  Tumors were excised at different time points during BAY-87-2243 or carrier treatment for western blot and immunohistol. investigations.  BAY-87-2243 markedly decreased nuclear HIF-1Î± expression and pimonidazole hypoxic fraction already after 3 days of drug treatment.  BAY-87-2243 prior to RT significantly reduced TCD50 from 123 to 100 Gy (p = 0.037).  Addnl. BAY-87-2243 application during RT did not decrease TCD50.  BAY-87-2243 before and during radiochemotherapy did not improve local tumor control.  Pronounced redn. of tumor hypoxia by application of BAY-87-2243 prior to RT improved local tumor control.  The results demonstrate that radiosensitizing effect importantly depends on treatment schedule.  The data support further investigations of HIF-1 pathway inhibitors for radiotherapy and of predictive tests to select patients who will benefit from this combined treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgoI5X74S9GbVg90H21EOLACvtfcHk0lg4oJz8f5rYMQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFGnt7jN&md5=d27ae373dda9abad4608d8d7a8e19960</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1186%2F1748-717X-9-207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1748-717X-9-207%26sid%3Dliteratum%253Aachs%26aulast%3DHelbig%26aufirst%3DL.%26aulast%3DKoi%26aufirst%3DL.%26aulast%3DBruchner%26aufirst%3DK.%26aulast%3DGurtner%26aufirst%3DK.%26aulast%3DHess-Stumpp%26aufirst%3DH.%26aulast%3DUnterschemmann%26aufirst%3DK.%26aulast%3DBaumann%26aufirst%3DM.%26aulast%3DZips%26aufirst%3DD.%26aulast%3DYaromina%26aufirst%3DA.%26atitle%3DBAY%252087-2243%252C%2520a%2520novel%2520inhibitor%2520of%2520hypoxia-induced%2520gene%2520activation%252C%2520improves%2520local%2520tumor%2520control%2520after%2520fractionated%2520irradiation%2520in%2520a%2520schedule-dependent%2520manner%2520in%2520head%2520and%2520neck%2520human%2520xenografts%26jtitle%3DRadiat.%2520Oncol.%26date%3D2014%26volume%3D9%26spage%3D207%26doi%3D10.1186%2F1748-717X-9-207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schockel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glasauer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basit, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bitschar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdmann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Algire, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagebarth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willems, P. H. G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopitz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koopman, W. J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heroult, M.</span></span> <span> </span><span class="NLM_article-title">Targeting mitochondrial complex I using BAY 87-2243 reduces melanoma tumor growth</span>. <i>Cancer Metab.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">11</span>, <span class="refDoi">Â DOI: 10.1186/s40170-015-0138-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1186%2Fs40170-015-0138-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=26500770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BC28zlslaqsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&pages=11&author=L.+Schockelauthor=A.+Glasauerauthor=F.+Basitauthor=K.+Bitscharauthor=H.+Truongauthor=G.+Erdmannauthor=C.+Algireauthor=A.+Hagebarthauthor=P.+H.+G.+M.+Willemsauthor=C.+Kopitzauthor=W.+J.+H.+Koopmanauthor=M.+Heroult&title=Targeting+mitochondrial+complex+I+using+BAY+87-2243+reduces+melanoma+tumor+growth&doi=10.1186%2Fs40170-015-0138-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting mitochondrial complex I using BAY 87-2243 reduces melanoma tumor growth</span></div><div class="casAuthors">Schockel Laura; Glasauer Andrea; Bitschar Katharina; Erdmann Gerrit; Algire Carolyn; Hagebarth Andrea; Kopitz Charlotte; Basit Farhan; Truong Hoa; Willems Peter Hgm; Koopman Werner Jh; Heroult Melanie</div><div class="citationInfo"><span class="NLM_cas:title">Cancer & metabolism</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">11</span>
        ISSN:<span class="NLM_cas:issn">2049-3002</span>.
    </div><div class="casAbstract">BACKGROUND:  Numerous studies have demonstrated that functional mitochondria are required for tumorigenesis, suggesting that mitochondrial oxidative phosphorylation (OXPHOS) might be a potential target for cancer therapy.  In this study, we investigated the effects of BAY 87-2243, a small molecule that inhibits the first OXPHOS enzyme (complex I), in melanoma in vitro and in vivo.  RESULTS:  BAY 87-2243 decreased mitochondrial oxygen consumption and induced partial depolarization of the mitochondrial membrane potential.  This was associated with increased reactive oxygen species (ROS) levels, lowering of total cellular ATP levels, activation of AMP-activated protein kinase (AMPK), and reduced cell viability.  The latter was rescued by the antioxidant vitamin E and high extracellular glucose levels (25 mM), indicating the involvement of ROS-induced cell death and a dependence on glycolysis for cell survival upon BAY 87-2243 treatment.  BAY 87-2243 significantly reduced tumor growth in various BRAF mutant melanoma mouse xenografts and patient-derived melanoma mouse models.  Furthermore, we provide evidence that inhibition of mutated BRAF using the specific small molecule inhibitor vemurafenib increased the OXPHOS dependency of BRAF mutant melanoma cells.  As a consequence, the combination of both inhibitors augmented the anti-tumor effect of BAY 87-2243 in a BRAF mutant melanoma mouse xenograft model.  CONCLUSIONS:  Taken together, our results suggest that complex I inhibition has potential clinical applications as a single agent in melanoma and also might be efficacious in combination with BRAF inhibitors in the treatment of patients with BRAF mutant melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSFUMsAIro3rCCEBeYuoi7AfW6udTcc2eYT-lO4-p5nIrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28zlslaqsQ%253D%253D&md5=8b76f8e4340ee263bd55564cbac4fea5</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1186%2Fs40170-015-0138-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40170-015-0138-0%26sid%3Dliteratum%253Aachs%26aulast%3DSchockel%26aufirst%3DL.%26aulast%3DGlasauer%26aufirst%3DA.%26aulast%3DBasit%26aufirst%3DF.%26aulast%3DBitschar%26aufirst%3DK.%26aulast%3DTruong%26aufirst%3DH.%26aulast%3DErdmann%26aufirst%3DG.%26aulast%3DAlgire%26aufirst%3DC.%26aulast%3DHagebarth%26aufirst%3DA.%26aulast%3DWillems%26aufirst%3DP.%2BH.%2BG.%2BM.%26aulast%3DKopitz%26aufirst%3DC.%26aulast%3DKoopman%26aufirst%3DW.%2BJ.%2BH.%26aulast%3DHeroult%26aufirst%3DM.%26atitle%3DTargeting%2520mitochondrial%2520complex%2520I%2520using%2520BAY%252087-2243%2520reduces%2520melanoma%2520tumor%2520growth%26jtitle%3DCancer%2520Metab.%26date%3D2015%26volume%3D3%26spage%3D11%26doi%3D10.1186%2Fs40170-015-0138-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gopal, Y. N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gammon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knighton, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pisaneschi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roszik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pramanik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudderth, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sui, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudgens, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reuben, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McQuade, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tetzlaff, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Francesco, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marszalek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piwnica-Worms, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeBerardinis, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, M. A.</span></span> <span> </span><span class="NLM_article-title">A novel mitochondrial inhibitor blocks MAPK pathway and overcomes MAPK inhibitor resistance in melanoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">6429</span>â <span class="NLM_lpage">6442</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-19-0836</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F1078-0432.CCR-19-0836" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=31439581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVSmsr%252FN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=6429-6442&author=Y.+N.+V.+Gopalauthor=S.+Gammonauthor=R.+Prasadauthor=B.+Knightonauthor=F.+Pisaneschiauthor=J.+Roszikauthor=N.+P.+Fengauthor=S.+Johnsonauthor=S.+Pramanikauthor=J.+Sudderthauthor=D.+W.+Suiauthor=C.+Hudgensauthor=G.+M.+Fischerauthor=W.+L.+Dengauthor=A.+Reubenauthor=W.+Y.+Pengauthor=J.+Wangauthor=J.+L.+McQuadeauthor=M.+T.+Tetzlaffauthor=M.+E.+Di+Francescoauthor=J.+Marszalekauthor=D.+Piwnica-Wormsauthor=R.+J.+DeBerardinisauthor=M.+A.+Davies&title=A+novel+mitochondrial+inhibitor+blocks+MAPK+pathway+and+overcomes+MAPK+inhibitor+resistance+in+melanoma&doi=10.1158%2F1078-0432.CCR-19-0836"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">A novel mitochondrial inhibitor blocks MAPK pathway and overcomes MAPK inhibitor resistance in melanoma</span></div><div class="casAuthors">Gopal, Y. N. Vashisht; Gammon, Seth; Prasad, Rishika; Knighton, Barbara; Pisaneschi, Federica; Roszik, Jason; Feng, Ningping; Johnson, Sarah; Pramanik, Snigdha; Sudderth, Jessica; Sui, Dawen; Hudgens, Courtney; Fischer, Grant M.; Deng, Wanleng; Reuben, Alexandre; Peng, Weiyi; Wang, Jian; McQuade, Jennifer L.; Tetzlaff, Michael T.; Di Francesco, Maria E.; Marszalek, Joe; Piwnica-Worms, David; DeBerardinis, Ralph J.; Davies, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6429-6442</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The purpose of this study is to det. if inhibition of mitochondrial oxidative phosphorylation (OxPhos) is an effective strategy against MAPK pathway inhibitor (MAPKi)-resistant BRAF-mutant melanomas.  Exptl. Design: The antimelanoma activity of IACS-010759 (OPi), a novel OxPhos complex I inhibitor, was evaluated in vitro and in vivo.  Mechanistic studies and predictors of response were evaluated using molecularly and metabolically stratified melanoma cell lines.  13C-labeling and targeted metabolomics were used to evaluate the effect of OPi on cellular energy utilization.  OxPhos inhibition in vivo was evaluated noninvasively by [18F]-fluoroazomycin arabinoside (FAZA) PET imaging.  Results: OPi potently inhibited OxPhos and the in vivo growth of multiple MAPKi-resistant BRAF-mutant melanoma models with high OxPhos at well-tolerated doses.  In vivo tumor regression with single-agent OPi treatment correlated with inhibition of both MAPK and mTOR complex I activity.  Unexpectedly, antitumor activity was not improved by combined treatment with MAPKi in vitro or in vivo.  Signaling and growth-inhibitory effects were mediated by LKB1-AMPK axis, and proportional to AMPK activation.  OPi increased glucose incorporation into glycolysis, inhibited glucose and glutamine incorporation into the mitochondrial tricarboxylic acid cycle, and decreased cellular nucleotide and amino acid pools.  Early changes in [18F]-FAZA PET uptake in vivo, and the degree of mTORC1 pathway inhibition in vitro, correlated with efficacy.  Conclusions: Targeting OxPhos with OPi has significant antitumor activity in MAPKi-resistant, BRAF-mutant melanomas, and merits further clin. investigation as a potential new strategy to overcome intrinsic and acquired resistance to MAPKi in patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaP_A-Tuw8abVg90H21EOLACvtfcHk0li_SQAzyiuwJQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVSmsr%252FN&md5=64e1eed6a183fbe8c64bcf8b1b1761b4</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-19-0836&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-19-0836%26sid%3Dliteratum%253Aachs%26aulast%3DGopal%26aufirst%3DY.%2BN.%2BV.%26aulast%3DGammon%26aufirst%3DS.%26aulast%3DPrasad%26aufirst%3DR.%26aulast%3DKnighton%26aufirst%3DB.%26aulast%3DPisaneschi%26aufirst%3DF.%26aulast%3DRoszik%26aufirst%3DJ.%26aulast%3DFeng%26aufirst%3DN.%2BP.%26aulast%3DJohnson%26aufirst%3DS.%26aulast%3DPramanik%26aufirst%3DS.%26aulast%3DSudderth%26aufirst%3DJ.%26aulast%3DSui%26aufirst%3DD.%2BW.%26aulast%3DHudgens%26aufirst%3DC.%26aulast%3DFischer%26aufirst%3DG.%2BM.%26aulast%3DDeng%26aufirst%3DW.%2BL.%26aulast%3DReuben%26aufirst%3DA.%26aulast%3DPeng%26aufirst%3DW.%2BY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DMcQuade%26aufirst%3DJ.%2BL.%26aulast%3DTetzlaff%26aufirst%3DM.%2BT.%26aulast%3DDi%2BFrancesco%26aufirst%3DM.%2BE.%26aulast%3DMarszalek%26aufirst%3DJ.%26aulast%3DPiwnica-Worms%26aufirst%3DD.%26aulast%3DDeBerardinis%26aufirst%3DR.%2BJ.%26aulast%3DDavies%26aufirst%3DM.%2BA.%26atitle%3DA%2520novel%2520mitochondrial%2520inhibitor%2520blocks%2520MAPK%2520pathway%2520and%2520overcomes%2520MAPK%2520inhibitor%2520resistance%2520in%2520melanoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2019%26volume%3D25%26spage%3D6429%26epage%3D6442%26doi%3D10.1158%2F1078-0432.CCR-19-0836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kircher, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McQuade, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haydu, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joon, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reuben, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Macedo, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carapeto, F. C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambati, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sreekumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudgens, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knighton, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawbi, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glitza, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gershenwald, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopal, Y. N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huse, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wargo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Futreal, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Putlri, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazar, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeBerardinis, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marszalek, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmen, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tetzlaff, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, M. A.</span></span> <span> </span><span class="NLM_article-title">Molecular profiling reveals unique immune and metabolic features of melanoma brain metastases</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">628</span>â <span class="NLM_lpage">645</span>, <span class="refDoi">Â DOI: 10.1158/2159-8290.CD-18-1489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F2159-8290.CD-18-1489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=30787016" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVGht7fE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=628-645&author=G.+M.+Fischerauthor=A.+Jalaliauthor=D.+A.+Kircherauthor=W.+C.+Leeauthor=J.+L.+McQuadeauthor=L.+E.+Hayduauthor=A.+Y.+Joonauthor=A.+Reubenauthor=M.+P.+de+Macedoauthor=F.+C.+L.+Carapetoauthor=C.+D.+Yangauthor=A.+Srivastavaauthor=C.+R.+Ambatiauthor=A.+Sreekumarauthor=C.+W.+Hudgensauthor=B.+Knightonauthor=W.+L.+Dengauthor=S.+D.+Fergusonauthor=H.+A.+Tawbiauthor=I.+C.+Glitzaauthor=J.+E.+Gershenwaldauthor=Y.+N.+V.+Gopalauthor=P.+Hwuauthor=J.+T.+Huseauthor=J.+A.+Wargoauthor=P.+A.+Futrealauthor=N.+Putlriauthor=A.+J.+Lazarauthor=R.+J.+DeBerardinisauthor=J.+R.+Marszalekauthor=J.+J.+Zhangauthor=S.+L.+Holmenauthor=M.+T.+Tetzlaffauthor=M.+A.+Davies&title=Molecular+profiling+reveals+unique+immune+and+metabolic+features+of+melanoma+brain+metastases&doi=10.1158%2F2159-8290.CD-18-1489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular profiling reveals unique immune and metabolic features of melanoma brain metastases</span></div><div class="casAuthors">Fischer, Grant M.; Jalali, Ali; Kircher, David A.; Lee, Won-Chul; McQuade, Jennifer L.; Haydu, Lauren E.; Joon, Aron Y.; Reuben, Alexandre; de Macedo, Mariana P.; Carapeto, Fernando C. L.; Yang, Chendong; Srivastava, Anuj; Ambati, Chandrashekar R.; Sreekumar, Arun; Hudgens, Courtney W.; Knighton, Barbara; Deng, Wanleng; Ferguson, Sherise D.; Tawbi, Hussein A.; Glitza, Isabella C.; Gershenwald, Jeffrey E.; Gopal, Y. N. Vashisht; Hwu, Patrick; Huse, Jason T.; Wargo, Jennifer A.; Futreal, P. Andrew; Putluri, Nagireddy; Lazar, Alexander J.; DeBerardinis, Ralph J.; Marszalek, Joseph R.; Zhang, Jianjun; Holmen, Sheri L.; Tetzlaff, Michael T.; Davies, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">628-645</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">There is a crit. need to improve our understanding of the pathogenesis of melanoma brain metastases (MBM).  Thus, we performed RNA sequencing on 88 resected MBMs and 42 patient-matched extracranial metastases tumors with sufficient tissue also underwent whole-exome sequencing, T-cell receptor sequencing, and IHC.  MBMs demonstrated heterogeneity of immune infiltrates that correlated with prior radiation and post-craniotomy survival.  Comparison with patient-matched extracranial metastases identified significant immunosuppression and enrichment of oxidative phosphorylation (OXPHOS) in MBMs.  Gene-expression anal. of intracranial and s.c. xenografts, and a spontaneous MBM model, confirmed increased OXPHOS gene expression in MBMs, which was also detected by direct metabolite profiling and [U-13C]-glucose tracing in vivo.  IACS-010759, an OXPHOS inhibitor currently in early-phase clin. trials, improved survival of mice bearing MAPK inhibitor-resistant intracranial melanoma xenografts and inhibited MBM formation in the spontaneous MBM model.  The results provide new insights into the pathogenesis and therapeutic resistance of MBMs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqekeeOZ790vLVg90H21EOLACvtfcHk0lgBTBG7UqCbxQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVGht7fE&md5=d8d07bbc84b7dabe7796cf33a8834e88</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-18-1489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-18-1489%26sid%3Dliteratum%253Aachs%26aulast%3DFischer%26aufirst%3DG.%2BM.%26aulast%3DJalali%26aufirst%3DA.%26aulast%3DKircher%26aufirst%3DD.%2BA.%26aulast%3DLee%26aufirst%3DW.%2BC.%26aulast%3DMcQuade%26aufirst%3DJ.%2BL.%26aulast%3DHaydu%26aufirst%3DL.%2BE.%26aulast%3DJoon%26aufirst%3DA.%2BY.%26aulast%3DReuben%26aufirst%3DA.%26aulast%3Dde%2BMacedo%26aufirst%3DM.%2BP.%26aulast%3DCarapeto%26aufirst%3DF.%2BC.%2BL.%26aulast%3DYang%26aufirst%3DC.%2BD.%26aulast%3DSrivastava%26aufirst%3DA.%26aulast%3DAmbati%26aufirst%3DC.%2BR.%26aulast%3DSreekumar%26aufirst%3DA.%26aulast%3DHudgens%26aufirst%3DC.%2BW.%26aulast%3DKnighton%26aufirst%3DB.%26aulast%3DDeng%26aufirst%3DW.%2BL.%26aulast%3DFerguson%26aufirst%3DS.%2BD.%26aulast%3DTawbi%26aufirst%3DH.%2BA.%26aulast%3DGlitza%26aufirst%3DI.%2BC.%26aulast%3DGershenwald%26aufirst%3DJ.%2BE.%26aulast%3DGopal%26aufirst%3DY.%2BN.%2BV.%26aulast%3DHwu%26aufirst%3DP.%26aulast%3DHuse%26aufirst%3DJ.%2BT.%26aulast%3DWargo%26aufirst%3DJ.%2BA.%26aulast%3DFutreal%26aufirst%3DP.%2BA.%26aulast%3DPutlri%26aufirst%3DN.%26aulast%3DLazar%26aufirst%3DA.%2BJ.%26aulast%3DDeBerardinis%26aufirst%3DR.%2BJ.%26aulast%3DMarszalek%26aufirst%3DJ.%2BR.%26aulast%3DZhang%26aufirst%3DJ.%2BJ.%26aulast%3DHolmen%26aufirst%3DS.%2BL.%26aulast%3DTetzlaff%26aufirst%3DM.%2BT.%26aulast%3DDavies%26aufirst%3DM.%2BA.%26atitle%3DMolecular%2520profiling%2520reveals%2520unique%2520immune%2520and%2520metabolic%2520features%2520of%2520melanoma%2520brain%2520metastases%26jtitle%3DCancer%2520Discovery%26date%3D2019%26volume%3D9%26spage%3D628%26epage%3D645%26doi%3D10.1158%2F2159-8290.CD-18-1489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fryknas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremberg, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senkowski, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olofsson, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DâArcy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gullbo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nygren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schughart, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linder, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsson, R.</span></span> <span> </span><span class="NLM_article-title">Iron chelators target both proliferating and quiescent cancer cells</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">38343</span>, <span class="refDoi">Â DOI: 10.1038/srep38343</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fsrep38343" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27924826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BC2sjkt1eitw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=38343&author=M.+Fryknasauthor=X.+N.+Zhangauthor=U.+Brembergauthor=W.+Senkowskiauthor=M.+H.+Olofssonauthor=P.+Brandtauthor=I.+Perssonauthor=P.+D%E2%80%99Arcyauthor=J.+Gullboauthor=P.+Nygrenauthor=L.+K.+Schughartauthor=S.+Linderauthor=R.+Larsson&title=Iron+chelators+target+both+proliferating+and+quiescent+cancer+cells&doi=10.1038%2Fsrep38343"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Iron chelators target both proliferating and quiescent cancer cells</span></div><div class="casAuthors">Fryknas Marten; Senkowski Wojciech; Gullbo Joachim; Larsson Rolf; Zhang Xiaonan; D'Arcy Padraig; Linder Stig; Zhang Xiaonan; Olofsson Maria Hagg; Linder Stig; Bremberg Ulf; Brandt Peter; Persson Ingmar; Gullbo Joachim; Nygren Peter; Schughart Leoni Kunz</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">38343</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Poorly vascularized areas of solid tumors contain quiescent cell populations that are resistant to cell cycle-active cancer drugs.  The compound VLX600 was recently identified to target quiescent tumor cells and to inhibit mitochondrial respiration.  We here performed gene expression analysis in order to characterize the cellular response to VLX600.  The compound-specific signature of VLX600 revealed a striking similarity to signatures generated by compounds known to chelate iron.  Validation experiments including addition of ferrous and ferric iron in excess, EXAFS measurements, and structure activity relationship analyses showed that VLX600 chelates iron and supported the hypothesis that the biological effects of this compound is due to iron chelation.  Compounds that chelate iron possess anti-cancer activity, an effect largely attributed to inhibition of ribonucleotide reductase in proliferating cells.  Here we show that iron chelators decrease mitochondrial energy production, an effect poorly tolerated by metabolically stressed tumor cells.  These pleiotropic features make iron chelators an attractive option for the treatment of solid tumors containing heterogeneous populations of proliferating and quiescent cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTXnn1YuaO7nf6BottYdIAWfW6udTcc2eZIct11p3rmfbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjkt1eitw%253D%253D&md5=229ef3e55508c28e7f6d9940c5c33cff</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1038%2Fsrep38343&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep38343%26sid%3Dliteratum%253Aachs%26aulast%3DFryknas%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DX.%2BN.%26aulast%3DBremberg%26aufirst%3DU.%26aulast%3DSenkowski%26aufirst%3DW.%26aulast%3DOlofsson%26aufirst%3DM.%2BH.%26aulast%3DBrandt%26aufirst%3DP.%26aulast%3DPersson%26aufirst%3DI.%26aulast%3DD%25E2%2580%2599Arcy%26aufirst%3DP.%26aulast%3DGullbo%26aufirst%3DJ.%26aulast%3DNygren%26aufirst%3DP.%26aulast%3DSchughart%26aufirst%3DL.%2BK.%26aulast%3DLinder%26aufirst%3DS.%26aulast%3DLarsson%26aufirst%3DR.%26atitle%3DIron%2520chelators%2520target%2520both%2520proliferating%2520and%2520quiescent%2520cancer%2520cells%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D38343%26doi%3D10.1038%2Fsrep38343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mody, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansfield, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vemireddy, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nygren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulbo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borad, M.</span></span> <span> </span><span class="NLM_article-title">A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">684</span>â <span class="NLM_lpage">692</span>, <span class="refDoi">Â DOI: 10.1007/s10637-018-0703-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1007%2Fs10637-018-0703-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=30460505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Ggur7L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=684-692&author=K.+Modyauthor=A.+S.+Mansfieldauthor=L.+Vemireddyauthor=P.+Nygrenauthor=J.+Gulboauthor=M.+Borad&title=A+phase+I+study+of+the+safety+and+tolerability+of+VLX600%2C+an+Iron+Chelator%2C+in+patients+with+refractory+advanced+solid+tumors&doi=10.1007%2Fs10637-018-0703-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors</span></div><div class="casAuthors">Mody, Kabir; Mansfield, Aaron S.; Vemireddy, Lalitha; Nygren, Peter; Gulbo, Joachim; Borad, Mitesh</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">684-692</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Introduction VLX600 is a novel iron chelator designed to interfere with intracellular iron metab., leading to inhibition of mitochondrial respiration and bioenergetic catastrophe and resultant tumor cell death.  Methods We conducted a multicenter, phase 1, dose escalation study to det. the safety and adverse event profile and the max. tolerated dose and recommended phase 2 dose of VLX600.  Other endpoints included pharmacokinetics, and preliminary evidence of anti-cancer efficacy as assessed according to RECIST 1.1 criteria.  VLX600 was administered i.v. on days 1, 8, and 15 of each 28-day treatment cycle.  Results Nineteen patients were enrolled, and seventeen received at least one dose of VLX600.  Dose increments were reduced to 50% after dose level 3 (40 mg) due to the occurrence of a grade 3 pulmonary embolism.  The study was then closed early due to slow recruitment.  No max. tolerated dose (MTD) nor RP2D had been identified at the time of study closure.  Overall, the drug was well tolerated and no DLTs were obsd.  Fourteen patients experienced drug-related adverse events of any grade.  The most frequently reported drug-related AEs were fatigue, nausea, constipation, vomiting, increased alk. phosphatase, anemia, and decreased appetite.  No formal efficacy or survival analyses were performed.  No objective responses were obsd., though six patients (32%) had stable disease as best response.  Conclusion VLX600 was reasonably well tolerated and, together with preclin. data, there is support for further efforts to explore its activity as single agent and in combination with drugs or radiation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGu9592XhXtrVg90H21EOLACvtfcHk0lgBTBG7UqCbxQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Ggur7L&md5=7aa131dc853164c76398f34d8a657c7e</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1007%2Fs10637-018-0703-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-018-0703-9%26sid%3Dliteratum%253Aachs%26aulast%3DMody%26aufirst%3DK.%26aulast%3DMansfield%26aufirst%3DA.%2BS.%26aulast%3DVemireddy%26aufirst%3DL.%26aulast%3DNygren%26aufirst%3DP.%26aulast%3DGulbo%26aufirst%3DJ.%26aulast%3DBorad%26aufirst%3DM.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520the%2520safety%2520and%2520tolerability%2520of%2520VLX600%252C%2520an%2520Iron%2520Chelator%252C%2520in%2520patients%2520with%2520refractory%2520advanced%2520solid%2520tumors%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2019%26volume%3D37%26spage%3D684%26epage%3D692%26doi%3D10.1007%2Fs10637-018-0703-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shestov, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Worth, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nath, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeper, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glickson, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, I. A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of mitochondrial Complex II by the anticancer agent lonidamine</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>291</i></span>,  <span class="NLM_fpage">42</span>â <span class="NLM_lpage">57</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M115.697516</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1074%2Fjbc.M115.697516" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=26521302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFSnsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=2016&pages=42-57&author=L.+L.+Guoauthor=A.+A.+Shestovauthor=A.+J.+Worthauthor=K.+Nathauthor=D.+S.+Nelsonauthor=D.+B.+Leeperauthor=J.+D.+Glicksonauthor=I.+A.+Blair&title=Inhibition+of+mitochondrial+Complex+II+by+the+anticancer+agent+lonidamine&doi=10.1074%2Fjbc.M115.697516"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Mitochondrial Complex II by the Anticancer Agent Lonidamine</span></div><div class="casAuthors">Guo, Lili; Shestov, Alexander A.; Worth, Andrew J.; Nath, Kavindra; Nelson, David S.; Leeper, Dennis B.; Glickson, Jerry D.; Blair, Ian A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">291</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">42-57</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The antitumor agent lonidamine (LND; 1-(2,4-dichlorobenzyl)-1H-indazole-3-carboxylic acid) is known to interfere with energy-yielding processes in cancer cells.  However, the effect of LND on central energy metab. has never been fully characterized.  In this study, we report that a significant amt. of succinate is accumulated in LND-treated cells.  LND inhibits the formation of fumarate and malate and suppresses succinate-induced respiration of isolated mitochondria.  Utilizing biochem. assays, we detd. that LND inhibits the succinate-ubiquinone reductase activity of respiratory complex II without fully blocking succinate dehydrogenase activity.  LND also induces cellular reactive oxygen species through complex II, which reduced the viability of the DB-1 melanoma cell line.  The ability of LND to promote cell death was potentiated by its suppression of the pentose phosphate pathway, which resulted in inhibition of NADPH and glutathione generation.  Using stable isotope tracers in combination with isotopologue anal., we showed that LND increased glutaminolysis but decreased reductive carboxylation of glutamine-derived Î±-ketoglutarate.  Our findings on the previously uncharacterized effects of LND may provide potential combinational therapeutic approaches for targeting cancer metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouPEhqlDUN5bVg90H21EOLACvtfcHk0lhZqTFbZ5pn9A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFSnsQ%253D%253D&md5=c89d9cf3dd79e98e478491a3e236b9c1</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M115.697516&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M115.697516%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DL.%2BL.%26aulast%3DShestov%26aufirst%3DA.%2BA.%26aulast%3DWorth%26aufirst%3DA.%2BJ.%26aulast%3DNath%26aufirst%3DK.%26aulast%3DNelson%26aufirst%3DD.%2BS.%26aulast%3DLeeper%26aufirst%3DD.%2BB.%26aulast%3DGlickson%26aufirst%3DJ.%2BD.%26aulast%3DBlair%26aufirst%3DI.%2BA.%26atitle%3DInhibition%2520of%2520mitochondrial%2520Complex%2520II%2520by%2520the%2520anticancer%2520agent%2520lonidamine%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2016%26volume%3D291%26spage%3D42%26epage%3D57%26doi%3D10.1074%2Fjbc.M115.697516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nath, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nancolas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shestov, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeper, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halestrap, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glickson, J. D.</span></span> <span> </span><span class="NLM_article-title">Mechanism of antineoplastic activity of lonidamine</span>. <i>Biochim. Biophys. Acta, Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1866</i></span>,  <span class="NLM_fpage">151</span>â <span class="NLM_lpage">162</span>, <span class="refDoi">Â DOI: 10.1016/j.bbcan.2016.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.bbcan.2016.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27497601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlSgs7vO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1866&publication_year=2016&pages=151-162&author=K.+Nathauthor=L.+L.+Guoauthor=B.+Nancolasauthor=D.+S.+Nelsonauthor=A.+A.+Shestovauthor=S.+C.+Leeauthor=J.+Romanauthor=R.+Zhouauthor=D.+B.+Leeperauthor=A.+P.+Halestrapauthor=I.+A.+Blairauthor=J.+D.+Glickson&title=Mechanism+of+antineoplastic+activity+of+lonidamine&doi=10.1016%2Fj.bbcan.2016.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of antineoplastic activity of lonidamine</span></div><div class="casAuthors">Nath, Kavindra; Guo, Lili; Nancolas, Bethany; Nelson, David S.; Shestov, Alexander A.; Lee, Seung-Cheol; Roman, Jeffrey; Zhou, Rong; Leeper, Dennis B.; Halestrap, Andrew P.; Blair, Ian A.; Glickson, Jerry D.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Reviews on Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">1866</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">151-162</span>CODEN:
                <span class="NLM_cas:coden">BBACEU</span>;
        ISSN:<span class="NLM_cas:issn">0304-419X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Lonidamine (LND) was initially introduced as an antispermatogenic agent.  It was later found to have anticancer activity sensitizing tumors to chemo-, radio-, and photodynamic-therapy and hyperthermia.  Although the mechanism of action remained unclear, LND treatment has been known to target metabolic pathways in cancer cells.  It has been reported to alter the bioenergetics of tumor cells by inhibiting glycolysis and mitochondrial respiration, while indirect evidence suggested that it also inhibited L-lactic acid efflux from cells mediated by members of the proton-linked monocarboxylate transporter (MCT) family and also pyruvate uptake into the mitochondria by the mitochondrial pyruvate carrier (MPC).  Recent studies have demonstrated that LND potently inhibits MPC activity in isolated rat liver mitochondria (Ki 2.5 Î¼M) and cooperatively inhibits L-lactate transport by MCT1, MCT2 and MCT4 expressed in Xenopus laevis oocytes with K0.5 and Hill coeff. values of 36-40 Î¼M and 1.65-1.85, resp.  In rat heart mitochondria LND inhibited the MPC with similar potency and uncoupled oxidn. of pyruvate was inhibited more effectively (IC50 â¼ 7 Î¼M) than other substrates including glutamate (IC50 â¼ 20 Î¼M).  LND inhibits the succinate-ubiquinone reductase activity of respiratory Complex II without fully blocking succinate dehydrogenase activity.  LND also induces cellular reactive oxygen species through Complex II and has been reported to promote cell death by suppression of the pentose phosphate pathway, which resulted in inhibition of NADPH and glutathione generation.  We conclude that MPC inhibition is the most sensitive anti-tumor target for LND, with addnl. inhibitory effects on MCT-mediated L-lactic acid efflux, Complex II and glutamine/glutamate oxidn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGOQV8MN2jHrVg90H21EOLACvtfcHk0lhZqTFbZ5pn9A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlSgs7vO&md5=81e080cd7465cb789eb02cb6f72fe539</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1016%2Fj.bbcan.2016.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbcan.2016.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DNath%26aufirst%3DK.%26aulast%3DGuo%26aufirst%3DL.%2BL.%26aulast%3DNancolas%26aufirst%3DB.%26aulast%3DNelson%26aufirst%3DD.%2BS.%26aulast%3DShestov%26aufirst%3DA.%2BA.%26aulast%3DLee%26aufirst%3DS.%2BC.%26aulast%3DRoman%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DR.%26aulast%3DLeeper%26aufirst%3DD.%2BB.%26aulast%3DHalestrap%26aufirst%3DA.%2BP.%26aulast%3DBlair%26aufirst%3DI.%2BA.%26aulast%3DGlickson%26aufirst%3DJ.%2BD.%26atitle%3DMechanism%2520of%2520antineoplastic%2520activity%2520of%2520lonidamine%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Rev.%2520Cancer%26date%3D2016%26volume%3D1866%26spage%3D151%26epage%3D162%26doi%3D10.1016%2Fj.bbcan.2016.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouari, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zielonka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zielonka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kresty, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalyanaraman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, M.</span></span> <span> </span><span class="NLM_article-title">Targeting lonidamine to mitochondria mitigates lung tumorigenesis and brain metastasis</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2205</span>, <span class="refDoi">Â DOI: 10.1038/s41467-019-10042-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fs41467-019-10042-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=31101821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BB3M7ntVKhtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=2205&author=G.+Chengauthor=Q.+Zhangauthor=J.+Panauthor=Y.+Leeauthor=O.+Ouariauthor=M.+Hardyauthor=M.+Zielonkaauthor=C.+R.+Myersauthor=J.+Zielonkaauthor=K.+Wehauthor=A.+C.+Changauthor=G.+A.+Chenauthor=L.+Krestyauthor=B.+Kalyanaramanauthor=M.+You&title=Targeting+lonidamine+to+mitochondria+mitigates+lung+tumorigenesis+and+brain+metastasis&doi=10.1038%2Fs41467-019-10042-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting lonidamine to mitochondria mitigates lung tumorigenesis and brain metastasis</span></div><div class="casAuthors">Cheng Gang; Zielonka Jacek; Kalyanaraman Balaraman; Cheng Gang; Zielonka Monika; Zielonka Jacek; Kalyanaraman Balaraman; Cheng Gang; Zhang Qi; Pan Jing; Zielonka Monika; Myers Charles R; Zielonka Jacek; Kalyanaraman Balaraman; You Ming; Zhang Qi; Pan Jing; Lee Yongik; Myers Charles R; You Ming; Ouari Olivier; Hardy Micael; Weh Katherine; Chang Andrew C; Chen Guoan; Kresty Laura</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2205</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Lung cancer often has a poor prognosis, with brain metastases a major reason for mortality.  We modified lonidamine (LND), an antiglycolytic drug with limited efficacy, to mitochondria-targeted mito-lonidamine (Mito-LND) which is 100-fold more potent.  Mito-LND, a tumor-selective inhibitor of oxidative phosphorylation, inhibits mitochondrial bioenergetics in lung cancer cells and mitigates lung cancer cell viability, growth, progression, and metastasis of lung cancer xenografts in mice.  Mito-LND blocks lung tumor development and brain metastasis by inhibiting mitochondrial bioenergetics, stimulating the formation of reactive oxygen species, oxidizing mitochondrial peroxiredoxin, inactivating AKT/mTOR/p70S6K signaling, and inducing autophagic cell death in lung cancer cells.  Mito-LND causes no toxicity in mice even when administered for eight weeks at 50 times the effective cancer inhibitory dose.  Collectively, these findings show that mitochondrial targeting of LND is a promising therapeutic approach for investigating the role of autophagy in mitigating lung cancer development and brain metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSvT4TvZUZc_T69zv1FsJFMfW6udTcc2eYrJ5nyo4iOsLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7ntVKhtQ%253D%253D&md5=02613d99917151b8580b61fc7cbbd50a</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1038%2Fs41467-019-10042-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-019-10042-1%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DPan%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DY.%26aulast%3DOuari%26aufirst%3DO.%26aulast%3DHardy%26aufirst%3DM.%26aulast%3DZielonka%26aufirst%3DM.%26aulast%3DMyers%26aufirst%3DC.%2BR.%26aulast%3DZielonka%26aufirst%3DJ.%26aulast%3DWeh%26aufirst%3DK.%26aulast%3DChang%26aufirst%3DA.%2BC.%26aulast%3DChen%26aufirst%3DG.%2BA.%26aulast%3DKresty%26aufirst%3DL.%26aulast%3DKalyanaraman%26aufirst%3DB.%26aulast%3DYou%26aufirst%3DM.%26atitle%3DTargeting%2520lonidamine%2520to%2520mitochondria%2520mitigates%2520lung%2520tumorigenesis%2520and%2520brain%2520metastasis%26jtitle%3DNat.%2520Commun.%26date%3D2019%26volume%3D10%26spage%3D2205%26doi%3D10.1038%2Fs41467-019-10042-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fry, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pudney, M.</span></span> <span> </span><span class="NLM_article-title">Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4â²-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">1545</span>â <span class="NLM_lpage">1553</span>, <span class="refDoi">Â DOI: 10.1016/0006-2952(92)90213-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2F0006-2952%2892%2990213-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1314606" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADyaK38XisVOqtrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=1992&pages=1545-1553&author=M.+Fryauthor=M.+Pudney&title=Site+of+action+of+the+antimalarial+hydroxynaphthoquinone%2C+2-%5Btrans-4-%284%E2%80%B2-chlorophenyl%29+cyclohexyl%5D-3-hydroxy-1%2C4-naphthoquinone&doi=10.1016%2F0006-2952%2892%2990213-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4'-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80)</span></div><div class="casAuthors">Fry, Mitchell; Pudney, Mary</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1545-53</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">The site of action of the antimalarial compd. 2-[trans-4-(4'-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80), would appear to be the mitochondrial respiratory chain.  Studies reported herein have demonstrated 566C80 to be a potent and selective mitochondrial inhibitor with mitochondria isolated from Plasmodium falciparum and P. yoelii.  Selective assay of individual respiratory chain complexes has shown the primary site of action of 566C80 to be the cytochrome bc1 complex (Complex III): supportive evidence from difference spectroscopy indicates the site of inhibition to lie between cytochromes b and c1 of this complex.  Using [14C]566C80, evidence is presented which suggests that 566C80 may become irreversibly bound to a polypeptide with an approx. mol. mass of 11,500 Da.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9fMI5cyRJT7Vg90H21EOLACvtfcHk0lgzJSEodCIa9Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XisVOqtrs%253D&md5=a45e691f8c26b9bd2caddab95c9e7c93</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2892%2990213-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252892%252990213-3%26sid%3Dliteratum%253Aachs%26aulast%3DFry%26aufirst%3DM.%26aulast%3DPudney%26aufirst%3DM.%26atitle%3DSite%2520of%2520action%2520of%2520the%2520antimalarial%2520hydroxynaphthoquinone%252C%25202-%255Btrans-4-%25284%25E2%2580%25B2-chlorophenyl%2529%2520cyclohexyl%255D-3-hydroxy-1%252C4-naphthoquinone%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1992%26volume%3D43%26spage%3D1545%26epage%3D1553%26doi%3D10.1016%2F0006-2952%2892%2990213-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mather, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darrouzet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valkova-Valchanova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooley, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntosh, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daldal, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidya, A. B.</span></span> <span> </span><span class="NLM_article-title">Uncovering the molecular mode of action of the antimalarial drug atovaquone using a bacterial system</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>280</i></span>,  <span class="NLM_fpage">27458</span>â <span class="NLM_lpage">27465</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M502319200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1074%2Fjbc.M502319200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=15917236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmt1Ggu7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=27458-27465&author=M.+W.+Matherauthor=E.+Darrouzetauthor=M.+Valkova-Valchanovaauthor=J.+W.+Cooleyauthor=M.+T.+McIntoshauthor=F.+Daldalauthor=A.+B.+Vaidya&title=Uncovering+the+molecular+mode+of+action+of+the+antimalarial+drug+atovaquone+using+a+bacterial+system&doi=10.1074%2Fjbc.M502319200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Uncovering the molecular mode of action of the antimalarial drug atovaquone using a bacterial system</span></div><div class="casAuthors">Mather, Michael W.; Darrouzet, Elisabeth; Valkova-Valchanova, Maria; Cooley, Jason W.; McIntosh, Michael T.; Daldal, Fevzi; Vaidya, Akhil B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">27458-27465</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Atovaquone is an antiparasitic drug that selectively inhibits electron transport through the parasite mitochondrial cytochrome bc1 complex and collapses the mitochondrial membrane potential at concns. far lower than those at which the mammalian system is affected.  Because this mol. represents a new class of antimicrobial agents, we seek a deeper understanding of its mode of action.  To that end, we employed site-directed mutagenesis of a bacterial cytochrome b, combined with biophys. and biochem. measurements.  A large scale domain movement involving the iron-sulfur protein subunit is required for electron transfer from cytochrome b-bound ubihydroquinone to cytochrome c1 of the cytochrome bc1 complex.  Here, we show that atovaquone blocks this domain movement by locking the iron-sulfur subunit in its cytochrome b-binding conformation.  Based on our malaria atovaquone resistance data, a series of cytochrome b mutants was produced that were predicted to have either enhanced or reduced sensitivity to atovaquone.  Mutations altering the bacterial cytochrome b at its ef loop to more closely resemble Plasmodium cytochrome b increased the sensitivity of the cytochrome bc1 complex to atovaquone.  A mutation within the ef loop that is assocd. with resistant malaria parasites rendered the complex resistant to atovaquone, thereby providing direct proof that the mutation causes atovaquone resistance.  This mutation resulted in a 10-fold redn. in the in vitro activity of the cytochrome bc1 complex, suggesting that it may exert a cost on efficiency of the cytochrome bc1 complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-Drz1XSE2hbVg90H21EOLACvtfcHk0lgzJSEodCIa9Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmt1Ggu7k%253D&md5=dfb350a3f23e0f48f92aa6723890db2b</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M502319200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M502319200%26sid%3Dliteratum%253Aachs%26aulast%3DMather%26aufirst%3DM.%2BW.%26aulast%3DDarrouzet%26aufirst%3DE.%26aulast%3DValkova-Valchanova%26aufirst%3DM.%26aulast%3DCooley%26aufirst%3DJ.%2BW.%26aulast%3DMcIntosh%26aufirst%3DM.%2BT.%26aulast%3DDaldal%26aufirst%3DF.%26aulast%3DVaidya%26aufirst%3DA.%2BB.%26atitle%3DUncovering%2520the%2520molecular%2520mode%2520of%2520action%2520of%2520the%2520antimalarial%2520drug%2520atovaquone%2520using%2520a%2520bacterial%2520system%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D27458%26epage%3D27465%26doi%3D10.1074%2Fjbc.M502319200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fokas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunz-Schughart, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folkes, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anbalagan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huether, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirovano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buffa, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stratford, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muschel, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenna, W. G.</span></span> <span> </span><span class="NLM_article-title">The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">12308</span>, <span class="refDoi">Â DOI: 10.1038/ncomms12308</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fncomms12308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27453292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1yru7%252FK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=12308&author=T.+M.+Ashtonauthor=E.+Fokasauthor=L.+A.+Kunz-Schughartauthor=L.+K.+Folkesauthor=S.+Anbalaganauthor=M.+Huetherauthor=C.+J.+Kellyauthor=G.+Pirovanoauthor=F.+M.+Buffaauthor=E.+M.+Hammondauthor=M.+Stratfordauthor=R.+J.+Muschelauthor=G.+S.+Higginsauthor=W.+G.+McKenna&title=The+anti-malarial+atovaquone+increases+radiosensitivity+by+alleviating+tumour+hypoxia&doi=10.1038%2Fncomms12308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia</span></div><div class="casAuthors">Ashton, Thomas M.; Fokas, Emmanouil; Kunz-Schughart, Leoni A.; Folkes, Lisa K.; Anbalagan, Selvakumar; Huether, Melanie; Kelly, Catherine J.; Pirovano, Giacomo; Buffa, Francesca M.; Hammond, Ester M.; Stratford, Michael; Muschel, Ruth J.; Higgins, Geoff S.; McKenna, William Gillies</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">12308</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Tumor hypoxia renders cancer cells resistant to cancer therapy, resulting in markedly worse clin. outcomes.  To find clin. candidate compds. that reduce hypoxia in tumors, we conduct a high-throughput screen for oxygen consumption rate (OCR) redn. and identify a no. of drugs with this property.  For this study we focus on the anti-malarial, atovaquone.  Atovaquone rapidly decreases the OCR by more than 80% in a wide range of cancer cell lines at pharmacol. concns.  In addn., atovaquone eradicates hypoxia in FaDu, HCT116 and H1299 spheroids.  Similarly, it reduces hypoxia in FaDu and HCT116 xenografts in nude mice, and causes a significant tumor growth delay when combined with radiation.  Atovaquone is a ubiquinone analog, and decreases the OCR by inhibiting mitochondrial complex III.  We are now undertaking clin. studies to assess whether atovaquone reduces tumor hypoxia in patients, thereby increasing the efficacy of radiotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGou4wtBQpnHGrVg90H21EOLACvtfcHk0lgzJSEodCIa9Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1yru7%252FK&md5=f7f5692ab92188af45a43cfd3dc5dacb</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1038%2Fncomms12308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms12308%26sid%3Dliteratum%253Aachs%26aulast%3DAshton%26aufirst%3DT.%2BM.%26aulast%3DFokas%26aufirst%3DE.%26aulast%3DKunz-Schughart%26aufirst%3DL.%2BA.%26aulast%3DFolkes%26aufirst%3DL.%2BK.%26aulast%3DAnbalagan%26aufirst%3DS.%26aulast%3DHuether%26aufirst%3DM.%26aulast%3DKelly%26aufirst%3DC.%2BJ.%26aulast%3DPirovano%26aufirst%3DG.%26aulast%3DBuffa%26aufirst%3DF.%2BM.%26aulast%3DHammond%26aufirst%3DE.%2BM.%26aulast%3DStratford%26aufirst%3DM.%26aulast%3DMuschel%26aufirst%3DR.%2BJ.%26aulast%3DHiggins%26aufirst%3DG.%2BS.%26aulast%3DMcKenna%26aufirst%3DW.%2BG.%26atitle%3DThe%2520anti-malarial%2520atovaquone%2520increases%2520radiosensitivity%2520by%2520alleviating%2520tumour%2520hypoxia%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D12308%26doi%3D10.1038%2Fncomms12308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fiorillo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanowitz, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mutti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krstic-Demonacos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappello, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Outschoorn, U. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotgia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lisanti, M. P.</span></span> <span> </span><span class="NLM_article-title">Repurposing atovaquone: Targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">34084</span>â <span class="NLM_lpage">34099</span>, <span class="refDoi">Â DOI: 10.18632/oncotarget.9122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.18632%2Foncotarget.9122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27136895" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BC28blsVehsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=34084-34099&author=M.+Fiorilloauthor=R.+Lambauthor=H.+B.+Tanowitzauthor=L.+Muttiauthor=M.+Krstic-Demonacosauthor=A.+R.+Cappelloauthor=U.+E.+Martinez-Outschoornauthor=F.+Sotgiaauthor=M.+P.+Lisanti&title=Repurposing+atovaquone%3A+Targeting+mitochondrial+complex+III+and+OXPHOS+to+eradicate+cancer+stem+cells&doi=10.18632%2Foncotarget.9122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposing atovaquone: targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells</span></div><div class="casAuthors">Fiorillo Marco; Lamb Rebecca; Sotgia Federica; Lisanti Michael P; Fiorillo Marco; Sotgia Federica; Lisanti Michael P; Fiorillo Marco; Cappello Anna Rita; Tanowitz Herbert B; Mutti Luciano; Krstic-Demonacos Marija; Martinez-Outschoorn Ubaldo E</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">34084-99</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Atovaquone is an FDA-approved anti-malarial drug, which first became clinically available in the year 2000.  Currently, its main usage is for the treatment of pneumocystis pneumonia (PCP) and/or toxoplasmosis in immune-compromised patients.  Atovaquone is a hydroxy-1,4-naphthoquinone analogue of ubiquinone, also known as Co-enzyme Q10 (CoQ10).  It is a well-tolerated drug that does not cause myelo-suppression.  Mechanistically, it is thought to act as a potent and selective OXPHOS inhibitor, by targeting the CoQ10-dependence of mitochondrial complex III.  Here, we show for the first time that atovaquone also has anti-cancer activity, directed against Cancer Stem-like Cells (CSCs).  More specifically, we demonstrate that atovaquone treatment of MCF7 breast cancer cells inhibits oxygen-consumption and metabolically induces aerobic glycolysis (the Warburg effect), as well as oxidative stress.  Remarkably, atovaquone potently inhibits the propagation of MCF7-derived CSCs, with an IC-50 of 1 Î¼M, as measured using the mammosphere assay.  Atovaquone also maintains this selectivity and potency in mixed populations of CSCs and non-CSCs.  Importantly, these results indicate that glycolysis itself is not sufficient to maintain the proliferation of CSCs, which is instead strictly dependent on mitochondrial function.  In addition to targeting the proliferation of CSCs, atovaquone also induces apoptosis in both CD44+/CD24low/- CSC and ALDH+ CSC populations, during exposure to anchorage-independent conditions for 12 hours.  However, it has no effect on oxygen consumption in normal human fibroblasts and, in this cellular context, behaves as an anti-inflammatory, consistent with the fact that it is well-tolerated in patients treated for infections.  Future studies in xenograft models and human clinical trials may be warranted, as the IC-50 of atovaquone's action on CSCs (1 Î¼M) is >50 times less than its average serum concentration in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTWq76aYVUugWHOrQ6qeX-mfW6udTcc2ea9XqM1QRu2Frntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28blsVehsQ%253D%253D&md5=5173cb92af46bc980a3b468a3d6eeae5</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.9122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.9122%26sid%3Dliteratum%253Aachs%26aulast%3DFiorillo%26aufirst%3DM.%26aulast%3DLamb%26aufirst%3DR.%26aulast%3DTanowitz%26aufirst%3DH.%2BB.%26aulast%3DMutti%26aufirst%3DL.%26aulast%3DKrstic-Demonacos%26aufirst%3DM.%26aulast%3DCappello%26aufirst%3DA.%2BR.%26aulast%3DMartinez-Outschoorn%26aufirst%3DU.%2BE.%26aulast%3DSotgia%26aufirst%3DF.%26aulast%3DLisanti%26aufirst%3DM.%2BP.%26atitle%3DRepurposing%2520atovaquone%253A%2520Targeting%2520mitochondrial%2520complex%2520III%2520and%2520OXPHOS%2520to%2520eradicate%2520cancer%2520stem%2520cells%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D34084%26epage%3D34099%26doi%3D10.18632%2Foncotarget.9122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, V. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bar-Natan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anahtar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toniolo, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroll, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giaccone, Z. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heppler, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, D. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marineau, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blonquist, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hetz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soiffer, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, D. A.</span></span> <span> </span><span class="NLM_article-title">Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">1845</span>â <span class="NLM_lpage">1853</span>, <span class="refDoi">Â DOI: 10.1182/blood-2015-07-660506</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1182%2Fblood-2015-07-660506" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27531676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlSiurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2016&pages=1845-1853&author=M.+Xiangauthor=H.+Kimauthor=V.+T.+Hoauthor=S.+R.+Walkerauthor=M.+Bar-Natanauthor=M.+Anahtarauthor=S.+H.+Liuauthor=P.+A.+Tonioloauthor=Y.+Krollauthor=N.+Jonesauthor=Z.+T.+Giacconeauthor=L.+N.+Hepplerauthor=D.+Q.+Yeauthor=J.+J.+Marineauauthor=D.+Shawauthor=J.+E.+Bradnerauthor=T.+Blonquistauthor=D.+Neubergauthor=C.+Hetzauthor=R.+M.+Stoneauthor=R.+J.+Soifferauthor=D.+A.+Frank&title=Gene+expression-based+discovery+of+atovaquone+as+a+STAT3+inhibitor+and+anticancer+agent&doi=10.1182%2Fblood-2015-07-660506"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent</span></div><div class="casAuthors">Xiang, Michael; Kim, Haesook; Ho, Vincent T.; Walker, Sarah R.; Bar-Natan, Michal; Anahtar, Melodi; Liu, Suhu; Toniolo, Patricia A.; Kroll, Yasmin; Jones, Nichole; Giaccone, Zachary T.; Heppler, Lisa N.; Ye, Darwin Q.; Marineau, Jason J.; Shaw, Daniel; Bradner, James E.; Blonquist, Traci; Neuberg, Donna; Hetz, Claudio; Stone, Richard M.; Soiffer, Robert J.; Frank, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1845-1853</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The oncogenic transcription factor signal transducer and activator of transcription 3 (STAT3) is frequently activated inappropriately in a wide range of hematol. and solid cancers, but clin. available therapies targeting STAT3 are lacking.  Using a computational strategy to identify compds. opposing the gene expression signature of STAT3, we discovered atovaquone (Mepron), an antimicrobial approved by the US Food and Drug Administration, to be a potent STAT3 inhibitor.  We show that, at drug concns. routinely achieved clin. in human plasma, atovaquone inhibits STAT3 phosphorylation, the expression of STAT3 target genes, and the viability of STAT3-dependent hematol. cancer cells.  These effects were also obsd. with atovaquone treatment of primary blasts isolated from patients with acute myelogenous leukemia or acute lymphocytic leukemia.  Atovaquone is not a kinase inhibitor but instead rapidly and specifically downregulates cell-surface expression of glycoprotein 130, which is required for STAT3 activation in multiple contexts.  The administration of oral atovaquone to mice inhibited tumor growth and prolonged survival in a murine model of multiple myeloma.  Finally, in patients with acute myelogenous leukemia treated with hematopoietic stem cell transplantation, extended use of atovaquone for Pneumocystis prophylaxis was assocd. with improved relapse-free survival.  These findings establish atovaquone as a novel, clin. accessible STAT3 inhibitor with evidence of anticancer efficacy in both animal models and humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7kci57tYtb7Vg90H21EOLACvtfcHk0lig-NprITHiSA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlSiurg%253D&md5=201e3d6ea0e204d1a631652caae8f987</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1182%2Fblood-2015-07-660506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2015-07-660506%26sid%3Dliteratum%253Aachs%26aulast%3DXiang%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DHo%26aufirst%3DV.%2BT.%26aulast%3DWalker%26aufirst%3DS.%2BR.%26aulast%3DBar-Natan%26aufirst%3DM.%26aulast%3DAnahtar%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DS.%2BH.%26aulast%3DToniolo%26aufirst%3DP.%2BA.%26aulast%3DKroll%26aufirst%3DY.%26aulast%3DJones%26aufirst%3DN.%26aulast%3DGiaccone%26aufirst%3DZ.%2BT.%26aulast%3DHeppler%26aufirst%3DL.%2BN.%26aulast%3DYe%26aufirst%3DD.%2BQ.%26aulast%3DMarineau%26aufirst%3DJ.%2BJ.%26aulast%3DShaw%26aufirst%3DD.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DBlonquist%26aufirst%3DT.%26aulast%3DNeuberg%26aufirst%3DD.%26aulast%3DHetz%26aufirst%3DC.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DSoiffer%26aufirst%3DR.%2BJ.%26aulast%3DFrank%26aufirst%3DD.%2BA.%26atitle%3DGene%2520expression-based%2520discovery%2520of%2520atovaquone%2520as%2520a%2520STAT3%2520inhibitor%2520and%2520anticancer%2520agent%26jtitle%3DBlood%26date%3D2016%26volume%3D128%26spage%3D1845%26epage%3D1853%26doi%3D10.1182%2Fblood-2015-07-660506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gangjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaware, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raghavan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihnat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shenoy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kisliuk, R. L.</span></span> <span> </span><span class="NLM_article-title">Single agents with designed combination chemotherapy potential: synthesis and evaluation of substituted pyrimido[4,5-b]indoles as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">1563</span>â <span class="NLM_lpage">1578</span>, <span class="refDoi">Â DOI: 10.1021/jm9011142</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9011142" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptlKntA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=1563-1578&author=A.+Gangjeeauthor=N.+Zawareauthor=S.+Raghavanauthor=M.+Ihnatauthor=S.+Shenoyauthor=R.+L.+Kisliuk&title=Single+agents+with+designed+combination+chemotherapy+potential%3A+synthesis+and+evaluation+of+substituted+pyrimido%5B4%2C5-b%5Dindoles+as+receptor+tyrosine+kinase+and+thymidylate+synthase+inhibitors+and+as+antitumor+agents&doi=10.1021%2Fjm9011142"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Single agents with designed combination chemotherapy potential: synthesis and evaluation of substituted pyrimido[4,5-b]indoles as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents</span></div><div class="casAuthors">Gangjee, Aleem; Zaware, Nilesh; Raghavan, Sudhir; Ihnat, Michael; Shenoy, Satyendra; Kisliuk, Roy L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1563-1578</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Combinations of antiangiogenic agents (AAs) with cytotoxic agents have shown significant promise in cancer treatment, and several such clin. trials are currently underway.  We have designed, synthesized, and evaluated two compds. I (R = H, Me) that each inhibit vascular endothelial growth factor receptor-2 (VEGFR-2) and platelet-derived growth factor receptor-Î² (PDGFR-Î²) for antiangiogenic effects and also inhibit human thymidylate synthase (hTS) for cytotoxic effects in single agents.  The synthesis of these compds. involved the nucleophilic displacement of the common intermediate 5-chloro-9H-pyrimido[4,5-b]indole-2,4-diamine with appropriate benzenethiols.  The inhibitory potency of both these single agents against VEGFR-2, PDGFR-Î², and hTS is better than or close to stds.  In a COLO-205 xenograft mouse model, one of the analogs significantly decreased tumor growth (tumor growth inhibition (TGI) = 76% at 35 mg/kg), liver metastases, and tumor blood vessels compared with a std. drug and with control and thus demonstrated potent tumor growth inhibition, inhibition of metastasis, and antiangiogenic effects in vivo.  These compds. afford combination chemotherapeutic potential in single agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOJB7QlDdAybVg90H21EOLACvtfcHk0ljrSNdGN5DF5g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptlKntA%253D%253D&md5=f4dcd7a6aa14c39435a1b515b0653f62</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1021%2Fjm9011142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9011142%26sid%3Dliteratum%253Aachs%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DZaware%26aufirst%3DN.%26aulast%3DRaghavan%26aufirst%3DS.%26aulast%3DIhnat%26aufirst%3DM.%26aulast%3DShenoy%26aufirst%3DS.%26aulast%3DKisliuk%26aufirst%3DR.%2BL.%26atitle%3DSingle%2520agents%2520with%2520designed%2520combination%2520chemotherapy%2520potential%253A%2520synthesis%2520and%2520evaluation%2520of%2520substituted%2520pyrimido%255B4%252C5-b%255Dindoles%2520as%2520receptor%2520tyrosine%2520kinase%2520and%2520thymidylate%2520synthase%2520inhibitors%2520and%2520as%2520antitumor%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D1563%26epage%3D1578%26doi%3D10.1021%2Fjm9011142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bastian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorpe, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Disch, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey-Downs, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devambatla, R. K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henthorn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphries, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vadvalkar, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihnat, M. A.</span></span> <span> </span><span class="NLM_article-title">A small molecule with anticancer and antimetastatic activities induces rapid mitochondrial-associated necrosis in breast cancer</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>353</i></span>,  <span class="NLM_fpage">392</span>â <span class="NLM_lpage">404</span>, <span class="refDoi">Â DOI: 10.1124/jpet.114.220335</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1124%2Fjpet.114.220335" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=25720766" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFaitr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2015&pages=392-404&author=A.+Bastianauthor=J.+E.+Thorpeauthor=B.+C.+Dischauthor=L.+C.+Bailey-Downsauthor=A.+Gangjeeauthor=R.+K.+V.+Devambatlaauthor=J.+Henthornauthor=K.+M.+Humphriesauthor=S.+S.+Vadvalkarauthor=M.+A.+Ihnat&title=A+small+molecule+with+anticancer+and+antimetastatic+activities+induces+rapid+mitochondrial-associated+necrosis+in+breast+cancer&doi=10.1124%2Fjpet.114.220335"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule with anticancer and antimetastatic activities induces rapid mitochondrial-associated necrosis in breast cancer</span></div><div class="casAuthors">Bastian, Anja; Thorpe, Jessica E.; Disch, Bryan C.; Bailey-Downs, Lora C.; Gangjee, Aleem; Devambatla, Ravi K. V.; Henthorn, Jim; Humphries, Kenneth M.; Vadvalkar, Shraddha S.; Ihnat, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">392-404</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Therapy for treatment-resistant breast cancer provides limited options and the response rates are low.  Therefore, the development of therapies with alternative chemotherapeutic strategies is necessary.  AG311 (5-[(4-methylphenyl)thio]-9H-pyrimido[4,5-b]indole-2,4-diamine), a small mol., is being investigated in preclin. and mechanistic studies for treatment of resistant breast cancer through necrosis, an alternative cell death mechanism.  In vitro, AG311 induces rapid necrosis in numerous cancer cell lines as evidenced by loss of membrane integrity, ATP depletion, HMGB1 (high-mobility group protein B1) translocation, nuclear swelling, and stable membrane blebbing in breast cancer cells.  Within minutes, exposure to AG311 also results in mitochondrial depolarization, superoxide prodn., and increased intracellular calcium levels.  Addnl., upregulation of mitochondrial oxidative phosphorylation results in sensitization to AG311.  This AG311-induced cell death can be partially prevented by treatment with the mitochondrial calcium uniporter inhibitor, Ru360 [(Î¼)[(HCO2)(NH3)4Ru]2OCl3], or an antioxidant, lipoic acid.  Addnl., AG311 does not increase apoptotic markers such as cleavage of poly (ADP-ribose) polymerase (PARP) or caspase-3 and -7 activity.  Importantly, in vivo studies in two orthotopic breast cancer mouse models (xenograft and allograft) demonstrate that AG311 retards tumor growth and reduces lung metastases better than clin. used agents and has no gross or histopathol. toxicity.  Together, these data suggest that AG311 is a first-in-class antitumor and antimetastatic agent inducing necrosis in breast cancer tumors, likely through the mitochondria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbjGbAk1F8t7Vg90H21EOLACvtfcHk0ljrSNdGN5DF5g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFaitr0%253D&md5=241fb2abf00cb24c87c615ce6f713f02</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.220335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.220335%26sid%3Dliteratum%253Aachs%26aulast%3DBastian%26aufirst%3DA.%26aulast%3DThorpe%26aufirst%3DJ.%2BE.%26aulast%3DDisch%26aufirst%3DB.%2BC.%26aulast%3DBailey-Downs%26aufirst%3DL.%2BC.%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DDevambatla%26aufirst%3DR.%2BK.%2BV.%26aulast%3DHenthorn%26aufirst%3DJ.%26aulast%3DHumphries%26aufirst%3DK.%2BM.%26aulast%3DVadvalkar%26aufirst%3DS.%2BS.%26aulast%3DIhnat%26aufirst%3DM.%2BA.%26atitle%3DA%2520small%2520molecule%2520with%2520anticancer%2520and%2520antimetastatic%2520activities%2520induces%2520rapid%2520mitochondrial-associated%2520necrosis%2520in%2520breast%2520cancer%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D353%26spage%3D392%26epage%3D404%26doi%3D10.1124%2Fjpet.114.220335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bastian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuzaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphries, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pharaoh, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doshi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaware, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihnat, M. A.</span></span> <span> </span><span class="NLM_article-title">AG311, a small molecule inhibitor of complex I and hypoxia-induced HIF-1 alpha stabilization</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>388</i></span>,  <span class="NLM_fpage">149</span>â <span class="NLM_lpage">157</span>, <span class="refDoi">Â DOI: 10.1016/j.canlet.2016.11.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.canlet.2016.11.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27939695" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVOjsbbI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=388&publication_year=2017&pages=149-157&author=A.+Bastianauthor=S.+Matsuzakiauthor=K.+M.+Humphriesauthor=G.+A.+Pharaohauthor=A.+Doshiauthor=N.+Zawareauthor=A.+Gangjeeauthor=M.+A.+Ihnat&title=AG311%2C+a+small+molecule+inhibitor+of+complex+I+and+hypoxia-induced+HIF-1+alpha+stabilization&doi=10.1016%2Fj.canlet.2016.11.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">AG311, a small molecule inhibitor of complex I and hypoxia-induced HIF-1Î± stabilization</span></div><div class="casAuthors">Bastian, Anja; Matsuzaki, Satoshi; Humphries, Kenneth M.; Pharaoh, Gavin A.; Doshi, Arpit; Zaware, Nilesh; Gangjee, Aleem; Ihnat, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">388</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">149-157</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Cancer cells have a unique metabolic profile and mitochondria have been shown to play an important role in chemoresistance, tumor progression and metastases.  This unique profile can be exploited by mitochondrial-targeted anticancer therapies.  A small anticancer mol., AG311, was previously shown to possess anticancer and antimetastatic activity in two cancer mouse models and to induce mitochondrial depolarization.  This study defines the mol. effects of AG311 on the mitochondria to elucidate its obsd. efficacy.  AG311 was found to competitively inhibit complex I activity at the ubiquinone-binding site.  Complex I as a target for AG311 was further established by measuring oxygen consumption rate in tumor tissue isolated from AG311-treated mice.  Cotreatment of cells and animals with AG311 and dichloroacetate, a pyruvate dehydrogenase kinase inhibitor that increases oxidative metab., resulted in synergistic cell kill and reduced tumor growth.  The inhibition of mitochondrial oxygen consumption by AG311 was found to reduce HIF-1Î± stabilization by increasing oxygen tension in hypoxic conditions.  Taken together, these results suggest that AG311 at least partially mediates its antitumor effect through inhibition of complex I, which could be exploited in its use as an anticancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofuguVO4Xs97Vg90H21EOLACvtfcHk0ljrSNdGN5DF5g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVOjsbbI&md5=d5ae6ecc0136aaae16dd809b8e4ff0f7</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2016.11.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2016.11.040%26sid%3Dliteratum%253Aachs%26aulast%3DBastian%26aufirst%3DA.%26aulast%3DMatsuzaki%26aufirst%3DS.%26aulast%3DHumphries%26aufirst%3DK.%2BM.%26aulast%3DPharaoh%26aufirst%3DG.%2BA.%26aulast%3DDoshi%26aufirst%3DA.%26aulast%3DZaware%26aufirst%3DN.%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DIhnat%26aufirst%3DM.%2BA.%26atitle%3DAG311%252C%2520a%2520small%2520molecule%2520inhibitor%2520of%2520complex%2520I%2520and%2520hypoxia-induced%2520HIF-1%2520alpha%2520stabilization%26jtitle%3DCancer%2520Lett.%26date%3D2017%26volume%3D388%26spage%3D149%26epage%3D157%26doi%3D10.1016%2Fj.canlet.2016.11.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zielonka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouari, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAllister, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrios, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwinell, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalyanaraman, B.</span></span> <span> </span><span class="NLM_article-title">Mitochondria-targeted analogues of metformin exhibit enhanced antiproliferative and radiosensitizing effects in pancreatic cancer cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">3904</span>â <span class="NLM_lpage">3915</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-15-2534</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F0008-5472.CAN-15-2534" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27216187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVyit7bJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=3904-3915&author=G.+Chengauthor=J.+Zielonkaauthor=O.+Ouariauthor=M.+Lopezauthor=D.+McAllisterauthor=K.+Boyleauthor=C.+S.+Barriosauthor=J.+J.+Weberauthor=B.+D.+Johnsonauthor=M.+Hardyauthor=M.+B.+Dwinellauthor=B.+Kalyanaraman&title=Mitochondria-targeted+analogues+of+metformin+exhibit+enhanced+antiproliferative+and+radiosensitizing+effects+in+pancreatic+cancer+cells&doi=10.1158%2F0008-5472.CAN-15-2534"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondria-Targeted Analogues of Metformin Exhibit Enhanced Antiproliferative and Radiosensitizing Effects in Pancreatic Cancer Cells</span></div><div class="casAuthors">Cheng, Gang; Zielonka, Jacek; Ouari, Olivier; Lopez, Marcos; McAllister, Donna; Boyle, Kathleen; Barrios, Christy S.; Weber, James J.; Johnson, Bryon D.; Hardy, Micael; Dwinell, Michael B.; Kalyanaraman, Balaraman</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3904-3915</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Metformin (Met) is an approved antidiabetic drug currently being explored for repurposing in cancer treatment based on recent evidence of its apparent chemopreventive properties.  Met is weakly cationic and targets the mitochondria to induce cytotoxic effects in tumor cells, albeit not very effectively.  We hypothesized that increasing its mitochondria-targeting potential by attaching a pos. charged lipophilic substituent would enhance the antitumor activity of Met.  In pursuit of this question, we synthesized a set of mitochondria-targeted Met analogs (Mito-Mets) with varying alkyl chain lengths contg. a triphenylphosphonium cation (TPP+).  In particular, the analog Mito-Met10, synthesized by attaching TPP+ to Met via a 10-carbon aliph. side chain, was nearly 1,000 times more efficacious than Met at inhibiting cell proliferation in pancreatic ductal adenocarcinoma (PDAC).  Notably, in PDAC cells, Mito-Met10 potently inhibited mitochondrial complex I, stimulating superoxide and AMPK activation, but had no effect in nontransformed control cells.  Moreover, Mito-Met10 potently triggered G1 cell-cycle phase arrest in PDAC cells, enhanced their radiosensitivity, and more potently abrogated PDAC growth in preclin. mouse models, compared with Met.  Collectively, our findings show how improving the mitochondrial targeting of Met enhances its anticancer activities, including aggressive cancers like PDAC in great need of more effective therapeutic options.  Cancer Res; 76(13); 3904-15. Â©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwe6dyucpsaLVg90H21EOLACvtfcHk0lgyikZLNVqZOg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVyit7bJ&md5=6e2d142c64d7ff181a80e3a1b01952b5</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-15-2534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-15-2534%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DG.%26aulast%3DZielonka%26aufirst%3DJ.%26aulast%3DOuari%26aufirst%3DO.%26aulast%3DLopez%26aufirst%3DM.%26aulast%3DMcAllister%26aufirst%3DD.%26aulast%3DBoyle%26aufirst%3DK.%26aulast%3DBarrios%26aufirst%3DC.%2BS.%26aulast%3DWeber%26aufirst%3DJ.%2BJ.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DHardy%26aufirst%3DM.%26aulast%3DDwinell%26aufirst%3DM.%2BB.%26aulast%3DKalyanaraman%26aufirst%3DB.%26atitle%3DMitochondria-targeted%2520analogues%2520of%2520metformin%2520exhibit%2520enhanced%2520antiproliferative%2520and%2520radiosensitizing%2520effects%2520in%2520pancreatic%2520cancer%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26spage%3D3904%26epage%3D3915%26doi%3D10.1158%2F0008-5472.CAN-15-2534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ju, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D. C.</span></span> <span> </span><span class="NLM_article-title">Carboxyamidotriazole inhibits oxidative phosphorylation in cancer cells and exerts synergistic anti-cancer effect with glycolysis inhibition</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>370</i></span>,  <span class="NLM_fpage">232</span>â <span class="NLM_lpage">241</span>, <span class="refDoi">Â DOI: 10.1016/j.canlet.2015.10.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.canlet.2015.10.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=26522259" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslGmtLvI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2016&pages=232-241&author=R.+Juauthor=L.+Guoauthor=J.+Liauthor=L.+Zhuauthor=X.+L.+Yuauthor=C.+Chenauthor=W.+Chenauthor=C.+Y.+Yeauthor=D.+C.+Zhang&title=Carboxyamidotriazole+inhibits+oxidative+phosphorylation+in+cancer+cells+and+exerts+synergistic+anti-cancer+effect+with+glycolysis+inhibition&doi=10.1016%2Fj.canlet.2015.10.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Carboxyamidotriazole inhibits oxidative phosphorylation in cancer cells and exerts synergistic anti-cancer effect with glycolysis inhibition</span></div><div class="casAuthors">Ju, Rui; Guo, Lei; Li, Juan; Zhu, Lei; Yu, Xiaoli; Chen, Chen; Chen, Wei; Ye, Caiying; Zhang, Dechang</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">232-241</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Targeting cancer cell metab. is a promising strategy against cancer.  Here, we confirmed that the anti-cancer drug carboxyamidotriazole (CAI) inhibited mitochondrial respiration in cancer cells for the first time and found a way to enhance its anti-cancer activity by further disturbing the energy metab.  CAI promoted glucose uptake and lactate prodn. when incubated with cancer cells.  The oxidative phosphorylation (OXPHOS) in cancer cells was inhibited by CAI, and the decrease in the activity of the respiratory chain complex I could be one explanation.  The anti-cancer effect of CAI was greatly potentiated when being combined with 2-deoxyglucose (2-DG).  The cancer cells treated with the combination of CAI and 2-DG were arrested in G2/M phase.  The apoptosis and necrosis rates were also increased.  In a mouse xenograft model, this combination was well tolerated and retarded the tumor growth.  The impairment of cancer cell survival was assocd. with significant cellular ATP decrease, suggesting that the combination of CAI and 2-DG could be one of the strategies to cause dual inhibition of energy pathways, which might be an effective therapeutic approach for a broad spectrum of tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKjl4hPSdLtrVg90H21EOLACvtfcHk0lgyikZLNVqZOg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslGmtLvI&md5=f8eb03de9ba482c039a82e25b662494f</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2015.10.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2015.10.025%26sid%3Dliteratum%253Aachs%26aulast%3DJu%26aufirst%3DR.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DX.%2BL.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DYe%26aufirst%3DC.%2BY.%26aulast%3DZhang%26aufirst%3DD.%2BC.%26atitle%3DCarboxyamidotriazole%2520inhibits%2520oxidative%2520phosphorylation%2520in%2520cancer%2520cells%2520and%2520exerts%2520synergistic%2520anti-cancer%2520effect%2520with%2520glycolysis%2520inhibition%26jtitle%3DCancer%2520Lett.%26date%3D2016%26volume%3D370%26spage%3D232%26epage%3D241%26doi%3D10.1016%2Fj.canlet.2015.10.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ju, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, C. Y.</span></span> <span> </span><span class="NLM_article-title">Metabolic mechanisms and a rational combinational application of carboxyamidotriazole in fighting pancreatic cancer progression after chemotherapy</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>367</i></span>,  <span class="NLM_fpage">20</span>â <span class="NLM_lpage">27</span>, <span class="refDoi">Â DOI: 10.1124/jpet.118.249326</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1124%2Fjpet.118.249326" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=30002095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVegtrzM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2018&pages=20-27&author=R.+Juauthor=K.+L.+Feiauthor=S.+Liauthor=C.+Chenauthor=L.+Zhuauthor=J.+Liauthor=D.+C.+Zhangauthor=L.+Guoauthor=C.+Y.+Ye&title=Metabolic+mechanisms+and+a+rational+combinational+application+of+carboxyamidotriazole+in+fighting+pancreatic+cancer+progression+after+chemotherapy&doi=10.1124%2Fjpet.118.249326"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic mechanisms and a rational combinational application of carboxyamidotriazole in fighting pancreatic cancer progression after chemotherapy</span></div><div class="casAuthors">Ju, Rui; Fei, Kailun; Li, Siang; Chen, Chen; Zhu, Lei; Li, Juan; Zhang, Dechang; Guo, Lei; Ye, Caiying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20-27</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The anticancer and anti-inflammatory effects of carboxyamidotriazole (CAI) have been demonstrated in several studies, but the underlying mechanisms remain to be elucidated.  This study showed that CAI caused metabolic reprogramming of pancreatic cancer cells.  The inhibition of mitochondrial oxidative metab. by CAI led to increased glutamine-dependent reductive carboxylation and enhanced glycolytic metab.  The presence of environmental substances that affect cellular metab., such as glutamine and pyruvate, attenuated the anticancer efficacy of CAI.  Based on the action of CAI: 1) when glutamine was removed, the NAD1/NADH ratio was decreased, the synthesis of cellular aspartate was reduced, and autophagy flux was blocked; and 2) when glycolysis was pharmacol. inhibited, the ATP level was significantly decreased, the cell viability was greatly inhibited, and the compensatory rescue effect of glutamine was eliminated.  When combined with chemotherapy, cotreatment with CAI and the glycolysis inhibitor 2-deoxyglucose (2-DG) inhibited the pancreatic cancer progression after chemotherapy.  As the inhibition of mitochondrial oxidative metab. can explain several anticancer activities of CAI reported previously, including inhibition of calcium entry and induction of reactive oxygen species, we demonstrate that inhibition of mitochondrial oxidative phosphorylation may be the fundamental mechanism of CAI.  The combination of CAI and 2-DG causes energy depletion in cancer cells, eliminating the rescue effect of the metabolic environment.  Inhibiting pancreatic cancer progression after chemotherapy is a rational application of this metab.-disturbing combination strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEVRSj5zAXsrVg90H21EOLACvtfcHk0lgyikZLNVqZOg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVegtrzM&md5=d74135697df24a203e96f64f2b6c947d</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1124%2Fjpet.118.249326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.118.249326%26sid%3Dliteratum%253Aachs%26aulast%3DJu%26aufirst%3DR.%26aulast%3DFei%26aufirst%3DK.%2BL.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DD.%2BC.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DYe%26aufirst%3DC.%2BY.%26atitle%3DMetabolic%2520mechanisms%2520and%2520a%2520rational%2520combinational%2520application%2520of%2520carboxyamidotriazole%2520in%2520fighting%2520pancreatic%2520cancer%2520progression%2520after%2520chemotherapy%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2018%26volume%3D367%26spage%3D20%26epage%3D27%26doi%3D10.1124%2Fjpet.118.249326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ju, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D. C.</span></span> <span> </span><span class="NLM_article-title">Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy</span>. <i>J. Immunother. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">246</span>, <span class="refDoi">Â DOI: 10.1186/s40425-019-0725-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1186%2Fs40425-019-0725-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=31511064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BB3MrnslOmuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=246&author=J.+Shiauthor=C.+Chenauthor=R.+Juauthor=Q.+Z.+Wangauthor=J.+Liauthor=L.+Guoauthor=C.+Y.+Yeauthor=D.+C.+Zhang&title=Carboxyamidotriazole+combined+with+IDO1-Kyn-AhR+pathway+inhibitors+profoundly+enhances+cancer+immunotherapy&doi=10.1186%2Fs40425-019-0725-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy</span></div><div class="casAuthors">Shi Jing; Chen Chen; Ju Rui; Wang Qingzhu; Li Juan; Guo Lei; Ye Caiying; Zhang Dechang</div><div class="citationInfo"><span class="NLM_cas:title">Journal for immunotherapy of cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">246</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Cancer immunotherapy has generated significant excitement, mainly as a result of the development of immune checkpoint inhibitors.  The blockade of PD-1 or its ligand with antibodies has resulted in impressive clinical efficacy.  However, a subset of patients does not respond to biologic therapeutics, and another subset suffers from severe immune-related adverse events in certain cases.  The modulation of the immune system with small molecules might yield surprising benefits.  METHODS:  CD8(+) cells were obtained through a magnetic cell sorting system (MACS), and their capabilities for IFN-Î³ release and PD-1 expression were analyzed.  The in vitro effects of drugs were studied in a coculture system of tumor cells and activated CD8(+) cells.  We further isolated the primary tumor cells in tumor-bearing mice treated with CAI, DMF, 1-MT or a combination (CAI and DMF/CAI and 1-MT) and analyzed the percentages of CD8(+) T cells and PD-1(+)CD8(+) T cells among TILs.  The selective anti-tumor immune reactions of the two drug combinations were confirmed in a coculture system consisting of B16-OVA cells and OVA-specific CTLs derived from OT-1 transgenic mice.  The anti-tumor effects of the single drugs or combined therapies were assessed according to their capability to slow tumor growth and extend the life span of tumor-bearing mice, and they were compared with the effects of PD-1 antibody.  RESULTS:  CAI increased IFN-Î³ release from activated T cells, which might strengthen the anti-proliferative and anti-metastatic effects on cancer cells.  However, CAI also stimulated IDO1-Kyn metabolic circuitry in the tumor microenvironment and facilitated tumor cell immune evasion.  Combining CAI with 1-MT or DMF disrupted PD-1 expression and promoted IFN-Î³ production in CD8(+) T cells, and it also increased T lymphocyte infiltration in the tumor microenvironment, inhibited tumor growth and prolonged the life spans of tumor-bearing mice.  CONCLUSION:  Inhibitors of the IDO1-Kyn-AhR pathway could abolish the negative effects of CAI on CD8(+) T cells and result in complementary and beneficial anti-tumor immune effects.  The combination of CAI with 1-MT or DMF greatly augmented the ability of CD8(+) T cells to kill malignant cells and showed a strong anti-cancer capability that was superior to that of either of the single agents was is comparable with that of anti-PD-1 antibody.  The combinations of small molecules utilized in this study may serve as valuable new immunotherapy strategies for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSAOIdPFXVpog5nADWVYHg1fW6udTcc2eZ1_zbL5CI847ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MrnslOmuw%253D%253D&md5=d5fae69617d17c7f0943555fa0a307af</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1186%2Fs40425-019-0725-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40425-019-0725-7%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DJu%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DQ.%2BZ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DYe%26aufirst%3DC.%2BY.%26aulast%3DZhang%26aufirst%3DD.%2BC.%26atitle%3DCarboxyamidotriazole%2520combined%2520with%2520IDO1-Kyn-AhR%2520pathway%2520inhibitors%2520profoundly%2520enhances%2520cancer%2520immunotherapy%26jtitle%3DJ.%2520Immunother.%2520Cancer%26date%3D2019%26volume%3D7%26spage%3D246%26doi%3D10.1186%2Fs40425-019-0725-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carey, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, M.</span></span> <span> </span><span class="NLM_article-title">Anti-cancer analogues ME-143 and ME-344 exert toxicity by directly inhibiting mitochondrial NADH: ubiquinone oxidoreductase (Complex I)</span>. <i>Am. J. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">689</span>â <span class="NLM_lpage">701</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=25973307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BC2MfjvFOlsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=689-701&author=S.+C.+Limauthor=K.+T.+Careyauthor=M.+McKenzie&title=Anti-cancer+analogues+ME-143+and+ME-344+exert+toxicity+by+directly+inhibiting+mitochondrial+NADH%3A+ubiquinone+oxidoreductase+%28Complex+I%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-cancer analogues ME-143 and ME-344 exert toxicity by directly inhibiting mitochondrial NADH: ubiquinone oxidoreductase (Complex I)</span></div><div class="casAuthors">Lim Sze Chern; Carey Kirstyn T; McKenzie Matthew</div><div class="citationInfo"><span class="NLM_cas:title">American journal of cancer research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">689-701</span>
        ISSN:<span class="NLM_cas:issn">2156-6976</span>.
    </div><div class="casAbstract">Isoflavonoids have been shown to inhibit tumor proliferation and metastasis by activating cell death pathways.  As such, they have been widely studied as potential therapies for cancer prevention.  The second generation synthetic isoflavan analogues ME-143 and ME-344 also exhibit anti-cancer effects, however their specific molecular targets have not been completely defined.  To identify these targets, we examined the effects of ME-143 and ME-344 on cellular metabolism and found that they are potent inhibitors of mitochondrial oxidative phosphorylation (OXPHOS) complex I (NADH: ubiquinone oxidoreductase) activity.  In isolated HEK293T mitochondria, ME-143 and ME-344 reduced complex I activity to 14.3% and 28.6% of control values respectively.  In addition to the inhibition of complex I, ME-344 also significantly inhibited mitochondrial complex III (ubiquinol: ferricytochrome-c oxidoreductase) activity by 10.8%.  This inhibition of complex I activity (and to a lesser extent complex III activity) was associated with a reduction in mitochondrial oxygen consumption.  In permeabilized HEK293T cells, ME-143 and ME-344 significantly reduced the maximum ADP-stimulated respiration rate to 62.3% and 70.0% of control levels respectively in the presence of complex I-linked substrates.  Conversely, complex II-linked respiration was unaffected by either drug.  We also observed that the inhibition of complex I-linked respiration caused the dissipation of the mitochondrial membrane potential (ÎÎ¨m).  Blue native (BN-PAGE) analysis revealed that prolonged loss of ÎÎ¨m results in the destabilization of the native OXPHOS complexes.  In particular, treatment of 143B osteosarcoma, HeLa and HEK293T human embryonic kidney cells with ME-344 for 4 h resulted in reduced steady-state levels of mature complex I.  Degradation of the complex I subunit NDUFA9, as well as the complex IV (ferrocytochrome c: oxygen oxidoreductase) subunit COXIV, was also evident.  The identification of OXPHOS complex I as a target of ME-143 and ME-344 advances our understanding of how these drugs induce cell death by disrupting mitochondrial metabolism, and will direct future work to maximize the anti-cancer capacity of these and other isoflavone-based compounds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTfz9l6WKV16p6KlWarZTAzfW6udTcc2eZ1_zbL5CI847ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MfjvFOlsw%253D%253D&md5=ab4c782a2fcabd76580daab14f664d90</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DS.%2BC.%26aulast%3DCarey%26aufirst%3DK.%2BT.%26aulast%3DMcKenzie%26aufirst%3DM.%26atitle%3DAnti-cancer%2520analogues%2520ME-143%2520and%2520ME-344%2520exert%2520toxicity%2520by%2520directly%2520inhibiting%2520mitochondrial%2520NADH%253A%2520ubiquinone%2520oxidoreductase%2520%2528Complex%2520I%2529%26jtitle%3DAm.%2520J.%2520Cancer%2520Res.%26date%3D2015%26volume%3D5%26spage%3D689%26epage%3D701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref187"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref187'); return false;" data-citation="" class="refNumLink">187</a></strong><div class="NLM_citation" id="cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Z. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manevich, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bethard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broome, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsend, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tew, K. D.</span></span> <span> </span><span class="NLM_article-title">Isoflavone ME-344 disrupts redox homeostasis and mitochondrial function by targeting heme oxygenase 1</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">4072</span>â <span class="NLM_lpage">4085</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-18-3503</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F0008-5472.CAN-18-3503" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=31227482" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFyjtb3J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=4072-4085&author=L.+L.+Zhangauthor=J.+Zhangauthor=Z.+W.+Yeauthor=Y.+Manevichauthor=L.+E.+Ballauthor=J.+R.+Bethardauthor=Y.+L.+Jiangauthor=A.+M.+Broomeauthor=A.+C.+Daltonauthor=G.+Y.+Wangauthor=D.+M.+Townsendauthor=K.+D.+Tew&title=Isoflavone+ME-344+disrupts+redox+homeostasis+and+mitochondrial+function+by+targeting+heme+oxygenase+1&doi=10.1158%2F0008-5472.CAN-18-3503"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Isoflavone ME-344 disrupts redox homeostasis and mitochondrial function by targeting heme oxygenase 1</span></div><div class="casAuthors">Zhang, Leilei; Zhang, Jie; Ye, Zhiwei; Manevich, Yefim; Ball, Lauren E.; Bethard, Jennifer R.; Jiang, Yu-Lin; Broome, Ann-Marie; Dalton, Annamarie C.; Wang, Gavin Y.; Townsend, Danyelle M.; Tew, Kenneth D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4072-4085</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">ME-344 is a second-generation isoflavone with unusual cytotoxic properties that is in clin. testing in cancer.  To identify targets that contribute to its anticancer activity and therapeutic index, we used lung cancer cell lines that are naturally sensitive or resistant to ME-344.  Drug-induced apoptosis was linked with enhanced levels of reactive oxygen species and this initiated a nuclear erythroid factor 2-like 2 signaling response, downstream of which, heme oxygenase 1 (HO-1) was also found to be time-dependently inhibited by ME-344.  ME-344 specifically bound to, and altered, HO-1 structure and increased HO-1 translocation from the rough endoplasmic reticulum to mitochondria, but only in drug-sensitive cells.  These effects did not occur in either drug-resistant or primary lung fibroblasts with lower HO-1 basal levels.  HO-1 was confirmed as a drug target by using surface plasmon resonance technol. and through interaction with a clickable ME-344 compd. (M2F) and subsequent proteomic analyses, showing direct binding of ME-344 with HO-1.  Proteomic anal. showed that clusters of mitochondrial proteins, including voltage-dependent anion-selective channels, were also impacted by ME-344.  Human lung cancer biopsies expressed higher levels of Nrf2 and HO-1 compared with normal tissues.  Overall, our data show that ME-344 inhibits HO-1 and impacts its mitochondrial translocation.  Other mitochondrial proteins are also affected, resulting in interference in tumor cell redox homeostasis and mitochondrial function.  These factors contribute to a beneficial therapeutic index and support continued clin. development of ME-344.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGbUvXxlK6qLVg90H21EOLACvtfcHk0lg8aWL01w6EVQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFyjtb3J&md5=ec43717669ba68c238f579d6ec0ecab9</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-18-3503&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-18-3503%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DL.%2BL.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYe%26aufirst%3DZ.%2BW.%26aulast%3DManevich%26aufirst%3DY.%26aulast%3DBall%26aufirst%3DL.%2BE.%26aulast%3DBethard%26aufirst%3DJ.%2BR.%26aulast%3DJiang%26aufirst%3DY.%2BL.%26aulast%3DBroome%26aufirst%3DA.%2BM.%26aulast%3DDalton%26aufirst%3DA.%2BC.%26aulast%3DWang%26aufirst%3DG.%2BY.%26aulast%3DTownsend%26aufirst%3DD.%2BM.%26aulast%3DTew%26aufirst%3DK.%2BD.%26atitle%3DIsoflavone%2520ME-344%2520disrupts%2520redox%2520homeostasis%2520and%2520mitochondrial%2520function%2520by%2520targeting%2520heme%2520oxygenase%25201%26jtitle%3DCancer%2520Res.%26date%3D2019%26volume%3D79%26spage%3D4072%26epage%3D4085%26doi%3D10.1158%2F0008-5472.CAN-18-3503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref188"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref188'); return false;" data-citation="" class="refNumLink">188</a></strong><div class="NLM_citation" id="cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyczechowska, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zapata, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullinax, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrero, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peruzzi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culicchia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochoa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grabacka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiss, K.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanisms of fenofibrate-induced metabolic catastrophe and glioblastoma cell death</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">182</span>â <span class="NLM_lpage">198</span>, <span class="refDoi">Â DOI: 10.1128/MCB.00562-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1128%2FMCB.00562-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=25332241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFertbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=182-198&author=A.+Wilkauthor=D.+Wyczechowskaauthor=A.+Zapataauthor=M.+Deanauthor=J.+Mullinaxauthor=L.+Marreroauthor=C.+Parsonsauthor=F.+Peruzziauthor=F.+Culicchiaauthor=A.+Ochoaauthor=M.+Grabackaauthor=K.+Reiss&title=Molecular+mechanisms+of+fenofibrate-induced+metabolic+catastrophe+and+glioblastoma+cell+death&doi=10.1128%2FMCB.00562-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of fenofibrate-induced metabolic catastrophe and glioblastoma cell death</span></div><div class="casAuthors">Wilk, Anna; Wyczechowska, Dorota; Zapata, Adriana; Dean, Matthew; Mullinax, Jennifer; Marrero, Luis; Parsons, Christopher; Peruzzi, Francesca; Culicchia, Frank; Ochoa, Augusto; Grabacka, Maja; Reiss, Krzysztof</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">182-198/1-182-198/17, 17 pp.</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">1098-5549</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Fenofibrate (FF) is a common lipid-lowering drug and a potent agonist of the peroxisome proliferator-activated receptor alpha (PPARÎ±).  FF and several other agonists of PPARÎ± have interesting anticancer properties, and our recent studies demonstrate that FF is very effective against tumor cells of neuroectodermal origin.  In spite of these promising anticancer effects, the mol. mechanism(s) of FF-induced tumor cell toxicity remains to be elucidated.  Here we report a novel PPARÎ±-independent mechanism explaining FF's cytotoxicity in vitro and in an intracranial mouse model of glioblastoma.  The mechanism involves accumulation of FF in the mitochondrial fraction, followed by immediate impairment of mitochondrial respiration at the level of complex I of the electron transport chain.  This mitochondrial action sensitizes tested glioblastoma cells to the PPARÎ±-dependent metabolic switch from glycolysis to fatty acid Î²-oxidn.  As a consequence, prolonged exposure to FF depletes intracellular ATP, activates the AMP-activated protein kinase-mammalian target of rapamycin-autophagy pathway, and results in extensive tumor cell death.  Interestingly, autophagy activators attenuate and autophagy inhibitors enhance FF-induced glioblastoma cytotoxicity.  Our results explain the mol. basis of FF-induced glioblastoma cytotoxicity and reveal a new supplemental therapeutic approach in which intracranial infusion of FF could selectively trigger metabolic catastrophe in glioblastoma cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHsh6CZvXYTLVg90H21EOLACvtfcHk0lj52x_fl3qhYw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFertbo%253D&md5=789381ef5a9f650d2fb5dd04a8cab2bc</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1128%2FMCB.00562-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.00562-14%26sid%3Dliteratum%253Aachs%26aulast%3DWilk%26aufirst%3DA.%26aulast%3DWyczechowska%26aufirst%3DD.%26aulast%3DZapata%26aufirst%3DA.%26aulast%3DDean%26aufirst%3DM.%26aulast%3DMullinax%26aufirst%3DJ.%26aulast%3DMarrero%26aufirst%3DL.%26aulast%3DParsons%26aufirst%3DC.%26aulast%3DPeruzzi%26aufirst%3DF.%26aulast%3DCulicchia%26aufirst%3DF.%26aulast%3DOchoa%26aufirst%3DA.%26aulast%3DGrabacka%26aufirst%3DM.%26aulast%3DReiss%26aufirst%3DK.%26atitle%3DMolecular%2520mechanisms%2520of%2520fenofibrate-induced%2520metabolic%2520catastrophe%2520and%2520glioblastoma%2520cell%2520death%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2015%26volume%3D35%26spage%3D182%26epage%3D198%26doi%3D10.1128%2FMCB.00562-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">189</a></strong><div class="NLM_citation" id="cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brunmair, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lest, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staniek, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gras, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scharf, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roden, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nohl, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldhausl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furnsinn, C.</span></span> <span> </span><span class="NLM_article-title">Fenofibrate impairs rat mitochondrial function by inhibition of respiratory complex I</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>311</i></span>,  <span class="NLM_fpage">109</span>â <span class="NLM_lpage">114</span>, <span class="refDoi">Â DOI: 10.1124/jpet.104.068312</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1124%2Fjpet.104.068312" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=15166256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD2cXosVKrtrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=311&publication_year=2004&pages=109-114&author=B.+Brunmairauthor=A.+Lestauthor=K.+Staniekauthor=F.+Grasauthor=N.+Scharfauthor=M.+Rodenauthor=H.+Nohlauthor=W.+Waldhauslauthor=C.+Furnsinn&title=Fenofibrate+impairs+rat+mitochondrial+function+by+inhibition+of+respiratory+complex+I&doi=10.1124%2Fjpet.104.068312"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Fenofibrate impairs rat mitochondrial function by inhibition of respiratory complex I</span></div><div class="casAuthors">Brunmair, Barbara; Lest, Andrea; Staniek, Katrin; Gras, Florian; Scharf, Nicole; Roden, Michael; Nohl, Hans; Waldhaeusl, Werner; Fuernsinn, Clemens</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">311</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">109-114</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Fibrates are used for the treatment of dyslipidemia and known to affect mitochondrial function in vitro.  To better understand the mechanisms underlying their mitochondrial effects, fibrate actions on complex I of the respiratory chain and cell respiration were studied in vitro.  In homogenates of rat skeletal muscle, fenofibrate, and to a lesser extent clofibrate, reduced the activity of complex I (10, 30, and 100 Î¼M fenofibrate: -41Â±7%, -70Â±2%, and -78Â±4%; 100 Î¼M clofibrate: -27Â±7%; p < 0.005 each).  Inhibition of complex I by fenofibrate (100 Î¼M) was confirmed by reduced state 3 respiration of isolated mitochondria consuming glutamate + malate as substrates for complex I (-33Â±4%; p < 0.0005), but not of such consuming succinate as substrate for complex II (-8Â±4%; NS).  In isolated rat muscle, 24-h fenofibrate exposure (25, 50, and 100 Î¼M) decreased CO2 prodn. from palmitate (-15Â±7%, -23Â±8%, and -22Â±7%; p < 0.05 each) and increased lactate release (+15Â±5%, +14Â±5%, and +17Â±6%; p < 0.02 each) indicating impaired cell respiration.  Ciprofibrate and gemfibrozil (but not bezafibrate) impaired cell respiration without any inhibition of complex I.  Our findings support the notion that individual fibrates induce mitochondrial dysfunction via different mol. mechanisms and show that fenofibrate predominantly acts by inhibition of complex I of the respiratory chain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_ZQ6TfI5YVLVg90H21EOLACvtfcHk0lj52x_fl3qhYw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXosVKrtrw%253D&md5=85fb2c5fa085e291e63636febed8c91a</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1124%2Fjpet.104.068312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.104.068312%26sid%3Dliteratum%253Aachs%26aulast%3DBrunmair%26aufirst%3DB.%26aulast%3DLest%26aufirst%3DA.%26aulast%3DStaniek%26aufirst%3DK.%26aulast%3DGras%26aufirst%3DF.%26aulast%3DScharf%26aufirst%3DN.%26aulast%3DRoden%26aufirst%3DM.%26aulast%3DNohl%26aufirst%3DH.%26aulast%3DWaldhausl%26aufirst%3DW.%26aulast%3DFurnsinn%26aufirst%3DC.%26atitle%3DFenofibrate%2520impairs%2520rat%2520mitochondrial%2520function%2520by%2520inhibition%2520of%2520respiratory%2520complex%2520I%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2004%26volume%3D311%26spage%3D109%26epage%3D114%26doi%3D10.1124%2Fjpet.104.068312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref190"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref190'); return false;" data-citation="" class="refNumLink">190</a></strong><div class="NLM_citation" id="cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Udeani, G. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerhauser, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosmeder, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinghorn, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriarty, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezzuto, J. M.</span></span> <span> </span><span class="NLM_article-title">Cancer chemopreventive activity mediated by deguelin, a naturally occurring rotenoid</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3424</span>â <span class="NLM_lpage">3428</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=9270008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADyaK2sXls1Shurs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1997&pages=3424-3428&author=G.+O.+Udeaniauthor=C.+Gerhauserauthor=C.+F.+Thomasauthor=R.+C.+Moonauthor=J.+W.+Kosmederauthor=A.+D.+Kinghornauthor=R.+M.+Moriartyauthor=J.+M.+Pezzuto&title=Cancer+chemopreventive+activity+mediated+by+deguelin%2C+a+naturally+occurring+rotenoid"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer chemopreventive activity mediated by deguelin, a naturally occurring rotenoid</span></div><div class="casAuthors">Udeani, George O.; Gerhauser, Clarissa; Thomas, Cathy F.; Moon, Richard C.; Kosmeder, Jerrome W.; Kinghorn, A. Douglas; Moriarty, Robert M.; Pezzuto, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3424-3428</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Deguelin, a natural product isolated from Mundulea sericea (Leguminosae), was shown previously to mediate strong inhibition of 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced ornithine decarboxylase (ODC) activity in cell culture and to reduce the formation of preneoplastic lesions when mouse mammary glands were exposed to 7,12-dimethylbenz(a)anthracene.  As reported currently, deguelin was synthesized and evaluated for chemopreventive activity in the two-stage 7,12-dimethylbenz(a)anthracene/TPA skin carcinogenesis model with CD-1 mice and in the N-methylnitrosourea mammary carcinogenesis model with Sprague Dawley rats.  In the mouse skin study, deguelin reduced tumor incidence from 60% in the control group to 10% in the group treated with a dose of 33 Î¼g, and multiplicity was reduced from 4.2 in the control group to 0.1 in the treatment group.  When the dose was increased 10-fold to 330 Î¼g, no tumors were obsd. in the treatment group.  These results correlated with the potential of deguelin to inhibit TPA-induced mouse epidermal ODC activity.  When applied topically as a single dose in a time range of 2 h before to 2 h after TPA treatment, deguelin (384 Î¼g) reduced ODC induction by TPA (6.17 Î¼g) by more than 85%.  Time course studies indicated that deguelin (33 Î¼g) inhibited TPA (1.17 Î¼g)-induced ODC activity by 70% without affecting the kinetics of induction over a period of 10 h.  Complete inhibition of ODC induction was obsd. at a dose of 330 Î¼g of deguelin.  In the rat mammary tumorigenesis study, intragastric administration of 2 or 4 mg of deguelin/kg of body wt. daily, 5 days/wk, reduced tumor multiplicity from 6.8 tumors/rat in the control group to 5.1 or 3.2 tumors/animal, resp.  At the 4 mg of deguelin/kg of body wt. dose level, the tumor latency period was significantly increased.  Tumor incidence, however, was unaffected.  These data indicate that deguelin exhibits cancer chemopreventive effects in skin and mammary tumorigenesis models and that addnl. studies are warranted to characterize the cancer chemopreventive or chemotherapeutic potential of this substance more fully.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptHkleDt5p1bVg90H21EOLACvtfcHk0lj52x_fl3qhYw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXls1Shurs%253D&md5=bd75d1453967572362dcb5c2382a63d8</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DUdeani%26aufirst%3DG.%2BO.%26aulast%3DGerhauser%26aufirst%3DC.%26aulast%3DThomas%26aufirst%3DC.%2BF.%26aulast%3DMoon%26aufirst%3DR.%2BC.%26aulast%3DKosmeder%26aufirst%3DJ.%2BW.%26aulast%3DKinghorn%26aufirst%3DA.%2BD.%26aulast%3DMoriarty%26aufirst%3DR.%2BM.%26aulast%3DPezzuto%26aufirst%3DJ.%2BM.%26atitle%3DCancer%2520chemopreventive%2520activity%2520mediated%2520by%2520deguelin%252C%2520a%2520naturally%2520occurring%2520rotenoid%26jtitle%3DCancer%2520Res.%26date%3D1997%26volume%3D57%26spage%3D3424%26epage%3D3428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref191"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref191'); return false;" data-citation="" class="refNumLink">191</a></strong><div class="NLM_citation" id="cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubet, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, M.</span></span> <span> </span><span class="NLM_article-title">Efficacy of deguelin and silibinin on benzo(a)pyrene-induced lung tumorigenesis in A/J mice</span>. <i>Neoplasia</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1053</span>â <span class="NLM_lpage">1057</span>, <span class="refDoi">Â DOI: 10.1593/neo.05532</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1593%2Fneo.05532" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=16354587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD28XptlShsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=1053-1057&author=Y.+Yanauthor=Y.+Wangauthor=Q.+Tanauthor=R.+A.+Lubetauthor=M.+You&title=Efficacy+of+deguelin+and+silibinin+on+benzo%28a%29pyrene-induced+lung+tumorigenesis+in+A%2FJ+mice&doi=10.1593%2Fneo.05532"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of deguelin and silibinin on benzo(a)pyrene-induced lung tumorigenesis in A/J mice</span></div><div class="casAuthors">Yan, Ying; Wang, Yian; Tan, Qing; Lubet, Ronald A.; You, Ming</div><div class="citationInfo"><span class="NLM_cas:title">Neoplasia (Ann Arbor, MI, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1053-1057</span>CODEN:
                <span class="NLM_cas:coden">NEOPFL</span>;
        ISSN:<span class="NLM_cas:issn">1522-8002</span>.
    
            (<span class="NLM_cas:orgname">Neoplasia Press Inc.</span>)
        </div><div class="casAbstract">We evaluated deguelin and silibinin in A/J mice treated with the tobacco-specific carcinogen benzo(a)pyrene (BP) for their ability to inhibit pulmonary adenoma formation and growth.  Animals were treated with either deguelin (5.0 or 10.0 mg/kg body wt., by gavage) or silibinin at doses of 0.05% and 0.1% in the diet, approx. 10 days before a single i.p. dose of BP.  We found that oral administration of deguelin reduced tumor multiplicity by 56% and tumor load by 78%, whereas silibinin treatment at doses of 0.05% and 0.1% in the diet did not show any significant efficacy on either tumor multiplicity or tumor load.  The result indicates that deguelin significantly inhibits pulmonary adenoma formation and growth in A/J mice.  Finding new and effective agents that can prevent lung cancer is urgently needed because cancer of the lungs remains the principal cause of cancer deaths in the United States and because effective chemoprevention of this cancer type remains elusive.  Thus, deguelin appears to be a promising new preventive agent for lung cancer and may be considered for further studies in other animal models and in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHP14e3lymVLVg90H21EOLACvtfcHk0lgNxCoiNPINcA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptlShsg%253D%253D&md5=057360a31ce858adfe295784ac689a79</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1593%2Fneo.05532&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1593%252Fneo.05532%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DTan%26aufirst%3DQ.%26aulast%3DLubet%26aufirst%3DR.%2BA.%26aulast%3DYou%26aufirst%3DM.%26atitle%3DEfficacy%2520of%2520deguelin%2520and%2520silibinin%2520on%2520benzo%2528a%2529pyrene-induced%2520lung%2520tumorigenesis%2520in%2520A%252FJ%2520mice%26jtitle%3DNeoplasia%26date%3D2005%26volume%3D7%26spage%3D1053%26epage%3D1057%26doi%3D10.1593%2Fneo.05532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref192"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref192'); return false;" data-citation="" class="refNumLink">192</a></strong><div class="NLM_citation" id="cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chun, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosmeder, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezzuto, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. Y.</span></span> <span> </span><span class="NLM_article-title">Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">291</span>â <span class="NLM_lpage">302</span>, <span class="refDoi">Â DOI: 10.1093/jnci/95.4.291</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1093%2Fjnci%2F95.4.291" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=12591985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD3sXisF2hsr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2003&pages=291-302&author=K.+H.+Chunauthor=J.+W.+Kosmederauthor=S.+H.+Sunauthor=J.+M.+Pezzutoauthor=R.+Lotanauthor=W.+K.+Hongauthor=H.+Y.+Lee&title=Effects+of+deguelin+on+the+phosphatidylinositol+3-kinase%2FAkt+pathway+and+apoptosis+in+premalignant+human+bronchial+epithelial+cells&doi=10.1093%2Fjnci%2F95.4.291"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells</span></div><div class="casAuthors">Chun, Kyung-Hee; Kosmeder, Jerome W., II; Sun, Shihua; Pezzuto, John M.; Lotan, Reuben; Hong, Waun Ki; Lee, Ho-Young</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">291-302</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Because lung cancer is the leading cause of cancer-related death, new approaches for preventing and controlling the disease are needed.  Chemoprevention approaches are both feasible and effective.  We evaluated the potential of deguelin, a natural plant product, as a lung cancer chemopreventive agent and investigated its mechanism of action.  The effects of deguelin on proliferation and apoptosis of normal, premalignant, and malignant human bronchial epithelial (HBE) cells were assessed by using the MTT assay, a flow cytometry-based TUNEL assay, and western blot analyses.  The effects of deguelin on the phosphatidylinositol 3-kinase (PI3K)/Akt and mitogen-activated protein kinase (MAPK) pathways were assessed by western blot analyses and with adenoviral vectors that expressed constitutively active Akt.  Deguelin treatment in vitro at doses attainable in vivo inhibited the growth of and induced apoptosis of premalignant and malignant HBE cells but had minimal effects on normal HBE cells.  Levels of phosphorylated Akt (pAkt) were higher in premalignant HBE cells than in normal HBE cells.  In premalignant HBE cells, deguelin inhibited PI3K activity and reduced pAkt levels and activity but had minimal effects on the MAPK pathway.  Although overexpression of a constitutively active Akt in premalignant and malignant HBE cells had no effect on growth inhibition mediated by N-(4-hydroxyphenyl)retinamide (4-HPR), a novel chemopreventive retinoid, it blocked deguelin-induced growth arrest and apoptosis.  The ability of deguelin to inhibit PI3K/Akt-mediated signaling pathways may contribute to the potency and specificity of this pro-apoptotic drug.  Because both premalignant and malignant HBE cells are more sensitive to deguelin than normal HBE cells, deguelin may have potential as both a chemopreventive agent for early stages of lung carcinogenesis and a therapeutic agent against lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1LF7fwFWsPbVg90H21EOLACvtfcHk0lgNxCoiNPINcA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXisF2hsr4%253D&md5=a8f0b010976d6612a63ba3dd1df8687e</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F95.4.291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F95.4.291%26sid%3Dliteratum%253Aachs%26aulast%3DChun%26aufirst%3DK.%2BH.%26aulast%3DKosmeder%26aufirst%3DJ.%2BW.%26aulast%3DSun%26aufirst%3DS.%2BH.%26aulast%3DPezzuto%26aufirst%3DJ.%2BM.%26aulast%3DLotan%26aufirst%3DR.%26aulast%3DHong%26aufirst%3DW.%2BK.%26aulast%3DLee%26aufirst%3DH.%2BY.%26atitle%3DEffects%2520of%2520deguelin%2520on%2520the%2520phosphatidylinositol%25203-kinase%252FAkt%2520pathway%2520and%2520apoptosis%2520in%2520premalignant%2520human%2520bronchial%2520epithelial%2520cells%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2003%26volume%3D95%26spage%3D291%26epage%3D302%26doi%3D10.1093%2Fjnci%2F95.4.291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref193"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref193'); return false;" data-citation="" class="refNumLink">193</a></strong><div class="NLM_citation" id="cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennessy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geo, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. Y.</span></span> <span> </span><span class="NLM_article-title">A novel derivative of the natural agent deguelin for cancer chemoprevention and therapy</span>. <i>Cancer Prev. Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">577</span>â <span class="NLM_lpage">587</span>, <span class="refDoi">Â DOI: 10.1158/1940-6207.CAPR-08-0184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F1940-6207.CAPR-08-0184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=19139008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptFKns7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2008&pages=577-587&author=W.+Y.+Kimauthor=D.+J.+Changauthor=B.+Hennessyauthor=H.+J.+Kangauthor=J.+Yooauthor=S.+H.+Hanauthor=Y.+S.+Kimauthor=H.+J.+Parkauthor=S.+Y.+Geoauthor=G.+Millsauthor=K.+W.+Kimauthor=W.+K.+Hongauthor=Y.+G.+Suhauthor=H.+Y.+Lee&title=A+novel+derivative+of+the+natural+agent+deguelin+for+cancer+chemoprevention+and+therapy&doi=10.1158%2F1940-6207.CAPR-08-0184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">A novel derivative of the natural agent deguelin for cancer chemoprevention and therapy</span></div><div class="casAuthors">Kim, Woo-Young; Chang, Dong Jo; Hennessy, Bryan; Kang, Hae Jin; Yoo, Jakyung; Han, Seung-Ho; Kim, Yoo-Shin; Park, Hyun-Ju; Geo, Seung-Yong; Mills, Gordon; Kim, Kyu-Won; Hong, Waun Ki; Suh, Young-Ger; Lee, Ho-Young</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Prevention Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">577-587</span>CODEN:
                <span class="NLM_cas:coden">CPRACC</span>;
        ISSN:<span class="NLM_cas:issn">1940-6207</span>.
    
            (<span class="NLM_cas:orgname">American Association of Cancer Research</span>)
        </div><div class="casAbstract">The natural compd. deguelin has promising preventive and therapeutic activity against diverse cancers by directly binding to heat shock protein-90 and thus suppressing its function.  Potential side effects of deguelin over a certain dose, however, could be a substantial obstacle to its clin. use.  To develop a deriv.(s) of deguelin with reduced potential side effects, we synthesized five deguelin analogs (SH-02, SH-03, SH-09, SH-14, and SH-15) and compared them with the parent compd. and each other for structural and biochem. features; soly.; and antiproliferative effects on normal, premalignant, and malignant human bronchial epithelial (HBE) and non-small-cell lung cancer (NSCLC) cell lines.  Four derivs. destabilized hypoxia-inducible factor-1Î± as potently as did deguelin.  Reversephase protein array (RPPA) anal. in H460 NSCLC cells revealed that deguelin and the derivs. suppressed expression of a no. of proteins including heat shock protein-90 clients and proteins involved in the phosphoinositide 3-kinase/Akt pathway.  One deriv., SH-14, showed several features of potential superiority for clin. use: the highest apoptotic activity; no detectable influence on Src/signal transducer and activator of transcription signaling, which can promote cancer progression and is closely related to pathogenesis of Parkinson's disease (deguelin, SH-02 and SH-03 strongly activated this signaling); better aq. soly.; and less cytotoxicity to immortalized HBE cells (vs. deguelin) at a dose (1 Î¼mol/L) that induced apoptotic activity in most premalignant and malignant HBE and NSCLC cell lines.  These collective results suggest that the novel deriv. SH-14 has strong potential for cancer chemoprevention and therapy, with equiv. efficacy and lesser toxicity (vs. deguelin).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokpOv6WSJPVbVg90H21EOLACvtfcHk0lgNxCoiNPINcA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptFKns7c%253D&md5=c928614b988e8aa0403c90cb5c86f017</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1158%2F1940-6207.CAPR-08-0184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1940-6207.CAPR-08-0184%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DW.%2BY.%26aulast%3DChang%26aufirst%3DD.%2BJ.%26aulast%3DHennessy%26aufirst%3DB.%26aulast%3DKang%26aufirst%3DH.%2BJ.%26aulast%3DYoo%26aufirst%3DJ.%26aulast%3DHan%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DY.%2BS.%26aulast%3DPark%26aufirst%3DH.%2BJ.%26aulast%3DGeo%26aufirst%3DS.%2BY.%26aulast%3DMills%26aufirst%3DG.%26aulast%3DKim%26aufirst%3DK.%2BW.%26aulast%3DHong%26aufirst%3DW.%2BK.%26aulast%3DSuh%26aufirst%3DY.%2BG.%26aulast%3DLee%26aufirst%3DH.%2BY.%26atitle%3DA%2520novel%2520derivative%2520of%2520the%2520natural%2520agent%2520deguelin%2520for%2520cancer%2520chemoprevention%2520and%2520therapy%26jtitle%3DCancer%2520Prev.%2520Res.%26date%3D2008%26volume%3D1%26spage%3D577%26epage%3D587%26doi%3D10.1158%2F1940-6207.CAPR-08-0184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref194"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref194'); return false;" data-citation="" class="refNumLink">194</a></strong><div class="NLM_citation" id="cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benej, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vibhute, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graves, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, Q. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koong, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giaccia, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papandreou, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denko, N. C.</span></span> <span> </span><span class="NLM_article-title">Papaverine and its derivatives radiosensitize solid tumors by inhibiting mitochondrial metabolism</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">10756</span>â <span class="NLM_lpage">10761</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1808945115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1073%2Fpnas.1808945115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=30201710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFyntrrI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=10756-10761&author=M.+Benejauthor=X.+Q.+Hongauthor=S.+Vibhuteauthor=S.+Scottauthor=J.+H.+Wuauthor=E.+Gravesauthor=Q.+T.+Leauthor=A.+C.+Koongauthor=A.+J.+Giacciaauthor=B.+Yuauthor=S.+C.+Chenauthor=I.+Papandreouauthor=N.+C.+Denko&title=Papaverine+and+its+derivatives+radiosensitize+solid+tumors+by+inhibiting+mitochondrial+metabolism&doi=10.1073%2Fpnas.1808945115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Papaverine and its derivatives radiosensitize solid tumors by inhibiting mitochondrial metabolism</span></div><div class="casAuthors">Benej, Martin; Hong, Xiangqian; Vibhute, Sandip; Scott, Sabina; Wu, Jinghai; Graves, Edward; Le, Quynh-Thu; Koong, Albert C.; Giaccia, Amato J.; Yu, Bing; Chen, Shih-Ching; Papandreou, Ioanna; Denko, Nicholas C.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">10756-10761</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Tumor hypoxia reduces the effectiveness of radiation therapy by limiting the biol. ED.  An acute increase in tumor oxygenation before radiation treatment should therefore significantly improve the tumor cell kill after radiation.  Efforts to increase oxygen delivery to the tumor have not shown pos. clin. results.  Here we show that targeting mitochondrial respiration results in a significant redn. of the tumor cells demand for oxygen, leading to increased tumor oxygenation and radiation response.  We identified an activity of the FDA-approved drug papaverine as an inhibitor of mitochondrial complex I.  We also provide genetic evidence that papaverine complex I inhibition is directly responsible for increased oxygenation and enhanced radiation response.  Furthermore, we describe derivs. of papaverine that have the potential to become clin. radiosensitizers with potentially fewer side effects.  Importantly, this radiosensitizing strategy will not sensitize well-oxygenated normal tissue, thereby increasing the therapeutic index of radiotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGQ3uohZ1qtrVg90H21EOLACvtfcHk0liELWYC3rmLOA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFyntrrI&md5=a5982bb3b146e5494354faf797dbe358</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1808945115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1808945115%26sid%3Dliteratum%253Aachs%26aulast%3DBenej%26aufirst%3DM.%26aulast%3DHong%26aufirst%3DX.%2BQ.%26aulast%3DVibhute%26aufirst%3DS.%26aulast%3DScott%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DJ.%2BH.%26aulast%3DGraves%26aufirst%3DE.%26aulast%3DLe%26aufirst%3DQ.%2BT.%26aulast%3DKoong%26aufirst%3DA.%2BC.%26aulast%3DGiaccia%26aufirst%3DA.%2BJ.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DS.%2BC.%26aulast%3DPapandreou%26aufirst%3DI.%26aulast%3DDenko%26aufirst%3DN.%2BC.%26atitle%3DPapaverine%2520and%2520its%2520derivatives%2520radiosensitize%2520solid%2520tumors%2520by%2520inhibiting%2520mitochondrial%2520metabolism%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2018%26volume%3D115%26spage%3D10756%26epage%3D10761%26doi%3D10.1073%2Fpnas.1808945115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref195"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref195'); return false;" data-citation="" class="refNumLink">195</a></strong><div class="NLM_citation" id="cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyason, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prochazka, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witting, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swettenham, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zobalova, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turanek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitz, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domann, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffler, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ralph, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuzil, J.</span></span> <span> </span><span class="NLM_article-title">alpha-tocopheryl succinate induces apoptosis by targeting ubiquinone-binding sites in mitochondrial respiratory complex II</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">4324</span>â <span class="NLM_lpage">4335</span>, <span class="refDoi">Â DOI: 10.1038/onc.2008.69</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fonc.2008.69" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=18372923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD1cXosFGisbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=4324-4335&author=L.+F.+Dongauthor=P.+Lowauthor=J.+C.+Dyasonauthor=X.+F.+Wangauthor=L.+Prochazkaauthor=P.+K.+Wittingauthor=R.+Freemanauthor=E.+Swettenhamauthor=K.+Valisauthor=J.+Liuauthor=R.+Zobalovaauthor=J.+Turanekauthor=D.+R.+Spitzauthor=F.+E.+Domannauthor=I.+E.+Schefflerauthor=S.+J.+Ralphauthor=J.+Neuzil&title=alpha-tocopheryl+succinate+induces+apoptosis+by+targeting+ubiquinone-binding+sites+in+mitochondrial+respiratory+complex+II&doi=10.1038%2Fonc.2008.69"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Î±-Tocopheryl succinate induces apoptosis by targeting ubiquinone-binding sites in mitochondrial respiratory complex II</span></div><div class="casAuthors">Dong, L.-F.; Low, P.; Dyason, J. C.; Wang, X.-F.; Prochazka, L.; Witting, P. K.; Freeman, R.; Swettenham, E.; Valis, K.; Liu, J.; Zobalova, R.; Turanek, J.; Spitz, D. R.; Domann, F. E.; Scheffler, I. E.; Ralph, S. J.; Neuzil, J.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">4324-4335</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Î±-Tocopheryl succinate (Î±-TOS) is a selective inducer of apoptosis in cancer cells, which involves the accumulation of reactive oxygen species (ROS).  The mol. target of Î±-TOS has not been identified.  Here, we show that Î±-TOS inhibits succinate dehydrogenase (SDH) activity of complex II (CII) by interacting with the proximal and distal ubiquinone (UbQ)-binding site (QP and QD, resp.).  This is based on biochem. analyses and mol. modeling, revealing similar or stronger interaction energy of Î±-TOS compared to that of UbQ for the QP and QD sites, resp.  CybL-mutant cells with dysfunctional CII failed to accumulate ROS and underwent apoptosis in the presence of Î±-TOS.  Similar resistance was obsd. when CybL was knocked down with siRNA.  Reconstitution of functional CII rendered CybL-mutant cells susceptible to Î±-TOS.  We propose that Î±-TOS displaces UbQ in CII causing electrons generated by SDH to recombine with mol. oxygen to yield ROS.  Our data highlight CII, a known tumor suppressor, as a novel target for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpfd1KY4cMJLVg90H21EOLACvtfcHk0liELWYC3rmLOA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXosFGisbs%253D&md5=5affc93d03ea9275d17854c95990521f</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1038%2Fonc.2008.69&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2008.69%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DL.%2BF.%26aulast%3DLow%26aufirst%3DP.%26aulast%3DDyason%26aufirst%3DJ.%2BC.%26aulast%3DWang%26aufirst%3DX.%2BF.%26aulast%3DProchazka%26aufirst%3DL.%26aulast%3DWitting%26aufirst%3DP.%2BK.%26aulast%3DFreeman%26aufirst%3DR.%26aulast%3DSwettenham%26aufirst%3DE.%26aulast%3DValis%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZobalova%26aufirst%3DR.%26aulast%3DTuranek%26aufirst%3DJ.%26aulast%3DSpitz%26aufirst%3DD.%2BR.%26aulast%3DDomann%26aufirst%3DF.%2BE.%26aulast%3DScheffler%26aufirst%3DI.%2BE.%26aulast%3DRalph%26aufirst%3DS.%2BJ.%26aulast%3DNeuzil%26aufirst%3DJ.%26atitle%3Dalpha-tocopheryl%2520succinate%2520induces%2520apoptosis%2520by%2520targeting%2520ubiquinone-binding%2520sites%2520in%2520mitochondrial%2520respiratory%2520complex%2520II%26jtitle%3DOncogene%26date%3D2008%26volume%3D27%26spage%3D4324%26epage%3D4335%26doi%3D10.1038%2Fonc.2008.69" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref196"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref196'); return false;" data-citation="" class="refNumLink">196</a></strong><div class="NLM_citation" id="cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Molina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyes-Leyva, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Malo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, J.</span></span> <span> </span><span class="NLM_article-title">The role of alpha tocopheryl succinate (alpha-TOS) as a potential anticancer agent</span>. <i>Nutr. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">167</span>â <span class="NLM_lpage">176</span>, <span class="refDoi">Â DOI: 10.1080/01635581.2014.863367</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1080%2F01635581.2014.863367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=24364743" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFyqt73L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2014&pages=167-176&author=A.+Angulo-Molinaauthor=J.+Reyes-Leyvaauthor=A.+Lopez-Maloauthor=J.+Hernandez&title=The+role+of+alpha+tocopheryl+succinate+%28alpha-TOS%29+as+a+potential+anticancer+agent&doi=10.1080%2F01635581.2014.863367"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of Alpha Tocopheryl Succinate (Î±-TOS) as a Potential Anticancer Agent</span></div><div class="casAuthors">Angulo-Molina, Aracely; Reyes-Leyva, Julio; Lopez-Malo, Aurelio; Hernandez, Jesus</div><div class="citationInfo"><span class="NLM_cas:title">Nutrition and Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">167-176</span>CODEN:
                <span class="NLM_cas:coden">NUCADQ</span>;
        ISSN:<span class="NLM_cas:issn">0163-5581</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">A review.  In recent years, efforts to improve cancer therapy have focused on developing new anticancer agents, such as mitocans.  These agents include vitamin E analogs and suppress cancer by inducing apoptosis by targeting mitochondria.  Alpha tocopheryl succinate (Î±-TOS) is the most effective form of vitamin E analogs causing inhibition of proliferation and apoptosis of cancer cells.  Both in vitro and in vivo studies have demonstrated that Î±-TOS selectively kills tumor cells with little or no effect on normal cells.  Treatment with Î±-TOS shows great promise for future clin. applications, as it causes cell death, at least in part, by selectively inducing apoptosis by mitochondrial destabilization.  This review presents an overview of perspectives on Î±-TOS and the potential uses of Î±-TOS in cancer treatment and other clin. applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrw46gSybtjrVg90H21EOLACvtfcHk0liELWYC3rmLOA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFyqt73L&md5=d49f48aa9d11cbf25fb320f5c12dd18d</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1080%2F01635581.2014.863367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F01635581.2014.863367%26sid%3Dliteratum%253Aachs%26aulast%3DAngulo-Molina%26aufirst%3DA.%26aulast%3DReyes-Leyva%26aufirst%3DJ.%26aulast%3DLopez-Malo%26aufirst%3DA.%26aulast%3DHernandez%26aufirst%3DJ.%26atitle%3DThe%2520role%2520of%2520alpha%2520tocopheryl%2520succinate%2520%2528alpha-TOS%2529%2520as%2520a%2520potential%2520anticancer%2520agent%26jtitle%3DNutr.%2520Cancer%26date%3D2014%26volume%3D66%26spage%3D167%26epage%3D176%26doi%3D10.1080%2F01635581.2014.863367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref197"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref197'); return false;" data-citation="" class="refNumLink">197</a></strong><div class="NLM_citation" id="cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zobalova, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marin-Hernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stantic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohlena, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Enriquez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butcher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunk, U. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witting, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno-Sanchez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffler, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ralph, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuzil, J.</span></span> <span> </span><span class="NLM_article-title">Suppression of tumor growth in vivo by the mitocan alpha-tocopheryl succinate requires respiratory complex II</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1593</span>â <span class="NLM_lpage">1600</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-08-2439</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F1078-0432.CCR-08-2439" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=19223492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisVWrsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=1593-1600&author=L.+F.+Dongauthor=R.+Freemanauthor=J.+Liuauthor=R.+Zobalovaauthor=A.+Marin-Hernandezauthor=M.+Stanticauthor=J.+Rohlenaauthor=K.+Valisauthor=S.+Rodriguez-Enriquezauthor=B.+Butcherauthor=J.+Goodwinauthor=U.+T.+Brunkauthor=P.+K.+Wittingauthor=R.+Moreno-Sanchezauthor=I.+E.+Schefflerauthor=S.+J.+Ralphauthor=J.+Neuzil&title=Suppression+of+tumor+growth+in+vivo+by+the+mitocan+alpha-tocopheryl+succinate+requires+respiratory+complex+II&doi=10.1158%2F1078-0432.CCR-08-2439"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Suppression of Tumor Growth In vivo by the Mitocan Î±-tocopheryl Succinate Requires Respiratory Complex II</span></div><div class="casAuthors">Dong, Lan-Feng; Freeman, Ruth; Liu, Ji; Zobalova, Renata; Marin-Hernandez, Alvaro; Stantic, Marina; Rohlena, Jakub; Valis, Karel; Rodriguez-Enriquez, Sara; Butcher, Bevan; Goodwin, Jacob; Brunk, Ulf T.; Witting, Paul K.; Moreno-Sanchez, Rafael; Scheffler, Immo E.; Ralph, Stephen J.; Neuzil, Jiri</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1593-1600</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Vitamin E analogs are potent novel anticancer drugs.  The purpose of this study was to elucidate the cellular target by which these agents, represented by Î±-tocopheryl succinate (Î±-TOS), suppress tumors in vivo, with the focus on the mitochondrial complex II (CII).  Chinese hamster lung fibroblasts with functional, dysfunctional, and reconstituted CII were transformed using H-Ras.  The cells were then used to form xenografts in immunocompromized mice, and response of the cells and the tumors to Î±-TOS was studied.  The CII-functional and CII-reconstituted cells, unlike their CII-dysfunctional counterparts, responded to Î±-TOS by reactive oxygen species generation and apoptosis execution.  Tumors derived from these cell lines reciprocated their responses to Î±-TOS.  Thus, growth of CII-functional and CII-reconstituted tumors was strongly suppressed by the agent, and this was accompanied by high level of apoptosis induction in the tumor cells.  On the other hand, Î±-TOS did not inhibit the CII-dysfuntional tumors.  We document in this report a novel paradigm, according to which the mitochondrial CII, which rarely mutates in human neoplasias, is a plausible target for anticancer drugs from the group of vitamin E analogs, providing support for their testing in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5yuVIYsaqOrVg90H21EOLACvtfcHk0ljGUibAo1igQg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisVWrsr8%253D&md5=bda8992e0be210e58513c9da6ce53632</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-2439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-2439%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DL.%2BF.%26aulast%3DFreeman%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZobalova%26aufirst%3DR.%26aulast%3DMarin-Hernandez%26aufirst%3DA.%26aulast%3DStantic%26aufirst%3DM.%26aulast%3DRohlena%26aufirst%3DJ.%26aulast%3DValis%26aufirst%3DK.%26aulast%3DRodriguez-Enriquez%26aufirst%3DS.%26aulast%3DButcher%26aufirst%3DB.%26aulast%3DGoodwin%26aufirst%3DJ.%26aulast%3DBrunk%26aufirst%3DU.%2BT.%26aulast%3DWitting%26aufirst%3DP.%2BK.%26aulast%3DMoreno-Sanchez%26aufirst%3DR.%26aulast%3DScheffler%26aufirst%3DI.%2BE.%26aulast%3DRalph%26aufirst%3DS.%2BJ.%26aulast%3DNeuzil%26aufirst%3DJ.%26atitle%3DSuppression%2520of%2520tumor%2520growth%2520in%2520vivo%2520by%2520the%2520mitocan%2520alpha-tocopheryl%2520succinate%2520requires%2520respiratory%2520complex%2520II%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D1593%26epage%3D1600%26doi%3D10.1158%2F1078-0432.CCR-08-2439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref198"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref198'); return false;" data-citation="" class="refNumLink">198</a></strong><div class="NLM_citation" id="cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H. W.</span></span> <span> </span><span class="NLM_article-title">Neoantimycin F, a streptomyces-derived natural product induces mitochondria-related apoptotic death in human non-small cell lung cancer cells</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1042</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2019.01042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.3389%2Ffphar.2019.01042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=31619992" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmsFWrur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1042&author=L.+Y.+Liuauthor=H.+R.+Zhuauthor=W.+Wuauthor=Y.+Y.+Shenauthor=X.+Linauthor=Y.+Wuauthor=L.+Liuauthor=J.+Tangauthor=Y.+J.+Zhouauthor=F.+Sunauthor=H.+W.+Lin&title=Neoantimycin+F%2C+a+streptomyces-derived+natural+product+induces+mitochondria-related+apoptotic+death+in+human+non-small+cell+lung+cancer+cells&doi=10.3389%2Ffphar.2019.01042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Neoantimycin F, a Streptomyces-derived natural product induces mitochondria-related apoptotic death in human non-small cell lung cancer cells</span></div><div class="casAuthors">Liu, Liyun; Zhu, Hongrui; Wu, Wei; Shen, Yaoyao; Lin, Xiao; Wu, Ying; Liu, Li; Tang, Jie; Zhou, Yongjun; Sun, Fan; Lin, Hou-Wen</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1042</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Streptomyces-derived natural products have been become a major focus of anti-tumor drug discovery studies.  Neoantimycin F (NAT-F), was isolated from Streptomyces conglobatus by our group.  Here, we examd. the anti-cancer activities and its underlying mol. mechanisms implicated in NAT-F-induced apoptosis of non-small cell lung cancer (NSCLC) cells.  Our results showed that NAT-F exerted excellent growth-inhibitory activity against PC9 and H1299 cells in a concn.-dependent manner.  NAT-F-induced cell cycle arrest at S and G0/G1 phase in PC9 and H1299 cells, resp.  Further investigation revealed that the key proteins (including cyclinD1, cyclinE1, cyclinB1, CDK2, and CDK4) were involved in the cell regulation by NAT-F.  Addnl., NAT-F significantly increased the prodn. of reactive oxygen species (ROS), induced DNA damage, nuclear condensation, and cell apoptosis in both cell lines.  Moreover, loss of the mitochondrial membrane potential (MMP) was markedly induced by NAT-F.  Addnl. results revealed that NAT-F could up-regulate pro-apoptotic protein Bax and down-regulate anti-apoptotic protein Bcl-2, Mcl-1, and Bcl-xL, resulting in cytochrome c release from mitochondria and sequential activation of caspase-9 and -3, as well as the cleavage of poly (ADP-ribose) polymerase.  Meanwhile, c-Jun N-terminal kinase (JNK), p38 MAPK (p38), and extracellular signal-regulated kinase (ERK) signaling pathway were also involved in anti-cancer activity of NAT-F in NSCLC cells.  Taken together, these findings indicated that NAT-F possessed anti-proliferative effect and induced apoptosis in NSCLC cells in vitro and may be conducive to promote the development of novel anti-NSCLC agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg1FOiotfW3bVg90H21EOLACvtfcHk0ljGUibAo1igQg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmsFWrur4%253D&md5=826b13be7844a5fe4cab728eb7c65ec1</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.01042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.01042%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%2BY.%26aulast%3DZhu%26aufirst%3DH.%2BR.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DShen%26aufirst%3DY.%2BY.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DY.%2BJ.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DLin%26aufirst%3DH.%2BW.%26atitle%3DNeoantimycin%2520F%252C%2520a%2520streptomyces-derived%2520natural%2520product%2520induces%2520mitochondria-related%2520apoptotic%2520death%2520in%2520human%2520non-small%2520cell%2520lung%2520cancer%2520cells%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D1042%26doi%3D10.3389%2Ffphar.2019.01042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref199"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref199'); return false;" data-citation="" class="refNumLink">199</a></strong><div class="NLM_citation" id="cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oliva, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markert, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everts, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moellering, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suto, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griguer, C. E.</span></span> <span> </span><span class="NLM_article-title">Identification of small molecule inhibitors of human cytochrome c oxidase that target chemoresistant glioma cells</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>291</i></span>,  <span class="NLM_fpage">24188</span>â <span class="NLM_lpage">24199</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M116.749978</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1074%2Fjbc.M116.749978" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27679486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVCitbrK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=2016&pages=24188-24199&author=C.+R.+Olivaauthor=T.+Markertauthor=L.+J.+Rossauthor=E.+L.+Whiteauthor=L.+Rasmussenauthor=W.+Zhangauthor=M.+Evertsauthor=D.+R.+Moelleringauthor=S.+M.+Baileyauthor=M.+J.+Sutoauthor=C.+E.+Griguer&title=Identification+of+small+molecule+inhibitors+of+human+cytochrome+c+oxidase+that+target+chemoresistant+glioma+cells&doi=10.1074%2Fjbc.M116.749978"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Small Molecule Inhibitors of Human Cytochrome c Oxidase That Target Chemoresistant Glioma Cells</span></div><div class="casAuthors">Oliva, Claudia R.; Markert, Tahireh; Ross, Larry J.; White, E. Lucile; Rasmussen, Lynn; Zhang, Wei; Everts, Maaike; Moellering, Douglas R.; Bailey, Shannon M.; Suto, Mark J.; Griguer, Corinne E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">291</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">24188-24199</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The enzyme cytochrome c oxidase (CcO) or complex IV (EC 1.9.3.1) is a large transmembrane protein complex that serves as the last enzyme in the respiratory electron transport chain of eukaryotic mitochondria.  CcO promotes the switch from glycolytic to oxidative phosphorylation (OXPHOS) metab. and has been assocd. with increased self-renewal characteristics in gliomas.  Increased CcO activity in tumors has been assocd. with tumor progression after chemotherapy failure, and patients with primary glioblastoma multiforme and high tumor CcO activity have worse clin. outcomes than those with low tumor CcO activity.  Therefore, CcO is an attractive target for cancer therapy.  The authors report the characterization of a CcO inhibitor (ADDA 5, 1-[2-(1-adamantyl)-ethoxy]-3-(3,4-dihydro-2(1H)-isoquinolinyl)-2-propanol hydrochloride) that was identified using a high throughput screening paradigm.  ADDA 5 demonstrated specificity for CcO, with no inhibition of other mitochondrial complexes or other relevant enzymes, and biochem. characterization showed that this compd. is a non-competitive inhibitor of cytochrome c.  When tested in cellular assays, ADDA 5 dose-dependently inhibited the proliferation of chemosensitive and chemoresistant glioma cells but did not display toxicity against non-cancer cells.  Furthermore, treatment with ADDA 5 led to significant inhibition of tumor growth in flank xenograft mouse models.  Importantly, ADDA 5 inhibited CcO activity and blocked cell proliferation and neurosphere formation in cultures of glioma stem cells, the cells implicated in tumor recurrence and resistance to therapy in patients with glioblastoma.  In summary, the authors have identified ADDA 5 as a lead CcO inhibitor for further optimization as a novel approach for the treatment of glioblastoma and related cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLMB7Q9zhRBbVg90H21EOLACvtfcHk0lhx4pcHT91eCA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVCitbrK&md5=07b4ae6e14504f66f3948d9df6ce89dc</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M116.749978&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M116.749978%26sid%3Dliteratum%253Aachs%26aulast%3DOliva%26aufirst%3DC.%2BR.%26aulast%3DMarkert%26aufirst%3DT.%26aulast%3DRoss%26aufirst%3DL.%2BJ.%26aulast%3DWhite%26aufirst%3DE.%2BL.%26aulast%3DRasmussen%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DEverts%26aufirst%3DM.%26aulast%3DMoellering%26aufirst%3DD.%2BR.%26aulast%3DBailey%26aufirst%3DS.%2BM.%26aulast%3DSuto%26aufirst%3DM.%2BJ.%26aulast%3DGriguer%26aufirst%3DC.%2BE.%26atitle%3DIdentification%2520of%2520small%2520molecule%2520inhibitors%2520of%2520human%2520cytochrome%2520c%2520oxidase%2520that%2520target%2520chemoresistant%2520glioma%2520cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2016%26volume%3D291%26spage%3D24188%26epage%3D24199%26doi%3D10.1074%2Fjbc.M116.749978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref200"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref200'); return false;" data-citation="" class="refNumLink">200</a></strong><div class="NLM_citation" id="cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salomon, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voehringer, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herzenberg, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khosla, C.</span></span> <span> </span><span class="NLM_article-title">Apoptolidin, a selective cytotoxic agent, is an inhibitor of F0F1-ATPase</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">71</span>â <span class="NLM_lpage">80</span>, <span class="refDoi">Â DOI: 10.1016/S1074-5521(00)00057-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2FS1074-5521%2800%2900057-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=11182320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhslGku7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2001&pages=71-80&author=A.+R.+Salomonauthor=D.+W.+Voehringerauthor=L.+A.+Herzenbergauthor=C.+Khosla&title=Apoptolidin%2C+a+selective+cytotoxic+agent%2C+is+an+inhibitor+of+F0F1-ATPase&doi=10.1016%2FS1074-5521%2800%2900057-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Apoptolidin, a selective cytotoxic agent, is an inhibitor of F0F1-ATPase</span></div><div class="casAuthors">Salomon, Arthur R.; Voehringer, David W.; Herzenberg, Leonard A.; Khosla, Chaitan</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">71-80</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Apoptolidin is a macrolide originally identified on the basis of its ability to selectively kill E1A and E1A/E1B19K transformed rat glial cells while not killing untransformed glial cells.  The goal of this study was to identify the mol. target of this newly discovered natural product.  Our approach to uncovering the mechanism of action of apoptolidin utilized a combination of mol. and cell-based pharmacol. assays as well as structural comparisons between apoptolidin and other macrocyclic polyketides with known mechanism of action.  Cell killing induced by apoptolidin was independent of p53 status, inhibited by BCL-2, and dependent on the action of caspase-9.  PARP was completely cleaved in the presence of 1 Î¼M apoptolidin within 6 h in a mouse lymphoma cell line.  Together these results suggested that apoptolidin might target a mitochondrial protein.  Structural comparisons between apoptolidin and other macrolides revealed significant similarity between the apoptolidin aglycon and oligomycin, a known inhibitor of mitochondrial F0F1-ATP synthase.  The relevance of this similarity was established by demonstrating that apoptolidin is a potent inhibitor of the F0F1-ATPase activity in intact yeast mitochondria as well as Triton X-100-solubilized ATPase prepns.  The Ki for apoptolidin was 4-5 Î¼M.  The selectivity of apoptolidin in the NCI-60 cell line panel was found to correlate well with that of several known anti-fungal natural products that inhibit the eukaryotic mitochondrial F0F1-ATP synthase.  Although the anti-fungal activities of macrolide inhibitors of the mitochondrial F0F1-ATP synthase such as oligomycin, ossamycin and cytovaricin are well-documented, their unusual selectivity toward certain cell types is not widely appreciated.  The recent discovery of apoptolidin, followed by the demonstration that it is an inhibitor of the mitochondrial F0F1-ATP synthase, highlights the potential relevance of these natural products as small mols. to modulate apoptotic pathways.  The mechanistic basis for selective cytotoxicity of mitochondrial ATP synthase inhibitors is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQwF06r02xebVg90H21EOLACvtfcHk0lhx4pcHT91eCA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhslGku7w%253D&md5=23c0d35ee3c59fafb6c54b20f74768ab</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1016%2FS1074-5521%2800%2900057-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1074-5521%252800%252900057-0%26sid%3Dliteratum%253Aachs%26aulast%3DSalomon%26aufirst%3DA.%2BR.%26aulast%3DVoehringer%26aufirst%3DD.%2BW.%26aulast%3DHerzenberg%26aufirst%3DL.%2BA.%26aulast%3DKhosla%26aufirst%3DC.%26atitle%3DApoptolidin%252C%2520a%2520selective%2520cytotoxic%2520agent%252C%2520is%2520an%2520inhibitor%2520of%2520F0F1-ATPase%26jtitle%3DChem.%2520Biol.%26date%3D2001%26volume%3D8%26spage%3D71%26epage%3D80%26doi%3D10.1016%2FS1074-5521%2800%2900057-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref201"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref201'); return false;" data-citation="" class="refNumLink">201</a></strong><div class="NLM_citation" id="cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koert, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuppan, J.</span></span> <span> </span><span class="NLM_article-title">Apoptolidin: Induction of apoptosis by a natural product</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">872</span>â <span class="NLM_lpage">893</span>, <span class="refDoi">Â DOI: 10.1002/anie.200502698</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1002%2Fanie.200502698" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD28XhsFKms7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2006&pages=872-893&author=P.+T.+Danielauthor=U.+Koertauthor=J.+Schuppan&title=Apoptolidin%3A+Induction+of+apoptosis+by+a+natural+product&doi=10.1002%2Fanie.200502698"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Apoptolidin: induction of apoptosis by a natural product</span></div><div class="casAuthors">Daniel, Peter T.; Koert, Ulrich; Schuppan, Julia</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">872-893</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Apoptolidin is a natural product that selectively induces apoptosis in several cancer cell lines.  Apoptosis, programmed cell death, is a biol. key pathway for regulating homeostasis and morphogenesis.  Apoptotic misregulations are connected with several diseases, in particular cancer.  The extrinsic way to apoptosis leads through death ligands and death receptors to the activation of the caspase cascade, which results in proteolytic degrdn. of the cell architecture.  The intrinsic pathway transmits signals of internal cellular damage to the mitochondrion, which loses its structural integrity, and forms an apoptosome that initiates the caspase cascade.  Compds. which regulate apoptosis are of high medical significance.  Many natural products regulate apoptotic pathways, and apoptolidin is one of them.  The known synthetic routes to apoptolidin are described and compared in this Review.  Selected further natural products which regulate apoptosis are introduced briefly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjTqYTnpRiNLVg90H21EOLACvtfcHk0lhx4pcHT91eCA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhsFKms7s%253D&md5=7babb0de2d97898131fb88ca59104590</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1002%2Fanie.200502698&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200502698%26sid%3Dliteratum%253Aachs%26aulast%3DDaniel%26aufirst%3DP.%2BT.%26aulast%3DKoert%26aufirst%3DU.%26aulast%3DSchuppan%26aufirst%3DJ.%26atitle%3DApoptolidin%253A%2520Induction%2520of%2520apoptosis%2520by%2520a%2520natural%2520product%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2006%26volume%3D45%26spage%3D872%26epage%3D893%26doi%3D10.1002%2Fanie.200502698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref202"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref202'); return false;" data-citation="" class="refNumLink">202</a></strong><div class="NLM_citation" id="cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wender, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jankowski, O. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longcore, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabet, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomikawa, T.</span></span> <span> </span><span class="NLM_article-title">Correlation of F0F1-ATPase inhibition and antiproliferative activity of apoptolidin analogues</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">589</span>â <span class="NLM_lpage">592</span>, <span class="refDoi">Â DOI: 10.1021/ol052800q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol052800q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD28XksV2kuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2006&pages=589-592&author=P.+A.+Wenderauthor=O.+D.+Jankowskiauthor=K.+Longcoreauthor=E.+A.+Tabetauthor=H.+Setoauthor=T.+Tomikawa&title=Correlation+of+F0F1-ATPase+inhibition+and+antiproliferative+activity+of+apoptolidin+analogues&doi=10.1021%2Fol052800q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Correlation of F0F1-ATPase Inhibition and Antiproliferative Activity of Apoptolidin Analogues</span></div><div class="casAuthors">Wender, Paul A.; Jankowski, Orion D.; Longcore, Kate; Tabet, Elie A.; Seto, Haruo; Tomikawa, Taijiro</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">589-592</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Apoptolidin exhibits potent and highly selective apoptosis inducing activity against sensitive cancer cell lines and is hypothesized to act by inhibition of mitochondrial F0F1-ATPase.  A series of apoptolidin derivs., including a new intermol. Diels-Alder adduct, were analyzed for antiproliferative activity in E1A-transformed rat fibroblasts.  Potent F0F1-ATPase inhibition was not a sufficient determinant of antiproliferative activity for several analogs, suggesting the existence of a secondary biol. target or more complex mode of action for apoptolidin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopFhthfrxoWLVg90H21EOLACvtfcHk0lhx4pcHT91eCA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XksV2kuw%253D%253D&md5=817268f87c70c4429c204866be124682</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1021%2Fol052800q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol052800q%26sid%3Dliteratum%253Aachs%26aulast%3DWender%26aufirst%3DP.%2BA.%26aulast%3DJankowski%26aufirst%3DO.%2BD.%26aulast%3DLongcore%26aufirst%3DK.%26aulast%3DTabet%26aufirst%3DE.%2BA.%26aulast%3DSeto%26aufirst%3DH.%26aulast%3DTomikawa%26aufirst%3DT.%26atitle%3DCorrelation%2520of%2520F0F1-ATPase%2520inhibition%2520and%2520antiproliferative%2520activity%2520of%2520apoptolidin%2520analogues%26jtitle%3DOrg.%2520Lett.%26date%3D2006%26volume%3D8%26spage%3D589%26epage%3D592%26doi%3D10.1021%2Fol052800q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref203"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref203'); return false;" data-citation="" class="refNumLink">203</a></strong><div class="NLM_citation" id="cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foretz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guigas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viollet, B.</span></span> <span> </span><span class="NLM_article-title">Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus</span>. <i>Nat. Rev. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">569</span>â <span class="NLM_lpage">589</span>, <span class="refDoi">Â DOI: 10.1038/s41574-019-0242-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fs41574-019-0242-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=31439934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1elu7jO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=569-589&author=M.+Foretzauthor=B.+Guigasauthor=B.+Viollet&title=Understanding+the+glucoregulatory+mechanisms+of+metformin+in+type+2+diabetes+mellitus&doi=10.1038%2Fs41574-019-0242-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus</span></div><div class="casAuthors">Foretz, Marc; Guigas, Bruno; Viollet, Benoit</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Endocrinology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">569-589</span>CODEN:
                <span class="NLM_cas:coden">NREABD</span>;
        ISSN:<span class="NLM_cas:issn">1759-5029</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Despite its position as the first-line drug for treatment of type 2 diabetes mellitus, the mechanisms underlying the plasma glucose level-lowering effects of metformin (1,1-dimethylbiguanide) still remain incompletely understood.  Metformin is thought to exert its primary antidiabetic action through the suppression of hepatic glucose prodn.  In addn., the discovery that metformin inhibits the mitochondrial respiratory chain complex 1 has placed energy metab. and activation of AMP-activated protein kinase (AMPK) at the center of its proposed mechanism of action.  However, the role of AMPK has been challenged and might only account for indirect changes in hepatic insulin sensitivity.  Various mechanisms involving alterations in cellular energy charge, AMP-mediated inhibition of adenylate cyclase or fructose-1,6-bisphosphatase 1 and modulation of the cellular redox state through direct inhibition of mitochondrial glycerol-3-phosphate dehydrogenase have been proposed for the acute inhibition of gluconeogenesis by metformin.  Emerging evidence suggests that metformin could improve obesity-induced meta-inflammation via direct and indirect effects on tissue-resident immune cells in metabolic organs (i.e., adipose tissue, the gastrointestinal tract and the liver).  Furthermore, the gastrointestinal tract also has a major role in metformin action through modulation of glucose-lowering hormone glucagon-like peptide 1 and the intestinal bile acid pool and alterations in gut microbiota compn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg0HgTCQ0mlrVg90H21EOLACvtfcHk0ljXEtOFwXaDJA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1elu7jO&md5=ac06ff9c088597be8156e3fa94e9b200</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1038%2Fs41574-019-0242-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41574-019-0242-2%26sid%3Dliteratum%253Aachs%26aulast%3DForetz%26aufirst%3DM.%26aulast%3DGuigas%26aufirst%3DB.%26aulast%3DViollet%26aufirst%3DB.%26atitle%3DUnderstanding%2520the%2520glucoregulatory%2520mechanisms%2520of%2520metformin%2520in%2520type%25202%2520diabetes%2520mellitus%26jtitle%3DNat.%2520Rev.%2520Endocrinol.%26date%3D2019%26volume%3D15%26spage%3D569%26epage%3D589%26doi%3D10.1038%2Fs41574-019-0242-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref204"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref204'); return false;" data-citation="" class="refNumLink">204</a></strong><div class="NLM_citation" id="cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">An, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, L.</span></span> <span> </span><span class="NLM_article-title">Current understanding of metformin effect on the control of hyperglycemia in diabetes</span>. <i>J. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>228</i></span>,  <span class="NLM_fpage">R97</span>â <span class="NLM_lpage">106</span>, <span class="refDoi">Â DOI: 10.1530/JOE-15-0447</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1530%2FJOE-15-0447" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=26743209" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFeksLnJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=2016&pages=R97-106&author=H.+Anauthor=L.+He&title=Current+understanding+of+metformin+effect+on+the+control+of+hyperglycemia+in+diabetes&doi=10.1530%2FJOE-15-0447"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Current understanding of metformin effect on the control of hyperglycemia in diabetes</span></div><div class="casAuthors">An, Hongying; He, Ling</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Endocrinology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">228</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">R97-R106</span>CODEN:
                <span class="NLM_cas:coden">JOENAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-0795</span>.
    
            (<span class="NLM_cas:orgname">BioScientifica Ltd.</span>)
        </div><div class="casAbstract">Metformin is a first-line oral anti-diabetic agent that has been used clin. to treat patients with type 2 diabetes for over 60 years.  Due to its efficacy in therapy and affordable price, metformin is taken by more than 150 million people each year.  Metformin improves hyperglycemia mainly through the suppression of hepatic gluconeogenesis along with the improvement of insulin signaling.  However, its mechanism of action remains partially understood and controversial, esp. in regard to the role of AMPK in metformin's action and the mechanism of AMPK activation.  In this review, we discuss recent advances in the understanding of metformin's suppression of hepatic glucose prodn. and the mechanism related to the improvement of insulin signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLtG_dyC4HzLVg90H21EOLACvtfcHk0ljXEtOFwXaDJA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFeksLnJ&md5=bf4ee8e5d4de88de490971074c7c4d1b</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1530%2FJOE-15-0447&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1530%252FJOE-15-0447%26sid%3Dliteratum%253Aachs%26aulast%3DAn%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DL.%26atitle%3DCurrent%2520understanding%2520of%2520metformin%2520effect%2520on%2520the%2520control%2520of%2520hyperglycemia%2520in%2520diabetes%26jtitle%3DJ.%2520Endocrinol.%26date%3D2016%26volume%3D228%26spage%3DR97%26epage%3D106%26doi%3D10.1530%2FJOE-15-0447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref205"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref205'); return false;" data-citation="" class="refNumLink">205</a></strong><div class="NLM_citation" id="cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evans, J. M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donnelly, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emslie-Smith, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alessi, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, A. D.</span></span> <span> </span><span class="NLM_article-title">Metformin and reduced risk of cancer in diabetic patients</span>. <i>BMJ.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>330</i></span>,  <span class="NLM_fpage">1304</span>â <span class="NLM_lpage">1305</span>, <span class="refDoi">Â DOI: 10.1136/bmj.38415.708634.F7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1136%2Fbmj.38415.708634.F7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=15849206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BD2M3oslCluw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2005&pages=1304-1305&author=J.+M.+M.+Evansauthor=L.+A.+Donnellyauthor=A.+M.+Emslie-Smithauthor=D.+R.+Alessiauthor=A.+D.+Morris&title=Metformin+and+reduced+risk+of+cancer+in+diabetic+patients&doi=10.1136%2Fbmj.38415.708634.F7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Metformin and reduced risk of cancer in diabetic patients</span></div><div class="casAuthors">Evans Josie M M; Donnelly Louise A; Emslie-Smith Alistair M; Alessi Dario R; Morris Andrew D</div><div class="citationInfo"><span class="NLM_cas:title">BMJ (Clinical research ed.)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">7503</span>),
    <span class="NLM_cas:pages">1304-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSv9UpYrCiq2fxQvRxYU81tfW6udTcc2eZMPlezgmpzdrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M3oslCluw%253D%253D&md5=513473e25d1ace9c0d503064a076ac26</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1136%2Fbmj.38415.708634.F7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmj.38415.708634.F7%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DJ.%2BM.%2BM.%26aulast%3DDonnelly%26aufirst%3DL.%2BA.%26aulast%3DEmslie-Smith%26aufirst%3DA.%2BM.%26aulast%3DAlessi%26aufirst%3DD.%2BR.%26aulast%3DMorris%26aufirst%3DA.%2BD.%26atitle%3DMetformin%2520and%2520reduced%2520risk%2520of%2520cancer%2520in%2520diabetic%2520patients%26jtitle%3DBMJ.%26date%3D2005%26volume%3D330%26spage%3D1304%26epage%3D1305%26doi%3D10.1136%2Fbmj.38415.708634.F7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref206"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref206'); return false;" data-citation="" class="refNumLink">206</a></strong><div class="NLM_citation" id="cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bowker, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majumdar, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veugelers, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. A.</span></span> <span> </span><span class="NLM_article-title">Increased cancer-related mortality for patients with type 2 diabetes who use sulforrylureas or insulin</span>. <i>Diabetes Care</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">254</span>â <span class="NLM_lpage">258</span>, <span class="refDoi">Â DOI: 10.2337/diacare.29.02.06.dc05-1558</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.2337%2Fdiacare.29.02.06.dc05-1558" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=16443869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BD28%252Flsl2jsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2006&pages=254-258&author=S.+L.+Bowkerauthor=S.+R.+Majumdarauthor=P.+Veugelersauthor=J.+A.+Johnson&title=Increased+cancer-related+mortality+for+patients+with+type+2+diabetes+who+use+sulforrylureas+or+insulin&doi=10.2337%2Fdiacare.29.02.06.dc05-1558"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin</span></div><div class="casAuthors">Bowker Samantha L; Majumdar Sumit R; Veugelers Paul; Johnson Jeffrey A</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes care</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">254-8</span>
        ISSN:<span class="NLM_cas:issn">0149-5992</span>.
    </div><div class="casAbstract">OBJECTIVE:  Numerous studies have identified an increased risk of cancer in type 2 diabetes.  We explored the association between antidiabetic therapies and cancer-related mortality in patients with type 2 diabetes, postulating that agents that increase insulin levels might promote cancer.  RESEARCH DESIGN AND METHODS:  This was a population-based cohort study using administrative databases from Saskatchewan Health.  Cancer-related mortality was compared among inception cohorts of metformin users and sulfonylurea monotherapy users.  Multivariate Cox regression was used to estimate the hazard ratio (HR) of cancer-related mortality, after adjusting for age, sex, insulin use, and chronic disease score.  All statistical tests were two-sided.  RESULTS:  We identified 10,309 new users of metformin or sulfonylureas with an average follow-up of 5.4 +/- 1.9 years (means +/- SD).  The mean age for the cohort was 63.4 +/- 13.3 years, and 55% were men.  Cancer mortality over follow-up was 4.9% (162 of 3,340) for sulfonylurea monotherapy users, 3.5% (245 of 6,969) for metformin users, and 5.8% (84 of 1,443) for subjects who used insulin.  After multivariate adjustment, the sulfonylurea cohort had greater cancer-related mortality compared with the metformin cohort (adjusted HR 1.3 [95% CI 1.1-1.6]; P = 0.012).  Insulin use was associated with an adjusted HR of cancer-related mortality of 1.9 (95% CI 1.5-2.4; P < 0.0001).  CONCLUSIONS:  Patients with type 2 diabetes exposed to sulfonylureas and exogenous insulin had a significantly increased risk of cancer-related mortality compared with patients exposed to metformin.  It is uncertain whether this increased risk is related to a deleterious effect of sulfonylurea and insulin or a protective effect of metformin or due to some unmeasured effect related to both choice of therapy and cancer risk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSYNejkz31lvEPI-fCgwosgfW6udTcc2eYtZvaH3t3TS7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28%252Flsl2jsQ%253D%253D&md5=530d3294add5756642cb36153a786c1b</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.2337%2Fdiacare.29.02.06.dc05-1558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdiacare.29.02.06.dc05-1558%26sid%3Dliteratum%253Aachs%26aulast%3DBowker%26aufirst%3DS.%2BL.%26aulast%3DMajumdar%26aufirst%3DS.%2BR.%26aulast%3DVeugelers%26aufirst%3DP.%26aulast%3DJohnson%26aufirst%3DJ.%2BA.%26atitle%3DIncreased%2520cancer-related%2520mortality%2520for%2520patients%2520with%2520type%25202%2520diabetes%2520who%2520use%2520sulforrylureas%2520or%2520insulin%26jtitle%3DDiabetes%2520Care%26date%3D2006%26volume%3D29%26spage%3D254%26epage%3D258%26doi%3D10.2337%2Fdiacare.29.02.06.dc05-1558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref207"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref207'); return false;" data-citation="" class="refNumLink">207</a></strong><div class="NLM_citation" id="cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ben Sahra, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Marchand-Brustel, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanti, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bost, F.</span></span> <span> </span><span class="NLM_article-title">Metformin in cancer therapy: a new perspective for an old antidiabetic drug?</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1092</span>â <span class="NLM_lpage">1099</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-09-1186</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F1535-7163.MCT-09-1186" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=20442309" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsleksr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=1092-1099&author=I.+Ben+Sahraauthor=Y.+Le+Marchand-Brustelauthor=J.+F.+Tantiauthor=F.+Bost&title=Metformin+in+cancer+therapy%3A+a+new+perspective+for+an+old+antidiabetic+drug%3F&doi=10.1158%2F1535-7163.MCT-09-1186"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Metformin in Cancer Therapy: A New Perspective for an Old Antidiabetic Drug?</span></div><div class="casAuthors">Ben Sahra, Issam; Le Marchand-Brustel, Yannick; Tanti, Jean-Francois; Bost, Frederic</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1092-1099</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Metformin is the most widely used antidiabetic drug in the world, and there is increasing evidence of a potential efficacy of this agent as an anticancer drug.  First, epidemiol. studies show a decrease in cancer incidence in metformin-treated patients.  Second, metformin decreases insulin resistance and indirectly reduces insulin level, a beneficial effect because insulin promotes cancer cell growth.  Third, several reports outline a direct inhibitory effect of metformin on cancer cell growth and an antitumoral action.  Finally, metformin activates the AMP activated protein kinase (AMPK) pathway, a major sensor of the energetic status of the cell, which has been proposed as a promising therapeutic target in cancer.  Mol Cancer Ther; 9(5); 1092-99.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAuiLOQqw_6bVg90H21EOLACvtfcHk0lievg8WW1JbHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsleksr0%253D&md5=e99658f7356a3ccfa83515ef3df4e62e</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-1186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-1186%26sid%3Dliteratum%253Aachs%26aulast%3DBen%2BSahra%26aufirst%3DI.%26aulast%3DLe%2BMarchand-Brustel%26aufirst%3DY.%26aulast%3DTanti%26aufirst%3DJ.%2BF.%26aulast%3DBost%26aufirst%3DF.%26atitle%3DMetformin%2520in%2520cancer%2520therapy%253A%2520a%2520new%2520perspective%2520for%2520an%2520old%2520antidiabetic%2520drug%253F%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D1092%26epage%3D1099%26doi%3D10.1158%2F1535-7163.MCT-09-1186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref208"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref208'); return false;" data-citation="" class="refNumLink">208</a></strong><div class="NLM_citation" id="cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iliopoulos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsichlis, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Struhl, K.</span></span> <span> </span><span class="NLM_article-title">Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">7507</span>â <span class="NLM_lpage">7511</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-09-2994</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F0008-5472.CAN-09-2994" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=19752085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Skt7rN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=7507-7511&author=H.+A.+Hirschauthor=D.+Iliopoulosauthor=P.+N.+Tsichlisauthor=K.+Struhl&title=Metformin+selectively+targets+cancer+stem+cells%2C+and+acts+together+with+chemotherapy+to+block+tumor+growth+and+prolong+remission&doi=10.1158%2F0008-5472.CAN-09-2994"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">Metformin Selectively Targets Cancer Stem Cells, and Acts Together with Chemotherapy to Block Tumor Growth and Prolong Remission</span></div><div class="casAuthors">Hirsch, Heather A.; Iliopoulos, Dimitrios; Tsichlis, Philip N.; Struhl, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7507-7511</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The cancer stem cell hypothesis suggests that, unlike most cancer cells within a tumor, cancer stem cells resist chemotherapeutic drugs and can regenerate the various cell types in the tumor, thereby causing relapse of the disease.  Thus, drugs that selectively target cancer stem cells offer great promise for cancer treatment, particularly in combination with chemotherapy.  Here, we show that low doses of metformin, a std. drug for diabetes, inhibits cellular transformation and selectively kills cancer stem cells in four genetically different types of breast cancer.  The combination of metformin and a well-defined chemotherapeutic agent, doxorubicin, kills both cancer stem cells and non-stem cancer cells in culture.  Furthermore, this combinatorial therapy reduces tumor mass and prevents relapse much more effectively than either drug alone in a xenograft mouse model.  Mice seem to remain tumor-free for at least 2 mo after combinatorial therapy with metformin and doxorubicin is ended.  These results provide further evidence supporting the cancer stem cell hypothesis, and they provide a rationale and exptl. basis for using the combination of metformin and chemotherapeutic drugs to improve treatment of patients with breast (and possibly other) cancers. [Cancer Res 2009;69(19):7507-11].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwIa9rqZiXgrVg90H21EOLACvtfcHk0lievg8WW1JbHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Skt7rN&md5=81ed04ee6b3755c2bb48c4b0f70c499f</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-2994&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-2994%26sid%3Dliteratum%253Aachs%26aulast%3DHirsch%26aufirst%3DH.%2BA.%26aulast%3DIliopoulos%26aufirst%3DD.%26aulast%3DTsichlis%26aufirst%3DP.%2BN.%26aulast%3DStruhl%26aufirst%3DK.%26atitle%3DMetformin%2520selectively%2520targets%2520cancer%2520stem%2520cells%252C%2520and%2520acts%2520together%2520with%2520chemotherapy%2520to%2520block%2520tumor%2520growth%2520and%2520prolong%2520remission%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D7507%26epage%3D7511%26doi%3D10.1158%2F0008-5472.CAN-09-2994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref209"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref209'); return false;" data-citation="" class="refNumLink">209</a></strong><div class="NLM_citation" id="cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lonardo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cioffi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sancho, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Ripoll, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trabulo, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorado, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hidalgo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heeschen, C.</span></span> <span> </span><span class="NLM_article-title">Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">e76518</span>, <span class="refDoi">Â DOI: 10.1371/journal.pone.0076518</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1371%2Fjournal.pone.0076518" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=24204632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1ymsLzO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e76518&author=E.+Lonardoauthor=M.+Cioffiauthor=P.+Sanchoauthor=Y.+Sanchez-Ripollauthor=S.+M.+Trabuloauthor=J.+Doradoauthor=A.+Balicauthor=M.+Hidalgoauthor=C.+Heeschen&title=Metformin+targets+the+metabolic+achilles+heel+of+human+pancreatic+cancer+stem+cells&doi=10.1371%2Fjournal.pone.0076518"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells</span></div><div class="casAuthors">Lonardo, Enza; Cioffi, Michele; Sancho, Patricia; Sanchez-Ripoll, Yolanda; Trabulo, Sara Maria; Dorado, Jorge; Balic, Anamaria; Hidalgo, Manuel; Heeschen, Christopher</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e76518</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Pancreatic ductal adenocarcinomas contain a subset of exclusively tumorigenic cancer stem cells (CSCs), which are capable of repopulating the entire heterogeneous cancer cell populations and are highly resistant to std. chemotherapy.  Here we demonstrate that metformin selectively ablated pancreatic CSCs as evidenced by diminished expression of pluripotency-assocd. genes and CSC-assocd. surface markers.  Subsequently, the ability of metformin-treated CSCs to clonally expand in vitro was irreversibly abrogated by inducing apoptosis.  In contrast, non-CSCs preferentially responded by cell cycle arrest, but were not eliminated by metformin treatment.  Mechanistically, metformin increased reactive oxygen species prodn. in CSC and reduced their mitochondrial transmembrane potential.  The subsequent induction of lethal energy crisis in CSCs was independent of AMPK/mTOR.  Finally, in primary cancer tissue xenograft models metformin effectively reduced tumor burden and prevented disease progression; if combined with a stroma-targeting smoothened inhibitor for enhanced tissue penetration, while gemcitabine actually appeared dispensable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxb8VFTRqs5rVg90H21EOLACvtfcHk0ljUJ1B9rvZzTw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1ymsLzO&md5=63d29c5b3286fb0bc610bffd0f1e8ea0</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0076518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0076518%26sid%3Dliteratum%253Aachs%26aulast%3DLonardo%26aufirst%3DE.%26aulast%3DCioffi%26aufirst%3DM.%26aulast%3DSancho%26aufirst%3DP.%26aulast%3DSanchez-Ripoll%26aufirst%3DY.%26aulast%3DTrabulo%26aufirst%3DS.%2BM.%26aulast%3DDorado%26aufirst%3DJ.%26aulast%3DBalic%26aufirst%3DA.%26aulast%3DHidalgo%26aufirst%3DM.%26aulast%3DHeeschen%26aufirst%3DC.%26atitle%3DMetformin%2520targets%2520the%2520metabolic%2520achilles%2520heel%2520of%2520human%2520pancreatic%2520cancer%2520stem%2520cells%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26spage%3De76518%26doi%3D10.1371%2Fjournal.pone.0076518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref210"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref210'); return false;" data-citation="" class="refNumLink">210</a></strong><div class="NLM_citation" id="cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anisimov, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berstein, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egormin, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piskunova, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popovich, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zabezhinski, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovalenko, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poroshina, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semenchenko, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Provinciali, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Re, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franceschi, C.</span></span> <span> </span><span class="NLM_article-title">Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice</span>. <i>Exp. Gerontol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">685</span>â <span class="NLM_lpage">693</span>, <span class="refDoi">Â DOI: 10.1016/j.exger.2005.07.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.exger.2005.07.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=16125352" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVWhurbF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2005&pages=685-693&author=V.+N.+Anisimovauthor=L.+M.+Bersteinauthor=P.+A.+Egorminauthor=T.+S.+Piskunovaauthor=I.+G.+Popovichauthor=M.+A.+Zabezhinskiauthor=I.+G.+Kovalenkoauthor=T.+E.+Poroshinaauthor=A.+V.+Semenchenkoauthor=M.+Provincialiauthor=F.+Reauthor=C.+Franceschi&title=Effect+of+metformin+on+life+span+and+on+the+development+of+spontaneous+mammary+tumors+in+HER-2%2Fneu+transgenic+mice&doi=10.1016%2Fj.exger.2005.07.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice</span></div><div class="casAuthors">Anisimov, Vladimir N.; Berstein, Lev M.; Egormin, Peter A.; Piskunova, Tatiana S.; Popovich, Irina G.; Zabezhinski, Mark A.; Kovalenko, Irina G.; Poroshina, Tatiana E.; Semenchenko, Anna V.; Provinciali, Mauro; Re, Francesca; Franceschi, Claudio</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Gerontology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">8-9</span>),
    <span class="NLM_cas:pages">685-693</span>CODEN:
                <span class="NLM_cas:coden">EXGEAB</span>;
        ISSN:<span class="NLM_cas:issn">0531-5565</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Studies in mammals have led to the suggestion that hyperglycemia and hyperinsulinemia are important factors both in aging and in the development of cancer.  Insulin/insulin-like growth factor 1 (IGF-1) signaling mols. that have been linked to longevity include DAF-2 and InR and their homologs in mammals, and inactivation of the corresponding genes is followed by increased life span in nematodes, fruit flies and mice.  It is possible that the life-prolonging effects of calorie restriction are due to decreasing IGF-1 levels.  A search of pharmacol. modulators of insulin/IGF-1 signaling pathway (which mimetic effects of life span extending mutations or calorie restriction) could be a perspective direction in regulation of longevity.  The chronic treatment of female transgenic HER-2/neu mice with metformin (100 mg/kg in drinking water) slightly decreased the food consumption but failed in reducing the body wt. or temp., slowed down the age-related rise in blood glucose and triglycerides level, as well as the age-related switch-off of estrous function, prolonged the mean life span by 8% (p<0.05), the mean life span of last 10% survivors by 13.1%, and the max. life span by 1 mo in comparison with control mice.  The demog. aging rate represented by the est. of resp. Gompertz's parameter was decreased 2.26 times.  The metformin-treatment significantly decreased the incidence and size of mammary adenocarcinomas in mice and increased the mean latency of the tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquypiouA6-lbVg90H21EOLACvtfcHk0ljUJ1B9rvZzTw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVWhurbF&md5=44465d0322e7286c74392ac47b7b4432</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1016%2Fj.exger.2005.07.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.exger.2005.07.007%26sid%3Dliteratum%253Aachs%26aulast%3DAnisimov%26aufirst%3DV.%2BN.%26aulast%3DBerstein%26aufirst%3DL.%2BM.%26aulast%3DEgormin%26aufirst%3DP.%2BA.%26aulast%3DPiskunova%26aufirst%3DT.%2BS.%26aulast%3DPopovich%26aufirst%3DI.%2BG.%26aulast%3DZabezhinski%26aufirst%3DM.%2BA.%26aulast%3DKovalenko%26aufirst%3DI.%2BG.%26aulast%3DPoroshina%26aufirst%3DT.%2BE.%26aulast%3DSemenchenko%26aufirst%3DA.%2BV.%26aulast%3DProvinciali%26aufirst%3DM.%26aulast%3DRe%26aufirst%3DF.%26aulast%3DFranceschi%26aufirst%3DC.%26atitle%3DEffect%2520of%2520metformin%2520on%2520life%2520span%2520and%2520on%2520the%2520development%2520of%2520spontaneous%2520mammary%2520tumors%2520in%2520HER-2%252Fneu%2520transgenic%2520mice%26jtitle%3DExp.%2520Gerontol.%26date%3D2005%26volume%3D40%26spage%3D685%26epage%3D693%26doi%3D10.1016%2Fj.exger.2005.07.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref211"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref211'); return false;" data-citation="" class="refNumLink">211</a></strong><div class="NLM_citation" id="cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tilley, J.</span>; <span class="NLM_string-name">Grimsby, J.</span>; <span class="NLM_string-name">Erickson, S.</span>; <span class="NLM_string-name">Berthel, S.</span></span> <span> </span><span class="NLM_article-title">Diabetes Drugs: Present and Emerging</span>. In  <i>Cardiovascular, Endocrine and Metabolic Diseases</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, D. J.</span></span>, Ed.; Burgerâs Medicinal Chemistry, Drug Discovery, and Development; <span class="NLM_publisher-name">John Wiley & Sons, Inc</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>, <span class="NLM_year">2010</span>; pp  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">31</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1002%2F0471266949.bmc198" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&pages=1-31&author=J.+Tilley&author=J.+Grimsby&author=S.+Erickson&author=S.+Berthelauthor=D.+J.+Abraham&title=Cardiovascular%2C+Endocrine+and+Metabolic+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1002%2F0471266949.bmc198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F0471266949.bmc198%26sid%3Dliteratum%253Aachs%26aulast%3DTilley%26aufirst%3DJ.%26atitle%3DDiabetes%2520Drugs%253A%2520Present%2520and%2520Emerging%26btitle%3DCardiovascular%252C%2520Endocrine%2520and%2520Metabolic%2520Diseases%26aulast%3DAbraham%26aufirst%3DD.%2BJ.%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26date%3D2010%26spage%3D1%26epage%3D31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref212"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref212'); return false;" data-citation="" class="refNumLink">212</a></strong><div class="NLM_citation" id="cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dallos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitagawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunnumakkara, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Memmott, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollander, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gills, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dennis, P. A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of lung tumorigenesis by metformin Is associated with decreased plasma IGF-I and diminished receptor tyrosine kinase signaling</span>. <i>Cancer Prev. Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">801</span>â <span class="NLM_lpage">810</span>, <span class="refDoi">Â DOI: 10.1158/1940-6207.CAPR-13-0058-T</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F1940-6207.CAPR-13-0058-T" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=23771523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1amt73P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=801-810&author=B.+J.+Quinnauthor=M.+Dallosauthor=H.+Kitagawaauthor=A.+B.+Kunnumakkaraauthor=R.+M.+Memmottauthor=M.+C.+Hollanderauthor=J.+J.+Gillsauthor=P.+A.+Dennis&title=Inhibition+of+lung+tumorigenesis+by+metformin+Is+associated+with+decreased+plasma+IGF-I+and+diminished+receptor+tyrosine+kinase+signaling&doi=10.1158%2F1940-6207.CAPR-13-0058-T"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit212R"><div class="casContent"><span class="casTitleNuber">212</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Lung Tumorigenesis by Metformin Is Associated with Decreased Plasma IGF-I and Diminished Receptor Tyrosine Kinase Signaling</span></div><div class="casAuthors">Quinn, Brendan J.; Dallos, Matthew; Kitagawa, Hiroshi; Kunnumakkara, Ajaikumar B.; Memmott, Regan M.; Hollander, M. Christine; Gills, Joell J.; Dennis, Phillip A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Prevention Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">801-810</span>CODEN:
                <span class="NLM_cas:coden">CPRACC</span>;
        ISSN:<span class="NLM_cas:issn">1940-6207</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Metformin is the most commonly prescribed drug for type II diabetes and is assocd. with decreased cancer risk.  Previously, we showed that metformin prevented tobacco carcinogen (NNK)-induced lung tumorigenesis in a non-diabetic mouse model, which was assocd. with decreased IGF-I/insulin receptor signaling but not activation of AMPK in lung tissues, as well as decreased circulating levels of IGF-I and insulin.  Here, we used liver IGF-I-deficient (LID) mice to det. the importance of IGF-I in NNK-induced lung tumorigenesis and chemoprevention by metformin.  LID mice had decreased lung tumor multiplicity and burden compared with wild-type (WT) mice.  Metformin further decreased lung tumorigenesis in LID mice without affecting IGF-I levels, suggesting that metformin can act through IGF-I-independent mechanisms.  In lung tissues, metformin decreased phosphorylation of multiple receptor tyrosine kinases (RTK) as well as levels of GTP-bound Ras independently of AMPK.  Metformin also diminished plasma levels of several cognate ligands for these RTKs.  Tissue distribution studies using [14C]-metformin showed that uptake of metformin was high in liver but four-fold lower in lungs, suggesting that the suppression of RTK activation by metformin occurs predominantly via systemic, indirect effects.  Systemic inhibition of circulating growth factors and local RTK signaling are new AMPK-independent mechanisms of action of metformin that could underlie its ability to prevent tobacco carcinogen-induced lung tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6tDMvbu-p0bVg90H21EOLACvtfcHk0ljUJ1B9rvZzTw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1amt73P&md5=e3545277bfd7f09dbf58a117063e2cb3</span></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1158%2F1940-6207.CAPR-13-0058-T&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1940-6207.CAPR-13-0058-T%26sid%3Dliteratum%253Aachs%26aulast%3DQuinn%26aufirst%3DB.%2BJ.%26aulast%3DDallos%26aufirst%3DM.%26aulast%3DKitagawa%26aufirst%3DH.%26aulast%3DKunnumakkara%26aufirst%3DA.%2BB.%26aulast%3DMemmott%26aufirst%3DR.%2BM.%26aulast%3DHollander%26aufirst%3DM.%2BC.%26aulast%3DGills%26aufirst%3DJ.%2BJ.%26aulast%3DDennis%26aufirst%3DP.%2BA.%26atitle%3DInhibition%2520of%2520lung%2520tumorigenesis%2520by%2520metformin%2520Is%2520associated%2520with%2520decreased%2520plasma%2520IGF-I%2520and%2520diminished%2520receptor%2520tyrosine%2520kinase%2520signaling%26jtitle%3DCancer%2520Prev.%2520Res.%26date%3D2013%26volume%3D6%26spage%3D801%26epage%3D810%26doi%3D10.1158%2F1940-6207.CAPR-13-0058-T" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref213"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref213'); return false;" data-citation="" class="refNumLink">213</a></strong><div class="NLM_citation" id="cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lam, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S. G.</span></span> <span> </span><span class="NLM_article-title">New metformin derivative HL156A prevents oral cancer progression by inhibiting the insulin-like growth factor/AKT/mammalian target of rapamycin pathways</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">699</span>â <span class="NLM_lpage">709</span>, <span class="refDoi">Â DOI: 10.1111/cas.13482</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1111%2Fcas.13482" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=29285837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVeqtrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2018&pages=699-709&author=T.+G.+Lamauthor=Y.+S.+Jeongauthor=S.+A.+Kimauthor=S.+G.+Ahn&title=New+metformin+derivative+HL156A+prevents+oral+cancer+progression+by+inhibiting+the+insulin-like+growth+factor%2FAKT%2Fmammalian+target+of+rapamycin+pathways&doi=10.1111%2Fcas.13482"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">New metformin derivative HL156A prevents oral cancer progression by inhibiting the insulin-like growth factor/AKT/mammalian target of rapamycin pathways</span></div><div class="casAuthors">Lam, Thuy Giang; Jeong, Yun Soo; Kim, Soo-A.; Ahn, Sang-Gun</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">699-709</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Metformin is a biguanide widely prescribed as an antidiabetic drug for type 2 diabetes mellitus patients.  The purpose of the present study was to observe the effects of the new metformin deriv., HL156A, on human oral cancer cell and to investigate its possible mechanisms.  It was obsd. that HL156A significantly decreased FaDu and YD-10B cell viability and colony formation in a dose-dependent way.  HL156A also markedly reduced wound closure and migration of FaDu and YD-10B cells.  We obsd. that HL156A decreased mitochondrial membrane potential and induced reactive oxygen species (ROS) levels and apoptotic cells with caspase-3 and -9 activation.  HL156A inhibited the expression and activation of insulin-like growth factor (IGF)-1 and its downstream proteins, AKT, mammalian target of rapamycin (mTOR), and ERK1/2.  In addn., HL156A activated AMP-activated protein kinase/nuclear factor kappa B (AMPK-NF-ÎºB) signaling of FaDu and YD-10B cells.  A xenograft mouse model further showed that HL156A suppressed AT84 mouse oral tumor growth, accompanied by down-regulated p-IGF-1, p-mTOR, proliferating cell nuclear antigen (PCNA) and promoted p-AMPK and TUNEL expression.  These results suggest the potential value of the new metformin deriv. HL156A as a candidate for a therapeutic modality for the treatment of oral cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4saWi6-sLmbVg90H21EOLACvtfcHk0liNsC6t_Qd2Fw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVeqtrs%253D&md5=6a51c0497656bc24413a75ede141f11d</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1111%2Fcas.13482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.13482%26sid%3Dliteratum%253Aachs%26aulast%3DLam%26aufirst%3DT.%2BG.%26aulast%3DJeong%26aufirst%3DY.%2BS.%26aulast%3DKim%26aufirst%3DS.%2BA.%26aulast%3DAhn%26aufirst%3DS.%2BG.%26atitle%3DNew%2520metformin%2520derivative%2520HL156A%2520prevents%2520oral%2520cancer%2520progression%2520by%2520inhibiting%2520the%2520insulin-like%2520growth%2520factor%252FAKT%252Fmammalian%2520target%2520of%2520rapamycin%2520pathways%26jtitle%3DCancer%2520Sci.%26date%3D2018%26volume%3D109%26spage%3D699%26epage%3D709%26doi%3D10.1111%2Fcas.13482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref214"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref214'); return false;" data-citation="" class="refNumLink">214</a></strong><div class="NLM_citation" id="cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berhoerster, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellinghaus, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haerter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greschat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wengner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haegebarth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess-Stumpp, H.</span></span> <span> </span><span class="NLM_article-title">Abstract 4503: BAY 87-2243, an inhibitor of HIF-1Î± activation and stabilization, showed promising anti-tumor efficacy either as monotherapy or in combination with anti-VEGF and chemotherapy agents in preclinical tumor models</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">4503</span>â <span class="NLM_lpage">4503</span>, <span class="refDoi">Â DOI: 10.1158/1538-7445.AM2011-4503</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F1538-7445.AM2011-4503" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=4503-4503&author=K.+Berhoersterauthor=P.+Ellinghausauthor=M.+Haerterauthor=S.+Greschatauthor=A.+Wengnerauthor=A.+Scholzauthor=A.+Haegebarthauthor=H.+Hess-Stumpp&title=Abstract+4503%3A+BAY+87-2243%2C+an+inhibitor+of+HIF-1%CE%B1+activation+and+stabilization%2C+showed+promising+anti-tumor+efficacy+either+as+monotherapy+or+in+combination+with+anti-VEGF+and+chemotherapy+agents+in+preclinical+tumor+models&doi=10.1158%2F1538-7445.AM2011-4503"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2011-4503&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2011-4503%26sid%3Dliteratum%253Aachs%26aulast%3DBerhoerster%26aufirst%3DK.%26aulast%3DEllinghaus%26aufirst%3DP.%26aulast%3DHaerter%26aufirst%3DM.%26aulast%3DGreschat%26aufirst%3DS.%26aulast%3DWengner%26aufirst%3DA.%26aulast%3DScholz%26aufirst%3DA.%26aulast%3DHaegebarth%26aufirst%3DA.%26aulast%3DHess-Stumpp%26aufirst%3DH.%26atitle%3DAbstract%25204503%253A%2520BAY%252087-2243%252C%2520an%2520inhibitor%2520of%2520HIF-1%25CE%25B1%2520activation%2520and%2520stabilization%252C%2520showed%2520promising%2520anti-tumor%2520efficacy%2520either%2520as%2520monotherapy%2520or%2520in%2520combination%2520with%2520anti-VEGF%2520and%2520chemotherapy%2520agents%2520in%2520preclinical%2520tumor%2520models%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D4503%26epage%3D4503%26doi%3D10.1158%2F1538-7445.AM2011-4503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref215"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref215'); return false;" data-citation="" class="refNumLink">215</a></strong><div class="NLM_citation" id="cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hess-Stumpp, H.</span></span> <span> </span><span class="NLM_article-title">Abstract LB-244: BAY 87-2243, an inhibitor of HIF-1Î± - induced gene activation, showed promising anti-tumor efficacy in combination with anti-angiogenic therapy and irradiation in preclinical tumor models</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">LB-244</span>, <span class="refDoi">Â DOI: 10.1158/1538-7445.AM2012-LB-244</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F1538-7445.AM2012-LB-244" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=LB-244&author=H.+Hess-Stumpp&title=Abstract+LB-244%3A+BAY+87-2243%2C+an+inhibitor+of+HIF-1%CE%B1+-+induced+gene+activation%2C+showed+promising+anti-tumor+efficacy+in+combination+with+anti-angiogenic+therapy+and+irradiation+in+preclinical+tumor+models&doi=10.1158%2F1538-7445.AM2012-LB-244"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2012-LB-244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2012-LB-244%26sid%3Dliteratum%253Aachs%26aulast%3DHess-Stumpp%26aufirst%3DH.%26atitle%3DAbstract%2520LB-244%253A%2520BAY%252087-2243%252C%2520an%2520inhibitor%2520of%2520HIF-1%25CE%25B1%2520-%2520induced%2520gene%2520activation%252C%2520showed%2520promising%2520anti-tumor%2520efficacy%2520in%2520combination%2520with%2520anti-angiogenic%2520therapy%2520and%2520irradiation%2520in%2520preclinical%2520tumor%2520models%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3DLB-244%26doi%3D10.1158%2F1538-7445.AM2012-LB-244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref216"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref216'); return false;" data-citation="" class="refNumLink">216</a></strong><div class="NLM_citation" id="cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yap, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahnert, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piha-Paul, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janku, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karp, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naing, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumbrava, E. E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pant, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subbiah, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsimberidou, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vellano, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahendra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francesco, M. E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marszalek, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meric-Bernstam, F.</span></span> <span> </span><span class="NLM_article-title">Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial electron transport chain, in patients (pts) with advanced solid tumors</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">3014</span>â <span class="NLM_lpage">3014</span>, <span class="refDoi">Â DOI: 10.1200/JCO.2019.37.15_suppl.3014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1200%2FJCO.2019.37.15_suppl.3014" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=3014-3014&author=T.+A.+Yapauthor=J.+R.+Ahnertauthor=S.+A.+Piha-Paulauthor=S.+Fuauthor=F.+Jankuauthor=D.+D.+Karpauthor=A.+Naingauthor=E.+E.+I.+Dumbravaauthor=S.+Pantauthor=V.+Subbiahauthor=A.+M.+Tsimberidouauthor=D.+S.+Hongauthor=K.+M.+Roseauthor=Q.+Xuauthor=C.+P.+Vellanoauthor=M.+Mahendraauthor=P.+Jonesauthor=M.+E.+D.+Francescoauthor=J.+R.+Marszalekauthor=F.+Meric-Bernstam&title=Phase+I+trial+of+IACS-010759+%28IACS%29%2C+a+potent%2C+selective+inhibitor+of+complex+I+of+the+mitochondrial+electron+transport+chain%2C+in+patients+%28pts%29+with+advanced+solid+tumors&doi=10.1200%2FJCO.2019.37.15_suppl.3014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.1200%2FJCO.2019.37.15_suppl.3014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2019.37.15_suppl.3014%26sid%3Dliteratum%253Aachs%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DAhnert%26aufirst%3DJ.%2BR.%26aulast%3DPiha-Paul%26aufirst%3DS.%2BA.%26aulast%3DFu%26aufirst%3DS.%26aulast%3DJanku%26aufirst%3DF.%26aulast%3DKarp%26aufirst%3DD.%2BD.%26aulast%3DNaing%26aufirst%3DA.%26aulast%3DDumbrava%26aufirst%3DE.%2BE.%2BI.%26aulast%3DPant%26aufirst%3DS.%26aulast%3DSubbiah%26aufirst%3DV.%26aulast%3DTsimberidou%26aufirst%3DA.%2BM.%26aulast%3DHong%26aufirst%3DD.%2BS.%26aulast%3DRose%26aufirst%3DK.%2BM.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DVellano%26aufirst%3DC.%2BP.%26aulast%3DMahendra%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DFrancesco%26aufirst%3DM.%2BE.%2BD.%26aulast%3DMarszalek%26aufirst%3DJ.%2BR.%26aulast%3DMeric-Bernstam%26aufirst%3DF.%26atitle%3DPhase%2520I%2520trial%2520of%2520IACS-010759%2520%2528IACS%2529%252C%2520a%2520potent%252C%2520selective%2520inhibitor%2520of%2520complex%2520I%2520of%2520the%2520mitochondrial%2520electron%2520transport%2520chain%252C%2520in%2520patients%2520%2528pts%2529%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2019%26volume%3D37%26spage%3D3014%26epage%3D3014%26doi%3D10.1200%2FJCO.2019.37.15_suppl.3014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref217"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref217'); return false;" data-citation="" class="refNumLink">217</a></strong><div class="NLM_citation" id="cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mansi, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degraeff, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newell, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaholm, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Button, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payne, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, I. E.</span></span> <span> </span><span class="NLM_article-title">A phase-II clinical and pharmacokinetic study of lonidamine in patients with advanced breast-cancer</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">593</span>â <span class="NLM_lpage">597</span>, <span class="refDoi">Â DOI: 10.1038/bjc.1991.356</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fbjc.1991.356" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1911204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADyaK38%252FgtFarug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1991&pages=593-597&author=J.+L.+Mansiauthor=A.+Degraeffauthor=D.+R.+Newellauthor=J.+Glaholmauthor=D.+Buttonauthor=M.+O.+Leachauthor=G.+Payneauthor=I.+E.+Smith&title=A+phase-II+clinical+and+pharmacokinetic+study+of+lonidamine+in+patients+with+advanced+breast-cancer&doi=10.1038%2Fbjc.1991.356"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II clinical and pharmacokinetic study of Lonidamine in patients with advanced breast cancer</span></div><div class="casAuthors">Mansi J L; de Graeff A; Newell D R; Glaholm J; Button D; Leach M O; Payne G; Smith I E</div><div class="citationInfo"><span class="NLM_cas:title">British journal of cancer</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">593-7</span>
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    </div><div class="casAbstract">Lonidamine is a substituted indazole carboxylic acid with a unique mechanism of action and early clinical studies have reported anti-tumour activity.  In a phase II study 32 patients with previously treated advanced breast cancer were given Lonidamine in a daily divided oral dose of 600 mg.  Of 28 patients evaluable for response, three (11%) achieved a partial response (4-24+ months) and three (11%) a minor response.  Two patients have stable disease (greater than 3 months) and 20 progressed.  Toxicity was very mild.  Sixteen (53%) of 31 patients had myalgia which lasted a median of 2 weeks.  This was investigated with nuclear magnetic resonance spectroscopy in four patients but the changes were unrelated to the degree of myalgia.  No other major side-effect was seen, and no dose reduction was required.  Lonidamine pharmacokinetics have been investigated in 17 patients 1 month after the start of therapy.  Lonidamine was detected in the plasma of all patients, but there was no clear relationship between Lonidamine levels and clinical response or toxicity.  Lonidamine appears to be active against advanced breast cancer and its low toxicity would allow combination studies with chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRdK09xcjEvgt0Q2ypr7jHkfW6udTcc2eb6NYSoXydsbbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK38%252FgtFarug%253D%253D&md5=53df069050bdecaf1c9329e1667480c0</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.1038%2Fbjc.1991.356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.1991.356%26sid%3Dliteratum%253Aachs%26aulast%3DMansi%26aufirst%3DJ.%2BL.%26aulast%3DDegraeff%26aufirst%3DA.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DGlaholm%26aufirst%3DJ.%26aulast%3DButton%26aufirst%3DD.%26aulast%3DLeach%26aufirst%3DM.%2BO.%26aulast%3DPayne%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DI.%2BE.%26atitle%3DA%2520phase-II%2520clinical%2520and%2520pharmacokinetic%2520study%2520of%2520lonidamine%2520in%2520patients%2520with%2520advanced%2520breast-cancer%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D1991%26volume%3D64%26spage%3D593%26epage%3D597%26doi%3D10.1038%2Fbjc.1991.356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref218"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref218'); return false;" data-citation="" class="refNumLink">218</a></strong><div class="NLM_citation" id="cit218"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Lena, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorusso, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latorre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanizza, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gargano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caporusso, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crucitta, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambiasi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzei, A.</span></span> <span> </span><span class="NLM_article-title">Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">364</span>â <span class="NLM_lpage">368</span>, <span class="refDoi">Â DOI: 10.1016/S0959-8049(00)00400-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2FS0959-8049%2800%2900400-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=11239758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhs1art7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2001&pages=364-368&author=M.+De+Lenaauthor=V.+Lorussoauthor=A.+Latorreauthor=G.+Fanizzaauthor=G.+Garganoauthor=L.+Caporussoauthor=M.+Guidaauthor=A.+Catinoauthor=E.+Crucittaauthor=D.+Sambiasiauthor=A.+Mazzei&title=Paclitaxel%2C+cisplatin+and+lonidamine+in+advanced+ovarian+cancer.+A+phase+II+study&doi=10.1016%2FS0959-8049%2800%2900400-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit218R"><div class="casContent"><span class="casTitleNuber">218</span><div class="casTitle"><span class="NLM_cas:atitle">Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study</span></div><div class="casAuthors">De Lena, M.; Lorusso, V.; Latorre, A.; Fanizza, G.; Gargano, G.; Caporusso, L.; Guida, M.; Catino, A.; Crucitta, E.; Sambiasi, D.; Mazzei, A.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">364-368</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A potential way to improve the results obtained with the std. carboplatin/cisplatin (CDDP)-Paclitaxel treatment regimen in advanced ovarian cancer is to incorporate a modulating agent such as lonidamine (LND).  In fact, LND has been shown to revert the resistance to cisplatin and to potentiate cisplatin activity in exptl. models and in clin. studies.  Thirty-five consecutive patients with advanced ovarian cancer, not previously treated with chemotherapy, were treated with Paclitaxel at a dose of 135 mg/m2 i.v. on day 1 (in a 3-h infusion) and cisplatin at a dose of 75 mg/m2 i.v. on day 2 plus LND orally at a dose of 450 mg/day for 6 consecutive days starting 2 days before chemotherapy, every 3 wk for 6 cycles.  Complete plus partial responses were obsd. in 8 (80%) out of the 10 women with measurable disease.  In the 25 patients with evaluable disease, only 4 clin. progressions were obsd. (16%).  Median progression-free survival (PFS) and overall survival (OS) were 28.5 [95% confidence interval (CI) 22.2-34.8] and 46.5 (95% CI 32.4-60.00) months, resp.  Grade 3-4 neutropenia was obsd. in 9 (26%) patients.  Alopecia, nausea, and vomiting (Grade 3) were obsd. in 33 (94%) and 5 (14%) patients, resp.  In conclusion, the combination of CDDP/Paclitaxel plus LND is active and tolerable in the treatment of advanced ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIq-ck0XHLELVg90H21EOLACvtfcHk0lho2MLOnos5IQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhs1art7k%253D&md5=72f223ec639b954abf9f7c12a34adb09</span></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=10.1016%2FS0959-8049%2800%2900400-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-8049%252800%252900400-7%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BLena%26aufirst%3DM.%26aulast%3DLorusso%26aufirst%3DV.%26aulast%3DLatorre%26aufirst%3DA.%26aulast%3DFanizza%26aufirst%3DG.%26aulast%3DGargano%26aufirst%3DG.%26aulast%3DCaporusso%26aufirst%3DL.%26aulast%3DGuida%26aufirst%3DM.%26aulast%3DCatino%26aufirst%3DA.%26aulast%3DCrucitta%26aufirst%3DE.%26aulast%3DSambiasi%26aufirst%3DD.%26aulast%3DMazzei%26aufirst%3DA.%26atitle%3DPaclitaxel%252C%2520cisplatin%2520and%2520lonidamine%2520in%2520advanced%2520ovarian%2520cancer.%2520A%2520phase%2520II%2520study%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2001%26volume%3D37%26spage%3D364%26epage%3D368%26doi%3D10.1016%2FS0959-8049%2800%2900400-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref219"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref219'); return false;" data-citation="" class="refNumLink">219</a></strong><div class="NLM_citation" id="cit219"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cervantes-Madrid, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duenas-Gonzalez, A.</span></span> <span> </span><span class="NLM_article-title">Reviving lonidamine and 6-diazo-5-oxo-L-norleucine to be used in combination for metabolic cancer therapy</span>. <i>BioMed Res. Int.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2015</i></span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">13</span>, <span class="refDoi">Â DOI: 10.1155/2015/690492</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1155%2F2015%2F690492" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2015&publication_year=2015&pages=1-13&author=D.+Cervantes-Madridauthor=Y.+Romeroauthor=A.+Duenas-Gonzalez&title=Reviving+lonidamine+and+6-diazo-5-oxo-L-norleucine+to+be+used+in+combination+for+metabolic+cancer+therapy&doi=10.1155%2F2015%2F690492"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1155%2F2015%2F690492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2015%252F690492%26sid%3Dliteratum%253Aachs%26aulast%3DCervantes-Madrid%26aufirst%3DD.%26aulast%3DRomero%26aufirst%3DY.%26aulast%3DDuenas-Gonzalez%26aufirst%3DA.%26atitle%3DReviving%2520lonidamine%2520and%25206-diazo-5-oxo-L-norleucine%2520to%2520be%2520used%2520in%2520combination%2520for%2520metabolic%2520cancer%2520therapy%26jtitle%3DBioMed%2520Res.%2520Int.%26date%3D2015%26volume%3D2015%26spage%3D1%26epage%3D13%26doi%3D10.1155%2F2015%2F690492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref220"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref220'); return false;" data-citation="" class="refNumLink">220</a></strong><div class="NLM_citation" id="cit220"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salabei, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibb, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, B. G.</span></span> <span> </span><span class="NLM_article-title">Comprehensive measurement of respiratory activity in permeabilized cells using extracellular flux analysis</span>. <i>Nat. Protoc.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">421</span>â <span class="NLM_lpage">38</span>, <span class="refDoi">Â DOI: 10.1038/nprot.2014.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fnprot.2014.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=24457333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1Cktrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=421-38&author=J.+K.+Salabeiauthor=A.+A.+Gibbauthor=B.+G.+Hill&title=Comprehensive+measurement+of+respiratory+activity+in+permeabilized+cells+using+extracellular+flux+analysis&doi=10.1038%2Fnprot.2014.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit220R"><div class="casContent"><span class="casTitleNuber">220</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive measurement of respiratory activity in permeabilized cells using extracellular flux analysis</span></div><div class="casAuthors">Salabei, Joshua K.; Gibb, Andrew A.; Hill, Bradford G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">421-438</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Extracellular flux (XF) anal. has become a mainstream method for measuring mitochondrial function in cells and tissues.  Although this technique is commonly used to measure bioenergetics in intact cells, we outline here a detailed XF protocol for measuring respiration in permeabilized cells.  Cells are permeabilized using saponin (SAP), digitonin (DIG) or recombinant perfringolysin O (rPFO) (XF-plasma membrane permeabilizer (PMP) reagent), and they are provided with specific substrates to measure complex I- or complex II-mediated respiratory activity, complex III+IV respiratory activity or complex IV activity.  Medium- and long-chain acylcarnitines or glutamine may also be provided for measuring fatty acid (FA) oxidn. or glutamine oxidn., resp.  This protocol uses a minimal no. of cells compared with other protocols and does not require isolation of mitochondria.  The results are highly reproducible, and mitochondria remain well coupled.  Collectively, this protocol provides comprehensive and detailed information regarding mitochondrial activity and efficiency, and, after preparative steps, it takes 6-8 h to complete.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosNLIbyikZobVg90H21EOLACvtfcHk0lho2MLOnos5IQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1Cktrk%253D&md5=d106bf025c855852f819c42f183c2374</span></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2014.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2014.018%26sid%3Dliteratum%253Aachs%26aulast%3DSalabei%26aufirst%3DJ.%2BK.%26aulast%3DGibb%26aufirst%3DA.%2BA.%26aulast%3DHill%26aufirst%3DB.%2BG.%26atitle%3DComprehensive%2520measurement%2520of%2520respiratory%2520activity%2520in%2520permeabilized%2520cells%2520using%2520extracellular%2520flux%2520analysis%26jtitle%3DNat.%2520Protoc.%26date%3D2014%26volume%3D9%26spage%3D421%26epage%3D38%26doi%3D10.1038%2Fnprot.2014.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref221"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref221'); return false;" data-citation="" class="refNumLink">221</a></strong><div class="NLM_citation" id="cit221"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span> <span> </span><span class="NLM_article-title">Targeting mitochondria by anthelmintic drug atovaquone sensitizes renal cell carcinoma to chemotherapy and immunotherapy</span>. <i>J. Biochem. Mol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">e22195</span>, <span class="refDoi">Â DOI: 10.1002/jbt.22195</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1002%2Fjbt.22195" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=30004155" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2018&pages=e22195&author=D.+H.+Chenauthor=X.+S.+Sunauthor=X.+J.+Zhangauthor=J.+Cao&title=Targeting+mitochondria+by+anthelmintic+drug+atovaquone+sensitizes+renal+cell+carcinoma+to+chemotherapy+and+immunotherapy&doi=10.1002%2Fjbt.22195"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.1002%2Fjbt.22195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjbt.22195%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DD.%2BH.%26aulast%3DSun%26aufirst%3DX.%2BS.%26aulast%3DZhang%26aufirst%3DX.%2BJ.%26aulast%3DCao%26aufirst%3DJ.%26atitle%3DTargeting%2520mitochondria%2520by%2520anthelmintic%2520drug%2520atovaquone%2520sensitizes%2520renal%2520cell%2520carcinoma%2520to%2520chemotherapy%2520and%2520immunotherapy%26jtitle%3DJ.%2520Biochem.%2520Mol.%2520Toxicol.%26date%3D2018%26volume%3D32%26spage%3De22195%26doi%3D10.1002%2Fjbt.22195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref222"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref222'); return false;" data-citation="" class="refNumLink">222</a></strong><div class="NLM_citation" id="cit222"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lv, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span> <span> </span><span class="NLM_article-title">Atovaquone enhances doxorubicinâs efficacy via inhibiting mitochondrial respiration and STAT3 in aggressive thyroid cancer</span>. <i>J. Bioenerg. Biomembr.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">263</span>â <span class="NLM_lpage">270</span>, <span class="refDoi">Â DOI: 10.1007/s10863-018-9755-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1007%2Fs10863-018-9755-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=29687367" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotF2gtb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2018&pages=263-270&author=Z.+Lvauthor=X.+T.+Yanauthor=L.+Y.+Luauthor=C.+Suauthor=Y.+He&title=Atovaquone+enhances+doxorubicin%E2%80%99s+efficacy+via+inhibiting+mitochondrial+respiration+and+STAT3+in+aggressive+thyroid+cancer&doi=10.1007%2Fs10863-018-9755-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit222R"><div class="casContent"><span class="casTitleNuber">222</span><div class="casTitle"><span class="NLM_cas:atitle">Atovaquone enhances doxorubicin's efficacy via inhibiting mitochondrial respiration and STAT3 in aggressive thyroid cancer</span></div><div class="casAuthors">Lv, Zhuo; Yan, Xintong; Lu, Liying; Su, Chun; He, Yin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Bioenergetics and Biomembranes</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">263-270</span>CODEN:
                <span class="NLM_cas:coden">JBBID4</span>;
        ISSN:<span class="NLM_cas:issn">0145-479X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The clin. management of anaplastic thyroid carcinoma and follicular thyroid carcinoma is challenging and requires an alternative therapeutic strategy.  Although atovaquone is an FDA-approved anti-malarial drug, studies has recently demonstrated its anti-cancer activities.  In line with these efforts, our study shows that atovaquone is an attractive candidate for thyroid cancer treatment.  We show that atovaquone significantly inhibits growth, migration and survival in a concn.-dependent manner in 8505C and FTC113 cells.  Mechanistically, atovaquone inhibits mitochondrial complex III activity, leading to mitochondrial respiration inhibition and redn. of ATP prodn. in thyroid cancer cells.  The inhibitory effects of atovaquone is reversed in mitochondrial respiration-deficient 8505C Ï0 cells, confirming mitochondrial respiration as the mechanism of atovaquone's action in thyroid cancer.  In addn., atovaquone suppresses phosphorylation of STAT3 in thyroid cancer wildype but not Ï0 cells, demonstrating that STAT3 phosphorylation inhibition by atovaquone is a consequence of mitochondrial respiration inhibition.  Notably, we further demonstrate that atovaquone significantly augments doxorubicin's inhibitory effects via suppressing mitochondrial respiration and STAT3.  Our findings suggest that atovaquone can be repurposed for thyroid cancer treatment.  Our work also highlights that targeting mitochondrial respiration may represent potential therapeutic strategy in thyroid cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeYmgFi_UDGbVg90H21EOLACvtfcHk0lie7myZyzH5jw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotF2gtb0%253D&md5=f1e9fdf3565adaea762b5ee33a39eb2b</span></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.1007%2Fs10863-018-9755-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10863-018-9755-y%26sid%3Dliteratum%253Aachs%26aulast%3DLv%26aufirst%3DZ.%26aulast%3DYan%26aufirst%3DX.%2BT.%26aulast%3DLu%26aufirst%3DL.%2BY.%26aulast%3DSu%26aufirst%3DC.%26aulast%3DHe%26aufirst%3DY.%26atitle%3DAtovaquone%2520enhances%2520doxorubicin%25E2%2580%2599s%2520efficacy%2520via%2520inhibiting%2520mitochondrial%2520respiration%2520and%2520STAT3%2520in%2520aggressive%2520thyroid%2520cancer%26jtitle%3DJ.%2520Bioenerg.%2520Biomembr.%26date%3D2018%26volume%3D50%26spage%3D263%26epage%3D270%26doi%3D10.1007%2Fs10863-018-9755-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref223"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref223'); return false;" data-citation="" class="refNumLink">223</a></strong><div class="NLM_citation" id="cit223"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizokami, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koshida, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namiki, M.</span></span> <span> </span><span class="NLM_article-title">Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo</span>. <i>Int. J. Urol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">587</span>â <span class="NLM_lpage">592</span>, <span class="refDoi">Â DOI: 10.1111/j.1442-2042.2006.01342.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1111%2Fj.1442-2042.2006.01342.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=16771730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD28XmslSitrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2006&pages=587-592&author=J.+Nagasawaauthor=A.+Mizokamiauthor=K.+Koshidaauthor=S.+Yoshidaauthor=K.+Naitoauthor=M.+Namiki&title=Novel+HER2+selective+tyrosine+kinase+inhibitor%2C+TAK-165%2C+inhibits+bladder%2C+kidney+and+androgen-independent+prostate+cancer+in+vitro+and+in+vivo&doi=10.1111%2Fj.1442-2042.2006.01342.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit223R"><div class="casContent"><span class="casTitleNuber">223</span><div class="casTitle"><span class="NLM_cas:atitle">Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo</span></div><div class="casAuthors">Nagasawa, Joji; Mizokami, Atsushi; Koshida, Kiyoshi; Yoshida, Sei; Naito, Kenichiro; Namiki, Mikio</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Urology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">587-592</span>CODEN:
                <span class="NLM_cas:coden">IJURF3</span>;
        ISSN:<span class="NLM_cas:issn">0919-8172</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Asia Pty Ltd.</span>)
        </div><div class="casAbstract">Purpose: TAK-165 is a new potent inhibitor of human epidermal growth factor receptor 2 (HER2) tyrosine kinase.  Several reports suggest HER2 expression in bladder cancer, renal cell carcinoma (RCC) and androgen-independent prostate cancer.  We therefore investigated the antitumor effect of TAK-165 on these urol. cancer cells.  Materials and methods: Western blot anal. was performed to confirm HER2 expression in cell lines.  To study in vitro efficacy, cells were treated with TAK-165 at various concns. for 72 h and then counted using a hemocytometer.  Then the IC50 value was calcd.  In the xenograft model, after the tumor reached 200-300 mm3 in vol., mice were orally administered TAK-165 10 mg/kg per day or 20 mg/kg per day or saline for 14 consecutive days (n = 6-8).  Results: HER2 expression was obsd. in HT1376, UMUC3, T24 (bladder), ACHN (kidney), DU145, LNCaP, LN-REC4 (prostate), although the expression level in these cells was weak compared with BT474 (a breast cancer cell line which expresses HER2 strongly).  IC50 was varied from 0.09 to greater than 25 Î¼mol/L in the bladder cancer cell line.  ACHN cells were less sensitive in vitro.  The prostate cancer cell lines studied were all sensitive (IC50 0.053-4.62 Î¼mol/L).  In the xenograft model, treatment with TAK-165 significantly inhibited growth of UMUC-3, ACHN, and LN-REC4.  The antitumor effect (T/C [%] = growth of TAK-165 treated tumor/av. growth of control tumor Ã 100) after 14 days treatment were 22.9%, 26.0%, and 26.5% in UMUC3, ACHN and LN-REC4, resp.  Conclusions: TAK-165 may be a hopeful new agent for bladder, kidney and androgen-independent prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU3g9-PiGTWbVg90H21EOLACvtfcHk0lie7myZyzH5jw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmslSitrY%253D&md5=5a946cdc377ea601f8813c33a47fdcaa</span></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.1111%2Fj.1442-2042.2006.01342.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1442-2042.2006.01342.x%26sid%3Dliteratum%253Aachs%26aulast%3DNagasawa%26aufirst%3DJ.%26aulast%3DMizokami%26aufirst%3DA.%26aulast%3DKoshida%26aufirst%3DK.%26aulast%3DYoshida%26aufirst%3DS.%26aulast%3DNaito%26aufirst%3DK.%26aulast%3DNamiki%26aufirst%3DM.%26atitle%3DNovel%2520HER2%2520selective%2520tyrosine%2520kinase%2520inhibitor%252C%2520TAK-165%252C%2520inhibits%2520bladder%252C%2520kidney%2520and%2520androgen-independent%2520prostate%2520cancer%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DInt.%2520J.%2520Urol.%26date%3D2006%26volume%3D13%26spage%3D587%26epage%3D592%26doi%3D10.1111%2Fj.1442-2042.2006.01342.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref224"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref224'); return false;" data-citation="" class="refNumLink">224</a></strong><div class="NLM_citation" id="cit224"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Si, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, S. Y.</span></span> <span> </span><span class="NLM_article-title">Rotenone induces apoptosis in human lung cancer cells by regulating autophagic flux</span>. <i>IUBMB Life</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">388</span>â <span class="NLM_lpage">393</span>, <span class="refDoi">Â DOI: 10.1002/iub.1493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1002%2Fiub.1493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27015848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC28XkvVymt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2016&pages=388-393&author=W.+S.+Huauthor=H.+Tianauthor=W.+M.+Yueauthor=L.+Liauthor=S.+H.+Liauthor=C.+Gaoauthor=L.+B.+Siauthor=L.+Qiauthor=M.+Luauthor=B.+Haoauthor=S.+Y.+Shan&title=Rotenone+induces+apoptosis+in+human+lung+cancer+cells+by+regulating+autophagic+flux&doi=10.1002%2Fiub.1493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit224R"><div class="casContent"><span class="casTitleNuber">224</span><div class="casTitle"><span class="NLM_cas:atitle">Rotenone induces apoptosis in human lung cancer cells by regulating autophagic flux</span></div><div class="casAuthors">Hu, Wensi; Tian, Hui; Yue, Weiming; Li, Lin; Li, Shuhai; Gao, Cun; Si, Libo; Qi, Lei; Lu, Ming; Hao, Bin; Shan, Shuyu</div><div class="citationInfo"><span class="NLM_cas:title">IUBMB Life</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">388-393</span>CODEN:
                <span class="NLM_cas:coden">IULIF8</span>;
        ISSN:<span class="NLM_cas:issn">1521-6543</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Reactive oxygen species (ROS) are at the center of many physiol. and pathol. processes.  ROS generated due to oxidative stress can potentiate both cancer initiation and progression.  Rotenone, which is an inhibitor of the mitochondrial electron transport chain complex I, results in the activation of NOX2 and release of ROS, and has been shown to display anticancer activity through the induction of apoptosis in various cancer cells.  The mechanistic link between rotenone-dependent activation of NOX2 and induction of apoptosis is still elusive.  In this study, we used the human lung cancer A549 cells to study the mol. mechanism(s) involved between rotenone-dependent activation of NOX2 and impairment of autophagic machinery.  We report that acute exposure to rotenone induced mild NOX2-dependent oxidative stress, which impaired the autophagic flux, resulting in cytosolic accumulation of LC3 and p62/STSQM1.  We further show that this induction occurs through the PI3K/Akt/mTORC1 signaling pathway.  We furthermore show that chronic exposure to rotenone lead to excessive NOX2-dependent ROS generation, increases autophagy, and decreases p62 level via increased-autophagic flux.  Taken together, this study is the first mechanistic elucidation of how rotenone can be used to potently target cancer cells without overhauling the entire cellular machinery.  Â© 2016 IUBMB Life, 2016.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3sri5rDep4bVg90H21EOLACvtfcHk0lgpYJJFgWvjNQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkvVymt7g%253D&md5=11a3d9d884c541458dece58cd882642b</span></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=10.1002%2Fiub.1493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fiub.1493%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DW.%2BS.%26aulast%3DTian%26aufirst%3DH.%26aulast%3DYue%26aufirst%3DW.%2BM.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DS.%2BH.%26aulast%3DGao%26aufirst%3DC.%26aulast%3DSi%26aufirst%3DL.%2BB.%26aulast%3DQi%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DM.%26aulast%3DHao%26aufirst%3DB.%26aulast%3DShan%26aufirst%3DS.%2BY.%26atitle%3DRotenone%2520induces%2520apoptosis%2520in%2520human%2520lung%2520cancer%2520cells%2520by%2520regulating%2520autophagic%2520flux%26jtitle%3DIUBMB%2520Life%26date%3D2016%26volume%3D68%26spage%3D388%26epage%3D393%26doi%3D10.1002%2Fiub.1493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref225"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref225'); return false;" data-citation="" class="refNumLink">225</a></strong><div class="NLM_citation" id="cit225"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragheb, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawler, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturgis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajwa, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melendez, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, J. P.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">8516</span>â <span class="NLM_lpage">8525</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M210432200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1074%2Fjbc.M210432200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=12496265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhsF2htrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=8516-8525&author=N.+Y.+Liauthor=K.+Raghebauthor=G.+Lawlerauthor=J.+Sturgisauthor=B.+Rajwaauthor=J.+A.+Melendezauthor=J.+P.+Robinson&title=Mitochondrial+complex+I+inhibitor+rotenone+induces+apoptosis+through+enhancing+mitochondrial+reactive+oxygen+species+production&doi=10.1074%2Fjbc.M210432200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit225R"><div class="casContent"><span class="casTitleNuber">225</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial Complex I Inhibitor Rotenone Induces Apoptosis through Enhancing Mitochondrial Reactive Oxygen Species Production</span></div><div class="casAuthors">Li, Nianyu; Ragheb, Kathy; Lawler, Gretchen; Sturgis, Jennie; Rajwa, Bartek; Melendez, J. Andres; Robinson, J. Paul</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">8516-8525</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Inhibition of mitochondrial respiratory chain complex I by rotenone had been found to induce cell death in a variety of cells.  However, the mechanism is still elusive.  Because reactive oxygen species (ROS) play an important role in apoptosis and inhibition of mitochondrial respiratory chain complex I by rotenone was thought to be able to elevate mitochondrial ROS prodn., we investigated the relationship between rotenone-induced apoptosis and mitochondrial reactive oxygen species.  Rotenone was able to induce mitochondrial complex I substrate-supported mitochondrial ROS prodn. both in isolated mitochondria from HL-60 cells as well as in cultured cells.  Rotenone-induced apoptosis was confirmed by DNA fragmentation, cytochrome c release, and caspase 3 activity.  A quant. correlation between rotenone-induced apoptosis and rotenone-induced mitochondrial ROS prodn. was identified.  Rotenone-induced apoptosis was inhibited by treatment with antioxidants (glutathione, N-acetylcysteine, and vitamin C).  The role of rotenone-induced mitochondrial ROS in apoptosis was also confirmed by the finding that HT1080 cells overexpressing magnesium superoxide dismutase were more resistant to rotenone-induced apoptosis than control cells.  These results suggest that rotenone is able to induce apoptosis via enhancing the amt. of mitochondrial reactive oxygen species prodn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQz9q2QbEOErVg90H21EOLACvtfcHk0lgpYJJFgWvjNQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhsF2htrg%253D&md5=3b5921aa876f55001b3c2e83cfead91e</span></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M210432200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M210432200%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DN.%2BY.%26aulast%3DRagheb%26aufirst%3DK.%26aulast%3DLawler%26aufirst%3DG.%26aulast%3DSturgis%26aufirst%3DJ.%26aulast%3DRajwa%26aufirst%3DB.%26aulast%3DMelendez%26aufirst%3DJ.%2BA.%26aulast%3DRobinson%26aufirst%3DJ.%2BP.%26atitle%3DMitochondrial%2520complex%2520I%2520inhibitor%2520rotenone%2520induces%2520apoptosis%2520through%2520enhancing%2520mitochondrial%2520reactive%2520oxygen%2520species%2520production%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D8516%26epage%3D8525%26doi%3D10.1074%2Fjbc.M210432200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref226"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref226'); return false;" data-citation="" class="refNumLink">226</a></strong><div class="NLM_citation" id="cit226"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Urra, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardenas, C.</span></span> <span> </span><span class="NLM_article-title">The mitochondrial complex(I) ty of cancer</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">118</span>, <span class="refDoi">Â DOI: 10.3389/fonc.2017.00118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.3389%2Ffonc.2017.00118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=28642839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BC1cjhtV2ltQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=118&author=F.+A.+Urraauthor=F.+Munozauthor=A.+Lovyauthor=C.+Cardenas&title=The+mitochondrial+complex%28I%29+ty+of+cancer&doi=10.3389%2Ffonc.2017.00118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit226R"><div class="casContent"><span class="casTitleNuber">226</span><div class="casTitle"><span class="NLM_cas:atitle">The Mitochondrial Complex(I)ty of Cancer</span></div><div class="casAuthors">Urra Felix A; Munoz Felipe; Cardenas Cesar; Urra Felix A; Munoz Felipe; Cardenas Cesar; Lovy Alenka; Cardenas Cesar; Cardenas Cesar</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">118</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Recent evidence highlights that the cancer cell energy requirements vary greatly from normal cells and that cancer cells exhibit different metabolic phenotypes with variable participation of both glycolysis and oxidative phosphorylation.  NADH-ubiquinone oxidoreductase (Complex I) is the largest complex of the mitochondrial electron transport chain and contributes about 40% of the proton motive force required for mitochondrial ATP synthesis.  In addition, Complex I plays an essential role in biosynthesis and redox control during proliferation, resistance to cell death, and metastasis of cancer cells.  Although knowledge about the structure and assembly of Complex I is increasing, information about the role of Complex I subunits in tumorigenesis is scarce and contradictory.  Several small molecule inhibitors of Complex I have been described as selective anticancer agents; however, pharmacologic and genetic interventions on Complex I have also shown pro-tumorigenic actions, involving different cellular signaling.  Here, we discuss the role of Complex I in tumorigenesis, focusing on the specific participation of Complex I subunits in proliferation and metastasis of cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS8CRa6PoWgXNy3lHz94U-GfW6udTcc2ebPXW51z6XNhrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjhtV2ltQ%253D%253D&md5=96b3d2e4ba3f12a9b399c30f34a95b57</span></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2017.00118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2017.00118%26sid%3Dliteratum%253Aachs%26aulast%3DUrra%26aufirst%3DF.%2BA.%26aulast%3DMunoz%26aufirst%3DF.%26aulast%3DLovy%26aufirst%3DA.%26aulast%3DCardenas%26aufirst%3DC.%26atitle%3DThe%2520mitochondrial%2520complex%2528I%2529%2520ty%2520of%2520cancer%26jtitle%3DFront.%2520Oncol.%26date%3D2017%26volume%3D7%26spage%3D118%26doi%3D10.3389%2Ffonc.2017.00118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref227"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref227'); return false;" data-citation="" class="refNumLink">227</a></strong><div class="NLM_citation" id="cit227"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hongo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kihara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kume, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niidome, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akaike, A.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase-3 beta activation mediates rotenone-induced cytotoxicity with the involvement of microtubule destabilization</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>426</i></span>,  <span class="NLM_fpage">94</span>â <span class="NLM_lpage">99</span>, <span class="refDoi">Â DOI: 10.1016/j.bbrc.2012.08.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.bbrc.2012.08.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=22922102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlSnsbjJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=426&publication_year=2012&pages=94-99&author=H.+Hongoauthor=T.+Kiharaauthor=T.+Kumeauthor=Y.+Izumiauthor=T.+Niidomeauthor=H.+Sugimotoauthor=A.+Akaike&title=Glycogen+synthase+kinase-3+beta+activation+mediates+rotenone-induced+cytotoxicity+with+the+involvement+of+microtubule+destabilization&doi=10.1016%2Fj.bbrc.2012.08.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit227R"><div class="casContent"><span class="casTitleNuber">227</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen synthase kinase-3Î² activation mediates rotenone-induced cytotoxicity with the involvement of microtubule destabilization</span></div><div class="casAuthors">Hongo, Haruyuki; Kihara, Takeshi; Kume, Toshiaki; Izumi, Yasuhiko; Niidome, Tetsuhiro; Sugimoto, Hachiro; Akaike, Akinori</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">426</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">94-99</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Rotenone, a mitochondrial complex I inhibitor, has been used to generate animal and cell culture models of Parkinson's disease.  Recent studies suggest that microtubule destabilization causes selective dopaminergic neuronal loss.  In this study, we investigated glycogen synthase kinase-3Î² (GSK3Î²) involvement in rotenone-induced microtubule destabilization.  Rotenone-induced cytotoxicity in SH-SY5Y cells was attenuated by the GSK3Î² inhibitor SB216763.  Tau, a microtubule-assocd. protein and substrate for GSK3Î², has been implicated in the pathogenesis of tauopathies such as Alzheimer's disease.  Rotenone induced an increase in phosphorylated tau, the effect of which was attenuated by concomitant treatment with SB216763.  Rotenone treatment also decreased tau expression in the microtubule fraction and increased tau expression in the cytosol fraction.  These effects were suppressed by SB216763, which suggests that rotenone reduces the capacity of tau to bind microtubules.  Rotenone treatment increased the amt. of free tubulin and reduced the amt. of polymd. tubulin, indicating that rotenone destabilizes microtubules.  Rotenone-induced microtubule destabilization was suppressed by SB216763 and taxol, a microtubule stabilizer.  Taxol prevented rotenone-induced cytotoxicity and morphol. changes.  Taken together, these results suggest that rotenone-induced cytotoxicity is mediated by microtubule destabilization via GSK3Î² activation, and that microtubule destabilization is caused by redn. in the binding capacity of tau to microtubules, which is a result of tau phosphorylation via GSK3Î² activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3UnP2g4mpk7Vg90H21EOLACvtfcHk0lgpYJJFgWvjNQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlSnsbjJ&md5=b9b767797823f8a3790753405e798f11</span></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2012.08.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2012.08.042%26sid%3Dliteratum%253Aachs%26aulast%3DHongo%26aufirst%3DH.%26aulast%3DKihara%26aufirst%3DT.%26aulast%3DKume%26aufirst%3DT.%26aulast%3DIzumi%26aufirst%3DY.%26aulast%3DNiidome%26aufirst%3DT.%26aulast%3DSugimoto%26aufirst%3DH.%26aulast%3DAkaike%26aufirst%3DA.%26atitle%3DGlycogen%2520synthase%2520kinase-3%2520beta%2520activation%2520mediates%2520rotenone-induced%2520cytotoxicity%2520with%2520the%2520involvement%2520of%2520microtubule%2520destabilization%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2012%26volume%3D426%26spage%3D94%26epage%3D99%26doi%3D10.1016%2Fj.bbrc.2012.08.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref228"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref228'); return false;" data-citation="" class="refNumLink">228</a></strong><div class="NLM_citation" id="cit228"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esser, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hossain, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Helm, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deisenhofer, J.</span></span> <span> </span><span class="NLM_article-title">Structure of antimycin A1, a specific electron transfer inhibitor of ubiquinol-cytochrome c oxidoreductase</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">4902</span>â <span class="NLM_lpage">4903</span>, <span class="refDoi">Â DOI: 10.1021/ja990190h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja990190h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADyaK1MXivFChtL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=1999&pages=4902-4903&author=H.+Kimauthor=L.+Esserauthor=M.+B.+Hossainauthor=D.+Xiaauthor=C.-A.+Yuauthor=J.+Rizoauthor=D.+van+der+Helmauthor=J.+Deisenhofer&title=Structure+of+antimycin+A1%2C+a+specific+electron+transfer+inhibitor+of+ubiquinol-cytochrome+c+oxidoreductase&doi=10.1021%2Fja990190h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit228R"><div class="casContent"><span class="casTitleNuber">228</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of Antimycin A1, a Specific Electron Transfer Inhibitor of Ubiquinol-Cytochrome c Oxidoreductase</span></div><div class="casAuthors">Kim, Hoeon; Esser, Lothar; Hossain, M. Bilayet; Xia, Di; Yu, Chang-An; Rizo, Josep; van der Helm, Dick; Deisenhofer, Johann</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">4902-4903</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The structure of antimycin a1 was detd. by X-ray crystallog. and two-dimensional NMR spectroscopy.  The crystal structure revealed two ring moieties, a planar 3-formylamino salicylic acid (FASA) and a puckered dilactone which are connected through an (N2-C9) amide bond bridge.  The carbonyl oxygen atom O3 of the benzamide group is the acceptor for an intramol. hydrogen bond, donated by the phenolic OH group of the 3-FASA ring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq00atr11s98rVg90H21EOLACvtfcHk0liuMjEaHoXg_Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXivFChtL4%253D&md5=68f6a8ca9686172007380f975c1cc78f</span></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=10.1021%2Fja990190h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja990190h%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.%26aulast%3DEsser%26aufirst%3DL.%26aulast%3DHossain%26aufirst%3DM.%2BB.%26aulast%3DXia%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DC.-A.%26aulast%3DRizo%26aufirst%3DJ.%26aulast%3Dvan%2Bder%2BHelm%26aufirst%3DD.%26aulast%3DDeisenhofer%26aufirst%3DJ.%26atitle%3DStructure%2520of%2520antimycin%2520A1%252C%2520a%2520specific%2520electron%2520transfer%2520inhibitor%2520of%2520ubiquinol-cytochrome%2520c%2520oxidoreductase%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1999%26volume%3D121%26spage%3D4902%26epage%3D4903%26doi%3D10.1021%2Fja990190h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref229"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref229'); return false;" data-citation="" class="refNumLink">229</a></strong><div class="NLM_citation" id="cit229"><span><span class="NLM_contrib-group"><span class="NLM_string-name">King, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radicchi-Mastroianni, M. A.</span></span> <span> </span><span class="NLM_article-title">Antimycin A-induced apoptosis of HL-60 cells</span>. <i>Cytometry</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">106</span>â <span class="NLM_lpage">112</span>, <span class="refDoi">Â DOI: 10.1002/cyto.10156</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1002%2Fcyto.10156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=12442310" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD38XptV2mt7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2002&pages=106-112&author=M.+A.+Kingauthor=M.+A.+Radicchi-Mastroianni&title=Antimycin+A-induced+apoptosis+of+HL-60+cells&doi=10.1002%2Fcyto.10156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit229R"><div class="casContent"><span class="casTitleNuber">229</span><div class="casTitle"><span class="NLM_cas:atitle">Antimycin A-induced apoptosis of HL-60 cells</span></div><div class="casAuthors">King, Malcolm A.; Radicchi-Mastroianni, Monica A.</div><div class="citationInfo"><span class="NLM_cas:title">Cytometry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">106-112</span>CODEN:
                <span class="NLM_cas:coden">CYTODQ</span>;
        ISSN:<span class="NLM_cas:issn">0196-4763</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Previous expts. in our lab. investigating apoptosis induced in HL-60 cells by camptothecin (CAM) have revealed that the sequence and rapidity of the apoptotic phenomena in an individual cell depend on the proliferative state of that cell when it encounters CAM.  The role of mitochondria in HL-60 apoptosis was explored using an inhibitor of oxidative phosphorylation, antimycin A (AMA).  Changes in cell light scatter, binding of annexin V-fluorescein isothiocyanate (FITC), uptake of propidium iodide (PI), and DNA content after membrane fixation/permeabilization were monitored by flow cytometry.  ZVAD-FMK was used to inhibit caspases.  Fluorescence microscopy was used to examine cell morphol.  Cells in the G1 phase of the cell cycle were the first to exhibit signs of apoptosis in response to 100 Î¼M AMA and some of these cells disintegrated without exposing to phosphatidylserine (PS).  Caspase inhibition prevented fragmentation of DNA, the nucleus, and the cell, but only delayed PS exposure and loss of plasma membrane integrity.  The highly active mitochondria of G1-phase HL-60 cells make them particularly sensitive to AMA.  PS exposure and plasma membrane damage are mediated by noncaspase mols. released from mitochondria.  We hypothesize that if mitochondria are subjected to a sufficiently severe insult, whether indirectly as a result of extensive CAM-induced DNA damage or directly by the effect of AMA on electron transport, the nature and quantities of the proapoptotic mols. released are such that apoptosis proceeds to the point of cell disintegration before the PS exposure pathway is complete.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqREW8m0QG2SrVg90H21EOLACvtfcHk0liuMjEaHoXg_Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XptV2mt7w%253D&md5=c5cbb4af3c006024b3122970088a459b</span></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=10.1002%2Fcyto.10156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcyto.10156%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DM.%2BA.%26aulast%3DRadicchi-Mastroianni%26aufirst%3DM.%2BA.%26atitle%3DAntimycin%2520A-induced%2520apoptosis%2520of%2520HL-60%2520cells%26jtitle%3DCytometry%26date%3D2002%26volume%3D49%26spage%3D106%26epage%3D112%26doi%3D10.1002%2Fcyto.10156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref230"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref230'); return false;" data-citation="" class="refNumLink">230</a></strong><div class="NLM_citation" id="cit230"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. Z.</span></span> <span> </span><span class="NLM_article-title">An ROS generator, antimycin A, inhibits the growth of HeLa cells via apoptosis</span>. <i>J. Cell. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">98</span>â <span class="NLM_lpage">109</span>, <span class="refDoi">Â DOI: 10.1002/jcb.21280</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1002%2Fjcb.21280" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=17372917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVegtLjE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2007&pages=98-109&author=W.+H.+Parkauthor=Y.+W.+Hanauthor=S.+H.+Kimauthor=S.+Z.+Kim&title=An+ROS+generator%2C+antimycin+A%2C+inhibits+the+growth+of+HeLa+cells+via+apoptosis&doi=10.1002%2Fjcb.21280"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit230R"><div class="casContent"><span class="casTitleNuber">230</span><div class="casTitle"><span class="NLM_cas:atitle">An ROS generator, antimycin A, inhibits the growth of HeLa cells via apoptosis</span></div><div class="casAuthors">Park, Woo Hyun; Han, Yong Whan; Kim, Suhn Hee; Kim, Sung Zoo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Biochemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">98-109</span>CODEN:
                <span class="NLM_cas:coden">JCEBD5</span>;
        ISSN:<span class="NLM_cas:issn">0730-2312</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Antimycin A (AMA), an inhibitor of electron transport in mitochondria, has been used as a reactive oxygen species (ROS) generator in biol. systems.  Here, we investigated the in vitro effect of AMA on apoptosis in HeLa cells.  AMA inhibited the growth of HeLa cells with an IC50 of about 50 Î¼M.  AMA efficiently induced apoptosis, as evidenced by flow cytometric detection of sub-G1 DNA content, annexin V binding assay, and DAPI staining.  This apoptotic process was accompanied by the loss of mitochondrial membrane potential (ÎÎ¨m), Bcl-2 down-regulation, Bax up-regulation, and PARP degrdn.  All caspase inhibitors used in this expt., esp. pan-caspase inhibitor (Z-VAD), could rescue some HeLa cells from AMA-induced cell death.  When we examd. the changes of the ROS, H2O2 or OÂ·-2, in AMA-treated cells, H2O2 and OÂ·-2 were markedly increased.  In addn., we detected the depletion of GSH content in AMA-treated cells.  Pan-caspase inhibitor showing the efficient anti-apoptotic effect significantly reduced GSH depletion by AMA.  Superoxide dismutase (SOD) and catalase did not reduce intracellular ROS, but these could strongly rescue the cells from apoptosis.  However, these anti-apoptotic effects were not accompanied by the recovery of GSH depletion.  Interestingly, catalase significantly decreased the CMF neg. (GSH depletion) and propidium iodide (PI) pos. cells, indicating that catalase strongly maintained the integrity of the cell membrane in CMF neg. cells.  Taken together, these results demonstrate that AMA potently generates ROS, induces the depletion of GSH content in HeLa cells, and strongly inhibits the growth of HeLa cells throughout apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQPQU-a9_fGbVg90H21EOLACvtfcHk0liuMjEaHoXg_Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVegtLjE&md5=33d19a3be05dc3ff34d3e74353a2e16f</span></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=10.1002%2Fjcb.21280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcb.21280%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DW.%2BH.%26aulast%3DHan%26aufirst%3DY.%2BW.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DS.%2BZ.%26atitle%3DAn%2520ROS%2520generator%252C%2520antimycin%2520A%252C%2520inhibits%2520the%2520growth%2520of%2520HeLa%2520cells%2520via%2520apoptosis%26jtitle%3DJ.%2520Cell.%2520Biochem.%26date%3D2007%26volume%3D102%26spage%3D98%26epage%3D109%26doi%3D10.1002%2Fjcb.21280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref231"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref231'); return false;" data-citation="" class="refNumLink">231</a></strong><div class="NLM_citation" id="cit231"><span><span class="NLM_contrib-group"><span class="NLM_string-name">King, M. A.</span></span> <span> </span><span class="NLM_article-title">Antimycin A-induced killing of HL-60 cells: Apoptosis initiated from within mitochondria does not necessarily proceed via caspase 9</span>. <i>Cytometry, Part A</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>63A</i></span>,  <span class="NLM_fpage">69</span>â <span class="NLM_lpage">76</span>, <span class="refDoi">Â DOI: 10.1002/cyto.a.20107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1002%2Fcyto.a.20107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD2MXisVSmsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63A&publication_year=2005&pages=69-76&author=M.+A.+King&title=Antimycin+A-induced+killing+of+HL-60+cells%3A+Apoptosis+initiated+from+within+mitochondria+does+not+necessarily+proceed+via+caspase+9&doi=10.1002%2Fcyto.a.20107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit231R"><div class="casContent"><span class="casTitleNuber">231</span><div class="casTitle"><span class="NLM_cas:atitle">Antimycin A-induced killing of HL-60 cells: Apoptosis initiated from within mitochondria does not necessarily proceed via caspase 9</span></div><div class="casAuthors">King, Malcolm Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Cytometry, Part A</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">63A</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">69-76</span>CODEN:
                <span class="NLM_cas:coden">CPAYAV</span>;
        ISSN:<span class="NLM_cas:issn">1552-4922</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Background: Antimycin A (AMA) inhibits mitochondrial electron transport, collapses the mitochondrial membrane potential, and causes the prodn. of reactive oxygen species.  Previous work by me and my colleagues has demonstrated that AMA causes an array of typical apoptotic phenomena in HL-60 cells.  The hypothesis that AMA causes HL-60 apoptosis by the intrinsic apoptotic pathway has now been tested.  Methods: Z-LEHD-FMK and Z-IETD-FMK were used as specific inhibitors of the initiator caspases 9 and 8, resp.  Caspase 3 activation, DNA fragmentation, and cellular disintegration were measured by flow cytometry.  Cytochrome c release, chromatin condensation, and nuclear fragmentation were measured by microscopy.  Results: AMA caused mitochondrial cytochrome c release and neither Z-LEHD-FMK nor Z-IETD-FMK inhibited that.  In the absence of caspase inhibition there was a very close correlation between cytochrome c release and caspase 3 activation.  Z-LEHD-FMK blocked caspase 3 activation but enhanced DNA fragmentation and failed to stop nuclear or cellular disintegration.  Z-IETD-FMK also blocked caspase 3 activation but, in contrast to Z-LEHD-FMK, delayed DNA fragmentation and disintegration of the nucleus and the cell.  Conclusions: The hypothesis to explain AMA-induced HL-60 apoptosis was clearly inadequate because: (a) caspase 9 inhibition did not prevent DNA fragmentation or cell death, (b) apoptosis proceeded in the absence of caspase-3 activation, (c) the main pathway leading to activation of the executioner caspases was by caspase-8 activation, but caspase 8 inhibition only delayed apoptosis, and (d) activation of caspases 8 and 9 may be necessary for caspase-3 activation.  Thus, in this cell model, apoptosis triggered from within the mitochondria does not necessarily proceed by caspase 9, and caspase 3 is not crit. to apoptosis.  The results provide further evidence that, when parts of the apoptotic network are blocked, a cell is able to complete the program of cell death by alternate pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxj9hM5fkJ_LVg90H21EOLACvtfcHk0liP6UqbUF4moA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXisVSmsbs%253D&md5=74fa7b8bc07197c363087ebfc5f055e8</span></div><a href="/servlet/linkout?suffix=cit231&amp;dbid=16384&amp;doi=10.1002%2Fcyto.a.20107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcyto.a.20107%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DM.%2BA.%26atitle%3DAntimycin%2520A-induced%2520killing%2520of%2520HL-60%2520cells%253A%2520Apoptosis%2520initiated%2520from%2520within%2520mitochondria%2520does%2520not%2520necessarily%2520proceed%2520via%2520caspase%25209%26jtitle%3DCytometry%252C%2520Part%2520A%26date%3D2005%26volume%3D63A%26spage%3D69%26epage%3D76%26doi%3D10.1002%2Fcyto.a.20107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref232"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref232'); return false;" data-citation="" class="refNumLink">232</a></strong><div class="NLM_citation" id="cit232"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W. J.</span></span> <span> </span><span class="NLM_article-title">Antimycin-type depsipeptides: discovery, biosynthesis, chemical synthesis, and bioactivities</span>. <i>Nat. Prod. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1146</span>â <span class="NLM_lpage">1165</span>, <span class="refDoi">Â DOI: 10.1039/C6NP00004E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1039%2FC6NP00004E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27307039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVSks7bI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2016&pages=1146-1165&author=J.+Liuauthor=X.+J.+Zhuauthor=S.+J.+Kimauthor=W.+J.+Zhang&title=Antimycin-type+depsipeptides%3A+discovery%2C+biosynthesis%2C+chemical+synthesis%2C+and+bioactivities&doi=10.1039%2FC6NP00004E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit232R"><div class="casContent"><span class="casTitleNuber">232</span><div class="casTitle"><span class="NLM_cas:atitle">Antimycin-type depsipeptides: discovery, biosynthesis, chemical synthesis, and bioactivities</span></div><div class="casAuthors">Liu, Joyce; Zhu, Xuejun; Kim, Seong Jong; Zhang, Wenjun</div><div class="citationInfo"><span class="NLM_cas:title">Natural Product Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1146-1165</span>CODEN:
                <span class="NLM_cas:coden">NPRRDF</span>;
        ISSN:<span class="NLM_cas:issn">0265-0568</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Up to 2016, antimycin-type depsipeptides are a family of natural products with great structural diversity and outstanding biol. activities.  These compds. have typically been isolated from actinomycetes and are generated from hybrid nonribosomal peptide synthetase (NRPS)-polyketide synthase (PKS) assembly lines.  We cover the literature on the 4 classes of antimycin-type depsipeptides, which differ by macrolactone ring size, and it discusses the discovery, biosynthesis, chem. synthesis, and biol. activities of this family of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpl9mGebKUjzbVg90H21EOLACvtfcHk0liP6UqbUF4moA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVSks7bI&md5=0666efbbed07896b750ab40d253218a3</span></div><a href="/servlet/linkout?suffix=cit232&amp;dbid=16384&amp;doi=10.1039%2FC6NP00004E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6NP00004E%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DX.%2BJ.%26aulast%3DKim%26aufirst%3DS.%2BJ.%26aulast%3DZhang%26aufirst%3DW.%2BJ.%26atitle%3DAntimycin-type%2520depsipeptides%253A%2520discovery%252C%2520biosynthesis%252C%2520chemical%2520synthesis%252C%2520and%2520bioactivities%26jtitle%3DNat.%2520Prod.%2520Rep.%26date%3D2016%26volume%3D33%26spage%3D1146%26epage%3D1165%26doi%3D10.1039%2FC6NP00004E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref233"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref233'); return false;" data-citation="" class="refNumLink">233</a></strong><div class="NLM_citation" id="cit233"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miyadera, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiomi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomoda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyoshi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osanai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omura, S.</span></span> <span> </span><span class="NLM_article-title">Atpenins, potent and specific inhibitors of mitochondrial complex II (succinate-ubiquinone oxidoreductase)</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">473</span>â <span class="NLM_lpage">477</span>, <span class="refDoi">Â DOI: 10.1073/pnas.0237315100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1073%2Fpnas.0237315100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=12515859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnvVKgsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=473-477&author=H.+Miyaderaauthor=K.+Shiomiauthor=H.+Uiauthor=Y.+Yamaguchiauthor=R.+Masumaauthor=H.+Tomodaauthor=H.+Miyoshiauthor=A.+Osanaiauthor=K.+Kitaauthor=S.+Omura&title=Atpenins%2C+potent+and+specific+inhibitors+of+mitochondrial+complex+II+%28succinate-ubiquinone+oxidoreductase%29&doi=10.1073%2Fpnas.0237315100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit233R"><div class="casContent"><span class="casTitleNuber">233</span><div class="casTitle"><span class="NLM_cas:atitle">Atpenins, potent and specific inhibitors of mitochondrial complex II (succinate-ubiquinone oxidoreductase)</span></div><div class="casAuthors">Miyadera, Hiroko; Shiomi, Kazuro; Ui, Hideaki; Yamaguchi, Yuichi; Masuma, Rokuro; Tomoda, Hiroshi; Miyoshi, Hideto; Osanai, Arihiro; Kita, Kiyoshi; Omura, Satoshi</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">473-477</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Enzymes in the mitochondrial respiratory chain are involved in various physiol. events in addn. to their essential role in the prodn. of ATP by oxidative phosphorylation.  The use of specific and potent inhibitors of complex I (NADH-ubiquinone reductase) and complex III (ubiquinol-cytochrome c reductase), such as rotenone and antimycin, resp., has allowed detn. of the role of these enzymes in physiol. processes.  However, unlike complexes I, III, and IV (cytochrome c oxidase), there are few potent and specific inhibitors of complex II (succinate-ubiquinone reductase) that have been described.  In this article, we report that atpenins potently and specifically inhibit the succinate-ubiquinone reductase activity of mitochondrial complex II.  Therefore, atpenins may be useful tools for clarifying the biochem. and structural properties of complex II, as well as for detg. its physiol. roles in mammalian tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMyyoczVOGm7Vg90H21EOLACvtfcHk0liP6UqbUF4moA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnvVKgsg%253D%253D&md5=cc26787f1d90d5aa0a38312794371888</span></div><a href="/servlet/linkout?suffix=cit233&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0237315100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0237315100%26sid%3Dliteratum%253Aachs%26aulast%3DMiyadera%26aufirst%3DH.%26aulast%3DShiomi%26aufirst%3DK.%26aulast%3DUi%26aufirst%3DH.%26aulast%3DYamaguchi%26aufirst%3DY.%26aulast%3DMasuma%26aufirst%3DR.%26aulast%3DTomoda%26aufirst%3DH.%26aulast%3DMiyoshi%26aufirst%3DH.%26aulast%3DOsanai%26aufirst%3DA.%26aulast%3DKita%26aufirst%3DK.%26aulast%3DOmura%26aufirst%3DS.%26atitle%3DAtpenins%252C%2520potent%2520and%2520specific%2520inhibitors%2520of%2520mitochondrial%2520complex%2520II%2520%2528succinate-ubiquinone%2520oxidoreductase%2529%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2003%26volume%3D100%26spage%3D473%26epage%3D477%26doi%3D10.1073%2Fpnas.0237315100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref234"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref234'); return false;" data-citation="" class="refNumLink">234</a></strong><div class="NLM_citation" id="cit234"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wojtovich, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brookes, P. S.</span></span> <span> </span><span class="NLM_article-title">The endogenous mitochondrial complex II inhibitor malonate regulates mitochondrial ATP-sensitive potassium channels: implications for ischemic preconditioning</span>. <i>Biochim. Biophys. Acta, Bioenerg.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>1777</i></span>,  <span class="NLM_fpage">882</span>â <span class="NLM_lpage">889</span>, <span class="refDoi">Â DOI: 10.1016/j.bbabio.2008.03.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.bbabio.2008.03.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsFCmur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1777&publication_year=2008&pages=882-889&author=A.+P.+Wojtovichauthor=P.+S.+Brookes&title=The+endogenous+mitochondrial+complex+II+inhibitor+malonate+regulates+mitochondrial+ATP-sensitive+potassium+channels%3A+implications+for+ischemic+preconditioning&doi=10.1016%2Fj.bbabio.2008.03.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit234R"><div class="casContent"><span class="casTitleNuber">234</span><div class="casTitle"><span class="NLM_cas:atitle">The endogenous mitochondrial complex II inhibitor malonate regulates mitochondrial ATP-sensitive potassium channels: Implications for ischemic preconditioning</span></div><div class="casAuthors">Wojtovich, Andrew P.; Brookes, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Bioenergetics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">1777</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">882-889</span>CODEN:
                <span class="NLM_cas:coden">BBBEB4</span>;
        ISSN:<span class="NLM_cas:issn">0005-2728</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Ischemic preconditioning (IPC) affords cardioprotection against ischemia-reperfusion (IR) injury, and while the mol. mechanisms of IPC are debated, the mitochondrial ATP-sensitive K+ channel (mKATP) has emerged as a candidate effector for several IPC signaling pathways.  The mol. identity of this channel is unknown, but significant pharmacol. overlap exists between mKATP and mitochondrial respiratory complex II (succinate dehydrogenase).  In this investigation, we utilized isolated cardiac mitochondria, Langendorff perfused hearts, and a variety of biochem. methods, to make the following observations: (i) the competitive complex II inhibitor malonate is formed in mitochondria under conditions resembling IPC. (ii) IPC leads to a reversible inhibition of complex II that has likely been missed in previous investigations due to the use of satg. concns. of succinate. (iii) malonate opens mKATP channels even when mitochondria are respiring on complex I-linked substrates, suggesting an effect of this inhibitor on the mKATP channel independent of complex II inhibition.  Together, these observations suggest that complex II inhibition by endogenously formed malonate may represent an important activation pathway for mKATP channels during IPC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjJ24A6ZgIbbVg90H21EOLACvtfcHk0ljVoJDDObn1pw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsFCmur4%253D&md5=475fde7556cb2289ef2cbb922452a1cb</span></div><a href="/servlet/linkout?suffix=cit234&amp;dbid=16384&amp;doi=10.1016%2Fj.bbabio.2008.03.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbabio.2008.03.025%26sid%3Dliteratum%253Aachs%26aulast%3DWojtovich%26aufirst%3DA.%2BP.%26aulast%3DBrookes%26aufirst%3DP.%2BS.%26atitle%3DThe%2520endogenous%2520mitochondrial%2520complex%2520II%2520inhibitor%2520malonate%2520regulates%2520mitochondrial%2520ATP-sensitive%2520potassium%2520channels%253A%2520implications%2520for%2520ischemic%2520preconditioning%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Bioenerg.%26date%3D2008%26volume%3D1777%26spage%3D882%26epage%3D889%26doi%3D10.1016%2Fj.bbabio.2008.03.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref235"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref235'); return false;" data-citation="" class="refNumLink">235</a></strong><div class="NLM_citation" id="cit235"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zuchora, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turski, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wielosz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urbanska, E. M.</span></span> <span> </span><span class="NLM_article-title">Protective effect of adenosine receptor agonists in a new model of epilepsy - seizures evoked by mitochondrial toxin, 3-nitropropionic acid, in mice</span>. <i>Neurosci. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>305</i></span>,  <span class="NLM_fpage">91</span>â <span class="NLM_lpage">94</span>, <span class="refDoi">Â DOI: 10.1016/S0304-3940(01)01816-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2FS0304-3940%2801%2901816-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=11376891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjsleitLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=305&publication_year=2001&pages=91-94&author=B.+Zuchoraauthor=W.+A.+Turskiauthor=M.+Wieloszauthor=E.+M.+Urbanska&title=Protective+effect+of+adenosine+receptor+agonists+in+a+new+model+of+epilepsy+-+seizures+evoked+by+mitochondrial+toxin%2C+3-nitropropionic+acid%2C+in+mice&doi=10.1016%2FS0304-3940%2801%2901816-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit235R"><div class="casContent"><span class="casTitleNuber">235</span><div class="casTitle"><span class="NLM_cas:atitle">Protective effect of adenosine receptor agonists in a new model of epilepsy - seizures evoked by mitochondrial toxin, 3-nitropropionic acid, in mice</span></div><div class="casAuthors">Zuchora, B.; Turski, W. A.; Wielosz, M.; Urbanska, E. M.</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience Letters</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">305</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">91-94</span>CODEN:
                <span class="NLM_cas:coden">NELED5</span>;
        ISSN:<span class="NLM_cas:issn">0304-3940</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">The role of adenosine receptor agonists in the convulsant activity of mitochondrial toxin, 3-nitropropionic acid (3-NPA), was studied in mice.  The occurrence of seizures evoked by peripheral application of 3-NPA was inhibited with the use of A1 adenosine receptor agonist, R-N6-phenylisopropyladenosine and A1/A2 agonist, 2-chloroadenosine.  Moreover, both drugs prevented 3-NPA-induced mortality.  Similarly, A1/A2 agonist, 5'-N-ethylcarboxamidoadenosine, protected against seizures evoked by the intracerebral administration of 3-NPA, and this effect was reversed by the co-application of adenosine receptor antagonist, 8-(p-sulfophenyl)theophylline.  Obtained results suggest that A1 adenosine receptor activation may modulate the chain of events leading to the development of 3-NPA-induced seizures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7T62v327Jl7Vg90H21EOLACvtfcHk0ljVoJDDObn1pw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjsleitLY%253D&md5=54bdaac9655d1c3ae4e56c0278d1735a</span></div><a href="/servlet/linkout?suffix=cit235&amp;dbid=16384&amp;doi=10.1016%2FS0304-3940%2801%2901816-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0304-3940%252801%252901816-X%26sid%3Dliteratum%253Aachs%26aulast%3DZuchora%26aufirst%3DB.%26aulast%3DTurski%26aufirst%3DW.%2BA.%26aulast%3DWielosz%26aufirst%3DM.%26aulast%3DUrbanska%26aufirst%3DE.%2BM.%26atitle%3DProtective%2520effect%2520of%2520adenosine%2520receptor%2520agonists%2520in%2520a%2520new%2520model%2520of%2520epilepsy%2520-%2520seizures%2520evoked%2520by%2520mitochondrial%2520toxin%252C%25203-nitropropionic%2520acid%252C%2520in%2520mice%26jtitle%3DNeurosci.%2520Lett.%26date%3D2001%26volume%3D305%26spage%3D91%26epage%3D94%26doi%3D10.1016%2FS0304-3940%2801%2901816-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref236"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref236'); return false;" data-citation="" class="refNumLink">236</a></strong><div class="NLM_citation" id="cit236"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuse, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanaoka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoji, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wada, H.</span></span> <span> </span><span class="NLM_article-title">â³Chemical preconditioningâ³ by 3-nitropropionate reduces ischemia-reperfusion injury in cardiac-arrested rat lungs</span>. <i>Transplantation</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">352</span>â <span class="NLM_lpage">359</span>, <span class="refDoi">Â DOI: 10.1097/00007890-200102150-00003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1097%2F00007890-200102150-00003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=11233893" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhvFegsLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2001&pages=352-359&author=T.+Hirataauthor=T.+Fukuseauthor=S.+Ishikawaauthor=S.+Hanaokaauthor=Q.+Chenauthor=T.+Shojiauthor=H.+Wada&title=%E2%80%B3Chemical+preconditioning%E2%80%B3+by+3-nitropropionate+reduces+ischemia-reperfusion+injury+in+cardiac-arrested+rat+lungs&doi=10.1097%2F00007890-200102150-00003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit236R"><div class="casContent"><span class="casTitleNuber">236</span><div class="casTitle"><span class="NLM_cas:atitle">"Chemical preconditioning" by 3-nitropropionate reduces ischemia-reperfusion injury in cardiac-arrested rat lungs</span></div><div class="casAuthors">Hirata, Toshiki; Fukuse, Tatsuo; Ishikawa, Shinya; Hanaoka, Shinji; Chen, Qing; Shoji, Tsuyoshi; Wada, Hiromi</div><div class="citationInfo"><span class="NLM_cas:title">Transplantation</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">352-359</span>CODEN:
                <span class="NLM_cas:coden">TRPLAU</span>;
        ISSN:<span class="NLM_cas:issn">0041-1337</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Chem. preconditioning was defined as the induction of resistance to massive disruption of energy metab. through prior chem. suppression of oxidative phosphorylation, by which phenomena similar to those resulting from increased ischemic tolerance as a result of ischemic preconditioning can be induced.  It could be induced by the inhibitor of either mitochondrial complex I or II.  We investigated whether or not chem. preconditioning by 3-nitro-propionate (an inhibitor of the mitochondrial complex II) can suppress ischemia-reperfusion injury in cardiac-arrested lungs, which will be the major problem in lung transplants donated from non-heart-beating cadavers.  In an isolated rat lung perfusion model with fresh rat blood as perfusate, administration of 3-nitropropionate (20 mg/kg) immediately before the induction of cardiac arrest attenuated pulmonary dysfunction during reperfusion after 1 h postmortem warm ischemia and 1 h cold preservation.  3-Nitropropionate administration reduced the mitochondrial respiratory functions (state 3 and state 4 respiration, and the respiratory control ratio) before cardiac arrest and kept them at a lower level of activity than when decreased by ischemia alone.  3-Nitropropionate administration also reduced the ATP levels immediately after drug administration.  However, 3-nitropropionate did not significantly reduce lipid peroxidn. in the lung tissue and mitochondria.  These results demonstrated that chem. preconditioning by 3-nitropropionate administration immediately before cardiac arrest suppressed succinate-related oxidn. during postmortem warm ischemia and reduced ischemia-reperfusion injury in cardiac arrested rat lungs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpq9NialLtw-bVg90H21EOLACvtfcHk0ljVoJDDObn1pw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhvFegsLs%253D&md5=0ba486cb25484b3e7ef1ceb331e7db5f</span></div><a href="/servlet/linkout?suffix=cit236&amp;dbid=16384&amp;doi=10.1097%2F00007890-200102150-00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00007890-200102150-00003%26sid%3Dliteratum%253Aachs%26aulast%3DHirata%26aufirst%3DT.%26aulast%3DFukuse%26aufirst%3DT.%26aulast%3DIshikawa%26aufirst%3DS.%26aulast%3DHanaoka%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DShoji%26aufirst%3DT.%26aulast%3DWada%26aufirst%3DH.%26atitle%3D%25E2%2580%25B3Chemical%2520preconditioning%25E2%2580%25B3%2520by%25203-nitropropionate%2520reduces%2520ischemia-reperfusion%2520injury%2520in%2520cardiac-arrested%2520rat%2520lungs%26jtitle%3DTransplantation%26date%3D2001%26volume%3D71%26spage%3D352%26epage%3D359%26doi%3D10.1097%2F00007890-200102150-00003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref237"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref237'); return false;" data-citation="" class="refNumLink">237</a></strong><div class="NLM_citation" id="cit237"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mogi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawakami, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Igarashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsushita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiomi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kita, K.</span></span> <span> </span><span class="NLM_article-title">Siccanin rediscovered as a species-selective succinate dehydrogenase inhibitor</span>. <i>J. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">383</span>â <span class="NLM_lpage">387</span>, <span class="refDoi">Â DOI: 10.1093/jb/mvp085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1093%2Fjb%2Fmvp085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=19505951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVKnurvI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2009&pages=383-387&author=T.+Mogiauthor=T.+Kawakamiauthor=H.+Araiauthor=Y.+Igarashiauthor=K.+Matsushitaauthor=M.+Moriauthor=K.+Shiomiauthor=S.+Omuraauthor=S.+Haradaauthor=K.+Kita&title=Siccanin+rediscovered+as+a+species-selective+succinate+dehydrogenase+inhibitor&doi=10.1093%2Fjb%2Fmvp085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit237R"><div class="casContent"><span class="casTitleNuber">237</span><div class="casTitle"><span class="NLM_cas:atitle">Siccanin Rediscovered as a Species-Selective Succinate Dehydrogenase Inhibitor</span></div><div class="casAuthors">Mogi, Tatsushi; Kawakami, Takuro; Arai, Hiroyuki; Igarashi, Yasuo; Matsushita, Kazunobu; Mori, Mihoko; Shiomi, Kazuro; Omura, Satoshi; Harada, Shigeharu; Kita, Kiyoshi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biochemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">383-387</span>CODEN:
                <span class="NLM_cas:coden">JOBIAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-924X</span>.
    
            (<span class="NLM_cas:orgname">Japanese Biochemical Society</span>)
        </div><div class="casAbstract">To identify antibiotics targeting to respiratory enzymes, we carried out matrix screening of a structurally varied natural compd. library with Pseudomonas aeruginosa membrane-bound respiratory enzymes.  We identified a succinate dehydrogenase inhibitor, siccanin (IC50, 0.9 Î¼M), which is a potent antibiotic against some pathogenic fungi like Trichophyton mentagrophytes and inhibits their mitochondrial succinate dehydrogenase.  We found that siccanin was effective against enzymes from P. aeruginosa, P. putida, rat and mouse mitochondria but ineffective or less effective against Escherichia coli, Corynebacterium glutamicum, and porcine mitochondria enzyme.  Action mode was mixed-type for quinone-dependent activity and noncompetitive for succinate-dependent activity, indicating the proximity of the inhibitor-binding site to the quinone-binding site.  Species-selective inhibition by siccanin is unique among succinate dehydrogenase inhibitors, and thus siccanin is a potential lead compd. for new chemotherapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf7I7O9g5QbrVg90H21EOLACvtfcHk0ljGdf24BRDQXA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVKnurvI&md5=33b85f3e82e840d0be6a76da1ee3941f</span></div><a href="/servlet/linkout?suffix=cit237&amp;dbid=16384&amp;doi=10.1093%2Fjb%2Fmvp085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjb%252Fmvp085%26sid%3Dliteratum%253Aachs%26aulast%3DMogi%26aufirst%3DT.%26aulast%3DKawakami%26aufirst%3DT.%26aulast%3DArai%26aufirst%3DH.%26aulast%3DIgarashi%26aufirst%3DY.%26aulast%3DMatsushita%26aufirst%3DK.%26aulast%3DMori%26aufirst%3DM.%26aulast%3DShiomi%26aufirst%3DK.%26aulast%3DOmura%26aufirst%3DS.%26aulast%3DHarada%26aufirst%3DS.%26aulast%3DKita%26aufirst%3DK.%26atitle%3DSiccanin%2520rediscovered%2520as%2520a%2520species-selective%2520succinate%2520dehydrogenase%2520inhibitor%26jtitle%3DJ.%2520Biochem.%26date%3D2009%26volume%3D146%26spage%3D383%26epage%3D387%26doi%3D10.1093%2Fjb%2Fmvp085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref238"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref238'); return false;" data-citation="" class="refNumLink">238</a></strong><div class="NLM_citation" id="cit238"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Portugal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaffel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spector, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nucci, M.</span></span> <span> </span><span class="NLM_article-title">Thiabendazole for the prophylaxis of strongyloidiasis in immunosuppressed patients with hematologic diseases: a randomized, double-blind placebo-controlled study</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">663</span>â <span class="NLM_lpage">664</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=12031927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD38XlsFCitL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2002&pages=663-664&author=R.+Portugalauthor=R.+Schaffelauthor=L.+Almeidaauthor=N.+Spectorauthor=M.+Nucci&title=Thiabendazole+for+the+prophylaxis+of+strongyloidiasis+in+immunosuppressed+patients+with+hematologic+diseases%3A+a+randomized%2C+double-blind+placebo-controlled+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit238R"><div class="casContent"><span class="casTitleNuber">238</span><div class="casTitle"><span class="NLM_cas:atitle">Thiabendazole for the prophylaxis of strongyloidiasis in immunosuppressed patients with hematologic diseases: A randomized, double-blind placebo-controlled study</span></div><div class="casAuthors">Portugal, Rodrigo; Schaffel, Rony; Almeida, Leandro; Spector, Nelson; Nucci, Marcio</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">663-664</span>CODEN:
                <span class="NLM_cas:coden">HAEMAX</span>;
        ISSN:<span class="NLM_cas:issn">0390-6078</span>.
    
            (<span class="NLM_cas:orgname">Ferrata Storti Foundation</span>)
        </div><div class="casAbstract">The aim of this study was to evaluate the efficacy of thiabendazole for prophylaxis of strongyloidiasis in patients with hematol. diseases, we performed a randomized, placebo-controlled trial.  The incidence of strongyloidiasis was similar in both groups (p=0.36), but the compliance was better in the placebo group (p=0.04).  This study does not support the use of thiabendazole prophylaxis in patients with hematol. diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjXq-N7JlAP7Vg90H21EOLACvtfcHk0ljGdf24BRDQXA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlsFCitL8%253D&md5=9d3f4378ec1b507f809ecac130c07239</span></div><a href="/servlet/linkout?suffix=cit238&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPortugal%26aufirst%3DR.%26aulast%3DSchaffel%26aufirst%3DR.%26aulast%3DAlmeida%26aufirst%3DL.%26aulast%3DSpector%26aufirst%3DN.%26aulast%3DNucci%26aufirst%3DM.%26atitle%3DThiabendazole%2520for%2520the%2520prophylaxis%2520of%2520strongyloidiasis%2520in%2520immunosuppressed%2520patients%2520with%2520hematologic%2520diseases%253A%2520a%2520randomized%252C%2520double-blind%2520placebo-controlled%2520study%26jtitle%3DHaematologica%26date%3D2002%26volume%3D87%26spage%3D663%26epage%3D664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref239"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref239'); return false;" data-citation="" class="refNumLink">239</a></strong><div class="NLM_citation" id="cit239"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blatt, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bednarski, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boitano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yung, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opipari, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glick, G. D.</span></span> <span> </span><span class="NLM_article-title">Benzodiazepine-induced superoxide signals B cell apoptosis: mechanistic insight and potential therapeutic utility</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">1123</span>â <span class="NLM_lpage">1132</span>, <span class="refDoi">Â DOI: 10.1172/JCI0216029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1172%2FJCI0216029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=12393848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD38XotFGlu74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2002&pages=1123-1132&author=N.+B.+Blattauthor=J.+J.+Bednarskiauthor=R.+E.+Warnerauthor=F.+Leonettiauthor=K.+M.+Johnsonauthor=A.+Boitanoauthor=R.+Yungauthor=B.+C.+Richardsonauthor=K.+J.+Johnsonauthor=J.+A.+Ellmanauthor=A.+W.+Opipariauthor=G.+D.+Glick&title=Benzodiazepine-induced+superoxide+signals+B+cell+apoptosis%3A+mechanistic+insight+and+potential+therapeutic+utility&doi=10.1172%2FJCI0216029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit239R"><div class="casContent"><span class="casTitleNuber">239</span><div class="casTitle"><span class="NLM_cas:atitle">Benzodiazepine-induced superoxide signals B cell apoptosis: mechanistic insight and potential therapeutic utility</span></div><div class="casAuthors">Blatt, Neal B.; Bednarski, Jeffrey J.; Warner, Roscoe E.; Leonetti, Francesco; Johnson, Kathryn M.; Boitano, Anthony; Yung, Raymond; Richardson, Bruce C.; Johnson, Kent J.; Ellman, Jonathan A.; Opipari, Anthony W., Jr.; Glick, Gary D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1123-1132</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">The properties of a proapoptotic 1,4-benzodiazepine, Bz-423, identified through combinatorial chem. and phenotype screening are described.  Bz-423 rapidly generated superoxide (O2-) in transformed Ramos B cells.  This O2- response originated from mitochondria prior to mitochondrial transmembrane gradient collapse and opening of the permeability transition pore.  Bz-423-induced O2- functioned as an upstream signal that initiated an apoptotic program characterized by cytochrome c release, mitochondrial depolarization, and caspase activation.  Pretreatment of cells with agents that either block the formation of Bz-423-induced O2- or scavenge free radicals attenuated the death cascade, which demonstrated that cell killing by Bz-423 depends on O2-.  Parallels between Ramos cells and germinal center B cells prompted expts. to det. whether Bz-423 had therapeutic activity in vivo.  This possibility was tested using the (NZB Ã NZW)F1 murine model of lupus, in which the pathol. enhanced survival and expansion of germinal center B cells mediate disease.  Administration of Bz-423 for 12 wk specifically controlled germinal center hyperplasia and reduced the histol. evidence of glomerulonephritis.  Collectively, these studies define a new structure-function relationship for benzodiazepines and point to a new target and mechanism that could be of value for developing improved drugs to manage systemic lupus erythematosus and related disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqflLiDdaZ-WrVg90H21EOLACvtfcHk0ljGdf24BRDQXA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XotFGlu74%253D&md5=09bbb0467077f3912ecc909b4e92ed15</span></div><a href="/servlet/linkout?suffix=cit239&amp;dbid=16384&amp;doi=10.1172%2FJCI0216029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI0216029%26sid%3Dliteratum%253Aachs%26aulast%3DBlatt%26aufirst%3DN.%2BB.%26aulast%3DBednarski%26aufirst%3DJ.%2BJ.%26aulast%3DWarner%26aufirst%3DR.%2BE.%26aulast%3DLeonetti%26aufirst%3DF.%26aulast%3DJohnson%26aufirst%3DK.%2BM.%26aulast%3DBoitano%26aufirst%3DA.%26aulast%3DYung%26aufirst%3DR.%26aulast%3DRichardson%26aufirst%3DB.%2BC.%26aulast%3DJohnson%26aufirst%3DK.%2BJ.%26aulast%3DEllman%26aufirst%3DJ.%2BA.%26aulast%3DOpipari%26aufirst%3DA.%2BW.%26aulast%3DGlick%26aufirst%3DG.%2BD.%26atitle%3DBenzodiazepine-induced%2520superoxide%2520signals%2520B%2520cell%2520apoptosis%253A%2520mechanistic%2520insight%2520and%2520potential%2520therapeutic%2520utility%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2002%26volume%3D110%26spage%3D1123%26epage%3D1132%26doi%3D10.1172%2FJCI0216029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref240"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref240'); return false;" data-citation="" class="refNumLink">240</a></strong><div class="NLM_citation" id="cit240"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhagavathula, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nerusu, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanosh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aslam, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundberg, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opipari, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glick, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varani, J.</span></span> <span> </span><span class="NLM_article-title">7-Chloro-5-(4-hydroxyphenyl)-1-methyl-3-(naphthalen-2-ylmethyl)-4,5-dihydro-1H-benzo[b][1,4]diazepin-2(3H)-one(Bz-423), a benzodiazepine, suppresses keratinocyte proliferation and has antipsoriatic activity in the human skin-severe, combined Immunodeficient mouse transplant model</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>324</i></span>,  <span class="NLM_fpage">938</span>â <span class="NLM_lpage">947</span>, <span class="refDoi">Â DOI: 10.1124/jpet.107.130955</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1124%2Fjpet.107.130955" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=18055879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD1cXivVajsrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=324&publication_year=2008&pages=938-947&author=N.+Bhagavathulaauthor=K.+C.+Nerusuauthor=A.+Hanoshauthor=M.+N.+Aslamauthor=T.+B.+Sundbergauthor=A.+W.+Opipariauthor=K.+Johnsonauthor=S.+Kangauthor=G.+D.+Glickauthor=J.+Varani&title=7-Chloro-5-%284-hydroxyphenyl%29-1-methyl-3-%28naphthalen-2-ylmethyl%29-4%2C5-dihydro-1H-benzo%5Bb%5D%5B1%2C4%5Ddiazepin-2%283H%29-one%28Bz-423%29%2C+a+benzodiazepine%2C+suppresses+keratinocyte+proliferation+and+has+antipsoriatic+activity+in+the+human+skin-severe%2C+combined+Immunodeficient+mouse+transplant+model&doi=10.1124%2Fjpet.107.130955"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit240R"><div class="casContent"><span class="casTitleNuber">240</span><div class="casTitle"><span class="NLM_cas:atitle">7-Chloro-5-(4-hydroxyphenyl)-1-methyl-3-(naphthalen-2-ylmethyl)-4,5-dihydro-1H-benzo[b][1,4]diazepin-2(3H)-one (Bz-423), a benzodiazepine, suppresses keratinocyte proliferation and has antipsoriatic activity in the human skin-severe, combined immunodeficient mouse transplant model</span></div><div class="casAuthors">Bhagavathula, Narasimharao; Nerusu, Kamalakar C.; Hanosh, Andrew; Aslam, Muhammad N.; Sundberg, Thomas B.; Opipari, Anthony W., Jr.; Johnson, Kent; Kang, Sewon; Glick, Gary D.; Varani, James</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">324</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">938-947</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">7-Chloro-5-(4-hydroxyphenyl)-1-methyl-3-(naphthalen-2-ylmethyl)-4,5-dihydro-1H-benzo[b][1,4]diazepin-2(3H)-one (Bz-423) is a benzodiazepine that has cytotoxic and cytostatic activity against a variety of cells in vivo and in vitro.  In the present study, we demonstrate that Bz-423 (formulated for topical delivery) reduces epidermal hyperplasia in human psoriatic skin after transplantation to severe, combined immunodeficient (scid) mice.  Bz-423 also suppresses the hyperplasia that develops in nonpsoriatic human skin as a consequence of transplantation to scid mice.  Proliferation of human epidermal keratinocytes in monolayer culture was suppressed by Bz-423 at concns. of 0.5 to 2.0 Î¼M (noncytotoxic concns.).  Keratinocyte growth inhibition was accompanied by increased oxidant generation in Bz-423-treated cells, and treatment with vitamin E along with Bz-423 reversed the growth inhibition.  Growth inhibition was accompanied by a redistribution of Î²-catenin from a cytoplasmic pool to the cell membrane and by reduced levels of c-myc and cyclin D1 (two mols. assocd. with Wnt pathway signaling).  Several analogs of Bz-423 were examd. for antiproliferative activity against human epidermal keratinocytes and human dermal fibroblasts in monolayer culture.  Each of the analogs tested suppressed growth of both cell types, but in all cases, keratinocytes were more sensitive than fibroblasts.  Two of the compds. were found to suppress epidermal hyperplasia induced with all-trans retinoic acid in organ cultures of human skin.  Taken together, these data show that Bz-423 and certain analogs produce biol. responses in skin cells in vitro and in vivo that are consistent with therapeutic goals for treating psoriasis or epidermal hyperplasia resulting from other causes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFfLW_vTc5CLVg90H21EOLACvtfcHk0ljKPPyEUMcgwQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXivVajsrc%253D&md5=d00ef858340d77f4dfb20b70073f0324</span></div><a href="/servlet/linkout?suffix=cit240&amp;dbid=16384&amp;doi=10.1124%2Fjpet.107.130955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.107.130955%26sid%3Dliteratum%253Aachs%26aulast%3DBhagavathula%26aufirst%3DN.%26aulast%3DNerusu%26aufirst%3DK.%2BC.%26aulast%3DHanosh%26aufirst%3DA.%26aulast%3DAslam%26aufirst%3DM.%2BN.%26aulast%3DSundberg%26aufirst%3DT.%2BB.%26aulast%3DOpipari%26aufirst%3DA.%2BW.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DKang%26aufirst%3DS.%26aulast%3DGlick%26aufirst%3DG.%2BD.%26aulast%3DVarani%26aufirst%3DJ.%26atitle%3D7-Chloro-5-%25284-hydroxyphenyl%2529-1-methyl-3-%2528naphthalen-2-ylmethyl%2529-4%252C5-dihydro-1H-benzo%255Bb%255D%255B1%252C4%255Ddiazepin-2%25283H%2529-one%2528Bz-423%2529%252C%2520a%2520benzodiazepine%252C%2520suppresses%2520keratinocyte%2520proliferation%2520and%2520has%2520antipsoriatic%2520activity%2520in%2520the%2520human%2520skin-severe%252C%2520combined%2520Immunodeficient%2520mouse%2520transplant%2520model%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2008%26volume%3D324%26spage%3D938%26epage%3D947%26doi%3D10.1124%2Fjpet.107.130955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref241"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref241'); return false;" data-citation="" class="refNumLink">241</a></strong><div class="NLM_citation" id="cit241"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boitano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swenson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opipari, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glick, G. D.</span></span> <span> </span><span class="NLM_article-title">Identification and validation of the mitochondrial F1F0-ATPase as the molecular target of the immunomodulatory benzodiazepine Bz-423</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">485</span>â <span class="NLM_lpage">496</span>, <span class="refDoi">Â DOI: 10.1016/j.chembiol.2005.02.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.chembiol.2005.02.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=15850986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjsFKitbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2005&pages=485-496&author=K.+M.+Johnsonauthor=X.+N.+Chenauthor=A.+Boitanoauthor=L.+Swensonauthor=A.+W.+Opipariauthor=G.+D.+Glick&title=Identification+and+validation+of+the+mitochondrial+F1F0-ATPase+as+the+molecular+target+of+the+immunomodulatory+benzodiazepine+Bz-423&doi=10.1016%2Fj.chembiol.2005.02.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit241R"><div class="casContent"><span class="casTitleNuber">241</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Validation of the Mitochondrial F1F0-ATPase as the Molecular Target of the Immunomodulatory Benzodiazepine Bz-423</span></div><div class="casAuthors">Johnson, Kathryn M.; Chen, Xueni; Boitano, Anthony; Swenson, Lara; Opipari, Anthony W.; Glick, Gary D.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">485-496</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: Bz-423 is a 1,4-benzodiazepine that suppresses disease in lupus-prone mice by selectively killing pathogenic lymphocytes, and it is less toxic compared to current lupus drugs.  Cells exposed to Bz-423 rapidly generate O2- within mitochondria, and this reactive oxygen species is the signal initiating apoptosis.  Phage display screening revealed that Bz-423 binds to the oligomycin sensitivity conferring protein (OSCP) component of the mitochondrial F1F0-ATPase.  Bz-423 inhibited the F1F0-ATPase in vitro, and reconstitution expts. demonstrated that inhibition was mediated by the OSCP.  This target was further validated by generating cells with reduced OSCP expression using RNA interference and studying the sensitivity of these cells to Bz-423.  Our findings help explain the efficacy and selectivity of Bz-423 for autoimmune lymphocytes and highlight the OSCP as a target to guide the development of novel lupus therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_3Wuow7vU27Vg90H21EOLACvtfcHk0ljKPPyEUMcgwQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjsFKitbs%253D&md5=76b57708848048569572a98f50a9a16c</span></div><a href="/servlet/linkout?suffix=cit241&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2005.02.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2005.02.012%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DK.%2BM.%26aulast%3DChen%26aufirst%3DX.%2BN.%26aulast%3DBoitano%26aufirst%3DA.%26aulast%3DSwenson%26aufirst%3DL.%26aulast%3DOpipari%26aufirst%3DA.%2BW.%26aulast%3DGlick%26aufirst%3DG.%2BD.%26atitle%3DIdentification%2520and%2520validation%2520of%2520the%2520mitochondrial%2520F1F0-ATPase%2520as%2520the%2520molecular%2520target%2520of%2520the%2520immunomodulatory%2520benzodiazepine%2520Bz-423%26jtitle%3DChem.%2520Biol.%26date%3D2005%26volume%3D12%26spage%3D485%26epage%3D496%26doi%3D10.1016%2Fj.chembiol.2005.02.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref242"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref242'); return false;" data-citation="" class="refNumLink">242</a></strong><div class="NLM_citation" id="cit242"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boitano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glick, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opipari, A. W.</span></span> <span> </span><span class="NLM_article-title">The proapoptotic benzodiazepine Bz-423 affects the growth and survival of malignant B cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">6870</span>â <span class="NLM_lpage">6876</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=14583485" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD3sXosVGns70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=6870-6876&author=A.+Boitanoauthor=J.+A.+Ellmanauthor=G.+D.+Glickauthor=A.+W.+Opipari&title=The+proapoptotic+benzodiazepine+Bz-423+affects+the+growth+and+survival+of+malignant+B+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit242R"><div class="casContent"><span class="casTitleNuber">242</span><div class="casTitle"><span class="NLM_cas:atitle">The proapoptotic benzodiazepine Bz-423 affects the growth and survival of malignant B cells</span></div><div class="casAuthors">Boitano, Anthony; Ellman, Jonathan A.; Glick, Gary D.; Opipari, Anthony W., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6870-6876</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Bz-423 is a novel proapoptotic 1,4-benzodiazepine that induces cell death via a superoxide signal.  Previous work has shown that Bz-423 ameliorates disease in animal models of systemic lupus erythematosus that also have features of lymphoproliferative disease.  Here we describe the effects of Bz-423 against a group of malignant B-cell lines derived from Burkitt's lymphoma.  These expts. demonstrate that Bz-423 has cytotoxic activity against all B-cell lines tested, regardless of EBV status or Bcl-2 and Bcl-xL expression levels.  In addn. to its cytotoxic properties, we found that Bz-423 is also a potent antiproliferative agent that induces a G1-phase arrest independent of p53.  Mechanistically, both the cytotoxicity and growth arrest are mediated by increased reactive oxygen species levels and appear independent of binding to the peripheral benzodiazepine receptor.  This work further defines the biol. activities of Bz-423 that are consistent with those of other compds. in clin. development for antineoplastic therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOW2im-U0TarVg90H21EOLACvtfcHk0ljKPPyEUMcgwQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXosVGns70%253D&md5=25b8ae53ee269285074aa7011b80f876</span></div><a href="/servlet/linkout?suffix=cit242&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoitano%26aufirst%3DA.%26aulast%3DEllman%26aufirst%3DJ.%2BA.%26aulast%3DGlick%26aufirst%3DG.%2BD.%26aulast%3DOpipari%26aufirst%3DA.%2BW.%26atitle%3DThe%2520proapoptotic%2520benzodiazepine%2520Bz-423%2520affects%2520the%2520growth%2520and%2520survival%2520of%2520malignant%2520B%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D6870%26epage%3D6876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref243"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref243'); return false;" data-citation="" class="refNumLink">243</a></strong><div class="NLM_citation" id="cit243"><span><span class="NLM_contrib-group"><span class="NLM_string-name">vanRaaij, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrahams, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, A. G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. E.</span></span> <span> </span><span class="NLM_article-title">The structure of bovine F-1-ATPase complexed with the antibiotic inhibitor aurovertin B</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">6913</span>â <span class="NLM_lpage">6917</span>, <span class="refDoi">Â DOI: 10.1073/pnas.93.14.6913</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1073%2Fpnas.93.14.6913" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=8692918" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1996&pages=6913-6917&author=M.+J.+vanRaaijauthor=J.+P.+Abrahamsauthor=A.+G.+W.+Leslieauthor=J.+E.+Walker&title=The+structure+of+bovine+F-1-ATPase+complexed+with+the+antibiotic+inhibitor+aurovertin+B&doi=10.1073%2Fpnas.93.14.6913"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit243&amp;dbid=16384&amp;doi=10.1073%2Fpnas.93.14.6913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.93.14.6913%26sid%3Dliteratum%253Aachs%26aulast%3DvanRaaij%26aufirst%3DM.%2BJ.%26aulast%3DAbrahams%26aufirst%3DJ.%2BP.%26aulast%3DLeslie%26aufirst%3DA.%2BG.%2BW.%26aulast%3DWalker%26aufirst%3DJ.%2BE.%26atitle%3DThe%2520structure%2520of%2520bovine%2520F-1-ATPase%2520complexed%2520with%2520the%2520antibiotic%2520inhibitor%2520aurovertin%2520B%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1996%26volume%3D93%26spage%3D6913%26epage%3D6917%26doi%3D10.1073%2Fpnas.93.14.6913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref244"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref244'); return false;" data-citation="" class="refNumLink">244</a></strong><div class="NLM_citation" id="cit244"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ebel, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lardy, H. A.</span></span> <span> </span><span class="NLM_article-title">Influence of aurovertin on mitochondrial atpase activity</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1975</span>,  <span class="NLM_volume"><i>250</i></span>,  <span class="NLM_fpage">4992</span>â <span class="NLM_lpage">4995</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=125277" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADyaE2MXkvFaqurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=250&publication_year=1975&pages=4992-4995&author=R.+E.+Ebelauthor=H.+A.+Lardy&title=Influence+of+aurovertin+on+mitochondrial+atpase+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit244R"><div class="casContent"><span class="casTitleNuber">244</span><div class="casTitle"><span class="NLM_cas:atitle">Influence of aurovertin on mitochondrial ATPase activity</span></div><div class="casAuthors">Ebel, Richard E.; Lardy, Henry A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1975</span>),
    <span class="NLM_cas:volume">250</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4992-5</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">The kinetic effects of the antibiotic aurovertin on the ATPase and ITPase activity of isolated rat liver mitochondrial ATPase were studied.  Unusual patterns of inhibition, decreasing slope, and increasing y-intercept values of double reciprocal plots, were obsd. with Mg-ATP as the substrate under various conditions.  Under specified conditions, aurovertin stimulated hydrolysis of Mg-ATP.  The inhibition of Mg-ITP hydrolysis was uncompetitive.  Aurovertin eliminated the HCO3- stimulation of Mg-ATP hydrolysis.  The implications of these findings for the mechanism of mitochondrial ATPase are briefly discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtrLH7bA6997Vg90H21EOLACvtfcHk0liS4eqRbaa7ww"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2MXkvFaqurw%253D&md5=46b0c116357cfc8d5b118b5b208df650</span></div><a href="/servlet/linkout?suffix=cit244&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEbel%26aufirst%3DR.%2BE.%26aulast%3DLardy%26aufirst%3DH.%2BA.%26atitle%3DInfluence%2520of%2520aurovertin%2520on%2520mitochondrial%2520atpase%2520activity%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1975%26volume%3D250%26spage%3D4992%26epage%3D4995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref245"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref245'); return false;" data-citation="" class="refNumLink">245</a></strong><div class="NLM_citation" id="cit245"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, M. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span> <span> </span><span class="NLM_article-title">Inhibiting neddylation modification alters mitochondrial morphology and reprograms energy metabolism in cancer cells</span>. <i>JCI Insight</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">e121582</span>, <span class="refDoi">Â DOI: 10.1172/jci.insight.121582</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1172%2Fjci.insight.121582" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=30668548" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2019&pages=e121582&author=Q.+Y.+Zhouauthor=H.+Liauthor=Y.+Y.+Liauthor=M.+J.+Tanauthor=S.+H.+Fanauthor=C.+Caoauthor=F.+L.+Mengauthor=L.+Zhuauthor=L.+L.+Zhaoauthor=M.+X.+Guanauthor=H.+C.+Jinauthor=Y.+Sun&title=Inhibiting+neddylation+modification+alters+mitochondrial+morphology+and+reprograms+energy+metabolism+in+cancer+cells&doi=10.1172%2Fjci.insight.121582"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit245&amp;dbid=16384&amp;doi=10.1172%2Fjci.insight.121582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252Fjci.insight.121582%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DQ.%2BY.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DY.%2BY.%26aulast%3DTan%26aufirst%3DM.%2BJ.%26aulast%3DFan%26aufirst%3DS.%2BH.%26aulast%3DCao%26aufirst%3DC.%26aulast%3DMeng%26aufirst%3DF.%2BL.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DL.%2BL.%26aulast%3DGuan%26aufirst%3DM.%2BX.%26aulast%3DJin%26aufirst%3DH.%2BC.%26aulast%3DSun%26aufirst%3DY.%26atitle%3DInhibiting%2520neddylation%2520modification%2520alters%2520mitochondrial%2520morphology%2520and%2520reprograms%2520energy%2520metabolism%2520in%2520cancer%2520cells%26jtitle%3DJCI%2520Insight%26date%3D2019%26volume%3D4%26spage%3De121582%26doi%3D10.1172%2Fjci.insight.121582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref246"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref246'); return false;" data-citation="" class="refNumLink">246</a></strong><div class="NLM_citation" id="cit246"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Lorenzo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Guzzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosenberg, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMahon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, B.</span></span> <span> </span><span class="NLM_article-title">Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">18226</span>â <span class="NLM_lpage">18231</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1317577110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1073%2Fpnas.1317577110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=24145418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVSmurbF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=18226-18231&author=P.+Yuanauthor=K.+Itoauthor=R.+Perez-Lorenzoauthor=C.+Del+Guzzoauthor=J.+H.+Leeauthor=C.+H.+Shenauthor=M.+W.+Bosenbergauthor=M.+McMahonauthor=L.+C.+Cantleyauthor=B.+Zheng&title=Phenformin+enhances+the+therapeutic+benefit+of+BRAF%28V600E%29+inhibition+in+melanoma&doi=10.1073%2Fpnas.1317577110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit246R"><div class="casContent"><span class="casTitleNuber">246</span><div class="casTitle"><span class="NLM_cas:atitle">Phenformin enhances the therapeutic benefit of BRAFV600E inhibition in melanoma</span></div><div class="casAuthors">Yuan, Ping; Ito, Koichi; Perez-Lorenzo, Rolando; Del Guzzo, Christina; Lee, Jung Hyun; Shen, Che-Hung; Bosenberg, Marcus W.; McMahon, Martin; Cantley, Lewis C.; Zheng, Bin</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">18226-18231,S18226/1-S18226/6</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Biguanides, such as the diabetes therapeutics metformin and phenformin, have demonstrated antitumor activity both in vitro and in vivo.  The energy-sensing AMP-activated protein kinase (AMPK) is known to be a major cellular target of biguanides.  Based on our discovery of cross-talk between the AMPK and v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) signaling pathways, we investigated the antitumor effects of combining phenformin with a BRAF inhibitor PLX4720 on the proliferation of BRAF-mutated melanoma cells in vitro and on BRAF-driven tumor growth in vivo.  Cotreatment of BRAF-mutated melanoma cell lines with phenformin and PLX4720 resulted in synergistic inhibition of cell viability, compared with the effects of the single agent alone.  Moreover, treatment with phenformin significantly delayed the development of resistance to PLX4720 in cultured melanoma cells.  Biochem. analyses showed that phenformin and PLX4720 exerted cooperative effects on inhibiting mTOR signaling and inducing apoptosis.  Noticeably, phenformin selectively targeted subpopulations of cells expressing JARID1B, a marker for slow cycling melanoma cells, whereas PLX4720 selectively targeted JARID1B-neg. cells.  Finally, in contrast to their use as single agents, the combination of phenformin and PLX4720 induced tumor regression in both nude mice bearing melanoma xenografts and in a genetically engineered BRAFV600E/PTENnull-driven mouse model of melanoma.  These results strongly suggest that significant therapeutic advantage may be achieved by combining AMPK activators such as phenformin with BRAF inhibitors for the treatment of melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7fg9gAwsMBbVg90H21EOLACvtfcHk0liS4eqRbaa7ww"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVSmurbF&md5=42126f04600f33e9dee7a5a83d56fd04</span></div><a href="/servlet/linkout?suffix=cit246&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1317577110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1317577110%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DP.%26aulast%3DIto%26aufirst%3DK.%26aulast%3DPerez-Lorenzo%26aufirst%3DR.%26aulast%3DDel%2BGuzzo%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DShen%26aufirst%3DC.%2BH.%26aulast%3DBosenberg%26aufirst%3DM.%2BW.%26aulast%3DMcMahon%26aufirst%3DM.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DZheng%26aufirst%3DB.%26atitle%3DPhenformin%2520enhances%2520the%2520therapeutic%2520benefit%2520of%2520BRAF%2528V600E%2529%2520inhibition%2520in%2520melanoma%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26spage%3D18226%26epage%3D18231%26doi%3D10.1073%2Fpnas.1317577110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref247"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref247'); return false;" data-citation="" class="refNumLink">247</a></strong><div class="NLM_citation" id="cit247"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boudreau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purkey, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hitz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robarge, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labadie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Nagro, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pusapati, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCleland, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderbilt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daemen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belvin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatzivassiliou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evangelista, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâBrien, T.</span></span> <span> </span><span class="NLM_article-title">Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">779</span>â <span class="NLM_lpage">786</span>, <span class="refDoi">Â DOI: 10.1038/nchembio.2143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fnchembio.2143" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27479743" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Kmu73K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=779-786&author=A.+Boudreauauthor=H.+E.+Purkeyauthor=A.+Hitzauthor=K.+Robargeauthor=D.+Petersonauthor=S.+Labadieauthor=M.+Kwongauthor=R.+Hongauthor=M.+Gaoauthor=C.+Del+Nagroauthor=R.+Pusapatiauthor=S.+G.+Maauthor=L.+Salphatiauthor=J.+Pangauthor=A.+H.+Zhouauthor=T.+Laiauthor=Y.+J.+Liauthor=Z.+G.+Chenauthor=B.+Q.+Weiauthor=I.+Yenauthor=S.+Siderisauthor=M.+McClelandauthor=R.+Firesteinauthor=L.+Corsonauthor=A.+Vanderbiltauthor=S.+Williamsauthor=A.+Daemenauthor=M.+Belvinauthor=C.+Eigenbrotauthor=P.+K.+Jacksonauthor=S.+Malekauthor=G.+Hatzivassiliouauthor=D.+Sampathauthor=M.+Evangelistaauthor=T.+O%E2%80%99Brien&title=Metabolic+plasticity+underpins+innate+and+acquired+resistance+to+LDHA+inhibition&doi=10.1038%2Fnchembio.2143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit247R"><div class="casContent"><span class="casTitleNuber">247</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition</span></div><div class="casAuthors">Boudreau, Aaron; Purkey, Hans E.; Hitz, Anna; Robarge, Kirk; Peterson, David; Labadie, Sharada; Kwong, Mandy; Hong, Rebecca; Gao, Min; Del Nagro, Christopher; Pusapati, Raju; Ma, Shuguang; Salphati, Laurent; Pang, Jodie; Zhou, Aihe; Lai, Tommy; Li, Yingjie; Chen, Zhongguo; Wei, Binqing; Yen, Ivana; Sideris, Steve; McCleland, Mark; Firestein, Ron; Corson, Laura; Vanderbilt, Alex; Williams, Simon; Daemen, Anneleen; Belvin, Marcia; Eigenbrot, Charles; Jackson, Peter K.; Malek, Shiva; Hatzivassiliou, Georgia; Sampath, Deepak; Evangelista, Marie; O'Brien, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">779-786</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Metabolic reprogramming in tumors represents a potential therapeutic target.  Herein we used shRNA depletion and a novel lactate dehydrogenase (LDHA) inhibitor, GNE-140, to probe the role of LDHA in tumor growth in vitro and in vivo.  In MIA PaCa-2 human pancreatic cells, LDHA inhibition rapidly affected global metab., although cell death only occurred after 2 d of continuous LDHA inhibition.  Pancreatic cell lines that utilize oxidative phosphorylation (OXPHOS) rather than glycolysis were inherently resistant to GNE-140, but could be resensitized to GNE-140 with the OXPHOS inhibitor phenformin.  Acquired resistance to GNE-140 was driven by activation of the AMPK-mTOR-S6K signaling pathway, which led to increased OXPHOS, and inhibitors targeting this pathway could prevent resistance.  Thus, combining an LDHA inhibitor with compds. targeting the mitochondrial or AMPK-S6K signaling axis may not only broaden the clin. utility of LDHA inhibitors beyond glycolytically dependent tumors but also reduce the emergence of resistance to LDHA inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4wdebEpeIa7Vg90H21EOLACvtfcHk0lhEFA1gv2G9Qw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Kmu73K&md5=28abbd7f174b422b7207a5f80352ce3e</span></div><a href="/servlet/linkout?suffix=cit247&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2143%26sid%3Dliteratum%253Aachs%26aulast%3DBoudreau%26aufirst%3DA.%26aulast%3DPurkey%26aufirst%3DH.%2BE.%26aulast%3DHitz%26aufirst%3DA.%26aulast%3DRobarge%26aufirst%3DK.%26aulast%3DPeterson%26aufirst%3DD.%26aulast%3DLabadie%26aufirst%3DS.%26aulast%3DKwong%26aufirst%3DM.%26aulast%3DHong%26aufirst%3DR.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DDel%2BNagro%26aufirst%3DC.%26aulast%3DPusapati%26aufirst%3DR.%26aulast%3DMa%26aufirst%3DS.%2BG.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DA.%2BH.%26aulast%3DLai%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DY.%2BJ.%26aulast%3DChen%26aufirst%3DZ.%2BG.%26aulast%3DWei%26aufirst%3DB.%2BQ.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DMcCleland%26aufirst%3DM.%26aulast%3DFirestein%26aufirst%3DR.%26aulast%3DCorson%26aufirst%3DL.%26aulast%3DVanderbilt%26aufirst%3DA.%26aulast%3DWilliams%26aufirst%3DS.%26aulast%3DDaemen%26aufirst%3DA.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DJackson%26aufirst%3DP.%2BK.%26aulast%3DMalek%26aufirst%3DS.%26aulast%3DHatzivassiliou%26aufirst%3DG.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DEvangelista%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DT.%26atitle%3DMetabolic%2520plasticity%2520underpins%2520innate%2520and%2520acquired%2520resistance%2520to%2520LDHA%2520inhibition%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2016%26volume%3D12%26spage%3D779%26epage%3D786%26doi%3D10.1038%2Fnchembio.2143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref248"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref248'); return false;" data-citation="" class="refNumLink">248</a></strong><div class="NLM_citation" id="cit248"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavazos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baran, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuruvilla, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gay, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battula, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreeff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daver, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marszalek, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konopleva, M.</span></span> <span> </span><span class="NLM_article-title">Targeting residual chemotherapy-resistant acute myeloid leukemia cells by a novel OXPHOS inhibitor IACS010759</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">2623</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2017&pages=2623&author=L.+N.+Hanauthor=A.+Cavazosauthor=N.+Baranauthor=Q.+Zhangauthor=V.+M.+Kuruvillaauthor=J.+P.+Gayauthor=N.+P.+Fengauthor=V.+L.+Battulaauthor=M.+Andreeffauthor=H.+M.+Kantarjianauthor=N.+Daverauthor=J.+R.+Marszalekauthor=M.+Konopleva&title=Targeting+residual+chemotherapy-resistant+acute+myeloid+leukemia+cells+by+a+novel+OXPHOS+inhibitor+IACS010759"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit248&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DL.%2BN.%26aulast%3DCavazos%26aufirst%3DA.%26aulast%3DBaran%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DKuruvilla%26aufirst%3DV.%2BM.%26aulast%3DGay%26aufirst%3DJ.%2BP.%26aulast%3DFeng%26aufirst%3DN.%2BP.%26aulast%3DBattula%26aufirst%3DV.%2BL.%26aulast%3DAndreeff%26aufirst%3DM.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DDaver%26aufirst%3DN.%26aulast%3DMarszalek%26aufirst%3DJ.%2BR.%26aulast%3DKonopleva%26aufirst%3DM.%26atitle%3DTargeting%2520residual%2520chemotherapy-resistant%2520acute%2520myeloid%2520leukemia%2520cells%2520by%2520a%2520novel%2520OXPHOS%2520inhibitor%2520IACS010759%26jtitle%3DBlood%26date%3D2017%26volume%3D130%26spage%3D2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref249"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref249'); return false;" data-citation="" class="refNumLink">249</a></strong><div class="NLM_citation" id="cit249"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sica, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo-San Pedro, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izzo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pol, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierredon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durand, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bossut, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chery, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souquere, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierron, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vartholomaiou, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamzami, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soussi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauvat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mondragon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kepp, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galluzzi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinou, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess-Stumpp, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegelbauer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroemer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maiuri, M. C.</span></span> <span> </span><span class="NLM_article-title">Lethal poisoning of cancer cells by respiratory chain inhibition plus dimethyl alpha-ketoglutarate</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">820</span>â <span class="NLM_lpage">834</span>, <span class="refDoi">Â DOI: 10.1016/j.celrep.2019.03.058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.celrep.2019.03.058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=30995479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1MXns1Gltro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=820-834&author=V.+Sicaauthor=J.+M.+Bravo-San+Pedroauthor=V.+Izzoauthor=J.+Polauthor=S.+Pierredonauthor=D.+Enotauthor=S.+Durandauthor=N.+Bossutauthor=A.+Cheryauthor=S.+Souquereauthor=G.+Pierronauthor=E.+Vartholomaiouauthor=N.+Zamzamiauthor=T.+Soussiauthor=A.+Sauvatauthor=L.+Mondragonauthor=O.+Keppauthor=L.+Galluzziauthor=J.+C.+Martinouauthor=H.+Hess-Stumppauthor=K.+Ziegelbauerauthor=G.+Kroemerauthor=M.+C.+Maiuri&title=Lethal+poisoning+of+cancer+cells+by+respiratory+chain+inhibition+plus+dimethyl+alpha-ketoglutarate&doi=10.1016%2Fj.celrep.2019.03.058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit249R"><div class="casContent"><span class="casTitleNuber">249</span><div class="casTitle"><span class="NLM_cas:atitle">Lethal Poisoning of Cancer Cells by Respiratory Chain Inhibition plus Dimethyl Î±-Ketoglutarate</span></div><div class="casAuthors">Sica, Valentina; Bravo-San Pedro, Jose Manuel; Izzo, Valentina; Pol, Jonathan; Pierredon, Sandra; Enot, David; Durand, Sylvere; Bossut, Noelie; Chery, Alexis; Souquere, Sylvie; Pierron, Gerard; Vartholomaiou, Evangelia; Zamzami, Naoufal; Soussi, Thierry; Sauvat, Allan; Mondragon, Laura; Kepp, Oliver; Galluzzi, Lorenzo; Martinou, Jean-Claude; Hess-Stumpp, Holger; Ziegelbauer, Karl; Kroemer, Guido; Maiuri, Maria Chiara</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">820-834.e9</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Inhibition of oxidative phosphorylation (OXPHOS) by 1-cyclopropyl-4-(4-[(5-methyl-3-(3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)methyl]pyridin-2-yl)piperazine (BAY87-2243, abbreviated as B87), a complex I inhibitor, fails to kill human cancer cells in vitro.  Driven by this consideration, we attempted to identify agents that engage in synthetically lethal interactions with B87.  Here, we report that di-Me Î±-ketoglutarate (DMKG), a cell-permeable precursor of Î±-ketoglutarate that lacks toxicity on its own, kills cancer cells when combined with B87 or other inhibitors of OXPHOS.  DMKG improved the antineoplastic effect of B87, both in vitro and in vivo.  This combination caused MDM2-dependent, tumor suppressor protein p53 (TP53)-independent transcriptional reprogramming and alternative exon usage affecting multiple glycolytic enzymes, completely blocking glycolysis.  Simultaneous inhibition of OXPHOS and glycolysis provoked a bioenergetic catastrophe culminating in the activation of a cell death program that involved disruption of the mitochondrial network and activation of PARP1, AIFM1, and APEX1.  These results unveil a metabolic liability of human cancer cells that may be harnessed for the development of therapeutic regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo50HaqR_NxBrVg90H21EOLACvtfcHk0lhEFA1gv2G9Qw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXns1Gltro%253D&md5=7b3138ef0862bc2c639ffc9e3be73389</span></div><a href="/servlet/linkout?suffix=cit249&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2019.03.058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2019.03.058%26sid%3Dliteratum%253Aachs%26aulast%3DSica%26aufirst%3DV.%26aulast%3DBravo-San%2BPedro%26aufirst%3DJ.%2BM.%26aulast%3DIzzo%26aufirst%3DV.%26aulast%3DPol%26aufirst%3DJ.%26aulast%3DPierredon%26aufirst%3DS.%26aulast%3DEnot%26aufirst%3DD.%26aulast%3DDurand%26aufirst%3DS.%26aulast%3DBossut%26aufirst%3DN.%26aulast%3DChery%26aufirst%3DA.%26aulast%3DSouquere%26aufirst%3DS.%26aulast%3DPierron%26aufirst%3DG.%26aulast%3DVartholomaiou%26aufirst%3DE.%26aulast%3DZamzami%26aufirst%3DN.%26aulast%3DSoussi%26aufirst%3DT.%26aulast%3DSauvat%26aufirst%3DA.%26aulast%3DMondragon%26aufirst%3DL.%26aulast%3DKepp%26aufirst%3DO.%26aulast%3DGalluzzi%26aufirst%3DL.%26aulast%3DMartinou%26aufirst%3DJ.%2BC.%26aulast%3DHess-Stumpp%26aufirst%3DH.%26aulast%3DZiegelbauer%26aufirst%3DK.%26aulast%3DKroemer%26aufirst%3DG.%26aulast%3DMaiuri%26aufirst%3DM.%2BC.%26atitle%3DLethal%2520poisoning%2520of%2520cancer%2520cells%2520by%2520respiratory%2520chain%2520inhibition%2520plus%2520dimethyl%2520alpha-ketoglutarate%26jtitle%3DCell%2520Rep.%26date%3D2019%26volume%3D27%26spage%3D820%26epage%3D834%26doi%3D10.1016%2Fj.celrep.2019.03.058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref250"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref250'); return false;" data-citation="" class="refNumLink">250</a></strong><div class="NLM_citation" id="cit250"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Navratilova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karasova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanova, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jirakova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budkova, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pachernik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smarda, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benes, P.</span></span> <span> </span><span class="NLM_article-title">Selective elimination of neuroblastoma cells by synergistic effect of Akt kinase inhibitor and tetrathiomolybdate</span>. <i>J. Cell. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1859</span>â <span class="NLM_lpage">1869</span>, <span class="refDoi">Â DOI: 10.1111/jcmm.13106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1111%2Fjcmm.13106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=28244639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlymtLzN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2017&pages=1859-1869&author=J.+Navratilovaauthor=M.+Karasovaauthor=M.+K.+Lanovaauthor=L.+Jirakovaauthor=Z.+Budkovaauthor=J.+Pachernikauthor=J.+Smardaauthor=P.+Benes&title=Selective+elimination+of+neuroblastoma+cells+by+synergistic+effect+of+Akt+kinase+inhibitor+and+tetrathiomolybdate&doi=10.1111%2Fjcmm.13106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit250R"><div class="casContent"><span class="casTitleNuber">250</span><div class="casTitle"><span class="NLM_cas:atitle">selective elimination of neuroblastoma cells by synergistic effect of akt kinase inhibitor and tetrathiomolybdate</span></div><div class="casAuthors">Navratilova, Jarmila; Karasova, Martina; Kohutkova Lanova, Martina; Jirakova, Ludmila; Budkova, Zuzana; Pachernik, Jiri; Smarda, Jan; Benes, Petr</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular and Molecular Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1859-1869</span>CODEN:
                <span class="NLM_cas:coden">JCMMC9</span>;
        ISSN:<span class="NLM_cas:issn">1582-4934</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Neuroblastoma is the most common extracranial solid tumor of infancy.  Pathol. activation of glucose consumption, glycolysis and glycolysis-activating Akt kinase occur frequently in neuroblastoma cells, and these changes correlate with poor prognosis of patients.  Therefore, several inhibitors of glucose utilization and the Akt kinase activity are in preclin. trials as potential anti-cancer drugs.  However, metabolic plasticity of cancer cells might undermine efficacy of this approach.  In this work, we identified oxidative phosphorylation as compensatory mechanism preserving viability of neuroblastoma cells with inhibited glucose uptake/Akt kinase.  It was oxidative phosphorylation that maintained intracellular level of ATP and proliferative capacity of these cells.  The oxidative phosphorylation inhibitors (rotenone, tetrathiomolybdate) synergized with inhibitor of the Akt kinase/glucose uptake in down-regulation of both viability of neuroblastoma cells and clonogenic potential of cells forming neuroblastoma spheroids.  Interestingly, tetrathiomolybdate acted as highly specific inhibitor of oxygen consumption and activator of lactate prodn. in neuroblastoma cells, but not in normal fibroblasts and neuronal cells.  Moreover, the reducing effect of tetrathiomolybdate on cell viability and the level of ATP in the cells with inhibited Akt kinase/glucose uptake was also selective for neuroblastoma cells.  Therefore, efficient elimination of neuroblastoma cells requires inhibition of both glucose uptake/Akt kinase and oxidative phosphorylation activities.  The use of tetrathiomolybdate as a mitochondrial inhibitor contributes to selectivity of this combined treatment, preferentially targeting neuroblastoma cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMH2M4zlJe-LVg90H21EOLACvtfcHk0lgqadoJ9XGMFA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlymtLzN&md5=859127547339a7fdfbe46a0290cc31e1</span></div><a href="/servlet/linkout?suffix=cit250&amp;dbid=16384&amp;doi=10.1111%2Fjcmm.13106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjcmm.13106%26sid%3Dliteratum%253Aachs%26aulast%3DNavratilova%26aufirst%3DJ.%26aulast%3DKarasova%26aufirst%3DM.%26aulast%3DLanova%26aufirst%3DM.%2BK.%26aulast%3DJirakova%26aufirst%3DL.%26aulast%3DBudkova%26aufirst%3DZ.%26aulast%3DPachernik%26aufirst%3DJ.%26aulast%3DSmarda%26aufirst%3DJ.%26aulast%3DBenes%26aufirst%3DP.%26atitle%3DSelective%2520elimination%2520of%2520neuroblastoma%2520cells%2520by%2520synergistic%2520effect%2520of%2520Akt%2520kinase%2520inhibitor%2520and%2520tetrathiomolybdate%26jtitle%3DJ.%2520Cell.%2520Mol.%2520Med.%26date%3D2017%26volume%3D21%26spage%3D1859%26epage%3D1869%26doi%3D10.1111%2Fjcmm.13106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref251"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref251'); return false;" data-citation="" class="refNumLink">251</a></strong><div class="NLM_citation" id="cit251"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovly, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span> <span> </span><span class="NLM_article-title">Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2249</span>â <span class="NLM_lpage">2256</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-13-1610</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F1078-0432.CCR-13-1610" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=24789032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnsFWitro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=2249-2256&author=C.+M.+Lovlyauthor=A.+T.+Shaw&title=Molecular+pathways%3A+resistance+to+kinase+inhibitors+and+implications+for+therapeutic+strategies&doi=10.1158%2F1078-0432.CCR-13-1610"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit251R"><div class="casContent"><span class="casTitleNuber">251</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Pathways: Resistance to Kinase Inhibitors and Implications for Therapeutic Strategies</span></div><div class="casAuthors">Lovly, Christine M.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2249-2256</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The development of targeted therapies has revolutionized the treatment of cancer patients.  The identification of "druggable" oncogenic kinases and the creation of small-mol. inhibitors designed to specifically target these mutant kinases have become an important therapeutic paradigm across several different malignancies.  Often these inhibitors induce dramatic clin. responses in molecularly defined cohorts.  However, resistance to such targeted therapies is an inevitable consequence of this therapeutic approach.  Resistance can be either primary (de novo) or acquired.  Mechanisms leading to primary resistance may be categorized as tumor intrinsic factors or as patient/drug-specific factors.  Acquired resistance may be mediated by target gene modification, activation of "bypass tracks" that serve as compensatory signaling loops, or histol. transformation.  This brief review is a snapshot of the complex problem of therapeutic resistance, with a focus on resistance to kinase inhibitors in EGF receptor mutant and ALK rearranged non-small cell lung cancer, BRAF-mutant melanoma, and BCR-ABL-pos. chronic myeloid leukemia.  We describe specific mechanisms of primary and acquired resistance and then review emerging strategies to delay or overcome drug resistance.  Clin Cancer Res; 20(9); 2249-56. Â©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2GZlYyyZMDbVg90H21EOLACvtfcHk0lgqadoJ9XGMFA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnsFWitro%253D&md5=81f6c66a07aab8b6db2c200dc701fb20</span></div><a href="/servlet/linkout?suffix=cit251&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-1610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-1610%26sid%3Dliteratum%253Aachs%26aulast%3DLovly%26aufirst%3DC.%2BM.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DMolecular%2520pathways%253A%2520resistance%2520to%2520kinase%2520inhibitors%2520and%2520implications%2520for%2520therapeutic%2520strategies%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D2249%26epage%3D2256%26doi%3D10.1158%2F1078-0432.CCR-13-1610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref252"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref252'); return false;" data-citation="" class="refNumLink">252</a></strong><div class="NLM_citation" id="cit252"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosenzweig, S. A.</span></span> <span> </span><span class="NLM_article-title">Acquired resistance to drugs targeting tyrosine kinases</span>. <i>Adv. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">71</span>â <span class="NLM_lpage">98</span>, <span class="refDoi">Â DOI: 10.1016/bs.acr.2018.02.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fbs.acr.2018.02.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=29551130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFGrsr3K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2018&pages=71-98&author=S.+A.+Rosenzweig&title=Acquired+resistance+to+drugs+targeting+tyrosine+kinases&doi=10.1016%2Fbs.acr.2018.02.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit252R"><div class="casContent"><span class="casTitleNuber">252</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance to drugs targeting tyrosine kinases</span></div><div class="casAuthors">Rosenzweig, Steven A.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">71-98</span>CODEN:
                <span class="NLM_cas:coden">ACRSAJ</span>;
        ISSN:<span class="NLM_cas:issn">0065-230X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Resistance to chemotherapeutic drugs exemplifies the greatest hindrance to effective treatment of cancer patients.  The mol. mechanisms responsible have been investigated for over 50 years and have revealed the lack of a single cause, but instead, multiple mechanisms including induced expression of membrane transporters that pump drugs out of cells (multidrug resistance (MDR) phenotype), changes in the glutathione system, and altered metab.  Treatment of cancer patients/cancer cells with chemotherapeutic agents and/or molecularly targeted drugs is accompanied by acquisition of resistance to the treatment administered.  Chemotherapeutic agent resistance was initially assumed to be due to induction of mutations leading to a resistant phenotype.  While this has occurred for molecularly targeted drugs, it is clear that drugs selectively targeting tyrosine kinases (TKs) cause the acquisition of mutational changes and resistance to inhibition.  The first TK to be targeted, Bcr-Abl, led to the generation of several drugs including imatinib, dasatinib, and sunitinib that provided a rich understanding of this phenomenon.  It became clear that mutations alone were not the only cause of resistance.  Addnl. mechanisms were involved, including alternative splicing, alternative/compensatory signaling pathways, and epigenetic changes.  This review will focus on resistance to tyrosine kinase inhibitors (TKIs), receptor TK (RTK)-directed antibodies, and antibodies that inactivate specific RTK ligands.  New approaches and concepts aimed at avoiding the generation of drug resistance will be examd.  Many RTKs, including the IGF-1R, are dependence receptors that induce ligand-independent apoptosis.  How this signaling paradigm has implications on therapeutic strategies will also be considered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_cTW4uq_tI7Vg90H21EOLACvtfcHk0lgqadoJ9XGMFA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFGrsr3K&md5=b294d72ac3c059b9319886740d5c0960</span></div><a href="/servlet/linkout?suffix=cit252&amp;dbid=16384&amp;doi=10.1016%2Fbs.acr.2018.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.acr.2018.02.003%26sid%3Dliteratum%253Aachs%26aulast%3DRosenzweig%26aufirst%3DS.%2BA.%26atitle%3DAcquired%2520resistance%2520to%2520drugs%2520targeting%2520tyrosine%2520kinases%26jtitle%3DAdv.%2520Cancer%2520Res.%26date%3D2018%26volume%3D138%26spage%3D71%26epage%3D98%26doi%3D10.1016%2Fbs.acr.2018.02.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref253"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref253'); return false;" data-citation="" class="refNumLink">253</a></strong><div class="NLM_citation" id="cit253"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D.</span></span> <span> </span><span class="NLM_article-title">Inhibition of oxidative phosphorylation suppresses the development of osimertinib resistance in a preclinical model of EGFR-driven lung adenocarcinoma</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">86313</span>â <span class="NLM_lpage">86325</span>, <span class="refDoi">Â DOI: 10.18632/oncotarget.13388</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.18632%2Foncotarget.13388" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27861144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BC2snnvVShtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=86313-86325&author=M.+J.+Martinauthor=C.+Eberleinauthor=M.+Taylorauthor=S.+Ashtonauthor=D.+Robinsonauthor=D.+Cross&title=Inhibition+of+oxidative+phosphorylation+suppresses+the+development+of+osimertinib+resistance+in+a+preclinical+model+of+EGFR-driven+lung+adenocarcinoma&doi=10.18632%2Foncotarget.13388"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit253R"><div class="casContent"><span class="casTitleNuber">253</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of oxidative phosphorylation suppresses the development of osimertinib resistance in a preclinical model of EGFR-driven lung adenocarcinoma</span></div><div class="casAuthors">Martin Matthew J; Eberlein Cath; Taylor Molly; Ashton Susan; Robinson David; Cross Darren; Martin Matthew J; Taylor Molly; Robinson David; Cross Darren</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">86313-86325</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Metabolic plasticity is an emerging hallmark of cancer, and increased glycolysis is often observed in transformed cells.  Small molecule inhibitors that target driver oncogenes can potentially inhibit the glycolytic pathway.  Osimertinib (AZD9291) is a novel EGFR tyrosine kinase inhibitor (TKI) that is potent and selective for sensitising (EGFRm) and T790M resistance mutations.  Clinical studies have shown osimertinib to be efficacious in patients with EGFRm/ T790M advanced NSCLC who have progressed after EGFR-TKI treatment.  However experience with targeted therapies suggests that acquired resistance may emerge.  Thus there is a need to characterize resistance mechanisms and to devise ways to prevent, delay or overcome osimertinib resistance.  We show here that osimertinib suppresses glycolysis in parental EGFR-mutant lung adenocarcinoma lines, but has not in osimertinib-resistant cell lines.  Critically, we show osimertinib treatment induces a strict dependence on mitochondrial oxidative phosphorylation (OxPhos), as OxPhos inhibitors significantly delay the long-term development of osimertinib resistance in osimertinib-sensitive lines.  Accordingly, growth conditions which promote a less glycolytic phenotype confer a degree of osimertinib resistance.  Our data support a model in which the combination of osimertinib and OxPhos inhibitors can delay or prevent resistance in osimertinib-naive tumour cells, and represents a novel strategy that warrants further pre-clinical investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQjOLGz8qj-J2LFM_lbR1VmfW6udTcc2eZvnH1uozgkdLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2snnvVShtQ%253D%253D&md5=77cbd0d5e55e53e6244f9a69fb2f3df3</span></div><a href="/servlet/linkout?suffix=cit253&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.13388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.13388%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DM.%2BJ.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DRobinson%26aufirst%3DD.%26aulast%3DCross%26aufirst%3DD.%26atitle%3DInhibition%2520of%2520oxidative%2520phosphorylation%2520suppresses%2520the%2520development%2520of%2520osimertinib%2520resistance%2520in%2520a%2520preclinical%2520model%2520of%2520EGFR-driven%2520lung%2520adenocarcinoma%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D86313%26epage%3D86325%26doi%3D10.18632%2Foncotarget.13388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref254"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref254'); return false;" data-citation="" class="refNumLink">254</a></strong><div class="NLM_citation" id="cit254"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez-Calderon, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham-Danis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeRyckere, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaberezhnyy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemta, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wempe, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollyea, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serkova, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeGregori, J.</span></span> <span> </span><span class="NLM_article-title">Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1360</span>â <span class="NLM_lpage">1372</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-14-2146</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F1078-0432.CCR-14-2146" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=25547679" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvVemsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=1360-1372&author=F.+Alvarez-Calderonauthor=M.+A.+Gregoryauthor=C.+Pham-Danisauthor=D.+DeRyckereauthor=B.+M.+Stevensauthor=V.+Zaberezhnyyauthor=A.+A.+Hillauthor=L.+Gemtaauthor=A.+Kumarauthor=V.+Kumarauthor=M.+F.+Wempeauthor=D.+A.+Pollyeaauthor=C.+T.+Jordanauthor=N.+J.+Serkovaauthor=D.+K.+Grahamauthor=J.+DeGregori&title=Tyrosine+kinase+inhibition+in+leukemia+induces+an+altered+metabolic+state+sensitive+to+mitochondrial+perturbations&doi=10.1158%2F1078-0432.CCR-14-2146"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit254R"><div class="casContent"><span class="casTitleNuber">254</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine Kinase Inhibition in Leukemia Induces an Altered Metabolic State Sensitive to Mitochondrial Perturbations</span></div><div class="casAuthors">Alvarez-Calderon, Francesca; Gregory, Mark A.; Pham-Danis, Catherine; De Ryckere, Deborah; Stevens, Brett M.; Zaberezhnyy, Vadym; Hill, Amanda A.; Gemta, Lelisa; Kumar, Amit; Kumar, Vijay; Wempe, Michael F.; Pollyea, Daniel A.; Jordan, Craig T.; Serkova, Natalie J.; Graham, Douglas K.; De Gregori, James</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1360-1372</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Although tyrosine kinase inhibitors (TKI) can be effective therapies for leukemia, they fail to fully eliminate leukemic cells and achieve durable remissions for many patients with advanced BCR-ABL+ leukemias or acute myelogenous leukemia (AML).  Through a large-scale synthetic lethal RNAi screen, we identified pyruvate dehydrogenase, the limiting enzyme for pyruvate entry into the mitochondrial tricarboxylic acid cycle, as crit. for the survival of chronic myelogenous leukemia (CML) cells upon BCR-ABL inhibition.  Here, we examd. the role of mitochondrial metab. in the survival of Ph+ leukemia and AML upon TK inhibition.  Exptl. Design: Ph+ cancer cell lines, AML cell lines, leukemia xenografts, cord blood, and patient samples were examd.  Results: We showed that the mitochondrial ATP-synthase inhibitor oligomycin-A greatly sensitized leukemia cells to TKI in vitro.  Surprisingly, oligomycin-A sensitized leukemia cells to BCR-ABL inhibition at concns. of 100- to 1,000-fold below those required for inhibition of respiration.  Oligomycin-A treatment rapidly led to mitochondrial membrane depolarization and reduced ATP levels, and promoted superoxide prodn. and leukemia cell apoptosis when combined with TKI.  Importantly, oligomycin-A enhanced elimination of BCR-ABL+ leukemia cells by TKI in a mouse model and in primary blast crisis CML samples.  Moreover, oligomycin-A also greatly potentiated the elimination of FLT3-dependent AML cells when combined with an FLT3 TKI, both in vitro and in vivo.  Conclusions: TKI therapy in leukemia cells creates a novel metabolic state that is highly sensitive to particular mitochondrial perturbations.  Targeting mitochondrial metab. as an adjuvant therapy could therefore improve therapeutic responses to TKI for patients with BCR-ABL+ and FLT3ITD leukemias.  Clin Cancer Res; 21(6); 1360-72. cpr2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkNCxdHg8ZAbVg90H21EOLACvtfcHk0lhT-JluFMXuCA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvVemsbs%253D&md5=cd9d6c3ed388b0ed4e965beab63f9705</span></div><a href="/servlet/linkout?suffix=cit254&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-2146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-2146%26sid%3Dliteratum%253Aachs%26aulast%3DAlvarez-Calderon%26aufirst%3DF.%26aulast%3DGregory%26aufirst%3DM.%2BA.%26aulast%3DPham-Danis%26aufirst%3DC.%26aulast%3DDeRyckere%26aufirst%3DD.%26aulast%3DStevens%26aufirst%3DB.%2BM.%26aulast%3DZaberezhnyy%26aufirst%3DV.%26aulast%3DHill%26aufirst%3DA.%2BA.%26aulast%3DGemta%26aufirst%3DL.%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DWempe%26aufirst%3DM.%2BF.%26aulast%3DPollyea%26aufirst%3DD.%2BA.%26aulast%3DJordan%26aufirst%3DC.%2BT.%26aulast%3DSerkova%26aufirst%3DN.%2BJ.%26aulast%3DGraham%26aufirst%3DD.%2BK.%26aulast%3DDeGregori%26aufirst%3DJ.%26atitle%3DTyrosine%2520kinase%2520inhibition%2520in%2520leukemia%2520induces%2520an%2520altered%2520metabolic%2520state%2520sensitive%2520to%2520mitochondrial%2520perturbations%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D1360%26epage%3D1372%26doi%3D10.1158%2F1078-0432.CCR-14-2146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref255"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref255'); return false;" data-citation="" class="refNumLink">255</a></strong><div class="NLM_citation" id="cit255"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asara, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granters, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span> <span> </span><span class="NLM_article-title">Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">237</span>â <span class="NLM_lpage">247</span>, <span class="refDoi">Â DOI: 10.1016/j.molcel.2008.12.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.molcel.2008.12.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=19187764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvVyltr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2009&pages=237-247&author=B.+Zhengauthor=J.+H.+Jeongauthor=J.+M.+Asaraauthor=Y.+Y.+Yuanauthor=S.+R.+Grantersauthor=L.+Chinauthor=L.+C.+Cantley&title=Oncogenic+B-RAF+negatively+regulates+the+tumor+suppressor+LKB1+to+promote+melanoma+cell+proliferation&doi=10.1016%2Fj.molcel.2008.12.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit255R"><div class="casContent"><span class="casTitleNuber">255</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation</span></div><div class="casAuthors">Zheng, Bin; Jeong, Joseph H.; Asara, John M.; Yuan, Yuan-Ying; Granter, Scott R.; Chin, Lynda; Cantley, Lewis C.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">237-247</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The LKB1-AMPK signaling pathway serves as a crit. cellular sensor coupling energy homeostasis to cell growth, proliferation, and survival.  However, how tumor cells suppress this signaling pathway to gain growth advantage under conditions of energy stress is largely unknown.  Here, we show that AMPK activation is suppressed in melanoma cells with the B-RAF V600E mutation and that downregulation of B-RAF signaling activates AMPK.  We find that in these cells LKB1 is phosphorylated by ERK and Rsk, two kinases downstream of B-RAF, and that this phosphorylation compromises the ability of LKB1 to bind and activate AMPK.  Furthermore, expression of a phosphorylation-deficient mutant of LKB1 allows activation of AMPK and inhibits melanoma cell proliferation and anchorage-independent cell growth.  Our findings provide a mol. linkage between the LKB1-AMPK and the RAF-MEK-ERK pathways and suggest that suppression of LKB1 function by B-RAF V600E plays an important role in B-RAF V600E-driven tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoE262UcrzgtbVg90H21EOLACvtfcHk0lhT-JluFMXuCA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvVyltr8%253D&md5=99e6766f229397eaad4e37ddb1ad326d</span></div><a href="/servlet/linkout?suffix=cit255&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2008.12.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2008.12.026%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DB.%26aulast%3DJeong%26aufirst%3DJ.%2BH.%26aulast%3DAsara%26aufirst%3DJ.%2BM.%26aulast%3DYuan%26aufirst%3DY.%2BY.%26aulast%3DGranters%26aufirst%3DS.%2BR.%26aulast%3DChin%26aufirst%3DL.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DOncogenic%2520B-RAF%2520negatively%2520regulates%2520the%2520tumor%2520suppressor%2520LKB1%2520to%2520promote%2520melanoma%2520cell%2520proliferation%26jtitle%3DMol.%2520Cell%26date%3D2009%26volume%3D33%26spage%3D237%26epage%3D247%26doi%3D10.1016%2Fj.molcel.2008.12.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref256"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref256'); return false;" data-citation="" class="refNumLink">256</a></strong><div class="NLM_citation" id="cit256"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wick, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drury, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakada, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfe, J. B.</span></span> <span> </span><span class="NLM_article-title">Localization of the primary metabolic block produced by 2-deoxyglucose</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1957</span>,  <span class="NLM_volume"><i>224</i></span>,  <span class="NLM_fpage">963</span>â <span class="NLM_lpage">969</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=13405925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADyaG2sXktlKrsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=224&publication_year=1957&pages=963-969&author=A.+N.+Wickauthor=D.+R.+Druryauthor=H.+I.+Nakadaauthor=J.+B.+Wolfe&title=Localization+of+the+primary+metabolic+block+produced+by+2-deoxyglucose"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit256R"><div class="casContent"><span class="casTitleNuber">256</span><div class="casTitle"><span class="NLM_cas:atitle">Localization of the primary metabolic block produced by 2-deoxyglucose</span></div><div class="casAuthors">Wick, Arne N.; Drury, Douglas R.; Nakada, Henry I.; Wolfe, Jack B.; Britton, Barbara; Grabowski, Ruth</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1957</span>),
    <span class="NLM_cas:volume">224</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">963-9</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">cf. C.A. 50, 482i.  Expts. were carried out to locate the metabolic block in glucose metabolism which occurs after the administration of 2-deoxyglucose to eviscerated animals.  The extrahepatic tissues oxidized only trace amts. of 2-deoxyglucose-C14; hence the compd. is blocked at some stage in its metabolism.  Since it did not influence the oxidation of injected acetate-C14, the metabolic block is in the glycolytic area.  Studies in vitro showed that 2-deoxyglucose-6-phosphate competitively inhibited formation of ketose from glucose-6-phosphate when purified rat-kidney phosphoglucoisomerase was used.  The primary block induced by 2-deoxyglucose is at the phosphoglucoisomerase level.  Possible secondary blocks are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWQ3LBZViyvLVg90H21EOLACvtfcHk0lhT-JluFMXuCA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaG2sXktlKrsQ%253D%253D&md5=c9c497383b3dc5f59f3a91b3c563c21f</span></div><a href="/servlet/linkout?suffix=cit256&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWick%26aufirst%3DA.%2BN.%26aulast%3DDrury%26aufirst%3DD.%2BR.%26aulast%3DNakada%26aufirst%3DH.%2BI.%26aulast%3DWolfe%26aufirst%3DJ.%2BB.%26atitle%3DLocalization%2520of%2520the%2520primary%2520metabolic%2520block%2520produced%2520by%25202-deoxyglucose%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1957%26volume%3D224%26spage%3D963%26epage%3D969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref257"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref257'); return false;" data-citation="" class="refNumLink">257</a></strong><div class="NLM_citation" id="cit257"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pelicano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, P.</span></span> <span> </span><span class="NLM_article-title">Glycolysis inhibition for anticancer treatment</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">4633</span>â <span class="NLM_lpage">4646</span>, <span class="refDoi">Â DOI: 10.1038/sj.onc.1209597</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fsj.onc.1209597" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=16892078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD28Xnsl2hs7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=4633-4646&author=H.+Pelicanoauthor=D.+S.+Martinauthor=R.+H.+Xuauthor=P.+Huang&title=Glycolysis+inhibition+for+anticancer+treatment&doi=10.1038%2Fsj.onc.1209597"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit257R"><div class="casContent"><span class="casTitleNuber">257</span><div class="casTitle"><span class="NLM_cas:atitle">Glycolysis inhibition for anticancer treatment</span></div><div class="casAuthors">Pelicano, H.; Martin, D. S.; Xu, R.-H.; Huang, P.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">4633-4646</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Most cancer cells exhibit increased glycolysis and use this metabolic pathway for generation of ATP as a main source of their energy supply.  This phenomenon is known as the Warburg effect and is considered as one of the most fundamental metabolic alterations during malignant transformation.  In recent years, there are significant progresses in our understanding of the underlying mechanisms and the potential therapeutic implications.  Biochem. and mol. studies suggest several possible mechanisms by which this metabolic alteration may evolve during cancer development.  These mechanisms include mitochondrial defects and malfunction, adaptation to hypoxic tumor microenvironment, oncogenic signaling, and abnormal expression of metabolic enzymes.  Importantly, the increased dependence of cancer cells on glycolytic pathway for ATP generation provides a biochem. basis for the design of therapeutic strategies to preferentially kill cancer cells by pharmacol. inhibition of glycolysis.  Several small mols. have emerged that exhibit promising anticancer activity in vitro and in vivo, as single agent or in combination with other therapeutic modalities.  The glycolytic inhibitors are particularly effective against cancer cells with mitochondrial defects or under hypoxic conditions, which are frequently assocd. with cellular resistance to conventional anticancer drugs and radiation therapy.  Because increased aerobic glycolysis is commonly seen in a wide spectrum of human cancers and hypoxia is present in most tumor microenvironment, development of novel glycolytic inhibitors as a new class of anticancer agents is likely to have broad therapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYJDZpML8A07Vg90H21EOLACvtfcHk0ljsuVjuTza4gA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xnsl2hs7Y%253D&md5=1315037e761c3f674a3acd7854873c61</span></div><a href="/servlet/linkout?suffix=cit257&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1209597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1209597%26sid%3Dliteratum%253Aachs%26aulast%3DPelicano%26aufirst%3DH.%26aulast%3DMartin%26aufirst%3DD.%2BS.%26aulast%3DXu%26aufirst%3DR.%2BH.%26aulast%3DHuang%26aufirst%3DP.%26atitle%3DGlycolysis%2520inhibition%2520for%2520anticancer%2520treatment%26jtitle%3DOncogene%26date%3D2006%26volume%3D25%26spage%3D4633%26epage%3D4646%26doi%3D10.1038%2Fsj.onc.1209597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref258"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref258'); return false;" data-citation="" class="refNumLink">258</a></strong><div class="NLM_citation" id="cit258"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raez, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricart, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiorean, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiPaola, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lima, C. M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlesselman, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolba, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langmuir, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroll, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurtoglu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenblatt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lampidis, T. J.</span></span> <span> </span><span class="NLM_article-title">A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">523</span>â <span class="NLM_lpage">530</span>, <span class="refDoi">Â DOI: 10.1007/s00280-012-2045-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1007%2Fs00280-012-2045-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=23228990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslaktLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2013&pages=523-530&author=L.+E.+Raezauthor=K.+Papadopoulosauthor=A.+D.+Ricartauthor=E.+G.+Chioreanauthor=R.+S.+DiPaolaauthor=M.+N.+Steinauthor=C.+M.+R.+Limaauthor=J.+J.+Schlesselmanauthor=K.+Tolbaauthor=V.+K.+Langmuirauthor=S.+Krollauthor=D.+T.+Jungauthor=M.+Kurtogluauthor=J.+Rosenblattauthor=T.+J.+Lampidis&title=A+phase+I+dose-escalation+trial+of+2-deoxy-D-glucose+alone+or+combined+with+docetaxel+in+patients+with+advanced+solid+tumors&doi=10.1007%2Fs00280-012-2045-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit258R"><div class="casContent"><span class="casTitleNuber">258</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors</span></div><div class="casAuthors">Raez, Luis E.; Papadopoulos, Kyriakos; Ricart, Alejandro D.; Chiorean, E. Gabriella; DiPaola, Robert S.; Stein, Mark N.; Rocha Lima, Caio M.; Schlesselman, James J.; Tolba, Khaled; Langmuir, Virginia K.; Kroll, Stewart; Jung, Donald T.; Kurtoglu, Metin; Rosenblatt, Joseph; Lampidis, Theodore J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">523-530</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose This phase I trial was initiated to evaluate the safety, pharmacokinetics (PK) and max. tolerated dose (MTD) of the glycolytic inhibitor, 2-deoxy-d-glucose (2DG) in combination with docetaxel, in patients with advanced solid tumors.  Methods A modified accelerated titrn. design was used. 2DG was administered orally once daily for 7 days every other week starting at a dose of 2 mg/kg and docetaxel was administered i.v. at 30 mg/m2 for 3 of every 4 wk beginning on day 1 of week 2.  Following the completion of dose escalation, cohorts of patients were then treated with 2DG for 21 days or every day of each 4-wk cycle for up to 12 cycles.  Results Thirty-four patients were enrolled: 21 on every other week, 6 on a 21 of 28-day cycle and 7 on the continuous 2DG dosing schedule.  There were no dose-limiting toxicities which met the MTD criteria.  The most common adverse events were fatigue, sweating, dizziness and nausea mimicking the hypoglycemic symptoms expected from 2DG administration.  Therefore, 63 mg/kg was selected as the clin. tolerable dose.  The most significant adverse effects noted at 63-88 mg/kg doses were reversible hyperglycemia (100 %), gastrointestinal bleeding (6 %) and reversible grade 3 QTc prolongation (22 %).  Eleven patients (32 %) had stable disease, 1 patient (3 %) partial response and 22 patients (66 %) progressive disease as their best response.  There was no PK interaction between 2DG and docetaxel.  Conclusion The recommended dose of 2DG in combination with weekly docetaxel is 63 mg/kg/day with tolerable adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ2YaHNgvkU7Vg90H21EOLACvtfcHk0ljsuVjuTza4gA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslaktLw%253D&md5=06d69744bde78fb532b960ae5cafe66e</span></div><a href="/servlet/linkout?suffix=cit258&amp;dbid=16384&amp;doi=10.1007%2Fs00280-012-2045-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-012-2045-1%26sid%3Dliteratum%253Aachs%26aulast%3DRaez%26aufirst%3DL.%2BE.%26aulast%3DPapadopoulos%26aufirst%3DK.%26aulast%3DRicart%26aufirst%3DA.%2BD.%26aulast%3DChiorean%26aufirst%3DE.%2BG.%26aulast%3DDiPaola%26aufirst%3DR.%2BS.%26aulast%3DStein%26aufirst%3DM.%2BN.%26aulast%3DLima%26aufirst%3DC.%2BM.%2BR.%26aulast%3DSchlesselman%26aufirst%3DJ.%2BJ.%26aulast%3DTolba%26aufirst%3DK.%26aulast%3DLangmuir%26aufirst%3DV.%2BK.%26aulast%3DKroll%26aufirst%3DS.%26aulast%3DJung%26aufirst%3DD.%2BT.%26aulast%3DKurtoglu%26aufirst%3DM.%26aulast%3DRosenblatt%26aufirst%3DJ.%26aulast%3DLampidis%26aufirst%3DT.%2BJ.%26atitle%3DA%2520phase%2520I%2520dose-escalation%2520trial%2520of%25202-deoxy-D-glucose%2520alone%2520or%2520combined%2520with%2520docetaxel%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2013%26volume%3D71%26spage%3D523%26epage%3D530%26doi%3D10.1007%2Fs00280-012-2045-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref259"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref259'); return false;" data-citation="" class="refNumLink">259</a></strong><div class="NLM_citation" id="cit259"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shim, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huh, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S. G.</span></span> <span> </span><span class="NLM_article-title">Inhibition of glioblastoma tumorspheres by combined treatment with 2-deoxyglucose and metformin</span>. <i>Neuro Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">197</span>â <span class="NLM_lpage">207</span>, <span class="refDoi">Â DOI: 10.1093/neuonc/now174</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref259/cit259&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1093%2Fneuonc%2Fnow174" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2016&pages=197-207&author=E.+H.+Kimauthor=J.+H.+Leeauthor=Y.+Ohauthor=I.+Kohauthor=J.+K.+Shimauthor=J.+Parkauthor=J.+Choiauthor=M.+Yunauthor=J.+Y.+Jeonauthor=Y.+M.+Huhauthor=J.+H.+Changauthor=S.+H.+Kimauthor=K.+S.+Kimauthor=J.+H.+Cheongauthor=P.+Kimauthor=S.+G.+Kang&title=Inhibition+of+glioblastoma+tumorspheres+by+combined+treatment+with+2-deoxyglucose+and+metformin&doi=10.1093%2Fneuonc%2Fnow174"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit259&amp;dbid=16384&amp;doi=10.1093%2Fneuonc%2Fnow174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fneuonc%252Fnow174%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DE.%2BH.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DOh%26aufirst%3DY.%26aulast%3DKoh%26aufirst%3DI.%26aulast%3DShim%26aufirst%3DJ.%2BK.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DYun%26aufirst%3DM.%26aulast%3DJeon%26aufirst%3DJ.%2BY.%26aulast%3DHuh%26aufirst%3DY.%2BM.%26aulast%3DChang%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DK.%2BS.%26aulast%3DCheong%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DP.%26aulast%3DKang%26aufirst%3DS.%2BG.%26atitle%3DInhibition%2520of%2520glioblastoma%2520tumorspheres%2520by%2520combined%2520treatment%2520with%25202-deoxyglucose%2520and%2520metformin%26jtitle%3DNeuro%2520Oncol.%26date%3D2016%26volume%3D19%26spage%3D197%26epage%3D207%26doi%3D10.1093%2Fneuonc%2Fnow174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref260"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref260'); return false;" data-citation="" class="refNumLink">260</a></strong><div class="NLM_citation" id="cit260"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zielonka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dranka, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAllister, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackinnon, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalyanaraman, B.</span></span> <span> </span><span class="NLM_article-title">Mitochondria-targeted drugs synergize with 2-deoxyglucose to trigger breast cancer cell death</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">2634</span>â <span class="NLM_lpage">2644</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-11-3928</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref260/cit260&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F0008-5472.CAN-11-3928" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref260/cit260&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=22431711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref260/cit260&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvF2ntbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=2634-2644&author=G.+Chengauthor=J.+Zielonkaauthor=B.+P.+Drankaauthor=D.+McAllisterauthor=A.+C.+Mackinnonauthor=J.+Josephauthor=B.+Kalyanaraman&title=Mitochondria-targeted+drugs+synergize+with+2-deoxyglucose+to+trigger+breast+cancer+cell+death&doi=10.1158%2F0008-5472.CAN-11-3928"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit260R"><div class="casContent"><span class="casTitleNuber">260</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondria-Targeted Drugs Synergize with 2-Deoxyglucose to Trigger Breast Cancer Cell Death</span></div><div class="casAuthors">Cheng, Gang; Zielonka, Jacek; Dranka, Brian P.; McAllister, Donna; MacKinnon, A. Craig, Jr.; Joseph, Joy; Kalyanaraman, Balaraman</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2634-2644</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cancer cells are long known to exhibit increased aerobic glycolysis, but glycolytic inhibition has not offered a viable chemotherapeutic strategy in part because of the systemic toxicity of antiglycolytic agents.  However, recent studies suggest that a combined inhibition of glycolysis and mitochondrial function may help overcome this issue.  In this study, we investigated the chemotherapeutic efficacies of mitochondria-targeted drugs (MTD) in combination with 2-deoxy-D-glucose (2-DG), a compd. that inhibits glycolysis.  Using the MTDs, termed Mito-CP and Mito-Q, we evaluated relative cytotoxic effects and mitochondrial bioenergetic changes in vitro.  Interestingly, both Mito-CP and Mito-Q synergized with 2-DG to decrease ATP levels in two cell lines.  However, with time, the cellular bioenergetic function and clonogenic survival were largely restored in some cells.  In a xenograft model of human breast cancer, combined treatment of Mito-CP and 2-DG led to significant tumor regression in the absence of significant morphol. changes in kidney, liver, or heart.  Collectively, our findings suggest that dual targeting of mitochondrial bioenergetic metab. with MTDs and glycolytic inhibitors such as 2-DG may offer a promising chemotherapeutic strategy.  Cancer Res; 72(10); 2634-44.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouqFTQiEMs27Vg90H21EOLACvtfcHk0lgbHIUScJUlmg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmvF2ntbk%253D&md5=581679e74622bf721881c0626f86c01a</span></div><a href="/servlet/linkout?suffix=cit260&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-3928&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-3928%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DG.%26aulast%3DZielonka%26aufirst%3DJ.%26aulast%3DDranka%26aufirst%3DB.%2BP.%26aulast%3DMcAllister%26aufirst%3DD.%26aulast%3DMackinnon%26aufirst%3DA.%2BC.%26aulast%3DJoseph%26aufirst%3DJ.%26aulast%3DKalyanaraman%26aufirst%3DB.%26atitle%3DMitochondria-targeted%2520drugs%2520synergize%2520with%25202-deoxyglucose%2520to%2520trigger%2520breast%2520cancer%2520cell%2520death%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D2634%26epage%3D2644%26doi%3D10.1158%2F0008-5472.CAN-11-3928" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref261"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref261'); return false;" data-citation="" class="refNumLink">261</a></strong><div class="NLM_citation" id="cit261"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fan, L. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Berberine combined with 2-deoxy-D-glucose synergistically enhances cancer cell proliferation inhibition via energy depletion and unfolded protein response disruption</span>. <i>Biochim. Biophys. Acta, Gen. Subj.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>1830</i></span>,  <span class="NLM_fpage">5175</span>â <span class="NLM_lpage">5183</span>, <span class="refDoi">Â DOI: 10.1016/j.bbagen.2013.07.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref261/cit261&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.bbagen.2013.07.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref261/cit261&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=23872355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref261/cit261&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsV2mt7%252FO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1830&publication_year=2013&pages=5175-5183&author=L.+X.+Fanauthor=C.+M.+Liuauthor=A.+H.+Gaoauthor=Y.+B.+Zhouauthor=J.+Li&title=Berberine+combined+with+2-deoxy-D-glucose+synergistically+enhances+cancer+cell+proliferation+inhibition+via+energy+depletion+and+unfolded+protein+response+disruption&doi=10.1016%2Fj.bbagen.2013.07.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit261R"><div class="casContent"><span class="casTitleNuber">261</span><div class="casTitle"><span class="NLM_cas:atitle">Berberine combined with 2-deoxy-D-glucose synergistically enhances cancer cell proliferation inhibition via energy depletion and unfolded protein response disruption</span></div><div class="casAuthors">Fan, Li-xia; Liu, Chang-mei; Gao, An-hui; Zhou, Yu-bo; Li, Jia</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, General Subjects</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1830</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5175-5183</span>CODEN:
                <span class="NLM_cas:coden">BBGSB3</span>;
        ISSN:<span class="NLM_cas:issn">0304-4165</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Targeting multiple aspects of cellular metab., such as both aerobic glycolysis and mitochondrial oxidative phosphorylation (OXPHOS), has the potential to improve cancer therapeutics.  Berberine (BBR), a widely used traditional Chinese medicine, exerts its antitumor effects by inhibiting OXPHOS.  2-Deoxy-D-glucose (2-DG) targets aerobic glycolysis and demonstrates potential anticancer effects in the clinic.  We hypothesized that BBR in combination with 2-DG would be more efficient than either agent alone against cancer cell growth.  The effects of BBR and 2-DG on cancer cell growth were evaluated using the Sulforhodamine B (SRB) method.  Cell death was detected with the PI uptake assay, and Western blot, Q-PCR and luciferase reporter assays were used for signaling pathway detection.  An adenovirus system was used for gene overexpression.  BBR combined with 2-DG synergistically enhanced the growth inhibition of cancer cells in vitro.  Further mechanistic studies showed that the combination drastically enhanced ATP depletion and strongly disrupted the unfolded protein response (UPR).  Overexpressing GRP78 partially prevented the cancer cell inhibition induced by both compds.  Here, we report for the first time that BBR and 2-DG have a synergistic effect on cancer cell growth inhibition related to ATP energy depletion and disruption of UPR.  Our results propose the potential use of BBR and 2-DG in combination as an anticancer treatment, reinforcing the hypothesis that targeting both aerobic glycolysis and OXPHOS provides more effective cancer therapy and highlighting the important role of UPR in the process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrd1QXPS2CE5bVg90H21EOLACvtfcHk0lgbHIUScJUlmg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsV2mt7%252FO&md5=bac311d2bd2a0d55498e5d23469267eb</span></div><a href="/servlet/linkout?suffix=cit261&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagen.2013.07.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagen.2013.07.010%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DL.%2BX.%26aulast%3DLiu%26aufirst%3DC.%2BM.%26aulast%3DGao%26aufirst%3DA.%2BH.%26aulast%3DZhou%26aufirst%3DY.%2BB.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DBerberine%2520combined%2520with%25202-deoxy-D-glucose%2520synergistically%2520enhances%2520cancer%2520cell%2520proliferation%2520inhibition%2520via%2520energy%2520depletion%2520and%2520unfolded%2520protein%2520response%2520disruption%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gen.%2520Subj.%26date%3D2013%26volume%3D1830%26spage%3D5175%26epage%3D5183%26doi%3D10.1016%2Fj.bbagen.2013.07.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref262"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref262'); return false;" data-citation="" class="refNumLink">262</a></strong><div class="NLM_citation" id="cit262"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oshima, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kishimoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beebe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brender, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rai, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benavides, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squadrito, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crooks, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mott, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrimp, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moses, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusewitt, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hathaway, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadhav, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trepel, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stott, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeonov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sklar, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norenberg, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linehan, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterson, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darley-Usmar, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishna, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neckers, L. M.</span></span> <span> </span><span class="NLM_article-title">Dynamic imaging of LDH inhibition in tumors reveals rapid in vivo metabolic rewiring and vulnerability to combination therapy</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1798</span>â <span class="NLM_lpage">1810</span>, <span class="refDoi">Â DOI: 10.1016/j.celrep.2020.01.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref262/cit262&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.celrep.2020.01.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref262/cit262&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=32049011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref262/cit262&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BB3cXotFektb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=1798-1810&author=N.+Oshimaauthor=R.+Ishidaauthor=S.+Kishimotoauthor=K.+Beebeauthor=J.+R.+Brenderauthor=K.+Yamamotoauthor=D.+Urbanauthor=G.+Raiauthor=M.+S.+Johnsonauthor=G.+Benavidesauthor=G.+L.+Squadritoauthor=D.+Crooksauthor=J.+Jacksonauthor=A.+Joshiauthor=B.+T.+Mottauthor=J.+H.+Shrimpauthor=M.+A.+Mosesauthor=M.+J.+Leeauthor=A.+Yunoauthor=T.+D.+Leeauthor=X.+Huauthor=T.+Andersonauthor=D.+Kusewittauthor=H.+H.+Hathawayauthor=A.+Jadhavauthor=D.+Picardauthor=J.+B.+Trepelauthor=J.+B.+Mitchellauthor=G.+M.+Stottauthor=W.+Mooreauthor=A.+Simeonovauthor=L.+A.+Sklarauthor=J.+P.+Norenbergauthor=W.+M.+Linehanauthor=D.+J.+Maloneyauthor=C.+V.+Dangauthor=A.+G.+Watersonauthor=M.+Hallauthor=V.+M.+Darley-Usmarauthor=M.+C.+Krishnaauthor=L.+M.+Neckers&title=Dynamic+imaging+of+LDH+inhibition+in+tumors+reveals+rapid+in+vivo+metabolic+rewiring+and+vulnerability+to+combination+therapy&doi=10.1016%2Fj.celrep.2020.01.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit262R"><div class="casContent"><span class="casTitleNuber">262</span><div class="casTitle"><span class="NLM_cas:atitle">Dynamic Imaging of LDH Inhibition in Tumors Reveals Rapid In Vivo Metabolic Rewiring and Vulnerability to Combination Therapy</span></div><div class="casAuthors">Oshima, Nobu; Ishida, Ryo; Kishimoto, Shun; Beebe, Kristin; Brender, Jeffrey R.; Yamamoto, Kazutoshi; Urban, Daniel; Rai, Ganesha; Johnson, Michelle S.; Benavides, Gloria; Squadrito, Giuseppe L.; Crooks, Dan; Jackson, Joseph; Joshi, Abhinav; Mott, Bryan T.; Shrimp, Jonathan H.; Moses, Michael A.; Lee, Min-Jung; Yuno, Akira; Lee, Tobie D.; Hu, Xin; Anderson, Tamara; Kusewitt, Donna; Hathaway, Helen H.; Jadhav, Ajit; Picard, Didier; Trepel, Jane B.; Mitchell, James B.; Stott, Gordon M.; Moore, William; Simeonov, Anton; Sklar, Larry A.; Norenberg, Jeffrey P.; Linehan, W. Marston; Maloney, David J.; Dang, Chi V.; Waterson, Alex G.; Hall, Matthew; Darley-Usmar, Victor M.; Krishna, Murali C.; Neckers, Leonard M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1798-1810.e4</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The reliance of many cancers on aerobic glycolysis has stimulated efforts to develop lactate dehydrogenase (LDH) inhibitors.  However, despite significant efforts, LDH inhibitors (LDHi) with sufficient specificity and in vivo activity to det. whether LDH is a feasible drug target are lacking.  We describe an LDHi with potent, on-target, in vivo activity.  Using hyperpolarized magnetic resonance spectroscopic imaging (HP-MRSI), we demonstrate in vivo LDH inhibition in two glycolytic cancer models, MIA PaCa-2 and HT29, and we correlate depth and duration of LDH inhibition with direct anti-tumor activity.  HP-MRSI also reveals a metabolic rewiring that occurs in vivo within 30 min of LDH inhibition, wherein pyruvate in a tumor is redirected toward mitochondrial metab.  Using HP-MRSI, we show that inhibition of mitochondrial complex 1 rapidly redirects tumor pyruvate toward lactate.  Inhibition of both mitochondrial complex 1 and LDH suppresses metabolic plasticity, causing metabolic quiescence in vitro and tumor growth inhibition in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXo-hnKU_CkrVg90H21EOLACvtfcHk0lgbHIUScJUlmg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXotFektb0%253D&md5=9cb03f50f7d5a21ee5a6b1c9b1dc2f0a</span></div><a href="/servlet/linkout?suffix=cit262&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2020.01.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2020.01.039%26sid%3Dliteratum%253Aachs%26aulast%3DOshima%26aufirst%3DN.%26aulast%3DIshida%26aufirst%3DR.%26aulast%3DKishimoto%26aufirst%3DS.%26aulast%3DBeebe%26aufirst%3DK.%26aulast%3DBrender%26aufirst%3DJ.%2BR.%26aulast%3DYamamoto%26aufirst%3DK.%26aulast%3DUrban%26aufirst%3DD.%26aulast%3DRai%26aufirst%3DG.%26aulast%3DJohnson%26aufirst%3DM.%2BS.%26aulast%3DBenavides%26aufirst%3DG.%26aulast%3DSquadrito%26aufirst%3DG.%2BL.%26aulast%3DCrooks%26aufirst%3DD.%26aulast%3DJackson%26aufirst%3DJ.%26aulast%3DJoshi%26aufirst%3DA.%26aulast%3DMott%26aufirst%3DB.%2BT.%26aulast%3DShrimp%26aufirst%3DJ.%2BH.%26aulast%3DMoses%26aufirst%3DM.%2BA.%26aulast%3DLee%26aufirst%3DM.%2BJ.%26aulast%3DYuno%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DT.%2BD.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DAnderson%26aufirst%3DT.%26aulast%3DKusewitt%26aufirst%3DD.%26aulast%3DHathaway%26aufirst%3DH.%2BH.%26aulast%3DJadhav%26aufirst%3DA.%26aulast%3DPicard%26aufirst%3DD.%26aulast%3DTrepel%26aufirst%3DJ.%2BB.%26aulast%3DMitchell%26aufirst%3DJ.%2BB.%26aulast%3DStott%26aufirst%3DG.%2BM.%26aulast%3DMoore%26aufirst%3DW.%26aulast%3DSimeonov%26aufirst%3DA.%26aulast%3DSklar%26aufirst%3DL.%2BA.%26aulast%3DNorenberg%26aufirst%3DJ.%2BP.%26aulast%3DLinehan%26aufirst%3DW.%2BM.%26aulast%3DMaloney%26aufirst%3DD.%2BJ.%26aulast%3DDang%26aufirst%3DC.%2BV.%26aulast%3DWaterson%26aufirst%3DA.%2BG.%26aulast%3DHall%26aufirst%3DM.%26aulast%3DDarley-Usmar%26aufirst%3DV.%2BM.%26aulast%3DKrishna%26aufirst%3DM.%2BC.%26aulast%3DNeckers%26aufirst%3DL.%2BM.%26atitle%3DDynamic%2520imaging%2520of%2520LDH%2520inhibition%2520in%2520tumors%2520reveals%2520rapid%2520in%2520vivo%2520metabolic%2520rewiring%2520and%2520vulnerability%2520to%2520combination%2520therapy%26jtitle%3DCell%2520Rep.%26date%3D2020%26volume%3D30%26spage%3D1798%26epage%3D1810%26doi%3D10.1016%2Fj.celrep.2020.01.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref263"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref263'); return false;" data-citation="" class="refNumLink">263</a></strong><div class="NLM_citation" id="cit263"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mayr, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haack, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freisinger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karall, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makowski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feichtinger, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolinski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahting, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meitinger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prokisch, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperl, W.</span></span> <span> </span><span class="NLM_article-title">Spectrum of combined respiratory chain defects</span>. <i>J. Inherited Metab. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">629</span>â <span class="NLM_lpage">640</span>, <span class="refDoi">Â DOI: 10.1007/s10545-015-9831-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref263/cit263&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1007%2Fs10545-015-9831-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref263/cit263&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=25778941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref263/cit263&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2MXks1amurs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2015&pages=629-640&author=J.+A.+Mayrauthor=T.+B.+Haackauthor=P.+Freisingerauthor=D.+Karallauthor=C.+Makowskiauthor=J.+Kochauthor=R.+G.+Feichtingerauthor=F.+A.+Zimmermannauthor=B.+Rolinskiauthor=U.+Ahtingauthor=T.+Meitingerauthor=H.+Prokischauthor=W.+Sperl&title=Spectrum+of+combined+respiratory+chain+defects&doi=10.1007%2Fs10545-015-9831-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit263R"><div class="casContent"><span class="casTitleNuber">263</span><div class="casTitle"><span class="NLM_cas:atitle">Spectrum of combined respiratory chain defects</span></div><div class="casAuthors">Mayr, Johannes A.; Haack, Tobias B.; Freisinger, Peter; Karall, Daniela; Makowski, Christine; Koch, Johannes; Feichtinger, Rene G.; Zimmermann, Franz A.; Rolinski, Boris; Ahting, Uwe; Meitinger, Thomas; Prokisch, Holger; Sperl, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Inherited Metabolic Disease</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">629-640</span>CODEN:
                <span class="NLM_cas:coden">JIMDDP</span>;
        ISSN:<span class="NLM_cas:issn">0141-8955</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Inherited disorders of mitochondrial energy metab. form a large and heterogeneous group of metabolic diseases.  More than 250 gene defects have been reported to date and this no. continues to grow.  Mitochondrial diseases can be grouped into (1) disorders of oxidative phosphorylation (OXPHOS) subunits and their assembly factors, (2) defects of mitochondrial DNA, RNA and protein synthesis, (3) defects in the substrate-generating upstream reactions of OXPHOS, (4) defects in relevant cofactors and (5) defects in mitochondrial homeostasis.  Deficiency of more than one respiratory chain enzyme is a common finding.  Combined defects are found in 49 % of the known disease-causing genes of mitochondrial energy metab. and in 57 % of patients with OXPHOS defects identified in our diagnostic center.  Combined defects of complexes I, III, IV and V are typically due to deficiency of mitochondrial DNA replication, RNA metab. or translation.  Defects in cofactors can result in combined defects of various combinations, and defects of mitochondrial homeostasis can result in a generalised decrease of all OXPHOS enzymes.  Noteworthy, identification of combined defects can be complicated by different degrees of severity of each affected enzyme.  Furthermore, even defects of single respiratory chain enzymes can result in combined defects due to aberrant formation of respiratory chain supercomplexes.  Combined OXPHOS defects have a great variety of clin. manifestations in terms of onset, course severity and tissue involvement.  They can present as classical encephalomyopathy but also with hepatopathy, nephropathy, haematol. findings and Perrault syndrome in a subset of disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHLKlpcFr_SLVg90H21EOLACvtfcHk0ljEsjU89cCmmA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXks1amurs%253D&md5=f815edf9b533ddf0ca1530e2c24dbb73</span></div><a href="/servlet/linkout?suffix=cit263&amp;dbid=16384&amp;doi=10.1007%2Fs10545-015-9831-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10545-015-9831-y%26sid%3Dliteratum%253Aachs%26aulast%3DMayr%26aufirst%3DJ.%2BA.%26aulast%3DHaack%26aufirst%3DT.%2BB.%26aulast%3DFreisinger%26aufirst%3DP.%26aulast%3DKarall%26aufirst%3DD.%26aulast%3DMakowski%26aufirst%3DC.%26aulast%3DKoch%26aufirst%3DJ.%26aulast%3DFeichtinger%26aufirst%3DR.%2BG.%26aulast%3DZimmermann%26aufirst%3DF.%2BA.%26aulast%3DRolinski%26aufirst%3DB.%26aulast%3DAhting%26aufirst%3DU.%26aulast%3DMeitinger%26aufirst%3DT.%26aulast%3DProkisch%26aufirst%3DH.%26aulast%3DSperl%26aufirst%3DW.%26atitle%3DSpectrum%2520of%2520combined%2520respiratory%2520chain%2520defects%26jtitle%3DJ.%2520Inherited%2520Metab.%2520Dis.%26date%3D2015%26volume%3D38%26spage%3D629%26epage%3D640%26doi%3D10.1007%2Fs10545-015-9831-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref264"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref264'); return false;" data-citation="" class="refNumLink">264</a></strong><div class="NLM_citation" id="cit264"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swalwell, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blakely, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salemi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiana, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compton, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, B. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turnbull, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFarland, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorburn, D. R.</span></span> <span> </span><span class="NLM_article-title">Respiratory chain complex I deficiency caused by mitochondrial DNA mutations</span>. <i>Eur. J. Hum. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">769</span>â <span class="NLM_lpage">775</span>, <span class="refDoi">Â DOI: 10.1038/ejhg.2011.18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref264/cit264&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fejhg.2011.18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref264/cit264&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=21364701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref264/cit264&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsFKqsrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=769-775&author=H.+Swalwellauthor=D.+M.+Kirbyauthor=E.+L.+Blakelyauthor=A.+Mitchellauthor=R.+Salemiauthor=C.+Sugianaauthor=A.+G.+Comptonauthor=E.+J.+Tuckerauthor=B.+X.+Keauthor=P.+J.+Lamontauthor=D.+M.+Turnbullauthor=R.+McFarlandauthor=R.+W.+Taylorauthor=D.+R.+Thorburn&title=Respiratory+chain+complex+I+deficiency+caused+by+mitochondrial+DNA+mutations&doi=10.1038%2Fejhg.2011.18"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit264R"><div class="casContent"><span class="casTitleNuber">264</span><div class="casTitle"><span class="NLM_cas:atitle">Respiratory chain complex I deficiency caused by mitochondrial DNA mutations</span></div><div class="casAuthors">Swalwell, Helen; Kirby, Denise M.; Blakely, Emma L.; Mitchell, Anna; Salemi, Renato; Sugiana, Canny; Compton, Alison G.; Tucker, Elena J.; Ke, Bi-Xia; Lamont, Phillipa J.; Turnbull, Douglass M.; McFarland, Robert; Taylor, Robert W.; Thorburn, David R.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Human Genetics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">769-775</span>CODEN:
                <span class="NLM_cas:coden">EJHGEU</span>;
        ISSN:<span class="NLM_cas:issn">1018-4813</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Defects of the mitochondrial respiratory chain are assocd. with a diverse spectrum of clin. phenotypes, and may be caused by mutations in either the nuclear or the mitochondrial genome (mitochondrial DNA (mtDNA)).  Isolated complex I deficiency is the most common enzyme defect in mitochondrial disorders, particularly in children in whom family history is often consistent with sporadic or autosomal recessive inheritance, implicating a nuclear genetic cause.  In contrast, although a no. of recurrent, pathogenic mtDNA mutations have been described, historically, these have been perceived as rare causes of paediatric complex I deficiency.  We reviewed the clin. and genetic findings in a large cohort of 109 paediatric patients with isolated complex I deficiency from 101 families.  Pathogenic mtDNA mutations were found in 29 of 101 probands (29%), 21 in MTND subunit genes and 8 in mtDNA tRNA genes.  Nuclear gene defects were inferred in 38 of 101 (38%) probands based on cell hybrid studies, mtDNA sequencing or mutation anal. (nuclear gene mutations were identified in 22 probands).  Leigh or Leigh-like disease was the most common clin. presentation in both mtDNA and nuclear genetic defects.  The median age at onset was higher in mtDNA patients (12 mo) than in patients with a nuclear gene defect (3 mo).  However, considerable overlap existed, with onset varying from 0 to >60 mo in both groups.  Our findings confirm that pathogenic mtDNA mutations are a significant cause of complex I deficiency in children.  In the absence of parental consanguinity, we recommend whole mitochondrial genome sequencing as a key approach to elucidate the underlying mol. genetic abnormality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnFp77syio77Vg90H21EOLACvtfcHk0ljEsjU89cCmmA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsFKqsrc%253D&md5=798728c3fdf3d9f4d7e25e6040ca129b</span></div><a href="/servlet/linkout?suffix=cit264&amp;dbid=16384&amp;doi=10.1038%2Fejhg.2011.18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fejhg.2011.18%26sid%3Dliteratum%253Aachs%26aulast%3DSwalwell%26aufirst%3DH.%26aulast%3DKirby%26aufirst%3DD.%2BM.%26aulast%3DBlakely%26aufirst%3DE.%2BL.%26aulast%3DMitchell%26aufirst%3DA.%26aulast%3DSalemi%26aufirst%3DR.%26aulast%3DSugiana%26aufirst%3DC.%26aulast%3DCompton%26aufirst%3DA.%2BG.%26aulast%3DTucker%26aufirst%3DE.%2BJ.%26aulast%3DKe%26aufirst%3DB.%2BX.%26aulast%3DLamont%26aufirst%3DP.%2BJ.%26aulast%3DTurnbull%26aufirst%3DD.%2BM.%26aulast%3DMcFarland%26aufirst%3DR.%26aulast%3DTaylor%26aufirst%3DR.%2BW.%26aulast%3DThorburn%26aufirst%3DD.%2BR.%26atitle%3DRespiratory%2520chain%2520complex%2520I%2520deficiency%2520caused%2520by%2520mitochondrial%2520DNA%2520mutations%26jtitle%3DEur.%2520J.%2520Hum.%2520Genet.%26date%3D2011%26volume%3D19%26spage%3D769%26epage%3D775%26doi%3D10.1038%2Fejhg.2011.18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref265"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref265'); return false;" data-citation="" class="refNumLink">265</a></strong><div class="NLM_citation" id="cit265"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dykens, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marroquin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadanaciva, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billis, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, Y.</span></span> <span> </span><span class="NLM_article-title">Biguanide-induced mitochondrial dysfunction yields increased lactate production and cytotoxicity of aerobically-poised HepG2 cells and human hepatocytes in vitro</span>. <i>Toxicol. Appl. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>233</i></span>,  <span class="NLM_fpage">203</span>â <span class="NLM_lpage">210</span>, <span class="refDoi">Â DOI: 10.1016/j.taap.2008.08.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref265/cit265&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.taap.2008.08.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref265/cit265&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=18817800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref265/cit265&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWrsrvE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=233&publication_year=2008&pages=203-210&author=J.+A.+Dykensauthor=J.+Jamiesonauthor=L.+Marroquinauthor=S.+Nadanacivaauthor=P.+A.+Billisauthor=Y.+Will&title=Biguanide-induced+mitochondrial+dysfunction+yields+increased+lactate+production+and+cytotoxicity+of+aerobically-poised+HepG2+cells+and+human+hepatocytes+in+vitro&doi=10.1016%2Fj.taap.2008.08.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit265R"><div class="casContent"><span class="casTitleNuber">265</span><div class="casTitle"><span class="NLM_cas:atitle">Biguanide-induced mitochondrial dysfunction yields increased lactate production and cytotoxicity of aerobically-poised HepG2 cells and human hepatocytes in vitro</span></div><div class="casAuthors">Dykens, James A.; Jamieson, Joseph; Marroquin, Lisa; Nadanaciva, Sashi; Billis, Puja A.; Will, Yvonne</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">233</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">203-210</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">As a class, the biguanides induce lactic acidosis, a hallmark of mitochondrial impairment.  To assess potential mitochondrial impairment, the authors evaluated the effects of metformin, buformin, and phenformin on: (1) viability of Hep G2 cells grown in galactose, (2) respiration by isolated mitochondria, (3) metabolic poise of Hep G2 and primary human hepatocytes, (4) activities of immunocaptured respiratory complexes, and (5) mitochondrial membrane potential and redox status in primary human hepatocytes.  Phenformin was the most cytotoxic of the 3 with buformin showing moderate toxicity, and metformin toxicity only at mM concns.  Importantly, Hep G2 cells grown in galactose are markedly more susceptible to biguanide toxicity compared to cells grown in glucose, indicating mitochondrial toxicity as a primary mode of action.  The same rank order of potency was obsd. for isolated mitochondrial respiration where preincubation (40 min) exacerbated respiratory impairment, and was required to reveal inhibition by metformin, suggesting intramitochondrial bioaccumulation.  Metabolic profiling of intact cells corroborated respiratory inhibition, but also revelaed compensatory increases in lactate prodn. from accelerated glycolysis.  High (mM) concns. of the drugs were needed to inhibit immunocaptured respiratory complexes, supporting the contention that bioaccumulation is involved.  The same rank order was found when monitoring mitochondrial membrane potential, ROS prodn., and glutathione levels in primary human hepatocytes.  In toto, these data indicate that biguanide-induced lactic acidosis can be attributed to the acceleration of glycolysis in response to mitochondrial impairment.  Indeed, the desired clin. outcome, viz., decreased blood glucose, could be due to increased glucose uptake and glycolytic flux in response to drug-induced mitochondrial dysfunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyusAn3IDvn7Vg90H21EOLACvtfcHk0lgbXATJAR8eSw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWrsrvE&md5=0498abf7a0f51d95c26cbcfd027eea86</span></div><a href="/servlet/linkout?suffix=cit265&amp;dbid=16384&amp;doi=10.1016%2Fj.taap.2008.08.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.taap.2008.08.013%26sid%3Dliteratum%253Aachs%26aulast%3DDykens%26aufirst%3DJ.%2BA.%26aulast%3DJamieson%26aufirst%3DJ.%26aulast%3DMarroquin%26aufirst%3DL.%26aulast%3DNadanaciva%26aufirst%3DS.%26aulast%3DBillis%26aufirst%3DP.%2BA.%26aulast%3DWill%26aufirst%3DY.%26atitle%3DBiguanide-induced%2520mitochondrial%2520dysfunction%2520yields%2520increased%2520lactate%2520production%2520and%2520cytotoxicity%2520of%2520aerobically-poised%2520HepG2%2520cells%2520and%2520human%2520hepatocytes%2520in%2520vitro%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2008%26volume%3D233%26spage%3D203%26epage%3D210%26doi%3D10.1016%2Fj.taap.2008.08.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref266"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref266'); return false;" data-citation="" class="refNumLink">266</a></strong><div class="NLM_citation" id="cit266"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsuzaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphries, K. M.</span></span> <span> </span><span class="NLM_article-title">Selective inhibition of deactivated mitochondrial complex I by biguanides</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2011</span>â <span class="NLM_lpage">2021</span>, <span class="refDoi">Â DOI: 10.1021/bi501473h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi501473h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjsVWktL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=2011-2021&author=S.+Matsuzakiauthor=K.+M.+Humphries&title=Selective+inhibition+of+deactivated+mitochondrial+complex+I+by+biguanides&doi=10.1021%2Fbi501473h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit266R"><div class="casContent"><span class="casTitleNuber">266</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of Deactivated Mitochondrial Complex I by Biguanides</span></div><div class="casAuthors">Matsuzaki, Satoshi; Humphries, Kenneth M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2011-2021</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Biguanides are widely used antihyperglycemic agents for diabetes mellitus and prediabetes treatment.  Complex I is the rate-limiting step of the mitochondrial electron transport chain (ETC), a major source of mitochondrial free radical prodn., and a known target of biguanides.  Complex I has two reversible conformational states, active and de-active.  The deactivated state is promoted in the absence of substrates but is rapidly and fully reversed to the active state in the presence of NADH.  The objective of this study was to det. the relative sensitivity of active/de-active complex I to biguanide-mediated inhibition and resulting superoxide radical (O2â¢-) prodn.  Using isolated rat heart mitochondria, we show that deactivation of complex I sensitizes it to metformin and phenformin (4- and 3-fold, resp.), but not to other known complex I inhibitors, such as rotenone.  Mitochondrial O2â¢- prodn. by deactivated complex I was measured fluorescently by NADH-dependent 2-hydroxyethidium formation at alk. pH to impede reactivation.  Superoxide prodn. was 260.4% higher than in active complex I at pH 9.4.  However, phenformin treatment of de-active complex I decreased O2â¢- prodn. by 14.9%, while rotenone increased prodn. by 42.9%.  Mitochondria isolated from rat hearts subjected to cardiac ischemia, a condition known to induce complex I deactivation, were sensitized to phenformin-mediated complex I inhibition.  This supports the idea that the effects of biguanides are likely to be influenced by the complex I state in vivo.  These results demonstrate that the complex I active and de-active states are a determinant in biguanide-mediated inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbHt2BvRy2B7Vg90H21EOLACvtfcHk0lgbXATJAR8eSw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjsVWktL4%253D&md5=36cecff6a7376699bc32a5673ed33e1c</span></div><a href="/servlet/linkout?suffix=cit266&amp;dbid=16384&amp;doi=10.1021%2Fbi501473h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi501473h%26sid%3Dliteratum%253Aachs%26aulast%3DMatsuzaki%26aufirst%3DS.%26aulast%3DHumphries%26aufirst%3DK.%2BM.%26atitle%3DSelective%2520inhibition%2520of%2520deactivated%2520mitochondrial%2520complex%2520I%2520by%2520biguanides%26jtitle%3DBiochemistry%26date%3D2015%26volume%3D54%26spage%3D2011%26epage%3D2021%26doi%3D10.1021%2Fbi501473h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref267"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref267'); return false;" data-citation="" class="refNumLink">267</a></strong><div class="NLM_citation" id="cit267"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilde, A.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyndrickx, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carton, D.</span></span> <span> </span><span class="NLM_article-title">A case of fatal rotenone poisoning in a child</span>. <i>J. Forensic Sci.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">1492</span>â <span class="NLM_lpage">1498</span>, <span class="refDoi">Â DOI: 10.1520/JFS11931J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref267/cit267&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1520%2FJFS11931J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref267/cit267&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=3783116" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1986&pages=1492-1498&author=A.-R.+Wildeauthor=A.+Heyndrickxauthor=D.+Carton&title=A+case+of+fatal+rotenone+poisoning+in+a+child&doi=10.1520%2FJFS11931J"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit267&amp;dbid=16384&amp;doi=10.1520%2FJFS11931J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1520%252FJFS11931J%26sid%3Dliteratum%253Aachs%26aulast%3DWilde%26aufirst%3DA.-R.%26aulast%3DHeyndrickx%26aufirst%3DA.%26aulast%3DCarton%26aufirst%3DD.%26atitle%3DA%2520case%2520of%2520fatal%2520rotenone%2520poisoning%2520in%2520a%2520child%26jtitle%3DJ.%2520Forensic%2520Sci.%26date%3D1986%26volume%3D31%26spage%3D1492%26epage%3D1498%26doi%3D10.1520%2FJFS11931J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref268"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref268'); return false;" data-citation="" class="refNumLink">268</a></strong><div class="NLM_citation" id="cit268"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wood, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alsahaf, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streete, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dargan, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, A. L.</span></span> <span> </span><span class="NLM_article-title">Fatality after deliberate ingestion of the pesticide rotenone: a case report</span>. <i>Critical Care</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">R280</span>â <span class="NLM_lpage">R284</span>, <span class="refDoi">Â DOI: 10.1186/cc3528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref268/cit268&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1186%2Fcc3528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref268/cit268&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=15987402" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2005&pages=R280-R284&author=D.+M.+Woodauthor=H.+Alsahafauthor=P.+Streeteauthor=P.+I.+Darganauthor=A.+L.+Jones&title=Fatality+after+deliberate+ingestion+of+the+pesticide+rotenone%3A+a+case+report&doi=10.1186%2Fcc3528"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit268&amp;dbid=16384&amp;doi=10.1186%2Fcc3528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fcc3528%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DD.%2BM.%26aulast%3DAlsahaf%26aufirst%3DH.%26aulast%3DStreete%26aufirst%3DP.%26aulast%3DDargan%26aufirst%3DP.%2BI.%26aulast%3DJones%26aufirst%3DA.%2BL.%26atitle%3DFatality%2520after%2520deliberate%2520ingestion%2520of%2520the%2520pesticide%2520rotenone%253A%2520a%2520case%2520report%26jtitle%3DCritical%2520Care%26date%3D2005%26volume%3D9%26spage%3DR280%26epage%3DR284%26doi%3D10.1186%2Fcc3528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref269"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref269'); return false;" data-citation="" class="refNumLink">269</a></strong><div class="NLM_citation" id="cit269"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swalwell, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blakely, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salemi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiana, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compton, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turnbull, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFarland, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorburn, D. R.</span></span> <span> </span><span class="NLM_article-title">Respiratory chain complex I deficiency caused by mitochondrial DNA mutations</span>. <i>Eur. J. Hum. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">769</span>â <span class="NLM_lpage">775</span>, <span class="refDoi">Â DOI: 10.1038/ejhg.2011.18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fejhg.2011.18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=21364701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsFKqsrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=769-775&author=H.+Swalwellauthor=D.+M.+Kirbyauthor=E.+L.+Blakelyauthor=A.+Mitchellauthor=R.+Salemiauthor=C.+Sugianaauthor=A.+G.+Comptonauthor=E.+J.+Tuckerauthor=X.+Keauthor=P.+J.+Lamontauthor=D.+M.+Turnbullauthor=R.+McFarlandauthor=R.+W.+Taylorauthor=D.+R.+Thorburn&title=Respiratory+chain+complex+I+deficiency+caused+by+mitochondrial+DNA+mutations&doi=10.1038%2Fejhg.2011.18"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit269R"><div class="casContent"><span class="casTitleNuber">269</span><div class="casTitle"><span class="NLM_cas:atitle">Respiratory chain complex I deficiency caused by mitochondrial DNA mutations</span></div><div class="casAuthors">Swalwell, Helen; Kirby, Denise M.; Blakely, Emma L.; Mitchell, Anna; Salemi, Renato; Sugiana, Canny; Compton, Alison G.; Tucker, Elena J.; Ke, Bi-Xia; Lamont, Phillipa J.; Turnbull, Douglass M.; McFarland, Robert; Taylor, Robert W.; Thorburn, David R.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Human Genetics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">769-775</span>CODEN:
                <span class="NLM_cas:coden">EJHGEU</span>;
        ISSN:<span class="NLM_cas:issn">1018-4813</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Defects of the mitochondrial respiratory chain are assocd. with a diverse spectrum of clin. phenotypes, and may be caused by mutations in either the nuclear or the mitochondrial genome (mitochondrial DNA (mtDNA)).  Isolated complex I deficiency is the most common enzyme defect in mitochondrial disorders, particularly in children in whom family history is often consistent with sporadic or autosomal recessive inheritance, implicating a nuclear genetic cause.  In contrast, although a no. of recurrent, pathogenic mtDNA mutations have been described, historically, these have been perceived as rare causes of paediatric complex I deficiency.  We reviewed the clin. and genetic findings in a large cohort of 109 paediatric patients with isolated complex I deficiency from 101 families.  Pathogenic mtDNA mutations were found in 29 of 101 probands (29%), 21 in MTND subunit genes and 8 in mtDNA tRNA genes.  Nuclear gene defects were inferred in 38 of 101 (38%) probands based on cell hybrid studies, mtDNA sequencing or mutation anal. (nuclear gene mutations were identified in 22 probands).  Leigh or Leigh-like disease was the most common clin. presentation in both mtDNA and nuclear genetic defects.  The median age at onset was higher in mtDNA patients (12 mo) than in patients with a nuclear gene defect (3 mo).  However, considerable overlap existed, with onset varying from 0 to >60 mo in both groups.  Our findings confirm that pathogenic mtDNA mutations are a significant cause of complex I deficiency in children.  In the absence of parental consanguinity, we recommend whole mitochondrial genome sequencing as a key approach to elucidate the underlying mol. genetic abnormality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnFp77syio77Vg90H21EOLACvtfcHk0lgbXATJAR8eSw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsFKqsrc%253D&md5=798728c3fdf3d9f4d7e25e6040ca129b</span></div><a href="/servlet/linkout?suffix=cit269&amp;dbid=16384&amp;doi=10.1038%2Fejhg.2011.18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fejhg.2011.18%26sid%3Dliteratum%253Aachs%26aulast%3DSwalwell%26aufirst%3DH.%26aulast%3DKirby%26aufirst%3DD.%2BM.%26aulast%3DBlakely%26aufirst%3DE.%2BL.%26aulast%3DMitchell%26aufirst%3DA.%26aulast%3DSalemi%26aufirst%3DR.%26aulast%3DSugiana%26aufirst%3DC.%26aulast%3DCompton%26aufirst%3DA.%2BG.%26aulast%3DTucker%26aufirst%3DE.%2BJ.%26aulast%3DKe%26aufirst%3DX.%26aulast%3DLamont%26aufirst%3DP.%2BJ.%26aulast%3DTurnbull%26aufirst%3DD.%2BM.%26aulast%3DMcFarland%26aufirst%3DR.%26aulast%3DTaylor%26aufirst%3DR.%2BW.%26aulast%3DThorburn%26aufirst%3DD.%2BR.%26atitle%3DRespiratory%2520chain%2520complex%2520I%2520deficiency%2520caused%2520by%2520mitochondrial%2520DNA%2520mutations%26jtitle%3DEur.%2520J.%2520Hum.%2520Genet.%26date%3D2011%26volume%3D19%26spage%3D769%26epage%3D775%26doi%3D10.1038%2Fejhg.2011.18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref270"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref270'); return false;" data-citation="" class="refNumLink">270</a></strong><div class="NLM_citation" id="cit270"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carithers, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardlie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barcus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Branton, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Britton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buia, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compton, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeLuca, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peter-Demchok, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelfand, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korzeniewski, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabiner, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roche, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segre, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shive, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobin, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Undale, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentino, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaught, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, H. M.</span></span> <span> </span><span class="NLM_article-title">Consortium, G. A novel approach to high-quality postmortem tissue procurement: the GTEx project</span>. <i>Biopreserv. Biobanking</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">311</span>â <span class="NLM_lpage">319</span>, <span class="refDoi">Â DOI: 10.1089/bio.2015.0032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref270/cit270&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1089%2Fbio.2015.0032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref270/cit270&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=26484571" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=311-319&author=L.+J.+Carithersauthor=K.+Ardlieauthor=M.+Barcusauthor=P.+A.+Brantonauthor=A.+Brittonauthor=S.+A.+Buiaauthor=C.+C.+Comptonauthor=D.+S.+DeLucaauthor=J.+Peter-Demchokauthor=E.+T.+Gelfandauthor=P.+Guanauthor=G.+E.+Korzeniewskiauthor=N.+C.+Lockhartauthor=C.+A.+Rabinerauthor=A.+K.+Raoauthor=K.+L.+Robinsonauthor=N.+V.+Rocheauthor=S.+J.+Sawyerauthor=A.+V.+Segreauthor=C.+E.+Shiveauthor=A.+M.+Smithauthor=L.+H.+Sobinauthor=A.+H.+Undaleauthor=K.+M.+Valentinoauthor=J.+Vaughtauthor=T.+R.+Youngauthor=H.+M.+Moore&title=Consortium%2C+G.+A+novel+approach+to+high-quality+postmortem+tissue+procurement%3A+the+GTEx+project&doi=10.1089%2Fbio.2015.0032"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit270&amp;dbid=16384&amp;doi=10.1089%2Fbio.2015.0032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fbio.2015.0032%26sid%3Dliteratum%253Aachs%26aulast%3DCarithers%26aufirst%3DL.%2BJ.%26aulast%3DArdlie%26aufirst%3DK.%26aulast%3DBarcus%26aufirst%3DM.%26aulast%3DBranton%26aufirst%3DP.%2BA.%26aulast%3DBritton%26aufirst%3DA.%26aulast%3DBuia%26aufirst%3DS.%2BA.%26aulast%3DCompton%26aufirst%3DC.%2BC.%26aulast%3DDeLuca%26aufirst%3DD.%2BS.%26aulast%3DPeter-Demchok%26aufirst%3DJ.%26aulast%3DGelfand%26aufirst%3DE.%2BT.%26aulast%3DGuan%26aufirst%3DP.%26aulast%3DKorzeniewski%26aufirst%3DG.%2BE.%26aulast%3DLockhart%26aufirst%3DN.%2BC.%26aulast%3DRabiner%26aufirst%3DC.%2BA.%26aulast%3DRao%26aufirst%3DA.%2BK.%26aulast%3DRobinson%26aufirst%3DK.%2BL.%26aulast%3DRoche%26aufirst%3DN.%2BV.%26aulast%3DSawyer%26aufirst%3DS.%2BJ.%26aulast%3DSegre%26aufirst%3DA.%2BV.%26aulast%3DShive%26aufirst%3DC.%2BE.%26aulast%3DSmith%26aufirst%3DA.%2BM.%26aulast%3DSobin%26aufirst%3DL.%2BH.%26aulast%3DUndale%26aufirst%3DA.%2BH.%26aulast%3DValentino%26aufirst%3DK.%2BM.%26aulast%3DVaught%26aufirst%3DJ.%26aulast%3DYoung%26aufirst%3DT.%2BR.%26aulast%3DMoore%26aufirst%3DH.%2BM.%26atitle%3DConsortium%252C%2520G.%2520A%2520novel%2520approach%2520to%2520high-quality%2520postmortem%2520tissue%2520procurement%253A%2520the%2520GTEx%2520project%26jtitle%3DBiopreserv.%2520Biobanking%26date%3D2015%26volume%3D13%26spage%3D311%26epage%3D319%26doi%3D10.1089%2Fbio.2015.0032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref271"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref271'); return false;" data-citation="" class="refNumLink">271</a></strong><div class="NLM_citation" id="cit271"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yap, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahnert, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piha-Paul, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, S. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janku, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karp, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naing, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumbrava, E. E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pant, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subbiah, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsimberidou, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vellano, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahendra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Francesco, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marszalek, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meric-Bernstam, F.</span></span> <span> </span><span class="NLM_article-title">Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial electron transport chain, in patients (pts) with advanced solid tumors</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">3014</span>â <span class="NLM_lpage">3014</span>, <span class="refDoi">Â DOI: 10.1200/JCO.2019.37.15_suppl.3014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref271/cit271&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1200%2FJCO.2019.37.15_suppl.3014" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=3014-3014&author=T.+A.+Yapauthor=J.+R.+Ahnertauthor=S.+A.+Piha-Paulauthor=S.+Q.+Fuauthor=F.+Jankuauthor=D.+D.+Karpauthor=A.+Naingauthor=E.+E.+I.+Dumbravaauthor=S.+Pantauthor=V.+Subbiahauthor=A.+M.+Tsimberidouauthor=D.+S.+Hongauthor=K.+M.+Roseauthor=Q.+Y.+Xuauthor=C.+P.+Vellanoauthor=M.+Mahendraauthor=P.+Jonesauthor=M.+E.+Di+Francescoauthor=J.+R.+Marszalekauthor=F.+Meric-Bernstam&title=Phase+I+trial+of+IACS-010759+%28IACS%29%2C+a+potent%2C+selective+inhibitor+of+complex+I+of+the+mitochondrial+electron+transport+chain%2C+in+patients+%28pts%29+with+advanced+solid+tumors&doi=10.1200%2FJCO.2019.37.15_suppl.3014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit271&amp;dbid=16384&amp;doi=10.1200%2FJCO.2019.37.15_suppl.3014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2019.37.15_suppl.3014%26sid%3Dliteratum%253Aachs%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DAhnert%26aufirst%3DJ.%2BR.%26aulast%3DPiha-Paul%26aufirst%3DS.%2BA.%26aulast%3DFu%26aufirst%3DS.%2BQ.%26aulast%3DJanku%26aufirst%3DF.%26aulast%3DKarp%26aufirst%3DD.%2BD.%26aulast%3DNaing%26aufirst%3DA.%26aulast%3DDumbrava%26aufirst%3DE.%2BE.%2BI.%26aulast%3DPant%26aufirst%3DS.%26aulast%3DSubbiah%26aufirst%3DV.%26aulast%3DTsimberidou%26aufirst%3DA.%2BM.%26aulast%3DHong%26aufirst%3DD.%2BS.%26aulast%3DRose%26aufirst%3DK.%2BM.%26aulast%3DXu%26aufirst%3DQ.%2BY.%26aulast%3DVellano%26aufirst%3DC.%2BP.%26aulast%3DMahendra%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DDi%2BFrancesco%26aufirst%3DM.%2BE.%26aulast%3DMarszalek%26aufirst%3DJ.%2BR.%26aulast%3DMeric-Bernstam%26aufirst%3DF.%26atitle%3DPhase%2520I%2520trial%2520of%2520IACS-010759%2520%2528IACS%2529%252C%2520a%2520potent%252C%2520selective%2520inhibitor%2520of%2520complex%2520I%2520of%2520the%2520mitochondrial%2520electron%2520transport%2520chain%252C%2520in%2520patients%2520%2528pts%2529%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2019%26volume%3D37%26spage%3D3014%26epage%3D3014%26doi%3D10.1200%2FJCO.2019.37.15_suppl.3014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref272"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref272'); return false;" data-citation="" class="refNumLink">272</a></strong><div class="NLM_citation" id="cit272"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Varga, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferdinandy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liaudet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacher, P.</span></span> <span> </span><span class="NLM_article-title">Drug-induced mitochondrial dysfunction and cardiotoxicity</span>. <i>Am. J. Physiol-Heart C</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>309</i></span>,  <span class="NLM_fpage">H1453</span>â <span class="NLM_lpage">H1467</span>, <span class="refDoi">Â DOI: 10.1152/ajpheart.00554.2015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref272/cit272&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1152%2Fajpheart.00554.2015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref272/cit272&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=26386112" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=309&publication_year=2015&pages=H1453-H1467&author=Z.+V.+Vargaauthor=P.+Ferdinandyauthor=L.+Liaudetauthor=P.+Pacher&title=Drug-induced+mitochondrial+dysfunction+and+cardiotoxicity&doi=10.1152%2Fajpheart.00554.2015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit272&amp;dbid=16384&amp;doi=10.1152%2Fajpheart.00554.2015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpheart.00554.2015%26sid%3Dliteratum%253Aachs%26aulast%3DVarga%26aufirst%3DZ.%2BV.%26aulast%3DFerdinandy%26aufirst%3DP.%26aulast%3DLiaudet%26aufirst%3DL.%26aulast%3DPacher%26aufirst%3DP.%26atitle%3DDrug-induced%2520mitochondrial%2520dysfunction%2520and%2520cardiotoxicity%26jtitle%3DAm.%2520J.%2520Physiol-Heart%2520C%26date%3D2015%26volume%3D309%26spage%3DH1453%26epage%3DH1467%26doi%3D10.1152%2Fajpheart.00554.2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref273"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref273'); return false;" data-citation="" class="refNumLink">273</a></strong><div class="NLM_citation" id="cit273"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clements, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalinka, S.</span></span> <span> </span><span class="NLM_article-title">Bridging functional and structural cardiotoxicity assays using human embryonic stem cell-derived cardiomyocytes for a more comprehensive risk assessment</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">241</span>â <span class="NLM_lpage">260</span>, <span class="refDoi">Â DOI: 10.1093/toxsci/kfv180</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1093%2Ftoxsci%2Fkfv180" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=26259608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGisrjI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2015&pages=241-260&author=M.+Clementsauthor=V.+Millarauthor=A.+S.+Williamsauthor=S.+Kalinka&title=Bridging+functional+and+structural+cardiotoxicity+assays+using+human+embryonic+stem+cell-derived+cardiomyocytes+for+a+more+comprehensive+risk+assessment&doi=10.1093%2Ftoxsci%2Fkfv180"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit273R"><div class="casContent"><span class="casTitleNuber">273</span><div class="casTitle"><span class="NLM_cas:atitle">Bridging functional and structural cardiotoxicity assays using human embryonic stem cell-derived cardiomyocytes for a more comprehensive risk assessment</span></div><div class="casAuthors">Clements, Mike; Millar, Val; Williams, Angela S.; Kalinka, Sian</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">241-260</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">More relevant and reliable preclin. cardiotoxicity tests are required to improve drug safety and reduce the cost of drug development.  Current in vitro testing strategies predominantly take the form of functional assays to predict the potential for drug-induced ECG abnormalities in vivo.  Cardiotoxicity can also be structural in nature, so a full and efficient assessment of cardiac liabilities for new chem. entities should account for both these phenomena.  As well as providing a more appropriate nonclin. model for in vitro cardiotoxicity testing, human stem cell-derived cardiomyocytes offer an integrated system to study drug impact on cardiomyocyte structure as well as function.  Employing human embryonic stem cell-derived cardiacmyocytes (hESC-CMs) on 3 assay platforms with complementary insights into cardiac biol. (multielectrode array assay, electrophysiol.; impedance assay, cell movement/beating; and high content anal. assay, subcellular structure) we profiled a panel of 13 drugs with well characterized cardiac liabilities (Amiodarone, Aspirin, Astemizole, Axitinib, AZT, Bepridil, Doxorubicin, E-4031, Mexiletine, Rosiglitazone, Sunitinib, Sibutramine, and Verapamil).  Our data show good correlations with previous studies and reported clin. observations.  Using multiparameter phenotypic profiling techniques we demonstrate the dynamic relationship that exists between functional and structural toxicity, and the benefits of this more holistic approach to risk assessment.  We conclude by showing for the first time how the advent of transparent MEA plate technol. enables functional and structural cardiotoxic responses to be recorded from the same cell population.  This approach more directly links changes in morphol. of the hESC-CMs with recorded electrophysiol. signatures, offering even greater insight into the wide range of potential drug impacts on cardiac physiol., with a throughput that is more amenable to early drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL2UD57jfwtLVg90H21EOLACvtfcHk0lgpn_nblY11Vw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGisrjI&md5=61b9f0c1e2449277825ae5dc1005fdee</span></div><a href="/servlet/linkout?suffix=cit273&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfv180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfv180%26sid%3Dliteratum%253Aachs%26aulast%3DClements%26aufirst%3DM.%26aulast%3DMillar%26aufirst%3DV.%26aulast%3DWilliams%26aufirst%3DA.%2BS.%26aulast%3DKalinka%26aufirst%3DS.%26atitle%3DBridging%2520functional%2520and%2520structural%2520cardiotoxicity%2520assays%2520using%2520human%2520embryonic%2520stem%2520cell-derived%2520cardiomyocytes%2520for%2520a%2520more%2520comprehensive%2520risk%2520assessment%26jtitle%3DToxicol.%2520Sci.%26date%3D2015%26volume%3D148%26spage%3D241%26epage%3D260%26doi%3D10.1093%2Ftoxsci%2Fkfv180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref274"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref274'); return false;" data-citation="" class="refNumLink">274</a></strong><div class="NLM_citation" id="cit274"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rana, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aleo, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gosink, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, Y.</span></span> <span> </span><span class="NLM_article-title">Evaluation of in vitro mitochondrial toxicity assays and physicochemical properties for prediction of organ toxicity using 228 pharmaceutical drugs</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">156</span>â <span class="NLM_lpage">167</span>, <span class="refDoi">Â DOI: 10.1021/acs.chemrestox.8b00246</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.8b00246" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref274/cit274&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVens7bM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2019&pages=156-167&author=P.+Ranaauthor=M.+D.+Aleoauthor=M.+Gosinkauthor=Y.+Will&title=Evaluation+of+in+vitro+mitochondrial+toxicity+assays+and+physicochemical+properties+for+prediction+of+organ+toxicity+using+228+pharmaceutical+drugs&doi=10.1021%2Facs.chemrestox.8b00246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit274R"><div class="casContent"><span class="casTitleNuber">274</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of in Vitro Mitochondrial Toxicity Assays and Physicochemical Properties for Prediction of Organ Toxicity Using 228 Pharmaceutical Drugs</span></div><div class="casAuthors">Rana, Payal; Aleo, Michael D.; Gosink, Mark; Will, Yvonne</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">156-167</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mitochondrial toxicity has been shown to contribute to a variety of organ toxicities such as liver, cardiac, and kidney.  In the past decades, two high-throughput applicable screening assays (isolated rat liver mitochondria; glucose-galactose grown HepG2 cells) to assess mitochondrial toxicity have been deployed in many pharmaceutical companies, and numerous publications have demonstrated its usefulness for mechanistic investigations.  However, only two publications have demonstrated the utility of these screens as a predictor of human drug-induced liver injury.  In the present study, the authors screened 73 hepatotoxicants, 46 cardiotoxicants, 49 nephrotoxicants, and 60 compds. not known to cause human organ toxicity for their effects on mitochondrial function(s) in the assays mentioned above.  Predictive performance was evaluated using specificity and sensitivity of the assays for predicting organ toxicity.  The authors' results show that the predictive performance of the mitochondrial assays are superior for hepatotoxicity as compared to cardiotoxicity and nephrotoxicity (sensitivity 63% vs. 33% and 28% with similar specificity of 93%), when the anal. was done at 100* Cmax (drug concn. in human plasma level).  The authors further explored the assocn. of mitochondrial toxicity with physicochem. properties such as calcd. log partition coeff. (cLogP), topol. polar surface area, ionization status, and mol. wt. of the drugs and found that cLogP was most significantly assocd. mitochondrial toxicity.  Since these assays are amenable to higher throughput, the authors recommend that chemists use these assays to perform structure activity relationship early in the drug discovery process, when chem. matter is abundant.  This assures that compds. that lack the propensity to cause mitochondrial dysfunction (and assocd. organ toxicity) will move forward into animals and humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7Rad7gm0MrLVg90H21EOLACvtfcHk0lgpn_nblY11Vw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVens7bM&md5=82bc95a1604961473a4e5fecb05aab79</span></div><a href="/servlet/linkout?suffix=cit274&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.8b00246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.8b00246%26sid%3Dliteratum%253Aachs%26aulast%3DRana%26aufirst%3DP.%26aulast%3DAleo%26aufirst%3DM.%2BD.%26aulast%3DGosink%26aufirst%3DM.%26aulast%3DWill%26aufirst%3DY.%26atitle%3DEvaluation%2520of%2520in%2520vitro%2520mitochondrial%2520toxicity%2520assays%2520and%2520physicochemical%2520properties%2520for%2520prediction%2520of%2520organ%2520toxicity%2520using%2520228%2520pharmaceutical%2520drugs%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2019%26volume%3D32%26spage%3D156%26epage%3D167%26doi%3D10.1021%2Facs.chemrestox.8b00246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref275"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref275'); return false;" data-citation="" class="refNumLink">275</a></strong><div class="NLM_citation" id="cit275"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aleo, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swiss, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonin, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, Y.</span></span> <span> </span><span class="NLM_article-title">Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1015</span>â <span class="NLM_lpage">1022</span>, <span class="refDoi">Â DOI: 10.1002/hep.27206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1002%2Fhep.27206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=24799086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGhtbnJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2014&pages=1015-1022&author=M.+D.+Aleoauthor=Y.+Luoauthor=R.+Swissauthor=P.+D.+Boninauthor=D.+M.+Potterauthor=Y.+Will&title=Human+drug-induced+liver+injury+severity+is+highly+associated+with+dual+inhibition+of+liver+mitochondrial+function+and+bile+salt+export+pump&doi=10.1002%2Fhep.27206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit275R"><div class="casContent"><span class="casTitleNuber">275</span><div class="casTitle"><span class="NLM_cas:atitle">Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump</span></div><div class="casAuthors">Aleo, Michael D.; Luo, Yi; Swiss, Rachel; Bonin, Paul D.; Potter, David M.; Will, Yvonne</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1015-1022</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) accounts for 20-40% of all instances of clin. hepatic failure and is a common reason for withdrawal of an approved drug or discontinuation of a potentially new drug from clin./nonclin. development.  Numerous individual risk factors contribute to the susceptibility to human DILI and its severity that are either compd.- and/or patient-specific.  Compd.-specific primary mechanisms linked to DILI include: cytotoxicity, reactive metabolite formation, inhibition of bile salt export pump (BSEP), and mitochondrial dysfunction.  Since BSEP is an energy-dependent protein responsible for the efflux of bile acids from hepatocytes, it was hypothesized that humans exposed to drugs that impair both mitochondrial energetics and BSEP functional activity are more sensitive to more severe manifestations of DILI than drugs that only have a single liability factor.  As annotated in the United States National Center for Toxicol. Research Liver Toxicity Knowledge Base (NCTR-LTKB), the inhibitory properties of 24 Most-DILI-, 28 Less-DILI-, and 20 No-DILI-concern drugs were investigated.  Drug potency for inhibiting BSEP or mitochondrial activity was generally correlated across human DILI concern categories.  However, drugs with dual potency as mitochondrial and BSEP inhibitors were highly assocd. with more severe human DILI, more restrictive product safety labeling related to liver injury, and appear more sensitive to the drug exposure (Cmax) where more restrictive labeling occurs.  Conclusion: These data affirm that severe manifestations of human DILI are multifactorial, highly assocd. with combinations of drug potency specifically related to known mechanisms of DILI (like mitochondrial and BSEP inhibition), and, along with patient-specific factors, lead to differences in the severity and exposure thresholds assocd. with clin. DILI. (Hepatol. 2014;60:1015-1022).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIKfBrKEsFMbVg90H21EOLACvtfcHk0lgpn_nblY11Vw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGhtbnJ&md5=9bc646d27738ab811ebc526d520c83bf</span></div><a href="/servlet/linkout?suffix=cit275&amp;dbid=16384&amp;doi=10.1002%2Fhep.27206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27206%26sid%3Dliteratum%253Aachs%26aulast%3DAleo%26aufirst%3DM.%2BD.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DSwiss%26aufirst%3DR.%26aulast%3DBonin%26aufirst%3DP.%2BD.%26aulast%3DPotter%26aufirst%3DD.%2BM.%26aulast%3DWill%26aufirst%3DY.%26atitle%3DHuman%2520drug-induced%2520liver%2520injury%2520severity%2520is%2520highly%2520associated%2520with%2520dual%2520inhibition%2520of%2520liver%2520mitochondrial%2520function%2520and%2520bile%2520salt%2520export%2520pump%26jtitle%3DHepatology%26date%3D2014%26volume%3D60%26spage%3D1015%26epage%3D1022%26doi%3D10.1002%2Fhep.27206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref276"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref276'); return false;" data-citation="" class="refNumLink">276</a></strong><div class="NLM_citation" id="cit276"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rana, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kogut, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhlaghi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aleo, M. D.</span></span> <span> </span><span class="NLM_article-title">Most influential physicochemical and in vitro assay descriptors for hepatotoxicity and nephrotoxicity prediction</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1780</span>, <span class="refDoi">Â DOI: 10.1021/acs.chemrestox.0c00040</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.0c00040" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnvFartb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2020&pages=1780&author=P.+Ranaauthor=S.+Kogutauthor=X.+Wenauthor=F.+Akhlaghiauthor=M.+D.+Aleo&title=Most+influential+physicochemical+and+in+vitro+assay+descriptors+for+hepatotoxicity+and+nephrotoxicity+prediction&doi=10.1021%2Facs.chemrestox.0c00040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit276R"><div class="casContent"><span class="casTitleNuber">276</span><div class="casTitle"><span class="NLM_cas:atitle">Most Influential Physicochemical and In Vitro Assay Descriptors for Hepatotoxicity and Nephrotoxicity Prediction</span></div><div class="casAuthors">Rana, Payal; Kogut, Stephen; Wen, Xuerong; Akhlaghi, Fatemeh; Aleo, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1780-1790</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Drug-induced organ injury is a major reason for drug candidate attrition in preclin. and clin. drug development.  The liver, kidneys, and heart have been recognized as the most common organ systems affected in safety-related attrition or the subject of black box warnings and postmarket drug withdrawals.  In silico physicochem. property calcns. and in vitro assays have been utilized sep. in the early stages of the drug discovery and development process to predict drug safety.  In this study, we combined physicochem. properties and in vitro cytotoxicity assays including mitochondrial dysfunction to build organ-specific univariate and multivariable logistic regression models to achieve odds ratios for the prediction of clin. hepatotoxicity, nephrotoxicity, and cardiotoxicity using 215 marketed drugs.  The multivariable hepatotoxic predictive model showed an odds ratio of 6.2 (95% confidence interval (CI) 1.7-22.8) or 7.5 (95% CI 3.2-17.8) for mitochondrial inhibition or drug plasma Cmax >1Î¼M for drugs assocd. with liver injury, resp.  The multivariable nephrotoxicity predictive model showed an odds ratio of 5.8 (95% CI 2.0-16.9), 6.4 (95% CI 1.1-39.3), or 15.9 (95% CI 2.8-89.0) for drug plasma Cmax >1Î¼M, mitochondrial inhibition, or hydrogen-bond-acceptor atoms >7 for drugs assocd. with kidney injury, resp.  Conversely, drugs with a total polar surface area â¥75 Ã were 79% (odds ratio 0.21, 95% CI 0.061-0.74) less likely to be assocd. with kidney injury.  Drugs belonging to the extended clearance classification system (ECCS) class 4, where renal secretion is the primary clearance mechanism (low permeability drugs that are bases/neutrals), were 4 (95% CI 1.8-9.5) times more likely to be assocd. with kidney injury with this data set.  Alternatively, ECCS class 2 drugs, where hepatic metab. is the primary clearance (high permeability drugs that are bases/neutrals) were 77% less likely (odds ratio 0.23 95% CI 0.095-0.54) to be assocd. with kidney injury.  A cardiotoxicity model was poorly defined using any of these drug physicochem. attributes.  Combining in silico physicochem. properties descriptors along with in vitro toxicity assays can be used to build predictive toxicity models to select small mol. therapeutics with less potential to cause liver and kidney organ toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoH-dHCC41dV7Vg90H21EOLACvtfcHk0lgpn_nblY11Vw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnvFartb8%253D&md5=3c6054a86323ef005316d93bc2e5e463</span></div><a href="/servlet/linkout?suffix=cit276&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.0c00040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.0c00040%26sid%3Dliteratum%253Aachs%26aulast%3DRana%26aufirst%3DP.%26aulast%3DKogut%26aufirst%3DS.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DAkhlaghi%26aufirst%3DF.%26aulast%3DAleo%26aufirst%3DM.%2BD.%26atitle%3DMost%2520influential%2520physicochemical%2520and%2520in%2520vitro%2520assay%2520descriptors%2520for%2520hepatotoxicity%2520and%2520nephrotoxicity%2520prediction%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2020%26volume%3D33%26spage%3D1780%26doi%3D10.1021%2Facs.chemrestox.0c00040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref277"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref277'); return false;" data-citation="" class="refNumLink">277</a></strong><div class="NLM_citation" id="cit277"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miralles-Linares, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puerta-Fernandez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernal-Lopez, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tinahones, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrade, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-Huelgas, R.</span></span> <span> </span><span class="NLM_article-title">Metformin-induced hepatotoxicity</span>. <i>Diabetes Care</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">E21</span>â <span class="NLM_lpage">E21</span>, <span class="refDoi">Â DOI: 10.2337/dc11-2306</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref277/cit277&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.2337%2Fdc11-2306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref277/cit277&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=22355024" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2012&pages=E21-E21&author=F.+Miralles-Linaresauthor=S.+Puerta-Fernandezauthor=M.+R.+Bernal-Lopezauthor=F.+J.+Tinahonesauthor=R.+J.+Andradeauthor=R.+Gomez-Huelgas&title=Metformin-induced+hepatotoxicity&doi=10.2337%2Fdc11-2306"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit277&amp;dbid=16384&amp;doi=10.2337%2Fdc11-2306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdc11-2306%26sid%3Dliteratum%253Aachs%26aulast%3DMiralles-Linares%26aufirst%3DF.%26aulast%3DPuerta-Fernandez%26aufirst%3DS.%26aulast%3DBernal-Lopez%26aufirst%3DM.%2BR.%26aulast%3DTinahones%26aufirst%3DF.%2BJ.%26aulast%3DAndrade%26aufirst%3DR.%2BJ.%26aulast%3DGomez-Huelgas%26aufirst%3DR.%26atitle%3DMetformin-induced%2520hepatotoxicity%26jtitle%3DDiabetes%2520Care%26date%3D2012%26volume%3D35%26spage%3DE21%26epage%3DE21%26doi%3D10.2337%2Fdc11-2306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref278"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref278'); return false;" data-citation="" class="refNumLink">278</a></strong><div class="NLM_citation" id="cit278"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koopman, W. J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Distelmaier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeitink, J. A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willems, P. H. G. M.</span></span> <span> </span><span class="NLM_article-title">OXPHOS mutations and neurodegeneration</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">9</span>â <span class="NLM_lpage">29</span>, <span class="refDoi">Â DOI: 10.1038/emboj.2012.300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref278/cit278&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Femboj.2012.300" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref278/cit278&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=23149385" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2012&pages=9-29&author=W.+J.+H.+Koopmanauthor=F.+Distelmaierauthor=J.+A.+M.+Smeitinkauthor=P.+H.+G.+M.+Willems&title=OXPHOS+mutations+and+neurodegeneration&doi=10.1038%2Femboj.2012.300"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit278&amp;dbid=16384&amp;doi=10.1038%2Femboj.2012.300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Femboj.2012.300%26sid%3Dliteratum%253Aachs%26aulast%3DKoopman%26aufirst%3DW.%2BJ.%2BH.%26aulast%3DDistelmaier%26aufirst%3DF.%26aulast%3DSmeitink%26aufirst%3DJ.%2BA.%2BM.%26aulast%3DWillems%26aufirst%3DP.%2BH.%2BG.%2BM.%26atitle%3DOXPHOS%2520mutations%2520and%2520neurodegeneration%26jtitle%3DEMBO%2520J.%26date%3D2012%26volume%3D32%26spage%3D9%26epage%3D29%26doi%3D10.1038%2Femboj.2012.300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref279"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref279'); return false;" data-citation="" class="refNumLink">279</a></strong><div class="NLM_citation" id="cit279"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cannon, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tapias, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Na, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honick, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drolet, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenamyre, J. T.</span></span> <span> </span><span class="NLM_article-title">A highly reproducible rotenone model of Parkinsonâs disease</span>. <i>Neurobiol. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">279</span>â <span class="NLM_lpage">290</span>, <span class="refDoi">Â DOI: 10.1016/j.nbd.2009.01.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref279/cit279&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.nbd.2009.01.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref279/cit279&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=19385059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref279/cit279&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkslKrsro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2009&pages=279-290&author=J.+R.+Cannonauthor=V.+Tapiasauthor=H.+M.+Naauthor=A.+S.+Honickauthor=R.+E.+Droletauthor=J.+T.+Greenamyre&title=A+highly+reproducible+rotenone+model+of+Parkinson%E2%80%99s+disease&doi=10.1016%2Fj.nbd.2009.01.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit279R"><div class="casContent"><span class="casTitleNuber">279</span><div class="casTitle"><span class="NLM_cas:atitle">A highly reproducible rotenone model of Parkinson's disease</span></div><div class="casAuthors">Cannon, Jason R.; Tapias, Victor; Na, Hye Mee; Honick, Anthony S.; Drolet, Robert E.; Greenamyre, J. Timothy</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Disease</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">279-290</span>CODEN:
                <span class="NLM_cas:coden">NUDIEM</span>;
        ISSN:<span class="NLM_cas:issn">0969-9961</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The systemic rotenone model of Parkinson's disease (PD) accurately replicates many aspects of the pathol. of human PD and has provided insights into the pathogenesis of PD.  The major limitation of the rotenone model has been its variability, both in terms of the percentage of animals that develop a clear-cut nigrostriatal lesion and the extent of that lesion.  The goal here was to develop an improved and highly reproducible rotenone model of PD.  In these studies, male Lewis rats in three age groups (3, 7 or 12-14 mo) were administered rotenone (2.75 or 3.0 mg/kg/day) in a specialized vehicle by daily i.p. injection.  All rotenone-treated animals developed bradykinesia, postural instability, and/or rigidity, which were reversed by apomorphine, consistent with a lesion of the nigrostriatal dopamine system.  Animals were sacrificed when the PD phenotype became debilitating.  Rotenone treatment caused a 45% loss of tyrosine hydroxylase-pos. substantia nigra neurons and a commensurate loss of striatal dopamine.  Addnl., in rotenone-treated animals, Î±-synuclein and poly-ubiquitin pos. aggregates were obsd. in dopamine neurons of the substantia nigra.  In summary, this version of the rotenone model is highly reproducible and may provide an excellent tool to test new neuroprotective strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvHrN5kMQacLVg90H21EOLACvtfcHk0liZqa7ZCT5K8w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkslKrsro%253D&md5=56750e35d55f67d7645612427451ceb9</span></div><a href="/servlet/linkout?suffix=cit279&amp;dbid=16384&amp;doi=10.1016%2Fj.nbd.2009.01.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nbd.2009.01.016%26sid%3Dliteratum%253Aachs%26aulast%3DCannon%26aufirst%3DJ.%2BR.%26aulast%3DTapias%26aufirst%3DV.%26aulast%3DNa%26aufirst%3DH.%2BM.%26aulast%3DHonick%26aufirst%3DA.%2BS.%26aulast%3DDrolet%26aufirst%3DR.%2BE.%26aulast%3DGreenamyre%26aufirst%3DJ.%2BT.%26atitle%3DA%2520highly%2520reproducible%2520rotenone%2520model%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DNeurobiol.%2520Dis.%26date%3D2009%26volume%3D34%26spage%3D279%26epage%3D290%26doi%3D10.1016%2Fj.nbd.2009.01.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref280"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref280'); return false;" data-citation="" class="refNumLink">280</a></strong><div class="NLM_citation" id="cit280"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benbow, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aubrecht, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nettleton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aleo, M. D.</span></span> <span> </span><span class="NLM_article-title">Predicting safety toleration of pharmaceutical chemical leads: Cytotoxicity correlations to exploratory toxicity studies</span>. <i>Toxicol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>197</i></span>,  <span class="NLM_fpage">175</span>â <span class="NLM_lpage">182</span>, <span class="refDoi">Â DOI: 10.1016/j.toxlet.2010.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref280/cit280&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.toxlet.2010.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref280/cit280&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=20576494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref280/cit280&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptVagu7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=197&publication_year=2010&pages=175-182&author=J.+W.+Benbowauthor=J.+Aubrechtauthor=M.+J.+Bankerauthor=D.+Nettletonauthor=M.+D.+Aleo&title=Predicting+safety+toleration+of+pharmaceutical+chemical+leads%3A+Cytotoxicity+correlations+to+exploratory+toxicity+studies&doi=10.1016%2Fj.toxlet.2010.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit280R"><div class="casContent"><span class="casTitleNuber">280</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting safety toleration of pharmaceutical chemical leads: Cytotoxicity correlations to exploratory toxicity studies</span></div><div class="casAuthors">Benbow, John W.; Aubrecht, Jiri; Banker, Michael J.; Nettleton, David; Aleo, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">197</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">175-182</span>CODEN:
                <span class="NLM_cas:coden">TOLED5</span>;
        ISSN:<span class="NLM_cas:issn">0378-4274</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">The selection and application of appropriate safety screening paradigms could revolutionize the drug discovery process by reducing safety-related attrition.  While mechanism specific genotoxicity and safety pharmacol. assays are routinely used in screening, the overall value of employing nonspecific cytotoxicity assays remains controversial.  A retrospective anal. of safety findings from rat exploratory toxicity studies (4-14 days) utilizing compds. that spanned broad therapeutic targets (protease, transport, G-protein-coupled receptors, and kinase inhibitors, cGMP modulators) demonstrated that safety toleration in vivo could be approximated using cytotoxicity values.  A composite safety score was calcd. for each compd. dose based on findings in each of the following categories: systemic toleration (mortality, food consumption, and adverse clin. signs), clin. chem./hematol. parameters (deviations from normal ranges), and multiorgan pathol. (necrosis or incidence/severity of histol. change).  Binning compds. into potent (LC50 < 10 Î¼M) and non-potent (LC50 > 100 Î¼M) cytotoxicants in vitro showed that compared to non-potent cytotoxicants the exposure to potent cytotoxicants in vivo resulted in higher overall severity scores at lower exposures.  Correlating overall toleration for individual compds. was further refined when in vivo exposure was considered.  When av. plasma exposure (Cpave) for a compd. exceeded its mean lethal concn. (LC50) in vitro (Cpave/LC50 > 1), higher overall severity scores were achieved compared to lower exposure margins (Cpave/LC50 <0.01).  Based on this anal., the ability to select lead series and individual compds. with better safety characteristics is presented.  In summary, cytotoxicity screening can be used to approx., not define, the safety characteristics of lead pharmaceutical series early in the drug discovery process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUhD17guOBELVg90H21EOLACvtfcHk0liZqa7ZCT5K8w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptVagu7s%253D&md5=0740fad66ffc69226d1e9971fab41ef5</span></div><a href="/servlet/linkout?suffix=cit280&amp;dbid=16384&amp;doi=10.1016%2Fj.toxlet.2010.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.toxlet.2010.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DBenbow%26aufirst%3DJ.%2BW.%26aulast%3DAubrecht%26aufirst%3DJ.%26aulast%3DBanker%26aufirst%3DM.%2BJ.%26aulast%3DNettleton%26aufirst%3DD.%26aulast%3DAleo%26aufirst%3DM.%2BD.%26atitle%3DPredicting%2520safety%2520toleration%2520of%2520pharmaceutical%2520chemical%2520leads%253A%2520Cytotoxicity%2520correlations%2520to%2520exploratory%2520toxicity%2520studies%26jtitle%3DToxicol.%2520Lett.%26date%3D2010%26volume%3D197%26spage%3D175%26epage%3D182%26doi%3D10.1016%2Fj.toxlet.2010.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref281"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref281'); return false;" data-citation="" class="refNumLink">281</a></strong><div class="NLM_citation" id="cit281"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeCrescenzo, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devraj, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellsworth, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fobian, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbs, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilles, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krieger-Burke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loesel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wager, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiteley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Physiochemical drug properties associated with in vivo toxicological outcomes</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4872</span>â <span class="NLM_lpage">4875</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2008.07.071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref281/cit281&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.bmcl.2008.07.071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref281/cit281&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=18691886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref281/cit281&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVOnsbjE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4872-4875&author=J.+D.+Hughesauthor=J.+Blaggauthor=D.+A.+Priceauthor=S.+Baileyauthor=G.+A.+DeCrescenzoauthor=R.+V.+Devrajauthor=E.+Ellsworthauthor=Y.+M.+Fobianauthor=M.+E.+Gibbsauthor=R.+W.+Gillesauthor=N.+Greeneauthor=E.+Huangauthor=T.+Krieger-Burkeauthor=J.+Loeselauthor=T.+Wagerauthor=L.+Whiteleyauthor=Y.+Zhang&title=Physiochemical+drug+properties+associated+with+in+vivo+toxicological+outcomes&doi=10.1016%2Fj.bmcl.2008.07.071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit281R"><div class="casContent"><span class="casTitleNuber">281</span><div class="casTitle"><span class="NLM_cas:atitle">Physiochemical drug properties associated with in vivo toxicological outcomes</span></div><div class="casAuthors">Hughes, Jason D.; Blagg, Julian; Price, David A.; Bailey, Simon; DeCrescenzo, Gary A.; Devraj, Rajesh V.; Ellsworth, Edmund; Fobian, Yvette M.; Gibbs, Michael E.; Gilles, Richard W.; Greene, Nigel; Huang, Enoch; Krieger-Burke, Teresa; Loesel, Jens; Wager, Travis; Whiteley, Larry; Zhang, Yao</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4872-4875</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Relationships between physicochem. drug properties and toxicity were inferred from a data set consisting of animal in vivo toleration (IVT) studies on 245 preclin. Pfizer compds.; an increased likelihood of toxic events was found for less polar, more lipophilic compds.  This trend held across a wide range of types of toxicity and across a broad swath of chem. space.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPMmGEpVF0mbVg90H21EOLACvtfcHk0ljCQZ2uebVy0A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVOnsbjE&md5=80ea5ced359112a363f38b3545cd7646</span></div><a href="/servlet/linkout?suffix=cit281&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.07.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.07.071%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DJ.%2BD.%26aulast%3DBlagg%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DDeCrescenzo%26aufirst%3DG.%2BA.%26aulast%3DDevraj%26aufirst%3DR.%2BV.%26aulast%3DEllsworth%26aufirst%3DE.%26aulast%3DFobian%26aufirst%3DY.%2BM.%26aulast%3DGibbs%26aufirst%3DM.%2BE.%26aulast%3DGilles%26aufirst%3DR.%2BW.%26aulast%3DGreene%26aufirst%3DN.%26aulast%3DHuang%26aufirst%3DE.%26aulast%3DKrieger-Burke%26aufirst%3DT.%26aulast%3DLoesel%26aufirst%3DJ.%26aulast%3DWager%26aufirst%3DT.%26aulast%3DWhiteley%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DPhysiochemical%2520drug%2520properties%2520associated%2520with%2520in%2520vivo%2520toxicological%2520outcomes%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D4872%26epage%3D4875%26doi%3D10.1016%2Fj.bmcl.2008.07.071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref282"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref282'); return false;" data-citation="" class="refNumLink">282</a></strong><div class="NLM_citation" id="cit282"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span> <span> </span><span class="NLM_article-title">Impact of physicochemical properties on dose and hepatotoxicity of oral drugs</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">494</span>â <span class="NLM_lpage">505</span>, <span class="refDoi">Â DOI: 10.1021/acs.chemrestox.8b00044</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.8b00044" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref282/cit282&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXos12ku7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2018&pages=494-505&author=P.+D.+Leeson&title=Impact+of+physicochemical+properties+on+dose+and+hepatotoxicity+of+oral+drugs&doi=10.1021%2Facs.chemrestox.8b00044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit282R"><div class="casContent"><span class="casTitleNuber">282</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of Physicochemical Properties on Dose and Hepatotoxicity of Oral Drugs</span></div><div class="casAuthors">Leeson, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">494-505</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A database contg. max. daily doses of 1841 marketed oral drugs was used to examine the influence of physicochem. properties on dose and hepatotoxicity (drug induced liver injury, DILI).  Drugs in the highest â¼20% dose range had significantly reduced mean lipophilicity and mol. wt., increased fractional surface area, increased % of acids, and decreased % of bases vs. drugs in the lower â¼60% dose range.  Drugs in the â¼20-40% dose range had intermediate mean properties, similar to the mean values for the full drug set.  Drugs that are both large and highly lipophilic almost invariably do not have doses in the upper â¼20% range.  The results show that oral druglike physicochem. properties are different according to these dose ranges, and this is consistent with maintenance of acceptable safety profiles as efficacious exposure increases.  Verified DILI annotations from a compilation of >1000 approved drugs (Chen, M.; et al. Drug Discov. Today, 2016, 21, 648) were used.  The drugs classified as "No DILI" (n = 163) had significantly lower dose and lipophilicity, and higher Fsp3 (fraction of carbon atoms that are sp3 hybridized) vs. the "Most DILI" (n = 163) drugs.  The percentages of acids were reduced and bases increased in the "No DILI" vs. the "Most DILI" groups.  Drugs classified as "Less DILI" or "Ambiguous DILI" had intermediate mean values of dose, lipophilicity, Fsp3, and % acids and bases.  The impact of lipophilicity and Fsp3 on DILI increases in the upper 20% vs. the lower 80% dose range, and a simple decision tree model predicted "No DILI" vs. "Most DILI" outcomes with 82% accuracy.  The model correctly classified 19 of 22 drugs (86%) that failed in development due to human hepatotoxicity.  Because many oral drugs lacking DILI annotations are predicted to be "Most DILI", the model is best used preclinically in conjunction with exptl. DILI mitigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhvPLJlGQ-ZrVg90H21EOLACvtfcHk0ljCQZ2uebVy0A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXos12ku7k%253D&md5=6a7c9b7b1070954a70655755ad6d0620</span></div><a href="/servlet/linkout?suffix=cit282&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.8b00044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.8b00044%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26atitle%3DImpact%2520of%2520physicochemical%2520properties%2520on%2520dose%2520and%2520hepatotoxicity%2520of%2520oral%2520drugs%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2018%26volume%3D31%26spage%3D494%26epage%3D505%26doi%3D10.1021%2Facs.chemrestox.8b00044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref283"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref283'); return false;" data-citation="" class="refNumLink">283</a></strong><div class="NLM_citation" id="cit283"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Will, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dykens, J.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial toxicity assessment in industry - a decade of technology development and insight</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1061</span>â <span class="NLM_lpage">1067</span>, <span class="refDoi">Â DOI: 10.1517/17425255.2014.939628</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref283/cit283&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1517%2F17425255.2014.939628" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref283/cit283&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=25023361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref283/cit283&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BC2cbisVKnsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=1061-1067&author=Y.+Willauthor=J.+Dykens&title=Mitochondrial+toxicity+assessment+in+industry+-+a+decade+of+technology+development+and+insight&doi=10.1517%2F17425255.2014.939628"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit283R"><div class="casContent"><span class="casTitleNuber">283</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial toxicity assessment in industry--a decade of technology development and insight</span></div><div class="casAuthors">Will Yvonne; Dykens James</div><div class="citationInfo"><span class="NLM_cas:title">Expert opinion on drug metabolism & toxicology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1061-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTpQipcnBZdL6cY7HFp97qMfW6udTcc2eZWbc41hzV657ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbisVKnsw%253D%253D&md5=9e0d90f03938471154fec1353ebce3fe</span></div><a href="/servlet/linkout?suffix=cit283&amp;dbid=16384&amp;doi=10.1517%2F17425255.2014.939628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.2014.939628%26sid%3Dliteratum%253Aachs%26aulast%3DWill%26aufirst%3DY.%26aulast%3DDykens%26aufirst%3DJ.%26atitle%3DMitochondrial%2520toxicity%2520assessment%2520in%2520industry%2520-%2520a%2520decade%2520of%2520technology%2520development%2520and%2520insight%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2014%26volume%3D10%26spage%3D1061%26epage%3D1067%26doi%3D10.1517%2F17425255.2014.939628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185'],'ref186':['cit186'],'ref187':['cit187'],'ref188':['cit188'],'ref189':['cit189'],'ref190':['cit190'],'ref191':['cit191'],'ref192':['cit192'],'ref193':['cit193'],'ref194':['cit194'],'ref195':['cit195'],'ref196':['cit196'],'ref197':['cit197'],'ref198':['cit198'],'ref199':['cit199'],'ref200':['cit200'],'ref201':['cit201'],'ref202':['cit202'],'ref203':['cit203'],'ref204':['cit204'],'ref205':['cit205'],'ref206':['cit206'],'ref207':['cit207'],'ref208':['cit208'],'ref209':['cit209'],'ref210':['cit210'],'ref211':['cit211'],'ref212':['cit212'],'ref213':['cit213'],'ref214':['cit214'],'ref215':['cit215'],'ref216':['cit216'],'ref217':['cit217'],'ref218':['cit218'],'ref219':['cit219'],'ref220':['cit220'],'ref221':['cit221'],'ref222':['cit222'],'ref223':['cit223'],'ref224':['cit224'],'ref225':['cit225'],'ref226':['cit226'],'ref227':['cit227'],'ref228':['cit228'],'ref229':['cit229'],'ref230':['cit230'],'ref231':['cit231'],'ref232':['cit232'],'ref233':['cit233'],'ref234':['cit234'],'ref235':['cit235'],'ref236':['cit236'],'ref237':['cit237'],'ref238':['cit238'],'ref239':['cit239'],'ref240':['cit240'],'ref241':['cit241'],'ref242':['cit242'],'ref243':['cit243'],'ref244':['cit244'],'ref245':['cit245'],'ref246':['cit246'],'ref247':['cit247'],'ref248':['cit248'],'ref249':['cit249'],'ref250':['cit250'],'ref251':['cit251'],'ref252':['cit252'],'ref253':['cit253'],'ref254':['cit254'],'ref255':['cit255'],'ref256':['cit256'],'ref257':['cit257'],'ref258':['cit258'],'ref259':['cit259'],'ref260':['cit260'],'ref261':['cit261'],'ref262':['cit262'],'ref263':['cit263'],'ref264':['cit264'],'ref265':['cit265'],'ref266':['cit266'],'ref267':['cit267'],'ref268':['cit268'],'ref269':['cit269'],'ref270':['cit270'],'ref271':['cit271'],'ref272':['cit272'],'ref273':['cit273'],'ref274':['cit274'],'ref275':['cit275'],'ref276':['cit276'],'ref277':['cit277'],'ref278':['cit278'],'ref279':['cit279'],'ref280':['cit280'],'ref281':['cit281'],'ref282':['cit282'],'ref283':['cit283']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 2 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Takayuki  Sakai</span>, <span class="hlFld-ContribAuthor ">Yoshiyuki  Matsuo</span>, <span class="hlFld-ContribAuthor ">Kensuke  Okuda</span>, <span class="hlFld-ContribAuthor ">Kiichi  Hirota</span>, <span class="hlFld-ContribAuthor ">Mieko  Tsuji</span>, <span class="hlFld-ContribAuthor ">Tasuku  Hirayama</span>, <span class="hlFld-ContribAuthor ">Hideko  Nagasawa</span>. </span><span class="cited-content_cbyCitation_article-title">Development of antitumor biguanides targeting energy metabolism and stress responses in the tumor microenvironment. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2021,</strong> <em>11 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-021-83708-w" title="DOI URL">https://doi.org/10.1038/s41598-021-83708-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-021-83708-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-021-83708-w%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DDevelopment%252Bof%252Bantitumor%252Bbiguanides%252Btargeting%252Benergy%252Bmetabolism%252Band%252Bstress%252Bresponses%252Bin%252Bthe%252Btumor%252Bmicroenvironment%26aulast%3DSakai%26aufirst%3DTakayuki%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gang  Cheng</span>, <span class="hlFld-ContribAuthor ">Micael  Hardy</span>, <span class="hlFld-ContribAuthor ">Paytsar  Topchyan</span>, <span class="hlFld-ContribAuthor ">Ryan  Zander</span>, <span class="hlFld-ContribAuthor ">Peter  Volberding</span>, <span class="hlFld-ContribAuthor ">Weiguo  Cui</span>, <span class="hlFld-ContribAuthor ">Balaraman  Kalyanaraman</span>. </span><span class="cited-content_cbyCitation_article-title">Mitochondria-targeted hydroxyurea inhibits OXPHOS and induces antiproliferative and immunomodulatory effects. </span><span class="cited-content_cbyCitation_journal-name">iScience</span><span> <strong>2021,</strong> <em>24 </em>
                                    (6)
                                     , 102673. <a href="https://doi.org/10.1016/j.isci.2021.102673" title="DOI URL">https://doi.org/10.1016/j.isci.2021.102673</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.isci.2021.102673&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.isci.2021.102673%26sid%3Dliteratum%253Aachs%26jtitle%3DiScience%26atitle%3DMitochondria-targeted%252Bhydroxyurea%252Binhibits%252BOXPHOS%252Band%252Binduces%252Bantiproliferative%252Band%252Bimmunomodulatory%252Beffects%26aulast%3DCheng%26aufirst%3DGang%26date%3D2021%26volume%3D24%26issue%3D6%26spage%3D102673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/medium/jm0c01013_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01013&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/medium/jm0c01013_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Function of OXPHOS complexes. The OXPHOS machinery consists of five multiprotein complexes (complex IâV), transferring electrons and creating an electrochemical proton gradient to drive the synthesis of adenosine triphosphate (ATP). Electrons are transferred from NADH or succinate to ubiquinone (Q) through complex I or II; then, the electrons are removed from QH<sub>2</sub> in complex III to form a proton gradient. In complex IV, electrons are transferred to the terminal electron acceptor oxygen (O<sub>2</sub>). All of the protons pumped into the intermembrane space by complex I, III, and IV create a proton gradient that facilitates ATP production by ATP synthase (complex V). Structural genes for each complex are listed in the table below. Genes encoded by mitochondrial DNA are highlighted in red.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01013&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/medium/jm0c01013_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of OXPHOS complexes. (A) Complex I consists of a peripheral arm and membrane arm. The 49 kDa (light yellow) and PSST (cyan) subunits forming the ubiquinone-binding pocket and ND1 subunit (gray) forming the entrance of the ubiquinone access channel are shown. The FMN and FeâS clusters that form the electron transfer chain are shown (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5LC5">5LC5</a>). (B) Complex II comprises four subunits: SDHA (Fp, green), SDHB (Ip, cyan), SDHC (CybL, yellow), SDHD (CybS, blue), with two ubiquinone-binding sites (Qp and Qd site) and a succinate binding site. The FeâS clusters and heme that are essential for electron transfer are shown. (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ZOY">1ZOY</a>). (C) Complex III is a symmetrical dimer with three core subunits: cytochrome <i>b</i> (cyt <i>b</i>, gray) with two b-type hemes (<i>b</i><sub>L</sub> and b<sub>H</sub>), cytochrome <i>c</i><sub>1</sub> (cyt <i>c</i><sub>1</sub>, yellow) and the ironâsulfur protein (ISP) with a FeâS cluster (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1BGY">1BGY</a>). (D) The structure of complex IV. Two heme molecules (heme <i>a</i> and heme <i>a</i><sub>3</sub>) along with two binuclear copper centers (Cu<sub>A</sub> and Cu<sub>B</sub>) embedded in the structure are critical for the electron transfer (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WAU">5WAU</a>). (E) Complex V (ATP synthase) is composed of the F<sub>o</sub> sector and F<sub>1</sub> sector (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CP6">6CP6</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01013&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/medium/jm0c01013_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. OXPHOS gene expression is higher than average in multiple cancer types. (A) ChowâRuskey Venn diagram shows 67 genes in common between Hallmark, KEGG, and GO (GO:0006119) OXPHOS gene sets with a custom literature-based gene set. (B) An OXPHOS gene set combining all four gene sets described above was mapped to 320 genes and associated expression values for TCGA patients. The pan-cancer heatmap shows z-score normalized gene expression values per patient with diseases ranked by average patient expression. KICH, ACC, LIHC, UVM, and DLBC have the highest average expression. (C) GSEA was performed to show enrichment significance of high expressing OXPHOS genes for each TCGA disease by ranking genes using average z-score value per gene per disease. A total of 10â¯000 random permutations were performed to illustrate the FDR-adjusted <i>p</i>-value significance. The top five diseases are shown (as ranked by NES). NES = normalized enrichment score; FDR= false discovery rate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01013&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/medium/jm0c01013_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. OXPHOS gene expression shown for TCGA BRCA (A) and LUAD (B) patients with matched tumor and normal samples. Violin plots show patient average z-scores for the OXPHOS union gene set are significantly increased in tumor samples compared to normal samples using a paired Wilcoxon test. Heatmaps show the top 30 OXPHOS genes as ranked by average fold change of tumor to normal expression per gene. Thirteen genes were in common between BRCA and LUAD top 30 gene lists: ADCK5, CCNB1, CDK1, COA6, IDH2, MRPS12, MRPS30, NDUFAF6, PGK1, SHMT2, TIMM17A, UQCC2, and UQCC3 (<i>p</i> = 1.19 Ã 10<sup>â07</sup>, Odds Ratio = 12.1). (C) There were 222 genes in BRCA and 185 genes in LUAD with average fold changes greater than zero. Of the 321 total OXPHOS genes, 155 had increased expression on average in both BRCA and LUAD. (D) Three of these common genes mapped to kinases (ADCK2, ADCK5, CDK1) are highlighted in magenta on a kinome map, while a total of 6 OXHPOS genes were mapped to kinases. ADCK2: BRCA W <i>p</i> = 2.59 Ã 10<sup>â10</sup>, LUAD W <i>p</i> = 0.365. ADCK5: BRCA W <i>p</i> = 4.17 Ã 10<sup>â09</sup>, LUAD W <i>p</i> = 4.59 Ã 10<sup>â10</sup>. CDK1: BRCA W <i>p</i> = 4.27 Ã 10<sup>â20</sup>, LUAD W <i>p</i> = 1.24e-10. The remaining 3 kinases (ADCK1, PDK4, PINK1) are colored green.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01013&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/medium/jm0c01013_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. TCGA OXPHOS Hotspot Variant Survey. (A) Hotspot gain-of-function variants were identified in 22 of 33 diseases with the highest percentage of patients with OXPHOS hotspot variants in LGG (81%) in which the majority of patients had an IDH1 R132 hotspot or IDH2 R172. (B) Oncoprint visualizations for several diseases with the highest number of OXPHOS hotspot variants from the top 20 mutated OXPHOS genes. The remaining top disease Oncoprints are in <a href="/doi/suppl/10.1021/acs.jmedchem.0c01013/suppl_file/jm0c01013_si_001.pdf" class="ext-link">Supplemental Figure 2</a>. (C) Lollipop visualizations of the hotspot variants for GBM, SKCM, and STAD. Oncoprint and lollipop visualizations generated using the Maftools package. IDH1 and RHOA amino acid coordinates use NM_005896 and NM_001664 transcripts, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01013&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/medium/jm0c01013_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Assays to monitor OXPHOS modulation. (A) Screening compounds in medium enriched with galactose versus glucose. Cells grown in a high glucose-containing medium use glycolysis for ATP generation while cells grown in a galactose-containing medium rely almost exclusively on mitochondria for their ATP production. (B) Determination of the oxygen consumption rate, mitochondrial potential, and NADH/NAD+ ratio is also indicative of the OXPHOS function. (C) Each OXPHOS complex has a unique enzymatic activity, which facilitates the determination of the compound function.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01013&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/medium/jm0c01013_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Structures of select biguanides as OXPHOS inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01013&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/medium/jm0c01013_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Structures of representative OXPHOS inhibitors. The model for binding of VLX600 to iron was reproduced from the original report.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01013&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/medium/jm0c01013_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Structures of representative OXPHOS inhibitors used for cancer treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01013&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/medium/jm0c01013_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Potential strategies to enhance the efficacy of OXPHOS inhibitors in clinical applications: utilize biomarkers to select patients sensitive to OXPHOS inhibitors, apply OXPHOS inhibitors in targeted therapy for resistant patients, and combine OXPHOS inhibitors with other metabolic modulators to achieve synthetic lethality.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01013&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/medium/jm0c01013_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Combination of metabolic modulators with OXPHOS inhibitors. (A) Metabolic pathways including glycolysis and lactate production were compensatorily upregulated in response to OXPHOS inhibition. (B) A combination of the glycolysis inhibitor and LDHA inhibitor with the OXPHOS inhibitor significantly shuts down the compensatory effect and leads to synthetic lethality.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01013&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/medium/jm0c01013_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Violin plot shows average z-scores for oxidative phosphorylation genes for GTEx tissue samples. Heart, muscle, and kidney tissues have the highest average expression of OXPHOS genes. GTEx patient RNA-Seq and sample attribute data were sourced from <a href="https://www.gtexportal.org/" class="extLink">https://www.gtexportal.org/</a>.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> RNA-Seq gene expression values were downloaded, upper-quartile normalized, and log2 + 1 transformed. RNA-Seq values were converted to z-scores per patient sample. EBV-transformed lymphocytes and cultured fibroblast samples were excluded.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01013&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/medium/jm0c01013_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Physicochemical property distributions of OXPHOS inhibitors. (A) cLogP distribution. (B) Topological polar surface area (tPSA) distribution. (C) Fraction of sp3 hybridized carbons (Fsp3) distribution. (D) Molecular weight (MW) distribution. (E) Hydrogen bond donor (HBD) counts distribution. (F) Hydrogen bond acceptor (HBA) counts distribution. High toxicity risk groups are labeled in red.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01013/20201203/images/large/jm0c01013_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01013&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i59">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18676" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18676" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 283 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luengo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gui, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vander
Heiden, M. G.</span></span> <span> </span><span class="NLM_article-title">Targeting metabolism for cancer therapy</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1161</span>â <span class="NLM_lpage">1180</span>, <span class="refDoi">Â DOI: 10.1016/j.chembiol.2017.08.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.chembiol.2017.08.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=28938091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFGgurfO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=1161-1180&author=A.+Luengoauthor=D.+Y.+Guiauthor=M.+G.+Vander%0AHeiden&title=Targeting+metabolism+for+cancer+therapy&doi=10.1016%2Fj.chembiol.2017.08.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Metabolism for Cancer Therapy</span></div><div class="casAuthors">Luengo, Alba; Gui, Dan Y.; Vander Heiden, Matthew G.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1161-1180</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Metabolic reprogramming contributes to tumor development and introduces metabolic liabilities that can be exploited to treat cancer.  Chemotherapies targeting metab. have been effective cancer treatments for decades, and the success of these therapies demonstrates that a therapeutic window exists to target malignant metab.  New insights into the differential metabolic dependencies of tumors have provided novel therapeutic strategies to exploit altered metab., some of which are being evaluated in preclin. models or clin. trials.  Here, we review our current understanding of cancer metab. and discuss how this might guide treatments targeting the metabolic requirements of tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUOppBTjvuc7Vg90H21EOLACvtfcHk0lgsXJO4shyQjg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFGgurfO&md5=c702238d8642e06df9accd5414b64936</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2017.08.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2017.08.028%26sid%3Dliteratum%253Aachs%26aulast%3DLuengo%26aufirst%3DA.%26aulast%3DGui%26aufirst%3DD.%2BY.%26aulast%3DVander%2BHeiden%26aufirst%3DM.%2BG.%26atitle%3DTargeting%2520metabolism%2520for%2520cancer%2520therapy%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2017%26volume%3D24%26spage%3D1161%26epage%3D1180%26doi%3D10.1016%2Fj.chembiol.2017.08.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locasale, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielas, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâSullivan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheahan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vander
Heiden, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitkup, D.</span></span> <span> </span><span class="NLM_article-title">Heterogeneity of tumor-induced gene expression changes in the human metabolic network</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">522</span>â <span class="NLM_lpage">529</span>, <span class="refDoi">Â DOI: 10.1038/nbt.2530</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fnbt.2530" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=23604282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmt1Sqs7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=522-529&author=J.+Huauthor=J.+W.+Locasaleauthor=J.+H.+Bielasauthor=J.+O%E2%80%99Sullivanauthor=K.+Sheahanauthor=L.+C.+Cantleyauthor=M.+G.+Vander%0AHeidenauthor=D.+Vitkup&title=Heterogeneity+of+tumor-induced+gene+expression+changes+in+the+human+metabolic+network&doi=10.1038%2Fnbt.2530"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Heterogeneity of tumor-induced gene expression changes in the human metabolic network</span></div><div class="casAuthors">Hu, Jie; Locasale, Jason W.; Bielas, Jason H.; O'Sullivan, Jacintha; Sheahan, Kieran; Cantley, Lewis C.; Vander Heiden, Matthew G.; Vitkup, Dennis</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">522-529</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Reprogramming of cellular metab. is an emerging hallmark of neoplastic transformation.  However, it is not known how the expression of metabolic genes in tumors differs from that in normal tissues, or whether different tumor types exhibit similar metabolic changes.  Here we compare expression patterns of metabolic genes across 22 diverse types of human tumors.  Overall, the metabolic gene expression program in tumors is similar to that in the corresponding normal tissues.  Although expression changes of some metabolic pathways (e.g., upregulation of nucleotide biosynthesis and glycolysis) are frequently obsd. across tumors, expression changes of other pathways (e.g., oxidative phosphorylation) are very heterogeneous.  Our anal. also suggests that the expression changes of some metabolic genes (e.g., isocitrate dehydrogenase and fumarate hydratase) may enhance or mimic the effects of recurrent mutations in tumors.  On the level of individual biochem. reactions, many hundreds of metabolic isoenzymes show significant and tumor-specific expression changes.  These isoenzymes are potential targets for anticancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocriTCxH6Jl7Vg90H21EOLACvtfcHk0lgsXJO4shyQjg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmt1Sqs7s%253D&md5=730c42d523bac78aa4b076c78239a6d6</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2530&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2530%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DLocasale%26aufirst%3DJ.%2BW.%26aulast%3DBielas%26aufirst%3DJ.%2BH.%26aulast%3DO%25E2%2580%2599Sullivan%26aufirst%3DJ.%26aulast%3DSheahan%26aufirst%3DK.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DVander%2BHeiden%26aufirst%3DM.%2BG.%26aulast%3DVitkup%26aufirst%3DD.%26atitle%3DHeterogeneity%2520of%2520tumor-induced%2520gene%2520expression%2520changes%2520in%2520the%2520human%2520metabolic%2520network%26jtitle%3DNat.%2520Biotechnol.%26date%3D2013%26volume%3D31%26spage%3D522%26epage%3D529%26doi%3D10.1038%2Fnbt.2530" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roesch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vultur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogeski, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speicher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korbel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laschke, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gimotty, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philipp, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krause, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patzold, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villanueva, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krepler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukunaga-Kalabis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastian, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herlyn, M.</span></span> <span> </span><span class="NLM_article-title">Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">811</span>â <span class="NLM_lpage">825</span>, <span class="refDoi">Â DOI: 10.1016/j.ccr.2013.05.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.ccr.2013.05.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=23764003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptFKku7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=811-825&author=A.+Roeschauthor=A.+Vulturauthor=I.+Bogeskiauthor=H.+Wangauthor=K.+M.+Zimmermannauthor=D.+Speicherauthor=C.+Korbelauthor=M.+W.+Laschkeauthor=P.+A.+Gimottyauthor=S.+E.+Philippauthor=E.+Krauseauthor=S.+Patzoldauthor=J.+Villanuevaauthor=C.+Kreplerauthor=M.+Fukunaga-Kalabisauthor=M.+Hothauthor=B.+C.+Bastianauthor=T.+Vogtauthor=M.+Herlyn&title=Overcoming+intrinsic+multidrug+resistance+in+melanoma+by+blocking+the+mitochondrial+respiratory+chain+of+slow-cycling+JARID1B%28high%29+cells&doi=10.1016%2Fj.ccr.2013.05.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells</span></div><div class="casAuthors">Roesch, Alexander; Vultur, Adina; Bogeski, Ivan; Wang, Huan; Zimmermann, Katharina M.; Speicher, David; Koerbel, Christina; Laschke, Matthias W.; Gimotty, Phyllis A.; Philipp, Stephan E.; Krause, Elmar; Paetzold, Sylvie; Villanueva, Jessie; Krepler, Clemens; Fukunaga-Kalabis, Mizuho; Hoth, Markus; Bastian, Boris C.; Vogt, Thomas; Herlyn, Meenhard</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">811-825</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Despite success with BRAFV600E inhibitors, therapeutic responses in patients with metastatic melanoma are short-lived because of the acquisition of drug resistance.  We identified a mechanism of intrinsic multidrug resistance based on the survival of a tumor cell subpopulation.  Treatment with various drugs, including cisplatin and vemurafenib, uniformly leads to enrichment of slow-cycling, long-term tumor-maintaining melanoma cells expressing the H3K4-demethylase JARID1B/KDM5B/PLU-1.  Proteome-profiling revealed an upregulation in enzymes of mitochondrial oxidative-ATP-synthesis (oxidative phosphorylation) in this subpopulation.  Inhibition of mitochondrial respiration blocked the emergence of the JARID1Bhigh subpopulation and sensitized melanoma cells to therapy, independent of their genotype.  Our findings support a two-tiered approach combining anticancer agents that eliminate rapidly proliferating melanoma cells with inhibitors of the drug-resistant slow-cycling subpopulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLdv3RllMhCbVg90H21EOLACvtfcHk0lhnXFykQvboYw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptFKku7s%253D&md5=ba9ce8134c1fc0f17c44aebae7e760f0</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2013.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2013.05.003%26sid%3Dliteratum%253Aachs%26aulast%3DRoesch%26aufirst%3DA.%26aulast%3DVultur%26aufirst%3DA.%26aulast%3DBogeski%26aufirst%3DI.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DZimmermann%26aufirst%3DK.%2BM.%26aulast%3DSpeicher%26aufirst%3DD.%26aulast%3DKorbel%26aufirst%3DC.%26aulast%3DLaschke%26aufirst%3DM.%2BW.%26aulast%3DGimotty%26aufirst%3DP.%2BA.%26aulast%3DPhilipp%26aufirst%3DS.%2BE.%26aulast%3DKrause%26aufirst%3DE.%26aulast%3DPatzold%26aufirst%3DS.%26aulast%3DVillanueva%26aufirst%3DJ.%26aulast%3DKrepler%26aufirst%3DC.%26aulast%3DFukunaga-Kalabis%26aufirst%3DM.%26aulast%3DHoth%26aufirst%3DM.%26aulast%3DBastian%26aufirst%3DB.%2BC.%26aulast%3DVogt%26aufirst%3DT.%26aulast%3DHerlyn%26aufirst%3DM.%26atitle%3DOvercoming%2520intrinsic%2520multidrug%2520resistance%2520in%2520melanoma%2520by%2520blocking%2520the%2520mitochondrial%2520respiratory%2520chain%2520of%2520slow-cycling%2520JARID1B%2528high%2529%2520cells%26jtitle%3DCancer%2520Cell%26date%3D2013%26volume%3D23%26spage%3D811%26epage%3D825%26doi%3D10.1016%2Fj.ccr.2013.05.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sriskanthadevan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeyaraju, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skrtic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurren, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gronda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jitkova, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukhai, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maclean, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laister, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goard, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullen, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penn, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minden, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schimmer, A. D.</span></span> <span> </span><span class="NLM_article-title">AML cells have low spare reserve capacity in their respiratory chain that renders them susceptible to oxidative metabolic stress</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">2120</span>â <span class="NLM_lpage">2130</span>, <span class="refDoi">Â DOI: 10.1182/blood-2014-08-594408</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1182%2Fblood-2014-08-594408" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=25631767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtV2mtbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2015&pages=2120-2130&author=S.+Sriskanthadevanauthor=D.+V.+Jeyarajuauthor=T.+E.+Chungauthor=S.+Prabhaauthor=W.+Xuauthor=M.+Skrticauthor=B.+Jhasauthor=R.+Hurrenauthor=M.+Grondaauthor=X.+M.+Wangauthor=Y.+Jitkovaauthor=M.+A.+Sukhaiauthor=F.+H.+Linauthor=N.+Macleanauthor=R.+Laisterauthor=C.+A.+Goardauthor=P.+J.+Mullenauthor=S.+Xieauthor=L.+Z.+Pennauthor=I.+M.+Rogersauthor=J.+E.+Dickauthor=M.+D.+Mindenauthor=A.+D.+Schimmer&title=AML+cells+have+low+spare+reserve+capacity+in+their+respiratory+chain+that+renders+them+susceptible+to+oxidative+metabolic+stress&doi=10.1182%2Fblood-2014-08-594408"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">AML cells have low spare reserve capacity in their respiratory chain that renders them susceptible to oxidative metabolic stress</span></div><div class="casAuthors">Sriskanthadevan, Shrivani; Jeyaraju, Danny V.; Chung, Timothy E.; Prabha, Swayam; Xu, Wei; Skrtic, Marko; Jhas, Bozhena; Hurren, Rose; Gronda, Marcela; Wang, Xiaoming; Jitkova, Yulia; Sukhai, Mahadeo A.; Lin, Feng-Hsu; MacLean, Neil; Laister, Rob; Goard, Carolyn A.; Mullen, Peter J.; Xie, Stephanie; Penn, Linda Z.; Rogers, Ian M.; Dick, John E.; Minden, Mark D.; Schimmer, Aaron D.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2120-2130</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Mitochondrial respiration is a crucial component of cellular metab. that can become dysregulated in cancer.  Compared with normal hematopoietic cells, acute myeloid leukemia (AML) cells and patient samples have higher mitochondrial mass, without a concomitant increase in respiratory chain complex activity.  Hence these cells have a lower spare reserve capacity in the respiratory chain and are more susceptible to oxidative stress.  We therefore tested the effects of increasing the electron flux through the respiratory chain as a strategy to induce oxidative stress and cell death preferentially in AML cells.  Treatment with the fatty acid palmitate induced oxidative stress and cell death in AML cells, and it suppressed tumor burden in leukemic cell lines and primary patient sample xenografts in the absence of overt toxicity to normal cells and organs.  These data highlight a unique metabolic vulnerability in AML, and identify a new therapeutic strategy that targets abnormal oxidative metab. in this malignancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlrSxX37aGirVg90H21EOLACvtfcHk0lhnXFykQvboYw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtV2mtbc%253D&md5=d3b672e10dadfdaca69257d5336fae81</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1182%2Fblood-2014-08-594408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2014-08-594408%26sid%3Dliteratum%253Aachs%26aulast%3DSriskanthadevan%26aufirst%3DS.%26aulast%3DJeyaraju%26aufirst%3DD.%2BV.%26aulast%3DChung%26aufirst%3DT.%2BE.%26aulast%3DPrabha%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DSkrtic%26aufirst%3DM.%26aulast%3DJhas%26aufirst%3DB.%26aulast%3DHurren%26aufirst%3DR.%26aulast%3DGronda%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DX.%2BM.%26aulast%3DJitkova%26aufirst%3DY.%26aulast%3DSukhai%26aufirst%3DM.%2BA.%26aulast%3DLin%26aufirst%3DF.%2BH.%26aulast%3DMaclean%26aufirst%3DN.%26aulast%3DLaister%26aufirst%3DR.%26aulast%3DGoard%26aufirst%3DC.%2BA.%26aulast%3DMullen%26aufirst%3DP.%2BJ.%26aulast%3DXie%26aufirst%3DS.%26aulast%3DPenn%26aufirst%3DL.%2BZ.%26aulast%3DRogers%26aufirst%3DI.%2BM.%26aulast%3DDick%26aufirst%3DJ.%2BE.%26aulast%3DMinden%26aufirst%3DM.%2BD.%26aulast%3DSchimmer%26aufirst%3DA.%2BD.%26atitle%3DAML%2520cells%2520have%2520low%2520spare%2520reserve%2520capacity%2520in%2520their%2520respiratory%2520chain%2520that%2520renders%2520them%2520susceptible%2520to%2520oxidative%2520metabolic%2520stress%26jtitle%3DBlood%26date%3D2015%26volume%3D125%26spage%3D2120%26epage%3D2130%26doi%3D10.1182%2Fblood-2014-08-594408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gui, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosios, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bush, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freinkman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vander Heiden, M. G.</span></span> <span> </span><span class="NLM_article-title">Supporting aspartate biosynthesis is an essential function of respiration in proliferating cells</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">552</span>â <span class="NLM_lpage">563</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2015.07.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.cell.2015.07.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=26232225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht12jsrrO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2015&pages=552-563&author=L.+B.+Sullivanauthor=D.+Y.+Guiauthor=A.+M.+Hosiosauthor=L.+N.+Bushauthor=E.+Freinkmanauthor=M.+G.+Vander+Heiden&title=Supporting+aspartate+biosynthesis+is+an+essential+function+of+respiration+in+proliferating+cells&doi=10.1016%2Fj.cell.2015.07.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Supporting aspartate biosynthesis is an essential function of respiration in proliferating cells</span></div><div class="casAuthors">Sullivan, Lucas B.; Gui, Dan Y.; Hosios, Aaron M.; Bush, Lauren N.; Freinkman, Elizaveta; Vander Heiden, Matthew G.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">552-563</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Mitochondrial respiration is important for cell proliferation; however, the specific metabolic requirements fulfilled by respiration to support proliferation have not been defined.  Here, the authors show that a major role of respiration in proliferating cells is to provide electron acceptors for aspartate biosynthesis.  This finding was consistent with the observation that cells lacking a functional respiratory chain are auxotrophic for pyruvate, which serves as an exogenous electron acceptor.  Further, the pyruvate requirement could be fulfilled with an alternative electron acceptor, Î±-ketobutyrate, which provides cells neither carbon nor ATP.  Î±-Ketobutyrate restores proliferation when respiration is inhibited, suggesting that an alternative electron acceptor can substitute for respiration to support proliferation.  The authors found that electron acceptors were limiting for producing aspartate, and that supplying aspartate enabled proliferation of respiration-deficient cells in the absence of exogenous electron acceptors.  Together, these data argue a major function of respiration in proliferating cells is to support aspartate biosynthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodRkr248gPCLVg90H21EOLACvtfcHk0lhnXFykQvboYw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht12jsrrO&md5=73ee8247da401b5dbdac31ca1954383e</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2015.07.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2015.07.017%26sid%3Dliteratum%253Aachs%26aulast%3DSullivan%26aufirst%3DL.%2BB.%26aulast%3DGui%26aufirst%3DD.%2BY.%26aulast%3DHosios%26aufirst%3DA.%2BM.%26aulast%3DBush%26aufirst%3DL.%2BN.%26aulast%3DFreinkman%26aufirst%3DE.%26aulast%3DVander%2BHeiden%26aufirst%3DM.%2BG.%26atitle%3DSupporting%2520aspartate%2520biosynthesis%2520is%2520an%2520essential%2520function%2520of%2520respiration%2520in%2520proliferating%2520cells%26jtitle%3DCell%26date%3D2015%26volume%3D162%26spage%3D552%26epage%3D563%26doi%3D10.1016%2Fj.cell.2015.07.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Birsoy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freinkman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abu-Remaileh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span> <span> </span><span class="NLM_article-title">An essential role of the mitochondrial electron transport chain in cell proliferation is to enable aspartate synthesis</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">540</span>â <span class="NLM_lpage">551</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2015.07.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.cell.2015.07.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=26232224" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht12jsrrL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2015&pages=540-551&author=K.+Birsoyauthor=T.+Wangauthor=W.+W.+Chenauthor=E.+Freinkmanauthor=M.+Abu-Remailehauthor=D.+M.+Sabatini&title=An+essential+role+of+the+mitochondrial+electron+transport+chain+in+cell+proliferation+is+to+enable+aspartate+synthesis&doi=10.1016%2Fj.cell.2015.07.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">An essential role of the mitochondrial electron transport chain in cell proliferation is to enable aspartate synthesis</span></div><div class="casAuthors">Birsoy, Kivanc; Wang, Tim; Chen, Walter W.; Freinkman, Elizaveta; Abu-Remaileh, Monther; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">540-551</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The mitochondrial electron transport chain (ETC) enables many metabolic processes, but why its inhibition suppresses cell proliferation is unclear.  It is also not well understood why pyruvate supplementation allows cells lacking ETC function to proliferate.  Here, the authors used a CRISPR-based genetic screen to identify genes whose loss sensitizes human cells to phenformin, a complex I inhibitor.  The screen yielded GOT1, the cytosolic aspartate aminotransferase, loss of which kills cells upon ETC inhibition.  GOT1 normally consumes aspartate to transfer electrons into mitochondria, but, upon ETC inhibition, it reverses to generate aspartate in the cytosol, which partially compensates for the loss of mitochondrial aspartate biosynthesis.  Pyruvate stimulates aspartate biosynthesis in a GOT1-dependent fashion, which is required for pyruvate to rescue proliferation of cells with ETC dysfunction.  Aspartate supplementation or overexpression of an aspartate transporter allows cells without ETC activity to proliferate.  Thus, enabling aspartate biosynthesis is an essential role of the ETC in cell proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSh9Ap9MlPcbVg90H21EOLACvtfcHk0lgmFDaJn-X_iA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht12jsrrL&md5=d2e142821b9e2e5ff8932c6ba60f0892</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2015.07.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2015.07.016%26sid%3Dliteratum%253Aachs%26aulast%3DBirsoy%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DW.%2BW.%26aulast%3DFreinkman%26aufirst%3DE.%26aulast%3DAbu-Remaileh%26aufirst%3DM.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DAn%2520essential%2520role%2520of%2520the%2520mitochondrial%2520electron%2520transport%2520chain%2520in%2520cell%2520proliferation%2520is%2520to%2520enable%2520aspartate%2520synthesis%26jtitle%3DCell%26date%3D2015%26volume%3D162%26spage%3D540%26epage%3D551%26doi%3D10.1016%2Fj.cell.2015.07.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Reyes, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardona, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McElroy, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kihshen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reczek, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinert, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piseaux, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budinger, G. R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandel, N. S.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial ubiquinol oxidation is necessary for tumour growth</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>585</i></span>,  <span class="NLM_fpage">288</span>â <span class="NLM_lpage">292</span>, <span class="refDoi">Â DOI: 10.1038/s41586-020-2475-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fs41586-020-2475-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=32641834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlCqtb3L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=585&publication_year=2020&pages=288-292&author=I.+Martinez-Reyesauthor=L.+R.+Cardonaauthor=H.+Kongauthor=K.+Vasanauthor=G.+S.+McElroyauthor=M.+Wernerauthor=H.+Kihshenauthor=C.+R.+Reczekauthor=S.+E.+Weinbergauthor=P.+Gaoauthor=E.+M.+Steinertauthor=R.+Piseauxauthor=G.+R.+S.+Budingerauthor=N.+S.+Chandel&title=Mitochondrial+ubiquinol+oxidation+is+necessary+for+tumour+growth&doi=10.1038%2Fs41586-020-2475-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial ubiquinol oxidation is necessary for tumour growth</span></div><div class="casAuthors">Martinez-Reyes, Inmaculada; Cardona, Luzivette Robles; Kong, Hyewon; Vasan, Karthik; McElroy, Gregory S.; Werner, Marie; Kihshen, Hermon; Reczek, Colleen R.; Weinberg, Samuel E.; Gao, Peng; Steinert, Elizabeth M.; Piseaux, Raul; Budinger, G. R. Scott; Chandel, Navdeep S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">585</span>
        (<span class="NLM_cas:issue">7824</span>),
    <span class="NLM_cas:pages">288-292</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: The mitochondrial electron transport chain (ETC) is necessary for tumor growth1-6 and its inhibition has demonstrated anti-tumor efficacy in combination with targeted therapies7-9.  Furthermore, human brain and lung tumors display robust glucose oxidn. by mitochondria10,11.  However, it is unclear why a functional ETC is necessary for tumor growth in vivo.  ETC function is coupled to the generation of ATP-i.e., oxidative phosphorylation and the prodn. of metabolites by the tricarboxylic acid (TCA) cycle.  Mitochondrial complexes I and II donate electrons to ubiquinone, resulting in the generation of ubiquinol and the regeneration of the NAD+ and FAD cofactors, and complex III oxidizes ubiquinol back to ubiquinone, which also serves as an electron acceptor for dihydroorotate dehydrogenase (DHODH)-an enzyme necessary for de novo pyrimidine synthesis.  Here we show impaired tumor growth in cancer cells that lack mitochondrial complex III.  This phenotype was rescued by ectopic expression of Ciona intestinalis alternative oxidase (AOX)12, which also oxidizes ubiquinol to ubiquinone.  Loss of mitochondrial complex I, II or DHODH diminished the tumor growth of AOX-expressing cancer cells deficient in mitochondrial complex III, which highlights the necessity of ubiquinone as an electron acceptor for tumor growth.  Cancer cells that lack mitochondrial complex III but can regenerate NAD+ by expression of the NADH oxidase from Lactobacillus brevis (LbNOX)13 targeted to the mitochondria or cytosol were still unable to grow tumors.  This suggests that regeneration of NAD+ is not sufficient to drive tumor growth in vivo.  Collectively, our findings indicate that tumor growth requires the ETC to oxidize ubiquinol, which is essential to drive the oxidative TCA cycle and DHODH activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH8z7CmqLcCbVg90H21EOLACvtfcHk0lgmFDaJn-X_iA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlCqtb3L&md5=2df7dc3ff7e24711c075a3e9f671c79c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fs41586-020-2475-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-020-2475-6%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez-Reyes%26aufirst%3DI.%26aulast%3DCardona%26aufirst%3DL.%2BR.%26aulast%3DKong%26aufirst%3DH.%26aulast%3DVasan%26aufirst%3DK.%26aulast%3DMcElroy%26aufirst%3DG.%2BS.%26aulast%3DWerner%26aufirst%3DM.%26aulast%3DKihshen%26aufirst%3DH.%26aulast%3DReczek%26aufirst%3DC.%2BR.%26aulast%3DWeinberg%26aufirst%3DS.%2BE.%26aulast%3DGao%26aufirst%3DP.%26aulast%3DSteinert%26aufirst%3DE.%2BM.%26aulast%3DPiseaux%26aufirst%3DR.%26aulast%3DBudinger%26aufirst%3DG.%2BR.%2BS.%26aulast%3DChandel%26aufirst%3DN.%2BS.%26atitle%3DMitochondrial%2520ubiquinol%2520oxidation%2520is%2520necessary%2520for%2520tumour%2520growth%26jtitle%3DNature%26date%3D2020%26volume%3D585%26spage%3D288%26epage%3D292%26doi%3D10.1038%2Fs41586-020-2475-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Birsoy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Possemato, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorbeer, F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayraktar, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiru, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yucel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clish, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span> <span> </span><span class="NLM_article-title">Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>508</i></span>,  <span class="NLM_fpage">108</span>â <span class="NLM_lpage">112</span>, <span class="refDoi">Â DOI: 10.1038/nature13110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fnature13110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=24670634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlsFyjs7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=508&publication_year=2014&pages=108-112&author=K.+Birsoyauthor=R.+Possematoauthor=F.+K.+Lorbeerauthor=E.+C.+Bayraktarauthor=P.+Thiruauthor=B.+Yucelauthor=T.+Wangauthor=W.+W.+Chenauthor=C.+B.+Clishauthor=D.+M.+Sabatini&title=Metabolic+determinants+of+cancer+cell+sensitivity+to+glucose+limitation+and+biguanides&doi=10.1038%2Fnature13110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides</span></div><div class="casAuthors">Birsoy, Kivanc; Possemato, Richard; Lorbeer, Franziska K.; Bayraktar, Erol C.; Thiru, Prathapan; Yucel, Burcu; Wang, Tim; Chen, Walter W.; Clish, Clary B.; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">508</span>
        (<span class="NLM_cas:issue">7494</span>),
    <span class="NLM_cas:pages">108-112</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">As the concns. of highly consumed nutrients, particularly glucose, are generally lower in tumors than in normal tissues, cancer cells must adapt their metab. to the tumor microenvironment.  A better understanding of these adaptations might reveal cancer cell liabilities that can be exploited for therapeutic benefit.  Here we developed a continuous-flow culture app. (Nutrostat) for maintaining proliferating cells in low-nutrient media for long periods of time, and used it to undertake competitive proliferation assays on a pooled collection of barcoded cancer cell lines cultured in low-glucose conditions.  Sensitivity to low glucose varies amongst cell lines, and an RNA interference (RNAi) screen pinpointed mitochondrial oxidative phosphorylation (OXPHOS) as the major pathway required for optimal proliferation in low glucose.  We found that cell lines most sensitive to low glucose are defective in the OXPHOS upregulation that is normally caused by glucose limitation as a result of either mitochondrial DNA (mtDNA) mutations in complex I genes or impaired glucose utilization.  These defects predict sensitivity to biguanides, antidiabetic drugs that inhibit OXPHOS, when cancer cells are grown in low glucose or as tumor xenografts.  Notably, the biguanide sensitivity of cancer cells with mtDNA mutations was reversed by ectopic expression of yeast NDI1, a ubiquinone oxidoreductase that allows bypass of complex I function.  Thus, we conclude that mtDNA mutations and impaired glucose utilization are potential biomarkers for identifying tumors with increased sensitivity to OXPHOS inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQuk6Z79FsXLVg90H21EOLACvtfcHk0lguwH5Zivx7Zw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlsFyjs7k%253D&md5=1678d30d921453149c0da2c87adf3ccd</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnature13110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13110%26sid%3Dliteratum%253Aachs%26aulast%3DBirsoy%26aufirst%3DK.%26aulast%3DPossemato%26aufirst%3DR.%26aulast%3DLorbeer%26aufirst%3DF.%2BK.%26aulast%3DBayraktar%26aufirst%3DE.%2BC.%26aulast%3DThiru%26aufirst%3DP.%26aulast%3DYucel%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DW.%2BW.%26aulast%3DClish%26aufirst%3DC.%2BB.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DMetabolic%2520determinants%2520of%2520cancer%2520cell%2520sensitivity%2520to%2520glucose%2520limitation%2520and%2520biguanides%26jtitle%3DNature%26date%3D2014%26volume%3D508%26spage%3D108%26epage%3D112%26doi%3D10.1038%2Fnature13110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naguib, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reczek, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watrud, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herzka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salas, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Amine, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Francesco, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marszalek, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappin, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandel, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trotman, L. C.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial complex I inhibitors expose a vulnerability for selective killing of Pten-null cells</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">58</span>â <span class="NLM_lpage">67</span>, <span class="refDoi">Â DOI: 10.1016/j.celrep.2018.03.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.celrep.2018.03.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=29617673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVKqtro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=58-67&author=A.+Naguibauthor=G.+Mathewauthor=C.+R.+Reczekauthor=K.+Watrudauthor=A.+Ambricoauthor=T.+Herzkaauthor=I.+C.+Salasauthor=M.+F.+Leeauthor=N.+El-Amineauthor=W.+Zhengauthor=M.+E.+Di+Francescoauthor=J.+R.+Marszalekauthor=D.+J.+Pappinauthor=N.+S.+Chandelauthor=L.+C.+Trotman&title=Mitochondrial+complex+I+inhibitors+expose+a+vulnerability+for+selective+killing+of+Pten-null+cells&doi=10.1016%2Fj.celrep.2018.03.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial Complex I Inhibitors Expose a Vulnerability for Selective Killing of Pten-Null Cells</span></div><div class="casAuthors">Naguib, Adam; Mathew, Grinu; Reczek, Colleen R.; Watrud, Kaitlin; Ambrico, Alexandra; Herzka, Tali; Salas, Irene Casanova; Lee, Matthew F.; El-Amine, Nour; Zheng, Wu; Di Francesco, M. Emilia; Marszalek, Joseph R.; Pappin, Darryl J.; Chandel, Navdeep S.; Trotman, Lloyd C.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-67</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A hallmark of advanced prostate cancer (PC) is the concomitant loss of PTEN and p53 function.  To selectively eliminate such cells, we screened cytotoxic compds. on Pten-/-;Trp53-/- fibroblasts and their Pten-WT ref.  Highly selective killing of Pten-null cells can be achieved by deguelin, a natural insecticide.  Deguelin eliminates Pten-deficient cells through inhibition of mitochondrial complex I (CI).  Five hundred-fold higher drug doses are needed to obtain the same killing of Pten-WT cells, even though deguelin blocks their electron transport chain equally well.  Selectivity arises because mitochondria of Pten-null cells consume ATP through complex V, instead of producing it.  The resulting glucose dependency can be exploited to selectively kill Pten-null cells with clin. relevant CI inhibitors, esp. if they are lipophilic.  In vivo, deguelin suppressed disease in our genetically engineered mouse model for metastatic PC.  Our data thus introduce a vulnerability for highly selective targeting of incurable PC with inhibitors of CI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSXqfatJ1anLVg90H21EOLACvtfcHk0lguwH5Zivx7Zw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVKqtro%253D&md5=175649704577b3877aaa723a0ab1ec4c</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2018.03.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2018.03.032%26sid%3Dliteratum%253Aachs%26aulast%3DNaguib%26aufirst%3DA.%26aulast%3DMathew%26aufirst%3DG.%26aulast%3DReczek%26aufirst%3DC.%2BR.%26aulast%3DWatrud%26aufirst%3DK.%26aulast%3DAmbrico%26aufirst%3DA.%26aulast%3DHerzka%26aufirst%3DT.%26aulast%3DSalas%26aufirst%3DI.%2BC.%26aulast%3DLee%26aufirst%3DM.%2BF.%26aulast%3DEl-Amine%26aufirst%3DN.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DDi%2BFrancesco%26aufirst%3DM.%2BE.%26aulast%3DMarszalek%26aufirst%3DJ.%2BR.%26aulast%3DPappin%26aufirst%3DD.%2BJ.%26aulast%3DChandel%26aufirst%3DN.%2BS.%26aulast%3DTrotman%26aufirst%3DL.%2BC.%26atitle%3DMitochondrial%2520complex%2520I%2520inhibitors%2520expose%2520a%2520vulnerability%2520for%2520selective%2520killing%2520of%2520Pten-null%2520cells%26jtitle%3DCell%2520Rep.%26date%3D2018%26volume%3D23%26spage%3D58%26epage%3D67%26doi%3D10.1016%2Fj.celrep.2018.03.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lissanu
Deribe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terranova, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Ledesma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullinax, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khor, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kochat, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asara, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadimitrakopoulou, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wistuba, I. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marszalek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Futreal, P. A.</span></span> <span> </span><span class="NLM_article-title">Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1047</span>â <span class="NLM_lpage">1057</span>, <span class="refDoi">Â DOI: 10.1038/s41591-018-0019-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fs41591-018-0019-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=29892061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFWru7jF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=1047-1057&author=Y.+Lissanu%0ADeribeauthor=Y.+Sunauthor=C.+Terranovaauthor=F.+Khanauthor=J.+Martinez-Ledesmaauthor=J.+Gayauthor=G.+Gaoauthor=R.+A.+Mullinaxauthor=T.+Khorauthor=N.+Fengauthor=Y.+H.+Linauthor=C.+C.+Wuauthor=C.+Reyesauthor=Q.+Pengauthor=F.+Robinsonauthor=A.+Inoueauthor=V.+Kochatauthor=C.+G.+Liuauthor=J.+M.+Asaraauthor=C.+Moranauthor=F.+Mullerauthor=J.+Wangauthor=B.+Fangauthor=V.+Papadimitrakopoulouauthor=I.+I.+Wistubaauthor=K.+Raiauthor=J.+Marszalekauthor=P.+A.+Futreal&title=Mutations+in+the+SWI%2FSNF+complex+induce+a+targetable+dependence+on+oxidative+phosphorylation+in+lung+cancer&doi=10.1038%2Fs41591-018-0019-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer</span></div><div class="casAuthors">Lissanu Deribe, Yonathan; Sun, Yuting; Terranova, Christopher; Khan, Fatima; Martinez-Ledesma, Juan; Gay, Jason; Gao, Guang; Mullinax, Robert A.; Khor, Tin; Feng, Ningping; Lin, Yu-Hsi; Wu, Chia-Chin; Reyes, Claudia; Peng, Qian; Robinson, Frederick; Inoue, Akira; Kochat, Veena; Liu, Chang-Gong; Asara, John M.; Moran, Cesar; Muller, Florian; Wang, Jing; Fang, Bingliang; Papadimitrakopoulou, Vali; Wistuba, Ignacio I.; Rai, Kunal; Marszalek, Joseph; Futreal, P. Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1047-1057</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Lung cancer is a devastating disease that remains a top cause of cancer mortality.  Despite improvements with targeted and immunotherapies, the majority of patients with lung cancer lack effective therapies, underscoring the need for addnl. treatment approaches.  Genomic studies have identified frequent alterations in components of the SWI/SNF chromatin remodeling complex including SMARCA4 and ARID1A.  To understand the mechanisms of tumorigenesis driven by mutations in this complex, we developed a genetically engineered mouse model of lung adenocarcinoma by ablating Smarca4 in the lung epithelium.  We demonstrate that Smarca4 acts as a bona fide tumor suppressor and cooperates with p53 loss and Kras activation.  Gene expression analyses revealed the signature of enhanced oxidative phosphorylation (OXPHOS) in SMARCA4 mutant tumors.  We further show that SMARCA4 mutant cells have enhanced oxygen consumption and increased respiratory capacity.  Importantly, SMARCA4 mutant lung cancer cell lines and xenograft tumors have marked sensitivity to inhibition of OXPHOS by a novel small mol., IACS-010759, that is under clin. development.  Mechanistically, we show that SMARCA4-deficient cells have a blunted transcriptional response to energy stress creating a therapeutically exploitable synthetic lethal interaction.  These findings provide the mechanistic basis for further development of OXPHOS inhibitors as therapeutics against SWI/SNF mutant tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEF3LTCtYtm7Vg90H21EOLACvtfcHk0liKF_WGZ-LBsg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFWru7jF&md5=4a8b608f4317ba3e44b9d4753a643242</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fs41591-018-0019-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41591-018-0019-5%26sid%3Dliteratum%253Aachs%26aulast%3DLissanu%2BDeribe%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DTerranova%26aufirst%3DC.%26aulast%3DKhan%26aufirst%3DF.%26aulast%3DMartinez-Ledesma%26aufirst%3DJ.%26aulast%3DGay%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DG.%26aulast%3DMullinax%26aufirst%3DR.%2BA.%26aulast%3DKhor%26aufirst%3DT.%26aulast%3DFeng%26aufirst%3DN.%26aulast%3DLin%26aufirst%3DY.%2BH.%26aulast%3DWu%26aufirst%3DC.%2BC.%26aulast%3DReyes%26aufirst%3DC.%26aulast%3DPeng%26aufirst%3DQ.%26aulast%3DRobinson%26aufirst%3DF.%26aulast%3DInoue%26aufirst%3DA.%26aulast%3DKochat%26aufirst%3DV.%26aulast%3DLiu%26aufirst%3DC.%2BG.%26aulast%3DAsara%26aufirst%3DJ.%2BM.%26aulast%3DMoran%26aufirst%3DC.%26aulast%3DMuller%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DFang%26aufirst%3DB.%26aulast%3DPapadimitrakopoulou%26aufirst%3DV.%26aulast%3DWistuba%26aufirst%3DI.%2BI.%26aulast%3DRai%26aufirst%3DK.%26aulast%3DMarszalek%26aufirst%3DJ.%26aulast%3DFutreal%26aufirst%3DP.%2BA.%26atitle%3DMutations%2520in%2520the%2520SWI%252FSNF%2520complex%2520induce%2520a%2520targetable%2520dependence%2520on%2520oxidative%2520phosphorylation%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26spage%3D1047%26epage%3D1057%26doi%3D10.1038%2Fs41591-018-0019-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sancho, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barneda, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heeschen, C.</span></span> <span> </span><span class="NLM_article-title">Hallmarks of cancer stem cell metabolism</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">1305</span>â <span class="NLM_lpage">1312</span>, <span class="refDoi">Â DOI: 10.1038/bjc.2016.152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fbjc.2016.152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27219018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC28Xos1Wnsrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2016&pages=1305-1312&author=P.+Sanchoauthor=D.+Barnedaauthor=C.+Heeschen&title=Hallmarks+of+cancer+stem+cell+metabolism&doi=10.1038%2Fbjc.2016.152"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Hallmarks of cancer stem cell metabolism</span></div><div class="casAuthors">Sancho, Patricia; Barneda, David; Heeschen, Christopher</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1305-1312</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cancer cells adapt cellular metab. to cope with their high proliferation rate.  Instead of primarily using oxidative phosphorylation (OXPHOS), cancer cells use less efficient glycolysis for the prodn. of ATP and building blocks (Warburg effect).  However, tumors are not uniform, but rather functionally heterogeneous and harbor a subset of cancer cells with stemness features.  Such cancer cells have the ability to repopulate the entire tumor and thus have been termed cancer stem cells (CSCs) or tumor-initiating cells (TICs).  As opposed to differentiated bulk tumor cells relying on glycolysis, CSCs show a distinct metabolic phenotype that, depending on the cancer type, can be highly glycolytic or OXPHOS dependent.  In either case, mitochondrial function is crit. and takes center stage in CSC functionality.  Remaining controversies in this young and emerging research field may be related to CSC isolation techniques and/or the use of less suitable model systems.  Still, the apparent dependence of CSCs on mitochondrial function, regardless of their primary metabolic phenotype, represents a previously unrecognised Achilles heel amendable for therapeutic intervention.  Elimination of highly chemoresistant CSCs as the root of many cancers via inhibition of mitochondrial function bears the potential to prevent relapse from disease and thus improve patients' long-term outcome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWf3G0xGM-TLVg90H21EOLACvtfcHk0liKF_WGZ-LBsg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xos1Wnsrw%253D&md5=5371db328bc3616ad92d716a47c4a26c</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2016.152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2016.152%26sid%3Dliteratum%253Aachs%26aulast%3DSancho%26aufirst%3DP.%26aulast%3DBarneda%26aufirst%3DD.%26aulast%3DHeeschen%26aufirst%3DC.%26atitle%3DHallmarks%2520of%2520cancer%2520stem%2520cell%2520metabolism%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2016%26volume%3D114%26spage%3D1305%26epage%3D1312%26doi%3D10.1038%2Fbjc.2016.152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuntz, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baquero, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michie, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tardito, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holyoake, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helgason, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottlieb, E.</span></span> <span> </span><span class="NLM_article-title">Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1234</span>â <span class="NLM_lpage">1240</span>, <span class="refDoi">Â DOI: 10.1038/nm.4399</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fnm.4399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=28920959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFSku7%252FE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=1234-1240&author=E.+M.+Kuntzauthor=P.+Baqueroauthor=A.+M.+Michieauthor=K.+Dunnauthor=S.+Tarditoauthor=T.+L.+Holyoakeauthor=G.+V.+Helgasonauthor=E.+Gottlieb&title=Targeting+mitochondrial+oxidative+phosphorylation+eradicates+therapy-resistant+chronic+myeloid+leukemia+stem+cells&doi=10.1038%2Fnm.4399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells</span></div><div class="casAuthors">Kuntz, Elodie M.; Baquero, Pablo; Michie, Alison M.; Dunn, Karen; Tardito, Saverio; Holyoake, Tessa L.; Helgason, G. Vignir; Gottlieb, Eyal</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1234-1240</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Treatment of chronic myeloid leukemia (CML) with imatinib mesylate and other second- and/or third-generation c-Abl-specific tyrosine kinase inhibitors (TKIs) has substantially extended patient survival.  However, TKIs primarily target differentiated cells and do not eliminate leukemic stem cells (LSCs).  Therefore, targeting minimal residual disease to prevent acquired resistance and/or disease relapse requires identification of new LSC-selective target(s) that can be exploited therapeutically.  Considering that malignant transformation involves cellular metabolic changes, which may in turn render the transformed cells susceptible to specific assaults in a selective manner, we searched for such vulnerabilities in CML LSCs.  We performed metabolic analyses on both stem cell-enriched (CD34+ and CD34+CD38-) and differentiated (CD34-) cells derived from individuals with CML, and we compared the signature of these cells with that of their normal counterparts.  Through combination of stable isotope-assisted metabolomics with functional assays, we demonstrate that primitive CML cells rely on upregulated oxidative metab. for their survival.  We also show that combination treatment with imatinib and tigecycline, an antibiotic that inhibits mitochondrial protein translation, selectively eradicates CML LSCs both in vitro and in a xenotransplantation model of human CML.  Our findings provide a strong rationale for investigation of the use of TKIs in combination with tigecycline to treat patients with CML with minimal residual disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_DS1g9Q8oLLVg90H21EOLACvtfcHk0libuvaK0Z1WRw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFSku7%252FE&md5=e3758c3177849483ae61fdb51351ba49</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnm.4399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.4399%26sid%3Dliteratum%253Aachs%26aulast%3DKuntz%26aufirst%3DE.%2BM.%26aulast%3DBaquero%26aufirst%3DP.%26aulast%3DMichie%26aufirst%3DA.%2BM.%26aulast%3DDunn%26aufirst%3DK.%26aulast%3DTardito%26aufirst%3DS.%26aulast%3DHolyoake%26aufirst%3DT.%2BL.%26aulast%3DHelgason%26aufirst%3DG.%2BV.%26aulast%3DGottlieb%26aufirst%3DE.%26atitle%3DTargeting%2520mitochondrial%2520oxidative%2520phosphorylation%2520eradicates%2520therapy-resistant%2520chronic%2520myeloid%2520leukemia%2520stem%2520cells%26jtitle%3DNat.%2520Med.%26date%3D2017%26volume%3D23%26spage%3D1234%26epage%3D1240%26doi%3D10.1038%2Fnm.4399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Viale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettazzoni, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyssiotis, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ying, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchesini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carugo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuliani, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kost-Alimova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nezi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deem, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapoor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunetto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asara, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffernan, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimmelman, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DePinho, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Draetta, G. F.</span></span> <span> </span><span class="NLM_article-title">Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>514</i></span>,  <span class="NLM_fpage">628</span>â <span class="NLM_lpage">632</span>, <span class="refDoi">Â DOI: 10.1038/nature13611</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fnature13611" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=25119024" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlGnt7vO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=514&publication_year=2014&pages=628-632&author=A.+Vialeauthor=P.+Pettazzoniauthor=C.+A.+Lyssiotisauthor=H.+Yingauthor=N.+Sanchezauthor=M.+Marchesiniauthor=A.+Carugoauthor=T.+Greenauthor=S.+Sethauthor=V.+Giulianiauthor=M.+Kost-Alimovaauthor=F.+Mullerauthor=S.+Collaauthor=L.+Neziauthor=G.+Genoveseauthor=A.+K.+Deemauthor=A.+Kapoorauthor=W.+Yaoauthor=E.+Brunettoauthor=Y.+Kangauthor=M.+Yuanauthor=J.+M.+Asaraauthor=Y.+A.+Wangauthor=T.+P.+Heffernanauthor=A.+C.+Kimmelmanauthor=H.+Wangauthor=J.+B.+Flemingauthor=L.+C.+Cantleyauthor=R.+A.+DePinhoauthor=G.+F.+Draetta&title=Oncogene+ablation-resistant+pancreatic+cancer+cells+depend+on+mitochondrial+function&doi=10.1038%2Fnature13611"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function</span></div><div class="casAuthors">Viale, Andrea; Pettazzoni, Piergiorgio; Lyssiotis, Costas A.; Ying, Haoqiang; Sanchez, Nora; Marchesini, Matteo; Carugo, Alessandro; Green, Tessa; Seth, Sahil; Giuliani, Virginia; Kost-Alimova, Maria; Muller, Florian; Colla, Simona; Nezi, Luigi; Genovese, Giannicola; Deem, Angela K.; Kapoor, Avnish; Yao, Wantong; Brunetto, Emanuela; Kang, Ya'an; Yuan, Min; Asara, John M.; Wang, Y. Alan; Heffernan, Timothy P.; Kimmelman, Alec C.; Wang, Huamin; Fleming, Jason B.; Cantley, Lewis C.; De Pinho, Ronald A.; Draetta, Giulio F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">514</span>
        (<span class="NLM_cas:issue">7524</span>),
    <span class="NLM_cas:pages">628-632</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers in western countries, with a median survival of 6 mo and an extremely low percentage of long-term surviving patients.  KRAS mutations are known to be a driver event of PDAC, but targeting mutant KRAS has proved challenging.  Targeting oncogene-driven signaling pathways is a clin. validated approach for several devastating diseases.  Still, despite marked tumor shrinkage, the frequency of relapse indicates that a fraction of tumor cells survives shut down of oncogenic signaling.  Here we explore the role of mutant KRAS in PDAC maintenance using a recently developed inducible mouse model of mutated Kras (KrasG12D, herein KRas) in a p53LoxP/WT background.  We demonstrate that a subpopulation of dormant tumor cells surviving oncogene ablation (surviving cells) and responsible for tumor relapse has features of cancer stem cells and relies on oxidative phosphorylation for survival.  Transcriptomic and metabolic analyses of surviving cells reveal prominent expression of genes governing mitochondrial function, autophagy and lysosome activity, as well as a strong reliance on mitochondrial respiration and a decreased dependence on glycolysis for cellular energetics.  Accordingly, surviving cells show high sensitivity to oxidative phosphorylation inhibitors, which can inhibit tumor recurrence.  Our integrated analyses illuminate a therapeutic strategy of combined targeting of the KRAS pathway and mitochondrial respiration to manage pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlrfVMNnxZUbVg90H21EOLACvtfcHk0libuvaK0Z1WRw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlGnt7vO&md5=4241d53d0bb097a2e8d5775948154a8d</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnature13611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13611%26sid%3Dliteratum%253Aachs%26aulast%3DViale%26aufirst%3DA.%26aulast%3DPettazzoni%26aufirst%3DP.%26aulast%3DLyssiotis%26aufirst%3DC.%2BA.%26aulast%3DYing%26aufirst%3DH.%26aulast%3DSanchez%26aufirst%3DN.%26aulast%3DMarchesini%26aufirst%3DM.%26aulast%3DCarugo%26aufirst%3DA.%26aulast%3DGreen%26aufirst%3DT.%26aulast%3DSeth%26aufirst%3DS.%26aulast%3DGiuliani%26aufirst%3DV.%26aulast%3DKost-Alimova%26aufirst%3DM.%26aulast%3DMuller%26aufirst%3DF.%26aulast%3DColla%26aufirst%3DS.%26aulast%3DNezi%26aufirst%3DL.%26aulast%3DGenovese%26aufirst%3DG.%26aulast%3DDeem%26aufirst%3DA.%2BK.%26aulast%3DKapoor%26aufirst%3DA.%26aulast%3DYao%26aufirst%3DW.%26aulast%3DBrunetto%26aufirst%3DE.%26aulast%3DKang%26aufirst%3DY.%26aulast%3DYuan%26aufirst%3DM.%26aulast%3DAsara%26aufirst%3DJ.%2BM.%26aulast%3DWang%26aufirst%3DY.%2BA.%26aulast%3DHeffernan%26aufirst%3DT.%2BP.%26aulast%3DKimmelman%26aufirst%3DA.%2BC.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DFleming%26aufirst%3DJ.%2BB.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DDePinho%26aufirst%3DR.%2BA.%26aulast%3DDraetta%26aufirst%3DG.%2BF.%26atitle%3DOncogene%2520ablation-resistant%2520pancreatic%2520cancer%2520cells%2520depend%2520on%2520mitochondrial%2520function%26jtitle%3DNature%26date%3D2014%26volume%3D514%26spage%3D628%26epage%3D632%26doi%3D10.1038%2Fnature13611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giltnane, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balko, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero-Zotano, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nixon, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrada, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lluch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Fidalgo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrejeva, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathmell, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fesik, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arteaga, C. L.</span></span> <span> </span><span class="NLM_article-title">MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">633</span>â <span class="NLM_lpage">647</span>, <span class="refDoi">Â DOI: 10.1016/j.cmet.2017.09.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.cmet.2017.09.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=28978427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Siur7I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2017&pages=633-647&author=K.+M.+Leeauthor=J.+M.+Giltnaneauthor=J.+M.+Balkoauthor=L.+J.+Schwarzauthor=A.+L.+Guerrero-Zotanoauthor=K.+E.+Hutchinsonauthor=M.+J.+Nixonauthor=M.+V.+Estradaauthor=V.+Sanchezauthor=M.+E.+Sandersauthor=T.+Leeauthor=H.+Gomezauthor=A.+Lluchauthor=A.+Perez-Fidalgoauthor=M.+M.+Wolfauthor=G.+Andrejevaauthor=J.+C.+Rathmellauthor=S.+W.+Fesikauthor=C.+L.+Arteaga&title=MYC+and+MCL1+cooperatively+promote+chemotherapy-resistant+breast+cancer+stem+cells+via+regulation+of+mitochondrial+oxidative+phosphorylation&doi=10.1016%2Fj.cmet.2017.09.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation</span></div><div class="casAuthors">Lee, Kyung-min; Giltnane, Jennifer M.; Balko, Justin M.; Schwarz, Luis J.; Guerrero-Zotano, Angel L.; Hutchinson, Katherine E.; Nixon, Mellissa J.; Estrada, Monica V.; Sanchez, Violeta; Sanders, Melinda E.; Lee, Taekyu; Gomez, Henry; Lluch, Ana; Perez-Fidalgo, J. Alejandro; Wolf, Melissa Magdalene; Andrejeva, Gabriela; Rathmell, Jeffrey C.; Fesik, Stephen W.; Arteaga, Carlos L.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">633-647.e7</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Most patients with advanced triple-neg. breast cancer (TNBC) develop drug resistance.  MYC and MCL1 are frequently co-amplified in drug-resistant TNBC after neoadjuvant chemotherapy.  Herein, we demonstrate that MYC and MCL1 cooperate in the maintenance of chemotherapy-resistant cancer stem cells (CSCs) in TNBC.  MYC and MCL1 increased mitochondrial oxidative phosphorylation (mtOXPHOS) and the generation of reactive oxygen species (ROS), processes involved in maintenance of CSCs.  A mutant of MCL1 that cannot localize in mitochondria reduced mtOXPHOS, ROS levels, and drug-resistant CSCs without affecting the anti-apoptotic function of MCL1.  Increased levels of ROS, a byproduct of activated mtOXPHOS, led to the accumulation of HIF-1Î±.  Pharmacol. inhibition of HIF-1Î± attenuated CSC enrichment and tumor initiation in vivo.  These data suggest that (1) MYC and MCL1 confer resistance to chemotherapy by expanding CSCs via mtOXPHOS and (2) targeting mitochondrial respiration and HIF-1Î± may reverse chemotherapy resistance in TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrePHBTkM8-9LVg90H21EOLACvtfcHk0liW25yMD2cq9Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Siur7I&md5=f4843d94793a47b7e8b8eb45b002b730</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2017.09.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2017.09.009%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%2BM.%26aulast%3DGiltnane%26aufirst%3DJ.%2BM.%26aulast%3DBalko%26aufirst%3DJ.%2BM.%26aulast%3DSchwarz%26aufirst%3DL.%2BJ.%26aulast%3DGuerrero-Zotano%26aufirst%3DA.%2BL.%26aulast%3DHutchinson%26aufirst%3DK.%2BE.%26aulast%3DNixon%26aufirst%3DM.%2BJ.%26aulast%3DEstrada%26aufirst%3DM.%2BV.%26aulast%3DSanchez%26aufirst%3DV.%26aulast%3DSanders%26aufirst%3DM.%2BE.%26aulast%3DLee%26aufirst%3DT.%26aulast%3DGomez%26aufirst%3DH.%26aulast%3DLluch%26aufirst%3DA.%26aulast%3DPerez-Fidalgo%26aufirst%3DA.%26aulast%3DWolf%26aufirst%3DM.%2BM.%26aulast%3DAndrejeva%26aufirst%3DG.%26aulast%3DRathmell%26aufirst%3DJ.%2BC.%26aulast%3DFesik%26aufirst%3DS.%2BW.%26aulast%3DArteaga%26aufirst%3DC.%2BL.%26atitle%3DMYC%2520and%2520MCL1%2520cooperatively%2520promote%2520chemotherapy-resistant%2520breast%2520cancer%2520stem%2520cells%2520via%2520regulation%2520of%2520mitochondrial%2520oxidative%2520phosphorylation%26jtitle%3DCell%2520Metab.%26date%3D2017%26volume%3D26%26spage%3D633%26epage%3D647%26doi%3D10.1016%2Fj.cmet.2017.09.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhalla, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girnun, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clish, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granter, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widlund, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiegelman, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puigserver, P.</span></span> <span> </span><span class="NLM_article-title">PGC1 alpha expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">287</span>â <span class="NLM_lpage">301</span>, <span class="refDoi">Â DOI: 10.1016/j.ccr.2012.11.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.ccr.2012.11.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=23416000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3sXis1Oqs7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=287-301&author=F.+Vazquezauthor=J.+H.+Limauthor=H.+Chimauthor=K.+Bhallaauthor=G.+Girnunauthor=K.+Pierceauthor=C.+B.+Clishauthor=S.+R.+Granterauthor=H.+R.+Widlundauthor=B.+M.+Spiegelmanauthor=P.+Puigserver&title=PGC1+alpha+expression+defines+a+subset+of+human+melanoma+tumors+with+increased+mitochondrial+capacity+and+resistance+to+oxidative+stress&doi=10.1016%2Fj.ccr.2012.11.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">PGC1Î± Expression Defines a Subset of Human Melanoma Tumors with Increased Mitochondrial Capacity and Resistance to Oxidative Stress</span></div><div class="casAuthors">Vazquez, Francisca; Lim, Ji-Hong; Chim, Helen; Bhalla, Kavita; Girnun, Geoff; Pierce, Kerry; Clish, Clary B.; Granter, Scott R.; Widlund, Hans R.; Spiegelman, Bruce M.; Puigserver, Pere</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">287-301</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Cancer cells reprogram their metab. using different strategies to meet energy and anabolic demands to maintain growth and survival.  Understanding the mol. and genetic determinants of these metabolic programs is crit. to successfully exploit them for therapy.  Here, we report that the oncogenic melanocyte lineage-specification transcription factor MITF drives PGC1Î± (PPARGC1A) overexpression in a subset of human melanomas and derived cell lines.  Functionally, PGC1Î± pos. melanoma cells exhibit increased mitochondrial energy metab. and reactive oxygen species (ROS) detoxification capacities that enable survival under oxidative stress conditions.  Conversely, PGC1Î± neg. melanoma cells are more glycolytic and sensitive to ROS-inducing drugs.  These results demonstrate that differences in PGC1Î± levels in melanoma tumors have a profound impact in their metab., biol., and drug sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW8PE2o4ONBLVg90H21EOLACvtfcHk0liW25yMD2cq9Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXis1Oqs7c%253D&md5=42d9791393a3b0fddb55e5db66ced740</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2012.11.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2012.11.020%26sid%3Dliteratum%253Aachs%26aulast%3DVazquez%26aufirst%3DF.%26aulast%3DLim%26aufirst%3DJ.%2BH.%26aulast%3DChim%26aufirst%3DH.%26aulast%3DBhalla%26aufirst%3DK.%26aulast%3DGirnun%26aufirst%3DG.%26aulast%3DPierce%26aufirst%3DK.%26aulast%3DClish%26aufirst%3DC.%2BB.%26aulast%3DGranter%26aufirst%3DS.%2BR.%26aulast%3DWidlund%26aufirst%3DH.%2BR.%26aulast%3DSpiegelman%26aufirst%3DB.%2BM.%26aulast%3DPuigserver%26aufirst%3DP.%26atitle%3DPGC1%2520alpha%2520expression%2520defines%2520a%2520subset%2520of%2520human%2520melanoma%2520tumors%2520with%2520increased%2520mitochondrial%2520capacity%2520and%2520resistance%2520to%2520oxidative%2520stress%26jtitle%3DCancer%2520Cell%26date%3D2013%26volume%3D23%26spage%3D287%26epage%3D301%26doi%3D10.1016%2Fj.ccr.2012.11.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Farge, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saland, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Toni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aroua, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosseini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosc, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraisse, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scotland, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larrue, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boutzen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feliu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolau-Travers, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassant-Sourdy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serhan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarry, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavitian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaoma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallar, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacovoni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linares, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montersino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellano, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griessinger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collette, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duchamp, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barreira, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gales, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delhommeau, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garmy-Susini, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portais, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danet-Desnoyers, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Recher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarry, J. E.</span></span> <span> </span><span class="NLM_article-title">Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">716</span>â <span class="NLM_lpage">735</span>, <span class="refDoi">Â DOI: 10.1158/2159-8290.CD-16-0441</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F2159-8290.CD-16-0441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=28416471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFCisrbF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=716-735&author=T.+Fargeauthor=E.+Salandauthor=F.+de+Toniauthor=N.+Arouaauthor=M.+Hosseiniauthor=R.+Perryauthor=C.+Boscauthor=M.+Sugitaauthor=L.+Stuaniauthor=M.+Fraisseauthor=S.+Scotlandauthor=C.+Larrueauthor=H.+Boutzenauthor=V.+Feliuauthor=M.+L.+Nicolau-Traversauthor=S.+Cassant-Sourdyauthor=N.+Broinauthor=M.+Davidauthor=N.+Serhanauthor=A.+Sarryauthor=S.+Tavitianauthor=T.+Kaomaauthor=L.+Vallarauthor=J.+Iacovoniauthor=L.+K.+Linaresauthor=C.+Montersinoauthor=R.+Castellanoauthor=E.+Griessingerauthor=Y.+Colletteauthor=O.+Duchampauthor=Y.+Barreiraauthor=P.+Hirschauthor=T.+Palamaauthor=L.+Galesauthor=F.+Delhommeauauthor=B.+H.+Garmy-Susiniauthor=J.+C.+Portaisauthor=F.+Vergezauthor=M.+Selakauthor=G.+Danet-Desnoyersauthor=M.+Carrollauthor=C.+Recherauthor=J.+E.+Sarry&title=Chemotherapy-resistant+human+acute+myeloid+leukemia+cells+are+not+enriched+for+leukemic+stem+cells+but+require+oxidative+metabolism&doi=10.1158%2F2159-8290.CD-16-0441"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism</span></div><div class="casAuthors">Farge, Thomas; Saland, Estelle; de Toni, Fabienne; Aroua, Nesrine; Hosseini, Mohsen; Perry, Robin; Bosc, Claudie; Sugita, Mayumi; Stuani, Lucille; Fraisse, Marine; Scotland, Sarah; Larrue, Clement; Boutzen, Heeleeena; Feeeeliu, Virginie; Nicolau-Travers, Marie-Laure; Cassant-Sourdy, Steeeeephanie; Broin, Nicolas; David, Marion; Serhan, Nizar; Sarry, Audrey; Tavitian, Suzanne; Kaoma, Tony; Vallar, Laurent; Iacovoni, Jason; Linares, Laetitia K.; Montersino, Camille; Castellano, Reeeeeemy; Griessinger, Emmanuel; Collette, Yves; Duchamp, Olivier; Barreira, Yara; Hirsch, Pierre; Palama, Tony; Gales, Lara; Delhommeau, Francois; Garmy-Susini, Barbara H.; Portais, Jean-Charles; Vergez, Francois; Selak, Mary; Danet-Desnoyers, Gwenn; Carroll, Martin; Reeeeeeecher, Christian; Sarry, Jean-Emmanuel</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">716-735</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Chemotherapy-resistant human acute myeloid leukemia (AML) cells are thought to be enriched in quiescent immature leukemic stem cells (LSC).  To validate this hypothesis in vivo, we developed a clin. relevant chemotherapeutic approach treating patient-derived xenografts (PDX) with cytarabine (AraC).  AraC residual AML cells are enriched in neither immature, quiescent cells nor LSCs.  Strikingly, AraC-resistant preexisting and persisting cells displayed high levels of reactive oxygen species, showed increased mitochondrial mass, and retained active polarized mitochondria, consistent with a high oxidative phosphorylation (OXPHOS) status.  AraC residual cells exhibited increased fatty-acid oxidn., upregulated CD36 expression, and a high OXPHOS gene signature predictive for treatment response in PDX and patients with AML.  High OXPHOS but not low OXPHOS human AML cell lines were chemoresistant in vivo.  Targeting mitochondrial protein synthesis, electron transfer, or fatty-acid oxidn. induced an energetic shift toward low OXPHOS and markedly enhanced antileukemic effects of AraC.  Together, this study demonstrates that essential mitochondrial functions contribute to AraC resistance in AML and are a robust hallmark of AraC sensitivity and a promising therapeutic avenue to treat AML residual disease.  Significance: AraC-resistant AML cells exhibit metabolic features and gene signatures consistent with a high OXPHOS status.  In these cells, targeting mitochondrial metab. through the CD36-FAO-OXPHOS axis induces an energetic shift toward low OXPHOS and strongly enhanced antileukemic effects of AraC, offering a promising avenue to design new therapeutic strategies and fight AraC resistance in AML.  Cancer Discov; 7(7); 716-35. Â©2017 AACR.  See related commentary by Schimmer, p. 670.  This article is highlighted in the In This Issue feature, p.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-lpeAaUawsbVg90H21EOLACvtfcHk0liW25yMD2cq9Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFCisrbF&md5=1490353bd019a1fbc41ee61ed77ba34d</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-16-0441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-16-0441%26sid%3Dliteratum%253Aachs%26aulast%3DFarge%26aufirst%3DT.%26aulast%3DSaland%26aufirst%3DE.%26aulast%3Dde%2BToni%26aufirst%3DF.%26aulast%3DAroua%26aufirst%3DN.%26aulast%3DHosseini%26aufirst%3DM.%26aulast%3DPerry%26aufirst%3DR.%26aulast%3DBosc%26aufirst%3DC.%26aulast%3DSugita%26aufirst%3DM.%26aulast%3DStuani%26aufirst%3DL.%26aulast%3DFraisse%26aufirst%3DM.%26aulast%3DScotland%26aufirst%3DS.%26aulast%3DLarrue%26aufirst%3DC.%26aulast%3DBoutzen%26aufirst%3DH.%26aulast%3DFeliu%26aufirst%3DV.%26aulast%3DNicolau-Travers%26aufirst%3DM.%2BL.%26aulast%3DCassant-Sourdy%26aufirst%3DS.%26aulast%3DBroin%26aufirst%3DN.%26aulast%3DDavid%26aufirst%3DM.%26aulast%3DSerhan%26aufirst%3DN.%26aulast%3DSarry%26aufirst%3DA.%26aulast%3DTavitian%26aufirst%3DS.%26aulast%3DKaoma%26aufirst%3DT.%26aulast%3DVallar%26aufirst%3DL.%26aulast%3DIacovoni%26aufirst%3DJ.%26aulast%3DLinares%26aufirst%3DL.%2BK.%26aulast%3DMontersino%26aufirst%3DC.%26aulast%3DCastellano%26aufirst%3DR.%26aulast%3DGriessinger%26aufirst%3DE.%26aulast%3DCollette%26aufirst%3DY.%26aulast%3DDuchamp%26aufirst%3DO.%26aulast%3DBarreira%26aufirst%3DY.%26aulast%3DHirsch%26aufirst%3DP.%26aulast%3DPalama%26aufirst%3DT.%26aulast%3DGales%26aufirst%3DL.%26aulast%3DDelhommeau%26aufirst%3DF.%26aulast%3DGarmy-Susini%26aufirst%3DB.%2BH.%26aulast%3DPortais%26aufirst%3DJ.%2BC.%26aulast%3DVergez%26aufirst%3DF.%26aulast%3DSelak%26aufirst%3DM.%26aulast%3DDanet-Desnoyers%26aufirst%3DG.%26aulast%3DCarroll%26aufirst%3DM.%26aulast%3DRecher%26aufirst%3DC.%26aulast%3DSarry%26aufirst%3DJ.%2BE.%26atitle%3DChemotherapy-resistant%2520human%2520acute%2520myeloid%2520leukemia%2520cells%2520are%2520not%2520enriched%2520for%2520leukemic%2520stem%2520cells%2520but%2520require%2520oxidative%2520metabolism%26jtitle%3DCancer%2520Discovery%26date%3D2017%26volume%3D7%26spage%3D716%26epage%3D735%26doi%3D10.1158%2F2159-8290.CD-16-0441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorence, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badillo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Francesco, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackintosh, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, X. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenzi, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marszalek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffernan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Draetta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Futreal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span> <span> </span><span class="NLM_article-title">Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">eaau1167</span>, <span class="refDoi">Â DOI: 10.1126/scitranslmed.aau1167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1126%2Fscitranslmed.aau1167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=31068440" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=eaau1167&author=L.+Zhangauthor=Y.+X.+Yaoauthor=S.+J.+Zhangauthor=Y.+Liuauthor=H.+Guoauthor=M.+Ahmedauthor=T.+Bellauthor=H.+Zhangauthor=G.+C.+Hanauthor=E.+Lorenceauthor=M.+Badilloauthor=S.+H.+Zhouauthor=Y.+T.+Sunauthor=M.+E.+Di+Francescoauthor=N.+P.+Fengauthor=R.+Haunauthor=R.+Lanauthor=S.+G.+Mackintoshauthor=X.+Z.+Maoauthor=X.+Z.+Songauthor=J.+H.+Zhangauthor=L.+V.+Phamauthor=P.+L.+Lorenziauthor=J.+Marszalekauthor=T.+Heffernanauthor=G.+Draettaauthor=P.+Jonesauthor=A.+Futrealauthor=K.+Nomieauthor=L.+H.+Wangauthor=M.+Wang&title=Metabolic+reprogramming+toward+oxidative+phosphorylation+identifies+a+therapeutic+target+for+mantle+cell+lymphoma&doi=10.1126%2Fscitranslmed.aau1167"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aau1167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aau1167%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DYao%26aufirst%3DY.%2BX.%26aulast%3DZhang%26aufirst%3DS.%2BJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DAhmed%26aufirst%3DM.%26aulast%3DBell%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DHan%26aufirst%3DG.%2BC.%26aulast%3DLorence%26aufirst%3DE.%26aulast%3DBadillo%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DS.%2BH.%26aulast%3DSun%26aufirst%3DY.%2BT.%26aulast%3DDi%2BFrancesco%26aufirst%3DM.%2BE.%26aulast%3DFeng%26aufirst%3DN.%2BP.%26aulast%3DHaun%26aufirst%3DR.%26aulast%3DLan%26aufirst%3DR.%26aulast%3DMackintosh%26aufirst%3DS.%2BG.%26aulast%3DMao%26aufirst%3DX.%2BZ.%26aulast%3DSong%26aufirst%3DX.%2BZ.%26aulast%3DZhang%26aufirst%3DJ.%2BH.%26aulast%3DPham%26aufirst%3DL.%2BV.%26aulast%3DLorenzi%26aufirst%3DP.%2BL.%26aulast%3DMarszalek%26aufirst%3DJ.%26aulast%3DHeffernan%26aufirst%3DT.%26aulast%3DDraetta%26aufirst%3DG.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DFutreal%26aufirst%3DA.%26aulast%3DNomie%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DL.%2BH.%26aulast%3DWang%26aufirst%3DM.%26atitle%3DMetabolic%2520reprogramming%2520toward%2520oxidative%2520phosphorylation%2520identifies%2520a%2520therapeutic%2520target%2520for%2520mantle%2520cell%2520lymphoma%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2019%26volume%3D11%26spage%3Deaau1167%26doi%3D10.1126%2Fscitranslmed.aau1167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenna, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunz-Schughart, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, G. S.</span></span> <span> </span><span class="NLM_article-title">Oxidative phosphorylation as an emerging target in cancer therapy</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">2482</span>â <span class="NLM_lpage">2490</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-17-3070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F1078-0432.CCR-17-3070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=29420223" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVKjsbnI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=2482-2490&author=T.+M.+Ashtonauthor=W.+G.+McKennaauthor=L.+A.+Kunz-Schughartauthor=G.+S.+Higgins&title=Oxidative+phosphorylation+as+an+emerging+target+in+cancer+therapy&doi=10.1158%2F1078-0432.CCR-17-3070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidative Phosphorylation as an Emerging Target in Cancer Therapy</span></div><div class="casAuthors">Ashton, Thomas M.; McKenna, W. Gillies; Kunz-Schughart, Leoni A.; Higgins, Geoff S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2482-2490</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Cancer cells have upregulated glycolysis compared with normal cells, which has led many to the assumption that oxidative phosphorylation (OXPHOS) is downregulated in all cancers.  However, recent studies have shown that OXPHOS can be also upregulated in certain cancers, including leukemias, lymphomas, pancreatic ductal adenocarcinoma, high OXPHOS subtype melanoma, and endometrial carcinoma, and that this can occur even in the face of active glycolysis.  OXPHOS inhibitors could therefore be used to target cancer subtypes in which OXPHOS is upregulated and to alleviate therapeutically adverse tumor hypoxia.  Several drugs including metformin, atovaquone, and arsenic trioxide are used clin. for non-oncol. indications, but emerging data demonstrate their potential use as OXPHOS inhibitors.  We highlight novel applications of OXPHOS inhibitors with a suitable therapeutic index to target cancer cell metab.  Clin Cancer Res; 24(11); 2482-90. Â©2018 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCsSJ9tK4SdrVg90H21EOLACvtfcHk0lgV4wPXB93V0w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVKjsbnI&md5=1cb7d3f2151ec4079de982206bb5e6af</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-3070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-3070%26sid%3Dliteratum%253Aachs%26aulast%3DAshton%26aufirst%3DT.%2BM.%26aulast%3DMcKenna%26aufirst%3DW.%2BG.%26aulast%3DKunz-Schughart%26aufirst%3DL.%2BA.%26aulast%3DHiggins%26aufirst%3DG.%2BS.%26atitle%3DOxidative%2520phosphorylation%2520as%2520an%2520emerging%2520target%2520in%2520cancer%2520therapy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26spage%3D2482%26epage%3D2490%26doi%3D10.1158%2F1078-0432.CCR-17-3070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sica, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo-San Pedro, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoll, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroemer, G.</span></span> <span> </span><span class="NLM_article-title">Oxidative phosphorylation as a potential therapeutic target for cancer therapy</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">10</span>â <span class="NLM_lpage">17</span>, <span class="refDoi">Â DOI: 10.1002/ijc.32616</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1002%2Fijc.32616" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=31396957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslCnsrvI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2020&pages=10-17&author=V.+Sicaauthor=J.+M.+Bravo-San+Pedroauthor=G.+Stollauthor=G.+Kroemer&title=Oxidative+phosphorylation+as+a+potential+therapeutic+target+for+cancer+therapy&doi=10.1002%2Fijc.32616"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidative phosphorylation as a potential therapeutic target for cancer therapy</span></div><div class="casAuthors">Sica, Valentina; Bravo-San Pedro, Jose Manuel; Stoll, Gautier; Kroemer, Guido</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">10-17</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  In contrast to prior belief, cancer cells require oxidative phosphorylation (OXPHOS) to strive, and exacerbated OXPHOS dependency frequently characterizes cancer stem cells, as well as primary or acquired resistance against chemotherapy or tyrosine kinase inhibitors.  A growing arsenal of therapeutic agents is being designed to suppress the transfer of mitochondria from stromal to malignant cells, to interfere with mitochondrial biogenesis, to directly inhibit respiratory chain complexes, or to disrupt mitochondrial function in other ways.  For the exptl. treatment of cancers, OXPHOS inhibitors can be advantageously combined with tyrosine kinase inhibitors, as well as with other strategies to inhibit glycolysis, thereby causing a lethal energy crisis.  Unfortunately, most of the preclin. data arguing in favor of OXPHOS inhibition have been obtained in xenograft models, in which human cancer cells are implanted in immunodeficient mice.  Future studies on OXPHOS inhibitors should elaborate optimal treatment schedules and combination regimens that stimulate-or at least are compatible with-anticancer immune responses for long-term tumor control.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6Ie7GAQZq1rVg90H21EOLACvtfcHk0lgV4wPXB93V0w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslCnsrvI&md5=0b966390751635974e6b91bd00626699</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fijc.32616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.32616%26sid%3Dliteratum%253Aachs%26aulast%3DSica%26aufirst%3DV.%26aulast%3DBravo-San%2BPedro%26aufirst%3DJ.%2BM.%26aulast%3DStoll%26aufirst%3DG.%26aulast%3DKroemer%26aufirst%3DG.%26atitle%3DOxidative%2520phosphorylation%2520as%2520a%2520potential%2520therapeutic%2520target%2520for%2520cancer%2520therapy%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2020%26volume%3D146%26spage%3D10%26epage%3D17%26doi%3D10.1002%2Fijc.32616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pernicova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korbonits, M.</span></span> <span> </span><span class="NLM_article-title">Metformin-mode of action and clinical implications for diabetes and cancer</span>. <i>Nat. Rev. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">143</span>â <span class="NLM_lpage">156</span>, <span class="refDoi">Â DOI: 10.1038/nrendo.2013.256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fnrendo.2013.256" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=24393785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtVSitA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=143-156&author=I.+Pernicovaauthor=M.+Korbonits&title=Metformin-mode+of+action+and+clinical+implications+for+diabetes+and+cancer&doi=10.1038%2Fnrendo.2013.256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Metformin-mode of action and clinical implications for diabetes and cancer</span></div><div class="casAuthors">Pernicova, Ida; Korbonits, Marta</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Endocrinology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">143-156</span>CODEN:
                <span class="NLM_cas:coden">NREABD</span>;
        ISSN:<span class="NLM_cas:issn">1759-5029</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Metformin has been the mainstay of therapy for diabetes mellitus for many years; however, the mechanistic aspects of metformin action remained ill-defined.  Recent advances revealed that this drug, in addn. to its glucose-lowering action, might be promising for specifically targeting metabolic differences between normal and abnormal metabolic signalling.  The knowledge gained from dissecting the principal mechanisms by which metformin works can help us to develop novel treatments.  The center of metformin's mechanism of action is the alteration of the energy metab. of the cell.  Metformin exerts its prevailing, glucose-lowering effect by inhibiting hepatic gluconeogenesis and opposing the action of glucagon.  The inhibition of mitochondrial complex I results in defective cAMP and protein kinase A signalling in response to glucagon.  Stimulation of 5'-AMP-activated protein kinase, although dispensable for the glucose-lowering effect of metformin, confers insulin sensitivity, mainly by modulating lipid metab.  Metformin might influence tumorigenesis, both indirectly, through the systemic redn. of insulin levels, and directly, via the induction of energetic stress; however, these effects require further investigation.  Here, we discuss the updated understanding of the antigluconeogenic action of metformin in the liver and the implications of the discoveries of metformin targets for the treatment of diabetes mellitus and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWcJQOW14oCLVg90H21EOLACvtfcHk0lgqz7ugkc5Lgw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtVSitA%253D%253D&md5=bca85cb11f26bf607ccee93506e0986e</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnrendo.2013.256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrendo.2013.256%26sid%3Dliteratum%253Aachs%26aulast%3DPernicova%26aufirst%3DI.%26aulast%3DKorbonits%26aufirst%3DM.%26atitle%3DMetformin-mode%2520of%2520action%2520and%2520clinical%2520implications%2520for%2520diabetes%2520and%2520cancer%26jtitle%3DNat.%2520Rev.%2520Endocrinol.%26date%3D2014%26volume%3D10%26spage%3D143%26epage%3D156%26doi%3D10.1038%2Fnrendo.2013.256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wheaton, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamanaka, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soberanes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anso, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glasauer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufour, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mutlu, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budigner, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandel, N. S.</span></span> <span> </span><span class="NLM_article-title">Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">e02242</span>, <span class="refDoi">Â DOI: 10.7554/eLife.02242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.7554%2FeLife.02242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=24843020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1SjsbfM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=e02242&author=W.+W.+Wheatonauthor=S.+E.+Weinbergauthor=R.+B.+Hamanakaauthor=S.+Soberanesauthor=L.+B.+Sullivanauthor=E.+Ansoauthor=A.+Glasauerauthor=E.+Dufourauthor=G.+M.+Mutluauthor=G.+S.+Budignerauthor=N.+S.+Chandel&title=Metformin+inhibits+mitochondrial+complex+I+of+cancer+cells+to+reduce+tumorigenesis&doi=10.7554%2FeLife.02242"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis</span></div><div class="casAuthors">Wheaton, William W.; Weinberg, Samuel E.; Hamanaka, Robert B.; Soberanes, Saul; Sullivan, Lucas B.; Anso, Elena; Glasauer, Andrea; Dufour, Eric; Mutlu, Gokhan M.; Budigner, G. R. Scott; Chandel, Navdeep S.</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e02242/1-e02242/18, 18</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">Recent epidemiol. and lab.-based studies suggest that the anti-diabetic drug metformin prevents cancer progression.  How metformin diminishes tumor growth is not fully understood.  In this study, we report that in human cancer cells, metformin inhibits mitochondrial complex I (NADH dehydrogenase) activity and cellular respiration.  Metformin inhibited cellular proliferation in the presence of glucose, but induced cell death upon glucose deprivation, indicating that cancer cells rely exclusively on glycolysis for survival in the presence of metformin.  Metformin also reduced hypoxic activation of hypoxia-inducible factor 1 (HIF-1).  All of these effects of metformin were reversed when the metformin-resistant Saccharomyces cerevisiae NADH dehydrogenase NDI1 was overexpressed.  In vivo, the administration of metformin to mice inhibited the growth of control human cancer cells but not those expressing NDI1.  Thus, we have demonstrated that metformin's inhibitory effects on cancer progression are cancer cell autonomous and depend on its ability to inhibit mitochondrial complex I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8q1O2aH9ltLVg90H21EOLACvtfcHk0lgqz7ugkc5Lgw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1SjsbfM&md5=3719e29f8fdbc7721b382b2f45b37ae9</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.7554%2FeLife.02242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.02242%26sid%3Dliteratum%253Aachs%26aulast%3DWheaton%26aufirst%3DW.%2BW.%26aulast%3DWeinberg%26aufirst%3DS.%2BE.%26aulast%3DHamanaka%26aufirst%3DR.%2BB.%26aulast%3DSoberanes%26aufirst%3DS.%26aulast%3DSullivan%26aufirst%3DL.%2BB.%26aulast%3DAnso%26aufirst%3DE.%26aulast%3DGlasauer%26aufirst%3DA.%26aulast%3DDufour%26aufirst%3DE.%26aulast%3DMutlu%26aufirst%3DG.%2BM.%26aulast%3DBudigner%26aufirst%3DG.%2BS.%26aulast%3DChandel%26aufirst%3DN.%2BS.%26atitle%3DMetformin%2520inhibits%2520mitochondrial%2520complex%2520I%2520of%2520cancer%2520cells%2520to%2520reduce%2520tumorigenesis%26jtitle%3DeLife%26date%3D2014%26volume%3D3%26spage%3De02242%26doi%3D10.7554%2FeLife.02242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Molina, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Protopopova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gera, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bristow, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAfoos, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morlacchi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ackroyd, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agip, A. N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Atrash, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asara, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardenhagen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrillo, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciurea, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czako, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deem, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daver, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Groot, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuliani, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirst, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khor, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konoplev, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lofton, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahendra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matre, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullinax, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peoples, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrocchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Canale, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serreli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theroff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiziani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DePinho, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toniatti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Draetta, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffernan, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konopleva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Francesco, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marszalek, J. R.</span></span> <span> </span><span class="NLM_article-title">An inhibitor of oxidative phosphorylation exploits cancer vulnerability</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1036</span>â <span class="NLM_lpage">1046</span>, <span class="refDoi">Â DOI: 10.1038/s41591-018-0052-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fs41591-018-0052-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=29892070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFWru7bN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=1036-1046&author=J.+R.+Molinaauthor=Y.+T.+Sunauthor=M.+Protopopovaauthor=S.+Geraauthor=M.+Bandiauthor=C.+Bristowauthor=T.+McAfoosauthor=P.+Morlacchiauthor=J.+Ackroydauthor=A.+N.+A.+Agipauthor=G.+Al-Atrashauthor=J.+Asaraauthor=J.+Bardenhagenauthor=C.+C.+Carrilloauthor=C.+Carrollauthor=E.+Changauthor=S.+Ciureaauthor=J.+B.+Crossauthor=B.+Czakoauthor=A.+Deemauthor=N.+Daverauthor=J.+F.+de+Grootauthor=J.+W.+Dongauthor=N.+P.+Fengauthor=G.+Gaoauthor=J.+Gayauthor=M.+G.+Doauthor=J.+Greerauthor=V.+Giulianiauthor=J.+Hanauthor=L.+N.+Hanauthor=V.+K.+Henryauthor=J.+Hirstauthor=S.+Huangauthor=Y.+Y.+Jiangauthor=Z.+J.+Kangauthor=T.+Khorauthor=S.+Konoplevauthor=Y.+H.+Linauthor=G.+Liuauthor=A.+Lodiauthor=T.+Loftonauthor=H.+Maauthor=M.+Mahendraauthor=P.+Matreauthor=R.+Mullinaxauthor=M.+Peoplesauthor=A.+Petrocchiauthor=J.+Rodriguez-Canaleauthor=R.+Serreliauthor=T.+Shiauthor=M.+Smithauthor=Y.+Tabeauthor=J.+Theroffauthor=S.+Tizianiauthor=Q.+Y.+Xuauthor=Q.+Zhangauthor=F.+Mullerauthor=R.+A.+DePinhoauthor=C.+Toniattiauthor=G.+F.+Draettaauthor=T.+P.+Heffernanauthor=M.+Konoplevaauthor=P.+Jonesauthor=M.+E.+Di+Francescoauthor=J.+R.+Marszalek&title=An+inhibitor+of+oxidative+phosphorylation+exploits+cancer+vulnerability&doi=10.1038%2Fs41591-018-0052-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">An inhibitor of oxidative phosphorylation exploits cancer vulnerability</span></div><div class="casAuthors">Molina, Jennifer R.; Sun, Yuting; Protopopova, Marina; Gera, Sonal; Bandi, Madhavi; Bristow, Christopher; McAfoos, Timothy; Morlacchi, Pietro; Ackroyd, Jeffrey; Agip, Ahmed-Noor A.; Al-Atrash, Gheath; Asara, John; Bardenhagen, Jennifer; Carrillo, Caroline C.; Carroll, Christopher; Chang, Edward; Ciurea, Stefan; Cross, Jason B.; Czako, Barbara; Deem, Angela; Daver, Naval; de Groot, John Frederick; Dong, Jian-Wen; Feng, Ningping; Gao, Guang; Gay, Jason; Do, Mary Geck; Greer, Jennifer; Giuliani, Virginia; Han, Jing; Han, Lina; Henry, Verlene K.; Hirst, Judy; Huang, Sha; Jiang, Yongying; Kang, Zhijun; Khor, Tin; Konoplev, Sergej; Lin, Yu-Hsi; Liu, Gang; Lodi, Alessia; Lofton, Timothy; Ma, Helen; Mahendra, Mikhila; Matre, Polina; Mullinax, Robert; Peoples, Michael; Petrocchi, Alessia; Rodriguez-Canale, Jaime; Serreli, Riccardo; Shi, Thomas; Smith, Melinda; Tabe, Yoko; Theroff, Jay; Tiziani, Stefano; Xu, Quanyun; Zhang, Qi; Muller, Florian; De Pinho, Ronald A.; Toniatti, Carlo; Draetta, Giulio F.; Heffernan, Timothy P.; Konopleva, Marina; Jones, Philip; Di Francesco, M. Emilia; Marszalek, Joseph R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1036-1046</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Metabolic reprograming is an emerging hallmark of tumor biol. and an actively pursued opportunity in discovery of oncol. drugs.  Extensive efforts have focused on therapeutic targeting of glycolysis, whereas drugging mitochondrial oxidative phosphorylation (OXPHOS) has remained largely unexplored, partly owing to an incomplete understanding of tumor contexts in which OXPHOS is essential.  Here, we report the discovery of IACS-010759, a clin.-grade small-mol. inhibitor of complex I of the mitochondrial electron transport chain.  Treatment with IACS-010759 robustly inhibited proliferation and induced apoptosis in models of brain cancer and acute myeloid leukemia (AML) reliant on OXPHOS, likely owing to a combination of energy depletion and reduced aspartate prodn. that leads to impaired nucleotide biosynthesis.  In models of brain cancer and AML, tumor growth was potently inhibited in vivo following IACS-010759 treatment at well-tolerated doses.  IACS-010759 is currently being evaluated in phase 1 clin. trials in relapsed/refractory AML and solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYy9jYNGBbO7Vg90H21EOLACvtfcHk0lgh-V6Xzqkbdw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFWru7bN&md5=51b8bf30a5897f8827d300377eb419f5</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fs41591-018-0052-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41591-018-0052-4%26sid%3Dliteratum%253Aachs%26aulast%3DMolina%26aufirst%3DJ.%2BR.%26aulast%3DSun%26aufirst%3DY.%2BT.%26aulast%3DProtopopova%26aufirst%3DM.%26aulast%3DGera%26aufirst%3DS.%26aulast%3DBandi%26aufirst%3DM.%26aulast%3DBristow%26aufirst%3DC.%26aulast%3DMcAfoos%26aufirst%3DT.%26aulast%3DMorlacchi%26aufirst%3DP.%26aulast%3DAckroyd%26aufirst%3DJ.%26aulast%3DAgip%26aufirst%3DA.%2BN.%2BA.%26aulast%3DAl-Atrash%26aufirst%3DG.%26aulast%3DAsara%26aufirst%3DJ.%26aulast%3DBardenhagen%26aufirst%3DJ.%26aulast%3DCarrillo%26aufirst%3DC.%2BC.%26aulast%3DCarroll%26aufirst%3DC.%26aulast%3DChang%26aufirst%3DE.%26aulast%3DCiurea%26aufirst%3DS.%26aulast%3DCross%26aufirst%3DJ.%2BB.%26aulast%3DCzako%26aufirst%3DB.%26aulast%3DDeem%26aufirst%3DA.%26aulast%3DDaver%26aufirst%3DN.%26aulast%3Dde%2BGroot%26aufirst%3DJ.%2BF.%26aulast%3DDong%26aufirst%3DJ.%2BW.%26aulast%3DFeng%26aufirst%3DN.%2BP.%26aulast%3DGao%26aufirst%3DG.%26aulast%3DGay%26aufirst%3DJ.%26aulast%3DDo%26aufirst%3DM.%2BG.%26aulast%3DGreer%26aufirst%3DJ.%26aulast%3DGiuliani%26aufirst%3DV.%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DHan%26aufirst%3DL.%2BN.%26aulast%3DHenry%26aufirst%3DV.%2BK.%26aulast%3DHirst%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DJiang%26aufirst%3DY.%2BY.%26aulast%3DKang%26aufirst%3DZ.%2BJ.%26aulast%3DKhor%26aufirst%3DT.%26aulast%3DKonoplev%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DY.%2BH.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DLodi%26aufirst%3DA.%26aulast%3DLofton%26aufirst%3DT.%26aulast%3DMa%26aufirst%3DH.%26aulast%3DMahendra%26aufirst%3DM.%26aulast%3DMatre%26aufirst%3DP.%26aulast%3DMullinax%26aufirst%3DR.%26aulast%3DPeoples%26aufirst%3DM.%26aulast%3DPetrocchi%26aufirst%3DA.%26aulast%3DRodriguez-Canale%26aufirst%3DJ.%26aulast%3DSerreli%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DM.%26aulast%3DTabe%26aufirst%3DY.%26aulast%3DTheroff%26aufirst%3DJ.%26aulast%3DTiziani%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DQ.%2BY.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DMuller%26aufirst%3DF.%26aulast%3DDePinho%26aufirst%3DR.%2BA.%26aulast%3DToniatti%26aufirst%3DC.%26aulast%3DDraetta%26aufirst%3DG.%2BF.%26aulast%3DHeffernan%26aufirst%3DT.%2BP.%26aulast%3DKonopleva%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DDi%2BFrancesco%26aufirst%3DM.%2BE.%26aulast%3DMarszalek%26aufirst%3DJ.%2BR.%26atitle%3DAn%2520inhibitor%2520of%2520oxidative%2520phosphorylation%2520exploits%2520cancer%2520vulnerability%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26spage%3D1036%26epage%3D1046%26doi%3D10.1038%2Fs41591-018-0052-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><a href="https://clinicaltrials.gov/" class="extLink">https://clinicaltrials.gov/</a> (accessed Sep 19, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fclinicaltrials.gov%2F+%28accessed+Sep+19%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M. J.</span></span> <span> </span><span class="NLM_article-title">Structure of mammalian respiratory supercomplex I1III2IV1</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>167</i></span>,  <span class="NLM_fpage">1598</span>â <span class="NLM_lpage">1609</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2016.11.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.cell.2016.11.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27912063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVSms7fO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2016&pages=1598-1609&author=M.+Wuauthor=J.+K.+Guauthor=R.+Y.+Guoauthor=Y.+S.+Huangauthor=M.+J.+Yang&title=Structure+of+mammalian+respiratory+supercomplex+I1III2IV1&doi=10.1016%2Fj.cell.2016.11.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of mammalian respiratory supercomplex I1III2IV1</span></div><div class="casAuthors">Wu, Meng; Gu, Jinke; Guo, Runyu; Huang, Yushen; Yang, Maojun</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1598-1609.e10</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The mammalian respiratory chain complexes assemble into supercomplexes (SCs) and reside in the inner mitochondrial membrane to transfer electrons and establish the proton gradient for complex V to synthesize ATP.  The precise arrangement of SCs is largely unknown.  Here, the authors report a 4.0-Ã cryo-electron microscopy (cryo-EM) structure of the major SC of porcine heart, the 1.7-MDa SCI1III2IV1 enzyme supercomplex .  Respiratory complex III (CIII; quinol-cytochrome c reductase) dimer and complex IV [CIV; cytochrome c oxidase (also COX)] bound at the same side of the L-shaped complex I (CI; ubiquinone reductase).  Several accessory or supernumerary subunits of CI, such as NDUFA11, NDUFB4, NDUFB8, and NDUFB9, directly contributed to the oligomerization of CI, CIII, and CIV.  Subunits COX7C and COX7A of CIV attached CIV to the concave surface formed by CIII and the distal end of the membrane arm of CI.  The structure suggested a possible mechanism by which electrons are transferred from NADH to cytochrome c and provided a platform for future functional dissection of respiration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqU5D7qe8MBELVg90H21EOLACvtfcHk0lgh-V6Xzqkbdw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVSms7fO&md5=039931d1e204eb876b52d465c11235fd</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2016.11.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2016.11.012%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DM.%26aulast%3DGu%26aufirst%3DJ.%2BK.%26aulast%3DGuo%26aufirst%3DR.%2BY.%26aulast%3DHuang%26aufirst%3DY.%2BS.%26aulast%3DYang%26aufirst%3DM.%2BJ.%26atitle%3DStructure%2520of%2520mammalian%2520respiratory%2520supercomplex%2520I1III2IV1%26jtitle%3DCell%26date%3D2016%26volume%3D167%26spage%3D1598%26epage%3D1609%26doi%3D10.1016%2Fj.cell.2016.11.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sousa, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vonck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhlbrandt, W.</span></span> <span> </span><span class="NLM_article-title">Functional asymmetry and electron flow in the bovine respirasome</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">e21290</span>, <span class="refDoi">Â DOI: 10.7554/eLife.21290</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.7554%2FeLife.21290" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27830641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVSru7nK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=e21290&author=J.+S.+Sousaauthor=D.+J.+Millsauthor=J.+Vonckauthor=W.+Kuhlbrandt&title=Functional+asymmetry+and+electron+flow+in+the+bovine+respirasome&doi=10.7554%2FeLife.21290"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Functional asymmetry and electron flow in the bovine respirasome</span></div><div class="casAuthors">Sousa, Joana S.; Mills, Deryck J.; Vonck, Janet; Kuehlbrandt, Werner</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e21290/1-e21290/17</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">Respirasomes are macromol. assemblies of the respiratory chain complexes I, III and IV in the inner mitochondrial membrane.  We detd. the structure of supercomplex I1III2IV1 from bovine heart mitochondria by cryo-EM at 9 Ã resoln.  Most protein-protein contacts between complex I, III and IV in the membrane are mediated by supernumerary subunits.  Of the two Rieske iron-sulfur cluster domains in the complex III dimer, one is resolved, indicating that this domain is immobile and unable to transfer electrons.  The central position of the active complex III monomer between complex I and IV in the respirasome is optimal for accepting reduced quinone from complex I over a short diffusion distance of 11 nm, and delivering reduced cytochrome c to complex IV.  The functional asymmetry of complex III provides strong evidence for directed electron flow from complex I to complex IV through the active complex III monomer in the mammalian supercomplex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqenZJeGzhaw7Vg90H21EOLACvtfcHk0lgh-V6Xzqkbdw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVSru7nK&md5=b608e92d89c1e39b5a670da0ebdaeba1</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.7554%2FeLife.21290&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.21290%26sid%3Dliteratum%253Aachs%26aulast%3DSousa%26aufirst%3DJ.%2BS.%26aulast%3DMills%26aufirst%3DD.%2BJ.%26aulast%3DVonck%26aufirst%3DJ.%26aulast%3DKuhlbrandt%26aufirst%3DW.%26atitle%3DFunctional%2520asymmetry%2520and%2520electron%2520flow%2520in%2520the%2520bovine%2520respirasome%26jtitle%3DeLife%26date%3D2016%26volume%3D5%26spage%3De21290%26doi%3D10.7554%2FeLife.21290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Letts, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiedorczuk, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sazanov, L. A.</span></span> <span> </span><span class="NLM_article-title">The architecture of respiratory supercomplexes</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>537</i></span>,  <span class="NLM_fpage">644</span>â <span class="NLM_lpage">648</span>, <span class="refDoi">Â DOI: 10.1038/nature19774</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fnature19774" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27654913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFClsrrM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=537&publication_year=2016&pages=644-648&author=J.+A.+Lettsauthor=K.+Fiedorczukauthor=L.+A.+Sazanov&title=The+architecture+of+respiratory+supercomplexes&doi=10.1038%2Fnature19774"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The architecture of respiratory supercomplexes</span></div><div class="casAuthors">Letts, James A.; Fiedorczuk, Karol; Sazanov, Leonid A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">537</span>
        (<span class="NLM_cas:issue">7622</span>),
    <span class="NLM_cas:pages">644-648</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Mitochondrial electron transport chain complexes are organized into supercomplexes responsible for carrying out cellular respiration.  Here we present three architectures of mammalian (ovine) supercomplexes detd. by cryo-electron microscopy.  We identify two distinct arrangements of supercomplex CICIII2CIV (the respirasome)-a major 'tight' form and a minor 'loose' form (resolved at the resoln. of 5.8 Ã and 6.7 Ã, resp.), which may represent different stages in supercomplex assembly or disassembly.  We have also detd. an architecture of supercomplex CICIII2 at 7.8 Ã resoln.  All obsd. d. can be attributed to the known 80 subunits of the individual complexes, including 132 transmembrane helixes.  The individual complexes form tight interactions that vary between the architectures, with complex IV subunit COX7a switching contact from complex III to complex I.  The arrangement of active sites within the supercomplex may help control reactive oxygen species prodn.  To our knowledge, these are the first complete architectures of the dominant, physiol. relevant state of the electron transport chain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr91FqsT_FIfrVg90H21EOLACvtfcHk0ljBWj8n7x0ZMA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFClsrrM&md5=e080b01abdee073c6e0459131bdeaf07</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnature19774&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature19774%26sid%3Dliteratum%253Aachs%26aulast%3DLetts%26aufirst%3DJ.%2BA.%26aulast%3DFiedorczuk%26aufirst%3DK.%26aulast%3DSazanov%26aufirst%3DL.%2BA.%26atitle%3DThe%2520architecture%2520of%2520respiratory%2520supercomplexes%26jtitle%3DNature%26date%3D2016%26volume%3D537%26spage%3D644%26epage%3D648%26doi%3D10.1038%2Fnature19774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M. J.</span></span> <span> </span><span class="NLM_article-title">The architecture of the mammalian respirasome</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>537</i></span>,  <span class="NLM_fpage">639</span>â <span class="NLM_lpage">643</span>, <span class="refDoi">Â DOI: 10.1038/nature19359</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fnature19359" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27654917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFClsr3I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=537&publication_year=2016&pages=639-643&author=J.+K.+Guauthor=M.+Wuauthor=R.+Y.+Guoauthor=K.+G.+Yanauthor=J.+L.+Leiauthor=N.+Gaoauthor=M.+J.+Yang&title=The+architecture+of+the+mammalian+respirasome&doi=10.1038%2Fnature19359"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The architecture of the mammalian respirasome</span></div><div class="casAuthors">Gu, Jinke; Wu, Meng; Guo, Runyu; Yan, Kaige; Lei, Jianlin; Gao, Ning; Yang, Maojun</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">537</span>
        (<span class="NLM_cas:issue">7622</span>),
    <span class="NLM_cas:pages">639-643</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The respiratory chain complexes I, III and IV (CI, CIII and CIV) are present in the bacterial membrane or the inner mitochondrial membrane and have a role of transferring electrons and establishing the proton gradient for ATP synthesis by complex V.  The respiratory chain complexes can assemble into supercomplexes (SCs), but their precise arrangement is unknown.  Here we report a 5.4 Ã cryo-electron microscopy structure of the major 1.7 megadalton SCI1III2IV1 respirasome purified from porcine heart.  The CIII dimer and CIV bind at the same side of the L-shaped CI, with their transmembrane domains essentially aligned to form a transmembrane disk.  Compared to free CI, the CI in the respirasome is more compact because of interactions with CIII and CIV.  The NDUFA11 and NDUFB9 supernumerary subunits of CI contribute to the oligomerization of CI and CIII.  The structure of the respirasome provides information on the precise arrangements of the respiratory chain complexes in mitochondria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB51UYyLnnwrVg90H21EOLACvtfcHk0ljBWj8n7x0ZMA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFClsr3I&md5=e6c15c9d3ced5e0250809ac3e2368773</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnature19359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature19359%26sid%3Dliteratum%253Aachs%26aulast%3DGu%26aufirst%3DJ.%2BK.%26aulast%3DWu%26aufirst%3DM.%26aulast%3DGuo%26aufirst%3DR.%2BY.%26aulast%3DYan%26aufirst%3DK.%2BG.%26aulast%3DLei%26aufirst%3DJ.%2BL.%26aulast%3DGao%26aufirst%3DN.%26aulast%3DYang%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520architecture%2520of%2520the%2520mammalian%2520respirasome%26jtitle%3DNature%26date%3D2016%26volume%3D537%26spage%3D639%26epage%3D643%26doi%3D10.1038%2Fnature19359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M. J.</span></span> <span> </span><span class="NLM_article-title">Architecture of human mitochondrial respiratory megacomplex I2III2IV2</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>170</i></span>,  <span class="NLM_fpage">1247</span>â <span class="NLM_lpage">1257</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2017.07.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.cell.2017.07.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=28844695" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlylsb%252FO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2017&pages=1247-1257&author=R.+Y.+Guoauthor=S.+Zongauthor=M.+Wuauthor=J.+K.+Guauthor=M.+J.+Yang&title=Architecture+of+human+mitochondrial+respiratory+megacomplex+I2III2IV2&doi=10.1016%2Fj.cell.2017.07.050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Architecture of human mitochondrial respiratory megacomplex I2III2IV2</span></div><div class="casAuthors">Guo, Runyu; Zong, Shuai; Wu, Meng; Gu, Jinke; Yang, Maojun</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1247-1257.e12</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The respiratory megacomplex represents the highest-order assembly of respiratory chain complexes, and it allows mitochondria to respond to energy-requiring conditions.  To understand its architecture, we examd. human respiratory chain megacomplex I2III2IV2 (MCI2III2IV2) with 140 subunits and a subset of assocd. cofactors using cryo-electron microscopy.  The MCI2III2IV2 megacomplex forms a circular structure with the dimeric CIII located in the center, where it is surrounded by 2 copies each of CI and CIV.  Two cytochrome mols. are positioned to accept electrons on the surface of the c1 state CIII dimer.  Analyses indicated that CII could insert into the gaps between CI and CIV to form a closed ring, which we termed the electron transport chain supercomplex.  The structure not only revealed the precise assignment of individual subunits of human CI and CIII, but also enabled future in-depth anal. of the electron transport chain as a whole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouObX0EVYN7LVg90H21EOLACvtfcHk0ljBWj8n7x0ZMA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlylsb%252FO&md5=51151bba713ee27ceb635527e8bbfbc8</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.07.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.07.050%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DR.%2BY.%26aulast%3DZong%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DM.%26aulast%3DGu%26aufirst%3DJ.%2BK.%26aulast%3DYang%26aufirst%3DM.%2BJ.%26atitle%3DArchitecture%2520of%2520human%2520mitochondrial%2520respiratory%2520megacomplex%2520I2III2IV2%26jtitle%3DCell%26date%3D2017%26volume%3D170%26spage%3D1247%26epage%3D1257%26doi%3D10.1016%2Fj.cell.2017.07.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Letts, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiedorczuk, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degliesposti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skehel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sazanov, L. A.</span></span> <span> </span><span class="NLM_article-title">Structures of respiratory supercomplex I+III2 reveal functional and conformational crosstalk</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">1131</span>â <span class="NLM_lpage">1146</span>, <span class="refDoi">Â DOI: 10.1016/j.molcel.2019.07.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.molcel.2019.07.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=31492636" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs12qs7%252FM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2019&pages=1131-1146&author=J.+A.+Lettsauthor=K.+Fiedorczukauthor=G.+Degliespostiauthor=M.+Skehelauthor=L.+A.+Sazanov&title=Structures+of+respiratory+supercomplex+I%2BIII2+reveal+functional+and+conformational+crosstalk&doi=10.1016%2Fj.molcel.2019.07.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of Respiratory Supercomplex I+III2 Reveal Functional and Conformational Crosstalk</span></div><div class="casAuthors">Letts, James A.; Fiedorczuk, Karol; Degliesposti, Gianluca; Skehel, Mark; Sazanov, Leonid A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1131-1146.e6</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The mitochondrial electron transport chain complexes are organized into supercomplexes (SCs) of defined stoichiometry, which have been proposed to regulate electron flux via substrate channeling.  We demonstrate that CoQ trapping in the isolated SC I+III2 limits complex (C)I turnover, arguing against channeling.  The SC structure, resolved at up to 3.8 Ã in four distinct states, suggests that CoQ oxidn. may be rate limiting because of unequal access of CoQ to the active sites of CIII2.  CI shows a transition between "closed" and "open" conformations, accompanied by the striking rotation of a key transmembrane helix.  Furthermore, the state of CI affects the conformational flexibility within CIII2, demonstrating crosstalk between the enzymes.  CoQ was identified at only three of the four binding sites in CIII2, suggesting that interaction with CI disrupts CIII2 symmetry in a functionally relevant manner.  Together, these observations indicate a more nuanced functional role for the SCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1uIOktwYRQrVg90H21EOLACvtfcHk0ljB_-WsDDe6jA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs12qs7%252FM&md5=fd10b0046a3268376468d7d5db135991</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2019.07.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2019.07.022%26sid%3Dliteratum%253Aachs%26aulast%3DLetts%26aufirst%3DJ.%2BA.%26aulast%3DFiedorczuk%26aufirst%3DK.%26aulast%3DDegliesposti%26aufirst%3DG.%26aulast%3DSkehel%26aufirst%3DM.%26aulast%3DSazanov%26aufirst%3DL.%2BA.%26atitle%3DStructures%2520of%2520respiratory%2520supercomplex%2520I%252BIII2%2520reveal%2520functional%2520and%2520conformational%2520crosstalk%26jtitle%3DMol.%2520Cell%26date%3D2019%26volume%3D75%26spage%3D1131%26epage%3D1146%26doi%3D10.1016%2Fj.molcel.2019.07.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Y. D.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial respiratory complex I: structure, function and implication in human diseases</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1266</span>â <span class="NLM_lpage">1277</span>, <span class="refDoi">Â DOI: 10.2174/092986709787846578</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.2174%2F092986709787846578" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=19355884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltVeqsb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=1266-1277&author=L.+K.+Sharmaauthor=J.+X.+Luauthor=Y.+D.+Bai&title=Mitochondrial+respiratory+complex+I%3A+structure%2C+function+and+implication+in+human+diseases&doi=10.2174%2F092986709787846578"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial respiratory complex I: structure, function and implication in human diseases</span></div><div class="casAuthors">Sharma, Lokendra K.; Lu, Jianxin; Bai, Yidong</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1266-1277</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Mitochondria are ubiquitous organelles in eukaryotic cells whose primary function is to generate energy supplies in the form of ATP through oxidative phosphorylation.  As the entry point for most electrons into the respiratory chain, NADH:ubiquinone oxidoreductase, or complex I, is the largest and least understood component of the mitochondrial oxidative phosphorylation system.  Substantial progress has been made in recent years in understanding its subunit compn., its assembly, the interaction among complex I and other respiratory components, and its role in oxidative stress and apoptosis.  This review provides an updated overview of the structure of complex I, as well as its cellular functions, and discusses the implication of complex I dysfunction in various human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOAZkT2bfgDbVg90H21EOLACvtfcHk0ljB_-WsDDe6jA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltVeqsb4%253D&md5=d6e05fca2d0c9eb5d0c1c073412d0247</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.2174%2F092986709787846578&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986709787846578%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DL.%2BK.%26aulast%3DLu%26aufirst%3DJ.%2BX.%26aulast%3DBai%26aufirst%3DY.%2BD.%26atitle%3DMitochondrial%2520respiratory%2520complex%2520I%253A%2520structure%252C%2520function%2520and%2520implication%2520in%2520human%2520diseases%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2009%26volume%3D16%26spage%3D1266%26epage%3D1277%26doi%3D10.2174%2F092986709787846578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parey, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegmund, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vonck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhlbrandt, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zickermann, V.</span></span> <span> </span><span class="NLM_article-title">Cryo-EM structure of respiratory complex I at work</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e39213</span>, <span class="refDoi">Â DOI: 10.7554/eLife.39213</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.7554%2FeLife.39213" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=30277212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlyrtbbP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&pages=e39213&author=K.+Pareyauthor=U.+Brandtauthor=H.+Xieauthor=D.+J.+Millsauthor=K.+Siegmundauthor=J.+Vonckauthor=W.+Kuhlbrandtauthor=V.+Zickermann&title=Cryo-EM+structure+of+respiratory+complex+I+at+work&doi=10.7554%2FeLife.39213"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Cryo-EM structure of respiratory complex I at work</span></div><div class="casAuthors">Parey, Kristian; Brandt, Ulrich; Xie, Hao; Mills, Deryck J.; Siegmund, Karin; Vonck, Janet; Kuehlbrandt, Werner; Zickermann, Volker</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e39213/1-e39213/28</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">Mitochondrial complex I has a key role in cellular energy metab., generating a major portion of the proton motive force that drives aerobic ATP synthesis.  The hydrophilic arm of the L-shaped â¼1 MDa membrane protein complex transfers electrons from NADH to ubiquinone, providing the energy to drive proton pumping at distant sites in the membrane arm.  The crit. steps of energy conversion are assocd. with the redox chem. of ubiquinone.  We report the cryo-EM structure of complete mitochondrial complex I from the aerobic yeast Yarrowia lipolytica both in the deactive form and after capturing the enzyme during steady-state activity.  The site of ubiquinone binding obsd. during turnover supports a two-state stabilization change mechanism for complex I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9CdwogB-8H7Vg90H21EOLACvtfcHk0ljB_-WsDDe6jA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlyrtbbP&md5=bd985b3dba1b6c962e176a42da8b8ea0</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.7554%2FeLife.39213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.39213%26sid%3Dliteratum%253Aachs%26aulast%3DParey%26aufirst%3DK.%26aulast%3DBrandt%26aufirst%3DU.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DMills%26aufirst%3DD.%2BJ.%26aulast%3DSiegmund%26aufirst%3DK.%26aulast%3DVonck%26aufirst%3DJ.%26aulast%3DKuhlbrandt%26aufirst%3DW.%26aulast%3DZickermann%26aufirst%3DV.%26atitle%3DCryo-EM%2520structure%2520of%2520respiratory%2520complex%2520I%2520at%2520work%26jtitle%3DeLife%26date%3D2018%26volume%3D7%26spage%3De39213%26doi%3D10.7554%2FeLife.39213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baradaran, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berrisford, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minhas, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sazanov, L. A.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the entire respiratory complex I</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>494</i></span>,  <span class="NLM_fpage">443</span>â <span class="NLM_lpage">448</span>, <span class="refDoi">Â DOI: 10.1038/nature11871</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fnature11871" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=23417064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtFWiu70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=494&publication_year=2013&pages=443-448&author=R.+Baradaranauthor=J.+M.+Berrisfordauthor=G.+S.+Minhasauthor=L.+A.+Sazanov&title=Crystal+structure+of+the+entire+respiratory+complex+I&doi=10.1038%2Fnature11871"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the entire respiratory complex I</span></div><div class="casAuthors">Baradaran, Rozbeh; Berrisford, John M.; Minhas, Gurdeep S.; Sazanov, Leonid A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">494</span>
        (<span class="NLM_cas:issue">7438</span>),
    <span class="NLM_cas:pages">443-448</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Complex I/NADH;ubiquinone reductase is the 1st and largest enzyme of the respiratory chain and plays a central role in cellular energy prodn. through the coupling of NADH:ubiquinone electron transfer to proton translocation.  It is also implicated in many common human neurodegenerative diseases.  Here, the authors report the 1st crystal structure of the entire, intact complex I (from Thermus thermophilus) at 3.3 Ã resoln.  The structure of the 536-kDa complex comprises 16 different subunits, with a total of 64 transmembrane helixes and 9 Fe-S clusters.  The core fold of subunit Nqo8 (ND1 in humans) was, unexpectedly, similar to a half-channel of the antiporter-like subunits.  Small subunits nearby formed a linked 2nd half-channel, which completed the 4th proton-translocation pathway (present in addn. to the channels in 3 antiporter-like subunits).  The quinone-binding site was unusually long, narrow, and enclosed.  The quinone headgroup bound at the deep end of this chamber, near Fe-S cluster N2.  Notably, the chamber was linked to the 4th channel by a 'funnel' of charged residues.  The link continued over the entire membrane domain as a flexible central axis of charged and polar residues, and probably plays a leading role in the propagation of conformational changes, aided by coupling elements.  The structure suggests that a unique, out-of-the-membrane quinone-reaction chamber enables the redox energy to drive concerted long-range conformational changes in the 4 antiporter-like domains, resulting in translocation of 4 protons per cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4GfRTgPHKVrVg90H21EOLACvtfcHk0ljUv-IJKW94Ag"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtFWiu70%253D&md5=9e0beca1b6c80367e223d74556b1d58e</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fnature11871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11871%26sid%3Dliteratum%253Aachs%26aulast%3DBaradaran%26aufirst%3DR.%26aulast%3DBerrisford%26aufirst%3DJ.%2BM.%26aulast%3DMinhas%26aufirst%3DG.%2BS.%26aulast%3DSazanov%26aufirst%3DL.%2BA.%26atitle%3DCrystal%2520structure%2520of%2520the%2520entire%2520respiratory%2520complex%2520I%26jtitle%3DNature%26date%3D2013%26volume%3D494%26spage%3D443%26epage%3D448%26doi%3D10.1038%2Fnature11871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hunte, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zickermann, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, U.</span></span> <span> </span><span class="NLM_article-title">Functional modules and structural basis of conformational coupling in mitochondrial complex I</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>329</i></span>,  <span class="NLM_fpage">448</span>â <span class="NLM_lpage">451</span>, <span class="refDoi">Â DOI: 10.1126/science.1191046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1126%2Fscience.1191046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=20595580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptVWgtrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=329&publication_year=2010&pages=448-451&author=C.+Hunteauthor=V.+Zickermannauthor=U.+Brandt&title=Functional+modules+and+structural+basis+of+conformational+coupling+in+mitochondrial+complex+I&doi=10.1126%2Fscience.1191046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Functional Modules and Structural Basis of Conformational Coupling in Mitochondrial Complex I</span></div><div class="casAuthors">Hunte, Carola; Zickermann, Volker; Brandt, Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">329</span>
        (<span class="NLM_cas:issue">5990</span>),
    <span class="NLM_cas:pages">448-451</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Proton-pumping respiratory complex I is one of the largest and most complicated membrane protein complexes.  Its function is crit. for efficient energy supply in aerobic cells, and malfunctions are implicated in many neurodegenerative disorders.  Here, we report an x-ray crystallog. anal. of mitochondrial complex I.  The positions of all iron-sulfur clusters relative to the membrane arm were detd. in the complete enzyme complex.  The ubiquinone redn. site resides close to 30 angstroms above the membrane domain.  The arrangement of functional modules suggests conformational coupling of redox chem. with proton pumping and essentially excludes direct mechanisms.  We suggest that a ~60-angstrom-long helical transmission element is crit. for transducing conformational energy to proton-pumping elements in the distal module of the membrane arm.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBztImW48wyLVg90H21EOLACvtfcHk0ljUv-IJKW94Ag"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptVWgtrY%253D&md5=fd3597e3d5270c741e925047561f073b</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1126%2Fscience.1191046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1191046%26sid%3Dliteratum%253Aachs%26aulast%3DHunte%26aufirst%3DC.%26aulast%3DZickermann%26aufirst%3DV.%26aulast%3DBrandt%26aufirst%3DU.%26atitle%3DFunctional%2520modules%2520and%2520structural%2520basis%2520of%2520conformational%2520coupling%2520in%2520mitochondrial%2520complex%2520I%26jtitle%3DScience%26date%3D2010%26volume%3D329%26spage%3D448%26epage%3D451%26doi%3D10.1126%2Fscience.1191046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zickermann, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nasiri, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegmund, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwalbe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunte, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, U.</span></span> <span> </span><span class="NLM_article-title">Mechanistic insight from the crystal structure of mitochondrial complex I</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>347</i></span>,  <span class="NLM_fpage">44</span>â <span class="NLM_lpage">49</span>, <span class="refDoi">Â DOI: 10.1126/science.1259859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1126%2Fscience.1259859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=25554780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsF2jsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2015&pages=44-49&author=V.+Zickermannauthor=C.+Wirthauthor=H.+Nasiriauthor=K.+Siegmundauthor=H.+Schwalbeauthor=C.+Hunteauthor=U.+Brandt&title=Mechanistic+insight+from+the+crystal+structure+of+mitochondrial+complex+I&doi=10.1126%2Fscience.1259859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic insight from the crystal structure of mitochondrial complex I</span></div><div class="casAuthors">Zickermann, Volker; Wirth, Christophe; Nasiri, Hamid; Siegmund, Karin; Schwalbe, Harald; Hunte, Carola; Brandt, Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">6217</span>),
    <span class="NLM_cas:pages">44-49</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Proton-pumping complex I/ubiquinone reductase (I) of the mitochondrial respiratory chain is among the largest and most complicated membrane protein complexes.  I contributes substantially to oxidative energy conversion in eukaryotic cells.  Its malfunctions are implicated in many hereditary and degenerative disorders.  Here, the authors report the x-ray crystal structure of I at a resoln. of 3.6-3.9 Ã, describing in detail the central subunits that execute the bioenergetic function.  A continuous axis of basic and acidic residues running centrally through the membrane arm was found to connect the ubiquinone redn. site in the hydrophilic arm to 4 putative proton-pumping units.  The binding position for a substrate analogous inhibitor and blockage of the predicted ubiquinone binding site provide a model for the "deactive" form of the enzyme.  The proposed transition into the active form is based on a concerted structural rearrangement at the ubiquinone redn. site, providing support for a 2-state stabilization-change mechanism of proton pumping.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcVpKidjRGvrVg90H21EOLACvtfcHk0ljUv-IJKW94Ag"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsF2jsg%253D%253D&md5=a0274bab4e65652e3dd656af7d966d3a</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1126%2Fscience.1259859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1259859%26sid%3Dliteratum%253Aachs%26aulast%3DZickermann%26aufirst%3DV.%26aulast%3DWirth%26aufirst%3DC.%26aulast%3DNasiri%26aufirst%3DH.%26aulast%3DSiegmund%26aufirst%3DK.%26aulast%3DSchwalbe%26aufirst%3DH.%26aulast%3DHunte%26aufirst%3DC.%26aulast%3DBrandt%26aufirst%3DU.%26atitle%3DMechanistic%2520insight%2520from%2520the%2520crystal%2520structure%2520of%2520mitochondrial%2520complex%2520I%26jtitle%3DScience%26date%3D2015%26volume%3D347%26spage%3D44%26epage%3D49%26doi%3D10.1126%2Fscience.1259859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uno, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyoshi, H.</span></span> <span> </span><span class="NLM_article-title">Exploring the quinone/inhibitor-binding pocket in mitochondrial respiratory complex I by chemical biology approaches</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>294</i></span>,  <span class="NLM_fpage">679</span>â <span class="NLM_lpage">696</span>, <span class="refDoi">Â DOI: 10.1074/jbc.RA118.006056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1074%2Fjbc.RA118.006056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=30425100" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1Cjtbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=294&publication_year=2019&pages=679-696&author=S.+P.+Unoauthor=H.+Kimuraauthor=M.+Muraiauthor=H.+Miyoshi&title=Exploring+the+quinone%2Finhibitor-binding+pocket+in+mitochondrial+respiratory+complex+I+by+chemical+biology+approaches&doi=10.1074%2Fjbc.RA118.006056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring the quinone/inhibitor-binding pocket in mitochondrial respiratory complex I by chemical biology approaches</span></div><div class="casAuthors">Uno, Shinpei; Kimura, Hironori; Murai, Masatoshi; Miyoshi, Hideto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">294</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">679-696</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">NADH-quinone oxidoreductase (respiratory complex I) couples NADH-to-quinone electron transfer to the translocation of protons across the membrane.  Even though the architecture of the quinone-access channel in the enzyme has been modeled by X-ray crystallog. and cryo-EM, conflicting findings raise the question whether the models fully reflect physiol. relevant states present throughout the catalytic cycle.  To gain further insights into the structural features of the binding pocket for quinone/inhibitor, we performed chem. biol. expts. using bovine heart sub-mitochondrial particles.  We synthesized ubiquinones (UQs) that are oversized ,(i.e., SF-UQs) or lipid-like (i.e., PC-UQs) and are highly unlikely to enter and transit the predicted narrow channel.  We found that SF-UQs and PC-UQs can be catalytically reduced by complex I, albeit only at moderate or low rates.  Moreover, quinone-site inhibitors completely blocked the catalytic redn. and the membrane potential formation coupled to this redn.  Photoaffinity-labeling expts. revealed that amiloride-type inhibitors bind to the interfacial domain of multiple core subunits (49 kDa, ND1, and PSST) and the 39-kDa supernumerary subunit, although the latter does not make up the channel cavity in the current models.  The binding of amilorides to the multiple target subunits was remarkably suppressed by other quinone-site inhibitors and SF-UQs.  Taken together, the present results are difficult to reconcile with the current channel models.  On the basis of comprehensive interpretations of the present results and of previous findings, we discuss the physiol. relevance of these models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrJm9y50UP1LVg90H21EOLACvtfcHk0liiVmuTNEw6PQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1Cjtbw%253D&md5=2140567aa4ce686fa6571be9fc50b10a</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1074%2Fjbc.RA118.006056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.RA118.006056%26sid%3Dliteratum%253Aachs%26aulast%3DUno%26aufirst%3DS.%2BP.%26aulast%3DKimura%26aufirst%3DH.%26aulast%3DMurai%26aufirst%3DM.%26aulast%3DMiyoshi%26aufirst%3DH.%26atitle%3DExploring%2520the%2520quinone%252Finhibitor-binding%2520pocket%2520in%2520mitochondrial%2520respiratory%2520complex%2520I%2520by%2520chemical%2520biology%2520approaches%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2019%26volume%3D294%26spage%3D679%26epage%3D696%26doi%3D10.1074%2Fjbc.RA118.006056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tocilescu, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fendel, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwicker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerscher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, U.</span></span> <span> </span><span class="NLM_article-title">Exploring the ubiquinone binding cavity of respiratory complex I</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>282</i></span>,  <span class="NLM_fpage">29514</span>â <span class="NLM_lpage">29520</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M704519200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1074%2Fjbc.M704519200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=17681940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtV2ntbbE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=29514-29520&author=M.+A.+Tocilescuauthor=U.+Fendelauthor=K.+Zwickerauthor=S.+Kerscherauthor=U.+Brandt&title=Exploring+the+ubiquinone+binding+cavity+of+respiratory+complex+I&doi=10.1074%2Fjbc.M704519200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring the ubiquinone binding cavity of respiratory complex I</span></div><div class="casAuthors">Tocilescu, Maja A.; Fendel, Uta; Zwicker, Klaus; Kerscher, Stefan; Brandt, Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">282</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">29514-29520</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Proton pumping respiratory complex I/ubiquinone reductase is a major player in mitochondrial energy conversion.  However, little is known about the mol. mechanism of this large membrane protein complex.  Understanding the details of ubiquinone redn. will be prerequisite for elucidating this mechanism.  Based on a recently published partial structure of the bacterial enzyme, the authors scanned the proposed ubiquinone-binding cavity of complex I by site-directed mutagenesis in the strictly aerobic yeast Yarrowia lipolytica.  The obsd. changes in catalytic activity and inhibitor sensitivity followed a consistent pattern and allowed the authors to define 3 functionally important regions near ubiquinone-reducing Fe-S cluster N2.  The authors identified a likely entry path for the substrate, ubiquinone, and defined a region involved in inhibitor binding within the cavity.  Finally, the authors were able to highlight a functionally crit. structural motif in the active site that consisted of Tyr-144 in the 49-kDa subunit, surrounded by 3 conserved hydrophobic residues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk5zzIPT6DTbVg90H21EOLACvtfcHk0liiVmuTNEw6PQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtV2ntbbE&md5=b87793238b13b906992950cc7fb7b2f9</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M704519200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M704519200%26sid%3Dliteratum%253Aachs%26aulast%3DTocilescu%26aufirst%3DM.%2BA.%26aulast%3DFendel%26aufirst%3DU.%26aulast%3DZwicker%26aufirst%3DK.%26aulast%3DKerscher%26aufirst%3DS.%26aulast%3DBrandt%26aufirst%3DU.%26atitle%3DExploring%2520the%2520ubiquinone%2520binding%2520cavity%2520of%2520respiratory%2520complex%2520I%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D29514%26epage%3D29520%26doi%3D10.1074%2Fjbc.M704519200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fendel, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tocilescu, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerscher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, U.</span></span> <span> </span><span class="NLM_article-title">Exploring the inhibitor binding pocket of respiratory complex I</span>. <i>Biochim. Biophys. Acta, Bioenerg.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>1777</i></span>,  <span class="NLM_fpage">660</span>â <span class="NLM_lpage">665</span>, <span class="refDoi">Â DOI: 10.1016/j.bbabio.2008.04.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.bbabio.2008.04.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=18486594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsFCms70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1777&publication_year=2008&pages=660-665&author=U.+Fendelauthor=M.+A.+Tocilescuauthor=S.+Kerscherauthor=U.+Brandt&title=Exploring+the+inhibitor+binding+pocket+of+respiratory+complex+I&doi=10.1016%2Fj.bbabio.2008.04.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring the inhibitor binding pocket of respiratory complex I</span></div><div class="casAuthors">Fendel, Uta; Tocilescu, Maja A.; Kerscher, Stefan; Brandt, Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Bioenergetics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">1777</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">660-665</span>CODEN:
                <span class="NLM_cas:coden">BBBEB4</span>;
        ISSN:<span class="NLM_cas:issn">0005-2728</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Numerous hydrophobic and amphipathic compds. including several detergents are known to inhibit the ubiquinone reductase reaction of respiratory chain complex I (proton pumping NADH:ubiquinone oxidoreductase).  Guided by the X-ray structure of the peripheral arm of complex I from Thermus thermophilus we have generated a large collection of site-directed mutants in the yeast Yarrowia lipolytica targeting the proposed ubiquinone and inhibitor binding pocket of this huge multiprotein complex at the interface of the 49-kDa and PSST subunits.  We could identify a no. of residues where mutations changed I 50 values for representatives from all three groups of hydrophobic inhibitors.  Many mutations around the domain of the 49-kDa subunit that is homologous to the [NiFe] center binding region of hydrogenase conferred resistance to DQA (class I/type A) and rotenone (class II/type B) indicating a wider overlap of the binding sites for these two types of inhibitors.  In contrast, a region near iron-sulfur cluster N2, where the binding of the n-alkyl-polyoxyethylene-ether detergent C12E8 (type C) was exclusively affected, appeared comparably well sepd.  Taken together, our data provide structure-based support for the presence of distinct but overlapping binding sites for hydrophobic inhibitors possibly extending into the ubiquinone redn. site of mitochondrial complex I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv-gMvoWhvHrVg90H21EOLACvtfcHk0liiVmuTNEw6PQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsFCms70%253D&md5=5bd4dbc81d0b221865e335daa74e9fd2</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.bbabio.2008.04.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbabio.2008.04.033%26sid%3Dliteratum%253Aachs%26aulast%3DFendel%26aufirst%3DU.%26aulast%3DTocilescu%26aufirst%3DM.%2BA.%26aulast%3DKerscher%26aufirst%3DS.%26aulast%3DBrandt%26aufirst%3DU.%26atitle%3DExploring%2520the%2520inhibitor%2520binding%2520pocket%2520of%2520respiratory%2520complex%2520I%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Bioenerg.%26date%3D2008%26volume%3D1777%26spage%3D660%26epage%3D665%26doi%3D10.1016%2Fj.bbabio.2008.04.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsuji, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyoshi, H.</span></span> <span> </span><span class="NLM_article-title">IACS-010759, a potent inhibitor of glycolysis-deficient hypoxic tumor cells, inhibits mitochondrial respiratory complex I through a unique mechanism</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>295</i></span>,  <span class="NLM_fpage">7481</span>, <span class="refDoi">Â DOI: 10.1074/jbc.RA120.013366</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1074%2Fjbc.RA120.013366" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=32295842" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1Wqt7vM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=295&publication_year=2020&pages=7481&author=A.+Tsujiauthor=T.+Akaoauthor=T.+Masuyaauthor=M.+Muraiauthor=H.+Miyoshi&title=IACS-010759%2C+a+potent+inhibitor+of+glycolysis-deficient+hypoxic+tumor+cells%2C+inhibits+mitochondrial+respiratory+complex+I+through+a+unique+mechanism&doi=10.1074%2Fjbc.RA120.013366"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">IACS-010759, a potent inhibitor of glycolysis-deficient hypoxic tumor cells, inhibits mitochondrial respiratory complex I through a unique mechanism</span></div><div class="casAuthors">Tsuji, Atsuhito; Akao, Takumi; Masuya, Takahiro; Murai, Masatoshi; Miyoshi, Hideto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">295</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7481-7492</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">1083-351X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The small mol. IACS-010759 has been reported to potently inhibit the proliferation of glycolysis-deficient hypoxic tumor cells by interfering with the functions of mitochondrial NADH-ubiquinone oxidoreductase (complex I) without exhibiting cytotoxicity at tolerated doses in normal cells.  Considering the significant cytotoxicity of conventional quinone-site inhibitors of complex I, such as piericidin and acetogenin families, we hypothesized that the mechanism of action of IACS-010759 on complex I differs from that of other known quinone-site inhibitors.  To test this possibility, here we investigated IACS-010759's mechanism in bovine heart submitochondrial particles.  We found that IACS-010759, like known quinone-site inhibitors, suppresses chem. modification by the tosyl reagent AL1 of Asp160 in the 49-kDa subunit, located deep in the interior of a previously proposed quinone-access channel.  However, contrary to the other inhibitors, IACS-010759 direction-dependently inhibited forward and reverse electron transfer and did not suppress binding of the quinazoline-type inhibitor [125I]AzQ to the N terminus of the 49-kDa subunit.  Photoaffinity labeling expts. revealed that the photoreactive deriv. [125I]IACS-010759-PD1 binds to the middle of the membrane subunit ND1 and that inhibitors that bind to the 49-kDa or PSST subunit cannot suppress the binding.  We conclude that IACS-010759's binding location in complex I differs from that of any other known inhibitor of the enzyme.  Our findings, along with those from previous study, reveal that the mechanisms of action of complex I inhibitors with widely different chem. properties are more diverse than can be accounted for by the quinone-access channel model proposed by structural biol. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYNQGiooIoy7Vg90H21EOLACvtfcHk0lhRsLFoU2y66Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1Wqt7vM&md5=2f2c06cef38bdf327edc2978a9175243</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1074%2Fjbc.RA120.013366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.RA120.013366%26sid%3Dliteratum%253Aachs%26aulast%3DTsuji%26aufirst%3DA.%26aulast%3DAkao%26aufirst%3DT.%26aulast%3DMasuya%26aufirst%3DT.%26aulast%3DMurai%26aufirst%3DM.%26aulast%3DMiyoshi%26aufirst%3DH.%26atitle%3DIACS-010759%252C%2520a%2520potent%2520inhibitor%2520of%2520glycolysis-deficient%2520hypoxic%2520tumor%2520cells%252C%2520inhibits%2520mitochondrial%2520respiratory%2520complex%2520I%2520through%2520a%2520unique%2520mechanism%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2020%26volume%3D295%26spage%3D7481%26doi%3D10.1074%2Fjbc.RA120.013366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartlam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Z. H.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of mitochondrial respiratory membrane protein complex II</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">1043</span>â <span class="NLM_lpage">1057</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2005.05.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.cell.2005.05.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=15989954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtF2nsbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2005&pages=1043-1057&author=F.+Sunauthor=X.+Huoauthor=Y.+J.+Zhaiauthor=A.+J.+Wangauthor=J.+X.+Xuauthor=D.+Suauthor=M.+Bartlamauthor=Z.+H.+Rao&title=Crystal+structure+of+mitochondrial+respiratory+membrane+protein+complex+II&doi=10.1016%2Fj.cell.2005.05.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of mitochondrial respiratory membrane protein complex II</span></div><div class="casAuthors">Sun, Fei; Huo, Xia; Zhai, Yujia; Wang, Aojin; Xu, Jianxing; Su, Dan; Bartlam, Mark; Rao, Zihe</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1043-1057</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The mitochondrial respiratory Complex II or succinate: ubiquinone oxidoreductase (SQR) is an integral membrane protein complex in both the tricarboxylic acid cycle and aerobic respiration.  Here we report the first crystal structure of Complex II from porcine heart at 2.4 Ã resoln. and its complex structure with inhibitors 3-nitropropionate and 2-thenoyltrifluoroacetone (TTFA) at 3.5 Ã resoln.  Complex II is comprised of two hydrophilic proteins, flavoprotein (Fp) and iron-sulfur protein (Ip), and two transmembrane proteins (CybL and CybS), as well as prosthetic groups required for electron transfer from succinate to ubiquinone.  The structure correlates the protein environments around prosthetic groups with their unique midpoint redox potentials.  Two ubiquinone binding sites are discussed and elucidated by TTFA binding.  The Complex II structure provides a bona fide model for study of the mitochondrial respiratory system and human mitochondrial diseases related to mutations in this complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobGlznAZ9XtLVg90H21EOLACvtfcHk0lichs8pW-OZhw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtF2nsbc%253D&md5=04ad855f63cbd25e31be9bf64df28b84</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2005.05.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2005.05.025%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DF.%26aulast%3DHuo%26aufirst%3DX.%26aulast%3DZhai%26aufirst%3DY.%2BJ.%26aulast%3DWang%26aufirst%3DA.%2BJ.%26aulast%3DXu%26aufirst%3DJ.%2BX.%26aulast%3DSu%26aufirst%3DD.%26aulast%3DBartlam%26aufirst%3DM.%26aulast%3DRao%26aufirst%3DZ.%2BH.%26atitle%3DCrystal%2520structure%2520of%2520mitochondrial%2520respiratory%2520membrane%2520protein%2520complex%2520II%26jtitle%3DCell%26date%3D2005%26volume%3D121%26spage%3D1043%26epage%3D1057%26doi%3D10.1016%2Fj.cell.2005.05.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maklashina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cecchini, G.</span></span> <span> </span><span class="NLM_article-title">The quinone-binding and catalytic site of complex II</span>. <i>Biochim. Biophys. Acta, Bioenerg.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1797</i></span>,  <span class="NLM_fpage">1877</span>â <span class="NLM_lpage">1882</span>, <span class="refDoi">Â DOI: 10.1016/j.bbabio.2010.02.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.bbabio.2010.02.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=20175986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVansrbE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1797&publication_year=2010&pages=1877-1882&author=E.+Maklashinaauthor=G.+Cecchini&title=The+quinone-binding+and+catalytic+site+of+complex+II&doi=10.1016%2Fj.bbabio.2010.02.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The quinone-binding and catalytic site of complex II</span></div><div class="casAuthors">Maklashina, Elena; Cecchini, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Bioenergetics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1797</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1877-1882</span>CODEN:
                <span class="NLM_cas:coden">BBBEB4</span>;
        ISSN:<span class="NLM_cas:issn">0005-2728</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  The complex II family of proteins includes succinate-quinone oxidoreductase (SQR) and quinol:fumarate oxidoreductase (QFR).  In the facultative bacterium, Escherichia coli, both are expressed as part of the aerobic (SQR) and anaerobic (QFR) respiratory chains.  SQR of E. coli is homologous to mitochondrial complex II and has proven to be an excellent model system for structure-function studies of the enzyme.  Both SQR and QFR of E. coli are tetrameric membrane-bound enzymes that couple succinate-fumarate interconversion with quinone/quinol redn./oxidn.  Both enzymes are capable of binding either ubiquinone or menaquinone; however, they have adopted different quinone-binding sites where catalytic reactions with quinones occur.  A comparison of the structures of the quinone-binding sites in SQR and QFR reveals how the enzymes have adapted in order to accommodate both benzoquinones and naphthoquinones.  A combination of structural, computational, and kinetic studies of members of the complex II family of enzymes has revealed that the catalytic quinone adopts different positions in the quinone-binding pocket.  These data suggest that movement of the quinone within the quinone-binding pocket is essential for catalysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvjswaQSgZ6LVg90H21EOLACvtfcHk0lichs8pW-OZhw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVansrbE&md5=0cafcfcc9e44d279759c786a771746c4</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.bbabio.2010.02.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbabio.2010.02.015%26sid%3Dliteratum%253Aachs%26aulast%3DMaklashina%26aufirst%3DE.%26aulast%3DCecchini%26aufirst%3DG.%26atitle%3DThe%2520quinone-binding%2520and%2520catalytic%2520site%2520of%2520complex%2520II%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Bioenerg.%26date%3D2010%26volume%3D1797%26spage%3D1877%26epage%3D1882%26doi%3D10.1016%2Fj.bbabio.2010.02.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bezawork-Geleta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohlena, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacak, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuzil, J.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial complex II: at the crossroads</span>. <i>Trends Biochem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">312</span>â <span class="NLM_lpage">325</span>, <span class="refDoi">Â DOI: 10.1016/j.tibs.2017.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.tibs.2017.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=28185716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVeitb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2017&pages=312-325&author=A.+Bezawork-Geletaauthor=J.+Rohlenaauthor=L.+F.+Dongauthor=K.+Pacakauthor=J.+Neuzil&title=Mitochondrial+complex+II%3A+at+the+crossroads&doi=10.1016%2Fj.tibs.2017.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial Complex II: At the Crossroads</span></div><div class="casAuthors">Bezawork-Geleta, Ayenachew; Rohlena, Jakub; Dong, Lanfeng; Pacak, Karel; Neuzil, Jiri</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biochemical Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">312-325</span>CODEN:
                <span class="NLM_cas:coden">TBSCDB</span>;
        ISSN:<span class="NLM_cas:issn">0968-0004</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Mitochondrial complex II (CII), also called succinate dehydrogenase (SDH), is a central purveyor of the reprogramming of metabolic and respiratory adaptation in response to various intrinsic and extrinsic stimuli and abnormalities.  In this review we discuss recent findings regarding SDH biogenesis, which requires four known assembly factors, and modulation of its enzymic activity by acetylation, succinylation, phosphorylation, and proteolysis.  We further focus on the emerging role of both genetic and epigenetic aberrations leading to SDH dysfunction assocd. with various clin. manifestations.  This review also covers the recent discovery of the role of SDH in inflammation-linked pathologies.  Conceivably, SDH is a potential target for several hard-to-treat conditions, including cancer, that remains to be fully exploited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfI9EMqCqg27Vg90H21EOLACvtfcHk0lichs8pW-OZhw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVeitb0%253D&md5=7b65555d34bfa8215e9eceb70e707716</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.tibs.2017.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tibs.2017.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DBezawork-Geleta%26aufirst%3DA.%26aulast%3DRohlena%26aufirst%3DJ.%26aulast%3DDong%26aufirst%3DL.%2BF.%26aulast%3DPacak%26aufirst%3DK.%26aulast%3DNeuzil%26aufirst%3DJ.%26atitle%3DMitochondrial%2520complex%2520II%253A%2520at%2520the%2520crossroads%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D2017%26volume%3D42%26spage%3D312%26epage%3D325%26doi%3D10.1016%2Fj.tibs.2017.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span> <span> </span><span class="NLM_article-title">Thiabendazole inhibits ubiquinone reduction activity of mitochondrial respiratory complex II via a water molecule mediated binding feature</span>. <i>Protein Cell</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">531</span>â <span class="NLM_lpage">542</span>, <span class="refDoi">Â DOI: 10.1007/s13238-011-1079-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1007%2Fs13238-011-1079-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=21822798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVShsrrM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=531-542&author=Q.+J.+Zhouauthor=Y.+J.+Zhaiauthor=J.+Z.+Louauthor=M.+Liuauthor=X.+Y.+Pangauthor=F.+Sun&title=Thiabendazole+inhibits+ubiquinone+reduction+activity+of+mitochondrial+respiratory+complex+II+via+a+water+molecule+mediated+binding+feature&doi=10.1007%2Fs13238-011-1079-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Thiabendazole inhibits ubiquinone reduction activity of mitochondrial respiratory complex II via a water molecule mediated binding feature</span></div><div class="casAuthors">Zhou, Qiangjun; Zhai, Yujia; Lou, Jizhong; Liu, Man; Pang, Xiaoyun; Sun, Fei</div><div class="citationInfo"><span class="NLM_cas:title">Protein & Cell</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">531-542</span>CODEN:
                <span class="NLM_cas:coden">PCREFB</span>;
        ISSN:<span class="NLM_cas:issn">1674-800X</span>.
    
            (<span class="NLM_cas:orgname">Higher Education Press</span>)
        </div><div class="casAbstract">The mitochondrial respiratory complex II or succinate:ubiquinone oxidoreductase (SQR) is a key membrane complex in both the tricarboxylic acid cycle and aerobic respiration.  Five disinfectant compds. were investigated with their potent inhibition effects on the ubiquinone redn. activity of the porcine mitochondrial SQR by enzymic assay and crystallog.  Crystal structure of the SQR bound with thiabendazole (TBZ) reveals a different inhibitor-binding feature at the ubiquinone binding site where a water mol. plays an important role.  The obvious inhibitory effect of TBZ based on the biochem. data (IC50 â¼100 Î¼mol/L) and the significant structure-based binding affinity calcn. (â¼94 Î¼mol/L) draw the suspicion of using TBZ as a good disinfectant compd. for nematode infections treatment and fruit storage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGop5Kr-Hw2UjLVg90H21EOLACvtfcHk0liZG--dN-HLuA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVShsrrM&md5=4600d5d1dc84c56f782878367499f727</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1007%2Fs13238-011-1079-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13238-011-1079-1%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DQ.%2BJ.%26aulast%3DZhai%26aufirst%3DY.%2BJ.%26aulast%3DLou%26aufirst%3DJ.%2BZ.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DPang%26aufirst%3DX.%2BY.%26aulast%3DSun%26aufirst%3DF.%26atitle%3DThiabendazole%2520inhibits%2520ubiquinone%2520reduction%2520activity%2520of%2520mitochondrial%2520respiratory%2520complex%2520II%2520via%2520a%2520water%2520molecule%2520mediated%2520binding%2520feature%26jtitle%3DProtein%2520Cell%26date%3D2011%26volume%3D2%26spage%3D531%26epage%3D542%26doi%3D10.1007%2Fs13238-011-1079-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobessi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tung, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, E. A.</span></span> <span> </span><span class="NLM_article-title">3-Nitropropionic acid is a suicide inhibitor of mitochondrial respiration that, upon oxidation by Complex II, forms a covalent adduct with a catalytic base arginine in the active site of the enzyme</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>281</i></span>,  <span class="NLM_fpage">5965</span>â <span class="NLM_lpage">5972</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M511270200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1074%2Fjbc.M511270200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=16371358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD28XhvVeju7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2006&pages=5965-5972&author=L.+S.+Huangauthor=G.+Sunauthor=D.+Cobessiauthor=A.+C.+Wangauthor=J.+T.+Shenauthor=E.+Y.+Tungauthor=V.+E.+Andersonauthor=E.+A.+Berry&title=3-Nitropropionic+acid+is+a+suicide+inhibitor+of+mitochondrial+respiration+that%2C+upon+oxidation+by+Complex+II%2C+forms+a+covalent+adduct+with+a+catalytic+base+arginine+in+the+active+site+of+the+enzyme&doi=10.1074%2Fjbc.M511270200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">3-Nitropropionic Acid Is a Suicide Inhibitor of Mitochondrial Respiration That, upon Oxidation by Complex II, Forms a Covalent Adduct with a Catalytic Base Arginine in the Active Site of the Enzyme</span></div><div class="casAuthors">Huang, Li-shar; Sun, Gang; Cobessi, David; Wang, Andy C.; Shen, John T.; Tung, Eric Y.; Anderson, Vernon E.; Berry, Edward A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">281</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5965-5972</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">We report three new structures of mitochondrial respiratory Complex II (succinate ubiquinone oxidoreductase, E.C. 1.3.5.1) at up to 2.1 Ã resoln., with various inhibitors.  The structures define the conformation of the bound inhibitors and suggest the residues involved in substrate binding and catalysis at the dicarboxylate site.  In particular they support the role of Arg297 as a general base catalyst accepting a proton in the dehydrogenation of succinate.  The dicarboxylate ligand in oxaloacetate-contg. crystals appears to be the same as that reported for Shewanella flavocytochrome c treated with fumarate.  The plant and fungal toxin 3-nitropropionic acid (3-NP), an irreversible inactivator of succinate dehydrogenase, forms a covalent adduct with the side chain of Arg297.  The modification eliminates a trypsin cleavage site in the flavoprotein, and tandem mass spectroscopic anal. of the new fragment shows the mass of Arg297 to be increased by 83 Da and to have the potential of losing 44 Da, consistent with decarboxylation, during fragmentation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqri-wDnBFEtLVg90H21EOLACvtfcHk0liZG--dN-HLuA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhvVeju7w%253D&md5=afbb05c11db4357ff3a7f9f2902afd5d</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M511270200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M511270200%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DL.%2BS.%26aulast%3DSun%26aufirst%3DG.%26aulast%3DCobessi%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DA.%2BC.%26aulast%3DShen%26aufirst%3DJ.%2BT.%26aulast%3DTung%26aufirst%3DE.%2BY.%26aulast%3DAnderson%26aufirst%3DV.%2BE.%26aulast%3DBerry%26aufirst%3DE.%2BA.%26atitle%3D3-Nitropropionic%2520acid%2520is%2520a%2520suicide%2520inhibitor%2520of%2520mitochondrial%2520respiration%2520that%252C%2520upon%2520oxidation%2520by%2520Complex%2520II%252C%2520forms%2520a%2520covalent%2520adduct%2520with%2520a%2520catalytic%2520base%2520arginine%2520in%2520the%2520active%2520site%2520of%2520the%2520enzyme%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2006%26volume%3D281%26spage%3D5965%26epage%3D5972%26doi%3D10.1074%2Fjbc.M511270200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, E. A.</span></span> <span> </span><span class="NLM_article-title">Crystallographic studies of the binding of ligands to the dicarboxylate site of Complex II, and the identity of the ligand in the â³oxaloacetate-inhibitedâ³ state</span>. <i>Biochim. Biophys. Acta, Bioenerg.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>1757</i></span>,  <span class="NLM_fpage">1073</span>â <span class="NLM_lpage">1083</span>, <span class="refDoi">Â DOI: 10.1016/j.bbabio.2006.06.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.bbabio.2006.06.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=16935256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVanurvN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1757&publication_year=2006&pages=1073-1083&author=L.+S.+Huangauthor=J.+T.+Shenauthor=A.+C.+Wangauthor=E.+A.+Berry&title=Crystallographic+studies+of+the+binding+of+ligands+to+the+dicarboxylate+site+of+Complex+II%2C+and+the+identity+of+the+ligand+in+the+%E2%80%B3oxaloacetate-inhibited%E2%80%B3+state&doi=10.1016%2Fj.bbabio.2006.06.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Crystallographic studies of the binding of ligands to the dicarboxylate site of Complex II, and the identity of the ligand in the "oxaloacetate-inhibited" state</span></div><div class="casAuthors">Huang, Li-Shar; Shen, John T.; Wang, Andy C.; Berry, Edward A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Bioenergetics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">1757</span>
        (<span class="NLM_cas:issue">9-10</span>),
    <span class="NLM_cas:pages">1073-1083</span>CODEN:
                <span class="NLM_cas:coden">BBBEB4</span>;
        ISSN:<span class="NLM_cas:issn">0005-2728</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Mitochondrial Complex II (succinate:ubiquinone oxidoreductase) is purified in a partially inactivated state, which can be activated by removal of tightly bound oxaloacetate (E. B. Kearney, et al., Biochem. Biophys. Res. Commun. 49 1115-1121).  We crystd. Complex II in the presence of oxaloacetate or with the endogenous inhibitor bound.  The structure showed a ligand essentially identical to the "malate-like intermediate" found in Shewanella Flavocytochrome c crystd. with fumarate (P. Taylor, et al., Nat. Struct. Biol. 6 1108-1112).  Crystn. of Complex II in the presence of excess fumarate also gave the malate-like intermediate or a mixt. of that and fumarate at the active site.  In order to more conveniently monitor the occupation state of the dicarboxylate site, we are developing a library of UV/Vis spectral effects induced by binding different ligands to the site.  Treatment with fumarate results in rapid development of the fumarate difference spectrum and then a very slow conversion into a species spectrally similar to the OAA-liganded complex.  Complex II is known to be capable of oxidizing malate to the enol form of oxaloacetate (Y. O. Belikova, et al., Biochim. Biophys. Acta 936 1-9).  The observations above suggest it may also be capable of interconverting fumarate and malate.  It may be useful for understanding the mechanism and regulation of the enzyme to identify the malate-like intermediate and its pathway of formation from oxaloacetate or fumarate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp89KlBK_X6vLVg90H21EOLACvtfcHk0lhJUirx8sM2eQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVanurvN&md5=e1d68bddf59e906f98e2c68e2354678f</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.bbabio.2006.06.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbabio.2006.06.015%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DL.%2BS.%26aulast%3DShen%26aufirst%3DJ.%2BT.%26aulast%3DWang%26aufirst%3DA.%2BC.%26aulast%3DBerry%26aufirst%3DE.%2BA.%26atitle%3DCrystallographic%2520studies%2520of%2520the%2520binding%2520of%2520ligands%2520to%2520the%2520dicarboxylate%2520site%2520of%2520Complex%2520II%252C%2520and%2520the%2520identity%2520of%2520the%2520ligand%2520in%2520the%2520%25E2%2580%25B3oxaloacetate-inhibited%25E2%2580%25B3%2520state%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Bioenerg.%26date%3D2006%26volume%3D1757%26spage%3D1073%26epage%3D1083%26doi%3D10.1016%2Fj.bbabio.2006.06.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Inaoka, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiba, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balogun, E. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagahama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuoka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohmori, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harada, S.</span></span> <span> </span><span class="NLM_article-title">Structural insights into the molecular design of flutolanil derivatives targeted for fumarate respiration of parasite mitochondria</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">15287</span>â <span class="NLM_lpage">15308</span>, <span class="refDoi">Â DOI: 10.3390/ijms160715287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.3390%2Fijms160715287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=26198225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVeitrjP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=15287-15308&author=D.+K.+Inaokaauthor=T.+Shibaauthor=D.+Satoauthor=E.+O.+Balogunauthor=T.+Sasakiauthor=M.+Nagahamaauthor=M.+Odaauthor=S.+Matsuokaauthor=J.+Ohmoriauthor=T.+Honmaauthor=M.+Inoueauthor=K.+Kitaauthor=S.+Harada&title=Structural+insights+into+the+molecular+design+of+flutolanil+derivatives+targeted+for+fumarate+respiration+of+parasite+mitochondria&doi=10.3390%2Fijms160715287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into the molecular design of flutolanil derivatives targeted for fumarate respiration of parasite mitochondria</span></div><div class="casAuthors">Inaoka, Daniel Ken; Shiba, Tomoo; Sato, Dan; Balogun, Emmanuel Oluwadare; Sasaki, Tsuyoshi; Nagahama, Madoka; Oda, Masatsugu; Matsuoka, Shigeru; Ohmori, Junko; Honma, Teruki; Inoue, Masayuki; Kita, Kiyoshi; Harada, Shigeharu</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">15287-15308</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Recent studies on the respiratory chain of Ascaris suum showed that the mitochondrial NADH-fumarate reductase system composed of complex I, rhodoquinone and complex II plays an important role in the anaerobic energy metab. of adult A. suum.  The system is the major pathway of energy metab. for adaptation to a hypoxic environment not only in parasitic organisms, but also in some types of human cancer cells.  Thus, enzymes of the pathway are potential targets for chemotherapy.  We found that flutolanil is an excellent inhibitor for A. suum complex II (IC50 = 0.058 Î¼M) but less effectively inhibits homologous porcine complex II (IC50 = 45.9 Î¼M).  In order to account for the specificity of flutolanil to A. suum complex II from the standpoint of structural biol., we detd. the crystal structures of A. suum and porcine complex IIs binding flutolanil and its deriv. compds.  The structures clearly demonstrated key interactions responsible for its high specificity to A. suum complex II and enabled us to find analog compds., which surpass flutolanil in both potency and specificity to A. suum complex II.  Structures of complex IIs binding these compds. will be helpful to accelerate structure-based drug design targeted for complex IIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_Pko-YiLNyrVg90H21EOLACvtfcHk0lhJUirx8sM2eQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVeitrjP&md5=4bae2fd0d741bfc9017fb5d3b4de66d0</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.3390%2Fijms160715287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms160715287%26sid%3Dliteratum%253Aachs%26aulast%3DInaoka%26aufirst%3DD.%2BK.%26aulast%3DShiba%26aufirst%3DT.%26aulast%3DSato%26aufirst%3DD.%26aulast%3DBalogun%26aufirst%3DE.%2BO.%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DNagahama%26aufirst%3DM.%26aulast%3DOda%26aufirst%3DM.%26aulast%3DMatsuoka%26aufirst%3DS.%26aulast%3DOhmori%26aufirst%3DJ.%26aulast%3DHonma%26aufirst%3DT.%26aulast%3DInoue%26aufirst%3DM.%26aulast%3DKita%26aufirst%3DK.%26aulast%3DHarada%26aufirst%3DS.%26atitle%3DStructural%2520insights%2520into%2520the%2520molecular%2520design%2520of%2520flutolanil%2520derivatives%2520targeted%2520for%2520fumarate%2520respiration%2520of%2520parasite%2520mitochondria%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2015%26volume%3D16%26spage%3D15287%26epage%3D15308%26doi%3D10.3390%2Fijms160715287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xia, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kachurin, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deisenhofer, J.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the cytochrome bc(1) complex from bovine heart mitochondria</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">60</span>, <span class="refDoi">Â DOI: 10.1126/science.277.5322.60</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1126%2Fscience.277.5322.60" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=9204897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADyaK2sXksVyhu70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=1997&pages=60&author=D.+Xiaauthor=C.+A.+Yuauthor=H.+Kimauthor=J.+Z.+Xiaauthor=A.+M.+Kachurinauthor=L.+Zhangauthor=L.+Yuauthor=J.+Deisenhofer&title=Crystal+structure+of+the+cytochrome+bc%281%29+complex+from+bovine+heart+mitochondria&doi=10.1126%2Fscience.277.5322.60"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the cytochrome bc1 complex from bovine heart mitochondria</span></div><div class="casAuthors">Xia, Di; Yu, Chang-An; Kim, Hoeon; Xia, Jia-Zhi; Kachurin, Anatoly M.; Zhang, Li; Yu, Linda; Deisenhofer, Johann</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">5322</span>),
    <span class="NLM_cas:pages">60-66</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">On the basis of x-ray diffraction data to a resoln. of 2.9 Ã, at. models of most protein components of the bovine ubiquinol-cytochrome c reductase (cytochrome bc1 complex) (I) were built, including core 1, core 2, cytochrome b, subunit 6, subunit 7, a C-terminal fragment of cytochrome c1, and an N-terminal fragment of the Fe-S protein.  The positions of the 4 Fe centers within I and the binding sites of the 2 specific respiratory inhibitors, antimycin A and myxothiazol, were identified.  The membrane-spanning region of each I monomer consisted of 13 transmembrane helixes, 8 of which belonged to cytochrome b.  Closely interacting monomers were arranged as sym. dimers and formed cavities through which the inhibitor binding pockets could be accessed.  The proteins, core 1 and core 2, were structurally similar to each other and consisted of 2 domains of roughly equal size and identical folding topol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGot3G2U821pybVg90H21EOLACvtfcHk0ljceCYt91EULA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXksVyhu70%253D&md5=28d7354b93bdd04e3f0e3f67d9f10764</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1126%2Fscience.277.5322.60&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.277.5322.60%26sid%3Dliteratum%253Aachs%26aulast%3DXia%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DC.%2BA.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DXia%26aufirst%3DJ.%2BZ.%26aulast%3DKachurin%26aufirst%3DA.%2BM.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DDeisenhofer%26aufirst%3DJ.%26atitle%3DCrystal%2520structure%2520of%2520the%2520cytochrome%2520bc%25281%2529%2520complex%2520from%2520bovine%2520heart%2520mitochondria%26jtitle%3DScience%26date%3D1997%26volume%3D277%26spage%3D60%26doi%3D10.1126%2Fscience.277.5322.60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Esser, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elberry, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, D.</span></span> <span> </span><span class="NLM_article-title">Crystallographic studies of quinol oxidation site inhibitors: a modified classification of inhibitors for the cytochrome bc(1) complex</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>341</i></span>,  <span class="NLM_fpage">281</span>â <span class="NLM_lpage">302</span>, <span class="refDoi">Â DOI: 10.1016/j.jmb.2004.05.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.jmb.2004.05.065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=15312779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVynsLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=2004&pages=281-302&author=L.+Esserauthor=B.+Quinnauthor=Y.+F.+Liauthor=M.+Zhangauthor=M.+Elberryauthor=L.+Yuauthor=C.+A.+Yuauthor=D.+Xia&title=Crystallographic+studies+of+quinol+oxidation+site+inhibitors%3A+a+modified+classification+of+inhibitors+for+the+cytochrome+bc%281%29+complex&doi=10.1016%2Fj.jmb.2004.05.065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Crystallographic studies of quinol oxidation site inhibitors: A modified classification of inhibitors for the cytochrome bc1 complex</span></div><div class="casAuthors">Esser, Lothar; Quinn, Byron; Li, Yong-Fu; Zhang, Minquan; Elberry, Maria; Yu, Linda; Yu, Chang-An; Di, Xia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">281-302</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Cytochrome bc1 is an integral membrane protein complex essential for cellular respiration and photosynthesis; it couples electron transfer from quinol to cytochrome c to proton translocation across the membrane.  Specific bc1 inhibitors have not only played crucial roles in elucidating the mechanism of bc1 function but have also provided leads for the development of novel antibiotics.  Crystal structures of bovine bc1 in complex with the specific Qo site inhibitors azoxystrobin, MOAS, myxothiazol, stigmatellin and 5-undecyl-6-hydroxy-4,7-dioxobenzothiazole were detd.  Interactions, conformational changes and possible mechanisms of resistance, specific to each inhibitor, were defined.  Residues and secondary structure elements that are capable of discriminating different classes of Qo site inhibitors were identified for the cytochrome b subunit.  Directions in the displacement of the cd1 helix of cytochrome b subunit in response to various Qo site inhibitors were correlated to the binary conformational switch of the extrinsic domain of the iron-sulfur protein subunit.  The new structural information, together with structures previously detd., provide a basis that, combined with biophys. and mutational data, suggest a modification to the existing classification of bc1 inhibitors.  Bc1 inhibitors are grouped into three classes: class P inhibitors bind to the Qo site, class N inhibitors bind to the Qi site and the class PN inhibitors target both sites.  Class P contains two subgroups, Pm and Pf, that are distinct by their ability to induce mobile or fixed conformation of iron-sulfur protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwlmXa-g_8ibVg90H21EOLACvtfcHk0ljceCYt91EULA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVynsLk%253D&md5=e066653a7e3d31bf41edf7f67a8e3270</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2004.05.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2004.05.065%26sid%3Dliteratum%253Aachs%26aulast%3DEsser%26aufirst%3DL.%26aulast%3DQuinn%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DY.%2BF.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DElberry%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DC.%2BA.%26aulast%3DXia%26aufirst%3DD.%26atitle%3DCrystallographic%2520studies%2520of%2520quinol%2520oxidation%2520site%2520inhibitors%253A%2520a%2520modified%2520classification%2520of%2520inhibitors%2520for%2520the%2520cytochrome%2520bc%25281%2529%2520complex%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2004%26volume%3D341%26spage%3D281%26epage%3D302%26doi%3D10.1016%2Fj.jmb.2004.05.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symersky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faraldo-Gomez, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, D. M.</span></span> <span> </span><span class="NLM_article-title">High-resolution cryo-EM analysis of the yeast ATP synthase in a lipid membrane</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>360</i></span>,  <span class="NLM_fpage">eaas9699</span>, <span class="refDoi">Â DOI: 10.1126/science.aas9699</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1126%2Fscience.aas9699" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=29650704" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=360&publication_year=2018&pages=eaas9699&author=A.+P.+Srivastavaauthor=M.+Luoauthor=W.+C.+Zhouauthor=J.+Symerskyauthor=D.+Y.+Baiauthor=M.+G.+Chambersauthor=J.+D.+Faraldo-Gomezauthor=M.+F.+Liaoauthor=D.+M.+Mueller&title=High-resolution+cryo-EM+analysis+of+the+yeast+ATP+synthase+in+a+lipid+membrane&doi=10.1126%2Fscience.aas9699"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1126%2Fscience.aas9699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aas9699%26sid%3Dliteratum%253Aachs%26aulast%3DSrivastava%26aufirst%3DA.%2BP.%26aulast%3DLuo%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DW.%2BC.%26aulast%3DSymersky%26aufirst%3DJ.%26aulast%3DBai%26aufirst%3DD.%2BY.%26aulast%3DChambers%26aufirst%3DM.%2BG.%26aulast%3DFaraldo-Gomez%26aufirst%3DJ.%2BD.%26aulast%3DLiao%26aufirst%3DM.%2BF.%26aulast%3DMueller%26aufirst%3DD.%2BM.%26atitle%3DHigh-resolution%2520cryo-EM%2520analysis%2520of%2520the%2520yeast%2520ATP%2520synthase%2520in%2520a%2520lipid%2520membrane%26jtitle%3DScience%26date%3D2018%26volume%3D360%26spage%3Deaas9699%26doi%3D10.1126%2Fscience.aas9699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, P. L.</span></span> <span> </span><span class="NLM_article-title">ATP synthase and the actions of inhibitors utilized to study its roles in human health, disease, and other scientific areas</span>. <i>Microbiol. Mol. Biol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">590</span>â <span class="NLM_lpage">641</span>, <span class="refDoi">Â DOI: 10.1128/MMBR.00016-08</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1128%2FMMBR.00016-08" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=19052322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD1MXps1Gktg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2008&pages=590-641&author=S.+Hongauthor=P.+L.+Pedersen&title=ATP+synthase+and+the+actions+of+inhibitors+utilized+to+study+its+roles+in+human+health%2C+disease%2C+and+other+scientific+areas&doi=10.1128%2FMMBR.00016-08"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">ATP synthase and the actions of inhibitors utilized to study its roles in human health, disease, and other scientific areas</span></div><div class="casAuthors">Hong, Sangjin; Pedersen, Peter L.</div><div class="citationInfo"><span class="NLM_cas:title">Microbiology and Molecular Biology Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">590-641</span>CODEN:
                <span class="NLM_cas:coden">MMBRF7</span>;
        ISSN:<span class="NLM_cas:issn">1092-2172</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A review.  ATP synthase, a double-motor enzyme, plays various roles in the cell, participating not only in ATP synthesis but in ATP hydrolysis-dependent processes and in the regulation of a proton gradient across some membrane-dependent systems.  Recent studies of ATP synthase as a potential mol. target for the treatment of some human diseases have displayed promising results, and this enzyme is now emerging as an attractive mol. target for the development of new therapies for a variety of diseases.  Significantly, ATP synthase, because of its complex structure, is inhibited by a no. of different inhibitors and provides diverse possibilities in the development of new ATP synthase-directed agents.  In this review, we classify over 250 natural and synthetic inhibitors of ATP synthase reported to date and present their inhibitory sites and their known or proposed modes of action.  The rich source of ATP synthase inhibitors and their known or purported sites of action presented in this review should provide valuable insights into their applications as potential scaffolds for new therapeutics for human and animal diseases as well as for the discovery of new pesticides and herbicides to help protect the world's food supply.  Finally, as ATP synthase is now known to consist of two unique nanomotors involved in making ATP from ADP and Pi, the information provided in this review may greatly assist those investigators entering the emerging field of nanotechnol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry4Ml0XiLFxLVg90H21EOLACvtfcHk0ljceCYt91EULA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXps1Gktg%253D%253D&md5=8a963fffa390545d34df022f5b9f4930</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1128%2FMMBR.00016-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMMBR.00016-08%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DS.%26aulast%3DPedersen%26aufirst%3DP.%2BL.%26atitle%3DATP%2520synthase%2520and%2520the%2520actions%2520of%2520inhibitors%2520utilized%2520to%2520study%2520its%2520roles%2520in%2520human%2520health%252C%2520disease%252C%2520and%2520other%2520scientific%2520areas%26jtitle%3DMicrobiol.%2520Mol.%2520Biol.%2520Rev.%26date%3D2008%26volume%3D72%26spage%3D590%26epage%3D641%26doi%3D10.1128%2FMMBR.00016-08" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pagliarini, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutter, J.</span></span> <span> </span><span class="NLM_article-title">Hallmarks of a new era in mitochondrial biochemistry</span>. <i>Genes Dev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">2615</span>â <span class="NLM_lpage">2627</span>, <span class="refDoi">Â DOI: 10.1101/gad.229724.113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1101%2Fgad.229724.113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=24352419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFChuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=2615-2627&author=D.+J.+Pagliariniauthor=J.+Rutter&title=Hallmarks+of+a+new+era+in+mitochondrial+biochemistry&doi=10.1101%2Fgad.229724.113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Hallmarks of a new era in mitochondrial biochemistry</span></div><div class="casAuthors">Pagliarini, David J.; Rutter, Jared</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2615-2627</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">A review.  Stemming from the pioneering studies of bioenergetics in the 1950s, 1960s, and 1970s, mitochondria have become ingrained in the collective psyche of scientists as the "powerhouses" of the cell.  While this remains a worthy moniker, more recent efforts have revealed that these organelles are home to a vast array of metabolic and signaling processes and possess a proteomic landscape that is both highly varied and largely uncharted.  As mitochondrial dysfunction is increasingly being implicated in a spectrum of human diseases, it is imperative that we construct a more complete framework of these organelles by systematically defining the functions of their component parts.  Powerful new approaches in biochem. and systems biol. are helping to fill in the gaps.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVbASorr3MPbVg90H21EOLACvtfcHk0ljtpjbDZdgNdw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFChuw%253D%253D&md5=a97e67615c437422141c3cd40145b497</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1101%2Fgad.229724.113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.229724.113%26sid%3Dliteratum%253Aachs%26aulast%3DPagliarini%26aufirst%3DD.%2BJ.%26aulast%3DRutter%26aufirst%3DJ.%26atitle%3DHallmarks%2520of%2520a%2520new%2520era%2520in%2520mitochondrial%2520biochemistry%26jtitle%3DGenes%2520Dev.%26date%3D2013%26volume%3D27%26spage%3D2615%26epage%3D2627%26doi%3D10.1101%2Fgad.229724.113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bell, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klimova, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenbart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moraes, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budinger, G. R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandel, N. S.</span></span> <span> </span><span class="NLM_article-title">The Q(o) site of the mitochondrial complex III is required for the transduction of hypoxic signaling via reactive oxygen species production</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>177</i></span>,  <span class="NLM_fpage">1029</span>â <span class="NLM_lpage">1036</span>, <span class="refDoi">Â DOI: 10.1083/jcb.200609074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1083%2Fjcb.200609074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=17562787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmvF2ru7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=177&publication_year=2007&pages=1029-1036&author=E.+L.+Bellauthor=T.+A.+Klimovaauthor=J.+Eisenbartauthor=C.+T.+Moraesauthor=M.+P.+Murphyauthor=G.+R.+S.+Budingerauthor=N.+S.+Chandel&title=The+Q%28o%29+site+of+the+mitochondrial+complex+III+is+required+for+the+transduction+of+hypoxic+signaling+via+reactive+oxygen+species+production&doi=10.1083%2Fjcb.200609074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">The Qo site of the mitochondrial complex III is required for the transduction of hypoxic signaling via reactive oxygen species production</span></div><div class="casAuthors">Bell, Eric L.; Klimova, Tatyana A.; Eisenbart, James; Moraes, Carlos T.; Murphy, Michael P.; Budinger, G. R. Scott; Chandel, Navdeep S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">177</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1029-1036</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Mammalian cells increase transcription of genes for adaptation to hypoxia through the stabilization of hypoxia-inducible factor 1Î± (HIF-1Î±) protein.  How cells transduce hypoxic signals to stabilize the HIF-1Î± protein remains unresolved.  We demonstrate that cells deficient in the complex III subunit cytochrome b, which are respiratory incompetent, increase ROS levels and stabilize the HIF-1Î± protein during hypoxia.  RNA interference of the complex III subunit Rieske iron sulfur protein in the cytochrome b-null cells and treatment of wild-type cells with stigmatellin abolished reactive oxygen species (ROS) generation at the Qo site of complex III.  These interventions maintained hydroxylation of HIF-1Î± protein and prevented stabilization of HIF-1Î± protein during hypoxia.  Antioxidants maintained hydroxylation of HIF-1Î± protein and prevented stabilization of HIF-1Î± protein during hypoxia.  Exogenous hydrogen peroxide under normoxia prevented hydroxylation of HIF-1Î± protein and stabilized HIF-1Î± protein.  These results provide genetic and pharmacol. evidence that the Qo site of complex III is required for the transduction of hypoxic signal by releasing ROS to stabilize the HIF-1Î± protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqotS4i8nOa0rVg90H21EOLACvtfcHk0ljtpjbDZdgNdw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmvF2ru7o%253D&md5=9e2d684659f0abbfdf8a192ba61dc6ae</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1083%2Fjcb.200609074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.200609074%26sid%3Dliteratum%253Aachs%26aulast%3DBell%26aufirst%3DE.%2BL.%26aulast%3DKlimova%26aufirst%3DT.%2BA.%26aulast%3DEisenbart%26aufirst%3DJ.%26aulast%3DMoraes%26aufirst%3DC.%2BT.%26aulast%3DMurphy%26aufirst%3DM.%2BP.%26aulast%3DBudinger%26aufirst%3DG.%2BR.%2BS.%26aulast%3DChandel%26aufirst%3DN.%2BS.%26atitle%3DThe%2520Q%2528o%2529%2520site%2520of%2520the%2520mitochondrial%2520complex%2520III%2520is%2520required%2520for%2520the%2520transduction%2520of%2520hypoxic%2520signaling%2520via%2520reactive%2520oxygen%2520species%2520production%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2007%26volume%3D177%26spage%3D1029%26epage%3D1036%26doi%3D10.1083%2Fjcb.200609074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stein, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imai, S.</span></span> <span> </span><span class="NLM_article-title">The dynamic regulation of NAD metabolism in mitochondria</span>. <i>Trends Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">420</span>â <span class="NLM_lpage">428</span>, <span class="refDoi">Â DOI: 10.1016/j.tem.2012.06.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.tem.2012.06.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=22819213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVOqtb%252FN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=420-428&author=L.+R.+Steinauthor=S.+Imai&title=The+dynamic+regulation+of+NAD+metabolism+in+mitochondria&doi=10.1016%2Fj.tem.2012.06.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">The dynamic regulation of NAD metabolism in mitochondria</span></div><div class="casAuthors">Stein, Liana Roberts; Imai, Shin-ichiro</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">420-428</span>CODEN:
                <span class="NLM_cas:coden">TENME4</span>;
        ISSN:<span class="NLM_cas:issn">1043-2760</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Mitochondria are intracellular powerhouses that produce ATP and carry out diverse functions for cellular energy metab.  Although the maintenance of an optimal NAD/NADH ratio is essential for mitochondrial function, it has recently become apparent that the maintenance of the mitochondrial NAD pool is also of crucial importance.  The biosynthesis, transport, and catabolism of NAD and its key intermediates play an important role in the regulation of NAD-consuming mediators, such as sirtuins, poly-ADP-ribose polymerases, and CD38/157 ectoenzymes, in intra- and extracellular compartments.  Mitochondrial NAD biosynthesis is also modulated in response to nutritional and environmental stimuli.  In this article, we discuss this dynamic regulation of NAD metab. in mitochondria to shed light on the intimate connection between NAD and mitochondrial function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_7T9cRqoaFbVg90H21EOLACvtfcHk0ljdGPfb16-bLw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVOqtb%252FN&md5=aabe2e6e8863913dae3567c5062f40f3</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.tem.2012.06.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tem.2012.06.005%26sid%3Dliteratum%253Aachs%26aulast%3DStein%26aufirst%3DL.%2BR.%26aulast%3DImai%26aufirst%3DS.%26atitle%3DThe%2520dynamic%2520regulation%2520of%2520NAD%2520metabolism%2520in%2520mitochondria%26jtitle%3DTrends%2520Endocrinol.%2520Metab.%26date%3D2012%26volume%3D23%26spage%3D420%26epage%3D428%26doi%3D10.1016%2Fj.tem.2012.06.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birsoy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mihaylova, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snitkin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stasinski, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yucel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayraktar, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carette, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clish, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brummelkamp, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of ATPIF1 ameliorates severe mitochondrial respiratory chain dysfunction in mammalian cells</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">27</span>â <span class="NLM_lpage">34</span>, <span class="refDoi">Â DOI: 10.1016/j.celrep.2014.02.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.celrep.2014.02.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=24685140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFCktLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=27-34&author=W.+W.+Chenauthor=K.+Birsoyauthor=M.+M.+Mihaylovaauthor=H.+Snitkinauthor=I.+Stasinskiauthor=B.+Yucelauthor=E.+C.+Bayraktarauthor=J.+E.+Caretteauthor=C.+B.+Clishauthor=T.+R.+Brummelkampauthor=D.+D.+Sabatiniauthor=D.+M.+Sabatini&title=Inhibition+of+ATPIF1+ameliorates+severe+mitochondrial+respiratory+chain+dysfunction+in+mammalian+cells&doi=10.1016%2Fj.celrep.2014.02.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of ATPIF1 Ameliorates Severe Mitochondrial Respiratory Chain Dysfunction in Mammalian Cells</span></div><div class="casAuthors">Chen, Walter W.; Birsoy, Kivanc; Mihaylova, Maria M.; Snitkin, Harriet; Stasinski, Iwona; Yucel, Burcu; Bayraktar, Erol C.; Carette, Jan E.; Clish, Clary B.; Brummelkamp, Thijn R.; Sabatini, David D.; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-34</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Mitochondrial respiratory chain disorders are characterized by loss of electron transport chain (ETC) activity.  Although the causes of many such diseases are known, there is a lack of effective therapies.  To identify genes that confer resistance to severe ETC dysfunction when inactivated, we performed a genome-wide genetic screen in haploid human cells with the mitochondrial complex III inhibitor antimycin.  This screen revealed that loss of ATPIF1 strongly protects against antimycin-induced ETC dysfunction and cell death by allowing for the maintenance of mitochondrial membrane potential.  ATPIF1 loss protects against other forms of ETC dysfunction and is even essential for the viability of human ÏÂ° cells lacking mitochondrial DNA, a system commonly used for studying ETC dysfunction.  Importantly, inhibition of ATPIF1 ameliorates complex III blockade in primary hepatocytes, a cell type afflicted in severe mitochondrial disease.  Altogether, these results suggest that inhibition of ATPIF1 can ameliorate severe ETC dysfunction in mitochondrial pathol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9ENNqggtkfbVg90H21EOLACvtfcHk0ljdGPfb16-bLw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFCktLw%253D&md5=cb5f695d125eb8ee763405ddc381cf76</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2014.02.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2014.02.046%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DW.%2BW.%26aulast%3DBirsoy%26aufirst%3DK.%26aulast%3DMihaylova%26aufirst%3DM.%2BM.%26aulast%3DSnitkin%26aufirst%3DH.%26aulast%3DStasinski%26aufirst%3DI.%26aulast%3DYucel%26aufirst%3DB.%26aulast%3DBayraktar%26aufirst%3DE.%2BC.%26aulast%3DCarette%26aufirst%3DJ.%2BE.%26aulast%3DClish%26aufirst%3DC.%2BB.%26aulast%3DBrummelkamp%26aufirst%3DT.%2BR.%26aulast%3DSabatini%26aufirst%3DD.%2BD.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DInhibition%2520of%2520ATPIF1%2520ameliorates%2520severe%2520mitochondrial%2520respiratory%2520chain%2520dysfunction%2520in%2520mammalian%2520cells%26jtitle%3DCell%2520Rep.%26date%3D2014%26volume%3D7%26spage%3D27%26epage%3D34%26doi%3D10.1016%2Fj.celrep.2014.02.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chandel, N. S.</span></span> <span> </span><span class="NLM_article-title">Mitochondria as signaling organelles</span>. <i>BMC Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">34</span>, <span class="refDoi">Â DOI: 10.1186/1741-7007-12-34</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1186%2F1741-7007-12-34" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=24884669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjt1ajsb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=34&author=N.+S.+Chandel&title=Mitochondria+as+signaling+organelles&doi=10.1186%2F1741-7007-12-34"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondria as signaling organelles</span></div><div class="casAuthors">Chandel, Navdeep S.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">34/1-34/7, 7</span>CODEN:
                <span class="NLM_cas:coden">BBMIF7</span>;
        ISSN:<span class="NLM_cas:issn">1741-7007</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review. Almost 20 yr ago, the discovery that mitochondrial release of cytochrome c initiates a cascade that leads to cell death brought about a wholesale change in how cell biologists think of mitochondria.  Formerly viewed as sites of biosynthesis and bioenergy prodn., these double membrane organelles could now be thought of as regulators of signal transduction.  Within a few years, multiple other mitochondria-centric signaling mechanisms have been proposed, including release of reactive O species and the scaffolding of signaling complexes on the outer mitochondrial membrane.  It has also been shown that mitochondrial dysfunction causes induction of stress responses, bolstering the idea that mitochondria communicate their fitness to the rest of the cell.  In the past decade, multiple new modes of mitochondrial signaling have been discovered.  These include the release of metabolites, mitochondrial motility and dynamics, and interaction with other organelles such as endoplasmic reticulum in regulating signaling.  Collectively these studies have established that mitochondria-dependent signaling has diverse physiol. and pathophysiol. outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOsteP0hdF47Vg90H21EOLACvtfcHk0ljdGPfb16-bLw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjt1ajsb8%253D&md5=8d1f5e1300f156947bb17f74706559fc</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1186%2F1741-7007-12-34&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1741-7007-12-34%26sid%3Dliteratum%253Aachs%26aulast%3DChandel%26aufirst%3DN.%2BS.%26atitle%3DMitochondria%2520as%2520signaling%2520organelles%26jtitle%3DBMC%2520Biol.%26date%3D2014%26volume%3D12%26spage%3D34%26doi%3D10.1186%2F1741-7007-12-34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whitaker-Menezes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Outschoorn, U. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flomenberg, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birbe, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witkiewicz, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavlides, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsirigos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ertel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pestell, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broda, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minetti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lisanti, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotgia, F.</span></span> <span> </span><span class="NLM_article-title">Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">4047</span>â <span class="NLM_lpage">4064</span>, <span class="refDoi">Â DOI: 10.4161/cc.10.23.18151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.4161%2Fcc.10.23.18151" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=22134189" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsV2mtrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=4047-4064&author=D.+Whitaker-Menezesauthor=U.+E.+Martinez-Outschoornauthor=N.+Flomenbergauthor=R.+C.+Birbeauthor=A.+K.+Witkiewiczauthor=A.+Howellauthor=S.+Pavlidesauthor=A.+Tsirigosauthor=A.+Ertelauthor=R.+G.+Pestellauthor=P.+Brodaauthor=C.+Minettiauthor=M.+P.+Lisantiauthor=F.+Sotgia&title=Hyperactivation+of+oxidative+mitochondrial+metabolism+in+epithelial+cancer+cells+in+situ%3A+visualizing+the+therapeutic+effects+of+metformin+in+tumor+tissue&doi=10.4161%2Fcc.10.23.18151"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue</span></div><div class="casAuthors">Whitaker-Menezes, Diana; Martinez-Outschoorn, Ubaldo E.; Flomenberg, Neal; Birbe, Ruth C.; Witkiewicz, Agnieszka K.; Howell, Anthony; Pavlides, Stephanos; Tsirigos, Aristotelis; Ertel, Adam; Pestell, Richard G.; Broda, Paolo; Minetti, Carlo; Lisanti, Michael P.; Sotgia, Federica</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4047-4064</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1538-4101</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">We have recently proposed a new mechanism for explaining energy transfer in cancer metab.  In this scenario, cancer cells behave as metabolic parasites, by extg. nutrients from normal host cells, such as fibroblasts, via the secretion of hydrogen peroxide as the initial trigger.  Oxidative stress in the tumor microenvironment then leads to autophagy-driven catabolism, mitochondrial dys-function and aerobic glycolysis.  This, in turn, produces high-energy nutrients (such as L-lactate, ketones and glutamine) that drive the anabolic growth of tumor cells, via oxidative mitochondrial metab.  A logical prediction of this new "parasitic" cancer model is that tumor-assocd. fibroblasts should show evidence of mitochondrial dys-function (mitophagy and aerobic glycolysis).  In contrast, epithelial cancer cells should increase their oxidative mitochondrial capacity.  To further test this hypothesis, here we subjected frozen sections from human breast tumors to a staining procedure that only detects functional mitochondria.  This method detects the in situ enzymic activity of cytochrome C oxidase (COX), also known as Complex IV.  Remarkably, cancer cells show an over-abundance of COX activity, while adjacent stromal cells remain essentially neg.  Adjacent normal ductal epithelial cells also show little or no COX activity, relative to epithelial cancer cells.  Thus, oxidative mitochondrial activity is selectively amplified in cancer cells.  Although COX activity staining has never been applied to cancer tissues, it could now be used routinely to distinguish cancer cells from normal cells, and to establish neg. margins during cancer surgery.  Similar results were obtained with NADH activity staining, which measures Complex I activity, and succinate dehydrogenase (SDH) activity staining, which measures Complex II activity.  COX and NADH activities were blocked by electron transport inhibitors, such as Metformin.  This has mechanistic and clin. implications for using Metformin as an anti-cancer drug, both for cancer therapy and chemo-prevention.  We also immuno-stained human breast cancers for a series of well-established protein biomarkers of metab.  More specifically, we now show that cancer-assocd. fibroblasts overexpress markers of autophagy (cathepsin B), mitophagy (BNIP3L) and aerobic glycolysis (MCT4).  Conversely, epithelial cancer cells show the overexpression of a mitochondrial membrane marker (TOMM20), as well as key components of Complex IV (MT-CO1) and Complex II (SDH-B).  We also validated our observations using a bioinformatics approach with data from >2,000 breast cancer patients, which showed the transcriptional upregulation of mitochondrial oxidative phosphorylation (OXPHOS) in human breast tumors (p < 10-20), and a specific assocn. with metastasis.  Therefore, upregulation of OXPHOS in epithelial tumor cells is a common feature of human breast cancers.  In summary, our data provide the first functional in vivo evidence that epithelial cancer cells perform enhanced mitochondrial oxidative phosphorylation, allowing them to produce high amts. of ATP.  Thus, we believe that mitochondria are both the "powerhouse" and "Achilles' heel" of cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXlAskwAucT7Vg90H21EOLACvtfcHk0licEQNzxqd8pA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsV2mtrk%253D&md5=847d969e30d882ddb9528cd3e3327577</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.4161%2Fcc.10.23.18151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.10.23.18151%26sid%3Dliteratum%253Aachs%26aulast%3DWhitaker-Menezes%26aufirst%3DD.%26aulast%3DMartinez-Outschoorn%26aufirst%3DU.%2BE.%26aulast%3DFlomenberg%26aufirst%3DN.%26aulast%3DBirbe%26aufirst%3DR.%2BC.%26aulast%3DWitkiewicz%26aufirst%3DA.%2BK.%26aulast%3DHowell%26aufirst%3DA.%26aulast%3DPavlides%26aufirst%3DS.%26aulast%3DTsirigos%26aufirst%3DA.%26aulast%3DErtel%26aufirst%3DA.%26aulast%3DPestell%26aufirst%3DR.%2BG.%26aulast%3DBroda%26aufirst%3DP.%26aulast%3DMinetti%26aufirst%3DC.%26aulast%3DLisanti%26aufirst%3DM.%2BP.%26aulast%3DSotgia%26aufirst%3DF.%26atitle%3DHyperactivation%2520of%2520oxidative%2520mitochondrial%2520metabolism%2520in%2520epithelial%2520cancer%2520cells%2520in%2520situ%253A%2520visualizing%2520the%2520therapeutic%2520effects%2520of%2520metformin%2520in%2520tumor%2520tissue%26jtitle%3DCell%2520Cycle%26date%3D2011%26volume%3D10%26spage%3D4047%26epage%3D4064%26doi%3D10.4161%2Fcc.10.23.18151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Broad Institute TCGA Genome Data Analysis Center</span> (<span class="NLM_year">2016</span>): Firehose stddata__2016_01_28
run. <span class="NLM_publisher-name">Broad Institute of MIT</span>: <span class="NLM_publisher-loc">Harvard</span>.<span class="refDoi">Â DOI: 10.7908/C11G0KM9</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.7908%2FC11G0KM9" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Broad+Institute+TCGA+Genome+Data+Analysis+Center+%282016%29%3A+Firehose+stddata__2016_01_28%0Arun.+Broad+Institute+of+MIT%3A+Harvard.+10.7908%2FC11G0KM9."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.7908%2FC11G0KM9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.7908%252FC11G0KM9%26sid%3Dliteratum%253Aachs%26aulast%3D%26date%3D2016%26pub%3DBroad%2520Institute%2520of%2520MIT%26doi%3D10.7908%2FC11G0KM9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liberzon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorvaldsdottir, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghandi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesirov, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamayo, P.</span></span> <span> </span><span class="NLM_article-title">The molecular signatures database hallmark gene set collection</span>. <i>Cell Syst.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">417</span>â <span class="NLM_lpage">425</span>, <span class="refDoi">Â DOI: 10.1016/j.cels.2015.12.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.cels.2015.12.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=26771021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFaltLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2015&pages=417-425&author=A.+Liberzonauthor=C.+Birgerauthor=H.+Thorvaldsdottirauthor=M.+Ghandiauthor=J.+P.+Mesirovauthor=P.+Tamayo&title=The+molecular+signatures+database+hallmark+gene+set+collection&doi=10.1016%2Fj.cels.2015.12.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">The Molecular Signatures Database Hallmark Gene Set Collection</span></div><div class="casAuthors">Liberzon, Arthur; Birger, Chet; Thorvaldsdottir, Helga; Ghandi, Mahmoud; Mesirov, Jill P.; Tamayo, Pablo</div><div class="citationInfo"><span class="NLM_cas:title">Cell Systems</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">417-425</span>CODEN:
                <span class="NLM_cas:coden">CSEYA4</span>;
        ISSN:<span class="NLM_cas:issn">2405-4712</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The Mol. Signatures Database (MSigDB) is one of the most widely used and comprehensive databases of gene sets for performing gene set enrichment anal.  Since its creation, MSigDB has grown beyond its roots in metabolic disease and cancer to include >10,000 gene sets.  These better represent a wider range of biol. processes and diseases, but the utility of the database is reduced by increased redundancy across, and heterogeneity within, gene sets.  To address this challenge, here we use a combination of automated approaches and expert curation to develop a collection of "hallmark" gene sets as part of MSigDB.  Each hallmark in this collection consists of a "refined" gene set, derived from multiple "founder" sets, that conveys a specific biol. state or process and displays coherent expression.  The hallmarks effectively summarize most of the relevant information of the original founder sets and, by reducing both variation and redundancy, provide more refined and concise inputs for gene set enrichment anal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBEddnjUes8rVg90H21EOLACvtfcHk0licEQNzxqd8pA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFaltLc%253D&md5=2438d023b171d006ca04b20b7fdfc665</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.cels.2015.12.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cels.2015.12.004%26sid%3Dliteratum%253Aachs%26aulast%3DLiberzon%26aufirst%3DA.%26aulast%3DBirger%26aufirst%3DC.%26aulast%3DThorvaldsdottir%26aufirst%3DH.%26aulast%3DGhandi%26aufirst%3DM.%26aulast%3DMesirov%26aufirst%3DJ.%2BP.%26aulast%3DTamayo%26aufirst%3DP.%26atitle%3DThe%2520molecular%2520signatures%2520database%2520hallmark%2520gene%2520set%2520collection%26jtitle%3DCell%2520Syst.%26date%3D2015%26volume%3D1%26spage%3D417%26epage%3D425%26doi%3D10.1016%2Fj.cels.2015.12.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kanehisa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, S.</span></span> <span> </span><span class="NLM_article-title">KEGG: Kyoto encyclopedia of genes and genomes</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">27</span>â <span class="NLM_lpage">30</span>, <span class="refDoi">Â DOI: 10.1093/nar/28.1.27</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1093%2Fnar%2F28.1.27" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10592173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhvVGqu74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2000&pages=27-30&author=M.+Kanehisaauthor=S.+Goto&title=KEGG%3A+Kyoto+encyclopedia+of+genes+and+genomes&doi=10.1093%2Fnar%2F28.1.27"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">KEGG: Kyoto Encyclopedia of Genes and Genomes</span></div><div class="casAuthors">Kanehisa, Minoru; Goto, Susumu</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-30</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">KEGG (Kyoto Encyclopedia of Genes and Genomes) is a knowledge base for systematic anal. of gene functions, linking genomic information with higher order functional information.  The genomic information is stored in the GENES database, which is a collection of gene catalogs for all the completely sequenced genomes and some partial genomes with up-to-date annotation of gene functions.  The higher order functional information is stored in the PATHWAY database, which contains graphical representations of cellular processes, such as metab., membrane transport, signal transduction and cell cycle.  The PATHWAY database is supplemented by a set of ortholog group tables for the information about conserved subpath-ways (pathway motifs), which are often encoded by positionally coupled genes on the chromosome and which are esp. useful in predicting gene functions.  A third database in KEGG is LIGAND for the information about chem. compds., enzyme mols. and enzymic reactions.  KEGG provides Java graphics tools for browsing genome maps, comparing two genome maps and manipulating expression maps, as well as computational tools for sequence comparison, graph comparison and path computation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVAZngEAfzebVg90H21EOLACvtfcHk0lizEGgnkP0adQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhvVGqu74%253D&md5=16eab4d6d4c3b6b987645f8ba2e84fe9</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1093%2Fnar%2F28.1.27&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252F28.1.27%26sid%3Dliteratum%253Aachs%26aulast%3DKanehisa%26aufirst%3DM.%26aulast%3DGoto%26aufirst%3DS.%26atitle%3DKEGG%253A%2520Kyoto%2520encyclopedia%2520of%2520genes%2520and%2520genomes%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2000%26volume%3D28%26spage%3D27%26epage%3D30%26doi%3D10.1093%2Fnar%2F28.1.27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harris, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ireland, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lomax, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashburner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foulger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eilbeck, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mungall, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bult, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drabkin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eppig, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ringwald, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balakrishnan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherry, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costanzo, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwight, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisk, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirschman, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nash, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sethuraman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theesfeld, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botstein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolinski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feierbach, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardini, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mundodi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhee, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apweiler, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimmer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chisholm, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaudet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kibbe, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kishore, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sternberg, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gwinn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannick, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wortman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berriman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Cruz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonellato, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaiswal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seigfried, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Consortium, G. O.</span></span> <span> </span><span class="NLM_article-title">The gene ontology (GO) database and informatics resource</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">258D</span>, <span class="refDoi">Â DOI: 10.1093/nar/gkh036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1093%2Fnar%2Fgkh036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=14681407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BD3srpvFyhtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2004&pages=258D&author=M.+A.+Harrisauthor=J.+Clarkauthor=A.+Irelandauthor=J.+Lomaxauthor=M.+Ashburnerauthor=R.+Foulgerauthor=K.+Eilbeckauthor=S.+Lewisauthor=B.+Marshallauthor=C.+Mungallauthor=J.+Richterauthor=G.+M.+Rubinauthor=J.+A.+Blakeauthor=C.+Bultauthor=M.+Dolanauthor=H.+Drabkinauthor=J.+T.+Eppigauthor=D.+P.+Hillauthor=L.+Niauthor=M.+Ringwaldauthor=R.+Balakrishnanauthor=J.+M.+Cherryauthor=K.+R.+Christieauthor=M.+C.+Costanzoauthor=S.+S.+Dwightauthor=S.+Engelauthor=D.+G.+Fiskauthor=J.+E.+Hirschmanauthor=E.+L.+Hongauthor=R.+S.+Nashauthor=A.+Sethuramanauthor=C.+L.+Theesfeldauthor=D.+Botsteinauthor=K.+Dolinskiauthor=B.+Feierbachauthor=T.+Berardiniauthor=S.+Mundodiauthor=S.+Y.+Rheeauthor=R.+Apweilerauthor=D.+Barrellauthor=E.+Camonauthor=E.+Dimmerauthor=V.+Leeauthor=R.+Chisholmauthor=P.+Gaudetauthor=W.+Kibbeauthor=R.+Kishoreauthor=E.+M.+Schwarzauthor=P.+Sternbergauthor=M.+Gwinnauthor=L.+Hannickauthor=J.+Wortmanauthor=M.+Berrimanauthor=V.+Woodauthor=N.+de+la+Cruzauthor=P.+Tonellatoauthor=P.+Jaiswalauthor=T.+Seigfriedauthor=R.+Whiteauthor=G.+O.+Consortium&title=The+gene+ontology+%28GO%29+database+and+informatics+resource&doi=10.1093%2Fnar%2Fgkh036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">The Gene Ontology (GO) database and informatics resource</span></div><div class="casAuthors">Harris M A; Clark J; Ireland A; Lomax J; Ashburner M; Foulger R; Eilbeck K; Lewis S; Marshall B; Mungall C; Richter J; Rubin G M; Blake J A; Bult C; Dolan M; Drabkin H; Eppig J T; Hill D P; Ni L; Ringwald M; Balakrishnan R; Cherry J M; Christie K R; Costanzo M C; Dwight S S; Engel S; Fisk D G; Hirschman J E; Hong E L; Nash R S; Sethuraman A; Theesfeld C L; Botstein D; Dolinski K; Feierbach B; Berardini T; Mundodi S; Rhee S Y; Apweiler R; Barrell D; Camon E; Dimmer E; Lee V; Chisholm R; Gaudet P; Kibbe W; Kishore R; Schwarz E M; Sternberg P; Gwinn M; Hannick L; Wortman J; Berriman M; Wood V; de la Cruz N; Tonellato P; Jaiswal P; Seigfried T; White R</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic acids research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">Database issue</span>),
    <span class="NLM_cas:pages">D258-61</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The Gene Ontology (GO) project (http://www. geneontology.org/) provides structured, controlled vocabularies and classifications that cover several domains of molecular and cellular biology and are freely available for community use in the annotation of genes, gene products and sequences.  Many model organism databases and genome annotation groups use the GO and contribute their annotation sets to the GO resource.  The GO database integrates the vocabularies and contributed annotations and provides full access to this information in several formats.  Members of the GO Consortium continually work collectively, involving outside experts as needed, to expand and update the GO vocabularies.  The GO Web resource also provides access to extensive documentation about the GO project and links to applications that use GO data for functional analyses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTEDpG4UCQUFROk4JA3soTqfW6udTcc2eYu3yEYuABAbbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3srpvFyhtw%253D%253D&md5=21f56d1ec289881d76badbafb67663bb</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkh036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkh036%26sid%3Dliteratum%253Aachs%26aulast%3DHarris%26aufirst%3DM.%2BA.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DIreland%26aufirst%3DA.%26aulast%3DLomax%26aufirst%3DJ.%26aulast%3DAshburner%26aufirst%3DM.%26aulast%3DFoulger%26aufirst%3DR.%26aulast%3DEilbeck%26aufirst%3DK.%26aulast%3DLewis%26aufirst%3DS.%26aulast%3DMarshall%26aufirst%3DB.%26aulast%3DMungall%26aufirst%3DC.%26aulast%3DRichter%26aufirst%3DJ.%26aulast%3DRubin%26aufirst%3DG.%2BM.%26aulast%3DBlake%26aufirst%3DJ.%2BA.%26aulast%3DBult%26aufirst%3DC.%26aulast%3DDolan%26aufirst%3DM.%26aulast%3DDrabkin%26aufirst%3DH.%26aulast%3DEppig%26aufirst%3DJ.%2BT.%26aulast%3DHill%26aufirst%3DD.%2BP.%26aulast%3DNi%26aufirst%3DL.%26aulast%3DRingwald%26aufirst%3DM.%26aulast%3DBalakrishnan%26aufirst%3DR.%26aulast%3DCherry%26aufirst%3DJ.%2BM.%26aulast%3DChristie%26aufirst%3DK.%2BR.%26aulast%3DCostanzo%26aufirst%3DM.%2BC.%26aulast%3DDwight%26aufirst%3DS.%2BS.%26aulast%3DEngel%26aufirst%3DS.%26aulast%3DFisk%26aufirst%3DD.%2BG.%26aulast%3DHirschman%26aufirst%3DJ.%2BE.%26aulast%3DHong%26aufirst%3DE.%2BL.%26aulast%3DNash%26aufirst%3DR.%2BS.%26aulast%3DSethuraman%26aufirst%3DA.%26aulast%3DTheesfeld%26aufirst%3DC.%2BL.%26aulast%3DBotstein%26aufirst%3DD.%26aulast%3DDolinski%26aufirst%3DK.%26aulast%3DFeierbach%26aufirst%3DB.%26aulast%3DBerardini%26aufirst%3DT.%26aulast%3DMundodi%26aufirst%3DS.%26aulast%3DRhee%26aufirst%3DS.%2BY.%26aulast%3DApweiler%26aufirst%3DR.%26aulast%3DBarrell%26aufirst%3DD.%26aulast%3DCamon%26aufirst%3DE.%26aulast%3DDimmer%26aufirst%3DE.%26aulast%3DLee%26aufirst%3DV.%26aulast%3DChisholm%26aufirst%3DR.%26aulast%3DGaudet%26aufirst%3DP.%26aulast%3DKibbe%26aufirst%3DW.%26aulast%3DKishore%26aufirst%3DR.%26aulast%3DSchwarz%26aufirst%3DE.%2BM.%26aulast%3DSternberg%26aufirst%3DP.%26aulast%3DGwinn%26aufirst%3DM.%26aulast%3DHannick%26aufirst%3DL.%26aulast%3DWortman%26aufirst%3DJ.%26aulast%3DBerriman%26aufirst%3DM.%26aulast%3DWood%26aufirst%3DV.%26aulast%3Dde%2Bla%2BCruz%26aufirst%3DN.%26aulast%3DTonellato%26aufirst%3DP.%26aulast%3DJaiswal%26aufirst%3DP.%26aulast%3DSeigfried%26aufirst%3DT.%26aulast%3DWhite%26aufirst%3DR.%26aulast%3DConsortium%26aufirst%3DG.%2BO.%26atitle%3DThe%2520gene%2520ontology%2520%2528GO%2529%2520database%2520and%2520informatics%2520resource%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2004%26volume%3D32%26spage%3D258D%26doi%3D10.1093%2Fnar%2Fgkh036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamayo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mootha, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukherjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillette, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulovich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomeroy, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golub, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lander, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesirov, J. P.</span></span> <span> </span><span class="NLM_article-title">Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">15545</span>â <span class="NLM_lpage">15550</span>, <span class="refDoi">Â DOI: 10.1073/pnas.0506580102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1073%2Fpnas.0506580102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=16199517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1ShtrnO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=15545-15550&author=A.+Subramanianauthor=P.+Tamayoauthor=V.+K.+Moothaauthor=S.+Mukherjeeauthor=B.+L.+Ebertauthor=M.+A.+Gilletteauthor=A.+Paulovichauthor=S.+L.+Pomeroyauthor=T.+R.+Golubauthor=E.+S.+Landerauthor=J.+P.+Mesirov&title=Gene+set+enrichment+analysis%3A+A+knowledge-based+approach+for+interpreting+genome-wide+expression+profiles&doi=10.1073%2Fpnas.0506580102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles</span></div><div class="casAuthors">Subramanian, Aravind; Tamayo, Pablo; Mootha, Vamsi K.; Mukherjee, Sayan; Ebert, Benjamin L.; Gillette, Michael A.; Paulovich, Amanda; Pomeroy, Scott L.; Golub, Todd R.; Lander, Eric S.; Mesirov, Jill P.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">15545-15550</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Although genomewide RNA expression anal. has become a routine tool in biomedical research, extg. biol. insight from such information remains a major challenge.  Here, we describe a powerful anal. method called Gene Set Enrichment Anal. (GSEA) for interpreting gene expression data.  The method derives its power by focusing on gene sets, i.e., groups of genes that share common biol. function, chromosomal location, or regulation.  We demonstrate how GSEA yields insights into several cancer-related data sets, including leukemia and lung cancer.  Notably, where single-gene anal. finds little similarity between two independent studies of patients survival in lung cancer, GSEA reveals many biol. pathways in common.  The GSEA method is embodied in a freely available software package, together with an initial database of 1,325 biol. defined gene sets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH2_E6gWd0yrVg90H21EOLACvtfcHk0ljSLkq8DHdQLQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1ShtrnO&md5=ca2eb221010f20379199e6442c65fc2e</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0506580102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0506580102%26sid%3Dliteratum%253Aachs%26aulast%3DSubramanian%26aufirst%3DA.%26aulast%3DTamayo%26aufirst%3DP.%26aulast%3DMootha%26aufirst%3DV.%2BK.%26aulast%3DMukherjee%26aufirst%3DS.%26aulast%3DEbert%26aufirst%3DB.%2BL.%26aulast%3DGillette%26aufirst%3DM.%2BA.%26aulast%3DPaulovich%26aufirst%3DA.%26aulast%3DPomeroy%26aufirst%3DS.%2BL.%26aulast%3DGolub%26aufirst%3DT.%2BR.%26aulast%3DLander%26aufirst%3DE.%2BS.%26aulast%3DMesirov%26aufirst%3DJ.%2BP.%26atitle%3DGene%2520set%2520enrichment%2520analysis%253A%2520A%2520knowledge-based%2520approach%2520for%2520interpreting%2520genome-wide%2520expression%2520profiles%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2005%26volume%3D102%26spage%3D15545%26epage%3D15550%26doi%3D10.1073%2Fpnas.0506580102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">R
Core Team</span> (<span class="NLM_year">2019</span>).  <i>R:
A language and environment for statistical computing</i>; <span class="NLM_publisher-name">R Foundation for Statistical Computing</span>: <span class="NLM_publisher-loc">Vienna, Austria</span>. <a href="https://www.R-project.org/" class="extLink">https://www.R-project.org/</a> (accessed Sep 19, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=R%0ACore+Team&title=R%3A%0AA+language+and+environment+for+statistical+computing"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3D%26date%3D2019%26btitle%3DR%253A%250AA%2520language%2520and%2520environment%2520for%2520statistical%2520computing%26pub%3DR%2520Foundation%2520for%2520Statistical%2520Computing" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Broad Institute TCGA Genome Data Analysis Center</span> (<span class="NLM_year">2016</span>): Firehose stddata_2016_01_28
run. <span class="NLM_publisher-name">Broad Institute of MIT</span>: <span class="NLM_publisher-loc">Harvard</span>. <span class="refDoi">Â DOI: 10.7908/C11G0KM9</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.7908%2FC11G0KM9" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Broad+Institute+TCGA+Genome+Data+Analysis+Center+%282016%29%3A+Firehose+stddata_2016_01_28%0Arun.+Broad+Institute+of+MIT%3A+Harvard.+10.7908%2FC11G0KM9."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.7908%2FC11G0KM9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.7908%252FC11G0KM9%26sid%3Dliteratum%253Aachs%26aulast%3D%26date%3D2016%26pub%3DBroad%2520Institute%2520of%2520MIT%26doi%3D10.7908%2FC11G0KM9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Candas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eldridge, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wachsmann-Hogiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chromy, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nantajit, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duru, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finkel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. J.</span></span> <span> </span><span class="NLM_article-title">Cyclin B1/Cdk1 coordinates mitochondrial respiration for cell-cycle G2/M progression</span>. <i>Dev. Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">217</span>â <span class="NLM_lpage">232</span>, <span class="refDoi">Â DOI: 10.1016/j.devcel.2014.03.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.devcel.2014.03.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=24746669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmsVCht7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2014&pages=217-232&author=Z.+Wangauthor=M.+Fanauthor=D.+Candasauthor=T.+Q.+Zhangauthor=L.+Qinauthor=A.+Eldridgeauthor=S.+Wachsmann-Hogiuauthor=K.+M.+Ahmedauthor=B.+A.+Chromyauthor=D.+Nantajitauthor=N.+Duruauthor=F.+Heauthor=M.+Chenauthor=T.+Finkelauthor=L.+S.+Weinsteinauthor=J.+J.+Li&title=Cyclin+B1%2FCdk1+coordinates+mitochondrial+respiration+for+cell-cycle+G2%2FM+progression&doi=10.1016%2Fj.devcel.2014.03.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin B1/Cdk1 Coordinates Mitochondrial Respiration for Cell-Cycle G2/M Progression</span></div><div class="casAuthors">Wang, Zhaoqing; Fan, Ming; Candas, Demet; Zhang, Tie-Qiao; Qin, Lili; Eldridge, Angela; Wachsmann-Hogiu, Sebastian; Ahmed, Kazi M.; Chromy, Brett A.; Nantajit, Danupon; Duru, Nadire; He, Fuchu; Chen, Min; Finkel, Toren; Weinstein, Lee S.; Li, Jian Jian</div><div class="citationInfo"><span class="NLM_cas:title">Developmental Cell</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">217-232</span>CODEN:
                <span class="NLM_cas:coden">DCEEBE</span>;
        ISSN:<span class="NLM_cas:issn">1534-5807</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A substantial amt. of mitochondrial energy is required for cell-cycle progression.  The mechanisms underlying the coordination of the mitochondrial respiration with cell-cycle progression, esp. the G2/M transition, remain to be elucidated.  Here, we show that a fraction of cyclin B1/Cdk1 proteins localizes to the matrix of mitochondria and phosphorylates a cluster of mitochondrial proteins, including the complex I (CI) subunits in the respiratory chain.  Cyclin B1/Cdk1-mediated CI phosphorylation enhances CI activity, whereas deficiency of such phosphorylation in each of the relevant CI subunits results in impairment of CI function.  Mitochondria-targeted cyclin B1/Cdk1 increases mitochondrial respiration with enhanced oxygen consumption and ATP generation, which provides cells with efficient bioenergy for G2/M transition and shortens overall cell-cycle time.  Thus, cyclin B1/Cdk1-mediated phosphorylation of mitochondrial substrates allows cells to sense and respond to increased energy demand for G2/M transition and, subsequently, to upregulate mitochondrial respiration for successful cell-cycle progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8A5dc209Mm7Vg90H21EOLACvtfcHk0lgZmXgn0oHURA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmsVCht7Y%253D&md5=2f95e9ad8d22502a7ce640f02fc0ecea</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.devcel.2014.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.devcel.2014.03.012%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DFan%26aufirst%3DM.%26aulast%3DCandas%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DT.%2BQ.%26aulast%3DQin%26aufirst%3DL.%26aulast%3DEldridge%26aufirst%3DA.%26aulast%3DWachsmann-Hogiu%26aufirst%3DS.%26aulast%3DAhmed%26aufirst%3DK.%2BM.%26aulast%3DChromy%26aufirst%3DB.%2BA.%26aulast%3DNantajit%26aufirst%3DD.%26aulast%3DDuru%26aufirst%3DN.%26aulast%3DHe%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DFinkel%26aufirst%3DT.%26aulast%3DWeinstein%26aufirst%3DL.%2BS.%26aulast%3DLi%26aufirst%3DJ.%2BJ.%26atitle%3DCyclin%2520B1%252FCdk1%2520coordinates%2520mitochondrial%2520respiration%2520for%2520cell-cycle%2520G2%252FM%2520progression%26jtitle%3DDev.%2520Cell%26date%3D2014%26volume%3D29%26spage%3D217%26epage%3D232%26doi%3D10.1016%2Fj.devcel.2014.03.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smolkova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jezek, P.</span></span> <span> </span><span class="NLM_article-title">The role of mitochondrial NADPH-dependent isocitrate dehydrogenase in cancer cells</span>. <i>Int. J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2012</i></span>,  <span class="NLM_fpage">273947</span>, <span class="refDoi">Â DOI: 10.1155/2012/273947</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1155%2F2012%2F273947" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=22675360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BC38npslaitA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2012&publication_year=2012&pages=273947&author=K.+Smolkovaauthor=P.+Jezek&title=The+role+of+mitochondrial+NADPH-dependent+isocitrate+dehydrogenase+in+cancer+cells&doi=10.1155%2F2012%2F273947"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of Mitochondrial NADPH-Dependent Isocitrate Dehydrogenase in Cancer Cells</span></div><div class="casAuthors">Smolkova Katarina; Jezek Petr</div><div class="citationInfo"><span class="NLM_cas:title">International journal of cell biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2012</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">273947</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Isocitrate dehydrogenase 2 (IDH2) is located in the mitochondrial matrix.  IDH2 acts in the forward Krebs cycle as an NADP(+)-consuming enzyme, providing NADPH for maintenance of the reduced glutathione and peroxiredoxin systems and for self-maintenance by reactivation of cystine-inactivated IDH2 by glutaredoxin 2.  In highly respiring cells, the resulting NAD(+) accumulation then induces sirtuin-3-mediated activating IDH2 deacetylation, thus increasing its protective function.  Reductive carboxylation of 2-oxoglutarate by IDH2 (in the reverse Krebs cycle direction), which consumes NADPH, may follow glutaminolysis of glutamine to 2-oxoglutarate in cancer cells.  When the reverse aconitase reaction and citrate efflux are added, this overall "anoxic" glutaminolysis mode may help highly malignant tumors survive aglycemia during hypoxia.  Intermittent glycolysis would hypothetically be required to provide ATP.  When oxidative phosphorylation is dormant, this mode causes substantial oxidative stress.  Arg172 mutants of human IDH2-frequently found with similar mutants of cytosolic IDH1 in grade 2 and 3 gliomas, secondary glioblastomas, and acute myeloid leukemia-catalyze reductive carboxylation of 2-oxoglutarate and reduction to D-2-hydroxyglutarate, which strengthens the neoplastic phenotype by competitive inhibition of histone demethylation and 5-methylcytosine hydroxylation, leading to genome-wide histone and DNA methylation alternations.  D-2-hydroxyglutarate also interferes with proline hydroxylation and thus may stabilize hypoxia-induced factor Î±.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSAE3tlxufovBpyrDyM_m9cfW6udTcc2eaPrJf4ajJuM7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38npslaitA%253D%253D&md5=a61ea44f8954fb09ec69aed9c2699b84</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1155%2F2012%2F273947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2012%252F273947%26sid%3Dliteratum%253Aachs%26aulast%3DSmolkova%26aufirst%3DK.%26aulast%3DJezek%26aufirst%3DP.%26atitle%3DThe%2520role%2520of%2520mitochondrial%2520NADPH-dependent%2520isocitrate%2520dehydrogenase%2520in%2520cancer%2520cells%26jtitle%3DInt.%2520J.%2520Cell%2520Biol.%26date%3D2012%26volume%3D2012%26spage%3D273947%26doi%3D10.1155%2F2012%2F273947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Z. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, X. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bode, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span> <span> </span><span class="NLM_article-title">Wild-type IDH2 promotes the Warburg effect and tumor growth through HIF1 alpha in lung cancer</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">4050</span>â <span class="NLM_lpage">4061</span>, <span class="refDoi">Â DOI: 10.7150/thno.21524</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.7150%2Fthno.21524" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=30128035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1MXivVSktbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=4050-4061&author=J.+J.+Liauthor=Y.+Heauthor=Z.+Q.+Tanauthor=J.+C.+Luauthor=L.+L.+Liauthor=X.+Songauthor=F.+Shiauthor=L.+L.+Xieauthor=S.+Youauthor=X.+J.+Luoauthor=N.+M.+Liauthor=Y.+S.+Liauthor=X.+L.+Liuauthor=M.+Tangauthor=X.+X.+Wengauthor=W.+Yiauthor=J.+Fanauthor=J.+Zhouauthor=G.+Qiangauthor=S.+J.+Qiuauthor=W.+Z.+Wuauthor=A.+M.+Bodeauthor=Y.+Cao&title=Wild-type+IDH2+promotes+the+Warburg+effect+and+tumor+growth+through+HIF1+alpha+in+lung+cancer&doi=10.7150%2Fthno.21524"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Wild-type IDH2 promotes the Warburg effect and tumor growth through HIF1Î± in lung cancer</span></div><div class="casAuthors">Li, Jiangjiang; He, Ya; Tan, Zheqiong; Lu, Jingchen; Li, Liling; Song, Xin; Shi, Feng; Xie, Longlong; You, Shuo; Luo, Xiangjian; Li, Namei; Li, Yueshuo; Liu, Xiaolan; Tang, Min; Weng, Xinxian; Yi, Wei; Fan, Jia; Zhou, Jian; Qiang, Gao; Qiu, Shuangjian; Wu, Weizhong; Bode, Ann M.; Cao, Ya</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4050-4061</span>CODEN:
                <span class="NLM_cas:coden">THERDS</span>;
        ISSN:<span class="NLM_cas:issn">1838-7640</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">Hotspot mutations of isocitrate dehydrogenase 1 and 2 (IDH1/2) have been studied in several cancers.  However, the function of wild-type IDH2 in lung cancer and the mechanism of its contribution to growth of cancer cells remain unknown.  Here, we explored the role and mechanism of wild-type IDH2 in promoting growth of lung cancer.  Methods: Information regarding genomic and clin. application focusing on IDH2 in cancer was examd. in several databases of more than 1,000 tumor samples.  IDH2 expression was assessed by immunohistochem. in tissues from lung cancer patients.  The biol. functions of IDH2 were evaluated by using cell-based assays and in vivo xenograft mouse models.  Results: Here we reported that wild-type IDH2 is up-regulated and is an indicator of poor survival in lung cancer and several other cancers.  Targeting IDH2 with shRNA resulted in decreased HIF1Î± expression, leading to the attenuation of lung cancer cell proliferation and tumor growth.  Treatment of lung cancer cells with AGI-6780 (a small mol. inhibitor of IDH2), PX-478 (an inhibitor of HIF1Î±) or incubation with octyl-Î±-KG inhibited lung cancer cell proliferation.  Conclusion: IDH2 promotes the Warburg effect and lung cancer cell growth, which is mediated through HIF1Î± activation followed by decreased Î±-KG.  Therefore, IDH2 could possibly serve as a novel therapeutic target for lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcAS3iSfZ7H7Vg90H21EOLACvtfcHk0lhfM2r5cyiPFQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXivVSktbk%253D&md5=77a5d86857629b0e7efbc62369557e89</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.7150%2Fthno.21524&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.21524%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%2BJ.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DTan%26aufirst%3DZ.%2BQ.%26aulast%3DLu%26aufirst%3DJ.%2BC.%26aulast%3DLi%26aufirst%3DL.%2BL.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DF.%26aulast%3DXie%26aufirst%3DL.%2BL.%26aulast%3DYou%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DX.%2BJ.%26aulast%3DLi%26aufirst%3DN.%2BM.%26aulast%3DLi%26aufirst%3DY.%2BS.%26aulast%3DLiu%26aufirst%3DX.%2BL.%26aulast%3DTang%26aufirst%3DM.%26aulast%3DWeng%26aufirst%3DX.%2BX.%26aulast%3DYi%26aufirst%3DW.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DQiang%26aufirst%3DG.%26aulast%3DQiu%26aufirst%3DS.%2BJ.%26aulast%3DWu%26aufirst%3DW.%2BZ.%26aulast%3DBode%26aufirst%3DA.%2BM.%26aulast%3DCao%26aufirst%3DY.%26atitle%3DWild-type%2520IDH2%2520promotes%2520the%2520Warburg%2520effect%2520and%2520tumor%2520growth%2520through%2520HIF1%2520alpha%2520in%2520lung%2520cancer%26jtitle%3DTheranostics%26date%3D2018%26volume%3D8%26spage%3D4050%26epage%3D4061%26doi%3D10.7150%2Fthno.21524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stuani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poupin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosc, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saland, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gales, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montersino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turtoi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaoma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farge, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larrue, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baran, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loric, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouchel, P.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GotanÃ¨gre, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernando, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cognet, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zavoriti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosseini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boutzen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Futreal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu-Van, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cam, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selak, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vey, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calmettes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pigneux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bidet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellano, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenaille, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turtoi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cazals, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bories, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibon, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolay, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronseaux, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marszalek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiNardo, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konopleva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collette, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linares, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellvert, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jourdan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">RÃ©cher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portais, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarry, J.-E.</span></span> <span> </span><span class="NLM_article-title">Combinatory therapy targeting mitochondrial oxidative phosphorylation improves efficacy of IDH mutant inhibitors in acute myeloid leukemia</span>. <i>bioRxiv</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_fpage">749580</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&pages=749580&author=L.+Stuaniauthor=M.+Sabatierauthor=F.+Wangauthor=N.+Poupinauthor=C.+Boscauthor=E.+Salandauthor=F.+Castelliauthor=L.+Galesauthor=C.+Montersinoauthor=E.+Boetauthor=E.+Turtoiauthor=T.+Kaomaauthor=T.+Fargeauthor=N.+Broinauthor=C.+Larrueauthor=N.+Baranauthor=M.+Contiauthor=S.+Loricauthor=P.-L.+Mouchelauthor=M.+Gotan%C3%A8greauthor=C.+Cassanauthor=L.+Fernandoauthor=G.+Cognetauthor=A.+Zavoritiauthor=M.+Hosseiniauthor=H.+Boutzenauthor=K.+Moritaauthor=A.+Futrealauthor=E.+Chu-Vanauthor=L.+L.+Camauthor=M.+Carrollauthor=M.+A.+Selakauthor=N.+Veyauthor=C.+Calmettesauthor=A.+Pigneuxauthor=A.+Bidetauthor=R.+Castellanoauthor=F.+Fenailleauthor=A.+Turtoiauthor=G.+Cazalsauthor=P.+Boriesauthor=Y.+Gibonauthor=B.+Nicolayauthor=S.+Ronseauxauthor=J.+Marszalekauthor=C.+D.+DiNardoauthor=M.+Konoplevaauthor=Y.+Colletteauthor=L.+K.+Linaresauthor=F.+Bellvertauthor=F.+Jourdanauthor=K.+Takahashiauthor=C.+R%C3%A9cherauthor=J.-C.+Portaisauthor=J.-E.+Sarry&title=Combinatory+therapy+targeting+mitochondrial+oxidative+phosphorylation+improves+efficacy+of+IDH+mutant+inhibitors+in+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStuani%26aufirst%3DL.%26aulast%3DSabatier%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DPoupin%26aufirst%3DN.%26aulast%3DBosc%26aufirst%3DC.%26aulast%3DSaland%26aufirst%3DE.%26aulast%3DCastelli%26aufirst%3DF.%26aulast%3DGales%26aufirst%3DL.%26aulast%3DMontersino%26aufirst%3DC.%26aulast%3DBoet%26aufirst%3DE.%26aulast%3DTurtoi%26aufirst%3DE.%26aulast%3DKaoma%26aufirst%3DT.%26aulast%3DFarge%26aufirst%3DT.%26aulast%3DBroin%26aufirst%3DN.%26aulast%3DLarrue%26aufirst%3DC.%26aulast%3DBaran%26aufirst%3DN.%26aulast%3DConti%26aufirst%3DM.%26aulast%3DLoric%26aufirst%3DS.%26aulast%3DMouchel%26aufirst%3DP.-L.%26aulast%3DGotan%25C3%25A8gre%26aufirst%3DM.%26aulast%3DCassan%26aufirst%3DC.%26aulast%3DFernando%26aufirst%3DL.%26aulast%3DCognet%26aufirst%3DG.%26aulast%3DZavoriti%26aufirst%3DA.%26aulast%3DHosseini%26aufirst%3DM.%26aulast%3DBoutzen%26aufirst%3DH.%26aulast%3DMorita%26aufirst%3DK.%26aulast%3DFutreal%26aufirst%3DA.%26aulast%3DChu-Van%26aufirst%3DE.%26aulast%3DCam%26aufirst%3DL.%2BL.%26aulast%3DCarroll%26aufirst%3DM.%26aulast%3DSelak%26aufirst%3DM.%2BA.%26aulast%3DVey%26aufirst%3DN.%26aulast%3DCalmettes%26aufirst%3DC.%26aulast%3DPigneux%26aufirst%3DA.%26aulast%3DBidet%26aufirst%3DA.%26aulast%3DCastellano%26aufirst%3DR.%26aulast%3DFenaille%26aufirst%3DF.%26aulast%3DTurtoi%26aufirst%3DA.%26aulast%3DCazals%26aufirst%3DG.%26aulast%3DBories%26aufirst%3DP.%26aulast%3DGibon%26aufirst%3DY.%26aulast%3DNicolay%26aufirst%3DB.%26aulast%3DRonseaux%26aufirst%3DS.%26aulast%3DMarszalek%26aufirst%3DJ.%26aulast%3DDiNardo%26aufirst%3DC.%2BD.%26aulast%3DKonopleva%26aufirst%3DM.%26aulast%3DCollette%26aufirst%3DY.%26aulast%3DLinares%26aufirst%3DL.%2BK.%26aulast%3DBellvert%26aufirst%3DF.%26aulast%3DJourdan%26aufirst%3DF.%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DR%25C3%25A9cher%26aufirst%3DC.%26aulast%3DPortais%26aufirst%3DJ.-C.%26aulast%3DSarry%26aufirst%3DJ.-E.%26atitle%3DCombinatory%2520therapy%2520targeting%2520mitochondrial%2520oxidative%2520phosphorylation%2520improves%2520efficacy%2520of%2520IDH%2520mutant%2520inhibitors%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DbioRxiv%26date%3D2019%26spage%3D749580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemire, B. D.</span></span> <span> </span><span class="NLM_article-title">Evolution, structure and membrane association of NDUFAF6, an assembly factor for NADH:ubiquinone oxidoreductase (Complex I)</span>. <i>Mitochondrion</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">13</span>â <span class="NLM_lpage">22</span>, <span class="refDoi">Â DOI: 10.1016/j.mito.2017.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.mito.2017.04.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=28476317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnsV2lsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=13-22&author=B.+D.+Lemire&title=Evolution%2C+structure+and+membrane+association+of+NDUFAF6%2C+an+assembly+factor+for+NADH%3Aubiquinone+oxidoreductase+%28Complex+I%29&doi=10.1016%2Fj.mito.2017.04.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Evolution, structure and membrane association of NDUFAF6, an assembly factor for NADH:ubiquinone oxidoreductase (Complex I)</span></div><div class="casAuthors">Lemire, Bernard D.</div><div class="citationInfo"><span class="NLM_cas:title">Mitochondrion</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13-22</span>CODEN:
                <span class="NLM_cas:coden">MITOCN</span>;
        ISSN:<span class="NLM_cas:issn">1567-7249</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The NADH:ubiquinone oxidoreductase (complex I) is the largest member of the mitochondrial respiratory chain.  Its FMN cofactor accepts two electrons from NADH and transfers them to ubiquinone via a chain of iron-sulfur centers.  A central core of 14 highly conserved subunits can couple electron transfer to proton translocation.  The mammalian enzyme has an addnl. â¼ 30 accessory subunits.  Complex I has important bioenergetic and metabolic functions and is a known source of reactive oxygen species; these functions link it to a no. of hereditary and degenerative diseases.  For many complex I deficiencies, the primary defect is not in a subunit-encoding gene, but rather in an assembly factor or chaperone that participates in the biogenesis of newly synthesized complex I from individual subunits and cofactors.  NDUFAF6 encodes a complex I assembly factor and mutations result in complex I deficiency, Leigh syndrome or Acadian variant Fanconi syndrome.  Human NDUFAF6 is a mitochondria-targeted 333-amino acid protein belonging to the family of squalene and phytoene synthases.  Sequence and structural information suggests that NDUFAF6 likely has enzymic activity, but one that has evolved considerable differences from canonical squalene and phytoene synthases.  Most but not all metazoans have an NDUFAF6 ortholog, indicating that in some organisms, complex I biogenesis does not require this protein.  NDUFAF6 is a peripheral membrane protein and predictions identify a conserved C-terminal attachment site that have implications for substrate access.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOP81Q60izarVg90H21EOLACvtfcHk0ljsfqvwZXITOw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnsV2lsrg%253D&md5=e4eb126e106f9e01a81e17e7fad3c3a7</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.mito.2017.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mito.2017.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DLemire%26aufirst%3DB.%2BD.%26atitle%3DEvolution%252C%2520structure%2520and%2520membrane%2520association%2520of%2520NDUFAF6%252C%2520an%2520assembly%2520factor%2520for%2520NADH%253Aubiquinone%2520oxidoreductase%2520%2528Complex%2520I%2529%26jtitle%3DMitochondrion%26date%3D2017%26volume%3D35%26spage%3D13%26epage%3D22%26doi%3D10.1016%2Fj.mito.2017.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Minton, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayraktar, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sviderskiy, V. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papagiannakopoulos, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birsoy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Possemato, R.</span></span> <span> </span><span class="NLM_article-title">Serine catabolism by SHMT2 is required for proper mitochondrial translation initiation and maintenance of formylmethionyl-tRNAs</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">610</span>â <span class="NLM_lpage">621</span>, <span class="refDoi">Â DOI: 10.1016/j.molcel.2018.01.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.molcel.2018.01.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=29452640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFSgsLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2018&pages=610-621&author=D.+R.+Mintonauthor=M.+Namauthor=D.+J.+McLaughlinauthor=J.+Shinauthor=E.+C.+Bayraktarauthor=S.+W.+Alvarezauthor=V.+O.+Sviderskiyauthor=T.+Papagiannakopoulosauthor=D.+M.+Sabatiniauthor=K.+Birsoyauthor=R.+Possemato&title=Serine+catabolism+by+SHMT2+is+required+for+proper+mitochondrial+translation+initiation+and+maintenance+of+formylmethionyl-tRNAs&doi=10.1016%2Fj.molcel.2018.01.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Serine Catabolism by SHMT2 Is Required for Proper Mitochondrial Translation Initiation and Maintenance of Formylmethionyl-tRNAs</span></div><div class="casAuthors">Minton, Denise R.; Nam, Minwoo; McLaughlin, Daniel J.; Shin, Jong; Bayraktar, Erol C.; Alvarez, Samantha W.; Sviderskiy, Vladislav O.; Papagiannakopoulos, Thales; Sabatini, David M.; Birsoy, Kivanc; Possemato, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">610-621.e5</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Upon glucose restriction, eukaryotic cells upregulate oxidative metab. to maintain homeostasis.  Using genetic screens, we find that the mitochondrial serine hydroxymethyltransferase (SHMT2) is required for robust mitochondrial oxygen consumption and low glucose proliferation.  SHMT2 catalyzes the first step in mitochondrial one-carbon metab., which, particularly in proliferating cells, produces tetrahydrofolate (THF)-conjugated one-carbon units used in cytoplasmic reactions despite the presence of a parallel cytoplasmic pathway.  Impairing cytoplasmic one-carbon metab. or blocking efflux of one-carbon units from mitochondria does not phenocopy SHMT2 loss, indicating that a mitochondrial THF cofactor is responsible for the obsd. phenotype.  The enzyme MTFMT utilizes one such cofactor, 10-formyl THF, producing formylmethionyl-tRNAs, specialized initiator tRNAs necessary for proper translation of mitochondrially encoded proteins.  Accordingly, SHMT2 null cells specifically fail to maintain formylmethionyl-tRNA pools and mitochondrially encoded proteins, phenotypes similar to those obsd. in MTFMT-deficient patients.  These findings provide a rationale for maintaining a compartmentalized one-carbon pathway in mitochondria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_Rpzyr03vWbVg90H21EOLACvtfcHk0ljsfqvwZXITOw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFSgsLY%253D&md5=398878e531d48c7ee4e01fc9be9e05d6</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2018.01.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2018.01.024%26sid%3Dliteratum%253Aachs%26aulast%3DMinton%26aufirst%3DD.%2BR.%26aulast%3DNam%26aufirst%3DM.%26aulast%3DMcLaughlin%26aufirst%3DD.%2BJ.%26aulast%3DShin%26aufirst%3DJ.%26aulast%3DBayraktar%26aufirst%3DE.%2BC.%26aulast%3DAlvarez%26aufirst%3DS.%2BW.%26aulast%3DSviderskiy%26aufirst%3DV.%2BO.%26aulast%3DPapagiannakopoulos%26aufirst%3DT.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26aulast%3DBirsoy%26aufirst%3DK.%26aulast%3DPossemato%26aufirst%3DR.%26atitle%3DSerine%2520catabolism%2520by%2520SHMT2%2520is%2520required%2520for%2520proper%2520mitochondrial%2520translation%2520initiation%2520and%2520maintenance%2520of%2520formylmethionyl-tRNAs%26jtitle%3DMol.%2520Cell%26date%3D2018%26volume%3D69%26spage%3D610%26epage%3D621%26doi%3D10.1016%2Fj.molcel.2018.01.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morscher, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ducker, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S. H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gitai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabinowitz, J. D.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial translation requires folate-dependent tRNA methylation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>554</i></span>,  <span class="NLM_fpage">128</span>â <span class="NLM_lpage">132</span>, <span class="refDoi">Â DOI: 10.1038/nature25460</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fnature25460" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=29364879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs12gsL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=554&publication_year=2018&pages=128-132&author=R.+J.+Morscherauthor=G.+S.+Duckerauthor=S.+H.+J.+Liauthor=J.+A.+Mayerauthor=Z.+Gitaiauthor=W.+Sperlauthor=J.+D.+Rabinowitz&title=Mitochondrial+translation+requires+folate-dependent+tRNA+methylation&doi=10.1038%2Fnature25460"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial translation requires folate-dependent tRNA methylation</span></div><div class="casAuthors">Morscher, Raphael J.; Ducker, Gregory S.; Li, Sophia Hsin-Jung; Mayer, Johannes A.; Gitai, Zemer; Sperl, Wolfgang; Rabinowitz, Joshua D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">554</span>
        (<span class="NLM_cas:issue">7690</span>),
    <span class="NLM_cas:pages">128-132</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Folates enable the activation and transfer of one-carbon units for the biosynthesis of purines, thymidine and methionine.  Antifolates are important immunosuppressive and anticancer agents.  In proliferating lymphocytes and human cancers, mitochondrial folate enzymes are particularly strongly upregulated.  This in part reflects the need for mitochondria to generate one-carbon units and export them to the cytosol for anabolic metab.  The full range of uses of folate-bound one-carbon units in the mitochondrial compartment itself, however, has not been thoroughly explored.  Here we show that loss of the catalytic activity of the mitochondrial folate enzyme serine hydroxymethyltransferase 2 (SHMT2), but not of other folate enzymes, leads to defective oxidative phosphorylation in human cells due to impaired mitochondrial translation.  We find that SHMT2, presumably by generating mitochondrial 5,10-methylenetetrahydrofolate, provides Me donors to produce the taurinomethyluridine base at the wobble position of select mitochondrial tRNAs.  Mitochondrial ribosome profiling in SHMT2-knockout human cells reveals that the lack of this modified base causes defective translation, with preferential mitochondrial ribosome stalling at certain lysine (AAG) and leucine (UUG) codons.  This results in the impaired expression of respiratory chain enzymes.  Stalling at these specific codons also occurs in certain inborn errors of mitochondrial metab.  Disruption of whole-cell folate metab., by either folate deficiency or antifolate treatment, also impairs the respiratory chain.  In summary, mammalian mitochondria use folate-bound one-carbon units to methylate tRNA, and this modification is required for mitochondrial translation and thus oxidative phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWhflym_kZO7Vg90H21EOLACvtfcHk0lhBgVu2zvsFiA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs12gsL0%253D&md5=6e198c91d31fb19fcec7b53a569fd109</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1038%2Fnature25460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature25460%26sid%3Dliteratum%253Aachs%26aulast%3DMorscher%26aufirst%3DR.%2BJ.%26aulast%3DDucker%26aufirst%3DG.%2BS.%26aulast%3DLi%26aufirst%3DS.%2BH.%2BJ.%26aulast%3DMayer%26aufirst%3DJ.%2BA.%26aulast%3DGitai%26aufirst%3DZ.%26aulast%3DSperl%26aufirst%3DW.%26aulast%3DRabinowitz%26aufirst%3DJ.%2BD.%26atitle%3DMitochondrial%2520translation%2520requires%2520folate-dependent%2520tRNA%2520methylation%26jtitle%3DNature%26date%3D2018%26volume%3D554%26spage%3D128%26epage%3D132%26doi%3D10.1038%2Fnature25460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez-Fonseca, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navas-Enamorado, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos-Ocana, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez-Camacho, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerra, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascajo, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Cuesta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horvath, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siendones, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casado, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez-Rios, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brea-Calvo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Lluch, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Ayala, D. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Aguilera, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matte, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prieto-Soler, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez-del-Toro, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">di Francesco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aon, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salviati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artuch, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Cabo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navas, P.</span></span> <span> </span><span class="NLM_article-title">ADCK2 haploinsufficiency reduces mitochondrial lipid oxidation and causes myopathy associated with CoQ deficiency</span>. <i>J. Clin. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1374</span>, <span class="refDoi">Â DOI: 10.3390/jcm8091374</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.3390%2Fjcm8091374" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2019&pages=1374&author=L.+Vazquez-Fonsecaauthor=J.+Schaferauthor=I.+Navas-Enamoradoauthor=C.+Santos-Ocanaauthor=J.+D.+Hernandez-Camachoauthor=I.+Guerraauthor=M.+V.+Cascajoauthor=A.+Sanchez-Cuestaauthor=Z.+Horvathauthor=E.+Siendonesauthor=C.+Jouauthor=M.+Casadoauthor=P.+Gutierrez-Riosauthor=G.+Brea-Calvoauthor=G.+Lopez-Lluchauthor=D.+J.+M.+Fernandez-Ayalaauthor=A.+B.+Cortesauthor=J.+C.+Rodriguez-Aguileraauthor=C.+Matteauthor=A.+Ribesauthor=S.+Y.+Prieto-Solerauthor=E.+Dominguez-del-Toroauthor=A.+di+Francescoauthor=M.+A.+Aonauthor=M.+Bernierauthor=L.+Salviatiauthor=R.+Artuchauthor=R.+de+Caboauthor=S.+Jacksonauthor=P.+Navas&title=ADCK2+haploinsufficiency+reduces+mitochondrial+lipid+oxidation+and+causes+myopathy+associated+with+CoQ+deficiency&doi=10.3390%2Fjcm8091374"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.3390%2Fjcm8091374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fjcm8091374%26sid%3Dliteratum%253Aachs%26aulast%3DVazquez-Fonseca%26aufirst%3DL.%26aulast%3DSchafer%26aufirst%3DJ.%26aulast%3DNavas-Enamorado%26aufirst%3DI.%26aulast%3DSantos-Ocana%26aufirst%3DC.%26aulast%3DHernandez-Camacho%26aufirst%3DJ.%2BD.%26aulast%3DGuerra%26aufirst%3DI.%26aulast%3DCascajo%26aufirst%3DM.%2BV.%26aulast%3DSanchez-Cuesta%26aufirst%3DA.%26aulast%3DHorvath%26aufirst%3DZ.%26aulast%3DSiendones%26aufirst%3DE.%26aulast%3DJou%26aufirst%3DC.%26aulast%3DCasado%26aufirst%3DM.%26aulast%3DGutierrez-Rios%26aufirst%3DP.%26aulast%3DBrea-Calvo%26aufirst%3DG.%26aulast%3DLopez-Lluch%26aufirst%3DG.%26aulast%3DFernandez-Ayala%26aufirst%3DD.%2BJ.%2BM.%26aulast%3DCortes%26aufirst%3DA.%2BB.%26aulast%3DRodriguez-Aguilera%26aufirst%3DJ.%2BC.%26aulast%3DMatte%26aufirst%3DC.%26aulast%3DRibes%26aufirst%3DA.%26aulast%3DPrieto-Soler%26aufirst%3DS.%2BY.%26aulast%3DDominguez-del-Toro%26aufirst%3DE.%26aulast%3Ddi%2BFrancesco%26aufirst%3DA.%26aulast%3DAon%26aufirst%3DM.%2BA.%26aulast%3DBernier%26aufirst%3DM.%26aulast%3DSalviati%26aufirst%3DL.%26aulast%3DArtuch%26aufirst%3DR.%26aulast%3Dde%2BCabo%26aufirst%3DR.%26aulast%3DJackson%26aufirst%3DS.%26aulast%3DNavas%26aufirst%3DP.%26atitle%3DADCK2%2520haploinsufficiency%2520reduces%2520mitochondrial%2520lipid%2520oxidation%2520and%2520causes%2520myopathy%2520associated%2520with%2520CoQ%2520deficiency%26jtitle%3DJ.%2520Clin.%2520Med.%26date%3D2019%26volume%3D8%26spage%3D1374%26doi%3D10.3390%2Fjcm8091374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thiriet, M.</span></span> <span> </span><span class="NLM_article-title">Protein Kinase Classification</span>. In  <i>Intracellular signaling mediators in the circulatory and ventilatory systems</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiriet, M.</span></span>, Ed.; <span class="NLM_publisher-name">Springer International Publishing</span>: <span class="NLM_publisher-loc">Cham</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=M.+Thirietauthor=M.+Thiriet&title=Intracellular+signaling+mediators+in+the+circulatory+and+ventilatory+systems"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DThiriet%26aufirst%3DM.%26atitle%3DProtein%2520Kinase%2520Classification%26btitle%3DIntracellular%2520signaling%2520mediators%2520in%2520the%2520circulatory%2520and%2520ventilatory%2520systems%26aulast%3DThiriet%26aufirst%3DM.%26pub%3DSpringer%2520International%2520Publishing%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattarai, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schram, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielski, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donoghue, M. T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonsson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravarty, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kandoth, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorelick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shamu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumer, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kundra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Razavi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reales, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Socci, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayakumaran, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zehir, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benayed, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandarlapaty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, B. S.</span></span> <span> </span><span class="NLM_article-title">Accelerating discovery of functional mutant alleles in cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">174</span>â <span class="NLM_lpage">183</span>, <span class="refDoi">Â DOI: 10.1158/2159-8290.CD-17-0321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F2159-8290.CD-17-0321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=29247016" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFCrt7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=174-183&author=M.+T.+Changauthor=T.+S.+Bhattaraiauthor=A.+M.+Schramauthor=C.+M.+Bielskiauthor=M.+T.+A.+Donoghueauthor=P.+Jonssonauthor=D.+Chakravartyauthor=S.+Phillipsauthor=C.+Kandothauthor=A.+Pensonauthor=A.+Gorelickauthor=T.+Shamuauthor=S.+Patelauthor=C.+Harrisauthor=J.+Gaoauthor=S.+O.+Sumerauthor=R.+Kundraauthor=P.+Razaviauthor=B.+T.+Liauthor=D.+N.+Realesauthor=N.+D.+Socciauthor=G.+Jayakumaranauthor=A.+Zehirauthor=R.+Benayedauthor=M.+E.+Arcilaauthor=S.+Chandarlapatyauthor=M.+Ladanyiauthor=N.+Schultzauthor=J.+Baselgaauthor=M.+F.+Bergerauthor=N.+Rosenauthor=D.+B.+Solitauthor=D.+M.+Hymanauthor=B.+S.+Taylor&title=Accelerating+discovery+of+functional+mutant+alleles+in+cancer&doi=10.1158%2F2159-8290.CD-17-0321"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Accelerating Discovery of Functional Mutant Alleles in Cancer</span></div><div class="casAuthors">Chang, Matthew T.; Bhattarai, Tripti Shrestha; Schram, Alison M.; Bielski, Craig M.; Donoghue, Mark T. A.; Jonsson, Philip; Chakravarty, Debyani; Phillips, Sarah; Kandoth, Cyriac; Penson, Alexander; Gorelick, Alexander; Shamu, Tambudzai; Patel, Swati; Harris, Christopher; Gao, Jian Jiong; Sumer, Selcuk Onur; Kundra, Ritika; Razavi, Pedram; Li, Bob T.; Reales, Dalicia N.; Socci, Nicholas D.; Jayakumaran, Gowtham; Zehir, Ahmet; Benayed, Ryma; Arcila, Maria E.; Chandarlapaty, Sarat; Ladanyi, Marc; Schultz, Nikolaus; Baselga, Jose; Berger, Michael F.; Rosen, Neal; Solit, David B.; Hyman, David M.; Taylor, Barry S.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">174-183</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Most mutations in cancer are rare, which complicates the identification of therapeutically significant mutations and thus limits the clin. impact of genomic profiling in patients with cancer.  Here, we analyzed 24,592 cancers including 10,336 prospectively sequenced patients with advanced disease to identify mutant residues arising more frequently than expected in the absence of selection.  We identified 1,165 statistically significant hotspot mutations of which 80% arose in 1 in 1,000 or fewer patients.  Of 55 recurrent in-frame indels, we validated that novel AKT1 duplications induced pathway hyperactivation and conferred AKT inhibitor sensitivity.  Cancer genes exhibit different rates of hotspot discovery with increasing sample size, with few approaching satn.  Consequently, 26% of all hotspots in therapeutically actionable oncogenes were novel.  Upon matching a subset of affected patients directly to molecularly targeted therapy, we obsd. radiog. and clin. responses.  Population-scale mutant allele discovery illustrates how the identification of driver mutations in cancer is far from complete.  Our systematic computational, exptl., and clin. anal. of hotspot mutations in approx. 25,000 human cancers demonstrates that the long right tail of biol. and therapeutically significant mutant alleles is still incompletely characterized.  Sharing prospective genomic data will accelerate hotspot identification, thereby expanding the reach of precision oncol. in patients with cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyHExer4GLcbVg90H21EOLACvtfcHk0lg2SgjISACbxQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFCrt7o%253D&md5=691bbfdf71137fa95192b2cbbd3e5fec</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-17-0321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-17-0321%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DM.%2BT.%26aulast%3DBhattarai%26aufirst%3DT.%2BS.%26aulast%3DSchram%26aufirst%3DA.%2BM.%26aulast%3DBielski%26aufirst%3DC.%2BM.%26aulast%3DDonoghue%26aufirst%3DM.%2BT.%2BA.%26aulast%3DJonsson%26aufirst%3DP.%26aulast%3DChakravarty%26aufirst%3DD.%26aulast%3DPhillips%26aufirst%3DS.%26aulast%3DKandoth%26aufirst%3DC.%26aulast%3DPenson%26aufirst%3DA.%26aulast%3DGorelick%26aufirst%3DA.%26aulast%3DShamu%26aufirst%3DT.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DHarris%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DSumer%26aufirst%3DS.%2BO.%26aulast%3DKundra%26aufirst%3DR.%26aulast%3DRazavi%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DB.%2BT.%26aulast%3DReales%26aufirst%3DD.%2BN.%26aulast%3DSocci%26aufirst%3DN.%2BD.%26aulast%3DJayakumaran%26aufirst%3DG.%26aulast%3DZehir%26aufirst%3DA.%26aulast%3DBenayed%26aufirst%3DR.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DChandarlapaty%26aufirst%3DS.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DSchultz%26aufirst%3DN.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DBerger%26aufirst%3DM.%2BF.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26aulast%3DHyman%26aufirst%3DD.%2BM.%26aulast%3DTaylor%26aufirst%3DB.%2BS.%26atitle%3DAccelerating%2520discovery%2520of%2520functional%2520mutant%2520alleles%2520in%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2018%26volume%3D8%26spage%3D174%26epage%3D183%26doi%3D10.1158%2F2159-8290.CD-17-0321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nussinov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, F.</span></span> <span> </span><span class="NLM_article-title">Review: Precision medicine and driver mutations: computational methods, functional assays and conformational principles for interpreting cancer drivers</span>. <i>PLoS Comput. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">e1006658</span>, <span class="refDoi">Â DOI: 10.1371/journal.pcbi.1006658</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1371%2Fjournal.pcbi.1006658" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=30921324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVSis7fK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=e1006658&author=R.+Nussinovauthor=H.+Jangauthor=C.+J.+Tsaiauthor=F.+Cheng&title=Review%3A+Precision+medicine+and+driver+mutations%3A+computational+methods%2C+functional+assays+and+conformational+principles+for+interpreting+cancer+drivers&doi=10.1371%2Fjournal.pcbi.1006658"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Review: precision medicine and driver mutations: computational methods, functional assays and conformational principles for interpreting cancer drivers</span></div><div class="casAuthors">Nussinov, Ruth; Jang, Hyunbum; Tsai, Chung-Jung; Cheng, Feixiong</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Computational Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e1006658/1-e1006658/54</span>CODEN:
                <span class="NLM_cas:coden">PCBLBG</span>;
        ISSN:<span class="NLM_cas:issn">1553-7358</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">At the root of the so-called precision medicine or precision oncol., which is our focus here, is the hypothesis that cancer treatment would be considerably better if therapies were guided by a tumor's genomic alterations.  This hypothesis has sparked major initiatives focusing on whole-genome and/or exome sequencing, creation of large databases, and developing tools for their statistical analyses-all aspiring to identify actionable alterations, and thus mol. targets, in a patient.  At the center of the massive amt. of collected sequence data is their interpretations that largely rest on statistical anal. and phenotypic observations.  Statistics is vital, because it guides identification of cancer-driving alterations.  However, statistics of mutations do not identify a change in protein conformation; therefore, it may not define sufficiently accurate actionable mutations, neglecting those that are rare.  Among the many thematic overviews of precision oncol., this review innovates by further comprehensively including precision pharmacol., and within this framework, articulating its protein structural landscape and consequences to cellular signaling pathways.  It provides the underlying physicochem. basis, thereby also opening the door to a broader community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0IoAh4ESb5rVg90H21EOLACvtfcHk0lg2SgjISACbxQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVSis7fK&md5=dee7b00c4bfff0f6f5cd9d7d203a5a63</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.1006658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.1006658%26sid%3Dliteratum%253Aachs%26aulast%3DNussinov%26aufirst%3DR.%26aulast%3DJang%26aufirst%3DH.%26aulast%3DTsai%26aufirst%3DC.%2BJ.%26aulast%3DCheng%26aufirst%3DF.%26atitle%3DReview%253A%2520Precision%2520medicine%2520and%2520driver%2520mutations%253A%2520computational%2520methods%252C%2520functional%2520assays%2520and%2520conformational%2520principles%2520for%2520interpreting%2520cancer%2520drivers%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2019%26volume%3D15%26spage%3De1006658%26doi%3D10.1371%2Fjournal.pcbi.1006658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mardis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanton, C.</span></span> <span> </span><span class="NLM_article-title">Prioritizing targets for precision cancer medicine</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">2295</span>â <span class="NLM_lpage">2303</span>, <span class="refDoi">Â DOI: 10.1093/annonc/mdu478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1093%2Fannonc%2Fmdu478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=25344359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BC2M3jtFCqtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=2295-2303&author=F.+Andreauthor=E.+Mardisauthor=M.+Salmauthor=J.+C.+Soriaauthor=L.+L.+Siuauthor=C.+Swanton&title=Prioritizing+targets+for+precision+cancer+medicine&doi=10.1093%2Fannonc%2Fmdu478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Prioritizing targets for precision cancer medicine</span></div><div class="casAuthors">Andre F; Mardis E; Salm M; Soria J-C; Siu L L; Swanton C</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2295-2303</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The implementation of cancer genomic testing into the clinical setting has brought major opportunities.  However, as our understanding of cancer initiation, maintenance and progression improves through detailed cancer genomic studies, the challenges associated with driver identification and target classification in the clinical setting become clearer.  Here, we review recent insights into cancer genomic testing in the clinical setting, and suggest a target classification approach that considers the levels of evidence supporting the prioritization of tumour drivers for therapeutic targeting in light of complex cancer clonal and sub-clonal structures and clinical successes and failures in the field.  We argue that such classification approaches, together with transparent reporting of both positive and negative clinical data and continued research to identify the sub-clonal dynamics of driver events during the disease course, will facilitate inter-trial comparisons, optimize patient informed consent and provide a critically balanced evaluation of genomic testing in clinical practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSgOUn0MkqMAPIW7hznt0zpfW6udTcc2ebS-C6e5_-ErLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M3jtFCqtw%253D%253D&md5=8eb716308c603785f18bf9c2430ed0af</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdu478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdu478%26sid%3Dliteratum%253Aachs%26aulast%3DAndre%26aufirst%3DF.%26aulast%3DMardis%26aufirst%3DE.%26aulast%3DSalm%26aufirst%3DM.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DSiu%26aufirst%3DL.%2BL.%26aulast%3DSwanton%26aufirst%3DC.%26atitle%3DPrioritizing%2520targets%2520for%2520precision%2520cancer%2520medicine%26jtitle%3DAnn.%2520Oncol.%26date%3D2014%26volume%3D25%26spage%3D2295%26epage%3D2303%26doi%3D10.1093%2Fannonc%2Fmdu478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grossman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heath, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferretti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varmus, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowy, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kibbe, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudt, L. M.</span></span> <span> </span><span class="NLM_article-title">Toward a shared vision for cancer genomic data</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>375</i></span>,  <span class="NLM_fpage">1109</span>â <span class="NLM_lpage">1112</span>, <span class="refDoi">Â DOI: 10.1056/NEJMp1607591</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1056%2FNEJMp1607591" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27653561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BC2svivFyntg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2016&pages=1109-1112&author=R.+L.+Grossmanauthor=A.+P.+Heathauthor=V.+Ferrettiauthor=H.+E.+Varmusauthor=D.+R.+Lowyauthor=W.+A.+Kibbeauthor=L.+M.+Staudt&title=Toward+a+shared+vision+for+cancer+genomic+data&doi=10.1056%2FNEJMp1607591"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Toward a Shared Vision for Cancer Genomic Data</span></div><div class="casAuthors">Grossman Robert L; Heath Allison P; Ferretti Vincent; Varmus Harold E; Lowy Douglas R; Kibbe Warren A; Staudt Louis M</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1109-12</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRZwIDiaUsY2DQLBVDQn4bCfW6udTcc2ebS-C6e5_-ErLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svivFyntg%253D%253D&md5=2a6eebabdf4e7c5b1efea3eb6ab49a5a</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1056%2FNEJMp1607591&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMp1607591%26sid%3Dliteratum%253Aachs%26aulast%3DGrossman%26aufirst%3DR.%2BL.%26aulast%3DHeath%26aufirst%3DA.%2BP.%26aulast%3DFerretti%26aufirst%3DV.%26aulast%3DVarmus%26aufirst%3DH.%2BE.%26aulast%3DLowy%26aufirst%3DD.%2BR.%26aulast%3DKibbe%26aufirst%3DW.%2BA.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26atitle%3DToward%2520a%2520shared%2520vision%2520for%2520cancer%2520genomic%2520data%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D375%26spage%3D1109%26epage%3D1112%26doi%3D10.1056%2FNEJMp1607591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mayakonda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assenov, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plass, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeffler, H. P.</span></span> <span> </span><span class="NLM_article-title">Maftools: efficient and comprehensive analysis of somatic variants in cancer</span>. <i>Genome Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1747</span>â <span class="NLM_lpage">1756</span>, <span class="refDoi">Â DOI: 10.1101/gr.239244.118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1101%2Fgr.239244.118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=30341162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXis1Shtb7M" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=1747-1756&author=A.+Mayakondaauthor=D.+C.+Linauthor=Y.+Assenovauthor=C.+Plassauthor=H.+P.+Koeffler&title=Maftools%3A+efficient+and+comprehensive+analysis+of+somatic+variants+in+cancer&doi=10.1101%2Fgr.239244.118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Maftools: efficient and comprehensive analysis of somatic variants in cancer</span></div><div class="casAuthors">Mayakonda, Anand; Lin, De-Chen; Assenov, Yassen; Plass, Christoph; Koeffler, H. Phillip</div><div class="citationInfo"><span class="NLM_cas:title">Genome Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1747-1756</span>CODEN:
                <span class="NLM_cas:coden">GEREFS</span>;
        ISSN:<span class="NLM_cas:issn">1088-9051</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">Numerous large-scale genomic studies of matched tumor-normal samples have established the somatic landscapes of most cancer types.  However, the downstream anal. of data from somatic mutations entails a no. of computational and statistical approaches, requiring usage of independent software and numerous tools.  Here, we describe an R Bioconductor package, Maftools, which offers a multitude of anal. and visualization modules that are commonly used in cancer genomic studies, including driver gene identification, pathway, signature, enrichment, and assocn. analyses.  Maftools only requires somatic variants in Mutation Annotation Format (MAF) and is independent of larger alignment files.  With the implementation of well-established statistical and computational methods, Maftools facilitates data-driven research and comparative anal. to discover novel results from publicly available data sets.  In the present study, using three of the well-annotated cohorts from The Cancer Genome Atlas (TCGA), we describe the application of Maftools to reproduce known results.  More importantly, we show that Maftools can also be used to uncover novel findings through integrative anal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW6Xk7CGN1L7Vg90H21EOLACvtfcHk0liqCozeEbyteA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXis1Shtb7M&md5=d9558d907292c3fee17f3ff49735005b</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1101%2Fgr.239244.118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgr.239244.118%26sid%3Dliteratum%253Aachs%26aulast%3DMayakonda%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DD.%2BC.%26aulast%3DAssenov%26aufirst%3DY.%26aulast%3DPlass%26aufirst%3DC.%26aulast%3DKoeffler%26aufirst%3DH.%2BP.%26atitle%3DMaftools%253A%2520efficient%2520and%2520comprehensive%2520analysis%2520of%2520somatic%2520variants%2520in%2520cancer%26jtitle%3DGenome%2520Res.%26date%3D2018%26volume%3D28%26spage%3D1747%26epage%3D1756%26doi%3D10.1101%2Fgr.239244.118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waitkus, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diplas, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, H.</span></span> <span> </span><span class="NLM_article-title">Biological role and therapeutic potential of IDH mutations in cancer</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">186</span>â <span class="NLM_lpage">195</span>, <span class="refDoi">Â DOI: 10.1016/j.ccell.2018.04.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.ccell.2018.04.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=29805076" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVajurbL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2018&pages=186-195&author=M.+S.+Waitkusauthor=B.+H.+Diplasauthor=H.+Yan&title=Biological+role+and+therapeutic+potential+of+IDH+mutations+in+cancer&doi=10.1016%2Fj.ccell.2018.04.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Biological Role and Therapeutic Potential of IDH Mutations in Cancer</span></div><div class="casAuthors">Waitkus, Matthew S.; Diplas, Bill H.; Yan, Hai</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">186-195</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Hotspot mutations in isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) occur in a variety of myeloid malignancies and solid tumors.  Mutant IDH proteins acquire a neomorphic enzyme activity to produce the putative oncometabolite D-2-hydroxyglutarate, which is thought to block cellular differentiation by competitively inhibiting Î±-ketoglutarate-dependent dioxygenases involved in histone and DNA demethylation.  Small-mol. inhibitors of mutant IDH1 and IDH2 have been developed and are progressing through pre-clin. and clin. development.  In this review, we provide an overview of mutant IDH-targeted therapy and discuss a no. of important recent pre-clin. studies using models of IDH-mutant solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2Xkgqc-UL3rVg90H21EOLACvtfcHk0liqCozeEbyteA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVajurbL&md5=fb4231473619c7e1e62465e1a08ed2a9</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2018.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2018.04.011%26sid%3Dliteratum%253Aachs%26aulast%3DWaitkus%26aufirst%3DM.%2BS.%26aulast%3DDiplas%26aufirst%3DB.%2BH.%26aulast%3DYan%26aufirst%3DH.%26atitle%3DBiological%2520role%2520and%2520therapeutic%2520potential%2520of%2520IDH%2520mutations%2520in%2520cancer%26jtitle%3DCancer%2520Cell%26date%3D2018%26volume%3D34%26spage%3D186%26epage%3D195%26doi%3D10.1016%2Fj.ccell.2018.04.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span> <span> </span><span class="NLM_article-title">IDH1/2 gene hotspot mutations in central nervous system tumours: analysis of 922 Chinese patients</span>. <i>Pathology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">675</span>â <span class="NLM_lpage">683</span>, <span class="refDoi">Â DOI: 10.1016/j.pathol.2016.07.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.pathol.2016.07.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27780605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslCktbfN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2016&pages=675-683&author=N.+Chenauthor=T.+Yuauthor=J.+Gongauthor=L.+Nieauthor=X.+Chenauthor=M.+Zhangauthor=M.+Xuauthor=J.+Tanauthor=Z.+Suauthor=J.+Zhongauthor=Q.+Zhou&title=IDH1%2F2+gene+hotspot+mutations+in+central+nervous+system+tumours%3A+analysis+of+922+Chinese+patients&doi=10.1016%2Fj.pathol.2016.07.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">IDH1/2 gene hotspot mutations in central nervous system tumours: analysis of 922 Chinese patients</span></div><div class="casAuthors">Chen, Ni; Yu, Tianpin; Gong, Jing; Nie, Ling; Chen, Xueqin; Zhang, Mengni; Xu, Miao; Tan, Junya; Su, Zhengzheng; Zhong, Jinjing; Zhou, Qiao</div><div class="citationInfo"><span class="NLM_cas:title">Pathology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">675-683</span>CODEN:
                <span class="NLM_cas:coden">PTLGAX</span>;
        ISSN:<span class="NLM_cas:issn">0031-3025</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Mutations of isocitrate dehydrogenase 1 (IDH1) or 2 (IDH2) genes have been identified as early mol. events in the development of astrocytomas and oligodendrogliomas.  Data regarding the status and prevalence of IDH1/2 mutations in Chinese patients are limited.  Herein we report our data from West China Hospital, a major Chinese medical center.  IDH1(R132H) mutation was analyzed by immunohistochem. with the mutation-specific IDH1(R132H) antibody in 1011 patients, including 922 central nervous system (CNS) tumors and 89 non-neoplastic CNS lesions, and PCR-based direct sequencing of IDH1/2 gene mutation in 570 of these samples.  Correlation with clinicopathol. features and immunohistochem. expression of p53, EGFR, PTEN and Ki-67 was examd.  Our data showed that IDH1/2 mutation was present in oligodendrogliomas, anaplastic oligodendrogliomas, diffuse or anaplastic astrocytomas, and glioblastomas, with decreasing frequency, but not in other types of CNS tumors or non-neoplastic lesions examd.  IDH1(R132) mutation was most frequent in oligodendrogliomas (57/62, 91.9%), with IDH1(R132H) mutation as the most frequent mutation form.  Only one case for each of the rare mutations (R132C, R132G, R132L, and R132S) was identified in the 570 samples analyzed by sequencing.  Younger age, low expression of p53 and low Ki-67 index were significantly correlated with IDH1 mutation status (p = 0.000).  All tumors with IDH1(R132) mutations were supratentorial, with frontal lobe as the most frequent site for IDH-mutated gliomas.  Only three IDH2(R172) mutation cases were detected in this series.  Univariate survival anal. in 459 glioma patients with diffusely infiltrating gliomas showed that IDH1 mutations as well as the more classical prognosticators (age, WHO grade, p53 and Ki-67 index) were of prognostic significance.  Multivariate anal. by Cox proportional hazard regression model demonstrated that lack of IDH1 mutation was an independent prognostic factor for both progression-free survival [relative risk (RR) = 2.450, 95% confidence interval (CI) = 1.351-4.444] and disease-specific survival (RR = 2.489, 95%CI = 1.155-5.363).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVf-nMldO1ErVg90H21EOLACvtfcHk0liqCozeEbyteA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslCktbfN&md5=a23346fd7e351f1444a9d3e58ce3884e</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2Fj.pathol.2016.07.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pathol.2016.07.010%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DN.%26aulast%3DYu%26aufirst%3DT.%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DNie%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DZ.%26aulast%3DZhong%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DQ.%26atitle%3DIDH1%252F2%2520gene%2520hotspot%2520mutations%2520in%2520central%2520nervous%2520system%2520tumours%253A%2520analysis%2520of%2520922%2520Chinese%2520patients%26jtitle%3DPathology%26date%3D2016%26volume%3D48%26spage%3D675%26epage%3D683%26doi%3D10.1016%2Fj.pathol.2016.07.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rocken, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behrens, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruger, S.</span></span> <span> </span><span class="NLM_article-title">Clinicopathological characteristics of RHOA mutations in a Central European gastric cancer cohort</span>. <i>J. Clin. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">70</span>â <span class="NLM_lpage">75</span>, <span class="refDoi">Â DOI: 10.1136/jclinpath-2015-202980</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1136%2Fjclinpath-2015-202980" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=26251521" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BC287gsFOisg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2016&pages=70-75&author=C.+Rockenauthor=H.+M.+Behrensauthor=C.+Bogerauthor=S.+Kruger&title=Clinicopathological+characteristics+of+RHOA+mutations+in+a+Central+European+gastric+cancer+cohort&doi=10.1136%2Fjclinpath-2015-202980"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Clinicopathological characteristics of RHOA mutations in a Central European gastric cancer cohort</span></div><div class="casAuthors">Rocken Christoph; Behrens Hans-Michael; Boger Christine; Kruger Sandra</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical pathology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">70-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Genomically stable gastric cancers (GCs) are enriched for the diffuse phenotype and hotspot mutations of RHOA.  Here we aimed to validate the occurrence, phenotype and clinicopathological characteristics of RHOA mutant GCs in an independent Central European GC cohort consisting of 415 patients.  The RHOA genotype (exon 2 and 3) was correlated with various genotypic, phenotypic and clinicopathological patient characteristics.  Sixteen (3.9%) tumours had a RHOA mutation including four hitherto unreported mutations, that is, p.G17Efs*24, p.V24F, p.T37A and p.L69R.  RHOA mutation was more prevalent in women (5.4% vs 2.8%), distal GCs (4.5% vs 2.4%), in poorly differentiated GCs (G3/G4; 4.8% vs 1.1%), T1/T2 tumours (6.2% vs 3.1%) and lacked distant metastases.  Nine RHOA mutant GCs had a diffuse, four an intestinal, two an unclassified and one a mixed Lauren phenotype.  KRAS and RHOA mutations were mutually exclusive.  A single case showed both a RHOA and a PIK3CA mutation.  No significant difference was found in the overall survival between RHOA mutant and wildtype GCs.  Our study confirms the occurrence and clinicopathological characteristics of RHOA hotspot mutations in an independent patient cohort.  However, we found no evidence for a prognostic or growth advantageous effect of RHOA mutations in GC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSi9f53xe7BppggzHGM8X5CfW6udTcc2eY7_SJ0UGIkDbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287gsFOisg%253D%253D&md5=12238bc396771b8eaa8ac65043ae7b5b</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1136%2Fjclinpath-2015-202980&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fjclinpath-2015-202980%26sid%3Dliteratum%253Aachs%26aulast%3DRocken%26aufirst%3DC.%26aulast%3DBehrens%26aufirst%3DH.%2BM.%26aulast%3DBoger%26aufirst%3DC.%26aulast%3DKruger%26aufirst%3DS.%26atitle%3DClinicopathological%2520characteristics%2520of%2520RHOA%2520mutations%2520in%2520a%2520Central%2520European%2520gastric%2520cancer%2520cohort%26jtitle%3DJ.%2520Clin.%2520Pathol.%26date%3D2016%26volume%3D69%26spage%3D70%26epage%3D75%26doi%3D10.1136%2Fjclinpath-2015-202980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kakiuchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishizawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotoh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatsuno, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katoh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ushiku, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funahashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tateishi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wada, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koike, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukayama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aburatani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, S.</span></span> <span> </span><span class="NLM_article-title">Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">583</span>â <span class="NLM_lpage">587</span>, <span class="refDoi">Â DOI: 10.1038/ng.2984</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fng.2984" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=24816255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnslGqtrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2014&pages=583-587&author=M.+Kakiuchiauthor=T.+Nishizawaauthor=H.+Uedaauthor=K.+Gotohauthor=A.+Tanakaauthor=A.+Hayashiauthor=S.+Yamamotoauthor=K.+Tatsunoauthor=H.+Katohauthor=Y.+Watanabeauthor=T.+Ichimuraauthor=T.+Ushikuauthor=S.+Funahashiauthor=K.+Tateishiauthor=I.+Wadaauthor=N.+Shimizuauthor=S.+Nomuraauthor=K.+Koikeauthor=Y.+Setoauthor=M.+Fukayamaauthor=H.+Aburataniauthor=S.+Ishikawa&title=Recurrent+gain-of-function+mutations+of+RHOA+in+diffuse-type+gastric+carcinoma&doi=10.1038%2Fng.2984"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma</span></div><div class="casAuthors">Kakiuchi, Miwako; Nishizawa, Takashi; Ueda, Hiroki; Gotoh, Kengo; Tanaka, Atsushi; Hayashi, Akimasa; Yamamoto, Shogo; Tatsuno, Kenji; Katoh, Hiroto; Watanabe, Yoshiaki; Ichimura, Takashi; Ushiku, Tetsuo; Funahashi, Shinichi; Tateishi, Keisuke; Wada, Ikuo; Shimizu, Nobuyuki; Nomura, Sachiyo; Koike, Kazuhiko; Seto, Yasuyuki; Fukayama, Masashi; Aburatani, Hiroyuki; Ishikawa, Shumpei</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">583-587</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Diffuse-type gastric carcinoma (DGC) is characterized by a highly malignant phenotype with prominent infiltration and stromal induction.  We performed whole-exome sequencing on 30 DGC cases and found recurrent RHOA nonsynonymous mutations.  With validation sequencing of an addnl. 57 cases, RHOA mutation was obsd. in 25.3% (22/87) of DGCs, with mutational hotspots affecting the Tyr42, Arg5 and Gly17 residues in RHOA protein.  These positions are highly conserved among RHO family members, and Tyr42 and Arg5 are located outside the guanine nucleotide-binding pocket.  Several lines of functional evidence indicated that mutant RHOA works in a gain-of-function manner.  Comparison of mutational profiles for the major gastric cancer subtypes showed that RHOA mutations occur specifically in DGCs, the majority of which were histopathol. characterized by the presence of poorly differentiated adenocarcinomas together with more differentiated components in the gastric mucosa.  Our findings identify a potential therapeutic target for this poor-prognosis subtype of gastric cancer with no available molecularly targeted drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo64ww_rUNuzbVg90H21EOLACvtfcHk0liuEqpX45TjfQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnslGqtrY%253D&md5=7f3aec15808cfcae7923c557c535fed5</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1038%2Fng.2984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.2984%26sid%3Dliteratum%253Aachs%26aulast%3DKakiuchi%26aufirst%3DM.%26aulast%3DNishizawa%26aufirst%3DT.%26aulast%3DUeda%26aufirst%3DH.%26aulast%3DGotoh%26aufirst%3DK.%26aulast%3DTanaka%26aufirst%3DA.%26aulast%3DHayashi%26aufirst%3DA.%26aulast%3DYamamoto%26aufirst%3DS.%26aulast%3DTatsuno%26aufirst%3DK.%26aulast%3DKatoh%26aufirst%3DH.%26aulast%3DWatanabe%26aufirst%3DY.%26aulast%3DIchimura%26aufirst%3DT.%26aulast%3DUshiku%26aufirst%3DT.%26aulast%3DFunahashi%26aufirst%3DS.%26aulast%3DTateishi%26aufirst%3DK.%26aulast%3DWada%26aufirst%3DI.%26aulast%3DShimizu%26aufirst%3DN.%26aulast%3DNomura%26aufirst%3DS.%26aulast%3DKoike%26aufirst%3DK.%26aulast%3DSeto%26aufirst%3DY.%26aulast%3DFukayama%26aufirst%3DM.%26aulast%3DAburatani%26aufirst%3DH.%26aulast%3DIshikawa%26aufirst%3DS.%26atitle%3DRecurrent%2520gain-of-function%2520mutations%2520of%2520RHOA%2520in%2520diffuse-type%2520gastric%2520carcinoma%26jtitle%3DNat.%2520Genet.%26date%3D2014%26volume%3D46%26spage%3D583%26epage%3D587%26doi%3D10.1038%2Fng.2984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oda, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekine, S.</span></span> <span> </span><span class="NLM_article-title">RHOA mutations and CLDN18-ARHGAP fusions in intestinal-type adenocarcinoma with anastomosing glands of the stomach</span>. <i>Mod. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">568</span>â <span class="NLM_lpage">575</span>, <span class="refDoi">Â DOI: 10.1038/s41379-018-0181-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fs41379-018-0181-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=30425335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlSrtb3I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2019&pages=568-575&author=T.+Hashimotoauthor=R.+Ogawaauthor=T.+Y.+Tangauthor=H.+Yoshidaauthor=H.+Taniguchiauthor=H.+Kataiauthor=I.+Odaauthor=S.+Sekine&title=RHOA+mutations+and+CLDN18-ARHGAP+fusions+in+intestinal-type+adenocarcinoma+with+anastomosing+glands+of+the+stomach&doi=10.1038%2Fs41379-018-0181-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">RHOA mutations and CLDN18-ARHGAP fusions in intestinal-type adenocarcinoma with anastomosing glands of the stomach</span></div><div class="casAuthors">Hashimoto, Taiki; Ogawa, Reiko; Tang, Tzu-Yin; Yoshida, Hiroshi; Taniguchi, Hirokazu; Katai, Hitoshi; Oda, Ichiro; Sekine, Shigeki</div><div class="citationInfo"><span class="NLM_cas:title">Modern Pathology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">568-575</span>CODEN:
                <span class="NLM_cas:coden">MODPEO</span>;
        ISSN:<span class="NLM_cas:issn">0893-3952</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A subtype of intestinal-type adenocarcinoma of the stomach, characterized by low-grade cytol. atypia and anastomosing glands, has been described in several reports under different names.  One of the remarkable features of these lesions, herein referred to as intestinal-type adenocarcinoma with anastomosing glands, is the frequent assocn. of poorly differentiated adenocarcinoma components.  Here we analyzed 44 intestinal-type adenocarcinomas with anastomosing glands focusing on the mol. abnormalities that are common in diffuse-type gastric cancers.  Next-generation sequencing identified RHOA and CDH1 mutations in 22 (50%) and one lesion (2%), resp.  Reverse transcription-PCR detected CLDN18-ARHGAP fusions in three lesions (7%).  Immunohistochem., none of the lesions showed abnormal p53 expression patterns whereas focal and diffuse loss of ARID1A was obsd. in four and one lesion, resp.  Examn. of 37 lesions of dysplasia and 26 usual-type intramucosal adenocarcinomas identified one RHOA mutation in adenocarcinoma and no CLDN18-ARHGAP fusions, indicating that these genetic alterations are highly specific to intestinal-type adenocarcinomas with anastomosing glands among differentiated-type intramucosal neoplasms.  The present study showed that intestinal-type adenocarcinoma with anastomosing glands represents a genetically distinct group of tumors with the frequent presence of RHOA mutations and CLDN18-ARHGAP fusions, which are thought to be specific to diffuse-type gastric cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLDADGiJ89H7Vg90H21EOLACvtfcHk0liuEqpX45TjfQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlSrtb3I&md5=f42aba8bc1f850c2307848f6eca27ee6</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1038%2Fs41379-018-0181-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41379-018-0181-9%26sid%3Dliteratum%253Aachs%26aulast%3DHashimoto%26aufirst%3DT.%26aulast%3DOgawa%26aufirst%3DR.%26aulast%3DTang%26aufirst%3DT.%2BY.%26aulast%3DYoshida%26aufirst%3DH.%26aulast%3DTaniguchi%26aufirst%3DH.%26aulast%3DKatai%26aufirst%3DH.%26aulast%3DOda%26aufirst%3DI.%26aulast%3DSekine%26aufirst%3DS.%26atitle%3DRHOA%2520mutations%2520and%2520CLDN18-ARHGAP%2520fusions%2520in%2520intestinal-type%2520adenocarcinoma%2520with%2520anastomosing%2520glands%2520of%2520the%2520stomach%26jtitle%3DMod.%2520Pathol.%26date%3D2019%26volume%3D32%26spage%3D568%26epage%3D575%26doi%3D10.1038%2Fs41379-018-0181-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodge, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papageorge, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stachler, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akarca, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Klerk, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derks, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierobon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoadley, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Church, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petricoin, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowy, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Der, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bass, A. J.</span></span> <span> </span><span class="NLM_article-title">Gain-of-function RHOA mutations promote focal adhesion kinase activation and dependency in diffuse gastric cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">288</span>â <span class="NLM_lpage">305</span>, <span class="refDoi">Â DOI: 10.1158/2159-8290.CD-19-0811</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F2159-8290.CD-19-0811" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=31771969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVGisb3N" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=288-305&author=H.+Zhangauthor=A.+Schaeferauthor=Y.+Wangauthor=R.+G.+Hodgeauthor=D.+R.+Blakeauthor=J.+N.+Diehlauthor=A.+G.+Papageorgeauthor=M.+D.+Stachlerauthor=J.+Liaoauthor=J.+Zhouauthor=Z.+Wuauthor=F.+G.+Akarcaauthor=L.+K.+de+Klerkauthor=S.+Derksauthor=M.+Pierobonauthor=K.+A.+Hoadleyauthor=T.+C.+Wangauthor=G.+Churchauthor=K.+K.+Wongauthor=E.+F.+Petricoinauthor=A.+D.+Coxauthor=D.+R.+Lowyauthor=C.+J.+Derauthor=A.+J.+Bass&title=Gain-of-function+RHOA+mutations+promote+focal+adhesion+kinase+activation+and+dependency+in+diffuse+gastric+cancer&doi=10.1158%2F2159-8290.CD-19-0811"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Gain-of-function RHOA mutations promote focal adhesion kinase activation and dependency in diffuse gastric cancer</span></div><div class="casAuthors">Zhang, Haisheng; Schaefer, Antje; Wang, Yichen; Hodge, Richard G.; Blake, Devon R.; Diehl, J. Nathaniel; Papageorge, Alex G.; Stachler, Matthew D.; Liao, Jennifer; Zhou, Jin; Wu, Zhong; Akarca, Fahire G.; de Klerk, Leonie K.; Derks, Sarah; Pierobon, Mariaelena; Hoadley, Katherine A.; Wang, Timothy C.; Church, George; Wong, Kwok-Kin; Petricoin, Emanuel F.; Cox, Adrienne D.; Lowy, Douglas R.; Der, Channing J.; Bass, Adam J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">288-305</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Diffuse gastric cancer (DGC) is a lethal malignancy lacking effective systemic therapy.  Among the most provocative recent results in DGC has been that of highly recurrent missense mutations in the GTPase RHOA.  The function of these mutations has remained unresolved.  We demonstrate that RHOAY42C, the most common RHOA mutation in DGC, is a gain-of-function oncogenic mutant, and that expression of RHOAY42C with inactivation of the canonical tumor suppressor Cdh1 induces metastatic DGC in a mouse model.  Biochem., RHOAY42C exhibits impaired GTP hydrolysis and enhances interaction with its effector ROCK.  RHOAY42C mutation and Cdh1 loss induce actin/cytoskeletal rearrangements and activity of focal adhesion kinase (FAK), which activates YAP-TAZ, PI3K-AKT, and Î²-catenin.  RHOAY42C murine models were sensitive to FAK inhibition and to combined YAP and PI3K pathway blockade.  These results, coupled with sensitivity to FAK inhibition in patient-derived DGC cell lines, nominate FAK as a novel target for these cancers.  The functional significance of recurrent RHOA mutations in DGC has remained unresolved.  Through biochem. studies and mouse modeling of the hotspot RHOAY42C mutation, we establish that these mutations are activating, detail their effects upon cell signaling, and define how RHOA-mediated FAK activation imparts sensitivity to pharmacol. FAK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomtMM-p2C5WLVg90H21EOLACvtfcHk0ljSi34rjdiPRQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVGisb3N&md5=9ddc924e7cd3402278c5916ca3075bdd</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-19-0811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-19-0811%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DSchaefer%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHodge%26aufirst%3DR.%2BG.%26aulast%3DBlake%26aufirst%3DD.%2BR.%26aulast%3DDiehl%26aufirst%3DJ.%2BN.%26aulast%3DPapageorge%26aufirst%3DA.%2BG.%26aulast%3DStachler%26aufirst%3DM.%2BD.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DAkarca%26aufirst%3DF.%2BG.%26aulast%3Dde%2BKlerk%26aufirst%3DL.%2BK.%26aulast%3DDerks%26aufirst%3DS.%26aulast%3DPierobon%26aufirst%3DM.%26aulast%3DHoadley%26aufirst%3DK.%2BA.%26aulast%3DWang%26aufirst%3DT.%2BC.%26aulast%3DChurch%26aufirst%3DG.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DPetricoin%26aufirst%3DE.%2BF.%26aulast%3DCox%26aufirst%3DA.%2BD.%26aulast%3DLowy%26aufirst%3DD.%2BR.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26aulast%3DBass%26aufirst%3DA.%2BJ.%26atitle%3DGain-of-function%2520RHOA%2520mutations%2520promote%2520focal%2520adhesion%2520kinase%2520activation%2520and%2520dependency%2520in%2520diffuse%2520gastric%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2020%26volume%3D10%26spage%3D288%26epage%3D305%26doi%3D10.1158%2F2159-8290.CD-19-0811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grassian, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Divakaruni, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slocum, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickers, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joud-Caldwell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handly, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straub, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Growney, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vander
Heiden, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagliarini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metallo, C. M.</span></span> <span> </span><span class="NLM_article-title">IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">3317</span>â <span class="NLM_lpage">3331</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-14-0772-T</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F0008-5472.CAN-14-0772-T" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=24755473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2cXps1Cmurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=3317-3331&author=A.+R.+Grassianauthor=S.+J.+Parkerauthor=S.+M.+Davidsonauthor=A.+S.+Divakaruniauthor=C.+R.+Greenauthor=X.+Zhangauthor=K.+L.+Slocumauthor=M.+Puauthor=F.+Linauthor=C.+Vickersauthor=C.+Joud-Caldwellauthor=F.+Chungauthor=H.+Yinauthor=E.+D.+Handlyauthor=C.+Straubauthor=J.+D.+Growneyauthor=M.+G.+Vander%0AHeidenauthor=A.+N.+Murphyauthor=R.+Pagliariniauthor=C.+M.+Metallo&title=IDH1+mutations+alter+citric+acid+cycle+metabolism+and+increase+dependence+on+oxidative+mitochondrial+metabolism&doi=10.1158%2F0008-5472.CAN-14-0772-T"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">IDH1 Mutations Alter Citric Acid Cycle Metabolism and Increase Dependence on Oxidative Mitochondrial Metabolism</span></div><div class="casAuthors">Grassian, Alexandra R.; Parker, Seth J.; Davidson, Shawn M.; Divakaruni, Ajit S.; Green, Courtney R.; Zhang, Xiamei; Slocum, Kelly L.; Pu, Minying; Lin, Fallon; Vickers, Chad; Joud-Caldwell, Carol; Chung, Franklin; Yin, Hong; Handly, Erika D.; Straub, Christopher; Growney, Joseph D.; Vander Heiden, Matthew G.; Murphy, Anne N.; Pagliarini, Raymond; Metallo, Christian M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3317-3331</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Oncogenic mutations in isocitrate dehydrogenase I and 2 (IDH1/2) occur in several types of cancer, but the metabolic consequences of these genetic changes are not fully understood.  In this study, we performed 13C metabolic flux anal. on a panel of isogenic cell lines contg. heterozygous IDH1/2 mutations.  We obsd. that under hypoxic conditions, IDH1-mutant cells exhibited increased oxidative tricarboxylic acid metab. along with decreased reductive glutamine metab., but not IDH2-mutant cells.  However, selective inhibition of mutant IDH1 enzyme function could not reverse the defect in reductive carboxylation activity.  Furthermore, this metabolic reprogramming increased the sensitivity of IDH1-mutant cells to hypoxia or electron transport chain inhibition in vitro.  Lastly, IDHl-mutant cells also grew poorly as s.c. xenografts within a hypoxic in vivo microenvironment.  Together, our results suggest therapeutic opportunities to exploit the metabolic vulnerabilities specific to IDH1 mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSn8rEPLZvc7Vg90H21EOLACvtfcHk0ljSi34rjdiPRQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXps1Cmurw%253D&md5=f75db701c8b99057cc2de565315467c0</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-0772-T&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-0772-T%26sid%3Dliteratum%253Aachs%26aulast%3DGrassian%26aufirst%3DA.%2BR.%26aulast%3DParker%26aufirst%3DS.%2BJ.%26aulast%3DDavidson%26aufirst%3DS.%2BM.%26aulast%3DDivakaruni%26aufirst%3DA.%2BS.%26aulast%3DGreen%26aufirst%3DC.%2BR.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DSlocum%26aufirst%3DK.%2BL.%26aulast%3DPu%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DF.%26aulast%3DVickers%26aufirst%3DC.%26aulast%3DJoud-Caldwell%26aufirst%3DC.%26aulast%3DChung%26aufirst%3DF.%26aulast%3DYin%26aufirst%3DH.%26aulast%3DHandly%26aufirst%3DE.%2BD.%26aulast%3DStraub%26aufirst%3DC.%26aulast%3DGrowney%26aufirst%3DJ.%2BD.%26aulast%3DVander%2BHeiden%26aufirst%3DM.%2BG.%26aulast%3DMurphy%26aufirst%3DA.%2BN.%26aulast%3DPagliarini%26aufirst%3DR.%26aulast%3DMetallo%26aufirst%3DC.%2BM.%26atitle%3DIDH1%2520mutations%2520alter%2520citric%2520acid%2520cycle%2520metabolism%2520and%2520increase%2520dependence%2520on%2520oxidative%2520mitochondrial%2520metabolism%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D3317%26epage%3D3331%26doi%3D10.1158%2F0008-5472.CAN-14-0772-T" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarry, J.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Recher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portais, J.-C.</span></span> <span> </span><span class="NLM_article-title">Catabolic flexibility enhances drug resistance but induces selective vulnerability to new mitochondrial-targeted therapeutic combinations in IDH mutant leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">5238</span>â <span class="NLM_lpage">5238</span>, <span class="refDoi">Â DOI: 10.1182/blood-2018-99-112523</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1182%2Fblood-2018-99-112523" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2018&pages=5238-5238&author=J.-E.+Sarryauthor=C.+Recherauthor=L.+Stuaniauthor=J.-C.+Portais&title=Catabolic+flexibility+enhances+drug+resistance+but+induces+selective+vulnerability+to+new+mitochondrial-targeted+therapeutic+combinations+in+IDH+mutant+leukemia&doi=10.1182%2Fblood-2018-99-112523"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1182%2Fblood-2018-99-112523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2018-99-112523%26sid%3Dliteratum%253Aachs%26aulast%3DSarry%26aufirst%3DJ.-E.%26aulast%3DRecher%26aufirst%3DC.%26aulast%3DStuani%26aufirst%3DL.%26aulast%3DPortais%26aufirst%3DJ.-C.%26atitle%3DCatabolic%2520flexibility%2520enhances%2520drug%2520resistance%2520but%2520induces%2520selective%2520vulnerability%2520to%2520new%2520mitochondrial-targeted%2520therapeutic%2520combinations%2520in%2520IDH%2520mutant%2520leukemia%26jtitle%3DBlood%26date%3D2018%26volume%3D132%26spage%3D5238%26epage%3D5238%26doi%3D10.1182%2Fblood-2018-99-112523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. H.</span></span> <span> </span><span class="NLM_article-title">RHOA in gastric cancer: functional roles and therapeutic potential</span>. <i>Front. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">438</span>, <span class="refDoi">Â DOI: 10.3389/fgene.2019.00438</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.3389%2Ffgene.2019.00438" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=31156701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsl2ntrzP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=438&author=S.+Namauthor=J.+H.+Kimauthor=D.+H.+Lee&title=RHOA+in+gastric+cancer%3A+functional+roles+and+therapeutic+potential&doi=10.3389%2Ffgene.2019.00438"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">RHOA in gastric cancer: functional roles and therapeutic potential</span></div><div class="casAuthors">Nam, Seungyoon; Kim, Jung Ho; Lee, Dae Ho</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Genetics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">438</span>CODEN:
                <span class="NLM_cas:coden">FGREBR</span>;
        ISSN:<span class="NLM_cas:issn">1664-8021</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  The well-known signal mediator and small GTPase family member, RHOA, has now been assocd. with the progression of specific malignancies.  In this review, we appraise the biomedical literature regarding the role of this enzyme in gastric cancer (GC) signaling, suggesting potential clin. significance.  To that end, we examd. RHOA activity, with regard to second-generation hallmarks of cancer, finding particular assocn. with the hallmark "activation of invasion and metastasis." Moreover, an abundance of studies show RHOA assocn. with Lauren classification diffuse subtype, in addn. to poorly differentiated GC.  With regard to therapeutic value, we found RHOA signaling to influence the activity of specific widely used chemotherapeutics, and its possible antagonism by various dietary constituents.  We also review currently available targeted therapies for GC.  The latter, however, showed a paucity of such agents, underscoring the urgent need for further investigation into treatments for this highly lethal malignancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCzvkdi-kb0bVg90H21EOLACvtfcHk0lgapreSwOII3Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsl2ntrzP&md5=5bc6f78ec48e565e09a49fcccfff5473</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.3389%2Ffgene.2019.00438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffgene.2019.00438%26sid%3Dliteratum%253Aachs%26aulast%3DNam%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DLee%26aufirst%3DD.%2BH.%26atitle%3DRHOA%2520in%2520gastric%2520cancer%253A%2520functional%2520roles%2520and%2520therapeutic%2520potential%26jtitle%3DFront.%2520Genet.%26date%3D2019%26volume%3D10%26spage%3D438%26doi%3D10.3389%2Ffgene.2019.00438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishizawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komura, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuroiwa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishimaru, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monnai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aburatani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, M.</span></span> <span> </span><span class="NLM_article-title">In vivo effects of mutant RHOA on tumor formation in an orthotopic inoculation model</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">1745</span>â <span class="NLM_lpage">1754</span>, <span class="refDoi">Â DOI: 10.3892/or.2019.7300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.3892%2For.2019.7300" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=31485674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlsV2itLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2019&pages=1745-1754&author=T.+Nishizawaauthor=K.+Nakanoauthor=E.+Fujiiauthor=D.+Komuraauthor=Y.+Kuroiwaauthor=C.+Ishimaruauthor=M.+Monnaiauthor=H.+Aburataniauthor=S.+Ishikawaauthor=M.+Suzuki&title=In+vivo+effects+of+mutant+RHOA+on+tumor+formation+in+an+orthotopic+inoculation+model&doi=10.3892%2For.2019.7300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo effects of mutant RHOA on tumor formation in an orthotopic inoculation model</span></div><div class="casAuthors">Nishizawa, Takashi; Nakano, Kiyotaka; Fujii, Etsuko; Komura, Daisuke; Kuroiwa, Yoshie; Ishimaru, Chisako; Monnai, Makoto; Aburatani, Hiroyuki; Ishikawa, Shumpei; Suzuki, Masami</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1745-1754</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1791-2431</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">The contribution of RHOA mutations to tumor morphol. was investigated using an orthotopic xenograft model using the gastric cancer cell line MKN74, in which WT or mutated (Y42C and Y42S) RHOA had been introduced.  When we conducted RNA sequencing to distinguish between the genes expressed in human tumor tissues from those in mouse stroma, the expression profiles of the tumors were clearly divided into a Y42C/Y42S group and a mock/WT group.  Through gene set enrichment anal., it was revealed that inflammation- and hypoxia-related pathways were enriched in the mock/WT tumors; however, cell metab.- and cell cycle-related pathways such as Myc, E2F, oxidative phosphorylation and G2M checkpoint were enriched in the Y42C/Y42S tumors.  In addn., the gene set related to ROCK signaling inhibition was enriched in the RHOA-mutated group, which indicated that a series of events are related to ROCK inhibition induced by RHOA mutations.  Furthermore, unlike mock/WT, the RHOA-mutated tumor cells had little antitumor host reaction in the invasive front, which is similar to the pattern of mucosal invasion in clin. RHOA-mutated DGC.  These transcriptome, pathol. analyses revealed that mutated RHOA functionally contributes to the acquisition of DGC features, which will accelerate our understanding of the contribution of RHOA mutations in DGC biol., the development of further therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVXonUwTCijrVg90H21EOLACvtfcHk0lgapreSwOII3Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlsV2itLs%253D&md5=fda4fb1f23c8896677db8b95eaee563c</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.3892%2For.2019.7300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2019.7300%26sid%3Dliteratum%253Aachs%26aulast%3DNishizawa%26aufirst%3DT.%26aulast%3DNakano%26aufirst%3DK.%26aulast%3DFujii%26aufirst%3DE.%26aulast%3DKomura%26aufirst%3DD.%26aulast%3DKuroiwa%26aufirst%3DY.%26aulast%3DIshimaru%26aufirst%3DC.%26aulast%3DMonnai%26aufirst%3DM.%26aulast%3DAburatani%26aufirst%3DH.%26aulast%3DIshikawa%26aufirst%3DS.%26aulast%3DSuzuki%26aufirst%3DM.%26atitle%3DIn%2520vivo%2520effects%2520of%2520mutant%2520RHOA%2520on%2520tumor%2520formation%2520in%2520an%2520orthotopic%2520inoculation%2520model%26jtitle%3DOncol.%2520Rep.%26date%3D2019%26volume%3D42%26spage%3D1745%26epage%3D1754%26doi%3D10.3892%2For.2019.7300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reznik, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senbabaoglu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riaz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarungbam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tickoo, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Ahmadie, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seshan, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hakimi, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sander, C.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial DNA copy number variation across human cancers</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">e10769</span>, <span class="refDoi">Â DOI: 10.7554/eLife.10769</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.7554%2FeLife.10769" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=26901439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotFGjsb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=e10769&author=E.+Reznikauthor=M.+L.+Millerauthor=Y.+Senbabaogluauthor=N.+Riazauthor=J.+Sarungbamauthor=S.+K.+Tickooauthor=H.+A.+Al-Ahmadieauthor=W.+Leeauthor=V.+E.+Seshanauthor=A.+A.+Hakimiauthor=C.+Sander&title=Mitochondrial+DNA+copy+number+variation+across+human+cancers&doi=10.7554%2FeLife.10769"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial DNA copy number variation across human cancers</span></div><div class="casAuthors">Reznik, Ed; Miller, Martin L.; Senbabaoglu, Yasin; Riaz, Nadeem; Sarungbam, Judy; Tickoo, Satish K.; Al-Ahmadie, Hikmat A.; Lee, William; Seshan, Venkatraman E.; Hakimi, A. Ari; Sander, Chris</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e10769/1-e10769/20</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">Mutations, deletions, and changes in copy no. of mitochondrial DNA (mtDNA), are obsd. throughout cancers.  Here, we survey mtDNA copy no. variation across 22 tumor types profiled by The Cancer Genome Atlas project.  We observe a tendency for some cancers, esp. of the bladder, breast, and kidney, to be depleted of mtDNA, relative to matched normal tissue.  Anal. of genetic context reveals an assocn. between incidence of several somatic alterations, including IDH1 mutations in gliomas, and mtDNA content.  In some but not all cancer types, mtDNA content is correlated with the expression of respiratory genes, and anticorrelated to the expression of immune response and cell-cycle genes.  In tandem with immunohistochem. evidence, we find that some tumors may compensate for mtDNA depletion to sustain levels of respiratory proteins.  Our results highlight the extent of mtDNA copy no. variation in tumors and point to related therapeutic opportunities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGo26OnVCagbVg90H21EOLACvtfcHk0lgapreSwOII3Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotFGjsb8%253D&md5=5ed342536bb679eedcdd732ad5e8080b</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.7554%2FeLife.10769&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.10769%26sid%3Dliteratum%253Aachs%26aulast%3DReznik%26aufirst%3DE.%26aulast%3DMiller%26aufirst%3DM.%2BL.%26aulast%3DSenbabaoglu%26aufirst%3DY.%26aulast%3DRiaz%26aufirst%3DN.%26aulast%3DSarungbam%26aufirst%3DJ.%26aulast%3DTickoo%26aufirst%3DS.%2BK.%26aulast%3DAl-Ahmadie%26aufirst%3DH.%2BA.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DSeshan%26aufirst%3DV.%2BE.%26aulast%3DHakimi%26aufirst%3DA.%2BA.%26aulast%3DSander%26aufirst%3DC.%26atitle%3DMitochondrial%2520DNA%2520copy%2520number%2520variation%2520across%2520human%2520cancers%26jtitle%3DeLife%26date%3D2016%26volume%3D5%26spage%3De10769%26doi%3D10.7554%2FeLife.10769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Birkenmeier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drose, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittig, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkelmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kafer, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doring, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichert, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansmann, M. L.</span></span> <span> </span><span class="NLM_article-title">Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma are highly dependent on oxidative phosphorylation</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">2231</span>â <span class="NLM_lpage">2246</span>, <span class="refDoi">Â DOI: 10.1002/ijc.29934</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1002%2Fijc.29934" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=26595876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC28XovFamsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2016&pages=2231-2246&author=K.+Birkenmeierauthor=S.+Droseauthor=I.+Wittigauthor=R.+Winkelmannauthor=V.+Kaferauthor=C.+Doringauthor=S.+Hartmannauthor=T.+Wenzauthor=A.+S.+Reichertauthor=U.+Brandtauthor=M.+L.+Hansmann&title=Hodgkin+and+Reed-Sternberg+cells+of+classical+Hodgkin+lymphoma+are+highly+dependent+on+oxidative+phosphorylation&doi=10.1002%2Fijc.29934"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma are highly dependent on oxidative phosphorylation</span></div><div class="casAuthors">Birkenmeier, Katrin; Droese, Stefan; Wittig, Ilka; Winkelmann, Ria; Kaefer, Viktoria; Doering, Claudia; Hartmann, Sylvia; Wenz, Tina; Reichert, Andreas S.; Brandt, Ulrich; Hansmann, Martin-Leo</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2231-2246</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The metabolic properties of lymphomas derived from germinal center (GC) B cells have important implications for therapeutic strategies.  In this study, we have compared metabolic features of Hodgkin-Reed-Sternberg (HRS) cells, the tumor cells of classical Hodgkin's lymphoma (cHL), one of the most frequent (post-)GC-derived B-cell lymphomas, with their normal GC B cell counterparts.  We found that the ratio of oxidative to nonoxidative energy conversion was clearly shifted toward oxidative phosphorylation (OXPHOS)-linked ATP synthesis in HRS cells as compared to GC B cells.  Mitochondrial mass, the expression of numerous key proteins of oxidative metab. and markers of mitochondrial biogenesis were markedly upregulated in cHL cell lines and in primary cHL cases.  NFkappaB promoted this shift to OXPHOS.  Functional anal. indicated that both cell growth and viability of HRS cells depended on OXPHOS.  The high rates of OXPHOS correlated with an almost complete lack of lactate prodn. in HRS cells not obsd. in other GC B-cell lymphoma cell lines.  Overall, we conclude that OXPHOS dominates energy conversion in HRS cells, while nonoxidative ATP prodn. plays a subordinate role.  Our results suggest that OXPHOS could be a new therapeutic target and may provide an avenue toward new treatment strategies in cHL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnuxqK7mMcwbVg90H21EOLACvtfcHk0li2CmIaDYFuQA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XovFamsQ%253D%253D&md5=17e77b41883428f195c7207a5283ad4d</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1002%2Fijc.29934&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.29934%26sid%3Dliteratum%253Aachs%26aulast%3DBirkenmeier%26aufirst%3DK.%26aulast%3DDrose%26aufirst%3DS.%26aulast%3DWittig%26aufirst%3DI.%26aulast%3DWinkelmann%26aufirst%3DR.%26aulast%3DKafer%26aufirst%3DV.%26aulast%3DDoring%26aufirst%3DC.%26aulast%3DHartmann%26aufirst%3DS.%26aulast%3DWenz%26aufirst%3DT.%26aulast%3DReichert%26aufirst%3DA.%2BS.%26aulast%3DBrandt%26aufirst%3DU.%26aulast%3DHansmann%26aufirst%3DM.%2BL.%26atitle%3DHodgkin%2520and%2520Reed-Sternberg%2520cells%2520of%2520classical%2520Hodgkin%2520lymphoma%2520are%2520highly%2520dependent%2520on%2520oxidative%2520phosphorylation%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2016%26volume%3D138%26spage%3D2231%26epage%3D2246%26doi%3D10.1002%2Fijc.29934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lanning, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castle, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leon, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tovar, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanghera, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKeigan, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filipp, F. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graveel, C. R.</span></span> <span> </span><span class="NLM_article-title">Metabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities</span>. <i>Cancer Metab.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">6</span>, <span class="refDoi">Â DOI: 10.1186/s40170-017-0168-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1186%2Fs40170-017-0168-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=28852500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BC1cbislymuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&pages=6&author=N.+J.+Lanningauthor=J.+P.+Castleauthor=S.+J.+Singhauthor=A.+N.+Leonauthor=E.+A.+Tovarauthor=A.+Sangheraauthor=J.+P.+MacKeiganauthor=F.+V.+Filippauthor=C.+R.+Graveel&title=Metabolic+profiling+of+triple-negative+breast+cancer+cells+reveals+metabolic+vulnerabilities&doi=10.1186%2Fs40170-017-0168-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities</span></div><div class="casAuthors">Lanning Nathan J; Leon Andre N; Castle Joshua P; Tovar Elizabeth A; MacKeigan Jeffrey P; Graveel Carrie R; Singh Simar J; Sanghera Amandeep; Filipp Fabian V; MacKeigan Jeffrey P</div><div class="citationInfo"><span class="NLM_cas:title">Cancer & metabolism</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6</span>
        ISSN:<span class="NLM_cas:issn">2049-3002</span>.
    </div><div class="casAbstract">BACKGROUND:  Among breast cancers, the triple-negative breast cancer (TNBC) subtype has the worst prognosis with no approved targeted therapies and only standard chemotherapy as the backbone of systemic therapy.  Unique metabolic changes in cancer progression provide innovative therapeutic opportunities.  The receptor tyrosine kinases (RTKs) epidermal growth factor receptor (EGFR), and MET receptor are highly expressed in TNBC, making both promising therapeutic targets.  RTK signaling profoundly alters cellular metabolism by increasing glucose consumption and subsequently diverting glucose carbon sources into metabolic pathways necessary to support the tumorigenesis.  Therefore, detailed metabolic profiles of TNBC subtypes and their response to tyrosine kinase inhibitors may identify therapeutic sensitivities.  METHODS:  We quantified the metabolic profiles of TNBC cell lines representing multiple TNBC subtypes using gas chromatography mass spectrometry.  In addition, we subjected MDA-MB-231, MDA-MB-468, Hs578T, and HCC70 cell lines to metabolic flux analysis of basal and maximal glycolytic and mitochondrial oxidative rates.  Metabolic pool size and flux measurements were performed in the presence and absence of the MET inhibitor, INC280/capmatinib, and the EGFR inhibitor, erlotinib.  Further, the sensitivities of these cells to modulators of core metabolic pathways were determined.  In addition, we annotated a rate-limiting metabolic enzymes library and performed a siRNA screen in combination with MET or EGFR inhibitors to validate synergistic effects.  RESULTS:  TNBC cell line models displayed significant metabolic heterogeneity with respect to basal and maximal metabolic rates and responses to RTK and metabolic pathway inhibitors.  Comprehensive systems biology analysis of metabolic perturbations, combined siRNA and tyrosine kinase inhibitor screens identified a core set of TCA cycle and fatty acid pathways whose perturbation sensitizes TNBC cells to small molecule targeting of receptor tyrosine kinases.  CONCLUSIONS:  Similar to the genomic heterogeneity observed in TNBC, our results reveal metabolic heterogeneity among TNBC subtypes and demonstrate that understanding metabolic profiles and drug responses may prove valuable in targeting TNBC subtypes and identifying therapeutic susceptibilities in TNBC patients.  Perturbation of metabolic pathways sensitizes TNBC to inhibition of receptor tyrosine kinases.  Such metabolic vulnerabilities offer promise for effective therapeutic targeting for TNBC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTLo7wd5Jz078yail4HZd-ifW6udTcc2eZlggVK81DQEbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbislymuw%253D%253D&md5=8b0fc545febd991c24720755f9c838ef</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1186%2Fs40170-017-0168-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40170-017-0168-x%26sid%3Dliteratum%253Aachs%26aulast%3DLanning%26aufirst%3DN.%2BJ.%26aulast%3DCastle%26aufirst%3DJ.%2BP.%26aulast%3DSingh%26aufirst%3DS.%2BJ.%26aulast%3DLeon%26aufirst%3DA.%2BN.%26aulast%3DTovar%26aufirst%3DE.%2BA.%26aulast%3DSanghera%26aufirst%3DA.%26aulast%3DMacKeigan%26aufirst%3DJ.%2BP.%26aulast%3DFilipp%26aufirst%3DF.%2BV.%26aulast%3DGraveel%26aufirst%3DC.%2BR.%26atitle%3DMetabolic%2520profiling%2520of%2520triple-negative%2520breast%2520cancer%2520cells%2520reveals%2520metabolic%2520vulnerabilities%26jtitle%3DCancer%2520Metab.%26date%3D2017%26volume%3D5%26spage%3D6%26doi%3D10.1186%2Fs40170-017-0168-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caro, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kishan, A. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanley, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapuy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ficarro, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polak, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tondera, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gounarides, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marto, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipp, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danial, N. N.</span></span> <span> </span><span class="NLM_article-title">Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">547</span>â <span class="NLM_lpage">560</span>, <span class="refDoi">Â DOI: 10.1016/j.ccr.2012.08.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.ccr.2012.08.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=23079663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFWitbbO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=547-560&author=P.+Caroauthor=A.+U.+Kishanauthor=E.+Norbergauthor=I.+A.+Stanleyauthor=B.+Chapuyauthor=S.+B.+Ficarroauthor=K.+Polakauthor=D.+Tonderaauthor=J.+Gounaridesauthor=H.+Yinauthor=F.+Zhouauthor=M.+R.+Greenauthor=L.+Chenauthor=S.+Montiauthor=J.+A.+Martoauthor=M.+A.+Shippauthor=N.+N.+Danial&title=Metabolic+signatures+uncover+distinct+targets+in+molecular+subsets+of+diffuse+large+B+cell+lymphoma&doi=10.1016%2Fj.ccr.2012.08.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic Signatures Uncover Distinct Targets in Molecular Subsets of Diffuse Large B Cell Lymphoma</span></div><div class="casAuthors">Caro, Pilar; Kishan, Amar U.; Norberg, Erik; Stanley, Illana A.; Chapuy, Bjoern; Ficarro, Scott B.; Polak, Klaudia; Tondera, Daniel; Gounarides, John; Yin, Hong; Zhou, Feng; Green, Michael R.; Chen, Linfeng; Monti, Stefano; Marto, Jarrod A.; Shipp, Margaret A.; Danial, Nika N.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">547-560</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Mol. signatures have identified several subsets of diffuse large B cell lymphoma (DLBCL) and rational targets within the B cell receptor (BCR) signaling axis.  The OxPhos-DLBCL subset, which harbors the signature of genes involved in mitochondrial metab., is insensitive to inhibition of BCR survival signaling but is functionally undefined.  We show that, compared with BCR-DLBCLs, OxPhos-DLBCLs display enhanced mitochondrial energy transduction, greater incorporation of nutrient-derived carbons into the tricarboxylic acid cycle, and increased glutathione levels.  Moreover, perturbation of the fatty acid oxidn. program and glutathione synthesis proved selectively toxic to this tumor subset.  Our anal. provides evidence for distinct metabolic fingerprints and assocd. survival mechanisms in DLBCL and may have therapeutic implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFccRUow25JbVg90H21EOLACvtfcHk0li2CmIaDYFuQA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFWitbbO&md5=cc9e0ced5202e9e61ec7ee3baf4d7306</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2012.08.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2012.08.014%26sid%3Dliteratum%253Aachs%26aulast%3DCaro%26aufirst%3DP.%26aulast%3DKishan%26aufirst%3DA.%2BU.%26aulast%3DNorberg%26aufirst%3DE.%26aulast%3DStanley%26aufirst%3DI.%2BA.%26aulast%3DChapuy%26aufirst%3DB.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DPolak%26aufirst%3DK.%26aulast%3DTondera%26aufirst%3DD.%26aulast%3DGounarides%26aufirst%3DJ.%26aulast%3DYin%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DGreen%26aufirst%3DM.%2BR.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DMonti%26aufirst%3DS.%26aulast%3DMarto%26aufirst%3DJ.%2BA.%26aulast%3DShipp%26aufirst%3DM.%2BA.%26aulast%3DDanial%26aufirst%3DN.%2BN.%26atitle%3DMetabolic%2520signatures%2520uncover%2520distinct%2520targets%2520in%2520molecular%2520subsets%2520of%2520diffuse%2520large%2520B%2520cell%2520lymphoma%26jtitle%3DCancer%2520Cell%26date%3D2012%26volume%3D22%26spage%3D547%26epage%3D560%26doi%3D10.1016%2Fj.ccr.2012.08.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabra, M. B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phung, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefebvre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alshetaiwi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locasale, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Digman, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mjolsness, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werb, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, D. A.</span></span> <span> </span><span class="NLM_article-title">Transcriptional diversity and bioenergetic shift in human breast cancer metastasis revealed by single-cell RNA sequencing</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">310</span>â <span class="NLM_lpage">320</span>, <span class="refDoi">Â DOI: 10.1038/s41556-020-0477-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fs41556-020-0477-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=32144411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksFCjur0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2020&pages=310-320&author=R.+T.+Davisauthor=K.+Blakeauthor=D.+Maauthor=M.+B.+I.+Gabraauthor=G.+A.+Hernandezauthor=A.+T.+Phungauthor=Y.+Yangauthor=D.+Maurerauthor=A.+Lefebvreauthor=H.+Alshetaiwiauthor=Z.+Xiaoauthor=J.+Liuauthor=J.+W.+Locasaleauthor=M.+A.+Digmanauthor=E.+Mjolsnessauthor=M.+Kongauthor=Z.+Werbauthor=D.+A.+Lawson&title=Transcriptional+diversity+and+bioenergetic+shift+in+human+breast+cancer+metastasis+revealed+by+single-cell+RNA+sequencing&doi=10.1038%2Fs41556-020-0477-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Transcriptional diversity and bioenergetic shift in human breast cancer metastasis revealed by single-cell RNA sequencing</span></div><div class="casAuthors">Davis, Ryan T.; Blake, Kerrigan; Ma, Dennis; Gabra, Mari B. Ishak; Hernandez, Grace A.; Phung, Anh T.; Yang, Ying; Maurer, Dustin; Lefebvre, Austin E. Y. T.; Alshetaiwi, Hamad; Xiao, Zhengtao; Liu, Juan; Locasale, Jason W.; Digman, Michelle A.; Mjolsness, Eric; Kong, Mei; Werb, Zena; Lawson, Devon A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">310-320</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: Although metastasis remains the cause of most cancer-related mortality, mechanisms governing seeding in distal tissues are poorly understood.  Here, we establish a robust method for the identification of global transcriptomic changes in rare metastatic cells during seeding using single-cell RNA sequencing and patient-derived-xenograft models of breast cancer.  We find that both primary tumors and micrometastases display transcriptional heterogeneity but micrometastases harbor a distinct transcriptome program conserved across patient-derived-xenograft models that is highly predictive of poor survival of patients.  Pathway anal. revealed mitochondrial oxidative phosphorylation as the top pathway upregulated in micrometastases, in contrast to higher levels of glycolytic enzymes in primary tumor cells, which we corroborated by flow cytometric and metabolomic analyses.  Pharmacol. inhibition of oxidative phosphorylation dramatically attenuated metastatic seeding in the lungs, which demonstrates the functional importance of oxidative phosphorylation in metastasis and highlights its potential as a therapeutic target to prevent metastatic spread in patients with breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrm60v_V_SPmrVg90H21EOLACvtfcHk0li0rKp3pW9wEQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksFCjur0%253D&md5=cc38756196aab2c523ee9bbbd0cb4021</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1038%2Fs41556-020-0477-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41556-020-0477-0%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DR.%2BT.%26aulast%3DBlake%26aufirst%3DK.%26aulast%3DMa%26aufirst%3DD.%26aulast%3DGabra%26aufirst%3DM.%2BB.%2BI.%26aulast%3DHernandez%26aufirst%3DG.%2BA.%26aulast%3DPhung%26aufirst%3DA.%2BT.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DMaurer%26aufirst%3DD.%26aulast%3DLefebvre%26aufirst%3DA.%26aulast%3DAlshetaiwi%26aufirst%3DH.%26aulast%3DXiao%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLocasale%26aufirst%3DJ.%2BW.%26aulast%3DDigman%26aufirst%3DM.%2BA.%26aulast%3DMjolsness%26aufirst%3DE.%26aulast%3DKong%26aufirst%3DM.%26aulast%3DWerb%26aufirst%3DZ.%26aulast%3DLawson%26aufirst%3DD.%2BA.%26atitle%3DTranscriptional%2520diversity%2520and%2520bioenergetic%2520shift%2520in%2520human%2520breast%2520cancer%2520metastasis%2520revealed%2520by%2520single-cell%2520RNA%2520sequencing%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2020%26volume%3D22%26spage%3D310%26epage%3D320%26doi%3D10.1038%2Fs41556-020-0477-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simoes, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serganova, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruchevsky, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leftin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shestov, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thaler, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukenick, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locasale, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasberg, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koutcher, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ackerstaff, E.</span></span> <span> </span><span class="NLM_article-title">Metabolic plasticity of metastatic breast cancer cells: adaptation to changes in the microenvironment</span>. <i>Neoplasia</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">671</span>â <span class="NLM_lpage">684</span>, <span class="refDoi">Â DOI: 10.1016/j.neo.2015.08.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.neo.2015.08.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=26408259" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVeqtbjL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=671-684&author=R.+V.+Simoesauthor=I.+S.+Serganovaauthor=N.+Kruchevskyauthor=A.+Leftinauthor=A.+A.+Shestovauthor=H.+T.+Thalerauthor=G.+Sukenickauthor=J.+W.+Locasaleauthor=R.+G.+Blasbergauthor=J.+A.+Koutcherauthor=E.+Ackerstaff&title=Metabolic+plasticity+of+metastatic+breast+cancer+cells%3A+adaptation+to+changes+in+the+microenvironment&doi=10.1016%2Fj.neo.2015.08.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic Plasticity of Metastatic Breast Cancer Cells: Adaptation to Changes in the Microenvironment</span></div><div class="casAuthors">Simoes, Rui V.; Serganova, Inna S.; Kruchevsky, Natalia; Leftin, Avigdor; Shestov, Alexander A.; Thaler, Howard T.; Sukenick, George; Locasale, Jason W.; Blasberg, Ronald G.; Koutcher, Jason A.; Ackerstaff, Ellen</div><div class="citationInfo"><span class="NLM_cas:title">Neoplasia (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">671-684</span>CODEN:
                <span class="NLM_cas:coden">NEOPFL</span>;
        ISSN:<span class="NLM_cas:issn">1476-5586</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Cancer cells adapt their metab. during tumorigenesis.  We studied two isogenic breast cancer cells lines (highly metastatic 4T1; nonmetastatic 67NR) to identify differences in their glucose and glutamine metab. in response to metabolic and environmental stress.  Dynamic magnetic resonance spectroscopy of 13C-isotopomers showed that 4T1 cells have higher glycolytic and tricarboxylic acid (TCA) cycle flux than 67NR cells and readily switch between glycolysis and oxidative phosphorylation (OXPHOS) in response to different extracellular environments.  OXPHOS activity increased with metastatic potential in isogenic cell lines derived from the same primary breast cancer: 4T1 > 4T07 and 168FARN (local micrometastasis only) > 67NR.  We obsd. a restricted TCA cycle flux at the succinate dehydrogenase step in 67NR cells (but not in 4T1 cells), leading to succinate accumulation and hindering OXPHOS.  In the four isogenic cell lines, environmental stresses modulated succinate dehydrogenase subunit A expression according to metastatic potential.  Moreover, glucose-derived lactate prodn. was more glutamine dependent in cell lines with higher metastatic potential.  These studies show clear differences in TCA cycle metab. between 4T1 and 67NR breast cancer cells.  They indicate that metastases-forming 4T1 cells are more adept at adjusting their metab. in response to environmental stress than isogenic, nonmetastatic 67NR cells.  We suggest that the metabolic plasticity and adaptability are more important to the metastatic breast cancer phenotype than rapid cell proliferation alone, which could 1) provide a new biomarker for early detection of this phenotype, possibly at the time of diagnosis, and 2) lead to new treatment strategies of metastatic breast cancer by targeting mitochondrial metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCrwKHrIpvVbVg90H21EOLACvtfcHk0li0rKp3pW9wEQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVeqtbjL&md5=2a4d5e141435c89d3d99da04474d3773</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2Fj.neo.2015.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neo.2015.08.005%26sid%3Dliteratum%253Aachs%26aulast%3DSimoes%26aufirst%3DR.%2BV.%26aulast%3DSerganova%26aufirst%3DI.%2BS.%26aulast%3DKruchevsky%26aufirst%3DN.%26aulast%3DLeftin%26aufirst%3DA.%26aulast%3DShestov%26aufirst%3DA.%2BA.%26aulast%3DThaler%26aufirst%3DH.%2BT.%26aulast%3DSukenick%26aufirst%3DG.%26aulast%3DLocasale%26aufirst%3DJ.%2BW.%26aulast%3DBlasberg%26aufirst%3DR.%2BG.%26aulast%3DKoutcher%26aufirst%3DJ.%2BA.%26aulast%3DAckerstaff%26aufirst%3DE.%26atitle%3DMetabolic%2520plasticity%2520of%2520metastatic%2520breast%2520cancer%2520cells%253A%2520adaptation%2520to%2520changes%2520in%2520the%2520microenvironment%26jtitle%3DNeoplasia%26date%3D2015%26volume%3D17%26spage%3D671%26epage%3D684%26doi%3D10.1016%2Fj.neo.2015.08.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scotland, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saland, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skuli, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Toni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boutzen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Micklow, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senegas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peyraud, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peyriga, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theodoro, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martineau, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danet-Desnoyers, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bono, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levade, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manenti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Junot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portais, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alet, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Recher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selak, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarry, J. E.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial energetic and AKT status mediate metabolic effects and apoptosis of metformin in human leukemic cells</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">2129</span>â <span class="NLM_lpage">2138</span>, <span class="refDoi">Â DOI: 10.1038/leu.2013.107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fleu.2013.107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=23568147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslaru7zO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=2129-2138&author=S.+Scotlandauthor=E.+Salandauthor=N.+Skuliauthor=F.+de+Toniauthor=H.+Boutzenauthor=E.+Micklowauthor=I.+Senegasauthor=R.+Peyraudauthor=L.+Peyrigaauthor=F.+Theodoroauthor=E.+Dumonauthor=Y.+Martineauauthor=G.+Danet-Desnoyersauthor=F.+Bonoauthor=C.+Rocherauthor=T.+Levadeauthor=S.+Manentiauthor=C.+Junotauthor=J.+C.+Portaisauthor=N.+Aletauthor=C.+Recherauthor=M.+A.+Selakauthor=M.+Carrollauthor=J.+E.+Sarry&title=Mitochondrial+energetic+and+AKT+status+mediate+metabolic+effects+and+apoptosis+of+metformin+in+human+leukemic+cells&doi=10.1038%2Fleu.2013.107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial energetic and AKT status mediate metabolic effects and apoptosis of metformin in human leukemic cells</span></div><div class="casAuthors">Scotland, S.; Saland, E.; Skuli, N.; de Toni, F.; Boutzen, H.; Micklow, E.; Senegas, I.; Peyraud, R.; Peyriga, L.; Theodoro, F.; Dumon, E.; Martineau, Y.; Danet-Desnoyers, G.; Bono, F.; Rocher, C.; Levade, T.; Manenti, S.; Junot, C.; Portais, J-C.; Alet, N.; Recher, C.; Selak, M. A.; Carroll, M.; Sarry, J-E.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2129-2138</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Previous reports demonstrate that metformin, an anti-diabetic drug, can decrease the risk of cancer and inhibit cancer cell growth.  However, its mechanism in cancer cells is still unknown.  Metformin significantly blocks cell cycle and inhibits cell proliferation and colony formation of leukemic cells.  However, the apoptotic response to metformin varies.  Furthermore, daily treatment with metformin induces apoptosis and reduces tumor growth in vivo.  While metformin induces early and transient activation of AMPK, inhibition of AMPKÎ±1/2 does not abrogate anti-proliferative or pro-apoptotic effects of metformin.  Metformin decreases electron transport chain complex I activity, oxygen consumption and mitochondrial ATP synthesis, while stimulating glycolysis for ATP and lactate prodn., pentose phosphate pathway for purine biosynthesis, fatty acid metab., as well as anaplerotic and mitochondrial gene expression.  Importantly, leukemic cells with high basal AKT phosphorylation, glucose consumption or glycolysis exhibit a markedly reduced induction of the Pasteur effect in response to metformin and are resistant to metformin-induced apoptosis.  Accordingly, glucose starvation or treatment with deoxyglucose or an AKT inhibitor induces sensitivity to metformin.  Overall, metformin elicits reprogramming of intermediary metab. leading to inhibition of cell proliferation in all leukemic cells and apoptosis only in leukemic cells responding to metformin with AKT phosphorylation and a strong Pasteur effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRpmYpLAxu5bVg90H21EOLACvtfcHk0lhGjFpDufYA-g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslaru7zO&md5=1d317587f742965aa66a4f311abeed7d</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1038%2Fleu.2013.107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2013.107%26sid%3Dliteratum%253Aachs%26aulast%3DScotland%26aufirst%3DS.%26aulast%3DSaland%26aufirst%3DE.%26aulast%3DSkuli%26aufirst%3DN.%26aulast%3Dde%2BToni%26aufirst%3DF.%26aulast%3DBoutzen%26aufirst%3DH.%26aulast%3DMicklow%26aufirst%3DE.%26aulast%3DSenegas%26aufirst%3DI.%26aulast%3DPeyraud%26aufirst%3DR.%26aulast%3DPeyriga%26aufirst%3DL.%26aulast%3DTheodoro%26aufirst%3DF.%26aulast%3DDumon%26aufirst%3DE.%26aulast%3DMartineau%26aufirst%3DY.%26aulast%3DDanet-Desnoyers%26aufirst%3DG.%26aulast%3DBono%26aufirst%3DF.%26aulast%3DRocher%26aufirst%3DC.%26aulast%3DLevade%26aufirst%3DT.%26aulast%3DManenti%26aufirst%3DS.%26aulast%3DJunot%26aufirst%3DC.%26aulast%3DPortais%26aufirst%3DJ.%2BC.%26aulast%3DAlet%26aufirst%3DN.%26aulast%3DRecher%26aufirst%3DC.%26aulast%3DSelak%26aufirst%3DM.%2BA.%26aulast%3DCarroll%26aufirst%3DM.%26aulast%3DSarry%26aufirst%3DJ.%2BE.%26atitle%3DMitochondrial%2520energetic%2520and%2520AKT%2520status%2520mediate%2520metabolic%2520effects%2520and%2520apoptosis%2520of%2520metformin%2520in%2520human%2520leukemic%2520cells%26jtitle%3DLeukemia%26date%3D2013%26volume%3D27%26spage%3D2129%26epage%3D2138%26doi%3D10.1038%2Fleu.2013.107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baccelli, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gareau, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehnertz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingras, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinella, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corneau, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayotte, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frechette, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blouin-Chagnon, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leveille, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boivin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacRae, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krosl, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiollier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavallee, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanshin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertomeu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulombe-Huntington, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St-Denis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordeleau, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucher, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roux, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemieux, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thibault, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hebert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauvageau, G.</span></span> <span> </span><span class="NLM_article-title">Mubritinib targets the electron transport chain complex I and reveals the landscape of OXPHOS dependency in acute myeloid leukemia</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">84</span>â <span class="NLM_lpage">99</span>, <span class="refDoi">Â DOI: 10.1016/j.ccell.2019.06.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.ccell.2019.06.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=31287994" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlersbzO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2019&pages=84-99&author=I.+Baccelliauthor=Y.+Gareauauthor=B.+Lehnertzauthor=S.+Gingrasauthor=J.+F.+Spinellaauthor=S.+Corneauauthor=N.+Mayotteauthor=S.+Girardauthor=M.+Frechetteauthor=V.+Blouin-Chagnonauthor=K.+Leveilleauthor=I.+Boivinauthor=T.+MacRaeauthor=J.+Kroslauthor=C.+Thiollierauthor=V.+P.+Lavalleeauthor=E.+Kanshinauthor=T.+Bertomeuauthor=J.+Coulombe-Huntingtonauthor=C.+St-Denisauthor=M.+E.+Bordeleauauthor=G.+Boucherauthor=P.+P.+Rouxauthor=S.+Lemieuxauthor=M.+Tyersauthor=P.+Thibaultauthor=J.+Hebertauthor=A.+Marinierauthor=G.+Sauvageau&title=Mubritinib+targets+the+electron+transport+chain+complex+I+and+reveals+the+landscape+of+OXPHOS+dependency+in+acute+myeloid+leukemia&doi=10.1016%2Fj.ccell.2019.06.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Mubritinib Targets the Electron Transport Chain Complex I and Reveals the Landscape of OXPHOS Dependency in Acute Myeloid Leukemia</span></div><div class="casAuthors">Baccelli, Irene; Gareau, Yves; Lehnertz, Bernhard; Gingras, Stephane; Spinella, Jean-Francois; Corneau, Sophie; Mayotte, Nadine; Girard, Simon; Frechette, Melanie; Blouin-Chagnon, Valerie; Leveille, Koryne; Boivin, Isabel; MacRae, Tara; Krosl, Jana; Thiollier, Clarisse; Lavallee, Vincent-Philippe; Kanshin, Evgeny; Bertomeu, Thierry; Coulombe-Huntington, Jasmin; St-Denis, Corinne; Bordeleau, Marie-Eve; Boucher, Genevieve; Roux, Philippe P.; Lemieux, Sebastien; Tyers, Mike; Thibault, Pierre; Hebert, Josee; Marinier, Anne; Sauvageau, Guy</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">84-99.e8</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">To identify therapeutic targets in acute myeloid leukemia (AML), we chem. interrogated 200 sequenced primary specimens.  Mubritinib, a known ERBB2 inhibitor, elicited strong anti-leukemic effects in vitro and in vivo.  In the context of AML, mubritinib functions through ubiquinone-dependent inhibition of electron transport chain (ETC) complex I activity.  Resistance to mubritinib characterized normal CD34+ hematopoietic cells and chemotherapy-sensitive AMLs, which displayed transcriptomic hallmarks of hypoxia.  Conversely, sensitivity correlated with mitochondrial function-related gene expression levels and characterized a large subset of chemotherapy-resistant AMLs with oxidative phosphorylation (OXPHOS) hyperactivity.  Altogether, our work thus identifies an ETC complex I inhibitor and reveals the genetic landscape of OXPHOS dependency in AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra90vl42LHXrVg90H21EOLACvtfcHk0lhGjFpDufYA-g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlersbzO&md5=f2627e1db6c0cddd427a44eba0ac9dd9</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2019.06.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2019.06.003%26sid%3Dliteratum%253Aachs%26aulast%3DBaccelli%26aufirst%3DI.%26aulast%3DGareau%26aufirst%3DY.%26aulast%3DLehnertz%26aufirst%3DB.%26aulast%3DGingras%26aufirst%3DS.%26aulast%3DSpinella%26aufirst%3DJ.%2BF.%26aulast%3DCorneau%26aufirst%3DS.%26aulast%3DMayotte%26aufirst%3DN.%26aulast%3DGirard%26aufirst%3DS.%26aulast%3DFrechette%26aufirst%3DM.%26aulast%3DBlouin-Chagnon%26aufirst%3DV.%26aulast%3DLeveille%26aufirst%3DK.%26aulast%3DBoivin%26aufirst%3DI.%26aulast%3DMacRae%26aufirst%3DT.%26aulast%3DKrosl%26aufirst%3DJ.%26aulast%3DThiollier%26aufirst%3DC.%26aulast%3DLavallee%26aufirst%3DV.%2BP.%26aulast%3DKanshin%26aufirst%3DE.%26aulast%3DBertomeu%26aufirst%3DT.%26aulast%3DCoulombe-Huntington%26aufirst%3DJ.%26aulast%3DSt-Denis%26aufirst%3DC.%26aulast%3DBordeleau%26aufirst%3DM.%2BE.%26aulast%3DBoucher%26aufirst%3DG.%26aulast%3DRoux%26aufirst%3DP.%2BP.%26aulast%3DLemieux%26aufirst%3DS.%26aulast%3DTyers%26aufirst%3DM.%26aulast%3DThibault%26aufirst%3DP.%26aulast%3DHebert%26aufirst%3DJ.%26aulast%3DMarinier%26aufirst%3DA.%26aulast%3DSauvageau%26aufirst%3DG.%26atitle%3DMubritinib%2520targets%2520the%2520electron%2520transport%2520chain%2520complex%2520I%2520and%2520reveals%2520the%2520landscape%2520of%2520OXPHOS%2520dependency%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DCancer%2520Cell%26date%3D2019%26volume%3D36%26spage%3D84%26epage%3D99%26doi%3D10.1016%2Fj.ccell.2019.06.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ye, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, X. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, G. S.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial and energy metabolism-related properties as novel indicators of lung cancer stem cells</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">820</span>â <span class="NLM_lpage">831</span>, <span class="refDoi">Â DOI: 10.1002/ijc.25944</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1002%2Fijc.25944" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=21520032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnvFansrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2011&pages=820-831&author=X.+Q.+Yeauthor=Q.+Liauthor=G.+H.+Wangauthor=F.+F.+Sunauthor=G.+J.+Huangauthor=X.+W.+Bianauthor=S.+C.+Yuauthor=G.+S.+Qian&title=Mitochondrial+and+energy+metabolism-related+properties+as+novel+indicators+of+lung+cancer+stem+cells&doi=10.1002%2Fijc.25944"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial and energy metabolism-related properties as novel indicators of lung cancer stem cells</span></div><div class="casAuthors">Ye, Xiao-Qun; Li, Qi; Wang, Guang-Hui; Sun, Fen-Fen; Huang, Gui-Jun; Bian, Xiu-Wu; Yu, Shi-Cang; Qian, Gui-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">820-831</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Energy metab. is the foundation of survival for all organisms, and mitochondria are the most important energy-supplying organelles in eukaryotic cells.  However, the mitochondrial and energy/metab.-related properties of cancer stem cells (CSCs), the stem cell-like subpopulation in tumor masses, remain unknown.  In our study, we compared the masses of mitochondria and mitochondrial DNA (mtDNA), the mitochondrial membrane potential (ÎÏm), oxygen/glucose consumption, and the concn. of reactive oxygen species (ROS) and ATP between lung CSCs (LCSCs) and non-LCSCs.  In addn., the change in features during differentiation was examd.  Some mitochondrial and energy metab.-related properties, such as perinuclear mitochondrial distribution, a lower quantity of mtDNA, higher ÎÏm, lower oxygen/glucose consumption, and lower intracellular concns. of ROS and ATP, can be used as indicators of LCSCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5oGtdCBkC3LVg90H21EOLACvtfcHk0lhGjFpDufYA-g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnvFansrw%253D&md5=dbd5de94171982142f01b6b6dcff2af2</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1002%2Fijc.25944&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.25944%26sid%3Dliteratum%253Aachs%26aulast%3DYe%26aufirst%3DX.%2BQ.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DG.%2BH.%26aulast%3DSun%26aufirst%3DF.%2BF.%26aulast%3DHuang%26aufirst%3DG.%2BJ.%26aulast%3DBian%26aufirst%3DX.%2BW.%26aulast%3DYu%26aufirst%3DS.%2BC.%26aulast%3DQian%26aufirst%3DG.%2BS.%26atitle%3DMitochondrial%2520and%2520energy%2520metabolism-related%2520properties%2520as%2520novel%2520indicators%2520of%2520lung%2520cancer%2520stem%2520cells%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2011%26volume%3D129%26spage%3D820%26epage%3D831%26doi%3D10.1002%2Fijc.25944" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janiszewska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suva, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riggi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamenkovic, I.</span></span> <span> </span><span class="NLM_article-title">Imp2 controls oxidative phosphorylation in glioblastoma cancer stem cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">1926</span>â <span class="NLM_lpage">1944</span>, <span class="refDoi">Â DOI: 10.1158/1538-7445.AM2012-1137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F1538-7445.AM2012-1137" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=1926-1944&author=M.+Janiszewskaauthor=M.+L.+Suvaauthor=N.+Riggiauthor=I.+Stamenkovic&title=Imp2+controls+oxidative+phosphorylation+in+glioblastoma+cancer+stem+cells&doi=10.1158%2F1538-7445.AM2012-1137"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2012-1137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2012-1137%26sid%3Dliteratum%253Aachs%26aulast%3DJaniszewska%26aufirst%3DM.%26aulast%3DSuva%26aufirst%3DM.%2BL.%26aulast%3DRiggi%26aufirst%3DN.%26aulast%3DStamenkovic%26aufirst%3DI.%26atitle%3DImp2%2520controls%2520oxidative%2520phosphorylation%2520in%2520glioblastoma%2520cancer%2520stem%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D1926%26epage%3D1944%26doi%3D10.1158%2F1538-7445.AM2012-1137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sancho, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgos-Ramos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavera, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kheir, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jagust, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoenhals, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barneda, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campos-Olivas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grana, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viera, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuneva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sainz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heeschen, C.</span></span> <span> </span><span class="NLM_article-title">MYC/PGC-1 alpha balance determines the metabolic phenotype and plasticity of pancreatic cancer stem cells</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">590</span>â <span class="NLM_lpage">605</span>, <span class="refDoi">Â DOI: 10.1016/j.cmet.2015.08.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.cmet.2015.08.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=26365176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsV2ls7bM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=590-605&author=P.+Sanchoauthor=E.+Burgos-Ramosauthor=A.+Taveraauthor=T.+B.+Kheirauthor=P.+Jagustauthor=M.+Schoenhalsauthor=D.+Barnedaauthor=K.+Sellersauthor=R.+Campos-Olivasauthor=O.+Granaauthor=C.+R.+Vieraauthor=M.+Yunevaauthor=B.+Sainzauthor=C.+Heeschen&title=MYC%2FPGC-1+alpha+balance+determines+the+metabolic+phenotype+and+plasticity+of+pancreatic+cancer+stem+cells&doi=10.1016%2Fj.cmet.2015.08.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">MYC/PGC-1Î± Balance Determines the Metabolic Phenotype and Plasticity of Pancreatic Cancer Stem Cells</span></div><div class="casAuthors">Sancho, Patricia; Burgos-Ramos, Emma; Tavera, Alejandra; Bou Kheir, Tony; Jagust, Petra; Schoenhals, Matthieu; Barneda, David; Sellers, Katherine; Campos-Olivas, Ramon; Grana, Osvaldo; Viera, Catarina R.; Yuneva, Mariia; Sainz, Bruno, Jr.; Heeschen, Christopher</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">590-605</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The anti-diabetic drug metformin targets pancreatic cancer stem cells (CSCs), but not their differentiated progenies (non-CSCs), which may be related to distinct metabolic phenotypes.  Here we conclusively demonstrate that while non-CSCs were highly glycolytic, CSCs were dependent on oxidative metab. (OXPHOS) with very limited metabolic plasticity.  Thus, mitochondrial inhibition, e.g., by metformin, translated into energy crisis and apoptosis.  However, resistant CSC clones eventually emerged during treatment with metformin due to their intermediate glycolytic/respiratory phenotype.  Mechanistically, suppression of MYC and subsequent increase of PGC-1Î± were identified as key determinants for the OXPHOS dependency of CSCs, which was abolished in resistant CSC clones.  Intriguingly, no resistance was obsd. for the mitochondrial ROS inducer menadione and resistance could also be prevented/reversed for metformin by genetic/pharmacol. inhibition of MYC.  Thus, the specific metabolic features of pancreatic CSCs are amendable to therapeutic intervention and could provide the basis for developing more effective therapies to combat this lethal cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-SwmwcfA1-LVg90H21EOLACvtfcHk0lgP8fXzuJZaHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsV2ls7bM&md5=9ca91da8a48f4d75779cfb2a549ead0a</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2015.08.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2015.08.015%26sid%3Dliteratum%253Aachs%26aulast%3DSancho%26aufirst%3DP.%26aulast%3DBurgos-Ramos%26aufirst%3DE.%26aulast%3DTavera%26aufirst%3DA.%26aulast%3DKheir%26aufirst%3DT.%2BB.%26aulast%3DJagust%26aufirst%3DP.%26aulast%3DSchoenhals%26aufirst%3DM.%26aulast%3DBarneda%26aufirst%3DD.%26aulast%3DSellers%26aufirst%3DK.%26aulast%3DCampos-Olivas%26aufirst%3DR.%26aulast%3DGrana%26aufirst%3DO.%26aulast%3DViera%26aufirst%3DC.%2BR.%26aulast%3DYuneva%26aufirst%3DM.%26aulast%3DSainz%26aufirst%3DB.%26aulast%3DHeeschen%26aufirst%3DC.%26atitle%3DMYC%252FPGC-1%2520alpha%2520balance%2520determines%2520the%2520metabolic%2520phenotype%2520and%2520plasticity%2520of%2520pancreatic%2520cancer%2520stem%2520cells%26jtitle%3DCell%2520Metab.%26date%3D2015%26volume%3D22%26spage%3D590%26epage%3D605%26doi%3D10.1016%2Fj.cmet.2015.08.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giltnane, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balko, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arteaga, C.</span></span> <span> </span><span class="NLM_article-title">MYC and MCL1 cooperatively promote chemotherapy-resistant cancer stem cells through regulation of mitochondrial biogenesis and oxidative phosphorylation</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">633</span>â <span class="NLM_lpage">647</span>, <span class="refDoi">Â DOI: 10.1158/1538-7445.AM2016-3328</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F1538-7445.AM2016-3328" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=633-647&author=K.+M.+Leeauthor=J.+Giltnaneauthor=J.+Balkoauthor=C.+Arteaga&title=MYC+and+MCL1+cooperatively+promote+chemotherapy-resistant+cancer+stem+cells+through+regulation+of+mitochondrial+biogenesis+and+oxidative+phosphorylation&doi=10.1158%2F1538-7445.AM2016-3328"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2016-3328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2016-3328%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%2BM.%26aulast%3DGiltnane%26aufirst%3DJ.%26aulast%3DBalko%26aufirst%3DJ.%26aulast%3DArteaga%26aufirst%3DC.%26atitle%3DMYC%2520and%2520MCL1%2520cooperatively%2520promote%2520chemotherapy-resistant%2520cancer%2520stem%2520cells%2520through%2520regulation%2520of%2520mitochondrial%2520biogenesis%2520and%2520oxidative%2520phosphorylation%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26spage%3D633%26epage%3D647%26doi%3D10.1158%2F1538-7445.AM2016-3328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lagadinou, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sach, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callahan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neering, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minhajuddin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grose, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâDwyer, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liesveld, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brookes, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, C. T.</span></span> <span> </span><span class="NLM_article-title">BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells</span>. <i>Cell Stem Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">329</span>â <span class="NLM_lpage">341</span>, <span class="refDoi">Â DOI: 10.1016/j.stem.2012.12.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.stem.2012.12.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=23333149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Gntbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=329-341&author=E.+D.+Lagadinouauthor=A.+Sachauthor=K.+Callahanauthor=R.+M.+Rossiauthor=S.+J.+Neeringauthor=M.+Minhajuddinauthor=J.+M.+Ashtonauthor=S.+S.+Peiauthor=V.+Groseauthor=K.+M.+O%E2%80%99Dwyerauthor=J.+L.+Liesveldauthor=P.+S.+Brookesauthor=M.+W.+Beckerauthor=C.+T.+Jordan&title=BCL-2+inhibition+targets+oxidative+phosphorylation+and+selectively+eradicates+quiescent+human+leukemia+stem+cells&doi=10.1016%2Fj.stem.2012.12.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells</span></div><div class="casAuthors">Lagadinou, Eleni D.; Sach, Alexander; Callahan, Kevin; Rossi, Randall M.; Neering, Sarah J.; Minhajuddin, Mohammad; Ashton, John M.; Pei, Shanshan; Grose, Valerie; O'Dwyer, Kristen M.; Liesveld, Jane L.; Brookes, Paul S.; Becker, Michael W.; Jordan, Craig T.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Stem Cell</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-341</span>CODEN:
                <span class="NLM_cas:coden">CSCEC4</span>;
        ISSN:<span class="NLM_cas:issn">1875-9777</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Most forms of chemotherapy employ mechanisms involving induction of oxidative stress, a strategy that can be effective due to the elevated oxidative state commonly obsd. in cancer cells.  However, recent studies have shown that relative redox levels in primary tumors can be heterogeneous, suggesting that regimens dependent on differential oxidative state may not be uniformly effective.  To investigate this issue in hematol. malignancies, we evaluated mechanisms controlling oxidative state in primary specimens derived from acute myelogenous leukemia (AML) patients.  Our studies demonstrate three striking findings.  First, the majority of functionally defined leukemia stem cells (LSCs) are characterized by relatively low levels of reactive oxygen species (termed "ROS-low").  Second, ROS-low LSCs aberrantly overexpress BCL-2.  Third, BCL-2 inhibition reduced oxidative phosphorylation and selectively eradicated quiescent LSCs.  Based on these findings, we propose a model wherein the unique physiol. of ROS-low LSCs provides an opportunity for selective targeting via disruption of BCL-2-dependent oxidative phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfldXzIARw0rVg90H21EOLACvtfcHk0lgP8fXzuJZaHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Gntbs%253D&md5=182aff14ca9f1ab26a13a9fb7e59c0a0</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2Fj.stem.2012.12.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.stem.2012.12.013%26sid%3Dliteratum%253Aachs%26aulast%3DLagadinou%26aufirst%3DE.%2BD.%26aulast%3DSach%26aufirst%3DA.%26aulast%3DCallahan%26aufirst%3DK.%26aulast%3DRossi%26aufirst%3DR.%2BM.%26aulast%3DNeering%26aufirst%3DS.%2BJ.%26aulast%3DMinhajuddin%26aufirst%3DM.%26aulast%3DAshton%26aufirst%3DJ.%2BM.%26aulast%3DPei%26aufirst%3DS.%2BS.%26aulast%3DGrose%26aufirst%3DV.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DK.%2BM.%26aulast%3DLiesveld%26aufirst%3DJ.%2BL.%26aulast%3DBrookes%26aufirst%3DP.%2BS.%26aulast%3DBecker%26aufirst%3DM.%2BW.%26aulast%3DJordan%26aufirst%3DC.%2BT.%26atitle%3DBCL-2%2520inhibition%2520targets%2520oxidative%2520phosphorylation%2520and%2520selectively%2520eradicates%2520quiescent%2520human%2520leukemia%2520stem%2520cells%26jtitle%3DCell%2520Stem%2520Cell%26date%3D2013%26volume%3D12%26spage%3D329%26epage%3D341%26doi%3D10.1016%2Fj.stem.2012.12.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janiszewska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suva, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riggi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houtkooper, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auwerx, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clement-Schatlo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radovanovic, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rheinbay, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Provero, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamenkovic, I.</span></span> <span> </span><span class="NLM_article-title">Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells</span>. <i>Genes Dev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1926</span>â <span class="NLM_lpage">1944</span>, <span class="refDoi">Â DOI: 10.1101/gad.188292.112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1101%2Fgad.188292.112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=22899010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVSlsb3K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=1926-1944&author=M.+Janiszewskaauthor=M.+L.+Suvaauthor=N.+Riggiauthor=R.+H.+Houtkooperauthor=J.+Auwerxauthor=V.+Clement-Schatloauthor=I.+Radovanovicauthor=E.+Rheinbayauthor=P.+Proveroauthor=I.+Stamenkovic&title=Imp2+controls+oxidative+phosphorylation+and+is+crucial+for+preserving+glioblastoma+cancer+stem+cells&doi=10.1101%2Fgad.188292.112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells</span></div><div class="casAuthors">Janiszewska, Michalina; Suva, Mario L.; Riggi, Nicolo; Houtkooper, Riekelt H.; Auwerz, Johan; Clement-Schatlo, Virginie; Radovanovic, Ivan; Rheinbay, Esther; Provero, Paolo; Stamenkovic, Ivan</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1926-1944</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">Growth of numerous cancer types is believed to be driven by a subpopulation of poorly differentiated cells, often referred to as cancer stem cells (CSCs), that have the capacity for self-renewal, tumor initiation, and generation of nontumorigenic progeny.  Despite their potentially key role in tumor establishment and maintenance, the energy requirements of these cells and the mechanisms that regulate their energy prodn. are unknown.  Here, we show that the oncofetal insulin-like growth factor 2 mRNA-binding protein 2 (IMP2, IGF2BP2) regulates oxidative phosphorylation (OXPHOS) in primary glioblastoma (GBM) sphere cultures (gliomaspheres), an established in vitro model for CSC expansion.  We demonstrate that IMP2 binds several mRNAs that encode mitochondrial respiratory chain complex subunits and that it interacts with complex I (NADH:ubiquinone oxidoreductase) proteins.  Depletion of IMP2 in gliomaspheres decreases their oxygen consumption rate and both complex I and complex IV activity that results in impaired clonogenicity in vitro and tumorigenicity in vivo.  Importantly, inhibition of OXPHOS but not of glycolysis abolishes GBM cell clonogenicity.  Our observations suggest that gliomaspheres depend on OXPHOS for their energy prodn. and survival and that IMP2 expression provides a key mechanism to ensure OXPHOS maintenance by delivering respiratory chain subunit-encoding mRNAs to mitochondria and contributing to complex I and complex IV assembly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQUr96F-y-SLVg90H21EOLACvtfcHk0lh2U2VOiVkbgA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVSlsb3K&md5=93f963a970386a4eb584b284349f0908</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1101%2Fgad.188292.112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.188292.112%26sid%3Dliteratum%253Aachs%26aulast%3DJaniszewska%26aufirst%3DM.%26aulast%3DSuva%26aufirst%3DM.%2BL.%26aulast%3DRiggi%26aufirst%3DN.%26aulast%3DHoutkooper%26aufirst%3DR.%2BH.%26aulast%3DAuwerx%26aufirst%3DJ.%26aulast%3DClement-Schatlo%26aufirst%3DV.%26aulast%3DRadovanovic%26aufirst%3DI.%26aulast%3DRheinbay%26aufirst%3DE.%26aulast%3DProvero%26aufirst%3DP.%26aulast%3DStamenkovic%26aufirst%3DI.%26atitle%3DImp2%2520controls%2520oxidative%2520phosphorylation%2520and%2520is%2520crucial%2520for%2520preserving%2520glioblastoma%2520cancer%2520stem%2520cells%26jtitle%3DGenes%2520Dev.%26date%3D2012%26volume%3D26%26spage%3D1926%26epage%3D1944%26doi%3D10.1101%2Fgad.188292.112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fiorillo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanowitz, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappello, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Outschoorn, U. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotgia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lisanti, M. P.</span></span> <span> </span><span class="NLM_article-title">Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs)</span>. <i>Aging</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1593</span>â <span class="NLM_lpage">1607</span>, <span class="refDoi">Â DOI: 10.18632/aging.100983</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.18632%2Faging.100983" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27344270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotlyrtb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=1593-1607&author=M.+Fiorilloauthor=R.+Lambauthor=H.+B.+Tanowitzauthor=A.+R.+Cappelloauthor=U.+E.+Martinez-Outschoornauthor=F.+Sotgiaauthor=M.+P.+Lisanti&title=Bedaquiline%2C+an+FDA-approved+antibiotic%2C+inhibits+mitochondrial+function+and+potently+blocks+the+proliferative+expansion+of+stem-like+cancer+cells+%28CSCs%29&doi=10.18632%2Faging.100983"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs)</span></div><div class="casAuthors">Fiorillo, Marco; Lamb, Rebecca; Tanowitz, Herbert B.; Cappello, Anna Rita; Martinez-Outschoorn, Ubaldo E.; Sotgia, Federica; Lisanti, Michael P.</div><div class="citationInfo"><span class="NLM_cas:title">Aging</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1593-1607</span>CODEN:
                <span class="NLM_cas:coden">AGINCN</span>;
        ISSN:<span class="NLM_cas:issn">1945-4589</span>.
    
            (<span class="NLM_cas:orgname">Impact Journals LLC</span>)
        </div><div class="casAbstract">Bedaquiline (a.k.a., Sirturo) is an anti-microbial agent, which is approved by the FDA for the treatment of multi-drug resistant pulmonary tuberculosis (TB).  Bedaquiline is a first-in-class diaryl-quinoline compd., that mechanistically inhibits the bacterial ATP-synthase, and shows potent activity against both drug-sensitive and drug-resistant TB.  Interestingly, eukaryotic mitochondria originally evolved from engulfed aerobic bacteria.  Thus, we hypothesized that, in mammalian cells, bedaquiline might also target the mitochondrial ATP-synthase, leading to mitochondrial dysfunction and ATP depletion.  Here, we show that bedaquiline has anti-cancer activity, directed against Cancer Stem-like Cells (CSCs).  More specifically, we demonstrate that bedaquiline treatment of MCF7 breast cancer cells inhibits mitochondrial oxygen-consumption, as well as glycolysis, but induces oxidative stress.  Importantly, bedaquiline significantly blocks the propagation and expansion of MCF7-derived CSCs, with an IC-50 of approx. 1-Î¼M, as detd. using the mammosphere assay.  Similarly, bedaquiline also reduces both the CD44+/CD24low/- CSC and ALDH+ CSC populations, under anchorage-independent growth conditions.  In striking contrast, bedaquiline significantly increases oxygen consumption in normal human fibroblasts, consistent with the fact that it is well-tolerated in patients treated for TB infections.  As such, future pre-clin. studies and human clin. trials in cancer patients may be warranted.  Interestingly, we also highlight that bedaquiline shares certain structural similarities with trans-piceatannol and trans-resveratrol, which are known natural flavonoid inhibitors of the mitochondrial ATP-synthase (complex V) and show anti-aging properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBH-lz9QVs9bVg90H21EOLACvtfcHk0lh2U2VOiVkbgA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotlyrtb0%253D&md5=f5a17262b385e1b1a6c0cb6c91dee919</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.18632%2Faging.100983&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Faging.100983%26sid%3Dliteratum%253Aachs%26aulast%3DFiorillo%26aufirst%3DM.%26aulast%3DLamb%26aufirst%3DR.%26aulast%3DTanowitz%26aufirst%3DH.%2BB.%26aulast%3DCappello%26aufirst%3DA.%2BR.%26aulast%3DMartinez-Outschoorn%26aufirst%3DU.%2BE.%26aulast%3DSotgia%26aufirst%3DF.%26aulast%3DLisanti%26aufirst%3DM.%2BP.%26atitle%3DBedaquiline%252C%2520an%2520FDA-approved%2520antibiotic%252C%2520inhibits%2520mitochondrial%2520function%2520and%2520potently%2520blocks%2520the%2520proliferative%2520expansion%2520of%2520stem-like%2520cancer%2520cells%2520%2528CSCs%2529%26jtitle%3DAging%26date%3D2016%26volume%3D8%26spage%3D1593%26epage%3D1607%26doi%3D10.18632%2Faging.100983" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, P. M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shieh, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jan, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuang, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, A. T. H.</span></span> <span> </span><span class="NLM_article-title">A preclinical evaluation of antimycin A as a potential antilung cancer stem cell agent</span>. <i>Evid. Based Complement. Alternat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>2013</i></span>,  <span class="NLM_fpage">1</span>, <span class="refDoi">Â DOI: 10.1155/2013/910451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1155%2F2013%2F910451" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2013&publication_year=2013&pages=1&author=C.+T.+Yehauthor=C.+L.+Suauthor=C.+Y.+F.+Huangauthor=J.+K.+Y.+Linauthor=W.+H.+Leeauthor=P.+M.+H.+Changauthor=Y.+L.+Kuoauthor=Y.+W.+Liuauthor=L.+S.+Wangauthor=C.+H.+Wuauthor=Y.+S.+Shiehauthor=Y.+H.+Janauthor=Y.+J.+Chuangauthor=M.+Hsiaoauthor=A.+T.+H.+Wu&title=A+preclinical+evaluation+of+antimycin+A+as+a+potential+antilung+cancer+stem+cell+agent&doi=10.1155%2F2013%2F910451"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1155%2F2013%2F910451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2013%252F910451%26sid%3Dliteratum%253Aachs%26aulast%3DYeh%26aufirst%3DC.%2BT.%26aulast%3DSu%26aufirst%3DC.%2BL.%26aulast%3DHuang%26aufirst%3DC.%2BY.%2BF.%26aulast%3DLin%26aufirst%3DJ.%2BK.%2BY.%26aulast%3DLee%26aufirst%3DW.%2BH.%26aulast%3DChang%26aufirst%3DP.%2BM.%2BH.%26aulast%3DKuo%26aufirst%3DY.%2BL.%26aulast%3DLiu%26aufirst%3DY.%2BW.%26aulast%3DWang%26aufirst%3DL.%2BS.%26aulast%3DWu%26aufirst%3DC.%2BH.%26aulast%3DShieh%26aufirst%3DY.%2BS.%26aulast%3DJan%26aufirst%3DY.%2BH.%26aulast%3DChuang%26aufirst%3DY.%2BJ.%26aulast%3DHsiao%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DA.%2BT.%2BH.%26atitle%3DA%2520preclinical%2520evaluation%2520of%2520antimycin%2520A%2520as%2520a%2520potential%2520antilung%2520cancer%2520stem%2520cell%2520agent%26jtitle%3DEvid.%2520Based%2520Complement.%2520Alternat.%2520Med.%26date%3D2013%26volume%3D2013%26spage%3D1%26doi%3D10.1155%2F2013%2F910451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fryknas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernlund, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fayad, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Milito, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olofsson, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogvadze, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pahlman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schughart, L. A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rickardson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darcy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gullbo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nygren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linder, S.</span></span> <span> </span><span class="NLM_article-title">Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">3295</span>, <span class="refDoi">Â DOI: 10.1038/ncomms4295</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fncomms4295" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=24548894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BC2cvmt1Snuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=3295&author=X.+N.+Zhangauthor=M.+Fryknasauthor=E.+Hernlundauthor=W.+Fayadauthor=A.+De+Militoauthor=M.+H.+Olofssonauthor=V.+Gogvadzeauthor=L.+Dangauthor=S.+Pahlmanauthor=L.+A.+K.+Schughartauthor=L.+Rickardsonauthor=P.+Darcyauthor=J.+Gullboauthor=P.+Nygrenauthor=R.+Larssonauthor=S.+Linder&title=Induction+of+mitochondrial+dysfunction+as+a+strategy+for+targeting+tumour+cells+in+metabolically+compromised+microenvironments&doi=10.1038%2Fncomms4295"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments</span></div><div class="casAuthors">Zhang Xiaonan; Fayad Walid; Fryknas Marten; Hernlund Emma; De Milito Angelo; Olofsson Maria Hagg; D'Arcy Padraig; Gogvadze Vladimir; Dang Long; Pahlman Sven; Schughart Leoni A Kunz; Rickardson Linda; Larsson Rolf; Gullbo Joachim; Nygren Peter; Linder Stig</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3295</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Abnormal vascularization of solid tumours results in the development of microenvironments deprived of oxygen and nutrients that harbour slowly growing and metabolically stressed cells.  Such cells display enhanced resistance to standard chemotherapeutic agents and repopulate tumours after therapy.  Here we identify the small molecule VLX600 as a drug that is preferentially active against quiescent cells in colon cancer 3-D microtissues.  The anticancer activity is associated with reduced mitochondrial respiration, leading to bioenergetic catastrophe and tumour cell death.  VLX600 shows enhanced cytotoxic activity under conditions of nutrient starvation.  Importantly, VLX600 displays tumour growth inhibition in vivo.  Our findings suggest that tumour cells in metabolically compromised microenvironments have a limited ability to respond to decreased mitochondrial function, and suggest a strategy for targeting the quiescent populations of tumour cells for improved cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR5TABksD1e0acY7HFp97qMfW6udTcc2eZ6tT7NQ_Gzf7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cvmt1Snuw%253D%253D&md5=0167667cf70a7a672960cd32bf8fe39c</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1038%2Fncomms4295&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms4295%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%2BN.%26aulast%3DFryknas%26aufirst%3DM.%26aulast%3DHernlund%26aufirst%3DE.%26aulast%3DFayad%26aufirst%3DW.%26aulast%3DDe%2BMilito%26aufirst%3DA.%26aulast%3DOlofsson%26aufirst%3DM.%2BH.%26aulast%3DGogvadze%26aufirst%3DV.%26aulast%3DDang%26aufirst%3DL.%26aulast%3DPahlman%26aufirst%3DS.%26aulast%3DSchughart%26aufirst%3DL.%2BA.%2BK.%26aulast%3DRickardson%26aufirst%3DL.%26aulast%3DDarcy%26aufirst%3DP.%26aulast%3DGullbo%26aufirst%3DJ.%26aulast%3DNygren%26aufirst%3DP.%26aulast%3DLarsson%26aufirst%3DR.%26aulast%3DLinder%26aufirst%3DS.%26atitle%3DInduction%2520of%2520mitochondrial%2520dysfunction%2520as%2520a%2520strategy%2520for%2520targeting%2520tumour%2520cells%2520in%2520metabolically%2520compromised%2520microenvironments%26jtitle%3DNat.%2520Commun.%26date%3D2014%26volume%3D5%26spage%3D3295%26doi%3D10.1038%2Fncomms4295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zacksenhaus, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrestha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vorobieva, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, P. E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ju, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nir, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial OXPHOS induced by RB1 deficiency in breast cancer: implications for anabolic metabolism, stemness, and metastasis</span>. <i>Trends in Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">768</span>â <span class="NLM_lpage">779</span>, <span class="refDoi">Â DOI: 10.1016/j.trecan.2017.09.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.trecan.2017.09.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=29120753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1MXksVygsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=768-779&author=E.+Zacksenhausauthor=M.+Shresthaauthor=J.+C.+Liuauthor=I.+Vorobievaauthor=P.+E.+D.+Chungauthor=Y.+J.+Juauthor=U.+Nirauthor=Z.+Jiang&title=Mitochondrial+OXPHOS+induced+by+RB1+deficiency+in+breast+cancer%3A+implications+for+anabolic+metabolism%2C+stemness%2C+and+metastasis&doi=10.1016%2Fj.trecan.2017.09.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial OXPHOS Induced by RB1 Deficiency in Breast Cancer: Implications for Anabolic Metabolism, Stemness, and Metastasis</span></div><div class="casAuthors">Zacksenhaus, Eldad; Shrestha, Mariusz; Liu, Jeff C.; Vorobieva, Ioulia; Chung, Philip E. D.; Ju, YoungJun; Nir, Uri; Jiang, Zhe</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">768-779</span>CODEN:
                <span class="NLM_cas:coden">TCRAB5</span>;
        ISSN:<span class="NLM_cas:issn">2405-8033</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  A switch from catabolic to anabolic metab., a major hallmark of cancer, enables rapid cell duplication, and is driven by multiple oncogenic alterations, including PIK3CA mutation, MYC amplification, and TP53 loss.  However, tumor growth requires active mitochondrial function and oxidative phosphorylation (OXPHOS).  Recently, loss of the retinoblastoma (RB1) tumor suppressor in breast cancer was shown to induce mitochondrial protein translation (MPT) and OXPHOS.  Here, we discuss how increased OXPHOS can enhance anabolic metab. and cell proliferation, as well as cancer stemness and metastasis.  Mitochondrial STAT3, FER/FER-T, and CHCHD2 are also implicated in OXPHOS.  We propose that RB1 loss represents a prototypic oncogenic alteration that promotes OXPHOS, that aggressive tumors acquire lethal combinations of oncogenes and tumor suppressors that stimulate anabolism vs. OXPHOS, and that targeting both metabolic pathways would be therapeutic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqG3gGHwo-LLbVg90H21EOLACvtfcHk0lgMlP64cAWvEg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXksVygsA%253D%253D&md5=09d3a5508deb5c89be61d39f6551de60</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1016%2Fj.trecan.2017.09.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.trecan.2017.09.002%26sid%3Dliteratum%253Aachs%26aulast%3DZacksenhaus%26aufirst%3DE.%26aulast%3DShrestha%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DJ.%2BC.%26aulast%3DVorobieva%26aufirst%3DI.%26aulast%3DChung%26aufirst%3DP.%2BE.%2BD.%26aulast%3DJu%26aufirst%3DY.%2BJ.%26aulast%3DNir%26aufirst%3DU.%26aulast%3DJiang%26aufirst%3DZ.%26atitle%3DMitochondrial%2520OXPHOS%2520induced%2520by%2520RB1%2520deficiency%2520in%2520breast%2520cancer%253A%2520implications%2520for%2520anabolic%2520metabolism%252C%2520stemness%252C%2520and%2520metastasis%26jtitle%3DTrends%2520in%2520Cancer%26date%3D2017%26volume%3D3%26spage%3D768%26epage%3D779%26doi%3D10.1016%2Fj.trecan.2017.09.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrestha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voisin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ju, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellecchia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fell, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muthuswamy, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Datti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egan, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schimmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zacksenhaus, E.</span></span> <span> </span><span class="NLM_article-title">RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">3739</span>â <span class="NLM_lpage">3757</span>, <span class="refDoi">Â DOI: 10.1172/JCI81568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1172%2FJCI81568" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27571409" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BC2szltVOqsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2016&pages=3739-3757&author=R.+A.+Jonesauthor=T.+J.+Robinsonauthor=J.+C.+Liuauthor=M.+Shresthaauthor=V.+Voisinauthor=Y.+Juauthor=P.+E.+Chungauthor=G.+Pellecchiaauthor=V.+L.+Fellauthor=S.+Baeauthor=L.+Muthuswamyauthor=A.+Dattiauthor=S.+E.+Eganauthor=Z.+Jiangauthor=G.+Leoneauthor=G.+D.+Baderauthor=A.+Schimmerauthor=E.+Zacksenhaus&title=RB1+deficiency+in+triple-negative+breast+cancer+induces+mitochondrial+protein+translation&doi=10.1172%2FJCI81568"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation</span></div><div class="casAuthors">Jones Robert A; Robinson Tyler J; Liu Jeff C; Shrestha Mariusz; Voisin Veronique; Ju YoungJun; Chung Philip E D; Pellecchia Giovanna; Fell Victoria L; Bae SooIn; Muthuswamy Lakshmi; Datti Alessandro; Egan Sean E; Jiang Zhe; Leone Gustavo; Bader Gary D; Schimmer Aaron; Zacksenhaus Eldad</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3739-3757</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Triple-negative breast cancer (TNBC) includes basal-like and claudin-low subtypes for which no specific treatment is currently available.  Although the retinoblastoma tumor-suppressor gene (RB1) is frequently lost together with TP53 in TNBC, it is not directly targetable.  There is thus great interest in identifying vulnerabilities downstream of RB1 that can be therapeutically exploited.  Here, we determined that combined inactivation of murine Rb and p53 in diverse mammary epithelial cells induced claudin-low-like TNBC with Met, Birc2/3-Mmp13-Yap1, and Pvt1-Myc amplifications.  Gene set enrichment analysis revealed that Rb/p53-deficient tumors showed elevated expression of the mitochondrial protein translation (MPT) gene pathway relative to tumors harboring p53 deletion alone.  Accordingly, bioinformatic, functional, and biochemical analyses showed that RB1-E2F complexes bind to MPT gene promoters to regulate transcription and control MPT.  Additionally, a screen of US Food and Drug Administration-approved (FDA-approved) drugs identified the MPT antagonist tigecycline (TIG) as a potent inhibitor of Rb/p53-deficient tumor cell proliferation.  TIG preferentially suppressed RB1-deficient TNBC cell proliferation, targeted both the bulk and cancer stem cell fraction, and strongly attenuated xenograft growth.  It also cooperated with sulfasalazine, an FDA-approved inhibitor of cystine xCT antiporter, in culture and xenograft assays.  Our results suggest that RB1 deficiency promotes cancer cell proliferation in part by enhancing mitochondrial function and identify TIG as a clinically approved drug for RB1-deficient TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT4-V_8AROavGhHGZei4OW9fW6udTcc2eZ6tT7NQ_Gzf7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2szltVOqsg%253D%253D&md5=c004a203c08d1c20c81ed552184010c0</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1172%2FJCI81568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI81568%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DR.%2BA.%26aulast%3DRobinson%26aufirst%3DT.%2BJ.%26aulast%3DLiu%26aufirst%3DJ.%2BC.%26aulast%3DShrestha%26aufirst%3DM.%26aulast%3DVoisin%26aufirst%3DV.%26aulast%3DJu%26aufirst%3DY.%26aulast%3DChung%26aufirst%3DP.%2BE.%26aulast%3DPellecchia%26aufirst%3DG.%26aulast%3DFell%26aufirst%3DV.%2BL.%26aulast%3DBae%26aufirst%3DS.%26aulast%3DMuthuswamy%26aufirst%3DL.%26aulast%3DDatti%26aufirst%3DA.%26aulast%3DEgan%26aufirst%3DS.%2BE.%26aulast%3DJiang%26aufirst%3DZ.%26aulast%3DLeone%26aufirst%3DG.%26aulast%3DBader%26aufirst%3DG.%2BD.%26aulast%3DSchimmer%26aufirst%3DA.%26aulast%3DZacksenhaus%26aufirst%3DE.%26atitle%3DRB1%2520deficiency%2520in%2520triple-negative%2520breast%2520cancer%2520induces%2520mitochondrial%2520protein%2520translation%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2016%26volume%3D126%26spage%3D3739%26epage%3D3757%26doi%3D10.1172%2FJCI81568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roskoski, R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>152</i></span>,  <span class="NLM_fpage">104609</span>, <span class="refDoi">Â DOI: 10.1016/j.phrs.2019.104609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.phrs.2019.104609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=31862477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisV2ktbrE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2020&pages=104609&author=R.+Roskoski&title=Properties+of+FDA-approved+small+molecule+protein+kinase+inhibitors%3A+A+2020+update&doi=10.1016%2Fj.phrs.2019.104609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update</span></div><div class="casAuthors">Roskoski, Robert Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104609</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Because genetic alterations including mutations, overexpression, translocations, and dysregulation of protein kinases are involved in the pathogenesis of many illnesses, this enzyme family is currently the subject of many drug discovery programs in the pharmaceutical industry.  The US FDA approved four small mol. protein kinase antagonists in 2019; these include entrectinib, erdafitinib, pexidartinib, and fedratinib.  Entrectinib binds to TRKA/B/C and ROS1 and is prescribed for the treatment of solid tumors with NTRK fusion proteins and for ROS1-postive non-small cell lung cancers.  Erdafitinib inhibits fibroblast growth factor receptors 1-4 and is used in the treatment of urothelial bladder cancers.  Pexidartinib is a CSF1R antagonist that is prescribed for the treatment of tenosynovial giant cell tumors.  Fedratinib blocks JAK2 and is used in the treatment of myelofibrosis.  Overall, the US FDA has approved 52 small mol. protein kinase inhibitors, nearly all of which are orally effective with the exceptions of temsirolimus (which is given i.v.) and netarsudil (an eye drop).  Of the 52 approved drugs, eleven inhibit protein-serine/threonine protein kinases, two are directed against dual specificity protein kinases, eleven target non-receptor protein-tyrosine kinases, and 28 block receptor protein-tyrosine kinases.  The data indicate that 46 of these drugs are used in the treatment of neoplastic diseases (eight against non-solid tumors such as leukemias and 41 against solid tumors including breast and lung cancers; some drugs are used against both tumor types).  Eight drugs are employed in the treatment of non-malignancies: fedratinib, myelofibrosis; ruxolitinib, myelofibrosis and polycythemia vera; fostamatinib, chronic immune thrombocytopenia; baricitinib, rheumatoid arthritis; sirolimus, renal graft vs. host disease; nintedanib, idiopathic pulmonary fibrosis; netarsudil, glaucoma; and tofacitinib, rheumatoid arthritis, Crohn disease, and ulcerative colitis.  Moreover, sirolimus and ibrutinib are used for the treatment of both neoplastic and non-neoplastic diseases.  Entrectinib and larotrectinib are tissue-agnostic anti-cancer small mol. protein kinase inhibitors.  These drugs are prescribed for the treatment of any solid cancer harboring NTRK1/2/3 fusion proteins regardless of the organ, tissue, anatomical location, or histol. type.  Of the 52 approved drugs, seventeen are used in the treatment of more than one disease.  Imatinib, for example, is approved for the treatment of eight disparate disorders.  The most common drug targets of the approved pharmaceuticals include BCR-Abl, B-Raf, vascular endothelial growth factor receptors (VEGFR), epidermal growth factor receptors (EGFR), and ALK.  Most of the approved small mol. protein kinase antagonists (49) bind to the protein kinase domain and six of them bind covalently.  In contrast, everolimus, temsirolimus, and sirolimus are larger mols. (MW â 1000) that bind to FK506 binding protein-12 (FKBP-12) to generate a complex that inhibits the mammalian target of rapamycin (mTOR) protein kinase complex.  This review presents the physicochem. properties of all of the FDA-approved small mol. protein kinase inhibitors.  Twenty-two of the 52 drugs have mol. wts. greater than 500, exceeding a Lipinski rule of five criterion.  Excluding the macrolides (everolimus, sirolimus, temsirolimus), the av. mol. wt. of the approved drugs is 480 with a range of 306 (ruxolitinib) to 615 (trametinib).  More than half of the antagonists (29) have lipophilic efficiency values of less than five while the recommended optima range from 5 to 10.  One of the troublesome problems with both targeted and cytotoxic drugs in the treatment of malignant diseases is the near universal development of resistance to every therapeutic modality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRgMvsJqanSLVg90H21EOLACvtfcHk0lj2ra3yO0FnrQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisV2ktbrE&md5=7753f0e8c04a145e15b09b3e55e09cde</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2019.104609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2019.104609%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DProperties%2520of%2520FDA-approved%2520small%2520molecule%2520protein%2520kinase%2520inhibitors%253A%2520A%25202020%2520update%26jtitle%3DPharmacol.%2520Res.%26date%3D2020%26volume%3D152%26spage%3D104609%26doi%3D10.1016%2Fj.phrs.2019.104609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vitiello, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowler, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loo, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Param, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moral, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonescu, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balachandran, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMatteo, R. P.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial inhibition augments the efficacy of imatinib by resetting the metabolic phenotype of gastrointestinal stromal tumor</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">972</span>â <span class="NLM_lpage">984</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-17-2697</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F1078-0432.CCR-17-2697" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=29246941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXislyrtbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=972-984&author=G.+A.+Vitielloauthor=B.+D.+Medinaauthor=S.+Zengauthor=T.+G.+Bowlerauthor=J.+Q.+Zhangauthor=J.+K.+Looauthor=N.+J.+Paramauthor=M.+Liuauthor=A.+J.+Moralauthor=J.+N.+Zhaoauthor=F.+Rossiauthor=C.+R.+Antonescuauthor=V.+P.+Balachandranauthor=J.+R.+Crossauthor=R.+P.+DeMatteo&title=Mitochondrial+inhibition+augments+the+efficacy+of+imatinib+by+resetting+the+metabolic+phenotype+of+gastrointestinal+stromal+tumor&doi=10.1158%2F1078-0432.CCR-17-2697"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial Inhibition Augments the Efficacy of Imatinib by Resetting the Metabolic Phenotype of Gastrointestinal Stromal Tumor</span></div><div class="casAuthors">Vitiello, Gerardo A.; Medina, Benjamin D.; Zeng, Shan; Bowler, Timothy G.; Zhang, Jennifer Q.; Loo, Jennifer K.; Param, Nesteene J.; Liu, Mengyuan; Moral, Alec J.; Zhao, Julia N.; Rossi, Ferdinand; Antonescu, Cristina R.; Balachandran, Vinod P.; Cross, Justin R.; De Matteo, Ronald P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">972-984</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Imatinib dramatically reduces gastrointestinal stromal tumor (GIST) 18F-FDG uptake, providing an early indicator of treatment response.  Despite decreased glucose internalization, many GIST cells persist, suggesting that alternative metabolic pathways are used for survival.  The role of mitochondria in imatinib-treated GIST is largely unknown.  Exptl. Design: We quantified the metabolic activity of several human GIST cell lines.  We treated human GIST xenografts and genetically engineered KitV558del/+ mice with the mitochondrial oxidative phosphorylation inhibitor VLX600 in combination with imatinib and analyzed tumor vol., wt., histol., mol. signaling, and cell cycle activity.  In vitro assays on human GIST cell lines were also performed.  Results: Imatinib therapy decreased glucose uptake and downstream glycolytic activity in GIST-T1 and HG129 cells by approx. half and upregulated mitochondrial enzymes and improved mitochondrial respiratory capacity.  Mitochondrial inhibition with VLX600 had a direct antitumor effect in vitro while appearing to promote glycolysis through increased AKT signaling and glucose transporter expression.  When combined with imatinib, VLX600 prevented imatinib-induced cell cycle escape and reduced p27 expression, leading to increased apoptosis when compared to imatinib alone.  In KitV558del/+ mice, VLX600 alone did not induce tumor cell death, but had a profound antitumor effect when combined with imatinib.  Conclusions: Our findings show that imatinib alters the metabolic phenotype of GIST, and this may contribute to imatinib resistance.  Our work offers preclin. proof of concept of metabolic targeting as an effective strategy for the treatment of GIST.  Clin Cancer Res; 24(4); 972-84. Â©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryVpvwzuJYMLVg90H21EOLACvtfcHk0lj2ra3yO0FnrQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXislyrtbY%253D&md5=b525679a1fbfa2fb1dc3551dfd669e55</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-2697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-2697%26sid%3Dliteratum%253Aachs%26aulast%3DVitiello%26aufirst%3DG.%2BA.%26aulast%3DMedina%26aufirst%3DB.%2BD.%26aulast%3DZeng%26aufirst%3DS.%26aulast%3DBowler%26aufirst%3DT.%2BG.%26aulast%3DZhang%26aufirst%3DJ.%2BQ.%26aulast%3DLoo%26aufirst%3DJ.%2BK.%26aulast%3DParam%26aufirst%3DN.%2BJ.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DMoral%26aufirst%3DA.%2BJ.%26aulast%3DZhao%26aufirst%3DJ.%2BN.%26aulast%3DRossi%26aufirst%3DF.%26aulast%3DAntonescu%26aufirst%3DC.%2BR.%26aulast%3DBalachandran%26aufirst%3DV.%2BP.%26aulast%3DCross%26aufirst%3DJ.%2BR.%26aulast%3DDeMatteo%26aufirst%3DR.%2BP.%26atitle%3DMitochondrial%2520inhibition%2520augments%2520the%2520efficacy%2520of%2520imatinib%2520by%2520resetting%2520the%2520metabolic%2520phenotype%2520of%2520gastrointestinal%2520stromal%2520tumor%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26spage%3D972%26epage%3D984%26doi%3D10.1158%2F1078-0432.CCR-17-2697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haq, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoag, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreu-Perez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edelman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederick, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurley, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nellore, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wargo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arany, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widlund, H. R.</span></span> <span> </span><span class="NLM_article-title">Oncogenic BRAF regulates oxidative metabolism via PGC1 alpha and MITF</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">302</span>â <span class="NLM_lpage">315</span>, <span class="refDoi">Â DOI: 10.1016/j.ccr.2013.02.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.ccr.2013.02.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=23477830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktVOksbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=302-315&author=R.+Haqauthor=J.+Shoagauthor=P.+Andreu-Perezauthor=S.+Yokoyamaauthor=H.+Edelmanauthor=G.+C.+Roweauthor=D.+T.+Frederickauthor=A.+D.+Hurleyauthor=A.+Nelloreauthor=A.+L.+Kungauthor=J.+A.+Wargoauthor=J.+S.+Songauthor=D.+E.+Fisherauthor=Z.+Aranyauthor=H.+R.+Widlund&title=Oncogenic+BRAF+regulates+oxidative+metabolism+via+PGC1+alpha+and+MITF&doi=10.1016%2Fj.ccr.2013.02.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogenic BRAF Regulates Oxidative Metabolism via PGC1Î± and MITF</span></div><div class="casAuthors">Haq, Rizwan; Shoag, Jonathan; Andreu-Perez, Pedro; Yokoyama, Satoru; Edelman, Hannah; Rowe, Glenn C.; Frederick, Dennie T.; Hurley, Aeron D.; Nellore, Abhinav; Kung, Andrew L.; Wargo, Jennifer A.; Song, Jun S.; Fisher, David E.; Arany, Zolt; Widlund, Hans R.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">302-315</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Activating mutations in BRAF are the most common genetic alterations in melanoma.  Inhibition of BRAF by small mols. leads to cell-cycle arrest and apoptosis.  We show here that BRAF inhibition also induces an oxidative phosphorylation gene program, mitochondrial biogenesis, and the increased expression of the mitochondrial master regulator, PGC1Î±.  We further show that a target of BRAF, the melanocyte lineage factor MITF, directly regulates the expression of PGC1Î±.  Melanomas with activation of the BRAF/MAPK pathway have suppressed levels of MITF and PGC1Î± and decreased oxidative metab.  Conversely, treatment of BRAF-mutated melanomas with BRAF inhibitors renders them addicted to oxidative phosphorylation.  Our data thus identify an adaptive metabolic program that limits the efficacy of BRAF inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvDmASYzGCu7Vg90H21EOLACvtfcHk0lj2ra3yO0FnrQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktVOksbk%253D&md5=118e15e89222a6bc79a3b6f872ee96fd</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2013.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2013.02.003%26sid%3Dliteratum%253Aachs%26aulast%3DHaq%26aufirst%3DR.%26aulast%3DShoag%26aufirst%3DJ.%26aulast%3DAndreu-Perez%26aufirst%3DP.%26aulast%3DYokoyama%26aufirst%3DS.%26aulast%3DEdelman%26aufirst%3DH.%26aulast%3DRowe%26aufirst%3DG.%2BC.%26aulast%3DFrederick%26aufirst%3DD.%2BT.%26aulast%3DHurley%26aufirst%3DA.%2BD.%26aulast%3DNellore%26aufirst%3DA.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DWargo%26aufirst%3DJ.%2BA.%26aulast%3DSong%26aufirst%3DJ.%2BS.%26aulast%3DFisher%26aufirst%3DD.%2BE.%26aulast%3DArany%26aufirst%3DZ.%26aulast%3DWidlund%26aufirst%3DH.%2BR.%26atitle%3DOncogenic%2520BRAF%2520regulates%2520oxidative%2520metabolism%2520via%2520PGC1%2520alpha%2520and%2520MITF%26jtitle%3DCancer%2520Cell%26date%3D2013%26volume%3D23%26spage%3D302%26epage%3D315%26doi%3D10.1016%2Fj.ccr.2013.02.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bajpai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Achreja, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edgar, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddiqa, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matulis, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBrayer, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rupji, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barwick, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lonial, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nooka, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boise, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagrath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shanmugam, M.</span></span> <span> </span><span class="NLM_article-title">Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1228</span>, <span class="refDoi">Â DOI: 10.1038/s41467-020-15051-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fs41467-020-15051-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=32144272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlt1Sgt7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1228&author=R.+Bajpaiauthor=A.+Sharmaauthor=A.+Achrejaauthor=C.+L.+Edgarauthor=C.+Weiauthor=A.+A.+Siddiqaauthor=V.+A.+Guptaauthor=S.+M.+Matulisauthor=S.+K.+McBrayerauthor=A.+Mittalauthor=M.+Rupjiauthor=B.+G.+Barwickauthor=S.+Lonialauthor=A.+K.+Nookaauthor=L.+H.+Boiseauthor=D.+Nagrathauthor=M.+Shanmugam&title=Electron+transport+chain+activity+is+a+predictor+and+target+for+venetoclax+sensitivity+in+multiple+myeloma&doi=10.1038%2Fs41467-020-15051-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma</span></div><div class="casAuthors">Bajpai, Richa; Sharma, Aditi; Achreja, Abhinav; Edgar, Claudia L.; Wei, Changyong; Siddiqa, Arusha A.; Gupta, Vikas A.; Matulis, Shannon M.; McBrayer, Samuel K.; Mittal, Anjali; Rupji, Manali; Barwick, Benjamin G.; Lonial, Sagar; Nooka, Ajay K.; Boise, Lawrence H.; Nagrath, Deepak; Shanmugam, Mala</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1228</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The BCL-2 antagonist venetoclax is highly effective in multiple myeloma (MM) patients exhibiting the 11;14 translocation, the mechanistic basis of which is unknown.  In evaluating cellular energetics and metab. of t(11;14) and non-t(11;14) MM, we det. that venetoclax-sensitive myeloma has reduced mitochondrial respiration.  Consistent with this, low electron transport chain (ETC) Complex I and Complex II activities correlate with venetoclax sensitivity.  Inhibition of Complex I, using IACS-010759, an orally bioavailable Complex I inhibitor in clin. trials, as well as succinate ubiquinone reductase (SQR) activity of Complex II, using thenoyltrifluoroacetone (TTFA) or introduction of SDHC R72C mutant, independently sensitize resistant MM to venetoclax.  We demonstrate that ETC inhibition increases BCL-2 dependence and the 'primed' state via the ATF4-BIM/NOXA axis.  Further, SQR activity correlates with venetoclax sensitivity in patient samples irresp. of t(11;14) status.  Use of SQR activity in a functional-biomarker informed manner may better select for MM patients responsive to venetoclax therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIekJotsNUVbVg90H21EOLACvtfcHk0liMEYV_NK1LAg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlt1Sgt7w%253D&md5=21d8e4083c7c5d7d8ea45de407efe134</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1038%2Fs41467-020-15051-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-020-15051-z%26sid%3Dliteratum%253Aachs%26aulast%3DBajpai%26aufirst%3DR.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DAchreja%26aufirst%3DA.%26aulast%3DEdgar%26aufirst%3DC.%2BL.%26aulast%3DWei%26aufirst%3DC.%26aulast%3DSiddiqa%26aufirst%3DA.%2BA.%26aulast%3DGupta%26aufirst%3DV.%2BA.%26aulast%3DMatulis%26aufirst%3DS.%2BM.%26aulast%3DMcBrayer%26aufirst%3DS.%2BK.%26aulast%3DMittal%26aufirst%3DA.%26aulast%3DRupji%26aufirst%3DM.%26aulast%3DBarwick%26aufirst%3DB.%2BG.%26aulast%3DLonial%26aufirst%3DS.%26aulast%3DNooka%26aufirst%3DA.%2BK.%26aulast%3DBoise%26aufirst%3DL.%2BH.%26aulast%3DNagrath%26aufirst%3DD.%26aulast%3DShanmugam%26aufirst%3DM.%26atitle%3DElectron%2520transport%2520chain%2520activity%2520is%2520a%2520predictor%2520and%2520target%2520for%2520venetoclax%2520sensitivity%2520in%2520multiple%2520myeloma%26jtitle%3DNat.%2520Commun.%26date%3D2020%26volume%3D11%26spage%3D1228%26doi%3D10.1038%2Fs41467-020-15051-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Senkowski, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olofsson, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isacson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoglund, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafsson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nygren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linder, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fryknas, M.</span></span> <span> </span><span class="NLM_article-title">Three-dimensional cell culture-based screening identifies the anthelmintic drug nitazoxanide as a candidate for treatment of colorectal cancer</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1504</span>â <span class="NLM_lpage">1516</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-14-0792</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F1535-7163.MCT-14-0792" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=25911689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsFOntLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=1504-1516&author=W.+Senkowskiauthor=X.+Zhangauthor=M.+H.+Olofssonauthor=R.+Isacsonauthor=U.+Hoglundauthor=M.+Gustafssonauthor=P.+Nygrenauthor=S.+Linderauthor=R.+Larssonauthor=M.+Fryknas&title=Three-dimensional+cell+culture-based+screening+identifies+the+anthelmintic+drug+nitazoxanide+as+a+candidate+for+treatment+of+colorectal+cancer&doi=10.1158%2F1535-7163.MCT-14-0792"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Three-Dimensional Cell Culture-Based Screening Identifies the Anthelmintic Drug Nitazoxanide as a Candidate for Treatment of Colorectal Cancer</span></div><div class="casAuthors">Senkowski, Wojciech; Zhang, Xiaonan; Olofsson, Maria Haegg; Isacson, Ruben; Hoeglund, Urban; Gustafsson, Mats; Nygren, Peter; Linder, Stig; Larsson, Rolf; Fryknaes, Marten</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1504-1516</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Because dormant cancer cells in hypoxic and nutrient-deprived regions of solid tumors provide a major obstacle to treatment, compds. targeting those cells might have clin. benefits.  Here, we describe a high-throughput drug screening approach, using glucose-deprived multicellular tumor spheroids (MCTS) with inner hypoxia, to identify compds. that specifically target this cell population.  We used a concept of drug repositioning-using known mols. for new indications.  This is a promising strategy to identify mols. for rapid clin. advancement.  By screening 1,600 compds. with documented clin. history, we aimed to identify candidates with unforeseen potential for repositioning as anticancer drugs.  Our screen identified five mols. with pronounced MCTS-selective activity: nitazoxanide, niclosamide, closantel, pyrvinium pamoate, and salinomycin.  Herein, we show that all five compds. inhibit mitochondrial respiration.  This suggests that cancer cells in low glucose concns. depend on oxidative phosphorylation rather than solely glycolysis.  Importantly, continuous exposure to the compds. was required to achieve effective treatment.  Nitazoxanide, an FDA-approved antiprotozoal drug with excellent pharmacokinetic and safety profile, is the only mol. among the screening hits that reaches high plasma concns. persisting for up to a few hours after single oral dose.  Nitazoxanide activated the AMPK pathway and downregulated c-Myc, mTOR, and Wnt signaling at clin. achievable concns.  Nitazoxanide combined with the cytotoxic drug irinotecan showed anticancer activity in vivo.  We here report that the FDA-approved anthelmintic drug nitazoxanide could be a potential candidate for advancement into cancer clin. trials.  Mol Cancer Ther; 14(6); 1504-16. cpr2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqml-pjMEW-7rVg90H21EOLACvtfcHk0liMEYV_NK1LAg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsFOntLg%253D&md5=101482f0d7752634f892c766186496e5</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0792&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0792%26sid%3Dliteratum%253Aachs%26aulast%3DSenkowski%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DOlofsson%26aufirst%3DM.%2BH.%26aulast%3DIsacson%26aufirst%3DR.%26aulast%3DHoglund%26aufirst%3DU.%26aulast%3DGustafsson%26aufirst%3DM.%26aulast%3DNygren%26aufirst%3DP.%26aulast%3DLinder%26aufirst%3DS.%26aulast%3DLarsson%26aufirst%3DR.%26aulast%3DFryknas%26aufirst%3DM.%26atitle%3DThree-dimensional%2520cell%2520culture-based%2520screening%2520identifies%2520the%2520anthelmintic%2520drug%2520nitazoxanide%2520as%2520a%2520candidate%2520for%2520treatment%2520of%2520colorectal%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26spage%3D1504%26epage%3D1516%26doi%3D10.1158%2F1535-7163.MCT-14-0792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wenzel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riefke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grundemann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krebs, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osterland, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golfier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rase, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ansari, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bickle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pampaloni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattheyer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stelzer, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parczyk, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prechtl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steigemann, P.</span></span> <span> </span><span class="NLM_article-title">3D high-content screening for the identification of compounds that target cells in dormant tumor spheroid regions</span>. <i>Exp. Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>323</i></span>,  <span class="NLM_fpage">131</span>â <span class="NLM_lpage">43</span>, <span class="refDoi">Â DOI: 10.1016/j.yexcr.2014.01.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.yexcr.2014.01.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=24480576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisFCiu78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=323&publication_year=2014&pages=131-43&author=C.+Wenzelauthor=B.+Riefkeauthor=S.+Grundemannauthor=A.+Krebsauthor=S.+Christianauthor=F.+Prinzauthor=M.+Osterlandauthor=S.+Golfierauthor=S.+Raseauthor=N.+Ansariauthor=M.+Esnerauthor=M.+Bickleauthor=F.+Pampaloniauthor=C.+Mattheyerauthor=E.+H.+Stelzerauthor=K.+Parczykauthor=S.+Prechtlauthor=P.+Steigemann&title=3D+high-content+screening+for+the+identification+of+compounds+that+target+cells+in+dormant+tumor+spheroid+regions&doi=10.1016%2Fj.yexcr.2014.01.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">3D high-content screening for the identification of compounds that target cells in dormant tumor spheroid regions</span></div><div class="casAuthors">Wenzel, Carsten; Riefke, Bjoern; Gruendemann, Stephan; Krebs, Alice; Christian, Sven; Prinz, Florian; Osterland, Marc; Golfier, Sven; Raese, Sebastian; Ansari, Nariman; Esner, Milan; Bickle, Marc; Pampaloni, Francesco; Mattheyer, Christian; Stelzer, Ernst H.; Parczyk, Karsten; Prechtl, Stefan; Steigemann, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Cell Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">323</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">131-143</span>CODEN:
                <span class="NLM_cas:coden">ECREAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-4827</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Cancer cells in poorly vascularized tumor regions need to adapt to an unfavorable metabolic microenvironment.  As distance from supplying blood vessels increases, oxygen and nutrient concns. decrease and cancer cells react by stopping cell cycle progression and becoming dormant.  As cytostatic drugs mainly target proliferating cells, cancer cell dormancy is considered as a major resistance mechanism to this class of anti-cancer drugs.  Therefore, substances that target cancer cells in poorly vascularized tumor regions have the potential to enhance cytostatic-based chemotherapy of solid tumors.With three-dimensional growth conditions, multicellular tumor spheroids (MCTS) reproduce several parameters of the tumor microenvironment, including oxygen and nutrient gradients as well as the development of dormant tumor regions.We here report the setup of a 3D cell culture compatible high-content screening system and the identification of nine substances from two com. available drug libraries that specifically target cells in inner MCTS core regions, while cells in outer MCTS regions or in 2D cell culture remain unaffected.  We elucidated the mode of action of the identified compds. as inhibitors of the respiratory chain and show that induction of cell death in inner MCTS core regions critically depends on extracellular glucose concns.  Finally, combinational treatment with cytostatics showed increased induction of cell death in MCTS.  The data presented here shows for the first time a high-content based screening setup on 3D tumor spheroids for the identification of substances that specifically induce cell death in inner tumor spheroid core regions.  This validates the approach to use 3D cell culture screening systems to identify substances that would not be detectable by 2D based screening in otherwise similar culture conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLuyxz92LlK7Vg90H21EOLACvtfcHk0lhyv97Bg_mJqA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisFCiu78%253D&md5=8397a1bfd22d0433d53f82f79ca3b61a</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2Fj.yexcr.2014.01.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yexcr.2014.01.017%26sid%3Dliteratum%253Aachs%26aulast%3DWenzel%26aufirst%3DC.%26aulast%3DRiefke%26aufirst%3DB.%26aulast%3DGrundemann%26aufirst%3DS.%26aulast%3DKrebs%26aufirst%3DA.%26aulast%3DChristian%26aufirst%3DS.%26aulast%3DPrinz%26aufirst%3DF.%26aulast%3DOsterland%26aufirst%3DM.%26aulast%3DGolfier%26aufirst%3DS.%26aulast%3DRase%26aufirst%3DS.%26aulast%3DAnsari%26aufirst%3DN.%26aulast%3DEsner%26aufirst%3DM.%26aulast%3DBickle%26aufirst%3DM.%26aulast%3DPampaloni%26aufirst%3DF.%26aulast%3DMattheyer%26aufirst%3DC.%26aulast%3DStelzer%26aufirst%3DE.%2BH.%26aulast%3DParczyk%26aufirst%3DK.%26aulast%3DPrechtl%26aufirst%3DS.%26aulast%3DSteigemann%26aufirst%3DP.%26atitle%3D3D%2520high-content%2520screening%2520for%2520the%2520identification%2520of%2520compounds%2520that%2520target%2520cells%2520in%2520dormant%2520tumor%2520spheroid%2520regions%26jtitle%3DExp.%2520Cell%2520Res.%26date%3D2014%26volume%3D323%26spage%3D131%26epage%3D43%26doi%3D10.1016%2Fj.yexcr.2014.01.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Puente, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azab, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azab, A. K.</span></span> <span> </span><span class="NLM_article-title">The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy</span>. <i>Hypoxia</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">83</span>â <span class="NLM_lpage">92</span>, <span class="refDoi">Â DOI: 10.2147/HP.S93413</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.2147%2FHP.S93413" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27774485" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BC2srlsV2ntQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&pages=83-92&author=B.+Muzauthor=P.+de+la+Puenteauthor=F.+Azabauthor=A.+K.+Azab&title=The+role+of+hypoxia+in+cancer+progression%2C+angiogenesis%2C+metastasis%2C+and+resistance+to+therapy&doi=10.2147%2FHP.S93413"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy</span></div><div class="casAuthors">Muz Barbara; de la Puente Pilar; Azab Feda; Azab Abdel Kareem</div><div class="citationInfo"><span class="NLM_cas:title">Hypoxia (Auckland, N.Z.)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">83-92</span>
        ISSN:<span class="NLM_cas:issn">2324-1128</span>.
    </div><div class="casAbstract">Hypoxia is a non-physiological level of oxygen tension, a phenomenon common in a majority of malignant tumors.  Tumor-hypoxia leads to advanced but dysfunctional vascularization and acquisition of epithelial-to-mesenchymal transition phenotype resulting in cell mobility and metastasis.  Hypoxia alters cancer cell metabolism and contributes to therapy resistance by inducing cell quiescence.  Hypoxia stimulates a complex cell signaling network in cancer cells, including the HIF, PI3K, MAPK, and NF B pathways, which interact with each other causing positive and negative feedback loops and enhancing or diminishing hypoxic effects.  This review provides background knowledge on the role of tumor hypoxia and the role of the HIF cell signaling involved in tumor blood vessel formation, metastasis, and development of the resistance to therapy.  Better understanding of the role of hypoxia in cancer progression will open new windows for the discovery of new therapeutics targeting hypoxic tumor cells and hypoxic microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQpEDGDmxV0EPx2phytoz6_fW6udTcc2ebi2hV6B6Colrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2srlsV2ntQ%253D%253D&md5=aa65f7fa9839ceffb5147fcb2aa8d2ba</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.2147%2FHP.S93413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FHP.S93413%26sid%3Dliteratum%253Aachs%26aulast%3DMuz%26aufirst%3DB.%26aulast%3Dde%2Bla%2BPuente%26aufirst%3DP.%26aulast%3DAzab%26aufirst%3DF.%26aulast%3DAzab%26aufirst%3DA.%2BK.%26atitle%3DThe%2520role%2520of%2520hypoxia%2520in%2520cancer%2520progression%252C%2520angiogenesis%252C%2520metastasis%252C%2520and%2520resistance%2520to%2520therapy%26jtitle%3DHypoxia%26date%3D2015%26volume%3D3%26spage%3D83%26epage%3D92%26doi%3D10.2147%2FHP.S93413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koido, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haga, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furuno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukahara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakurai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tani, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomida, A.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial deficiency impairs hypoxic induction of HIF-1 transcriptional activity and retards tumor growth</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">11841</span>â <span class="NLM_lpage">11854</span>, <span class="refDoi">Â DOI: 10.18632/oncotarget.14415</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.18632%2Foncotarget.14415" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=28060746" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BC1c7jtVOmtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=11841-11854&author=M.+Koidoauthor=N.+Hagaauthor=A.+Furunoauthor=S.+Tsukaharaauthor=J.+Sakuraiauthor=Y.+Taniauthor=S.+Satoauthor=A.+Tomida&title=Mitochondrial+deficiency+impairs+hypoxic+induction+of+HIF-1+transcriptional+activity+and+retards+tumor+growth&doi=10.18632%2Foncotarget.14415"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial deficiency impairs hypoxic induction of HIF-1 transcriptional activity and retards tumor growth</span></div><div class="casAuthors">Koido Masaru; Haga Naomi; Furuno Aki; Tsukahara Satomi; Sakurai Junko; Tani Yuri; Sato Shigeo; Tomida Akihiro; Koido Masaru; Tomida Akihiro</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">11841-11854</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Mitochondria can be involved in regulating cellular stress response to hypoxia and tumor growth, but little is known about that mechanistic relationship.  Here, we show that mitochondrial deficiency severely retards tumor xenograft growth with impairing hypoxic induction of HIF-1 transcriptional activity.  Using mtDNA-deficient Ï0 cells, we found that HIF-1 pathway activation was comparable in slow-growing Ï0 xenografts and rapid-growing parental xenografts.  Interestingly, we found that ex vivo Ï0 cells derived from Ï0 xenografts exhibited slightly increased HIF-1Î± expression and modest HIF-1 pathway activation regardless of oxygen concentration.  Surprisingly, Ï0 cells, as well as parental cells treated with oxidative phosphorylation inhibitors, were unable to boost HIF-1 transcriptional activity during hypoxia, although HIF-1Î± protein levels were ordinarily increased in these cells under hypoxic conditions.  These findings indicate that mitochondrial deficiency causes loss of hypoxia-induced HIF-1 transcriptional activity and thereby might lead to a constitutive HIF-1 pathway activation as a cellular adaptation mechanism in tumor microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRr6PjoGs2VCqe0F5ixvZgXfW6udTcc2ebi2hV6B6Colrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7jtVOmtw%253D%253D&md5=6c2201ac5090711f97b1b2feba09e7fa</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.14415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.14415%26sid%3Dliteratum%253Aachs%26aulast%3DKoido%26aufirst%3DM.%26aulast%3DHaga%26aufirst%3DN.%26aulast%3DFuruno%26aufirst%3DA.%26aulast%3DTsukahara%26aufirst%3DS.%26aulast%3DSakurai%26aufirst%3DJ.%26aulast%3DTani%26aufirst%3DY.%26aulast%3DSato%26aufirst%3DS.%26aulast%3DTomida%26aufirst%3DA.%26atitle%3DMitochondrial%2520deficiency%2520impairs%2520hypoxic%2520induction%2520of%2520HIF-1%2520transcriptional%2520activity%2520and%2520retards%2520tumor%2520growth%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D11841%26epage%3D11854%26doi%3D10.18632%2Foncotarget.14415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chua, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufour, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dassa, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rustin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagen, T.</span></span> <span> </span><span class="NLM_article-title">Stabilization of hypoxia-inducible factor-1alpha protein in hypoxia occurs independently of mitochondrial reactive oxygen species production</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>285</i></span>,  <span class="NLM_fpage">31277</span>â <span class="NLM_lpage">31284</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M110.158485</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1074%2Fjbc.M110.158485" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=20675386" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1aqtrnK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=2010&pages=31277-31284&author=Y.+L.+Chuaauthor=E.+Dufourauthor=E.+P.+Dassaauthor=P.+Rustinauthor=H.+T.+Jacobsauthor=C.+T.+Taylorauthor=T.+Hagen&title=Stabilization+of+hypoxia-inducible+factor-1alpha+protein+in+hypoxia+occurs+independently+of+mitochondrial+reactive+oxygen+species+production&doi=10.1074%2Fjbc.M110.158485"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Stabilization of Hypoxia-inducible Factor-1Î± Protein in Hypoxia Occurs Independently of Mitochondrial Reactive Oxygen Species Production</span></div><div class="casAuthors">Chua, Yee Liu; Dufour, Eric; Dassa, Emmanuel P.; Rustin, Pierre; Jacobs, Howard T.; Taylor, Cormac T.; Hagen, Thilo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">285</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">31277-31284</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The transcription factor hypoxia-inducible factor-1Î± (HIF-1Î±) is a master regulator of the cellular response to low oxygen.  HIF-1Î± protein accumulates in hypoxia due to inhibition of prolyl hydroxylase enzymes, which under normoxic conditions use mol. oxygen to hydroxylate HIF-1Î± on two conserved proline residues (Pro402 and Pro564), thus targeting the protein for 26 S proteasome-dependent degrdn.  A functional mitochondrial electron transport chain is known to be necessary for HIF-1Î± stabilization in hypoxia.  It has been reported that reactive oxygen species (ROS), produced under hypoxia by complex III of the mitochondrial electron transport chain, play a crit. role in the stabilization of the HIF-1Î± protein, possibly by directly inhibiting prolyl hydroxylase enzymes.  In contrast, we found that ROS prodn. by complex III is not required for hypoxia-induced HIF-1Î± stabilization.  Thus, reestablishing mitochondrial oxygen consumption in the presence of a complex III inhibitor by using an artificial electron donor to complex IV or by overexpressing Ciona intestinalis alternative oxidase results in HIF-1Î± protein stabilization in hypoxia.  Furthermore, five inhibitors that target different sites of the mitochondrial electron transport chain have similar effects on the HIF-1Î± protein half-life in hypoxia but vary in their effects on mitochondrial ROS prodn.  Finally, ROS do not regulate prolyl hydroxylase activity directly.  We conclude that HIF-1Î± protein stabilization in hypoxia occurs independently of mitochondrial ROS prodn.  However, mitochondria can modulate the cellular hypoxic response through altered respiratory activity, likely by regulating the cellular oxygen availability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_s55UK1NpCbVg90H21EOLACvtfcHk0ljWowrDtEOk5w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1aqtrnK&md5=f7f4b8592bc558fdea69e5ace627b977</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M110.158485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M110.158485%26sid%3Dliteratum%253Aachs%26aulast%3DChua%26aufirst%3DY.%2BL.%26aulast%3DDufour%26aufirst%3DE.%26aulast%3DDassa%26aufirst%3DE.%2BP.%26aulast%3DRustin%26aufirst%3DP.%26aulast%3DJacobs%26aufirst%3DH.%2BT.%26aulast%3DTaylor%26aufirst%3DC.%2BT.%26aulast%3DHagen%26aufirst%3DT.%26atitle%3DStabilization%2520of%2520hypoxia-inducible%2520factor-1alpha%2520protein%2520in%2520hypoxia%2520occurs%2520independently%2520of%2520mitochondrial%2520reactive%2520oxygen%2520species%2520production%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2010%26volume%3D285%26spage%3D31277%26epage%3D31284%26doi%3D10.1074%2Fjbc.M110.158485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ellinghaus, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heisler, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unterschemmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haerter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greschat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flamme, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oehme, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thierauch, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michels, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess-Stumpp, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegelbauer, K.</span></span> <span> </span><span class="NLM_article-title">BAY 87-2243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumor activities by inhibition of mitochondrial complex I</span>. <i>Cancer Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">611</span>â <span class="NLM_lpage">624</span>, <span class="refDoi">Â DOI: 10.1002/cam4.112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1002%2Fcam4.112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=24403227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsF2htLbL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=611-624&author=P.+Ellinghausauthor=I.+Heislerauthor=K.+Unterschemmannauthor=M.+Haerterauthor=H.+Beckauthor=S.+Greschatauthor=A.+Ehrmannauthor=H.+Summerauthor=I.+Flammeauthor=F.+Oehmeauthor=K.+Thierauchauthor=M.+Michelsauthor=H.+Hess-Stumppauthor=K.+Ziegelbauer&title=BAY+87-2243%2C+a+highly+potent+and+selective+inhibitor+of+hypoxia-induced+gene+activation+has+antitumor+activities+by+inhibition+of+mitochondrial+complex+I&doi=10.1002%2Fcam4.112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">BAY 87-2243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumor activities by inhibition of mitochondrial complex I</span></div><div class="casAuthors">Ellinghaus, Peter; Heisler, Iring; Unterschemmann, Kerstin; Haerter, Michael; Beck, Hartmut; Greschat, Susanne; Ehrmann, Alexander; Summer, Holger; Flamme, Ingo; Oehme, Felix; Thierauch, Karlheinz; Michels, Martin; Hess-Stumpp, Holger; Ziegelbauer, Karl</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">611-624</span>CODEN:
                <span class="NLM_cas:coden">CMAEDL</span>;
        ISSN:<span class="NLM_cas:issn">2045-7634</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">The activation of the transcription factor hypoxia-inducible factor-1 (HIF-1) plays an essential role in tumor development, tumor progression, and resistance to chemo- and radiotherapy.  In order to identify compds. targeting the HIF pathway, a small mol. library was screened using a luciferase-driven HIF-1 reporter cell line under hypoxia.  The high-throughput screening led to the identification of a class of aminoalkyl-substituted compds. that inhibited hypoxia-induced HIF-1 target gene expression in human lung cancer cell lines at low nanomolar concns.  Lead structure BAY 87-2243 was found to inhibit HIF-1Î± and HIF-2Î± protein accumulation under hypoxic conditions in non-small cell lung cancer (NSCLC) cell line H460 but had no effect on HIF-1Î± protein levels induced by the hypoxia mimetics desferrioxamine or cobalt chloride.  BAY 87-2243 had no effect on HIF target gene expression levels in RCC4 cells lacking Von Hippel-Lindau (VHL) activity nor did the compd. affect the activity of HIF prolyl hydroxylase-2.  Antitumor activity of BAY 87-2243, suppression of HIF-1Î± protein levels, and redn. of HIF-1 target gene expression in vivo were demonstrated in a H460 xenograft model.  BAY 87-2243 did not inhibit cell proliferation under std. conditions.  However under glucose depletion, a condition favoring mitochondrial ATP generation as energy source, BAY 87-2243 inhibited cell proliferation in the nanomolar range.  Further expts. revealed that BAY 87-2243 inhibits mitochondrial complex I activity but has no effect on complex III activity.  Interference with mitochondrial function to reduce hypoxia-induced HIF-1 activity in tumors might be an interesting therapeutic approach to overcome chemo- and radiotherapy-resistance of hypoxic tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmP6qdK8PRqrVg90H21EOLACvtfcHk0ljWowrDtEOk5w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsF2htLbL&md5=7ff152754b6379af91c65c838b0a1c3f</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1002%2Fcam4.112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcam4.112%26sid%3Dliteratum%253Aachs%26aulast%3DEllinghaus%26aufirst%3DP.%26aulast%3DHeisler%26aufirst%3DI.%26aulast%3DUnterschemmann%26aufirst%3DK.%26aulast%3DHaerter%26aufirst%3DM.%26aulast%3DBeck%26aufirst%3DH.%26aulast%3DGreschat%26aufirst%3DS.%26aulast%3DEhrmann%26aufirst%3DA.%26aulast%3DSummer%26aufirst%3DH.%26aulast%3DFlamme%26aufirst%3DI.%26aulast%3DOehme%26aufirst%3DF.%26aulast%3DThierauch%26aufirst%3DK.%26aulast%3DMichels%26aufirst%3DM.%26aulast%3DHess-Stumpp%26aufirst%3DH.%26aulast%3DZiegelbauer%26aufirst%3DK.%26atitle%3DBAY%252087-2243%252C%2520a%2520highly%2520potent%2520and%2520selective%2520inhibitor%2520of%2520hypoxia-induced%2520gene%2520activation%2520has%2520antitumor%2520activities%2520by%2520inhibition%2520of%2520mitochondrial%2520complex%2520I%26jtitle%3DCancer%2520Med.%26date%3D2013%26volume%3D2%26spage%3D611%26epage%3D624%26doi%3D10.1002%2Fcam4.112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, X.</span></span> <span> </span><span class="NLM_article-title">Metabolic control of T-cell immunity via epigenetic mechanisms</span>. <i>Cell. Mol. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">203</span>â <span class="NLM_lpage">205</span>, <span class="refDoi">Â DOI: 10.1038/cmi.2017.115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fcmi.2017.115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=29082922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BC1M7lslOhtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=203-205&author=X.+Zhangauthor=J.+Liuauthor=X.+Cao&title=Metabolic+control+of+T-cell+immunity+via+epigenetic+mechanisms&doi=10.1038%2Fcmi.2017.115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic control of T-cell immunity via epigenetic mechanisms</span></div><div class="casAuthors">Zhang Xiaomin; Liu Juan; Cao Xuetao; Cao Xuetao</div><div class="citationInfo"><span class="NLM_cas:title">Cellular & molecular immunology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">203-205</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQnXgNumm1KP9enUz0lpNqnfW6udTcc2eZXs4vTr5Aai7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7lslOhtw%253D%253D&md5=692e59181e02a767a454def39060a3d9</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1038%2Fcmi.2017.115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcmi.2017.115%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DCao%26aufirst%3DX.%26atitle%3DMetabolic%2520control%2520of%2520T-cell%2520immunity%2520via%2520epigenetic%2520mechanisms%26jtitle%3DCell.%2520Mol.%2520Immunol.%26date%3D2018%26volume%3D15%26spage%3D203%26epage%3D205%26doi%3D10.1038%2Fcmi.2017.115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gatza, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahl, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opipari, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundberg, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glick, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrara, J. L.</span></span> <span> </span><span class="NLM_article-title">Manipulating the bioenergetics of alloreactive T cells causes their selective apoptosis and arrests graft-versus-host disease</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">67ra8</span>, <span class="refDoi">Â DOI: 10.1126/scitranslmed.3001975</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1126%2Fscitranslmed.3001975" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=21270339" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=67ra8&author=E.+Gatzaauthor=D.+R.+Wahlauthor=A.+W.+Opipariauthor=T.+B.+Sundbergauthor=P.+Reddyauthor=C.+Liuauthor=G.+D.+Glickauthor=J.+L.+Ferrara&title=Manipulating+the+bioenergetics+of+alloreactive+T+cells+causes+their+selective+apoptosis+and+arrests+graft-versus-host+disease&doi=10.1126%2Fscitranslmed.3001975"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3001975&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3001975%26sid%3Dliteratum%253Aachs%26aulast%3DGatza%26aufirst%3DE.%26aulast%3DWahl%26aufirst%3DD.%2BR.%26aulast%3DOpipari%26aufirst%3DA.%2BW.%26aulast%3DSundberg%26aufirst%3DT.%2BB.%26aulast%3DReddy%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DGlick%26aufirst%3DG.%2BD.%26aulast%3DFerrara%26aufirst%3DJ.%2BL.%26atitle%3DManipulating%2520the%2520bioenergetics%2520of%2520alloreactive%2520T%2520cells%2520causes%2520their%2520selective%2520apoptosis%2520and%2520arrests%2520graft-versus-host%2520disease%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2011%26volume%3D3%26spage%3D67ra8%26doi%3D10.1126%2Fscitranslmed.3001975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wahl, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glick, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opipari, A. W.</span></span> <span> </span><span class="NLM_article-title">Characterization of the metabolic phenotype of chronically activated lymphocytes</span>. <i>Lupus</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1492</span>â <span class="NLM_lpage">1501</span>, <span class="refDoi">Â DOI: 10.1177/0961203310373109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1177%2F0961203310373109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=20647250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1SisbvL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2010&pages=1492-1501&author=D.+R.+Wahlauthor=B.+Petersenauthor=R.+Warnerauthor=B.+C.+Richardsonauthor=G.+D.+Glickauthor=A.+W.+Opipari&title=Characterization+of+the+metabolic+phenotype+of+chronically+activated+lymphocytes&doi=10.1177%2F0961203310373109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the metabolic phenotype of chronically activated lymphocytes</span></div><div class="casAuthors">Wahl, D. R.; Petersen, B.; Warner, R.; Richardson, B. C.; Glick, G. D.; Opipari, A. W.</div><div class="citationInfo"><span class="NLM_cas:title">Lupus</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1492-1501</span>CODEN:
                <span class="NLM_cas:coden">LUPUES</span>;
        ISSN:<span class="NLM_cas:issn">0961-2033</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">Activated lymphocytes proliferate, secrete cytokines, and can make antibodies.  Normally activated B and T cells meet the bioenergetic demand for these processes by up-regulating aerobic glycolysis.  In contrast, several lines of evidence suggest that pathogenic lymphocytes in autoimmune diseases like lupus meet ATP demands through oxidative phosphorylation.  Using 13C-glucose as a stable tracer, we found that splenocytes from mice with lupus derive the same fraction of lactate from glucose as control animals, suggesting comparable levels of glycolysis and non-oxidative ATP prodn.  However, lupus splenocytes increase glucose oxidn. by 40% over healthy control animals.  The ratio between pentose phosphate cycle (PPC) activity and glycolysis is the same for each group, indicating that increased glucose oxidn. is due to increased activity of the TCA cycle in lupus splenocytes.  Repetitive stimulation of cultured human T cells was used to model chronic lymphocyte activation, a phenotype assocd. with lupus.  Chronically activated T cells rely primarily on oxidative metab. for ATP synthesis suggesting that chronic antigen stimulation may be the basis for the metabolic findings obsd. in lupus mice.  Identification of disease-related bioenergetic phenotypes should contribute to new diagnostic and therapeutic strategies for immune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpy3z-gVsUbgbVg90H21EOLACvtfcHk0lgsvXb_9yB1Mw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1SisbvL&md5=e2e2358ec97b2eb102e0b4b38fc5a7f6</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1177%2F0961203310373109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0961203310373109%26sid%3Dliteratum%253Aachs%26aulast%3DWahl%26aufirst%3DD.%2BR.%26aulast%3DPetersen%26aufirst%3DB.%26aulast%3DWarner%26aufirst%3DR.%26aulast%3DRichardson%26aufirst%3DB.%2BC.%26aulast%3DGlick%26aufirst%3DG.%2BD.%26aulast%3DOpipari%26aufirst%3DA.%2BW.%26atitle%3DCharacterization%2520of%2520the%2520metabolic%2520phenotype%2520of%2520chronically%2520activated%2520lymphocytes%26jtitle%3DLupus%26date%3D2010%26volume%3D19%26spage%3D1492%26epage%3D1501%26doi%3D10.1177%2F0961203310373109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leone, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, J. D.</span></span> <span> </span><span class="NLM_article-title">Metabolism of immune cells in cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">516</span>, <span class="refDoi">Â DOI: 10.1038/s41568-020-0273-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fs41568-020-0273-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=32632251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlaitrvO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2020&pages=516&author=R.+D.+Leoneauthor=J.+D.+Powell&title=Metabolism+of+immune+cells+in+cancer&doi=10.1038%2Fs41568-020-0273-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism of immune cells in cancer</span></div><div class="casAuthors">Leone, Robert D.; Powell, Jonathan D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">516-531</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: Through the successes of checkpoint blockade and adoptive cellular therapy, immunotherapy has become an established treatment modality for cancer.  Cellular metab. has emerged as a crit. determinant of the viability and function of both cancer cells and immune cells.  In order to sustain prodigious anabolic needs, tumors employ a specialized metab. that differs from untransformed somatic cells.  This metab. leads to a tumor microenvironment that is commonly acidic, hypoxic and/or depleted of crit. nutrients required by immune cells.  In this context, tumor metab. itself is a checkpoint that can limit immune-mediated tumor destruction.  Because our understanding of immune cell metab. and cancer metab. has grown significantly in the past decade, we are on the cusp of being able to unravel the interaction of cancer cell metab. and immune metab. in therapeutically meaningful ways.  Although there are metabolic processes that are seemingly fundamental to both cancer and responding immune cells, metabolic heterogeneity and plasticity may serve to distinguish the two.  As such, understanding the differential metabolic requirements of the diverse cells that comprise an immune response to cancer offers an opportunity to selectively regulate immune cell function.  Such a nuanced evaluation of cancer and immune metab. can uncover metabolic vulnerabilities and therapeutic windows upon which to intervene for enhanced immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrR0xV0Vx2JbVg90H21EOLACvtfcHk0lgsvXb_9yB1Mw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlaitrvO&md5=00bd3f1ad849e1c5ad282ffca6e6b736</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1038%2Fs41568-020-0273-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41568-020-0273-y%26sid%3Dliteratum%253Aachs%26aulast%3DLeone%26aufirst%3DR.%2BD.%26aulast%3DPowell%26aufirst%3DJ.%2BD.%26atitle%3DMetabolism%2520of%2520immune%2520cells%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2020%26volume%3D20%26spage%3D516%26doi%3D10.1038%2Fs41568-020-0273-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salmond, R. J.</span></span> <span> </span><span class="NLM_article-title">mTOR regulation of glycolytic metabolism in T cells</span>. <i>Front. Cell Dev. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">122</span>, <span class="refDoi">Â DOI: 10.3389/fcell.2018.00122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.3389%2Ffcell.2018.00122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=30320109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BB3czpt1ertA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&pages=122&author=R.+J.+Salmond&title=mTOR+regulation+of+glycolytic+metabolism+in+T+cells&doi=10.3389%2Ffcell.2018.00122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR Regulation of Glycolytic Metabolism in T Cells</span></div><div class="casAuthors">Salmond Robert J</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in cell and developmental biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">122</span>
        ISSN:<span class="NLM_cas:issn">2296-634X</span>.
    </div><div class="casAbstract">T cell activation, differentiation and effector function is intrinsically linked to the regulation of metabolic pathways.  Evidence has shown that inflammatory T cell responses are dependent upon the adoption of aerobic glycolytic metabolism.  Furthermore, activation and regulation of the mechanistic target of rapamycin signaling pathway serves a key determinant of T cell metabolism, with subsequent effects on T cell effector responses.  In this mini-review, we discuss the mechanisms underpinning the function of the Warburg effect in T cell responses and the role of mTOR in these processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQpNpVRuQHC2bYtC3U5jeOifW6udTcc2eYY0TbKbCxdS7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3czpt1ertA%253D%253D&md5=67a879880570804682299d2d9b23ec25</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.3389%2Ffcell.2018.00122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffcell.2018.00122%26sid%3Dliteratum%253Aachs%26aulast%3DSalmond%26aufirst%3DR.%2BJ.%26atitle%3DmTOR%2520regulation%2520of%2520glycolytic%2520metabolism%2520in%2520T%2520cells%26jtitle%3DFront.%2520Cell%2520Dev.%2520Biol.%26date%3D2018%26volume%3D6%26spage%3D122%26doi%3D10.3389%2Ffcell.2018.00122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diskin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palsson-McDermott, E. M.</span></span> <span> </span><span class="NLM_article-title">Metabolic modulation in macrophage effector function</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">270</span>, <span class="refDoi">Â DOI: 10.3389/fimmu.2018.00270</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.3389%2Ffimmu.2018.00270" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=29520272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1ahsLnI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=270&author=C.+Diskinauthor=E.+M.+Palsson-McDermott&title=Metabolic+modulation+in+macrophage+effector+function&doi=10.3389%2Ffimmu.2018.00270"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic modulation in macrophage effector function</span></div><div class="casAuthors">Diskin, Ciana; Palsson-McDermott, Eva M.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">270/1-270/17</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Traditionally cellular respiration or metab. has been viewed as catabolic and anabolic pathways generating energy and biosynthetic precursors required for growth and general cellular maintenance.  However, growing literature provides evidence of a much broader role for metabolic reactions and processes in controlling immunol. effector functions.  Much of this research into immunometabolism has focused on macrophages, cells that are central in pro- as well as anti-inflammatory responses-responses that in turn are a direct result of metabolic reprogramming.  As we learn more about the precise role of metabolic pathways and pathway intermediates in immune function, a novel opportunity to target immunometabolism therapeutically has emerged.  Here, we review the current understanding of the regulation of macrophage function through metabolic remodeling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKNesU-BBWX7Vg90H21EOLACvtfcHk0lgsvXb_9yB1Mw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1ahsLnI&md5=55848a095c712d064477c26bcdf2a10d</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2018.00270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2018.00270%26sid%3Dliteratum%253Aachs%26aulast%3DDiskin%26aufirst%3DC.%26aulast%3DPalsson-McDermott%26aufirst%3DE.%2BM.%26atitle%3DMetabolic%2520modulation%2520in%2520macrophage%2520effector%2520function%26jtitle%3DFront.%2520Immunol.%26date%3D2018%26volume%3D9%26spage%3D270%26doi%3D10.3389%2Ffimmu.2018.00270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tcyganov, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabrilovich, D. I.</span></span> <span> </span><span class="NLM_article-title">The nature of myeloid-derived suppressor cells in the tumor microenvironment</span>. <i>Trends Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">208</span>â <span class="NLM_lpage">220</span>, <span class="refDoi">Â DOI: 10.1016/j.it.2016.01.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.it.2016.01.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=26858199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFKltbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=208-220&author=V.+Kumarauthor=S.+Patelauthor=E.+Tcyganovauthor=D.+I.+Gabrilovich&title=The+nature+of+myeloid-derived+suppressor+cells+in+the+tumor+microenvironment&doi=10.1016%2Fj.it.2016.01.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment</span></div><div class="casAuthors">Kumar, Vinit; Patel, Sima; Tcyganov, Evgenii; Gabrilovich, Dmitry I.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Immunology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">208-220</span>CODEN:
                <span class="NLM_cas:coden">TIRMAE</span>;
        ISSN:<span class="NLM_cas:issn">1471-4906</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Myeloid-derived suppressor cells (MDSC) are one of the major components of the tumor microenvironment.  The main feature of these cells is their potent immune suppressive activity.  MDSC are generated in the bone marrow and, in tumor-bearing hosts, migrate to peripheral lymphoid organs and the tumor to contribute to the formation of the tumor microenvironment.  Recent findings have revealed differences in the function and fate of MDSC in the tumor and peripheral lymphoid organs.  We review these findings here and, in this context, we discuss the current understanding as to the nature of these differences, the underlying mechanisms, and their potential impact on the regulation of tumor progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8ikkrNPPenrVg90H21EOLACvtfcHk0licNuUyjMLHEA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFKltbc%253D&md5=333aec052efcefad2de3f8a5b572637d</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1016%2Fj.it.2016.01.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.it.2016.01.004%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DTcyganov%26aufirst%3DE.%26aulast%3DGabrilovich%26aufirst%3DD.%2BI.%26atitle%3DThe%2520nature%2520of%2520myeloid-derived%2520suppressor%2520cells%2520in%2520the%2520tumor%2520microenvironment%26jtitle%3DTrends%2520Immunol.%26date%3D2016%26volume%3D37%26spage%3D208%26epage%3D220%26doi%3D10.1016%2Fj.it.2016.01.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glick, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossignol, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyssiotis, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurd, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrara, J. L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tkachev, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byersdorfer, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boros, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opipari, A. W.</span></span> <span> </span><span class="NLM_article-title">Anaplerotic metabolism of alloreactive T cells provides a metabolic approach to treat graft-versus-host disease</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>351</i></span>,  <span class="NLM_fpage">298</span>â <span class="NLM_lpage">307</span>, <span class="refDoi">Â DOI: 10.1124/jpet.114.218099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1124%2Fjpet.114.218099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=25125579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslKisbzI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2014&pages=298-307&author=G.+D.+Glickauthor=R.+Rossignolauthor=C.+A.+Lyssiotisauthor=D.+Wahlauthor=C.+Leschauthor=B.+Sanchezauthor=X.+K.+Liuauthor=L.+Y.+Haoauthor=C.+Taylorauthor=A.+Hurdauthor=J.+L.+M.+Ferraraauthor=V.+Tkachevauthor=C.+A.+Byersdorferauthor=L.+Borosauthor=A.+W.+Opipari&title=Anaplerotic+metabolism+of+alloreactive+T+cells+provides+a+metabolic+approach+to+treat+graft-versus-host+disease&doi=10.1124%2Fjpet.114.218099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplerotic metabolism of alloreactive T cells provides a metabolic approach to treat graft-versus-host disease</span></div><div class="casAuthors">Glick, Gary D.; Rossignol, Rodrigue; Lyssiotis, Costas A.; Wahl, Daniel; Lesch, Charles; Sanchez, Brian; Liu, Xikui; Hao, Ling-Yang; Taylor, Clarke; Hurd, Alexander; Ferrara, James L. M.; Tkachev, Victor; Byersdorfer, Craig A.; Boros, Laszlo; Opipari, Anthony W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">351</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">298-307, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">T-cell activation requires increased ATP and biosynthesis to support proliferation and effector function.  Most models of T-cell activation are based on in vitro culture systems and posit that aerobic glycolysis is employed to meet increased energetic and biosynthetic demands.  By contrast, T cells activated in vivo by alloantigens in graft-vs.-host disease (GVHD) increase mitochondrial oxygen consumption, fatty acid uptake and oxidn., with small increases of glucose uptake and aerobic glycolysis.  Here we show that these differences are not a consequence of alloactivation, because T cells activated in vitro either in a mixed lymphocyte reaction to the same alloantigens used in vivo or with agonistic anti-CD3/anti-CD28 antibodies increased aerobic glycolysis.  Using targeted metabolic 13C tracer fate assocns., we elucidated the metabolic pathway(s) employed by alloreactive T cells in vivo that support this phenotype.  We find that glutamine (Gln)-dependent tricarboxylic acid cycle anaplerosis is increased in alloreactive T cells and that Gln carbon contributes to ribose biosynthesis.  Pharmacol. modulation of oxidative phosphorylation rapidly reduces anaplerosis in alloreactive T cells and improves GVHD.  On the basis of these data, we propose a model of T-cell metab. that is relevant to activated lymphocytes in vivo, with implications for the discovery of new drugs for immune disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJFflA0P_Ii7Vg90H21EOLACvtfcHk0licNuUyjMLHEA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslKisbzI&md5=9eda7d2a42d22d75ee2859ad8b32eef3</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.218099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.218099%26sid%3Dliteratum%253Aachs%26aulast%3DGlick%26aufirst%3DG.%2BD.%26aulast%3DRossignol%26aufirst%3DR.%26aulast%3DLyssiotis%26aufirst%3DC.%2BA.%26aulast%3DWahl%26aufirst%3DD.%26aulast%3DLesch%26aufirst%3DC.%26aulast%3DSanchez%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DX.%2BK.%26aulast%3DHao%26aufirst%3DL.%2BY.%26aulast%3DTaylor%26aufirst%3DC.%26aulast%3DHurd%26aufirst%3DA.%26aulast%3DFerrara%26aufirst%3DJ.%2BL.%2BM.%26aulast%3DTkachev%26aufirst%3DV.%26aulast%3DByersdorfer%26aufirst%3DC.%2BA.%26aulast%3DBoros%26aufirst%3DL.%26aulast%3DOpipari%26aufirst%3DA.%2BW.%26atitle%3DAnaplerotic%2520metabolism%2520of%2520alloreactive%2520T%2520cells%2520provides%2520a%2520metabolic%2520approach%2520to%2520treat%2520graft-versus-host%2520disease%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D351%26spage%3D298%26epage%3D307%26doi%3D10.1124%2Fjpet.114.218099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burwell, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadtochiy, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brookes, P. S.</span></span> <span> </span><span class="NLM_article-title">Cardioprotection by metabolic shut-down and gradual wake-up</span>. <i>J. Mol. Cell. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">804</span>â <span class="NLM_lpage">810</span>, <span class="refDoi">Â DOI: 10.1016/j.yjmcc.2009.02.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.yjmcc.2009.02.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=19285082" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtVSht7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2009&pages=804-810&author=L.+S.+Burwellauthor=S.+M.+Nadtochiyauthor=P.+S.+Brookes&title=Cardioprotection+by+metabolic+shut-down+and+gradual+wake-up&doi=10.1016%2Fj.yjmcc.2009.02.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Cardioprotection by metabolic shut-down and gradual wake-up</span></div><div class="casAuthors">Burwell, Lindsay S.; Nadtochiy, Sergiy M.; Brookes, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular and Cellular Cardiology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">804-810</span>CODEN:
                <span class="NLM_cas:coden">JMCDAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-2828</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Mitochondria play a crit. role in cardiac function, and are also increasingly recognized as end effectors for various cardioprotective signaling pathways.  Mitochondria use oxygen as a substrate, so by default their respiration is inhibited during hypoxia/ischemia.  However, at reperfusion a surge of oxygen and metabolic substrates into the cell is thought to lead to rapid reestablishment of respiration, a burst of reactive oxygen species (ROS) generation and mitochondrial Ca2+ overload.  Subsequently these events ppt. opening of the mitochondrial permeability transition (PT) pore, which leads to myocardial cell death and dysfunction.  Given that mitochondrial respiration is already inhibited during hypoxia/ischemia, it is somewhat surprising that many respiratory inhibitors can improve recovery from ischemia-reperfusion (IR) injury.  In addn. ischemic preconditioning (IPC), in which short non-lethal cycles of IR can protect against subsequent prolonged IR injury, is known to lead to endogenous inhibition of several respiratory complexes and glycolysis.  This has led to a hypothesis that the wash-out of inhibitors or reversal of endogenous inhibition at reperfusion may afford protection by facilitating a more gradual wake-up of mitochondrial function, thereby avoiding a burst of ROS and Ca2+ overload.  This paper will review the evidence in support of this hypothesis, with a focus on inhibition of each of the mitochondrial respiratory complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqItjFgDsQHcrVg90H21EOLACvtfcHk0licNuUyjMLHEA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtVSht7Y%253D&md5=31fbf76d06eeb2fe1f9dd471f6d60bf7</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.yjmcc.2009.02.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yjmcc.2009.02.026%26sid%3Dliteratum%253Aachs%26aulast%3DBurwell%26aufirst%3DL.%2BS.%26aulast%3DNadtochiy%26aufirst%3DS.%2BM.%26aulast%3DBrookes%26aufirst%3DP.%2BS.%26atitle%3DCardioprotection%2520by%2520metabolic%2520shut-down%2520and%2520gradual%2520wake-up%26jtitle%3DJ.%2520Mol.%2520Cell.%2520Cardiol.%26date%3D2009%26volume%3D46%26spage%3D804%26epage%3D810%26doi%3D10.1016%2Fj.yjmcc.2009.02.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camara, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stowe, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoppel, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesnefsky, E. J.</span></span> <span> </span><span class="NLM_article-title">Modulation of electron transport protects cardiac mitochondria and decreases myocardial injury during ischemia and reperfusion</span>. <i>Am. J. Physiol. Cell Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>292</i></span>,  <span class="NLM_fpage">C137</span>â <span class="NLM_lpage">147</span>, <span class="refDoi">Â DOI: 10.1152/ajpcell.00270.2006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1152%2Fajpcell.00270.2006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=16971498" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD2sXisFCrtbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=292&publication_year=2007&pages=C137-147&author=Q.+Chenauthor=A.+K.+Camaraauthor=D.+F.+Stoweauthor=C.+L.+Hoppelauthor=E.+J.+Lesnefsky&title=Modulation+of+electron+transport+protects+cardiac+mitochondria+and+decreases+myocardial+injury+during+ischemia+and+reperfusion&doi=10.1152%2Fajpcell.00270.2006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of electron transport protects cardiac mitochondria and decreases myocardial injury during ischemia and reperfusion</span></div><div class="casAuthors">Chen, Qun; Camara, Amadou K. S.; Stowe, David F.; Hoppel, Charles L.; Lesnefsky, Edward J.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Physiology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">292</span>
        (<span class="NLM_cas:issue">1, Pt. 1</span>),
    <span class="NLM_cas:pages">C137-C147</span>CODEN:
                <span class="NLM_cas:coden">AJPHAP</span>;
        ISSN:<span class="NLM_cas:issn">0002-9513</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">A review.  Mitochondria are increasingly recognized as lynchpins in the evolution of cardiac injury during ischemia and reperfusion.  This review addresses the emerging concept that modulation of mitochondrial respiration during and immediately following an episode of ischemia can attenuate the extent of myocardial injury.  The blockade of electron transport and the partial uncoupling of respiration are two mechanisms whereby manipulation of mitochondrial metab. during ischemia decreases cardiac injury.  Although protection by inhibition of electron transport or uncoupling of respiration initially appears to be counterintuitive, the continuation of mitochondrial oxidative phosphorylation in the pathol. milieu of ischemia generates reactive oxygen species, mitochondrial calcium overload, and the release of cytochrome c.  The initial target of these deleterious mitochondrial-driven processes is the mitochondria themselves.  Consequences to the cardiomyocyte, in turn, include oxidative damage, the onset of mitochondrial permeability transition, and activation of apoptotic cascades, all favoring cardiomyocyte death.  Ischemia-induced mitochondrial damage carried forward into reperfusion further amplifies these mechanisms of mitochondrial-driven myocyte injury.  Interruption of mitochondrial respiration during early reperfusion by pharmacol. blockade of electron transport or even recurrent hypoxia or brief ischemia paradoxically decreases cardiac injury.  It increasingly appears that the cardioprotective paradigms of ischemic preconditioning and post-conditioning utilize modulation of mitochondrial oxidative metab. as a key effector mechanism.  The initially counterintuitive approach to inhibit mitochondrial respiration provides a new cardioprotective paradigm to decrease cellular injury during both ischemia and reperfusion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFV4YFMYs3arVg90H21EOLACvtfcHk0lhTdgvMwTYVnQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXisFCrtbo%253D&md5=424c7a16c836cb8d15df9ec788918dca</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1152%2Fajpcell.00270.2006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpcell.00270.2006%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DCamara%26aufirst%3DA.%2BK.%26aulast%3DStowe%26aufirst%3DD.%2BF.%26aulast%3DHoppel%26aufirst%3DC.%2BL.%26aulast%3DLesnefsky%26aufirst%3DE.%2BJ.%26atitle%3DModulation%2520of%2520electron%2520transport%2520protects%2520cardiac%2520mitochondria%2520and%2520decreases%2520myocardial%2520injury%2520during%2520ischemia%2520and%2520reperfusion%26jtitle%3DAm.%2520J.%2520Physiol.%2520Cell%2520Physiol.%26date%3D2007%26volume%3D292%26spage%3DC137%26epage%3D147%26doi%3D10.1152%2Fajpcell.00270.2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, I. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, I. Y.</span></span> <span> </span><span class="NLM_article-title">Modification of glycolysis affects cell sensitivity to apoptosis induced by oxidative stress and mediated by mitochondria</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>313</i></span>,  <span class="NLM_fpage">984</span>â <span class="NLM_lpage">991</span>, <span class="refDoi">Â DOI: 10.1016/j.bbrc.2003.12.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.bbrc.2003.12.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=14706639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD2cXosFCm" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=313&publication_year=2004&pages=984-991&author=D.+W.+Jeongauthor=T.+S.+Kimauthor=I.+T.+Choauthor=I.+Y.+Kim&title=Modification+of+glycolysis+affects+cell+sensitivity+to+apoptosis+induced+by+oxidative+stress+and+mediated+by+mitochondria&doi=10.1016%2Fj.bbrc.2003.12.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Modification of glycolysis affects cell sensitivity to apoptosis induced by oxidative stress and mediated by mitochondria</span></div><div class="casAuthors">Jeong, Dae-won; Kim, Tae-Soo; Cho, Il Taeg; Kim, Ick Young</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">313</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">984-991</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science</span>)
        </div><div class="casAbstract">The effect of alteration of the glycolytic pathway on cell damage induced by oxidative stress was investigated with dihydrofolate reductase-deficient Chinese hamster ovary (CHO) cells that either overexpress cytosolic glycerol-3-phosphate dehydrogenase (CHO/cGPDH cells) or are depleted of the A subunit of lactate dehydrogenase as a result of anti-sense RNA expression (CHO/anti-LDH cells).  The extent of oxidative phosphorylation in CHO/anti-LDH and CHO/cGPDH cells was increased and decreased, resp., relative to that in parental CHO cells, as revealed by measurement of the intracellular content of ATP, the rate of cellular O2 consumption, the mitochondrial membrane potential (ÎÎ¨m), and the generation of reactive oxygen species.  The sensitivity of these cell lines to cell death induced by the exogenous oxidant tert-Bu hydroperoxide decreased according to the rank order CHO/anti-LDH > CHO > CHO/cGPDH.  Exogenous pyruvate markedly increased the sensitivity of CHO/cGPDH cells to oxidant-induced death.  The differences among the three cell lines in susceptibility to oxidant-induced death were reflected in the proportion of oxidant-treated cells with a subdiploid DNA content, with a collapsed ÎÎ¨m, and with cytochrome c in the cytosol, indicating that death was mediated by apoptosis.  These results demonstrate that the influx of respiratory substrate into mitochondria is an important determinant of cell sensitivity to oxidant-induced apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHI8kF2mhqALVg90H21EOLACvtfcHk0lhTdgvMwTYVnQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXosFCm&md5=19e19165c98698c2c0cde2450e9f1c45</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2003.12.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2003.12.033%26sid%3Dliteratum%253Aachs%26aulast%3DJeong%26aufirst%3DD.%2BW.%26aulast%3DKim%26aufirst%3DT.%2BS.%26aulast%3DCho%26aufirst%3DI.%2BT.%26aulast%3DKim%26aufirst%3DI.%2BY.%26atitle%3DModification%2520of%2520glycolysis%2520affects%2520cell%2520sensitivity%2520to%2520apoptosis%2520induced%2520by%2520oxidative%2520stress%2520and%2520mediated%2520by%2520mitochondria%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2004%26volume%3D313%26spage%3D984%26epage%3D991%26doi%3D10.1016%2Fj.bbrc.2003.12.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vaughn, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, M.</span></span> <span> </span><span class="NLM_article-title">Glucose metabolism inhibits apoptosis in neurons and cancer cells by redox inactivation of cytochrome c</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1477</span>â <span class="NLM_lpage">1483</span>, <span class="refDoi">Â DOI: 10.1038/ncb1807</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fncb1807" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=19029908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVentbbE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=1477-1483&author=A.+E.+Vaughnauthor=M.+Deshmukh&title=Glucose+metabolism+inhibits+apoptosis+in+neurons+and+cancer+cells+by+redox+inactivation+of+cytochrome+c&doi=10.1038%2Fncb1807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Glucose metabolism inhibits apoptosis in neurons and cancer cells by redox inactivation of cytochrome c</span></div><div class="casAuthors">Vaughn, Allyson E.; Deshmukh, Mohanish</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1477-1483</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Neurons and cancer cells use glucose extensively, yet the precise advantage of this adaptation remains unclear.  These two seemingly disparate cell types also show an increased regulation of the apoptotic pathway, which allows for their long-term survival.  Here, we show that both neurons and cancer cells strictly inhibit cytochrome c-mediated apoptosis by a mechanism dependent on glucose metab.  We report that the pro-apoptotic activity of cytochrome c is influenced by its redox state and that increases in reactive oxygen species (ROS) following an apoptotic insult lead to the oxidn. and activation of cytochrome c.  In healthy neurons and cancer cells, however, cytochrome c is reduced and held inactive by intracellular glutathione (GSH), generated as a result of glucose metab. by the pentose phosphate pathway.  These results uncover a striking similarity in apoptosis regulation between neurons and cancer cells and provide insight into an adaptive advantage offered by the Warburg effect for cancer cell evasion of apoptosis and for long-term neuronal survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe03U9SKMYw7Vg90H21EOLACvtfcHk0lhTdgvMwTYVnQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVentbbE&md5=e08afc286f343190c84d0940a77efb19</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1038%2Fncb1807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncb1807%26sid%3Dliteratum%253Aachs%26aulast%3DVaughn%26aufirst%3DA.%2BE.%26aulast%3DDeshmukh%26aufirst%3DM.%26atitle%3DGlucose%2520metabolism%2520inhibits%2520apoptosis%2520in%2520neurons%2520and%2520cancer%2520cells%2520by%2520redox%2520inactivation%2520of%2520cytochrome%2520c%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2008%26volume%3D10%26spage%3D1477%26epage%3D1483%26doi%3D10.1038%2Fncb1807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoppel, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesnefsky, E. J.</span></span> <span> </span><span class="NLM_article-title">Blockade of electron transport before cardiac ischemia with the reversible inhibitor amobarbital protects rat heart mitochondria</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>316</i></span>,  <span class="NLM_fpage">200</span>â <span class="NLM_lpage">207</span>, <span class="refDoi">Â DOI: 10.1124/jpet.105.091702</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1124%2Fjpet.105.091702" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=16174799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhsleqtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2006&pages=200-207&author=Q.+Chenauthor=C.+L.+Hoppelauthor=E.+J.+Lesnefsky&title=Blockade+of+electron+transport+before+cardiac+ischemia+with+the+reversible+inhibitor+amobarbital+protects+rat+heart+mitochondria&doi=10.1124%2Fjpet.105.091702"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Blockade of electron transport before cardiac ischemia with the reversible inhibitor amobarbital protects rat heart mitochondria</span></div><div class="casAuthors">Chen, Qun; Hoppel, Charles L.; Lesnefsky, Edward J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">316</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">200-207</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Cardiac ischemia damages the mitochondrial electron transport chain.  Irreversible blockade of electron transport at complex I by rotenone decreases ischemic damage to cardiac mitochondria by decreasing the loss of cytochrome c and preserving respiration through cytochrome oxidase.  Therapeutic intervention to protect myocardium during ischemia and reperfusion requires the use of a reversible inhibitor that allows resumption of oxidative metab. during reperfusion.  Amobarbital is a reversible inhibitor at the rotenone site of complex I.  We asked whether amobarbital administered immediately before ischemia protected respiratory function.  Isolated rat hearts were perfused for 15 min followed by 25-min global ischemia at 37Â°.  Amobarbital-treated hearts received drug for 1 min before ischemia.  Subsarcolemmal (SSM) and interfibrillar (IFM) populations of mitochondria were isolated after ischemia, and oxidative phosphorylation was measured.  Amobarbital protected oxidative phosphorylation, including through cytochrome oxidase, in both SSM and IFM in a dose-dependent manner, with an optimal dose of 2 to 2.5 mM.  Amobarbital also preserved cytochrome c content in both SSM and IFM.  Thus, reversible blockade of the electron transport chain during ischemia protects mitochondrial respiration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj-3A9Kx8mDrVg90H21EOLACvtfcHk0lhvK_svhzcAYQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhsleqtg%253D%253D&md5=ddb82ae9cc62734e7d785620a7b7f79d</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.091702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.091702%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DHoppel%26aufirst%3DC.%2BL.%26aulast%3DLesnefsky%26aufirst%3DE.%2BJ.%26atitle%3DBlockade%2520of%2520electron%2520transport%2520before%2520cardiac%2520ischemia%2520with%2520the%2520reversible%2520inhibitor%2520amobarbital%2520protects%2520rat%2520heart%2520mitochondria%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2006%26volume%3D316%26spage%3D200%26epage%3D207%26doi%3D10.1124%2Fjpet.105.091702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aidakkak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stowe, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesnefsky, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camara, A. K. S.</span></span> <span> </span><span class="NLM_article-title">Inhibited mitochondrial respiration by amobarbital during cardiac ischaemia improves redox state and reduces matrix Ca2+ overload and ROS release</span>. <i>Cardiovasc. Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">406</span>â <span class="NLM_lpage">415</span>, <span class="refDoi">Â DOI: 10.1016/j.cardiores.2007.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.cardiores.2007.08.008" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2007&pages=406-415&author=M.+Aidakkakauthor=D.+F.+Stoweauthor=Q.+Chenauthor=E.+J.+Lesnefskyauthor=A.+K.+S.+Camara&title=Inhibited+mitochondrial+respiration+by+amobarbital+during+cardiac+ischaemia+improves+redox+state+and+reduces+matrix+Ca2%2B+overload+and+ROS+release&doi=10.1016%2Fj.cardiores.2007.08.008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1016%2Fj.cardiores.2007.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cardiores.2007.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DAidakkak%26aufirst%3DM.%26aulast%3DStowe%26aufirst%3DD.%2BF.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DLesnefsky%26aufirst%3DE.%2BJ.%26aulast%3DCamara%26aufirst%3DA.%2BK.%2BS.%26atitle%3DInhibited%2520mitochondrial%2520respiration%2520by%2520amobarbital%2520during%2520cardiac%2520ischaemia%2520improves%2520redox%2520state%2520and%2520reduces%2520matrix%2520Ca2%252B%2520overload%2520and%2520ROS%2520release%26jtitle%3DCardiovasc.%2520Res.%26date%3D2007%26volume%3D77%26spage%3D406%26epage%3D415%26doi%3D10.1016%2Fj.cardiores.2007.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCormack, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanley, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolff, A. A.</span></span> <span> </span><span class="NLM_article-title">Ranolazine: a novel metabolic modulator for the treatment of angina</span>. <i>Gen. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">639</span>â <span class="NLM_lpage">645</span>, <span class="refDoi">Â DOI: 10.1016/S0306-3623(97)00301-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2FS0306-3623%2897%2900301-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=9559312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADyaK1cXisVSmsrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1998&pages=639-645&author=J.+G.+McCormackauthor=W.+C.+Stanleyauthor=A.+A.+Wolff&title=Ranolazine%3A+a+novel+metabolic+modulator+for+the+treatment+of+angina&doi=10.1016%2FS0306-3623%2897%2900301-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Ranolazine: a novel metabolic modulator for the treatment of angina</span></div><div class="casAuthors">McCormack, James G.; Stanley, William C.; Wolff, Andrew A.</div><div class="citationInfo"><span class="NLM_cas:title">General Pharmacology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">639-645</span>CODEN:
                <span class="NLM_cas:coden">GEPHDP</span>;
        ISSN:<span class="NLM_cas:issn">0306-3623</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review with â¼40 refs.  1. Ranolazine shifts ATP prodn. away from fatty acid oxidn. toward glucose oxidn.  2. Because more oxygen is required to phosphorylate a given amt. of ATP during fatty acid oxidn. than during carbohydrate oxidn., the ranolazine-induced shift in substrate selection reduces the cell's demand for oxygen without decreasing its ability to do work.  The shift also maintains coupling of glycolysis to glucose oxidn. during ischemia, thus reducing tissue acidosis.  3. This unique, non-hemodynamic mechanism offers the potential to treat angina without reducing blood pressure, heart rate or myocardial contractility.  4. At least three double-blind, randomized, placebo-controlled clin. trials have yielded data consistent with this hypothesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobLv0eFcDoQrVg90H21EOLACvtfcHk0lhvK_svhzcAYQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXisVSmsrc%253D&md5=153f2ecebae88b181cced9eed6e1ae93</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1016%2FS0306-3623%2897%2900301-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0306-3623%252897%252900301-7%26sid%3Dliteratum%253Aachs%26aulast%3DMcCormack%26aufirst%3DJ.%2BG.%26aulast%3DStanley%26aufirst%3DW.%2BC.%26aulast%3DWolff%26aufirst%3DA.%2BA.%26atitle%3DRanolazine%253A%2520a%2520novel%2520metabolic%2520modulator%2520for%2520the%2520treatment%2520of%2520angina%26jtitle%3DGen.%2520Pharmacol.%26date%3D1998%26volume%3D30%26spage%3D639%26epage%3D645%26doi%3D10.1016%2FS0306-3623%2897%2900301-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wyatt, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skene, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veitch, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hue, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mccormack, J. G.</span></span> <span> </span><span class="NLM_article-title">The antianginal agent ranolazine Is a weak inhibitor of the respiratory Complex-I, but with greater potency in broken or uncoupled than in coupled mitochondria</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">1599</span>â <span class="NLM_lpage">1606</span>, <span class="refDoi">Â DOI: 10.1016/0006-2952(95)02042-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2F0006-2952%2895%2902042-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=7503762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADyaK2MXpvVWltr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1995&pages=1599-1606&author=K.+M.+Wyattauthor=C.+Skeneauthor=K.+Veitchauthor=L.+Hueauthor=J.+G.+Mccormack&title=The+antianginal+agent+ranolazine+Is+a+weak+inhibitor+of+the+respiratory+Complex-I%2C+but+with+greater+potency+in+broken+or+uncoupled+than+in+coupled+mitochondria&doi=10.1016%2F0006-2952%2895%2902042-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">The antianginal agent ranolazine is a weak inhibitor of the respiratory complex I, but with greater potency in broken or uncoupled than in coupled mitochondria</span></div><div class="casAuthors">Wyatt, Katrina M.; Skene, Caroline; Veitch, Keith; Hue, Louis; McCormack, James G.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1599-606</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Ranolazine (RS-43285) has shown antianginal effects in clin. trials and cardiac anti-ischemic activity in several in vivo and in vitro animal models, but without affecting hemodynamics.  Its mechanism is thought to mainly involve a switch in substrate utilization from fatty acids to glucose to, thus, improve efficiency of O2 use; however, its precise mol. target(s) are unknown.  In studies to investigate its action further, using isolated rat heart mitochondria, ranolazine was found to weakly inhibit (pIC50 values > 300 Î¼M) respiration by coupled mitochondria provided with NAD+-linked substrates but not with succinate.  With broken mitochondrial membranes or submitochondrial particles, ranolazine inhibited NADH but not succinate oxidn. and with pIC50 values in the lower range of 3-50 Î¼M.  Studies with different electron acceptors and respiratory inhibitors indicated that it inhibits respiratory Complex I at a site between ferricyanide and mendadione and ubiquinone-1 redn. (i.e. at a similar locus to rotenone).  However, unlike rotenone, ranolazine was an uncompetitive inhibitor with respect to ubiquinone-1.  Ranolazine inhibition of Complex I was reversible and occurred also with mitochondria from pig, guinea pig, and human heart, and rat liver.  Further studies using rat heart mitochondria in different energization states (i.e. broken, uncoupled, or coupled) showed a 50-100-fold shift to greater potency of ranolazine in the broken compared to the coupled; with the uncoupled it was about 2-fold less potent than the broken.  These shifts in potency were not found with rotenone or amytal.  Studies with radiolabeled ranolazine showed that it bound to mitochondrial membranes with greater affinity in the broken compared to the coupled or uncoupled conditions.  Rotenone displaced radiolabeled ranolazine from its binding site.  This property of ranolazine may play some in its anti-ischemic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkP6-MMnFKQrVg90H21EOLACvtfcHk0lhvK_svhzcAYQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXpvVWltr8%253D&md5=0f4e1afda8849f6fe15ec615e0642692</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2895%2902042-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252895%252902042-X%26sid%3Dliteratum%253Aachs%26aulast%3DWyatt%26aufirst%3DK.%2BM.%26aulast%3DSkene%26aufirst%3DC.%26aulast%3DVeitch%26aufirst%3DK.%26aulast%3DHue%26aufirst%3DL.%26aulast%3DMccormack%26aufirst%3DJ.%2BG.%26atitle%3DThe%2520antianginal%2520agent%2520ranolazine%2520Is%2520a%2520weak%2520inhibitor%2520of%2520the%2520respiratory%2520Complex-I%252C%2520but%2520with%2520greater%2520potency%2520in%2520broken%2520or%2520uncoupled%2520than%2520in%2520coupled%2520mitochondria%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1995%26volume%3D50%26spage%3D1599%26epage%3D1606%26doi%3D10.1016%2F0006-2952%2895%2902042-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wojtovich, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brookes, P. S.</span></span> <span> </span><span class="NLM_article-title">The complex II inhibitor atpenin A5 protects against cardiac ischemia-reperfusion injury via activation of mitochondrial K-ATP channels</span>. <i>Basic Res. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">121</span>â <span class="NLM_lpage">129</span>, <span class="refDoi">Â DOI: 10.1007/s00395-009-0001-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1007%2Fs00395-009-0001-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=19242645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVSisL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2009&pages=121-129&author=A.+P.+Wojtovichauthor=P.+S.+Brookes&title=The+complex+II+inhibitor+atpenin+A5+protects+against+cardiac+ischemia-reperfusion+injury+via+activation+of+mitochondrial+K-ATP+channels&doi=10.1007%2Fs00395-009-0001-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">The complex II inhibitor atpenin A5 protects against cardiac ischemia-reperfusion injury via activation of mitochondrial KATP channels</span></div><div class="casAuthors">Wojtovich, Andrew P.; Brookes, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">Basic Research in Cardiology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">121-129</span>CODEN:
                <span class="NLM_cas:coden">BRCAB7</span>;
        ISSN:<span class="NLM_cas:issn">0300-8428</span>.
    
            (<span class="NLM_cas:orgname">Steinkopff Verlag</span>)
        </div><div class="casAbstract">The cardioprotective effects of ischemic preconditioning (IPC) can be mimicked or blocked by pharmacol. agents, which modulate the mitochondrial ATP-sensitive potassium (mKATP) channel, thereby implicating this channel in the mechanism of IPC.  Cardioprotection can also be achieved via inhibition of mitochondrial respiratory complex II, and significant pharmacol. overlap exists between complex II inhibitors and mKATP channel agonists.  However, the relationship between complex II and the mKATP channel remains unclear.  Atpenin A5 (AA5) is a potent and specific complex II inhibitor, and herein we report that AA5 (1 nM) also activates the mKATP channel and protects against simulated ischemia-reperfusion (IR) injury in isolated cardiomyocytes.  Similar to known mKATP agonists, AA5-mediated protection was sensitive to the mKATP antagonists 5-hydroxydecanoate (5HD) and glyburide.  Notably, the optimal mKATP opening and protective concn. of AA5 had no effect on complex II enzymic activity, suggesting an interaction of AA5 with complex II, but not inhibition of the complex per se, is necessary for protection.  A cardioprotective effect of AA5 was also obsd. in isolated perfused hearts, wherein AA5 increased post-IR contractile function and decreased infarct size, in a 5HD-sensitive manner.  In conclusion, the specific complex II inhibitor AA5 is the most potent mKATP activator discovered to date, and provides a novel method of activating mKATP channels and protecting the heart from IR injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxHQQgJptwI7Vg90H21EOLACvtfcHk0lhkHw4EbYuKaA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVSisL4%253D&md5=83cc7391a1ad168e6c1bc050deb7121a</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1007%2Fs00395-009-0001-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00395-009-0001-y%26sid%3Dliteratum%253Aachs%26aulast%3DWojtovich%26aufirst%3DA.%2BP.%26aulast%3DBrookes%26aufirst%3DP.%2BS.%26atitle%3DThe%2520complex%2520II%2520inhibitor%2520atpenin%2520A5%2520protects%2520against%2520cardiac%2520ischemia-reperfusion%2520injury%2520via%2520activation%2520of%2520mitochondrial%2520K-ATP%2520channels%26jtitle%3DBasic%2520Res.%2520Cardiol.%26date%3D2009%26volume%3D104%26spage%3D121%26epage%3D129%26doi%3D10.1007%2Fs00395-009-0001-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drose, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bleier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, U.</span></span> <span> </span><span class="NLM_article-title">A common mechanism links differently acting Complex II inhibitors to cardioprotection: modulation of mitochondrial reactive oxygen species production</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">814</span>â <span class="NLM_lpage">822</span>, <span class="refDoi">Â DOI: 10.1124/mol.110.070342</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1124%2Fmol.110.070342" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=21278232" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BC3Mvksleitw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2011&pages=814-822&author=S.+Droseauthor=L.+Bleierauthor=U.+Brandt&title=A+common+mechanism+links+differently+acting+Complex+II+inhibitors+to+cardioprotection%3A+modulation+of+mitochondrial+reactive+oxygen+species+production&doi=10.1124%2Fmol.110.070342"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">A common mechanism links differently acting complex II inhibitors to cardioprotection: modulation of mitochondrial reactive oxygen species production</span></div><div class="casAuthors">Drose Stefan; Bleier Lea; Brandt Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">Molecular pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">814-22</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In this study, we have analyzed the effect of different cardioprotective complex II inhibitors on the mitochondrial production of reactive oxygen species (ROS) because ROS seem to be essential for signaling during preconditioning to prevent ischemia/reperfusion injury.  Despite different binding sites and concentrations required for half-maximal inhibition-ranging from nanomolar for the Q site inhibitor atpenin A5 to millimolar for the succinate analog malonate-all inhibitors modulated ROS production in the same ambivalent fashion: they promoted the generation of superoxide at the Q(o) site of complex III under conditions of "oxidant-induced reduction" but attenuated ROS generated at complex I due to reverse electron transfer.  All inhibitors showed these ambivalent effects independent of the presence of K(+).  These findings suggest a direct modulation of mitochondrial ROS generation during cardioprotection via complex II inhibition and question the recently proposed role of complex II as a regulatory component of the putative mitochondrial K(ATP) channel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQF_CEOTX_Zxb7NkxioyDXTfW6udTcc2eYna-jWZfcXBrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mvksleitw%253D%253D&md5=78d9bffad4940551e0fa09b8df741daf</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1124%2Fmol.110.070342&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.110.070342%26sid%3Dliteratum%253Aachs%26aulast%3DDrose%26aufirst%3DS.%26aulast%3DBleier%26aufirst%3DL.%26aulast%3DBrandt%26aufirst%3DU.%26atitle%3DA%2520common%2520mechanism%2520links%2520differently%2520acting%2520Complex%2520II%2520inhibitors%2520to%2520cardioprotection%253A%2520modulation%2520of%2520mitochondrial%2520reactive%2520oxygen%2520species%2520production%26jtitle%3DMol.%2520Pharmacol.%26date%3D2011%26volume%3D79%26spage%3D814%26epage%3D822%26doi%3D10.1124%2Fmol.110.070342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rena, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardie, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, E. R.</span></span> <span> </span><span class="NLM_article-title">The mechanisms of action of metformin</span>. <i>Diabetologia</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1577</span>â <span class="NLM_lpage">1585</span>, <span class="refDoi">Â DOI: 10.1007/s00125-017-4342-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1007%2Fs00125-017-4342-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=28776086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1yiurvP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1577-1585&author=G.+Renaauthor=D.+G.+Hardieauthor=E.+R.+Pearson&title=The+mechanisms+of+action+of+metformin&doi=10.1007%2Fs00125-017-4342-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">The mechanisms of action of metformin</span></div><div class="casAuthors">Rena, Graham; Hardie, D. Grahame; Pearson, Ewan R.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetologia</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1577-1585</span>CODEN:
                <span class="NLM_cas:coden">DBTGAJ</span>;
        ISSN:<span class="NLM_cas:issn">0012-186X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Metformin is a widely-used drug that results in clear benefits in relation to glucose metab. and diabetes-related complications.  The mechanisms underlying these benefits are complex and still not fully understood.  Physiol., metformin has been shown to reduce hepatic glucose prodn., yet not all of its effects can be explained by this mechanism and there is increasing evidence of a key role for the gut.  At the mol. level the findings vary depending on the doses of metformin used and duration of treatment, with clear differences between acute and chronic administration.  Metformin has been shown to act via both AMP-activated protein kinase (AMPK)-dependent and AMPK-independent mechanisms; by inhibition of mitochondrial respiration but also perhaps by inhibition of mitochondrial glycerophosphate dehydrogenase, and a mechanism involving the lysosome.  In the last 10 years, we have moved from a simple picture, that metformin improves glycemia by acting on the liver via AMPK activation, to a much more complex picture reflecting its multiple modes of action.  More work is required to truly understand how this drug works in its target population: individuals with type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1XNiaJVVDOLVg90H21EOLACvtfcHk0lhkHw4EbYuKaA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1yiurvP&md5=52c9c90d4a3968f61a500ec87884dab4</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1007%2Fs00125-017-4342-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00125-017-4342-z%26sid%3Dliteratum%253Aachs%26aulast%3DRena%26aufirst%3DG.%26aulast%3DHardie%26aufirst%3DD.%2BG.%26aulast%3DPearson%26aufirst%3DE.%2BR.%26atitle%3DThe%2520mechanisms%2520of%2520action%2520of%2520metformin%26jtitle%3DDiabetologia%26date%3D2017%26volume%3D60%26spage%3D1577%26epage%3D1585%26doi%3D10.1007%2Fs00125-017-4342-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devine, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redondo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinsella, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breen, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEneaney, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munsey, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivaprasadarao, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Findlay, J. B.</span></span> <span> </span><span class="NLM_article-title">Novel mitochondrial complex I inhibitors restore glucose-handling abilities of high-fat fed mice</span>. <i>J. Mol. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">261</span>â <span class="NLM_lpage">271</span>, <span class="refDoi">Â DOI: 10.1530/JME-15-0225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1530%2FJME-15-0225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=26759391" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslOlt7rL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2016&pages=261-271&author=D.+S.+Martinauthor=S.+Leonardauthor=R.+Devineauthor=C.+Redondoauthor=G.+K.+Kinsellaauthor=C.+J.+Breenauthor=V.+McEneaneyauthor=M.+F.+Rooneyauthor=T.+S.+Munseyauthor=R.+K.+Porterauthor=A.+Sivaprasadaraoauthor=J.+C.+Stephensauthor=J.+B.+Findlay&title=Novel+mitochondrial+complex+I+inhibitors+restore+glucose-handling+abilities+of+high-fat+fed+mice&doi=10.1530%2FJME-15-0225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mitochondrial complex I inhibitors restore glucose-handling abilities of high-fat fed mice</span></div><div class="casAuthors">Martin, Darren S. D.; Leonard, Siobhan; Devine, Robert; Redondo, Clara; Kinsella, Gemma K.; Breen, Conor J.; McEneaney, Victoria; Rooney, Mary F.; Munsey, Tim S.; Porter, Richard K.; Sivaprasadarao, Asipu; Stephens, John C.; Findlay, John B. C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Endocrinology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">261-271</span>CODEN:
                <span class="NLM_cas:coden">JMLEEI</span>;
        ISSN:<span class="NLM_cas:issn">0952-5041</span>.
    
            (<span class="NLM_cas:orgname">BioScientifica Ltd.</span>)
        </div><div class="casAbstract">Metformin is the main drug of choice for treating type 2 diabetes, yet the therapeutic regimens and side effects of the compd. are all undesirable and can lead to reduced compliance.  The aim of this study was to elucidate the mechanism of action of two novel compds. which improved glucose handling and wt. gain in mice on a high-fat diet.  Wildtype C57Bl/6 male mice were fed on a high-fat diet and treated with novel, anti-diabetic compds.  Both compds. restored the glucose handling ability of these mice.  At a cellular level, these compds. achieve this by inhibiting complex I activity in mitochondria, leading to AMP-activated protein kinase activation and subsequent increased glucose uptake by the cells, as measured in the mouse C2C12 muscle cell line.  Based on the inhibition of NADH dehydrogenase (IC50 27Î¼molL-1), one of these compds. is close to a thousand fold more potent than metformin.  There are no indications of off target effects.  The compds. have the potential to have a greater anti-diabetic effect at a lower dose than metformin and may represent a new anti-diabetic compd. class.  The mechanism of action appears not to be as an insulin sensitizer but rather as an insulin substitute.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoL6N8DXMcaN7Vg90H21EOLACvtfcHk0lizkJhGeObyGw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslOlt7rL&md5=bec695982d143851a4b49ba5de3cb837</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1530%2FJME-15-0225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1530%252FJME-15-0225%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DD.%2BS.%26aulast%3DLeonard%26aufirst%3DS.%26aulast%3DDevine%26aufirst%3DR.%26aulast%3DRedondo%26aufirst%3DC.%26aulast%3DKinsella%26aufirst%3DG.%2BK.%26aulast%3DBreen%26aufirst%3DC.%2BJ.%26aulast%3DMcEneaney%26aufirst%3DV.%26aulast%3DRooney%26aufirst%3DM.%2BF.%26aulast%3DMunsey%26aufirst%3DT.%2BS.%26aulast%3DPorter%26aufirst%3DR.%2BK.%26aulast%3DSivaprasadarao%26aufirst%3DA.%26aulast%3DStephens%26aufirst%3DJ.%2BC.%26aulast%3DFindlay%26aufirst%3DJ.%2BB.%26atitle%3DNovel%2520mitochondrial%2520complex%2520I%2520inhibitors%2520restore%2520glucose-handling%2520abilities%2520of%2520high-fat%2520fed%2520mice%26jtitle%3DJ.%2520Mol.%2520Endocrinol.%26date%3D2016%26volume%3D56%26spage%3D261%26epage%3D271%26doi%3D10.1530%2FJME-15-0225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flores, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krall, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jelinek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miranda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grigorian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graeber, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evseenko, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coller, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christofk, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowry, W. E.</span></span> <span> </span><span class="NLM_article-title">Lactate dehydrogenase activity drives hair follicle stem cell activation</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1017</span>â <span class="NLM_lpage">1026</span>, <span class="refDoi">Â DOI: 10.1038/ncb3575</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fncb3575" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=28812580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlKjtb3F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=1017-1026&author=A.+Floresauthor=J.+Schellauthor=A.+S.+Krallauthor=D.+Jelinekauthor=M.+Mirandaauthor=M.+Grigorianauthor=D.+Braasauthor=A.+C.+Whiteauthor=J.+L.+Zhouauthor=N.+A.+Grahamauthor=T.+Graeberauthor=P.+Sethauthor=D.+Evseenkoauthor=H.+A.+Collerauthor=J.+Rutterauthor=H.+R.+Christofkauthor=W.+E.+Lowry&title=Lactate+dehydrogenase+activity+drives+hair+follicle+stem+cell+activation&doi=10.1038%2Fncb3575"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Lactate dehydrogenase activity drives hair follicle stem cell activation</span></div><div class="casAuthors">Flores, Aimee; Schell, John; Krall, Abigail S.; Jelinek, David; Miranda, Matilde; Grigorian, Melina; Braas, Daniel; White, Andrew C.; Zhou, Jessica L.; Graham, Nicholas A.; Graeber, Thomas; Seth, Pankaj; Evseenko, Denis; Coller, Hilary A.; Rutter, Jared; Christofk, Heather R.; Lowry, William E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1017-1026</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Although normally dormant, hair follicle stem cells (HFSCs) quickly become activated to divide during a new hair cycle.  The quiescence of HFSCs is known to be regulated by a no. of intrinsic and extrinsic mechanisms.  Here we provide several lines of evidence to demonstrate that HFSCs utilize glycolytic metab. and produce significantly more lactate than other cells in the epidermis.  Furthermore, lactate generation appears to be crit. for the activation of HFSCs as deletion of lactate dehydrogenase (Ldha) prevented their activation.  Conversely, genetically promoting lactate prodn. in HFSCs through mitochondrial pyruvate carrier 1 (Mpc1) deletion accelerated their activation and the hair cycle.  Finally, we identify small mols. that increase lactate prodn. by stimulating Myc levels or inhibiting Mpc1 carrier activity and can topically induce the hair cycle.  These data suggest that HFSCs maintain a metabolic state that allows them to remain dormant and yet quickly respond to appropriate proliferative stimuli.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4OuPv43seibVg90H21EOLACvtfcHk0lizkJhGeObyGw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlKjtb3F&md5=92499916ee28424785ce7fa6a1519506</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1038%2Fncb3575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncb3575%26sid%3Dliteratum%253Aachs%26aulast%3DFlores%26aufirst%3DA.%26aulast%3DSchell%26aufirst%3DJ.%26aulast%3DKrall%26aufirst%3DA.%2BS.%26aulast%3DJelinek%26aufirst%3DD.%26aulast%3DMiranda%26aufirst%3DM.%26aulast%3DGrigorian%26aufirst%3DM.%26aulast%3DBraas%26aufirst%3DD.%26aulast%3DWhite%26aufirst%3DA.%2BC.%26aulast%3DZhou%26aufirst%3DJ.%2BL.%26aulast%3DGraham%26aufirst%3DN.%2BA.%26aulast%3DGraeber%26aufirst%3DT.%26aulast%3DSeth%26aufirst%3DP.%26aulast%3DEvseenko%26aufirst%3DD.%26aulast%3DColler%26aufirst%3DH.%2BA.%26aulast%3DRutter%26aufirst%3DJ.%26aulast%3DChristofk%26aufirst%3DH.%2BR.%26aulast%3DLowry%26aufirst%3DW.%2BE.%26atitle%3DLactate%2520dehydrogenase%2520activity%2520drives%2520hair%2520follicle%2520stem%2520cell%2520activation%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2017%26volume%3D19%26spage%3D1017%26epage%3D1026%26doi%3D10.1038%2Fncb3575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Son, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mun, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kook, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, K. S.</span></span> <span> </span><span class="NLM_article-title">A novel and safe small molecule enhances hair follicle regeneration by facilitating metabolic reprogramming</span>. <i>Exp. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">15</span>, <span class="refDoi">Â DOI: 10.1038/s12276-018-0185-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fs12276-018-0185-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=30523246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFCktbrL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2018&pages=1-15&author=M.+J.+Sonauthor=J.+K.+Jeongauthor=Y.+Kwonauthor=J.+S.+Ryuauthor=S.+J.+Munauthor=H.+J.+Kimauthor=S.+W.+Kimauthor=S.+Yooauthor=J.+Kookauthor=H.+Leeauthor=J.+Kimauthor=K.+S.+Chung&title=A+novel+and+safe+small+molecule+enhances+hair+follicle+regeneration+by+facilitating+metabolic+reprogramming&doi=10.1038%2Fs12276-018-0185-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Cell-penetrating artificial mitochondria-targeting peptide-conjugated metallothionein 1A alleviates mitochondrial damage in Parkinson's disease models</span></div><div class="casAuthors">Kang, Young Cheol; Son, Minuk; Kang, Sora; Im, Suyeol; Piao, Ying; Lim, Kwang Suk; Song, Min-Young; Park, Kang-Sik; Kim, Yong-Hee; Pak, Youngmi Kim</div><div class="citationInfo"><span class="NLM_cas:title">Experimental & Molecular Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1-13</span>CODEN:
                <span class="NLM_cas:coden">EMMEF3</span>;
        ISSN:<span class="NLM_cas:issn">2092-6413</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">An excess of reactive oxygen species (ROS) relative to the antioxidant capacity causes oxidative stress, which plays a role in the development of Parkinson's disease (PD).  Because mitochondria are both sites of ROS generation and targets of ROS damage, the delivery of antioxidants to mitochondria might prevent or alleviate PD.  To transduce the antioxidant protein human metallothionein 1A (hMT1A) into mitochondria, we computationally designed a cell-penetrating artificial mitochondria-targeting peptide (CAMP).  The recombinant CAMP-conjugated hMT1A fusion protein (CAMP-hMT1A) successfully localized to the mitochondria.  Treating a cell culture model of PD with CAMP-hMT1A restored tyrosine hydroxylase expression and mitochondrial activity and reduced ROS prodn.  Furthermore, injection of CAMP-hMT1A into the brain of a mouse model of PD rescued movement impairment and dopaminergic neuronal degeneration.  CAMP-hMT1A delivery into mitochondria might be therapeutic against PD by alleviating mitochondrial damage, and we predict that CAMP could be used to deliver other cargo proteins to the mitochondria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFFVO9GLAQebVg90H21EOLACvtfcHk0lizkJhGeObyGw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFCktbrL&md5=c44cd32d370f7f68263c544946d2e31b</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1038%2Fs12276-018-0185-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs12276-018-0185-z%26sid%3Dliteratum%253Aachs%26aulast%3DSon%26aufirst%3DM.%2BJ.%26aulast%3DJeong%26aufirst%3DJ.%2BK.%26aulast%3DKwon%26aufirst%3DY.%26aulast%3DRyu%26aufirst%3DJ.%2BS.%26aulast%3DMun%26aufirst%3DS.%2BJ.%26aulast%3DKim%26aufirst%3DH.%2BJ.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DYoo%26aufirst%3DS.%26aulast%3DKook%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DChung%26aufirst%3DK.%2BS.%26atitle%3DA%2520novel%2520and%2520safe%2520small%2520molecule%2520enhances%2520hair%2520follicle%2520regeneration%2520by%2520facilitating%2520metabolic%2520reprogramming%26jtitle%3DExp.%2520Mol.%2520Med.%26date%3D2018%26volume%3D50%26spage%3D1%26epage%3D15%26doi%3D10.1038%2Fs12276-018-0185-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gohil, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheth, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wojtovich, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perocchi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clish, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayata, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brookes, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mootha, V. K.</span></span> <span> </span><span class="NLM_article-title">Nutrient-sensitized screening for drugs that shift energy metabolism from mitochondrial respiration to glycolysis</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">249</span>â <span class="NLM_lpage">255</span>, <span class="refDoi">Â DOI: 10.1038/nbt.1606</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fnbt.1606" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=20160716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitVWnsL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=249-255&author=V.+M.+Gohilauthor=S.+A.+Shethauthor=R.+Nilssonauthor=A.+P.+Wojtovichauthor=J.+H.+Leeauthor=F.+Perocchiauthor=W.+Chenauthor=C.+B.+Clishauthor=C.+Ayataauthor=P.+S.+Brookesauthor=V.+K.+Mootha&title=Nutrient-sensitized+screening+for+drugs+that+shift+energy+metabolism+from+mitochondrial+respiration+to+glycolysis&doi=10.1038%2Fnbt.1606"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Nutrient-sensitized screening for drugs that shift energy metabolism from mitochondrial respiration to glycolysis</span></div><div class="casAuthors">Gohil, Vishal M.; Sheth, Sunil A.; Nilsson, Roland; Wojtovich, Andrew P.; Lee, Jeong Hyun; Perocchi, Fabiana; Chen, William; Clish, Clary B.; Ayata, Cenk; Brookes, Paul S.; Mootha, Vamsi K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">249-255</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Most cells have the inherent capacity to shift their reliance on glycolysis relative to oxidative metab., and studies in model systems have shown that targeting such shifts may be useful in treating or preventing a variety of diseases ranging from cancer to ischemic injury.  However, we currently have a limited no. of mechanistically distinct classes of drugs that alter the relative activities of these two pathways.  We screen for such compds. by scoring the ability of >3500 small mols. to selectively impair growth and viability of human fibroblasts in media contg. either galactose or glucose as the sole sugar source.  We identify several clin. used drugs never linked to energy metab., including the antiemetic meclizine, which attenuates mitochondrial respiration through a mechanism distinct from that of canonical inhibitors.  We further show that meclizine pretreatment confers cardioprotection and neuroprotection against ischemia-reperfusion injury in murine models.  Nutrient-sensitized screening may provide a useful framework for understanding gene function and drug action within the context of energy metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGof1g9JzGGiFLVg90H21EOLACvtfcHk0ljAbtjeBoydwQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitVWnsL0%253D&md5=3156e31467369716d7dff37487015015</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1606&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1606%26sid%3Dliteratum%253Aachs%26aulast%3DGohil%26aufirst%3DV.%2BM.%26aulast%3DSheth%26aufirst%3DS.%2BA.%26aulast%3DNilsson%26aufirst%3DR.%26aulast%3DWojtovich%26aufirst%3DA.%2BP.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DPerocchi%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DClish%26aufirst%3DC.%2BB.%26aulast%3DAyata%26aufirst%3DC.%26aulast%3DBrookes%26aufirst%3DP.%2BS.%26aulast%3DMootha%26aufirst%3DV.%2BK.%26atitle%3DNutrient-sensitized%2520screening%2520for%2520drugs%2520that%2520shift%2520energy%2520metabolism%2520from%2520mitochondrial%2520respiration%2520to%2520glycolysis%26jtitle%3DNat.%2520Biotechnol.%26date%3D2010%26volume%3D28%26spage%3D249%26epage%3D255%26doi%3D10.1038%2Fnbt.1606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrova-Benedict, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buncic, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, D. C.</span></span> <span> </span><span class="NLM_article-title">Nonviability of cells with oxidative defects in galactose medium: a screening test for affected patient fibroblasts</span>. <i>Biochem. Med. Metab. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">122</span>â <span class="NLM_lpage">126</span>, <span class="refDoi">Â DOI: 10.1016/0885-4505(92)90056-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2F0885-4505%2892%2990056-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1329873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADyaK38Xmt12gtbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=1992&pages=122-126&author=B.+H.+Robinsonauthor=R.+Petrova-Benedictauthor=J.+R.+Buncicauthor=D.+C.+Wallace&title=Nonviability+of+cells+with+oxidative+defects+in+galactose+medium%3A+a+screening+test+for+affected+patient+fibroblasts&doi=10.1016%2F0885-4505%2892%2990056-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Nonviability of cells with oxidative defects in galactose medium:  a screening test for affected patient fibroblasts</span></div><div class="casAuthors">Robinson, B. H.; Petrova-Benedict, R.; Buncic, J. R.; Wallace, D. C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Medicine and Metabolic Biology</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">122-6</span>CODEN:
                <span class="NLM_cas:coden">BMMBES</span>;
        ISSN:<span class="NLM_cas:issn">0885-4505</span>.
    </div><div class="casAbstract">Diagnosis of respiratory chain defects in cultured skin fibroblasts is a difficult diagnostic procedure.  The feasibility of using survival of skin fibroblasts in culture medium with galactose as the major C source was investigated as a method of quickly diagnosing cell lines compromised in oxidative metab.  Cells from patients with most forms of cytochrome oxidase deficiency, cells with complex I deficiency, cells with multiple respiratory chain defects and cells with severe pyruvate dehydrogenase (PDH) complex deficiency failed to survive when subcultured in galactose (5 mM) medium.  Cells from patients with Lebers hereditary optic neuropathy, Kearns-Sayre syndrome, myoclonus-epilepsy-lactic acidosis-stroke, the hepatic form of cytochrome oxidase deficiency, and mild PDH complex deficiency survived well in galactose-contg. medium.  This could be used as a rapid screening test for skin fibroblasts with major oxidative defects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo61ebnsG3l7Vg90H21EOLACvtfcHk0ljAbtjeBoydwQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38Xmt12gtbw%253D&md5=085b11e9e3935712adbddcbaec6c6828</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1016%2F0885-4505%2892%2990056-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0885-4505%252892%252990056-5%26sid%3Dliteratum%253Aachs%26aulast%3DRobinson%26aufirst%3DB.%2BH.%26aulast%3DPetrova-Benedict%26aufirst%3DR.%26aulast%3DBuncic%26aufirst%3DJ.%2BR.%26aulast%3DWallace%26aufirst%3DD.%2BC.%26atitle%3DNonviability%2520of%2520cells%2520with%2520oxidative%2520defects%2520in%2520galactose%2520medium%253A%2520a%2520screening%2520test%2520for%2520affected%2520patient%2520fibroblasts%26jtitle%3DBiochem.%2520Med.%2520Metab.%2520Biol.%26date%3D1992%26volume%3D48%26spage%3D122%26epage%3D126%26doi%3D10.1016%2F0885-4505%2892%2990056-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marroquin, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hynes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dykens, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, Y.</span></span> <span> </span><span class="NLM_article-title">Circumventing the Crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">539</span>â <span class="NLM_lpage">547</span>, <span class="refDoi">Â DOI: 10.1093/toxsci/kfm052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1093%2Ftoxsci%2Fkfm052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=17361016" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsV2is7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2007&pages=539-547&author=L.+D.+Marroquinauthor=J.+Hynesauthor=J.+A.+Dykensauthor=J.+D.+Jamiesonauthor=Y.+Will&title=Circumventing+the+Crabtree+effect%3A+replacing+media+glucose+with+galactose+increases+susceptibility+of+HepG2+cells+to+mitochondrial+toxicants&doi=10.1093%2Ftoxsci%2Fkfm052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Circumventing the Crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants</span></div><div class="casAuthors">Marroquin, Lisa D.; Hynes, James; Dykens, James A.; Jamieson, Joseph D.; Will, Yvonne</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">539-547</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-6080</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Many highly proliferative cells generate almost all ATP via glycolysis despite abundant O2 and a normal complement of fully functional mitochondria, a circumstance known as the Crabtree effect.  Such anaerobically poised cells are resistant to xenobiotics that impair mitochondrial function, such as the inhibitors rotenone, antimycin, oligomycin, and compds. like carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP), that uncouple the respiratory electron transfer system from phosphorylation.  These cells are also resistant to the toxicity of many drugs whose deleterious side effect profiles are either caused, or exacerbated, by impairment of mitochondrial function.  Drug-induced mitochondrial toxicity is shown by members of important drug classes, including the thiazolidinediones, statins, fibrates, antivirals, antibiotics, and anticancer agents.  To increase detection of drug-induced mitochondrial effects in a preclin. cell-based assay, HepG2 cells were forced to rely on mitochondrial oxidative phosphorylation rather than glycolysis by substituting galactose for glucose in the growth media.  Oxygen consumption doubles in galactose-grown HepG2 cells and their susceptibility to canonical mitochondrial toxicants correspondingly increases.  Similarly, toxicity of several drugs with known mitochondrial liabilities is more readily apparent in aerobically poised HepG2 cells compared to glucose-grown cells.  Some drugs were equally toxic to both glucose- and galactose-grown cells, suggesting that mitochondrial impairment is likely secondary to other cytotoxic mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2Zb0elenmNbVg90H21EOLACvtfcHk0ljAbtjeBoydwQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsV2is7w%253D&md5=53d6a955ad0a942d1ced5043668bed19</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfm052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfm052%26sid%3Dliteratum%253Aachs%26aulast%3DMarroquin%26aufirst%3DL.%2BD.%26aulast%3DHynes%26aufirst%3DJ.%26aulast%3DDykens%26aufirst%3DJ.%2BA.%26aulast%3DJamieson%26aufirst%3DJ.%2BD.%26aulast%3DWill%26aufirst%3DY.%26atitle%3DCircumventing%2520the%2520Crabtree%2520effect%253A%2520replacing%2520media%2520glucose%2520with%2520galactose%2520increases%2520susceptibility%2520of%2520HepG2%2520cells%2520to%2520mitochondrial%2520toxicants%26jtitle%3DToxicol.%2520Sci.%26date%3D2007%26volume%3D97%26spage%3D539%26epage%3D547%26doi%3D10.1093%2Ftoxsci%2Fkfm052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brand, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholls, D. G.</span></span> <span> </span><span class="NLM_article-title">Assessing mitochondrial dysfunction in cells</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>435</i></span>,  <span class="NLM_fpage">297</span>â <span class="NLM_lpage">312</span>, <span class="refDoi">Â DOI: 10.1042/BJ20110162</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1042%2FBJ20110162" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=21726199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvFOjurs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=435&publication_year=2011&pages=297-312&author=M.+D.+Brandauthor=D.+G.+Nicholls&title=Assessing+mitochondrial+dysfunction+in+cells&doi=10.1042%2FBJ20110162"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Assessing mitochondrial dysfunction in cells</span></div><div class="casAuthors">Brand, Martin D.; Nicholls, David G.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">435</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">297-312</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Assessing mitochondrial dysfunction requires definition of the dysfunction to be investigated.  Usually, it is the ability of the mitochondria to make ATP appropriately in response to energy demands.  Where other functions are of interest, tailored solns. are required.  Dysfunction can be assessed in isolated mitochondria, in cells or in vivo, with different balances between precise exptl. control and physiol. relevance.  There are many methods to measure mitochondrial function and dysfunction in these systems.  Generally, measurements of fluxes give more information about the ability to make ATP than do measurements of intermediates and potentials.  For isolated mitochondria, the best assay is mitochondrial respiratory control: the increase in respiration rate in response to ADP.  For intact cells, the best assay is the equiv. measurement of cell respiratory control, which reports the rate of ATP prodn., the proton leak rate, the coupling efficiency, the max. respiratory rate, the respiratory control ratio and the spare respiratory capacity.  Measurements of membrane potential provide useful addnl. information.  Measurement of both respiration and potential during appropriate titrns. enables the identification of the primary sites of effectors and the distribution of control, allowing deeper quant. analyses.  Many other measurements in current use can be more problematic, as discussed in the present review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpogtjN5LPjXrVg90H21EOLACvtfcHk0lhpnConiToTXQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvFOjurs%253D&md5=fd7d4c6ffa1d0ba4427fc27dcafb7d1d</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1042%2FBJ20110162&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20110162%26sid%3Dliteratum%253Aachs%26aulast%3DBrand%26aufirst%3DM.%2BD.%26aulast%3DNicholls%26aufirst%3DD.%2BG.%26atitle%3DAssessing%2520mitochondrial%2520dysfunction%2520in%2520cells%26jtitle%3DBiochem.%2520J.%26date%3D2011%26volume%3D435%26spage%3D297%26epage%3D312%26doi%3D10.1042%2FBJ20110162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tilmant, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerets, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Ron, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bento-Pereira, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atienzar, F. A.</span></span> <span> </span><span class="NLM_article-title">In vitro screening of cell bioenergetics to assess mitochondrial dysfunction in drug development</span>. <i>Toxicol. In Vitro</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">374</span>â <span class="NLM_lpage">383</span>, <span class="refDoi">Â DOI: 10.1016/j.tiv.2018.07.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.tiv.2018.07.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=30030051" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVCntrnE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2018&pages=374-383&author=K.+Tilmantauthor=H.+Geretsauthor=P.+De+Ronauthor=E.+Hanonauthor=C.+Bento-Pereiraauthor=F.+A.+Atienzar&title=In+vitro+screening+of+cell+bioenergetics+to+assess+mitochondrial+dysfunction+in+drug+development&doi=10.1016%2Fj.tiv.2018.07.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro screening of cell bioenergetics to assess mitochondrial dysfunction in drug development</span></div><div class="casAuthors">Tilmant, K.; Gerets, H.; De Ron, P.; Hanon, E.; Bento-Pereira, C.; Atienzar, F. A.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology In Vitro</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">374-383</span>CODEN:
                <span class="NLM_cas:coden">TIVIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0887-2333</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Drug-induced mitochondrial toxicity is considered as a common cellular mechanism that can induce a variety of organ toxicities.  In the present manuscript, 17 in vitro mitochondrial toxic drugs, reported to induce Drug-Induced Liver Injury (DILI) and 6 non-mitochondrial toxic drugs (3 with DILI and 3 without DILI concern), were tested in HepG2 cells using a bioenergetics system.  The 17 mitochondrial toxic drugs represent a wide variety of mitochondrial dysfunctions as well as DILI and include 4 pairs of drugs which are structurally related but assocd. with different DILI concerns in human.  Cell bioenergetics were measured using the XF96e analyzer which simultaneous monitor oxygen consumption rate (OCR) and extracellular acidification rate (ECAR), indirect measurements of oxidative phosphorylation and glycolysis, resp.  OCR assocd. with ATP prodn., maximal respiration, proton leak and spare respiratory capacity, were also assessed.  Duplicate expts. resulted in a sensitivity of 82% (14/17) and specificity of 83% (5/6).  The addn. of stressors improved specificity considerably.  Cut-offs, statistics and rules are clearly discussed to facilitate the use of this assay for screening purposes.  Overall, the authors consider that this assay should be part of the battery of safety screening assays at early stages of drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwxA5f95FBMrVg90H21EOLACvtfcHk0lhpnConiToTXQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVCntrnE&md5=ba0bfeecf14ad629a4a0b3dfef5ee8c8</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1016%2Fj.tiv.2018.07.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tiv.2018.07.012%26sid%3Dliteratum%253Aachs%26aulast%3DTilmant%26aufirst%3DK.%26aulast%3DGerets%26aufirst%3DH.%26aulast%3DDe%2BRon%26aufirst%3DP.%26aulast%3DHanon%26aufirst%3DE.%26aulast%3DBento-Pereira%26aufirst%3DC.%26aulast%3DAtienzar%26aufirst%3DF.%2BA.%26atitle%3DIn%2520vitro%2520screening%2520of%2520cell%2520bioenergetics%2520to%2520assess%2520mitochondrial%2520dysfunction%2520in%2520drug%2520development%26jtitle%3DToxicol.%2520In%2520Vitro%26date%3D2018%26volume%3D52%26spage%3D374%26epage%3D383%26doi%3D10.1016%2Fj.tiv.2018.07.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, N. M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theurey, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adam-Vizi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazan, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernardi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolanos, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culmsee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duchen, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dussmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiskum, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galindo, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardingham, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardwick, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jekabsons, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonas, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipton, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manfredi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattson, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Methner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholls, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polster, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pozzan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzuto, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satrustegui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slack, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanson, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swerdlow, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ying, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joselin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gioran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinho, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watters, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvucci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llorente-Folch, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bano, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ankarcrona, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prehn, J. H. M.</span></span> <span> </span><span class="NLM_article-title">Guidelines on experimental methods to assess mitochondrial dysfunction in cellular models of neurodegenerative diseases</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">542</span>â <span class="NLM_lpage">572</span>, <span class="refDoi">Â DOI: 10.1038/s41418-017-0020-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fs41418-017-0020-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=29229998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkslagsbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=542-572&author=N.+M.+C.+Connollyauthor=P.+Theureyauthor=V.+Adam-Viziauthor=N.+G.+Bazanauthor=P.+Bernardiauthor=J.+P.+Bolanosauthor=C.+Culmseeauthor=V.+L.+Dawsonauthor=M.+Deshmukhauthor=M.+R.+Duchenauthor=H.+Dussmannauthor=G.+Fiskumauthor=M.+F.+Galindoauthor=G.+E.+Hardinghamauthor=J.+M.+Hardwickauthor=M.+B.+Jekabsonsauthor=E.+A.+Jonasauthor=J.+Jordanauthor=S.+A.+Liptonauthor=G.+Manfrediauthor=M.+P.+Mattsonauthor=B.+McLaughlinauthor=A.+Methnerauthor=A.+N.+Murphyauthor=M.+P.+Murphyauthor=D.+G.+Nichollsauthor=B.+M.+Polsterauthor=T.+Pozzanauthor=R.+Rizzutoauthor=J.+Satrusteguiauthor=R.+S.+Slackauthor=R.+A.+Swansonauthor=R.+H.+Swerdlowauthor=Y.+Willauthor=Z.+Yingauthor=A.+Joselinauthor=A.+Gioranauthor=C.+M.+Pinhoauthor=O.+Wattersauthor=M.+Salvucciauthor=I.+Llorente-Folchauthor=D.+S.+Parkauthor=D.+Banoauthor=M.+Ankarcronaauthor=P.+Pizzoauthor=J.+H.+M.+Prehn&title=Guidelines+on+experimental+methods+to+assess+mitochondrial+dysfunction+in+cellular+models+of+neurodegenerative+diseases&doi=10.1038%2Fs41418-017-0020-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Guidelines on experimental methods to assess mitochondrial dysfunction in cellular models of neurodegenerative diseases</span></div><div class="casAuthors">Connolly, Niamh M. C.; Theurey, Pierre; Adam-Vizi, Vera; Bazan, Nicolas G.; Bernardi, Paolo; Bolanos, Juan P.; Culmsee, Carsten; Dawson, Valina L.; Deshmukh, Mohanish; Duchen, Michael R.; Dussmann, Heiko; Fiskum, Gary; Galindo, Maria F.; Hardingham, Giles E.; Hardwick, J. Marie; Jekabsons, Mika B.; Jonas, Elizabeth A.; Jordan, Joaquin; Lipton, Stuart A.; Manfredi, Giovanni; Mattson, Mark P.; McLaughlin, BethAnn; Methner, Axel; Murphy, Anne N.; Murphy, Michael P.; Nicholls, David G.; Polster, Brian M.; Pozzan, Tullio; Rizzuto, Rosario; Satrustegui, Jorgina; Slack, Ruth S.; Swanson, Raymond A.; Swerdlow, Russell H.; Will, Yvonne; Ying, Zheng; Joselin, Alvin; Gioran, Anna; Moreira Pinho, Catarina; Watters, Orla; Salvucci, Manuela; Llorente-Folch, Irene; Park, David S.; Bano, Daniele; Ankarcrona, Maria; Pizzo, Paola; Prehn, Jochen H. M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Differentiation</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">542-572</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Neurodegenerative diseases are a spectrum of chronic, debilitating disorders characterised by the progressive degeneration and death of neurons.  Mitochondrial dysfunction has been implicated in most neurodegenerative diseases, but in many instances it is unclear whether such dysfunction is a cause or an effect of the underlying pathol., and whether it represents a viable therapeutic target.  It is therefore imperative to utilize and optimize cellular models and exptl. techniques appropriate to det. the contribution of mitochondrial dysfunction to neurodegenerative disease phenotypes.  In this consensus article, we collate details on and discuss pitfalls of existing exptl. approaches to assess mitochondrial function in in vitro cellular models of neurodegenerative diseases, including specific protocols for the measurement of oxygen consumption rate in primary neuron cultures, and single-neuron, time-lapse fluorescence imaging of the mitochondrial membrane potential and mitochondrial NAD(P)H.  As part of the Cellular Bioenergetics of Neurodegenerative Diseases (CeBioND) consortium (www.cebiond.org), we are performing cross-disease analyses to identify common and distinct mol. mechanisms involved in mitochondrial bioenergetic dysfunction in cellular models of Alzheimer's, Parkinson's, and Huntington's diseases.  Here we provide detailed guidelines and protocols as standardised across the five collaborating labs. of the CeBioND consortium, with addnl. contributions from other experts in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq95eOahbCNrbVg90H21EOLACvtfcHk0lhpnConiToTXQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkslagsbY%253D&md5=338513b244a7c1b447ee19159a76e7d9</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1038%2Fs41418-017-0020-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41418-017-0020-4%26sid%3Dliteratum%253Aachs%26aulast%3DConnolly%26aufirst%3DN.%2BM.%2BC.%26aulast%3DTheurey%26aufirst%3DP.%26aulast%3DAdam-Vizi%26aufirst%3DV.%26aulast%3DBazan%26aufirst%3DN.%2BG.%26aulast%3DBernardi%26aufirst%3DP.%26aulast%3DBolanos%26aufirst%3DJ.%2BP.%26aulast%3DCulmsee%26aufirst%3DC.%26aulast%3DDawson%26aufirst%3DV.%2BL.%26aulast%3DDeshmukh%26aufirst%3DM.%26aulast%3DDuchen%26aufirst%3DM.%2BR.%26aulast%3DDussmann%26aufirst%3DH.%26aulast%3DFiskum%26aufirst%3DG.%26aulast%3DGalindo%26aufirst%3DM.%2BF.%26aulast%3DHardingham%26aufirst%3DG.%2BE.%26aulast%3DHardwick%26aufirst%3DJ.%2BM.%26aulast%3DJekabsons%26aufirst%3DM.%2BB.%26aulast%3DJonas%26aufirst%3DE.%2BA.%26aulast%3DJordan%26aufirst%3DJ.%26aulast%3DLipton%26aufirst%3DS.%2BA.%26aulast%3DManfredi%26aufirst%3DG.%26aulast%3DMattson%26aufirst%3DM.%2BP.%26aulast%3DMcLaughlin%26aufirst%3DB.%26aulast%3DMethner%26aufirst%3DA.%26aulast%3DMurphy%26aufirst%3DA.%2BN.%26aulast%3DMurphy%26aufirst%3DM.%2BP.%26aulast%3DNicholls%26aufirst%3DD.%2BG.%26aulast%3DPolster%26aufirst%3DB.%2BM.%26aulast%3DPozzan%26aufirst%3DT.%26aulast%3DRizzuto%26aufirst%3DR.%26aulast%3DSatrustegui%26aufirst%3DJ.%26aulast%3DSlack%26aufirst%3DR.%2BS.%26aulast%3DSwanson%26aufirst%3DR.%2BA.%26aulast%3DSwerdlow%26aufirst%3DR.%2BH.%26aulast%3DWill%26aufirst%3DY.%26aulast%3DYing%26aufirst%3DZ.%26aulast%3DJoselin%26aufirst%3DA.%26aulast%3DGioran%26aufirst%3DA.%26aulast%3DPinho%26aufirst%3DC.%2BM.%26aulast%3DWatters%26aufirst%3DO.%26aulast%3DSalvucci%26aufirst%3DM.%26aulast%3DLlorente-Folch%26aufirst%3DI.%26aulast%3DPark%26aufirst%3DD.%2BS.%26aulast%3DBano%26aufirst%3DD.%26aulast%3DAnkarcrona%26aufirst%3DM.%26aulast%3DPizzo%26aufirst%3DP.%26aulast%3DPrehn%26aufirst%3DJ.%2BH.%2BM.%26atitle%3DGuidelines%2520on%2520experimental%2520methods%2520to%2520assess%2520mitochondrial%2520dysfunction%2520in%2520cellular%2520models%2520of%2520neurodegenerative%2520diseases%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2018%26volume%3D25%26spage%3D542%26epage%3D572%26doi%3D10.1038%2Fs41418-017-0020-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perry, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbieri, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelbard, H. A.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial membrane potential probes and the proton gradient: a practical usage guide</span>. <i>BioTechniques</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">98</span>â <span class="NLM_lpage">115</span>, <span class="refDoi">Â DOI: 10.2144/000113610</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.2144%2F000113610" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=21486251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvFGrtb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=98-115&author=S.+W.+Perryauthor=J.+P.+Normanauthor=J.+Barbieriauthor=E.+B.+Brownauthor=H.+A.+Gelbard&title=Mitochondrial+membrane+potential+probes+and+the+proton+gradient%3A+a+practical+usage+guide&doi=10.2144%2F000113610"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial membrane potential probes and the proton gradient: a practical usage guide</span></div><div class="casAuthors">Perry, Seth W.; Norman, John P.; Barbieri, Justin; Brown, Edward B.; Gelbard, Harris A.</div><div class="citationInfo"><span class="NLM_cas:title">BioTechniques</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">98-100,102-104,106,108,110-115</span>CODEN:
                <span class="NLM_cas:coden">BTNQDO</span>;
        ISSN:<span class="NLM_cas:issn">0736-6205</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Fluorescent probes for monitoring mitochondrial membrane potential are frequently used for assessing mitochondrial function, particularly in the context of cell fate detn. in biol. and biomedical research.  However, valid interpretation of results obtained with such probes requires careful consideration of numerous controls, as well as possible effects of non-protonic charges on dye behavior.  In this context, we provide an overview of some of the important tech. considerations, controls, and parallel complementary assays that can be employed to help ensure appropriate interpretation of results, thus providing a practical usage guide for monitoring mitochondrial membrane potentials with cationic probes.  In total, this review will help illustrate both the strengths and potential pitfalls of common mitochondrial membrane potential dyes, and highlight best-usage approaches for their efficacious application in life sciences research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbiG_ThFfCMbVg90H21EOLACvtfcHk0lgmD8RMmtsKjQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvFGrtb0%253D&md5=88634b0b0ab36d3d9f4e734fa69411fa</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.2144%2F000113610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2144%252F000113610%26sid%3Dliteratum%253Aachs%26aulast%3DPerry%26aufirst%3DS.%2BW.%26aulast%3DNorman%26aufirst%3DJ.%2BP.%26aulast%3DBarbieri%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DE.%2BB.%26aulast%3DGelbard%26aufirst%3DH.%2BA.%26atitle%3DMitochondrial%2520membrane%2520potential%2520probes%2520and%2520the%2520proton%2520gradient%253A%2520a%2520practical%2520usage%2520guide%26jtitle%3DBioTechniques%26date%3D2011%26volume%3D50%26spage%3D98%26epage%3D115%26doi%3D10.2144%2F000113610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jastroch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Divakaruni, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mookerjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treberg, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brand, M. D.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial proton and electron leaks</span>. <i>Essays Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">53</span>â <span class="NLM_lpage">67</span>, <span class="refDoi">Â DOI: 10.1042/bse0470053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1042%2Fbse0470053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=20533900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvFKkt78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2010&pages=53-67&author=M.+Jastrochauthor=A.+S.+Divakaruniauthor=S.+Mookerjeeauthor=J.+R.+Trebergauthor=M.+D.+Brand&title=Mitochondrial+proton+and+electron+leaks&doi=10.1042%2Fbse0470053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial proton and electron leaks</span></div><div class="casAuthors">Jastroch, Martin; Divakaruni, Ajit S.; Mookerjee, Shona; Treberg, Jason R.; Brand, Martin D.</div><div class="citationInfo"><span class="NLM_cas:title">Essays in Biochemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">Mitochondrial Function</span>),
    <span class="NLM_cas:pages">53-67</span>CODEN:
                <span class="NLM_cas:coden">ESBIAV</span>;
        ISSN:<span class="NLM_cas:issn">0071-1365</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Mitochondrial proton and electron leak have a major impact on mitochondrial coupling efficiency and prodn. of reactive oxygen species.  In the first part of this chapter, we address the mol. nature of the basal and inducible proton leak pathways, and their physiol. importance.  The basal leak is unregulated, and a major proportion can be attributed to mitochondrial anion carriers, whereas the proton leak through the lipid bilayer appears to be minor.  The basal proton leak is cell-type specific and correlates with metabolic rate.  The inducible leak through the ANT (adenine nucleotide translocase) and UCPs (uncoupling proteins) can be activated by fatty acids, superoxide or lipid peroxidn. products.  The physiol. role of inducible leak through UCP1 in mammalian brown adipose tissue is heat prodn., whereas the roles of non-mammalian UCP1 and its paralogous proteins, in particular UCP2 and UCP3, are not yet resolved.  The second part of the chapter focuses on the electron leak that occurs in the mitochondrial electron transport chain.  Exit of electrons prior to the redn. of oxygen to water at cytochrome c oxidase causes superoxide prodn.  As the mechanisms of electron leak are crucial to understanding their physiol. relevance, we summarize the mechanisms and topol. of electron leak from complexes I and III in studies using isolated mitochondria.  We also highlight recent progress and challenges of assessing electron leak in the living cell.  Finally, we emphasize the importance of proton and electron leak as therapeutic targets in body mass regulation and insulin secretion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrM97KNAYlxp7Vg90H21EOLACvtfcHk0lgmD8RMmtsKjQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvFKkt78%253D&md5=a842d59c70b92905d220a55b4b61551a</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1042%2Fbse0470053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbse0470053%26sid%3Dliteratum%253Aachs%26aulast%3DJastroch%26aufirst%3DM.%26aulast%3DDivakaruni%26aufirst%3DA.%2BS.%26aulast%3DMookerjee%26aufirst%3DS.%26aulast%3DTreberg%26aufirst%3DJ.%2BR.%26aulast%3DBrand%26aufirst%3DM.%2BD.%26atitle%3DMitochondrial%2520proton%2520and%2520electron%2520leaks%26jtitle%3DEssays%2520Biochem.%26date%3D2010%26volume%3D47%26spage%3D53%26epage%3D67%26doi%3D10.1042%2Fbse0470053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ying, W. H.</span></span> <span> </span><span class="NLM_article-title">NAD(+)/ NADH and NADP(+)/NADPH in cellular functions and cell death: Regulation and biological consequences</span>. <i>Antioxid. Redox Signaling</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">179</span>â <span class="NLM_lpage">206</span>, <span class="refDoi">Â DOI: 10.1089/ars.2007.1672</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1089%2Fars.2007.1672" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=18020963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1ShtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=179-206&author=W.+H.+Ying&title=NAD%28%2B%29%2F+NADH+and+NADP%28%2B%29%2FNADPH+in+cellular+functions+and+cell+death%3A+Regulation+and+biological+consequences&doi=10.1089%2Fars.2007.1672"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">NAD+/NADH and NADP+/NADPH in Cellular Functions and Cell Death: Regulation and Biological Consequences</span></div><div class="casAuthors">Ying, Weihai</div><div class="citationInfo"><span class="NLM_cas:title">Antioxidants & Redox Signaling</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-206</span>CODEN:
                <span class="NLM_cas:coden">ARSIF2</span>;
        ISSN:<span class="NLM_cas:issn">1523-0864</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">A review.  Accumulating evidence has suggested that NAD (including NAD+ and NADH) and NADP (including NADP+ and NADPH) could belong to the fundamental common mediators of various biol. processes, including energy metab., mitochondrial functions, calcium homeostasis, antioxidn./generation of oxidative stress, gene expression, immunol. functions, aging, and cell death.  First, it is established that NAD mediates energy metab. and mitochondrial functions; second, NADPH is a key component in cellular antioxidn. systems; and NADH-dependent reactive oxygen species (ROS) generation from mitochondria and NADPH oxidase-dependent ROS generation are two crit. mechanisms of ROS generation; third, cyclic ADP-ribose and several other mols. that are generated from NAD and NADP could mediate calcium homeostasis; fourth, NAD and NADP modulate multiple key factors in cell death, such as mitochondrial permeability transition, energy state, poly(ADP-ribose) polymerase-1, and apoptosis-inducing factor; and fifth, NAD and NADP profoundly affect aging-influencing factors such as oxidative stress and mitochondrial activities, and NAD-dependent sirtuins also mediate the aging process.  Moreover, many recent studies have suggested novel paradigms of NAD and NADP metab.  Future investigation into the metab. and biol. functions of NAD and NADP may expose fundamental properties of life, and suggest new strategies for treating diseases and slowing the aging process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob_u0TKtM48LVg90H21EOLACvtfcHk0ljVJp5IuHTNAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1ShtA%253D%253D&md5=9690d9d5e0df236658c9e5b641ffd13b</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1089%2Fars.2007.1672&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fars.2007.1672%26sid%3Dliteratum%253Aachs%26aulast%3DYing%26aufirst%3DW.%2BH.%26atitle%3DNAD%2528%252B%2529%252F%2520NADH%2520and%2520NADP%2528%252B%2529%252FNADPH%2520in%2520cellular%2520functions%2520and%2520cell%2520death%253A%2520Regulation%2520and%2520biological%2520consequences%26jtitle%3DAntioxid.%2520Redox%2520Signaling%26date%3D2008%26volume%3D10%26spage%3D179%26epage%3D206%26doi%3D10.1089%2Fars.2007.1672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spinazzi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casarin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertegato, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salviati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angelini, C.</span></span> <span> </span><span class="NLM_article-title">Assessment of mitochondrial respiratory chain enzymatic activities on tissues and cultured cells</span>. <i>Nat. Protoc.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1235</span>â <span class="NLM_lpage">1246</span>, <span class="refDoi">Â DOI: 10.1038/nprot.2012.058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fnprot.2012.058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=22653162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC38XnslWgtrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=1235-1246&author=M.+Spinazziauthor=A.+Casarinauthor=V.+Pertegatoauthor=L.+Salviatiauthor=C.+Angelini&title=Assessment+of+mitochondrial+respiratory+chain+enzymatic+activities+on+tissues+and+cultured+cells&doi=10.1038%2Fnprot.2012.058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of mitochondrial respiratory chain enzymatic activities on tissues and cultured cells</span></div><div class="casAuthors">Spinazzi, Marco; Casarin, Alberto; Pertegato, Vanessa; Salviati, Leonardo; Angelini, Corrado</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1235-1246, S1235/1</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The assessment of mitochondrial respiratory chain (RC) enzymic activities is essential for investigating mitochondrial function in several situations, including mitochondrial disorders, diabetes, cancer, aging and neurodegeneration, as well as for many toxicol. assays.  Muscle is the most commonly analyzed tissue because of its high metabolic rates and accessibility, although other tissues and cultured cell lines can be used.  We describe a step-by-step protocol for a simple and reliable assessment of the RC enzymic function (complexes I-IV) for minute quantities of muscle, cultured cells and isolated mitochondria from a variety of species and tissues, by using a single-wavelength spectrophotometer.  An efficient tissue disruption and the choice for each assay of specific buffers, substrates, adjuvants and detergents in a narrow concn. range allow maximal sensitivity, specificity and linearity of the kinetics.  This protocol can be completed in 3 h.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJxT-BOo_P9LVg90H21EOLACvtfcHk0lhIgOvVDQAQGw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnslWgtrg%253D&md5=d8b99fedb21e9c14895868d1fac12448</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2012.058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2012.058%26sid%3Dliteratum%253Aachs%26aulast%3DSpinazzi%26aufirst%3DM.%26aulast%3DCasarin%26aufirst%3DA.%26aulast%3DPertegato%26aufirst%3DV.%26aulast%3DSalviati%26aufirst%3DL.%26aulast%3DAngelini%26aufirst%3DC.%26atitle%3DAssessment%2520of%2520mitochondrial%2520respiratory%2520chain%2520enzymatic%2520activities%2520on%2520tissues%2520and%2520cultured%2520cells%26jtitle%3DNat.%2520Protoc.%26date%3D2012%26volume%3D7%26spage%3D1235%26epage%3D1246%26doi%3D10.1038%2Fnprot.2012.058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Q. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Brabander, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parada, L. F.</span></span> <span> </span><span class="NLM_article-title">Gboxin is an oxidative phosphorylation inhibitor that targets glioblastoma</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>567</i></span>,  <span class="NLM_fpage">341</span>â <span class="NLM_lpage">346</span>, <span class="refDoi">Â DOI: 10.1038/s41586-019-0993-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fs41586-019-0993-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=30842654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmsV2iurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=567&publication_year=2019&pages=341-346&author=Y.+F.+Shiauthor=S.+K.+Limauthor=Q.+R.+Liangauthor=S.+V.+Iyerauthor=H.+Y.+Wangauthor=Z.+L.+Wangauthor=X.+H.+Xieauthor=D.+C.+Sunauthor=Y.+J.+Chenauthor=V.+Tabarauthor=P.+Gutinauthor=N.+Williamsauthor=J.+K.+De+Brabanderauthor=L.+F.+Parada&title=Gboxin+is+an+oxidative+phosphorylation+inhibitor+that+targets+glioblastoma&doi=10.1038%2Fs41586-019-0993-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Gboxin is an oxidative phosphorylation inhibitor that targets glioblastoma</span></div><div class="casAuthors">Shi, Yufeng; Lim, S. Kyun; Liang, Qiren; Iyer, Swathi V.; Wang, Hua-Yu; Wang, Zilai; Xie, Xuanhua; Sun, Daochun; Chen, Yu-Jung; Tabar, Viviane; Gutin, Philip; Williams, Noelle; De Brabander, Jef K.; Parada, Luis F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">567</span>
        (<span class="NLM_cas:issue">7748</span>),
    <span class="NLM_cas:pages">341-346</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Cancer-specific inhibitors that reflect the unique metabolic needs of cancer cells are rare.  Here we describe Gboxin, a small mol. that specifically inhibits the growth of primary mouse and human glioblastoma cells but not that of mouse embryonic fibroblasts or neonatal astrocytes.  Gboxin rapidly and irreversibly compromises oxygen consumption in glioblastoma cells.  Gboxin relies on its pos. charge to assoc. with mitochondrial oxidative phosphorylation complexes in a manner that is dependent on the proton gradient of the inner mitochondrial membrane, and it inhibits the activity of F0F1 ATP synthase.  Gboxin-resistant cells require a functional mitochondrial permeability transition pore that regulates pH and thus impedes the accumulation of Gboxin in the mitochondrial matrix.  Administration of a metabolically stable Gboxin analog inhibits glioblastoma allografts and patient-derived xenografts.  Gboxin toxicity extends to established human cancer cell lines of diverse organ origin, and shows that the increased proton gradient and pH in cancer cell mitochondria is a mode of action that can be targeted in the development of antitumor reagents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqUFaigZHY4rVg90H21EOLACvtfcHk0lhIgOvVDQAQGw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmsV2iurg%253D&md5=a37c5d43053bc43d5e7e73d01ef61212</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1038%2Fs41586-019-0993-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-019-0993-x%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DY.%2BF.%26aulast%3DLim%26aufirst%3DS.%2BK.%26aulast%3DLiang%26aufirst%3DQ.%2BR.%26aulast%3DIyer%26aufirst%3DS.%2BV.%26aulast%3DWang%26aufirst%3DH.%2BY.%26aulast%3DWang%26aufirst%3DZ.%2BL.%26aulast%3DXie%26aufirst%3DX.%2BH.%26aulast%3DSun%26aufirst%3DD.%2BC.%26aulast%3DChen%26aufirst%3DY.%2BJ.%26aulast%3DTabar%26aufirst%3DV.%26aulast%3DGutin%26aufirst%3DP.%26aulast%3DWilliams%26aufirst%3DN.%26aulast%3DDe%2BBrabander%26aufirst%3DJ.%2BK.%26aulast%3DParada%26aufirst%3DL.%2BF.%26atitle%3DGboxin%2520is%2520an%2520oxidative%2520phosphorylation%2520inhibitor%2520that%2520targets%2520glioblastoma%26jtitle%3DNature%26date%3D2019%26volume%3D567%26spage%3D341%26epage%3D346%26doi%3D10.1038%2Fs41586-019-0993-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lofton, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bristow, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carugo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullinax, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyers, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuliani, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czako, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mseeh, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asara, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morlacchi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peoples, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tieu, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmoes, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenzi, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DePinho, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Draetta, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toniatti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffernan, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marszalek, J. R.</span></span> <span> </span><span class="NLM_article-title">Functional genomics reveals synthetic lethality between phosphogluconate dehydrogenase and oxidative phosphorylation</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">469</span>â <span class="NLM_lpage">482</span>, <span class="refDoi">Â DOI: 10.1016/j.celrep.2018.12.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.celrep.2018.12.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=30625329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1MXms1yitQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=469-482&author=Y.+Sunauthor=M.+Bandiauthor=T.+Loftonauthor=M.+Smithauthor=C.+A.+Bristowauthor=A.+Carugoauthor=N.+Rogersauthor=P.+Leonardauthor=Q.+Changauthor=R.+Mullinaxauthor=J.+Hanauthor=X.+Shiauthor=S.+Sethauthor=B.+A.+Meyersauthor=M.+Millerauthor=L.+L.+Miaoauthor=X.+Y.+Maauthor=N.+P.+Fengauthor=V.+Giulianiauthor=M.+G.+Doauthor=B.+Czakoauthor=W.+S.+Palmerauthor=F.+Mseehauthor=J.+M.+Asaraauthor=Y.+Y.+Jiangauthor=P.+Morlacchiauthor=S.+P.+Zhaoauthor=M.+Peoplesauthor=T.+N.+Tieuauthor=M.+O.+Warmoesauthor=P.+L.+Lorenziauthor=F.+L.+Mullerauthor=R.+A.+DePinhoauthor=G.+F.+Draettaauthor=C.+Toniattiauthor=P.+Jonesauthor=T.+P.+Heffernanauthor=J.+R.+Marszalek&title=Functional+genomics+reveals+synthetic+lethality+between+phosphogluconate+dehydrogenase+and+oxidative+phosphorylation&doi=10.1016%2Fj.celrep.2018.12.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Functional Genomics Reveals Synthetic Lethality between Phosphogluconate Dehydrogenase and Oxidative Phosphorylation</span></div><div class="casAuthors">Sun, Yuting; Bandi, Madhavi; Lofton, Timothy; Smith, Melinda; Bristow, Christopher A.; Carugo, Alessandro; Rogers, Norma; Leonard, Paul; Chang, Qing; Mullinax, Robert; Han, Jing; Shi, Xi; Seth, Sahil; Meyers, Brooke A.; Miller, Meredith; Miao, Lili; Ma, Xiaoyan; Feng, Ningping; Giuliani, Virginia; Geck Do, Mary; Czako, Barbara; Palmer, Wylie S.; Mseeh, Faika; Asara, John M.; Jiang, Yongying; Morlacchi, Pietro; Zhao, Shuping; Peoples, Michael; Tieu, Trang N.; Warmoes, Marc O.; Lorenzi, Philip L.; Muller, Florian L.; De Pinho, Ronald A.; Draetta, Giulio F.; Toniatti, Carlo; Jones, Philip; Heffernan, Timothy P.; Marszalek, Joseph R.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">469-482.e5</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The plasticity of a preexisting regulatory circuit compromises the effectiveness of targeted therapies, and leveraging genetic vulnerabilities in cancer cells may overcome such adaptations.  Hereditary leiomyomatosis renal cell carcinoma (HLRCC) is characterized by oxidative phosphorylation (OXPHOS) deficiency caused by fumarate hydratase (FH) nullizyogosity.  To identify metabolic genes that are synthetically lethal with OXPHOS deficiency, we conducted a genetic loss-of-function screen and found that phosphogluconate dehydrogenase (PGD) inhibition robustly blocks the proliferation of FH mutant cancer cells both in vitro and in vivo.  Mechanistically, PGD inhibition blocks glycolysis, suppresses reductive carboxylation of glutamine, and increases the NADP+/NADPH ratio to disrupt redox homeostasis.  Furthermore, in the OXPHOS-proficient context, blocking OXPHOS using the small-mol. inhibitor IACS-010759 enhances sensitivity to PGD inhibition in vitro and in vivo.  Together, our study reveals a dependency on PGD in OXPHOS-deficient tumors that might inform therapeutic intervention in specific patient populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFxV9JZbezMbVg90H21EOLACvtfcHk0ljlQRl2XY4wow"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXms1yitQ%253D%253D&md5=9f93c828b588d802c6f3d0bf5813e9cb</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2018.12.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2018.12.043%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DY.%26aulast%3DBandi%26aufirst%3DM.%26aulast%3DLofton%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DM.%26aulast%3DBristow%26aufirst%3DC.%2BA.%26aulast%3DCarugo%26aufirst%3DA.%26aulast%3DRogers%26aufirst%3DN.%26aulast%3DLeonard%26aufirst%3DP.%26aulast%3DChang%26aufirst%3DQ.%26aulast%3DMullinax%26aufirst%3DR.%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DSeth%26aufirst%3DS.%26aulast%3DMeyers%26aufirst%3DB.%2BA.%26aulast%3DMiller%26aufirst%3DM.%26aulast%3DMiao%26aufirst%3DL.%2BL.%26aulast%3DMa%26aufirst%3DX.%2BY.%26aulast%3DFeng%26aufirst%3DN.%2BP.%26aulast%3DGiuliani%26aufirst%3DV.%26aulast%3DDo%26aufirst%3DM.%2BG.%26aulast%3DCzako%26aufirst%3DB.%26aulast%3DPalmer%26aufirst%3DW.%2BS.%26aulast%3DMseeh%26aufirst%3DF.%26aulast%3DAsara%26aufirst%3DJ.%2BM.%26aulast%3DJiang%26aufirst%3DY.%2BY.%26aulast%3DMorlacchi%26aufirst%3DP.%26aulast%3DZhao%26aufirst%3DS.%2BP.%26aulast%3DPeoples%26aufirst%3DM.%26aulast%3DTieu%26aufirst%3DT.%2BN.%26aulast%3DWarmoes%26aufirst%3DM.%2BO.%26aulast%3DLorenzi%26aufirst%3DP.%2BL.%26aulast%3DMuller%26aufirst%3DF.%2BL.%26aulast%3DDePinho%26aufirst%3DR.%2BA.%26aulast%3DDraetta%26aufirst%3DG.%2BF.%26aulast%3DToniatti%26aufirst%3DC.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DHeffernan%26aufirst%3DT.%2BP.%26aulast%3DMarszalek%26aufirst%3DJ.%2BR.%26atitle%3DFunctional%2520genomics%2520reveals%2520synthetic%2520lethality%2520between%2520phosphogluconate%2520dehydrogenase%2520and%2520oxidative%2520phosphorylation%26jtitle%3DCell%2520Rep.%26date%3D2019%26volume%3D26%26spage%3D469%26epage%3D482%26doi%3D10.1016%2Fj.celrep.2018.12.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beltran, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yelensky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frampton, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downing, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacDonald, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarosz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tagawa, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanus, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosquera, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronin, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, M. A.</span></span> <span> </span><span class="NLM_article-title">Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity</span>. <i>Eur. Urol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">920</span>â <span class="NLM_lpage">926</span>, <span class="refDoi">Â DOI: 10.1016/j.eururo.2012.08.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.eururo.2012.08.053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=22981675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlGntrjL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2013&pages=920-926&author=H.+Beltranauthor=R.+Yelenskyauthor=G.+M.+Framptonauthor=K.+Parkauthor=S.+R.+Downingauthor=T.+Y.+MacDonaldauthor=M.+Jaroszauthor=D.+Lipsonauthor=S.+T.+Tagawaauthor=D.+M.+Nanusauthor=P.+J.+Stephensauthor=J.+M.+Mosqueraauthor=M.+T.+Croninauthor=M.+A.+Rubin&title=Targeted+next-generation+sequencing+of+advanced+prostate+cancer+identifies+potential+therapeutic+targets+and+disease+heterogeneity&doi=10.1016%2Fj.eururo.2012.08.053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease Heterogeneity</span></div><div class="casAuthors">Beltran, Himisha; Yelensky, Roman; Frampton, Garrett M.; Park, Kyung; Downing, Sean R.; MacDonald, Theresa Y.; Jarosz, Mirna; Lipson, Doron; Tagawa, Scott T.; Nanus, David M.; Stephens, Philip J.; Mosquera, Juan Miguel; Cronin, Maureen T.; Rubin, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">European Urology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">920-926</span>CODEN:
                <span class="NLM_cas:coden">EUURAV</span>;
        ISSN:<span class="NLM_cas:issn">0302-2838</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Background: Most personalized cancer care strategies involving DNA sequencing are highly reliant on acquiring sufficient fresh or frozen tissue.  It has been challenging to comprehensively evaluate the genome of advanced prostate cancer (PCa) because of limited access to metastatic tissue.  Objective: To demonstrate the feasibility of a novel next-generation sequencing (NGS)-based platform that can be used with archival formalin-fixed paraffin-embedded (FFPE) biopsy tissue to evaluate the spectrum of DNA alterations seen in advanced PCa.  Design, setting, and participants: FFPE samples (including archival prostatectomies and prostate needle biopsies) were obtained from 45 patients representing the spectrum of disease: localized PCa, metastatic hormone-naive PCa, and metastatic castration-resistant PCa (CRPC).  We also assessed paired primaries and metastases to understand disease heterogeneity and disease progression.  Intervention: At least 50 ng of tumor DNA was extd. from FFPE samples and used for hybridization capture and NGS using the Illumina HiSeq 2000 platform.  Outcome measures and statistical anal.: A total of 3320 exons of 182 cancer-assocd. genes and 37 introns of 14 commonly rearranged genes were evaluated for genomic alterations.  Resulsts and limitations: We obtained an av. sequencing depth of >900X.  Overall, 44% of CRPCs harbored genomic alterations involving the androgen receptor gene (AR), including AR copy no. gain (24% of CRPCs) or AR point mutation (20% of CRPCs).  Other recurrent mutations included transmembrane protease, serine 2 gene (TMPRSS2):v-ets erythroblastosis virus E26 oncogene homolog (avian) gene (ERG) fusion (44%); phosphatase and tensin homolog gene (PTEN) loss (44%); tumor protein p53 gene (TP53) mutation (40%); retinoblastoma gene (RB) loss (28%); v-myc myelocytomatosis viral oncogene homolog (avian) gene (MYC) gain (12%); and phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit Î± gene (PIK3CA) mutation (4%).  There was a high incidence of genomic alterations involving key genes important for DNA repair, including breast cancer 2, early onset gene (BRCA2) loss (12%) and ataxia telangiectasia mutated gene (ATM) mutations (8%); these alterations are potentially targetable with poly(ADP-ribose)polymerase inhibitors.  A novel and actionable rearrangement involving the v-raf murine sarcoma viral oncogene homolog B1 gene (BRAF) was also detected.  Conclusions: This first-in-principle study demonstrates the feasibility of performing in-depth DNA analyses using FFPE tissue and brings new insight toward understanding the genomic landscape within advanced PCa.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsI-Y6MADh47Vg90H21EOLACvtfcHk0lhdmHu-ff05Rw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlGntrjL&md5=97b35e71616f8b4a7020078630d3059a</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1016%2Fj.eururo.2012.08.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.eururo.2012.08.053%26sid%3Dliteratum%253Aachs%26aulast%3DBeltran%26aufirst%3DH.%26aulast%3DYelensky%26aufirst%3DR.%26aulast%3DFrampton%26aufirst%3DG.%2BM.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DDowning%26aufirst%3DS.%2BR.%26aulast%3DMacDonald%26aufirst%3DT.%2BY.%26aulast%3DJarosz%26aufirst%3DM.%26aulast%3DLipson%26aufirst%3DD.%26aulast%3DTagawa%26aufirst%3DS.%2BT.%26aulast%3DNanus%26aufirst%3DD.%2BM.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DMosquera%26aufirst%3DJ.%2BM.%26aulast%3DCronin%26aufirst%3DM.%2BT.%26aulast%3DRubin%26aufirst%3DM.%2BA.%26atitle%3DTargeted%2520next-generation%2520sequencing%2520of%2520advanced%2520prostate%2520cancer%2520identifies%2520potential%2520therapeutic%2520targets%2520and%2520disease%2520heterogeneity%26jtitle%3DEur.%2520Urol.%26date%3D2013%26volume%3D63%26spage%3D920%26epage%3D926%26doi%3D10.1016%2Fj.eururo.2012.08.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stiles, B. L.</span></span> <span> </span><span class="NLM_article-title">PTEN: tumor suppressor and metabolic regulator</span>. <i>Front. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">338</span>, <span class="refDoi">Â DOI: 10.3389/fendo.2018.00338</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.3389%2Ffendo.2018.00338" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=30038596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BB3c7ht1WrsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=338&author=C.+Y.+Chenauthor=J.+Y.+Chenauthor=L.+N.+Heauthor=B.+L.+Stiles&title=PTEN%3A+tumor+suppressor+and+metabolic+regulator&doi=10.3389%2Ffendo.2018.00338"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">PTEN: Tumor Suppressor and Metabolic Regulator</span></div><div class="casAuthors">Chen Chien-Yu; Chen Jingyu; He Lina; Stiles Bangyan L; Stiles Bangyan L</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in endocrinology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">338</span>
        ISSN:<span class="NLM_cas:issn">1664-2392</span>.
    </div><div class="casAbstract">Phosphatase and Tensin Homolog deleted on Chromosome 10 (PTEN) is a dual phosphatase with both protein and lipid phosphatase activities.  PTEN was first discovered as a tumor suppressor with growth and survival regulatory functions.  In recent years, the function of PTEN as a metabolic regulator has attracted significant attention.  As the lipid phosphatase that dephosphorylates phosphatidylinositol-3, 4, 5-phosphate (PIP3), PTEN reduces the level of PIP3, a critical 2nd messenger mediating the signal of not only growth factors but also insulin.  In this review, we introduced the discovery of PTEN, the PTEN-regulated canonical and nuclear signals, and PTEN regulation.  We then focused on the role of PTEN and PTEN-regulated signals in metabolic regulation.  This included the role of PTEN in glycolysis, gluconeogenesis, glycogen synthesis, lipid metabolism as well as mitochondrial metabolism.  We also included how PTEN and PTEN regulated metabolic functions may act paradoxically toward insulin sensitivity and tumor metabolism and growth.  Further understanding of how PTEN regulates metabolism and how such regulations lead to different biological outcomes is necessary for interventions targeting at the PTEN-regulated signals in either cancer or diabetes treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQD8rCBbEd17SM8MEzWGjS9fW6udTcc2eYFe0Fns-EpzLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7ht1WrsA%253D%253D&md5=251cfe39fd7465710509a5d9c0d7fcdc</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.3389%2Ffendo.2018.00338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffendo.2018.00338%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.%2BY.%26aulast%3DChen%26aufirst%3DJ.%2BY.%26aulast%3DHe%26aufirst%3DL.%2BN.%26aulast%3DStiles%26aufirst%3DB.%2BL.%26atitle%3DPTEN%253A%2520tumor%2520suppressor%2520and%2520metabolic%2520regulator%26jtitle%3DFront.%2520Endocrinol.%26date%3D2018%26volume%3D9%26spage%3D338%26doi%3D10.3389%2Ffendo.2018.00338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vlietstra, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Alewijk, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermans, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Steenbrugge, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapman, J.</span></span> <span> </span><span class="NLM_article-title">Frequent inactivation of PTEN in prostate cancer cell lines and xenografts</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">2720</span>â <span class="NLM_lpage">2723</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=9661880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADyaK1cXksFCqsbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1998&pages=2720-2723&author=R.+J.+Vlietstraauthor=D.+C.+van+Alewijkauthor=K.+G.+Hermansauthor=G.+J.+van+Steenbruggeauthor=J.+Trapman&title=Frequent+inactivation+of+PTEN+in+prostate+cancer+cell+lines+and+xenografts"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Frequent inactivation of PTEN in prostate cancer cell lines and xenografts</span></div><div class="casAuthors">Vlietstra, Remko J.; Van Alewijk, Dirk C. J. G.; Hermans, Karin G. L.; Van Steenbrugge, Gert J.; Trapman, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2720-2723</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Loss of chromosome 10q is a frequently obsd. genetic defect in prostate cancer.  Recently, the PTEN/MMAC1 tumor suppressor gene was identified and mapped to chromosome 10q23.3.  The authors studied PTEN structure and expression in 4 in vitro cell lines and 11 in vivo xenografts derived from six primary and nine metastatic human prostate cancers.  DNA samples were allelotyped for eight polymorphic markers within and surrounding the PTEN gene.  Addnl., the nine PTEN exons were tested for deletions.  In five samples (PC3, PC133, PCEW, PC295, and PC324), homozygous deletions of the PTEN gene or parts of the gene were detected.  PC295 contained a small homozygous deletion encompassing PTEN exon 5.  In two DNAs (PC82 and PC346), nonsense mutations were found, and in two (LNCaP and PC374), frame-shift mutations were found.  Missense mutations were not detected.  PTEN mRNA expression was clearly obsd. in all cell lines and xenografts without large homozygous deletions, showing that PTEN down-regulation is not an important mechanism of PTEN inactivation.  The high frequency (60%) of PTEN mutations and deletions indicates a significant role of this tumor suppressor gene in the pathogenesis of prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZJMu-jwfpQbVg90H21EOLACvtfcHk0lhdmHu-ff05Rw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXksFCqsbc%253D&md5=b64bc13e2ec5d299208f275501857d68</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVlietstra%26aufirst%3DR.%2BJ.%26aulast%3Dvan%2BAlewijk%26aufirst%3DD.%2BC.%26aulast%3DHermans%26aufirst%3DK.%2BG.%26aulast%3Dvan%2BSteenbrugge%26aufirst%3DG.%2BJ.%26aulast%3DTrapman%26aufirst%3DJ.%26atitle%3DFrequent%2520inactivation%2520of%2520PTEN%2520in%2520prostate%2520cancer%2520cell%2520lines%2520and%2520xenografts%26jtitle%3DCancer%2520Res.%26date%3D1998%26volume%3D58%26spage%3D2720%26epage%3D2723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cotter, P. D.</span></span> <span> </span><span class="NLM_article-title">Genomic rearrangements of PTEN in prostate cancer</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">240</span>, <span class="refDoi">Â DOI: 10.3389/fonc.2013.00240</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.3389%2Ffonc.2013.00240" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=24062990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BC2cflt12jsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=240&author=S.+Phinauthor=M.+W.+Mooreauthor=P.+D.+Cotter&title=Genomic+rearrangements+of+PTEN+in+prostate+cancer&doi=10.3389%2Ffonc.2013.00240"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Genomic Rearrangements of PTEN in Prostate Cancer</span></div><div class="casAuthors">Phin Sopheap; Moore Mathew W; Cotter Philip D</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">240</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">The phosphatase and tensin homolog gene (PTEN) on chromosome 10q23.3 is a negative regulator of the PIK3/Akt survival pathway and is the most frequently deleted tumor suppressor gene in prostate cancer.  Monoallelic loss of PTEN is present in up to 60% of localized prostate cancers and complete loss of PTEN in prostate cancer is linked to metastasis and androgen-independent progression.  Studies on the genomic status of PTEN in prostate cancer initially used a two-color fluorescence in situ hybridization (FISH) assay for PTEN copy number detection in formalin fixed paraffin embedded tissue preparations.  More recently, a four-color FISH assay containing two additional control probes flanking the PTEN locus with a lower false-positive rate was reported.  Combined with the detection of other critical genomic biomarkers for prostate cancer such as ERG, androgen receptor, and MYC, the evaluation of PTEN genomic status has proven to be invaluable for patient stratification and management.  Although less frequent than allelic deletions, point mutations in the gene and epigenetic silencing are also known to contribute to loss of PTEN function, and ultimately to prostate cancer initiation.  Overall, it is clear that PTEN is a powerful biomarker for prostate cancer.  Used as a companion diagnostic for emerging therapeutic drugs, FISH analysis of PTEN is promisingly moving human prostate cancer closer to more effective cancer management and therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTiyQIXPBx6kYxhnOQkIHOxfW6udTcc2eYIcSsojS34arntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cflt12jsQ%253D%253D&md5=5d197daa05f995aba985b2cd11dc3d69</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2013.00240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2013.00240%26sid%3Dliteratum%253Aachs%26aulast%3DPhin%26aufirst%3DS.%26aulast%3DMoore%26aufirst%3DM.%2BW.%26aulast%3DCotter%26aufirst%3DP.%2BD.%26atitle%3DGenomic%2520rearrangements%2520of%2520PTEN%2520in%2520prostate%2520cancer%26jtitle%3DFront.%2520Oncol.%26date%3D2013%26volume%3D3%26spage%3D240%26doi%3D10.3389%2Ffonc.2013.00240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vial, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Detaille, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guigas, B.</span></span> <span> </span><span class="NLM_article-title">Role of mitochondria in the mechanism(s) of action of metformin</span>. <i>Front. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">294</span>, <span class="refDoi">Â DOI: 10.3389/fendo.2019.00294</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.3389%2Ffendo.2019.00294" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=31133988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BB3M3gt1Onsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=294&author=G.+Vialauthor=D.+Detailleauthor=B.+Guigas&title=Role+of+mitochondria+in+the+mechanism%28s%29+of+action+of+metformin&doi=10.3389%2Ffendo.2019.00294"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Mitochondria in the Mechanism(s) of Action of Metformin</span></div><div class="casAuthors">Vial Guillaume; Vial Guillaume; Detaille Dominique; Guigas Bruno</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in endocrinology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">294</span>
        ISSN:<span class="NLM_cas:issn">1664-2392</span>.
    </div><div class="casAbstract">Metformin is a drug from the biguanide family that is used for decades as the first-line therapeutic choice for the treatment of type 2 diabetes.  Despite its worldwide democratization, owing to its clinical efficacy, high safety profile and cheap cost, the exact mechanism(s) of action of this anti-hyperglycemic molecule with pleiotropic properties still remains to be fully elucidated.  The concept that metformin would exert some of its actions though modulation of the mitochondrial bioenergetics was initially forged in the 50s but undeniably revived at the beginning of the twenty-first century when it was shown to induce a weak but specific inhibition of the mitochondrial respiratory-chain complex 1.  Furthermore, metformin has been reported to reduce generation of reactive oxygen species at the complex 1 and to prevent mitochondrial-mediated apoptosis, suggesting that it can protect against oxidative stress-induced cell death.  Nevertheless, despite some recent progress and the demonstration of its key role in the inhibition of hepatic gluconeogenesis, the exact nature of the mitochondrial interaction between the drug and the complex 1 is still poorly characterized.  Recent studies reported that metformin may also have anti-neoplastic properties by inhibiting cancer cell growth and proliferation, at least partly through its mitochondrial action.  As such, many trials are currently conducted for exploring the repositioning of metformin as a potential drug for cancer therapy.  In this mini-review, we discuss both historical and more recent findings on the central role played by the interaction between metformin and the mitochondria in its cellular mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSfCHeylKUnZRWfpMXQLRstfW6udTcc2eYIcSsojS34arntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3gt1Onsg%253D%253D&md5=82b173c693cb30cd0840998a359da78b</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.3389%2Ffendo.2019.00294&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffendo.2019.00294%26sid%3Dliteratum%253Aachs%26aulast%3DVial%26aufirst%3DG.%26aulast%3DDetaille%26aufirst%3DD.%26aulast%3DGuigas%26aufirst%3DB.%26atitle%3DRole%2520of%2520mitochondria%2520in%2520the%2520mechanism%2528s%2529%2520of%2520action%2520of%2520metformin%26jtitle%3DFront.%2520Endocrinol.%26date%3D2019%26volume%3D10%26spage%3D294%26doi%3D10.3389%2Ffendo.2019.00294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zakikhani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowling, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantus, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonenberg, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollak, M.</span></span> <span> </span><span class="NLM_article-title">Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">10269</span>â <span class="NLM_lpage">10273</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-06-1500</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F0008-5472.CAN-06-1500" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=17062558" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFGjsrvK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=10269-10273&author=M.+Zakikhaniauthor=R.+Dowlingauthor=I.+G.+Fantusauthor=N.+Sonenbergauthor=M.+Pollak&title=Metformin+is+an+AMP+kinase-dependent+growth+inhibitor+for+breast+cancer+cells&doi=10.1158%2F0008-5472.CAN-06-1500"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Metformin is an AMP Kinase-Dependent Growth Inhibitor for Breast Cancer Cells</span></div><div class="casAuthors">Zakikhani, Mahvash; Dowling, Ryan; Fantus, I. George; Sonenberg, Nahum; Pollak, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">10269-10273</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Recent population studies provide clues that the use of metformin may be assocd. with reduced incidence and improved prognosis of certain cancers.  This drug is widely used in the treatment of type 2 diabetes, where it is often referred to as an "insulin sensitizer" because it not only lowers blood glucose but also reduces the hyperinsulinemia assocd. with insulin resistance.  As insulin and insulin-like growth factors stimulate proliferation of many normal and transformed cell types, agents that facilitate signaling through these receptors would be expected to enhance proliferation.  We show here that metformin acts as a growth inhibitor rather than an insulin sensitizer for epithelial cells.  Breast cancer cells can be protected against metformin-induced growth inhibition by small interfering RNA against AMP kinase.  This shows that AMP kinase pathway activation by metformin, recently shown to be necessary for metformin inhibition of gluconeogenesis in hepatocytes, is also involved in metformin-induced growth inhibition of epithelial cells.  The growth inhibition was assocd. with decreased mammalian target of rapamycin and S6 kinase activation and a general decrease in mRNA translation.  These results provide evidence for a mechanism that may contribute to the antineoplastic effects of metformin suggested by recent population studies and justify further work to explore potential roles for activators of AMP kinase in cancer prevention and treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3WMUDTWsgYrVg90H21EOLACvtfcHk0liwvSU2sisLdw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFGjsrvK&md5=7de1b4c02ce71146445523af4e21ff11</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-1500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-1500%26sid%3Dliteratum%253Aachs%26aulast%3DZakikhani%26aufirst%3DM.%26aulast%3DDowling%26aufirst%3DR.%26aulast%3DFantus%26aufirst%3DI.%2BG.%26aulast%3DSonenberg%26aufirst%3DN.%26aulast%3DPollak%26aufirst%3DM.%26atitle%3DMetformin%2520is%2520an%2520AMP%2520kinase-dependent%2520growth%2520inhibitor%2520for%2520breast%2520cancer%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D10269%26epage%3D10273%26doi%3D10.1158%2F0008-5472.CAN-06-1500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dowling, R. J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouaaz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiyota, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Awar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stambolic, V.</span></span> <span> </span><span class="NLM_article-title">Metformin pharmacokinetics in mouse tumors: implications for human therapy</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">567</span>â <span class="NLM_lpage">568</span>, <span class="refDoi">Â DOI: 10.1016/j.cmet.2016.03.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.cmet.2016.03.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27076069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsVWmt78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=567-568&author=R.+J.+O.+Dowlingauthor=S.+Lamauthor=C.+Bassiauthor=S.+Mouaazauthor=A.+Amanauthor=T.+Kiyotaauthor=R.+Al-Awarauthor=P.+J.+Goodwinauthor=V.+Stambolic&title=Metformin+pharmacokinetics+in+mouse+tumors%3A+implications+for+human+therapy&doi=10.1016%2Fj.cmet.2016.03.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Metformin Pharmacokinetics in Mouse Tumors: Implications for Human Therapy</span></div><div class="casAuthors">Dowling, Ryan J. O.; Lam, Sonya; Bassi, Christian; Mouaaz, Samar; Aman, Ahmed; Kiyota, Taira; Al-awar, Rima; Goodwin, Pamela J.; Stambolic, Vuk</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">567-568</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review discussing mouse models of antitumor action of metformin and its pharmacokinetics.  It also discusses that consistent delivery of metformin at effective antitumor concns. will allow It also discusses comprehensive characterization of metformin's mechanism of action and assessment of its efficacy as a viable anticancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXYhX75e3hlbVg90H21EOLACvtfcHk0ljRTpQQ3VSipw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsVWmt78%253D&md5=3cdf6c9753104d3f16751b3b6a8343d1</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2016.03.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2016.03.006%26sid%3Dliteratum%253Aachs%26aulast%3DDowling%26aufirst%3DR.%2BJ.%2BO.%26aulast%3DLam%26aufirst%3DS.%26aulast%3DBassi%26aufirst%3DC.%26aulast%3DMouaaz%26aufirst%3DS.%26aulast%3DAman%26aufirst%3DA.%26aulast%3DKiyota%26aufirst%3DT.%26aulast%3DAl-Awar%26aufirst%3DR.%26aulast%3DGoodwin%26aufirst%3DP.%2BJ.%26aulast%3DStambolic%26aufirst%3DV.%26atitle%3DMetformin%2520pharmacokinetics%2520in%2520mouse%2520tumors%253A%2520implications%2520for%2520human%2520therapy%26jtitle%3DCell%2520Metab.%26date%3D2016%26volume%3D23%26spage%3D567%26epage%3D568%26doi%3D10.1016%2Fj.cmet.2016.03.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elgendy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosseini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiszmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzarella, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cazzoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curigliano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeCensi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonanni, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budillon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelicci, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssens, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogris, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baccarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanfrancone, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weckwerth, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foiani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minucci, S.</span></span> <span> </span><span class="NLM_article-title">Combination of hypoglycemia and metformin impairs tumor metabolic plasticity and growth by modulating the PP2A-GSK3 beta-MCL-1 axis</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">798</span>â <span class="NLM_lpage">815</span>, <span class="refDoi">Â DOI: 10.1016/j.ccell.2019.03.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.ccell.2019.03.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=31031016" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1MXosVSgtbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2019&pages=798-815&author=M.+Elgendyauthor=M.+Ciroauthor=A.+Hosseiniauthor=J.+Weiszmannauthor=L.+Mazzarellaauthor=E.+Ferrariauthor=R.+Cazzoliauthor=G.+Curiglianoauthor=A.+DeCensiauthor=B.+Bonanniauthor=A.+Budillonauthor=P.+G.+Pelicciauthor=V.+Janssensauthor=M.+Ogrisauthor=M.+Baccariniauthor=L.+Lanfranconeauthor=W.+Weckwerthauthor=M.+Foianiauthor=S.+Minucci&title=Combination+of+hypoglycemia+and+metformin+impairs+tumor+metabolic+plasticity+and+growth+by+modulating+the+PP2A-GSK3+beta-MCL-1+axis&doi=10.1016%2Fj.ccell.2019.03.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of Hypoglycemia and Metformin Impairs Tumor Metabolic Plasticity and Growth by Modulating the PP2A-GSK3Î²-MCL-1 Axis</span></div><div class="casAuthors">Elgendy, Mohamed; Ciro, Marco; Hosseini, Amir; Weiszmann, Jakob; Mazzarella, Luca; Ferrari, Elisa; Cazzoli, Riccardo; Curigliano, Giuseppe; DeCensi, Andrea; Bonanni, Bernardo; Budillon, Alfredo; Pelicci, Pier Giuseppe; Janssens, Veerle; Ogris, Manfred; Baccarini, Manuela; Lanfrancone, Luisa; Weckwerth, Wolfram; Foiani, Marco; Minucci, Saverio</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">798-815.e5</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Tumor cells may adapt to metabolic challenges by alternating between glycolysis and oxidative phosphorylation (OXPHOS).  To target this metabolic plasticity, we combined intermittent fasting, a clin. feasible approach to reduce glucose availability, with the OXPHOS inhibitor metformin.  In mice exposed to 24-h feeding/fasting cycles, metformin impaired tumor growth only when administered during fasting-induced hypoglycemia.  Synergistic anti-neoplastic effects of the metformin/hypoglycemia combination were mediated by glycogen synthase kinase 3Î² (GSK3Î²) activation downstream of PP2A, leading to a decline in the pro-survival protein MCL-1, and cell death.  Mechanistically, specific activation of the PP2A-GSK3Î² axis was the sum of metformin-induced inhibition of CIP2A, a PP2A suppressor, and of upregulation of the PP2A regulatory subunit B56d by low glucose, leading to an active PP2A-B56d complex with high affinity toward GSK3Î².</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRILTKao3tHbVg90H21EOLACvtfcHk0ljRTpQQ3VSipw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXosVSgtbg%253D&md5=ea976a0b726fa45a869a0af745f98736</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2019.03.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2019.03.007%26sid%3Dliteratum%253Aachs%26aulast%3DElgendy%26aufirst%3DM.%26aulast%3DCiro%26aufirst%3DM.%26aulast%3DHosseini%26aufirst%3DA.%26aulast%3DWeiszmann%26aufirst%3DJ.%26aulast%3DMazzarella%26aufirst%3DL.%26aulast%3DFerrari%26aufirst%3DE.%26aulast%3DCazzoli%26aufirst%3DR.%26aulast%3DCurigliano%26aufirst%3DG.%26aulast%3DDeCensi%26aufirst%3DA.%26aulast%3DBonanni%26aufirst%3DB.%26aulast%3DBudillon%26aufirst%3DA.%26aulast%3DPelicci%26aufirst%3DP.%2BG.%26aulast%3DJanssens%26aufirst%3DV.%26aulast%3DOgris%26aufirst%3DM.%26aulast%3DBaccarini%26aufirst%3DM.%26aulast%3DLanfrancone%26aufirst%3DL.%26aulast%3DWeckwerth%26aufirst%3DW.%26aulast%3DFoiani%26aufirst%3DM.%26aulast%3DMinucci%26aufirst%3DS.%26atitle%3DCombination%2520of%2520hypoglycemia%2520and%2520metformin%2520impairs%2520tumor%2520metabolic%2520plasticity%2520and%2520growth%2520by%2520modulating%2520the%2520PP2A-GSK3%2520beta-MCL-1%2520axis%26jtitle%3DCancer%2520Cell%26date%3D2019%26volume%3D35%26spage%3D798%26epage%3D815%26doi%3D10.1016%2Fj.ccell.2019.03.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollak, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirst, J.</span></span> <span> </span><span class="NLM_article-title">Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>462</i></span>,  <span class="NLM_fpage">475</span>â <span class="NLM_lpage">487</span>, <span class="refDoi">Â DOI: 10.1042/BJ20140620</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1042%2FBJ20140620" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=25017630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVeksb7M" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2014&pages=475-487&author=H.+R.+Bridgesauthor=A.+J.+Jonesauthor=M.+N.+Pollakauthor=J.+Hirst&title=Effects+of+metformin+and+other+biguanides+on+oxidative+phosphorylation+in+mitochondria&doi=10.1042%2FBJ20140620"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria</span></div><div class="casAuthors">Bridges, Hannah R.; Jones, Andrew J. Y.; Pollak, Michael N.; Hirst, Judy</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">475-487</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">The biguanide metformin is widely prescribed for Type II diabetes and has anti-neoplastic activity in lab. models.  Despite evidence that inhibition of mitochondrial respiratory complex I by metformin is the primary cause of its cell-lineage-specific actions and therapeutic effects, the mol. interaction(s) between metformin and complex I remain uncharacterized.  In the present paper, we describe the effects of five pharmacol. relevant biguanides on oxidative phosphorylation in mammalian mitochondria.  We report that biguanides inhibit complex I by inhibiting ubiquinone redn. (but not competitively) and, independently, stimulate reactive oxygen species prodn. by the complex I flavin.  Biguanides also inhibit mitochondrial ATP synthase, and two of them inhibit only ATP hydrolysis, not synthesis.  Thus we identify biguanides as a new class of complex I and ATP synthase inhibitor.  By comparing biguanide effects on isolated complex I and cultured cells, we distinguish three anti-diabetic and potentially anti-neoplastic biguanides (metformin, buformin and phenformin) from two anti-malarial biguanides (cycloguanil and proguanil): the former are accumulated into mammalian mitochondria and affect oxidative phosphorylation, whereas the latter are excluded so act only on the parasite.  Our mechanistic and pharmacokinetic insights are relevant to understanding and developing the role of biguanides in new and existing therapeutic applications, including cancer, diabetes and malaria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooOOWC7Pvp_7Vg90H21EOLACvtfcHk0lhfdqU9ik3H7A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVeksb7M&md5=553caf4d88caa939a4a8dd526ed4e13c</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1042%2FBJ20140620&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20140620%26sid%3Dliteratum%253Aachs%26aulast%3DBridges%26aufirst%3DH.%2BR.%26aulast%3DJones%26aufirst%3DA.%2BJ.%26aulast%3DPollak%26aufirst%3DM.%2BN.%26aulast%3DHirst%26aufirst%3DJ.%26atitle%3DEffects%2520of%2520metformin%2520and%2520other%2520biguanides%2520on%2520oxidative%2520phosphorylation%2520in%2520mitochondria%26jtitle%3DBiochem.%2520J.%26date%3D2014%26volume%3D462%26spage%3D475%26epage%3D487%26doi%3D10.1042%2FBJ20140620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pollak, M. N.</span></span> <span> </span><span class="NLM_article-title">Investigating metformin for cancer prevention and treatment: the end of the beginning</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">778</span>â <span class="NLM_lpage">790</span>, <span class="refDoi">Â DOI: 10.1158/2159-8290.CD-12-0263</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F2159-8290.CD-12-0263" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=22926251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlGgsb3O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=778-790&author=M.+N.+Pollak&title=Investigating+metformin+for+cancer+prevention+and+treatment%3A+the+end+of+the+beginning&doi=10.1158%2F2159-8290.CD-12-0263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Investigating Metformin for Cancer Prevention and Treatment: The End of the Beginning</span></div><div class="casAuthors">Pollak, Michael N.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">778-790</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Lab. research and pharmacoepidemiol. are providing converging evidence that the widely used antidiabetic drug metformin has antineoplastic activity, but there are caveats.  Although population studies suggest that metformin exposure is assocd. with reduced cancer risk and/or improved prognosis, these data are mostly retrospective and nonrandomized.  Lab. models show antineoplastic activity, but metformin concns. used in many expts. exceed those achieved with conventional doses used for diabetes treatment.  Ongoing translational research should be useful in guiding design of clin. trials, not only to evaluate metformin at conventional antidiabetic doses, where redn. of elevated insulin levels may contribute to antineoplastic activity for certain subsets of patients, but also to explore more aggressive dosing of biguanides, which may lead to reprogramming of energy metab. in a manner that could provide important opportunities for synthetic lethality through rational drug combinations or in the context of genetic lesions assocd. with hypersensitivity to energetic stress.  Significance: There are tantalizing clues that justify the investigation of antineoplastic activities of biguanides.  The complexity of their biol. effects requires further translational research to guide clin. trial design.  Cancer Discov; 2(9); 778-90. Â©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpd63Z56aY40rVg90H21EOLACvtfcHk0lhfdqU9ik3H7A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlGgsb3O&md5=e251de39cd610d015d44527822154d49</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-12-0263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-12-0263%26sid%3Dliteratum%253Aachs%26aulast%3DPollak%26aufirst%3DM.%2BN.%26atitle%3DInvestigating%2520metformin%2520for%2520cancer%2520prevention%2520and%2520treatment%253A%2520the%2520end%2520of%2520the%2520beginning%26jtitle%3DCancer%2520Discovery%26date%3D2012%26volume%3D2%26spage%3D778%26epage%3D790%26doi%3D10.1158%2F2159-8290.CD-12-0263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boukalova, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stursa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ezrova, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerny, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezawork-Geleta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pecinova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drahota, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuzil, J.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial targeting of metformin enhances its activity against pancreatic cancer</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">2875</span>â <span class="NLM_lpage">2886</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-15-1021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F1535-7163.MCT-15-1021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27765848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFynt7vL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=2875-2886&author=S.+Boukalovaauthor=J.+Stursaauthor=L.+Wernerauthor=Z.+Ezrovaauthor=J.+Cernyauthor=A.+Bezawork-Geletaauthor=A.+Pecinovaauthor=L.+F.+Dongauthor=Z.+Drahotaauthor=J.+Neuzil&title=Mitochondrial+targeting+of+metformin+enhances+its+activity+against+pancreatic+cancer&doi=10.1158%2F1535-7163.MCT-15-1021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial Targeting of Metformin Enhances Its Activity against Pancreatic Cancer</span></div><div class="casAuthors">Boukalova, Stepana; Stursa, Jan; Werner, Lukas; Ezrova, Zuzana; Cerny, Jiri; Bezawork-Geleta, Ayenachew; Pecinova, Alena; Dong, Lanfeng; Drahota, Zdenek; Neuzil, Jiri</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2875-2886</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Pancreatic cancer is one of the hardest-to-treat types of neoplastic diseases.  Metformin, a widely prescribed drug against type 2 diabetes mellitus, is being trialed as an agent against pancreatic cancer, although its efficacy is low.  With the idea of delivering metformin to its mol. target, the mitochondrial complex I (CI), we tagged the agent with the mitochondrial vector, triphenylphosphonium group.  Mitochondrially targeted metformin (MitoMet) was found to kill a panel of pancreatic cancer cells three to four orders of magnitude more efficiently than found for the parental compd.  Respiration assessment documented CI as the mol. target for MitoMet, which was corroborated by mol. modeling.  MitoMet also efficiently suppressed pancreatic tumors in three mouse models.  We propose that the novel mitochondrially targeted agent is clin. highly intriguing, and it has a potential to greatly improve the bleak prospects of patients with pancreatic cancer.  Mol Cancer Ther; 15(12); 2875-86. 2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg7XRRxwPY3rVg90H21EOLACvtfcHk0lgHuqgKBBsEWA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFynt7vL&md5=15a12f077f56cd6423dbc404b228cbe1</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-1021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-1021%26sid%3Dliteratum%253Aachs%26aulast%3DBoukalova%26aufirst%3DS.%26aulast%3DStursa%26aufirst%3DJ.%26aulast%3DWerner%26aufirst%3DL.%26aulast%3DEzrova%26aufirst%3DZ.%26aulast%3DCerny%26aufirst%3DJ.%26aulast%3DBezawork-Geleta%26aufirst%3DA.%26aulast%3DPecinova%26aufirst%3DA.%26aulast%3DDong%26aufirst%3DL.%2BF.%26aulast%3DDrahota%26aufirst%3DZ.%26aulast%3DNeuzil%26aufirst%3DJ.%26atitle%3DMitochondrial%2520targeting%2520of%2520metformin%2520enhances%2520its%2520activity%2520against%2520pancreatic%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26spage%3D2875%26epage%3D2886%26doi%3D10.1158%2F1535-7163.MCT-15-1021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pollak, M.</span></span> <span> </span><span class="NLM_article-title">Potential applications for biguanides in oncology</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">3693</span>â <span class="NLM_lpage">3700</span>, <span class="refDoi">Â DOI: 10.1172/JCI67232</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1172%2FJCI67232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=23999444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVenu7bF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2013&pages=3693-3700&author=M.+Pollak&title=Potential+applications+for+biguanides+in+oncology&doi=10.1172%2FJCI67232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Potential applications for biguanides in oncology</span></div><div class="casAuthors">Pollak, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3693-3700</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  Metformin is widely prescribed for the treatment of type II diabetes.  Recently, it has been proposed that this compd. or related biguanides may have antineoplastic activity.  Biguanides may exploit specific metabolic vulnerabilities of transformed cells by acting on them directly, or may act by indirect mechanisms that involve alterations of the host environment.  Preclin. data suggest that drug exposure levels are a key determinant of proposed direct actions.  With respect to indirect mechanisms, it will be important to det. whether recently demonstrated metformin-induced changes in levels of candidate systemic mediators such as insulin or inflammatory cytokines are of sufficient magnitude to achieve therapeutic benefit.  Results of the first generation of clin. trials now in progress are eagerly anticipated.  Ongoing investigations may justify a second generation of trials that explore pharmacokinetic optimization, rational drug combinations, synthetic lethality strategies, novel biguanides, and the use of predictive biomarkers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj7_vP2GmvzLVg90H21EOLACvtfcHk0lgHuqgKBBsEWA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVenu7bF&md5=19d8e4713e9effcf64af8c8a8e6fcd1d</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1172%2FJCI67232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI67232%26sid%3Dliteratum%253Aachs%26aulast%3DPollak%26aufirst%3DM.%26atitle%3DPotential%2520applications%2520for%2520biguanides%2520in%2520oncology%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2013%26volume%3D123%26spage%3D3693%26epage%3D3700%26doi%3D10.1172%2FJCI67232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mcguinness, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talbert, R. L.</span></span> <span> </span><span class="NLM_article-title">Phenformin-induced lactic-acidosis - a forgotten adverse drug reaction</span>. <i>Ann. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1183</span>â <span class="NLM_lpage">1187</span>, <span class="refDoi">Â DOI: 10.1177/106002809302701004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1177%2F106002809302701004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=8251683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADyaK2c%252Fnt1Orsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1993&pages=1183-1187&author=M.+E.+Mcguinnessauthor=R.+L.+Talbert&title=Phenformin-induced+lactic-acidosis+-+a+forgotten+adverse+drug+reaction&doi=10.1177%2F106002809302701004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Phenformin-induced lactic acidosis: a forgotten adverse drug reaction</span></div><div class="casAuthors">McGuinness M E; Talbert R L</div><div class="citationInfo"><span class="NLM_cas:title">The Annals of pharmacotherapy</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1183-7</span>
        ISSN:<span class="NLM_cas:issn">1060-0280</span>.
    </div><div class="casAbstract">OBJECTIVE:  To document a case of severe metabolic and lactic acidosis secondary to phenformin.  This adverse effect has almost been forgotten as 15 years have passed since its withdrawal from the US market.  CASE SUMMARY:  A 64-year-old man presented with a four-day history of left upper abdominal pain and a one-week history of constipation and diarrhea.  His arterial blood gases were pH 6.7, pCO2 2.80 kPa, and pO2 12.00 kPa with 90% oxygen saturation on room air.  Serum chemistries indicated an unmeasurable serum bicarbonate concentration, anion gap 52 mmol/L, lactate concentration 29.5 mmol/L, blood urea nitrogen 6.63 mmol/L, creatinine 229.84 mumol/L, and blood glucose 4.35 mmol/L.  There were low levels of urine and serum ketones.  In the emergency department, he required resuscitation for hypotension and bradycardia.  His diagnosis was lactic and ketoacidosis secondary to phenformin.  The patient was treated with NaCl 0.9%, sodium bicarbonate, insulin, and hemodialysis.  Although he survived the initial insult of lactic and ketoacidosis, his hospital course was complicated and he died on hospital day 105.  CONCLUSIONS:  Treatment of lactic acidosis is difficult and challenging.  The continued availability of phenformin in neighboring countries, and the renewed interest in biguanide therapy for treating diabetes mellitus make it an important diagnosis of exclusion in diabetic patients who present with severe acidosis.  Metformin, another biguanide under investigation for the treatment of diabetes mellitus, is associated with a much lower incidence of lactic acidosis than is phenformin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT3yEWY8NqsaBJ5E29YNGvQfW6udTcc2eZjPeiFyRwKHLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2c%252Fnt1Orsw%253D%253D&md5=f9782924f1839b89472c40406ed8f4c4</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1177%2F106002809302701004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F106002809302701004%26sid%3Dliteratum%253Aachs%26aulast%3DMcguinness%26aufirst%3DM.%2BE.%26aulast%3DTalbert%26aufirst%3DR.%2BL.%26atitle%3DPhenformin-induced%2520lactic-acidosis%2520-%2520a%2520forgotten%2520adverse%2520drug%2520reaction%26jtitle%3DAnn.%2520Pharmacother.%26date%3D1993%26volume%3D27%26spage%3D1183%26epage%3D1187%26doi%3D10.1177%2F106002809302701004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shim, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yook, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huh, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, J. H.</span></span> <span> </span><span class="NLM_article-title">Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with Temozolomide and a newly designed biguanide (HL156A)</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">65643</span>â <span class="NLM_lpage">65659</span>, <span class="refDoi">Â DOI: 10.18632/oncotarget.11595</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.18632%2Foncotarget.11595" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27582539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BC2szmsVGluw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=65643-65659&author=J.+Choiauthor=J.+H.+Leeauthor=I.+Kohauthor=J.+K.+Shimauthor=J.+Parkauthor=J.+Y.+Jeonauthor=M.+Yunauthor=S.+H.+Kimauthor=J.+I.+Yookauthor=E.+H.+Kimauthor=J.+H.+Changauthor=S.+H.+Kimauthor=Y.+M.+Huhauthor=S.+J.+Leeauthor=M.+Pollakauthor=P.+Kimauthor=S.+G.+Kangauthor=J.+H.+Cheong&title=Inhibiting+stemness+and+invasive+properties+of+glioblastoma+tumorsphere+by+combined+treatment+with+Temozolomide+and+a+newly+designed+biguanide+%28HL156A%29&doi=10.18632%2Foncotarget.11595"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (HL156A)</span></div><div class="casAuthors">Choi Junjeong; Choi Junjeong; Lee Ji-Hyun; Shim Jin-Kyoung; Park Junseong; Kim Eui Hyun; Chang Jong Hee; Kim Sun Ho; Kang Seok-Gu; Koh Ilkyoo; Kim Pilnam; Jeon Jeong Yong; Yun Mijin; Kim Se Hoon; Yook Jong In; Huh Yong Min; Lee Su Jae; Pollak Michael; Cheong Jae-Ho</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">65643-65659</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Studies have investigated biguanide-derived agents for the treatment of cancers and have reported their effects against tumorspheres (TSs).  The purpose of this study was determining the effects of HL156A, a newly designed biguanide with improved pharmacokinetics, on glioblastoma TSs (GMB TSs) and assess the feasibility of this drug as a new line of therapy against glioblastoma, alone or combined with a conventional therapeutic agent, temozolomide(TMZ).  The effects of HL156A, alone and combined with TMZ, on the stemness and invasive properties of GBM TSs and survival of orthotopic xenograft animals were assessed.  HL156A, combined with TMZ, inhibited the stemness of GBM TSs, proven by neurosphere formation assay and marker expression.  Three-dimensional collagen matrix invasion assays provided evidence that combined treatment inhibited invasive properties, compared with control and TMZ-alone treatment groups.  TMZ alone and combined treatment repressed the expression of epithelial-mesenchymal transition-related genes.  A gene ontology comparison of TMZ and combination-treatment groups revealed altered expression of genes encoding proteins involved in cellular adhesion and migration.  Combined treatment with HL156A and TMZ showed survival benefits in an orthotopic xenograft mouse model.  The inhibitory effect of combination treatment on the stemness and invasive properties of GBM TSs suggest the potential usage of this regimen as a novel strategy for the treatment of GBM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS4YQ9NwXQVQSSm0e6ZOaemfW6udTcc2eZjPeiFyRwKHLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2szmsVGluw%253D%253D&md5=9bccb22236fb3a64fb982645dc2dbb37</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.11595&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.11595%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DKoh%26aufirst%3DI.%26aulast%3DShim%26aufirst%3DJ.%2BK.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DJeon%26aufirst%3DJ.%2BY.%26aulast%3DYun%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DYook%26aufirst%3DJ.%2BI.%26aulast%3DKim%26aufirst%3DE.%2BH.%26aulast%3DChang%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DHuh%26aufirst%3DY.%2BM.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DPollak%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DP.%26aulast%3DKang%26aufirst%3DS.%2BG.%26aulast%3DCheong%26aufirst%3DJ.%2BH.%26atitle%3DInhibiting%2520stemness%2520and%2520invasive%2520properties%2520of%2520glioblastoma%2520tumorsphere%2520by%2520combined%2520treatment%2520with%2520Temozolomide%2520and%2520a%2520newly%2520designed%2520biguanide%2520%2528HL156A%2529%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D65643%26epage%3D65659%26doi%3D10.18632%2Foncotarget.11595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rha, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beom, S. H. B. S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yim, D.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâNeill, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janku, F.</span></span> <span> </span><span class="NLM_article-title">Abstract CT021: Phase I study of an oxidative phosphorylation inhibitor IM156 in patients with advanced solid tumors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">CT021</span>â <span class="NLM_lpage">CT021</span>, <span class="refDoi">Â DOI: 10.1158/1538-7445.SABCS18-CT021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F1538-7445.SABCS18-CT021" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=CT021-CT021&author=S.+Y.+Rhaauthor=S.+H.+B.+S.+H.+Beomauthor=G.+M.+Kimauthor=Y.+G.+Shinauthor=D.-S.+Yimauthor=H.+S.+Kimauthor=J.+H.+Changauthor=J.-H.+Cheongauthor=Y.+W.+Leeauthor=Y.+S.+Chongauthor=V.+O%E2%80%99Neillauthor=S.+H.+Yooauthor=F.+Janku&title=Abstract+CT021%3A+Phase+I+study+of+an+oxidative+phosphorylation+inhibitor+IM156+in+patients+with+advanced+solid+tumors&doi=10.1158%2F1538-7445.SABCS18-CT021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.SABCS18-CT021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.SABCS18-CT021%26sid%3Dliteratum%253Aachs%26aulast%3DRha%26aufirst%3DS.%2BY.%26aulast%3DBeom%26aufirst%3DS.%2BH.%2BB.%2BS.%2BH.%26aulast%3DKim%26aufirst%3DG.%2BM.%26aulast%3DShin%26aufirst%3DY.%2BG.%26aulast%3DYim%26aufirst%3DD.-S.%26aulast%3DKim%26aufirst%3DH.%2BS.%26aulast%3DChang%26aufirst%3DJ.%2BH.%26aulast%3DCheong%26aufirst%3DJ.-H.%26aulast%3DLee%26aufirst%3DY.%2BW.%26aulast%3DChong%26aufirst%3DY.%2BS.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DV.%26aulast%3DYoo%26aufirst%3DS.%2BH.%26aulast%3DJanku%26aufirst%3DF.%26atitle%3DAbstract%2520CT021%253A%2520Phase%2520I%2520study%2520of%2520an%2520oxidative%2520phosphorylation%2520inhibitor%2520IM156%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D2019%26volume%3D79%26spage%3DCT021%26epage%3DCT021%26doi%3D10.1158%2F1538-7445.SABCS18-CT021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Helbig, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruchner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurtner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess-Stumpp, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unterschemmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zips, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yaromina, A.</span></span> <span> </span><span class="NLM_article-title">BAY 87-2243, a novel inhibitor of hypoxia-induced gene activation, improves local tumor control after fractionated irradiation in a schedule-dependent manner in head and neck human xenografts</span>. <i>Radiat. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">207</span>, <span class="refDoi">Â DOI: 10.1186/1748-717X-9-207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1186%2F1748-717X-9-207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=25234922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFGnt7jN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=207&author=L.+Helbigauthor=L.+Koiauthor=K.+Bruchnerauthor=K.+Gurtnerauthor=H.+Hess-Stumppauthor=K.+Unterschemmannauthor=M.+Baumannauthor=D.+Zipsauthor=A.+Yaromina&title=BAY+87-2243%2C+a+novel+inhibitor+of+hypoxia-induced+gene+activation%2C+improves+local+tumor+control+after+fractionated+irradiation+in+a+schedule-dependent+manner+in+head+and+neck+human+xenografts&doi=10.1186%2F1748-717X-9-207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">BAY 87-2243, a novel inhibitor of hypoxia-induced gene activation, improves local tumor control after fractionated irradiation in a schedule-dependent manner in head and neck human xenografts</span></div><div class="casAuthors">Helbig, Linda; Koi, Lydia; Bruechner, Kerstin; Gurtner, Kristin; Hess-Stumpp, Holger; Unterschemmann, Kerstin; Baumann, Michael; Zips, Daniel; Yaromina, Ala</div><div class="citationInfo"><span class="NLM_cas:title">Radiation Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">207/1-207/19, 19 pp.</span>CODEN:
                <span class="NLM_cas:coden">ROANCM</span>;
        ISSN:<span class="NLM_cas:issn">1748-717X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">The transcription factor hypoxia-inducible factor-1 (HIF-1) pathway plays an important role in tumor response to cytotoxic treatments.  We investigated the effects of a novel small mol. inhibitor of mitochondrial complex I and hypoxia-induced HIF-1 activity BAY-87-2243, on tumor microenvironment and response of human squamous cell carcinoma (hSCC) to clin. relevant fractionated radiotherapy (RT) with and without concomitant chemotherapy.  When UT-SCC-5 hSCC xenografts in nude mice reached 6 mm in diam. BAY-87-2243 or carrier was administered before and/or during RT or radiochemotherapy with concomitant cisplatin (RCT).  Local tumor control was evaluated 150 days after irradn. and the doses to control 50% of tumors (TCD50) were compared between treatment arms.  Tumors were excised at different time points during BAY-87-2243 or carrier treatment for western blot and immunohistol. investigations.  BAY-87-2243 markedly decreased nuclear HIF-1Î± expression and pimonidazole hypoxic fraction already after 3 days of drug treatment.  BAY-87-2243 prior to RT significantly reduced TCD50 from 123 to 100 Gy (p = 0.037).  Addnl. BAY-87-2243 application during RT did not decrease TCD50.  BAY-87-2243 before and during radiochemotherapy did not improve local tumor control.  Pronounced redn. of tumor hypoxia by application of BAY-87-2243 prior to RT improved local tumor control.  The results demonstrate that radiosensitizing effect importantly depends on treatment schedule.  The data support further investigations of HIF-1 pathway inhibitors for radiotherapy and of predictive tests to select patients who will benefit from this combined treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgoI5X74S9GbVg90H21EOLACvtfcHk0lhVja05y9WrBw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFGnt7jN&md5=d27ae373dda9abad4608d8d7a8e19960</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1186%2F1748-717X-9-207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1748-717X-9-207%26sid%3Dliteratum%253Aachs%26aulast%3DHelbig%26aufirst%3DL.%26aulast%3DKoi%26aufirst%3DL.%26aulast%3DBruchner%26aufirst%3DK.%26aulast%3DGurtner%26aufirst%3DK.%26aulast%3DHess-Stumpp%26aufirst%3DH.%26aulast%3DUnterschemmann%26aufirst%3DK.%26aulast%3DBaumann%26aufirst%3DM.%26aulast%3DZips%26aufirst%3DD.%26aulast%3DYaromina%26aufirst%3DA.%26atitle%3DBAY%252087-2243%252C%2520a%2520novel%2520inhibitor%2520of%2520hypoxia-induced%2520gene%2520activation%252C%2520improves%2520local%2520tumor%2520control%2520after%2520fractionated%2520irradiation%2520in%2520a%2520schedule-dependent%2520manner%2520in%2520head%2520and%2520neck%2520human%2520xenografts%26jtitle%3DRadiat.%2520Oncol.%26date%3D2014%26volume%3D9%26spage%3D207%26doi%3D10.1186%2F1748-717X-9-207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schockel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glasauer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basit, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bitschar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdmann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Algire, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagebarth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willems, P. H. G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopitz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koopman, W. J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heroult, M.</span></span> <span> </span><span class="NLM_article-title">Targeting mitochondrial complex I using BAY 87-2243 reduces melanoma tumor growth</span>. <i>Cancer Metab.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">11</span>, <span class="refDoi">Â DOI: 10.1186/s40170-015-0138-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1186%2Fs40170-015-0138-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=26500770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BC28zlslaqsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&pages=11&author=L.+Schockelauthor=A.+Glasauerauthor=F.+Basitauthor=K.+Bitscharauthor=H.+Truongauthor=G.+Erdmannauthor=C.+Algireauthor=A.+Hagebarthauthor=P.+H.+G.+M.+Willemsauthor=C.+Kopitzauthor=W.+J.+H.+Koopmanauthor=M.+Heroult&title=Targeting+mitochondrial+complex+I+using+BAY+87-2243+reduces+melanoma+tumor+growth&doi=10.1186%2Fs40170-015-0138-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting mitochondrial complex I using BAY 87-2243 reduces melanoma tumor growth</span></div><div class="casAuthors">Schockel Laura; Glasauer Andrea; Bitschar Katharina; Erdmann Gerrit; Algire Carolyn; Hagebarth Andrea; Kopitz Charlotte; Basit Farhan; Truong Hoa; Willems Peter Hgm; Koopman Werner Jh; Heroult Melanie</div><div class="citationInfo"><span class="NLM_cas:title">Cancer & metabolism</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">11</span>
        ISSN:<span class="NLM_cas:issn">2049-3002</span>.
    </div><div class="casAbstract">BACKGROUND:  Numerous studies have demonstrated that functional mitochondria are required for tumorigenesis, suggesting that mitochondrial oxidative phosphorylation (OXPHOS) might be a potential target for cancer therapy.  In this study, we investigated the effects of BAY 87-2243, a small molecule that inhibits the first OXPHOS enzyme (complex I), in melanoma in vitro and in vivo.  RESULTS:  BAY 87-2243 decreased mitochondrial oxygen consumption and induced partial depolarization of the mitochondrial membrane potential.  This was associated with increased reactive oxygen species (ROS) levels, lowering of total cellular ATP levels, activation of AMP-activated protein kinase (AMPK), and reduced cell viability.  The latter was rescued by the antioxidant vitamin E and high extracellular glucose levels (25 mM), indicating the involvement of ROS-induced cell death and a dependence on glycolysis for cell survival upon BAY 87-2243 treatment.  BAY 87-2243 significantly reduced tumor growth in various BRAF mutant melanoma mouse xenografts and patient-derived melanoma mouse models.  Furthermore, we provide evidence that inhibition of mutated BRAF using the specific small molecule inhibitor vemurafenib increased the OXPHOS dependency of BRAF mutant melanoma cells.  As a consequence, the combination of both inhibitors augmented the anti-tumor effect of BAY 87-2243 in a BRAF mutant melanoma mouse xenograft model.  CONCLUSIONS:  Taken together, our results suggest that complex I inhibition has potential clinical applications as a single agent in melanoma and also might be efficacious in combination with BRAF inhibitors in the treatment of patients with BRAF mutant melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSFUMsAIro3rCCEBeYuoi7AfW6udTcc2eYMMExtBBGavrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28zlslaqsQ%253D%253D&md5=8b76f8e4340ee263bd55564cbac4fea5</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1186%2Fs40170-015-0138-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40170-015-0138-0%26sid%3Dliteratum%253Aachs%26aulast%3DSchockel%26aufirst%3DL.%26aulast%3DGlasauer%26aufirst%3DA.%26aulast%3DBasit%26aufirst%3DF.%26aulast%3DBitschar%26aufirst%3DK.%26aulast%3DTruong%26aufirst%3DH.%26aulast%3DErdmann%26aufirst%3DG.%26aulast%3DAlgire%26aufirst%3DC.%26aulast%3DHagebarth%26aufirst%3DA.%26aulast%3DWillems%26aufirst%3DP.%2BH.%2BG.%2BM.%26aulast%3DKopitz%26aufirst%3DC.%26aulast%3DKoopman%26aufirst%3DW.%2BJ.%2BH.%26aulast%3DHeroult%26aufirst%3DM.%26atitle%3DTargeting%2520mitochondrial%2520complex%2520I%2520using%2520BAY%252087-2243%2520reduces%2520melanoma%2520tumor%2520growth%26jtitle%3DCancer%2520Metab.%26date%3D2015%26volume%3D3%26spage%3D11%26doi%3D10.1186%2Fs40170-015-0138-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gopal, Y. N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gammon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knighton, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pisaneschi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roszik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pramanik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudderth, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sui, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudgens, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reuben, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McQuade, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tetzlaff, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Francesco, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marszalek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piwnica-Worms, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeBerardinis, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, M. A.</span></span> <span> </span><span class="NLM_article-title">A novel mitochondrial inhibitor blocks MAPK pathway and overcomes MAPK inhibitor resistance in melanoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">6429</span>â <span class="NLM_lpage">6442</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-19-0836</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F1078-0432.CCR-19-0836" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=31439581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVSmsr%252FN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=6429-6442&author=Y.+N.+V.+Gopalauthor=S.+Gammonauthor=R.+Prasadauthor=B.+Knightonauthor=F.+Pisaneschiauthor=J.+Roszikauthor=N.+P.+Fengauthor=S.+Johnsonauthor=S.+Pramanikauthor=J.+Sudderthauthor=D.+W.+Suiauthor=C.+Hudgensauthor=G.+M.+Fischerauthor=W.+L.+Dengauthor=A.+Reubenauthor=W.+Y.+Pengauthor=J.+Wangauthor=J.+L.+McQuadeauthor=M.+T.+Tetzlaffauthor=M.+E.+Di+Francescoauthor=J.+Marszalekauthor=D.+Piwnica-Wormsauthor=R.+J.+DeBerardinisauthor=M.+A.+Davies&title=A+novel+mitochondrial+inhibitor+blocks+MAPK+pathway+and+overcomes+MAPK+inhibitor+resistance+in+melanoma&doi=10.1158%2F1078-0432.CCR-19-0836"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">A novel mitochondrial inhibitor blocks MAPK pathway and overcomes MAPK inhibitor resistance in melanoma</span></div><div class="casAuthors">Gopal, Y. N. Vashisht; Gammon, Seth; Prasad, Rishika; Knighton, Barbara; Pisaneschi, Federica; Roszik, Jason; Feng, Ningping; Johnson, Sarah; Pramanik, Snigdha; Sudderth, Jessica; Sui, Dawen; Hudgens, Courtney; Fischer, Grant M.; Deng, Wanleng; Reuben, Alexandre; Peng, Weiyi; Wang, Jian; McQuade, Jennifer L.; Tetzlaff, Michael T.; Di Francesco, Maria E.; Marszalek, Joe; Piwnica-Worms, David; DeBerardinis, Ralph J.; Davies, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6429-6442</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The purpose of this study is to det. if inhibition of mitochondrial oxidative phosphorylation (OxPhos) is an effective strategy against MAPK pathway inhibitor (MAPKi)-resistant BRAF-mutant melanomas.  Exptl. Design: The antimelanoma activity of IACS-010759 (OPi), a novel OxPhos complex I inhibitor, was evaluated in vitro and in vivo.  Mechanistic studies and predictors of response were evaluated using molecularly and metabolically stratified melanoma cell lines.  13C-labeling and targeted metabolomics were used to evaluate the effect of OPi on cellular energy utilization.  OxPhos inhibition in vivo was evaluated noninvasively by [18F]-fluoroazomycin arabinoside (FAZA) PET imaging.  Results: OPi potently inhibited OxPhos and the in vivo growth of multiple MAPKi-resistant BRAF-mutant melanoma models with high OxPhos at well-tolerated doses.  In vivo tumor regression with single-agent OPi treatment correlated with inhibition of both MAPK and mTOR complex I activity.  Unexpectedly, antitumor activity was not improved by combined treatment with MAPKi in vitro or in vivo.  Signaling and growth-inhibitory effects were mediated by LKB1-AMPK axis, and proportional to AMPK activation.  OPi increased glucose incorporation into glycolysis, inhibited glucose and glutamine incorporation into the mitochondrial tricarboxylic acid cycle, and decreased cellular nucleotide and amino acid pools.  Early changes in [18F]-FAZA PET uptake in vivo, and the degree of mTORC1 pathway inhibition in vitro, correlated with efficacy.  Conclusions: Targeting OxPhos with OPi has significant antitumor activity in MAPKi-resistant, BRAF-mutant melanomas, and merits further clin. investigation as a potential new strategy to overcome intrinsic and acquired resistance to MAPKi in patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaP_A-Tuw8abVg90H21EOLACvtfcHk0licOmuREDn3ZQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVSmsr%252FN&md5=64e1eed6a183fbe8c64bcf8b1b1761b4</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-19-0836&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-19-0836%26sid%3Dliteratum%253Aachs%26aulast%3DGopal%26aufirst%3DY.%2BN.%2BV.%26aulast%3DGammon%26aufirst%3DS.%26aulast%3DPrasad%26aufirst%3DR.%26aulast%3DKnighton%26aufirst%3DB.%26aulast%3DPisaneschi%26aufirst%3DF.%26aulast%3DRoszik%26aufirst%3DJ.%26aulast%3DFeng%26aufirst%3DN.%2BP.%26aulast%3DJohnson%26aufirst%3DS.%26aulast%3DPramanik%26aufirst%3DS.%26aulast%3DSudderth%26aufirst%3DJ.%26aulast%3DSui%26aufirst%3DD.%2BW.%26aulast%3DHudgens%26aufirst%3DC.%26aulast%3DFischer%26aufirst%3DG.%2BM.%26aulast%3DDeng%26aufirst%3DW.%2BL.%26aulast%3DReuben%26aufirst%3DA.%26aulast%3DPeng%26aufirst%3DW.%2BY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DMcQuade%26aufirst%3DJ.%2BL.%26aulast%3DTetzlaff%26aufirst%3DM.%2BT.%26aulast%3DDi%2BFrancesco%26aufirst%3DM.%2BE.%26aulast%3DMarszalek%26aufirst%3DJ.%26aulast%3DPiwnica-Worms%26aufirst%3DD.%26aulast%3DDeBerardinis%26aufirst%3DR.%2BJ.%26aulast%3DDavies%26aufirst%3DM.%2BA.%26atitle%3DA%2520novel%2520mitochondrial%2520inhibitor%2520blocks%2520MAPK%2520pathway%2520and%2520overcomes%2520MAPK%2520inhibitor%2520resistance%2520in%2520melanoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2019%26volume%3D25%26spage%3D6429%26epage%3D6442%26doi%3D10.1158%2F1078-0432.CCR-19-0836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kircher, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McQuade, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haydu, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joon, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reuben, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Macedo, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carapeto, F. C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambati, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sreekumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudgens, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knighton, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawbi, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glitza, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gershenwald, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopal, Y. N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huse, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wargo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Futreal, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Putlri, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazar, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeBerardinis, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marszalek, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmen, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tetzlaff, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, M. A.</span></span> <span> </span><span class="NLM_article-title">Molecular profiling reveals unique immune and metabolic features of melanoma brain metastases</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">628</span>â <span class="NLM_lpage">645</span>, <span class="refDoi">Â DOI: 10.1158/2159-8290.CD-18-1489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F2159-8290.CD-18-1489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=30787016" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVGht7fE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=628-645&author=G.+M.+Fischerauthor=A.+Jalaliauthor=D.+A.+Kircherauthor=W.+C.+Leeauthor=J.+L.+McQuadeauthor=L.+E.+Hayduauthor=A.+Y.+Joonauthor=A.+Reubenauthor=M.+P.+de+Macedoauthor=F.+C.+L.+Carapetoauthor=C.+D.+Yangauthor=A.+Srivastavaauthor=C.+R.+Ambatiauthor=A.+Sreekumarauthor=C.+W.+Hudgensauthor=B.+Knightonauthor=W.+L.+Dengauthor=S.+D.+Fergusonauthor=H.+A.+Tawbiauthor=I.+C.+Glitzaauthor=J.+E.+Gershenwaldauthor=Y.+N.+V.+Gopalauthor=P.+Hwuauthor=J.+T.+Huseauthor=J.+A.+Wargoauthor=P.+A.+Futrealauthor=N.+Putlriauthor=A.+J.+Lazarauthor=R.+J.+DeBerardinisauthor=J.+R.+Marszalekauthor=J.+J.+Zhangauthor=S.+L.+Holmenauthor=M.+T.+Tetzlaffauthor=M.+A.+Davies&title=Molecular+profiling+reveals+unique+immune+and+metabolic+features+of+melanoma+brain+metastases&doi=10.1158%2F2159-8290.CD-18-1489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular profiling reveals unique immune and metabolic features of melanoma brain metastases</span></div><div class="casAuthors">Fischer, Grant M.; Jalali, Ali; Kircher, David A.; Lee, Won-Chul; McQuade, Jennifer L.; Haydu, Lauren E.; Joon, Aron Y.; Reuben, Alexandre; de Macedo, Mariana P.; Carapeto, Fernando C. L.; Yang, Chendong; Srivastava, Anuj; Ambati, Chandrashekar R.; Sreekumar, Arun; Hudgens, Courtney W.; Knighton, Barbara; Deng, Wanleng; Ferguson, Sherise D.; Tawbi, Hussein A.; Glitza, Isabella C.; Gershenwald, Jeffrey E.; Gopal, Y. N. Vashisht; Hwu, Patrick; Huse, Jason T.; Wargo, Jennifer A.; Futreal, P. Andrew; Putluri, Nagireddy; Lazar, Alexander J.; DeBerardinis, Ralph J.; Marszalek, Joseph R.; Zhang, Jianjun; Holmen, Sheri L.; Tetzlaff, Michael T.; Davies, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">628-645</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">There is a crit. need to improve our understanding of the pathogenesis of melanoma brain metastases (MBM).  Thus, we performed RNA sequencing on 88 resected MBMs and 42 patient-matched extracranial metastases tumors with sufficient tissue also underwent whole-exome sequencing, T-cell receptor sequencing, and IHC.  MBMs demonstrated heterogeneity of immune infiltrates that correlated with prior radiation and post-craniotomy survival.  Comparison with patient-matched extracranial metastases identified significant immunosuppression and enrichment of oxidative phosphorylation (OXPHOS) in MBMs.  Gene-expression anal. of intracranial and s.c. xenografts, and a spontaneous MBM model, confirmed increased OXPHOS gene expression in MBMs, which was also detected by direct metabolite profiling and [U-13C]-glucose tracing in vivo.  IACS-010759, an OXPHOS inhibitor currently in early-phase clin. trials, improved survival of mice bearing MAPK inhibitor-resistant intracranial melanoma xenografts and inhibited MBM formation in the spontaneous MBM model.  The results provide new insights into the pathogenesis and therapeutic resistance of MBMs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqekeeOZ790vLVg90H21EOLACvtfcHk0lh6s8jmmKpHdw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVGht7fE&md5=d8d07bbc84b7dabe7796cf33a8834e88</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-18-1489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-18-1489%26sid%3Dliteratum%253Aachs%26aulast%3DFischer%26aufirst%3DG.%2BM.%26aulast%3DJalali%26aufirst%3DA.%26aulast%3DKircher%26aufirst%3DD.%2BA.%26aulast%3DLee%26aufirst%3DW.%2BC.%26aulast%3DMcQuade%26aufirst%3DJ.%2BL.%26aulast%3DHaydu%26aufirst%3DL.%2BE.%26aulast%3DJoon%26aufirst%3DA.%2BY.%26aulast%3DReuben%26aufirst%3DA.%26aulast%3Dde%2BMacedo%26aufirst%3DM.%2BP.%26aulast%3DCarapeto%26aufirst%3DF.%2BC.%2BL.%26aulast%3DYang%26aufirst%3DC.%2BD.%26aulast%3DSrivastava%26aufirst%3DA.%26aulast%3DAmbati%26aufirst%3DC.%2BR.%26aulast%3DSreekumar%26aufirst%3DA.%26aulast%3DHudgens%26aufirst%3DC.%2BW.%26aulast%3DKnighton%26aufirst%3DB.%26aulast%3DDeng%26aufirst%3DW.%2BL.%26aulast%3DFerguson%26aufirst%3DS.%2BD.%26aulast%3DTawbi%26aufirst%3DH.%2BA.%26aulast%3DGlitza%26aufirst%3DI.%2BC.%26aulast%3DGershenwald%26aufirst%3DJ.%2BE.%26aulast%3DGopal%26aufirst%3DY.%2BN.%2BV.%26aulast%3DHwu%26aufirst%3DP.%26aulast%3DHuse%26aufirst%3DJ.%2BT.%26aulast%3DWargo%26aufirst%3DJ.%2BA.%26aulast%3DFutreal%26aufirst%3DP.%2BA.%26aulast%3DPutlri%26aufirst%3DN.%26aulast%3DLazar%26aufirst%3DA.%2BJ.%26aulast%3DDeBerardinis%26aufirst%3DR.%2BJ.%26aulast%3DMarszalek%26aufirst%3DJ.%2BR.%26aulast%3DZhang%26aufirst%3DJ.%2BJ.%26aulast%3DHolmen%26aufirst%3DS.%2BL.%26aulast%3DTetzlaff%26aufirst%3DM.%2BT.%26aulast%3DDavies%26aufirst%3DM.%2BA.%26atitle%3DMolecular%2520profiling%2520reveals%2520unique%2520immune%2520and%2520metabolic%2520features%2520of%2520melanoma%2520brain%2520metastases%26jtitle%3DCancer%2520Discovery%26date%3D2019%26volume%3D9%26spage%3D628%26epage%3D645%26doi%3D10.1158%2F2159-8290.CD-18-1489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fryknas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremberg, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senkowski, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olofsson, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DâArcy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gullbo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nygren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schughart, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linder, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsson, R.</span></span> <span> </span><span class="NLM_article-title">Iron chelators target both proliferating and quiescent cancer cells</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">38343</span>, <span class="refDoi">Â DOI: 10.1038/srep38343</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fsrep38343" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27924826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BC2sjkt1eitw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=38343&author=M.+Fryknasauthor=X.+N.+Zhangauthor=U.+Brembergauthor=W.+Senkowskiauthor=M.+H.+Olofssonauthor=P.+Brandtauthor=I.+Perssonauthor=P.+D%E2%80%99Arcyauthor=J.+Gullboauthor=P.+Nygrenauthor=L.+K.+Schughartauthor=S.+Linderauthor=R.+Larsson&title=Iron+chelators+target+both+proliferating+and+quiescent+cancer+cells&doi=10.1038%2Fsrep38343"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Iron chelators target both proliferating and quiescent cancer cells</span></div><div class="casAuthors">Fryknas Marten; Senkowski Wojciech; Gullbo Joachim; Larsson Rolf; Zhang Xiaonan; D'Arcy Padraig; Linder Stig; Zhang Xiaonan; Olofsson Maria Hagg; Linder Stig; Bremberg Ulf; Brandt Peter; Persson Ingmar; Gullbo Joachim; Nygren Peter; Schughart Leoni Kunz</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">38343</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Poorly vascularized areas of solid tumors contain quiescent cell populations that are resistant to cell cycle-active cancer drugs.  The compound VLX600 was recently identified to target quiescent tumor cells and to inhibit mitochondrial respiration.  We here performed gene expression analysis in order to characterize the cellular response to VLX600.  The compound-specific signature of VLX600 revealed a striking similarity to signatures generated by compounds known to chelate iron.  Validation experiments including addition of ferrous and ferric iron in excess, EXAFS measurements, and structure activity relationship analyses showed that VLX600 chelates iron and supported the hypothesis that the biological effects of this compound is due to iron chelation.  Compounds that chelate iron possess anti-cancer activity, an effect largely attributed to inhibition of ribonucleotide reductase in proliferating cells.  Here we show that iron chelators decrease mitochondrial energy production, an effect poorly tolerated by metabolically stressed tumor cells.  These pleiotropic features make iron chelators an attractive option for the treatment of solid tumors containing heterogeneous populations of proliferating and quiescent cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTXnn1YuaO7nf6BottYdIAWfW6udTcc2eb_L2dXvl0dZrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjkt1eitw%253D%253D&md5=229ef3e55508c28e7f6d9940c5c33cff</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1038%2Fsrep38343&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep38343%26sid%3Dliteratum%253Aachs%26aulast%3DFryknas%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DX.%2BN.%26aulast%3DBremberg%26aufirst%3DU.%26aulast%3DSenkowski%26aufirst%3DW.%26aulast%3DOlofsson%26aufirst%3DM.%2BH.%26aulast%3DBrandt%26aufirst%3DP.%26aulast%3DPersson%26aufirst%3DI.%26aulast%3DD%25E2%2580%2599Arcy%26aufirst%3DP.%26aulast%3DGullbo%26aufirst%3DJ.%26aulast%3DNygren%26aufirst%3DP.%26aulast%3DSchughart%26aufirst%3DL.%2BK.%26aulast%3DLinder%26aufirst%3DS.%26aulast%3DLarsson%26aufirst%3DR.%26atitle%3DIron%2520chelators%2520target%2520both%2520proliferating%2520and%2520quiescent%2520cancer%2520cells%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D38343%26doi%3D10.1038%2Fsrep38343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mody, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansfield, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vemireddy, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nygren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulbo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borad, M.</span></span> <span> </span><span class="NLM_article-title">A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">684</span>â <span class="NLM_lpage">692</span>, <span class="refDoi">Â DOI: 10.1007/s10637-018-0703-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1007%2Fs10637-018-0703-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=30460505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Ggur7L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=684-692&author=K.+Modyauthor=A.+S.+Mansfieldauthor=L.+Vemireddyauthor=P.+Nygrenauthor=J.+Gulboauthor=M.+Borad&title=A+phase+I+study+of+the+safety+and+tolerability+of+VLX600%2C+an+Iron+Chelator%2C+in+patients+with+refractory+advanced+solid+tumors&doi=10.1007%2Fs10637-018-0703-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors</span></div><div class="casAuthors">Mody, Kabir; Mansfield, Aaron S.; Vemireddy, Lalitha; Nygren, Peter; Gulbo, Joachim; Borad, Mitesh</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">684-692</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Introduction VLX600 is a novel iron chelator designed to interfere with intracellular iron metab., leading to inhibition of mitochondrial respiration and bioenergetic catastrophe and resultant tumor cell death.  Methods We conducted a multicenter, phase 1, dose escalation study to det. the safety and adverse event profile and the max. tolerated dose and recommended phase 2 dose of VLX600.  Other endpoints included pharmacokinetics, and preliminary evidence of anti-cancer efficacy as assessed according to RECIST 1.1 criteria.  VLX600 was administered i.v. on days 1, 8, and 15 of each 28-day treatment cycle.  Results Nineteen patients were enrolled, and seventeen received at least one dose of VLX600.  Dose increments were reduced to 50% after dose level 3 (40 mg) due to the occurrence of a grade 3 pulmonary embolism.  The study was then closed early due to slow recruitment.  No max. tolerated dose (MTD) nor RP2D had been identified at the time of study closure.  Overall, the drug was well tolerated and no DLTs were obsd.  Fourteen patients experienced drug-related adverse events of any grade.  The most frequently reported drug-related AEs were fatigue, nausea, constipation, vomiting, increased alk. phosphatase, anemia, and decreased appetite.  No formal efficacy or survival analyses were performed.  No objective responses were obsd., though six patients (32%) had stable disease as best response.  Conclusion VLX600 was reasonably well tolerated and, together with preclin. data, there is support for further efforts to explore its activity as single agent and in combination with drugs or radiation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGu9592XhXtrVg90H21EOLACvtfcHk0lj_mucFKkDByA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Ggur7L&md5=7aa131dc853164c76398f34d8a657c7e</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1007%2Fs10637-018-0703-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-018-0703-9%26sid%3Dliteratum%253Aachs%26aulast%3DMody%26aufirst%3DK.%26aulast%3DMansfield%26aufirst%3DA.%2BS.%26aulast%3DVemireddy%26aufirst%3DL.%26aulast%3DNygren%26aufirst%3DP.%26aulast%3DGulbo%26aufirst%3DJ.%26aulast%3DBorad%26aufirst%3DM.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520the%2520safety%2520and%2520tolerability%2520of%2520VLX600%252C%2520an%2520Iron%2520Chelator%252C%2520in%2520patients%2520with%2520refractory%2520advanced%2520solid%2520tumors%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2019%26volume%3D37%26spage%3D684%26epage%3D692%26doi%3D10.1007%2Fs10637-018-0703-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shestov, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Worth, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nath, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeper, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glickson, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, I. A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of mitochondrial Complex II by the anticancer agent lonidamine</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>291</i></span>,  <span class="NLM_fpage">42</span>â <span class="NLM_lpage">57</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M115.697516</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1074%2Fjbc.M115.697516" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=26521302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFSnsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=2016&pages=42-57&author=L.+L.+Guoauthor=A.+A.+Shestovauthor=A.+J.+Worthauthor=K.+Nathauthor=D.+S.+Nelsonauthor=D.+B.+Leeperauthor=J.+D.+Glicksonauthor=I.+A.+Blair&title=Inhibition+of+mitochondrial+Complex+II+by+the+anticancer+agent+lonidamine&doi=10.1074%2Fjbc.M115.697516"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Mitochondrial Complex II by the Anticancer Agent Lonidamine</span></div><div class="casAuthors">Guo, Lili; Shestov, Alexander A.; Worth, Andrew J.; Nath, Kavindra; Nelson, David S.; Leeper, Dennis B.; Glickson, Jerry D.; Blair, Ian A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">291</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">42-57</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The antitumor agent lonidamine (LND; 1-(2,4-dichlorobenzyl)-1H-indazole-3-carboxylic acid) is known to interfere with energy-yielding processes in cancer cells.  However, the effect of LND on central energy metab. has never been fully characterized.  In this study, we report that a significant amt. of succinate is accumulated in LND-treated cells.  LND inhibits the formation of fumarate and malate and suppresses succinate-induced respiration of isolated mitochondria.  Utilizing biochem. assays, we detd. that LND inhibits the succinate-ubiquinone reductase activity of respiratory complex II without fully blocking succinate dehydrogenase activity.  LND also induces cellular reactive oxygen species through complex II, which reduced the viability of the DB-1 melanoma cell line.  The ability of LND to promote cell death was potentiated by its suppression of the pentose phosphate pathway, which resulted in inhibition of NADPH and glutathione generation.  Using stable isotope tracers in combination with isotopologue anal., we showed that LND increased glutaminolysis but decreased reductive carboxylation of glutamine-derived Î±-ketoglutarate.  Our findings on the previously uncharacterized effects of LND may provide potential combinational therapeutic approaches for targeting cancer metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouPEhqlDUN5bVg90H21EOLACvtfcHk0lj_mucFKkDByA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFSnsQ%253D%253D&md5=c89d9cf3dd79e98e478491a3e236b9c1</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M115.697516&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M115.697516%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DL.%2BL.%26aulast%3DShestov%26aufirst%3DA.%2BA.%26aulast%3DWorth%26aufirst%3DA.%2BJ.%26aulast%3DNath%26aufirst%3DK.%26aulast%3DNelson%26aufirst%3DD.%2BS.%26aulast%3DLeeper%26aufirst%3DD.%2BB.%26aulast%3DGlickson%26aufirst%3DJ.%2BD.%26aulast%3DBlair%26aufirst%3DI.%2BA.%26atitle%3DInhibition%2520of%2520mitochondrial%2520Complex%2520II%2520by%2520the%2520anticancer%2520agent%2520lonidamine%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2016%26volume%3D291%26spage%3D42%26epage%3D57%26doi%3D10.1074%2Fjbc.M115.697516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nath, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nancolas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shestov, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeper, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halestrap, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glickson, J. D.</span></span> <span> </span><span class="NLM_article-title">Mechanism of antineoplastic activity of lonidamine</span>. <i>Biochim. Biophys. Acta, Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1866</i></span>,  <span class="NLM_fpage">151</span>â <span class="NLM_lpage">162</span>, <span class="refDoi">Â DOI: 10.1016/j.bbcan.2016.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.bbcan.2016.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27497601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlSgs7vO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1866&publication_year=2016&pages=151-162&author=K.+Nathauthor=L.+L.+Guoauthor=B.+Nancolasauthor=D.+S.+Nelsonauthor=A.+A.+Shestovauthor=S.+C.+Leeauthor=J.+Romanauthor=R.+Zhouauthor=D.+B.+Leeperauthor=A.+P.+Halestrapauthor=I.+A.+Blairauthor=J.+D.+Glickson&title=Mechanism+of+antineoplastic+activity+of+lonidamine&doi=10.1016%2Fj.bbcan.2016.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of antineoplastic activity of lonidamine</span></div><div class="casAuthors">Nath, Kavindra; Guo, Lili; Nancolas, Bethany; Nelson, David S.; Shestov, Alexander A.; Lee, Seung-Cheol; Roman, Jeffrey; Zhou, Rong; Leeper, Dennis B.; Halestrap, Andrew P.; Blair, Ian A.; Glickson, Jerry D.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Reviews on Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">1866</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">151-162</span>CODEN:
                <span class="NLM_cas:coden">BBACEU</span>;
        ISSN:<span class="NLM_cas:issn">0304-419X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Lonidamine (LND) was initially introduced as an antispermatogenic agent.  It was later found to have anticancer activity sensitizing tumors to chemo-, radio-, and photodynamic-therapy and hyperthermia.  Although the mechanism of action remained unclear, LND treatment has been known to target metabolic pathways in cancer cells.  It has been reported to alter the bioenergetics of tumor cells by inhibiting glycolysis and mitochondrial respiration, while indirect evidence suggested that it also inhibited L-lactic acid efflux from cells mediated by members of the proton-linked monocarboxylate transporter (MCT) family and also pyruvate uptake into the mitochondria by the mitochondrial pyruvate carrier (MPC).  Recent studies have demonstrated that LND potently inhibits MPC activity in isolated rat liver mitochondria (Ki 2.5 Î¼M) and cooperatively inhibits L-lactate transport by MCT1, MCT2 and MCT4 expressed in Xenopus laevis oocytes with K0.5 and Hill coeff. values of 36-40 Î¼M and 1.65-1.85, resp.  In rat heart mitochondria LND inhibited the MPC with similar potency and uncoupled oxidn. of pyruvate was inhibited more effectively (IC50 â¼ 7 Î¼M) than other substrates including glutamate (IC50 â¼ 20 Î¼M).  LND inhibits the succinate-ubiquinone reductase activity of respiratory Complex II without fully blocking succinate dehydrogenase activity.  LND also induces cellular reactive oxygen species through Complex II and has been reported to promote cell death by suppression of the pentose phosphate pathway, which resulted in inhibition of NADPH and glutathione generation.  We conclude that MPC inhibition is the most sensitive anti-tumor target for LND, with addnl. inhibitory effects on MCT-mediated L-lactic acid efflux, Complex II and glutamine/glutamate oxidn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGOQV8MN2jHrVg90H21EOLACvtfcHk0lhfIPAl2P0dFg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlSgs7vO&md5=81e080cd7465cb789eb02cb6f72fe539</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1016%2Fj.bbcan.2016.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbcan.2016.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DNath%26aufirst%3DK.%26aulast%3DGuo%26aufirst%3DL.%2BL.%26aulast%3DNancolas%26aufirst%3DB.%26aulast%3DNelson%26aufirst%3DD.%2BS.%26aulast%3DShestov%26aufirst%3DA.%2BA.%26aulast%3DLee%26aufirst%3DS.%2BC.%26aulast%3DRoman%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DR.%26aulast%3DLeeper%26aufirst%3DD.%2BB.%26aulast%3DHalestrap%26aufirst%3DA.%2BP.%26aulast%3DBlair%26aufirst%3DI.%2BA.%26aulast%3DGlickson%26aufirst%3DJ.%2BD.%26atitle%3DMechanism%2520of%2520antineoplastic%2520activity%2520of%2520lonidamine%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Rev.%2520Cancer%26date%3D2016%26volume%3D1866%26spage%3D151%26epage%3D162%26doi%3D10.1016%2Fj.bbcan.2016.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouari, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zielonka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zielonka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kresty, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalyanaraman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, M.</span></span> <span> </span><span class="NLM_article-title">Targeting lonidamine to mitochondria mitigates lung tumorigenesis and brain metastasis</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2205</span>, <span class="refDoi">Â DOI: 10.1038/s41467-019-10042-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fs41467-019-10042-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=31101821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BB3M7ntVKhtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=2205&author=G.+Chengauthor=Q.+Zhangauthor=J.+Panauthor=Y.+Leeauthor=O.+Ouariauthor=M.+Hardyauthor=M.+Zielonkaauthor=C.+R.+Myersauthor=J.+Zielonkaauthor=K.+Wehauthor=A.+C.+Changauthor=G.+A.+Chenauthor=L.+Krestyauthor=B.+Kalyanaramanauthor=M.+You&title=Targeting+lonidamine+to+mitochondria+mitigates+lung+tumorigenesis+and+brain+metastasis&doi=10.1038%2Fs41467-019-10042-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting lonidamine to mitochondria mitigates lung tumorigenesis and brain metastasis</span></div><div class="casAuthors">Cheng Gang; Zielonka Jacek; Kalyanaraman Balaraman; Cheng Gang; Zielonka Monika; Zielonka Jacek; Kalyanaraman Balaraman; Cheng Gang; Zhang Qi; Pan Jing; Zielonka Monika; Myers Charles R; Zielonka Jacek; Kalyanaraman Balaraman; You Ming; Zhang Qi; Pan Jing; Lee Yongik; Myers Charles R; You Ming; Ouari Olivier; Hardy Micael; Weh Katherine; Chang Andrew C; Chen Guoan; Kresty Laura</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2205</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Lung cancer often has a poor prognosis, with brain metastases a major reason for mortality.  We modified lonidamine (LND), an antiglycolytic drug with limited efficacy, to mitochondria-targeted mito-lonidamine (Mito-LND) which is 100-fold more potent.  Mito-LND, a tumor-selective inhibitor of oxidative phosphorylation, inhibits mitochondrial bioenergetics in lung cancer cells and mitigates lung cancer cell viability, growth, progression, and metastasis of lung cancer xenografts in mice.  Mito-LND blocks lung tumor development and brain metastasis by inhibiting mitochondrial bioenergetics, stimulating the formation of reactive oxygen species, oxidizing mitochondrial peroxiredoxin, inactivating AKT/mTOR/p70S6K signaling, and inducing autophagic cell death in lung cancer cells.  Mito-LND causes no toxicity in mice even when administered for eight weeks at 50 times the effective cancer inhibitory dose.  Collectively, these findings show that mitochondrial targeting of LND is a promising therapeutic approach for investigating the role of autophagy in mitigating lung cancer development and brain metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSvT4TvZUZc_T69zv1FsJFMfW6udTcc2eZWJtWTQgWgubntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7ntVKhtQ%253D%253D&md5=02613d99917151b8580b61fc7cbbd50a</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1038%2Fs41467-019-10042-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-019-10042-1%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DPan%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DY.%26aulast%3DOuari%26aufirst%3DO.%26aulast%3DHardy%26aufirst%3DM.%26aulast%3DZielonka%26aufirst%3DM.%26aulast%3DMyers%26aufirst%3DC.%2BR.%26aulast%3DZielonka%26aufirst%3DJ.%26aulast%3DWeh%26aufirst%3DK.%26aulast%3DChang%26aufirst%3DA.%2BC.%26aulast%3DChen%26aufirst%3DG.%2BA.%26aulast%3DKresty%26aufirst%3DL.%26aulast%3DKalyanaraman%26aufirst%3DB.%26aulast%3DYou%26aufirst%3DM.%26atitle%3DTargeting%2520lonidamine%2520to%2520mitochondria%2520mitigates%2520lung%2520tumorigenesis%2520and%2520brain%2520metastasis%26jtitle%3DNat.%2520Commun.%26date%3D2019%26volume%3D10%26spage%3D2205%26doi%3D10.1038%2Fs41467-019-10042-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fry, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pudney, M.</span></span> <span> </span><span class="NLM_article-title">Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4â²-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">1545</span>â <span class="NLM_lpage">1553</span>, <span class="refDoi">Â DOI: 10.1016/0006-2952(92)90213-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2F0006-2952%2892%2990213-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1314606" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADyaK38XisVOqtrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=1992&pages=1545-1553&author=M.+Fryauthor=M.+Pudney&title=Site+of+action+of+the+antimalarial+hydroxynaphthoquinone%2C+2-%5Btrans-4-%284%E2%80%B2-chlorophenyl%29+cyclohexyl%5D-3-hydroxy-1%2C4-naphthoquinone&doi=10.1016%2F0006-2952%2892%2990213-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4'-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80)</span></div><div class="casAuthors">Fry, Mitchell; Pudney, Mary</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1545-53</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">The site of action of the antimalarial compd. 2-[trans-4-(4'-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80), would appear to be the mitochondrial respiratory chain.  Studies reported herein have demonstrated 566C80 to be a potent and selective mitochondrial inhibitor with mitochondria isolated from Plasmodium falciparum and P. yoelii.  Selective assay of individual respiratory chain complexes has shown the primary site of action of 566C80 to be the cytochrome bc1 complex (Complex III): supportive evidence from difference spectroscopy indicates the site of inhibition to lie between cytochromes b and c1 of this complex.  Using [14C]566C80, evidence is presented which suggests that 566C80 may become irreversibly bound to a polypeptide with an approx. mol. mass of 11,500 Da.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9fMI5cyRJT7Vg90H21EOLACvtfcHk0lhF0_Z5VwcW-w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XisVOqtrs%253D&md5=a45e691f8c26b9bd2caddab95c9e7c93</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2892%2990213-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252892%252990213-3%26sid%3Dliteratum%253Aachs%26aulast%3DFry%26aufirst%3DM.%26aulast%3DPudney%26aufirst%3DM.%26atitle%3DSite%2520of%2520action%2520of%2520the%2520antimalarial%2520hydroxynaphthoquinone%252C%25202-%255Btrans-4-%25284%25E2%2580%25B2-chlorophenyl%2529%2520cyclohexyl%255D-3-hydroxy-1%252C4-naphthoquinone%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1992%26volume%3D43%26spage%3D1545%26epage%3D1553%26doi%3D10.1016%2F0006-2952%2892%2990213-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mather, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darrouzet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valkova-Valchanova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooley, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntosh, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daldal, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidya, A. B.</span></span> <span> </span><span class="NLM_article-title">Uncovering the molecular mode of action of the antimalarial drug atovaquone using a bacterial system</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>280</i></span>,  <span class="NLM_fpage">27458</span>â <span class="NLM_lpage">27465</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M502319200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1074%2Fjbc.M502319200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=15917236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmt1Ggu7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=27458-27465&author=M.+W.+Matherauthor=E.+Darrouzetauthor=M.+Valkova-Valchanovaauthor=J.+W.+Cooleyauthor=M.+T.+McIntoshauthor=F.+Daldalauthor=A.+B.+Vaidya&title=Uncovering+the+molecular+mode+of+action+of+the+antimalarial+drug+atovaquone+using+a+bacterial+system&doi=10.1074%2Fjbc.M502319200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Uncovering the molecular mode of action of the antimalarial drug atovaquone using a bacterial system</span></div><div class="casAuthors">Mather, Michael W.; Darrouzet, Elisabeth; Valkova-Valchanova, Maria; Cooley, Jason W.; McIntosh, Michael T.; Daldal, Fevzi; Vaidya, Akhil B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">27458-27465</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Atovaquone is an antiparasitic drug that selectively inhibits electron transport through the parasite mitochondrial cytochrome bc1 complex and collapses the mitochondrial membrane potential at concns. far lower than those at which the mammalian system is affected.  Because this mol. represents a new class of antimicrobial agents, we seek a deeper understanding of its mode of action.  To that end, we employed site-directed mutagenesis of a bacterial cytochrome b, combined with biophys. and biochem. measurements.  A large scale domain movement involving the iron-sulfur protein subunit is required for electron transfer from cytochrome b-bound ubihydroquinone to cytochrome c1 of the cytochrome bc1 complex.  Here, we show that atovaquone blocks this domain movement by locking the iron-sulfur subunit in its cytochrome b-binding conformation.  Based on our malaria atovaquone resistance data, a series of cytochrome b mutants was produced that were predicted to have either enhanced or reduced sensitivity to atovaquone.  Mutations altering the bacterial cytochrome b at its ef loop to more closely resemble Plasmodium cytochrome b increased the sensitivity of the cytochrome bc1 complex to atovaquone.  A mutation within the ef loop that is assocd. with resistant malaria parasites rendered the complex resistant to atovaquone, thereby providing direct proof that the mutation causes atovaquone resistance.  This mutation resulted in a 10-fold redn. in the in vitro activity of the cytochrome bc1 complex, suggesting that it may exert a cost on efficiency of the cytochrome bc1 complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-Drz1XSE2hbVg90H21EOLACvtfcHk0lhF0_Z5VwcW-w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmt1Ggu7k%253D&md5=dfb350a3f23e0f48f92aa6723890db2b</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M502319200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M502319200%26sid%3Dliteratum%253Aachs%26aulast%3DMather%26aufirst%3DM.%2BW.%26aulast%3DDarrouzet%26aufirst%3DE.%26aulast%3DValkova-Valchanova%26aufirst%3DM.%26aulast%3DCooley%26aufirst%3DJ.%2BW.%26aulast%3DMcIntosh%26aufirst%3DM.%2BT.%26aulast%3DDaldal%26aufirst%3DF.%26aulast%3DVaidya%26aufirst%3DA.%2BB.%26atitle%3DUncovering%2520the%2520molecular%2520mode%2520of%2520action%2520of%2520the%2520antimalarial%2520drug%2520atovaquone%2520using%2520a%2520bacterial%2520system%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D27458%26epage%3D27465%26doi%3D10.1074%2Fjbc.M502319200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fokas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunz-Schughart, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folkes, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anbalagan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huether, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirovano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buffa, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stratford, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muschel, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenna, W. G.</span></span> <span> </span><span class="NLM_article-title">The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">12308</span>, <span class="refDoi">Â DOI: 10.1038/ncomms12308</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fncomms12308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27453292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1yru7%252FK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=12308&author=T.+M.+Ashtonauthor=E.+Fokasauthor=L.+A.+Kunz-Schughartauthor=L.+K.+Folkesauthor=S.+Anbalaganauthor=M.+Huetherauthor=C.+J.+Kellyauthor=G.+Pirovanoauthor=F.+M.+Buffaauthor=E.+M.+Hammondauthor=M.+Stratfordauthor=R.+J.+Muschelauthor=G.+S.+Higginsauthor=W.+G.+McKenna&title=The+anti-malarial+atovaquone+increases+radiosensitivity+by+alleviating+tumour+hypoxia&doi=10.1038%2Fncomms12308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia</span></div><div class="casAuthors">Ashton, Thomas M.; Fokas, Emmanouil; Kunz-Schughart, Leoni A.; Folkes, Lisa K.; Anbalagan, Selvakumar; Huether, Melanie; Kelly, Catherine J.; Pirovano, Giacomo; Buffa, Francesca M.; Hammond, Ester M.; Stratford, Michael; Muschel, Ruth J.; Higgins, Geoff S.; McKenna, William Gillies</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">12308</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Tumor hypoxia renders cancer cells resistant to cancer therapy, resulting in markedly worse clin. outcomes.  To find clin. candidate compds. that reduce hypoxia in tumors, we conduct a high-throughput screen for oxygen consumption rate (OCR) redn. and identify a no. of drugs with this property.  For this study we focus on the anti-malarial, atovaquone.  Atovaquone rapidly decreases the OCR by more than 80% in a wide range of cancer cell lines at pharmacol. concns.  In addn., atovaquone eradicates hypoxia in FaDu, HCT116 and H1299 spheroids.  Similarly, it reduces hypoxia in FaDu and HCT116 xenografts in nude mice, and causes a significant tumor growth delay when combined with radiation.  Atovaquone is a ubiquinone analog, and decreases the OCR by inhibiting mitochondrial complex III.  We are now undertaking clin. studies to assess whether atovaquone reduces tumor hypoxia in patients, thereby increasing the efficacy of radiotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGou4wtBQpnHGrVg90H21EOLACvtfcHk0lhF0_Z5VwcW-w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1yru7%252FK&md5=f7f5692ab92188af45a43cfd3dc5dacb</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1038%2Fncomms12308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms12308%26sid%3Dliteratum%253Aachs%26aulast%3DAshton%26aufirst%3DT.%2BM.%26aulast%3DFokas%26aufirst%3DE.%26aulast%3DKunz-Schughart%26aufirst%3DL.%2BA.%26aulast%3DFolkes%26aufirst%3DL.%2BK.%26aulast%3DAnbalagan%26aufirst%3DS.%26aulast%3DHuether%26aufirst%3DM.%26aulast%3DKelly%26aufirst%3DC.%2BJ.%26aulast%3DPirovano%26aufirst%3DG.%26aulast%3DBuffa%26aufirst%3DF.%2BM.%26aulast%3DHammond%26aufirst%3DE.%2BM.%26aulast%3DStratford%26aufirst%3DM.%26aulast%3DMuschel%26aufirst%3DR.%2BJ.%26aulast%3DHiggins%26aufirst%3DG.%2BS.%26aulast%3DMcKenna%26aufirst%3DW.%2BG.%26atitle%3DThe%2520anti-malarial%2520atovaquone%2520increases%2520radiosensitivity%2520by%2520alleviating%2520tumour%2520hypoxia%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D12308%26doi%3D10.1038%2Fncomms12308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fiorillo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanowitz, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mutti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krstic-Demonacos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappello, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Outschoorn, U. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotgia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lisanti, M. P.</span></span> <span> </span><span class="NLM_article-title">Repurposing atovaquone: Targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">34084</span>â <span class="NLM_lpage">34099</span>, <span class="refDoi">Â DOI: 10.18632/oncotarget.9122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.18632%2Foncotarget.9122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27136895" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BC28blsVehsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=34084-34099&author=M.+Fiorilloauthor=R.+Lambauthor=H.+B.+Tanowitzauthor=L.+Muttiauthor=M.+Krstic-Demonacosauthor=A.+R.+Cappelloauthor=U.+E.+Martinez-Outschoornauthor=F.+Sotgiaauthor=M.+P.+Lisanti&title=Repurposing+atovaquone%3A+Targeting+mitochondrial+complex+III+and+OXPHOS+to+eradicate+cancer+stem+cells&doi=10.18632%2Foncotarget.9122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposing atovaquone: targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells</span></div><div class="casAuthors">Fiorillo Marco; Lamb Rebecca; Sotgia Federica; Lisanti Michael P; Fiorillo Marco; Sotgia Federica; Lisanti Michael P; Fiorillo Marco; Cappello Anna Rita; Tanowitz Herbert B; Mutti Luciano; Krstic-Demonacos Marija; Martinez-Outschoorn Ubaldo E</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">34084-99</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Atovaquone is an FDA-approved anti-malarial drug, which first became clinically available in the year 2000.  Currently, its main usage is for the treatment of pneumocystis pneumonia (PCP) and/or toxoplasmosis in immune-compromised patients.  Atovaquone is a hydroxy-1,4-naphthoquinone analogue of ubiquinone, also known as Co-enzyme Q10 (CoQ10).  It is a well-tolerated drug that does not cause myelo-suppression.  Mechanistically, it is thought to act as a potent and selective OXPHOS inhibitor, by targeting the CoQ10-dependence of mitochondrial complex III.  Here, we show for the first time that atovaquone also has anti-cancer activity, directed against Cancer Stem-like Cells (CSCs).  More specifically, we demonstrate that atovaquone treatment of MCF7 breast cancer cells inhibits oxygen-consumption and metabolically induces aerobic glycolysis (the Warburg effect), as well as oxidative stress.  Remarkably, atovaquone potently inhibits the propagation of MCF7-derived CSCs, with an IC-50 of 1 Î¼M, as measured using the mammosphere assay.  Atovaquone also maintains this selectivity and potency in mixed populations of CSCs and non-CSCs.  Importantly, these results indicate that glycolysis itself is not sufficient to maintain the proliferation of CSCs, which is instead strictly dependent on mitochondrial function.  In addition to targeting the proliferation of CSCs, atovaquone also induces apoptosis in both CD44+/CD24low/- CSC and ALDH+ CSC populations, during exposure to anchorage-independent conditions for 12 hours.  However, it has no effect on oxygen consumption in normal human fibroblasts and, in this cellular context, behaves as an anti-inflammatory, consistent with the fact that it is well-tolerated in patients treated for infections.  Future studies in xenograft models and human clinical trials may be warranted, as the IC-50 of atovaquone's action on CSCs (1 Î¼M) is >50 times less than its average serum concentration in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTWq76aYVUugWHOrQ6qeX-mfW6udTcc2eYD4-xxPpbdK7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28blsVehsQ%253D%253D&md5=5173cb92af46bc980a3b468a3d6eeae5</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.9122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.9122%26sid%3Dliteratum%253Aachs%26aulast%3DFiorillo%26aufirst%3DM.%26aulast%3DLamb%26aufirst%3DR.%26aulast%3DTanowitz%26aufirst%3DH.%2BB.%26aulast%3DMutti%26aufirst%3DL.%26aulast%3DKrstic-Demonacos%26aufirst%3DM.%26aulast%3DCappello%26aufirst%3DA.%2BR.%26aulast%3DMartinez-Outschoorn%26aufirst%3DU.%2BE.%26aulast%3DSotgia%26aufirst%3DF.%26aulast%3DLisanti%26aufirst%3DM.%2BP.%26atitle%3DRepurposing%2520atovaquone%253A%2520Targeting%2520mitochondrial%2520complex%2520III%2520and%2520OXPHOS%2520to%2520eradicate%2520cancer%2520stem%2520cells%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D34084%26epage%3D34099%26doi%3D10.18632%2Foncotarget.9122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, V. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bar-Natan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anahtar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toniolo, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroll, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giaccone, Z. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heppler, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, D. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marineau, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blonquist, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hetz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soiffer, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, D. A.</span></span> <span> </span><span class="NLM_article-title">Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">1845</span>â <span class="NLM_lpage">1853</span>, <span class="refDoi">Â DOI: 10.1182/blood-2015-07-660506</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1182%2Fblood-2015-07-660506" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27531676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlSiurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2016&pages=1845-1853&author=M.+Xiangauthor=H.+Kimauthor=V.+T.+Hoauthor=S.+R.+Walkerauthor=M.+Bar-Natanauthor=M.+Anahtarauthor=S.+H.+Liuauthor=P.+A.+Tonioloauthor=Y.+Krollauthor=N.+Jonesauthor=Z.+T.+Giacconeauthor=L.+N.+Hepplerauthor=D.+Q.+Yeauthor=J.+J.+Marineauauthor=D.+Shawauthor=J.+E.+Bradnerauthor=T.+Blonquistauthor=D.+Neubergauthor=C.+Hetzauthor=R.+M.+Stoneauthor=R.+J.+Soifferauthor=D.+A.+Frank&title=Gene+expression-based+discovery+of+atovaquone+as+a+STAT3+inhibitor+and+anticancer+agent&doi=10.1182%2Fblood-2015-07-660506"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent</span></div><div class="casAuthors">Xiang, Michael; Kim, Haesook; Ho, Vincent T.; Walker, Sarah R.; Bar-Natan, Michal; Anahtar, Melodi; Liu, Suhu; Toniolo, Patricia A.; Kroll, Yasmin; Jones, Nichole; Giaccone, Zachary T.; Heppler, Lisa N.; Ye, Darwin Q.; Marineau, Jason J.; Shaw, Daniel; Bradner, James E.; Blonquist, Traci; Neuberg, Donna; Hetz, Claudio; Stone, Richard M.; Soiffer, Robert J.; Frank, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1845-1853</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The oncogenic transcription factor signal transducer and activator of transcription 3 (STAT3) is frequently activated inappropriately in a wide range of hematol. and solid cancers, but clin. available therapies targeting STAT3 are lacking.  Using a computational strategy to identify compds. opposing the gene expression signature of STAT3, we discovered atovaquone (Mepron), an antimicrobial approved by the US Food and Drug Administration, to be a potent STAT3 inhibitor.  We show that, at drug concns. routinely achieved clin. in human plasma, atovaquone inhibits STAT3 phosphorylation, the expression of STAT3 target genes, and the viability of STAT3-dependent hematol. cancer cells.  These effects were also obsd. with atovaquone treatment of primary blasts isolated from patients with acute myelogenous leukemia or acute lymphocytic leukemia.  Atovaquone is not a kinase inhibitor but instead rapidly and specifically downregulates cell-surface expression of glycoprotein 130, which is required for STAT3 activation in multiple contexts.  The administration of oral atovaquone to mice inhibited tumor growth and prolonged survival in a murine model of multiple myeloma.  Finally, in patients with acute myelogenous leukemia treated with hematopoietic stem cell transplantation, extended use of atovaquone for Pneumocystis prophylaxis was assocd. with improved relapse-free survival.  These findings establish atovaquone as a novel, clin. accessible STAT3 inhibitor with evidence of anticancer efficacy in both animal models and humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7kci57tYtb7Vg90H21EOLACvtfcHk0liY2q6CsxQbUg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlSiurg%253D&md5=201e3d6ea0e204d1a631652caae8f987</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1182%2Fblood-2015-07-660506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2015-07-660506%26sid%3Dliteratum%253Aachs%26aulast%3DXiang%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DHo%26aufirst%3DV.%2BT.%26aulast%3DWalker%26aufirst%3DS.%2BR.%26aulast%3DBar-Natan%26aufirst%3DM.%26aulast%3DAnahtar%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DS.%2BH.%26aulast%3DToniolo%26aufirst%3DP.%2BA.%26aulast%3DKroll%26aufirst%3DY.%26aulast%3DJones%26aufirst%3DN.%26aulast%3DGiaccone%26aufirst%3DZ.%2BT.%26aulast%3DHeppler%26aufirst%3DL.%2BN.%26aulast%3DYe%26aufirst%3DD.%2BQ.%26aulast%3DMarineau%26aufirst%3DJ.%2BJ.%26aulast%3DShaw%26aufirst%3DD.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DBlonquist%26aufirst%3DT.%26aulast%3DNeuberg%26aufirst%3DD.%26aulast%3DHetz%26aufirst%3DC.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DSoiffer%26aufirst%3DR.%2BJ.%26aulast%3DFrank%26aufirst%3DD.%2BA.%26atitle%3DGene%2520expression-based%2520discovery%2520of%2520atovaquone%2520as%2520a%2520STAT3%2520inhibitor%2520and%2520anticancer%2520agent%26jtitle%3DBlood%26date%3D2016%26volume%3D128%26spage%3D1845%26epage%3D1853%26doi%3D10.1182%2Fblood-2015-07-660506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gangjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaware, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raghavan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihnat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shenoy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kisliuk, R. L.</span></span> <span> </span><span class="NLM_article-title">Single agents with designed combination chemotherapy potential: synthesis and evaluation of substituted pyrimido[4,5-b]indoles as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">1563</span>â <span class="NLM_lpage">1578</span>, <span class="refDoi">Â DOI: 10.1021/jm9011142</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9011142" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptlKntA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=1563-1578&author=A.+Gangjeeauthor=N.+Zawareauthor=S.+Raghavanauthor=M.+Ihnatauthor=S.+Shenoyauthor=R.+L.+Kisliuk&title=Single+agents+with+designed+combination+chemotherapy+potential%3A+synthesis+and+evaluation+of+substituted+pyrimido%5B4%2C5-b%5Dindoles+as+receptor+tyrosine+kinase+and+thymidylate+synthase+inhibitors+and+as+antitumor+agents&doi=10.1021%2Fjm9011142"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Single agents with designed combination chemotherapy potential: synthesis and evaluation of substituted pyrimido[4,5-b]indoles as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents</span></div><div class="casAuthors">Gangjee, Aleem; Zaware, Nilesh; Raghavan, Sudhir; Ihnat, Michael; Shenoy, Satyendra; Kisliuk, Roy L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1563-1578</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Combinations of antiangiogenic agents (AAs) with cytotoxic agents have shown significant promise in cancer treatment, and several such clin. trials are currently underway.  We have designed, synthesized, and evaluated two compds. I (R = H, Me) that each inhibit vascular endothelial growth factor receptor-2 (VEGFR-2) and platelet-derived growth factor receptor-Î² (PDGFR-Î²) for antiangiogenic effects and also inhibit human thymidylate synthase (hTS) for cytotoxic effects in single agents.  The synthesis of these compds. involved the nucleophilic displacement of the common intermediate 5-chloro-9H-pyrimido[4,5-b]indole-2,4-diamine with appropriate benzenethiols.  The inhibitory potency of both these single agents against VEGFR-2, PDGFR-Î², and hTS is better than or close to stds.  In a COLO-205 xenograft mouse model, one of the analogs significantly decreased tumor growth (tumor growth inhibition (TGI) = 76% at 35 mg/kg), liver metastases, and tumor blood vessels compared with a std. drug and with control and thus demonstrated potent tumor growth inhibition, inhibition of metastasis, and antiangiogenic effects in vivo.  These compds. afford combination chemotherapeutic potential in single agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOJB7QlDdAybVg90H21EOLACvtfcHk0lg3bhZHfFRWMw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptlKntA%253D%253D&md5=f4dcd7a6aa14c39435a1b515b0653f62</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1021%2Fjm9011142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9011142%26sid%3Dliteratum%253Aachs%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DZaware%26aufirst%3DN.%26aulast%3DRaghavan%26aufirst%3DS.%26aulast%3DIhnat%26aufirst%3DM.%26aulast%3DShenoy%26aufirst%3DS.%26aulast%3DKisliuk%26aufirst%3DR.%2BL.%26atitle%3DSingle%2520agents%2520with%2520designed%2520combination%2520chemotherapy%2520potential%253A%2520synthesis%2520and%2520evaluation%2520of%2520substituted%2520pyrimido%255B4%252C5-b%255Dindoles%2520as%2520receptor%2520tyrosine%2520kinase%2520and%2520thymidylate%2520synthase%2520inhibitors%2520and%2520as%2520antitumor%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D1563%26epage%3D1578%26doi%3D10.1021%2Fjm9011142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bastian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorpe, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Disch, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey-Downs, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devambatla, R. K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henthorn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphries, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vadvalkar, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihnat, M. A.</span></span> <span> </span><span class="NLM_article-title">A small molecule with anticancer and antimetastatic activities induces rapid mitochondrial-associated necrosis in breast cancer</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>353</i></span>,  <span class="NLM_fpage">392</span>â <span class="NLM_lpage">404</span>, <span class="refDoi">Â DOI: 10.1124/jpet.114.220335</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1124%2Fjpet.114.220335" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=25720766" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFaitr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2015&pages=392-404&author=A.+Bastianauthor=J.+E.+Thorpeauthor=B.+C.+Dischauthor=L.+C.+Bailey-Downsauthor=A.+Gangjeeauthor=R.+K.+V.+Devambatlaauthor=J.+Henthornauthor=K.+M.+Humphriesauthor=S.+S.+Vadvalkarauthor=M.+A.+Ihnat&title=A+small+molecule+with+anticancer+and+antimetastatic+activities+induces+rapid+mitochondrial-associated+necrosis+in+breast+cancer&doi=10.1124%2Fjpet.114.220335"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule with anticancer and antimetastatic activities induces rapid mitochondrial-associated necrosis in breast cancer</span></div><div class="casAuthors">Bastian, Anja; Thorpe, Jessica E.; Disch, Bryan C.; Bailey-Downs, Lora C.; Gangjee, Aleem; Devambatla, Ravi K. V.; Henthorn, Jim; Humphries, Kenneth M.; Vadvalkar, Shraddha S.; Ihnat, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">392-404</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Therapy for treatment-resistant breast cancer provides limited options and the response rates are low.  Therefore, the development of therapies with alternative chemotherapeutic strategies is necessary.  AG311 (5-[(4-methylphenyl)thio]-9H-pyrimido[4,5-b]indole-2,4-diamine), a small mol., is being investigated in preclin. and mechanistic studies for treatment of resistant breast cancer through necrosis, an alternative cell death mechanism.  In vitro, AG311 induces rapid necrosis in numerous cancer cell lines as evidenced by loss of membrane integrity, ATP depletion, HMGB1 (high-mobility group protein B1) translocation, nuclear swelling, and stable membrane blebbing in breast cancer cells.  Within minutes, exposure to AG311 also results in mitochondrial depolarization, superoxide prodn., and increased intracellular calcium levels.  Addnl., upregulation of mitochondrial oxidative phosphorylation results in sensitization to AG311.  This AG311-induced cell death can be partially prevented by treatment with the mitochondrial calcium uniporter inhibitor, Ru360 [(Î¼)[(HCO2)(NH3)4Ru]2OCl3], or an antioxidant, lipoic acid.  Addnl., AG311 does not increase apoptotic markers such as cleavage of poly (ADP-ribose) polymerase (PARP) or caspase-3 and -7 activity.  Importantly, in vivo studies in two orthotopic breast cancer mouse models (xenograft and allograft) demonstrate that AG311 retards tumor growth and reduces lung metastases better than clin. used agents and has no gross or histopathol. toxicity.  Together, these data suggest that AG311 is a first-in-class antitumor and antimetastatic agent inducing necrosis in breast cancer tumors, likely through the mitochondria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbjGbAk1F8t7Vg90H21EOLACvtfcHk0lg3bhZHfFRWMw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFaitr0%253D&md5=241fb2abf00cb24c87c615ce6f713f02</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.220335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.220335%26sid%3Dliteratum%253Aachs%26aulast%3DBastian%26aufirst%3DA.%26aulast%3DThorpe%26aufirst%3DJ.%2BE.%26aulast%3DDisch%26aufirst%3DB.%2BC.%26aulast%3DBailey-Downs%26aufirst%3DL.%2BC.%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DDevambatla%26aufirst%3DR.%2BK.%2BV.%26aulast%3DHenthorn%26aufirst%3DJ.%26aulast%3DHumphries%26aufirst%3DK.%2BM.%26aulast%3DVadvalkar%26aufirst%3DS.%2BS.%26aulast%3DIhnat%26aufirst%3DM.%2BA.%26atitle%3DA%2520small%2520molecule%2520with%2520anticancer%2520and%2520antimetastatic%2520activities%2520induces%2520rapid%2520mitochondrial-associated%2520necrosis%2520in%2520breast%2520cancer%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D353%26spage%3D392%26epage%3D404%26doi%3D10.1124%2Fjpet.114.220335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bastian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuzaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphries, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pharaoh, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doshi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaware, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihnat, M. A.</span></span> <span> </span><span class="NLM_article-title">AG311, a small molecule inhibitor of complex I and hypoxia-induced HIF-1 alpha stabilization</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>388</i></span>,  <span class="NLM_fpage">149</span>â <span class="NLM_lpage">157</span>, <span class="refDoi">Â DOI: 10.1016/j.canlet.2016.11.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.canlet.2016.11.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27939695" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVOjsbbI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=388&publication_year=2017&pages=149-157&author=A.+Bastianauthor=S.+Matsuzakiauthor=K.+M.+Humphriesauthor=G.+A.+Pharaohauthor=A.+Doshiauthor=N.+Zawareauthor=A.+Gangjeeauthor=M.+A.+Ihnat&title=AG311%2C+a+small+molecule+inhibitor+of+complex+I+and+hypoxia-induced+HIF-1+alpha+stabilization&doi=10.1016%2Fj.canlet.2016.11.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">AG311, a small molecule inhibitor of complex I and hypoxia-induced HIF-1Î± stabilization</span></div><div class="casAuthors">Bastian, Anja; Matsuzaki, Satoshi; Humphries, Kenneth M.; Pharaoh, Gavin A.; Doshi, Arpit; Zaware, Nilesh; Gangjee, Aleem; Ihnat, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">388</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">149-157</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Cancer cells have a unique metabolic profile and mitochondria have been shown to play an important role in chemoresistance, tumor progression and metastases.  This unique profile can be exploited by mitochondrial-targeted anticancer therapies.  A small anticancer mol., AG311, was previously shown to possess anticancer and antimetastatic activity in two cancer mouse models and to induce mitochondrial depolarization.  This study defines the mol. effects of AG311 on the mitochondria to elucidate its obsd. efficacy.  AG311 was found to competitively inhibit complex I activity at the ubiquinone-binding site.  Complex I as a target for AG311 was further established by measuring oxygen consumption rate in tumor tissue isolated from AG311-treated mice.  Cotreatment of cells and animals with AG311 and dichloroacetate, a pyruvate dehydrogenase kinase inhibitor that increases oxidative metab., resulted in synergistic cell kill and reduced tumor growth.  The inhibition of mitochondrial oxygen consumption by AG311 was found to reduce HIF-1Î± stabilization by increasing oxygen tension in hypoxic conditions.  Taken together, these results suggest that AG311 at least partially mediates its antitumor effect through inhibition of complex I, which could be exploited in its use as an anticancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofuguVO4Xs97Vg90H21EOLACvtfcHk0lg3bhZHfFRWMw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVOjsbbI&md5=d5ae6ecc0136aaae16dd809b8e4ff0f7</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2016.11.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2016.11.040%26sid%3Dliteratum%253Aachs%26aulast%3DBastian%26aufirst%3DA.%26aulast%3DMatsuzaki%26aufirst%3DS.%26aulast%3DHumphries%26aufirst%3DK.%2BM.%26aulast%3DPharaoh%26aufirst%3DG.%2BA.%26aulast%3DDoshi%26aufirst%3DA.%26aulast%3DZaware%26aufirst%3DN.%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DIhnat%26aufirst%3DM.%2BA.%26atitle%3DAG311%252C%2520a%2520small%2520molecule%2520inhibitor%2520of%2520complex%2520I%2520and%2520hypoxia-induced%2520HIF-1%2520alpha%2520stabilization%26jtitle%3DCancer%2520Lett.%26date%3D2017%26volume%3D388%26spage%3D149%26epage%3D157%26doi%3D10.1016%2Fj.canlet.2016.11.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zielonka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouari, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAllister, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrios, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwinell, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalyanaraman, B.</span></span> <span> </span><span class="NLM_article-title">Mitochondria-targeted analogues of metformin exhibit enhanced antiproliferative and radiosensitizing effects in pancreatic cancer cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">3904</span>â <span class="NLM_lpage">3915</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-15-2534</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F0008-5472.CAN-15-2534" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27216187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVyit7bJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=3904-3915&author=G.+Chengauthor=J.+Zielonkaauthor=O.+Ouariauthor=M.+Lopezauthor=D.+McAllisterauthor=K.+Boyleauthor=C.+S.+Barriosauthor=J.+J.+Weberauthor=B.+D.+Johnsonauthor=M.+Hardyauthor=M.+B.+Dwinellauthor=B.+Kalyanaraman&title=Mitochondria-targeted+analogues+of+metformin+exhibit+enhanced+antiproliferative+and+radiosensitizing+effects+in+pancreatic+cancer+cells&doi=10.1158%2F0008-5472.CAN-15-2534"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondria-Targeted Analogues of Metformin Exhibit Enhanced Antiproliferative and Radiosensitizing Effects in Pancreatic Cancer Cells</span></div><div class="casAuthors">Cheng, Gang; Zielonka, Jacek; Ouari, Olivier; Lopez, Marcos; McAllister, Donna; Boyle, Kathleen; Barrios, Christy S.; Weber, James J.; Johnson, Bryon D.; Hardy, Micael; Dwinell, Michael B.; Kalyanaraman, Balaraman</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3904-3915</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Metformin (Met) is an approved antidiabetic drug currently being explored for repurposing in cancer treatment based on recent evidence of its apparent chemopreventive properties.  Met is weakly cationic and targets the mitochondria to induce cytotoxic effects in tumor cells, albeit not very effectively.  We hypothesized that increasing its mitochondria-targeting potential by attaching a pos. charged lipophilic substituent would enhance the antitumor activity of Met.  In pursuit of this question, we synthesized a set of mitochondria-targeted Met analogs (Mito-Mets) with varying alkyl chain lengths contg. a triphenylphosphonium cation (TPP+).  In particular, the analog Mito-Met10, synthesized by attaching TPP+ to Met via a 10-carbon aliph. side chain, was nearly 1,000 times more efficacious than Met at inhibiting cell proliferation in pancreatic ductal adenocarcinoma (PDAC).  Notably, in PDAC cells, Mito-Met10 potently inhibited mitochondrial complex I, stimulating superoxide and AMPK activation, but had no effect in nontransformed control cells.  Moreover, Mito-Met10 potently triggered G1 cell-cycle phase arrest in PDAC cells, enhanced their radiosensitivity, and more potently abrogated PDAC growth in preclin. mouse models, compared with Met.  Collectively, our findings show how improving the mitochondrial targeting of Met enhances its anticancer activities, including aggressive cancers like PDAC in great need of more effective therapeutic options.  Cancer Res; 76(13); 3904-15. Â©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwe6dyucpsaLVg90H21EOLACvtfcHk0ljkiOStV8aXZw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVyit7bJ&md5=6e2d142c64d7ff181a80e3a1b01952b5</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-15-2534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-15-2534%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DG.%26aulast%3DZielonka%26aufirst%3DJ.%26aulast%3DOuari%26aufirst%3DO.%26aulast%3DLopez%26aufirst%3DM.%26aulast%3DMcAllister%26aufirst%3DD.%26aulast%3DBoyle%26aufirst%3DK.%26aulast%3DBarrios%26aufirst%3DC.%2BS.%26aulast%3DWeber%26aufirst%3DJ.%2BJ.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DHardy%26aufirst%3DM.%26aulast%3DDwinell%26aufirst%3DM.%2BB.%26aulast%3DKalyanaraman%26aufirst%3DB.%26atitle%3DMitochondria-targeted%2520analogues%2520of%2520metformin%2520exhibit%2520enhanced%2520antiproliferative%2520and%2520radiosensitizing%2520effects%2520in%2520pancreatic%2520cancer%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26spage%3D3904%26epage%3D3915%26doi%3D10.1158%2F0008-5472.CAN-15-2534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ju, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D. C.</span></span> <span> </span><span class="NLM_article-title">Carboxyamidotriazole inhibits oxidative phosphorylation in cancer cells and exerts synergistic anti-cancer effect with glycolysis inhibition</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>370</i></span>,  <span class="NLM_fpage">232</span>â <span class="NLM_lpage">241</span>, <span class="refDoi">Â DOI: 10.1016/j.canlet.2015.10.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.canlet.2015.10.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=26522259" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslGmtLvI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2016&pages=232-241&author=R.+Juauthor=L.+Guoauthor=J.+Liauthor=L.+Zhuauthor=X.+L.+Yuauthor=C.+Chenauthor=W.+Chenauthor=C.+Y.+Yeauthor=D.+C.+Zhang&title=Carboxyamidotriazole+inhibits+oxidative+phosphorylation+in+cancer+cells+and+exerts+synergistic+anti-cancer+effect+with+glycolysis+inhibition&doi=10.1016%2Fj.canlet.2015.10.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Carboxyamidotriazole inhibits oxidative phosphorylation in cancer cells and exerts synergistic anti-cancer effect with glycolysis inhibition</span></div><div class="casAuthors">Ju, Rui; Guo, Lei; Li, Juan; Zhu, Lei; Yu, Xiaoli; Chen, Chen; Chen, Wei; Ye, Caiying; Zhang, Dechang</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">232-241</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Targeting cancer cell metab. is a promising strategy against cancer.  Here, we confirmed that the anti-cancer drug carboxyamidotriazole (CAI) inhibited mitochondrial respiration in cancer cells for the first time and found a way to enhance its anti-cancer activity by further disturbing the energy metab.  CAI promoted glucose uptake and lactate prodn. when incubated with cancer cells.  The oxidative phosphorylation (OXPHOS) in cancer cells was inhibited by CAI, and the decrease in the activity of the respiratory chain complex I could be one explanation.  The anti-cancer effect of CAI was greatly potentiated when being combined with 2-deoxyglucose (2-DG).  The cancer cells treated with the combination of CAI and 2-DG were arrested in G2/M phase.  The apoptosis and necrosis rates were also increased.  In a mouse xenograft model, this combination was well tolerated and retarded the tumor growth.  The impairment of cancer cell survival was assocd. with significant cellular ATP decrease, suggesting that the combination of CAI and 2-DG could be one of the strategies to cause dual inhibition of energy pathways, which might be an effective therapeutic approach for a broad spectrum of tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKjl4hPSdLtrVg90H21EOLACvtfcHk0ljkiOStV8aXZw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslGmtLvI&md5=f8eb03de9ba482c039a82e25b662494f</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2015.10.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2015.10.025%26sid%3Dliteratum%253Aachs%26aulast%3DJu%26aufirst%3DR.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DX.%2BL.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DYe%26aufirst%3DC.%2BY.%26aulast%3DZhang%26aufirst%3DD.%2BC.%26atitle%3DCarboxyamidotriazole%2520inhibits%2520oxidative%2520phosphorylation%2520in%2520cancer%2520cells%2520and%2520exerts%2520synergistic%2520anti-cancer%2520effect%2520with%2520glycolysis%2520inhibition%26jtitle%3DCancer%2520Lett.%26date%3D2016%26volume%3D370%26spage%3D232%26epage%3D241%26doi%3D10.1016%2Fj.canlet.2015.10.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ju, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, C. Y.</span></span> <span> </span><span class="NLM_article-title">Metabolic mechanisms and a rational combinational application of carboxyamidotriazole in fighting pancreatic cancer progression after chemotherapy</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>367</i></span>,  <span class="NLM_fpage">20</span>â <span class="NLM_lpage">27</span>, <span class="refDoi">Â DOI: 10.1124/jpet.118.249326</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1124%2Fjpet.118.249326" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=30002095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVegtrzM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2018&pages=20-27&author=R.+Juauthor=K.+L.+Feiauthor=S.+Liauthor=C.+Chenauthor=L.+Zhuauthor=J.+Liauthor=D.+C.+Zhangauthor=L.+Guoauthor=C.+Y.+Ye&title=Metabolic+mechanisms+and+a+rational+combinational+application+of+carboxyamidotriazole+in+fighting+pancreatic+cancer+progression+after+chemotherapy&doi=10.1124%2Fjpet.118.249326"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic mechanisms and a rational combinational application of carboxyamidotriazole in fighting pancreatic cancer progression after chemotherapy</span></div><div class="casAuthors">Ju, Rui; Fei, Kailun; Li, Siang; Chen, Chen; Zhu, Lei; Li, Juan; Zhang, Dechang; Guo, Lei; Ye, Caiying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20-27</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The anticancer and anti-inflammatory effects of carboxyamidotriazole (CAI) have been demonstrated in several studies, but the underlying mechanisms remain to be elucidated.  This study showed that CAI caused metabolic reprogramming of pancreatic cancer cells.  The inhibition of mitochondrial oxidative metab. by CAI led to increased glutamine-dependent reductive carboxylation and enhanced glycolytic metab.  The presence of environmental substances that affect cellular metab., such as glutamine and pyruvate, attenuated the anticancer efficacy of CAI.  Based on the action of CAI: 1) when glutamine was removed, the NAD1/NADH ratio was decreased, the synthesis of cellular aspartate was reduced, and autophagy flux was blocked; and 2) when glycolysis was pharmacol. inhibited, the ATP level was significantly decreased, the cell viability was greatly inhibited, and the compensatory rescue effect of glutamine was eliminated.  When combined with chemotherapy, cotreatment with CAI and the glycolysis inhibitor 2-deoxyglucose (2-DG) inhibited the pancreatic cancer progression after chemotherapy.  As the inhibition of mitochondrial oxidative metab. can explain several anticancer activities of CAI reported previously, including inhibition of calcium entry and induction of reactive oxygen species, we demonstrate that inhibition of mitochondrial oxidative phosphorylation may be the fundamental mechanism of CAI.  The combination of CAI and 2-DG causes energy depletion in cancer cells, eliminating the rescue effect of the metabolic environment.  Inhibiting pancreatic cancer progression after chemotherapy is a rational application of this metab.-disturbing combination strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEVRSj5zAXsrVg90H21EOLACvtfcHk0lgT1w5vDi0UUA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVegtrzM&md5=d74135697df24a203e96f64f2b6c947d</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1124%2Fjpet.118.249326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.118.249326%26sid%3Dliteratum%253Aachs%26aulast%3DJu%26aufirst%3DR.%26aulast%3DFei%26aufirst%3DK.%2BL.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DD.%2BC.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DYe%26aufirst%3DC.%2BY.%26atitle%3DMetabolic%2520mechanisms%2520and%2520a%2520rational%2520combinational%2520application%2520of%2520carboxyamidotriazole%2520in%2520fighting%2520pancreatic%2520cancer%2520progression%2520after%2520chemotherapy%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2018%26volume%3D367%26spage%3D20%26epage%3D27%26doi%3D10.1124%2Fjpet.118.249326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ju, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D. C.</span></span> <span> </span><span class="NLM_article-title">Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy</span>. <i>J. Immunother. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">246</span>, <span class="refDoi">Â DOI: 10.1186/s40425-019-0725-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1186%2Fs40425-019-0725-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=31511064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BB3MrnslOmuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=246&author=J.+Shiauthor=C.+Chenauthor=R.+Juauthor=Q.+Z.+Wangauthor=J.+Liauthor=L.+Guoauthor=C.+Y.+Yeauthor=D.+C.+Zhang&title=Carboxyamidotriazole+combined+with+IDO1-Kyn-AhR+pathway+inhibitors+profoundly+enhances+cancer+immunotherapy&doi=10.1186%2Fs40425-019-0725-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy</span></div><div class="casAuthors">Shi Jing; Chen Chen; Ju Rui; Wang Qingzhu; Li Juan; Guo Lei; Ye Caiying; Zhang Dechang</div><div class="citationInfo"><span class="NLM_cas:title">Journal for immunotherapy of cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">246</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Cancer immunotherapy has generated significant excitement, mainly as a result of the development of immune checkpoint inhibitors.  The blockade of PD-1 or its ligand with antibodies has resulted in impressive clinical efficacy.  However, a subset of patients does not respond to biologic therapeutics, and another subset suffers from severe immune-related adverse events in certain cases.  The modulation of the immune system with small molecules might yield surprising benefits.  METHODS:  CD8(+) cells were obtained through a magnetic cell sorting system (MACS), and their capabilities for IFN-Î³ release and PD-1 expression were analyzed.  The in vitro effects of drugs were studied in a coculture system of tumor cells and activated CD8(+) cells.  We further isolated the primary tumor cells in tumor-bearing mice treated with CAI, DMF, 1-MT or a combination (CAI and DMF/CAI and 1-MT) and analyzed the percentages of CD8(+) T cells and PD-1(+)CD8(+) T cells among TILs.  The selective anti-tumor immune reactions of the two drug combinations were confirmed in a coculture system consisting of B16-OVA cells and OVA-specific CTLs derived from OT-1 transgenic mice.  The anti-tumor effects of the single drugs or combined therapies were assessed according to their capability to slow tumor growth and extend the life span of tumor-bearing mice, and they were compared with the effects of PD-1 antibody.  RESULTS:  CAI increased IFN-Î³ release from activated T cells, which might strengthen the anti-proliferative and anti-metastatic effects on cancer cells.  However, CAI also stimulated IDO1-Kyn metabolic circuitry in the tumor microenvironment and facilitated tumor cell immune evasion.  Combining CAI with 1-MT or DMF disrupted PD-1 expression and promoted IFN-Î³ production in CD8(+) T cells, and it also increased T lymphocyte infiltration in the tumor microenvironment, inhibited tumor growth and prolonged the life spans of tumor-bearing mice.  CONCLUSION:  Inhibitors of the IDO1-Kyn-AhR pathway could abolish the negative effects of CAI on CD8(+) T cells and result in complementary and beneficial anti-tumor immune effects.  The combination of CAI with 1-MT or DMF greatly augmented the ability of CD8(+) T cells to kill malignant cells and showed a strong anti-cancer capability that was superior to that of either of the single agents was is comparable with that of anti-PD-1 antibody.  The combinations of small molecules utilized in this study may serve as valuable new immunotherapy strategies for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSAOIdPFXVpog5nADWVYHg1fW6udTcc2eYuGTGudW7Hlbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MrnslOmuw%253D%253D&md5=d5fae69617d17c7f0943555fa0a307af</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1186%2Fs40425-019-0725-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40425-019-0725-7%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DJu%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DQ.%2BZ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DYe%26aufirst%3DC.%2BY.%26aulast%3DZhang%26aufirst%3DD.%2BC.%26atitle%3DCarboxyamidotriazole%2520combined%2520with%2520IDO1-Kyn-AhR%2520pathway%2520inhibitors%2520profoundly%2520enhances%2520cancer%2520immunotherapy%26jtitle%3DJ.%2520Immunother.%2520Cancer%26date%3D2019%26volume%3D7%26spage%3D246%26doi%3D10.1186%2Fs40425-019-0725-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carey, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, M.</span></span> <span> </span><span class="NLM_article-title">Anti-cancer analogues ME-143 and ME-344 exert toxicity by directly inhibiting mitochondrial NADH: ubiquinone oxidoreductase (Complex I)</span>. <i>Am. J. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">689</span>â <span class="NLM_lpage">701</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=25973307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BC2MfjvFOlsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=689-701&author=S.+C.+Limauthor=K.+T.+Careyauthor=M.+McKenzie&title=Anti-cancer+analogues+ME-143+and+ME-344+exert+toxicity+by+directly+inhibiting+mitochondrial+NADH%3A+ubiquinone+oxidoreductase+%28Complex+I%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-cancer analogues ME-143 and ME-344 exert toxicity by directly inhibiting mitochondrial NADH: ubiquinone oxidoreductase (Complex I)</span></div><div class="casAuthors">Lim Sze Chern; Carey Kirstyn T; McKenzie Matthew</div><div class="citationInfo"><span class="NLM_cas:title">American journal of cancer research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">689-701</span>
        ISSN:<span class="NLM_cas:issn">2156-6976</span>.
    </div><div class="casAbstract">Isoflavonoids have been shown to inhibit tumor proliferation and metastasis by activating cell death pathways.  As such, they have been widely studied as potential therapies for cancer prevention.  The second generation synthetic isoflavan analogues ME-143 and ME-344 also exhibit anti-cancer effects, however their specific molecular targets have not been completely defined.  To identify these targets, we examined the effects of ME-143 and ME-344 on cellular metabolism and found that they are potent inhibitors of mitochondrial oxidative phosphorylation (OXPHOS) complex I (NADH: ubiquinone oxidoreductase) activity.  In isolated HEK293T mitochondria, ME-143 and ME-344 reduced complex I activity to 14.3% and 28.6% of control values respectively.  In addition to the inhibition of complex I, ME-344 also significantly inhibited mitochondrial complex III (ubiquinol: ferricytochrome-c oxidoreductase) activity by 10.8%.  This inhibition of complex I activity (and to a lesser extent complex III activity) was associated with a reduction in mitochondrial oxygen consumption.  In permeabilized HEK293T cells, ME-143 and ME-344 significantly reduced the maximum ADP-stimulated respiration rate to 62.3% and 70.0% of control levels respectively in the presence of complex I-linked substrates.  Conversely, complex II-linked respiration was unaffected by either drug.  We also observed that the inhibition of complex I-linked respiration caused the dissipation of the mitochondrial membrane potential (ÎÎ¨m).  Blue native (BN-PAGE) analysis revealed that prolonged loss of ÎÎ¨m results in the destabilization of the native OXPHOS complexes.  In particular, treatment of 143B osteosarcoma, HeLa and HEK293T human embryonic kidney cells with ME-344 for 4 h resulted in reduced steady-state levels of mature complex I.  Degradation of the complex I subunit NDUFA9, as well as the complex IV (ferrocytochrome c: oxygen oxidoreductase) subunit COXIV, was also evident.  The identification of OXPHOS complex I as a target of ME-143 and ME-344 advances our understanding of how these drugs induce cell death by disrupting mitochondrial metabolism, and will direct future work to maximize the anti-cancer capacity of these and other isoflavone-based compounds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTfz9l6WKV16p6KlWarZTAzfW6udTcc2eYuGTGudW7Hlbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MfjvFOlsw%253D%253D&md5=ab4c782a2fcabd76580daab14f664d90</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DS.%2BC.%26aulast%3DCarey%26aufirst%3DK.%2BT.%26aulast%3DMcKenzie%26aufirst%3DM.%26atitle%3DAnti-cancer%2520analogues%2520ME-143%2520and%2520ME-344%2520exert%2520toxicity%2520by%2520directly%2520inhibiting%2520mitochondrial%2520NADH%253A%2520ubiquinone%2520oxidoreductase%2520%2528Complex%2520I%2529%26jtitle%3DAm.%2520J.%2520Cancer%2520Res.%26date%3D2015%26volume%3D5%26spage%3D689%26epage%3D701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref187"><div class="reference"><strong class="refLabel"><a href="#ref187" class="rightTabRefNumLink">187</a></strong><div class="NLM_citation" id="rightTab-cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Z. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manevich, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bethard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broome, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsend, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tew, K. D.</span></span> <span> </span><span class="NLM_article-title">Isoflavone ME-344 disrupts redox homeostasis and mitochondrial function by targeting heme oxygenase 1</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">4072</span>â <span class="NLM_lpage">4085</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-18-3503</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F0008-5472.CAN-18-3503" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=31227482" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFyjtb3J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=4072-4085&author=L.+L.+Zhangauthor=J.+Zhangauthor=Z.+W.+Yeauthor=Y.+Manevichauthor=L.+E.+Ballauthor=J.+R.+Bethardauthor=Y.+L.+Jiangauthor=A.+M.+Broomeauthor=A.+C.+Daltonauthor=G.+Y.+Wangauthor=D.+M.+Townsendauthor=K.+D.+Tew&title=Isoflavone+ME-344+disrupts+redox+homeostasis+and+mitochondrial+function+by+targeting+heme+oxygenase+1&doi=10.1158%2F0008-5472.CAN-18-3503"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Isoflavone ME-344 disrupts redox homeostasis and mitochondrial function by targeting heme oxygenase 1</span></div><div class="casAuthors">Zhang, Leilei; Zhang, Jie; Ye, Zhiwei; Manevich, Yefim; Ball, Lauren E.; Bethard, Jennifer R.; Jiang, Yu-Lin; Broome, Ann-Marie; Dalton, Annamarie C.; Wang, Gavin Y.; Townsend, Danyelle M.; Tew, Kenneth D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4072-4085</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">ME-344 is a second-generation isoflavone with unusual cytotoxic properties that is in clin. testing in cancer.  To identify targets that contribute to its anticancer activity and therapeutic index, we used lung cancer cell lines that are naturally sensitive or resistant to ME-344.  Drug-induced apoptosis was linked with enhanced levels of reactive oxygen species and this initiated a nuclear erythroid factor 2-like 2 signaling response, downstream of which, heme oxygenase 1 (HO-1) was also found to be time-dependently inhibited by ME-344.  ME-344 specifically bound to, and altered, HO-1 structure and increased HO-1 translocation from the rough endoplasmic reticulum to mitochondria, but only in drug-sensitive cells.  These effects did not occur in either drug-resistant or primary lung fibroblasts with lower HO-1 basal levels.  HO-1 was confirmed as a drug target by using surface plasmon resonance technol. and through interaction with a clickable ME-344 compd. (M2F) and subsequent proteomic analyses, showing direct binding of ME-344 with HO-1.  Proteomic anal. showed that clusters of mitochondrial proteins, including voltage-dependent anion-selective channels, were also impacted by ME-344.  Human lung cancer biopsies expressed higher levels of Nrf2 and HO-1 compared with normal tissues.  Overall, our data show that ME-344 inhibits HO-1 and impacts its mitochondrial translocation.  Other mitochondrial proteins are also affected, resulting in interference in tumor cell redox homeostasis and mitochondrial function.  These factors contribute to a beneficial therapeutic index and support continued clin. development of ME-344.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGbUvXxlK6qLVg90H21EOLACvtfcHk0lgfczs10-4v_Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFyjtb3J&md5=ec43717669ba68c238f579d6ec0ecab9</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-18-3503&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-18-3503%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DL.%2BL.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYe%26aufirst%3DZ.%2BW.%26aulast%3DManevich%26aufirst%3DY.%26aulast%3DBall%26aufirst%3DL.%2BE.%26aulast%3DBethard%26aufirst%3DJ.%2BR.%26aulast%3DJiang%26aufirst%3DY.%2BL.%26aulast%3DBroome%26aufirst%3DA.%2BM.%26aulast%3DDalton%26aufirst%3DA.%2BC.%26aulast%3DWang%26aufirst%3DG.%2BY.%26aulast%3DTownsend%26aufirst%3DD.%2BM.%26aulast%3DTew%26aufirst%3DK.%2BD.%26atitle%3DIsoflavone%2520ME-344%2520disrupts%2520redox%2520homeostasis%2520and%2520mitochondrial%2520function%2520by%2520targeting%2520heme%2520oxygenase%25201%26jtitle%3DCancer%2520Res.%26date%3D2019%26volume%3D79%26spage%3D4072%26epage%3D4085%26doi%3D10.1158%2F0008-5472.CAN-18-3503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref188"><div class="reference"><strong class="refLabel"><a href="#ref188" class="rightTabRefNumLink">188</a></strong><div class="NLM_citation" id="rightTab-cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyczechowska, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zapata, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullinax, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrero, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peruzzi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culicchia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochoa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grabacka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiss, K.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanisms of fenofibrate-induced metabolic catastrophe and glioblastoma cell death</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">182</span>â <span class="NLM_lpage">198</span>, <span class="refDoi">Â DOI: 10.1128/MCB.00562-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1128%2FMCB.00562-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=25332241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFertbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=182-198&author=A.+Wilkauthor=D.+Wyczechowskaauthor=A.+Zapataauthor=M.+Deanauthor=J.+Mullinaxauthor=L.+Marreroauthor=C.+Parsonsauthor=F.+Peruzziauthor=F.+Culicchiaauthor=A.+Ochoaauthor=M.+Grabackaauthor=K.+Reiss&title=Molecular+mechanisms+of+fenofibrate-induced+metabolic+catastrophe+and+glioblastoma+cell+death&doi=10.1128%2FMCB.00562-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of fenofibrate-induced metabolic catastrophe and glioblastoma cell death</span></div><div class="casAuthors">Wilk, Anna; Wyczechowska, Dorota; Zapata, Adriana; Dean, Matthew; Mullinax, Jennifer; Marrero, Luis; Parsons, Christopher; Peruzzi, Francesca; Culicchia, Frank; Ochoa, Augusto; Grabacka, Maja; Reiss, Krzysztof</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">182-198/1-182-198/17, 17 pp.</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">1098-5549</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Fenofibrate (FF) is a common lipid-lowering drug and a potent agonist of the peroxisome proliferator-activated receptor alpha (PPARÎ±).  FF and several other agonists of PPARÎ± have interesting anticancer properties, and our recent studies demonstrate that FF is very effective against tumor cells of neuroectodermal origin.  In spite of these promising anticancer effects, the mol. mechanism(s) of FF-induced tumor cell toxicity remains to be elucidated.  Here we report a novel PPARÎ±-independent mechanism explaining FF's cytotoxicity in vitro and in an intracranial mouse model of glioblastoma.  The mechanism involves accumulation of FF in the mitochondrial fraction, followed by immediate impairment of mitochondrial respiration at the level of complex I of the electron transport chain.  This mitochondrial action sensitizes tested glioblastoma cells to the PPARÎ±-dependent metabolic switch from glycolysis to fatty acid Î²-oxidn.  As a consequence, prolonged exposure to FF depletes intracellular ATP, activates the AMP-activated protein kinase-mammalian target of rapamycin-autophagy pathway, and results in extensive tumor cell death.  Interestingly, autophagy activators attenuate and autophagy inhibitors enhance FF-induced glioblastoma cytotoxicity.  Our results explain the mol. basis of FF-induced glioblastoma cytotoxicity and reveal a new supplemental therapeutic approach in which intracranial infusion of FF could selectively trigger metabolic catastrophe in glioblastoma cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHsh6CZvXYTLVg90H21EOLACvtfcHk0lgfczs10-4v_Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFertbo%253D&md5=789381ef5a9f650d2fb5dd04a8cab2bc</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1128%2FMCB.00562-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.00562-14%26sid%3Dliteratum%253Aachs%26aulast%3DWilk%26aufirst%3DA.%26aulast%3DWyczechowska%26aufirst%3DD.%26aulast%3DZapata%26aufirst%3DA.%26aulast%3DDean%26aufirst%3DM.%26aulast%3DMullinax%26aufirst%3DJ.%26aulast%3DMarrero%26aufirst%3DL.%26aulast%3DParsons%26aufirst%3DC.%26aulast%3DPeruzzi%26aufirst%3DF.%26aulast%3DCulicchia%26aufirst%3DF.%26aulast%3DOchoa%26aufirst%3DA.%26aulast%3DGrabacka%26aufirst%3DM.%26aulast%3DReiss%26aufirst%3DK.%26atitle%3DMolecular%2520mechanisms%2520of%2520fenofibrate-induced%2520metabolic%2520catastrophe%2520and%2520glioblastoma%2520cell%2520death%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2015%26volume%3D35%26spage%3D182%26epage%3D198%26doi%3D10.1128%2FMCB.00562-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">189</a></strong><div class="NLM_citation" id="rightTab-cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brunmair, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lest, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staniek, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gras, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scharf, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roden, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nohl, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldhausl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furnsinn, C.</span></span> <span> </span><span class="NLM_article-title">Fenofibrate impairs rat mitochondrial function by inhibition of respiratory complex I</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>311</i></span>,  <span class="NLM_fpage">109</span>â <span class="NLM_lpage">114</span>, <span class="refDoi">Â DOI: 10.1124/jpet.104.068312</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1124%2Fjpet.104.068312" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=15166256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD2cXosVKrtrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=311&publication_year=2004&pages=109-114&author=B.+Brunmairauthor=A.+Lestauthor=K.+Staniekauthor=F.+Grasauthor=N.+Scharfauthor=M.+Rodenauthor=H.+Nohlauthor=W.+Waldhauslauthor=C.+Furnsinn&title=Fenofibrate+impairs+rat+mitochondrial+function+by+inhibition+of+respiratory+complex+I&doi=10.1124%2Fjpet.104.068312"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Fenofibrate impairs rat mitochondrial function by inhibition of respiratory complex I</span></div><div class="casAuthors">Brunmair, Barbara; Lest, Andrea; Staniek, Katrin; Gras, Florian; Scharf, Nicole; Roden, Michael; Nohl, Hans; Waldhaeusl, Werner; Fuernsinn, Clemens</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">311</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">109-114</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Fibrates are used for the treatment of dyslipidemia and known to affect mitochondrial function in vitro.  To better understand the mechanisms underlying their mitochondrial effects, fibrate actions on complex I of the respiratory chain and cell respiration were studied in vitro.  In homogenates of rat skeletal muscle, fenofibrate, and to a lesser extent clofibrate, reduced the activity of complex I (10, 30, and 100 Î¼M fenofibrate: -41Â±7%, -70Â±2%, and -78Â±4%; 100 Î¼M clofibrate: -27Â±7%; p < 0.005 each).  Inhibition of complex I by fenofibrate (100 Î¼M) was confirmed by reduced state 3 respiration of isolated mitochondria consuming glutamate + malate as substrates for complex I (-33Â±4%; p < 0.0005), but not of such consuming succinate as substrate for complex II (-8Â±4%; NS).  In isolated rat muscle, 24-h fenofibrate exposure (25, 50, and 100 Î¼M) decreased CO2 prodn. from palmitate (-15Â±7%, -23Â±8%, and -22Â±7%; p < 0.05 each) and increased lactate release (+15Â±5%, +14Â±5%, and +17Â±6%; p < 0.02 each) indicating impaired cell respiration.  Ciprofibrate and gemfibrozil (but not bezafibrate) impaired cell respiration without any inhibition of complex I.  Our findings support the notion that individual fibrates induce mitochondrial dysfunction via different mol. mechanisms and show that fenofibrate predominantly acts by inhibition of complex I of the respiratory chain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_ZQ6TfI5YVLVg90H21EOLACvtfcHk0liUoGWEyVnIcQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXosVKrtrw%253D&md5=85fb2c5fa085e291e63636febed8c91a</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1124%2Fjpet.104.068312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.104.068312%26sid%3Dliteratum%253Aachs%26aulast%3DBrunmair%26aufirst%3DB.%26aulast%3DLest%26aufirst%3DA.%26aulast%3DStaniek%26aufirst%3DK.%26aulast%3DGras%26aufirst%3DF.%26aulast%3DScharf%26aufirst%3DN.%26aulast%3DRoden%26aufirst%3DM.%26aulast%3DNohl%26aufirst%3DH.%26aulast%3DWaldhausl%26aufirst%3DW.%26aulast%3DFurnsinn%26aufirst%3DC.%26atitle%3DFenofibrate%2520impairs%2520rat%2520mitochondrial%2520function%2520by%2520inhibition%2520of%2520respiratory%2520complex%2520I%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2004%26volume%3D311%26spage%3D109%26epage%3D114%26doi%3D10.1124%2Fjpet.104.068312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref190"><div class="reference"><strong class="refLabel"><a href="#ref190" class="rightTabRefNumLink">190</a></strong><div class="NLM_citation" id="rightTab-cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Udeani, G. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerhauser, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosmeder, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinghorn, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriarty, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezzuto, J. M.</span></span> <span> </span><span class="NLM_article-title">Cancer chemopreventive activity mediated by deguelin, a naturally occurring rotenoid</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3424</span>â <span class="NLM_lpage">3428</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=9270008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADyaK2sXls1Shurs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1997&pages=3424-3428&author=G.+O.+Udeaniauthor=C.+Gerhauserauthor=C.+F.+Thomasauthor=R.+C.+Moonauthor=J.+W.+Kosmederauthor=A.+D.+Kinghornauthor=R.+M.+Moriartyauthor=J.+M.+Pezzuto&title=Cancer+chemopreventive+activity+mediated+by+deguelin%2C+a+naturally+occurring+rotenoid"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer chemopreventive activity mediated by deguelin, a naturally occurring rotenoid</span></div><div class="casAuthors">Udeani, George O.; Gerhauser, Clarissa; Thomas, Cathy F.; Moon, Richard C.; Kosmeder, Jerrome W.; Kinghorn, A. Douglas; Moriarty, Robert M.; Pezzuto, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3424-3428</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Deguelin, a natural product isolated from Mundulea sericea (Leguminosae), was shown previously to mediate strong inhibition of 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced ornithine decarboxylase (ODC) activity in cell culture and to reduce the formation of preneoplastic lesions when mouse mammary glands were exposed to 7,12-dimethylbenz(a)anthracene.  As reported currently, deguelin was synthesized and evaluated for chemopreventive activity in the two-stage 7,12-dimethylbenz(a)anthracene/TPA skin carcinogenesis model with CD-1 mice and in the N-methylnitrosourea mammary carcinogenesis model with Sprague Dawley rats.  In the mouse skin study, deguelin reduced tumor incidence from 60% in the control group to 10% in the group treated with a dose of 33 Î¼g, and multiplicity was reduced from 4.2 in the control group to 0.1 in the treatment group.  When the dose was increased 10-fold to 330 Î¼g, no tumors were obsd. in the treatment group.  These results correlated with the potential of deguelin to inhibit TPA-induced mouse epidermal ODC activity.  When applied topically as a single dose in a time range of 2 h before to 2 h after TPA treatment, deguelin (384 Î¼g) reduced ODC induction by TPA (6.17 Î¼g) by more than 85%.  Time course studies indicated that deguelin (33 Î¼g) inhibited TPA (1.17 Î¼g)-induced ODC activity by 70% without affecting the kinetics of induction over a period of 10 h.  Complete inhibition of ODC induction was obsd. at a dose of 330 Î¼g of deguelin.  In the rat mammary tumorigenesis study, intragastric administration of 2 or 4 mg of deguelin/kg of body wt. daily, 5 days/wk, reduced tumor multiplicity from 6.8 tumors/rat in the control group to 5.1 or 3.2 tumors/animal, resp.  At the 4 mg of deguelin/kg of body wt. dose level, the tumor latency period was significantly increased.  Tumor incidence, however, was unaffected.  These data indicate that deguelin exhibits cancer chemopreventive effects in skin and mammary tumorigenesis models and that addnl. studies are warranted to characterize the cancer chemopreventive or chemotherapeutic potential of this substance more fully.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptHkleDt5p1bVg90H21EOLACvtfcHk0liUoGWEyVnIcQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXls1Shurs%253D&md5=bd75d1453967572362dcb5c2382a63d8</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DUdeani%26aufirst%3DG.%2BO.%26aulast%3DGerhauser%26aufirst%3DC.%26aulast%3DThomas%26aufirst%3DC.%2BF.%26aulast%3DMoon%26aufirst%3DR.%2BC.%26aulast%3DKosmeder%26aufirst%3DJ.%2BW.%26aulast%3DKinghorn%26aufirst%3DA.%2BD.%26aulast%3DMoriarty%26aufirst%3DR.%2BM.%26aulast%3DPezzuto%26aufirst%3DJ.%2BM.%26atitle%3DCancer%2520chemopreventive%2520activity%2520mediated%2520by%2520deguelin%252C%2520a%2520naturally%2520occurring%2520rotenoid%26jtitle%3DCancer%2520Res.%26date%3D1997%26volume%3D57%26spage%3D3424%26epage%3D3428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref191"><div class="reference"><strong class="refLabel"><a href="#ref191" class="rightTabRefNumLink">191</a></strong><div class="NLM_citation" id="rightTab-cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubet, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, M.</span></span> <span> </span><span class="NLM_article-title">Efficacy of deguelin and silibinin on benzo(a)pyrene-induced lung tumorigenesis in A/J mice</span>. <i>Neoplasia</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1053</span>â <span class="NLM_lpage">1057</span>, <span class="refDoi">Â DOI: 10.1593/neo.05532</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1593%2Fneo.05532" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=16354587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD28XptlShsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=1053-1057&author=Y.+Yanauthor=Y.+Wangauthor=Q.+Tanauthor=R.+A.+Lubetauthor=M.+You&title=Efficacy+of+deguelin+and+silibinin+on+benzo%28a%29pyrene-induced+lung+tumorigenesis+in+A%2FJ+mice&doi=10.1593%2Fneo.05532"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of deguelin and silibinin on benzo(a)pyrene-induced lung tumorigenesis in A/J mice</span></div><div class="casAuthors">Yan, Ying; Wang, Yian; Tan, Qing; Lubet, Ronald A.; You, Ming</div><div class="citationInfo"><span class="NLM_cas:title">Neoplasia (Ann Arbor, MI, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1053-1057</span>CODEN:
                <span class="NLM_cas:coden">NEOPFL</span>;
        ISSN:<span class="NLM_cas:issn">1522-8002</span>.
    
            (<span class="NLM_cas:orgname">Neoplasia Press Inc.</span>)
        </div><div class="casAbstract">We evaluated deguelin and silibinin in A/J mice treated with the tobacco-specific carcinogen benzo(a)pyrene (BP) for their ability to inhibit pulmonary adenoma formation and growth.  Animals were treated with either deguelin (5.0 or 10.0 mg/kg body wt., by gavage) or silibinin at doses of 0.05% and 0.1% in the diet, approx. 10 days before a single i.p. dose of BP.  We found that oral administration of deguelin reduced tumor multiplicity by 56% and tumor load by 78%, whereas silibinin treatment at doses of 0.05% and 0.1% in the diet did not show any significant efficacy on either tumor multiplicity or tumor load.  The result indicates that deguelin significantly inhibits pulmonary adenoma formation and growth in A/J mice.  Finding new and effective agents that can prevent lung cancer is urgently needed because cancer of the lungs remains the principal cause of cancer deaths in the United States and because effective chemoprevention of this cancer type remains elusive.  Thus, deguelin appears to be a promising new preventive agent for lung cancer and may be considered for further studies in other animal models and in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHP14e3lymVLVg90H21EOLACvtfcHk0liUoGWEyVnIcQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptlShsg%253D%253D&md5=057360a31ce858adfe295784ac689a79</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1593%2Fneo.05532&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1593%252Fneo.05532%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DTan%26aufirst%3DQ.%26aulast%3DLubet%26aufirst%3DR.%2BA.%26aulast%3DYou%26aufirst%3DM.%26atitle%3DEfficacy%2520of%2520deguelin%2520and%2520silibinin%2520on%2520benzo%2528a%2529pyrene-induced%2520lung%2520tumorigenesis%2520in%2520A%252FJ%2520mice%26jtitle%3DNeoplasia%26date%3D2005%26volume%3D7%26spage%3D1053%26epage%3D1057%26doi%3D10.1593%2Fneo.05532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref192"><div class="reference"><strong class="refLabel"><a href="#ref192" class="rightTabRefNumLink">192</a></strong><div class="NLM_citation" id="rightTab-cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chun, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosmeder, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezzuto, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. Y.</span></span> <span> </span><span class="NLM_article-title">Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">291</span>â <span class="NLM_lpage">302</span>, <span class="refDoi">Â DOI: 10.1093/jnci/95.4.291</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1093%2Fjnci%2F95.4.291" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=12591985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD3sXisF2hsr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2003&pages=291-302&author=K.+H.+Chunauthor=J.+W.+Kosmederauthor=S.+H.+Sunauthor=J.+M.+Pezzutoauthor=R.+Lotanauthor=W.+K.+Hongauthor=H.+Y.+Lee&title=Effects+of+deguelin+on+the+phosphatidylinositol+3-kinase%2FAkt+pathway+and+apoptosis+in+premalignant+human+bronchial+epithelial+cells&doi=10.1093%2Fjnci%2F95.4.291"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells</span></div><div class="casAuthors">Chun, Kyung-Hee; Kosmeder, Jerome W., II; Sun, Shihua; Pezzuto, John M.; Lotan, Reuben; Hong, Waun Ki; Lee, Ho-Young</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">291-302</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Because lung cancer is the leading cause of cancer-related death, new approaches for preventing and controlling the disease are needed.  Chemoprevention approaches are both feasible and effective.  We evaluated the potential of deguelin, a natural plant product, as a lung cancer chemopreventive agent and investigated its mechanism of action.  The effects of deguelin on proliferation and apoptosis of normal, premalignant, and malignant human bronchial epithelial (HBE) cells were assessed by using the MTT assay, a flow cytometry-based TUNEL assay, and western blot analyses.  The effects of deguelin on the phosphatidylinositol 3-kinase (PI3K)/Akt and mitogen-activated protein kinase (MAPK) pathways were assessed by western blot analyses and with adenoviral vectors that expressed constitutively active Akt.  Deguelin treatment in vitro at doses attainable in vivo inhibited the growth of and induced apoptosis of premalignant and malignant HBE cells but had minimal effects on normal HBE cells.  Levels of phosphorylated Akt (pAkt) were higher in premalignant HBE cells than in normal HBE cells.  In premalignant HBE cells, deguelin inhibited PI3K activity and reduced pAkt levels and activity but had minimal effects on the MAPK pathway.  Although overexpression of a constitutively active Akt in premalignant and malignant HBE cells had no effect on growth inhibition mediated by N-(4-hydroxyphenyl)retinamide (4-HPR), a novel chemopreventive retinoid, it blocked deguelin-induced growth arrest and apoptosis.  The ability of deguelin to inhibit PI3K/Akt-mediated signaling pathways may contribute to the potency and specificity of this pro-apoptotic drug.  Because both premalignant and malignant HBE cells are more sensitive to deguelin than normal HBE cells, deguelin may have potential as both a chemopreventive agent for early stages of lung carcinogenesis and a therapeutic agent against lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1LF7fwFWsPbVg90H21EOLACvtfcHk0lixd35PEi8ZJw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXisF2hsr4%253D&md5=a8f0b010976d6612a63ba3dd1df8687e</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F95.4.291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F95.4.291%26sid%3Dliteratum%253Aachs%26aulast%3DChun%26aufirst%3DK.%2BH.%26aulast%3DKosmeder%26aufirst%3DJ.%2BW.%26aulast%3DSun%26aufirst%3DS.%2BH.%26aulast%3DPezzuto%26aufirst%3DJ.%2BM.%26aulast%3DLotan%26aufirst%3DR.%26aulast%3DHong%26aufirst%3DW.%2BK.%26aulast%3DLee%26aufirst%3DH.%2BY.%26atitle%3DEffects%2520of%2520deguelin%2520on%2520the%2520phosphatidylinositol%25203-kinase%252FAkt%2520pathway%2520and%2520apoptosis%2520in%2520premalignant%2520human%2520bronchial%2520epithelial%2520cells%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2003%26volume%3D95%26spage%3D291%26epage%3D302%26doi%3D10.1093%2Fjnci%2F95.4.291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref193"><div class="reference"><strong class="refLabel"><a href="#ref193" class="rightTabRefNumLink">193</a></strong><div class="NLM_citation" id="rightTab-cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennessy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geo, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. Y.</span></span> <span> </span><span class="NLM_article-title">A novel derivative of the natural agent deguelin for cancer chemoprevention and therapy</span>. <i>Cancer Prev. Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">577</span>â <span class="NLM_lpage">587</span>, <span class="refDoi">Â DOI: 10.1158/1940-6207.CAPR-08-0184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F1940-6207.CAPR-08-0184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=19139008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptFKns7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2008&pages=577-587&author=W.+Y.+Kimauthor=D.+J.+Changauthor=B.+Hennessyauthor=H.+J.+Kangauthor=J.+Yooauthor=S.+H.+Hanauthor=Y.+S.+Kimauthor=H.+J.+Parkauthor=S.+Y.+Geoauthor=G.+Millsauthor=K.+W.+Kimauthor=W.+K.+Hongauthor=Y.+G.+Suhauthor=H.+Y.+Lee&title=A+novel+derivative+of+the+natural+agent+deguelin+for+cancer+chemoprevention+and+therapy&doi=10.1158%2F1940-6207.CAPR-08-0184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">A novel derivative of the natural agent deguelin for cancer chemoprevention and therapy</span></div><div class="casAuthors">Kim, Woo-Young; Chang, Dong Jo; Hennessy, Bryan; Kang, Hae Jin; Yoo, Jakyung; Han, Seung-Ho; Kim, Yoo-Shin; Park, Hyun-Ju; Geo, Seung-Yong; Mills, Gordon; Kim, Kyu-Won; Hong, Waun Ki; Suh, Young-Ger; Lee, Ho-Young</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Prevention Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">577-587</span>CODEN:
                <span class="NLM_cas:coden">CPRACC</span>;
        ISSN:<span class="NLM_cas:issn">1940-6207</span>.
    
            (<span class="NLM_cas:orgname">American Association of Cancer Research</span>)
        </div><div class="casAbstract">The natural compd. deguelin has promising preventive and therapeutic activity against diverse cancers by directly binding to heat shock protein-90 and thus suppressing its function.  Potential side effects of deguelin over a certain dose, however, could be a substantial obstacle to its clin. use.  To develop a deriv.(s) of deguelin with reduced potential side effects, we synthesized five deguelin analogs (SH-02, SH-03, SH-09, SH-14, and SH-15) and compared them with the parent compd. and each other for structural and biochem. features; soly.; and antiproliferative effects on normal, premalignant, and malignant human bronchial epithelial (HBE) and non-small-cell lung cancer (NSCLC) cell lines.  Four derivs. destabilized hypoxia-inducible factor-1Î± as potently as did deguelin.  Reversephase protein array (RPPA) anal. in H460 NSCLC cells revealed that deguelin and the derivs. suppressed expression of a no. of proteins including heat shock protein-90 clients and proteins involved in the phosphoinositide 3-kinase/Akt pathway.  One deriv., SH-14, showed several features of potential superiority for clin. use: the highest apoptotic activity; no detectable influence on Src/signal transducer and activator of transcription signaling, which can promote cancer progression and is closely related to pathogenesis of Parkinson's disease (deguelin, SH-02 and SH-03 strongly activated this signaling); better aq. soly.; and less cytotoxicity to immortalized HBE cells (vs. deguelin) at a dose (1 Î¼mol/L) that induced apoptotic activity in most premalignant and malignant HBE and NSCLC cell lines.  These collective results suggest that the novel deriv. SH-14 has strong potential for cancer chemoprevention and therapy, with equiv. efficacy and lesser toxicity (vs. deguelin).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokpOv6WSJPVbVg90H21EOLACvtfcHk0lixd35PEi8ZJw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptFKns7c%253D&md5=c928614b988e8aa0403c90cb5c86f017</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1158%2F1940-6207.CAPR-08-0184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1940-6207.CAPR-08-0184%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DW.%2BY.%26aulast%3DChang%26aufirst%3DD.%2BJ.%26aulast%3DHennessy%26aufirst%3DB.%26aulast%3DKang%26aufirst%3DH.%2BJ.%26aulast%3DYoo%26aufirst%3DJ.%26aulast%3DHan%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DY.%2BS.%26aulast%3DPark%26aufirst%3DH.%2BJ.%26aulast%3DGeo%26aufirst%3DS.%2BY.%26aulast%3DMills%26aufirst%3DG.%26aulast%3DKim%26aufirst%3DK.%2BW.%26aulast%3DHong%26aufirst%3DW.%2BK.%26aulast%3DSuh%26aufirst%3DY.%2BG.%26aulast%3DLee%26aufirst%3DH.%2BY.%26atitle%3DA%2520novel%2520derivative%2520of%2520the%2520natural%2520agent%2520deguelin%2520for%2520cancer%2520chemoprevention%2520and%2520therapy%26jtitle%3DCancer%2520Prev.%2520Res.%26date%3D2008%26volume%3D1%26spage%3D577%26epage%3D587%26doi%3D10.1158%2F1940-6207.CAPR-08-0184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref194"><div class="reference"><strong class="refLabel"><a href="#ref194" class="rightTabRefNumLink">194</a></strong><div class="NLM_citation" id="rightTab-cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benej, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vibhute, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graves, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, Q. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koong, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giaccia, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papandreou, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denko, N. C.</span></span> <span> </span><span class="NLM_article-title">Papaverine and its derivatives radiosensitize solid tumors by inhibiting mitochondrial metabolism</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">10756</span>â <span class="NLM_lpage">10761</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1808945115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1073%2Fpnas.1808945115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=30201710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFyntrrI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=10756-10761&author=M.+Benejauthor=X.+Q.+Hongauthor=S.+Vibhuteauthor=S.+Scottauthor=J.+H.+Wuauthor=E.+Gravesauthor=Q.+T.+Leauthor=A.+C.+Koongauthor=A.+J.+Giacciaauthor=B.+Yuauthor=S.+C.+Chenauthor=I.+Papandreouauthor=N.+C.+Denko&title=Papaverine+and+its+derivatives+radiosensitize+solid+tumors+by+inhibiting+mitochondrial+metabolism&doi=10.1073%2Fpnas.1808945115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Papaverine and its derivatives radiosensitize solid tumors by inhibiting mitochondrial metabolism</span></div><div class="casAuthors">Benej, Martin; Hong, Xiangqian; Vibhute, Sandip; Scott, Sabina; Wu, Jinghai; Graves, Edward; Le, Quynh-Thu; Koong, Albert C.; Giaccia, Amato J.; Yu, Bing; Chen, Shih-Ching; Papandreou, Ioanna; Denko, Nicholas C.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">10756-10761</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Tumor hypoxia reduces the effectiveness of radiation therapy by limiting the biol. ED.  An acute increase in tumor oxygenation before radiation treatment should therefore significantly improve the tumor cell kill after radiation.  Efforts to increase oxygen delivery to the tumor have not shown pos. clin. results.  Here we show that targeting mitochondrial respiration results in a significant redn. of the tumor cells demand for oxygen, leading to increased tumor oxygenation and radiation response.  We identified an activity of the FDA-approved drug papaverine as an inhibitor of mitochondrial complex I.  We also provide genetic evidence that papaverine complex I inhibition is directly responsible for increased oxygenation and enhanced radiation response.  Furthermore, we describe derivs. of papaverine that have the potential to become clin. radiosensitizers with potentially fewer side effects.  Importantly, this radiosensitizing strategy will not sensitize well-oxygenated normal tissue, thereby increasing the therapeutic index of radiotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGQ3uohZ1qtrVg90H21EOLACvtfcHk0lixd35PEi8ZJw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFyntrrI&md5=a5982bb3b146e5494354faf797dbe358</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1808945115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1808945115%26sid%3Dliteratum%253Aachs%26aulast%3DBenej%26aufirst%3DM.%26aulast%3DHong%26aufirst%3DX.%2BQ.%26aulast%3DVibhute%26aufirst%3DS.%26aulast%3DScott%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DJ.%2BH.%26aulast%3DGraves%26aufirst%3DE.%26aulast%3DLe%26aufirst%3DQ.%2BT.%26aulast%3DKoong%26aufirst%3DA.%2BC.%26aulast%3DGiaccia%26aufirst%3DA.%2BJ.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DS.%2BC.%26aulast%3DPapandreou%26aufirst%3DI.%26aulast%3DDenko%26aufirst%3DN.%2BC.%26atitle%3DPapaverine%2520and%2520its%2520derivatives%2520radiosensitize%2520solid%2520tumors%2520by%2520inhibiting%2520mitochondrial%2520metabolism%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2018%26volume%3D115%26spage%3D10756%26epage%3D10761%26doi%3D10.1073%2Fpnas.1808945115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref195"><div class="reference"><strong class="refLabel"><a href="#ref195" class="rightTabRefNumLink">195</a></strong><div class="NLM_citation" id="rightTab-cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyason, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prochazka, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witting, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swettenham, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zobalova, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turanek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitz, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domann, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffler, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ralph, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuzil, J.</span></span> <span> </span><span class="NLM_article-title">alpha-tocopheryl succinate induces apoptosis by targeting ubiquinone-binding sites in mitochondrial respiratory complex II</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">4324</span>â <span class="NLM_lpage">4335</span>, <span class="refDoi">Â DOI: 10.1038/onc.2008.69</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fonc.2008.69" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=18372923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD1cXosFGisbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=4324-4335&author=L.+F.+Dongauthor=P.+Lowauthor=J.+C.+Dyasonauthor=X.+F.+Wangauthor=L.+Prochazkaauthor=P.+K.+Wittingauthor=R.+Freemanauthor=E.+Swettenhamauthor=K.+Valisauthor=J.+Liuauthor=R.+Zobalovaauthor=J.+Turanekauthor=D.+R.+Spitzauthor=F.+E.+Domannauthor=I.+E.+Schefflerauthor=S.+J.+Ralphauthor=J.+Neuzil&title=alpha-tocopheryl+succinate+induces+apoptosis+by+targeting+ubiquinone-binding+sites+in+mitochondrial+respiratory+complex+II&doi=10.1038%2Fonc.2008.69"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Î±-Tocopheryl succinate induces apoptosis by targeting ubiquinone-binding sites in mitochondrial respiratory complex II</span></div><div class="casAuthors">Dong, L.-F.; Low, P.; Dyason, J. C.; Wang, X.-F.; Prochazka, L.; Witting, P. K.; Freeman, R.; Swettenham, E.; Valis, K.; Liu, J.; Zobalova, R.; Turanek, J.; Spitz, D. R.; Domann, F. E.; Scheffler, I. E.; Ralph, S. J.; Neuzil, J.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">4324-4335</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Î±-Tocopheryl succinate (Î±-TOS) is a selective inducer of apoptosis in cancer cells, which involves the accumulation of reactive oxygen species (ROS).  The mol. target of Î±-TOS has not been identified.  Here, we show that Î±-TOS inhibits succinate dehydrogenase (SDH) activity of complex II (CII) by interacting with the proximal and distal ubiquinone (UbQ)-binding site (QP and QD, resp.).  This is based on biochem. analyses and mol. modeling, revealing similar or stronger interaction energy of Î±-TOS compared to that of UbQ for the QP and QD sites, resp.  CybL-mutant cells with dysfunctional CII failed to accumulate ROS and underwent apoptosis in the presence of Î±-TOS.  Similar resistance was obsd. when CybL was knocked down with siRNA.  Reconstitution of functional CII rendered CybL-mutant cells susceptible to Î±-TOS.  We propose that Î±-TOS displaces UbQ in CII causing electrons generated by SDH to recombine with mol. oxygen to yield ROS.  Our data highlight CII, a known tumor suppressor, as a novel target for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpfd1KY4cMJLVg90H21EOLACvtfcHk0lgdiTNNzKcpyg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXosFGisbs%253D&md5=5affc93d03ea9275d17854c95990521f</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1038%2Fonc.2008.69&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2008.69%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DL.%2BF.%26aulast%3DLow%26aufirst%3DP.%26aulast%3DDyason%26aufirst%3DJ.%2BC.%26aulast%3DWang%26aufirst%3DX.%2BF.%26aulast%3DProchazka%26aufirst%3DL.%26aulast%3DWitting%26aufirst%3DP.%2BK.%26aulast%3DFreeman%26aufirst%3DR.%26aulast%3DSwettenham%26aufirst%3DE.%26aulast%3DValis%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZobalova%26aufirst%3DR.%26aulast%3DTuranek%26aufirst%3DJ.%26aulast%3DSpitz%26aufirst%3DD.%2BR.%26aulast%3DDomann%26aufirst%3DF.%2BE.%26aulast%3DScheffler%26aufirst%3DI.%2BE.%26aulast%3DRalph%26aufirst%3DS.%2BJ.%26aulast%3DNeuzil%26aufirst%3DJ.%26atitle%3Dalpha-tocopheryl%2520succinate%2520induces%2520apoptosis%2520by%2520targeting%2520ubiquinone-binding%2520sites%2520in%2520mitochondrial%2520respiratory%2520complex%2520II%26jtitle%3DOncogene%26date%3D2008%26volume%3D27%26spage%3D4324%26epage%3D4335%26doi%3D10.1038%2Fonc.2008.69" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref196"><div class="reference"><strong class="refLabel"><a href="#ref196" class="rightTabRefNumLink">196</a></strong><div class="NLM_citation" id="rightTab-cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Molina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyes-Leyva, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Malo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, J.</span></span> <span> </span><span class="NLM_article-title">The role of alpha tocopheryl succinate (alpha-TOS) as a potential anticancer agent</span>. <i>Nutr. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">167</span>â <span class="NLM_lpage">176</span>, <span class="refDoi">Â DOI: 10.1080/01635581.2014.863367</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1080%2F01635581.2014.863367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=24364743" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFyqt73L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2014&pages=167-176&author=A.+Angulo-Molinaauthor=J.+Reyes-Leyvaauthor=A.+Lopez-Maloauthor=J.+Hernandez&title=The+role+of+alpha+tocopheryl+succinate+%28alpha-TOS%29+as+a+potential+anticancer+agent&doi=10.1080%2F01635581.2014.863367"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of Alpha Tocopheryl Succinate (Î±-TOS) as a Potential Anticancer Agent</span></div><div class="casAuthors">Angulo-Molina, Aracely; Reyes-Leyva, Julio; Lopez-Malo, Aurelio; Hernandez, Jesus</div><div class="citationInfo"><span class="NLM_cas:title">Nutrition and Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">167-176</span>CODEN:
                <span class="NLM_cas:coden">NUCADQ</span>;
        ISSN:<span class="NLM_cas:issn">0163-5581</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">A review.  In recent years, efforts to improve cancer therapy have focused on developing new anticancer agents, such as mitocans.  These agents include vitamin E analogs and suppress cancer by inducing apoptosis by targeting mitochondria.  Alpha tocopheryl succinate (Î±-TOS) is the most effective form of vitamin E analogs causing inhibition of proliferation and apoptosis of cancer cells.  Both in vitro and in vivo studies have demonstrated that Î±-TOS selectively kills tumor cells with little or no effect on normal cells.  Treatment with Î±-TOS shows great promise for future clin. applications, as it causes cell death, at least in part, by selectively inducing apoptosis by mitochondrial destabilization.  This review presents an overview of perspectives on Î±-TOS and the potential uses of Î±-TOS in cancer treatment and other clin. applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrw46gSybtjrVg90H21EOLACvtfcHk0lgdiTNNzKcpyg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFyqt73L&md5=d49f48aa9d11cbf25fb320f5c12dd18d</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1080%2F01635581.2014.863367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F01635581.2014.863367%26sid%3Dliteratum%253Aachs%26aulast%3DAngulo-Molina%26aufirst%3DA.%26aulast%3DReyes-Leyva%26aufirst%3DJ.%26aulast%3DLopez-Malo%26aufirst%3DA.%26aulast%3DHernandez%26aufirst%3DJ.%26atitle%3DThe%2520role%2520of%2520alpha%2520tocopheryl%2520succinate%2520%2528alpha-TOS%2529%2520as%2520a%2520potential%2520anticancer%2520agent%26jtitle%3DNutr.%2520Cancer%26date%3D2014%26volume%3D66%26spage%3D167%26epage%3D176%26doi%3D10.1080%2F01635581.2014.863367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref197"><div class="reference"><strong class="refLabel"><a href="#ref197" class="rightTabRefNumLink">197</a></strong><div class="NLM_citation" id="rightTab-cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zobalova, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marin-Hernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stantic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohlena, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Enriquez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butcher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunk, U. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witting, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno-Sanchez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffler, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ralph, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuzil, J.</span></span> <span> </span><span class="NLM_article-title">Suppression of tumor growth in vivo by the mitocan alpha-tocopheryl succinate requires respiratory complex II</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1593</span>â <span class="NLM_lpage">1600</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-08-2439</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F1078-0432.CCR-08-2439" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=19223492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisVWrsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=1593-1600&author=L.+F.+Dongauthor=R.+Freemanauthor=J.+Liuauthor=R.+Zobalovaauthor=A.+Marin-Hernandezauthor=M.+Stanticauthor=J.+Rohlenaauthor=K.+Valisauthor=S.+Rodriguez-Enriquezauthor=B.+Butcherauthor=J.+Goodwinauthor=U.+T.+Brunkauthor=P.+K.+Wittingauthor=R.+Moreno-Sanchezauthor=I.+E.+Schefflerauthor=S.+J.+Ralphauthor=J.+Neuzil&title=Suppression+of+tumor+growth+in+vivo+by+the+mitocan+alpha-tocopheryl+succinate+requires+respiratory+complex+II&doi=10.1158%2F1078-0432.CCR-08-2439"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Suppression of Tumor Growth In vivo by the Mitocan Î±-tocopheryl Succinate Requires Respiratory Complex II</span></div><div class="casAuthors">Dong, Lan-Feng; Freeman, Ruth; Liu, Ji; Zobalova, Renata; Marin-Hernandez, Alvaro; Stantic, Marina; Rohlena, Jakub; Valis, Karel; Rodriguez-Enriquez, Sara; Butcher, Bevan; Goodwin, Jacob; Brunk, Ulf T.; Witting, Paul K.; Moreno-Sanchez, Rafael; Scheffler, Immo E.; Ralph, Stephen J.; Neuzil, Jiri</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1593-1600</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Vitamin E analogs are potent novel anticancer drugs.  The purpose of this study was to elucidate the cellular target by which these agents, represented by Î±-tocopheryl succinate (Î±-TOS), suppress tumors in vivo, with the focus on the mitochondrial complex II (CII).  Chinese hamster lung fibroblasts with functional, dysfunctional, and reconstituted CII were transformed using H-Ras.  The cells were then used to form xenografts in immunocompromized mice, and response of the cells and the tumors to Î±-TOS was studied.  The CII-functional and CII-reconstituted cells, unlike their CII-dysfunctional counterparts, responded to Î±-TOS by reactive oxygen species generation and apoptosis execution.  Tumors derived from these cell lines reciprocated their responses to Î±-TOS.  Thus, growth of CII-functional and CII-reconstituted tumors was strongly suppressed by the agent, and this was accompanied by high level of apoptosis induction in the tumor cells.  On the other hand, Î±-TOS did not inhibit the CII-dysfuntional tumors.  We document in this report a novel paradigm, according to which the mitochondrial CII, which rarely mutates in human neoplasias, is a plausible target for anticancer drugs from the group of vitamin E analogs, providing support for their testing in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5yuVIYsaqOrVg90H21EOLACvtfcHk0lgdiTNNzKcpyg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisVWrsr8%253D&md5=bda8992e0be210e58513c9da6ce53632</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-2439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-2439%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DL.%2BF.%26aulast%3DFreeman%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZobalova%26aufirst%3DR.%26aulast%3DMarin-Hernandez%26aufirst%3DA.%26aulast%3DStantic%26aufirst%3DM.%26aulast%3DRohlena%26aufirst%3DJ.%26aulast%3DValis%26aufirst%3DK.%26aulast%3DRodriguez-Enriquez%26aufirst%3DS.%26aulast%3DButcher%26aufirst%3DB.%26aulast%3DGoodwin%26aufirst%3DJ.%26aulast%3DBrunk%26aufirst%3DU.%2BT.%26aulast%3DWitting%26aufirst%3DP.%2BK.%26aulast%3DMoreno-Sanchez%26aufirst%3DR.%26aulast%3DScheffler%26aufirst%3DI.%2BE.%26aulast%3DRalph%26aufirst%3DS.%2BJ.%26aulast%3DNeuzil%26aufirst%3DJ.%26atitle%3DSuppression%2520of%2520tumor%2520growth%2520in%2520vivo%2520by%2520the%2520mitocan%2520alpha-tocopheryl%2520succinate%2520requires%2520respiratory%2520complex%2520II%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D1593%26epage%3D1600%26doi%3D10.1158%2F1078-0432.CCR-08-2439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref198"><div class="reference"><strong class="refLabel"><a href="#ref198" class="rightTabRefNumLink">198</a></strong><div class="NLM_citation" id="rightTab-cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H. W.</span></span> <span> </span><span class="NLM_article-title">Neoantimycin F, a streptomyces-derived natural product induces mitochondria-related apoptotic death in human non-small cell lung cancer cells</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1042</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2019.01042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.3389%2Ffphar.2019.01042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=31619992" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmsFWrur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1042&author=L.+Y.+Liuauthor=H.+R.+Zhuauthor=W.+Wuauthor=Y.+Y.+Shenauthor=X.+Linauthor=Y.+Wuauthor=L.+Liuauthor=J.+Tangauthor=Y.+J.+Zhouauthor=F.+Sunauthor=H.+W.+Lin&title=Neoantimycin+F%2C+a+streptomyces-derived+natural+product+induces+mitochondria-related+apoptotic+death+in+human+non-small+cell+lung+cancer+cells&doi=10.3389%2Ffphar.2019.01042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Neoantimycin F, a Streptomyces-derived natural product induces mitochondria-related apoptotic death in human non-small cell lung cancer cells</span></div><div class="casAuthors">Liu, Liyun; Zhu, Hongrui; Wu, Wei; Shen, Yaoyao; Lin, Xiao; Wu, Ying; Liu, Li; Tang, Jie; Zhou, Yongjun; Sun, Fan; Lin, Hou-Wen</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1042</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Streptomyces-derived natural products have been become a major focus of anti-tumor drug discovery studies.  Neoantimycin F (NAT-F), was isolated from Streptomyces conglobatus by our group.  Here, we examd. the anti-cancer activities and its underlying mol. mechanisms implicated in NAT-F-induced apoptosis of non-small cell lung cancer (NSCLC) cells.  Our results showed that NAT-F exerted excellent growth-inhibitory activity against PC9 and H1299 cells in a concn.-dependent manner.  NAT-F-induced cell cycle arrest at S and G0/G1 phase in PC9 and H1299 cells, resp.  Further investigation revealed that the key proteins (including cyclinD1, cyclinE1, cyclinB1, CDK2, and CDK4) were involved in the cell regulation by NAT-F.  Addnl., NAT-F significantly increased the prodn. of reactive oxygen species (ROS), induced DNA damage, nuclear condensation, and cell apoptosis in both cell lines.  Moreover, loss of the mitochondrial membrane potential (MMP) was markedly induced by NAT-F.  Addnl. results revealed that NAT-F could up-regulate pro-apoptotic protein Bax and down-regulate anti-apoptotic protein Bcl-2, Mcl-1, and Bcl-xL, resulting in cytochrome c release from mitochondria and sequential activation of caspase-9 and -3, as well as the cleavage of poly (ADP-ribose) polymerase.  Meanwhile, c-Jun N-terminal kinase (JNK), p38 MAPK (p38), and extracellular signal-regulated kinase (ERK) signaling pathway were also involved in anti-cancer activity of NAT-F in NSCLC cells.  Taken together, these findings indicated that NAT-F possessed anti-proliferative effect and induced apoptosis in NSCLC cells in vitro and may be conducive to promote the development of novel anti-NSCLC agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg1FOiotfW3bVg90H21EOLACvtfcHk0lhdJ2UcZveLwQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmsFWrur4%253D&md5=826b13be7844a5fe4cab728eb7c65ec1</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.01042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.01042%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%2BY.%26aulast%3DZhu%26aufirst%3DH.%2BR.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DShen%26aufirst%3DY.%2BY.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DY.%2BJ.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DLin%26aufirst%3DH.%2BW.%26atitle%3DNeoantimycin%2520F%252C%2520a%2520streptomyces-derived%2520natural%2520product%2520induces%2520mitochondria-related%2520apoptotic%2520death%2520in%2520human%2520non-small%2520cell%2520lung%2520cancer%2520cells%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D1042%26doi%3D10.3389%2Ffphar.2019.01042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref199"><div class="reference"><strong class="refLabel"><a href="#ref199" class="rightTabRefNumLink">199</a></strong><div class="NLM_citation" id="rightTab-cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oliva, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markert, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everts, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moellering, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suto, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griguer, C. E.</span></span> <span> </span><span class="NLM_article-title">Identification of small molecule inhibitors of human cytochrome c oxidase that target chemoresistant glioma cells</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>291</i></span>,  <span class="NLM_fpage">24188</span>â <span class="NLM_lpage">24199</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M116.749978</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1074%2Fjbc.M116.749978" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27679486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVCitbrK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=2016&pages=24188-24199&author=C.+R.+Olivaauthor=T.+Markertauthor=L.+J.+Rossauthor=E.+L.+Whiteauthor=L.+Rasmussenauthor=W.+Zhangauthor=M.+Evertsauthor=D.+R.+Moelleringauthor=S.+M.+Baileyauthor=M.+J.+Sutoauthor=C.+E.+Griguer&title=Identification+of+small+molecule+inhibitors+of+human+cytochrome+c+oxidase+that+target+chemoresistant+glioma+cells&doi=10.1074%2Fjbc.M116.749978"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Small Molecule Inhibitors of Human Cytochrome c Oxidase That Target Chemoresistant Glioma Cells</span></div><div class="casAuthors">Oliva, Claudia R.; Markert, Tahireh; Ross, Larry J.; White, E. Lucile; Rasmussen, Lynn; Zhang, Wei; Everts, Maaike; Moellering, Douglas R.; Bailey, Shannon M.; Suto, Mark J.; Griguer, Corinne E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">291</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">24188-24199</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The enzyme cytochrome c oxidase (CcO) or complex IV (EC 1.9.3.1) is a large transmembrane protein complex that serves as the last enzyme in the respiratory electron transport chain of eukaryotic mitochondria.  CcO promotes the switch from glycolytic to oxidative phosphorylation (OXPHOS) metab. and has been assocd. with increased self-renewal characteristics in gliomas.  Increased CcO activity in tumors has been assocd. with tumor progression after chemotherapy failure, and patients with primary glioblastoma multiforme and high tumor CcO activity have worse clin. outcomes than those with low tumor CcO activity.  Therefore, CcO is an attractive target for cancer therapy.  The authors report the characterization of a CcO inhibitor (ADDA 5, 1-[2-(1-adamantyl)-ethoxy]-3-(3,4-dihydro-2(1H)-isoquinolinyl)-2-propanol hydrochloride) that was identified using a high throughput screening paradigm.  ADDA 5 demonstrated specificity for CcO, with no inhibition of other mitochondrial complexes or other relevant enzymes, and biochem. characterization showed that this compd. is a non-competitive inhibitor of cytochrome c.  When tested in cellular assays, ADDA 5 dose-dependently inhibited the proliferation of chemosensitive and chemoresistant glioma cells but did not display toxicity against non-cancer cells.  Furthermore, treatment with ADDA 5 led to significant inhibition of tumor growth in flank xenograft mouse models.  Importantly, ADDA 5 inhibited CcO activity and blocked cell proliferation and neurosphere formation in cultures of glioma stem cells, the cells implicated in tumor recurrence and resistance to therapy in patients with glioblastoma.  In summary, the authors have identified ADDA 5 as a lead CcO inhibitor for further optimization as a novel approach for the treatment of glioblastoma and related cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLMB7Q9zhRBbVg90H21EOLACvtfcHk0lhdJ2UcZveLwQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVCitbrK&md5=07b4ae6e14504f66f3948d9df6ce89dc</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M116.749978&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M116.749978%26sid%3Dliteratum%253Aachs%26aulast%3DOliva%26aufirst%3DC.%2BR.%26aulast%3DMarkert%26aufirst%3DT.%26aulast%3DRoss%26aufirst%3DL.%2BJ.%26aulast%3DWhite%26aufirst%3DE.%2BL.%26aulast%3DRasmussen%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DEverts%26aufirst%3DM.%26aulast%3DMoellering%26aufirst%3DD.%2BR.%26aulast%3DBailey%26aufirst%3DS.%2BM.%26aulast%3DSuto%26aufirst%3DM.%2BJ.%26aulast%3DGriguer%26aufirst%3DC.%2BE.%26atitle%3DIdentification%2520of%2520small%2520molecule%2520inhibitors%2520of%2520human%2520cytochrome%2520c%2520oxidase%2520that%2520target%2520chemoresistant%2520glioma%2520cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2016%26volume%3D291%26spage%3D24188%26epage%3D24199%26doi%3D10.1074%2Fjbc.M116.749978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref200"><div class="reference"><strong class="refLabel"><a href="#ref200" class="rightTabRefNumLink">200</a></strong><div class="NLM_citation" id="rightTab-cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salomon, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voehringer, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herzenberg, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khosla, C.</span></span> <span> </span><span class="NLM_article-title">Apoptolidin, a selective cytotoxic agent, is an inhibitor of F0F1-ATPase</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">71</span>â <span class="NLM_lpage">80</span>, <span class="refDoi">Â DOI: 10.1016/S1074-5521(00)00057-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2FS1074-5521%2800%2900057-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=11182320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhslGku7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2001&pages=71-80&author=A.+R.+Salomonauthor=D.+W.+Voehringerauthor=L.+A.+Herzenbergauthor=C.+Khosla&title=Apoptolidin%2C+a+selective+cytotoxic+agent%2C+is+an+inhibitor+of+F0F1-ATPase&doi=10.1016%2FS1074-5521%2800%2900057-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Apoptolidin, a selective cytotoxic agent, is an inhibitor of F0F1-ATPase</span></div><div class="casAuthors">Salomon, Arthur R.; Voehringer, David W.; Herzenberg, Leonard A.; Khosla, Chaitan</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">71-80</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Apoptolidin is a macrolide originally identified on the basis of its ability to selectively kill E1A and E1A/E1B19K transformed rat glial cells while not killing untransformed glial cells.  The goal of this study was to identify the mol. target of this newly discovered natural product.  Our approach to uncovering the mechanism of action of apoptolidin utilized a combination of mol. and cell-based pharmacol. assays as well as structural comparisons between apoptolidin and other macrocyclic polyketides with known mechanism of action.  Cell killing induced by apoptolidin was independent of p53 status, inhibited by BCL-2, and dependent on the action of caspase-9.  PARP was completely cleaved in the presence of 1 Î¼M apoptolidin within 6 h in a mouse lymphoma cell line.  Together these results suggested that apoptolidin might target a mitochondrial protein.  Structural comparisons between apoptolidin and other macrolides revealed significant similarity between the apoptolidin aglycon and oligomycin, a known inhibitor of mitochondrial F0F1-ATP synthase.  The relevance of this similarity was established by demonstrating that apoptolidin is a potent inhibitor of the F0F1-ATPase activity in intact yeast mitochondria as well as Triton X-100-solubilized ATPase prepns.  The Ki for apoptolidin was 4-5 Î¼M.  The selectivity of apoptolidin in the NCI-60 cell line panel was found to correlate well with that of several known anti-fungal natural products that inhibit the eukaryotic mitochondrial F0F1-ATP synthase.  Although the anti-fungal activities of macrolide inhibitors of the mitochondrial F0F1-ATP synthase such as oligomycin, ossamycin and cytovaricin are well-documented, their unusual selectivity toward certain cell types is not widely appreciated.  The recent discovery of apoptolidin, followed by the demonstration that it is an inhibitor of the mitochondrial F0F1-ATP synthase, highlights the potential relevance of these natural products as small mols. to modulate apoptotic pathways.  The mechanistic basis for selective cytotoxicity of mitochondrial ATP synthase inhibitors is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQwF06r02xebVg90H21EOLACvtfcHk0lg___P-3-qj_w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhslGku7w%253D&md5=23c0d35ee3c59fafb6c54b20f74768ab</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1016%2FS1074-5521%2800%2900057-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1074-5521%252800%252900057-0%26sid%3Dliteratum%253Aachs%26aulast%3DSalomon%26aufirst%3DA.%2BR.%26aulast%3DVoehringer%26aufirst%3DD.%2BW.%26aulast%3DHerzenberg%26aufirst%3DL.%2BA.%26aulast%3DKhosla%26aufirst%3DC.%26atitle%3DApoptolidin%252C%2520a%2520selective%2520cytotoxic%2520agent%252C%2520is%2520an%2520inhibitor%2520of%2520F0F1-ATPase%26jtitle%3DChem.%2520Biol.%26date%3D2001%26volume%3D8%26spage%3D71%26epage%3D80%26doi%3D10.1016%2FS1074-5521%2800%2900057-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref201"><div class="reference"><strong class="refLabel"><a href="#ref201" class="rightTabRefNumLink">201</a></strong><div class="NLM_citation" id="rightTab-cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koert, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuppan, J.</span></span> <span> </span><span class="NLM_article-title">Apoptolidin: Induction of apoptosis by a natural product</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">872</span>â <span class="NLM_lpage">893</span>, <span class="refDoi">Â DOI: 10.1002/anie.200502698</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1002%2Fanie.200502698" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD28XhsFKms7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2006&pages=872-893&author=P.+T.+Danielauthor=U.+Koertauthor=J.+Schuppan&title=Apoptolidin%3A+Induction+of+apoptosis+by+a+natural+product&doi=10.1002%2Fanie.200502698"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Apoptolidin: induction of apoptosis by a natural product</span></div><div class="casAuthors">Daniel, Peter T.; Koert, Ulrich; Schuppan, Julia</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">872-893</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Apoptolidin is a natural product that selectively induces apoptosis in several cancer cell lines.  Apoptosis, programmed cell death, is a biol. key pathway for regulating homeostasis and morphogenesis.  Apoptotic misregulations are connected with several diseases, in particular cancer.  The extrinsic way to apoptosis leads through death ligands and death receptors to the activation of the caspase cascade, which results in proteolytic degrdn. of the cell architecture.  The intrinsic pathway transmits signals of internal cellular damage to the mitochondrion, which loses its structural integrity, and forms an apoptosome that initiates the caspase cascade.  Compds. which regulate apoptosis are of high medical significance.  Many natural products regulate apoptotic pathways, and apoptolidin is one of them.  The known synthetic routes to apoptolidin are described and compared in this Review.  Selected further natural products which regulate apoptosis are introduced briefly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjTqYTnpRiNLVg90H21EOLACvtfcHk0lg___P-3-qj_w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhsFKms7s%253D&md5=7babb0de2d97898131fb88ca59104590</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1002%2Fanie.200502698&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200502698%26sid%3Dliteratum%253Aachs%26aulast%3DDaniel%26aufirst%3DP.%2BT.%26aulast%3DKoert%26aufirst%3DU.%26aulast%3DSchuppan%26aufirst%3DJ.%26atitle%3DApoptolidin%253A%2520Induction%2520of%2520apoptosis%2520by%2520a%2520natural%2520product%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2006%26volume%3D45%26spage%3D872%26epage%3D893%26doi%3D10.1002%2Fanie.200502698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref202"><div class="reference"><strong class="refLabel"><a href="#ref202" class="rightTabRefNumLink">202</a></strong><div class="NLM_citation" id="rightTab-cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wender, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jankowski, O. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longcore, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabet, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomikawa, T.</span></span> <span> </span><span class="NLM_article-title">Correlation of F0F1-ATPase inhibition and antiproliferative activity of apoptolidin analogues</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">589</span>â <span class="NLM_lpage">592</span>, <span class="refDoi">Â DOI: 10.1021/ol052800q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol052800q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD28XksV2kuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2006&pages=589-592&author=P.+A.+Wenderauthor=O.+D.+Jankowskiauthor=K.+Longcoreauthor=E.+A.+Tabetauthor=H.+Setoauthor=T.+Tomikawa&title=Correlation+of+F0F1-ATPase+inhibition+and+antiproliferative+activity+of+apoptolidin+analogues&doi=10.1021%2Fol052800q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Correlation of F0F1-ATPase Inhibition and Antiproliferative Activity of Apoptolidin Analogues</span></div><div class="casAuthors">Wender, Paul A.; Jankowski, Orion D.; Longcore, Kate; Tabet, Elie A.; Seto, Haruo; Tomikawa, Taijiro</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">589-592</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Apoptolidin exhibits potent and highly selective apoptosis inducing activity against sensitive cancer cell lines and is hypothesized to act by inhibition of mitochondrial F0F1-ATPase.  A series of apoptolidin derivs., including a new intermol. Diels-Alder adduct, were analyzed for antiproliferative activity in E1A-transformed rat fibroblasts.  Potent F0F1-ATPase inhibition was not a sufficient determinant of antiproliferative activity for several analogs, suggesting the existence of a secondary biol. target or more complex mode of action for apoptolidin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopFhthfrxoWLVg90H21EOLACvtfcHk0ljaVUqEtvqruQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XksV2kuw%253D%253D&md5=817268f87c70c4429c204866be124682</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1021%2Fol052800q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol052800q%26sid%3Dliteratum%253Aachs%26aulast%3DWender%26aufirst%3DP.%2BA.%26aulast%3DJankowski%26aufirst%3DO.%2BD.%26aulast%3DLongcore%26aufirst%3DK.%26aulast%3DTabet%26aufirst%3DE.%2BA.%26aulast%3DSeto%26aufirst%3DH.%26aulast%3DTomikawa%26aufirst%3DT.%26atitle%3DCorrelation%2520of%2520F0F1-ATPase%2520inhibition%2520and%2520antiproliferative%2520activity%2520of%2520apoptolidin%2520analogues%26jtitle%3DOrg.%2520Lett.%26date%3D2006%26volume%3D8%26spage%3D589%26epage%3D592%26doi%3D10.1021%2Fol052800q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref203"><div class="reference"><strong class="refLabel"><a href="#ref203" class="rightTabRefNumLink">203</a></strong><div class="NLM_citation" id="rightTab-cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foretz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guigas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viollet, B.</span></span> <span> </span><span class="NLM_article-title">Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus</span>. <i>Nat. Rev. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">569</span>â <span class="NLM_lpage">589</span>, <span class="refDoi">Â DOI: 10.1038/s41574-019-0242-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fs41574-019-0242-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=31439934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1elu7jO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=569-589&author=M.+Foretzauthor=B.+Guigasauthor=B.+Viollet&title=Understanding+the+glucoregulatory+mechanisms+of+metformin+in+type+2+diabetes+mellitus&doi=10.1038%2Fs41574-019-0242-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus</span></div><div class="casAuthors">Foretz, Marc; Guigas, Bruno; Viollet, Benoit</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Endocrinology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">569-589</span>CODEN:
                <span class="NLM_cas:coden">NREABD</span>;
        ISSN:<span class="NLM_cas:issn">1759-5029</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Despite its position as the first-line drug for treatment of type 2 diabetes mellitus, the mechanisms underlying the plasma glucose level-lowering effects of metformin (1,1-dimethylbiguanide) still remain incompletely understood.  Metformin is thought to exert its primary antidiabetic action through the suppression of hepatic glucose prodn.  In addn., the discovery that metformin inhibits the mitochondrial respiratory chain complex 1 has placed energy metab. and activation of AMP-activated protein kinase (AMPK) at the center of its proposed mechanism of action.  However, the role of AMPK has been challenged and might only account for indirect changes in hepatic insulin sensitivity.  Various mechanisms involving alterations in cellular energy charge, AMP-mediated inhibition of adenylate cyclase or fructose-1,6-bisphosphatase 1 and modulation of the cellular redox state through direct inhibition of mitochondrial glycerol-3-phosphate dehydrogenase have been proposed for the acute inhibition of gluconeogenesis by metformin.  Emerging evidence suggests that metformin could improve obesity-induced meta-inflammation via direct and indirect effects on tissue-resident immune cells in metabolic organs (i.e., adipose tissue, the gastrointestinal tract and the liver).  Furthermore, the gastrointestinal tract also has a major role in metformin action through modulation of glucose-lowering hormone glucagon-like peptide 1 and the intestinal bile acid pool and alterations in gut microbiota compn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg0HgTCQ0mlrVg90H21EOLACvtfcHk0ljaVUqEtvqruQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1elu7jO&md5=ac06ff9c088597be8156e3fa94e9b200</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1038%2Fs41574-019-0242-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41574-019-0242-2%26sid%3Dliteratum%253Aachs%26aulast%3DForetz%26aufirst%3DM.%26aulast%3DGuigas%26aufirst%3DB.%26aulast%3DViollet%26aufirst%3DB.%26atitle%3DUnderstanding%2520the%2520glucoregulatory%2520mechanisms%2520of%2520metformin%2520in%2520type%25202%2520diabetes%2520mellitus%26jtitle%3DNat.%2520Rev.%2520Endocrinol.%26date%3D2019%26volume%3D15%26spage%3D569%26epage%3D589%26doi%3D10.1038%2Fs41574-019-0242-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref204"><div class="reference"><strong class="refLabel"><a href="#ref204" class="rightTabRefNumLink">204</a></strong><div class="NLM_citation" id="rightTab-cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">An, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, L.</span></span> <span> </span><span class="NLM_article-title">Current understanding of metformin effect on the control of hyperglycemia in diabetes</span>. <i>J. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>228</i></span>,  <span class="NLM_fpage">R97</span>â <span class="NLM_lpage">106</span>, <span class="refDoi">Â DOI: 10.1530/JOE-15-0447</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1530%2FJOE-15-0447" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=26743209" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFeksLnJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=2016&pages=R97-106&author=H.+Anauthor=L.+He&title=Current+understanding+of+metformin+effect+on+the+control+of+hyperglycemia+in+diabetes&doi=10.1530%2FJOE-15-0447"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Current understanding of metformin effect on the control of hyperglycemia in diabetes</span></div><div class="casAuthors">An, Hongying; He, Ling</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Endocrinology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">228</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">R97-R106</span>CODEN:
                <span class="NLM_cas:coden">JOENAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-0795</span>.
    
            (<span class="NLM_cas:orgname">BioScientifica Ltd.</span>)
        </div><div class="casAbstract">Metformin is a first-line oral anti-diabetic agent that has been used clin. to treat patients with type 2 diabetes for over 60 years.  Due to its efficacy in therapy and affordable price, metformin is taken by more than 150 million people each year.  Metformin improves hyperglycemia mainly through the suppression of hepatic gluconeogenesis along with the improvement of insulin signaling.  However, its mechanism of action remains partially understood and controversial, esp. in regard to the role of AMPK in metformin's action and the mechanism of AMPK activation.  In this review, we discuss recent advances in the understanding of metformin's suppression of hepatic glucose prodn. and the mechanism related to the improvement of insulin signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLtG_dyC4HzLVg90H21EOLACvtfcHk0ljaVUqEtvqruQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFeksLnJ&md5=bf4ee8e5d4de88de490971074c7c4d1b</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1530%2FJOE-15-0447&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1530%252FJOE-15-0447%26sid%3Dliteratum%253Aachs%26aulast%3DAn%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DL.%26atitle%3DCurrent%2520understanding%2520of%2520metformin%2520effect%2520on%2520the%2520control%2520of%2520hyperglycemia%2520in%2520diabetes%26jtitle%3DJ.%2520Endocrinol.%26date%3D2016%26volume%3D228%26spage%3DR97%26epage%3D106%26doi%3D10.1530%2FJOE-15-0447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref205"><div class="reference"><strong class="refLabel"><a href="#ref205" class="rightTabRefNumLink">205</a></strong><div class="NLM_citation" id="rightTab-cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evans, J. M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donnelly, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emslie-Smith, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alessi, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, A. D.</span></span> <span> </span><span class="NLM_article-title">Metformin and reduced risk of cancer in diabetic patients</span>. <i>BMJ.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>330</i></span>,  <span class="NLM_fpage">1304</span>â <span class="NLM_lpage">1305</span>, <span class="refDoi">Â DOI: 10.1136/bmj.38415.708634.F7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1136%2Fbmj.38415.708634.F7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=15849206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BD2M3oslCluw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2005&pages=1304-1305&author=J.+M.+M.+Evansauthor=L.+A.+Donnellyauthor=A.+M.+Emslie-Smithauthor=D.+R.+Alessiauthor=A.+D.+Morris&title=Metformin+and+reduced+risk+of+cancer+in+diabetic+patients&doi=10.1136%2Fbmj.38415.708634.F7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Metformin and reduced risk of cancer in diabetic patients</span></div><div class="casAuthors">Evans Josie M M; Donnelly Louise A; Emslie-Smith Alistair M; Alessi Dario R; Morris Andrew D</div><div class="citationInfo"><span class="NLM_cas:title">BMJ (Clinical research ed.)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">7503</span>),
    <span class="NLM_cas:pages">1304-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSv9UpYrCiq2fxQvRxYU81tfW6udTcc2eame4lEafNZEbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M3oslCluw%253D%253D&md5=513473e25d1ace9c0d503064a076ac26</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1136%2Fbmj.38415.708634.F7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmj.38415.708634.F7%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DJ.%2BM.%2BM.%26aulast%3DDonnelly%26aufirst%3DL.%2BA.%26aulast%3DEmslie-Smith%26aufirst%3DA.%2BM.%26aulast%3DAlessi%26aufirst%3DD.%2BR.%26aulast%3DMorris%26aufirst%3DA.%2BD.%26atitle%3DMetformin%2520and%2520reduced%2520risk%2520of%2520cancer%2520in%2520diabetic%2520patients%26jtitle%3DBMJ.%26date%3D2005%26volume%3D330%26spage%3D1304%26epage%3D1305%26doi%3D10.1136%2Fbmj.38415.708634.F7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref206"><div class="reference"><strong class="refLabel"><a href="#ref206" class="rightTabRefNumLink">206</a></strong><div class="NLM_citation" id="rightTab-cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bowker, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majumdar, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veugelers, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. A.</span></span> <span> </span><span class="NLM_article-title">Increased cancer-related mortality for patients with type 2 diabetes who use sulforrylureas or insulin</span>. <i>Diabetes Care</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">254</span>â <span class="NLM_lpage">258</span>, <span class="refDoi">Â DOI: 10.2337/diacare.29.02.06.dc05-1558</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.2337%2Fdiacare.29.02.06.dc05-1558" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=16443869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BD28%252Flsl2jsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2006&pages=254-258&author=S.+L.+Bowkerauthor=S.+R.+Majumdarauthor=P.+Veugelersauthor=J.+A.+Johnson&title=Increased+cancer-related+mortality+for+patients+with+type+2+diabetes+who+use+sulforrylureas+or+insulin&doi=10.2337%2Fdiacare.29.02.06.dc05-1558"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin</span></div><div class="casAuthors">Bowker Samantha L; Majumdar Sumit R; Veugelers Paul; Johnson Jeffrey A</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes care</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">254-8</span>
        ISSN:<span class="NLM_cas:issn">0149-5992</span>.
    </div><div class="casAbstract">OBJECTIVE:  Numerous studies have identified an increased risk of cancer in type 2 diabetes.  We explored the association between antidiabetic therapies and cancer-related mortality in patients with type 2 diabetes, postulating that agents that increase insulin levels might promote cancer.  RESEARCH DESIGN AND METHODS:  This was a population-based cohort study using administrative databases from Saskatchewan Health.  Cancer-related mortality was compared among inception cohorts of metformin users and sulfonylurea monotherapy users.  Multivariate Cox regression was used to estimate the hazard ratio (HR) of cancer-related mortality, after adjusting for age, sex, insulin use, and chronic disease score.  All statistical tests were two-sided.  RESULTS:  We identified 10,309 new users of metformin or sulfonylureas with an average follow-up of 5.4 +/- 1.9 years (means +/- SD).  The mean age for the cohort was 63.4 +/- 13.3 years, and 55% were men.  Cancer mortality over follow-up was 4.9% (162 of 3,340) for sulfonylurea monotherapy users, 3.5% (245 of 6,969) for metformin users, and 5.8% (84 of 1,443) for subjects who used insulin.  After multivariate adjustment, the sulfonylurea cohort had greater cancer-related mortality compared with the metformin cohort (adjusted HR 1.3 [95% CI 1.1-1.6]; P = 0.012).  Insulin use was associated with an adjusted HR of cancer-related mortality of 1.9 (95% CI 1.5-2.4; P < 0.0001).  CONCLUSIONS:  Patients with type 2 diabetes exposed to sulfonylureas and exogenous insulin had a significantly increased risk of cancer-related mortality compared with patients exposed to metformin.  It is uncertain whether this increased risk is related to a deleterious effect of sulfonylurea and insulin or a protective effect of metformin or due to some unmeasured effect related to both choice of therapy and cancer risk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSYNejkz31lvEPI-fCgwosgfW6udTcc2eame4lEafNZEbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28%252Flsl2jsQ%253D%253D&md5=530d3294add5756642cb36153a786c1b</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.2337%2Fdiacare.29.02.06.dc05-1558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdiacare.29.02.06.dc05-1558%26sid%3Dliteratum%253Aachs%26aulast%3DBowker%26aufirst%3DS.%2BL.%26aulast%3DMajumdar%26aufirst%3DS.%2BR.%26aulast%3DVeugelers%26aufirst%3DP.%26aulast%3DJohnson%26aufirst%3DJ.%2BA.%26atitle%3DIncreased%2520cancer-related%2520mortality%2520for%2520patients%2520with%2520type%25202%2520diabetes%2520who%2520use%2520sulforrylureas%2520or%2520insulin%26jtitle%3DDiabetes%2520Care%26date%3D2006%26volume%3D29%26spage%3D254%26epage%3D258%26doi%3D10.2337%2Fdiacare.29.02.06.dc05-1558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref207"><div class="reference"><strong class="refLabel"><a href="#ref207" class="rightTabRefNumLink">207</a></strong><div class="NLM_citation" id="rightTab-cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ben Sahra, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Marchand-Brustel, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanti, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bost, F.</span></span> <span> </span><span class="NLM_article-title">Metformin in cancer therapy: a new perspective for an old antidiabetic drug?</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1092</span>â <span class="NLM_lpage">1099</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-09-1186</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F1535-7163.MCT-09-1186" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=20442309" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsleksr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=1092-1099&author=I.+Ben+Sahraauthor=Y.+Le+Marchand-Brustelauthor=J.+F.+Tantiauthor=F.+Bost&title=Metformin+in+cancer+therapy%3A+a+new+perspective+for+an+old+antidiabetic+drug%3F&doi=10.1158%2F1535-7163.MCT-09-1186"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Metformin in Cancer Therapy: A New Perspective for an Old Antidiabetic Drug?</span></div><div class="casAuthors">Ben Sahra, Issam; Le Marchand-Brustel, Yannick; Tanti, Jean-Francois; Bost, Frederic</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1092-1099</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Metformin is the most widely used antidiabetic drug in the world, and there is increasing evidence of a potential efficacy of this agent as an anticancer drug.  First, epidemiol. studies show a decrease in cancer incidence in metformin-treated patients.  Second, metformin decreases insulin resistance and indirectly reduces insulin level, a beneficial effect because insulin promotes cancer cell growth.  Third, several reports outline a direct inhibitory effect of metformin on cancer cell growth and an antitumoral action.  Finally, metformin activates the AMP activated protein kinase (AMPK) pathway, a major sensor of the energetic status of the cell, which has been proposed as a promising therapeutic target in cancer.  Mol Cancer Ther; 9(5); 1092-99.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAuiLOQqw_6bVg90H21EOLACvtfcHk0livPamaLp2KAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsleksr0%253D&md5=e99658f7356a3ccfa83515ef3df4e62e</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-1186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-1186%26sid%3Dliteratum%253Aachs%26aulast%3DBen%2BSahra%26aufirst%3DI.%26aulast%3DLe%2BMarchand-Brustel%26aufirst%3DY.%26aulast%3DTanti%26aufirst%3DJ.%2BF.%26aulast%3DBost%26aufirst%3DF.%26atitle%3DMetformin%2520in%2520cancer%2520therapy%253A%2520a%2520new%2520perspective%2520for%2520an%2520old%2520antidiabetic%2520drug%253F%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D1092%26epage%3D1099%26doi%3D10.1158%2F1535-7163.MCT-09-1186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref208"><div class="reference"><strong class="refLabel"><a href="#ref208" class="rightTabRefNumLink">208</a></strong><div class="NLM_citation" id="rightTab-cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iliopoulos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsichlis, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Struhl, K.</span></span> <span> </span><span class="NLM_article-title">Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">7507</span>â <span class="NLM_lpage">7511</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-09-2994</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F0008-5472.CAN-09-2994" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=19752085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Skt7rN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=7507-7511&author=H.+A.+Hirschauthor=D.+Iliopoulosauthor=P.+N.+Tsichlisauthor=K.+Struhl&title=Metformin+selectively+targets+cancer+stem+cells%2C+and+acts+together+with+chemotherapy+to+block+tumor+growth+and+prolong+remission&doi=10.1158%2F0008-5472.CAN-09-2994"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">Metformin Selectively Targets Cancer Stem Cells, and Acts Together with Chemotherapy to Block Tumor Growth and Prolong Remission</span></div><div class="casAuthors">Hirsch, Heather A.; Iliopoulos, Dimitrios; Tsichlis, Philip N.; Struhl, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7507-7511</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The cancer stem cell hypothesis suggests that, unlike most cancer cells within a tumor, cancer stem cells resist chemotherapeutic drugs and can regenerate the various cell types in the tumor, thereby causing relapse of the disease.  Thus, drugs that selectively target cancer stem cells offer great promise for cancer treatment, particularly in combination with chemotherapy.  Here, we show that low doses of metformin, a std. drug for diabetes, inhibits cellular transformation and selectively kills cancer stem cells in four genetically different types of breast cancer.  The combination of metformin and a well-defined chemotherapeutic agent, doxorubicin, kills both cancer stem cells and non-stem cancer cells in culture.  Furthermore, this combinatorial therapy reduces tumor mass and prevents relapse much more effectively than either drug alone in a xenograft mouse model.  Mice seem to remain tumor-free for at least 2 mo after combinatorial therapy with metformin and doxorubicin is ended.  These results provide further evidence supporting the cancer stem cell hypothesis, and they provide a rationale and exptl. basis for using the combination of metformin and chemotherapeutic drugs to improve treatment of patients with breast (and possibly other) cancers. [Cancer Res 2009;69(19):7507-11].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwIa9rqZiXgrVg90H21EOLACvtfcHk0livPamaLp2KAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Skt7rN&md5=81ed04ee6b3755c2bb48c4b0f70c499f</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-2994&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-2994%26sid%3Dliteratum%253Aachs%26aulast%3DHirsch%26aufirst%3DH.%2BA.%26aulast%3DIliopoulos%26aufirst%3DD.%26aulast%3DTsichlis%26aufirst%3DP.%2BN.%26aulast%3DStruhl%26aufirst%3DK.%26atitle%3DMetformin%2520selectively%2520targets%2520cancer%2520stem%2520cells%252C%2520and%2520acts%2520together%2520with%2520chemotherapy%2520to%2520block%2520tumor%2520growth%2520and%2520prolong%2520remission%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D7507%26epage%3D7511%26doi%3D10.1158%2F0008-5472.CAN-09-2994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref209"><div class="reference"><strong class="refLabel"><a href="#ref209" class="rightTabRefNumLink">209</a></strong><div class="NLM_citation" id="rightTab-cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lonardo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cioffi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sancho, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Ripoll, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trabulo, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorado, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hidalgo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heeschen, C.</span></span> <span> </span><span class="NLM_article-title">Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">e76518</span>, <span class="refDoi">Â DOI: 10.1371/journal.pone.0076518</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1371%2Fjournal.pone.0076518" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=24204632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1ymsLzO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e76518&author=E.+Lonardoauthor=M.+Cioffiauthor=P.+Sanchoauthor=Y.+Sanchez-Ripollauthor=S.+M.+Trabuloauthor=J.+Doradoauthor=A.+Balicauthor=M.+Hidalgoauthor=C.+Heeschen&title=Metformin+targets+the+metabolic+achilles+heel+of+human+pancreatic+cancer+stem+cells&doi=10.1371%2Fjournal.pone.0076518"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells</span></div><div class="casAuthors">Lonardo, Enza; Cioffi, Michele; Sancho, Patricia; Sanchez-Ripoll, Yolanda; Trabulo, Sara Maria; Dorado, Jorge; Balic, Anamaria; Hidalgo, Manuel; Heeschen, Christopher</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e76518</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Pancreatic ductal adenocarcinomas contain a subset of exclusively tumorigenic cancer stem cells (CSCs), which are capable of repopulating the entire heterogeneous cancer cell populations and are highly resistant to std. chemotherapy.  Here we demonstrate that metformin selectively ablated pancreatic CSCs as evidenced by diminished expression of pluripotency-assocd. genes and CSC-assocd. surface markers.  Subsequently, the ability of metformin-treated CSCs to clonally expand in vitro was irreversibly abrogated by inducing apoptosis.  In contrast, non-CSCs preferentially responded by cell cycle arrest, but were not eliminated by metformin treatment.  Mechanistically, metformin increased reactive oxygen species prodn. in CSC and reduced their mitochondrial transmembrane potential.  The subsequent induction of lethal energy crisis in CSCs was independent of AMPK/mTOR.  Finally, in primary cancer tissue xenograft models metformin effectively reduced tumor burden and prevented disease progression; if combined with a stroma-targeting smoothened inhibitor for enhanced tissue penetration, while gemcitabine actually appeared dispensable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxb8VFTRqs5rVg90H21EOLACvtfcHk0livPamaLp2KAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1ymsLzO&md5=63d29c5b3286fb0bc610bffd0f1e8ea0</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0076518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0076518%26sid%3Dliteratum%253Aachs%26aulast%3DLonardo%26aufirst%3DE.%26aulast%3DCioffi%26aufirst%3DM.%26aulast%3DSancho%26aufirst%3DP.%26aulast%3DSanchez-Ripoll%26aufirst%3DY.%26aulast%3DTrabulo%26aufirst%3DS.%2BM.%26aulast%3DDorado%26aufirst%3DJ.%26aulast%3DBalic%26aufirst%3DA.%26aulast%3DHidalgo%26aufirst%3DM.%26aulast%3DHeeschen%26aufirst%3DC.%26atitle%3DMetformin%2520targets%2520the%2520metabolic%2520achilles%2520heel%2520of%2520human%2520pancreatic%2520cancer%2520stem%2520cells%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26spage%3De76518%26doi%3D10.1371%2Fjournal.pone.0076518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref210"><div class="reference"><strong class="refLabel"><a href="#ref210" class="rightTabRefNumLink">210</a></strong><div class="NLM_citation" id="rightTab-cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anisimov, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berstein, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egormin, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piskunova, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popovich, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zabezhinski, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovalenko, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poroshina, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semenchenko, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Provinciali, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Re, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franceschi, C.</span></span> <span> </span><span class="NLM_article-title">Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice</span>. <i>Exp. Gerontol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">685</span>â <span class="NLM_lpage">693</span>, <span class="refDoi">Â DOI: 10.1016/j.exger.2005.07.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.exger.2005.07.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=16125352" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVWhurbF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2005&pages=685-693&author=V.+N.+Anisimovauthor=L.+M.+Bersteinauthor=P.+A.+Egorminauthor=T.+S.+Piskunovaauthor=I.+G.+Popovichauthor=M.+A.+Zabezhinskiauthor=I.+G.+Kovalenkoauthor=T.+E.+Poroshinaauthor=A.+V.+Semenchenkoauthor=M.+Provincialiauthor=F.+Reauthor=C.+Franceschi&title=Effect+of+metformin+on+life+span+and+on+the+development+of+spontaneous+mammary+tumors+in+HER-2%2Fneu+transgenic+mice&doi=10.1016%2Fj.exger.2005.07.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice</span></div><div class="casAuthors">Anisimov, Vladimir N.; Berstein, Lev M.; Egormin, Peter A.; Piskunova, Tatiana S.; Popovich, Irina G.; Zabezhinski, Mark A.; Kovalenko, Irina G.; Poroshina, Tatiana E.; Semenchenko, Anna V.; Provinciali, Mauro; Re, Francesca; Franceschi, Claudio</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Gerontology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">8-9</span>),
    <span class="NLM_cas:pages">685-693</span>CODEN:
                <span class="NLM_cas:coden">EXGEAB</span>;
        ISSN:<span class="NLM_cas:issn">0531-5565</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Studies in mammals have led to the suggestion that hyperglycemia and hyperinsulinemia are important factors both in aging and in the development of cancer.  Insulin/insulin-like growth factor 1 (IGF-1) signaling mols. that have been linked to longevity include DAF-2 and InR and their homologs in mammals, and inactivation of the corresponding genes is followed by increased life span in nematodes, fruit flies and mice.  It is possible that the life-prolonging effects of calorie restriction are due to decreasing IGF-1 levels.  A search of pharmacol. modulators of insulin/IGF-1 signaling pathway (which mimetic effects of life span extending mutations or calorie restriction) could be a perspective direction in regulation of longevity.  The chronic treatment of female transgenic HER-2/neu mice with metformin (100 mg/kg in drinking water) slightly decreased the food consumption but failed in reducing the body wt. or temp., slowed down the age-related rise in blood glucose and triglycerides level, as well as the age-related switch-off of estrous function, prolonged the mean life span by 8% (p<0.05), the mean life span of last 10% survivors by 13.1%, and the max. life span by 1 mo in comparison with control mice.  The demog. aging rate represented by the est. of resp. Gompertz's parameter was decreased 2.26 times.  The metformin-treatment significantly decreased the incidence and size of mammary adenocarcinomas in mice and increased the mean latency of the tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquypiouA6-lbVg90H21EOLACvtfcHk0lhvA2NqpnwO-Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVWhurbF&md5=44465d0322e7286c74392ac47b7b4432</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1016%2Fj.exger.2005.07.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.exger.2005.07.007%26sid%3Dliteratum%253Aachs%26aulast%3DAnisimov%26aufirst%3DV.%2BN.%26aulast%3DBerstein%26aufirst%3DL.%2BM.%26aulast%3DEgormin%26aufirst%3DP.%2BA.%26aulast%3DPiskunova%26aufirst%3DT.%2BS.%26aulast%3DPopovich%26aufirst%3DI.%2BG.%26aulast%3DZabezhinski%26aufirst%3DM.%2BA.%26aulast%3DKovalenko%26aufirst%3DI.%2BG.%26aulast%3DPoroshina%26aufirst%3DT.%2BE.%26aulast%3DSemenchenko%26aufirst%3DA.%2BV.%26aulast%3DProvinciali%26aufirst%3DM.%26aulast%3DRe%26aufirst%3DF.%26aulast%3DFranceschi%26aufirst%3DC.%26atitle%3DEffect%2520of%2520metformin%2520on%2520life%2520span%2520and%2520on%2520the%2520development%2520of%2520spontaneous%2520mammary%2520tumors%2520in%2520HER-2%252Fneu%2520transgenic%2520mice%26jtitle%3DExp.%2520Gerontol.%26date%3D2005%26volume%3D40%26spage%3D685%26epage%3D693%26doi%3D10.1016%2Fj.exger.2005.07.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref211"><div class="reference"><strong class="refLabel"><a href="#ref211" class="rightTabRefNumLink">211</a></strong><div class="NLM_citation" id="rightTab-cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tilley, J.</span>; <span class="NLM_string-name">Grimsby, J.</span>; <span class="NLM_string-name">Erickson, S.</span>; <span class="NLM_string-name">Berthel, S.</span></span> <span> </span><span class="NLM_article-title">Diabetes Drugs: Present and Emerging</span>. In  <i>Cardiovascular, Endocrine and Metabolic Diseases</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, D. J.</span></span>, Ed.; Burgerâs Medicinal Chemistry, Drug Discovery, and Development; <span class="NLM_publisher-name">John Wiley & Sons, Inc</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>, <span class="NLM_year">2010</span>; pp  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">31</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1002%2F0471266949.bmc198" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&pages=1-31&author=J.+Tilley&author=J.+Grimsby&author=S.+Erickson&author=S.+Berthelauthor=D.+J.+Abraham&title=Cardiovascular%2C+Endocrine+and+Metabolic+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1002%2F0471266949.bmc198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F0471266949.bmc198%26sid%3Dliteratum%253Aachs%26aulast%3DTilley%26aufirst%3DJ.%26atitle%3DDiabetes%2520Drugs%253A%2520Present%2520and%2520Emerging%26btitle%3DCardiovascular%252C%2520Endocrine%2520and%2520Metabolic%2520Diseases%26aulast%3DAbraham%26aufirst%3DD.%2BJ.%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26date%3D2010%26spage%3D1%26epage%3D31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref212"><div class="reference"><strong class="refLabel"><a href="#ref212" class="rightTabRefNumLink">212</a></strong><div class="NLM_citation" id="rightTab-cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dallos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitagawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunnumakkara, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Memmott, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollander, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gills, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dennis, P. A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of lung tumorigenesis by metformin Is associated with decreased plasma IGF-I and diminished receptor tyrosine kinase signaling</span>. <i>Cancer Prev. Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">801</span>â <span class="NLM_lpage">810</span>, <span class="refDoi">Â DOI: 10.1158/1940-6207.CAPR-13-0058-T</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F1940-6207.CAPR-13-0058-T" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=23771523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1amt73P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=801-810&author=B.+J.+Quinnauthor=M.+Dallosauthor=H.+Kitagawaauthor=A.+B.+Kunnumakkaraauthor=R.+M.+Memmottauthor=M.+C.+Hollanderauthor=J.+J.+Gillsauthor=P.+A.+Dennis&title=Inhibition+of+lung+tumorigenesis+by+metformin+Is+associated+with+decreased+plasma+IGF-I+and+diminished+receptor+tyrosine+kinase+signaling&doi=10.1158%2F1940-6207.CAPR-13-0058-T"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit212R"><div class="casContent"><span class="casTitleNuber">212</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Lung Tumorigenesis by Metformin Is Associated with Decreased Plasma IGF-I and Diminished Receptor Tyrosine Kinase Signaling</span></div><div class="casAuthors">Quinn, Brendan J.; Dallos, Matthew; Kitagawa, Hiroshi; Kunnumakkara, Ajaikumar B.; Memmott, Regan M.; Hollander, M. Christine; Gills, Joell J.; Dennis, Phillip A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Prevention Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">801-810</span>CODEN:
                <span class="NLM_cas:coden">CPRACC</span>;
        ISSN:<span class="NLM_cas:issn">1940-6207</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Metformin is the most commonly prescribed drug for type II diabetes and is assocd. with decreased cancer risk.  Previously, we showed that metformin prevented tobacco carcinogen (NNK)-induced lung tumorigenesis in a non-diabetic mouse model, which was assocd. with decreased IGF-I/insulin receptor signaling but not activation of AMPK in lung tissues, as well as decreased circulating levels of IGF-I and insulin.  Here, we used liver IGF-I-deficient (LID) mice to det. the importance of IGF-I in NNK-induced lung tumorigenesis and chemoprevention by metformin.  LID mice had decreased lung tumor multiplicity and burden compared with wild-type (WT) mice.  Metformin further decreased lung tumorigenesis in LID mice without affecting IGF-I levels, suggesting that metformin can act through IGF-I-independent mechanisms.  In lung tissues, metformin decreased phosphorylation of multiple receptor tyrosine kinases (RTK) as well as levels of GTP-bound Ras independently of AMPK.  Metformin also diminished plasma levels of several cognate ligands for these RTKs.  Tissue distribution studies using [14C]-metformin showed that uptake of metformin was high in liver but four-fold lower in lungs, suggesting that the suppression of RTK activation by metformin occurs predominantly via systemic, indirect effects.  Systemic inhibition of circulating growth factors and local RTK signaling are new AMPK-independent mechanisms of action of metformin that could underlie its ability to prevent tobacco carcinogen-induced lung tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6tDMvbu-p0bVg90H21EOLACvtfcHk0lhvA2NqpnwO-Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1amt73P&md5=e3545277bfd7f09dbf58a117063e2cb3</span></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1158%2F1940-6207.CAPR-13-0058-T&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1940-6207.CAPR-13-0058-T%26sid%3Dliteratum%253Aachs%26aulast%3DQuinn%26aufirst%3DB.%2BJ.%26aulast%3DDallos%26aufirst%3DM.%26aulast%3DKitagawa%26aufirst%3DH.%26aulast%3DKunnumakkara%26aufirst%3DA.%2BB.%26aulast%3DMemmott%26aufirst%3DR.%2BM.%26aulast%3DHollander%26aufirst%3DM.%2BC.%26aulast%3DGills%26aufirst%3DJ.%2BJ.%26aulast%3DDennis%26aufirst%3DP.%2BA.%26atitle%3DInhibition%2520of%2520lung%2520tumorigenesis%2520by%2520metformin%2520Is%2520associated%2520with%2520decreased%2520plasma%2520IGF-I%2520and%2520diminished%2520receptor%2520tyrosine%2520kinase%2520signaling%26jtitle%3DCancer%2520Prev.%2520Res.%26date%3D2013%26volume%3D6%26spage%3D801%26epage%3D810%26doi%3D10.1158%2F1940-6207.CAPR-13-0058-T" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref213"><div class="reference"><strong class="refLabel"><a href="#ref213" class="rightTabRefNumLink">213</a></strong><div class="NLM_citation" id="rightTab-cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lam, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S. G.</span></span> <span> </span><span class="NLM_article-title">New metformin derivative HL156A prevents oral cancer progression by inhibiting the insulin-like growth factor/AKT/mammalian target of rapamycin pathways</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">699</span>â <span class="NLM_lpage">709</span>, <span class="refDoi">Â DOI: 10.1111/cas.13482</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1111%2Fcas.13482" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=29285837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVeqtrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2018&pages=699-709&author=T.+G.+Lamauthor=Y.+S.+Jeongauthor=S.+A.+Kimauthor=S.+G.+Ahn&title=New+metformin+derivative+HL156A+prevents+oral+cancer+progression+by+inhibiting+the+insulin-like+growth+factor%2FAKT%2Fmammalian+target+of+rapamycin+pathways&doi=10.1111%2Fcas.13482"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">New metformin derivative HL156A prevents oral cancer progression by inhibiting the insulin-like growth factor/AKT/mammalian target of rapamycin pathways</span></div><div class="casAuthors">Lam, Thuy Giang; Jeong, Yun Soo; Kim, Soo-A.; Ahn, Sang-Gun</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">699-709</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Metformin is a biguanide widely prescribed as an antidiabetic drug for type 2 diabetes mellitus patients.  The purpose of the present study was to observe the effects of the new metformin deriv., HL156A, on human oral cancer cell and to investigate its possible mechanisms.  It was obsd. that HL156A significantly decreased FaDu and YD-10B cell viability and colony formation in a dose-dependent way.  HL156A also markedly reduced wound closure and migration of FaDu and YD-10B cells.  We obsd. that HL156A decreased mitochondrial membrane potential and induced reactive oxygen species (ROS) levels and apoptotic cells with caspase-3 and -9 activation.  HL156A inhibited the expression and activation of insulin-like growth factor (IGF)-1 and its downstream proteins, AKT, mammalian target of rapamycin (mTOR), and ERK1/2.  In addn., HL156A activated AMP-activated protein kinase/nuclear factor kappa B (AMPK-NF-ÎºB) signaling of FaDu and YD-10B cells.  A xenograft mouse model further showed that HL156A suppressed AT84 mouse oral tumor growth, accompanied by down-regulated p-IGF-1, p-mTOR, proliferating cell nuclear antigen (PCNA) and promoted p-AMPK and TUNEL expression.  These results suggest the potential value of the new metformin deriv. HL156A as a candidate for a therapeutic modality for the treatment of oral cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4saWi6-sLmbVg90H21EOLACvtfcHk0lihbgr2Xw67Jg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVeqtrs%253D&md5=6a51c0497656bc24413a75ede141f11d</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1111%2Fcas.13482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.13482%26sid%3Dliteratum%253Aachs%26aulast%3DLam%26aufirst%3DT.%2BG.%26aulast%3DJeong%26aufirst%3DY.%2BS.%26aulast%3DKim%26aufirst%3DS.%2BA.%26aulast%3DAhn%26aufirst%3DS.%2BG.%26atitle%3DNew%2520metformin%2520derivative%2520HL156A%2520prevents%2520oral%2520cancer%2520progression%2520by%2520inhibiting%2520the%2520insulin-like%2520growth%2520factor%252FAKT%252Fmammalian%2520target%2520of%2520rapamycin%2520pathways%26jtitle%3DCancer%2520Sci.%26date%3D2018%26volume%3D109%26spage%3D699%26epage%3D709%26doi%3D10.1111%2Fcas.13482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref214"><div class="reference"><strong class="refLabel"><a href="#ref214" class="rightTabRefNumLink">214</a></strong><div class="NLM_citation" id="rightTab-cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berhoerster, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellinghaus, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haerter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greschat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wengner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haegebarth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess-Stumpp, H.</span></span> <span> </span><span class="NLM_article-title">Abstract 4503: BAY 87-2243, an inhibitor of HIF-1Î± activation and stabilization, showed promising anti-tumor efficacy either as monotherapy or in combination with anti-VEGF and chemotherapy agents in preclinical tumor models</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">4503</span>â <span class="NLM_lpage">4503</span>, <span class="refDoi">Â DOI: 10.1158/1538-7445.AM2011-4503</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F1538-7445.AM2011-4503" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=4503-4503&author=K.+Berhoersterauthor=P.+Ellinghausauthor=M.+Haerterauthor=S.+Greschatauthor=A.+Wengnerauthor=A.+Scholzauthor=A.+Haegebarthauthor=H.+Hess-Stumpp&title=Abstract+4503%3A+BAY+87-2243%2C+an+inhibitor+of+HIF-1%CE%B1+activation+and+stabilization%2C+showed+promising+anti-tumor+efficacy+either+as+monotherapy+or+in+combination+with+anti-VEGF+and+chemotherapy+agents+in+preclinical+tumor+models&doi=10.1158%2F1538-7445.AM2011-4503"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2011-4503&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2011-4503%26sid%3Dliteratum%253Aachs%26aulast%3DBerhoerster%26aufirst%3DK.%26aulast%3DEllinghaus%26aufirst%3DP.%26aulast%3DHaerter%26aufirst%3DM.%26aulast%3DGreschat%26aufirst%3DS.%26aulast%3DWengner%26aufirst%3DA.%26aulast%3DScholz%26aufirst%3DA.%26aulast%3DHaegebarth%26aufirst%3DA.%26aulast%3DHess-Stumpp%26aufirst%3DH.%26atitle%3DAbstract%25204503%253A%2520BAY%252087-2243%252C%2520an%2520inhibitor%2520of%2520HIF-1%25CE%25B1%2520activation%2520and%2520stabilization%252C%2520showed%2520promising%2520anti-tumor%2520efficacy%2520either%2520as%2520monotherapy%2520or%2520in%2520combination%2520with%2520anti-VEGF%2520and%2520chemotherapy%2520agents%2520in%2520preclinical%2520tumor%2520models%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D4503%26epage%3D4503%26doi%3D10.1158%2F1538-7445.AM2011-4503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref215"><div class="reference"><strong class="refLabel"><a href="#ref215" class="rightTabRefNumLink">215</a></strong><div class="NLM_citation" id="rightTab-cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hess-Stumpp, H.</span></span> <span> </span><span class="NLM_article-title">Abstract LB-244: BAY 87-2243, an inhibitor of HIF-1Î± - induced gene activation, showed promising anti-tumor efficacy in combination with anti-angiogenic therapy and irradiation in preclinical tumor models</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">LB-244</span>, <span class="refDoi">Â DOI: 10.1158/1538-7445.AM2012-LB-244</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F1538-7445.AM2012-LB-244" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=LB-244&author=H.+Hess-Stumpp&title=Abstract+LB-244%3A+BAY+87-2243%2C+an+inhibitor+of+HIF-1%CE%B1+-+induced+gene+activation%2C+showed+promising+anti-tumor+efficacy+in+combination+with+anti-angiogenic+therapy+and+irradiation+in+preclinical+tumor+models&doi=10.1158%2F1538-7445.AM2012-LB-244"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2012-LB-244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2012-LB-244%26sid%3Dliteratum%253Aachs%26aulast%3DHess-Stumpp%26aufirst%3DH.%26atitle%3DAbstract%2520LB-244%253A%2520BAY%252087-2243%252C%2520an%2520inhibitor%2520of%2520HIF-1%25CE%25B1%2520-%2520induced%2520gene%2520activation%252C%2520showed%2520promising%2520anti-tumor%2520efficacy%2520in%2520combination%2520with%2520anti-angiogenic%2520therapy%2520and%2520irradiation%2520in%2520preclinical%2520tumor%2520models%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3DLB-244%26doi%3D10.1158%2F1538-7445.AM2012-LB-244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref216"><div class="reference"><strong class="refLabel"><a href="#ref216" class="rightTabRefNumLink">216</a></strong><div class="NLM_citation" id="rightTab-cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yap, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahnert, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piha-Paul, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janku, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karp, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naing, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumbrava, E. E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pant, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subbiah, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsimberidou, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vellano, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahendra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francesco, M. E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marszalek, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meric-Bernstam, F.</span></span> <span> </span><span class="NLM_article-title">Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial electron transport chain, in patients (pts) with advanced solid tumors</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">3014</span>â <span class="NLM_lpage">3014</span>, <span class="refDoi">Â DOI: 10.1200/JCO.2019.37.15_suppl.3014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1200%2FJCO.2019.37.15_suppl.3014" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=3014-3014&author=T.+A.+Yapauthor=J.+R.+Ahnertauthor=S.+A.+Piha-Paulauthor=S.+Fuauthor=F.+Jankuauthor=D.+D.+Karpauthor=A.+Naingauthor=E.+E.+I.+Dumbravaauthor=S.+Pantauthor=V.+Subbiahauthor=A.+M.+Tsimberidouauthor=D.+S.+Hongauthor=K.+M.+Roseauthor=Q.+Xuauthor=C.+P.+Vellanoauthor=M.+Mahendraauthor=P.+Jonesauthor=M.+E.+D.+Francescoauthor=J.+R.+Marszalekauthor=F.+Meric-Bernstam&title=Phase+I+trial+of+IACS-010759+%28IACS%29%2C+a+potent%2C+selective+inhibitor+of+complex+I+of+the+mitochondrial+electron+transport+chain%2C+in+patients+%28pts%29+with+advanced+solid+tumors&doi=10.1200%2FJCO.2019.37.15_suppl.3014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.1200%2FJCO.2019.37.15_suppl.3014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2019.37.15_suppl.3014%26sid%3Dliteratum%253Aachs%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DAhnert%26aufirst%3DJ.%2BR.%26aulast%3DPiha-Paul%26aufirst%3DS.%2BA.%26aulast%3DFu%26aufirst%3DS.%26aulast%3DJanku%26aufirst%3DF.%26aulast%3DKarp%26aufirst%3DD.%2BD.%26aulast%3DNaing%26aufirst%3DA.%26aulast%3DDumbrava%26aufirst%3DE.%2BE.%2BI.%26aulast%3DPant%26aufirst%3DS.%26aulast%3DSubbiah%26aufirst%3DV.%26aulast%3DTsimberidou%26aufirst%3DA.%2BM.%26aulast%3DHong%26aufirst%3DD.%2BS.%26aulast%3DRose%26aufirst%3DK.%2BM.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DVellano%26aufirst%3DC.%2BP.%26aulast%3DMahendra%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DFrancesco%26aufirst%3DM.%2BE.%2BD.%26aulast%3DMarszalek%26aufirst%3DJ.%2BR.%26aulast%3DMeric-Bernstam%26aufirst%3DF.%26atitle%3DPhase%2520I%2520trial%2520of%2520IACS-010759%2520%2528IACS%2529%252C%2520a%2520potent%252C%2520selective%2520inhibitor%2520of%2520complex%2520I%2520of%2520the%2520mitochondrial%2520electron%2520transport%2520chain%252C%2520in%2520patients%2520%2528pts%2529%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2019%26volume%3D37%26spage%3D3014%26epage%3D3014%26doi%3D10.1200%2FJCO.2019.37.15_suppl.3014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref217"><div class="reference"><strong class="refLabel"><a href="#ref217" class="rightTabRefNumLink">217</a></strong><div class="NLM_citation" id="rightTab-cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mansi, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degraeff, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newell, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaholm, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Button, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payne, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, I. E.</span></span> <span> </span><span class="NLM_article-title">A phase-II clinical and pharmacokinetic study of lonidamine in patients with advanced breast-cancer</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">593</span>â <span class="NLM_lpage">597</span>, <span class="refDoi">Â DOI: 10.1038/bjc.1991.356</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fbjc.1991.356" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1911204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADyaK38%252FgtFarug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1991&pages=593-597&author=J.+L.+Mansiauthor=A.+Degraeffauthor=D.+R.+Newellauthor=J.+Glaholmauthor=D.+Buttonauthor=M.+O.+Leachauthor=G.+Payneauthor=I.+E.+Smith&title=A+phase-II+clinical+and+pharmacokinetic+study+of+lonidamine+in+patients+with+advanced+breast-cancer&doi=10.1038%2Fbjc.1991.356"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II clinical and pharmacokinetic study of Lonidamine in patients with advanced breast cancer</span></div><div class="casAuthors">Mansi J L; de Graeff A; Newell D R; Glaholm J; Button D; Leach M O; Payne G; Smith I E</div><div class="citationInfo"><span class="NLM_cas:title">British journal of cancer</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">593-7</span>
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    </div><div class="casAbstract">Lonidamine is a substituted indazole carboxylic acid with a unique mechanism of action and early clinical studies have reported anti-tumour activity.  In a phase II study 32 patients with previously treated advanced breast cancer were given Lonidamine in a daily divided oral dose of 600 mg.  Of 28 patients evaluable for response, three (11%) achieved a partial response (4-24+ months) and three (11%) a minor response.  Two patients have stable disease (greater than 3 months) and 20 progressed.  Toxicity was very mild.  Sixteen (53%) of 31 patients had myalgia which lasted a median of 2 weeks.  This was investigated with nuclear magnetic resonance spectroscopy in four patients but the changes were unrelated to the degree of myalgia.  No other major side-effect was seen, and no dose reduction was required.  Lonidamine pharmacokinetics have been investigated in 17 patients 1 month after the start of therapy.  Lonidamine was detected in the plasma of all patients, but there was no clear relationship between Lonidamine levels and clinical response or toxicity.  Lonidamine appears to be active against advanced breast cancer and its low toxicity would allow combination studies with chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRdK09xcjEvgt0Q2ypr7jHkfW6udTcc2ebt4-DIj7VkoLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK38%252FgtFarug%253D%253D&md5=53df069050bdecaf1c9329e1667480c0</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.1038%2Fbjc.1991.356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.1991.356%26sid%3Dliteratum%253Aachs%26aulast%3DMansi%26aufirst%3DJ.%2BL.%26aulast%3DDegraeff%26aufirst%3DA.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DGlaholm%26aufirst%3DJ.%26aulast%3DButton%26aufirst%3DD.%26aulast%3DLeach%26aufirst%3DM.%2BO.%26aulast%3DPayne%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DI.%2BE.%26atitle%3DA%2520phase-II%2520clinical%2520and%2520pharmacokinetic%2520study%2520of%2520lonidamine%2520in%2520patients%2520with%2520advanced%2520breast-cancer%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D1991%26volume%3D64%26spage%3D593%26epage%3D597%26doi%3D10.1038%2Fbjc.1991.356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref218"><div class="reference"><strong class="refLabel"><a href="#ref218" class="rightTabRefNumLink">218</a></strong><div class="NLM_citation" id="rightTab-cit218"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Lena, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorusso, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latorre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanizza, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gargano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caporusso, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crucitta, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambiasi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzei, A.</span></span> <span> </span><span class="NLM_article-title">Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">364</span>â <span class="NLM_lpage">368</span>, <span class="refDoi">Â DOI: 10.1016/S0959-8049(00)00400-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2FS0959-8049%2800%2900400-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=11239758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhs1art7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2001&pages=364-368&author=M.+De+Lenaauthor=V.+Lorussoauthor=A.+Latorreauthor=G.+Fanizzaauthor=G.+Garganoauthor=L.+Caporussoauthor=M.+Guidaauthor=A.+Catinoauthor=E.+Crucittaauthor=D.+Sambiasiauthor=A.+Mazzei&title=Paclitaxel%2C+cisplatin+and+lonidamine+in+advanced+ovarian+cancer.+A+phase+II+study&doi=10.1016%2FS0959-8049%2800%2900400-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit218R"><div class="casContent"><span class="casTitleNuber">218</span><div class="casTitle"><span class="NLM_cas:atitle">Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study</span></div><div class="casAuthors">De Lena, M.; Lorusso, V.; Latorre, A.; Fanizza, G.; Gargano, G.; Caporusso, L.; Guida, M.; Catino, A.; Crucitta, E.; Sambiasi, D.; Mazzei, A.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">364-368</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A potential way to improve the results obtained with the std. carboplatin/cisplatin (CDDP)-Paclitaxel treatment regimen in advanced ovarian cancer is to incorporate a modulating agent such as lonidamine (LND).  In fact, LND has been shown to revert the resistance to cisplatin and to potentiate cisplatin activity in exptl. models and in clin. studies.  Thirty-five consecutive patients with advanced ovarian cancer, not previously treated with chemotherapy, were treated with Paclitaxel at a dose of 135 mg/m2 i.v. on day 1 (in a 3-h infusion) and cisplatin at a dose of 75 mg/m2 i.v. on day 2 plus LND orally at a dose of 450 mg/day for 6 consecutive days starting 2 days before chemotherapy, every 3 wk for 6 cycles.  Complete plus partial responses were obsd. in 8 (80%) out of the 10 women with measurable disease.  In the 25 patients with evaluable disease, only 4 clin. progressions were obsd. (16%).  Median progression-free survival (PFS) and overall survival (OS) were 28.5 [95% confidence interval (CI) 22.2-34.8] and 46.5 (95% CI 32.4-60.00) months, resp.  Grade 3-4 neutropenia was obsd. in 9 (26%) patients.  Alopecia, nausea, and vomiting (Grade 3) were obsd. in 33 (94%) and 5 (14%) patients, resp.  In conclusion, the combination of CDDP/Paclitaxel plus LND is active and tolerable in the treatment of advanced ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIq-ck0XHLELVg90H21EOLACvtfcHk0lisERs7Dn800A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhs1art7k%253D&md5=72f223ec639b954abf9f7c12a34adb09</span></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=10.1016%2FS0959-8049%2800%2900400-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-8049%252800%252900400-7%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BLena%26aufirst%3DM.%26aulast%3DLorusso%26aufirst%3DV.%26aulast%3DLatorre%26aufirst%3DA.%26aulast%3DFanizza%26aufirst%3DG.%26aulast%3DGargano%26aufirst%3DG.%26aulast%3DCaporusso%26aufirst%3DL.%26aulast%3DGuida%26aufirst%3DM.%26aulast%3DCatino%26aufirst%3DA.%26aulast%3DCrucitta%26aufirst%3DE.%26aulast%3DSambiasi%26aufirst%3DD.%26aulast%3DMazzei%26aufirst%3DA.%26atitle%3DPaclitaxel%252C%2520cisplatin%2520and%2520lonidamine%2520in%2520advanced%2520ovarian%2520cancer.%2520A%2520phase%2520II%2520study%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2001%26volume%3D37%26spage%3D364%26epage%3D368%26doi%3D10.1016%2FS0959-8049%2800%2900400-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref219"><div class="reference"><strong class="refLabel"><a href="#ref219" class="rightTabRefNumLink">219</a></strong><div class="NLM_citation" id="rightTab-cit219"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cervantes-Madrid, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duenas-Gonzalez, A.</span></span> <span> </span><span class="NLM_article-title">Reviving lonidamine and 6-diazo-5-oxo-L-norleucine to be used in combination for metabolic cancer therapy</span>. <i>BioMed Res. Int.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2015</i></span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">13</span>, <span class="refDoi">Â DOI: 10.1155/2015/690492</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1155%2F2015%2F690492" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2015&publication_year=2015&pages=1-13&author=D.+Cervantes-Madridauthor=Y.+Romeroauthor=A.+Duenas-Gonzalez&title=Reviving+lonidamine+and+6-diazo-5-oxo-L-norleucine+to+be+used+in+combination+for+metabolic+cancer+therapy&doi=10.1155%2F2015%2F690492"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1155%2F2015%2F690492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2015%252F690492%26sid%3Dliteratum%253Aachs%26aulast%3DCervantes-Madrid%26aufirst%3DD.%26aulast%3DRomero%26aufirst%3DY.%26aulast%3DDuenas-Gonzalez%26aufirst%3DA.%26atitle%3DReviving%2520lonidamine%2520and%25206-diazo-5-oxo-L-norleucine%2520to%2520be%2520used%2520in%2520combination%2520for%2520metabolic%2520cancer%2520therapy%26jtitle%3DBioMed%2520Res.%2520Int.%26date%3D2015%26volume%3D2015%26spage%3D1%26epage%3D13%26doi%3D10.1155%2F2015%2F690492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref220"><div class="reference"><strong class="refLabel"><a href="#ref220" class="rightTabRefNumLink">220</a></strong><div class="NLM_citation" id="rightTab-cit220"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salabei, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibb, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, B. G.</span></span> <span> </span><span class="NLM_article-title">Comprehensive measurement of respiratory activity in permeabilized cells using extracellular flux analysis</span>. <i>Nat. Protoc.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">421</span>â <span class="NLM_lpage">38</span>, <span class="refDoi">Â DOI: 10.1038/nprot.2014.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fnprot.2014.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=24457333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1Cktrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=421-38&author=J.+K.+Salabeiauthor=A.+A.+Gibbauthor=B.+G.+Hill&title=Comprehensive+measurement+of+respiratory+activity+in+permeabilized+cells+using+extracellular+flux+analysis&doi=10.1038%2Fnprot.2014.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit220R"><div class="casContent"><span class="casTitleNuber">220</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive measurement of respiratory activity in permeabilized cells using extracellular flux analysis</span></div><div class="casAuthors">Salabei, Joshua K.; Gibb, Andrew A.; Hill, Bradford G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">421-438</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Extracellular flux (XF) anal. has become a mainstream method for measuring mitochondrial function in cells and tissues.  Although this technique is commonly used to measure bioenergetics in intact cells, we outline here a detailed XF protocol for measuring respiration in permeabilized cells.  Cells are permeabilized using saponin (SAP), digitonin (DIG) or recombinant perfringolysin O (rPFO) (XF-plasma membrane permeabilizer (PMP) reagent), and they are provided with specific substrates to measure complex I- or complex II-mediated respiratory activity, complex III+IV respiratory activity or complex IV activity.  Medium- and long-chain acylcarnitines or glutamine may also be provided for measuring fatty acid (FA) oxidn. or glutamine oxidn., resp.  This protocol uses a minimal no. of cells compared with other protocols and does not require isolation of mitochondria.  The results are highly reproducible, and mitochondria remain well coupled.  Collectively, this protocol provides comprehensive and detailed information regarding mitochondrial activity and efficiency, and, after preparative steps, it takes 6-8 h to complete.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosNLIbyikZobVg90H21EOLACvtfcHk0lisERs7Dn800A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1Cktrk%253D&md5=d106bf025c855852f819c42f183c2374</span></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2014.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2014.018%26sid%3Dliteratum%253Aachs%26aulast%3DSalabei%26aufirst%3DJ.%2BK.%26aulast%3DGibb%26aufirst%3DA.%2BA.%26aulast%3DHill%26aufirst%3DB.%2BG.%26atitle%3DComprehensive%2520measurement%2520of%2520respiratory%2520activity%2520in%2520permeabilized%2520cells%2520using%2520extracellular%2520flux%2520analysis%26jtitle%3DNat.%2520Protoc.%26date%3D2014%26volume%3D9%26spage%3D421%26epage%3D38%26doi%3D10.1038%2Fnprot.2014.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref221"><div class="reference"><strong class="refLabel"><a href="#ref221" class="rightTabRefNumLink">221</a></strong><div class="NLM_citation" id="rightTab-cit221"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span> <span> </span><span class="NLM_article-title">Targeting mitochondria by anthelmintic drug atovaquone sensitizes renal cell carcinoma to chemotherapy and immunotherapy</span>. <i>J. Biochem. Mol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">e22195</span>, <span class="refDoi">Â DOI: 10.1002/jbt.22195</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1002%2Fjbt.22195" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=30004155" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2018&pages=e22195&author=D.+H.+Chenauthor=X.+S.+Sunauthor=X.+J.+Zhangauthor=J.+Cao&title=Targeting+mitochondria+by+anthelmintic+drug+atovaquone+sensitizes+renal+cell+carcinoma+to+chemotherapy+and+immunotherapy&doi=10.1002%2Fjbt.22195"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.1002%2Fjbt.22195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjbt.22195%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DD.%2BH.%26aulast%3DSun%26aufirst%3DX.%2BS.%26aulast%3DZhang%26aufirst%3DX.%2BJ.%26aulast%3DCao%26aufirst%3DJ.%26atitle%3DTargeting%2520mitochondria%2520by%2520anthelmintic%2520drug%2520atovaquone%2520sensitizes%2520renal%2520cell%2520carcinoma%2520to%2520chemotherapy%2520and%2520immunotherapy%26jtitle%3DJ.%2520Biochem.%2520Mol.%2520Toxicol.%26date%3D2018%26volume%3D32%26spage%3De22195%26doi%3D10.1002%2Fjbt.22195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref222"><div class="reference"><strong class="refLabel"><a href="#ref222" class="rightTabRefNumLink">222</a></strong><div class="NLM_citation" id="rightTab-cit222"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lv, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span> <span> </span><span class="NLM_article-title">Atovaquone enhances doxorubicinâs efficacy via inhibiting mitochondrial respiration and STAT3 in aggressive thyroid cancer</span>. <i>J. Bioenerg. Biomembr.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">263</span>â <span class="NLM_lpage">270</span>, <span class="refDoi">Â DOI: 10.1007/s10863-018-9755-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1007%2Fs10863-018-9755-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=29687367" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotF2gtb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2018&pages=263-270&author=Z.+Lvauthor=X.+T.+Yanauthor=L.+Y.+Luauthor=C.+Suauthor=Y.+He&title=Atovaquone+enhances+doxorubicin%E2%80%99s+efficacy+via+inhibiting+mitochondrial+respiration+and+STAT3+in+aggressive+thyroid+cancer&doi=10.1007%2Fs10863-018-9755-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit222R"><div class="casContent"><span class="casTitleNuber">222</span><div class="casTitle"><span class="NLM_cas:atitle">Atovaquone enhances doxorubicin's efficacy via inhibiting mitochondrial respiration and STAT3 in aggressive thyroid cancer</span></div><div class="casAuthors">Lv, Zhuo; Yan, Xintong; Lu, Liying; Su, Chun; He, Yin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Bioenergetics and Biomembranes</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">263-270</span>CODEN:
                <span class="NLM_cas:coden">JBBID4</span>;
        ISSN:<span class="NLM_cas:issn">0145-479X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The clin. management of anaplastic thyroid carcinoma and follicular thyroid carcinoma is challenging and requires an alternative therapeutic strategy.  Although atovaquone is an FDA-approved anti-malarial drug, studies has recently demonstrated its anti-cancer activities.  In line with these efforts, our study shows that atovaquone is an attractive candidate for thyroid cancer treatment.  We show that atovaquone significantly inhibits growth, migration and survival in a concn.-dependent manner in 8505C and FTC113 cells.  Mechanistically, atovaquone inhibits mitochondrial complex III activity, leading to mitochondrial respiration inhibition and redn. of ATP prodn. in thyroid cancer cells.  The inhibitory effects of atovaquone is reversed in mitochondrial respiration-deficient 8505C Ï0 cells, confirming mitochondrial respiration as the mechanism of atovaquone's action in thyroid cancer.  In addn., atovaquone suppresses phosphorylation of STAT3 in thyroid cancer wildype but not Ï0 cells, demonstrating that STAT3 phosphorylation inhibition by atovaquone is a consequence of mitochondrial respiration inhibition.  Notably, we further demonstrate that atovaquone significantly augments doxorubicin's inhibitory effects via suppressing mitochondrial respiration and STAT3.  Our findings suggest that atovaquone can be repurposed for thyroid cancer treatment.  Our work also highlights that targeting mitochondrial respiration may represent potential therapeutic strategy in thyroid cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeYmgFi_UDGbVg90H21EOLACvtfcHk0lhICcSNN87LtA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotF2gtb0%253D&md5=f1e9fdf3565adaea762b5ee33a39eb2b</span></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.1007%2Fs10863-018-9755-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10863-018-9755-y%26sid%3Dliteratum%253Aachs%26aulast%3DLv%26aufirst%3DZ.%26aulast%3DYan%26aufirst%3DX.%2BT.%26aulast%3DLu%26aufirst%3DL.%2BY.%26aulast%3DSu%26aufirst%3DC.%26aulast%3DHe%26aufirst%3DY.%26atitle%3DAtovaquone%2520enhances%2520doxorubicin%25E2%2580%2599s%2520efficacy%2520via%2520inhibiting%2520mitochondrial%2520respiration%2520and%2520STAT3%2520in%2520aggressive%2520thyroid%2520cancer%26jtitle%3DJ.%2520Bioenerg.%2520Biomembr.%26date%3D2018%26volume%3D50%26spage%3D263%26epage%3D270%26doi%3D10.1007%2Fs10863-018-9755-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref223"><div class="reference"><strong class="refLabel"><a href="#ref223" class="rightTabRefNumLink">223</a></strong><div class="NLM_citation" id="rightTab-cit223"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizokami, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koshida, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namiki, M.</span></span> <span> </span><span class="NLM_article-title">Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo</span>. <i>Int. J. Urol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">587</span>â <span class="NLM_lpage">592</span>, <span class="refDoi">Â DOI: 10.1111/j.1442-2042.2006.01342.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1111%2Fj.1442-2042.2006.01342.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=16771730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD28XmslSitrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2006&pages=587-592&author=J.+Nagasawaauthor=A.+Mizokamiauthor=K.+Koshidaauthor=S.+Yoshidaauthor=K.+Naitoauthor=M.+Namiki&title=Novel+HER2+selective+tyrosine+kinase+inhibitor%2C+TAK-165%2C+inhibits+bladder%2C+kidney+and+androgen-independent+prostate+cancer+in+vitro+and+in+vivo&doi=10.1111%2Fj.1442-2042.2006.01342.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit223R"><div class="casContent"><span class="casTitleNuber">223</span><div class="casTitle"><span class="NLM_cas:atitle">Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo</span></div><div class="casAuthors">Nagasawa, Joji; Mizokami, Atsushi; Koshida, Kiyoshi; Yoshida, Sei; Naito, Kenichiro; Namiki, Mikio</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Urology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">587-592</span>CODEN:
                <span class="NLM_cas:coden">IJURF3</span>;
        ISSN:<span class="NLM_cas:issn">0919-8172</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Asia Pty Ltd.</span>)
        </div><div class="casAbstract">Purpose: TAK-165 is a new potent inhibitor of human epidermal growth factor receptor 2 (HER2) tyrosine kinase.  Several reports suggest HER2 expression in bladder cancer, renal cell carcinoma (RCC) and androgen-independent prostate cancer.  We therefore investigated the antitumor effect of TAK-165 on these urol. cancer cells.  Materials and methods: Western blot anal. was performed to confirm HER2 expression in cell lines.  To study in vitro efficacy, cells were treated with TAK-165 at various concns. for 72 h and then counted using a hemocytometer.  Then the IC50 value was calcd.  In the xenograft model, after the tumor reached 200-300 mm3 in vol., mice were orally administered TAK-165 10 mg/kg per day or 20 mg/kg per day or saline for 14 consecutive days (n = 6-8).  Results: HER2 expression was obsd. in HT1376, UMUC3, T24 (bladder), ACHN (kidney), DU145, LNCaP, LN-REC4 (prostate), although the expression level in these cells was weak compared with BT474 (a breast cancer cell line which expresses HER2 strongly).  IC50 was varied from 0.09 to greater than 25 Î¼mol/L in the bladder cancer cell line.  ACHN cells were less sensitive in vitro.  The prostate cancer cell lines studied were all sensitive (IC50 0.053-4.62 Î¼mol/L).  In the xenograft model, treatment with TAK-165 significantly inhibited growth of UMUC-3, ACHN, and LN-REC4.  The antitumor effect (T/C [%] = growth of TAK-165 treated tumor/av. growth of control tumor Ã 100) after 14 days treatment were 22.9%, 26.0%, and 26.5% in UMUC3, ACHN and LN-REC4, resp.  Conclusions: TAK-165 may be a hopeful new agent for bladder, kidney and androgen-independent prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU3g9-PiGTWbVg90H21EOLACvtfcHk0lhICcSNN87LtA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmslSitrY%253D&md5=5a946cdc377ea601f8813c33a47fdcaa</span></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.1111%2Fj.1442-2042.2006.01342.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1442-2042.2006.01342.x%26sid%3Dliteratum%253Aachs%26aulast%3DNagasawa%26aufirst%3DJ.%26aulast%3DMizokami%26aufirst%3DA.%26aulast%3DKoshida%26aufirst%3DK.%26aulast%3DYoshida%26aufirst%3DS.%26aulast%3DNaito%26aufirst%3DK.%26aulast%3DNamiki%26aufirst%3DM.%26atitle%3DNovel%2520HER2%2520selective%2520tyrosine%2520kinase%2520inhibitor%252C%2520TAK-165%252C%2520inhibits%2520bladder%252C%2520kidney%2520and%2520androgen-independent%2520prostate%2520cancer%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DInt.%2520J.%2520Urol.%26date%3D2006%26volume%3D13%26spage%3D587%26epage%3D592%26doi%3D10.1111%2Fj.1442-2042.2006.01342.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref224"><div class="reference"><strong class="refLabel"><a href="#ref224" class="rightTabRefNumLink">224</a></strong><div class="NLM_citation" id="rightTab-cit224"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Si, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, S. Y.</span></span> <span> </span><span class="NLM_article-title">Rotenone induces apoptosis in human lung cancer cells by regulating autophagic flux</span>. <i>IUBMB Life</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">388</span>â <span class="NLM_lpage">393</span>, <span class="refDoi">Â DOI: 10.1002/iub.1493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1002%2Fiub.1493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27015848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC28XkvVymt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2016&pages=388-393&author=W.+S.+Huauthor=H.+Tianauthor=W.+M.+Yueauthor=L.+Liauthor=S.+H.+Liauthor=C.+Gaoauthor=L.+B.+Siauthor=L.+Qiauthor=M.+Luauthor=B.+Haoauthor=S.+Y.+Shan&title=Rotenone+induces+apoptosis+in+human+lung+cancer+cells+by+regulating+autophagic+flux&doi=10.1002%2Fiub.1493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit224R"><div class="casContent"><span class="casTitleNuber">224</span><div class="casTitle"><span class="NLM_cas:atitle">Rotenone induces apoptosis in human lung cancer cells by regulating autophagic flux</span></div><div class="casAuthors">Hu, Wensi; Tian, Hui; Yue, Weiming; Li, Lin; Li, Shuhai; Gao, Cun; Si, Libo; Qi, Lei; Lu, Ming; Hao, Bin; Shan, Shuyu</div><div class="citationInfo"><span class="NLM_cas:title">IUBMB Life</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">388-393</span>CODEN:
                <span class="NLM_cas:coden">IULIF8</span>;
        ISSN:<span class="NLM_cas:issn">1521-6543</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Reactive oxygen species (ROS) are at the center of many physiol. and pathol. processes.  ROS generated due to oxidative stress can potentiate both cancer initiation and progression.  Rotenone, which is an inhibitor of the mitochondrial electron transport chain complex I, results in the activation of NOX2 and release of ROS, and has been shown to display anticancer activity through the induction of apoptosis in various cancer cells.  The mechanistic link between rotenone-dependent activation of NOX2 and induction of apoptosis is still elusive.  In this study, we used the human lung cancer A549 cells to study the mol. mechanism(s) involved between rotenone-dependent activation of NOX2 and impairment of autophagic machinery.  We report that acute exposure to rotenone induced mild NOX2-dependent oxidative stress, which impaired the autophagic flux, resulting in cytosolic accumulation of LC3 and p62/STSQM1.  We further show that this induction occurs through the PI3K/Akt/mTORC1 signaling pathway.  We furthermore show that chronic exposure to rotenone lead to excessive NOX2-dependent ROS generation, increases autophagy, and decreases p62 level via increased-autophagic flux.  Taken together, this study is the first mechanistic elucidation of how rotenone can be used to potently target cancer cells without overhauling the entire cellular machinery.  Â© 2016 IUBMB Life, 2016.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3sri5rDep4bVg90H21EOLACvtfcHk0lhICcSNN87LtA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkvVymt7g%253D&md5=11a3d9d884c541458dece58cd882642b</span></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=10.1002%2Fiub.1493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fiub.1493%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DW.%2BS.%26aulast%3DTian%26aufirst%3DH.%26aulast%3DYue%26aufirst%3DW.%2BM.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DS.%2BH.%26aulast%3DGao%26aufirst%3DC.%26aulast%3DSi%26aufirst%3DL.%2BB.%26aulast%3DQi%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DM.%26aulast%3DHao%26aufirst%3DB.%26aulast%3DShan%26aufirst%3DS.%2BY.%26atitle%3DRotenone%2520induces%2520apoptosis%2520in%2520human%2520lung%2520cancer%2520cells%2520by%2520regulating%2520autophagic%2520flux%26jtitle%3DIUBMB%2520Life%26date%3D2016%26volume%3D68%26spage%3D388%26epage%3D393%26doi%3D10.1002%2Fiub.1493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref225"><div class="reference"><strong class="refLabel"><a href="#ref225" class="rightTabRefNumLink">225</a></strong><div class="NLM_citation" id="rightTab-cit225"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragheb, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawler, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturgis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajwa, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melendez, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, J. P.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">8516</span>â <span class="NLM_lpage">8525</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M210432200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1074%2Fjbc.M210432200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=12496265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhsF2htrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=8516-8525&author=N.+Y.+Liauthor=K.+Raghebauthor=G.+Lawlerauthor=J.+Sturgisauthor=B.+Rajwaauthor=J.+A.+Melendezauthor=J.+P.+Robinson&title=Mitochondrial+complex+I+inhibitor+rotenone+induces+apoptosis+through+enhancing+mitochondrial+reactive+oxygen+species+production&doi=10.1074%2Fjbc.M210432200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit225R"><div class="casContent"><span class="casTitleNuber">225</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial Complex I Inhibitor Rotenone Induces Apoptosis through Enhancing Mitochondrial Reactive Oxygen Species Production</span></div><div class="casAuthors">Li, Nianyu; Ragheb, Kathy; Lawler, Gretchen; Sturgis, Jennie; Rajwa, Bartek; Melendez, J. Andres; Robinson, J. Paul</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">8516-8525</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Inhibition of mitochondrial respiratory chain complex I by rotenone had been found to induce cell death in a variety of cells.  However, the mechanism is still elusive.  Because reactive oxygen species (ROS) play an important role in apoptosis and inhibition of mitochondrial respiratory chain complex I by rotenone was thought to be able to elevate mitochondrial ROS prodn., we investigated the relationship between rotenone-induced apoptosis and mitochondrial reactive oxygen species.  Rotenone was able to induce mitochondrial complex I substrate-supported mitochondrial ROS prodn. both in isolated mitochondria from HL-60 cells as well as in cultured cells.  Rotenone-induced apoptosis was confirmed by DNA fragmentation, cytochrome c release, and caspase 3 activity.  A quant. correlation between rotenone-induced apoptosis and rotenone-induced mitochondrial ROS prodn. was identified.  Rotenone-induced apoptosis was inhibited by treatment with antioxidants (glutathione, N-acetylcysteine, and vitamin C).  The role of rotenone-induced mitochondrial ROS in apoptosis was also confirmed by the finding that HT1080 cells overexpressing magnesium superoxide dismutase were more resistant to rotenone-induced apoptosis than control cells.  These results suggest that rotenone is able to induce apoptosis via enhancing the amt. of mitochondrial reactive oxygen species prodn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQz9q2QbEOErVg90H21EOLACvtfcHk0lj6K3DGQXl_fw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhsF2htrg%253D&md5=3b5921aa876f55001b3c2e83cfead91e</span></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M210432200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M210432200%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DN.%2BY.%26aulast%3DRagheb%26aufirst%3DK.%26aulast%3DLawler%26aufirst%3DG.%26aulast%3DSturgis%26aufirst%3DJ.%26aulast%3DRajwa%26aufirst%3DB.%26aulast%3DMelendez%26aufirst%3DJ.%2BA.%26aulast%3DRobinson%26aufirst%3DJ.%2BP.%26atitle%3DMitochondrial%2520complex%2520I%2520inhibitor%2520rotenone%2520induces%2520apoptosis%2520through%2520enhancing%2520mitochondrial%2520reactive%2520oxygen%2520species%2520production%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D8516%26epage%3D8525%26doi%3D10.1074%2Fjbc.M210432200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref226"><div class="reference"><strong class="refLabel"><a href="#ref226" class="rightTabRefNumLink">226</a></strong><div class="NLM_citation" id="rightTab-cit226"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Urra, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardenas, C.</span></span> <span> </span><span class="NLM_article-title">The mitochondrial complex(I) ty of cancer</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">118</span>, <span class="refDoi">Â DOI: 10.3389/fonc.2017.00118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.3389%2Ffonc.2017.00118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=28642839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BC1cjhtV2ltQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=118&author=F.+A.+Urraauthor=F.+Munozauthor=A.+Lovyauthor=C.+Cardenas&title=The+mitochondrial+complex%28I%29+ty+of+cancer&doi=10.3389%2Ffonc.2017.00118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit226R"><div class="casContent"><span class="casTitleNuber">226</span><div class="casTitle"><span class="NLM_cas:atitle">The Mitochondrial Complex(I)ty of Cancer</span></div><div class="casAuthors">Urra Felix A; Munoz Felipe; Cardenas Cesar; Urra Felix A; Munoz Felipe; Cardenas Cesar; Lovy Alenka; Cardenas Cesar; Cardenas Cesar</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">118</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Recent evidence highlights that the cancer cell energy requirements vary greatly from normal cells and that cancer cells exhibit different metabolic phenotypes with variable participation of both glycolysis and oxidative phosphorylation.  NADH-ubiquinone oxidoreductase (Complex I) is the largest complex of the mitochondrial electron transport chain and contributes about 40% of the proton motive force required for mitochondrial ATP synthesis.  In addition, Complex I plays an essential role in biosynthesis and redox control during proliferation, resistance to cell death, and metastasis of cancer cells.  Although knowledge about the structure and assembly of Complex I is increasing, information about the role of Complex I subunits in tumorigenesis is scarce and contradictory.  Several small molecule inhibitors of Complex I have been described as selective anticancer agents; however, pharmacologic and genetic interventions on Complex I have also shown pro-tumorigenic actions, involving different cellular signaling.  Here, we discuss the role of Complex I in tumorigenesis, focusing on the specific participation of Complex I subunits in proliferation and metastasis of cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS8CRa6PoWgXNy3lHz94U-GfW6udTcc2eZzPexo8hKmJbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjhtV2ltQ%253D%253D&md5=96b3d2e4ba3f12a9b399c30f34a95b57</span></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2017.00118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2017.00118%26sid%3Dliteratum%253Aachs%26aulast%3DUrra%26aufirst%3DF.%2BA.%26aulast%3DMunoz%26aufirst%3DF.%26aulast%3DLovy%26aufirst%3DA.%26aulast%3DCardenas%26aufirst%3DC.%26atitle%3DThe%2520mitochondrial%2520complex%2528I%2529%2520ty%2520of%2520cancer%26jtitle%3DFront.%2520Oncol.%26date%3D2017%26volume%3D7%26spage%3D118%26doi%3D10.3389%2Ffonc.2017.00118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref227"><div class="reference"><strong class="refLabel"><a href="#ref227" class="rightTabRefNumLink">227</a></strong><div class="NLM_citation" id="rightTab-cit227"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hongo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kihara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kume, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niidome, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akaike, A.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase-3 beta activation mediates rotenone-induced cytotoxicity with the involvement of microtubule destabilization</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>426</i></span>,  <span class="NLM_fpage">94</span>â <span class="NLM_lpage">99</span>, <span class="refDoi">Â DOI: 10.1016/j.bbrc.2012.08.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.bbrc.2012.08.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=22922102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlSnsbjJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=426&publication_year=2012&pages=94-99&author=H.+Hongoauthor=T.+Kiharaauthor=T.+Kumeauthor=Y.+Izumiauthor=T.+Niidomeauthor=H.+Sugimotoauthor=A.+Akaike&title=Glycogen+synthase+kinase-3+beta+activation+mediates+rotenone-induced+cytotoxicity+with+the+involvement+of+microtubule+destabilization&doi=10.1016%2Fj.bbrc.2012.08.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit227R"><div class="casContent"><span class="casTitleNuber">227</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen synthase kinase-3Î² activation mediates rotenone-induced cytotoxicity with the involvement of microtubule destabilization</span></div><div class="casAuthors">Hongo, Haruyuki; Kihara, Takeshi; Kume, Toshiaki; Izumi, Yasuhiko; Niidome, Tetsuhiro; Sugimoto, Hachiro; Akaike, Akinori</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">426</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">94-99</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Rotenone, a mitochondrial complex I inhibitor, has been used to generate animal and cell culture models of Parkinson's disease.  Recent studies suggest that microtubule destabilization causes selective dopaminergic neuronal loss.  In this study, we investigated glycogen synthase kinase-3Î² (GSK3Î²) involvement in rotenone-induced microtubule destabilization.  Rotenone-induced cytotoxicity in SH-SY5Y cells was attenuated by the GSK3Î² inhibitor SB216763.  Tau, a microtubule-assocd. protein and substrate for GSK3Î², has been implicated in the pathogenesis of tauopathies such as Alzheimer's disease.  Rotenone induced an increase in phosphorylated tau, the effect of which was attenuated by concomitant treatment with SB216763.  Rotenone treatment also decreased tau expression in the microtubule fraction and increased tau expression in the cytosol fraction.  These effects were suppressed by SB216763, which suggests that rotenone reduces the capacity of tau to bind microtubules.  Rotenone treatment increased the amt. of free tubulin and reduced the amt. of polymd. tubulin, indicating that rotenone destabilizes microtubules.  Rotenone-induced microtubule destabilization was suppressed by SB216763 and taxol, a microtubule stabilizer.  Taxol prevented rotenone-induced cytotoxicity and morphol. changes.  Taken together, these results suggest that rotenone-induced cytotoxicity is mediated by microtubule destabilization via GSK3Î² activation, and that microtubule destabilization is caused by redn. in the binding capacity of tau to microtubules, which is a result of tau phosphorylation via GSK3Î² activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3UnP2g4mpk7Vg90H21EOLACvtfcHk0lj6K3DGQXl_fw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlSnsbjJ&md5=b9b767797823f8a3790753405e798f11</span></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2012.08.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2012.08.042%26sid%3Dliteratum%253Aachs%26aulast%3DHongo%26aufirst%3DH.%26aulast%3DKihara%26aufirst%3DT.%26aulast%3DKume%26aufirst%3DT.%26aulast%3DIzumi%26aufirst%3DY.%26aulast%3DNiidome%26aufirst%3DT.%26aulast%3DSugimoto%26aufirst%3DH.%26aulast%3DAkaike%26aufirst%3DA.%26atitle%3DGlycogen%2520synthase%2520kinase-3%2520beta%2520activation%2520mediates%2520rotenone-induced%2520cytotoxicity%2520with%2520the%2520involvement%2520of%2520microtubule%2520destabilization%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2012%26volume%3D426%26spage%3D94%26epage%3D99%26doi%3D10.1016%2Fj.bbrc.2012.08.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref228"><div class="reference"><strong class="refLabel"><a href="#ref228" class="rightTabRefNumLink">228</a></strong><div class="NLM_citation" id="rightTab-cit228"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esser, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hossain, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Helm, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deisenhofer, J.</span></span> <span> </span><span class="NLM_article-title">Structure of antimycin A1, a specific electron transfer inhibitor of ubiquinol-cytochrome c oxidoreductase</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">4902</span>â <span class="NLM_lpage">4903</span>, <span class="refDoi">Â DOI: 10.1021/ja990190h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja990190h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADyaK1MXivFChtL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=1999&pages=4902-4903&author=H.+Kimauthor=L.+Esserauthor=M.+B.+Hossainauthor=D.+Xiaauthor=C.-A.+Yuauthor=J.+Rizoauthor=D.+van+der+Helmauthor=J.+Deisenhofer&title=Structure+of+antimycin+A1%2C+a+specific+electron+transfer+inhibitor+of+ubiquinol-cytochrome+c+oxidoreductase&doi=10.1021%2Fja990190h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit228R"><div class="casContent"><span class="casTitleNuber">228</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of Antimycin A1, a Specific Electron Transfer Inhibitor of Ubiquinol-Cytochrome c Oxidoreductase</span></div><div class="casAuthors">Kim, Hoeon; Esser, Lothar; Hossain, M. Bilayet; Xia, Di; Yu, Chang-An; Rizo, Josep; van der Helm, Dick; Deisenhofer, Johann</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">4902-4903</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The structure of antimycin a1 was detd. by X-ray crystallog. and two-dimensional NMR spectroscopy.  The crystal structure revealed two ring moieties, a planar 3-formylamino salicylic acid (FASA) and a puckered dilactone which are connected through an (N2-C9) amide bond bridge.  The carbonyl oxygen atom O3 of the benzamide group is the acceptor for an intramol. hydrogen bond, donated by the phenolic OH group of the 3-FASA ring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq00atr11s98rVg90H21EOLACvtfcHk0lhBqfI8xPbEXg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXivFChtL4%253D&md5=68f6a8ca9686172007380f975c1cc78f</span></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=10.1021%2Fja990190h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja990190h%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.%26aulast%3DEsser%26aufirst%3DL.%26aulast%3DHossain%26aufirst%3DM.%2BB.%26aulast%3DXia%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DC.-A.%26aulast%3DRizo%26aufirst%3DJ.%26aulast%3Dvan%2Bder%2BHelm%26aufirst%3DD.%26aulast%3DDeisenhofer%26aufirst%3DJ.%26atitle%3DStructure%2520of%2520antimycin%2520A1%252C%2520a%2520specific%2520electron%2520transfer%2520inhibitor%2520of%2520ubiquinol-cytochrome%2520c%2520oxidoreductase%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1999%26volume%3D121%26spage%3D4902%26epage%3D4903%26doi%3D10.1021%2Fja990190h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref229"><div class="reference"><strong class="refLabel"><a href="#ref229" class="rightTabRefNumLink">229</a></strong><div class="NLM_citation" id="rightTab-cit229"><span><span class="NLM_contrib-group"><span class="NLM_string-name">King, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radicchi-Mastroianni, M. A.</span></span> <span> </span><span class="NLM_article-title">Antimycin A-induced apoptosis of HL-60 cells</span>. <i>Cytometry</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">106</span>â <span class="NLM_lpage">112</span>, <span class="refDoi">Â DOI: 10.1002/cyto.10156</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1002%2Fcyto.10156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=12442310" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD38XptV2mt7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2002&pages=106-112&author=M.+A.+Kingauthor=M.+A.+Radicchi-Mastroianni&title=Antimycin+A-induced+apoptosis+of+HL-60+cells&doi=10.1002%2Fcyto.10156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit229R"><div class="casContent"><span class="casTitleNuber">229</span><div class="casTitle"><span class="NLM_cas:atitle">Antimycin A-induced apoptosis of HL-60 cells</span></div><div class="casAuthors">King, Malcolm A.; Radicchi-Mastroianni, Monica A.</div><div class="citationInfo"><span class="NLM_cas:title">Cytometry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">106-112</span>CODEN:
                <span class="NLM_cas:coden">CYTODQ</span>;
        ISSN:<span class="NLM_cas:issn">0196-4763</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Previous expts. in our lab. investigating apoptosis induced in HL-60 cells by camptothecin (CAM) have revealed that the sequence and rapidity of the apoptotic phenomena in an individual cell depend on the proliferative state of that cell when it encounters CAM.  The role of mitochondria in HL-60 apoptosis was explored using an inhibitor of oxidative phosphorylation, antimycin A (AMA).  Changes in cell light scatter, binding of annexin V-fluorescein isothiocyanate (FITC), uptake of propidium iodide (PI), and DNA content after membrane fixation/permeabilization were monitored by flow cytometry.  ZVAD-FMK was used to inhibit caspases.  Fluorescence microscopy was used to examine cell morphol.  Cells in the G1 phase of the cell cycle were the first to exhibit signs of apoptosis in response to 100 Î¼M AMA and some of these cells disintegrated without exposing to phosphatidylserine (PS).  Caspase inhibition prevented fragmentation of DNA, the nucleus, and the cell, but only delayed PS exposure and loss of plasma membrane integrity.  The highly active mitochondria of G1-phase HL-60 cells make them particularly sensitive to AMA.  PS exposure and plasma membrane damage are mediated by noncaspase mols. released from mitochondria.  We hypothesize that if mitochondria are subjected to a sufficiently severe insult, whether indirectly as a result of extensive CAM-induced DNA damage or directly by the effect of AMA on electron transport, the nature and quantities of the proapoptotic mols. released are such that apoptosis proceeds to the point of cell disintegration before the PS exposure pathway is complete.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqREW8m0QG2SrVg90H21EOLACvtfcHk0lhBqfI8xPbEXg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XptV2mt7w%253D&md5=c5cbb4af3c006024b3122970088a459b</span></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=10.1002%2Fcyto.10156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcyto.10156%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DM.%2BA.%26aulast%3DRadicchi-Mastroianni%26aufirst%3DM.%2BA.%26atitle%3DAntimycin%2520A-induced%2520apoptosis%2520of%2520HL-60%2520cells%26jtitle%3DCytometry%26date%3D2002%26volume%3D49%26spage%3D106%26epage%3D112%26doi%3D10.1002%2Fcyto.10156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref230"><div class="reference"><strong class="refLabel"><a href="#ref230" class="rightTabRefNumLink">230</a></strong><div class="NLM_citation" id="rightTab-cit230"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. Z.</span></span> <span> </span><span class="NLM_article-title">An ROS generator, antimycin A, inhibits the growth of HeLa cells via apoptosis</span>. <i>J. Cell. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">98</span>â <span class="NLM_lpage">109</span>, <span class="refDoi">Â DOI: 10.1002/jcb.21280</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1002%2Fjcb.21280" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=17372917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVegtLjE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2007&pages=98-109&author=W.+H.+Parkauthor=Y.+W.+Hanauthor=S.+H.+Kimauthor=S.+Z.+Kim&title=An+ROS+generator%2C+antimycin+A%2C+inhibits+the+growth+of+HeLa+cells+via+apoptosis&doi=10.1002%2Fjcb.21280"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit230R"><div class="casContent"><span class="casTitleNuber">230</span><div class="casTitle"><span class="NLM_cas:atitle">An ROS generator, antimycin A, inhibits the growth of HeLa cells via apoptosis</span></div><div class="casAuthors">Park, Woo Hyun; Han, Yong Whan; Kim, Suhn Hee; Kim, Sung Zoo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Biochemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">98-109</span>CODEN:
                <span class="NLM_cas:coden">JCEBD5</span>;
        ISSN:<span class="NLM_cas:issn">0730-2312</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Antimycin A (AMA), an inhibitor of electron transport in mitochondria, has been used as a reactive oxygen species (ROS) generator in biol. systems.  Here, we investigated the in vitro effect of AMA on apoptosis in HeLa cells.  AMA inhibited the growth of HeLa cells with an IC50 of about 50 Î¼M.  AMA efficiently induced apoptosis, as evidenced by flow cytometric detection of sub-G1 DNA content, annexin V binding assay, and DAPI staining.  This apoptotic process was accompanied by the loss of mitochondrial membrane potential (ÎÎ¨m), Bcl-2 down-regulation, Bax up-regulation, and PARP degrdn.  All caspase inhibitors used in this expt., esp. pan-caspase inhibitor (Z-VAD), could rescue some HeLa cells from AMA-induced cell death.  When we examd. the changes of the ROS, H2O2 or OÂ·-2, in AMA-treated cells, H2O2 and OÂ·-2 were markedly increased.  In addn., we detected the depletion of GSH content in AMA-treated cells.  Pan-caspase inhibitor showing the efficient anti-apoptotic effect significantly reduced GSH depletion by AMA.  Superoxide dismutase (SOD) and catalase did not reduce intracellular ROS, but these could strongly rescue the cells from apoptosis.  However, these anti-apoptotic effects were not accompanied by the recovery of GSH depletion.  Interestingly, catalase significantly decreased the CMF neg. (GSH depletion) and propidium iodide (PI) pos. cells, indicating that catalase strongly maintained the integrity of the cell membrane in CMF neg. cells.  Taken together, these results demonstrate that AMA potently generates ROS, induces the depletion of GSH content in HeLa cells, and strongly inhibits the growth of HeLa cells throughout apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQPQU-a9_fGbVg90H21EOLACvtfcHk0lhBqfI8xPbEXg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVegtLjE&md5=33d19a3be05dc3ff34d3e74353a2e16f</span></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=10.1002%2Fjcb.21280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcb.21280%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DW.%2BH.%26aulast%3DHan%26aufirst%3DY.%2BW.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DS.%2BZ.%26atitle%3DAn%2520ROS%2520generator%252C%2520antimycin%2520A%252C%2520inhibits%2520the%2520growth%2520of%2520HeLa%2520cells%2520via%2520apoptosis%26jtitle%3DJ.%2520Cell.%2520Biochem.%26date%3D2007%26volume%3D102%26spage%3D98%26epage%3D109%26doi%3D10.1002%2Fjcb.21280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref231"><div class="reference"><strong class="refLabel"><a href="#ref231" class="rightTabRefNumLink">231</a></strong><div class="NLM_citation" id="rightTab-cit231"><span><span class="NLM_contrib-group"><span class="NLM_string-name">King, M. A.</span></span> <span> </span><span class="NLM_article-title">Antimycin A-induced killing of HL-60 cells: Apoptosis initiated from within mitochondria does not necessarily proceed via caspase 9</span>. <i>Cytometry, Part A</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>63A</i></span>,  <span class="NLM_fpage">69</span>â <span class="NLM_lpage">76</span>, <span class="refDoi">Â DOI: 10.1002/cyto.a.20107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1002%2Fcyto.a.20107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD2MXisVSmsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63A&publication_year=2005&pages=69-76&author=M.+A.+King&title=Antimycin+A-induced+killing+of+HL-60+cells%3A+Apoptosis+initiated+from+within+mitochondria+does+not+necessarily+proceed+via+caspase+9&doi=10.1002%2Fcyto.a.20107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit231R"><div class="casContent"><span class="casTitleNuber">231</span><div class="casTitle"><span class="NLM_cas:atitle">Antimycin A-induced killing of HL-60 cells: Apoptosis initiated from within mitochondria does not necessarily proceed via caspase 9</span></div><div class="casAuthors">King, Malcolm Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Cytometry, Part A</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">63A</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">69-76</span>CODEN:
                <span class="NLM_cas:coden">CPAYAV</span>;
        ISSN:<span class="NLM_cas:issn">1552-4922</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Background: Antimycin A (AMA) inhibits mitochondrial electron transport, collapses the mitochondrial membrane potential, and causes the prodn. of reactive oxygen species.  Previous work by me and my colleagues has demonstrated that AMA causes an array of typical apoptotic phenomena in HL-60 cells.  The hypothesis that AMA causes HL-60 apoptosis by the intrinsic apoptotic pathway has now been tested.  Methods: Z-LEHD-FMK and Z-IETD-FMK were used as specific inhibitors of the initiator caspases 9 and 8, resp.  Caspase 3 activation, DNA fragmentation, and cellular disintegration were measured by flow cytometry.  Cytochrome c release, chromatin condensation, and nuclear fragmentation were measured by microscopy.  Results: AMA caused mitochondrial cytochrome c release and neither Z-LEHD-FMK nor Z-IETD-FMK inhibited that.  In the absence of caspase inhibition there was a very close correlation between cytochrome c release and caspase 3 activation.  Z-LEHD-FMK blocked caspase 3 activation but enhanced DNA fragmentation and failed to stop nuclear or cellular disintegration.  Z-IETD-FMK also blocked caspase 3 activation but, in contrast to Z-LEHD-FMK, delayed DNA fragmentation and disintegration of the nucleus and the cell.  Conclusions: The hypothesis to explain AMA-induced HL-60 apoptosis was clearly inadequate because: (a) caspase 9 inhibition did not prevent DNA fragmentation or cell death, (b) apoptosis proceeded in the absence of caspase-3 activation, (c) the main pathway leading to activation of the executioner caspases was by caspase-8 activation, but caspase 8 inhibition only delayed apoptosis, and (d) activation of caspases 8 and 9 may be necessary for caspase-3 activation.  Thus, in this cell model, apoptosis triggered from within the mitochondria does not necessarily proceed by caspase 9, and caspase 3 is not crit. to apoptosis.  The results provide further evidence that, when parts of the apoptotic network are blocked, a cell is able to complete the program of cell death by alternate pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxj9hM5fkJ_LVg90H21EOLACvtfcHk0liMzzOOj6QJCw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXisVSmsbs%253D&md5=74fa7b8bc07197c363087ebfc5f055e8</span></div><a href="/servlet/linkout?suffix=cit231&amp;dbid=16384&amp;doi=10.1002%2Fcyto.a.20107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcyto.a.20107%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DM.%2BA.%26atitle%3DAntimycin%2520A-induced%2520killing%2520of%2520HL-60%2520cells%253A%2520Apoptosis%2520initiated%2520from%2520within%2520mitochondria%2520does%2520not%2520necessarily%2520proceed%2520via%2520caspase%25209%26jtitle%3DCytometry%252C%2520Part%2520A%26date%3D2005%26volume%3D63A%26spage%3D69%26epage%3D76%26doi%3D10.1002%2Fcyto.a.20107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref232"><div class="reference"><strong class="refLabel"><a href="#ref232" class="rightTabRefNumLink">232</a></strong><div class="NLM_citation" id="rightTab-cit232"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W. J.</span></span> <span> </span><span class="NLM_article-title">Antimycin-type depsipeptides: discovery, biosynthesis, chemical synthesis, and bioactivities</span>. <i>Nat. Prod. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1146</span>â <span class="NLM_lpage">1165</span>, <span class="refDoi">Â DOI: 10.1039/C6NP00004E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1039%2FC6NP00004E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27307039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVSks7bI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2016&pages=1146-1165&author=J.+Liuauthor=X.+J.+Zhuauthor=S.+J.+Kimauthor=W.+J.+Zhang&title=Antimycin-type+depsipeptides%3A+discovery%2C+biosynthesis%2C+chemical+synthesis%2C+and+bioactivities&doi=10.1039%2FC6NP00004E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit232R"><div class="casContent"><span class="casTitleNuber">232</span><div class="casTitle"><span class="NLM_cas:atitle">Antimycin-type depsipeptides: discovery, biosynthesis, chemical synthesis, and bioactivities</span></div><div class="casAuthors">Liu, Joyce; Zhu, Xuejun; Kim, Seong Jong; Zhang, Wenjun</div><div class="citationInfo"><span class="NLM_cas:title">Natural Product Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1146-1165</span>CODEN:
                <span class="NLM_cas:coden">NPRRDF</span>;
        ISSN:<span class="NLM_cas:issn">0265-0568</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Up to 2016, antimycin-type depsipeptides are a family of natural products with great structural diversity and outstanding biol. activities.  These compds. have typically been isolated from actinomycetes and are generated from hybrid nonribosomal peptide synthetase (NRPS)-polyketide synthase (PKS) assembly lines.  We cover the literature on the 4 classes of antimycin-type depsipeptides, which differ by macrolactone ring size, and it discusses the discovery, biosynthesis, chem. synthesis, and biol. activities of this family of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpl9mGebKUjzbVg90H21EOLACvtfcHk0liMzzOOj6QJCw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVSks7bI&md5=0666efbbed07896b750ab40d253218a3</span></div><a href="/servlet/linkout?suffix=cit232&amp;dbid=16384&amp;doi=10.1039%2FC6NP00004E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6NP00004E%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DX.%2BJ.%26aulast%3DKim%26aufirst%3DS.%2BJ.%26aulast%3DZhang%26aufirst%3DW.%2BJ.%26atitle%3DAntimycin-type%2520depsipeptides%253A%2520discovery%252C%2520biosynthesis%252C%2520chemical%2520synthesis%252C%2520and%2520bioactivities%26jtitle%3DNat.%2520Prod.%2520Rep.%26date%3D2016%26volume%3D33%26spage%3D1146%26epage%3D1165%26doi%3D10.1039%2FC6NP00004E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref233"><div class="reference"><strong class="refLabel"><a href="#ref233" class="rightTabRefNumLink">233</a></strong><div class="NLM_citation" id="rightTab-cit233"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miyadera, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiomi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomoda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyoshi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osanai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omura, S.</span></span> <span> </span><span class="NLM_article-title">Atpenins, potent and specific inhibitors of mitochondrial complex II (succinate-ubiquinone oxidoreductase)</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">473</span>â <span class="NLM_lpage">477</span>, <span class="refDoi">Â DOI: 10.1073/pnas.0237315100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1073%2Fpnas.0237315100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=12515859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnvVKgsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=473-477&author=H.+Miyaderaauthor=K.+Shiomiauthor=H.+Uiauthor=Y.+Yamaguchiauthor=R.+Masumaauthor=H.+Tomodaauthor=H.+Miyoshiauthor=A.+Osanaiauthor=K.+Kitaauthor=S.+Omura&title=Atpenins%2C+potent+and+specific+inhibitors+of+mitochondrial+complex+II+%28succinate-ubiquinone+oxidoreductase%29&doi=10.1073%2Fpnas.0237315100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit233R"><div class="casContent"><span class="casTitleNuber">233</span><div class="casTitle"><span class="NLM_cas:atitle">Atpenins, potent and specific inhibitors of mitochondrial complex II (succinate-ubiquinone oxidoreductase)</span></div><div class="casAuthors">Miyadera, Hiroko; Shiomi, Kazuro; Ui, Hideaki; Yamaguchi, Yuichi; Masuma, Rokuro; Tomoda, Hiroshi; Miyoshi, Hideto; Osanai, Arihiro; Kita, Kiyoshi; Omura, Satoshi</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">473-477</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Enzymes in the mitochondrial respiratory chain are involved in various physiol. events in addn. to their essential role in the prodn. of ATP by oxidative phosphorylation.  The use of specific and potent inhibitors of complex I (NADH-ubiquinone reductase) and complex III (ubiquinol-cytochrome c reductase), such as rotenone and antimycin, resp., has allowed detn. of the role of these enzymes in physiol. processes.  However, unlike complexes I, III, and IV (cytochrome c oxidase), there are few potent and specific inhibitors of complex II (succinate-ubiquinone reductase) that have been described.  In this article, we report that atpenins potently and specifically inhibit the succinate-ubiquinone reductase activity of mitochondrial complex II.  Therefore, atpenins may be useful tools for clarifying the biochem. and structural properties of complex II, as well as for detg. its physiol. roles in mammalian tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMyyoczVOGm7Vg90H21EOLACvtfcHk0liMzzOOj6QJCw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnvVKgsg%253D%253D&md5=cc26787f1d90d5aa0a38312794371888</span></div><a href="/servlet/linkout?suffix=cit233&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0237315100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0237315100%26sid%3Dliteratum%253Aachs%26aulast%3DMiyadera%26aufirst%3DH.%26aulast%3DShiomi%26aufirst%3DK.%26aulast%3DUi%26aufirst%3DH.%26aulast%3DYamaguchi%26aufirst%3DY.%26aulast%3DMasuma%26aufirst%3DR.%26aulast%3DTomoda%26aufirst%3DH.%26aulast%3DMiyoshi%26aufirst%3DH.%26aulast%3DOsanai%26aufirst%3DA.%26aulast%3DKita%26aufirst%3DK.%26aulast%3DOmura%26aufirst%3DS.%26atitle%3DAtpenins%252C%2520potent%2520and%2520specific%2520inhibitors%2520of%2520mitochondrial%2520complex%2520II%2520%2528succinate-ubiquinone%2520oxidoreductase%2529%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2003%26volume%3D100%26spage%3D473%26epage%3D477%26doi%3D10.1073%2Fpnas.0237315100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref234"><div class="reference"><strong class="refLabel"><a href="#ref234" class="rightTabRefNumLink">234</a></strong><div class="NLM_citation" id="rightTab-cit234"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wojtovich, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brookes, P. S.</span></span> <span> </span><span class="NLM_article-title">The endogenous mitochondrial complex II inhibitor malonate regulates mitochondrial ATP-sensitive potassium channels: implications for ischemic preconditioning</span>. <i>Biochim. Biophys. Acta, Bioenerg.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>1777</i></span>,  <span class="NLM_fpage">882</span>â <span class="NLM_lpage">889</span>, <span class="refDoi">Â DOI: 10.1016/j.bbabio.2008.03.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.bbabio.2008.03.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsFCmur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1777&publication_year=2008&pages=882-889&author=A.+P.+Wojtovichauthor=P.+S.+Brookes&title=The+endogenous+mitochondrial+complex+II+inhibitor+malonate+regulates+mitochondrial+ATP-sensitive+potassium+channels%3A+implications+for+ischemic+preconditioning&doi=10.1016%2Fj.bbabio.2008.03.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit234R"><div class="casContent"><span class="casTitleNuber">234</span><div class="casTitle"><span class="NLM_cas:atitle">The endogenous mitochondrial complex II inhibitor malonate regulates mitochondrial ATP-sensitive potassium channels: Implications for ischemic preconditioning</span></div><div class="casAuthors">Wojtovich, Andrew P.; Brookes, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Bioenergetics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">1777</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">882-889</span>CODEN:
                <span class="NLM_cas:coden">BBBEB4</span>;
        ISSN:<span class="NLM_cas:issn">0005-2728</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Ischemic preconditioning (IPC) affords cardioprotection against ischemia-reperfusion (IR) injury, and while the mol. mechanisms of IPC are debated, the mitochondrial ATP-sensitive K+ channel (mKATP) has emerged as a candidate effector for several IPC signaling pathways.  The mol. identity of this channel is unknown, but significant pharmacol. overlap exists between mKATP and mitochondrial respiratory complex II (succinate dehydrogenase).  In this investigation, we utilized isolated cardiac mitochondria, Langendorff perfused hearts, and a variety of biochem. methods, to make the following observations: (i) the competitive complex II inhibitor malonate is formed in mitochondria under conditions resembling IPC. (ii) IPC leads to a reversible inhibition of complex II that has likely been missed in previous investigations due to the use of satg. concns. of succinate. (iii) malonate opens mKATP channels even when mitochondria are respiring on complex I-linked substrates, suggesting an effect of this inhibitor on the mKATP channel independent of complex II inhibition.  Together, these observations suggest that complex II inhibition by endogenously formed malonate may represent an important activation pathway for mKATP channels during IPC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjJ24A6ZgIbbVg90H21EOLACvtfcHk0lgQaUtNzdRxsQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsFCmur4%253D&md5=475fde7556cb2289ef2cbb922452a1cb</span></div><a href="/servlet/linkout?suffix=cit234&amp;dbid=16384&amp;doi=10.1016%2Fj.bbabio.2008.03.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbabio.2008.03.025%26sid%3Dliteratum%253Aachs%26aulast%3DWojtovich%26aufirst%3DA.%2BP.%26aulast%3DBrookes%26aufirst%3DP.%2BS.%26atitle%3DThe%2520endogenous%2520mitochondrial%2520complex%2520II%2520inhibitor%2520malonate%2520regulates%2520mitochondrial%2520ATP-sensitive%2520potassium%2520channels%253A%2520implications%2520for%2520ischemic%2520preconditioning%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Bioenerg.%26date%3D2008%26volume%3D1777%26spage%3D882%26epage%3D889%26doi%3D10.1016%2Fj.bbabio.2008.03.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref235"><div class="reference"><strong class="refLabel"><a href="#ref235" class="rightTabRefNumLink">235</a></strong><div class="NLM_citation" id="rightTab-cit235"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zuchora, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turski, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wielosz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urbanska, E. M.</span></span> <span> </span><span class="NLM_article-title">Protective effect of adenosine receptor agonists in a new model of epilepsy - seizures evoked by mitochondrial toxin, 3-nitropropionic acid, in mice</span>. <i>Neurosci. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>305</i></span>,  <span class="NLM_fpage">91</span>â <span class="NLM_lpage">94</span>, <span class="refDoi">Â DOI: 10.1016/S0304-3940(01)01816-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2FS0304-3940%2801%2901816-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=11376891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjsleitLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=305&publication_year=2001&pages=91-94&author=B.+Zuchoraauthor=W.+A.+Turskiauthor=M.+Wieloszauthor=E.+M.+Urbanska&title=Protective+effect+of+adenosine+receptor+agonists+in+a+new+model+of+epilepsy+-+seizures+evoked+by+mitochondrial+toxin%2C+3-nitropropionic+acid%2C+in+mice&doi=10.1016%2FS0304-3940%2801%2901816-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit235R"><div class="casContent"><span class="casTitleNuber">235</span><div class="casTitle"><span class="NLM_cas:atitle">Protective effect of adenosine receptor agonists in a new model of epilepsy - seizures evoked by mitochondrial toxin, 3-nitropropionic acid, in mice</span></div><div class="casAuthors">Zuchora, B.; Turski, W. A.; Wielosz, M.; Urbanska, E. M.</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience Letters</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">305</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">91-94</span>CODEN:
                <span class="NLM_cas:coden">NELED5</span>;
        ISSN:<span class="NLM_cas:issn">0304-3940</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">The role of adenosine receptor agonists in the convulsant activity of mitochondrial toxin, 3-nitropropionic acid (3-NPA), was studied in mice.  The occurrence of seizures evoked by peripheral application of 3-NPA was inhibited with the use of A1 adenosine receptor agonist, R-N6-phenylisopropyladenosine and A1/A2 agonist, 2-chloroadenosine.  Moreover, both drugs prevented 3-NPA-induced mortality.  Similarly, A1/A2 agonist, 5'-N-ethylcarboxamidoadenosine, protected against seizures evoked by the intracerebral administration of 3-NPA, and this effect was reversed by the co-application of adenosine receptor antagonist, 8-(p-sulfophenyl)theophylline.  Obtained results suggest that A1 adenosine receptor activation may modulate the chain of events leading to the development of 3-NPA-induced seizures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7T62v327Jl7Vg90H21EOLACvtfcHk0lgQaUtNzdRxsQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjsleitLY%253D&md5=54bdaac9655d1c3ae4e56c0278d1735a</span></div><a href="/servlet/linkout?suffix=cit235&amp;dbid=16384&amp;doi=10.1016%2FS0304-3940%2801%2901816-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0304-3940%252801%252901816-X%26sid%3Dliteratum%253Aachs%26aulast%3DZuchora%26aufirst%3DB.%26aulast%3DTurski%26aufirst%3DW.%2BA.%26aulast%3DWielosz%26aufirst%3DM.%26aulast%3DUrbanska%26aufirst%3DE.%2BM.%26atitle%3DProtective%2520effect%2520of%2520adenosine%2520receptor%2520agonists%2520in%2520a%2520new%2520model%2520of%2520epilepsy%2520-%2520seizures%2520evoked%2520by%2520mitochondrial%2520toxin%252C%25203-nitropropionic%2520acid%252C%2520in%2520mice%26jtitle%3DNeurosci.%2520Lett.%26date%3D2001%26volume%3D305%26spage%3D91%26epage%3D94%26doi%3D10.1016%2FS0304-3940%2801%2901816-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref236"><div class="reference"><strong class="refLabel"><a href="#ref236" class="rightTabRefNumLink">236</a></strong><div class="NLM_citation" id="rightTab-cit236"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuse, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanaoka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoji, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wada, H.</span></span> <span> </span><span class="NLM_article-title">â³Chemical preconditioningâ³ by 3-nitropropionate reduces ischemia-reperfusion injury in cardiac-arrested rat lungs</span>. <i>Transplantation</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">352</span>â <span class="NLM_lpage">359</span>, <span class="refDoi">Â DOI: 10.1097/00007890-200102150-00003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1097%2F00007890-200102150-00003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=11233893" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhvFegsLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2001&pages=352-359&author=T.+Hirataauthor=T.+Fukuseauthor=S.+Ishikawaauthor=S.+Hanaokaauthor=Q.+Chenauthor=T.+Shojiauthor=H.+Wada&title=%E2%80%B3Chemical+preconditioning%E2%80%B3+by+3-nitropropionate+reduces+ischemia-reperfusion+injury+in+cardiac-arrested+rat+lungs&doi=10.1097%2F00007890-200102150-00003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit236R"><div class="casContent"><span class="casTitleNuber">236</span><div class="casTitle"><span class="NLM_cas:atitle">"Chemical preconditioning" by 3-nitropropionate reduces ischemia-reperfusion injury in cardiac-arrested rat lungs</span></div><div class="casAuthors">Hirata, Toshiki; Fukuse, Tatsuo; Ishikawa, Shinya; Hanaoka, Shinji; Chen, Qing; Shoji, Tsuyoshi; Wada, Hiromi</div><div class="citationInfo"><span class="NLM_cas:title">Transplantation</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">352-359</span>CODEN:
                <span class="NLM_cas:coden">TRPLAU</span>;
        ISSN:<span class="NLM_cas:issn">0041-1337</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Chem. preconditioning was defined as the induction of resistance to massive disruption of energy metab. through prior chem. suppression of oxidative phosphorylation, by which phenomena similar to those resulting from increased ischemic tolerance as a result of ischemic preconditioning can be induced.  It could be induced by the inhibitor of either mitochondrial complex I or II.  We investigated whether or not chem. preconditioning by 3-nitro-propionate (an inhibitor of the mitochondrial complex II) can suppress ischemia-reperfusion injury in cardiac-arrested lungs, which will be the major problem in lung transplants donated from non-heart-beating cadavers.  In an isolated rat lung perfusion model with fresh rat blood as perfusate, administration of 3-nitropropionate (20 mg/kg) immediately before the induction of cardiac arrest attenuated pulmonary dysfunction during reperfusion after 1 h postmortem warm ischemia and 1 h cold preservation.  3-Nitropropionate administration reduced the mitochondrial respiratory functions (state 3 and state 4 respiration, and the respiratory control ratio) before cardiac arrest and kept them at a lower level of activity than when decreased by ischemia alone.  3-Nitropropionate administration also reduced the ATP levels immediately after drug administration.  However, 3-nitropropionate did not significantly reduce lipid peroxidn. in the lung tissue and mitochondria.  These results demonstrated that chem. preconditioning by 3-nitropropionate administration immediately before cardiac arrest suppressed succinate-related oxidn. during postmortem warm ischemia and reduced ischemia-reperfusion injury in cardiac arrested rat lungs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpq9NialLtw-bVg90H21EOLACvtfcHk0lgQaUtNzdRxsQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhvFegsLs%253D&md5=0ba486cb25484b3e7ef1ceb331e7db5f</span></div><a href="/servlet/linkout?suffix=cit236&amp;dbid=16384&amp;doi=10.1097%2F00007890-200102150-00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00007890-200102150-00003%26sid%3Dliteratum%253Aachs%26aulast%3DHirata%26aufirst%3DT.%26aulast%3DFukuse%26aufirst%3DT.%26aulast%3DIshikawa%26aufirst%3DS.%26aulast%3DHanaoka%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DShoji%26aufirst%3DT.%26aulast%3DWada%26aufirst%3DH.%26atitle%3D%25E2%2580%25B3Chemical%2520preconditioning%25E2%2580%25B3%2520by%25203-nitropropionate%2520reduces%2520ischemia-reperfusion%2520injury%2520in%2520cardiac-arrested%2520rat%2520lungs%26jtitle%3DTransplantation%26date%3D2001%26volume%3D71%26spage%3D352%26epage%3D359%26doi%3D10.1097%2F00007890-200102150-00003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref237"><div class="reference"><strong class="refLabel"><a href="#ref237" class="rightTabRefNumLink">237</a></strong><div class="NLM_citation" id="rightTab-cit237"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mogi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawakami, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Igarashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsushita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiomi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kita, K.</span></span> <span> </span><span class="NLM_article-title">Siccanin rediscovered as a species-selective succinate dehydrogenase inhibitor</span>. <i>J. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">383</span>â <span class="NLM_lpage">387</span>, <span class="refDoi">Â DOI: 10.1093/jb/mvp085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1093%2Fjb%2Fmvp085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=19505951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVKnurvI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2009&pages=383-387&author=T.+Mogiauthor=T.+Kawakamiauthor=H.+Araiauthor=Y.+Igarashiauthor=K.+Matsushitaauthor=M.+Moriauthor=K.+Shiomiauthor=S.+Omuraauthor=S.+Haradaauthor=K.+Kita&title=Siccanin+rediscovered+as+a+species-selective+succinate+dehydrogenase+inhibitor&doi=10.1093%2Fjb%2Fmvp085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit237R"><div class="casContent"><span class="casTitleNuber">237</span><div class="casTitle"><span class="NLM_cas:atitle">Siccanin Rediscovered as a Species-Selective Succinate Dehydrogenase Inhibitor</span></div><div class="casAuthors">Mogi, Tatsushi; Kawakami, Takuro; Arai, Hiroyuki; Igarashi, Yasuo; Matsushita, Kazunobu; Mori, Mihoko; Shiomi, Kazuro; Omura, Satoshi; Harada, Shigeharu; Kita, Kiyoshi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biochemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">383-387</span>CODEN:
                <span class="NLM_cas:coden">JOBIAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-924X</span>.
    
            (<span class="NLM_cas:orgname">Japanese Biochemical Society</span>)
        </div><div class="casAbstract">To identify antibiotics targeting to respiratory enzymes, we carried out matrix screening of a structurally varied natural compd. library with Pseudomonas aeruginosa membrane-bound respiratory enzymes.  We identified a succinate dehydrogenase inhibitor, siccanin (IC50, 0.9 Î¼M), which is a potent antibiotic against some pathogenic fungi like Trichophyton mentagrophytes and inhibits their mitochondrial succinate dehydrogenase.  We found that siccanin was effective against enzymes from P. aeruginosa, P. putida, rat and mouse mitochondria but ineffective or less effective against Escherichia coli, Corynebacterium glutamicum, and porcine mitochondria enzyme.  Action mode was mixed-type for quinone-dependent activity and noncompetitive for succinate-dependent activity, indicating the proximity of the inhibitor-binding site to the quinone-binding site.  Species-selective inhibition by siccanin is unique among succinate dehydrogenase inhibitors, and thus siccanin is a potential lead compd. for new chemotherapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf7I7O9g5QbrVg90H21EOLACvtfcHk0lifXvUtkOArQA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVKnurvI&md5=33b85f3e82e840d0be6a76da1ee3941f</span></div><a href="/servlet/linkout?suffix=cit237&amp;dbid=16384&amp;doi=10.1093%2Fjb%2Fmvp085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjb%252Fmvp085%26sid%3Dliteratum%253Aachs%26aulast%3DMogi%26aufirst%3DT.%26aulast%3DKawakami%26aufirst%3DT.%26aulast%3DArai%26aufirst%3DH.%26aulast%3DIgarashi%26aufirst%3DY.%26aulast%3DMatsushita%26aufirst%3DK.%26aulast%3DMori%26aufirst%3DM.%26aulast%3DShiomi%26aufirst%3DK.%26aulast%3DOmura%26aufirst%3DS.%26aulast%3DHarada%26aufirst%3DS.%26aulast%3DKita%26aufirst%3DK.%26atitle%3DSiccanin%2520rediscovered%2520as%2520a%2520species-selective%2520succinate%2520dehydrogenase%2520inhibitor%26jtitle%3DJ.%2520Biochem.%26date%3D2009%26volume%3D146%26spage%3D383%26epage%3D387%26doi%3D10.1093%2Fjb%2Fmvp085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref238"><div class="reference"><strong class="refLabel"><a href="#ref238" class="rightTabRefNumLink">238</a></strong><div class="NLM_citation" id="rightTab-cit238"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Portugal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaffel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spector, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nucci, M.</span></span> <span> </span><span class="NLM_article-title">Thiabendazole for the prophylaxis of strongyloidiasis in immunosuppressed patients with hematologic diseases: a randomized, double-blind placebo-controlled study</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">663</span>â <span class="NLM_lpage">664</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=12031927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD38XlsFCitL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2002&pages=663-664&author=R.+Portugalauthor=R.+Schaffelauthor=L.+Almeidaauthor=N.+Spectorauthor=M.+Nucci&title=Thiabendazole+for+the+prophylaxis+of+strongyloidiasis+in+immunosuppressed+patients+with+hematologic+diseases%3A+a+randomized%2C+double-blind+placebo-controlled+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit238R"><div class="casContent"><span class="casTitleNuber">238</span><div class="casTitle"><span class="NLM_cas:atitle">Thiabendazole for the prophylaxis of strongyloidiasis in immunosuppressed patients with hematologic diseases: A randomized, double-blind placebo-controlled study</span></div><div class="casAuthors">Portugal, Rodrigo; Schaffel, Rony; Almeida, Leandro; Spector, Nelson; Nucci, Marcio</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">663-664</span>CODEN:
                <span class="NLM_cas:coden">HAEMAX</span>;
        ISSN:<span class="NLM_cas:issn">0390-6078</span>.
    
            (<span class="NLM_cas:orgname">Ferrata Storti Foundation</span>)
        </div><div class="casAbstract">The aim of this study was to evaluate the efficacy of thiabendazole for prophylaxis of strongyloidiasis in patients with hematol. diseases, we performed a randomized, placebo-controlled trial.  The incidence of strongyloidiasis was similar in both groups (p=0.36), but the compliance was better in the placebo group (p=0.04).  This study does not support the use of thiabendazole prophylaxis in patients with hematol. diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjXq-N7JlAP7Vg90H21EOLACvtfcHk0lifXvUtkOArQA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlsFCitL8%253D&md5=9d3f4378ec1b507f809ecac130c07239</span></div><a href="/servlet/linkout?suffix=cit238&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPortugal%26aufirst%3DR.%26aulast%3DSchaffel%26aufirst%3DR.%26aulast%3DAlmeida%26aufirst%3DL.%26aulast%3DSpector%26aufirst%3DN.%26aulast%3DNucci%26aufirst%3DM.%26atitle%3DThiabendazole%2520for%2520the%2520prophylaxis%2520of%2520strongyloidiasis%2520in%2520immunosuppressed%2520patients%2520with%2520hematologic%2520diseases%253A%2520a%2520randomized%252C%2520double-blind%2520placebo-controlled%2520study%26jtitle%3DHaematologica%26date%3D2002%26volume%3D87%26spage%3D663%26epage%3D664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref239"><div class="reference"><strong class="refLabel"><a href="#ref239" class="rightTabRefNumLink">239</a></strong><div class="NLM_citation" id="rightTab-cit239"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blatt, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bednarski, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boitano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yung, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opipari, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glick, G. D.</span></span> <span> </span><span class="NLM_article-title">Benzodiazepine-induced superoxide signals B cell apoptosis: mechanistic insight and potential therapeutic utility</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">1123</span>â <span class="NLM_lpage">1132</span>, <span class="refDoi">Â DOI: 10.1172/JCI0216029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1172%2FJCI0216029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=12393848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD38XotFGlu74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2002&pages=1123-1132&author=N.+B.+Blattauthor=J.+J.+Bednarskiauthor=R.+E.+Warnerauthor=F.+Leonettiauthor=K.+M.+Johnsonauthor=A.+Boitanoauthor=R.+Yungauthor=B.+C.+Richardsonauthor=K.+J.+Johnsonauthor=J.+A.+Ellmanauthor=A.+W.+Opipariauthor=G.+D.+Glick&title=Benzodiazepine-induced+superoxide+signals+B+cell+apoptosis%3A+mechanistic+insight+and+potential+therapeutic+utility&doi=10.1172%2FJCI0216029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit239R"><div class="casContent"><span class="casTitleNuber">239</span><div class="casTitle"><span class="NLM_cas:atitle">Benzodiazepine-induced superoxide signals B cell apoptosis: mechanistic insight and potential therapeutic utility</span></div><div class="casAuthors">Blatt, Neal B.; Bednarski, Jeffrey J.; Warner, Roscoe E.; Leonetti, Francesco; Johnson, Kathryn M.; Boitano, Anthony; Yung, Raymond; Richardson, Bruce C.; Johnson, Kent J.; Ellman, Jonathan A.; Opipari, Anthony W., Jr.; Glick, Gary D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1123-1132</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">The properties of a proapoptotic 1,4-benzodiazepine, Bz-423, identified through combinatorial chem. and phenotype screening are described.  Bz-423 rapidly generated superoxide (O2-) in transformed Ramos B cells.  This O2- response originated from mitochondria prior to mitochondrial transmembrane gradient collapse and opening of the permeability transition pore.  Bz-423-induced O2- functioned as an upstream signal that initiated an apoptotic program characterized by cytochrome c release, mitochondrial depolarization, and caspase activation.  Pretreatment of cells with agents that either block the formation of Bz-423-induced O2- or scavenge free radicals attenuated the death cascade, which demonstrated that cell killing by Bz-423 depends on O2-.  Parallels between Ramos cells and germinal center B cells prompted expts. to det. whether Bz-423 had therapeutic activity in vivo.  This possibility was tested using the (NZB Ã NZW)F1 murine model of lupus, in which the pathol. enhanced survival and expansion of germinal center B cells mediate disease.  Administration of Bz-423 for 12 wk specifically controlled germinal center hyperplasia and reduced the histol. evidence of glomerulonephritis.  Collectively, these studies define a new structure-function relationship for benzodiazepines and point to a new target and mechanism that could be of value for developing improved drugs to manage systemic lupus erythematosus and related disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqflLiDdaZ-WrVg90H21EOLACvtfcHk0lifXvUtkOArQA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XotFGlu74%253D&md5=09bbb0467077f3912ecc909b4e92ed15</span></div><a href="/servlet/linkout?suffix=cit239&amp;dbid=16384&amp;doi=10.1172%2FJCI0216029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI0216029%26sid%3Dliteratum%253Aachs%26aulast%3DBlatt%26aufirst%3DN.%2BB.%26aulast%3DBednarski%26aufirst%3DJ.%2BJ.%26aulast%3DWarner%26aufirst%3DR.%2BE.%26aulast%3DLeonetti%26aufirst%3DF.%26aulast%3DJohnson%26aufirst%3DK.%2BM.%26aulast%3DBoitano%26aufirst%3DA.%26aulast%3DYung%26aufirst%3DR.%26aulast%3DRichardson%26aufirst%3DB.%2BC.%26aulast%3DJohnson%26aufirst%3DK.%2BJ.%26aulast%3DEllman%26aufirst%3DJ.%2BA.%26aulast%3DOpipari%26aufirst%3DA.%2BW.%26aulast%3DGlick%26aufirst%3DG.%2BD.%26atitle%3DBenzodiazepine-induced%2520superoxide%2520signals%2520B%2520cell%2520apoptosis%253A%2520mechanistic%2520insight%2520and%2520potential%2520therapeutic%2520utility%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2002%26volume%3D110%26spage%3D1123%26epage%3D1132%26doi%3D10.1172%2FJCI0216029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref240"><div class="reference"><strong class="refLabel"><a href="#ref240" class="rightTabRefNumLink">240</a></strong><div class="NLM_citation" id="rightTab-cit240"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhagavathula, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nerusu, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanosh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aslam, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundberg, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opipari, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glick, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varani, J.</span></span> <span> </span><span class="NLM_article-title">7-Chloro-5-(4-hydroxyphenyl)-1-methyl-3-(naphthalen-2-ylmethyl)-4,5-dihydro-1H-benzo[b][1,4]diazepin-2(3H)-one(Bz-423), a benzodiazepine, suppresses keratinocyte proliferation and has antipsoriatic activity in the human skin-severe, combined Immunodeficient mouse transplant model</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>324</i></span>,  <span class="NLM_fpage">938</span>â <span class="NLM_lpage">947</span>, <span class="refDoi">Â DOI: 10.1124/jpet.107.130955</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1124%2Fjpet.107.130955" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=18055879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD1cXivVajsrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=324&publication_year=2008&pages=938-947&author=N.+Bhagavathulaauthor=K.+C.+Nerusuauthor=A.+Hanoshauthor=M.+N.+Aslamauthor=T.+B.+Sundbergauthor=A.+W.+Opipariauthor=K.+Johnsonauthor=S.+Kangauthor=G.+D.+Glickauthor=J.+Varani&title=7-Chloro-5-%284-hydroxyphenyl%29-1-methyl-3-%28naphthalen-2-ylmethyl%29-4%2C5-dihydro-1H-benzo%5Bb%5D%5B1%2C4%5Ddiazepin-2%283H%29-one%28Bz-423%29%2C+a+benzodiazepine%2C+suppresses+keratinocyte+proliferation+and+has+antipsoriatic+activity+in+the+human+skin-severe%2C+combined+Immunodeficient+mouse+transplant+model&doi=10.1124%2Fjpet.107.130955"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit240R"><div class="casContent"><span class="casTitleNuber">240</span><div class="casTitle"><span class="NLM_cas:atitle">7-Chloro-5-(4-hydroxyphenyl)-1-methyl-3-(naphthalen-2-ylmethyl)-4,5-dihydro-1H-benzo[b][1,4]diazepin-2(3H)-one (Bz-423), a benzodiazepine, suppresses keratinocyte proliferation and has antipsoriatic activity in the human skin-severe, combined immunodeficient mouse transplant model</span></div><div class="casAuthors">Bhagavathula, Narasimharao; Nerusu, Kamalakar C.; Hanosh, Andrew; Aslam, Muhammad N.; Sundberg, Thomas B.; Opipari, Anthony W., Jr.; Johnson, Kent; Kang, Sewon; Glick, Gary D.; Varani, James</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">324</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">938-947</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">7-Chloro-5-(4-hydroxyphenyl)-1-methyl-3-(naphthalen-2-ylmethyl)-4,5-dihydro-1H-benzo[b][1,4]diazepin-2(3H)-one (Bz-423) is a benzodiazepine that has cytotoxic and cytostatic activity against a variety of cells in vivo and in vitro.  In the present study, we demonstrate that Bz-423 (formulated for topical delivery) reduces epidermal hyperplasia in human psoriatic skin after transplantation to severe, combined immunodeficient (scid) mice.  Bz-423 also suppresses the hyperplasia that develops in nonpsoriatic human skin as a consequence of transplantation to scid mice.  Proliferation of human epidermal keratinocytes in monolayer culture was suppressed by Bz-423 at concns. of 0.5 to 2.0 Î¼M (noncytotoxic concns.).  Keratinocyte growth inhibition was accompanied by increased oxidant generation in Bz-423-treated cells, and treatment with vitamin E along with Bz-423 reversed the growth inhibition.  Growth inhibition was accompanied by a redistribution of Î²-catenin from a cytoplasmic pool to the cell membrane and by reduced levels of c-myc and cyclin D1 (two mols. assocd. with Wnt pathway signaling).  Several analogs of Bz-423 were examd. for antiproliferative activity against human epidermal keratinocytes and human dermal fibroblasts in monolayer culture.  Each of the analogs tested suppressed growth of both cell types, but in all cases, keratinocytes were more sensitive than fibroblasts.  Two of the compds. were found to suppress epidermal hyperplasia induced with all-trans retinoic acid in organ cultures of human skin.  Taken together, these data show that Bz-423 and certain analogs produce biol. responses in skin cells in vitro and in vivo that are consistent with therapeutic goals for treating psoriasis or epidermal hyperplasia resulting from other causes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFfLW_vTc5CLVg90H21EOLACvtfcHk0ljqyup9gHlt3Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXivVajsrc%253D&md5=d00ef858340d77f4dfb20b70073f0324</span></div><a href="/servlet/linkout?suffix=cit240&amp;dbid=16384&amp;doi=10.1124%2Fjpet.107.130955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.107.130955%26sid%3Dliteratum%253Aachs%26aulast%3DBhagavathula%26aufirst%3DN.%26aulast%3DNerusu%26aufirst%3DK.%2BC.%26aulast%3DHanosh%26aufirst%3DA.%26aulast%3DAslam%26aufirst%3DM.%2BN.%26aulast%3DSundberg%26aufirst%3DT.%2BB.%26aulast%3DOpipari%26aufirst%3DA.%2BW.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DKang%26aufirst%3DS.%26aulast%3DGlick%26aufirst%3DG.%2BD.%26aulast%3DVarani%26aufirst%3DJ.%26atitle%3D7-Chloro-5-%25284-hydroxyphenyl%2529-1-methyl-3-%2528naphthalen-2-ylmethyl%2529-4%252C5-dihydro-1H-benzo%255Bb%255D%255B1%252C4%255Ddiazepin-2%25283H%2529-one%2528Bz-423%2529%252C%2520a%2520benzodiazepine%252C%2520suppresses%2520keratinocyte%2520proliferation%2520and%2520has%2520antipsoriatic%2520activity%2520in%2520the%2520human%2520skin-severe%252C%2520combined%2520Immunodeficient%2520mouse%2520transplant%2520model%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2008%26volume%3D324%26spage%3D938%26epage%3D947%26doi%3D10.1124%2Fjpet.107.130955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref241"><div class="reference"><strong class="refLabel"><a href="#ref241" class="rightTabRefNumLink">241</a></strong><div class="NLM_citation" id="rightTab-cit241"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boitano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swenson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opipari, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glick, G. D.</span></span> <span> </span><span class="NLM_article-title">Identification and validation of the mitochondrial F1F0-ATPase as the molecular target of the immunomodulatory benzodiazepine Bz-423</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">485</span>â <span class="NLM_lpage">496</span>, <span class="refDoi">Â DOI: 10.1016/j.chembiol.2005.02.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.chembiol.2005.02.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=15850986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjsFKitbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2005&pages=485-496&author=K.+M.+Johnsonauthor=X.+N.+Chenauthor=A.+Boitanoauthor=L.+Swensonauthor=A.+W.+Opipariauthor=G.+D.+Glick&title=Identification+and+validation+of+the+mitochondrial+F1F0-ATPase+as+the+molecular+target+of+the+immunomodulatory+benzodiazepine+Bz-423&doi=10.1016%2Fj.chembiol.2005.02.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit241R"><div class="casContent"><span class="casTitleNuber">241</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Validation of the Mitochondrial F1F0-ATPase as the Molecular Target of the Immunomodulatory Benzodiazepine Bz-423</span></div><div class="casAuthors">Johnson, Kathryn M.; Chen, Xueni; Boitano, Anthony; Swenson, Lara; Opipari, Anthony W.; Glick, Gary D.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">485-496</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: Bz-423 is a 1,4-benzodiazepine that suppresses disease in lupus-prone mice by selectively killing pathogenic lymphocytes, and it is less toxic compared to current lupus drugs.  Cells exposed to Bz-423 rapidly generate O2- within mitochondria, and this reactive oxygen species is the signal initiating apoptosis.  Phage display screening revealed that Bz-423 binds to the oligomycin sensitivity conferring protein (OSCP) component of the mitochondrial F1F0-ATPase.  Bz-423 inhibited the F1F0-ATPase in vitro, and reconstitution expts. demonstrated that inhibition was mediated by the OSCP.  This target was further validated by generating cells with reduced OSCP expression using RNA interference and studying the sensitivity of these cells to Bz-423.  Our findings help explain the efficacy and selectivity of Bz-423 for autoimmune lymphocytes and highlight the OSCP as a target to guide the development of novel lupus therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_3Wuow7vU27Vg90H21EOLACvtfcHk0ljqyup9gHlt3Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjsFKitbs%253D&md5=76b57708848048569572a98f50a9a16c</span></div><a href="/servlet/linkout?suffix=cit241&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2005.02.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2005.02.012%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DK.%2BM.%26aulast%3DChen%26aufirst%3DX.%2BN.%26aulast%3DBoitano%26aufirst%3DA.%26aulast%3DSwenson%26aufirst%3DL.%26aulast%3DOpipari%26aufirst%3DA.%2BW.%26aulast%3DGlick%26aufirst%3DG.%2BD.%26atitle%3DIdentification%2520and%2520validation%2520of%2520the%2520mitochondrial%2520F1F0-ATPase%2520as%2520the%2520molecular%2520target%2520of%2520the%2520immunomodulatory%2520benzodiazepine%2520Bz-423%26jtitle%3DChem.%2520Biol.%26date%3D2005%26volume%3D12%26spage%3D485%26epage%3D496%26doi%3D10.1016%2Fj.chembiol.2005.02.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref242"><div class="reference"><strong class="refLabel"><a href="#ref242" class="rightTabRefNumLink">242</a></strong><div class="NLM_citation" id="rightTab-cit242"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boitano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glick, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opipari, A. W.</span></span> <span> </span><span class="NLM_article-title">The proapoptotic benzodiazepine Bz-423 affects the growth and survival of malignant B cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">6870</span>â <span class="NLM_lpage">6876</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=14583485" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD3sXosVGns70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=6870-6876&author=A.+Boitanoauthor=J.+A.+Ellmanauthor=G.+D.+Glickauthor=A.+W.+Opipari&title=The+proapoptotic+benzodiazepine+Bz-423+affects+the+growth+and+survival+of+malignant+B+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit242R"><div class="casContent"><span class="casTitleNuber">242</span><div class="casTitle"><span class="NLM_cas:atitle">The proapoptotic benzodiazepine Bz-423 affects the growth and survival of malignant B cells</span></div><div class="casAuthors">Boitano, Anthony; Ellman, Jonathan A.; Glick, Gary D.; Opipari, Anthony W., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6870-6876</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Bz-423 is a novel proapoptotic 1,4-benzodiazepine that induces cell death via a superoxide signal.  Previous work has shown that Bz-423 ameliorates disease in animal models of systemic lupus erythematosus that also have features of lymphoproliferative disease.  Here we describe the effects of Bz-423 against a group of malignant B-cell lines derived from Burkitt's lymphoma.  These expts. demonstrate that Bz-423 has cytotoxic activity against all B-cell lines tested, regardless of EBV status or Bcl-2 and Bcl-xL expression levels.  In addn. to its cytotoxic properties, we found that Bz-423 is also a potent antiproliferative agent that induces a G1-phase arrest independent of p53.  Mechanistically, both the cytotoxicity and growth arrest are mediated by increased reactive oxygen species levels and appear independent of binding to the peripheral benzodiazepine receptor.  This work further defines the biol. activities of Bz-423 that are consistent with those of other compds. in clin. development for antineoplastic therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOW2im-U0TarVg90H21EOLACvtfcHk0lg-SKGdwlK5Pg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXosVGns70%253D&md5=25b8ae53ee269285074aa7011b80f876</span></div><a href="/servlet/linkout?suffix=cit242&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoitano%26aufirst%3DA.%26aulast%3DEllman%26aufirst%3DJ.%2BA.%26aulast%3DGlick%26aufirst%3DG.%2BD.%26aulast%3DOpipari%26aufirst%3DA.%2BW.%26atitle%3DThe%2520proapoptotic%2520benzodiazepine%2520Bz-423%2520affects%2520the%2520growth%2520and%2520survival%2520of%2520malignant%2520B%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D6870%26epage%3D6876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref243"><div class="reference"><strong class="refLabel"><a href="#ref243" class="rightTabRefNumLink">243</a></strong><div class="NLM_citation" id="rightTab-cit243"><span><span class="NLM_contrib-group"><span class="NLM_string-name">vanRaaij, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrahams, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, A. G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. E.</span></span> <span> </span><span class="NLM_article-title">The structure of bovine F-1-ATPase complexed with the antibiotic inhibitor aurovertin B</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">6913</span>â <span class="NLM_lpage">6917</span>, <span class="refDoi">Â DOI: 10.1073/pnas.93.14.6913</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1073%2Fpnas.93.14.6913" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=8692918" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1996&pages=6913-6917&author=M.+J.+vanRaaijauthor=J.+P.+Abrahamsauthor=A.+G.+W.+Leslieauthor=J.+E.+Walker&title=The+structure+of+bovine+F-1-ATPase+complexed+with+the+antibiotic+inhibitor+aurovertin+B&doi=10.1073%2Fpnas.93.14.6913"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit243&amp;dbid=16384&amp;doi=10.1073%2Fpnas.93.14.6913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.93.14.6913%26sid%3Dliteratum%253Aachs%26aulast%3DvanRaaij%26aufirst%3DM.%2BJ.%26aulast%3DAbrahams%26aufirst%3DJ.%2BP.%26aulast%3DLeslie%26aufirst%3DA.%2BG.%2BW.%26aulast%3DWalker%26aufirst%3DJ.%2BE.%26atitle%3DThe%2520structure%2520of%2520bovine%2520F-1-ATPase%2520complexed%2520with%2520the%2520antibiotic%2520inhibitor%2520aurovertin%2520B%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1996%26volume%3D93%26spage%3D6913%26epage%3D6917%26doi%3D10.1073%2Fpnas.93.14.6913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref244"><div class="reference"><strong class="refLabel"><a href="#ref244" class="rightTabRefNumLink">244</a></strong><div class="NLM_citation" id="rightTab-cit244"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ebel, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lardy, H. A.</span></span> <span> </span><span class="NLM_article-title">Influence of aurovertin on mitochondrial atpase activity</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1975</span>,  <span class="NLM_volume"><i>250</i></span>,  <span class="NLM_fpage">4992</span>â <span class="NLM_lpage">4995</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=125277" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADyaE2MXkvFaqurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=250&publication_year=1975&pages=4992-4995&author=R.+E.+Ebelauthor=H.+A.+Lardy&title=Influence+of+aurovertin+on+mitochondrial+atpase+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit244R"><div class="casContent"><span class="casTitleNuber">244</span><div class="casTitle"><span class="NLM_cas:atitle">Influence of aurovertin on mitochondrial ATPase activity</span></div><div class="casAuthors">Ebel, Richard E.; Lardy, Henry A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1975</span>),
    <span class="NLM_cas:volume">250</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4992-5</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">The kinetic effects of the antibiotic aurovertin on the ATPase and ITPase activity of isolated rat liver mitochondrial ATPase were studied.  Unusual patterns of inhibition, decreasing slope, and increasing y-intercept values of double reciprocal plots, were obsd. with Mg-ATP as the substrate under various conditions.  Under specified conditions, aurovertin stimulated hydrolysis of Mg-ATP.  The inhibition of Mg-ITP hydrolysis was uncompetitive.  Aurovertin eliminated the HCO3- stimulation of Mg-ATP hydrolysis.  The implications of these findings for the mechanism of mitochondrial ATPase are briefly discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtrLH7bA6997Vg90H21EOLACvtfcHk0lg-SKGdwlK5Pg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2MXkvFaqurw%253D&md5=46b0c116357cfc8d5b118b5b208df650</span></div><a href="/servlet/linkout?suffix=cit244&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEbel%26aufirst%3DR.%2BE.%26aulast%3DLardy%26aufirst%3DH.%2BA.%26atitle%3DInfluence%2520of%2520aurovertin%2520on%2520mitochondrial%2520atpase%2520activity%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1975%26volume%3D250%26spage%3D4992%26epage%3D4995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref245"><div class="reference"><strong class="refLabel"><a href="#ref245" class="rightTabRefNumLink">245</a></strong><div class="NLM_citation" id="rightTab-cit245"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, M. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span> <span> </span><span class="NLM_article-title">Inhibiting neddylation modification alters mitochondrial morphology and reprograms energy metabolism in cancer cells</span>. <i>JCI Insight</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">e121582</span>, <span class="refDoi">Â DOI: 10.1172/jci.insight.121582</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1172%2Fjci.insight.121582" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=30668548" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2019&pages=e121582&author=Q.+Y.+Zhouauthor=H.+Liauthor=Y.+Y.+Liauthor=M.+J.+Tanauthor=S.+H.+Fanauthor=C.+Caoauthor=F.+L.+Mengauthor=L.+Zhuauthor=L.+L.+Zhaoauthor=M.+X.+Guanauthor=H.+C.+Jinauthor=Y.+Sun&title=Inhibiting+neddylation+modification+alters+mitochondrial+morphology+and+reprograms+energy+metabolism+in+cancer+cells&doi=10.1172%2Fjci.insight.121582"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit245&amp;dbid=16384&amp;doi=10.1172%2Fjci.insight.121582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252Fjci.insight.121582%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DQ.%2BY.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DY.%2BY.%26aulast%3DTan%26aufirst%3DM.%2BJ.%26aulast%3DFan%26aufirst%3DS.%2BH.%26aulast%3DCao%26aufirst%3DC.%26aulast%3DMeng%26aufirst%3DF.%2BL.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DL.%2BL.%26aulast%3DGuan%26aufirst%3DM.%2BX.%26aulast%3DJin%26aufirst%3DH.%2BC.%26aulast%3DSun%26aufirst%3DY.%26atitle%3DInhibiting%2520neddylation%2520modification%2520alters%2520mitochondrial%2520morphology%2520and%2520reprograms%2520energy%2520metabolism%2520in%2520cancer%2520cells%26jtitle%3DJCI%2520Insight%26date%3D2019%26volume%3D4%26spage%3De121582%26doi%3D10.1172%2Fjci.insight.121582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref246"><div class="reference"><strong class="refLabel"><a href="#ref246" class="rightTabRefNumLink">246</a></strong><div class="NLM_citation" id="rightTab-cit246"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Lorenzo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Guzzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosenberg, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMahon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, B.</span></span> <span> </span><span class="NLM_article-title">Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">18226</span>â <span class="NLM_lpage">18231</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1317577110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1073%2Fpnas.1317577110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=24145418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVSmurbF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=18226-18231&author=P.+Yuanauthor=K.+Itoauthor=R.+Perez-Lorenzoauthor=C.+Del+Guzzoauthor=J.+H.+Leeauthor=C.+H.+Shenauthor=M.+W.+Bosenbergauthor=M.+McMahonauthor=L.+C.+Cantleyauthor=B.+Zheng&title=Phenformin+enhances+the+therapeutic+benefit+of+BRAF%28V600E%29+inhibition+in+melanoma&doi=10.1073%2Fpnas.1317577110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit246R"><div class="casContent"><span class="casTitleNuber">246</span><div class="casTitle"><span class="NLM_cas:atitle">Phenformin enhances the therapeutic benefit of BRAFV600E inhibition in melanoma</span></div><div class="casAuthors">Yuan, Ping; Ito, Koichi; Perez-Lorenzo, Rolando; Del Guzzo, Christina; Lee, Jung Hyun; Shen, Che-Hung; Bosenberg, Marcus W.; McMahon, Martin; Cantley, Lewis C.; Zheng, Bin</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">18226-18231,S18226/1-S18226/6</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Biguanides, such as the diabetes therapeutics metformin and phenformin, have demonstrated antitumor activity both in vitro and in vivo.  The energy-sensing AMP-activated protein kinase (AMPK) is known to be a major cellular target of biguanides.  Based on our discovery of cross-talk between the AMPK and v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) signaling pathways, we investigated the antitumor effects of combining phenformin with a BRAF inhibitor PLX4720 on the proliferation of BRAF-mutated melanoma cells in vitro and on BRAF-driven tumor growth in vivo.  Cotreatment of BRAF-mutated melanoma cell lines with phenformin and PLX4720 resulted in synergistic inhibition of cell viability, compared with the effects of the single agent alone.  Moreover, treatment with phenformin significantly delayed the development of resistance to PLX4720 in cultured melanoma cells.  Biochem. analyses showed that phenformin and PLX4720 exerted cooperative effects on inhibiting mTOR signaling and inducing apoptosis.  Noticeably, phenformin selectively targeted subpopulations of cells expressing JARID1B, a marker for slow cycling melanoma cells, whereas PLX4720 selectively targeted JARID1B-neg. cells.  Finally, in contrast to their use as single agents, the combination of phenformin and PLX4720 induced tumor regression in both nude mice bearing melanoma xenografts and in a genetically engineered BRAFV600E/PTENnull-driven mouse model of melanoma.  These results strongly suggest that significant therapeutic advantage may be achieved by combining AMPK activators such as phenformin with BRAF inhibitors for the treatment of melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7fg9gAwsMBbVg90H21EOLACvtfcHk0ljkLCjJNUT-kg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVSmurbF&md5=42126f04600f33e9dee7a5a83d56fd04</span></div><a href="/servlet/linkout?suffix=cit246&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1317577110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1317577110%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DP.%26aulast%3DIto%26aufirst%3DK.%26aulast%3DPerez-Lorenzo%26aufirst%3DR.%26aulast%3DDel%2BGuzzo%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DShen%26aufirst%3DC.%2BH.%26aulast%3DBosenberg%26aufirst%3DM.%2BW.%26aulast%3DMcMahon%26aufirst%3DM.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DZheng%26aufirst%3DB.%26atitle%3DPhenformin%2520enhances%2520the%2520therapeutic%2520benefit%2520of%2520BRAF%2528V600E%2529%2520inhibition%2520in%2520melanoma%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26spage%3D18226%26epage%3D18231%26doi%3D10.1073%2Fpnas.1317577110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref247"><div class="reference"><strong class="refLabel"><a href="#ref247" class="rightTabRefNumLink">247</a></strong><div class="NLM_citation" id="rightTab-cit247"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boudreau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purkey, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hitz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robarge, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labadie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Nagro, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pusapati, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCleland, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderbilt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daemen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belvin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatzivassiliou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evangelista, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâBrien, T.</span></span> <span> </span><span class="NLM_article-title">Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">779</span>â <span class="NLM_lpage">786</span>, <span class="refDoi">Â DOI: 10.1038/nchembio.2143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fnchembio.2143" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27479743" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Kmu73K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=779-786&author=A.+Boudreauauthor=H.+E.+Purkeyauthor=A.+Hitzauthor=K.+Robargeauthor=D.+Petersonauthor=S.+Labadieauthor=M.+Kwongauthor=R.+Hongauthor=M.+Gaoauthor=C.+Del+Nagroauthor=R.+Pusapatiauthor=S.+G.+Maauthor=L.+Salphatiauthor=J.+Pangauthor=A.+H.+Zhouauthor=T.+Laiauthor=Y.+J.+Liauthor=Z.+G.+Chenauthor=B.+Q.+Weiauthor=I.+Yenauthor=S.+Siderisauthor=M.+McClelandauthor=R.+Firesteinauthor=L.+Corsonauthor=A.+Vanderbiltauthor=S.+Williamsauthor=A.+Daemenauthor=M.+Belvinauthor=C.+Eigenbrotauthor=P.+K.+Jacksonauthor=S.+Malekauthor=G.+Hatzivassiliouauthor=D.+Sampathauthor=M.+Evangelistaauthor=T.+O%E2%80%99Brien&title=Metabolic+plasticity+underpins+innate+and+acquired+resistance+to+LDHA+inhibition&doi=10.1038%2Fnchembio.2143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit247R"><div class="casContent"><span class="casTitleNuber">247</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition</span></div><div class="casAuthors">Boudreau, Aaron; Purkey, Hans E.; Hitz, Anna; Robarge, Kirk; Peterson, David; Labadie, Sharada; Kwong, Mandy; Hong, Rebecca; Gao, Min; Del Nagro, Christopher; Pusapati, Raju; Ma, Shuguang; Salphati, Laurent; Pang, Jodie; Zhou, Aihe; Lai, Tommy; Li, Yingjie; Chen, Zhongguo; Wei, Binqing; Yen, Ivana; Sideris, Steve; McCleland, Mark; Firestein, Ron; Corson, Laura; Vanderbilt, Alex; Williams, Simon; Daemen, Anneleen; Belvin, Marcia; Eigenbrot, Charles; Jackson, Peter K.; Malek, Shiva; Hatzivassiliou, Georgia; Sampath, Deepak; Evangelista, Marie; O'Brien, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">779-786</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Metabolic reprogramming in tumors represents a potential therapeutic target.  Herein we used shRNA depletion and a novel lactate dehydrogenase (LDHA) inhibitor, GNE-140, to probe the role of LDHA in tumor growth in vitro and in vivo.  In MIA PaCa-2 human pancreatic cells, LDHA inhibition rapidly affected global metab., although cell death only occurred after 2 d of continuous LDHA inhibition.  Pancreatic cell lines that utilize oxidative phosphorylation (OXPHOS) rather than glycolysis were inherently resistant to GNE-140, but could be resensitized to GNE-140 with the OXPHOS inhibitor phenformin.  Acquired resistance to GNE-140 was driven by activation of the AMPK-mTOR-S6K signaling pathway, which led to increased OXPHOS, and inhibitors targeting this pathway could prevent resistance.  Thus, combining an LDHA inhibitor with compds. targeting the mitochondrial or AMPK-S6K signaling axis may not only broaden the clin. utility of LDHA inhibitors beyond glycolytically dependent tumors but also reduce the emergence of resistance to LDHA inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4wdebEpeIa7Vg90H21EOLACvtfcHk0lihobVDibO_Vg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Kmu73K&md5=28abbd7f174b422b7207a5f80352ce3e</span></div><a href="/servlet/linkout?suffix=cit247&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2143%26sid%3Dliteratum%253Aachs%26aulast%3DBoudreau%26aufirst%3DA.%26aulast%3DPurkey%26aufirst%3DH.%2BE.%26aulast%3DHitz%26aufirst%3DA.%26aulast%3DRobarge%26aufirst%3DK.%26aulast%3DPeterson%26aufirst%3DD.%26aulast%3DLabadie%26aufirst%3DS.%26aulast%3DKwong%26aufirst%3DM.%26aulast%3DHong%26aufirst%3DR.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DDel%2BNagro%26aufirst%3DC.%26aulast%3DPusapati%26aufirst%3DR.%26aulast%3DMa%26aufirst%3DS.%2BG.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DA.%2BH.%26aulast%3DLai%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DY.%2BJ.%26aulast%3DChen%26aufirst%3DZ.%2BG.%26aulast%3DWei%26aufirst%3DB.%2BQ.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DMcCleland%26aufirst%3DM.%26aulast%3DFirestein%26aufirst%3DR.%26aulast%3DCorson%26aufirst%3DL.%26aulast%3DVanderbilt%26aufirst%3DA.%26aulast%3DWilliams%26aufirst%3DS.%26aulast%3DDaemen%26aufirst%3DA.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DJackson%26aufirst%3DP.%2BK.%26aulast%3DMalek%26aufirst%3DS.%26aulast%3DHatzivassiliou%26aufirst%3DG.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DEvangelista%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DT.%26atitle%3DMetabolic%2520plasticity%2520underpins%2520innate%2520and%2520acquired%2520resistance%2520to%2520LDHA%2520inhibition%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2016%26volume%3D12%26spage%3D779%26epage%3D786%26doi%3D10.1038%2Fnchembio.2143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref248"><div class="reference"><strong class="refLabel"><a href="#ref248" class="rightTabRefNumLink">248</a></strong><div class="NLM_citation" id="rightTab-cit248"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavazos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baran, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuruvilla, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gay, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battula, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreeff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daver, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marszalek, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konopleva, M.</span></span> <span> </span><span class="NLM_article-title">Targeting residual chemotherapy-resistant acute myeloid leukemia cells by a novel OXPHOS inhibitor IACS010759</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">2623</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2017&pages=2623&author=L.+N.+Hanauthor=A.+Cavazosauthor=N.+Baranauthor=Q.+Zhangauthor=V.+M.+Kuruvillaauthor=J.+P.+Gayauthor=N.+P.+Fengauthor=V.+L.+Battulaauthor=M.+Andreeffauthor=H.+M.+Kantarjianauthor=N.+Daverauthor=J.+R.+Marszalekauthor=M.+Konopleva&title=Targeting+residual+chemotherapy-resistant+acute+myeloid+leukemia+cells+by+a+novel+OXPHOS+inhibitor+IACS010759"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit248&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DL.%2BN.%26aulast%3DCavazos%26aufirst%3DA.%26aulast%3DBaran%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DKuruvilla%26aufirst%3DV.%2BM.%26aulast%3DGay%26aufirst%3DJ.%2BP.%26aulast%3DFeng%26aufirst%3DN.%2BP.%26aulast%3DBattula%26aufirst%3DV.%2BL.%26aulast%3DAndreeff%26aufirst%3DM.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DDaver%26aufirst%3DN.%26aulast%3DMarszalek%26aufirst%3DJ.%2BR.%26aulast%3DKonopleva%26aufirst%3DM.%26atitle%3DTargeting%2520residual%2520chemotherapy-resistant%2520acute%2520myeloid%2520leukemia%2520cells%2520by%2520a%2520novel%2520OXPHOS%2520inhibitor%2520IACS010759%26jtitle%3DBlood%26date%3D2017%26volume%3D130%26spage%3D2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref249"><div class="reference"><strong class="refLabel"><a href="#ref249" class="rightTabRefNumLink">249</a></strong><div class="NLM_citation" id="rightTab-cit249"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sica, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo-San Pedro, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izzo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pol, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierredon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durand, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bossut, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chery, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souquere, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierron, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vartholomaiou, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamzami, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soussi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauvat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mondragon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kepp, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galluzzi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinou, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess-Stumpp, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegelbauer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroemer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maiuri, M. C.</span></span> <span> </span><span class="NLM_article-title">Lethal poisoning of cancer cells by respiratory chain inhibition plus dimethyl alpha-ketoglutarate</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">820</span>â <span class="NLM_lpage">834</span>, <span class="refDoi">Â DOI: 10.1016/j.celrep.2019.03.058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.celrep.2019.03.058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=30995479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1MXns1Gltro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=820-834&author=V.+Sicaauthor=J.+M.+Bravo-San+Pedroauthor=V.+Izzoauthor=J.+Polauthor=S.+Pierredonauthor=D.+Enotauthor=S.+Durandauthor=N.+Bossutauthor=A.+Cheryauthor=S.+Souquereauthor=G.+Pierronauthor=E.+Vartholomaiouauthor=N.+Zamzamiauthor=T.+Soussiauthor=A.+Sauvatauthor=L.+Mondragonauthor=O.+Keppauthor=L.+Galluzziauthor=J.+C.+Martinouauthor=H.+Hess-Stumppauthor=K.+Ziegelbauerauthor=G.+Kroemerauthor=M.+C.+Maiuri&title=Lethal+poisoning+of+cancer+cells+by+respiratory+chain+inhibition+plus+dimethyl+alpha-ketoglutarate&doi=10.1016%2Fj.celrep.2019.03.058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit249R"><div class="casContent"><span class="casTitleNuber">249</span><div class="casTitle"><span class="NLM_cas:atitle">Lethal Poisoning of Cancer Cells by Respiratory Chain Inhibition plus Dimethyl Î±-Ketoglutarate</span></div><div class="casAuthors">Sica, Valentina; Bravo-San Pedro, Jose Manuel; Izzo, Valentina; Pol, Jonathan; Pierredon, Sandra; Enot, David; Durand, Sylvere; Bossut, Noelie; Chery, Alexis; Souquere, Sylvie; Pierron, Gerard; Vartholomaiou, Evangelia; Zamzami, Naoufal; Soussi, Thierry; Sauvat, Allan; Mondragon, Laura; Kepp, Oliver; Galluzzi, Lorenzo; Martinou, Jean-Claude; Hess-Stumpp, Holger; Ziegelbauer, Karl; Kroemer, Guido; Maiuri, Maria Chiara</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">820-834.e9</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Inhibition of oxidative phosphorylation (OXPHOS) by 1-cyclopropyl-4-(4-[(5-methyl-3-(3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)methyl]pyridin-2-yl)piperazine (BAY87-2243, abbreviated as B87), a complex I inhibitor, fails to kill human cancer cells in vitro.  Driven by this consideration, we attempted to identify agents that engage in synthetically lethal interactions with B87.  Here, we report that di-Me Î±-ketoglutarate (DMKG), a cell-permeable precursor of Î±-ketoglutarate that lacks toxicity on its own, kills cancer cells when combined with B87 or other inhibitors of OXPHOS.  DMKG improved the antineoplastic effect of B87, both in vitro and in vivo.  This combination caused MDM2-dependent, tumor suppressor protein p53 (TP53)-independent transcriptional reprogramming and alternative exon usage affecting multiple glycolytic enzymes, completely blocking glycolysis.  Simultaneous inhibition of OXPHOS and glycolysis provoked a bioenergetic catastrophe culminating in the activation of a cell death program that involved disruption of the mitochondrial network and activation of PARP1, AIFM1, and APEX1.  These results unveil a metabolic liability of human cancer cells that may be harnessed for the development of therapeutic regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo50HaqR_NxBrVg90H21EOLACvtfcHk0lgTb9VF_DXFkA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXns1Gltro%253D&md5=7b3138ef0862bc2c639ffc9e3be73389</span></div><a href="/servlet/linkout?suffix=cit249&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2019.03.058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2019.03.058%26sid%3Dliteratum%253Aachs%26aulast%3DSica%26aufirst%3DV.%26aulast%3DBravo-San%2BPedro%26aufirst%3DJ.%2BM.%26aulast%3DIzzo%26aufirst%3DV.%26aulast%3DPol%26aufirst%3DJ.%26aulast%3DPierredon%26aufirst%3DS.%26aulast%3DEnot%26aufirst%3DD.%26aulast%3DDurand%26aufirst%3DS.%26aulast%3DBossut%26aufirst%3DN.%26aulast%3DChery%26aufirst%3DA.%26aulast%3DSouquere%26aufirst%3DS.%26aulast%3DPierron%26aufirst%3DG.%26aulast%3DVartholomaiou%26aufirst%3DE.%26aulast%3DZamzami%26aufirst%3DN.%26aulast%3DSoussi%26aufirst%3DT.%26aulast%3DSauvat%26aufirst%3DA.%26aulast%3DMondragon%26aufirst%3DL.%26aulast%3DKepp%26aufirst%3DO.%26aulast%3DGalluzzi%26aufirst%3DL.%26aulast%3DMartinou%26aufirst%3DJ.%2BC.%26aulast%3DHess-Stumpp%26aufirst%3DH.%26aulast%3DZiegelbauer%26aufirst%3DK.%26aulast%3DKroemer%26aufirst%3DG.%26aulast%3DMaiuri%26aufirst%3DM.%2BC.%26atitle%3DLethal%2520poisoning%2520of%2520cancer%2520cells%2520by%2520respiratory%2520chain%2520inhibition%2520plus%2520dimethyl%2520alpha-ketoglutarate%26jtitle%3DCell%2520Rep.%26date%3D2019%26volume%3D27%26spage%3D820%26epage%3D834%26doi%3D10.1016%2Fj.celrep.2019.03.058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref250"><div class="reference"><strong class="refLabel"><a href="#ref250" class="rightTabRefNumLink">250</a></strong><div class="NLM_citation" id="rightTab-cit250"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Navratilova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karasova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanova, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jirakova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budkova, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pachernik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smarda, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benes, P.</span></span> <span> </span><span class="NLM_article-title">Selective elimination of neuroblastoma cells by synergistic effect of Akt kinase inhibitor and tetrathiomolybdate</span>. <i>J. Cell. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1859</span>â <span class="NLM_lpage">1869</span>, <span class="refDoi">Â DOI: 10.1111/jcmm.13106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1111%2Fjcmm.13106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=28244639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlymtLzN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2017&pages=1859-1869&author=J.+Navratilovaauthor=M.+Karasovaauthor=M.+K.+Lanovaauthor=L.+Jirakovaauthor=Z.+Budkovaauthor=J.+Pachernikauthor=J.+Smardaauthor=P.+Benes&title=Selective+elimination+of+neuroblastoma+cells+by+synergistic+effect+of+Akt+kinase+inhibitor+and+tetrathiomolybdate&doi=10.1111%2Fjcmm.13106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit250R"><div class="casContent"><span class="casTitleNuber">250</span><div class="casTitle"><span class="NLM_cas:atitle">selective elimination of neuroblastoma cells by synergistic effect of akt kinase inhibitor and tetrathiomolybdate</span></div><div class="casAuthors">Navratilova, Jarmila; Karasova, Martina; Kohutkova Lanova, Martina; Jirakova, Ludmila; Budkova, Zuzana; Pachernik, Jiri; Smarda, Jan; Benes, Petr</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular and Molecular Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1859-1869</span>CODEN:
                <span class="NLM_cas:coden">JCMMC9</span>;
        ISSN:<span class="NLM_cas:issn">1582-4934</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Neuroblastoma is the most common extracranial solid tumor of infancy.  Pathol. activation of glucose consumption, glycolysis and glycolysis-activating Akt kinase occur frequently in neuroblastoma cells, and these changes correlate with poor prognosis of patients.  Therefore, several inhibitors of glucose utilization and the Akt kinase activity are in preclin. trials as potential anti-cancer drugs.  However, metabolic plasticity of cancer cells might undermine efficacy of this approach.  In this work, we identified oxidative phosphorylation as compensatory mechanism preserving viability of neuroblastoma cells with inhibited glucose uptake/Akt kinase.  It was oxidative phosphorylation that maintained intracellular level of ATP and proliferative capacity of these cells.  The oxidative phosphorylation inhibitors (rotenone, tetrathiomolybdate) synergized with inhibitor of the Akt kinase/glucose uptake in down-regulation of both viability of neuroblastoma cells and clonogenic potential of cells forming neuroblastoma spheroids.  Interestingly, tetrathiomolybdate acted as highly specific inhibitor of oxygen consumption and activator of lactate prodn. in neuroblastoma cells, but not in normal fibroblasts and neuronal cells.  Moreover, the reducing effect of tetrathiomolybdate on cell viability and the level of ATP in the cells with inhibited Akt kinase/glucose uptake was also selective for neuroblastoma cells.  Therefore, efficient elimination of neuroblastoma cells requires inhibition of both glucose uptake/Akt kinase and oxidative phosphorylation activities.  The use of tetrathiomolybdate as a mitochondrial inhibitor contributes to selectivity of this combined treatment, preferentially targeting neuroblastoma cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMH2M4zlJe-LVg90H21EOLACvtfcHk0lgTb9VF_DXFkA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlymtLzN&md5=859127547339a7fdfbe46a0290cc31e1</span></div><a href="/servlet/linkout?suffix=cit250&amp;dbid=16384&amp;doi=10.1111%2Fjcmm.13106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjcmm.13106%26sid%3Dliteratum%253Aachs%26aulast%3DNavratilova%26aufirst%3DJ.%26aulast%3DKarasova%26aufirst%3DM.%26aulast%3DLanova%26aufirst%3DM.%2BK.%26aulast%3DJirakova%26aufirst%3DL.%26aulast%3DBudkova%26aufirst%3DZ.%26aulast%3DPachernik%26aufirst%3DJ.%26aulast%3DSmarda%26aufirst%3DJ.%26aulast%3DBenes%26aufirst%3DP.%26atitle%3DSelective%2520elimination%2520of%2520neuroblastoma%2520cells%2520by%2520synergistic%2520effect%2520of%2520Akt%2520kinase%2520inhibitor%2520and%2520tetrathiomolybdate%26jtitle%3DJ.%2520Cell.%2520Mol.%2520Med.%26date%3D2017%26volume%3D21%26spage%3D1859%26epage%3D1869%26doi%3D10.1111%2Fjcmm.13106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref251"><div class="reference"><strong class="refLabel"><a href="#ref251" class="rightTabRefNumLink">251</a></strong><div class="NLM_citation" id="rightTab-cit251"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovly, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span> <span> </span><span class="NLM_article-title">Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2249</span>â <span class="NLM_lpage">2256</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-13-1610</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F1078-0432.CCR-13-1610" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=24789032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnsFWitro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=2249-2256&author=C.+M.+Lovlyauthor=A.+T.+Shaw&title=Molecular+pathways%3A+resistance+to+kinase+inhibitors+and+implications+for+therapeutic+strategies&doi=10.1158%2F1078-0432.CCR-13-1610"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit251R"><div class="casContent"><span class="casTitleNuber">251</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Pathways: Resistance to Kinase Inhibitors and Implications for Therapeutic Strategies</span></div><div class="casAuthors">Lovly, Christine M.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2249-2256</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The development of targeted therapies has revolutionized the treatment of cancer patients.  The identification of "druggable" oncogenic kinases and the creation of small-mol. inhibitors designed to specifically target these mutant kinases have become an important therapeutic paradigm across several different malignancies.  Often these inhibitors induce dramatic clin. responses in molecularly defined cohorts.  However, resistance to such targeted therapies is an inevitable consequence of this therapeutic approach.  Resistance can be either primary (de novo) or acquired.  Mechanisms leading to primary resistance may be categorized as tumor intrinsic factors or as patient/drug-specific factors.  Acquired resistance may be mediated by target gene modification, activation of "bypass tracks" that serve as compensatory signaling loops, or histol. transformation.  This brief review is a snapshot of the complex problem of therapeutic resistance, with a focus on resistance to kinase inhibitors in EGF receptor mutant and ALK rearranged non-small cell lung cancer, BRAF-mutant melanoma, and BCR-ABL-pos. chronic myeloid leukemia.  We describe specific mechanisms of primary and acquired resistance and then review emerging strategies to delay or overcome drug resistance.  Clin Cancer Res; 20(9); 2249-56. Â©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2GZlYyyZMDbVg90H21EOLACvtfcHk0lhSbG-uYzapwg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnsFWitro%253D&md5=81f6c66a07aab8b6db2c200dc701fb20</span></div><a href="/servlet/linkout?suffix=cit251&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-1610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-1610%26sid%3Dliteratum%253Aachs%26aulast%3DLovly%26aufirst%3DC.%2BM.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DMolecular%2520pathways%253A%2520resistance%2520to%2520kinase%2520inhibitors%2520and%2520implications%2520for%2520therapeutic%2520strategies%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D2249%26epage%3D2256%26doi%3D10.1158%2F1078-0432.CCR-13-1610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref252"><div class="reference"><strong class="refLabel"><a href="#ref252" class="rightTabRefNumLink">252</a></strong><div class="NLM_citation" id="rightTab-cit252"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosenzweig, S. A.</span></span> <span> </span><span class="NLM_article-title">Acquired resistance to drugs targeting tyrosine kinases</span>. <i>Adv. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">71</span>â <span class="NLM_lpage">98</span>, <span class="refDoi">Â DOI: 10.1016/bs.acr.2018.02.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fbs.acr.2018.02.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=29551130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFGrsr3K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2018&pages=71-98&author=S.+A.+Rosenzweig&title=Acquired+resistance+to+drugs+targeting+tyrosine+kinases&doi=10.1016%2Fbs.acr.2018.02.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit252R"><div class="casContent"><span class="casTitleNuber">252</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance to drugs targeting tyrosine kinases</span></div><div class="casAuthors">Rosenzweig, Steven A.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">71-98</span>CODEN:
                <span class="NLM_cas:coden">ACRSAJ</span>;
        ISSN:<span class="NLM_cas:issn">0065-230X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Resistance to chemotherapeutic drugs exemplifies the greatest hindrance to effective treatment of cancer patients.  The mol. mechanisms responsible have been investigated for over 50 years and have revealed the lack of a single cause, but instead, multiple mechanisms including induced expression of membrane transporters that pump drugs out of cells (multidrug resistance (MDR) phenotype), changes in the glutathione system, and altered metab.  Treatment of cancer patients/cancer cells with chemotherapeutic agents and/or molecularly targeted drugs is accompanied by acquisition of resistance to the treatment administered.  Chemotherapeutic agent resistance was initially assumed to be due to induction of mutations leading to a resistant phenotype.  While this has occurred for molecularly targeted drugs, it is clear that drugs selectively targeting tyrosine kinases (TKs) cause the acquisition of mutational changes and resistance to inhibition.  The first TK to be targeted, Bcr-Abl, led to the generation of several drugs including imatinib, dasatinib, and sunitinib that provided a rich understanding of this phenomenon.  It became clear that mutations alone were not the only cause of resistance.  Addnl. mechanisms were involved, including alternative splicing, alternative/compensatory signaling pathways, and epigenetic changes.  This review will focus on resistance to tyrosine kinase inhibitors (TKIs), receptor TK (RTK)-directed antibodies, and antibodies that inactivate specific RTK ligands.  New approaches and concepts aimed at avoiding the generation of drug resistance will be examd.  Many RTKs, including the IGF-1R, are dependence receptors that induce ligand-independent apoptosis.  How this signaling paradigm has implications on therapeutic strategies will also be considered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_cTW4uq_tI7Vg90H21EOLACvtfcHk0lhSbG-uYzapwg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFGrsr3K&md5=b294d72ac3c059b9319886740d5c0960</span></div><a href="/servlet/linkout?suffix=cit252&amp;dbid=16384&amp;doi=10.1016%2Fbs.acr.2018.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.acr.2018.02.003%26sid%3Dliteratum%253Aachs%26aulast%3DRosenzweig%26aufirst%3DS.%2BA.%26atitle%3DAcquired%2520resistance%2520to%2520drugs%2520targeting%2520tyrosine%2520kinases%26jtitle%3DAdv.%2520Cancer%2520Res.%26date%3D2018%26volume%3D138%26spage%3D71%26epage%3D98%26doi%3D10.1016%2Fbs.acr.2018.02.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref253"><div class="reference"><strong class="refLabel"><a href="#ref253" class="rightTabRefNumLink">253</a></strong><div class="NLM_citation" id="rightTab-cit253"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D.</span></span> <span> </span><span class="NLM_article-title">Inhibition of oxidative phosphorylation suppresses the development of osimertinib resistance in a preclinical model of EGFR-driven lung adenocarcinoma</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">86313</span>â <span class="NLM_lpage">86325</span>, <span class="refDoi">Â DOI: 10.18632/oncotarget.13388</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.18632%2Foncotarget.13388" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=27861144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BC2snnvVShtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=86313-86325&author=M.+J.+Martinauthor=C.+Eberleinauthor=M.+Taylorauthor=S.+Ashtonauthor=D.+Robinsonauthor=D.+Cross&title=Inhibition+of+oxidative+phosphorylation+suppresses+the+development+of+osimertinib+resistance+in+a+preclinical+model+of+EGFR-driven+lung+adenocarcinoma&doi=10.18632%2Foncotarget.13388"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit253R"><div class="casContent"><span class="casTitleNuber">253</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of oxidative phosphorylation suppresses the development of osimertinib resistance in a preclinical model of EGFR-driven lung adenocarcinoma</span></div><div class="casAuthors">Martin Matthew J; Eberlein Cath; Taylor Molly; Ashton Susan; Robinson David; Cross Darren; Martin Matthew J; Taylor Molly; Robinson David; Cross Darren</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">86313-86325</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Metabolic plasticity is an emerging hallmark of cancer, and increased glycolysis is often observed in transformed cells.  Small molecule inhibitors that target driver oncogenes can potentially inhibit the glycolytic pathway.  Osimertinib (AZD9291) is a novel EGFR tyrosine kinase inhibitor (TKI) that is potent and selective for sensitising (EGFRm) and T790M resistance mutations.  Clinical studies have shown osimertinib to be efficacious in patients with EGFRm/ T790M advanced NSCLC who have progressed after EGFR-TKI treatment.  However experience with targeted therapies suggests that acquired resistance may emerge.  Thus there is a need to characterize resistance mechanisms and to devise ways to prevent, delay or overcome osimertinib resistance.  We show here that osimertinib suppresses glycolysis in parental EGFR-mutant lung adenocarcinoma lines, but has not in osimertinib-resistant cell lines.  Critically, we show osimertinib treatment induces a strict dependence on mitochondrial oxidative phosphorylation (OxPhos), as OxPhos inhibitors significantly delay the long-term development of osimertinib resistance in osimertinib-sensitive lines.  Accordingly, growth conditions which promote a less glycolytic phenotype confer a degree of osimertinib resistance.  Our data support a model in which the combination of osimertinib and OxPhos inhibitors can delay or prevent resistance in osimertinib-naive tumour cells, and represents a novel strategy that warrants further pre-clinical investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQjOLGz8qj-J2LFM_lbR1VmfW6udTcc2ebNlgpj8RwmI7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2snnvVShtQ%253D%253D&md5=77cbd0d5e55e53e6244f9a69fb2f3df3</span></div><a href="/servlet/linkout?suffix=cit253&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.13388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.13388%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DM.%2BJ.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DRobinson%26aufirst%3DD.%26aulast%3DCross%26aufirst%3DD.%26atitle%3DInhibition%2520of%2520oxidative%2520phosphorylation%2520suppresses%2520the%2520development%2520of%2520osimertinib%2520resistance%2520in%2520a%2520preclinical%2520model%2520of%2520EGFR-driven%2520lung%2520adenocarcinoma%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D86313%26epage%3D86325%26doi%3D10.18632%2Foncotarget.13388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref254"><div class="reference"><strong class="refLabel"><a href="#ref254" class="rightTabRefNumLink">254</a></strong><div class="NLM_citation" id="rightTab-cit254"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez-Calderon, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham-Danis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeRyckere, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaberezhnyy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemta, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wempe, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollyea, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serkova, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeGregori, J.</span></span> <span> </span><span class="NLM_article-title">Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1360</span>â <span class="NLM_lpage">1372</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-14-2146</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F1078-0432.CCR-14-2146" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=25547679" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvVemsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=1360-1372&author=F.+Alvarez-Calderonauthor=M.+A.+Gregoryauthor=C.+Pham-Danisauthor=D.+DeRyckereauthor=B.+M.+Stevensauthor=V.+Zaberezhnyyauthor=A.+A.+Hillauthor=L.+Gemtaauthor=A.+Kumarauthor=V.+Kumarauthor=M.+F.+Wempeauthor=D.+A.+Pollyeaauthor=C.+T.+Jordanauthor=N.+J.+Serkovaauthor=D.+K.+Grahamauthor=J.+DeGregori&title=Tyrosine+kinase+inhibition+in+leukemia+induces+an+altered+metabolic+state+sensitive+to+mitochondrial+perturbations&doi=10.1158%2F1078-0432.CCR-14-2146"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit254R"><div class="casContent"><span class="casTitleNuber">254</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine Kinase Inhibition in Leukemia Induces an Altered Metabolic State Sensitive to Mitochondrial Perturbations</span></div><div class="casAuthors">Alvarez-Calderon, Francesca; Gregory, Mark A.; Pham-Danis, Catherine; De Ryckere, Deborah; Stevens, Brett M.; Zaberezhnyy, Vadym; Hill, Amanda A.; Gemta, Lelisa; Kumar, Amit; Kumar, Vijay; Wempe, Michael F.; Pollyea, Daniel A.; Jordan, Craig T.; Serkova, Natalie J.; Graham, Douglas K.; De Gregori, James</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1360-1372</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Although tyrosine kinase inhibitors (TKI) can be effective therapies for leukemia, they fail to fully eliminate leukemic cells and achieve durable remissions for many patients with advanced BCR-ABL+ leukemias or acute myelogenous leukemia (AML).  Through a large-scale synthetic lethal RNAi screen, we identified pyruvate dehydrogenase, the limiting enzyme for pyruvate entry into the mitochondrial tricarboxylic acid cycle, as crit. for the survival of chronic myelogenous leukemia (CML) cells upon BCR-ABL inhibition.  Here, we examd. the role of mitochondrial metab. in the survival of Ph+ leukemia and AML upon TK inhibition.  Exptl. Design: Ph+ cancer cell lines, AML cell lines, leukemia xenografts, cord blood, and patient samples were examd.  Results: We showed that the mitochondrial ATP-synthase inhibitor oligomycin-A greatly sensitized leukemia cells to TKI in vitro.  Surprisingly, oligomycin-A sensitized leukemia cells to BCR-ABL inhibition at concns. of 100- to 1,000-fold below those required for inhibition of respiration.  Oligomycin-A treatment rapidly led to mitochondrial membrane depolarization and reduced ATP levels, and promoted superoxide prodn. and leukemia cell apoptosis when combined with TKI.  Importantly, oligomycin-A enhanced elimination of BCR-ABL+ leukemia cells by TKI in a mouse model and in primary blast crisis CML samples.  Moreover, oligomycin-A also greatly potentiated the elimination of FLT3-dependent AML cells when combined with an FLT3 TKI, both in vitro and in vivo.  Conclusions: TKI therapy in leukemia cells creates a novel metabolic state that is highly sensitive to particular mitochondrial perturbations.  Targeting mitochondrial metab. as an adjuvant therapy could therefore improve therapeutic responses to TKI for patients with BCR-ABL+ and FLT3ITD leukemias.  Clin Cancer Res; 21(6); 1360-72. cpr2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkNCxdHg8ZAbVg90H21EOLACvtfcHk0lho0WAysWYONA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvVemsbs%253D&md5=cd9d6c3ed388b0ed4e965beab63f9705</span></div><a href="/servlet/linkout?suffix=cit254&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-2146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-2146%26sid%3Dliteratum%253Aachs%26aulast%3DAlvarez-Calderon%26aufirst%3DF.%26aulast%3DGregory%26aufirst%3DM.%2BA.%26aulast%3DPham-Danis%26aufirst%3DC.%26aulast%3DDeRyckere%26aufirst%3DD.%26aulast%3DStevens%26aufirst%3DB.%2BM.%26aulast%3DZaberezhnyy%26aufirst%3DV.%26aulast%3DHill%26aufirst%3DA.%2BA.%26aulast%3DGemta%26aufirst%3DL.%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DWempe%26aufirst%3DM.%2BF.%26aulast%3DPollyea%26aufirst%3DD.%2BA.%26aulast%3DJordan%26aufirst%3DC.%2BT.%26aulast%3DSerkova%26aufirst%3DN.%2BJ.%26aulast%3DGraham%26aufirst%3DD.%2BK.%26aulast%3DDeGregori%26aufirst%3DJ.%26atitle%3DTyrosine%2520kinase%2520inhibition%2520in%2520leukemia%2520induces%2520an%2520altered%2520metabolic%2520state%2520sensitive%2520to%2520mitochondrial%2520perturbations%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D1360%26epage%3D1372%26doi%3D10.1158%2F1078-0432.CCR-14-2146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref255"><div class="reference"><strong class="refLabel"><a href="#ref255" class="rightTabRefNumLink">255</a></strong><div class="NLM_citation" id="rightTab-cit255"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asara, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granters, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span> <span> </span><span class="NLM_article-title">Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">237</span>â <span class="NLM_lpage">247</span>, <span class="refDoi">Â DOI: 10.1016/j.molcel.2008.12.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.molcel.2008.12.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=19187764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvVyltr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2009&pages=237-247&author=B.+Zhengauthor=J.+H.+Jeongauthor=J.+M.+Asaraauthor=Y.+Y.+Yuanauthor=S.+R.+Grantersauthor=L.+Chinauthor=L.+C.+Cantley&title=Oncogenic+B-RAF+negatively+regulates+the+tumor+suppressor+LKB1+to+promote+melanoma+cell+proliferation&doi=10.1016%2Fj.molcel.2008.12.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit255R"><div class="casContent"><span class="casTitleNuber">255</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation</span></div><div class="casAuthors">Zheng, Bin; Jeong, Joseph H.; Asara, John M.; Yuan, Yuan-Ying; Granter, Scott R.; Chin, Lynda; Cantley, Lewis C.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">237-247</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The LKB1-AMPK signaling pathway serves as a crit. cellular sensor coupling energy homeostasis to cell growth, proliferation, and survival.  However, how tumor cells suppress this signaling pathway to gain growth advantage under conditions of energy stress is largely unknown.  Here, we show that AMPK activation is suppressed in melanoma cells with the B-RAF V600E mutation and that downregulation of B-RAF signaling activates AMPK.  We find that in these cells LKB1 is phosphorylated by ERK and Rsk, two kinases downstream of B-RAF, and that this phosphorylation compromises the ability of LKB1 to bind and activate AMPK.  Furthermore, expression of a phosphorylation-deficient mutant of LKB1 allows activation of AMPK and inhibits melanoma cell proliferation and anchorage-independent cell growth.  Our findings provide a mol. linkage between the LKB1-AMPK and the RAF-MEK-ERK pathways and suggest that suppression of LKB1 function by B-RAF V600E plays an important role in B-RAF V600E-driven tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoE262UcrzgtbVg90H21EOLACvtfcHk0lho0WAysWYONA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvVyltr8%253D&md5=99e6766f229397eaad4e37ddb1ad326d</span></div><a href="/servlet/linkout?suffix=cit255&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2008.12.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2008.12.026%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DB.%26aulast%3DJeong%26aufirst%3DJ.%2BH.%26aulast%3DAsara%26aufirst%3DJ.%2BM.%26aulast%3DYuan%26aufirst%3DY.%2BY.%26aulast%3DGranters%26aufirst%3DS.%2BR.%26aulast%3DChin%26aufirst%3DL.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DOncogenic%2520B-RAF%2520negatively%2520regulates%2520the%2520tumor%2520suppressor%2520LKB1%2520to%2520promote%2520melanoma%2520cell%2520proliferation%26jtitle%3DMol.%2520Cell%26date%3D2009%26volume%3D33%26spage%3D237%26epage%3D247%26doi%3D10.1016%2Fj.molcel.2008.12.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref256"><div class="reference"><strong class="refLabel"><a href="#ref256" class="rightTabRefNumLink">256</a></strong><div class="NLM_citation" id="rightTab-cit256"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wick, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drury, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakada, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfe, J. B.</span></span> <span> </span><span class="NLM_article-title">Localization of the primary metabolic block produced by 2-deoxyglucose</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1957</span>,  <span class="NLM_volume"><i>224</i></span>,  <span class="NLM_fpage">963</span>â <span class="NLM_lpage">969</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=13405925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADyaG2sXktlKrsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=224&publication_year=1957&pages=963-969&author=A.+N.+Wickauthor=D.+R.+Druryauthor=H.+I.+Nakadaauthor=J.+B.+Wolfe&title=Localization+of+the+primary+metabolic+block+produced+by+2-deoxyglucose"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit256R"><div class="casContent"><span class="casTitleNuber">256</span><div class="casTitle"><span class="NLM_cas:atitle">Localization of the primary metabolic block produced by 2-deoxyglucose</span></div><div class="casAuthors">Wick, Arne N.; Drury, Douglas R.; Nakada, Henry I.; Wolfe, Jack B.; Britton, Barbara; Grabowski, Ruth</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1957</span>),
    <span class="NLM_cas:volume">224</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">963-9</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">cf. C.A. 50, 482i.  Expts. were carried out to locate the metabolic block in glucose metabolism which occurs after the administration of 2-deoxyglucose to eviscerated animals.  The extrahepatic tissues oxidized only trace amts. of 2-deoxyglucose-C14; hence the compd. is blocked at some stage in its metabolism.  Since it did not influence the oxidation of injected acetate-C14, the metabolic block is in the glycolytic area.  Studies in vitro showed that 2-deoxyglucose-6-phosphate competitively inhibited formation of ketose from glucose-6-phosphate when purified rat-kidney phosphoglucoisomerase was used.  The primary block induced by 2-deoxyglucose is at the phosphoglucoisomerase level.  Possible secondary blocks are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWQ3LBZViyvLVg90H21EOLACvtfcHk0lhs2-noZu-yyA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaG2sXktlKrsQ%253D%253D&md5=c9c497383b3dc5f59f3a91b3c563c21f</span></div><a href="/servlet/linkout?suffix=cit256&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWick%26aufirst%3DA.%2BN.%26aulast%3DDrury%26aufirst%3DD.%2BR.%26aulast%3DNakada%26aufirst%3DH.%2BI.%26aulast%3DWolfe%26aufirst%3DJ.%2BB.%26atitle%3DLocalization%2520of%2520the%2520primary%2520metabolic%2520block%2520produced%2520by%25202-deoxyglucose%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1957%26volume%3D224%26spage%3D963%26epage%3D969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref257"><div class="reference"><strong class="refLabel"><a href="#ref257" class="rightTabRefNumLink">257</a></strong><div class="NLM_citation" id="rightTab-cit257"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pelicano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, P.</span></span> <span> </span><span class="NLM_article-title">Glycolysis inhibition for anticancer treatment</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">4633</span>â <span class="NLM_lpage">4646</span>, <span class="refDoi">Â DOI: 10.1038/sj.onc.1209597</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fsj.onc.1209597" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=16892078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD28Xnsl2hs7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=4633-4646&author=H.+Pelicanoauthor=D.+S.+Martinauthor=R.+H.+Xuauthor=P.+Huang&title=Glycolysis+inhibition+for+anticancer+treatment&doi=10.1038%2Fsj.onc.1209597"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit257R"><div class="casContent"><span class="casTitleNuber">257</span><div class="casTitle"><span class="NLM_cas:atitle">Glycolysis inhibition for anticancer treatment</span></div><div class="casAuthors">Pelicano, H.; Martin, D. S.; Xu, R.-H.; Huang, P.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">4633-4646</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Most cancer cells exhibit increased glycolysis and use this metabolic pathway for generation of ATP as a main source of their energy supply.  This phenomenon is known as the Warburg effect and is considered as one of the most fundamental metabolic alterations during malignant transformation.  In recent years, there are significant progresses in our understanding of the underlying mechanisms and the potential therapeutic implications.  Biochem. and mol. studies suggest several possible mechanisms by which this metabolic alteration may evolve during cancer development.  These mechanisms include mitochondrial defects and malfunction, adaptation to hypoxic tumor microenvironment, oncogenic signaling, and abnormal expression of metabolic enzymes.  Importantly, the increased dependence of cancer cells on glycolytic pathway for ATP generation provides a biochem. basis for the design of therapeutic strategies to preferentially kill cancer cells by pharmacol. inhibition of glycolysis.  Several small mols. have emerged that exhibit promising anticancer activity in vitro and in vivo, as single agent or in combination with other therapeutic modalities.  The glycolytic inhibitors are particularly effective against cancer cells with mitochondrial defects or under hypoxic conditions, which are frequently assocd. with cellular resistance to conventional anticancer drugs and radiation therapy.  Because increased aerobic glycolysis is commonly seen in a wide spectrum of human cancers and hypoxia is present in most tumor microenvironment, development of novel glycolytic inhibitors as a new class of anticancer agents is likely to have broad therapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYJDZpML8A07Vg90H21EOLACvtfcHk0lhs2-noZu-yyA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xnsl2hs7Y%253D&md5=1315037e761c3f674a3acd7854873c61</span></div><a href="/servlet/linkout?suffix=cit257&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1209597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1209597%26sid%3Dliteratum%253Aachs%26aulast%3DPelicano%26aufirst%3DH.%26aulast%3DMartin%26aufirst%3DD.%2BS.%26aulast%3DXu%26aufirst%3DR.%2BH.%26aulast%3DHuang%26aufirst%3DP.%26atitle%3DGlycolysis%2520inhibition%2520for%2520anticancer%2520treatment%26jtitle%3DOncogene%26date%3D2006%26volume%3D25%26spage%3D4633%26epage%3D4646%26doi%3D10.1038%2Fsj.onc.1209597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref258"><div class="reference"><strong class="refLabel"><a href="#ref258" class="rightTabRefNumLink">258</a></strong><div class="NLM_citation" id="rightTab-cit258"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raez, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricart, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiorean, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiPaola, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lima, C. M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlesselman, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolba, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langmuir, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroll, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurtoglu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenblatt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lampidis, T. J.</span></span> <span> </span><span class="NLM_article-title">A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">523</span>â <span class="NLM_lpage">530</span>, <span class="refDoi">Â DOI: 10.1007/s00280-012-2045-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1007%2Fs00280-012-2045-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=23228990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslaktLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2013&pages=523-530&author=L.+E.+Raezauthor=K.+Papadopoulosauthor=A.+D.+Ricartauthor=E.+G.+Chioreanauthor=R.+S.+DiPaolaauthor=M.+N.+Steinauthor=C.+M.+R.+Limaauthor=J.+J.+Schlesselmanauthor=K.+Tolbaauthor=V.+K.+Langmuirauthor=S.+Krollauthor=D.+T.+Jungauthor=M.+Kurtogluauthor=J.+Rosenblattauthor=T.+J.+Lampidis&title=A+phase+I+dose-escalation+trial+of+2-deoxy-D-glucose+alone+or+combined+with+docetaxel+in+patients+with+advanced+solid+tumors&doi=10.1007%2Fs00280-012-2045-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit258R"><div class="casContent"><span class="casTitleNuber">258</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors</span></div><div class="casAuthors">Raez, Luis E.; Papadopoulos, Kyriakos; Ricart, Alejandro D.; Chiorean, E. Gabriella; DiPaola, Robert S.; Stein, Mark N.; Rocha Lima, Caio M.; Schlesselman, James J.; Tolba, Khaled; Langmuir, Virginia K.; Kroll, Stewart; Jung, Donald T.; Kurtoglu, Metin; Rosenblatt, Joseph; Lampidis, Theodore J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">523-530</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose This phase I trial was initiated to evaluate the safety, pharmacokinetics (PK) and max. tolerated dose (MTD) of the glycolytic inhibitor, 2-deoxy-d-glucose (2DG) in combination with docetaxel, in patients with advanced solid tumors.  Methods A modified accelerated titrn. design was used. 2DG was administered orally once daily for 7 days every other week starting at a dose of 2 mg/kg and docetaxel was administered i.v. at 30 mg/m2 for 3 of every 4 wk beginning on day 1 of week 2.  Following the completion of dose escalation, cohorts of patients were then treated with 2DG for 21 days or every day of each 4-wk cycle for up to 12 cycles.  Results Thirty-four patients were enrolled: 21 on every other week, 6 on a 21 of 28-day cycle and 7 on the continuous 2DG dosing schedule.  There were no dose-limiting toxicities which met the MTD criteria.  The most common adverse events were fatigue, sweating, dizziness and nausea mimicking the hypoglycemic symptoms expected from 2DG administration.  Therefore, 63 mg/kg was selected as the clin. tolerable dose.  The most significant adverse effects noted at 63-88 mg/kg doses were reversible hyperglycemia (100 %), gastrointestinal bleeding (6 %) and reversible grade 3 QTc prolongation (22 %).  Eleven patients (32 %) had stable disease, 1 patient (3 %) partial response and 22 patients (66 %) progressive disease as their best response.  There was no PK interaction between 2DG and docetaxel.  Conclusion The recommended dose of 2DG in combination with weekly docetaxel is 63 mg/kg/day with tolerable adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ2YaHNgvkU7Vg90H21EOLACvtfcHk0ljyKGzntcGdag"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslaktLw%253D&md5=06d69744bde78fb532b960ae5cafe66e</span></div><a href="/servlet/linkout?suffix=cit258&amp;dbid=16384&amp;doi=10.1007%2Fs00280-012-2045-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-012-2045-1%26sid%3Dliteratum%253Aachs%26aulast%3DRaez%26aufirst%3DL.%2BE.%26aulast%3DPapadopoulos%26aufirst%3DK.%26aulast%3DRicart%26aufirst%3DA.%2BD.%26aulast%3DChiorean%26aufirst%3DE.%2BG.%26aulast%3DDiPaola%26aufirst%3DR.%2BS.%26aulast%3DStein%26aufirst%3DM.%2BN.%26aulast%3DLima%26aufirst%3DC.%2BM.%2BR.%26aulast%3DSchlesselman%26aufirst%3DJ.%2BJ.%26aulast%3DTolba%26aufirst%3DK.%26aulast%3DLangmuir%26aufirst%3DV.%2BK.%26aulast%3DKroll%26aufirst%3DS.%26aulast%3DJung%26aufirst%3DD.%2BT.%26aulast%3DKurtoglu%26aufirst%3DM.%26aulast%3DRosenblatt%26aufirst%3DJ.%26aulast%3DLampidis%26aufirst%3DT.%2BJ.%26atitle%3DA%2520phase%2520I%2520dose-escalation%2520trial%2520of%25202-deoxy-D-glucose%2520alone%2520or%2520combined%2520with%2520docetaxel%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2013%26volume%3D71%26spage%3D523%26epage%3D530%26doi%3D10.1007%2Fs00280-012-2045-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref259"><div class="reference"><strong class="refLabel"><a href="#ref259" class="rightTabRefNumLink">259</a></strong><div class="NLM_citation" id="rightTab-cit259"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shim, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huh, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S. G.</span></span> <span> </span><span class="NLM_article-title">Inhibition of glioblastoma tumorspheres by combined treatment with 2-deoxyglucose and metformin</span>. <i>Neuro Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">197</span>â <span class="NLM_lpage">207</span>, <span class="refDoi">Â DOI: 10.1093/neuonc/now174</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref259/cit259&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1093%2Fneuonc%2Fnow174" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2016&pages=197-207&author=E.+H.+Kimauthor=J.+H.+Leeauthor=Y.+Ohauthor=I.+Kohauthor=J.+K.+Shimauthor=J.+Parkauthor=J.+Choiauthor=M.+Yunauthor=J.+Y.+Jeonauthor=Y.+M.+Huhauthor=J.+H.+Changauthor=S.+H.+Kimauthor=K.+S.+Kimauthor=J.+H.+Cheongauthor=P.+Kimauthor=S.+G.+Kang&title=Inhibition+of+glioblastoma+tumorspheres+by+combined+treatment+with+2-deoxyglucose+and+metformin&doi=10.1093%2Fneuonc%2Fnow174"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit259&amp;dbid=16384&amp;doi=10.1093%2Fneuonc%2Fnow174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fneuonc%252Fnow174%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DE.%2BH.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DOh%26aufirst%3DY.%26aulast%3DKoh%26aufirst%3DI.%26aulast%3DShim%26aufirst%3DJ.%2BK.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DYun%26aufirst%3DM.%26aulast%3DJeon%26aufirst%3DJ.%2BY.%26aulast%3DHuh%26aufirst%3DY.%2BM.%26aulast%3DChang%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DK.%2BS.%26aulast%3DCheong%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DP.%26aulast%3DKang%26aufirst%3DS.%2BG.%26atitle%3DInhibition%2520of%2520glioblastoma%2520tumorspheres%2520by%2520combined%2520treatment%2520with%25202-deoxyglucose%2520and%2520metformin%26jtitle%3DNeuro%2520Oncol.%26date%3D2016%26volume%3D19%26spage%3D197%26epage%3D207%26doi%3D10.1093%2Fneuonc%2Fnow174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref260"><div class="reference"><strong class="refLabel"><a href="#ref260" class="rightTabRefNumLink">260</a></strong><div class="NLM_citation" id="rightTab-cit260"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zielonka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dranka, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAllister, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackinnon, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalyanaraman, B.</span></span> <span> </span><span class="NLM_article-title">Mitochondria-targeted drugs synergize with 2-deoxyglucose to trigger breast cancer cell death</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">2634</span>â <span class="NLM_lpage">2644</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-11-3928</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref260/cit260&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1158%2F0008-5472.CAN-11-3928" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref260/cit260&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=22431711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref260/cit260&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvF2ntbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=2634-2644&author=G.+Chengauthor=J.+Zielonkaauthor=B.+P.+Drankaauthor=D.+McAllisterauthor=A.+C.+Mackinnonauthor=J.+Josephauthor=B.+Kalyanaraman&title=Mitochondria-targeted+drugs+synergize+with+2-deoxyglucose+to+trigger+breast+cancer+cell+death&doi=10.1158%2F0008-5472.CAN-11-3928"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit260R"><div class="casContent"><span class="casTitleNuber">260</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondria-Targeted Drugs Synergize with 2-Deoxyglucose to Trigger Breast Cancer Cell Death</span></div><div class="casAuthors">Cheng, Gang; Zielonka, Jacek; Dranka, Brian P.; McAllister, Donna; MacKinnon, A. Craig, Jr.; Joseph, Joy; Kalyanaraman, Balaraman</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2634-2644</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cancer cells are long known to exhibit increased aerobic glycolysis, but glycolytic inhibition has not offered a viable chemotherapeutic strategy in part because of the systemic toxicity of antiglycolytic agents.  However, recent studies suggest that a combined inhibition of glycolysis and mitochondrial function may help overcome this issue.  In this study, we investigated the chemotherapeutic efficacies of mitochondria-targeted drugs (MTD) in combination with 2-deoxy-D-glucose (2-DG), a compd. that inhibits glycolysis.  Using the MTDs, termed Mito-CP and Mito-Q, we evaluated relative cytotoxic effects and mitochondrial bioenergetic changes in vitro.  Interestingly, both Mito-CP and Mito-Q synergized with 2-DG to decrease ATP levels in two cell lines.  However, with time, the cellular bioenergetic function and clonogenic survival were largely restored in some cells.  In a xenograft model of human breast cancer, combined treatment of Mito-CP and 2-DG led to significant tumor regression in the absence of significant morphol. changes in kidney, liver, or heart.  Collectively, our findings suggest that dual targeting of mitochondrial bioenergetic metab. with MTDs and glycolytic inhibitors such as 2-DG may offer a promising chemotherapeutic strategy.  Cancer Res; 72(10); 2634-44.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouqFTQiEMs27Vg90H21EOLACvtfcHk0ljyKGzntcGdag"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmvF2ntbk%253D&md5=581679e74622bf721881c0626f86c01a</span></div><a href="/servlet/linkout?suffix=cit260&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-3928&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-3928%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DG.%26aulast%3DZielonka%26aufirst%3DJ.%26aulast%3DDranka%26aufirst%3DB.%2BP.%26aulast%3DMcAllister%26aufirst%3DD.%26aulast%3DMackinnon%26aufirst%3DA.%2BC.%26aulast%3DJoseph%26aufirst%3DJ.%26aulast%3DKalyanaraman%26aufirst%3DB.%26atitle%3DMitochondria-targeted%2520drugs%2520synergize%2520with%25202-deoxyglucose%2520to%2520trigger%2520breast%2520cancer%2520cell%2520death%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D2634%26epage%3D2644%26doi%3D10.1158%2F0008-5472.CAN-11-3928" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref261"><div class="reference"><strong class="refLabel"><a href="#ref261" class="rightTabRefNumLink">261</a></strong><div class="NLM_citation" id="rightTab-cit261"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fan, L. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Berberine combined with 2-deoxy-D-glucose synergistically enhances cancer cell proliferation inhibition via energy depletion and unfolded protein response disruption</span>. <i>Biochim. Biophys. Acta, Gen. Subj.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>1830</i></span>,  <span class="NLM_fpage">5175</span>â <span class="NLM_lpage">5183</span>, <span class="refDoi">Â DOI: 10.1016/j.bbagen.2013.07.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref261/cit261&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.bbagen.2013.07.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref261/cit261&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=23872355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref261/cit261&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsV2mt7%252FO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1830&publication_year=2013&pages=5175-5183&author=L.+X.+Fanauthor=C.+M.+Liuauthor=A.+H.+Gaoauthor=Y.+B.+Zhouauthor=J.+Li&title=Berberine+combined+with+2-deoxy-D-glucose+synergistically+enhances+cancer+cell+proliferation+inhibition+via+energy+depletion+and+unfolded+protein+response+disruption&doi=10.1016%2Fj.bbagen.2013.07.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit261R"><div class="casContent"><span class="casTitleNuber">261</span><div class="casTitle"><span class="NLM_cas:atitle">Berberine combined with 2-deoxy-D-glucose synergistically enhances cancer cell proliferation inhibition via energy depletion and unfolded protein response disruption</span></div><div class="casAuthors">Fan, Li-xia; Liu, Chang-mei; Gao, An-hui; Zhou, Yu-bo; Li, Jia</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, General Subjects</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1830</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5175-5183</span>CODEN:
                <span class="NLM_cas:coden">BBGSB3</span>;
        ISSN:<span class="NLM_cas:issn">0304-4165</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Targeting multiple aspects of cellular metab., such as both aerobic glycolysis and mitochondrial oxidative phosphorylation (OXPHOS), has the potential to improve cancer therapeutics.  Berberine (BBR), a widely used traditional Chinese medicine, exerts its antitumor effects by inhibiting OXPHOS.  2-Deoxy-D-glucose (2-DG) targets aerobic glycolysis and demonstrates potential anticancer effects in the clinic.  We hypothesized that BBR in combination with 2-DG would be more efficient than either agent alone against cancer cell growth.  The effects of BBR and 2-DG on cancer cell growth were evaluated using the Sulforhodamine B (SRB) method.  Cell death was detected with the PI uptake assay, and Western blot, Q-PCR and luciferase reporter assays were used for signaling pathway detection.  An adenovirus system was used for gene overexpression.  BBR combined with 2-DG synergistically enhanced the growth inhibition of cancer cells in vitro.  Further mechanistic studies showed that the combination drastically enhanced ATP depletion and strongly disrupted the unfolded protein response (UPR).  Overexpressing GRP78 partially prevented the cancer cell inhibition induced by both compds.  Here, we report for the first time that BBR and 2-DG have a synergistic effect on cancer cell growth inhibition related to ATP energy depletion and disruption of UPR.  Our results propose the potential use of BBR and 2-DG in combination as an anticancer treatment, reinforcing the hypothesis that targeting both aerobic glycolysis and OXPHOS provides more effective cancer therapy and highlighting the important role of UPR in the process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrd1QXPS2CE5bVg90H21EOLACvtfcHk0ljyKGzntcGdag"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsV2mt7%252FO&md5=bac311d2bd2a0d55498e5d23469267eb</span></div><a href="/servlet/linkout?suffix=cit261&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagen.2013.07.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagen.2013.07.010%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DL.%2BX.%26aulast%3DLiu%26aufirst%3DC.%2BM.%26aulast%3DGao%26aufirst%3DA.%2BH.%26aulast%3DZhou%26aufirst%3DY.%2BB.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DBerberine%2520combined%2520with%25202-deoxy-D-glucose%2520synergistically%2520enhances%2520cancer%2520cell%2520proliferation%2520inhibition%2520via%2520energy%2520depletion%2520and%2520unfolded%2520protein%2520response%2520disruption%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gen.%2520Subj.%26date%3D2013%26volume%3D1830%26spage%3D5175%26epage%3D5183%26doi%3D10.1016%2Fj.bbagen.2013.07.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref262"><div class="reference"><strong class="refLabel"><a href="#ref262" class="rightTabRefNumLink">262</a></strong><div class="NLM_citation" id="rightTab-cit262"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oshima, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kishimoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beebe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brender, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rai, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benavides, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squadrito, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crooks, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mott, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrimp, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moses, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusewitt, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hathaway, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadhav, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trepel, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stott, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeonov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sklar, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norenberg, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linehan, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterson, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darley-Usmar, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishna, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neckers, L. M.</span></span> <span> </span><span class="NLM_article-title">Dynamic imaging of LDH inhibition in tumors reveals rapid in vivo metabolic rewiring and vulnerability to combination therapy</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1798</span>â <span class="NLM_lpage">1810</span>, <span class="refDoi">Â DOI: 10.1016/j.celrep.2020.01.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref262/cit262&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.celrep.2020.01.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref262/cit262&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=32049011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref262/cit262&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BB3cXotFektb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=1798-1810&author=N.+Oshimaauthor=R.+Ishidaauthor=S.+Kishimotoauthor=K.+Beebeauthor=J.+R.+Brenderauthor=K.+Yamamotoauthor=D.+Urbanauthor=G.+Raiauthor=M.+S.+Johnsonauthor=G.+Benavidesauthor=G.+L.+Squadritoauthor=D.+Crooksauthor=J.+Jacksonauthor=A.+Joshiauthor=B.+T.+Mottauthor=J.+H.+Shrimpauthor=M.+A.+Mosesauthor=M.+J.+Leeauthor=A.+Yunoauthor=T.+D.+Leeauthor=X.+Huauthor=T.+Andersonauthor=D.+Kusewittauthor=H.+H.+Hathawayauthor=A.+Jadhavauthor=D.+Picardauthor=J.+B.+Trepelauthor=J.+B.+Mitchellauthor=G.+M.+Stottauthor=W.+Mooreauthor=A.+Simeonovauthor=L.+A.+Sklarauthor=J.+P.+Norenbergauthor=W.+M.+Linehanauthor=D.+J.+Maloneyauthor=C.+V.+Dangauthor=A.+G.+Watersonauthor=M.+Hallauthor=V.+M.+Darley-Usmarauthor=M.+C.+Krishnaauthor=L.+M.+Neckers&title=Dynamic+imaging+of+LDH+inhibition+in+tumors+reveals+rapid+in+vivo+metabolic+rewiring+and+vulnerability+to+combination+therapy&doi=10.1016%2Fj.celrep.2020.01.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit262R"><div class="casContent"><span class="casTitleNuber">262</span><div class="casTitle"><span class="NLM_cas:atitle">Dynamic Imaging of LDH Inhibition in Tumors Reveals Rapid In Vivo Metabolic Rewiring and Vulnerability to Combination Therapy</span></div><div class="casAuthors">Oshima, Nobu; Ishida, Ryo; Kishimoto, Shun; Beebe, Kristin; Brender, Jeffrey R.; Yamamoto, Kazutoshi; Urban, Daniel; Rai, Ganesha; Johnson, Michelle S.; Benavides, Gloria; Squadrito, Giuseppe L.; Crooks, Dan; Jackson, Joseph; Joshi, Abhinav; Mott, Bryan T.; Shrimp, Jonathan H.; Moses, Michael A.; Lee, Min-Jung; Yuno, Akira; Lee, Tobie D.; Hu, Xin; Anderson, Tamara; Kusewitt, Donna; Hathaway, Helen H.; Jadhav, Ajit; Picard, Didier; Trepel, Jane B.; Mitchell, James B.; Stott, Gordon M.; Moore, William; Simeonov, Anton; Sklar, Larry A.; Norenberg, Jeffrey P.; Linehan, W. Marston; Maloney, David J.; Dang, Chi V.; Waterson, Alex G.; Hall, Matthew; Darley-Usmar, Victor M.; Krishna, Murali C.; Neckers, Leonard M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1798-1810.e4</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The reliance of many cancers on aerobic glycolysis has stimulated efforts to develop lactate dehydrogenase (LDH) inhibitors.  However, despite significant efforts, LDH inhibitors (LDHi) with sufficient specificity and in vivo activity to det. whether LDH is a feasible drug target are lacking.  We describe an LDHi with potent, on-target, in vivo activity.  Using hyperpolarized magnetic resonance spectroscopic imaging (HP-MRSI), we demonstrate in vivo LDH inhibition in two glycolytic cancer models, MIA PaCa-2 and HT29, and we correlate depth and duration of LDH inhibition with direct anti-tumor activity.  HP-MRSI also reveals a metabolic rewiring that occurs in vivo within 30 min of LDH inhibition, wherein pyruvate in a tumor is redirected toward mitochondrial metab.  Using HP-MRSI, we show that inhibition of mitochondrial complex 1 rapidly redirects tumor pyruvate toward lactate.  Inhibition of both mitochondrial complex 1 and LDH suppresses metabolic plasticity, causing metabolic quiescence in vitro and tumor growth inhibition in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXo-hnKU_CkrVg90H21EOLACvtfcHk0ljqQBw29UAXbA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXotFektb0%253D&md5=9cb03f50f7d5a21ee5a6b1c9b1dc2f0a</span></div><a href="/servlet/linkout?suffix=cit262&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2020.01.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2020.01.039%26sid%3Dliteratum%253Aachs%26aulast%3DOshima%26aufirst%3DN.%26aulast%3DIshida%26aufirst%3DR.%26aulast%3DKishimoto%26aufirst%3DS.%26aulast%3DBeebe%26aufirst%3DK.%26aulast%3DBrender%26aufirst%3DJ.%2BR.%26aulast%3DYamamoto%26aufirst%3DK.%26aulast%3DUrban%26aufirst%3DD.%26aulast%3DRai%26aufirst%3DG.%26aulast%3DJohnson%26aufirst%3DM.%2BS.%26aulast%3DBenavides%26aufirst%3DG.%26aulast%3DSquadrito%26aufirst%3DG.%2BL.%26aulast%3DCrooks%26aufirst%3DD.%26aulast%3DJackson%26aufirst%3DJ.%26aulast%3DJoshi%26aufirst%3DA.%26aulast%3DMott%26aufirst%3DB.%2BT.%26aulast%3DShrimp%26aufirst%3DJ.%2BH.%26aulast%3DMoses%26aufirst%3DM.%2BA.%26aulast%3DLee%26aufirst%3DM.%2BJ.%26aulast%3DYuno%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DT.%2BD.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DAnderson%26aufirst%3DT.%26aulast%3DKusewitt%26aufirst%3DD.%26aulast%3DHathaway%26aufirst%3DH.%2BH.%26aulast%3DJadhav%26aufirst%3DA.%26aulast%3DPicard%26aufirst%3DD.%26aulast%3DTrepel%26aufirst%3DJ.%2BB.%26aulast%3DMitchell%26aufirst%3DJ.%2BB.%26aulast%3DStott%26aufirst%3DG.%2BM.%26aulast%3DMoore%26aufirst%3DW.%26aulast%3DSimeonov%26aufirst%3DA.%26aulast%3DSklar%26aufirst%3DL.%2BA.%26aulast%3DNorenberg%26aufirst%3DJ.%2BP.%26aulast%3DLinehan%26aufirst%3DW.%2BM.%26aulast%3DMaloney%26aufirst%3DD.%2BJ.%26aulast%3DDang%26aufirst%3DC.%2BV.%26aulast%3DWaterson%26aufirst%3DA.%2BG.%26aulast%3DHall%26aufirst%3DM.%26aulast%3DDarley-Usmar%26aufirst%3DV.%2BM.%26aulast%3DKrishna%26aufirst%3DM.%2BC.%26aulast%3DNeckers%26aufirst%3DL.%2BM.%26atitle%3DDynamic%2520imaging%2520of%2520LDH%2520inhibition%2520in%2520tumors%2520reveals%2520rapid%2520in%2520vivo%2520metabolic%2520rewiring%2520and%2520vulnerability%2520to%2520combination%2520therapy%26jtitle%3DCell%2520Rep.%26date%3D2020%26volume%3D30%26spage%3D1798%26epage%3D1810%26doi%3D10.1016%2Fj.celrep.2020.01.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref263"><div class="reference"><strong class="refLabel"><a href="#ref263" class="rightTabRefNumLink">263</a></strong><div class="NLM_citation" id="rightTab-cit263"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mayr, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haack, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freisinger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karall, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makowski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feichtinger, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolinski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahting, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meitinger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prokisch, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperl, W.</span></span> <span> </span><span class="NLM_article-title">Spectrum of combined respiratory chain defects</span>. <i>J. Inherited Metab. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">629</span>â <span class="NLM_lpage">640</span>, <span class="refDoi">Â DOI: 10.1007/s10545-015-9831-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref263/cit263&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1007%2Fs10545-015-9831-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref263/cit263&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=25778941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref263/cit263&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2MXks1amurs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2015&pages=629-640&author=J.+A.+Mayrauthor=T.+B.+Haackauthor=P.+Freisingerauthor=D.+Karallauthor=C.+Makowskiauthor=J.+Kochauthor=R.+G.+Feichtingerauthor=F.+A.+Zimmermannauthor=B.+Rolinskiauthor=U.+Ahtingauthor=T.+Meitingerauthor=H.+Prokischauthor=W.+Sperl&title=Spectrum+of+combined+respiratory+chain+defects&doi=10.1007%2Fs10545-015-9831-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit263R"><div class="casContent"><span class="casTitleNuber">263</span><div class="casTitle"><span class="NLM_cas:atitle">Spectrum of combined respiratory chain defects</span></div><div class="casAuthors">Mayr, Johannes A.; Haack, Tobias B.; Freisinger, Peter; Karall, Daniela; Makowski, Christine; Koch, Johannes; Feichtinger, Rene G.; Zimmermann, Franz A.; Rolinski, Boris; Ahting, Uwe; Meitinger, Thomas; Prokisch, Holger; Sperl, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Inherited Metabolic Disease</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">629-640</span>CODEN:
                <span class="NLM_cas:coden">JIMDDP</span>;
        ISSN:<span class="NLM_cas:issn">0141-8955</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Inherited disorders of mitochondrial energy metab. form a large and heterogeneous group of metabolic diseases.  More than 250 gene defects have been reported to date and this no. continues to grow.  Mitochondrial diseases can be grouped into (1) disorders of oxidative phosphorylation (OXPHOS) subunits and their assembly factors, (2) defects of mitochondrial DNA, RNA and protein synthesis, (3) defects in the substrate-generating upstream reactions of OXPHOS, (4) defects in relevant cofactors and (5) defects in mitochondrial homeostasis.  Deficiency of more than one respiratory chain enzyme is a common finding.  Combined defects are found in 49 % of the known disease-causing genes of mitochondrial energy metab. and in 57 % of patients with OXPHOS defects identified in our diagnostic center.  Combined defects of complexes I, III, IV and V are typically due to deficiency of mitochondrial DNA replication, RNA metab. or translation.  Defects in cofactors can result in combined defects of various combinations, and defects of mitochondrial homeostasis can result in a generalised decrease of all OXPHOS enzymes.  Noteworthy, identification of combined defects can be complicated by different degrees of severity of each affected enzyme.  Furthermore, even defects of single respiratory chain enzymes can result in combined defects due to aberrant formation of respiratory chain supercomplexes.  Combined OXPHOS defects have a great variety of clin. manifestations in terms of onset, course severity and tissue involvement.  They can present as classical encephalomyopathy but also with hepatopathy, nephropathy, haematol. findings and Perrault syndrome in a subset of disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHLKlpcFr_SLVg90H21EOLACvtfcHk0ljqQBw29UAXbA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXks1amurs%253D&md5=f815edf9b533ddf0ca1530e2c24dbb73</span></div><a href="/servlet/linkout?suffix=cit263&amp;dbid=16384&amp;doi=10.1007%2Fs10545-015-9831-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10545-015-9831-y%26sid%3Dliteratum%253Aachs%26aulast%3DMayr%26aufirst%3DJ.%2BA.%26aulast%3DHaack%26aufirst%3DT.%2BB.%26aulast%3DFreisinger%26aufirst%3DP.%26aulast%3DKarall%26aufirst%3DD.%26aulast%3DMakowski%26aufirst%3DC.%26aulast%3DKoch%26aufirst%3DJ.%26aulast%3DFeichtinger%26aufirst%3DR.%2BG.%26aulast%3DZimmermann%26aufirst%3DF.%2BA.%26aulast%3DRolinski%26aufirst%3DB.%26aulast%3DAhting%26aufirst%3DU.%26aulast%3DMeitinger%26aufirst%3DT.%26aulast%3DProkisch%26aufirst%3DH.%26aulast%3DSperl%26aufirst%3DW.%26atitle%3DSpectrum%2520of%2520combined%2520respiratory%2520chain%2520defects%26jtitle%3DJ.%2520Inherited%2520Metab.%2520Dis.%26date%3D2015%26volume%3D38%26spage%3D629%26epage%3D640%26doi%3D10.1007%2Fs10545-015-9831-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref264"><div class="reference"><strong class="refLabel"><a href="#ref264" class="rightTabRefNumLink">264</a></strong><div class="NLM_citation" id="rightTab-cit264"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swalwell, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blakely, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salemi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiana, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compton, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, B. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turnbull, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFarland, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorburn, D. R.</span></span> <span> </span><span class="NLM_article-title">Respiratory chain complex I deficiency caused by mitochondrial DNA mutations</span>. <i>Eur. J. Hum. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">769</span>â <span class="NLM_lpage">775</span>, <span class="refDoi">Â DOI: 10.1038/ejhg.2011.18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref264/cit264&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fejhg.2011.18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref264/cit264&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=21364701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref264/cit264&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsFKqsrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=769-775&author=H.+Swalwellauthor=D.+M.+Kirbyauthor=E.+L.+Blakelyauthor=A.+Mitchellauthor=R.+Salemiauthor=C.+Sugianaauthor=A.+G.+Comptonauthor=E.+J.+Tuckerauthor=B.+X.+Keauthor=P.+J.+Lamontauthor=D.+M.+Turnbullauthor=R.+McFarlandauthor=R.+W.+Taylorauthor=D.+R.+Thorburn&title=Respiratory+chain+complex+I+deficiency+caused+by+mitochondrial+DNA+mutations&doi=10.1038%2Fejhg.2011.18"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit264R"><div class="casContent"><span class="casTitleNuber">264</span><div class="casTitle"><span class="NLM_cas:atitle">Respiratory chain complex I deficiency caused by mitochondrial DNA mutations</span></div><div class="casAuthors">Swalwell, Helen; Kirby, Denise M.; Blakely, Emma L.; Mitchell, Anna; Salemi, Renato; Sugiana, Canny; Compton, Alison G.; Tucker, Elena J.; Ke, Bi-Xia; Lamont, Phillipa J.; Turnbull, Douglass M.; McFarland, Robert; Taylor, Robert W.; Thorburn, David R.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Human Genetics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">769-775</span>CODEN:
                <span class="NLM_cas:coden">EJHGEU</span>;
        ISSN:<span class="NLM_cas:issn">1018-4813</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Defects of the mitochondrial respiratory chain are assocd. with a diverse spectrum of clin. phenotypes, and may be caused by mutations in either the nuclear or the mitochondrial genome (mitochondrial DNA (mtDNA)).  Isolated complex I deficiency is the most common enzyme defect in mitochondrial disorders, particularly in children in whom family history is often consistent with sporadic or autosomal recessive inheritance, implicating a nuclear genetic cause.  In contrast, although a no. of recurrent, pathogenic mtDNA mutations have been described, historically, these have been perceived as rare causes of paediatric complex I deficiency.  We reviewed the clin. and genetic findings in a large cohort of 109 paediatric patients with isolated complex I deficiency from 101 families.  Pathogenic mtDNA mutations were found in 29 of 101 probands (29%), 21 in MTND subunit genes and 8 in mtDNA tRNA genes.  Nuclear gene defects were inferred in 38 of 101 (38%) probands based on cell hybrid studies, mtDNA sequencing or mutation anal. (nuclear gene mutations were identified in 22 probands).  Leigh or Leigh-like disease was the most common clin. presentation in both mtDNA and nuclear genetic defects.  The median age at onset was higher in mtDNA patients (12 mo) than in patients with a nuclear gene defect (3 mo).  However, considerable overlap existed, with onset varying from 0 to >60 mo in both groups.  Our findings confirm that pathogenic mtDNA mutations are a significant cause of complex I deficiency in children.  In the absence of parental consanguinity, we recommend whole mitochondrial genome sequencing as a key approach to elucidate the underlying mol. genetic abnormality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnFp77syio77Vg90H21EOLACvtfcHk0lgTP7AP8ubUhw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsFKqsrc%253D&md5=798728c3fdf3d9f4d7e25e6040ca129b</span></div><a href="/servlet/linkout?suffix=cit264&amp;dbid=16384&amp;doi=10.1038%2Fejhg.2011.18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fejhg.2011.18%26sid%3Dliteratum%253Aachs%26aulast%3DSwalwell%26aufirst%3DH.%26aulast%3DKirby%26aufirst%3DD.%2BM.%26aulast%3DBlakely%26aufirst%3DE.%2BL.%26aulast%3DMitchell%26aufirst%3DA.%26aulast%3DSalemi%26aufirst%3DR.%26aulast%3DSugiana%26aufirst%3DC.%26aulast%3DCompton%26aufirst%3DA.%2BG.%26aulast%3DTucker%26aufirst%3DE.%2BJ.%26aulast%3DKe%26aufirst%3DB.%2BX.%26aulast%3DLamont%26aufirst%3DP.%2BJ.%26aulast%3DTurnbull%26aufirst%3DD.%2BM.%26aulast%3DMcFarland%26aufirst%3DR.%26aulast%3DTaylor%26aufirst%3DR.%2BW.%26aulast%3DThorburn%26aufirst%3DD.%2BR.%26atitle%3DRespiratory%2520chain%2520complex%2520I%2520deficiency%2520caused%2520by%2520mitochondrial%2520DNA%2520mutations%26jtitle%3DEur.%2520J.%2520Hum.%2520Genet.%26date%3D2011%26volume%3D19%26spage%3D769%26epage%3D775%26doi%3D10.1038%2Fejhg.2011.18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref265"><div class="reference"><strong class="refLabel"><a href="#ref265" class="rightTabRefNumLink">265</a></strong><div class="NLM_citation" id="rightTab-cit265"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dykens, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marroquin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadanaciva, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billis, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, Y.</span></span> <span> </span><span class="NLM_article-title">Biguanide-induced mitochondrial dysfunction yields increased lactate production and cytotoxicity of aerobically-poised HepG2 cells and human hepatocytes in vitro</span>. <i>Toxicol. Appl. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>233</i></span>,  <span class="NLM_fpage">203</span>â <span class="NLM_lpage">210</span>, <span class="refDoi">Â DOI: 10.1016/j.taap.2008.08.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref265/cit265&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.taap.2008.08.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref265/cit265&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=18817800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref265/cit265&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWrsrvE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=233&publication_year=2008&pages=203-210&author=J.+A.+Dykensauthor=J.+Jamiesonauthor=L.+Marroquinauthor=S.+Nadanacivaauthor=P.+A.+Billisauthor=Y.+Will&title=Biguanide-induced+mitochondrial+dysfunction+yields+increased+lactate+production+and+cytotoxicity+of+aerobically-poised+HepG2+cells+and+human+hepatocytes+in+vitro&doi=10.1016%2Fj.taap.2008.08.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit265R"><div class="casContent"><span class="casTitleNuber">265</span><div class="casTitle"><span class="NLM_cas:atitle">Biguanide-induced mitochondrial dysfunction yields increased lactate production and cytotoxicity of aerobically-poised HepG2 cells and human hepatocytes in vitro</span></div><div class="casAuthors">Dykens, James A.; Jamieson, Joseph; Marroquin, Lisa; Nadanaciva, Sashi; Billis, Puja A.; Will, Yvonne</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">233</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">203-210</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">As a class, the biguanides induce lactic acidosis, a hallmark of mitochondrial impairment.  To assess potential mitochondrial impairment, the authors evaluated the effects of metformin, buformin, and phenformin on: (1) viability of Hep G2 cells grown in galactose, (2) respiration by isolated mitochondria, (3) metabolic poise of Hep G2 and primary human hepatocytes, (4) activities of immunocaptured respiratory complexes, and (5) mitochondrial membrane potential and redox status in primary human hepatocytes.  Phenformin was the most cytotoxic of the 3 with buformin showing moderate toxicity, and metformin toxicity only at mM concns.  Importantly, Hep G2 cells grown in galactose are markedly more susceptible to biguanide toxicity compared to cells grown in glucose, indicating mitochondrial toxicity as a primary mode of action.  The same rank order of potency was obsd. for isolated mitochondrial respiration where preincubation (40 min) exacerbated respiratory impairment, and was required to reveal inhibition by metformin, suggesting intramitochondrial bioaccumulation.  Metabolic profiling of intact cells corroborated respiratory inhibition, but also revelaed compensatory increases in lactate prodn. from accelerated glycolysis.  High (mM) concns. of the drugs were needed to inhibit immunocaptured respiratory complexes, supporting the contention that bioaccumulation is involved.  The same rank order was found when monitoring mitochondrial membrane potential, ROS prodn., and glutathione levels in primary human hepatocytes.  In toto, these data indicate that biguanide-induced lactic acidosis can be attributed to the acceleration of glycolysis in response to mitochondrial impairment.  Indeed, the desired clin. outcome, viz., decreased blood glucose, could be due to increased glucose uptake and glycolytic flux in response to drug-induced mitochondrial dysfunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyusAn3IDvn7Vg90H21EOLACvtfcHk0lgTP7AP8ubUhw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWrsrvE&md5=0498abf7a0f51d95c26cbcfd027eea86</span></div><a href="/servlet/linkout?suffix=cit265&amp;dbid=16384&amp;doi=10.1016%2Fj.taap.2008.08.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.taap.2008.08.013%26sid%3Dliteratum%253Aachs%26aulast%3DDykens%26aufirst%3DJ.%2BA.%26aulast%3DJamieson%26aufirst%3DJ.%26aulast%3DMarroquin%26aufirst%3DL.%26aulast%3DNadanaciva%26aufirst%3DS.%26aulast%3DBillis%26aufirst%3DP.%2BA.%26aulast%3DWill%26aufirst%3DY.%26atitle%3DBiguanide-induced%2520mitochondrial%2520dysfunction%2520yields%2520increased%2520lactate%2520production%2520and%2520cytotoxicity%2520of%2520aerobically-poised%2520HepG2%2520cells%2520and%2520human%2520hepatocytes%2520in%2520vitro%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2008%26volume%3D233%26spage%3D203%26epage%3D210%26doi%3D10.1016%2Fj.taap.2008.08.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref266"><div class="reference"><strong class="refLabel"><a href="#ref266" class="rightTabRefNumLink">266</a></strong><div class="NLM_citation" id="rightTab-cit266"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsuzaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphries, K. M.</span></span> <span> </span><span class="NLM_article-title">Selective inhibition of deactivated mitochondrial complex I by biguanides</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2011</span>â <span class="NLM_lpage">2021</span>, <span class="refDoi">Â DOI: 10.1021/bi501473h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi501473h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjsVWktL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=2011-2021&author=S.+Matsuzakiauthor=K.+M.+Humphries&title=Selective+inhibition+of+deactivated+mitochondrial+complex+I+by+biguanides&doi=10.1021%2Fbi501473h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit266R"><div class="casContent"><span class="casTitleNuber">266</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of Deactivated Mitochondrial Complex I by Biguanides</span></div><div class="casAuthors">Matsuzaki, Satoshi; Humphries, Kenneth M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2011-2021</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Biguanides are widely used antihyperglycemic agents for diabetes mellitus and prediabetes treatment.  Complex I is the rate-limiting step of the mitochondrial electron transport chain (ETC), a major source of mitochondrial free radical prodn., and a known target of biguanides.  Complex I has two reversible conformational states, active and de-active.  The deactivated state is promoted in the absence of substrates but is rapidly and fully reversed to the active state in the presence of NADH.  The objective of this study was to det. the relative sensitivity of active/de-active complex I to biguanide-mediated inhibition and resulting superoxide radical (O2â¢-) prodn.  Using isolated rat heart mitochondria, we show that deactivation of complex I sensitizes it to metformin and phenformin (4- and 3-fold, resp.), but not to other known complex I inhibitors, such as rotenone.  Mitochondrial O2â¢- prodn. by deactivated complex I was measured fluorescently by NADH-dependent 2-hydroxyethidium formation at alk. pH to impede reactivation.  Superoxide prodn. was 260.4% higher than in active complex I at pH 9.4.  However, phenformin treatment of de-active complex I decreased O2â¢- prodn. by 14.9%, while rotenone increased prodn. by 42.9%.  Mitochondria isolated from rat hearts subjected to cardiac ischemia, a condition known to induce complex I deactivation, were sensitized to phenformin-mediated complex I inhibition.  This supports the idea that the effects of biguanides are likely to be influenced by the complex I state in vivo.  These results demonstrate that the complex I active and de-active states are a determinant in biguanide-mediated inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbHt2BvRy2B7Vg90H21EOLACvtfcHk0lgENOE1MCjO7Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjsVWktL4%253D&md5=36cecff6a7376699bc32a5673ed33e1c</span></div><a href="/servlet/linkout?suffix=cit266&amp;dbid=16384&amp;doi=10.1021%2Fbi501473h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi501473h%26sid%3Dliteratum%253Aachs%26aulast%3DMatsuzaki%26aufirst%3DS.%26aulast%3DHumphries%26aufirst%3DK.%2BM.%26atitle%3DSelective%2520inhibition%2520of%2520deactivated%2520mitochondrial%2520complex%2520I%2520by%2520biguanides%26jtitle%3DBiochemistry%26date%3D2015%26volume%3D54%26spage%3D2011%26epage%3D2021%26doi%3D10.1021%2Fbi501473h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref267"><div class="reference"><strong class="refLabel"><a href="#ref267" class="rightTabRefNumLink">267</a></strong><div class="NLM_citation" id="rightTab-cit267"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilde, A.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyndrickx, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carton, D.</span></span> <span> </span><span class="NLM_article-title">A case of fatal rotenone poisoning in a child</span>. <i>J. Forensic Sci.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">1492</span>â <span class="NLM_lpage">1498</span>, <span class="refDoi">Â DOI: 10.1520/JFS11931J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref267/cit267&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1520%2FJFS11931J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref267/cit267&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=3783116" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1986&pages=1492-1498&author=A.-R.+Wildeauthor=A.+Heyndrickxauthor=D.+Carton&title=A+case+of+fatal+rotenone+poisoning+in+a+child&doi=10.1520%2FJFS11931J"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit267&amp;dbid=16384&amp;doi=10.1520%2FJFS11931J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1520%252FJFS11931J%26sid%3Dliteratum%253Aachs%26aulast%3DWilde%26aufirst%3DA.-R.%26aulast%3DHeyndrickx%26aufirst%3DA.%26aulast%3DCarton%26aufirst%3DD.%26atitle%3DA%2520case%2520of%2520fatal%2520rotenone%2520poisoning%2520in%2520a%2520child%26jtitle%3DJ.%2520Forensic%2520Sci.%26date%3D1986%26volume%3D31%26spage%3D1492%26epage%3D1498%26doi%3D10.1520%2FJFS11931J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref268"><div class="reference"><strong class="refLabel"><a href="#ref268" class="rightTabRefNumLink">268</a></strong><div class="NLM_citation" id="rightTab-cit268"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wood, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alsahaf, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streete, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dargan, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, A. L.</span></span> <span> </span><span class="NLM_article-title">Fatality after deliberate ingestion of the pesticide rotenone: a case report</span>. <i>Critical Care</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">R280</span>â <span class="NLM_lpage">R284</span>, <span class="refDoi">Â DOI: 10.1186/cc3528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref268/cit268&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1186%2Fcc3528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref268/cit268&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=15987402" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2005&pages=R280-R284&author=D.+M.+Woodauthor=H.+Alsahafauthor=P.+Streeteauthor=P.+I.+Darganauthor=A.+L.+Jones&title=Fatality+after+deliberate+ingestion+of+the+pesticide+rotenone%3A+a+case+report&doi=10.1186%2Fcc3528"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit268&amp;dbid=16384&amp;doi=10.1186%2Fcc3528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fcc3528%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DD.%2BM.%26aulast%3DAlsahaf%26aufirst%3DH.%26aulast%3DStreete%26aufirst%3DP.%26aulast%3DDargan%26aufirst%3DP.%2BI.%26aulast%3DJones%26aufirst%3DA.%2BL.%26atitle%3DFatality%2520after%2520deliberate%2520ingestion%2520of%2520the%2520pesticide%2520rotenone%253A%2520a%2520case%2520report%26jtitle%3DCritical%2520Care%26date%3D2005%26volume%3D9%26spage%3DR280%26epage%3DR284%26doi%3D10.1186%2Fcc3528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref269"><div class="reference"><strong class="refLabel"><a href="#ref269" class="rightTabRefNumLink">269</a></strong><div class="NLM_citation" id="rightTab-cit269"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swalwell, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blakely, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salemi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiana, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compton, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turnbull, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFarland, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorburn, D. R.</span></span> <span> </span><span class="NLM_article-title">Respiratory chain complex I deficiency caused by mitochondrial DNA mutations</span>. <i>Eur. J. Hum. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">769</span>â <span class="NLM_lpage">775</span>, <span class="refDoi">Â DOI: 10.1038/ejhg.2011.18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Fejhg.2011.18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=21364701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsFKqsrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=769-775&author=H.+Swalwellauthor=D.+M.+Kirbyauthor=E.+L.+Blakelyauthor=A.+Mitchellauthor=R.+Salemiauthor=C.+Sugianaauthor=A.+G.+Comptonauthor=E.+J.+Tuckerauthor=X.+Keauthor=P.+J.+Lamontauthor=D.+M.+Turnbullauthor=R.+McFarlandauthor=R.+W.+Taylorauthor=D.+R.+Thorburn&title=Respiratory+chain+complex+I+deficiency+caused+by+mitochondrial+DNA+mutations&doi=10.1038%2Fejhg.2011.18"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit269R"><div class="casContent"><span class="casTitleNuber">269</span><div class="casTitle"><span class="NLM_cas:atitle">Respiratory chain complex I deficiency caused by mitochondrial DNA mutations</span></div><div class="casAuthors">Swalwell, Helen; Kirby, Denise M.; Blakely, Emma L.; Mitchell, Anna; Salemi, Renato; Sugiana, Canny; Compton, Alison G.; Tucker, Elena J.; Ke, Bi-Xia; Lamont, Phillipa J.; Turnbull, Douglass M.; McFarland, Robert; Taylor, Robert W.; Thorburn, David R.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Human Genetics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">769-775</span>CODEN:
                <span class="NLM_cas:coden">EJHGEU</span>;
        ISSN:<span class="NLM_cas:issn">1018-4813</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Defects of the mitochondrial respiratory chain are assocd. with a diverse spectrum of clin. phenotypes, and may be caused by mutations in either the nuclear or the mitochondrial genome (mitochondrial DNA (mtDNA)).  Isolated complex I deficiency is the most common enzyme defect in mitochondrial disorders, particularly in children in whom family history is often consistent with sporadic or autosomal recessive inheritance, implicating a nuclear genetic cause.  In contrast, although a no. of recurrent, pathogenic mtDNA mutations have been described, historically, these have been perceived as rare causes of paediatric complex I deficiency.  We reviewed the clin. and genetic findings in a large cohort of 109 paediatric patients with isolated complex I deficiency from 101 families.  Pathogenic mtDNA mutations were found in 29 of 101 probands (29%), 21 in MTND subunit genes and 8 in mtDNA tRNA genes.  Nuclear gene defects were inferred in 38 of 101 (38%) probands based on cell hybrid studies, mtDNA sequencing or mutation anal. (nuclear gene mutations were identified in 22 probands).  Leigh or Leigh-like disease was the most common clin. presentation in both mtDNA and nuclear genetic defects.  The median age at onset was higher in mtDNA patients (12 mo) than in patients with a nuclear gene defect (3 mo).  However, considerable overlap existed, with onset varying from 0 to >60 mo in both groups.  Our findings confirm that pathogenic mtDNA mutations are a significant cause of complex I deficiency in children.  In the absence of parental consanguinity, we recommend whole mitochondrial genome sequencing as a key approach to elucidate the underlying mol. genetic abnormality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnFp77syio77Vg90H21EOLACvtfcHk0lgENOE1MCjO7Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsFKqsrc%253D&md5=798728c3fdf3d9f4d7e25e6040ca129b</span></div><a href="/servlet/linkout?suffix=cit269&amp;dbid=16384&amp;doi=10.1038%2Fejhg.2011.18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fejhg.2011.18%26sid%3Dliteratum%253Aachs%26aulast%3DSwalwell%26aufirst%3DH.%26aulast%3DKirby%26aufirst%3DD.%2BM.%26aulast%3DBlakely%26aufirst%3DE.%2BL.%26aulast%3DMitchell%26aufirst%3DA.%26aulast%3DSalemi%26aufirst%3DR.%26aulast%3DSugiana%26aufirst%3DC.%26aulast%3DCompton%26aufirst%3DA.%2BG.%26aulast%3DTucker%26aufirst%3DE.%2BJ.%26aulast%3DKe%26aufirst%3DX.%26aulast%3DLamont%26aufirst%3DP.%2BJ.%26aulast%3DTurnbull%26aufirst%3DD.%2BM.%26aulast%3DMcFarland%26aufirst%3DR.%26aulast%3DTaylor%26aufirst%3DR.%2BW.%26aulast%3DThorburn%26aufirst%3DD.%2BR.%26atitle%3DRespiratory%2520chain%2520complex%2520I%2520deficiency%2520caused%2520by%2520mitochondrial%2520DNA%2520mutations%26jtitle%3DEur.%2520J.%2520Hum.%2520Genet.%26date%3D2011%26volume%3D19%26spage%3D769%26epage%3D775%26doi%3D10.1038%2Fejhg.2011.18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref270"><div class="reference"><strong class="refLabel"><a href="#ref270" class="rightTabRefNumLink">270</a></strong><div class="NLM_citation" id="rightTab-cit270"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carithers, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardlie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barcus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Branton, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Britton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buia, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compton, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeLuca, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peter-Demchok, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelfand, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korzeniewski, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabiner, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roche, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segre, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shive, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobin, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Undale, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentino, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaught, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, H. M.</span></span> <span> </span><span class="NLM_article-title">Consortium, G. A novel approach to high-quality postmortem tissue procurement: the GTEx project</span>. <i>Biopreserv. Biobanking</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">311</span>â <span class="NLM_lpage">319</span>, <span class="refDoi">Â DOI: 10.1089/bio.2015.0032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref270/cit270&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1089%2Fbio.2015.0032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref270/cit270&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=26484571" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=311-319&author=L.+J.+Carithersauthor=K.+Ardlieauthor=M.+Barcusauthor=P.+A.+Brantonauthor=A.+Brittonauthor=S.+A.+Buiaauthor=C.+C.+Comptonauthor=D.+S.+DeLucaauthor=J.+Peter-Demchokauthor=E.+T.+Gelfandauthor=P.+Guanauthor=G.+E.+Korzeniewskiauthor=N.+C.+Lockhartauthor=C.+A.+Rabinerauthor=A.+K.+Raoauthor=K.+L.+Robinsonauthor=N.+V.+Rocheauthor=S.+J.+Sawyerauthor=A.+V.+Segreauthor=C.+E.+Shiveauthor=A.+M.+Smithauthor=L.+H.+Sobinauthor=A.+H.+Undaleauthor=K.+M.+Valentinoauthor=J.+Vaughtauthor=T.+R.+Youngauthor=H.+M.+Moore&title=Consortium%2C+G.+A+novel+approach+to+high-quality+postmortem+tissue+procurement%3A+the+GTEx+project&doi=10.1089%2Fbio.2015.0032"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit270&amp;dbid=16384&amp;doi=10.1089%2Fbio.2015.0032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fbio.2015.0032%26sid%3Dliteratum%253Aachs%26aulast%3DCarithers%26aufirst%3DL.%2BJ.%26aulast%3DArdlie%26aufirst%3DK.%26aulast%3DBarcus%26aufirst%3DM.%26aulast%3DBranton%26aufirst%3DP.%2BA.%26aulast%3DBritton%26aufirst%3DA.%26aulast%3DBuia%26aufirst%3DS.%2BA.%26aulast%3DCompton%26aufirst%3DC.%2BC.%26aulast%3DDeLuca%26aufirst%3DD.%2BS.%26aulast%3DPeter-Demchok%26aufirst%3DJ.%26aulast%3DGelfand%26aufirst%3DE.%2BT.%26aulast%3DGuan%26aufirst%3DP.%26aulast%3DKorzeniewski%26aufirst%3DG.%2BE.%26aulast%3DLockhart%26aufirst%3DN.%2BC.%26aulast%3DRabiner%26aufirst%3DC.%2BA.%26aulast%3DRao%26aufirst%3DA.%2BK.%26aulast%3DRobinson%26aufirst%3DK.%2BL.%26aulast%3DRoche%26aufirst%3DN.%2BV.%26aulast%3DSawyer%26aufirst%3DS.%2BJ.%26aulast%3DSegre%26aufirst%3DA.%2BV.%26aulast%3DShive%26aufirst%3DC.%2BE.%26aulast%3DSmith%26aufirst%3DA.%2BM.%26aulast%3DSobin%26aufirst%3DL.%2BH.%26aulast%3DUndale%26aufirst%3DA.%2BH.%26aulast%3DValentino%26aufirst%3DK.%2BM.%26aulast%3DVaught%26aufirst%3DJ.%26aulast%3DYoung%26aufirst%3DT.%2BR.%26aulast%3DMoore%26aufirst%3DH.%2BM.%26atitle%3DConsortium%252C%2520G.%2520A%2520novel%2520approach%2520to%2520high-quality%2520postmortem%2520tissue%2520procurement%253A%2520the%2520GTEx%2520project%26jtitle%3DBiopreserv.%2520Biobanking%26date%3D2015%26volume%3D13%26spage%3D311%26epage%3D319%26doi%3D10.1089%2Fbio.2015.0032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref271"><div class="reference"><strong class="refLabel"><a href="#ref271" class="rightTabRefNumLink">271</a></strong><div class="NLM_citation" id="rightTab-cit271"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yap, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahnert, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piha-Paul, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, S. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janku, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karp, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naing, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumbrava, E. E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pant, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subbiah, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsimberidou, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vellano, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahendra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Francesco, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marszalek, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meric-Bernstam, F.</span></span> <span> </span><span class="NLM_article-title">Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial electron transport chain, in patients (pts) with advanced solid tumors</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">3014</span>â <span class="NLM_lpage">3014</span>, <span class="refDoi">Â DOI: 10.1200/JCO.2019.37.15_suppl.3014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref271/cit271&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1200%2FJCO.2019.37.15_suppl.3014" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=3014-3014&author=T.+A.+Yapauthor=J.+R.+Ahnertauthor=S.+A.+Piha-Paulauthor=S.+Q.+Fuauthor=F.+Jankuauthor=D.+D.+Karpauthor=A.+Naingauthor=E.+E.+I.+Dumbravaauthor=S.+Pantauthor=V.+Subbiahauthor=A.+M.+Tsimberidouauthor=D.+S.+Hongauthor=K.+M.+Roseauthor=Q.+Y.+Xuauthor=C.+P.+Vellanoauthor=M.+Mahendraauthor=P.+Jonesauthor=M.+E.+Di+Francescoauthor=J.+R.+Marszalekauthor=F.+Meric-Bernstam&title=Phase+I+trial+of+IACS-010759+%28IACS%29%2C+a+potent%2C+selective+inhibitor+of+complex+I+of+the+mitochondrial+electron+transport+chain%2C+in+patients+%28pts%29+with+advanced+solid+tumors&doi=10.1200%2FJCO.2019.37.15_suppl.3014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit271&amp;dbid=16384&amp;doi=10.1200%2FJCO.2019.37.15_suppl.3014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2019.37.15_suppl.3014%26sid%3Dliteratum%253Aachs%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DAhnert%26aufirst%3DJ.%2BR.%26aulast%3DPiha-Paul%26aufirst%3DS.%2BA.%26aulast%3DFu%26aufirst%3DS.%2BQ.%26aulast%3DJanku%26aufirst%3DF.%26aulast%3DKarp%26aufirst%3DD.%2BD.%26aulast%3DNaing%26aufirst%3DA.%26aulast%3DDumbrava%26aufirst%3DE.%2BE.%2BI.%26aulast%3DPant%26aufirst%3DS.%26aulast%3DSubbiah%26aufirst%3DV.%26aulast%3DTsimberidou%26aufirst%3DA.%2BM.%26aulast%3DHong%26aufirst%3DD.%2BS.%26aulast%3DRose%26aufirst%3DK.%2BM.%26aulast%3DXu%26aufirst%3DQ.%2BY.%26aulast%3DVellano%26aufirst%3DC.%2BP.%26aulast%3DMahendra%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DDi%2BFrancesco%26aufirst%3DM.%2BE.%26aulast%3DMarszalek%26aufirst%3DJ.%2BR.%26aulast%3DMeric-Bernstam%26aufirst%3DF.%26atitle%3DPhase%2520I%2520trial%2520of%2520IACS-010759%2520%2528IACS%2529%252C%2520a%2520potent%252C%2520selective%2520inhibitor%2520of%2520complex%2520I%2520of%2520the%2520mitochondrial%2520electron%2520transport%2520chain%252C%2520in%2520patients%2520%2528pts%2529%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2019%26volume%3D37%26spage%3D3014%26epage%3D3014%26doi%3D10.1200%2FJCO.2019.37.15_suppl.3014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref272"><div class="reference"><strong class="refLabel"><a href="#ref272" class="rightTabRefNumLink">272</a></strong><div class="NLM_citation" id="rightTab-cit272"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Varga, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferdinandy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liaudet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacher, P.</span></span> <span> </span><span class="NLM_article-title">Drug-induced mitochondrial dysfunction and cardiotoxicity</span>. <i>Am. J. Physiol-Heart C</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>309</i></span>,  <span class="NLM_fpage">H1453</span>â <span class="NLM_lpage">H1467</span>, <span class="refDoi">Â DOI: 10.1152/ajpheart.00554.2015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref272/cit272&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1152%2Fajpheart.00554.2015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref272/cit272&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=26386112" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=309&publication_year=2015&pages=H1453-H1467&author=Z.+V.+Vargaauthor=P.+Ferdinandyauthor=L.+Liaudetauthor=P.+Pacher&title=Drug-induced+mitochondrial+dysfunction+and+cardiotoxicity&doi=10.1152%2Fajpheart.00554.2015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit272&amp;dbid=16384&amp;doi=10.1152%2Fajpheart.00554.2015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpheart.00554.2015%26sid%3Dliteratum%253Aachs%26aulast%3DVarga%26aufirst%3DZ.%2BV.%26aulast%3DFerdinandy%26aufirst%3DP.%26aulast%3DLiaudet%26aufirst%3DL.%26aulast%3DPacher%26aufirst%3DP.%26atitle%3DDrug-induced%2520mitochondrial%2520dysfunction%2520and%2520cardiotoxicity%26jtitle%3DAm.%2520J.%2520Physiol-Heart%2520C%26date%3D2015%26volume%3D309%26spage%3DH1453%26epage%3DH1467%26doi%3D10.1152%2Fajpheart.00554.2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref273"><div class="reference"><strong class="refLabel"><a href="#ref273" class="rightTabRefNumLink">273</a></strong><div class="NLM_citation" id="rightTab-cit273"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clements, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalinka, S.</span></span> <span> </span><span class="NLM_article-title">Bridging functional and structural cardiotoxicity assays using human embryonic stem cell-derived cardiomyocytes for a more comprehensive risk assessment</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">241</span>â <span class="NLM_lpage">260</span>, <span class="refDoi">Â DOI: 10.1093/toxsci/kfv180</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1093%2Ftoxsci%2Fkfv180" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=26259608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGisrjI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2015&pages=241-260&author=M.+Clementsauthor=V.+Millarauthor=A.+S.+Williamsauthor=S.+Kalinka&title=Bridging+functional+and+structural+cardiotoxicity+assays+using+human+embryonic+stem+cell-derived+cardiomyocytes+for+a+more+comprehensive+risk+assessment&doi=10.1093%2Ftoxsci%2Fkfv180"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit273R"><div class="casContent"><span class="casTitleNuber">273</span><div class="casTitle"><span class="NLM_cas:atitle">Bridging functional and structural cardiotoxicity assays using human embryonic stem cell-derived cardiomyocytes for a more comprehensive risk assessment</span></div><div class="casAuthors">Clements, Mike; Millar, Val; Williams, Angela S.; Kalinka, Sian</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">241-260</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">More relevant and reliable preclin. cardiotoxicity tests are required to improve drug safety and reduce the cost of drug development.  Current in vitro testing strategies predominantly take the form of functional assays to predict the potential for drug-induced ECG abnormalities in vivo.  Cardiotoxicity can also be structural in nature, so a full and efficient assessment of cardiac liabilities for new chem. entities should account for both these phenomena.  As well as providing a more appropriate nonclin. model for in vitro cardiotoxicity testing, human stem cell-derived cardiomyocytes offer an integrated system to study drug impact on cardiomyocyte structure as well as function.  Employing human embryonic stem cell-derived cardiacmyocytes (hESC-CMs) on 3 assay platforms with complementary insights into cardiac biol. (multielectrode array assay, electrophysiol.; impedance assay, cell movement/beating; and high content anal. assay, subcellular structure) we profiled a panel of 13 drugs with well characterized cardiac liabilities (Amiodarone, Aspirin, Astemizole, Axitinib, AZT, Bepridil, Doxorubicin, E-4031, Mexiletine, Rosiglitazone, Sunitinib, Sibutramine, and Verapamil).  Our data show good correlations with previous studies and reported clin. observations.  Using multiparameter phenotypic profiling techniques we demonstrate the dynamic relationship that exists between functional and structural toxicity, and the benefits of this more holistic approach to risk assessment.  We conclude by showing for the first time how the advent of transparent MEA plate technol. enables functional and structural cardiotoxic responses to be recorded from the same cell population.  This approach more directly links changes in morphol. of the hESC-CMs with recorded electrophysiol. signatures, offering even greater insight into the wide range of potential drug impacts on cardiac physiol., with a throughput that is more amenable to early drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL2UD57jfwtLVg90H21EOLACvtfcHk0ljFkWeAgsMmSg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGisrjI&md5=61b9f0c1e2449277825ae5dc1005fdee</span></div><a href="/servlet/linkout?suffix=cit273&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfv180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfv180%26sid%3Dliteratum%253Aachs%26aulast%3DClements%26aufirst%3DM.%26aulast%3DMillar%26aufirst%3DV.%26aulast%3DWilliams%26aufirst%3DA.%2BS.%26aulast%3DKalinka%26aufirst%3DS.%26atitle%3DBridging%2520functional%2520and%2520structural%2520cardiotoxicity%2520assays%2520using%2520human%2520embryonic%2520stem%2520cell-derived%2520cardiomyocytes%2520for%2520a%2520more%2520comprehensive%2520risk%2520assessment%26jtitle%3DToxicol.%2520Sci.%26date%3D2015%26volume%3D148%26spage%3D241%26epage%3D260%26doi%3D10.1093%2Ftoxsci%2Fkfv180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref274"><div class="reference"><strong class="refLabel"><a href="#ref274" class="rightTabRefNumLink">274</a></strong><div class="NLM_citation" id="rightTab-cit274"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rana, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aleo, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gosink, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, Y.</span></span> <span> </span><span class="NLM_article-title">Evaluation of in vitro mitochondrial toxicity assays and physicochemical properties for prediction of organ toxicity using 228 pharmaceutical drugs</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">156</span>â <span class="NLM_lpage">167</span>, <span class="refDoi">Â DOI: 10.1021/acs.chemrestox.8b00246</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.8b00246" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref274/cit274&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVens7bM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2019&pages=156-167&author=P.+Ranaauthor=M.+D.+Aleoauthor=M.+Gosinkauthor=Y.+Will&title=Evaluation+of+in+vitro+mitochondrial+toxicity+assays+and+physicochemical+properties+for+prediction+of+organ+toxicity+using+228+pharmaceutical+drugs&doi=10.1021%2Facs.chemrestox.8b00246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit274R"><div class="casContent"><span class="casTitleNuber">274</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of in Vitro Mitochondrial Toxicity Assays and Physicochemical Properties for Prediction of Organ Toxicity Using 228 Pharmaceutical Drugs</span></div><div class="casAuthors">Rana, Payal; Aleo, Michael D.; Gosink, Mark; Will, Yvonne</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">156-167</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mitochondrial toxicity has been shown to contribute to a variety of organ toxicities such as liver, cardiac, and kidney.  In the past decades, two high-throughput applicable screening assays (isolated rat liver mitochondria; glucose-galactose grown HepG2 cells) to assess mitochondrial toxicity have been deployed in many pharmaceutical companies, and numerous publications have demonstrated its usefulness for mechanistic investigations.  However, only two publications have demonstrated the utility of these screens as a predictor of human drug-induced liver injury.  In the present study, the authors screened 73 hepatotoxicants, 46 cardiotoxicants, 49 nephrotoxicants, and 60 compds. not known to cause human organ toxicity for their effects on mitochondrial function(s) in the assays mentioned above.  Predictive performance was evaluated using specificity and sensitivity of the assays for predicting organ toxicity.  The authors' results show that the predictive performance of the mitochondrial assays are superior for hepatotoxicity as compared to cardiotoxicity and nephrotoxicity (sensitivity 63% vs. 33% and 28% with similar specificity of 93%), when the anal. was done at 100* Cmax (drug concn. in human plasma level).  The authors further explored the assocn. of mitochondrial toxicity with physicochem. properties such as calcd. log partition coeff. (cLogP), topol. polar surface area, ionization status, and mol. wt. of the drugs and found that cLogP was most significantly assocd. mitochondrial toxicity.  Since these assays are amenable to higher throughput, the authors recommend that chemists use these assays to perform structure activity relationship early in the drug discovery process, when chem. matter is abundant.  This assures that compds. that lack the propensity to cause mitochondrial dysfunction (and assocd. organ toxicity) will move forward into animals and humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7Rad7gm0MrLVg90H21EOLACvtfcHk0ljAjdlSZbnvLQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVens7bM&md5=82bc95a1604961473a4e5fecb05aab79</span></div><a href="/servlet/linkout?suffix=cit274&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.8b00246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.8b00246%26sid%3Dliteratum%253Aachs%26aulast%3DRana%26aufirst%3DP.%26aulast%3DAleo%26aufirst%3DM.%2BD.%26aulast%3DGosink%26aufirst%3DM.%26aulast%3DWill%26aufirst%3DY.%26atitle%3DEvaluation%2520of%2520in%2520vitro%2520mitochondrial%2520toxicity%2520assays%2520and%2520physicochemical%2520properties%2520for%2520prediction%2520of%2520organ%2520toxicity%2520using%2520228%2520pharmaceutical%2520drugs%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2019%26volume%3D32%26spage%3D156%26epage%3D167%26doi%3D10.1021%2Facs.chemrestox.8b00246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref275"><div class="reference"><strong class="refLabel"><a href="#ref275" class="rightTabRefNumLink">275</a></strong><div class="NLM_citation" id="rightTab-cit275"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aleo, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swiss, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonin, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, Y.</span></span> <span> </span><span class="NLM_article-title">Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1015</span>â <span class="NLM_lpage">1022</span>, <span class="refDoi">Â DOI: 10.1002/hep.27206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1002%2Fhep.27206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=24799086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGhtbnJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2014&pages=1015-1022&author=M.+D.+Aleoauthor=Y.+Luoauthor=R.+Swissauthor=P.+D.+Boninauthor=D.+M.+Potterauthor=Y.+Will&title=Human+drug-induced+liver+injury+severity+is+highly+associated+with+dual+inhibition+of+liver+mitochondrial+function+and+bile+salt+export+pump&doi=10.1002%2Fhep.27206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit275R"><div class="casContent"><span class="casTitleNuber">275</span><div class="casTitle"><span class="NLM_cas:atitle">Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump</span></div><div class="casAuthors">Aleo, Michael D.; Luo, Yi; Swiss, Rachel; Bonin, Paul D.; Potter, David M.; Will, Yvonne</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1015-1022</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) accounts for 20-40% of all instances of clin. hepatic failure and is a common reason for withdrawal of an approved drug or discontinuation of a potentially new drug from clin./nonclin. development.  Numerous individual risk factors contribute to the susceptibility to human DILI and its severity that are either compd.- and/or patient-specific.  Compd.-specific primary mechanisms linked to DILI include: cytotoxicity, reactive metabolite formation, inhibition of bile salt export pump (BSEP), and mitochondrial dysfunction.  Since BSEP is an energy-dependent protein responsible for the efflux of bile acids from hepatocytes, it was hypothesized that humans exposed to drugs that impair both mitochondrial energetics and BSEP functional activity are more sensitive to more severe manifestations of DILI than drugs that only have a single liability factor.  As annotated in the United States National Center for Toxicol. Research Liver Toxicity Knowledge Base (NCTR-LTKB), the inhibitory properties of 24 Most-DILI-, 28 Less-DILI-, and 20 No-DILI-concern drugs were investigated.  Drug potency for inhibiting BSEP or mitochondrial activity was generally correlated across human DILI concern categories.  However, drugs with dual potency as mitochondrial and BSEP inhibitors were highly assocd. with more severe human DILI, more restrictive product safety labeling related to liver injury, and appear more sensitive to the drug exposure (Cmax) where more restrictive labeling occurs.  Conclusion: These data affirm that severe manifestations of human DILI are multifactorial, highly assocd. with combinations of drug potency specifically related to known mechanisms of DILI (like mitochondrial and BSEP inhibition), and, along with patient-specific factors, lead to differences in the severity and exposure thresholds assocd. with clin. DILI. (Hepatol. 2014;60:1015-1022).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIKfBrKEsFMbVg90H21EOLACvtfcHk0ljAjdlSZbnvLQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGhtbnJ&md5=9bc646d27738ab811ebc526d520c83bf</span></div><a href="/servlet/linkout?suffix=cit275&amp;dbid=16384&amp;doi=10.1002%2Fhep.27206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27206%26sid%3Dliteratum%253Aachs%26aulast%3DAleo%26aufirst%3DM.%2BD.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DSwiss%26aufirst%3DR.%26aulast%3DBonin%26aufirst%3DP.%2BD.%26aulast%3DPotter%26aufirst%3DD.%2BM.%26aulast%3DWill%26aufirst%3DY.%26atitle%3DHuman%2520drug-induced%2520liver%2520injury%2520severity%2520is%2520highly%2520associated%2520with%2520dual%2520inhibition%2520of%2520liver%2520mitochondrial%2520function%2520and%2520bile%2520salt%2520export%2520pump%26jtitle%3DHepatology%26date%3D2014%26volume%3D60%26spage%3D1015%26epage%3D1022%26doi%3D10.1002%2Fhep.27206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref276"><div class="reference"><strong class="refLabel"><a href="#ref276" class="rightTabRefNumLink">276</a></strong><div class="NLM_citation" id="rightTab-cit276"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rana, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kogut, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhlaghi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aleo, M. D.</span></span> <span> </span><span class="NLM_article-title">Most influential physicochemical and in vitro assay descriptors for hepatotoxicity and nephrotoxicity prediction</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1780</span>, <span class="refDoi">Â DOI: 10.1021/acs.chemrestox.0c00040</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.0c00040" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnvFartb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2020&pages=1780&author=P.+Ranaauthor=S.+Kogutauthor=X.+Wenauthor=F.+Akhlaghiauthor=M.+D.+Aleo&title=Most+influential+physicochemical+and+in+vitro+assay+descriptors+for+hepatotoxicity+and+nephrotoxicity+prediction&doi=10.1021%2Facs.chemrestox.0c00040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit276R"><div class="casContent"><span class="casTitleNuber">276</span><div class="casTitle"><span class="NLM_cas:atitle">Most Influential Physicochemical and In Vitro Assay Descriptors for Hepatotoxicity and Nephrotoxicity Prediction</span></div><div class="casAuthors">Rana, Payal; Kogut, Stephen; Wen, Xuerong; Akhlaghi, Fatemeh; Aleo, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1780-1790</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Drug-induced organ injury is a major reason for drug candidate attrition in preclin. and clin. drug development.  The liver, kidneys, and heart have been recognized as the most common organ systems affected in safety-related attrition or the subject of black box warnings and postmarket drug withdrawals.  In silico physicochem. property calcns. and in vitro assays have been utilized sep. in the early stages of the drug discovery and development process to predict drug safety.  In this study, we combined physicochem. properties and in vitro cytotoxicity assays including mitochondrial dysfunction to build organ-specific univariate and multivariable logistic regression models to achieve odds ratios for the prediction of clin. hepatotoxicity, nephrotoxicity, and cardiotoxicity using 215 marketed drugs.  The multivariable hepatotoxic predictive model showed an odds ratio of 6.2 (95% confidence interval (CI) 1.7-22.8) or 7.5 (95% CI 3.2-17.8) for mitochondrial inhibition or drug plasma Cmax >1Î¼M for drugs assocd. with liver injury, resp.  The multivariable nephrotoxicity predictive model showed an odds ratio of 5.8 (95% CI 2.0-16.9), 6.4 (95% CI 1.1-39.3), or 15.9 (95% CI 2.8-89.0) for drug plasma Cmax >1Î¼M, mitochondrial inhibition, or hydrogen-bond-acceptor atoms >7 for drugs assocd. with kidney injury, resp.  Conversely, drugs with a total polar surface area â¥75 Ã were 79% (odds ratio 0.21, 95% CI 0.061-0.74) less likely to be assocd. with kidney injury.  Drugs belonging to the extended clearance classification system (ECCS) class 4, where renal secretion is the primary clearance mechanism (low permeability drugs that are bases/neutrals), were 4 (95% CI 1.8-9.5) times more likely to be assocd. with kidney injury with this data set.  Alternatively, ECCS class 2 drugs, where hepatic metab. is the primary clearance (high permeability drugs that are bases/neutrals) were 77% less likely (odds ratio 0.23 95% CI 0.095-0.54) to be assocd. with kidney injury.  A cardiotoxicity model was poorly defined using any of these drug physicochem. attributes.  Combining in silico physicochem. properties descriptors along with in vitro toxicity assays can be used to build predictive toxicity models to select small mol. therapeutics with less potential to cause liver and kidney organ toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoH-dHCC41dV7Vg90H21EOLACvtfcHk0ljAjdlSZbnvLQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnvFartb8%253D&md5=3c6054a86323ef005316d93bc2e5e463</span></div><a href="/servlet/linkout?suffix=cit276&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.0c00040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.0c00040%26sid%3Dliteratum%253Aachs%26aulast%3DRana%26aufirst%3DP.%26aulast%3DKogut%26aufirst%3DS.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DAkhlaghi%26aufirst%3DF.%26aulast%3DAleo%26aufirst%3DM.%2BD.%26atitle%3DMost%2520influential%2520physicochemical%2520and%2520in%2520vitro%2520assay%2520descriptors%2520for%2520hepatotoxicity%2520and%2520nephrotoxicity%2520prediction%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2020%26volume%3D33%26spage%3D1780%26doi%3D10.1021%2Facs.chemrestox.0c00040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref277"><div class="reference"><strong class="refLabel"><a href="#ref277" class="rightTabRefNumLink">277</a></strong><div class="NLM_citation" id="rightTab-cit277"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miralles-Linares, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puerta-Fernandez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernal-Lopez, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tinahones, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrade, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-Huelgas, R.</span></span> <span> </span><span class="NLM_article-title">Metformin-induced hepatotoxicity</span>. <i>Diabetes Care</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">E21</span>â <span class="NLM_lpage">E21</span>, <span class="refDoi">Â DOI: 10.2337/dc11-2306</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref277/cit277&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.2337%2Fdc11-2306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref277/cit277&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=22355024" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2012&pages=E21-E21&author=F.+Miralles-Linaresauthor=S.+Puerta-Fernandezauthor=M.+R.+Bernal-Lopezauthor=F.+J.+Tinahonesauthor=R.+J.+Andradeauthor=R.+Gomez-Huelgas&title=Metformin-induced+hepatotoxicity&doi=10.2337%2Fdc11-2306"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit277&amp;dbid=16384&amp;doi=10.2337%2Fdc11-2306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdc11-2306%26sid%3Dliteratum%253Aachs%26aulast%3DMiralles-Linares%26aufirst%3DF.%26aulast%3DPuerta-Fernandez%26aufirst%3DS.%26aulast%3DBernal-Lopez%26aufirst%3DM.%2BR.%26aulast%3DTinahones%26aufirst%3DF.%2BJ.%26aulast%3DAndrade%26aufirst%3DR.%2BJ.%26aulast%3DGomez-Huelgas%26aufirst%3DR.%26atitle%3DMetformin-induced%2520hepatotoxicity%26jtitle%3DDiabetes%2520Care%26date%3D2012%26volume%3D35%26spage%3DE21%26epage%3DE21%26doi%3D10.2337%2Fdc11-2306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref278"><div class="reference"><strong class="refLabel"><a href="#ref278" class="rightTabRefNumLink">278</a></strong><div class="NLM_citation" id="rightTab-cit278"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koopman, W. J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Distelmaier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeitink, J. A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willems, P. H. G. M.</span></span> <span> </span><span class="NLM_article-title">OXPHOS mutations and neurodegeneration</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">9</span>â <span class="NLM_lpage">29</span>, <span class="refDoi">Â DOI: 10.1038/emboj.2012.300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref278/cit278&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1038%2Femboj.2012.300" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref278/cit278&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=23149385" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2012&pages=9-29&author=W.+J.+H.+Koopmanauthor=F.+Distelmaierauthor=J.+A.+M.+Smeitinkauthor=P.+H.+G.+M.+Willems&title=OXPHOS+mutations+and+neurodegeneration&doi=10.1038%2Femboj.2012.300"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit278&amp;dbid=16384&amp;doi=10.1038%2Femboj.2012.300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Femboj.2012.300%26sid%3Dliteratum%253Aachs%26aulast%3DKoopman%26aufirst%3DW.%2BJ.%2BH.%26aulast%3DDistelmaier%26aufirst%3DF.%26aulast%3DSmeitink%26aufirst%3DJ.%2BA.%2BM.%26aulast%3DWillems%26aufirst%3DP.%2BH.%2BG.%2BM.%26atitle%3DOXPHOS%2520mutations%2520and%2520neurodegeneration%26jtitle%3DEMBO%2520J.%26date%3D2012%26volume%3D32%26spage%3D9%26epage%3D29%26doi%3D10.1038%2Femboj.2012.300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref279"><div class="reference"><strong class="refLabel"><a href="#ref279" class="rightTabRefNumLink">279</a></strong><div class="NLM_citation" id="rightTab-cit279"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cannon, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tapias, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Na, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honick, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drolet, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenamyre, J. T.</span></span> <span> </span><span class="NLM_article-title">A highly reproducible rotenone model of Parkinsonâs disease</span>. <i>Neurobiol. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">279</span>â <span class="NLM_lpage">290</span>, <span class="refDoi">Â DOI: 10.1016/j.nbd.2009.01.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref279/cit279&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.nbd.2009.01.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref279/cit279&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=19385059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref279/cit279&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkslKrsro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2009&pages=279-290&author=J.+R.+Cannonauthor=V.+Tapiasauthor=H.+M.+Naauthor=A.+S.+Honickauthor=R.+E.+Droletauthor=J.+T.+Greenamyre&title=A+highly+reproducible+rotenone+model+of+Parkinson%E2%80%99s+disease&doi=10.1016%2Fj.nbd.2009.01.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit279R"><div class="casContent"><span class="casTitleNuber">279</span><div class="casTitle"><span class="NLM_cas:atitle">A highly reproducible rotenone model of Parkinson's disease</span></div><div class="casAuthors">Cannon, Jason R.; Tapias, Victor; Na, Hye Mee; Honick, Anthony S.; Drolet, Robert E.; Greenamyre, J. Timothy</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Disease</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">279-290</span>CODEN:
                <span class="NLM_cas:coden">NUDIEM</span>;
        ISSN:<span class="NLM_cas:issn">0969-9961</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The systemic rotenone model of Parkinson's disease (PD) accurately replicates many aspects of the pathol. of human PD and has provided insights into the pathogenesis of PD.  The major limitation of the rotenone model has been its variability, both in terms of the percentage of animals that develop a clear-cut nigrostriatal lesion and the extent of that lesion.  The goal here was to develop an improved and highly reproducible rotenone model of PD.  In these studies, male Lewis rats in three age groups (3, 7 or 12-14 mo) were administered rotenone (2.75 or 3.0 mg/kg/day) in a specialized vehicle by daily i.p. injection.  All rotenone-treated animals developed bradykinesia, postural instability, and/or rigidity, which were reversed by apomorphine, consistent with a lesion of the nigrostriatal dopamine system.  Animals were sacrificed when the PD phenotype became debilitating.  Rotenone treatment caused a 45% loss of tyrosine hydroxylase-pos. substantia nigra neurons and a commensurate loss of striatal dopamine.  Addnl., in rotenone-treated animals, Î±-synuclein and poly-ubiquitin pos. aggregates were obsd. in dopamine neurons of the substantia nigra.  In summary, this version of the rotenone model is highly reproducible and may provide an excellent tool to test new neuroprotective strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvHrN5kMQacLVg90H21EOLACvtfcHk0lisqxKjjYXwLQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkslKrsro%253D&md5=56750e35d55f67d7645612427451ceb9</span></div><a href="/servlet/linkout?suffix=cit279&amp;dbid=16384&amp;doi=10.1016%2Fj.nbd.2009.01.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nbd.2009.01.016%26sid%3Dliteratum%253Aachs%26aulast%3DCannon%26aufirst%3DJ.%2BR.%26aulast%3DTapias%26aufirst%3DV.%26aulast%3DNa%26aufirst%3DH.%2BM.%26aulast%3DHonick%26aufirst%3DA.%2BS.%26aulast%3DDrolet%26aufirst%3DR.%2BE.%26aulast%3DGreenamyre%26aufirst%3DJ.%2BT.%26atitle%3DA%2520highly%2520reproducible%2520rotenone%2520model%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DNeurobiol.%2520Dis.%26date%3D2009%26volume%3D34%26spage%3D279%26epage%3D290%26doi%3D10.1016%2Fj.nbd.2009.01.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref280"><div class="reference"><strong class="refLabel"><a href="#ref280" class="rightTabRefNumLink">280</a></strong><div class="NLM_citation" id="rightTab-cit280"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benbow, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aubrecht, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nettleton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aleo, M. D.</span></span> <span> </span><span class="NLM_article-title">Predicting safety toleration of pharmaceutical chemical leads: Cytotoxicity correlations to exploratory toxicity studies</span>. <i>Toxicol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>197</i></span>,  <span class="NLM_fpage">175</span>â <span class="NLM_lpage">182</span>, <span class="refDoi">Â DOI: 10.1016/j.toxlet.2010.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref280/cit280&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.toxlet.2010.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref280/cit280&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=20576494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref280/cit280&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptVagu7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=197&publication_year=2010&pages=175-182&author=J.+W.+Benbowauthor=J.+Aubrechtauthor=M.+J.+Bankerauthor=D.+Nettletonauthor=M.+D.+Aleo&title=Predicting+safety+toleration+of+pharmaceutical+chemical+leads%3A+Cytotoxicity+correlations+to+exploratory+toxicity+studies&doi=10.1016%2Fj.toxlet.2010.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit280R"><div class="casContent"><span class="casTitleNuber">280</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting safety toleration of pharmaceutical chemical leads: Cytotoxicity correlations to exploratory toxicity studies</span></div><div class="casAuthors">Benbow, John W.; Aubrecht, Jiri; Banker, Michael J.; Nettleton, David; Aleo, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">197</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">175-182</span>CODEN:
                <span class="NLM_cas:coden">TOLED5</span>;
        ISSN:<span class="NLM_cas:issn">0378-4274</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">The selection and application of appropriate safety screening paradigms could revolutionize the drug discovery process by reducing safety-related attrition.  While mechanism specific genotoxicity and safety pharmacol. assays are routinely used in screening, the overall value of employing nonspecific cytotoxicity assays remains controversial.  A retrospective anal. of safety findings from rat exploratory toxicity studies (4-14 days) utilizing compds. that spanned broad therapeutic targets (protease, transport, G-protein-coupled receptors, and kinase inhibitors, cGMP modulators) demonstrated that safety toleration in vivo could be approximated using cytotoxicity values.  A composite safety score was calcd. for each compd. dose based on findings in each of the following categories: systemic toleration (mortality, food consumption, and adverse clin. signs), clin. chem./hematol. parameters (deviations from normal ranges), and multiorgan pathol. (necrosis or incidence/severity of histol. change).  Binning compds. into potent (LC50 < 10 Î¼M) and non-potent (LC50 > 100 Î¼M) cytotoxicants in vitro showed that compared to non-potent cytotoxicants the exposure to potent cytotoxicants in vivo resulted in higher overall severity scores at lower exposures.  Correlating overall toleration for individual compds. was further refined when in vivo exposure was considered.  When av. plasma exposure (Cpave) for a compd. exceeded its mean lethal concn. (LC50) in vitro (Cpave/LC50 > 1), higher overall severity scores were achieved compared to lower exposure margins (Cpave/LC50 <0.01).  Based on this anal., the ability to select lead series and individual compds. with better safety characteristics is presented.  In summary, cytotoxicity screening can be used to approx., not define, the safety characteristics of lead pharmaceutical series early in the drug discovery process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUhD17guOBELVg90H21EOLACvtfcHk0lisqxKjjYXwLQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptVagu7s%253D&md5=0740fad66ffc69226d1e9971fab41ef5</span></div><a href="/servlet/linkout?suffix=cit280&amp;dbid=16384&amp;doi=10.1016%2Fj.toxlet.2010.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.toxlet.2010.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DBenbow%26aufirst%3DJ.%2BW.%26aulast%3DAubrecht%26aufirst%3DJ.%26aulast%3DBanker%26aufirst%3DM.%2BJ.%26aulast%3DNettleton%26aufirst%3DD.%26aulast%3DAleo%26aufirst%3DM.%2BD.%26atitle%3DPredicting%2520safety%2520toleration%2520of%2520pharmaceutical%2520chemical%2520leads%253A%2520Cytotoxicity%2520correlations%2520to%2520exploratory%2520toxicity%2520studies%26jtitle%3DToxicol.%2520Lett.%26date%3D2010%26volume%3D197%26spage%3D175%26epage%3D182%26doi%3D10.1016%2Fj.toxlet.2010.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref281"><div class="reference"><strong class="refLabel"><a href="#ref281" class="rightTabRefNumLink">281</a></strong><div class="NLM_citation" id="rightTab-cit281"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeCrescenzo, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devraj, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellsworth, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fobian, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbs, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilles, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krieger-Burke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loesel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wager, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiteley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Physiochemical drug properties associated with in vivo toxicological outcomes</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4872</span>â <span class="NLM_lpage">4875</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2008.07.071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref281/cit281&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1016%2Fj.bmcl.2008.07.071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref281/cit281&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=18691886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref281/cit281&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVOnsbjE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4872-4875&author=J.+D.+Hughesauthor=J.+Blaggauthor=D.+A.+Priceauthor=S.+Baileyauthor=G.+A.+DeCrescenzoauthor=R.+V.+Devrajauthor=E.+Ellsworthauthor=Y.+M.+Fobianauthor=M.+E.+Gibbsauthor=R.+W.+Gillesauthor=N.+Greeneauthor=E.+Huangauthor=T.+Krieger-Burkeauthor=J.+Loeselauthor=T.+Wagerauthor=L.+Whiteleyauthor=Y.+Zhang&title=Physiochemical+drug+properties+associated+with+in+vivo+toxicological+outcomes&doi=10.1016%2Fj.bmcl.2008.07.071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit281R"><div class="casContent"><span class="casTitleNuber">281</span><div class="casTitle"><span class="NLM_cas:atitle">Physiochemical drug properties associated with in vivo toxicological outcomes</span></div><div class="casAuthors">Hughes, Jason D.; Blagg, Julian; Price, David A.; Bailey, Simon; DeCrescenzo, Gary A.; Devraj, Rajesh V.; Ellsworth, Edmund; Fobian, Yvette M.; Gibbs, Michael E.; Gilles, Richard W.; Greene, Nigel; Huang, Enoch; Krieger-Burke, Teresa; Loesel, Jens; Wager, Travis; Whiteley, Larry; Zhang, Yao</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4872-4875</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Relationships between physicochem. drug properties and toxicity were inferred from a data set consisting of animal in vivo toleration (IVT) studies on 245 preclin. Pfizer compds.; an increased likelihood of toxic events was found for less polar, more lipophilic compds.  This trend held across a wide range of types of toxicity and across a broad swath of chem. space.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPMmGEpVF0mbVg90H21EOLACvtfcHk0ljOdvpxYh4GjQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVOnsbjE&md5=80ea5ced359112a363f38b3545cd7646</span></div><a href="/servlet/linkout?suffix=cit281&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.07.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.07.071%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DJ.%2BD.%26aulast%3DBlagg%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DDeCrescenzo%26aufirst%3DG.%2BA.%26aulast%3DDevraj%26aufirst%3DR.%2BV.%26aulast%3DEllsworth%26aufirst%3DE.%26aulast%3DFobian%26aufirst%3DY.%2BM.%26aulast%3DGibbs%26aufirst%3DM.%2BE.%26aulast%3DGilles%26aufirst%3DR.%2BW.%26aulast%3DGreene%26aufirst%3DN.%26aulast%3DHuang%26aufirst%3DE.%26aulast%3DKrieger-Burke%26aufirst%3DT.%26aulast%3DLoesel%26aufirst%3DJ.%26aulast%3DWager%26aufirst%3DT.%26aulast%3DWhiteley%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DPhysiochemical%2520drug%2520properties%2520associated%2520with%2520in%2520vivo%2520toxicological%2520outcomes%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D4872%26epage%3D4875%26doi%3D10.1016%2Fj.bmcl.2008.07.071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref282"><div class="reference"><strong class="refLabel"><a href="#ref282" class="rightTabRefNumLink">282</a></strong><div class="NLM_citation" id="rightTab-cit282"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span> <span> </span><span class="NLM_article-title">Impact of physicochemical properties on dose and hepatotoxicity of oral drugs</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">494</span>â <span class="NLM_lpage">505</span>, <span class="refDoi">Â DOI: 10.1021/acs.chemrestox.8b00044</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.8b00044" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref282/cit282&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A528%3ADC%252BC1cXos12ku7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2018&pages=494-505&author=P.+D.+Leeson&title=Impact+of+physicochemical+properties+on+dose+and+hepatotoxicity+of+oral+drugs&doi=10.1021%2Facs.chemrestox.8b00044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit282R"><div class="casContent"><span class="casTitleNuber">282</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of Physicochemical Properties on Dose and Hepatotoxicity of Oral Drugs</span></div><div class="casAuthors">Leeson, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">494-505</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A database contg. max. daily doses of 1841 marketed oral drugs was used to examine the influence of physicochem. properties on dose and hepatotoxicity (drug induced liver injury, DILI).  Drugs in the highest â¼20% dose range had significantly reduced mean lipophilicity and mol. wt., increased fractional surface area, increased % of acids, and decreased % of bases vs. drugs in the lower â¼60% dose range.  Drugs in the â¼20-40% dose range had intermediate mean properties, similar to the mean values for the full drug set.  Drugs that are both large and highly lipophilic almost invariably do not have doses in the upper â¼20% range.  The results show that oral druglike physicochem. properties are different according to these dose ranges, and this is consistent with maintenance of acceptable safety profiles as efficacious exposure increases.  Verified DILI annotations from a compilation of >1000 approved drugs (Chen, M.; et al. Drug Discov. Today, 2016, 21, 648) were used.  The drugs classified as "No DILI" (n = 163) had significantly lower dose and lipophilicity, and higher Fsp3 (fraction of carbon atoms that are sp3 hybridized) vs. the "Most DILI" (n = 163) drugs.  The percentages of acids were reduced and bases increased in the "No DILI" vs. the "Most DILI" groups.  Drugs classified as "Less DILI" or "Ambiguous DILI" had intermediate mean values of dose, lipophilicity, Fsp3, and % acids and bases.  The impact of lipophilicity and Fsp3 on DILI increases in the upper 20% vs. the lower 80% dose range, and a simple decision tree model predicted "No DILI" vs. "Most DILI" outcomes with 82% accuracy.  The model correctly classified 19 of 22 drugs (86%) that failed in development due to human hepatotoxicity.  Because many oral drugs lacking DILI annotations are predicted to be "Most DILI", the model is best used preclinically in conjunction with exptl. DILI mitigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhvPLJlGQ-ZrVg90H21EOLACvtfcHk0ljOdvpxYh4GjQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXos12ku7k%253D&md5=6a7c9b7b1070954a70655755ad6d0620</span></div><a href="/servlet/linkout?suffix=cit282&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.8b00044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.8b00044%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26atitle%3DImpact%2520of%2520physicochemical%2520properties%2520on%2520dose%2520and%2520hepatotoxicity%2520of%2520oral%2520drugs%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2018%26volume%3D31%26spage%3D494%26epage%3D505%26doi%3D10.1021%2Facs.chemrestox.8b00044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref283"><div class="reference"><strong class="refLabel"><a href="#ref283" class="rightTabRefNumLink">283</a></strong><div class="NLM_citation" id="rightTab-cit283"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Will, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dykens, J.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial toxicity assessment in industry - a decade of technology development and insight</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1061</span>â <span class="NLM_lpage">1067</span>, <span class="refDoi">Â DOI: 10.1517/17425255.2014.939628</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref283/cit283&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=10.1517%2F17425255.2014.939628" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref283/cit283&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=25023361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref283/cit283&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;key=1%3ACAS%3A280%3ADC%252BC2cbisVKnsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=1061-1067&author=Y.+Willauthor=J.+Dykens&title=Mitochondrial+toxicity+assessment+in+industry+-+a+decade+of+technology+development+and+insight&doi=10.1517%2F17425255.2014.939628"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit283R"><div class="casContent"><span class="casTitleNuber">283</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial toxicity assessment in industry--a decade of technology development and insight</span></div><div class="casAuthors">Will Yvonne; Dykens James</div><div class="citationInfo"><span class="NLM_cas:title">Expert opinion on drug metabolism & toxicology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1061-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTpQipcnBZdL6cY7HFp97qMfW6udTcc2eaCtpHJxyUYn7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbisVKnsw%253D%253D&md5=9e0d90f03938471154fec1353ebce3fe</span></div><a href="/servlet/linkout?suffix=cit283&amp;dbid=16384&amp;doi=10.1517%2F17425255.2014.939628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.2014.939628%26sid%3Dliteratum%253Aachs%26aulast%3DWill%26aufirst%3DY.%26aulast%3DDykens%26aufirst%3DJ.%26atitle%3DMitochondrial%2520toxicity%2520assessment%2520in%2520industry%2520-%2520a%2520decade%2520of%2520technology%2520development%2520and%2520insight%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2014%26volume%3D10%26spage%3D1061%26epage%3D1067%26doi%3D10.1517%2F17425255.2014.939628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5LC5" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5LC5','PDB','5LC5'); return false;">PDB: 5LC5</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ZOY" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ZOY','PDB','1ZOY'); return false;">PDB: 1ZOY</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1BGY" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1BGY','PDB','1BGY'); return false;">PDB: 1BGY</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WAU" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WAU','PDB','5WAU'); return false;">PDB: 5WAU</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CP6" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CP6','PDB','6CP6'); return false;">PDB: 6CP6</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i51"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01013">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_31615"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01013?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01013</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Heatmap; oncoprints for brain lower grade gliomOXPHOS structure genes; OXPHOS assembly factors and biogenesis genes; canonical glycolysis genes; list of physicochemical properties of 45 OXPHOS inhibitors (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01013/suppl_file/jm0c01013_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01013/suppl_file/jm0c01013_si_001.pdf">jm0c01013_si_001.pdf (1.12 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01013&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-23%3BrequestedJournal%3Ajournal%3Ajmcmar%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01013%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01013" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                14MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799e5877c442332","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
